{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "I want this code to do the followings: \n",
    "1. take a search parameter\n",
    "2. make sure that we don't already have the info \n",
    "3. if not, put all of the information in a database"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'FullStudiesResponse': {'APIVrs': '1.01.02', 'DataVrs': '2020:04:21 21:56:06.523', 'Expression': 'depression', 'NStudiesAvail': 336905, 'NStudiesFound': 20868, 'MinRank': 1, 'MaxRank': 100, 'NStudiesReturned': 100, 'FullStudies': [{'Rank': 1, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01083628', 'OrgStudyIdInfo': {'OrgStudyId': '68556-35551-01'}, 'Organization': {'OrgFullName': 'University of California, San Francisco', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Text Messaging and Cognitive Behavioral Therapy for Depression', 'OfficialTitle': 'Automated Text Messaging to Increase Engagement in Cognitive Behavioral Therapy (CBT) for Depression', 'Acronym': 'HealthySMS'}, 'StatusModule': {'StatusVerifiedDate': 'July 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 2017', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 19, 2010', 'StudyFirstSubmitQCDate': 'March 8, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 10, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'December 21, 2018', 'ResultsFirstSubmitQCDate': 'July 2, 2019', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 12, 2019', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 2, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 12, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of California, San Francisco', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study aims to asses whether adding automated text messaging to group cognitive behavioral therapy for depression increases engagement which may lead to improved outcomes.', 'DetailedDescription': \"Background: Cognitive Behavioral Therapy (CBT) for depression is efficacious, but effectiveness is limited when implemented in low-income settings due to engagement difficulties including nonadherence with skill-building homework and early discontinuation of treatment. Automated messaging can be used in clinical settings to increase dosage of depression treatment and encourage sustained engagement with psychotherapy.\\n\\nObjectives: The aim of this study was to test whether a text messaging adjunct (mood monitoring text messages, treatment-related text messages, and a clinician dashboard to display patient data) increases engagement and improves clinical outcomes in a group CBT treatment for depression. Specifically, the investigators aim to assess whether the text messaging adjunct led to an increase in group therapy sessions attended, an increase in duration of therapy attended, and reductions in Patient Health Questionnaire-9 item (PHQ-9) symptoms compared with the control condition of standard group CBT in a sample of low-income Spanish speaking Latino patients.\\n\\nMethods: Patients in an outpatient behavioral health clinic were assigned to standard group CBT for depression (control condition; n=40) or the same treatment with the addition of a text messaging adjunct (n=45). The adjunct consisted of a daily mood monitoring message, a daily message reiterating the theme of that week's content, and medication and appointment reminders. Mood data and qualitative responses were sent to a Web-based platform (HealthySMS) for review by the therapist and displayed in session as a tool for teaching CBT skills.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['mhealth', 'depression', 'latinos', 'text messaging', 'CBT', 'SMS']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '85', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Group CBT for Depression with MoodText'\", 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Group cognitive behavioral therapy utilizing the BRIGHT manual for depression along with automated text messaging for mood monitoring and reminder of session content', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Group CBT for Depression with MoodText']}}, {'ArmGroupLabel': 'Group CBT for Depression', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Standard group cognitive behavioral therapy utilizing the BRIGHT manual for depression', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Group CBT for Depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Group CBT for Depression with MoodText', 'InterventionDescription': 'Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Group CBT for Depression with MoodText'\"]}, 'InterventionOtherNameList': {'InterventionOtherName': ['Group CBT for Depression with HealthySMS']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Group CBT for Depression', 'InterventionDescription': 'Standard group CBT for depression using BRIGHT manual', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group CBT for Depression']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'PHQ-9 Depression Symptoms', 'PrimaryOutcomeDescription': 'The PHQ-9 (Patient Health Questionnaire - 9) is commonly used to screen for depression and to monitor progression of depressive symptoms over time. The scores represent the following depression severity: 0-4: minimal depression, 5-9: mild depression, 10-14: moderate depression, 15-19: moderately severe, 20-27: severe. A score of 10 is often recommended as the cut-off score for diagnosing an episode of depression that may require treatment.', 'PrimaryOutcomeTimeFrame': '16 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Attendance', 'SecondaryOutcomeDescription': 'Number of sessions attended', 'SecondaryOutcomeTimeFrame': '16 weeks'}, {'SecondaryOutcomeMeasure': 'Duration of Therapy Attended', 'SecondaryOutcomeDescription': 'Number of weeks until patients dropped out of therapy', 'SecondaryOutcomeTimeFrame': '16 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nParticipation in CBT group at San Francisco General Hospital\\n\\nExclusion Criteria:\\n\\nActive suicidality\\nActive and severe psychosis', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '100 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Adrian Aguilera, Ph.D.', 'OverallOfficialAffiliation': 'University of California, San Francisco', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'San Francisco General Hospital', 'LocationCity': 'San Francisco', 'LocationState': 'California', 'LocationZip': '94110', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Latino Mental Health Research Program', 'SeeAlsoLinkURL': 'http://medschool.ucsf.edu/latino/'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Group CBT With Text Messaging Adjunct', 'FlowGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Group CBT for Depression', 'FlowGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '45'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '40'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '45'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '40'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '0'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Group CBT With Text Messaging Adjunct', 'BaselineGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Group CBT for Depression', 'BaselineGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '45'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '40'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '85'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '45'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '40'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '85'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '51.71', 'BaselineMeasurementSpread': '11.55'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '51.83', 'BaselineMeasurementSpread': '11.73'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '51.75', 'BaselineMeasurementSpread': '11.62'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '38'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '29'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '67'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '7'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '11'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '18'}]}}]}}]}}, {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '45'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '40'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '85'}]}}, {'BaselineCategoryTitle': 'Not Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '45'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '40'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '85'}]}}]}}]}}, {'BaselineMeasureTitle': 'PHQ-9', 'BaselineMeasureDescription': 'The PHQ-9 (Patient Health Questionnaire - 9) is commonly used to screen for depression and to monitor progression of depressive symptoms over time. The scores represent the following depression severity: 0-4: minimal depression, 5-9: mild depression, 10-14: moderate depression, 15-19: moderately severe, 20-27: severe. A score of 10 is often recommended as the cut-off score for diagnosing an episode of depression that may require treatment.', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'units on a scale', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '13.36', 'BaselineMeasurementSpread': '5.96'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '13.13', 'BaselineMeasurementSpread': '4.99'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '13.25', 'BaselineMeasurementSpread': '5.68'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'PHQ-9 Depression Symptoms', 'OutcomeMeasureDescription': 'The PHQ-9 (Patient Health Questionnaire - 9) is commonly used to screen for depression and to monitor progression of depressive symptoms over time. The scores represent the following depression severity: 0-4: minimal depression, 5-9: mild depression, 10-14: moderate depression, 15-19: moderately severe, 20-27: severe. A score of 10 is often recommended as the cut-off score for diagnosing an episode of depression that may require treatment.', 'OutcomeMeasurePopulationDescription': 'The number of participants analyzed in this intention-to-treat analyses represents the number of participants that provided PHQ-9 scores at the end of the study period, at 16 weeks. Because the PHQ-9 was filled in during psychotherapy sessions, this number is smaller than the original sample (n=44, n=38) due to patient drop-out of psychotherapy.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': '16 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Group CBT With Text Messaging Adjunct', 'OutcomeGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Group CBT for Depression', 'OutcomeGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '18'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '9'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6', 'OutcomeMeasurementSpread': '4.2'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '12.67', 'OutcomeMeasurementSpread': '6.4'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Attendance', 'OutcomeMeasureDescription': 'Number of sessions attended', 'OutcomeMeasurePopulationDescription': 'For the attendance analyses, 3 patients (1 in the intervention and 2 in the control) were excluded, because the study ended before these patients had been offered 16 sessions of psychotherapy.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'sessions', 'OutcomeMeasureTimeFrame': '16 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Group CBT With Text Messaging Adjunct', 'OutcomeGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Group CBT for Depression', 'OutcomeGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '44'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '38'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6', 'OutcomeMeasurementSpread': '2.3'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '2.5', 'OutcomeMeasurementSpread': '1.4'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Duration of Therapy Attended', 'OutcomeMeasureDescription': 'Number of weeks until patients dropped out of therapy', 'OutcomeMeasurePopulationDescription': 'For the duration of therapy analyses, 3 patients (1 in the intervention and 2 in the control) were excluded, because the study ended before these patients had been offered 16 sessions of psychotherapy.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Full Range', 'OutcomeMeasureUnitOfMeasure': 'weeks', 'OutcomeMeasureTimeFrame': '16 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Group CBT With Text Messaging Adjunct', 'OutcomeGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Group CBT for Depression', 'OutcomeGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '44'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '38'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '13.5', 'OutcomeMeasurementLowerLimit': '1', 'OutcomeMeasurementUpperLimit': '16'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '3', 'OutcomeMeasurementLowerLimit': '1', 'OutcomeMeasurementUpperLimit': '16'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Group CBT With Text Messaging Adjunct', 'EventGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '45', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '45'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Group CBT for Depression', 'EventGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '40', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '40'}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No', 'AgreementRestrictiveAgreement': 'No'}, 'PointOfContact': {'PointOfContactTitle': 'Dr. Adrian Aguilera', 'PointOfContactOrganization': 'University of California, Berkeley', 'PointOfContactEMail': 'aguila@berkeley.edu', 'PointOfContactPhone': '510-642-8564'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 2, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01979302', 'OrgStudyIdInfo': {'OrgStudyId': 'R01MH082425', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH082425&Fy=all'}, 'Organization': {'OrgFullName': 'Weill Medical College of Cornell University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effectiveness of a Depression Care Management Initiative in Home Healthcare', 'OfficialTitle': 'Effectiveness of a Depression Care Management Initiative in Home Healthcare'}, 'StatusModule': {'StatusVerifiedDate': 'July 2014', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2013', 'PrimaryCompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'September 26, 2013', 'StudyFirstSubmitQCDate': 'November 1, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 8, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 9, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 10, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Weill Medical College of Cornell University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Depression in older home healthcare patients occurs very often, is typically not treated appropriately, and leads to poor health outcomes. This study tests an intervention, called \"Depression Care for Patients at Home\" or the Depression CAREPATH, designed to help home healthcare nurses work with the patients, their family, and their doctors in managing depression treat depression according to clinical guidelines and to manage its treatment over time. Patient outcomes, measured at 3, 6, and 12 months, include guideline-consistent changes in depression treatment and reduction in depressive symptoms.', 'DetailedDescription': 'The goal of this research is to improve depression treatment and outcomes among elderly home healthcare patients. Homecare nursing is a major source of health care for a large and growing number of medically ill or injured older adults who are homebound by illness or disability. Clinically significant depression is twice as prevalent in this patient population compared to similarly aged primary care patients. Depression can be effectively treated in older adults, and treatment guidelines have been developed to help physicians make treatment decisions for their depressed older patients. However, medical home healthcare patients rarely receive guideline-consistent treatment for depression. This research tests the effectiveness of an intervention, Depression Care for Patients at Home\" (CAREPATH), on two outcomes: 1. Depression treatment (i.e., initiate treatment or have a change in treatment that is consistent with guidelines), and 2. Depressive symptoms (i.e., reduction in depressive symptoms over time). The CAREPATH protocol was designed in partnership with home healthcare providers. It includes the major elements of depression care management models that have proven effective in primary care but restructures these elements to fit the clinical needs of home healthcare patients and for consistency with home healthcare practice. The intervention itself is designed to be ecologically sensitive to maximize the feasibility and generalizability of the program. The CAREPATH Intervention is being tested within six home healthcare agencies located in Vermont/New Hampshire, New York, Pennsylvania, Michigan, Florida, and Arkansas. The design includes randomization of ~20 teams of nurses to CAREPATH or usual care. The impact of CAREPATH on depression treatment is tested with all eligible patients (N~600) using data collected routinely by all agencies as these are the kinds of data that agencies typically use for quality assurance. Depressive symptoms outcomes are tested using the Hamilton Depression Rating Scale (HDRS) collected by researcher staff from (N=300) patients who consent to in-person baseline and telephone follow-up interviews at 12, 24, and 52 weeks.\\n\\nData Plan: H1 Depression Treatment : Patients of CAREPATH home nurses with clinically significant depressive symptoms will be more likely to receive a \"guideline-based step\" in their treatment of depression than patients of nurses providing usual care. This analysis will be tested using the merged administrative data set. A mixed-effects logistic regression analyses will compare patients in the intervention and usual care groups on change in depression treatment received. The primary independent variable (a fixed effect) is group and the dependent variable is change (from start-of-care to discharge to guideline consistent treatment received (yes/no). The structure of these data from this cluster randomized trial involves three level mixed-effects models in which patients are nested within nurse and nurse within team supervisor. These analyses will be preceded by mixed-effects models that compare groups on sociodemographic and clinical variables. Those variables that differ significantly will be included as covariates in the primary analysis that examines the intervention effect (described above).\\n\\nH2 Depressive Symptoms: Patients of CAREPATH home nurses with clinically significant depressive symptoms will have greater reduction in depressive symptomatology (HDRS change from baseline) by 3, 6 and 12 months of the baseline interview than patients receiving usual care. This analysis will be tested using data collected from patient research interviews. A mixed-effects linear regression analyses will compare patients in the intervention and usual care groups on change in severity of depressive symptoms from baseline. Covariates in the model will be selected as described in H1.\\n\\nD9.3 Exploratory Analyses: . S1. Different Outcomes:. Whether the intervention reduces the risk of poor outcomes as measured by Medicare\\'s \"Outcome-Based Quality Indicators\" (OBQI) and targeted adverse events, including: decline in activities of daily living, discharge to hospital, and/or falls. This analysis will be tested using the merged administrative data set. Mixed-effects analyses will be conducted on the following OBQI outcomes and adverse events. Mixed-effects linear regression will be used for the continuous measures (e.g., ADL decline) whereas mixed-effects logistic regression analyses will be used on binary outcomes (e.g., fall). The choice of covariates and the structure of the data will conform to that described for H1. We anticipate that some of these exploratory analyses will be sufficiently power for statistical tests (e.g., decline in ADL), yet others (e.g., adverse fall events) will be examined for the direction and magnitude of effects rather than statistical significance.\\n\\nS2 Patient Characteristics as Moderators: Whether the effects of the intervention on patient outcomes and quality of care differ by depression severity, patient location (e.g., rural vs. urban), race/ethnicity (White, Black, Hispanic, Native American), availability of social support (caregiver), health status, or cognitive impairment. Separate models will examine each patient characteristic as a moderator using mixed-effects linear or logistic regression analyses. The independent variables will include intervention and the respective hypothesized mediating (from post baseline) or moderating (from baseline) effects (described below). Initially the main effects will be tested. Then subsequent models will examine the incremental contribution of the interaction of intervention with each of the hypothesized moderating effects.\\n\\nD10 POWER ANALYSIS Power analyses for the primary hypotheses were conducted based on the following assumptions about sample size: 5 agencies; 4 nurse teams per agency, 5 nurses per team, and 5 patients subjects per nurse. These assumptions result in a patient sample size of 500 patients (5*4*5*5). We estimate that the number of patients who consent to research interviews will be about half of the patients who are eligible based in the agency\\'s database data (i.e., 60% participation at baseline; 85% of baseline patients eligible for follow-up). Thus the number of patients in the agency\\'s database that could be included in analyses using the this source of data will be at least 1,000.\\n\\nOther assumptions for the power analyses included a two-tailed alpha = 0.05, 12 and 24 week follow-up assessments for each subject, and an attrition rate of 15%. This rate is based on our six month follow-up rates as well as our experience with other samples of community-dwelling frail elders (e.g., home care patients), where we have found that obtaining the first interview is far more difficult than following older adults overtime once they have met and talked with us. Because computer algorithms are not readily available for conducting power analyses for three-level mixed-effects models, power estimates for testing H1 and H2 are based on simulations described below, that involved 1000 simulation runs for each combination of specifications.\\n\\nH1 Depression Treatment: The simulations considered two intraclass correlations reflecting variations in level 1 (subject-level intraclass correlation within nurse) and level 2 (nurse-level intraclass correlation within team). Statistical power to detect the hypothesized effects with the anticipated sample size, will exceed >80%.\\n\\nH2 Depressive Symptoms: Power analyses was conducted based on simulation using Mixed-effects models for level 1 and level 2 level random intercepts 3-level linear mixed effects regression model. We hypothesized medium intervention effects (Cohen\\'s d) with a standardized group mean difference in HDRS change from the baseline: 0.5 and 0.6. (These correspond to differences in HDRS changes = 3.43, and 4.11 based on an estimated residual standard deviation = 6.85 of HAM-D changes from the TRIAD study.) The table shows that power to detect effect size > 0.5 is adequate (>80%).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Geriatric Depression', 'Depression Care Management', 'home healthcare', 'nurse training intervention']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '310', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression CAREPATH', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients receiving care from Nurses trained in depression care management', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression CAREPATH']}}, {'ArmGroupLabel': 'Usual Care', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Patients under the care of nurses who were trained in depression assessment and usual care', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Usual Care']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Depression CAREPATH', 'InterventionDescription': 'Nurses receive training and agency support in depression assessment and depression care management', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression CAREPATH']}}, {'InterventionType': 'Other', 'InterventionName': 'Usual Care', 'InterventionDescription': 'Nurses receive training in depression assessment and review of usual care procedures.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Usual Care']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression Severity', 'PrimaryOutcomeDescription': 'Assessment of depression severity using the Hamilton Depression Rating Scale', 'PrimaryOutcomeTimeFrame': '2 week'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Guideline Consistent change in depression treatment', 'SecondaryOutcomeDescription': 'Patient home healthcare records reviewed for evidence that patients received a change in depression treatment (e.g., antidepressant initiation, dose change, augmentation, switch)', 'SecondaryOutcomeTimeFrame': '60 Days'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nNew home healthcare patient\\nAge 65 years or older\\nDepressed Mood or Anhedonia recorded by visiting nurse\\nEnglish or Spanish speaking\\n\\nExclusion Criteria:\\n\\nHigh suicide risk, i.e. intent or plan to attempt suicide in near future as defined by the suicide risk assessment.\\nSignificant Cognitive Impairment: Mini-mental Status Exam below 20\\nSevere hearing impairment or aphasic\\nLife expectancy less than 6 months (CMS 485)', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '65 Years', 'StdAgeList': {'StdAge': ['Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Martha L Bruce, PhD, MPH', 'OverallOfficialAffiliation': 'Weill Medical College of Cornell University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Weill Cornell Medical College, Westchester Division', 'LocationCity': 'White Plains', 'LocationState': 'New York', 'LocationZip': '10605', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '21716043', 'ReferenceType': 'background', 'ReferenceCitation': 'Bruce ML, Sheeran T, Raue PJ, Reilly CF, Greenberg RL, Pomerantz JC, Meyers BS, Weinberger MI, Johnston CL. Depression care for patients at home (Depression CAREPATH): intervention development and implementation, part 1. Home Healthc Nurse. 2011 Jul-Aug;29(7):416-26. doi: 10.1097/NHH.0b013e31821fe9f7.'}, {'ReferencePMID': '21881429', 'ReferenceType': 'background', 'ReferenceCitation': 'Bruce ML, Raue PJ, Sheeran T, Reilly C, Pomerantz JC, Meyers BS, Weinberger MI, Zukowski D. Depression Care for Patients at Home (Depression CAREPATH): home care depression care management protocol, part 2. Home Healthc Nurse. 2011 Sep;29(8):480-9. doi: 10.1097/NHH.0b013e318229d75b.'}, {'ReferencePMID': '27739067', 'ReferenceType': 'derived', 'ReferenceCitation': 'Bruce ML, Lohman MC, Greenberg RL, Bao Y, Raue PJ. Integrating Depression Care Management into Medicare Home Health Reduces Risk of 30- and 60-Day Hospitalization: The Depression Care for Patients at Home Cluster-Randomized Trial. J Am Geriatr Soc. 2016 Nov;64(11):2196-2203. doi: 10.1111/jgs.14440. Epub 2016 Oct 14.'}, {'ReferencePMID': '25384017', 'ReferenceType': 'derived', 'ReferenceCitation': 'Bruce ML, Raue PJ, Reilly CF, Greenberg RL, Meyers BS, Banerjee S, Pickett YR, Sheeran TF, Ghesquiere A, Zukowski DM, Rosas VH, McLaughlin J, Pledger L, Doyle J, Joachim P, Leon AC. Clinical effectiveness of integrating depression care management into medicare home health: the Depression CAREPATH Randomized trial. JAMA Intern Med. 2015 Jan;175(1):55-64. doi: 10.1001/jamainternmed.2014.5835.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Website describing Depression CAREPATH protocol and offering free nurse e-training in depression care management as well as depression assessment using the 9-item Patient Health Questionnaire with older adults', 'SeeAlsoLinkURL': 'http://mentalhealthtrainingnetwork.org/'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 3, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01453790', 'OrgStudyIdInfo': {'OrgStudyId': '214808'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '214808-7', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'UC Davis'}]}, 'Organization': {'OrgFullName': 'University of California, Davis', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Parent Specific Depression Education and Motivation', 'OfficialTitle': 'Effectiveness of Parent Specific Depression Education and Motivation on Intent to Seek Follow-Up Care for Potential Depression Symptoms'}, 'StatusModule': {'StatusVerifiedDate': 'June 2012', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2011'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2011', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'January 2012', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'October 11, 2011', 'StudyFirstSubmitQCDate': 'October 13, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 18, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'May 24, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 30, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of California, Davis', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': \"Children's Miracle Network\", 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'This project is an investigator-initiated, randomized-controlled trial of the effectiveness of written and verbal parent-specific depression education and motivational advice in increasing participants self-disclosed intention to seek follow-up care for possible depression symptoms. The control condition is written and verbal general depression education and advice. Hypothesis: the office-based experimental intervention of written and verbal parent-specific depression and emotional health education and motivational advice increases intention to seek follow-up services for emotional health or depression, when compared to written and verbal general depression education and advice.', 'DetailedDescription': 'Maternal depression is a common problem, debilitating for mothers and affecting parenting practices with negative effects on the behavior, development, and physical health of children. The value of identifying and treating maternal depression for child development and well-being is well documented. Unfortunately, there are multiple barriers to the recognition and treatment of maternal depression. This is particularly problematic in younger women, as they are less often seen for health care. The overall objective of this project is to test whether the uptake of follow-up recommendations for potential depression by mothers identified by screening in clinical settings is improved by parent-specific targetting of depression education and motivational advice.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depressive Symptoms']}, 'KeywordList': {'Keyword': ['depression', 'treatment', 'motivation to seek follow up']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Triple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '104', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Parent-Specific Depression Education-Motivation', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Mothers receive depression education (verbal and written) with messages targeted to parent status which are drawn from previous research. They also receive motivational messages at 2 days via telephone.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Parent-Specific Depression Education and Motivation']}}, {'ArmGroupLabel': 'General Depression Education', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Mothers receive general depression education (verbal and written) which are drawn from previous research. They also receive attention control telephone calls at 2 days.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: General Depression Education-Motivation']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Parent-Specific Depression Education and Motivation', 'InterventionDescription': 'Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Parent-Specific Depression Education-Motivation']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'General Depression Education-Motivation', 'InterventionDescription': 'General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['General Depression Education']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression Follow-Up Care Seeking', 'PrimaryOutcomeDescription': \"Mothers' self-reported attempts at obtaining follow-up services for emotional health or depression.\", 'PrimaryOutcomeTimeFrame': 'at 2 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Intention to Seek Depression Follow-Up Care', 'SecondaryOutcomeDescription': 'Three item scale measure of intention to seek care (any) for follow-up of positive depression screen.', 'SecondaryOutcomeTimeFrame': 'at 2 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nParent of a child between the ages of 2 days and 12 years who is a patient of the UC Davis Pediatric Clinic.\\nPrimary, female caregiver\\nFeeling down, depressed, or hopeless or little interest or pleasure in doing things.\\nNot currently receiving care from a mental health practitioner.\\nComfortable speaking English without an interpreter.\\n\\nExclusion Criteria:\\n\\nParent of a child younger than 2 days or older than 12 years.\\nDad, Foster parent, or other short term guardian.\\nCurrently in treatment with a mental health practitioner.\\nLimited English Proficiency', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'UC Davis Medical Center, General Pediatrics', 'LocationCity': 'Sacramento', 'LocationState': 'California', 'LocationZip': '95817', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25906700', 'ReferenceType': 'derived', 'ReferenceCitation': 'Fernandez y Garcia E, Joseph J, Wilson MD, Hinton L, Simon G, Ludman E, Scott F, Kravitz RL. Pediatric-based intervention to motivate mothers to seek follow-up for depression screens: The Motivating Our Mothers (MOM) trial. Acad Pediatr. 2015 May-Jun;15(3):311-8. doi: 10.1016/j.acap.2014.11.008.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 4, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01402206', 'OrgStudyIdInfo': {'OrgStudyId': 'Madrs 2010'}, 'Organization': {'OrgFullName': 'Göteborg University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Management of Depression in Primary Care', 'OfficialTitle': 'Management of Depression in Primary Health Care: a Controlled Trial on the Effectiveness of Regular, Structured, Patient-centered Visits'}, 'StatusModule': {'StatusVerifiedDate': 'August 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2010'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2013', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2014', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 27, 2011', 'StudyFirstSubmitQCDate': 'July 25, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 26, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 15, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 16, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Göteborg University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Vastra Gotaland Region', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Most people in Sweden with mild to moderate depression are treated in primary care, but follow-up is unstructured, and we know little about whether structured, follow-up would affect the prognosis for depression and working life. The purpose of this study is to determine the effectiveness of regular, structured, patient-centered visits on mild to moderate depression.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Intervention', 'Primary health care']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '258', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Structured patient visits', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Participants in the intervention group visit their general practitioner at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Structured patient-centered follow up of depression']}}, {'ArmGroupLabel': 'Treatment as usual', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'The control group receives treatment as usual by general practitioner (no intervention).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Structured patient-centered follow up of depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Structured patient-centered follow up of depression', 'InterventionDescription': 'All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.\\n\\nThe control group receives treatment as usual (no intervention).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Structured patient visits', 'Treatment as usual']}, 'InterventionOtherNameList': {'InterventionOtherName': ['MADRS/MADRS-S depression rating scale']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Depressive symptoms', 'PrimaryOutcomeDescription': 'Depressive symptoms will be assessed using the Beck Depression Inventory (BDI-II), a self-administered questionnaire that measures the symptoms and severity of the depression.', 'PrimaryOutcomeTimeFrame': '3, 6 and 12 months.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Quality of life', 'SecondaryOutcomeDescription': \"Each patient's quality of life will be assessed using the EuroQoL-5D questionnaire that measures five dimensions of quality of life\", 'SecondaryOutcomeTimeFrame': '3, 6 and 12 months'}, {'SecondaryOutcomeMeasure': 'Prescriptions for antidepressants', 'SecondaryOutcomeDescription': 'Information on Antidepressant use will be collected from patient records from start of the study and the 12-month follow-up period', 'SecondaryOutcomeTimeFrame': '12-month follow-up period'}, {'SecondaryOutcomeMeasure': 'Change in Activity/work ability', 'SecondaryOutcomeDescription': \"Will be measured by Work Ability Index (WAI) and the Karaseks Job Strain Model Questionnaire. The Work Ability Index is used for evaluating people's work capacity and Karaseks Job Strain Model Questionnaire is used for evaluating Demands-Control in work place\", 'SecondaryOutcomeTimeFrame': '12-month follow-up period'}, {'SecondaryOutcomeMeasure': 'sick-listing data', 'SecondaryOutcomeDescription': 'Data on sick-listing is derived from primary care record fom baseline to 3 months follow up and from patient interview from 3 to 12 months', 'SecondaryOutcomeTimeFrame': '12 month follow up'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria\\n\\nAge 18 years and up\\nAttends a participating primary health care center in the region\\nDiagnosis of mild/moderate depressive disorder (new episode)\\nNo change in possible antidepressant maintenance therapy during the preceding 1 month\\nProvided written informed consent\\n\\nExclusion criteria\\n\\nAntidepressant medication initiated or changed during the preceding 1 month\\nPatient diagnosed with major depressive disorder (BDI-II >28)\\nPatients diagnosed of severe mental psychiatric disorder (i.e. bipolar disorder, antisocial personality disorder, psychosis, substance use disorder or other serious mental disorder)\\nSuicidal ideation or intentions\\nInability to speak and understand Swedish language well enough to take part in the activities required in the study.\\nCognitive impairment that makes it impossible to take part in the activities required in the study\\nDoes not provide written informed consent to participation in the study', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Cecila Björkelund, Professor', 'OverallOfficialAffiliation': 'Göteborg University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Gothenburg', 'LocationCity': 'Gothenburg', 'LocationCountry': 'Sweden'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28103816', 'ReferenceType': 'derived', 'ReferenceCitation': 'Wikberg C, Westman J, Petersson EL, Larsson ME, André M, Eggertsen R, Thorn J, Ågren H, Björkelund C. Use of a self-rating scale to monitor depression severity in recurrent GP consultations in primary care - does it really make a difference? A randomised controlled study. BMC Fam Pract. 2017 Jan 19;18(1):6. doi: 10.1186/s12875-016-0578-9.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Our homepage at University of Gothenburg (in swedish)', 'SeeAlsoLinkURL': 'http://www.medicine.gu.se/avdelningar/samhallsmedicin_folkhalsa/allmanmedicin/'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 5, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01096316', 'OrgStudyIdInfo': {'OrgStudyId': '37061-G'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R01MH085668', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH085668&Fy=all'}]}, 'Organization': {'OrgFullName': 'University of Washington', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Depression Attention for Women Now (The DAWN Study)', 'OfficialTitle': 'Reducing Disparities and Improving Care for Depression in OB-GYN Clinics: Depression Attention for Women Now (The DAWN Study)', 'Acronym': 'DAWN'}, 'StatusModule': {'StatusVerifiedDate': 'January 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 25, 2010', 'StudyFirstSubmitQCDate': 'March 29, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 31, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'June 27, 2014', 'ResultsFirstSubmitQCDate': 'August 25, 2014', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 27, 2014', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 6, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 4, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Jurgen Unutzer', 'ResponsiblePartyInvestigatorTitle': 'Professor and Chair, Psychiatry & Behavioral Sciences', 'ResponsiblePartyInvestigatorAffiliation': 'University of Washington'}, 'LeadSponsor': {'LeadSponsorName': 'University of Washington', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Major depressive disorder (MDD) is a common disabling illness that disproportionately affects women, with prevalence rates two times those of men. In addition to suffering, MDD has been shown to have a marked effect on social and vocational functioning, with increased disability, lost productivity, and excess mortality. Women with MDD have an increased prevalence of comorbid anxiety disorders and medical conditions.\\n\\nOur model of care utilizes a social worker as a depression care manager (DCM) to support both patients and physicians in optimizing care in the OB-GYN clinical setting. This intervention will be compared to usual care for depression.', 'DetailedDescription': 'A large number of women receive their routine care in OB-GYN clinics, including a disproportionate percentage of low-income and minority women. For many of these women, OG-GYNs are the only provider they see on a regular basis. OB-GYNs take care of women across their lifespan, addressing gynecologic, health care maintenance, pregnancy and primary care concerns in their everyday practices. There are multiple aspects of OG-GYN care that are uniquely suited for detection and treatment of depression, but there are also significant barriers to such care that must be addressed.\\n\\nIn this randomized controlled trial, we are testing this depression care management program for women attending two OB-GYN clinics in the University of Washington health care system. Our research aims to test the hypothesis that a depression care management intervention, integrated into the OB-GYN clinic setting, will improve treatment outcomes for depression, functional outcomes, and satisfaction with depression care. The results of our research will greatly impact clinical care by satisfying an unmet need for effective depression services for women seen in OB-GYN clinical settings.\\n\\nThe study compares a depression care management intervention, delivered by a depression care manager, to usual care for depression in the clinics. The primary aims of the study are to evaluate, compared to usual care, a depression intervention consisting of enhanced education, engagement, and depression care management (with a choice of antidepressant medication monitoring and/or provision of brief psychotherapy).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depressive Disorder']}, 'KeywordList': {'Keyword': ['mood disorders', 'depressive disorder', 'women', 'depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '205', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:\\n\\nenhanced education of patients and providers\\nengagement of patients\\ndepression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression Care Management']}}, {'ArmGroupLabel': 'Usual Care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Depression Care Management', 'InterventionDescription': \"The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Study Intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression Treatment Outcome', 'PrimaryOutcomeDescription': 'Impact of the intervention on depression treatment outcomes, including change in depressive symptoms and treatment response. In particular, the depression scale from the Hopkins Symptom Checklist 20 (SCL-20) was used to assess depression severity at the assessments. The SCL-20 ranges from 0 (no depression) to 4 (severe depression),', 'PrimaryOutcomeTimeFrame': '12 months'}, {'PrimaryOutcomeMeasure': 'Functional Outcome', 'PrimaryOutcomeDescription': 'Impact of the intervention on functional outcomes of patients. Functional impairment was measured using the Sheehan Disability Scale. The Sheehan disability scale is the average of 3 items assessing impairment in social, work and family responsibilities. Each item is rated 0 (no impairment) to 10 (totally impaired) and the 3 ratings are averaged for the Sheehan disability scale reported below.', 'PrimaryOutcomeTimeFrame': '12 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quality of Depression Care Indicators', 'SecondaryOutcomeDescription': 'Intervention impact on quality of depression care indicators and satisfaction with depression care. Number of participants receiving 4 or more mental health visits are reported. Receiving 4 or more mental health visits has previously been used in depression randomized control trials as a measure of the quality of depression treatment received by a patient', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Potential Facilitators and Barriers to Sustainability', 'SecondaryOutcomeDescription': \"Providers' and administrators' perceived barriers and facilitators to continue providing the intervention after study end.\", 'SecondaryOutcomeTimeFrame': '18 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPHQ-9 score ≥10 for Major Depressive Disorder (with 1 cardinal symptom) and/or ≥10 for Dysthymia (with 1 cardinal symptom)\\nMINI confirmation of PHQ-9 diagnoses\\nAccess to a telephone\\nEnglish-speaking\\n\\nExclusion Criteria:\\n\\nHigh suicide risk (PHQ-9 response)\\n≥2 prior suicide attempts\\nLifetime history of schizophrenia or bipolar disorder (MINI response)\\nSubstance abuse/dependence within the previous 3 months (CAGE-AID)\\nCurrent severe intimate partner violence\\nCurrently seeing a psychiatrist', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jurgen Unutzer, MD, MPH, MA', 'OverallOfficialAffiliation': 'University of Washington', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': \"Women's Clinic at Harborview Medical Center\", 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationZip': '98104', 'LocationCountry': 'United States'}, {'LocationFacility': \"Women's Health Care Center at University of Washington Medical Center (Roosevelt Clinic)\", 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationZip': '98195', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24807320', 'ReferenceType': 'result', 'ReferenceCitation': 'Melville JL, Reed SD, Russo J, Croicu CA, Ludman E, LaRocco-Cockburn A, Katon W. Improving care for depression in obstetrics and gynecology: a randomized controlled trial. Obstet Gynecol. 2014 Jun;123(6):1237-46. doi: 10.1097/AOG.0000000000000231.'}, {'ReferencePMID': '23969800', 'ReferenceType': 'result', 'ReferenceCitation': 'Cerimele JM, Vanderlip ER, Croicu CA, Melville JL, Russo J, Reed SD, Katon W. Presenting symptoms of women with depression in an obstetrics and gynecology setting. Obstet Gynecol. 2013 Aug;122(2 Pt 1):313-8. doi: 10.1097/AOG.0b013e31829999ee.'}, {'ReferencePMID': '23939510', 'ReferenceType': 'result', 'ReferenceCitation': 'LaRocco-Cockburn A, Reed SD, Melville J, Croicu C, Russo JE, Inspektor M, Edmondson E, Katon W. Improving depression treatment for women: integrating a collaborative care depression intervention into OB-GYN care. Contemp Clin Trials. 2013 Nov;36(2):362-70. doi: 10.1016/j.cct.2013.08.001. Epub 2013 Aug 9. Erratum in: Contemp Clin Trials. 2014 Jan;37(1):166.'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Intervention', 'FlowGroupDescription': 'The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:\\n\\nenhanced education of patients and providers\\nengagement of patients\\ndepression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation.\\n\\nDepression Care Management: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST,'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Usual Care', 'FlowGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '102'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '103'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '87'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '94'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '15'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '9'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '15'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '9'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'Baseline data from the intervention arms were examined for statistically significant differences using t tests, chi squares and logistic regression analyses.', 'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Intervention', 'BaselineGroupDescription': 'The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:\\n\\nenhanced education of patients and providers\\nengagement of patients\\ndepression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation.\\n\\nDepression Care Management: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST,'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Usual Care', 'BaselineGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '102'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '103'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '205'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '39.47', 'BaselineMeasurementSpread': '12.11'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '38.59', 'BaselineMeasurementSpread': '12.10'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '39.02', 'BaselineMeasurementSpread': '12.09'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '102'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '103'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '205'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Depression Treatment Outcome', 'OutcomeMeasureDescription': 'Impact of the intervention on depression treatment outcomes, including change in depressive symptoms and treatment response. In particular, the depression scale from the Hopkins Symptom Checklist 20 (SCL-20) was used to assess depression severity at the assessments. The SCL-20 ranges from 0 (no depression) to 4 (severe depression),', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': '12 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Intervention', 'OutcomeGroupDescription': 'The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:\\n\\nenhanced education of patients and providers\\nengagement of patients\\ndepression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation.\\n\\nDepression Care Management: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST,'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Usual Care', 'OutcomeGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '102'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '103'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.96', 'OutcomeMeasurementSpread': '0.65'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1.33', 'OutcomeMeasurementSpread': '0.75'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Functional Outcome', 'OutcomeMeasureDescription': 'Impact of the intervention on functional outcomes of patients. Functional impairment was measured using the Sheehan Disability Scale. The Sheehan disability scale is the average of 3 items assessing impairment in social, work and family responsibilities. Each item is rated 0 (no impairment) to 10 (totally impaired) and the 3 ratings are averaged for the Sheehan disability scale reported below.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': '12 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Intervention', 'OutcomeGroupDescription': 'The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:\\n\\nenhanced education of patients and providers\\nengagement of patients\\ndepression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation.\\n\\nDepression Care Management: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST,'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Usual Care', 'OutcomeGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '102'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '103'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3.69', 'OutcomeMeasurementSpread': '2.70'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '4.03', 'OutcomeMeasurementSpread': '2.70'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Quality of Depression Care Indicators', 'OutcomeMeasureDescription': 'Intervention impact on quality of depression care indicators and satisfaction with depression care. Number of participants receiving 4 or more mental health visits are reported. Receiving 4 or more mental health visits has previously been used in depression randomized control trials as a measure of the quality of depression treatment received by a patient', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'participants', 'OutcomeMeasureTimeFrame': '12 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Intervention', 'OutcomeGroupDescription': 'The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:\\n\\nenhanced education of patients and providers\\nengagement of patients\\ndepression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation.\\n\\nDepression Care Management: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST,'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Usual Care', 'OutcomeGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '102'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '103'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '67'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '28'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Potential Facilitators and Barriers to Sustainability', 'OutcomeMeasureDescription': \"Providers' and administrators' perceived barriers and facilitators to continue providing the intervention after study end.\", 'OutcomeMeasureReportingStatus': 'Not Posted', 'OutcomeMeasureTimeFrame': '18 months'}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Intervention', 'EventGroupDescription': \"The intervention will integrate care between a depression care manager(DCM), consulting study team (psychiatry OB-GYN physician) and OB-GYN clinic providers.\\n\\nDepression Care Management: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). The DCM in a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the 12-month intervention. Patients choose either medication or Problem-Solving Treatment. Depressive symptoms are assessed at each visit with the PHQ-9. Patients with inadequate response after 4 to 8 weeks to the first choice will switch or combine treatments. DCMs partcipate in weekly caseload review with a psychiatrist and Ob-Gyn physician who make treatment recommendations that the DCM then communicates to the patient's own Ob-Gyn physician who writes all prescriptions.\", 'EventGroupSeriousNumAffected': '1', 'EventGroupSeriousNumAtRisk': '102', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '102'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Usual Care', 'EventGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.', 'EventGroupSeriousNumAffected': '1', 'EventGroupSeriousNumAtRisk': '103', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '103'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Psychiatric ER visits or hospitalization', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'We assessed at each objective follow-up all psychiatric emergency room visits and psychiatric hospitalizations. These were also spontaneously sent to us via EMR if the ER visit or hospitalization occurred in the University hospitals', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '102'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '103'}]}}]}}, 'MoreInfoModule': {'LimitationsAndCaveats': {}, 'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Jurgen Unutzer MD MPH MA, Professor and Chair', 'PointOfContactOrganization': 'Dept Psychiatry & Behavioral Sciences University of Washington', 'PointOfContactEMail': 'unutzer@uw.edu', 'PointOfContactPhone': '206-543-3752'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 6, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04218214', 'OrgStudyIdInfo': {'OrgStudyId': '2017-0716'}, 'Organization': {'OrgFullName': 'RAND', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Mixed Methods Implementation Evaluation of an Integrated Depression and Microfinance Program for Women in Vietnam', 'OfficialTitle': 'LIFE-DM Implementation Study: A Mixed Methods Implementation Evaluation of an Integrated Depression and Microfinance Program for Women in Vietnam', 'Acronym': 'LIFE-DM'}, 'StatusModule': {'StatusVerifiedDate': 'November 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 7, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 31, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 11, 2018', 'StudyFirstSubmitQCDate': 'January 2, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 6, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 2, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 6, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Victoria K. Ngo, PhD', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'RAND'}, 'LeadSponsor': {'LeadSponsorName': 'RAND', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Grand Challenges Canada', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Basic Needs Vietnam', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Danang Psychiatric Hospital', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This is an implementation project to develop a model to support implementation of LIFE-DM, an evidence-based practice (EBP) program that integrates depression management with microfinance services to address both poverty and depression among low-income women in Vietnam. This evaluation is a mixed methods study that will 1) describe the development of community-partnered implementation process, 2) study the effectiveness of the training and implementation support plan on provider and patient outcomes, and 3) identify factors that impact implementation success.', 'DetailedDescription': 'Livelihood Integration for Effective Depression Management (LIFE-DM) aims to address the dual challenges of poverty and depression faced by women in Vietnam by integrating evidence-based treatment for depression management and microfinance services. With funding from NIMH, the investigators established initial evidence for the effectiveness of LIFE-DM in reducing depression and improving functioning, social support, self-efficacy, and income at six months. These treatment effects were maintained at twelve months, suggesting that the LIFE-DM program may be an effective strategy to break the cycle of depression and poverty in low-income women.\\n\\nFor the Grand Challenges of Canada (GCC) Transition to Scale Grant, the investigators developed a model to scale up the program in the public health and social system across two provinces, Danang and Thua Thien Hue through 1) the training of local trainers from the psychiatric hospital to support local implementation, 2) development of a supervision model, and 3) use of a learning collaborative.\\n\\nTo evaluate the success of the model, the investigators will conduct a mixed methods implementation study that will assess implementation and patient outcomes according to the RE-AIM framework, as well as identify barriers and facilitators to implementation.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['depression', 'poverty']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'Yes', 'TargetDuration': '6 Months', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '141', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'LIFE-DM Group', 'ArmGroupDescription': \"The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and microfinance loans of 2 million VND. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union.\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)', 'InterventionDescription': \"Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['LIFE-DM Group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Livelihood Integration for Effective Depression Management', 'behavior activation', 'problem solving', 'microfinance']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Provider Adoption of LIFE-DM and Depression Care - Count', 'PrimaryOutcomeDescription': 'Delivery of LIFE-DM and depression care components (Counts of depression care components delivered - # of screening, assessment, LIFEDM, individual therapy, medication, loans)', 'PrimaryOutcomeTimeFrame': 'one year'}, {'PrimaryOutcomeMeasure': 'Provider Adoption of LIFE-DM and Depression Care - Percentage', 'PrimaryOutcomeDescription': 'Delivery of LIFE-DM and depression care components (% of depression care components delivered - screening, assessment, LIFEDM, individual therapy, medication, loans based on eligible cases)', 'PrimaryOutcomeTimeFrame': 'one year'}, {'PrimaryOutcomeMeasure': 'Patient Depression Scores (PHQ) Change from Baseline to 6 month', 'PrimaryOutcomeDescription': 'Patients will be assessed for depression using self-reported depression measure (PHQ). The Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders. The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as \"0\" (not at all) to \"3\" (nearly every day). Total scores are used and they range from 0 to 27, with PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively.', 'PrimaryOutcomeTimeFrame': '0, 6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Provider Participation', 'SecondaryOutcomeDescription': 'Provider Participation in Training Activities (Count / % of workshop attendance, supervision meetings, and learning collaborative meetings)', 'SecondaryOutcomeTimeFrame': '0-12 months'}, {'SecondaryOutcomeMeasure': 'Provider Implementation Quality', 'SecondaryOutcomeDescription': 'Supervisor Rated LIFE-DM session adherence and quality. Supervision of groups involve observation of group facilitation by supervisors, who provide adherence and quality ratings of sessions. Each item is assessed on a 4 point scale - 0 (did not do), 1 (delivered but poor), 2 (average), and 3 (excellent). The items are averaged to provide a session specific score of adherence and quality. Session adherence / quality scores are used to compute provider level adherence and quality averages. Each supervisor was expected to provide ratings for a minimum of 3 assessments out of the 12 group sessions. These session ratings are used to compute the average adherence and quality score for each provider.', 'SecondaryOutcomeTimeFrame': 'throughout the study implementation period, about 1 year'}, {'SecondaryOutcomeMeasure': 'Implementation Barriers and Facilitators', 'SecondaryOutcomeDescription': 'Qualitative Interviews of Providers and Program Staff to Assess Barriers and Facilitators of Implementation', 'SecondaryOutcomeTimeFrame': 'one year'}, {'SecondaryOutcomeMeasure': 'Change in Patient Functioning', 'SecondaryOutcomeDescription': 'Patient - SF-12 - Change in functioning from baseline to 6 months. The SF-12 Health Survey is a 12-item subset of the SF-36v2™ that measures the same eight domains of health (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health). It is a brief, reliable measure of overall health status. Scores are calibrated so that 50 is the average score or norm. This norm-based score allows comparison among the three surveys and across the more than 19,000 studies published in the past 20 years', 'SecondaryOutcomeTimeFrame': '0 and 6 months'}, {'SecondaryOutcomeMeasure': 'Change in Patient Family Functioning', 'SecondaryOutcomeDescription': \"Patient - McMaster Family Functioning Scale - Change from baseline to 6 months. This is a 12 item scale (on a 4 point scale). the average score across items is used to determine the degree of problematic family functioning. A score of 2.00 or above indicates problematic family functioning. The higher the score, the more problematic the family member perceives the family's overall functioning.\", 'SecondaryOutcomeTimeFrame': '0 and 6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ndepression - based on Patient Health Questionnaire Total Score = > 9\\nlow-income\\nfemale\\nages 18 - 60\\n\\nExclusion Criteria:\\n\\npsychosis risk\\nmania risk\\nsubstance abuse risk\\nhigh suicide risk\\nphysical disabilities\\nsignificant cognitive impairments', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'GenderBased': 'Yes', 'GenderDescription': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '60 Years', 'StdAgeList': {'StdAge': ['Adult']}, 'StudyPopulation': 'Study participants are recruited from community health clinics that are implementing LIFE-DM and depression care services in the GCC funded transition to scale grant. These participants are 18-60 years old, have elevated depressive symptoms (PHQ 9 > 9), have economic disadvantage, and are interested in participating in an integrated depression and livelihood program. Patients with severe mental illness, such as psychosis, mania, substance abuse, or high risk of suicide are also excluded and referred to psychiatric hospital for higher level of care. Those who have disabilities, significant cognitive impairments, and chronic illness that may interfere with their ability to participate in group therapy are also excluded and referred to other more individualized support.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Victoria Ngo, PhD', 'OverallOfficialAffiliation': 'RAND', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Commune Health Stations', 'LocationCity': 'Huế', 'LocationState': 'Thua Thien Hue', 'LocationCountry': 'Vietnam'}, {'LocationFacility': 'Commune Health Stations', 'LocationCity': 'Da Nang', 'LocationCountry': 'Vietnam'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 7, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02239367', 'OrgStudyIdInfo': {'OrgStudyId': '1401014663'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'P30MH085943', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=P30MH085943&Fy=all'}]}, 'Organization': {'OrgFullName': 'Weill Medical College of Cornell University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Depression Decision Aid: Feasibility Pilot', 'OfficialTitle': 'Electronic Depression Decision Aid for Nurses in Primary Care: Development and Implementation in a Diverse Low-Income Population'}, 'StatusModule': {'StatusVerifiedDate': 'January 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 30, 2014', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 13, 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 13, 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'September 4, 2014', 'StudyFirstSubmitQCDate': 'September 10, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 12, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 23, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 25, 2017', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Weill Medical College of Cornell University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The goal of this proposed pilot study is to test the feasibility and acceptability of a Depression Decision Aid (DDA) protocol integrated into the Electronic Health Record (EHR) and used by nurses with depressed ambulatory care patients. The Depression Decision Aid protocol is a streamlined adaptation of an in-person Shared Decision-Making (SDM) intervention, and its goal is to increase patient involvement in clinically appropriate treatment decision-making as a way of strengthening treatment engagement and outcomes. The protocol guides ambulatory care nurses in helping depressed patients (Patient Health Questionnaire-9 [PHQ-9] >10) develop informed treatment preferences through a process of education and values clarification. We will target patients in the general medical clinic, whether currently receiving depression treatment or not, because depression is highly prevalent but often poorly managed in this population.', 'DetailedDescription': \"The aims of this project are to evaluate the acceptability and feasibility of an electronic Depression Decision Aid protocol with nurses and patients using questionnaire and administrative data.\\n\\nOne to two nurses will deliver the Decision Aid protocol to 40 low-income patients (aged 21 and over) scoring >10 via routine PHQ-9 screening. Consenting nurses will be assessed regarding their satisfaction with the protocol following its use with each patient subject. Nurse fidelity to the protocol will be evaluated via their documentation of protocol use in the EHR. Consenting patient subjects will be assessed at baseline; week 1 to determine their decision about depression treatment, satisfaction with the decision-making process; and week 12 to determine treatment initiation or change, treatment adherence, and depressive status. Medical records will also be examined for documentation of medication prescription and other depression treatments.\\n\\nThe study will test the following hypothesis concerning the Depression Decision Aid protocol:\\n\\n1. Feasibility and Acceptability: a) At least 85% of each nurse's intervention sessions will meet fidelity standards via Electronic Health Record (EHR) data; b) Nurses will report high levels of satisfaction with the Decision Aid; c) Patients will report high levels of satisfaction with the decision-making process;\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '18', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression Decision Aid protocol', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention. Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower the elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression Decision Aid']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Depression Decision Aid', 'InterventionDescription': 'The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression Decision Aid protocol']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Shared Decision Making']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Use of Depression Decision Aid protocol', 'PrimaryOutcomeDescription': \"The number of nurse's intervention sessions based on Electronic Health Record data\", 'PrimaryOutcomeTimeFrame': '12 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Satisfaction with the Decision Aid Measure', 'SecondaryOutcomeDescription': 'The Nurse Satisfaction Scale includes a measure of usefulness, clarity, ease of use, and feasibility in terms of timing when using the Decision Aid.', 'SecondaryOutcomeTimeFrame': '12 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n21 years and older\\nMedical outpatient presenting to the Lincoln Hospital ambulatory care clinic or geriatric sub-specialty clinic\\nScreen positive for depression (Patient Health Questionnaire-9 score of 10 or greater)\\n\\nExclusion Criteria:\\n\\nPresence of significant alcohol or substance abuse, psychotic disorder, or bipolar disorder\\nHigh suicide risk\\nCognitive impairment: Mini Mental Status Exam (MMSE) score less than 24.\\nAcute or severe medical illness (ie. delirium, metastatic cancer, decompensated cardiac, liver, or kidney failure, major surgery, stroke, or myocardial infarction during the three months prior to entry.\\nInability to speak English or Spanish\\nAphasia interfering with communication', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '21 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Patrick J Raue, Ph.D.', 'OverallOfficialAffiliation': 'Weill Medical College of Cornell University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Lincoln Hospital- the New York City Health and Hospitals Corporation (HHC)', 'LocationCity': 'Bronx', 'LocationState': 'New York', 'LocationZip': '10451', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 8, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02378272', 'OrgStudyIdInfo': {'OrgStudyId': 'RS 1938-2013'}, 'Organization': {'OrgFullName': 'Göteborg University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Care Manager - Coordinating Care for Person Centered Management of Depression in Primary Care', 'OfficialTitle': 'RCT on Care Manager Organization for Management of Mild-moderate Depression in the Primary Care Setting, Sweden', 'Acronym': 'PRIM-CARE'}, 'StatusModule': {'StatusVerifiedDate': 'April 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 31, 2017', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 2, 2015', 'StudyFirstSubmitQCDate': 'March 3, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 4, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'April 25, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 29, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Göteborg University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': \"The aim of the project is to explore if a complementary addition of a care manager for depression treatment in the primary care setting has positive effects concerning reduction of the patients' depressive symptoms as well as improvement of daily function and quality of life in a short- and long-term perspective compared with the traditional Swedish primary care organization. The aim is also to evaluate the care manager function in a health economic perspective.\\n\\nThe specific aims are to develop and evaluate an evidence-based care manager program for patients with mild to moderate depression and to compare the evidence-based care manager program to treatment as usual (TAU) in terms of their short- and long-term effects on symptom remission, treatment adherence, care satisfaction, and self-efficacy as well as to perform a cost - effectiveness analysis of the care manager program, i.e. to evaluate the effects of the program on patients' health in relation to the running costs of the program.\", 'DetailedDescription': \"Methods The research questions will be tested in a randomised controlled trial with follow ups 3 and 6 months in the primary care setting in cooperation between universities of Gothenburg, Karolinska Institute and primary care centres (PCC) of regions/county councils of Västra Götaland, and Dalarna.\\n\\nDesign A cluster randomized controlled trial of two groups (intervention and control). Randomization will be at the level of the primary care centers (PCCs).\\n\\nPopulation of study Patients aged 18 and up that visit one of 20 different urban and rural PCCs.\\n\\nRandomization All PCCs in the participating regions without employed onsite mental health professionals are invited to participate in the study. Around twenty practices will be matched into 10 blocks by depression treatment practices, thereafter 1 practice from each block will be randomly assigned to receive the care manager intervention program.\\n\\nIntervention At the intervention practices, a district nurse will apply around 15-25% of working time as care coordinator for management of care for the patients with depression. Before patient recruitment begins, physicians and the nurse/district nurse (care manager) will participate in sessions for training in providing clinical services (patient information and education on patient's preferred treatment, assessment of patient's depressive symptoms and regular telephone contacts, follow up visits etc).\\n\\nRecruitment of patients and Data collection Patients aged 18 and up that visit primary health care centres and are diagnosed by the General Practitioner (GP) with light/medium depression disorder according to PRIME-MD (4). The patients will be monitored up to 6 months after inclusion in the study by an individual interview (first visit, 3 and 6 months).\\n\\nAll parameters will be assessed at baseline and 3 and 6 months; prescription of antidepressants, number of days of labour lost, socio-demographic and economic variables, alcohol consumption, physical activity, and ethnicity. BDI-II, EuroQoL-5D, Work Ability Instrument (WAI) Karasek Job strain Model , medication, other treatment (psychological, counselling, or other).\\n\\nFor somatic health reasons, also blood pressure and p-glucose will be monitored, and blood samples for bio-bank storage.\\n\\nOutcome criteria Change in: depression symptoms (BDI-II), work ability index (WAI), Job strain (Karasek), EQ-5D, QALYs from baseline to 3 and 6 months. Amount of sick listing (days, %), days of labour lost.\\n\\nStatistical analysis Analysis of covariance, controlling for baseline value, will be used to estimate the overall treatment effectiveness (difference in score) at final follow-up. Subgroup analysis by gender as well as age adjustments will also be performed.\\n\\nPower calculation The primary variable is the level of depression (as measured by the BDI-II) and analyzed in an ANCOVA model with repeated measures. In order to detect an effect of 3 units in the difference between the two groups, with a power of 80% and a significance level of 10% (two-sided) about 200 patients is needed in each group (9). The underlying assumption is a standard deviation in the group of 10 units, a within-subject correlation of 0.4, and a within-cluster-correlation of 0.1, i.e. a design effect of 1.9 to correct for having a cluster analysis.\\n\\nCost-effectiveness analysis A cost- effectiveness analysis (CEA) with quality-adjusted life years (QALY) as measure of effect will be performed.\\n\\nThe region Västra Götaland has proclaimed interest in the study, and financially supports the study.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Care Manager', 'Primary Care', 'Depressive symptoms', 'quality of life', 'return to work']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '376', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Care manager for depression', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'A district nurse will apply around 15-25% of working time as care coordinator (care manager for depression) at PCC for management of care for all recruited patients with depression', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: care manager for depression']}}, {'ArmGroupLabel': 'Treatment As Usual', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Management of recruited patients with depression continued as usually applied at PCC'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'care manager for depression', 'InterventionDescription': \"District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Care manager for depression']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change of level of depression (Self-reported level of depressive symptoms measured by Beck Depression Inventory II)', 'PrimaryOutcomeDescription': 'Self-reported level of depressive symptoms measured by Beck Depression Inventory II', 'PrimaryOutcomeTimeFrame': '0- 6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Sick-listing (Amount of sick-listing days during 0-6 months observation period)', 'SecondaryOutcomeDescription': 'Amount of sick-listing days during 0-6 months observation period', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Change of level of job strain (Perception of job strain measured by Karasek Job Strain Model)', 'SecondaryOutcomeDescription': 'Perception of job strain measured by Karasek Job Strain Model', 'SecondaryOutcomeTimeFrame': '0-6 months'}, {'SecondaryOutcomeMeasure': 'Change of level of Quality of Life (Self-reported level of perceived Quality of Life measured by EQ-5D)', 'SecondaryOutcomeDescription': 'Self-reported level of perceived Quality of Life measured by EQ-5D', 'SecondaryOutcomeTimeFrame': '0- 6 months'}, {'SecondaryOutcomeMeasure': 'Change of level of Work Ability (Self-reported level of perceived work ability measured by Work Ability Index)', 'SecondaryOutcomeDescription': 'Self-reported level of perceived work ability measured by Work Ability Index', 'SecondaryOutcomeTimeFrame': '0 - 6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ndiagnosed mild-moderate depression,\\n18 years an up,\\nattending primary care center\\n\\nExclusion Criteria:\\n\\nschizophrenia,\\nabuse/addiction,\\npsychosis,\\nbipolar syndrome,\\nsuicidal ideation or earlier suicide attempt,\\nongoing deep depression,\\ngeneralized anxiety syndrome,\\nnot communicable in Swedish', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Cecilia Björkelund', 'OverallOfficialAffiliation': 'Göteborg University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Department of Primary Health Care, Sahlgrenska Academy', 'LocationCity': 'Gothenburg', 'LocationState': 'Region Västra Götaland', 'LocationZip': '40530', 'LocationCountry': 'Sweden'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '29426288', 'ReferenceType': 'background', 'ReferenceCitation': 'Björkelund C, Svenningsson I, Hange D, Udo C, Petersson EL, Ariai N, Nejati S, Wessman C, Wikberg C, André M, Wallin L, Westman J. Clinical effectiveness of care managers in collaborative care for patients with depression in Swedish primary health care: a pragmatic cluster randomized controlled trial. BMC Fam Pract. 2018 Feb 9;19(1):28. doi: 10.1186/s12875-018-0711-z.'}, {'ReferencePMID': '30420353', 'ReferenceType': 'background', 'ReferenceCitation': 'Holst A, Ginter A, Björkelund C, Hange D, Petersson EL, Svenningsson I, Westman J, André M, Wikberg C, Wallin L, Möller C, Svensson M. Cost-effectiveness of a care manager collaborative care programme for patients with depression in primary care: economic evaluation of a pragmatic randomised controlled study. BMJ Open. 2018 Nov 12;8(11):e024741. doi: 10.1136/bmjopen-2018-024741.'}, {'ReferencePMID': '31351444', 'ReferenceType': 'derived', 'ReferenceCitation': 'Svenningsson I, Petersson EL, Udo C, Westman J, Björkelund C, Wallin L. Process evaluation of a cluster randomised intervention in Swedish primary care: using care managers in collaborative care to improve care quality for patients with depression. BMC Fam Pract. 2019 Jul 27;20(1):108. doi: 10.1186/s12875-019-0998-4.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T6054', 'ConditionBrowseLeafName': 'Quality of Life', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 9, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01277432', 'OrgStudyIdInfo': {'OrgStudyId': 'CRE-2010-281'}, 'Organization': {'OrgFullName': 'Chinese University of Hong Kong', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Prevalence Study of Depression in Chinese Patients With Type 2 Diabetes (HK13)', 'OfficialTitle': 'A Multicentre Study to Investigate the Prevalence and Factors Associated With Depression in Chinese Patients With Type 2 Diabetes', 'Acronym': 'DD2'}, 'StatusModule': {'StatusVerifiedDate': 'August 2015', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2010'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'February 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 14, 2011', 'StudyFirstSubmitQCDate': 'January 14, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 17, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 20, 2015', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 24, 2015', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Juliana Chan', 'ResponsiblePartyInvestigatorTitle': 'Professor Chan', 'ResponsiblePartyInvestigatorAffiliation': 'Chinese University of Hong Kong'}, 'LeadSponsor': {'LeadSponsorName': 'Chinese University of Hong Kong', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Asia Diabetes Foundation', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': \"The investigators aim to:\\n\\nEstimate the prevalence of depression in a consecutive cohort of Chinese patients diagnosed with Type 2 Diabetes (T2D) living in areas of China with different socioeconomical affluence\\nExamine patients' awareness of the frequent coexistence of these 2 conditions\\nAnalyze the associations between depression and T2D, in particularly the role of metabolic control, socioeconomical status and cognitive-psychological-behavioral factors\\nTo document the predisposing, precipitating and perpetuating factors for depression and their interrelationships in Chinese type 2 diabetic patients\", 'DetailedDescription': 'Overall objectives of this multicentre study are to document;\\n\\nthe prevalence and diagnosis rates of depression in type 2 diabetic (T2D) patients attending 7 centres in 4 major cities in China including Hong Kong (HK), Shanghai (SH), Guangzhou (GZ) and Beijing (BJ)\\nthe predisposing, precipitating and perpetuating factors for depression and their interrelationships in Chinese T2D patients\\n\\nThis study includes two phases. In the phase I pilot study, the investigators shall confirm and compare the validity of Patient Health Questionnaire (PHQ-9) and Clinical Epidemiological Scale for Depression (CESD) in predicting depression in Chinese T2D patients using the SCID as a gold standard. Other questionaires which measure personal and external factors, diabetes associated distress and anxiety, quality of life, mental wellness, self efficacy, health-related behavior and compliance will also be used to document possible predisposing, precipitating and perpetuating factors for depression in diabetes. These results will be used to select a set of tools which are most informative in the evaluation of depression and mental wellness in T2D patients based on their predictions for health behavior, compliance and metabolic control. A random sample of 100 T2D patients will be recruited from 3 Diabetes Centres in GZ, BJ and HK who will complete a full set of questionnaires and structured clinical assessments using a web-based electronic portal. In each of the three centres, all patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ>10 and/or CES>16) and a random sample of 20 subjects with no or mild symptoms will undergo face-to-face interview by psychiatrists using the following instruments: SCID, BDI, SSI-28 (somatization), Coping (Brief Cope 28, Chinese version).\\n\\nIn Phase II, the investigators shall use a subset of the most informative questionaires to document the rates of depression (diagnosed and undiagnosed) and cognitive-psychological-behavioral factors in a consecutive cohort of Chinese patients with T2D and its associations with metabolic control and psychological behavioral factors. In each of the 7 participating centres in HK, SH, BJ and GZ, 500 consecutive patients will undergo comprehensive clinical assessments for risk factors, complications and medications the JADE (Joint Asia Diabetes Evaluation) e-portal, giving a total of 3500 patients.\\n\\nThis survey which documents the rate of depression in T2D patients using similar methodologies will provide a comprehensive data set for exploratory analysis of the multicausality and heterogeneity of clinical presentation and risk factors in Chinese populations. Once this cohort is established and subject to availability of future funding, they can be followed up prospectively to validate and discover risk factors for new onset of depression. Apart from raising awareness, these data are essential in our design of care models and interventions to tailor the unmet needs of these patients. Data from this study will also provide insights into the effects of rapid acculturation and migration on the double burden of diabetes and depression in Chinese populations.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Diabetes', 'Depression']}, 'KeywordList': {'Keyword': ['Diabetes', 'Depression']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'EnrollmentInfo': {'EnrollmentCount': '3218', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Psychiatrist interview', 'ArmGroupDescription': \"All patients will receive the same assessments as the 'active comparator' arm, but in addition those patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ>10 and/or CES>16) and a random sample of subjects with no or mild symptoms will also undergo a face-to-face interview by a trained clinician or psychiatrist using the following instruments:\\n\\nMINI\\nSSI-28 (somatization)\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Psychiatrist Interview']}}, {'ArmGroupLabel': 'Depression screening', 'ArmGroupDescription': 'All study participants will undergo a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal.\\n\\nAll patients will also undergo detailed psychological and behavioral assessments using validated questionnaires.\\n\\nSeveral specialist questionnaires will also be conducted with all patients, including those on depression, self care and quality of life;\\n\\nPatient Health Questionnaire (PHQ-9)\\nDepression Anxiety and Stress Scale (DASS-21)\\nDiabetes Distress Scale (DDS-17)\\nLife events questions (Inter-Heart Study)\\nDiabetes Empowerment Scale (C-DES 20)\\nSummary of Diabetes Self Care Activities (SDSCA-15)\\nEuroqol-5D (EQ-5D)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression screening - control']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Psychiatrist Interview', 'InterventionDescription': 'Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:\\n\\nMINI\\nSSI-28 (somatization)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Psychiatrist interview']}}, {'InterventionType': 'Other', 'InterventionName': 'Depression screening - control', 'InterventionDescription': 'All study participants will undergo;\\n\\na comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal\\na detailed psychological and behavioral assessments using validated questionnaires\\nseveral specialist questionnaires on depression, self care and quality of life', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression screening']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression and psychological well-being', 'PrimaryOutcomeDescription': 'Depression (PHQ-9, CESD)\\nDepression Anxiety and Stress Scale (DASS-21)\\nDiabetes Stress Scale (DSS-17)', 'PrimaryOutcomeTimeFrame': '1 year'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Percentage of patients who attain 2 or more of the 'ABC' targets\", 'SecondaryOutcomeDescription': 'Percentage of patients who attain 2 or more of the following 3 targets:\\n\\nHbA1c <7%\\nBP <130/80 mmHg\\nLDL cholesterol <2.6 mmol/L', 'SecondaryOutcomeTimeFrame': '1 year'}, {'SecondaryOutcomeMeasure': 'Self care and Efficacy', 'SecondaryOutcomeDescription': 'Diabetes Empowerment Scale (C-DES)\\nSummary of Diabetes Self Care Activities (SDSCA-15)', 'SecondaryOutcomeTimeFrame': '1 year'}, {'SecondaryOutcomeMeasure': 'Quality of life', 'SecondaryOutcomeDescription': 'Using EuroQol-5D (EQ-5D) tool', 'SecondaryOutcomeTimeFrame': '1 year'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients diagnosed with type 2 diabetes\\nAged ≥25 and <75 years inclusive\\nChinese ethnicity\\n\\nExclusion Criteria:\\n\\nPatients with mental/physical handicap and/or difficulty in communication such as deafness, mental retardation\\nPatients with disabling diseases or reduced life expectancy such as severe heart failure, stroke, respiratory diseases, or late stages of cancer\\nPatients diagnosed with type 1 diabetes, defined as presentation with diabetic ketoacidosis or unprovoked ketosis or requirement of continuous insulin requirement within 12 months of diagnosis', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '25 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Tertiary Hospitals and community centre', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Juliana Chan, MD', 'OverallOfficialAffiliation': 'Chinese University of Hong Kong', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': '1st Affiliated Hosp, Peking University', 'LocationCity': 'Beijing', 'LocationCountry': 'China'}, {'LocationFacility': 'China-Japan Friendship Hospital', 'LocationCity': 'Beijing', 'LocationCountry': 'China'}, {'LocationFacility': 'Peking Union Hospital', 'LocationCity': 'Beijing', 'LocationCountry': 'China'}, {'LocationFacility': \"Peking University People's Hospital\", 'LocationCity': 'Bejing', 'LocationCountry': 'China'}, {'LocationFacility': 'Third Affiliated Hospital of Sun Yat-Sen University', 'LocationCity': 'Guangzhou', 'LocationCountry': 'China'}, {'LocationFacility': \"Shanghai Sixth People's Hospital\", 'LocationCity': 'Shanghai', 'LocationCountry': 'China'}, {'LocationFacility': 'YCK Diabetes Assessment Centre, Prince of Wales Hospital', 'LocationCity': 'Shatin', 'LocationCountry': 'Hong Kong'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Works of the Asia Diabetes Foundation', 'SeeAlsoLinkURL': 'http://www.adf.org.hk'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003920', 'ConditionMeshTerm': 'Diabetes Mellitus'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5702', 'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5698', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafAsFound': 'Diabetes', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10222', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M23990', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6445', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 10, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02232854', 'OrgStudyIdInfo': {'OrgStudyId': '1130230'}, 'Organization': {'OrgFullName': 'University of Chile', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Training and Supervision Program for Depression Management', 'OfficialTitle': 'Comprehensive Technology-Assisted Training and Supervision Program to Enhance Depression Management in Primary Care'}, 'StatusModule': {'StatusVerifiedDate': 'October 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2014', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 7, 2014', 'StudyFirstSubmitQCDate': 'September 2, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 5, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 24, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 25, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Graciela Rojas Castillo', 'ResponsiblePartyInvestigatorTitle': 'Dr.med. Psychyatrist', 'ResponsiblePartyInvestigatorAffiliation': 'University of Chile'}, 'LeadSponsor': {'LeadSponsorName': 'University of Chile', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'According to the literature the management of depressive disorders at primary care level is not always consistent with guidelines. The main objective of this study is to test whether a Comprehensive Technology-Assisted Training and Supervision Program will improve depression management in Primary Health Care clinics in Santiago, Chile.', 'DetailedDescription': 'A cluster randomized controlled clinical trial will be conducted in four Primary Health Care (PHC) clinics in Santiago, Chile.\\n\\nThe sample selection of the PHC clinics will be performed in two steps. Firstly, two urban municipalities of Santiago Metropolitan Region, Chile, will be randomly selected if they work with the Faculty of Medicine of the U.Chile and have at least two PHC.Municipalities with a high Human Development Index, high percentage of immigrants and older population, and Psychiatry residents working in PHC , will be excluded.Secondly in each selected municipalities,two PHC will be randomly selected for the active and control arm.\\n\\nTo detect a difference of 20%, in a one-sided model, with an alpha of 5% and power of 80%, 152 depressed persons, 76 to each group, will be required for the study. A design effect of 2.42 was estimated. After applying the design effect the sample needed increased to 368 depressed persons. Considering a retention rate of approximately 85%, 434 depressed cases will be needed required for the study, hence 109 cases in each of the 4 primary health care clinics.\\n\\nAnalysis and presentation of the results will be in accordance with CONSORT guidelines for randomized clinical trials, with the primary comparative analysis being conducted on an intention to treat basis and due emphasis placed on confidence intervals for the between-arm comparisons.\\n\\nInitially descriptive analysis to assess the balance between two groups will be conducted. The primary analysis will employ multilevel multivariable lineal regression to investigate differences in the PHQ-9 scores between groups at 3 and 6 months after randomization, adjusting for baseline outcome variable scores. Sensitivity analysis making different assumptions will be conducted to investigate the potential effects of missing data. Similar analysis will be done for the secondary outcomes measures.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '256', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression training/supervision program', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'A complex intervention, which will include:\\n\\nPrimary Health Care team training in depression\\nA focus group, after training\\nTelephone monitoring of patients\\nWeb-based supervision of clinicians', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression training/supervision program']}}, {'ArmGroupLabel': 'Usual Care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Patients in the control group will receive all the interventions that are guaranteed for persons with depression in Chile: treatment in Primary Health Care clinics with the Primary Health Care team and referral to the regional specialized psychiatric service.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Depression training/supervision program', 'InterventionDescription': 'The intervention will be composed of:\\n\\nTraining of Primary Health Care teams to ensure compliance to the \"Clinical Guidelines of the Ministry of Health for the Treatment of Depression\". Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.\\nAfter the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.\\nPrimary Health Care clinics\\' trained administrative staff will contact patients from a call-center to support treatment adherence.\\nPsychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients\\' progress, and their response to treatment.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression training/supervision program']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change from Baseline Depressive Symptomatology at 3 months', 'PrimaryOutcomeDescription': 'Depressive symptomatology measured with the Patient Health Questionnaire - Nine Item (PHQ-9) at 3 months after patient recruitment.', 'PrimaryOutcomeTimeFrame': 'Baseline , 3 months'}, {'PrimaryOutcomeMeasure': 'Change from Baseline Depressive Symptomatology at 6 months', 'PrimaryOutcomeDescription': 'Depressive symptomatology measured with the Patient Health Questionnaire - Nine Item (PHQ-9) at 6 months after patient recruitment.', 'PrimaryOutcomeTimeFrame': 'Baseline, 6 months.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Adherence to depression treatment at patient's level\", 'SecondaryOutcomeTimeFrame': '3 and 6 months after baseline.'}, {'SecondaryOutcomeMeasure': 'Change from Baseline Quality of life at 3 and 6 months', 'SecondaryOutcomeDescription': \"Quality of life at patient's level measured with the Health Survey, Short form (SF-36), at 3 months and 6 months after patient recruitment.\", 'SecondaryOutcomeTimeFrame': 'Baseline , 3 months, 6 months.'}, {'SecondaryOutcomeMeasure': 'Change from Baseline Clinical Outcomes at 3 and 6 months', 'SecondaryOutcomeDescription': \"Clinical outcomes at patient's level measured with the Outcome Questionnaire-45.2 (OQ-45.2), at 3 months and 6 months after patient recruitment.\", 'SecondaryOutcomeTimeFrame': 'Baseline , 3 months, 6 months.'}, {'SecondaryOutcomeMeasure': \"Use of Health Care services at patient's level\", 'SecondaryOutcomeDescription': \"Use of Health Care services at patient's level measured with and ad-hoc built questionnaire.\", 'SecondaryOutcomeTimeFrame': '3 and 6 months after baseline'}, {'SecondaryOutcomeMeasure': 'Rate of treated depressed cases at Primary Care team level', 'SecondaryOutcomeTimeFrame': '12 months before randomization and 12 months after.'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nsigning written informed consent\\nage between 18-65 years\\ncurrent depressive episode, according to the Mini-International Neuropsychiatric Interview (MINI)\\n\\nExclusion Criteria:\\n\\ncurrent depression treatment\\nno access to telephone', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'CESFAM Garín', 'LocationCity': 'Quinta Normal', 'LocationState': 'Santiago', 'LocationCountry': 'Chile'}, {'LocationFacility': 'CESFAM Lo Franco', 'LocationCity': 'Quinta Normal', 'LocationState': 'Santiago', 'LocationCountry': 'Chile'}, {'LocationFacility': 'CESFAM Barros Luco', 'LocationCity': 'San Miguel', 'LocationState': 'Santiago', 'LocationCountry': 'Chile'}, {'LocationFacility': 'CESFAM Recreo', 'LocationCity': 'San Miguel', 'LocationState': 'Santiago', 'LocationCountry': 'Chile'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26201546', 'ReferenceType': 'derived', 'ReferenceCitation': 'Rojas G, Martínez P, Vöhringer PA, Martínez V, Castro-Lara A, Fritsch R. Comprehensive technology-assisted training and supervision program to enhance depression management in primary care in Santiago, Chile: study protocol for a cluster randomized controlled trial. Trials. 2015 Jul 24;16:311. doi: 10.1186/s13063-015-0845-4.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 11, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01152307', 'OrgStudyIdInfo': {'OrgStudyId': 'CSR-DQ1-002'}, 'Organization': {'OrgFullName': 'University of Massachusetts, Boston', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Measuring Quality of Decisions About Treatment of Depression', 'OfficialTitle': 'Measuring Quality of Decisions About Treatment of Depression'}, 'StatusModule': {'StatusVerifiedDate': 'July 2012', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2010'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2010', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2010', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 22, 2010', 'StudyFirstSubmitQCDate': 'June 25, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 29, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'June 12, 2012', 'ResultsFirstSubmitQCDate': 'July 13, 2012', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 20, 2012', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 13, 2012', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 20, 2012', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Carol Cosenza', 'ResponsiblePartyInvestigatorTitle': 'Project Manager', 'ResponsiblePartyInvestigatorAffiliation': 'University of Massachusetts, Boston'}, 'LeadSponsor': {'LeadSponsorName': 'University of Massachusetts, Boston', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Foundation for Informed Medical Decision Making', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Massachusetts General Hospital', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this randomized controlled trial is to examine the impact of a patient decision aid on the quality of decisions about managing symptoms of depression. In particular, we will examine whether the decision aid increases knowledge about depression/managing depression symptoms and concordance between goals and treatment choices.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Depressive disorder', 'Decision Making', 'Decision Aids', 'Decision Quality Instrument']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '405', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Decision Aid', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Group receiving the decision aid (DVD/booklet)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: DVD/Booklet: Coping with Symptoms of Depression']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Group not receiving the decision aid (DVD/booklet)'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'DVD/Booklet: Coping with Symptoms of Depression', 'InterventionDescription': 'DVD and booklet that provides information about treatment choices for depression symptoms', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Decision Aid']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Decision aids', 'Shared decision making programs']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression Knowledge', 'PrimaryOutcomeDescription': 'Total knowledge score from factual questions about depression and methods for managing depression symptoms. Score is the percent of knowledge items answered correctly (0 - 100%).', 'PrimaryOutcomeTimeFrame': '2 weeks, on average'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Value Concordance', 'SecondaryOutcomeDescription': \"Measure of how concordant respondents' actual decisions about treatment for their depression are with their stated beliefs\", 'SecondaryOutcomeTimeFrame': '2 weeks, on average'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAged 18+\\nIn the last 12 months, talked to a health care provider about starting or stopping a treatment (prescription medicine for depression or counseling)\\n\\nExclusion Criteria:\\n\\nnone', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Patricia M Gallagher, PhD', 'OverallOfficialAffiliation': 'Center for Survey Research, University of Massachusetts, Boston', 'OverallOfficialRole': 'Study Director'}, {'OverallOfficialName': 'Karen R Sepucha, PhD', 'OverallOfficialAffiliation': 'Massachusetts General Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Center for Survey Research - University of Massachusetts Boston', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02125', 'LocationCountry': 'United States'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'Eligible patients received a mailed survey and were randomly selected to receive a DVD or no DVD and booklet about depression.', 'FlowRecruitmentDetails': 'Patients were recruited through online and newspaper ads by the Center for Survey Research in 17 cities: Atlanta, Baltimore, Boston, Chicago, Dallas-Ft. Worth, Denver, Detroit, Ft. Myers, Houston, Los Angeles, Minneapolis, New York, Phoenix, Portland, Raleigh-Durham, San Francisco, Washington, D.C. August 5, 2010-Jan 10, 2011.', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Decision Aid', 'FlowGroupDescription': 'Group receiving the decision aid (DVD/booklet)'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Control', 'FlowGroupDescription': 'Group not receiving the decision aid (DVD/booklet)'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '191'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '214'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '191'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '214'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '0'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Decision Aid', 'BaselineGroupDescription': 'Group receiving the decision aid (DVD/booklet)'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Control', 'BaselineGroupDescription': 'Group not receiving the decision aid (DVD/booklet)'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '191'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '214'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '405'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '186'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '209'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '395'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '10'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '39.5', 'BaselineMeasurementSpread': '13.4'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '43.5', 'BaselineMeasurementSpread': '16.8'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '42', 'BaselineMeasurementSpread': '15.4'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '122'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '144'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '266'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '69'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '70'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '139'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '191'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '214'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '405'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Depression Knowledge', 'OutcomeMeasureDescription': 'Total knowledge score from factual questions about depression and methods for managing depression symptoms. Score is the percent of knowledge items answered correctly (0 - 100%).', 'OutcomeMeasurePopulationDescription': 'Participants were randomized to receive the DVD and booklet.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'percent of correct responses', 'OutcomeMeasureTimeFrame': '2 weeks, on average', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Decision Aid', 'OutcomeGroupDescription': 'Group receiving the decision aid (DVD/booklet)'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Control', 'OutcomeGroupDescription': 'Group not receiving the decision aid (DVD/booklet)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '191'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '214'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '67.0', 'OutcomeMeasurementSpread': '14.1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '63.6', 'OutcomeMeasurementSpread': '12.5'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'We tested for a difference in the mean total knowledge score between the decision aid and control groups using independent t-test (2 sided). With 100 patients in each arm, the study had more than 90% power to detect a 10% difference in knowledge assuming a common standard deviation of 18%.', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.01', 'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided', 'OutcomeAnalysisParamType': 'Mean Difference (Net)', 'OutcomeAnalysisParamValue': '3.42', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.76', 'OutcomeAnalysisCIUpperLimit': '6.09', 'OutcomeAnalysisDispersionType': 'Standard Deviation', 'OutcomeAnalysisDispersionValue': '1.6'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Value Concordance', 'OutcomeMeasureDescription': \"Measure of how concordant respondents' actual decisions about treatment for their depression are with their stated beliefs\", 'OutcomeMeasureReportingStatus': 'Not Posted', 'OutcomeMeasureTimeFrame': '2 weeks, on average'}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': 'August 5, 2010 through January 10, 2011.', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Decision Aid', 'EventGroupDescription': 'Group receiving the decision aid (DVD/booklet)', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '191', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '191'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Control', 'EventGroupDescription': 'Group not receiving the decision aid (DVD/booklet)', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '214', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '214'}]}}, 'MoreInfoModule': {'LimitationsAndCaveats': {}, 'CertainAgreement': {'AgreementPISponsorEmployee': 'No', 'AgreementRestrictiveAgreement': 'No'}, 'PointOfContact': {'PointOfContactTitle': 'Dr. Karen Sepucha', 'PointOfContactOrganization': 'Massachusetts General Hospital', 'PointOfContactEMail': 'ksepucha@partners.org', 'PointOfContactPhone': '617-724-3350'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 12, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01342536', 'OrgStudyIdInfo': {'OrgStudyId': '2011-0109, 2011-0234'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MD005905-01A1', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MD005905-01A1&Fy=all'}]}, 'Organization': {'OrgFullName': 'University of Wisconsin, Madison', 'OrgClass': 'OTHER'}, 'BriefTitle': 'African American Depression Intervention Trial (AADI)', 'OfficialTitle': 'A Culturally Adapted Depression Intervention for African American Adults', 'Acronym': 'AADI'}, 'StatusModule': {'StatusVerifiedDate': 'May 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 14, 2011', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 25, 2011', 'StudyFirstSubmitQCDate': 'April 26, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 27, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'May 6, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 8, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of Wisconsin, Madison', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute on Minority Health and Health Disparities (NIMHD)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Primary Aim 1: Examine effectiveness of the Oh Happy Day Class (OHDC) compared to the Coping With Depression (CWD)in increasing retention, adherence, engagement, satisfaction, and treatment-seeking. The investigators hypothesize the OHDC compared to the CWD will result in greater increases in: 1a. retention, 1b. adherence, 1c. engagement, and 1d. satisfaction at the middle and end of the intervention, and 2.e. greater increase in treatment-seeking 3-, 6-, 9-, and 12- months post-intervention. Outcome measures: logs: attendance, homework completion, class-participation level; Client Satisfaction Inventory; and Cornell Service Index. Primary Aim 2: Examine effectiveness of the OHDC in reducing symptoms of depression at the middle and immediate end of the intervention, and 3-, 6-, 9-, and 12- months post-intervention. The investigators hypothesize the OHDC will result in greater reduction in depressive symptoms compared to the CWD at 3-months post-intervention. Outcome measures: Center for Epidemiologic Studies Depression Scale and Quick Inventory of Depression Symptoms. Secondary Aim 3: Examine the effectiveness of the OHDC in improving self-reports of mental and physical health status and reducing self-reports of perceived disability. The investigators hypothesize the OHDC compared to the CWD will result in greater self-report of: 3a. improved mental and physical health status, and 3b. reduced self-report of disability at the immediate end of the intervention and 3-,6-, 9-, 12- months post-intervention. Outcome measures: SF-12 Health Survey, and World Health Organization Disability Assessment Schedule.\\n\\nPublic Health Impact: Based on CAI research, the OHDC has the potential to be four times more effective than the CWD. If our hypotheses are proven, the OHDC will be the first evidence-based culturally adapted depression intervention designed specifically for African American men and women between the ages of 30-60.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Major Depressive Disorder']}, 'KeywordList': {'Keyword': ['Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '160', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'lifestyle counseling (OHDC)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Oh Happy Day Class (OHDC) is a culturally-specific, 12-week cognitive behavioral group counseling intervention designed for African American adults experiencing depression', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)']}}, {'ArmGroupLabel': 'lifestyle counseling (CWD)', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Coping with Depression Course (CWD) is a 8-week cognitive behavioral group counseling depression intervention', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)', 'InterventionDescription': 'The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.\\n\\nThe CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.\\n\\nArms: lifestyle counseling (OHDC), lifestyle counseling (CWD)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['lifestyle counseling (CWD)', 'lifestyle counseling (OHDC)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Center for Epidemiologic Studies Depression Scale (CES-D)', 'PrimaryOutcomeDescription': 'Center for Epidemiologic Studies Depression Scale (CES-D). The CES-D scale is a 20-item self-report inventory developed by NIMH to assess the frequency and severity of depression symptoms in the past week. Respondents indicate how often each symptom was experienced during the past week on a four-point scale from \"Rarely or none of the time (0)\", \"Some or a little of the time (1)\", \"Occasionally or a moderate amount of the time (2)\", or \"Most or all of the time (3)\". Item scores are summed for analyses, with a possible range 0-60. A standard cutoff score of 16 indicates depressive symptoms.', 'PrimaryOutcomeTimeFrame': 'up to 4 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quick Inventory of Depressive Symptomatology (QIDS)', 'SecondaryOutcomeDescription': 'The 16-item Quick Inventory of Depressive Symptomatology (QIDS) using DSM-IV criteria assesses depressive symptom severity and symptom change. The QIDS has a clinician-rated and self-report format. Studies show high internal consistency for the QIDS-CR (0.85) and QIDS-SR(0.86). Scores range from 0-27 and higher scores suggest higher severity. The QIDS also has high concurrent validity with the SF-12.', 'SecondaryOutcomeTimeFrame': 'up to 4 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nInclusion criteria. Self-identified African-American men and women, between the ages of 30 to 60, with symptoms of depression as evidenced by data from the Composite International Diagnostic Interview 2.1 (CIDI). Although age of inclusion is broad, our pilot studies have shown positive outcomes with mixed aged groups\\n\\nExclusion Criteria:\\n\\nExclusion criteria. Individuals will be excluded from the study if they have: (1) self-reported alcohol or other drug abuse/dependence, (2) major psychotic illnesses, such as schizophrenia as evidenced by results of the CIDI, (3) self-reported changes in antidepressants (dosage or type) less than 6 weeks prior to participating in the study, (4) self-report of current psychotherapy treatment, or (5) self-report of current suicidal ideations (our psychiatrist will conduct additional suicide risk assessment and facilitate referral for appropriate care.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '30 Years', 'MaximumAge': '60 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Earlise C Ward, Ph.D.', 'OverallOfficialAffiliation': 'University of Wisconsin, Madison', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Mental Health Center of Dane County', 'LocationCity': 'Madison', 'LocationState': 'Wisconsin', 'LocationZip': '53703', 'LocationCountry': 'United States'}, {'LocationFacility': 'Milwaukee Health Services, INC', 'LocationCity': 'Milwaukee', 'LocationState': 'Wisconsin', 'LocationZip': '53216', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000003865', 'ConditionMeshTerm': 'Depressive Disorder, Major'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafAsFound': 'Major Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 13, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01014312', 'OrgStudyIdInfo': {'OrgStudyId': 'P30MH085943-02', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=P30MH085943-02&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'P30MH085943-02', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=P30MH085943-02&Fy=all'}, {'SecondaryId': 'P30MH085943', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=P30MH085943&Fy=all'}, {'SecondaryId': 'DATR A4-GPC', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'National Institute of Mental Health'}]}, 'Organization': {'OrgFullName': 'Weill Medical College of Cornell University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Treatment for Depressed Primary Care Patients', 'OfficialTitle': 'Community-Based Depression Care Management for Elderly Primary Care Patients'}, 'StatusModule': {'StatusVerifiedDate': 'February 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 1, 2009', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 30, 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 30, 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 3, 2009', 'StudyFirstSubmitQCDate': 'November 13, 2009', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 16, 2009', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'February 17, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 23, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Weill Medical College of Cornell University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This research study develop a collaborative depression care management model (C-DCM) that encourages collaboration between primary care physicians (PCPs) and trained social workers employed by community-based, public and nonprofit mental health clinics.', 'DetailedDescription': 'Major depression affects 5%-9% of older primary care patients, is often chronic or recurrent and disabling, and leads to frequent use of medical services. Most depressed elders are treated by primary care physicians (PCPs) and prior research has shown that collaboration between primary care physicians and depression care managers is effective in treating depression. The challenge has been in securing third-party reimbursement for such services.\\n\\nThis research study will address this barrier by developing a collaborative depression care management model (C-DCM) that encourages collaboration between PCPs and trained social workers employed by community-based, public and nonprofit mental health clinics. In addition to developing C-DCM, a total of 112 primary care outpatients will participate in this study to test whether C-DCM is more effective than the standard of care in decreasing the severity of depression and disability experienced by older adults. Each subject will be randomized into either Usual Care or C-DCM. All subjects will be assessed at Baseline and at 2 and 4 months while the C-DCM subjects will also meet with social worker depression case managers bi-weekly over four months. If shown effective, C-DCM may bring to bear an available, yet untapped resource in the care of depressed elders.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '11', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression Care Management (DCM)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will receive Depression Care Management.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression Care Management (DCM)']}}, {'ArmGroupLabel': 'Enhanced Care', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': \"Participants will receive the standard of care from their primary care physicians enhanced by a summary of the study's diagnostic interview.\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Enhanced Care']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Depression Care Management (DCM)', 'InterventionDescription': \"Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression Care Management (DCM)']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Enhanced Care', 'InterventionDescription': \"Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Enhanced Care']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Reduction in severity of depression over 16 weeks as measured by the Montgomery Asberg Depression Rating Scale (MADRS).', 'PrimaryOutcomeTimeFrame': 'Measured at Baseline, 8 weeks, and 16 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Reduction in disability over 16 weeks as measured by the World Health Organization Disability Scale (WHODAS).', 'SecondaryOutcomeTimeFrame': 'Measured at Baseline, 8 weeks, and 16 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAge 60 years and older: This study focuses on the clinical complexities of late-life depression and its treatment. Family Services of Westchester (our partner community mental health agency) offers geriatric mental health counseling services to adults age 60 and older.\\nDiagnosis of unipolar major depression\\nMADRS score >=18: Depression of such severity in primary care patients requires treatment.\\nCANE score >0: Reflects the presence of at least one unmet need in the domains of housing, self-care, safety, finances, benefits, legal matters, transportation, etc. and thus need for social services.\\nCapacity to provide written consent for both research assessment and depression care management: PCPs will be asked to clinically evaluate prospective participants' capacity to consent and document it in their medical record.\\nWorking knowledge of English: Command in English sufficient for comprehending questionnaires of the study and/or for understanding the DCM therapists. English does not have to be the subject's first language.\\n\\nExclusion Criteria:\\n\\nPsychotic depression: This will be determined by the Structured Clinical Interview for DSM Disorders(SCID) assessment; presence of delusions and or hallucinations. This is a severe disorder typically referred for treatment to mental health specialists.\\nActive suicidal ideation: This will be determined by the SCID and MADRS assessments. Older patients at these levels of risk for self-harm typically are referred to mental health specialists.\\nAntisocial personality by Diagnostic and Statistical Manual of Mental Disorders (DSM)IV: This disorder will possibly interfere with adherence to research procedures and treatment.\\nSignificant Cognitive Impairment (MMSE score <24) or clinical diagnosis of dementia by DSM-IV: These conditions may limit the patient's ability to participate in treatment and require social service interventions exceeding those available through the proposed depression care management models.\\nCurrent participation in specialist psychiatric care: Such patients will require the development of collaborative arrangements for depression care management which differ from those being tested in this study.\\nAcute or severe medical illness: i.e., delirium, metastatic cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry; or drugs often causing depression, e.g., steroids, reserpine, alpha-methyl-dopa, tamoxifen, vincristine.\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '60 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jo Anne Sirey, Ph.D.', 'OverallOfficialAffiliation': 'Weill Medical College of Cornell University', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'George S. Alexopoulos, M.D.', 'OverallOfficialAffiliation': 'Weill Medical College of Cornell University', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Westchester Medical Group Practices', 'LocationCity': 'White Plains', 'LocationState': 'New York', 'LocationZip': '10605', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 14, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01013220', 'OrgStudyIdInfo': {'OrgStudyId': 'R01MH076227', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH076227&Fy=all'}, 'Organization': {'OrgFullName': 'Florida State University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Depression Management at the Workplace', 'OfficialTitle': 'Influencing Employer Purchasing Behavior', 'Acronym': 'DMW'}, 'StatusModule': {'StatusVerifiedDate': 'December 2014', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2014', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 2014', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 12, 2009', 'StudyFirstSubmitQCDate': 'November 12, 2009', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 13, 2009', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'December 15, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 16, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Florida State University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Colorado Business Group on Health', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'University of South Florida', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': \"Randomized trials demonstrate that depression management products can improve clinical and organizational outcomes sufficiently for selected employers to realize a return on investment. Rather than usual care marketing which uses voltage-enhanced promises to sell voltage-diminished products, the investigators designed an evidence-based (EB) intervention to encourage employers to purchase a depression management product that offers the type, intensity and duration of care shown to provide clinical and organizational value. In an RCT designed to examine employer benefit purchasing behavior of depression products in 360 employer members of over 20 regional business coalitions, the research team proposes: (a) to compare the impact of evidence-based (EB) to usual care (UC) presentations on employer benefit purchasing behavior, and (b) to identify mediators and organizational moderators of intervention impact on employer benefit purchasing behavior.\\n\\nThis study addresses what policy analysts argue is one of the most pivotal problems in the translation of evidence-based care to 'real world' settings: whether purchasers can be influenced to buy health care products on the basis of value rather than cost. In the likely event that EB > UC, the study will provide encouragement to use an evidence-based approach to market new health care products to private payers on the basis of the product's clinical and organizational value. UC may achieve comparable outcomes to EB if the limiting factors in benefit purchasing are organizational, purchasing group and vendor constraints that no intervention can meaningfully modify. Support for this scenario would encourage the targeted marketing of new products to coalition members with empirically identified organizational, purchasing group and vendor characteristics, using usual care strategies.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['depression', 'depression care management', 'financing', 'absenteeism', 'presenteeism', 'employer decisions to purchase health care benefits']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '293', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression Product Detailing', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Employers receive education on how to purchase high quality depression management products to improve the quality of depression treatment depressed employees receive. Materials delivered in this arm of the study are available at www.caremanagementfordepression.org', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression Product Detailing']}}, {'ArmGroupLabel': 'Depression HEDIS Detailing', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Employers receive education on how to obtain and use HEDIS depression indicators to encourage health plans to improve the quality of depression treatment depressed employees receive', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression HEDIS detailing']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Depression Product Detailing', 'InterventionDescription': 'two hour academic detailing of depression management products to employees with responsibility for purchasing health care benefits\\ntechnical assistance in purchasing high quality depression management products', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression Product Detailing']}}, {'InterventionType': 'Other', 'InterventionName': 'Depression HEDIS detailing', 'InterventionDescription': 'academic detailing to employees responsible for purchasing health care benefits on how to use HEDIS indicators for depression to assure their depressed employees receive high quality care for the condition\\ntechnical assistance', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression HEDIS Detailing']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'employer purchase of depression management product', 'PrimaryOutcomeTimeFrame': 'two years after intervention'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'fidelity of depression management model purchased to evidence-based models', 'SecondaryOutcomeTimeFrame': 'two years after intervention'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nCoalitions who belong to the National Business Coalition on Health are eligible if:\\n\\nthey have 30+ employer purchasers/affiliates as members\\nthey act as more than purchasing agents\\n(3)they did not participate in the research team's preliminary studies on this topic.\\n\\nEmployers of participating coalitions are eligible if:\\n\\nthey are a public or private organization providing health care benefits to 100+ domestic employees\\nthey have not purchased a depression management product in the past two years.\\n\\nExclusion Criteria:\\n\\nNone\", 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kathryn Rost, PhD', 'OverallOfficialAffiliation': 'Florida State University, College of Medicine', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Colorado Business Group on Health', 'LocationCity': 'Denver', 'LocationState': 'Colorado', 'LocationZip': '80226', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25519705', 'ReferenceType': 'derived', 'ReferenceCitation': 'Rost KM, Meng H, Xu S. Work productivity loss from depression: evidence from an employer survey. BMC Health Serv Res. 2014 Dec 18;14:597. doi: 10.1186/s12913-014-0597-y.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'materials for academic detailing of depression management products', 'SeeAlsoLinkURL': 'http://www.caremanagementfordepression.org'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 15, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03983291', 'OrgStudyIdInfo': {'OrgStudyId': 'Version 1.1'}, 'Organization': {'OrgFullName': 'Zentrum für Angst und Depressionsbehandlung Zürich', 'OrgClass': 'OTHER'}, 'BriefTitle': 'FaReWell Depression - Facial Exercise Program to Treat Depression', 'OfficialTitle': 'Facial Rehabilitation of Wellbeing in Depression: a Randomized Controled Trial of a Facial Physiotherapeutic Exercise Program in the Treatment of Depression'}, 'StatusModule': {'StatusVerifiedDate': 'June 2019', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 1, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 15, 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'May 31, 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 10, 2019', 'StudyFirstSubmitQCDate': 'June 10, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 12, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 11, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 14, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Zentrum für Angst und Depressionsbehandlung Zürich', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study investigates if a physiotherapeutic exercise program designed to relax facial muscles associated with the expression of negative emotions and to activate and strengthen facial muscles associated with the expression of positive emotions can reduce the symptoms of depression and improve wellbeing and quality of life in the affected patients.', 'DetailedDescription': 'Activity of the facial musculature expresses emotions, but also generates proprioceptive signals to the emotional brain that maintain and reinforce the expressed emotions. This has been described by Charles Darwin and William James in the facial feedback hypothesis.\\n\\nStudies have shown that interruption of facial feedback by the injection of botulinum toxin into the corrugator and procerus muscles, which express negative emotions like sadness, anger, and fear, can reduce the symptoms of depression.\\n\\nIn the present study we investigate, if similar effects can be achieved by a relaxing massage of these and other muscles that are associated with the expression of negative emotions and if strengthening exercises of muscles that express positive emotions, the zygomaticus and orbicularis oculi muscles, can contribute to the rehabilitation of positive emotionality in depression. After instruction by a physiotherapist, participants will practice the exercises daily for 15 minutes.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'For six weeks one arm receives the FaReWell Depression intervention and one arm receives a control resting intervention. The former arm continues on the FaReWell Depression intervention while the latter arm is switched to the FaReWell Depression intervention for another six weeks.', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '40', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'FaReWell Depression', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Physiotherapeutic exercises for the relaxation of facial muscles associated with the expression of negative emotions and for the activation and strengthening of facial muscles associated with the expression of positive emotions 15 minutes daily', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: FaReWell Depression']}}, {'ArmGroupLabel': 'Resting exercise', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Resting 15 minutes daily', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: FaReWell Depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'FaReWell Depression', 'InterventionDescription': 'Facial massage and force exercise', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['FaReWell Depression', 'Resting exercise']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Montgomery-Asberg Depression Rating Scale (MADRS)', 'PrimaryOutcomeDescription': 'The Montgomery-Asberg Depression Rating Scale (MADRS) is an expert rating scale with 10 items for the measurement of the severity of depressive symptoms. Change in depression severity is measured as change in the total score of the scale (0-60 points).', 'PrimaryOutcomeTimeFrame': '6 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Montgomery-Asberg Depression Rating Scale (MADRS)', 'SecondaryOutcomeDescription': 'The Montgomery-Asberg Depression Rating Scale (MADRS) is an expert rating scale with 10 items for the measurement of the severity of depressive symptoms. Change in depression severity is measured as change in the total score of the scale (0-60 points).', 'SecondaryOutcomeTimeFrame': '3, 9, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in Patient-Health-Questionnaire-9 (PHQ-9)', 'SecondaryOutcomeDescription': 'The Patient-Health-Questionnaire-9 (PHQ-9) is a self-rating scale with 9 items for the measurement of the severity of depressive symptoms. Change in depression severity is measured as change in the total score of the scale (0-27 points).', 'SecondaryOutcomeTimeFrame': '3, 6, 9, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in Snaith-Hamilton-Pleasure-Scale (SHAPS-D)', 'SecondaryOutcomeDescription': 'The Snaith-Hamilton-Pleasure-Scale (SHAPS-D) is a self-rating scale with 14 items for the measurement of pleasure. Change in anhedonia (inability to experience pleasure) is measured as change in the total score of the scale (0-14 points).', 'SecondaryOutcomeTimeFrame': '3, 6, 9, 12 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMild to moderate unipolar depression\\nStable treatment for at least 6 weeks\\n\\nExclusion Criteria:\\n\\nOrganic mental disorders\\nMental disorders due to psychoactive substance use\\nSchizophrenia and other psychotic disorders\\nPrevious cosmetic procedures (botulinum toxin, fillers, lifting)\\nFacial palsy\\nFacial skin disorders', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Patricia Waldvogel, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+41 44 3866600', 'CentralContactEMail': 'PWaldvogel@zadz.ch'}, {'CentralContactName': 'Axel Wollmer, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+49 151 53136738', 'CentralContactEMail': 'axel.wollmer@unibas.ch'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Patricia Waldvogel, PhD', 'OverallOfficialAffiliation': 'Zentrum für Angst und Depressionsbehandlung Zürich', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Zentrum für Angst- und Depressionsbehandlung', 'LocationStatus': 'Recruiting', 'LocationCity': 'Zürich', 'LocationZip': '8008', 'LocationCountry': 'Switzerland', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Patricia Waldvogel, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+41 44 3866600', 'LocationContactEMail': 'PWaldvogel@zadz.ch'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M19673', 'ConditionBrowseLeafName': 'Facies', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 16, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01794598', 'OrgStudyIdInfo': {'OrgStudyId': '5132'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '5132-03-8R0ER', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Duke legacy protocol ID'}]}, 'Organization': {'OrgFullName': 'Duke University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Preliminary Study Examining Heart Failure Patients Responses to Depression Education', 'OfficialTitle': 'HF-ACTION Depression Education Substudy'}, 'StatusModule': {'StatusVerifiedDate': 'February 2013', 'OverallStatus': 'Terminated', 'WhyStopped': 'Terminated', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2004'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2006', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2006', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 17, 2012', 'StudyFirstSubmitQCDate': 'February 15, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 20, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 19, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 22, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Duke University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Purpose of the Study: The significant impact of depression on the poor prognosis and functional restrain, recognition and successful treatment of depression in patients with Chronic Heart Failure (CHF) may result in improvement of overall outcome of those patients. However, depression comorbid with CHF has been overlooked in the real practice. Therefore, the investigators are proposing a study to 1) assess the prognostic impact of depression in patients with stable CHF who have been managed as outpatients, and 2) assess whether provision of depression education to CHF patients will improve the care of depression.\\n\\nPatients with chronic heart failure are enrolled into this study with a half of them are randomly assigned to receive a packet of depression education materials and then other half not. Participants and investigators both are blinded to the assignment. All the participants are provided a toll free phone number to contact the research team as needed. Depressive symptoms and patients knowledge of depression are assessed at baseline prior to randomization and at 1-month and 6-month following the enrollment.\\n\\nResponses of the study participants, such as change of depressive symptoms, and requests for psychiatric help are examined between two groups.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Chronic Heart Failure']}, 'KeywordList': {'Keyword': ['Heart failure', 'depression', 'depression care education']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignMaskingInfo': {'DesignMasking': 'Triple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '270', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Educational materials', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Receiving educational materials of depression care', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Receiving educational material of depression care']}}, {'ArmGroupLabel': 'No educational materials', 'ArmGroupType': 'Sham Comparator', 'ArmGroupDescription': 'Receiving an envelope but no inclusion of educational materials of depression care', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Receiving educational material of depression care']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Receiving educational material of depression care', 'InterventionDescription': 'The educational material provides patients about depression management', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Educational materials', 'No educational materials']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in recognition of study participant to depression care', 'PrimaryOutcomeDescription': 'To assess whether the provision of depression education materials will increase knowledge of the impact depression has on Congestive Heart Failure patients. This will be measured through study participants completion of a questionnaire to record their views on depression and depression care in a non-psychiatric setting.', 'PrimaryOutcomeTimeFrame': 'Baseline, 1 month and 6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in response of study participant to depression care', 'SecondaryOutcomeDescription': 'Response of participants to depression care was measured by use of the Beck Depression Inventory scale (BDI), PHQ-9 (the 9 items of the depression scale of the Patient Health Questionnaire) and an anxiety questionnaire and a toll-free contact number to access free psychiatric consultants at the coordinating center. A contact log was kept documenting subject ID, reason for call, number of contacts and duration of the call.', 'SecondaryOutcomeTimeFrame': 'Baseline, 1 month, and 6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nInclusion Criteria\\n\\nLVEF ≤ 35%.\\nNYHA class II, III, or IV heart failure for the previous three months despite a minimum of 6 weeks of treatment.\\nMust be on optimal heart failure therapy according to AHA/ACC and HFSA heart failure guidelines, including treatment with ACEI and beta-blocker therapy, or have documented rationale for variation, including intolerance, contraindication, patient preference, or personal physician's judgment.\\n\\nExclusion Criteria:\\n\\nAge less than 18.\\nCurrently pregnant or intending to become pregnant in the next year.\\nCardiovascular procedure or hospitalization for any reason planned in the next 6 months.\\nExpectation of receiving a cardiac transplant in the next six months.\\nUnable to provide the study consent.\\nParticipation another clinical trial(s) that may interfere with follow-up or data collection for this study, or that may affect cardiovascular mortality.\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Wei Jiang, MD', 'OverallOfficialAffiliation': 'Duke University', 'OverallOfficialRole': 'Principal Investigator'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006333', 'ConditionMeshTerm': 'Heart Failure'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8004', 'ConditionBrowseLeafName': 'Heart Failure', 'ConditionBrowseLeafAsFound': 'Heart Failure', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}}, {'Rank': 17, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00930293', 'OrgStudyIdInfo': {'OrgStudyId': 'R01MH085874', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH085874&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH085874', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH085874&Fy=all'}, {'SecondaryId': 'MH085874-01'}, {'SecondaryId': 'PRO08070009'}, {'SecondaryId': 'PCC: DSIR 84-CT'}]}, 'Organization': {'OrgFullName': 'University of Pittsburgh', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety', 'OfficialTitle': 'Personalizing Treatment of Depression Complicated by Panic Features-Pilot Study'}, 'StatusModule': {'StatusVerifiedDate': 'January 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2012', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 26, 2009', 'StudyFirstSubmitQCDate': 'June 26, 2009', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 30, 2009', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'December 19, 2013', 'ResultsFirstSubmitQCDate': 'January 7, 2016', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'February 9, 2016', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 7, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 9, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Jill Cyranowski', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor of Psychiatry and Psychology', 'ResponsiblePartyInvestigatorAffiliation': 'University of Pittsburgh'}, 'LeadSponsor': {'LeadSponsorName': 'University of Pittsburgh', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study will examine the feasibility and efficacy of a personalized psychotherapy treatment for people with depression and co-occurring anxiety.', 'DetailedDescription': \"Approximately one half of all depressed psychiatric patients also meet the criteria for an anxiety disorder. Compared to people with only depression, people with both depression and panic features experience poorer psychological and social functioning, a greater risk of suicide, less response to medication and therapy treatment, and a greater risk of recurring symptoms. Because people with depression and co-occurring anxiety features do not achieve full symptom remission with either medication or therapy alone, this study will use a treatment that combines the two. A commonly used type of depression medication called a selective serotonin reuptake inhibitor (SSRI) will be combined with a specialized therapy developed to address depression with co-occurring symptoms of panic, anxiety, and avoidance. This study will also test a computer-based method of assessing mood and anxiety symptom profiles and outcomes to determine whether participants find this method acceptable and clinicians find it useful.\\n\\nParticipation in this study will last 20 weeks, with follow-up visits occurring 4 and 8 months after starting. Participants will be randomly assigned to receive either an individualized therapy for depression and anxiety, called interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS), or a standard therapy for depression, called brief supportive psychotherapy (BSP). All participants will complete up to 16 therapy sessions and receive a standard SSRI treatment with the medication citalopram hydrobromide. During the IPT-PS treatment, a study therapist will examine regular computer updates of depression and anxiety scores for participants and talk to them about identifying and addressing life stressors that trigger symptoms. During the BSP treatment, a study therapist will encourage participants to arrive at their own solutions by emphasizing the participants' strengths and examining what has worked in the past.\\n\\nParticipants will complete assessments weekly during the 20 weeks of the study intervention and at 4- and 8-month follow-up visits. These assessments will include self-report questionnaires about symptoms, medication side effects, and treatment adherence; vital sign and weight measurements; and a clinical interview. Regular assessments of medication effectiveness and side effects will occur every 1 to 4 weeks. Starting at the second study visit, participants will also complete monthly computer-based questionnaires about depression and anxiety symptoms.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression', 'Anxiety']}, 'KeywordList': {'Keyword': ['Interpersonal Psychotherapy']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '50', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Personalized Depression Care', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication (citalopram) treatment.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)', 'Drug: Citalopram hydrobromide']}}, {'ArmGroupLabel': 'Standard Depression Care', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication (citalopram) treatment.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Brief Supportive Psychotherapy (BSP)', 'Drug: Citalopram hydrobromide']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)', 'InterventionDescription': '16 weekly IPT-PS sessions, each lasting approximately 45 minutes', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Personalized Depression Care']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Brief Supportive Psychotherapy (BSP)', 'InterventionDescription': '16 weekly BPS sessions, each lasting approximately 45 minutes', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Standard Depression Care']}}, {'InterventionType': 'Drug', 'InterventionName': 'Citalopram hydrobromide', 'InterventionDescription': 'A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Personalized Depression Care', 'Standard Depression Care']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Celexa']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Number of Participants Meeting Depression Remission Criteria', 'PrimaryOutcomeDescription': 'Depression remission defined as 3 consecutive weeks of HRSD-17 scores that on average, < or = 7', 'PrimaryOutcomeTimeFrame': 'Measured at baseline and weekly for up to 20 weeks of acute treatment'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Weeks to Depression Remission', 'SecondaryOutcomeDescription': 'Kaplan-Meier survival analyses to determine time to depression remission (defined as average HRSD-17 score < or = 7 for three consecutive weeks).\\n\\nAnalyses run with the full intent to treat sample (censoring patients who dropped out at time of termination)', 'SecondaryOutcomeTimeFrame': 'Measured at baseline and weekly for up to 20 weeks of treatment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nCurrently in an episode of nonpsychotic major depression, as defined by the DSM-IV and documented by both the Structured Clinical Interview for Axis I, DSM-IV Disorders (SCID) and by a rating of greater than 15 on the 25-item Hamilton Rating Scale for Depression (HRSD)\\nPanic spectrum risk category of at least 7, as defined by the Panic-Agoraphobic Spectrum Self-Report (PAS-SR), last month version\\nNot currently receiving effective treatment\\nParticipants with suicidal ideation are eligible as long as outpatient treatment is deemed safe.\\n\\nExclusion Criteria:\\n\\nHistory of manic or hypomanic episode(s)\\nHistory of schizophrenia or schizoaffective disorder\\nMood disorder due to a general medical condition or induced by substance use\\nPresence of psychosis\\nCurrent pregnancy or plans to become pregnant\\nCurrent primary diagnosis of anorexia nervosa or bulimia nervosa (this does not include an eating disorder not otherwise specified [NOS])\\nCurrent primary diagnosis of severe obsessive-compulsive disorder (OCD), as determined by clinician evaluation of symptom severity and temporal onset of symptoms\\nDrug or alcohol abuse or dependence within the past 3 months (participants with episodic abuse related to mood episodes will not be excluded)\\nSatisfies full DSM-IV criteria for antisocial personality disorder, as determined by SCID-II evaluation\\nRequires inpatient treatment because of suicidal risk or psychotic symptoms (current suicidal thinking or parasuicidal behavior is not exclusionary if, in clinician judgment, it can be managed on an outpatient basis)\\n\\nAny of the following medical conditions:\\n\\nAn index episode that is secondary to the effect of medically prescribed drugs, i.e., reserpine, antihistamines, etc.\\nPresence of significant uncontrolled medical illness including cardiovascular disorder, kidney or liver disease, epilepsy, untreated hypertension, or unstabilized endocrine disease (stable medical conditions such as well-controlled diabetes or HIV positive status are not exclusionary provided the participant meets other inclusion and exclusion criteria)\\nCurrent treatment with a pharmacologic, over-the-counter, or herbal therapy for depression or anxiety (unless the participant wishes to discontinue an ineffective treatment)\\nHistory of poor or failed treatment response to an adequate dose and duration of citalopram', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jill M. Cyranowski, PhD', 'OverallOfficialAffiliation': 'University of Pittsburgh', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Western Psychiatric Institute and Clinic', 'LocationCity': 'Pittsburgh', 'LocationState': 'Pennsylvania', 'LocationZip': '15213', 'LocationCountry': 'United States'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Personalized Depression Care', 'FlowGroupDescription': 'Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.\\n\\nInterpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Standard Depression Care', 'FlowGroupDescription': 'Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.\\n\\nBrief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '24'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '26'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '17'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '19'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '7'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '7'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Personalized Depression Care', 'BaselineGroupDescription': 'Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.\\n\\nInterpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Standard Depression Care', 'BaselineGroupDescription': 'Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.\\n\\nBrief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '24'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '26'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '50'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '30.37', 'BaselineMeasurementSpread': '11.41'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '31.09', 'BaselineMeasurementSpread': '10.27'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '30.74', 'BaselineMeasurementSpread': '10.72'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '24'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '26'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '50'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '19'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '18'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '37'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '8'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '13'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '24'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '26'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '50'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Number of Participants Meeting Depression Remission Criteria', 'OutcomeMeasureDescription': 'Depression remission defined as 3 consecutive weeks of HRSD-17 scores that on average, < or = 7', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'participants', 'OutcomeMeasureTimeFrame': 'Measured at baseline and weekly for up to 20 weeks of acute treatment', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Personalized Depression Care', 'OutcomeGroupDescription': 'Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.\\n\\nInterpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Standard Depression Care', 'OutcomeGroupDescription': 'Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.\\n\\nBrief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '24'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '26'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '10'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '15'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Weeks to Depression Remission', 'OutcomeMeasureDescription': 'Kaplan-Meier survival analyses to determine time to depression remission (defined as average HRSD-17 score < or = 7 for three consecutive weeks).\\n\\nAnalyses run with the full intent to treat sample (censoring patients who dropped out at time of termination)', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Error', 'OutcomeMeasureUnitOfMeasure': 'weeks', 'OutcomeMeasureTimeFrame': 'Measured at baseline and weekly for up to 20 weeks of treatment', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Personalized Depression Care', 'OutcomeGroupDescription': 'Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.\\n\\nInterpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Standard Depression Care', 'OutcomeGroupDescription': 'Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.\\n\\nBrief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '24'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '26'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '13.99', 'OutcomeMeasurementSpread': '1.47'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '11.59', 'OutcomeMeasurementSpread': '1.31'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Personalized Depression Care', 'EventGroupDescription': 'Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.\\n\\nInterpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '24', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '24'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Standard Depression Care', 'EventGroupDescription': 'Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.\\n\\nBrief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '26', 'EventGroupOtherNumAffected': '1', 'EventGroupOtherNumAtRisk': '26'}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Unexplained Visual Disturbance', 'OtherEventOrganSystem': 'General disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '24'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '26'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Jill M. Cyranowski, PhD', 'PointOfContactOrganization': 'University of Pittsburgh', 'PointOfContactEMail': 'cyranowskijm@upmc.edu', 'PointOfContactPhone': '412-246-5588'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000003909', 'InterventionMeshTerm': 'Dexetimide'}, {'InterventionMeshId': 'D000015283', 'InterventionMeshTerm': 'Citalopram'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000017367', 'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'}, {'InterventionAncestorId': 'D000014179', 'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'}, {'InterventionAncestorId': 'D000049990', 'InterventionAncestorTerm': 'Membrane Transport Modulators'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000018490', 'InterventionAncestorTerm': 'Serotonin Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000018687', 'InterventionAncestorTerm': 'Antidepressive Agents, Second-Generation'}, {'InterventionAncestorId': 'D000000928', 'InterventionAncestorTerm': 'Antidepressive Agents'}, {'InterventionAncestorId': 'D000011619', 'InterventionAncestorTerm': 'Psychotropic Drugs'}, {'InterventionAncestorId': 'D000000978', 'InterventionAncestorTerm': 'Antiparkinson Agents'}, {'InterventionAncestorId': 'D000018726', 'InterventionAncestorTerm': 'Anti-Dyskinesia Agents'}, {'InterventionAncestorId': 'D000010276', 'InterventionAncestorTerm': 'Parasympatholytics'}, {'InterventionAncestorId': 'D000001337', 'InterventionAncestorTerm': 'Autonomic Agents'}, {'InterventionAncestorId': 'D000018373', 'InterventionAncestorTerm': 'Peripheral Nervous System Agents'}, {'InterventionAncestorId': 'D000018727', 'InterventionAncestorTerm': 'Muscarinic Antagonists'}, {'InterventionAncestorId': 'D000018680', 'InterventionAncestorTerm': 'Cholinergic Antagonists'}, {'InterventionAncestorId': 'D000018678', 'InterventionAncestorTerm': 'Cholinergic Agents'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16566', 'InterventionBrowseLeafName': 'Citalopram', 'InterventionBrowseLeafAsFound': 'Citalopram Hydrobromide', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M5687', 'InterventionBrowseLeafName': 'Dexetimide', 'InterventionBrowseLeafAsFound': 'Citalopram Hydrobromide', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M14095', 'InterventionBrowseLeafName': 'Serotonin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M18232', 'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2828', 'InterventionBrowseLeafName': 'Antidepressive Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M13057', 'InterventionBrowseLeafName': 'Psychotropic Drugs', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2876', 'InterventionBrowseLeafName': 'Antiparkinson Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M11772', 'InterventionBrowseLeafName': 'Parasympatholytics', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19385', 'InterventionBrowseLeafName': 'Muscarinic Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19344', 'InterventionBrowseLeafName': 'Cholinergic Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19342', 'InterventionBrowseLeafName': 'Cholinergic Agents', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr', 'InterventionBrowseBranchName': 'Psychotropic Drugs'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'AnDyAg', 'InterventionBrowseBranchName': 'Anti-Dyskinesia Agents'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M2905', 'ConditionBrowseLeafName': 'Anxiety Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 18, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00105833', 'OrgStudyIdInfo': {'OrgStudyId': 'MHI 20-020'}, 'Organization': {'OrgFullName': 'VA Office of Research and Development', 'OrgClass': 'FED'}, 'BriefTitle': 'Improving Outcomes of Depression in Primary Care', 'OfficialTitle': 'Improving Outcomes of Depression in Primary Care', 'Acronym': 'DEP-PC'}, 'StatusModule': {'StatusVerifiedDate': 'March 2009', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2002'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2004', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2008', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 16, 2005', 'StudyFirstSubmitQCDate': 'March 16, 2005', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 17, 2005', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'April 6, 2015', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 7, 2015', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'US Department of Veterans Affairs', 'LeadSponsorClass': 'FED'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Depression is common in primary care settings, and associated with substantial physical and psychosocial impairment and increased healthcare utilization. Despite efforts to educate primary care providers, depression is often undetected or undertreated in primary care settings. The main objective of this study was to determine the impact of a low-intensity, care management intervention on depression treatment outcomes of patients in a VA primary care setting.', 'DetailedDescription': 'OBJECTIVE(S): The primary objective of the study was to determine the impact of a low-intensity, care management intervention on depression treatment outcomes of patients in a VA primary care setting. Secondary objectives were to determine the extent to which primary care clinicians adhere to major depression treatment guidelines, the extent to which the intervention impacts healthcare utilization, and to examine the impact of provider and patient covariates (including pain and adherence) on depression treatment response PLAN: Randomized controlled trial. METHODS: All clinicians first participated in the MacArthur Depression Education Program (DEP). After stratification by discipline and site, clinicians were randomized to receive the Depression Decision Support (DDS) intervention versus usual care (which included an on-site mental health team). Patients were nested within clinician intervention status. DDS intervention clinicians received serial reports of depression severity scores and other clinical data for their enrolled patients. The DDS care manager made one telephone contact with each intervention patient, and invited patients to attend a depression group education session. The DDS team monitored patient depression severity over time, and targeted additional time and effort towards patients not showing improvement. Additional DDS intervention included making further recommendations to primary care clinicians, and in some cases, a one-time consultation with the DDS psychiatrist.\\n\\nPotential subjects were identified from lists of patients due for appointments with primary care clinicians, and were contacted for telephone screening. Patients were enrolled if they had Patient Health Questionnaire (PHQ-9) scores >10 or a Hopkins Symptom Checklist (SCL-20) score of > 1.0 at a subsequent in-person interview. There were no restrictions by age or sex. Patients were excluded if they had psychotic symptoms, dementia, serious suicidal ideation, very severe depression (PHQ-9 >25), or had been treated by mental health clinicians within the previous six months. The intervention lasted 12 months. Depression symptom severity (SCL-20) and health related quality of life (SF-36V) at 6 and 12-months were primary outcomes. Primary analyses employed mixed-model repeated measure analyses of covariance, which include a random effect for clinician and fixed effects for time and intervention status.\\n\\nFINDINGS TO DATE: Five Portland VA clinic sites and 41 clinicians participated. 3,103 patients were screened, and 402 patients were enrolled. Three hundred seventy-five met final eligibility criteria. There were no adverse events. SCL-20 scores improved in both groups over 12 months (slope: -.382; 95% CI -.488, -.276), but there was no effect of the intervention on SCL-20 or Short Form-36V compared to usual care. There was greater initial improvement in PHQ-9 for intervention patients (p=.030); however, this effect diminished over time. At 12 months, intervention patients reported greater satisfaction (p=.002), and were more likely to have received antidepressants. To date, 10 manuscripts supported by the project have been published. One manuscript examining associations between stressful live events and depression outcomes has been submitted for publication.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '400', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Arm 1', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Multifaceted collaborative intervention for depression based in primary care', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Collaborative Care - Depression Decision Support (DDS)']}}, {'ArmGroupLabel': 'Arm 2', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Treatment as usual'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Collaborative Care - Depression Decision Support (DDS)', 'InterventionDescription': 'Multifaceted collaborative intervention for depression based in primary care', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Arm 1']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Depression Decision Support (DDS)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Symptom Checklist SCL-20 score', 'PrimaryOutcomeTimeFrame': 'SCL-20 score over 12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPrimary care patients of eligible providers with depression (Patient Health Questionnaire [PHQ-9] depression scores of 10 to 25 or Hopkins Symptom Checklist-20 [SCL-20] scores >= 1.0)\\n\\nExclusion Criteria:\\n\\nPatients who had received treatment from mental health specialists within the previous 6 months; who had received a diagnosis of psychotic disorder, dementia, or bipolar disorder; or who were considered to be terminally ill', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Steven K. Dobscha, MD', 'OverallOfficialAffiliation': 'VA Portland Health Care System, Portland, OR', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Martha S. Gerrity, MD MPH PhD', 'OverallOfficialAffiliation': 'VA Portland Health Care System, Portland, OR', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'VA Portland Health Care System, Portland, OR', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97239', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '18071900', 'ReferenceType': 'result', 'ReferenceCitation': 'Snyder K, Dobscha SK, Ganzini L, Hoffman WF, Delorit MA. Clinical outcomes of integrated psychiatric and general medical care. Community Ment Health J. 2008 Jun;44(3):147-54. Epub 2007 Dec 11.'}, {'ReferencePMID': '17336659', 'ReferenceType': 'result', 'ReferenceCitation': 'Williams JW Jr, Gerrity M, Holsinger T, Dobscha S, Gaynes B, Dietrich A. Systematic review of multifaceted interventions to improve depression care. Gen Hosp Psychiatry. 2007 Mar-Apr;29(2):91-116. Review.'}, {'ReferencePMID': '17250493', 'ReferenceType': 'result', 'ReferenceCitation': 'Dobscha SK, Corson K, Pruitt S, Crutchfield M, Gerrity MS. Measuring depression and pain with home health monitors. Telemed J E Health. 2006 Dec;12(6):702-6.'}, {'ReferencePMID': '17015865', 'ReferenceType': 'result', 'ReferenceCitation': 'Dobscha SK, Corson K, Hickam DH, Perrin NA, Kraemer DF, Gerrity MS. Depression decision support in primary care: a cluster randomized trial. Ann Intern Med. 2006 Oct 3;145(7):477-87.'}, {'ReferencePMID': '17634781', 'ReferenceType': 'result', 'ReferenceCitation': 'Gerrity MS, Corson K, Dobscha SK. Screening for posttraumatic stress disorder in VA primary care patients with depression symptoms. J Gen Intern Med. 2007 Sep;22(9):1321-4. Epub 2007 Jul 17.'}, {'ReferencePMID': '18071094', 'ReferenceType': 'result', 'ReferenceCitation': 'Dobscha SK, Corson K, Gerrity MS. Depression treatment preferences of VA primary care patients. Psychosomatics. 2007 Nov-Dec;48(6):482-8.'}, {'ReferencePMID': '17029000', 'ReferenceType': 'result', 'ReferenceCitation': 'Dobscha SK, Winterbottom LM, Snodgrass LS. Reducing drug costs at a Veterans Affairs hospital by increasing market-share of generic fluoxetine. Community Ment Health J. 2007 Feb;43(1):75-84. Epub 2006 Sep 22.'}, {'ReferencePMID': '15609737', 'ReferenceType': 'result', 'ReferenceCitation': 'Corson K, Gerrity MS, Dobscha SK. Screening for depression and suicidality in a VA primary care setting: 2 items are better than 1 item. Am J Manag Care. 2004 Nov;10(11 Pt 2):839-45.'}, {'ReferencePMID': '15785225', 'ReferenceType': 'result', 'ReferenceCitation': 'Dobscha SK, Corson K, Solodky J, Gerrity MS. Use of videoconferencing for depression research: enrollment, retention, and patient satisfaction. Telemed J E Health. 2005 Feb;11(1):84-9.'}, {'ReferencePMID': '12556600', 'ReferenceType': 'result', 'ReferenceCitation': 'Dobscha SK, Anderson TA, Hoffman WF, Winterbottom LM, Turner EH, Snodgrass LS, Hauser P. Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center. Psychiatr Serv. 2003 Feb;54(2):195-200.'}, {'ReferencePMID': '12850654', 'ReferenceType': 'result', 'ReferenceCitation': 'Dobscha SK, Gerrity MS, Corson K, Bahr A, Cuilwik NM. Measuring adherence to depression treatment guidelines in a VA primary care clinic. Gen Hosp Psychiatry. 2003 Jul-Aug;25(4):230-7.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 19, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03811041', 'OrgStudyIdInfo': {'OrgStudyId': '29BRC18.0221'}, 'Organization': {'OrgFullName': 'University Hospital, Brest', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Adolescent Depression Associated With Parental Depression', 'OfficialTitle': 'Adolescent Depression Associated With Parental Depression : Screening, Prevalence and Secondary Prevention From the Meeting of Depressed Parents on Primary Care', 'Acronym': 'AdoDesP'}, 'StatusModule': {'StatusVerifiedDate': 'March 2020', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 28, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 28, 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'March 28, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'January 15, 2019', 'StudyFirstSubmitQCDate': 'January 17, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 22, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 26, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 27, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University Hospital, Brest', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Depression is difficult to identify, prevent and treat in adolescents because of complex and stigmatized multiform symptoms and pathways of care.\\n\\nIn children the existence of a parental depression is a significant and recognized risk factor for the development of a depression. It is regularly reported that 30% of adolescents of depressed parents have depression themselves. General Practitioners (GP) have significant access to the depression of adults, potentially parents of teenagers. In fact, 20% of patients in the regular active file of one GP have depression. The primary health care system could provide indirect but voluminous and unprecedented access to the identification of adolescent depression at an early stage from the encounter of depressed parents.\\n\\nThe difficulties of articulation between primary care (PC) and mental health devices are demonstrated. They disrupt the care pathways of adolescents detected in PC, prevention, and may even disturb early detection of depression. An organized joint between the PC and a specialized mental health service for adolescents (\"Maison Des Adolescents\" MDA) could promote the process of screening and preventing depression of adolescents of depressed parents encountered in PC.\\n\\nIn addition, if the effects of parental depression on adolescents are established, they remain complex and interactive. They vary by age and sex of the child but also the sex of the parent. A concomitant study of adolescent and parent depression will provide data to analyze the prevalence of depressed parent adolescent depression and to define risk or protection factors.\\n\\nAdoDesP study is a cluster randomised trial (randomisation of the GPs) which compare a group of adolescent with PC articulated with mental health service (MDA) and an other group without articulation (routine cares).\\n\\nA third group of depressed adolescents will be constituted to analyse parental depression of depressed adolescents.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Diagnostic', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '1068', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'PC articulated with MDA', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM).Finally, the patient will be oriented to the MDA of Brest and will meet again the GP at 6 and 12 month to answers the same tests.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: MDA']}}, {'ArmGroupLabel': 'Routine cares', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM). Finally, the patient will be oriented to the routine cares and will meet again the GP at 6 and 12 month to answers the same tests.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Routine Cares']}}, {'ArmGroupLabel': 'Parental depression', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Parental depression will be studied. Depressed adolescent encountered in MDA of Marseille for confirmation of depression with 3 tests : ADRS, CDI and PedsQL. If positive, the parent will come to the MDA for a screening test of depression (HSCL25). Parents and adolescent are seen only once.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Parental depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'MDA', 'InterventionDescription': 'Depressed adolescents of depressed parents will be oriented to the MDA of Brest for depression cares.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['PC articulated with MDA']}}, {'InterventionType': 'Other', 'InterventionName': 'Routine Cares', 'InterventionDescription': 'Depressed adolescents of depressed parents will be oriented to routine cares for depression cares.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Routine cares']}}, {'InterventionType': 'Other', 'InterventionName': 'Parental depression', 'InterventionDescription': 'Parents of depressed adolescents will be met for a screening test of depression.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Parental depression']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Changes in adolescents' depression intensity\", 'PrimaryOutcomeDescription': 'The depression intensity will be evaluated by Child DepressionInventory (CDI)scale at Day 0, Months 6 and 12 and the investigators will compare its evolution between group 1 and 2. Each of the 27 items is scored 0, 1 or 2 and the total score is the sum of all items. Score between 0 and 9 mean minor depression, 10 to 18 is mild depression, 19 to 29 is moderate depression and 30 to 63 is for the severe depressions.', 'PrimaryOutcomeTimeFrame': 'Day 0, Month6 and Month12'}, {'PrimaryOutcomeMeasure': \"Changes in adolescents' quality of live\", 'PrimaryOutcomeDescription': 'The quality of live will be evaluated by Pediatric Quality of Life InventoryTM (PedsQL) scale at Day 0, Months 6 and 12 and the investigators will compare its evolution between group 1 and 2. 3 scores will be calculated : psychosocial health summary score (average score of 15 items), physical health summary score (average score of 8 items) and the total score (average score of all items). Scores are between 0 and 100% and the higher scores indicate better Health-Related Quality of Life.', 'PrimaryOutcomeTimeFrame': 'Day 0, Month6 and Month12'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Prevalence of adolescent depression with depressed parent', 'SecondaryOutcomeDescription': 'With group 1 and 2, the investigators will calculate de prevalence of adolescent depression when a parent is depressed. Adolescent depression will be assessed by Adolescent Depression Rating Scale (ADRS). This scale is composed of 8 true (1)/false(0) questions. The score is the sum of all item. An adolescent is consider depressed when his score is higher than 4.', 'SecondaryOutcomeTimeFrame': 'Day 0'}, {'SecondaryOutcomeMeasure': 'Prevalence of parental depression with depressed adolescent', 'SecondaryOutcomeDescription': 'With group 3, the investigators will calculate de prevalence of parental depression when a adolescent is depressed. Parental depression will be assessed by Hopkins Symptom Checklist (HSCL25). This scale is composed of 25 questions with 4 answers (1-4). The score is the average score of the 25 items. The parent is considered depressed when the score is higher or equal to 1.75.', 'SecondaryOutcomeTimeFrame': 'Day 0'}, {'SecondaryOutcomeMeasure': 'Risk and protection factors', 'SecondaryOutcomeDescription': 'With the 3 groups, the investigators will isolate risk and protection factors for adolescent of depressed parents and for parents of depressed adolescents. Sociodemographics informations will be used and protective or risk factors may be highlighted from the study of some of the medico-psychological and social characteristics of families.', 'SecondaryOutcomeTimeFrame': 'Day 0'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nParents of groups 1 and 2 :\\n\\nMajor patient consulting his GP\\nDepressed patient\\nParent of adolescent aged between 11 and 18 years old\\n\\nAdolescents of groups 1 and 2 :\\n\\nAged more than 11 and less than 18 years old\\nParent included in the study and whose depression is confirmed by HSCL25 scale\\n\\nParents of group 3 :\\n\\nParent of depressed adolescent under care at the MDA of Marseille, included in the study and whose depression is confirmed by HSCL25 scale\\n\\nAdolescents of group 3 :\\n\\nAged more than 11 and less than 18 years old\\nDepressed patient\\nUnder care at the MDA of Marseille since less than 1 month\\n\\nExclusion Criteria:\\n\\nParents of groups 1, 2 and 3 :\\n\\nMinor patient\\nEnable to give his consent\\nPatient with guardianship or curatorship\\nNon consenting patient\\nPregnant or nursing mother\\n\\nAdolescents of groups 1 and 2 :\\n\\nAged < 11 or ≥18\\nParent whose depression isn't confirmed by HSCL25 scale\\nNon consenting adolescent\\nPregnant or nursing mother\\n\\nAdolescent of group 3 :\\n\\nAged < 11 or ≥18\\nNon depressed adolescent\\nNon consenting patient\\nPregnant or nursing mother\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '11 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Guillaume BRONSARD, Pr', 'CentralContactRole': 'Contact', 'CentralContactPhone': '0298015010', 'CentralContactEMail': 'guillaume.bronsard@chu-brest.fr'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Dr Andro-De-Schotten', 'LocationStatus': 'Recruiting', 'LocationCity': 'Brest', 'LocationZip': '29200', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Anne-Cécile ANDRO-DE-SCHOTTEN, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr GLOANEC', 'LocationStatus': 'Recruiting', 'LocationCity': 'Brest', 'LocationZip': '29200', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Isabelle GLOANEC, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr MOUDEN', 'LocationStatus': 'Recruiting', 'LocationCity': 'Brest', 'LocationZip': '29200', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jean-Hervé MOUDEN, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Phan', 'LocationStatus': 'Recruiting', 'LocationCity': 'Brest', 'LocationZip': '29200', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Thi Xuân-Mai PHAN, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Volant-Le-Berre', 'LocationStatus': 'Recruiting', 'LocationCity': 'Brest', 'LocationZip': '29200', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Charlotte VOLANT-LE-BERRE, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Wauters', 'LocationStatus': 'Recruiting', 'LocationCity': 'Brest', 'LocationZip': '29200', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Thomas WAUTERS, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr CAMILLERI', 'LocationStatus': 'Recruiting', 'LocationCity': 'Gouesnou', 'LocationZip': '29850', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Claire CAMILLERI, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Magueres', 'LocationStatus': 'Recruiting', 'LocationCity': 'Gouesnou', 'LocationZip': '29850', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Catherine MAGUERES, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Ben Yahmed', 'LocationStatus': 'Recruiting', 'LocationCity': 'Guipavas', 'LocationZip': '29490', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Khalil BEN YAHMED, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Le Grignou', 'LocationStatus': 'Recruiting', 'LocationCity': 'Guissény', 'LocationZip': '29880', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Caroline LE GRIGNOU, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': \"Dr Ac'h\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Landerneau', 'LocationZip': '29800', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': \"Sylvie AC'H, Dr\", 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Le Goff', 'LocationStatus': 'Recruiting', 'LocationCity': 'Landerneau', 'LocationZip': '29800', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Delphine LE GOFF, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Monnier', 'LocationStatus': 'Recruiting', 'LocationCity': 'Landerneau', 'LocationZip': '29800', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Brigitte MONNIER, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr PITMAN', 'LocationStatus': 'Recruiting', 'LocationCity': 'Landivisiau', 'LocationZip': '29400', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Roberto PITMAN, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Beck-Robert', 'LocationStatus': 'Recruiting', 'LocationCity': 'Lanmeur', 'LocationZip': '29260', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Emilie BECK-ROBERT, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Crenn-Corvez', 'LocationStatus': 'Recruiting', 'LocationCity': 'Lanmeur', 'LocationZip': '29260', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hélène CRENN-CORVEZ, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr CHIRON', 'LocationStatus': 'Recruiting', 'LocationCity': 'Le Relecq-Kerhuon', 'LocationZip': '29480', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Benoit CHIRON, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr CONNAN', 'LocationStatus': 'Recruiting', 'LocationCity': 'Le Relecq-Kerhuon', 'LocationZip': '29480', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Elodie CONNAN, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Cazuguel', 'LocationStatus': 'Recruiting', 'LocationCity': 'Locmaria-Plouzané', 'LocationZip': '29280', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yann CAZUGUEL, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Gasnier', 'LocationStatus': 'Recruiting', 'LocationCity': 'Ploudalmezeau', 'LocationZip': '29830', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Anne-laure GASNIER, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr Coat-Gourio', 'LocationStatus': 'Recruiting', 'LocationCity': 'Plougastel-Daoulas', 'LocationZip': '29470', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Christine COAT-GOURIO, Dr', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dr MAZE', 'LocationStatus': 'Recruiting', 'LocationCity': 'Saint-Renan', 'LocationZip': '29290', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Maryline MAZE, Dr', 'LocationContactRole': 'Contact'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Yes', 'IPDSharingDescription': 'All collected data that underlie results in a publication', 'IPDSharingInfoTypeList': {'IPDSharingInfoType': ['Study Protocol']}, 'IPDSharingTimeFrame': 'Data will be available beginning 3 years and ending fifteen years following the final study report completion', 'IPDSharingAccessCriteria': 'Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10890', 'ConditionBrowseLeafName': 'Neoplasm Metastasis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 20, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01143896', 'OrgStudyIdInfo': {'OrgStudyId': 'SDP 10-044'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '10-05', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'VA Central IRB'}]}, 'Organization': {'OrgFullName': 'VA Office of Research and Development', 'OrgClass': 'FED'}, 'BriefTitle': 'Hepatitis C Translating Initiatives for Depression Into Effective Solutions', 'OfficialTitle': 'Hepatitis C Translating Initiatives for Depression Into Solutions', 'Acronym': 'HEPTIDES'}, 'StatusModule': {'StatusVerifiedDate': 'April 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 2012'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2014', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 11, 2010', 'StudyFirstSubmitQCDate': 'June 11, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 14, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'January 4, 2016', 'ResultsFirstSubmitQCDate': 'March 11, 2016', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'April 11, 2016', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'April 12, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 16, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'VA Office of Research and Development', 'LeadSponsorClass': 'FED'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Chronic infection with hepatitis C (CHC) is a common and expensive condition, and it disproportionately affects Veterans. Treatment with antiviral therapy reduces liver disease progression and improves health related quality of life. However, ~70% of Veterans with CHC are considered ineligible for antiviral treatment. Most of these patients are excluded due to the presence of co-existing depression and substance use. The proposed project will adapt and adopt an evidence-based collaborative depression care model in CHC clinics. By removing the leading contraindication for antiviral treatment, this project will potentially yield benefits that go far beyond the obvious quality of life benefit from antidepressant therapy itself.', 'DetailedDescription': 'Project Background and Rationale: Depression is highly prevalent, yet under-diagnosed and under-treated in CHC. Treatment models that increase collaborative management of depression by mental health and physical health clinicians can improve quality and outcomes, and collaborative care models have been identified as the best-practice for depression in VA primary care settings. However, the antiviral treatment for CHC patients may not benefit from the existing primary care-mental health integration because the antiviral treatment is time-limited and conducted in specialty clinics. Although there is little evidence evaluating the effects of collaborative depression care in specialty settings, QUERI HIV-hepatitis initiated one of the first such efforts that effectively implemented collaborative depression care in HIV clinics. Built on this experience, an intensive yet focused collaborative care model in CHC clinics may be effective in improving not only depression but also CHC care. This proposed study, \"Hepatitis-Translating Initiatives for Depression into Effective Solutions (HEP-TIDES)\" will target this issue.\\n\\nProject Objectives: The proposal has three overarching primary aims and one exploratory aim. The primary aims are (1) adapt and adopt the collaborative care model for improving depression care in specialty CHC care settings, (2) compare the effectiveness of HEP-TIDES to usual care in improving CHC care, and (3) compare the effectiveness of HEP-TIDES to usual care in improving depression care. The exploratory aim is to evaluate the cost-effectiveness of HEP-TIDES versus usual care.\\n\\nProject Methods: HEP-TIDES is a multi-site, multi-method implementation project. HEP-TIDES will use evidence-based quality improvement (EBQI) methods to adapt and implement depression screening and the collaborative care model for depression in the CHC clinics at 4 disparate VA facilities (aim 1). HEP-TIDES will involve CHC and mental health providers working with an off-site depression care team comprised of a depression care nurse manager, pharmacist, and a psychiatrist. The purpose of the team will be to support CHC and mental health clinicians in delivering evidence-based stepped-care depression treatment. The adapted model will also take into account the substance use disorders among CHC patients. HEP-TIDES implementation will be assessed using a formative evaluation of the implementation process and a summative evaluation of a randomized controlled implementation trial of collaborative depression care in 242 patients (aims 2 and 3).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Hepatitis C', 'Depression']}, 'KeywordList': {'Keyword': ['Hepatitis C', 'Depression', 'Collaborative care', 'Antiviral treatment']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '309', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Arm 1: Depression Collaborative Care', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression collaborative care model']}}, {'ArmGroupLabel': 'Arm 2: Usual Care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Depression collaborative care model', 'InterventionDescription': \"The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Arm 1: Depression Collaborative Care']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment', 'PrimaryOutcomeDescription': 'Antiviral treatment initiation was measured dichotomously by assigning a value of 1 if the patient received at least one prescription of interferon within 12 months of enrollment, and a value of 0 otherwise.', 'PrimaryOutcomeTimeFrame': '12 months'}, {'PrimaryOutcomeMeasure': 'Depression Care: Treatment Response', 'PrimaryOutcomeDescription': 'Depression outcomes were assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Depression treatment response was defined as a 50% or greater decrease in the mean SCL-20 score compared with baseline.', 'PrimaryOutcomeTimeFrame': 'Baseline and 12 months'}, {'PrimaryOutcomeMeasure': 'Depression Care: Depression Remission', 'PrimaryOutcomeDescription': 'Depression outcomes were assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Remission was defined as an item mean SCL-20 score of less than 0.5.', 'PrimaryOutcomeTimeFrame': 'Baseline and 12 months'}, {'PrimaryOutcomeMeasure': 'Depression Care: Change From Baseline in Number of Depression Free Days (DFDs) at 12 Months', 'PrimaryOutcomeDescription': 'The change in Depression Free Days was assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Depression-free days (DFDs) were calculated using an SCL-20 score of less than 0.5 for depression-free and 2.0 or higher for fully symptomatic, and scores in between were assigned a linear proportional value.', 'PrimaryOutcomeTimeFrame': 'From Baseline to 12 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quality of Hepatitis C Care: Quality Indicators: Proportion of QIs Received', 'SecondaryOutcomeDescription': 'Quality of CHC Indicator Measure is based on a Delphi panel-derived list of quality indicators (QI) in CHC care. The list spans the following domains of care, i.e., CHC-specific function of care (diagnosis, specialty evaluation, treatment, etc); general function of care (diagnosis, treatment, follow-up); and mode of care (encounter, medication, immunization, counseling, etc). Adherence to a given QI is scored as 1 if there is evidence in the patient EMR for the indicator being satisfied. The quality of CHC care at the patient level is calculated by dividing the number of QIs for which that individual received the indicated care by the number of QIs for which the individual is eligible for during the length of time the patient is enrolled in the HEP-TIDES 12-month study timeframe.', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Medication Adherence: Medication Possession Ratio', 'SecondaryOutcomeDescription': \"Medication adherence was measured using the Medication Possession Ratio (MPR) calculation: Pharmacy refill data was used to calculate a medication possession ratio (MPR), by dividing the number of days supply of a medication received by the number of day's supply the patient needed to be able to take the medication continuously. An MPR closer to 1.0 indicates better adherence and has been associated with lower rates of hospital admission in veterans and greater symptom improvement.\", 'SecondaryOutcomeTimeFrame': '12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nconfirmed untreated infection (positive HCV RNA test)\\ncurrent PHQ-9 score of 10 or more\\ncurrent treatment in the CHC clinic\\n\\nExclusion Criteria:\\n\\nnon-Veterans\\npatients who do not have access to a telephone\\npatients with current suicidal ideation\\npatients with significant cognitive impairment as indicated by a score > 10 on the Blessed Orientation Memory and Concentration Test\\npatients with a chart diagnosis of schizophrenia\\npatients with a chart diagnosis of bipolar disorder who have been hospitalized for a mental health condition within the last 12 months', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '99 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Fasiha Kanwal, MBBS MD', 'OverallOfficialAffiliation': 'Michael E. DeBakey VA Medical Center, Houston, TX', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Jeffrey M. Pyne, MD', 'OverallOfficialAffiliation': 'Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Brian Dieckgraefe, MD', 'OverallOfficialAffiliation': 'St. Louis VA Medical Center John Cochran Division, St. Louis, MO', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Matthew Goetz, MD', 'OverallOfficialAffiliation': 'VA Greater Los Angeles Healthcare System', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock', 'LocationCity': 'Little Rock', 'LocationState': 'Arkansas', 'LocationZip': '72205-5484', 'LocationCountry': 'United States'}, {'LocationFacility': 'VA Greater Los Angeles Healthcare System, West Los Angeles, CA', 'LocationCity': 'West Los Angeles', 'LocationState': 'California', 'LocationZip': '90073', 'LocationCountry': 'United States'}, {'LocationFacility': 'St. Louis VA Medical Center John Cochran Division, St. Louis, MO', 'LocationCity': 'St Louis', 'LocationState': 'Missouri', 'LocationZip': '63106', 'LocationCountry': 'United States'}, {'LocationFacility': 'Michael E. DeBakey VA Medical Center, Houston, TX', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25952310', 'ReferenceType': 'result', 'ReferenceCitation': 'Pyne JM. Expanding the Scope of Integrated Behavioral Health Care for Patients With Hepatitis C Virus. Clin Gastroenterol Hepatol. 2015 Nov;13(11):2015-6. doi: 10.1016/j.cgh.2015.04.174. Epub 2015 May 5.'}, {'ReferencePMID': '26429337', 'ReferenceType': 'result', 'ReferenceCitation': 'Zuchowski JL, Hamilton AB, Pyne JM, Clark JA, Naik AD, Smith DL, Kanwal F. Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment. BMC Gastroenterol. 2015 Oct 1;15:124. doi: 10.1186/s12876-015-0356-5.'}, {'ReferencePMID': '27364808', 'ReferenceType': 'derived', 'ReferenceCitation': 'Kanwal F, Pyne JM, Tavakoli-Tabasi S, Nicholson S, Dieckgraefe B, Storay E, Bidwell Goetz M, Smith DL, Sansgiry S, Gifford A, Asch SM. Collaborative Care for Depression in Chronic Hepatitis C Clinics. Psychiatr Serv. 2016 Oct 1;67(10):1076-1082. Epub 2016 Jul 1.'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowRecruitmentDetails': 'We recruited a total of 309 patients from CHC clinics at 4 VAs (Houston, St Louis, Little Rock, and Los Angeles) between April 2012 and September 2013. Of these, 292 patients completed baseline interviews. Follow-up data-collection interviews were completed for 263 (90.1%) participants at 6-months and 242 (78.3%) participants at 12-months.', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Arm 1: Depression Collaborative Care', 'FlowGroupDescription': \"Depression collaborative care model: The depression collaborative care arm will include a stepped-care model. The five steps are expected to include symptom and self-management monitoring by depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM will provide education about depression and depression treatment options, assess the patient's treatment preferences and barriers, assess the patient's current depression severity and mental health comorbidity, initiate a self-management plan, and assess treatment adherence. The DCM will use the alcohol screening and brief intervention. The DCM will also screen for street drug use and will recommend referral of participants who are using street drugs to the local substance abuse treatment programs.\"}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Arm 2: Usual Care', 'FlowGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '156'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '153'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '114'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '128'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '42'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '25'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Did not complete Baseline Interview', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '5'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '4'}]}}, {'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '18'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '13'}]}}, {'FlowDropWithdrawType': 'Withdrawal by Subject', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '13'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '5'}]}}, {'FlowDropWithdrawType': 'Death', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '6'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '3'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'A total of 292 participants completed baseline interviews.', 'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Arm 1: Depression Collaborative Care', 'BaselineGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\"}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Arm 2: Usual Care', 'BaselineGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '145'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '147'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '292'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '59', 'BaselineMeasurementSpread': '5.8'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '59', 'BaselineMeasurementSpread': '5.2'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '59', 'BaselineMeasurementSpread': '5.5'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '12'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '139'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '141'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '280'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race/Ethnicity, Customized', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'White Non-Hispanic', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '59'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '41'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '100'}]}}]}}, {'BaselineClassTitle': 'Black or African American', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '72'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '91'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '163'}]}}]}}, {'BaselineClassTitle': 'Other', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '14'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '15'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '29'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '145'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '147'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '292'}]}}]}}]}}, {'BaselineMeasureTitle': 'Marital Status', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Single, Never Married', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '45'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '68'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '113'}]}}]}}, {'BaselineClassTitle': 'Married', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '14'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '16'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '30'}]}}]}}, {'BaselineClassTitle': 'Other (divorced, widowed, separated, no response)', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '86'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '63'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '149'}]}}]}}]}}, {'BaselineMeasureTitle': 'Annual Income', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Less than $20,000', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '60'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '57'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '117'}]}}]}}, {'BaselineClassTitle': 'Over $20,000', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '43'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '41'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '84'}]}}]}}, {'BaselineClassTitle': \"Don't Know/Refused\", 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '42'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '49'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '91'}]}}]}}]}}, {'BaselineMeasureTitle': 'History of Mood Disorders', 'BaselineMeasureDescription': 'In the last 6 months, did you receive care for personal or emotional problems, feeling down, worried or anxious, or alcohol or drug problem?', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Yes', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '65'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '67'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '132'}]}}]}}, {'BaselineClassTitle': 'No', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '80'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '78'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '158'}]}}]}}, {'BaselineClassTitle': \"Don't Know/Refused\", 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2'}]}}]}}]}}, {'BaselineMeasureTitle': 'Taking antidepressant meds at baseline', 'BaselineMeasureDescription': 'Do you have a current prescription for any anti-depressant medications, such as prozac or lexapro?', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Yes', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '71'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '67'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '138'}]}}]}}, {'BaselineClassTitle': 'No', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '71'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '79'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '150'}]}}]}}, {'BaselineClassTitle': \"Don't Know/Refused\", 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment', 'OutcomeMeasureDescription': 'Antiviral treatment initiation was measured dichotomously by assigning a value of 1 if the patient received at least one prescription of interferon within 12 months of enrollment, and a value of 0 otherwise.', 'OutcomeMeasurePopulationDescription': 'intent to treat', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'participants', 'OutcomeMeasureTimeFrame': '12 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Arm 1: Depression Collaborative Care', 'OutcomeGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Arm 2: Usual Care', 'OutcomeGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '114'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '128'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '11'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '7'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Quality of Hepatitis C Care: Quality Indicators: Proportion of QIs Received', 'OutcomeMeasureDescription': 'Quality of CHC Indicator Measure is based on a Delphi panel-derived list of quality indicators (QI) in CHC care. The list spans the following domains of care, i.e., CHC-specific function of care (diagnosis, specialty evaluation, treatment, etc); general function of care (diagnosis, treatment, follow-up); and mode of care (encounter, medication, immunization, counseling, etc). Adherence to a given QI is scored as 1 if there is evidence in the patient EMR for the indicator being satisfied. The quality of CHC care at the patient level is calculated by dividing the number of QIs for which that individual received the indicated care by the number of QIs for which the individual is eligible for during the length of time the patient is enrolled in the HEP-TIDES 12-month study timeframe.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'proportion of QIs met', 'OutcomeMeasureTimeFrame': '12 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Arm 1: Depression Collaborative Care', 'OutcomeGroupDescription': \"Depression collaborative care model: The depression collaborative care arm will include a stepped-care model. The five steps are expected to include symptom and self-management monitoring by depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM will provide education about depression and depression treatment options, assess the patient's treatment preferences and barriers, assess the patient's current depression severity and mental health comorbidity, initiate a self-management plan, and assess treatment adherence. The DCM will use the alcohol screening and brief intervention. The DCM will also screen for street drug use and will recommend referral of participants who are using street drugs to the local substance abuse treatment programs.\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Arm 2: Usual Care', 'OutcomeGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '114'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '128'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '.89', 'OutcomeMeasurementSpread': '.16'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '.83', 'OutcomeMeasurementSpread': '.19'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Medication Adherence: Medication Possession Ratio', 'OutcomeMeasureDescription': \"Medication adherence was measured using the Medication Possession Ratio (MPR) calculation: Pharmacy refill data was used to calculate a medication possession ratio (MPR), by dividing the number of days supply of a medication received by the number of day's supply the patient needed to be able to take the medication continuously. An MPR closer to 1.0 indicates better adherence and has been associated with lower rates of hospital admission in veterans and greater symptom improvement.\", 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'medication posession ratio', 'OutcomeMeasureTimeFrame': '12 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Arm 1: Depression Collaborative Care', 'OutcomeGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Arm 2: Usual Care', 'OutcomeGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '114'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '128'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '.83', 'OutcomeMeasurementSpread': '.20'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '.78', 'OutcomeMeasurementSpread': '.24'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Depression Care: Treatment Response', 'OutcomeMeasureDescription': 'Depression outcomes were assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Depression treatment response was defined as a 50% or greater decrease in the mean SCL-20 score compared with baseline.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'participants', 'OutcomeMeasureTimeFrame': 'Baseline and 12 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Arm 1: Depression Collaborative Care', 'OutcomeGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Arm 2: Usual Care', 'OutcomeGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '114'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '128'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '36'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '19'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Depression Care: Depression Remission', 'OutcomeMeasureDescription': 'Depression outcomes were assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Remission was defined as an item mean SCL-20 score of less than 0.5.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'participants', 'OutcomeMeasureTimeFrame': 'Baseline and 12 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Arm 1: Depression Collaborative Care', 'OutcomeGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Arm 2: Usual Care', 'OutcomeGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '114'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '128'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '22'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '9'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Depression Care: Change From Baseline in Number of Depression Free Days (DFDs) at 12 Months', 'OutcomeMeasureDescription': 'The change in Depression Free Days was assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Depression-free days (DFDs) were calculated using an SCL-20 score of less than 0.5 for depression-free and 2.0 or higher for fully symptomatic, and scores in between were assigned a linear proportional value.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'Depression Free Days (DFDs)', 'OutcomeMeasureTimeFrame': 'From Baseline to 12 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Arm 1: Depression Collaborative Care', 'OutcomeGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Arm 2: Usual Care', 'OutcomeGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '114'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '128'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '118.74', 'OutcomeMeasurementSpread': '106.68'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '109.30', 'OutcomeMeasurementSpread': '117.88'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': '12 months', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Arm 1: Depression Collaborative Care', 'EventGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\", 'EventGroupSeriousNumAffected': '6', 'EventGroupSeriousNumAtRisk': '145', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '145'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Arm 2: Usual Care', 'EventGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.', 'EventGroupSeriousNumAffected': '3', 'EventGroupSeriousNumAtRisk': '147', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '147'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Death (IRB determined unrelated to the study)', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventNotes': 'Specific cause of death unavailable', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '6', 'SeriousEventStatsNumAffected': '6', 'SeriousEventStatsNumAtRisk': '145'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '147'}]}}]}}, 'MoreInfoModule': {'LimitationsAndCaveats': {}, 'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Fasiha Kanwal, MD, MSHS', 'PointOfContactOrganization': 'Michael E. DeBakey VA Medical Center', 'PointOfContactEMail': 'Fasiha.Kanwal@va.gov', 'PointOfContactPhone': '(713) 440-4495'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006506', 'ConditionMeshTerm': 'Hepatitis A'}, {'ConditionMeshId': 'D000006526', 'ConditionMeshTerm': 'Hepatitis C'}, {'ConditionMeshId': 'D000006505', 'ConditionMeshTerm': 'Hepatitis'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000008107', 'ConditionAncestorTerm': 'Liver Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000006525', 'ConditionAncestorTerm': 'Hepatitis, Viral, Human'}, {'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}, {'ConditionAncestorId': 'D000004769', 'ConditionAncestorTerm': 'Enterovirus Infections'}, {'ConditionAncestorId': 'D000010850', 'ConditionAncestorTerm': 'Picornaviridae Infections'}, {'ConditionAncestorId': 'D000012327', 'ConditionAncestorTerm': 'RNA Virus Infections'}, {'ConditionAncestorId': 'D000018178', 'ConditionAncestorTerm': 'Flaviviridae Infections'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M8174', 'ConditionBrowseLeafName': 'Hepatitis', 'ConditionBrowseLeafAsFound': 'Hepatitis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8175', 'ConditionBrowseLeafName': 'Hepatitis A', 'ConditionBrowseLeafAsFound': 'Hepatitis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8194', 'ConditionBrowseLeafName': 'Hepatitis C', 'ConditionBrowseLeafAsFound': 'Hepatitis C', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9690', 'ConditionBrowseLeafName': 'Liver Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7466', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5838', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8193', 'ConditionBrowseLeafName': 'Hepatitis, Viral, Human', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6513', 'ConditionBrowseLeafName': 'Enterovirus Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12328', 'ConditionBrowseLeafName': 'Picornaviridae Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13732', 'ConditionBrowseLeafName': 'RNA Virus Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M18907', 'ConditionBrowseLeafName': 'Flaviviridae Infections', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}]}}}}}, {'Rank': 21, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03062215', 'OrgStudyIdInfo': {'OrgStudyId': 'CAiCBT'}, 'Organization': {'OrgFullName': 'Silver Cloud Health', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Efficacy of a Culturally Adapted Cognitive Behavioural Internet-delivered Treatment for Depression', 'OfficialTitle': 'Assessing the Efficacy of a Culturally Adapted Cognitive Behavioural Internet-delivered Treatment for Depression: Protocol for a Randomised Controlled Trial', 'Acronym': 'CAiCBT'}, 'StatusModule': {'StatusVerifiedDate': 'September 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 2, 2016', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 1, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 1, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 14, 2017', 'StudyFirstSubmitQCDate': 'February 20, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 23, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'September 7, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 10, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Silver Cloud Health', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Irish Research Council', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The study seeks to evaluate the efficacy of a culturally adapted internet-delivered treatment for depression in Colombia. The research involves two studies: (a) the cultural adaptation of the Space from Depression cognitive-behavioural internet-delivered programme, and (b) the implementation of the culturally adapted intervention using a randomised controlled trial methodology. The study will be a first contribution of a culturally adapted low-intensity internet-delivered intervention with Latin Americans.', 'DetailedDescription': 'Depression is the principal cause of disability in the world. High rates of prevalence of depression in general populations and college students have been found worldwide and in various cultural groups. For instance, a 12-month prevalence rate has been estimated in the U.S. at 9.5% and in Europe at 8.5% of the population. In Colombia, 12-month prevalence is between 6.2% and 12.1%. The Colombian National Mental Health Survey has estimated point prevalence of mild to moderate depressive symptoms at 15.6% and severe depressive symptoms at 4.2% of adults. On the other hand, there are significant barriers for accessing mental health services in Colombia. About 50% of the population does not have access to health services, while the majority of the population with mental health problems do not have adequate mental health insurance coverage.\\n\\nAlthough low-intensity interventions for depression have been developed in western high-income countries and these interventions therefore have been influenced by their specific cultural context (for example, Ireland, UK, Australia), it is important to consider how cultural context may impact on the adaptation for use in LMICs such as Colombia. The authors argue that cultural aspects need to be taken into consideration when translating and adapting interventions to help guarantee similar results to what have been achieved in high-income countries.\\n\\nGeneral method Aims and Hypothesis: We aim to assess the efficacy of a culturally adapted cognitive behavioural internet-delivered treatment for college students with depressive symptoms in Colombia. In line with other studies in high-income countries (HICs), and using an already established intervention, we hypothesise that the culturally adapted Space from Depression programme will be efficacious, with significant changes within the treatment group and differences post-treatment between the active treatment and the waiting list control group.\\n\\nThe study is a mixed method approach utilising in study 1, quantitative and qualitative methods to assist in the cultural adaptation of the Space from Depression intervention and in study 2 a randomised control design to examine the efficacy of the culturally-adapted intervention.\\n\\nProcedure The programme Space from Depression will be culturally adapted for a Colombian population using cultural sensitivity and ecological validity frameworks, including principles from cross-cultural assessment research. (Study 1). Once the programme is culturally adapted, it will be tested using a randomised controlled trial methodology (Study 2).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Culturally adapted psychotherapy', 'Internet-delivered treatment', 'Depression', 'Latin America']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '127', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Space from depression', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions depression. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page. Also, users have a supporter, who will give feedback asynchronously (D Richards et al., 2015). Research on the SilverCloud interventions has yielded significant clinical outcomes (D Richards et al., 2015).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Space from Depression']}}, {'ArmGroupLabel': 'Control Group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Waiting list'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Space from Depression', 'InterventionDescription': 'Space from Depression programme (Yo puedo sentirme Bien -Spanish version) consists of seven modules of cognitive-behavioural therapy. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Space from depression']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Yo puedo sentirme bien']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Patient Health Questionnaire -9', 'PrimaryOutcomeDescription': 'depression symptoms', 'PrimaryOutcomeTimeFrame': '6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Generalised Anxiety Disorder 7', 'SecondaryOutcomeDescription': 'anxiety symptoms', 'SecondaryOutcomeTimeFrame': '6 months'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Satisfaction with Treatment Questionnaire', 'OtherOutcomeDescription': 'Patient satisfaction', 'OtherOutcomeTimeFrame': '2 months'}, {'OtherOutcomeMeasure': 'Helpful Aspects of Therapy Questionnaire', 'OtherOutcomeDescription': 'Significant events', 'OtherOutcomeTimeFrame': 'weekly for 7 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n18 years old and above\\nMild to moderately severe depressive symptoms: (PHQ-9 score 10-19)\\n\\nExclusion Criteria:\\n\\nSevere depressive symptoms >19 on PHQ-9\\nSuicidal ideation or intent: Score of 2 or above on PHQ-9 question 9\\nPsychosis\\nCurrently in psychological treatment for depression\\nOn medication for less than 1 month\\nAlcohol or drugs misuse\\nPrevious diagnosis of an organic mental health disorder\\nDepression preceding or coinciding a diagnosed medical condition', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Derek Richards, PhD', 'OverallOfficialAffiliation': 'Trinity College Dublin', 'OverallOfficialRole': 'Study Director'}, {'OverallOfficialName': 'Alicia Salamanca, MSc', 'OverallOfficialAffiliation': 'Trinity College Dublin', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University Los Andes', 'LocationCity': 'Bogota', 'LocationCountry': 'Colombia'}, {'LocationFacility': 'University of Bucaramanga', 'LocationCity': 'Bucaramanga', 'LocationCountry': 'Colombia'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '11581110', 'ReferenceType': 'background', 'ReferenceCitation': 'Ayuso-Mateos JL, Vázquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P, Wilkinson C, Lasa L, Page H, Dunn G, Wilkinson G; ODIN Group. Depressive disorders in Europe: prevalence figures from the ODIN study. Br J Psychiatry. 2001 Oct;179:308-16.'}, {'ReferencePMID': '15939839', 'ReferenceType': 'background', 'ReferenceCitation': 'Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):617-27. Erratum in: Arch Gen Psychiatry. 2005 Jul;62(7):709. Merikangas, Kathleen R [added].'}, {'ReferencePMID': '21791035', 'ReferenceType': 'background', 'ReferenceCitation': 'Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, Levinson D, Matschinger H, Mora ME, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011 Jul 26;9:90. doi: 10.1186/1741-7015-9-90.'}, {'ReferencePMID': '15173149', 'ReferenceType': 'background', 'ReferenceCitation': 'Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, Angermeyer MC, Bernert S, de Girolamo G, Morosini P, Polidori G, Kikkawa T, Kawakami N, Ono Y, Takeshima T, Uda H, Karam EG, Fayyad JA, Karam AN, Mneimneh ZN, Medina-Mora ME, Borges G, Lara C, de Graaf R, Ormel J, Gureje O, Shen Y, Huang Y, Zhang M, Alonso J, Haro JM, Vilagut G, Bromet EJ, Gluzman S, Webb C, Kessler RC, Merikangas KR, Anthony JC, Von Korff MR, Wang PS, Brugha TS, Aguilar-Gaxiola S, Lee S, Heeringa S, Pennell BE, Zaslavsky AM, Ustun TB, Chatterji S; WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004 Jun 2;291(21):2581-90.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Bernal, Sáez-Santiago E. Culturally centered psychosocial interventions. Journal of Community Psychology. 2006;34(2):121.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Richards D, Timulak L, Hevey D. A comparison of two online cognitive-behavioural interventions for symptoms of depression in a student population: The role of therapist responsiveness. Counselling & Psychotherapy Research. 2013;13(3):184-93.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Ministry of Health. National Mental Health survey. Bogota, Colombia: Ministry of Health; 2015. Report No.: 978-958-8903-19-4.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Rodriguez J. La atención de Salud Mental en América Latina y el caribe. Rev Psiquiatr Urug. 2007;71(2):117-24.'}, {'ReferencePMID': '21787063', 'ReferenceType': 'background', 'ReferenceCitation': 'Merz EL, Malcarne VL, Roesch SC, Riley N, Sadler GR. A multigroup confirmatory factor analysis of the Patient Health Questionnaire-9 among English- and Spanish-speaking Latinas. Cultur Divers Ethnic Minor Psychol. 2011 Jul;17(3):309-316. doi: 10.1037/a0023883.'}, {'ReferencePMID': '11556941', 'ReferenceType': 'background', 'ReferenceCitation': 'Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.'}, {'ReferencePMID': '10568646', 'ReferenceType': 'background', 'ReferenceCitation': 'Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999 Nov 10;282(18):1737-44.'}, {'ReferencePMID': '17874169', 'ReferenceType': 'background', 'ReferenceCitation': 'Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med. 2007 Nov;22(11):1596-602. Epub 2007 Sep 14.'}, {'ReferencePMID': '26523885', 'ReferenceType': 'background', 'ReferenceCitation': \"Richards D, Timulak L, O'Brien E, Hayes C, Vigano N, Sharry J, Doherty G. A randomized controlled trial of an internet-delivered treatment: Its potential as a low-intensity community intervention for adults with symptoms of depression. Behav Res Ther. 2015 Dec;75:20-31. doi: 10.1016/j.brat.2015.10.005. Epub 2015 Oct 21.\"}, {'ReferencePMID': '16717171', 'ReferenceType': 'background', 'ReferenceCitation': 'Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7.'}, {'ReferencePMID': '20089179', 'ReferenceType': 'background', 'ReferenceCitation': 'García-Campayo J, Zamorano E, Ruiz MA, Pardo A, Pérez-Páramo M, López-Gómez V, Freire O, Rejas J. Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool. Health Qual Life Outcomes. 2010 Jan 20;8:8. doi: 10.1186/1477-7525-8-8.'}, {'ReferencePMID': '3191302', 'ReferenceType': 'background', 'ReferenceCitation': 'Llewelyn SP. Psychological therapy as viewed by clients and therapists. Br J Clin Psychol. 1988 Sep;27(3):223-37.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Elliott R, Slatick E, Urman M. Qualitative change process research on psychotherapy: Alternative strategies. Psychological Test and Assessment Modeling. 2001;43(3):69.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Richards D, Timulak L. Satisfaction with therapist-delivered vs. self-administered online cognitive behavioural treatments for depression symptoms in college students. British Journal of Guidance & Counselling. 2013;41(2):193-207.'}, {'ReferencePMID': '32003749', 'ReferenceType': 'derived', 'ReferenceCitation': 'Salamanca-Sanabria A, Richards D, Timulak L, Connell S, Mojica Perilla M, Parra-Villa Y, Castro-Camacho L. A Culturally Adapted Cognitive Behavioral Internet-Delivered Intervention for Depressive Symptoms: Randomized Controlled Trial. JMIR Ment Health. 2020 Jan 31;7(1):e13392. doi: 10.2196/13392.'}, {'ReferencePMID': '29482586', 'ReferenceType': 'derived', 'ReferenceCitation': 'Salamanca-Sanabria A, Richards D, Timulak L, Castro-Camacho L, Mojica-Perilla M, Parra-Villa Y. Assessing the efficacy of a culturally adapted cognitive behavioural internet-delivered treatment for depression: protocol for a randomised controlled trial. BMC Psychiatry. 2018 Feb 27;18(1):53. doi: 10.1186/s12888-018-1634-x.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 22, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01159041', 'OrgStudyIdInfo': {'OrgStudyId': '1R01MH082861', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH082861&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH082856-01A2', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH082856-01A2&Fy=all'}, {'SecondaryId': 'R01MH082861-01A2', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH082861-01A2&Fy=all'}]}, 'Organization': {'OrgFullName': 'Boston University Charles River Campus', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Systems of Support Study for Childhood Depression', 'OfficialTitle': 'Evaluation of Family Focused Treatment for Childhood Depression', 'Acronym': 'SOS'}, 'StatusModule': {'StatusVerifiedDate': 'January 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2010'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 7, 2010', 'StudyFirstSubmitQCDate': 'July 7, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 9, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 22, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 24, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Martha C. Tompson', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Boston University Charles River Campus'}, 'LeadSponsor': {'LeadSponsorName': 'Boston University Charles River Campus', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of California, Los Angeles', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'This study is designed to compare two treatments for depression in pre-adolescent (7-13 year old) children. A family-focused treatment will be compared to an individual child-focused treatment in this 14-week intervention.', 'DetailedDescription': 'Childhood-onset depression is an impairing and often recurrent and persistent disorder that impacts current and later development resulting in high personal, social, and economic costs. Despite the costs of early-onset depression, the emphasis in current practice parameters on an initial course of psychosocial treatment, and extensive research on adolescent depression, we currently lack randomized controlled trials evaluating psychosocial treatments for children with depressive disorders.\\n\\nThe present proposal aims to address this gap in knowledge regarding optimal psychosocial treatment strategies for children suffering from depressive disorders. We propose a 2-site randomized controlled trial to evaluate the efficacy of Family Focused Treatment (FFT), as compared to an individual client-centered psychotherapy (IP) modeled after \"usual\" community care. FFT adopts an interpersonal model for understanding how depressive symptoms are maintained, emphasizes developing family skills/strategies for altering interpersonal processes, and works on building a family environment that supports recovery and enhances stress resistance and resilience. This approach may be particularly appropriate to the developmental needs of depressed children, given their dependence on parents, the potential of FFT to address the needs of multiple family members, and our data supporting benefits on depression, functioning, and other co-occurring symptoms.\\n\\nThe proposed project will enroll 140 children (ages 8-12) with depressive disorders. Children will be randomly assigned to receive a 14-week trial of either FFT or IP. At study entry, immediately post-treatment, and at a 9-month post-treatment follow-up all participants will undergo intensive evaluation of clinical state and psychosocial and family functioning.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression, children, adolescent, family']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '134', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Family Focused Treatment (FFT)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': '15 session family-based treatment emphasizing improving relationship skills to combat depression symptoms and support recovery.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Family Focused Treatment (FFT)']}}, {'ArmGroupLabel': 'Individual Treatment (IP)', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': '15 session individually-based treatment to assist children in understanding the causes of their symptoms.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Individual Treatment (IP)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Family Focused Treatment (FFT)', 'InterventionDescription': 'FFT is designed to specifically address the developmental needs of school-aged children and their parents through an emphasis on fostering positive and supportive parent-child interactions that scaffold the development of a positive self, to help parents provide the child additional positive feedback on his/her developmentally appropriate achievements, and to enhance family and child coping. This treatment is conducted with the child and his/her parent(s) and includes education about depression, communication training, relationship enhancement, and problem-solving.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Family Focused Treatment (FFT)']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Individual Treatment (IP)', 'InterventionDescription': \"The goals of the treatment are to foster the therapeutic relationship, to provide a supportive and empathic setting where the child can come to better understand his/her emotions/feelings and address issues underlying current symptoms. Therapeutic goals will be addressed through reflection and clarification of feelings/emotions and understanding the child's perception of the context of depressed feelings.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Individual Treatment (IP)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Adequate Depression Treatment Response', 'PrimaryOutcomeDescription': \"50% improvement on Children's Depression Rating Scale-Revised\", 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Interviewer-rated Depression Severity', 'SecondaryOutcomeDescription': \"Children's Depression Rating Scale-Revised (CDRS-R) measures depression severity over the past two weeks. The 17-item CDRS-R has total scores ranging from 17 to 113 with scores of 40 or greater considered indicative of a depression diagnosis. Used in pharmacological and psychosocial treatment studies, it provides comparability across studies.\", 'SecondaryOutcomeTimeFrame': '3 Months'}, {'SecondaryOutcomeMeasure': \"Children's Self-Report of Depression Symptoms\", 'SecondaryOutcomeDescription': 'Child Depression Inventory (CDI) is a 27-item self-report measure. Scores range from 0 to 54 with higher scores reflecting higher levels of symptoms.', 'SecondaryOutcomeTimeFrame': '3 Months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ncurrent Depressive Disorder\\nages 7-13 years\\nliving with at least one biological parent willing to participate\\n\\nExclusion Criteria:\\n\\nthought disturbance\\nsevere conduct disorders\\nunstable on antidepressant medications\\ncontinuation in current non-study treatment\\nnon-English speaking', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '7 Years', 'MaximumAge': '13 Years', 'StdAgeList': {'StdAge': ['Child']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'UCLA Semel Institute for Neuroscience and Human Behavior', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90095', 'LocationCountry': 'United States'}, {'LocationFacility': 'Boston University', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02215', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '17953128', 'ReferenceType': 'background', 'ReferenceCitation': 'Tompson MC, Pierre CB, Haber FM, Fogler JM, Groff AR, Asarnow JR. Family-focused treatment for childhood-onset depressive disorders: results of an open trial. Clin Child Psychol Psychiatry. 2007 Jul;12(3):403-20.'}, {'ReferencePMID': '22537731', 'ReferenceType': 'result', 'ReferenceCitation': 'Tompson MC, Boger KD, Asarnow JR. Enhancing the developmental appropriateness of treatment for depression in youth: integrating the family in treatment. Child Adolesc Psychiatr Clin N Am. 2012 Apr;21(2):345-84. doi: 10.1016/j.chc.2012.01.003. Epub 2012 Mar 17. Review.'}, {'ReferencePMID': '28545757', 'ReferenceType': 'result', 'ReferenceCitation': 'Tompson MC, Sugar CA, Langer DA, Asarnow JR. A Randomized Clinical Trial Comparing Family-Focused Treatment and Individual Supportive Therapy for Depression in Childhood and Early Adolescence. J Am Acad Child Adolesc Psychiatry. 2017 Jun;56(6):515-523. doi: 10.1016/j.jaac.2017.03.018. Epub 2017 Apr 7.'}, {'ReferencePMID': '28966545', 'ReferenceType': 'result', 'ReferenceCitation': 'Tompson MC, Langer DA, Hughes JL, Asarnow JR. Family-Focused Treatment for Childhood Depression: Model and Case Illustrations. Cogn Behav Pract. 2017 Aug;24(3):269-287. doi: 10.1016/j.cbpra.2016.06.003.'}, {'ReferencePMID': '31840263', 'ReferenceType': 'derived', 'ReferenceCitation': 'Asarnow JR, Tompson MC, Klomhaus AM, Babeva K, Langer DA, Sugar CA. Randomized controlled trial of family-focused treatment for child depression compared to individual psychotherapy: one-year outcomes. J Child Psychol Psychiatry. 2019 Dec 15. doi: 10.1111/jcpp.13162. [Epub ahead of print]'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 23, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02030782', 'OrgStudyIdInfo': {'OrgStudyId': 'HS009908'}, 'Organization': {'OrgFullName': 'Agency for Healthcare Research and Quality (AHRQ)', 'OrgClass': 'FED'}, 'BriefTitle': 'Youth Partners in Care: Depression and Quality Improvement', 'OfficialTitle': 'Youth Partners in Care: Depression & Quality Improvement', 'Acronym': 'YPIC'}, 'StatusModule': {'StatusVerifiedDate': 'December 2008', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 1999'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2003', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2003', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 19, 2012', 'StudyFirstSubmitQCDate': 'January 7, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 9, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 7, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 9, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Agency for Healthcare Research and Quality (AHRQ)', 'LeadSponsorClass': 'FED'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'RAND', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Kaiser Permanente', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'University of Pittsburgh', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Venice Family Clinic', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'This randomized effectiveness trial evaluates a quality improvement intervention aimed at providing access to evidence-based depression treatments (particularly cognitive-behavior therapy for depression and or pharmacotherapy) through primary care for youth ages 13-21, as compared to enhanced usual care. The major hypothesis is that the quality improvement intervention will be associated with improved outcomes, relative to enhanced usual care.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['depression', 'quality improvement', 'treatment', 'adolescents']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '418', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Usual Care', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Patients received usual care through primary care, enhanced by provider education regarding depression evaluation and management (1-2 hour training, plus study manual)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Usual Care']}}, {'ArmGroupLabel': 'Quality Improvement for Depression', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Quality Improvement (QI) for depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Quality Improvement (QI) for depression', 'InterventionDescription': 'Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Quality Improvement for Depression']}}, {'InterventionType': 'Other', 'InterventionName': 'Usual Care', 'InterventionDescription': 'Usual care enhanced by provider education regarding depression evaluation and management', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Usual Care']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Self-reported depressive symptoms on the CES-D (Center for Epidemiologic Studies Depression Scale)', 'PrimaryOutcomeTimeFrame': '6-months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'mental health related quality of life as assessed using self-report on the Medical Outcomes Study Short Form 12 Health Survey.', 'SecondaryOutcomeTimeFrame': '6 months, with follow up at 12 and 18 months'}, {'SecondaryOutcomeMeasure': 'satisfaction with care', 'SecondaryOutcomeTimeFrame': '6 months with follow up at 12 and 18 months'}, {'SecondaryOutcomeMeasure': 'Rates of mental health care, counseling/psychotherapy, and medication treatment.', 'SecondaryOutcomeDescription': 'Youth self report on the study version of the Service Assessment for Children & Adolescents provided measures of rates of mental health care(dichotomous indicator of whether any mental health treatment received), counseling/psychotherapy (dichotomous indicator of whether counseling/psychotherapy was received, number of counseling/psychotherapy sessions), and medication treatment (dichotomous indicator of whether youth received any medication treatment for mental health problems). These measures were obtained using .', 'SecondaryOutcomeTimeFrame': '6-months with follow-up at 12 and 18 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMet either of two criteria: 1) endorsed \"stem items\" for major depression or dysthymia from the 12-month Composite International Diagnostic Interview(CIDI-12,2.1) modified slightly to conform to diagnostic criteria for adolescents, 1-week or more of past-month depressive symptoms, and a total Center for Epidemiological Studies- Depression Scale(CES-D)40 score ≥ 16, or 2) CES-D score ≥ 24.\\nAge 13-21\\nPresented at primary care clinic\\n\\nExclusion Criteria:\\n\\nnot English-speaking\\nprovider not in study\\nsibling already in study\\ncompleted eligibility screener previously', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '13 Years', 'MaximumAge': '21 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Joan R Asarnow, PhD', 'OverallOfficialAffiliation': 'University of California, Los Angeles', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of California', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90024', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kaiser Permanente Los Angeles Medical Center', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationFacility': 'Venice Family Clinic', 'LocationCity': 'Venice', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationFacility': 'Ventura County Medical Center', 'LocationCity': 'Ventura', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Pittsburgh', 'LocationCity': 'Pittsburgh', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '12222079', 'ReferenceType': 'background', 'ReferenceCitation': 'Asarnow JR, Jaycox LH, Anderson M. Depression among youth in primary care models for delivering mental health services. Child Adolesc Psychiatr Clin N Am. 2002 Jul;11(3):477-97, viii.'}, {'ReferencePMID': '11430853', 'ReferenceType': 'background', 'ReferenceCitation': 'Wells KB, Kataoka SH, Asarnow JR. Affective disorders in children and adolescents: addressing unmet need in primary care settings. Biol Psychiatry. 2001 Jun 15;49(12):1111-20. Review.'}, {'ReferencePMID': '19651711', 'ReferenceType': 'result', 'ReferenceCitation': 'Asarnow JR, Jaycox LH, Tang L, Duan N, LaBorde AP, Zeledon LR, Anderson M, Murray PJ, Landon C, Rea MM, Wells KB. Long-term benefits of short-term quality improvement interventions for depressed youths in primary care. Am J Psychiatry. 2009 Sep;166(9):1002-10. doi: 10.1176/appi.ajp.2009.08121909. Epub 2009 Aug 3.'}, {'ReferencePMID': '15657324', 'ReferenceType': 'result', 'ReferenceCitation': 'Asarnow JR, Jaycox LH, Duan N, LaBorde AP, Rea MM, Murray P, Anderson M, Landon C, Tang L, Wells KB. Effectiveness of a quality improvement intervention for adolescent depression in primary care clinics: a randomized controlled trial. JAMA. 2005 Jan 19;293(3):311-9.'}, {'ReferencePMID': '16502131', 'ReferenceType': 'result', 'ReferenceCitation': \"Jaycox LH, Asarnow JR, Sherbourne CD, Rea MM, LaBorde AP, Wells KB. Adolescent primary care patients' preferences for depression treatment. Adm Policy Ment Health. 2006 Mar;33(2):198-207.\"}, {'ReferencePMID': '16310125', 'ReferenceType': 'result', 'ReferenceCitation': 'Asarnow JR, Jaycox LH, Duan N, LaBorde AP, Rea MM, Tang L, Anderson M, Murray P, Landon C, Tang B, Huizar DP, Wells KB. Depression and role impairment among adolescents in primary care clinics. J Adolesc Health. 2005 Dec;37(6):477-83.'}, {'ReferencePMID': '19797376', 'ReferenceType': 'result', 'ReferenceCitation': 'Ngo VK, Asarnow JR, Lange J, Jaycox LH, Rea MM, Landon C, Tang L, Miranda J. Outcomes for youths from racial-ethnic minority groups in a quality improvement intervention for depression treatment. Psychiatr Serv. 2009 Oct;60(10):1357-64. doi: 10.1176/ps.2009.60.10.1357.'}, {'ReferencePMID': '18937226', 'ReferenceType': 'result', 'ReferenceCitation': 'Tang L, Duan N, Klap R, Asarnow JR, Belin TR. Applying permutation tests with adjustment for covariates and attrition weights to randomized trials of health-services interventions. Stat Med. 2009 Jan 15;28(1):65-74. doi: 10.1002/sim.3453.'}, {'ReferencePMID': '18018807', 'ReferenceType': 'result', 'ReferenceCitation': 'Goldstein RB, Asarnow JR, Jaycox LH, Shoptaw S, Murray PJ. Correlates of \"non-problematic\" and \"problematic\" substance use among depressed adolescents in primary care. J Addict Dis. 2007;26(3):39-52.'}, {'ReferencePMID': '17658983', 'ReferenceType': 'result', 'ReferenceCitation': 'Fordwood SR, Asarnow JR, Huizar DP, Reise SP. Suicide attempts among depressed adolescents in primary care. J Clin Child Adolesc Psychol. 2007 Jul-Sep;36(3):392-404.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 24, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00755235', 'OrgStudyIdInfo': {'OrgStudyId': 'R21MH082924', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R21MH082924&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R21MH082924', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R21MH082924&Fy=all'}, {'SecondaryId': 'DSIR 82-SEDR'}]}, 'Organization': {'OrgFullName': 'Kaiser Permanente', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Feasibility of Depression Care Management by E-mail', 'OfficialTitle': 'Pilot Trial of Depression Care Management by Electronic Secure Messaging'}, 'StatusModule': {'StatusVerifiedDate': 'October 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2010', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 2010', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'September 17, 2008', 'StudyFirstSubmitQCDate': 'September 17, 2008', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 18, 2008', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'July 22, 2011', 'ResultsFirstSubmitQCDate': 'May 31, 2012', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'June 1, 2012', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 11, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 13, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Kaiser Permanente', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study will test whether an electronic system that monitors and sends messages to help people with depression could be feasible, acceptable, and potentially effective as a treatment.', 'DetailedDescription': 'Symptoms of depression, such as persistent sadness, problems sleeping, and inability to feel pleasure, interfere with the daily lives of more than 20 million Americans. Previous research indicates that telephone care management systems improve the quality and outcomes of depression care, but are too expensive to be used widely. Using secure messaging over e-mail would be more cost effective than telephone care. This study will examine whether a secure messaging care management program would be feasible, based on whether participants are willing to sign up for and continue with the program, and whether the program has a positive effect on those participants enrolled in the program.\\n\\nPotential participants for this study will be contacted via e-mail, with a follow-up telephone call if they do not respond to the e-mail message. Only people who have used e-mails in the past year and who are starting antidepressant treatment will be contacted. The percentage of people contacted who enroll will be recorded.\\n\\nParticipation in this study will last 6 months. Participants will be randomly assigned to receive either a secure messaging care management program, based on effective telephone management programs, or their usual care with no intervention. Those receiving the secure messaging program will receive an initial welcome message and monitoring messages approximately 2, 6, and 10 weeks after treatment has begun. The monitoring messages will include structured assessments of depression severity, medication adherence, medication side effects, and barriers to continuing treatment. Participants who do not respond to monitoring messages will receive up to two e-mailed reminders. Care managers will analyze the results of monitoring messages, provide feedback and recommendations to physicians, coordinate physician follow-ups, and facilitate emergency care or specialty referrals. Care managers will also provide patients with motivation, based on semi-scripted protocols, and education concerning their disorder and treatment. Measures of the success of the study will be taken at enrollment and after 6 months of participation. Specific measurements will include the response rate of recruitment e-mails, response rate for follow-up data collection, proportion of those in the secure messaging program who complete the monitoring assessments, effects of the program on antidepressant treatment, and effects of the program on patient satisfaction.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Primary care', 'Effectiveness', 'Care management']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '208', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '1', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will receive depression care management by secure messaging.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression care management by secure messaging']}}, {'ArmGroupLabel': '2', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Participants will receive their usual care, with no additional education or care management services.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Depression care management by secure messaging', 'InterventionDescription': \"Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}, 'InterventionOtherNameList': {'InterventionOtherName': ['online messaging', 'email']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': '20-Item Symptom Checklist Depression Scale', 'PrimaryOutcomeDescription': '20-item depression severity scalse adapted from longer SCL-90. Mean score ranges from 0 to 4 with scores above 1.5 indicating moderate depression.', 'PrimaryOutcomeTimeFrame': 'Measured at baseline and after 6 months of treatment'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Treatment Satisfaction', 'SecondaryOutcomeDescription': 'Single item seven point scale ranging from \"very satisfied\" to \"very dissatisfied\"', 'SecondaryOutcomeTimeFrame': 'Measured after 6 months of treatment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatient at Capitol Hill or Rainier clinics of Group Health Cooperative in Seattle\\nNew prescription of an antidepressant, defined by an interval of at least 180 days since a previous antidepressant prescription\\nIndication of depression, defined by a visit diagnosis of major depressive disorder (Internal Classification of Diseases 9th Revision [ICD9] codes 296.2x or 296.3x) within 30 days of the first prescription\\nHas used secure messaging, or e-mailing, at least twice in the last 12 months\\n\\nExclusion Criteria:\\n\\nAny diagnosis of psychotic disorder or bipolar disorder in the prior 2 years\\nAny prescription for mood stabilizer or antipsychotic medication in the prior 2 years', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Gregory E. Simon, MD, MPH', 'OverallOfficialAffiliation': 'Group Health Cooperative Center for Health Studies', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Group Health Cooperative Center for Health Studies', 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationZip': '98101', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '21384219', 'ReferenceType': 'result', 'ReferenceCitation': 'Simon GE, Ralston JD, Savarino J, Pabiniak C, Wentzel C, Operskalski BH. Randomized trial of depression follow-up care by online messaging. J Gen Intern Med. 2011 Jul;26(7):698-704. doi: 10.1007/s11606-011-1679-8. Epub 2011 Mar 8.'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Secure Messaging Care Management', 'FlowGroupDescription': 'Participants will receive depression care management by secure messaging.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Usual Care', 'FlowGroupDescription': 'Participants will receive their usual care, with no additional education or care management services.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '106'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '102'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '104'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '93'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '2'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '9'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Secure Messaging Care Management', 'BaselineGroupDescription': 'Participants will receive depression care management by secure messaging.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Usual Care', 'BaselineGroupDescription': 'Participants will receive their usual care, with no additional education or care management services.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '106'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '102'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '208'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '96'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '94'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '190'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '10'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '8'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '18'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '48', 'BaselineMeasurementSpread': '9'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '48', 'BaselineMeasurementSpread': '10'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '48', 'BaselineMeasurementSpread': '9'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '76'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '74'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '150'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '30'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '28'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '58'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '106'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '102'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '208'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': '20-Item Symptom Checklist Depression Scale', 'OutcomeMeasureDescription': '20-item depression severity scalse adapted from longer SCL-90. Mean score ranges from 0 to 4 with scores above 1.5 indicating moderate depression.', 'OutcomeMeasurePopulationDescription': 'Analysis included all participants participating in outcome assessment', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': 'Measured at baseline and after 6 months of treatment', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Secure Messaging Care Management', 'OutcomeGroupDescription': 'Participants will receive depression care management by secure messaging.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Usual Care', 'OutcomeGroupDescription': 'Participants will receive their usual care, with no additional education or care management services.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '104'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '93'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.95', 'OutcomeMeasurementSpread': '0.71'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1.17', 'OutcomeMeasurementSpread': '0.81'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Treatment Satisfaction', 'OutcomeMeasureDescription': 'Single item seven point scale ranging from \"very satisfied\" to \"very dissatisfied\"', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'participants', 'OutcomeMeasureTimeFrame': 'Measured after 6 months of treatment', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Secure Messaging Care Management', 'OutcomeGroupDescription': 'Participants will receive depression care management by secure messaging.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Usual Care', 'OutcomeGroupDescription': 'Participants will receive their usual care, with no additional education or care management services.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '104'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '93'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Very Satisfied', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '56'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '31'}]}}]}}, {'OutcomeClassTitle': 'Less than very satisfied', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '48'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '62'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '1', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Secure Messaging Care Management', 'EventGroupDescription': 'Participants will receive depression care management by secure messaging.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '104', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '104'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Usual Care', 'EventGroupDescription': 'Participants will receive their usual care, with no additional education or care management services.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '93', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '93'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Suicide attempt', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '104'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '93'}]}}]}}, 'MoreInfoModule': {'LimitationsAndCaveats': {}, 'CertainAgreement': {'AgreementPISponsorEmployee': 'No', 'AgreementRestrictiveAgreement': 'No'}, 'PointOfContact': {'PointOfContactTitle': 'Gregory Simon, Principal Investigator', 'PointOfContactOrganization': 'Group Health Research Institute', 'PointOfContactEMail': 'simon.g@ghc.org', 'PointOfContactPhone': '206-287-2979'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 25, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02335554', 'OrgStudyIdInfo': {'OrgStudyId': '81RR-2R'}, 'Organization': {'OrgFullName': 'Oregon Center for Applied Science, Inc.', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Internet Program for Workers With Subthreshold Depression', 'OfficialTitle': 'Multimedia Internet-Based Program for Workers With Subthreshold Depression', 'Acronym': 'WorkDep'}, 'StatusModule': {'StatusVerifiedDate': 'January 2015', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 2012'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2013', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2013', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 7, 2015', 'StudyFirstSubmitQCDate': 'January 8, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 9, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 9, 2015', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 12, 2015', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Oregon Center for Applied Science, Inc.', 'LeadSponsorClass': 'INDUSTRY'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Depression is one of the most prevalent mental disorders to afflict adults. It seriously impacts role functioning and often takes a recurrent or chronic course. Because most adults who suffer from depression never receive treatment, there is a critical need to develop interventions that can be easily implemented and widely disseminated. Interventions that reduce the performance-impairing symptoms of subclinical depression and prevent the onset of major depression can improve employee well-being, while reducing healthcare costs and improving productivity. This project produced a mobile-web program to activate cognitive behavioral skills in workers with subthreshold depression, reduce depression symptoms, improve functioning in the workplace, and potentially reduce the risk for escalation to full-syndrome depression.', 'DetailedDescription': 'The responsive mobile-web MoodHacker app was designed to: (a) educate users about depression; (b) educate users about the logistics and benefits of mood and activity monitoring; (c) promote daily mood and activity monitoring; (d) help users increase their positive activity engagement; (e) help users decrease negative thinking and increase positive thinking; and (f) promote daily practice of the skills taught.\\n\\nProgram content was adapted from the Coping with Depression group therapy course [18], enhanced with mindfulness-based [22] and other evidence-based positive psychology strategies [23-25]. Content for the application was refined based on input from experts in the field who had extensive experience working with adult employees at risk for depression. Additional program modifications were made based on data from individual interviews and iterative user testing with the population of interest during the formative and production phases of the project.\\n\\nThe MoodHacker user experience is structured around twelve learning objectives delivered through daily emails, in-app messaging, and in the \"Articles & Videos\" library. Daily emails (Figure 1) are sent to engage users in program content, provide sequenced guidance through the learning objectives in the articles and whiteboard-style videos, give tips for getting the most out of MoodHacker, and prompt the user to track their mood and activities daily. Users are encouraged to view the articles and videos as ordered, but viewing is not restricted, and users can view content according to their interest. The emails, articles and videos promote practice of the featured cognitive and behavioral skills outside the app experience.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Subthreshold', 'Employees', 'Internet', 'Mobile', 'cognitive-behavioral']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '300', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'MoodHacker', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in the treatment condition were emailed a link to the MoodHacker mobile-web app and instructed to use the program for the next six weeks. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: MoodHacker']}}, {'ArmGroupLabel': 'Alternative Care', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Alternative care participants were emailed and encouraged to browse links to vetted online information about depression. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline and were given access to the MoodHacker program after the 10-week assessment', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Alternative Care']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'MoodHacker', 'InterventionDescription': 'Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['MoodHacker']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Internet program for workers with subthreshold depression']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Alternative Care', 'InterventionDescription': 'Online information about depression from government and other trusted sources to educate users about depression.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Alternative Care']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression symptoms as assessed by the Patient Health Questionnaire-9 (PHQ-9)', 'PrimaryOutcomeDescription': 'Depressive symptomatology was assessed at each assessment point using the self-reported Patient Health Questionnaire-9 scale to assess the nine DSM-IV major depression symptoms. The PHQ-9 is a self-report version of the Primary Care Evaluation of Mental Disorders (PRIME-MD) and has been shown to be a reliable and valid brief depression assessment tool.', 'PrimaryOutcomeTimeFrame': '10 week follow-up'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Activation of positive self-care and life-choice behaviors', 'SecondaryOutcomeDescription': 'How actively individuals are taking care of themselves, including making positive life choices, was expected to increase as a result of the intervention. Behavioral activation was measured using the Behavioral Activation for Depression Scale Short Form (BADS). This scale consists of 9 items.', 'SecondaryOutcomeTimeFrame': '6-week posttest and 10-week follow-up'}, {'SecondaryOutcomeMeasure': 'Change in negative thinking', 'SecondaryOutcomeDescription': 'Change in negative thinking was assessed using the Automatic Thoughts Questionnaire - Revised scale Short Form (ATQ-R-SF). A 12-item adaptation of the ATQ-R instrument asked respondents to rate how many times over the past week they have had thoughts that are consistent with 12 negative self-statements.', 'SecondaryOutcomeTimeFrame': '6-week posttest and 10-week follow-up'}, {'SecondaryOutcomeMeasure': 'Knowledge about depression', 'SecondaryOutcomeDescription': 'Treatment participants were assessed for an increase in knowledge about depression. The scale consisted of 14 multiple-choice items based on the 12 learning objectives addressed in the MoodHacker articles and videos.', 'SecondaryOutcomeTimeFrame': '6-week posttest and 10-week follow-up'}, {'SecondaryOutcomeMeasure': 'Worker productivity as assessed by the Work Limitations Questionnaire', 'SecondaryOutcomeDescription': \"Worker productivity was assessed using the Work Limitations Questionnaire (WLQ). The WLQ Short Form consists of 10 items divided into four subscales measuring the degree to which a person was limited in their job's (1) time demands; (2) physical demands; (3) mental demands; and (4) output demands.\", 'SecondaryOutcomeTimeFrame': '6-week posttest and 10-week follow-up'}, {'SecondaryOutcomeMeasure': 'Worksite outcomes as assessed by the Workplace Outcomes Suite', 'SecondaryOutcomeDescription': 'Worksite outcomes were also assessed using the Workplace Outcomes Suite (WOS). The WOS is designed as an open-access instrument to facilitate empirical research on Employee Assistance Program (EAP) interventions. The suite contains five 5-item scales that assess: absenteeism, presenteeism, work engagement, life satisfaction, and workplace distress.', 'SecondaryOutcomeTimeFrame': '6-week posttest and 10-week follow-up'}, {'SecondaryOutcomeMeasure': 'User satisfaction as assessed by the System Usability Scale', 'SecondaryOutcomeDescription': 'Treatment participants completed the System Usability Scale, which is a quantitative measure of program ease of use. The scale includes 10 items. Users were asked to what degree they agreed or disagreed with program use and satisfaction statements on a 6-point scale (1=strongly disagree; 6=strongly agree).', 'SecondaryOutcomeTimeFrame': '6 week posttest'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n18 years or older\\nmild-to-moderate depressive symptoms as measured by the PHQ-9 (score of 10-19)\\nnot currently suicidal or meeting criteria for bipolar or schizo-affective disorder\\nemployed at least part-time\\nEnglish speaking\\naccess to a high-speed internet connection\\n\\nExclusion Criteria:\\n\\nyounger than 18 years old\\nsevere depressive symptoms as measured by the PHQ-9 (score of 20+)\\ncurrently suicidal or meeting criteria for bipolar or schizo-affective disorder\\nemployed less than part-time or unemployed\\nnot English speaking\\nno access to a high-speed internet connection', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Amy J Birney, MPH, MCHES', 'OverallOfficialAffiliation': 'Oregon Center for Applied Science', 'OverallOfficialRole': 'Principal Investigator'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26813737', 'ReferenceType': 'derived', 'ReferenceCitation': 'Birney AJ, Gunn R, Russell JK, Ary DV. MoodHacker Mobile Web App With Email for Adults to Self-Manage Mild-to-Moderate Depression: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2016 Jan 26;4(1):e8. doi: 10.2196/mhealth.4231.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 26, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02069301', 'OrgStudyIdInfo': {'OrgStudyId': '5R34MH094648-02', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=5R34MH094648-02&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '5R34MH094648-02', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=5R34MH094648-02&Fy=all'}]}, 'Organization': {'OrgFullName': 'RAND', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Evaluation of an Integrated Microfinance and Depression Care Program for Women', 'OfficialTitle': 'Development of an Integrated Microfinance and Depression Care Program for Women', 'Acronym': 'LIFE-DM'}, 'StatusModule': {'StatusVerifiedDate': 'November 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 2014', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 10, 2014', 'StudyFirstSubmitQCDate': 'February 19, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 24, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 28, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 30, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Victoria K. Ngo, PhD', 'ResponsiblePartyInvestigatorTitle': 'Behavior Scientist', 'ResponsiblePartyInvestigatorAffiliation': 'RAND'}, 'LeadSponsor': {'LeadSponsorName': 'RAND', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}, {'CollaboratorName': 'Danang Psychiatric Hospital', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The study evaluates LIFE-DM, an integrated microfinance and collaborative care intervention by comparing it to enhanced treatment as usual (national guideline antidepressant care and referral to microfinance resources) in Vietnam. Intervention effects at baseline, 6 month, and 12 month follow-up on patient outcomes, including depression, anxiety, quality of life, functioning, self-efficacy, satisfaction, and income will be compared across the two conditions.', 'DetailedDescription': 'Depression is one of the largest contributors to the world\\'s health burden. Prior work in the Partners in Care study has shown that evidence-based service delivery programs for depression can improve health outcomes in depressed patients, and especially in minorities, largely overcoming disparities in outcomes from care between whites and minorities. Effective treatments exist, but they do not reach many depressed individuals, especially in resource-poor communities--ethnic minorities, rural residents in the United States, and individuals in most of the developing world.\\n\\nWomen, in particular, are at risk for depression and poverty. Integrating programs that treat depression and address livelihood concerns may improve engagement in depression treatment and improve mental health and functioning for patients in low-resource settings. The proposed study would integrate depression care with existing \"microfinance\" programs, which provide poverty-alleviation services including small loans, savings programs, and vocational training to women.\\n\\nThis project will (1) conduct qualitative studies of barriers and facilitators of women\\'s successful use of existing depression care and microfinance programs; (2) adapt and integrate the depression care and microfinance services; (3) train Women\\'s Union facilitators to deliver the integrated depression care and microfinance program; and conduct evaluation of LIFE-DM program to assess acceptability, feasibility, and preliminary effectiveness. The non-randomized control trial compares the integrated microfinance and collaborative care intervention with enhanced treatment as usual (national guideline antidepressant care and referral to microfinance resources) at the Women\\'s Union in Danang city in Vietnam.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Behavior Activation', 'Problem solving therapy', 'Depression Treatment', 'depression care integration', 'microfinance', 'livelihood']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '166', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Integrated Depression/Microfinance Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'LIFE-DM is a Depression and Microfinance integrated program using behavior activation and problem solving therapy applied to both depression and livelihood. Livelihood support include microfinance loans, personal finance, and income-generation skills.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Integrated Depression/Microfinance Group', 'Other: Treatment as Usual', 'Other: Livelihood Support']}}, {'ArmGroupLabel': 'Treatment as Usual', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Currently treatment as usual in this province includes national guidelines for antidepressant care for depression and referral for microfinance/livelihood programs', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Treatment as Usual']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Integrated Depression/Microfinance Group', 'InterventionDescription': 'LIFE-DM Integrated Depression and Microfinance group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Integrated Depression/Microfinance Group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['LIFE-DM Group']}}, {'InterventionType': 'Other', 'InterventionName': 'Treatment as Usual', 'InterventionDescription': 'National Guideline for antidepressant care', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Integrated Depression/Microfinance Group', 'Treatment as Usual']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Guideline antidepressant care', 'Fluoxetine, Amitrytaline', 'other antidepressants']}}, {'InterventionType': 'Other', 'InterventionName': 'Livelihood Support', 'InterventionDescription': 'Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Integrated Depression/Microfinance Group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Microfinance loans']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Depression Score from the Patient Health Questionnaire', 'PrimaryOutcomeDescription': 'The PHQ-9 is a nine-item validated tool measuring depressive symptoms based on DSM-IV criteria. The answers are rated on a scale from zero (not at all) to three (nearly every day). Total scores range from 0-27, subdivided into five categories of depression severity: 1 to 4 is minimal; 5 to 9 is mild; 10 to 14 is moderate; 15 to 19 is moderate-severe; and 20 and above is severe. The PHQ-9 has been widely used internationally including in Vietnam.', 'PrimaryOutcomeTimeFrame': '0, 6, 12 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Quality of Life Score from Quality of Life and Enjoyment and Satisfaction Questionnaire', 'SecondaryOutcomeDescription': 'The Quality of Life Enjoyment and Satisfaction Questionnaire is a self-report measure designed to enable investigators to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning. The summary scores were found to be reliable and valid measures of these dimensions in a group of depressed outpatients. The Q-LES-Q measures were related to, but not redundant with, measures of overall severity of illness or severity of depression within this sample. These findings suggest that the Q-LES-Q measures may be sensitive to important differences among depressed patients that are not detected by the measures usually employed.', 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}, {'SecondaryOutcomeMeasure': 'Change in Self-Efficacy Score from Self Efficacy Survey', 'SecondaryOutcomeDescription': 'Items were developed to assess effectiveness of a goal-setting and planning intervention (Macleod et al., 2008). Self-efficacy is assessed via 4-items that measure locus of control, materials and skills to complete goals, confidence, and optimism. Self-efficacy is rated on a 9-point scale from 1 (\"Not at all\") to 9 (\"To a great extent\").', 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}, {'SecondaryOutcomeMeasure': 'Change in Social Support Index from Medical Outcome Study Social Support Survey', 'SecondaryOutcomeDescription': 'A brief, multidimensional, selfadministered, social support survey that was developed for patients in the Medical Outcomes Study (MOS), a two-year study of patients with chronic conditions. This survey was designed to be comprehensive in terms of recent thinking about the various dimensions of social support.', 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}, {'SecondaryOutcomeMeasure': 'Change in health and mental health functioning scores from Medical Outcomes Study Short Form Health Survey (SF-12)', 'SecondaryOutcomeDescription': 'The SF-12v2 is a 12-item survey that measures the same eight domains of health. The domains scores are summarized into two composite scores: Physical Component Summary and Mental Component Summary scores. The survey is a brief, reliable measure of overall health status. It is useful in large population health surveys and has been used in Vietnamese populations.', 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}, {'SecondaryOutcomeMeasure': 'Change in Anxiety Symptom Score from Generalized Anxiety Disorder (GAD-7) Scale', 'SecondaryOutcomeDescription': 'The GAD-7 is a 7-item anxiety scale used for screening and assessing symptom severity of GAD. GAD and depression symptoms frequently occurred together, but factor analysis confirmed them as distinct dimensions, and they had independent effects on functional impairment and disability. Self-report and interviewer-administered versions of GAD-7 were in good agreement.', 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}, {'SecondaryOutcomeMeasure': 'Change in Behavior Activation Score from the Behavior Activation for Depression Scale Short Form (BADS-SF)', 'SecondaryOutcomeDescription': 'The abbreviated BADS-SF is a nine-item scale measuring factors expected to change as a function of behavioral activation, including activation and avoidance', 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}, {'SecondaryOutcomeMeasure': 'Change in household wealth indicators from Economic Well-Being Inventory', 'SecondaryOutcomeDescription': 'The economic well-being inventory collect various indicators of self-reported household wealth: housing materials, land ownership, home ownership, and selling and purchasing of assets such as livestock and durable goods (car, bicycle, radio, TV), as well as income, savings, and debt. This economic well-being inventory was used in the Danang Household Mental Health Survey.', 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}, {'SecondaryOutcomeMeasure': 'Change in number and type of income generating activities from the Employment and business Activities Questionnaire', 'SecondaryOutcomeDescription': 'We developed questionnaire to measure income generating activities, which include questions about participation and number of hours in types of employment and income generating activities in Low-Income countries, including formal salaried employment, farming and planting food, selling goods and services, property rentals, etc.', 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}, {'SecondaryOutcomeMeasure': 'Treatment Acceptability Score from Help-Seeking Behavior Questionnaire', 'SecondaryOutcomeDescription': \"This measure consists of items that assesses 1) resources in the community, 2) participant's help seeking history, 3) perceived effectiveness, and 4) acceptability of a variety of strategies used for depression care.\", 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}, {'SecondaryOutcomeMeasure': 'Depression Stigma Score from the Depression Stigma Questionnaire', 'SecondaryOutcomeDescription': '18 item questionnaire about perceived and personal stigma related to depression.', 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}, {'SecondaryOutcomeMeasure': 'Social Capital Score from Social Capital Assessment Tool', 'SecondaryOutcomeDescription': 'The short version of the Adapted Social Capital Assessment Tool (SASCAT) is a nine-item tool measures the structural (quantity of social relationships) and cognitive (quality of social relationships) components of social capital as well as citizenship. The measure derived from the Adapted Social Capital Assessment Tool (A-SCAT) (Harpham et al., 2002). The measures has been used in many international settings, including developing countries.', 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}, {'SecondaryOutcomeMeasure': 'Total Score Client Service Satisfaction Questionnaire', 'SecondaryOutcomeDescription': 'A standardized measure with strong psychometric properties that could be used to assess general satisfaction across varied health and human services. The CSQ Scales® (CSQ) measure may be used to assess client satisfaction with mental health services, as a program evaluation tool, or to assess client satisfaction within and across programs (intra- or inter-program) and demographic groups.', 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}, {'SecondaryOutcomeMeasure': 'Number of Participants Demonstrating Mental Health Literacy with Depression Vignette', 'SecondaryOutcomeDescription': 'Vignette describes someone with the minimal number of symptoms necessary for major depression (according to DSM description). Respondents were asked an open-ended question, ``What would you say, if anything, is wrong with Mary?\\'\\' Only answers including \" depression \" are considered a correct response.', 'SecondaryOutcomeTimeFrame': '0, 12 months'}, {'SecondaryOutcomeMeasure': 'Number of Participants with Depression Diagnosis - MINI International Neuropsychiatric Interview, Version 6.0 (MINI)', 'SecondaryOutcomeDescription': 'The MINI is a brief structured psychiatric interview used to diagnose for multiple axis I DSM-IV mental disorders. In this study, the MINI is used to assess for major depressive episodes. Using DSM-IV criteria (at least 5 symptoms of depression over a 2 week period; endorsement of depressed mood or anhedonia were necessary for diagnosis) the interviewers can distinguish between past, current, and recurrent episodes of depression. The MINI is a reliable and valid alternative to the longer Structured Clinical Interview for Diagnostic. The MINI has been used widely in developing countries and administered by non-mental health providers.', 'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ndepression, low-income\\n\\nExclusion Criteria:\\n\\npsychosis, mania, substance abuse, high suicide risk, physical disabilities, significant cognitive impairments', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '55 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Victoria K Ngo, PhD', 'OverallOfficialAffiliation': 'RAND', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Hoa Cuong Bac Commune Health Station', 'LocationCity': 'Da Nang', 'LocationCountry': 'Vietnam'}, {'LocationFacility': 'Hoa Cuong Nam Commune Health Station', 'LocationCity': 'Da Nang', 'LocationCountry': 'Vietnam'}, {'LocationFacility': 'Hoa Hiep Nam Commune Health Station', 'LocationCity': 'Da Nang', 'LocationCountry': 'Vietnam'}, {'LocationFacility': 'Hoa Minh Commune Health Station', 'LocationCity': 'Da Nang', 'LocationCountry': 'Vietnam'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25568593', 'ReferenceType': 'result', 'ReferenceCitation': 'Ngo VK, Weiss B, Lam T, Dang T, Nguyen T, Nguyen MH. The Vietnam Multicomponent Collaborative Care for Depression Program: Development of Depression Care for Low- and Middle-Income Nations. J Cogn Psychother. 2014;28(3):156-167.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000005473', 'InterventionMeshTerm': 'Fluoxetine'}, {'InterventionMeshId': 'D000000928', 'InterventionMeshTerm': 'Antidepressive Agents'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000017367', 'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'}, {'InterventionAncestorId': 'D000014179', 'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'}, {'InterventionAncestorId': 'D000049990', 'InterventionAncestorTerm': 'Membrane Transport Modulators'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000018490', 'InterventionAncestorTerm': 'Serotonin Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000018687', 'InterventionAncestorTerm': 'Antidepressive Agents, Second-Generation'}, {'InterventionAncestorId': 'D000011619', 'InterventionAncestorTerm': 'Psychotropic Drugs'}, {'InterventionAncestorId': 'D000065690', 'InterventionAncestorTerm': 'Cytochrome P-450 CYP2D6 Inhibitors'}, {'InterventionAncestorId': 'D000065607', 'InterventionAncestorTerm': 'Cytochrome P-450 Enzyme Inhibitors'}, {'InterventionAncestorId': 'D000004791', 'InterventionAncestorTerm': 'Enzyme Inhibitors'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M7184', 'InterventionBrowseLeafName': 'Fluoxetine', 'InterventionBrowseLeafAsFound': 'Fluoxetine', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2828', 'InterventionBrowseLeafName': 'Antidepressive Agents', 'InterventionBrowseLeafAsFound': 'Antidepressant', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M14095', 'InterventionBrowseLeafName': 'Serotonin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M18232', 'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M13057', 'InterventionBrowseLeafName': 'Psychotropic Drugs', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M29124', 'InterventionBrowseLeafName': 'Cytochrome P-450 Enzyme Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr', 'InterventionBrowseBranchName': 'Psychotropic Drugs'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 27, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03887390', 'OrgStudyIdInfo': {'OrgStudyId': '120560'}, 'Organization': {'OrgFullName': 'Laval University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Depression Medication Choice Decision Aid', 'OfficialTitle': 'Implementation of the Depression Medication Choice Decision Aid in a Canadian Context: A Feasibility Trial'}, 'StatusModule': {'StatusVerifiedDate': 'March 2020', 'OverallStatus': 'Terminated', 'WhyStopped': 'First the study failed to recruit the required sample size. Second, we no longer have acess to the clinics, due to the coronavirus outbreak', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 22, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 28, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 20, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 12, 2019', 'StudyFirstSubmitQCDate': 'March 21, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 25, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 20, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 24, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Annie Leblanc', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Laval University'}, 'LeadSponsor': {'LeadSponsorName': 'Laval University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Réseau-1 Québec', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'CERSSPL', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The quality of care for patients facing depression, one of the most prevalent chronic diseases, needs improvement. Despite its high incidence, depression remains sub-optimally managed, particularly in primary care, where most patients suffering from depression receive care. Successfully treated depressive patients can potentially improve their burden of disease and significantly improve their quality of life, but not without the best treatment adapted to their contexts, preferences, and expectations. Clinical research provides essential knowledge for the delivery of quality care which is unfortunately seldom applied in daily practice.\\n\\nOne of the preferred methods for overcoming this lack of quality of care is shared decision making: a collaborative process between a clinician and patient that relies on the consideration of scientific evidence, in addition to the values and preferences of the patient. The use of decision aids supports this process by presenting scientific information in an accessible manner while focusing on patient-centered discussion. We developed and rigorously evaluated, in the United States, a decision aid regarding pharmaceutical treatment options for depression, Depression Medication Choice, to be used by health professionals and patients during clinical encounters. The integration and impact of Depression Medication Choice, in primary care practices in a Canadian context is unknown.\\n\\nThe specific objectives of this study are threefold: (i) Evaluate the potential impact of the use of Depression Medication Choice by health professionals and patients during clinical encounters on measures of the quality of the decisional process and on health issues important to the patient and health professional; (ii) Document the processes and optimal measures to take to successfully realize projects on a larger scale; and (iii) Evaluate the feasibility of performing patient-centered studies in a realistic context, minimally disturbing to the study environment, in the primary care context in Quebec, Canada.\\n\\nOnce completed, the estimated potential impact of this decision aid and shared decision making in primary care in a Canadian context will have been measured, progressing toward high-quality patient-centered care. Moreover, it will be possible to optimally perform future studies in realistic contexts while minimizing the burden on the clinics, their health professionals, and their patients.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Decision Aid', 'Shared Decision Making', 'Primary Care', 'Comparative Effectiveness Research']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'This is a mixed-method feasibility study centered on a pilot clinical trial in family medicine groups in Quebec, Canada, accompanied by a realistic qualitative evaluation of process.', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)', 'DesignMaskingDescription': 'Patients will be randomly assigned to one of two groups (intervention or usual care) using a computer-generated sequence. Due to the nature of the study, patients, health professionals, and members of the research team cannot be masked to the allocation.'}}, 'EnrollmentInfo': {'EnrollmentCount': '3', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Usual Care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Participants in this arm will receive care as usual.'}, {'ArmGroupLabel': 'Depression Medication Choice', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in this arm will have the Depression Medication Choice decision aid be made available to their clinician to be used during their clinical encounter.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression Medication Choice']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Depression Medication Choice', 'InterventionDescription': 'The Depression Medication Choice tool is a series of cards emphasizing issues that are important for the patient and the health care professional when choosing antidepressants: weight change, sexual issues, sleep, cost, side effects, and stopping approach. The Depression Medication Choice tool uses clear language and is designed to improve the understanding of patients regarding the different attributes of antidepressants, and for use during clinical encounters.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression Medication Choice']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Changes in decisional conflict assessed by the Decisional Conflict Scale (DCS)', 'PrimaryOutcomeDescription': 'Participants and clinicians will complete a Decisional Conflict Scale so that their level of decisional conflict may be measured. This measure, validated in French, comprises 16-items grouped into factors impacting the feeling of comfort toward making the decision. Scores range from 0 (no decisional conflict) to 100 (extremely high decisional conflict). A participant version as well as a clinician version of the DCS will be used.', 'PrimaryOutcomeTimeFrame': \"Immediately following each participant's first clinical encounter and every subsequent scheduled visit for the approximate 6-month study intervention duration\"}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Participant engagement assessed by the Observing Patient Involvement in Decision Making instrument (OPTION) and video recordings', 'SecondaryOutcomeDescription': 'The level to which the clinicians engage the participants in decision making will be evaluated via the 12-item OPTION scale, an observational measurement scored 0 to 100 percent. Independent reviewers will assess the level of engagement using video recordings of the clinical encounters.', 'SecondaryOutcomeTimeFrame': \"At each participant's scheduled clinical encounter, for up to 6 months post-recruitment\"}, {'SecondaryOutcomeMeasure': 'Changes in severity of symptoms assessed by the Patient Health Questionnaire (PHQ-9)', 'SecondaryOutcomeDescription': 'Participants will complete the PHQ-9, a severity of depression measurement using a 4-point Likert-type scale. Scores range between 0 and 27 and correspond to depression severity. Depression severity may be: none-minimal (0 to 4), mild (5 to 9), moderate (10-14), moderately severe (15-19), or severe (20-27).', 'SecondaryOutcomeTimeFrame': \"Immediately prior to each participant's first clinical encounter and every subsequent scheduled visit for the approximate 6-month study intervention duration\"}, {'SecondaryOutcomeMeasure': 'Decision making preference assessed by questionnaire', 'SecondaryOutcomeDescription': \"Participants will be asked to answer a single question with a 5-point Likert-type scale to rate their decision making preferences. Lower values indicate participants' preference for making decisions themselves while higher values indicate a preference for their doctor to make the decision for them. An intermediate value indicates participants' preference for shared decision making.\", 'SecondaryOutcomeTimeFrame': \"Immediately prior to each participant's first clinical encounter\"}, {'SecondaryOutcomeMeasure': 'Global quality of life assessed by questionnaire', 'SecondaryOutcomeDescription': 'Participants will be asked to answer a single question with a 10-point Likert-type scale to rate their quality of life. The question is scored from 1 (very bad) to 10 (very good).', 'SecondaryOutcomeTimeFrame': 'Immediately prior to the first clinical encounter'}, {'SecondaryOutcomeMeasure': \"Changes in medication adherence assessed by participants' pharmacy records\", 'SecondaryOutcomeDescription': 'The following data will be extracted for the duration of trial participation: new prescriptions filled and the associated renewal dates as well as the types of medication (depression-related).', 'SecondaryOutcomeTimeFrame': 'Following the approximate 6-month study intervention completion'}, {'SecondaryOutcomeMeasure': 'Fidelity to the intervention delivery', 'SecondaryOutcomeDescription': 'Independent reviewers will evaluate the fidelity with which the Depression Medication Choice tool is used during the clinical encounters via video observation. The control of fidelity list is specific to the Depression Medication Choice tool. This will also allow us to validate the contamination level of the clinicians who will navigate between both groups.', 'SecondaryOutcomeTimeFrame': 'The entire duration of the discussion between the clinician and participant regarding depression medication during each scheduled visit for the approximate 6-month study intervention duration'}, {'SecondaryOutcomeMeasure': 'Changes in knowledge assessed by questionnaire', 'SecondaryOutcomeDescription': 'Participants will be asked to complete a questionnaire assessing their knowledge of the illness (depression) and the advantages and disadvantages of 15 pharmacological treatments. Participants may choose to answer true, false, or unsure. Correct answeres are are given a score of 1 and incorrect answers (or if a participant answered \"unsure\") is given a score of 0. A mean knowledge score is calculated from the totaled items for comparison.', 'SecondaryOutcomeTimeFrame': \"Immediately following each participant's clinical encounter and every subsequent visit for the approximate 6-month study intervention duration\"}, {'SecondaryOutcomeMeasure': 'Changes in satisfaction and acceptability by questionnaire', 'SecondaryOutcomeDescription': 'Participants and clinicians will be asked to rate their level of satisfaction and acceptability of the decision aid by completing a 5-question questionnaire. The 7-point Likert-type scale is scored from 5 to 35 with higher values corresponding to higher levels of satisfaction and acceptability.', 'SecondaryOutcomeTimeFrame': 'Immediately following the first clinical encounter and every subsequent visit for the approximate 6-month study intervention duration'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAlready have or receive a depression diagnosis (according to the treating clinician)\\nSpeak English of French\\nHave no major obstacles providing clear written consent\\nDiscuss the possibility of taking antidepressants during the clinical encounter', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Annie LeBlanc, PhD', 'OverallOfficialAffiliation': 'Laval University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Groupe de médecine de famille universitaire Maizerets', 'LocationCity': 'Québec', 'LocationZip': 'G1J 2G1', 'LocationCountry': 'Canada'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26414670', 'ReferenceType': 'background', 'ReferenceCitation': 'LeBlanc A, Herrin J, Williams MD, Inselman JW, Branda ME, Shah ND, Heim EM, Dick SR, Linzer M, Boehm DH, Dall-Winther KM, Matthews MR, Yost KJ, Shepel KK, Montori VM. Shared Decision Making for Antidepressants in Primary Care: A Cluster Randomized Trial. JAMA Intern Med. 2015 Nov;175(11):1761-70. doi: 10.1001/jamainternmed.2015.5214.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 28, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02491034', 'OrgStudyIdInfo': {'OrgStudyId': '2015-0336'}, 'Organization': {'OrgFullName': 'The University of Texas at Arlington', 'OrgClass': 'OTHER'}, 'BriefTitle': 'DESEO: DEpression Screening and Education: Options to Reduce Barriers to Treatment', 'OfficialTitle': 'DESEO: DEpression Screening and Education: Options to Reduce Barriers to Treatment', 'Acronym': 'DESEO'}, 'StatusModule': {'StatusVerifiedDate': 'July 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2015', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 30, 2017', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 30, 2017', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 2, 2015', 'StudyFirstSubmitQCDate': 'July 6, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 7, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 6, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 10, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'The University of Texas at Arlington', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Texas Southwestern Medical Center', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this project is to implement a Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement. This project will be conducted at one community health center whose patient population is majority Hispanic.', 'DetailedDescription': 'Barriers to depression treatment among Hispanic populations include persistent stigma, inadequate doctor patient communication (DPC) and resultant sub-optimal use of anti-depressant medications. Stigma is primarily perpetuated due to inadequate disease literacy and cultural factors. Common concerns about depression treatments among Hispanics include fears about the addictive and harmful properties of antidepressants, worries about taking too many pills, and the stigma attached to taking psychotropic medications.\\n\\nPrimary care settings often are the gateway to identifying undiagnosed or untreated mental health disorders, particularly for people with comorbid physical health conditions. Hispanics, in particular, are more likely to receive mental health care in primary care settings. Recent recommendations from the U.S. Preventive Services Task Force are that primary care providers screen adult patients for depression only if systems are in place to ensure adequate treatment and follow-up.\\n\\nProject Purpose, Goals and Objectives Purpose: The purpose of this project is to implement a Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement. This project will be conducted at one community health center whose patient population is majority Hispanic.\\n\\nGoal #1: Patients who screen positive for depression will engage in the Depression Education Intervention (DEI) (two sessions) with a trained Depression Educator.\\n\\nObjectives:\\n\\nTo increase knowledge of depression (signs/symptoms, causes, risk factors, treatment, cultural beliefs, and its role in chronic disease) among Hispanics in a primary care setting as measured by changes in scores from pre- to post- DEI on the Knowledge of Depression-MCQ scale.\\nTo reduce perceived cultural stigma about depression and its treatment through a culturally and linguistically appropriate educational intervention as measured by changes in scores from pre- to post- DEI on the Stigma Checklist for Latinos in Primary Care.\\nTo increase engagement in depression treatment in primary care by Hispanic patients as measured by the iPad Depression Screening application, which will record the treatment decision after the diagnosis and measure the number of patients engaged in depression treatment of any kind (pharmacotherapy, counseling, other behavioral intervention) at the time of the DEI and one month after completion of the DEI.\\n\\nGoal #2: In order to identify patients with depression, all adult primary care patients will be screened for depression utilizing the 9-item Patient Health Questionnaire (PHQ-9) via the iPad Depression Screening application.\\n\\nObjectives:\\n\\nTo systematically screen all adult primary care patients with an iPad Depression Screening application as measured by number of patients screened compared to the number eligible for screening.\\nTo increase provider detection of depression in patients through the proper use and interpretation of the PHQ-9 as measured by depression diagnoses recorded in the EHR.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Hispanics', 'Stigma', 'Barriers to Treatment']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '350', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Depression Education Intervention', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression Education Intervention']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Depression Education Intervention', 'InterventionDescription': 'Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The number of Hispanic patients diagnosed with depression who went on to begin depression treatment.', 'PrimaryOutcomeTimeFrame': 'One month post DEI'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAdult primary care patients\\n\\nExclusion Criteria:\\n\\nprevious diagnosis of depression and currently in treatment', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Katherine Sanchez, PhD', 'OverallOfficialAffiliation': 'The University of Texas at Arlington', 'OverallOfficialRole': 'Principal Investigator'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31638915', 'ReferenceType': 'derived', 'ReferenceCitation': 'Sanchez K, Killian MO, Eghaneyan BH, Cabassa LJ, Trivedi MH. Culturally adapted depression education and engagement in treatment among Hispanics in primary care: outcomes from a pilot feasibility study. BMC Fam Pract. 2019 Oct 21;20(1):140. doi: 10.1186/s12875-019-1031-7.'}, {'ReferencePMID': '29788998', 'ReferenceType': 'derived', 'ReferenceCitation': 'Lopez V, Sanchez K, Killian MO, Eghaneyan BH. Depression screening and education: an examination of mental health literacy and stigma in a sample of Hispanic women. BMC Public Health. 2018 May 22;18(1):646. doi: 10.1186/s12889-018-5516-4.'}, {'ReferencePMID': '27473569', 'ReferenceType': 'derived', 'ReferenceCitation': 'Sanchez K, Eghaneyan BH, Trivedi MH. Depression Screening and Education: Options to Reduce Barriers to Treatment (DESEO): protocol for an educational intervention study. BMC Health Serv Res. 2016 Jul 29;16:322. doi: 10.1186/s12913-016-1575-3.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 29, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01887639', 'OrgStudyIdInfo': {'OrgStudyId': 'NIS-NAR-XXX-2013/1'}, 'Organization': {'OrgFullName': 'AstraZeneca', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial', 'OfficialTitle': 'Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial: PANTHER Study', 'Acronym': 'PANTHER'}, 'StatusModule': {'StatusVerifiedDate': 'July 2015', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2013'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2014', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 2014', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 25, 2013', 'StudyFirstSubmitQCDate': 'June 25, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 27, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 29, 2015', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 30, 2015', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'AstraZeneca', 'LeadSponsorClass': 'INDUSTRY'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'A non interventional, descriptive, longitudinal cohort study is designed, trying to obtain local data about the prevalence of non remitted depressed patients after an antidepressant treatment, and to get information about sociodemographic and clinical characteristics of these patients as well as features of their treatments and compare them with those of the patients that achieve remission. Also the effect of patient´s expectation in the treatment outcome will be examined.', 'DetailedDescription': 'A non interventional, descriptive, longitudinal cohort study is designed, trying to obtain local data about the prevalence of non remitted depressed patients after an antidepressant treatment, and to get information about sociodemographic and clinical characteristics of these patients as well as features of their treatments and compare them with those of the patients that achieve remission. Also the effect of patient´s expectation in the treatment outcome will be examined.\\n\\nNon psychotic depressed patients that are initiating an antidepressant treatment will be recruited. Socio demographic and clinical features will be recorded as well as their expectations before the treatment. Severity of depression and treatment characteristics will be recorded after 4 to 8 weeks of drug treatment at an adequate dose. Variables will be compared between the patients that will achieve remission and those that do not.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Non-psychotic Unipolar Major Depression']}, 'KeywordList': {'Keyword': ['Non-psychotic unipolar major depression', 'Resistant depression']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'Yes', 'TargetDuration': '12 Weeks', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '200', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Unipolar major depression', 'ArmGroupDescription': 'Outpatients Individuals between 18 and 75 years old with a current episode of non-psychotic unipolar major depression that are treated with an antidepressant drug according to physician´s current and usual practice.'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Percentage of patients with unipolar major depression that do not achieve remission after one antidepressant treatment.', 'PrimaryOutcomeDescription': 'Non psychotic depressed patients that are initiating an antidepressant treatment will be recruited. Socio demographic and clinical features will be recorded as well as their expectations before the treatment. Severity of depression and treatment characteristics will be recorded after drug treatment at an adequate dose. Variables will be compared between the patients that will achieve remission and those that do not.', 'PrimaryOutcomeTimeFrame': '12 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Clinical, therapeutic and socio-demographic characteristics of resistant depression patients and comparisson of them with the characteristics of the sample of depressed patients in remission.', 'SecondaryOutcomeDescription': 'Description of the clinical (Clinical history, episode features, BDI and HAM D17 scores), therapeutic (Type of drug, dose used, treatment period, adherence, presence and type of psychosocial therapy) and socio-demographic (age, gender, civil status, employment status, cohabitation, health insurance) characteristics of resistant depression patients and to compare them with the characteristics of the sample of depressed patients in remission.', 'SecondaryOutcomeTimeFrame': '12 weeks'}, {'SecondaryOutcomeMeasure': 'Comparison of the depression severity change assessed by the physician with the evaluation done by the patient', 'SecondaryOutcomeDescription': 'Comparison of the depression severity change assessed by the physician with the evaluation done by the patient by means of the BDI.', 'SecondaryOutcomeTimeFrame': '12 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nFemale and male aged 18 to 75 years old. Outpatients with a current episode of non-psychotic unipolar major depression according to the DSM IV-TR.\\n\\nSeverity of illness assessed by means of a score ≥ 14 in the HAM D17 Have not been medicated for the current depression episode with an antidepressant Provision of subject informed consent\\n\\nExclusion Criteria:\\n\\nPatients participating in any clinical trial, the subject cannot take part in this study.\\n\\nThe individual has participated in the last 3 months (including this study) or is participating in a clinical trial.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Individuals between 18 and 75 years old that have non-psychotic unipolar major depression and have not been treated for the current episode.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Research Site', 'LocationCity': 'Buenos Aires', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Caba', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Chaco', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Cordoba', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Rosario', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Research Site', 'LocationCity': 'San Salvador de Jujuy', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Santa Fe', 'LocationCountry': 'Argentina'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Tucuman', 'LocationCountry': 'Argentina'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Synopsis', 'SeeAlsoLinkURL': 'http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1832&filename=NIS-NAR-XXX-2013-1_AZ_Synopsis.pdf'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000003865', 'ConditionMeshTerm': 'Depressive Disorder, Major'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafAsFound': 'Major Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 30, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01128764', 'OrgStudyIdInfo': {'OrgStudyId': 'R34MH083092', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH083092&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R34MH083092', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH083092&Fy=all'}]}, 'Organization': {'OrgFullName': 'Brown University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Integrated Treatment for Comorbid Depression and Obesity in Adolescents', 'OfficialTitle': 'Integrated Treatment for Comorbid Depression and Obesity in Adolescents'}, 'StatusModule': {'StatusVerifiedDate': 'July 2014', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2013', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2013', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 21, 2010', 'StudyFirstSubmitQCDate': 'May 21, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 24, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 28, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 29, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Anthony Spirito', 'ResponsiblePartyInvestigatorTitle': 'Professor', 'ResponsiblePartyInvestigatorAffiliation': 'National Institute of Mental Health (NIMH)'}, 'LeadSponsor': {'LeadSponsorName': 'Brown University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Lifetime prevalence of major depression is estimated at 28% by age 18 (Lewinsohn et al., 1999), with higher cumulative rates in females (35%) than males (19%). Approximately 17% of children and adolescents in the United States are obese as defined by a BMI above the 95th percentile, with more than 30% falling between the 85th and 95th percentiles (Ogden et al., 2008). Overweight children and adolescents are at increased risk for type 2 diabetes (Pinhas-Hamiel et al., 1996) and overwhelming risk for adult obesity (Guo et al., 1994). There is a substantial percentage of adolescents who are both overweight and depressed with estimates from clinical samples averaging 25%. Treatment of teens with comorbid medical and psychiatric conditions such as overweight/obesity and depression has received little to no attention in the psychosocial treatment research literature. Due to the large number of adolescents who are both depressed and overweight, developing a behavioral treatment that addresses both problems simultaneously has important public health significance. The purpose of this proposal is to combine treatments for depression and overweight to address these co-occurring conditions in one intervention. The long-term objectives of this research are to develop efficient and effective treatments for co-occurring physical and emotional disorders. The research program will be divided into 3 major phases: a development phase (Stage 1a), a pilot study phase (Stage 1b), and a revision phase. During the development phase (Stage 1a), a treatment for overweight teens and CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating. As part of this phase, we will adapt existing intervention manuals and therapist training materials, and gain some initial clinical experience with the intervention via an open trial with 6 teens. During the randomized pilot study phase (Stage 1b), the integrated intervention will be compared to a control group receiving CBT treatment for depression alone (N=40 in total). During the pilot phase, the feasibility and acceptability of administering the program will be assessed. In addition, we will compare change in depressed mood at end of treatment and 6 month follow-up periods across the two groups. During the revision phase, the intervention manual will be further developed and refined, based on experiences and observations made during the development and pilot study phases.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression', 'Overweight']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '36', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'CBT for depression and healthy lifestyle plus exercise', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: CBT for depression and healthy lifestyle plus exercise']}}, {'ArmGroupLabel': 'CBT for depression', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'CBT for depression only', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: CBT for depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'CBT for depression and healthy lifestyle plus exercise', 'InterventionDescription': 'CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CBT for depression and healthy lifestyle plus exercise']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'CBT for depression', 'InterventionDescription': 'Standard CBT treatment for depressed teens that addresses depression using CBT techniques only', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CBT for depression']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'depressed mood', 'PrimaryOutcomeTimeFrame': 'baseline, posttreatment , 6 month follow-up'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'weight', 'SecondaryOutcomeTimeFrame': 'baseline, posttreatment, 6 month foll-up'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAdolescents must: 1) be between the ages of 12 and 18 years (18 year olds must still be in high school and living at home); 2) be at or above the 85th percentile with reference to age and gender-specific Body Mass Index (BMI); 3) have at least one parent available to participate in the treatment protocol; 4) speak English; 5) agree to study participation and random assignment; and 6) be available for follow-up. In order to meet the depressed mood criterion, adolescents must have a primary diagnosis of major depressive disorder (single or recurrent), based on the KSADS-PL with a CGI-Severity ≥ 3 for depression and CDRS ≥ 36. Participants must be healthy, as established by their primary care physician, in order to participate in the exercise program -\\n\\nExclusion Criteria:\\n\\nAdolescents will be excluded if: 1) they are currently receiving psychotherapy or participating in another weight loss program (only can have been in a weight loss program in the past); 2) they have a medical condition that would interfere with the prescribed dietary plan or participation in physical activity; 3) they are developmentally delayed such that the intervention materials will not be appropriate; 4) they are actively suicidal at intake; 5) they have not been on a stable dose of a psychostimulant for 6 months to ensure that a recently prescribed psychostimulant is not contributing to weight loss; 6) teens on an SSRI will not be allowed to participate due to potential effects of medication on weight loss; 7) they have a substance abuse or dependence diagnosis; or 8) they have failed a medication or psychotherapy trial for depression in the past.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '12 Years', 'MaximumAge': '18 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Anthony Spirito, PhD', 'OverallOfficialAffiliation': 'Brown University', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Elissa Jelalian, PhD', 'OverallOfficialAffiliation': 'Brown University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Brown University', 'LocationCity': 'Providence', 'LocationState': 'Rhode Island', 'LocationZip': '02912', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000050177', 'ConditionMeshTerm': 'Overweight'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001835', 'ConditionAncestorTerm': 'Body Weight'}, {'ConditionAncestorId': 'D000012816', 'ConditionAncestorTerm': 'Signs and Symptoms'}, {'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M11284', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M24773', 'ConditionBrowseLeafName': 'Overweight', 'ConditionBrowseLeafAsFound': 'Overweight', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3696', 'ConditionBrowseLeafName': 'Body Weight', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 31, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02890615', 'OrgStudyIdInfo': {'OrgStudyId': 'SMHC 16-15'}, 'Organization': {'OrgFullName': 'McGill University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'CanDirect: Effectiveness of a Telephone-supported Depression Self-care Intervention for Cancer Survivors', 'OfficialTitle': 'Effectiveness of a Telephone-supported Depression Self-care Intervention for Cancer Survivors', 'Acronym': 'CanDirect'}, 'StatusModule': {'StatusVerifiedDate': 'February 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2016'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 24, 2016', 'StudyFirstSubmitQCDate': 'August 31, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 7, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'February 18, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 19, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Jane McCusker, MD DrPH', 'ResponsiblePartyInvestigatorTitle': 'Professor Emerita and Full Professor Post-Retirement', 'ResponsiblePartyInvestigatorAffiliation': 'McGill University'}, 'LeadSponsor': {'LeadSponsorName': 'McGill University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'Depressive symptoms are common in cancer survivors; 15% or more of cancer patients, even 1 year after diagnosis, experience depressive symptoms that can have a negative impact on their quality of life. Canadian care guidelines for cancer survivors recommend supporting the active engagement of survivors in their self-care.\\n\\nThis study is an evaluation of the effect of a depression self-care program which includes a self-care toolkit and support in the form of regular telephone calls from a self-care coach.\\n\\nThe toolkit contains tools that help cancer survivors:\\n\\nLearn new information to better understand depression. This can help people feel that they are not alone, and that their experience is not abnormal. Better understanding a condition also helps people feel more confident in their communications with health care professionals and can make it easier to share their experience with family and friends.\\nLearn and practice new coping skills. This can help people feel confident that they can engage in the behaviours that have been shown to be beneficial for mood, e.g. restructuring thoughts, problem solving, and planning pleasant activities.\\n\\nPeople eligible for the study are aged 18 and over, 1-10 years post-diagnosis, have completed primary cancer treatment (chemotherapy, radiation therapy or surgery) for any type of cancer, and have moderate depressive symptoms (as measured by a Patient Health Questionnaire (PHQ-9) score of 8-19). Recruitment will be conducted at cancer care centres in Montreal and at the Princess Margaret Cancer Centre in Toronto, and via community cancer support groups in Quebec and Ontario. Each participant enrolled in the study will receive the self-care toolkit (half will receive the toolkit and support calls at the start of the study, and half will receive the toolkit at the end), and will be followed for 6 months.\\n\\nThis proposed self-care program is innovative in its approach to the treatment of depression and has the potential to significantly improve the quality of life for Canadian cancer survivors with persistent depressive symptoms. The results of the study will determine whether the supported depression self-care program for cancer survivors is effective. The program is designed to be sustainable and widely applicable as it involves minimal costs, and the coaching can be delivered by telephone by volunteers in hospital and community settings. Investigators will work with clinical stakeholders and patient representatives to ensure that deliverables are relevant to the target population. Specific deliverables (in both French and English) include: a toolkit with a manual describing its use; a manual detailing coaching procedures; reports for decision makers and community cancer care groups; and short summaries for stakeholder groups.', 'DetailedDescription': 'This pragmatic randomized controlled superiority trial aims to assess the effectiveness of a telephone-supported depression SCI in cancer survivors with moderate depressive symptoms when given in addition to usual care, in comparison to usual care only. Because of the pragmatic nature of this trial, members of both groups will continue to receive \"usual care\" for their depression, which may vary widely depending on local resources and medical practice. At each follow-up, participants are asked about specific treatment they have received for depression since entering the study (antidepressant medication initiation, discontinuation, change of dose, or psychotherapy) and their participation in community support groups and related activities; investigators will explore whether this care mediates the effects of the intervention. The study includes safeguards for participants who become suicidal or severely depressed during the study.\\n\\nResearch questions\\n\\nAmong cancer survivors in the post-treatment phase who have moderate to moderately-severe depressive symptoms [Patient Health Questionnaire (PHQ-9) score 8-19]:\\n\\nPrimary research question: What is the effect of a telephone-supported depression self-care intervention (SCI) plus usual care compared to usual care only (control group CTL) on the primary outcome - severity of depression symptoms as measured by the Centre for Epidemiologic Studies Depression Scale (CES-D) 6 months after randomization? Hypothesis: Participants who receive the SCI will have better 6 month primary outcomes than those randomized to the Control group.\\n\\nSecondary questions:\\n\\nWhat are the effects of the SCI on: CES-D score at 3 months; depression diagnosis at 6 months; and mental health related quality of life, activation, severity of anxiety symptoms at 3 and 6 months, and use of health services over 6 months? Hypothesis: Participants who receive the SCI will have better health outcomes and lower use of health services than those randomized to the Control group.\\n\\nAre the effects of the SCI on the primary outcome modified by 5 primary baseline patient characteristics [major depression diagnosis; antidepressant medication; activation; recruitment source (clinical vs community); and level of education ] or by 9 secondary patient characteristics [cancer type, ongoing adjuvant cancer treatment (yes, no), years from cancer diagnosis (quartiles), severity of anxiety (as measured by the Hospital Anxiety and Depression Scale - Anxiety subscale (HADS-A)), physical health-related quality of life (as measured by the Physical Component Summary (PCS) of the Short Form Health Survey (SF-12)) (quartiles), sex, age (quartiles), family support for self-management (quartiles), province of residence (Quebec, Ontario)].\\n\\nHypothesis and support Effect moderators (or modifiers) represent variables e.g. patient characteristics, measured at baseline, that interact with treatment to change outcome for each sub-group. These specify for whom treatment is most effective and can improve power in subsequent trials by better selection of study groups for stratification. In selecting those potential modifiers/moderators that will be pre-specified for testing, investigators followed consensus criteria for assessment of these factors. Pinctus proposes 5 criteria for systematic reviews of randomized controlled trials confirming moderator effects: 1) was the analysis a priori; 2) was selection of factors for analysis clinically plausible and either theory-based or evidence-based; 3) were moderators measured prior to randomization; 4) adequate quality of measurement; 5) explicit test of the interaction between moderator and treatment. For meta-analyses exploring moderator effects, criteria 1 and 2 are not required.\\n\\nInvestigators will analyze 5 possible moderators using sub-group analyses:\\n\\nMajor depression They hypothesize that the intervention will be more effective among participants with a diagnosis of major depression (measured through the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders Disorders - Major Depressive Syndrome in the Mood Disorders Module (SCID)) than those without. A meta-analysis of psychosocial interventions in cancer populations found that studies in which patients were pre-selected for higher levels of distress found greater effectiveness of the intervention. A meta-analysis of depression self-care interventions also reported greater effectiveness in patients with major depression, although only in univariate analysis.\\n\\nAntidepressant medication Investigators hypothesize that the intervention will be more effective among participants with baseline antidepressant medication than those without. A meta-analysis found that the combination of psychotherapy and pharmacotherapy is more effective in the treatment of depression than psychotherapy alone.\\n\\nActivation Investigators hypothesize that the intervention will be more effective among participants with higher baseline activation than those with lower levels. As there is no accepted cut-point on the Patient Activation Measure (PAM) scale, higher activation will be defined as a PAM score in the highest quartile. In a randomized controlled trial of the depression self-care intervention among primary care patients with chronic physical conditions, investigators found that coaching was more effective among patients with higher baseline self-efficacy (one component of activation).\\n\\nRecruitment source Investigators hypothesize that the intervention will be more effective among participants recruited from community settings than from clinical settings. A meta-analysis of depression self-care interventions also reported lower effectiveness in patients studied in clinical settings, although only in univariate analysis. Participants recruited from community settings in this study (e.g., from community groups and social media) will already be selected to be more motivated to participate actively in the intervention.\\n\\nLevel of education Investigators hypothesize that the intervention will be more effective among participants with higher education, defined as some education beyond high school (e.g, diploma or university), compared with those with only high school or less education. Investigators are not aware of evidence supporting this hypothesis, but the use of paper and pencil and electronic tools will be more familiar to those with a higher level of education.\\n\\nIn addition to these 5 hypothesized moderators, investigators propose to examine the following 9 secondary potential baseline moderators, each with a maximum of 4 categories:\\n\\ncancer type, ongoing adjuvant cancer treatment (yes, no), years from cancer diagnosis (quartiles), severity of anxiety (HADS), physical health-related quality of life (PCS) (quartiles), sex, age (quartiles), family support for self-management (quartiles), province of residence (Quebec, Ontario).\\n\\nIn the Intervention group, is greater adherence to the SCI (e.g., use of self-care tools, completion of written exercises and mood monitoring, goal setting, greater number of coaching contacts) associated with better primary and secondary outcomes? Hypothesis: Participants who adhere to the SCI, particularly those who actively engage with the Cognitive behavioural therapy (CBT)-based tools will have greater reductions in depressive symptoms, diagnoses, and severity of anxiety symptoms, and greater increases in activation and quality of life.\\nEconomic analysis:\\n\\nAn economic analysis of the SCI is beyond the scope of this study. In the current study, investigators collect patient-reported data on use of health services and request additional (optional) consent for linkage to health care administrative data (the Ontario Health Insurance Plan (OHIP) Claims database and the Discharge Abstract Database (DAD)). They plan to seek additional funding for analyses of these use of services and administrative data for a future study on impact of the SCI on use of services. They will only extract use of services data for patients who consent to this optional element, and only for a period 12 months before and 12 months after the date of enrolment in the present trial. Patients who consent to use of their administrative data are asked to provide their OHIP number to allow researchers to extract the required data.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Survivors', 'Self Care']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '246', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression Self-care Intervention (SCI)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': \"Intervention group participants will receive the Depression Self-Care Toolkit for Cancer Survivors and will be supported by telephone by a coach who will help to activate them, guide them through the materials, help in selecting appropriate tools, and provide positive reinforcement. Coach contacts will be made every week for 3 months followed by 3 monthly contacts, up to a maximum of 15 contacts, lasting 10-20 minutes each.\\n\\nThe coach uses a stepped approach (i.e. educate about depression, initiate mood monitoring, determine participant's goals with respect to reducing depressive symptoms, and help with the use of specific tools). A suggested script is provided for the coach as a framework for each call. Tailoring of the SCI to different participants will be based on problems, depressive symptoms (from the PHQ-9), or concerns a participant may raise during the call.\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression self-care']}}, {'ArmGroupLabel': 'Control group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Members of both groups will continue to receive \"usual care\" for their depression. We will not interfere with usual care beyond recommending that participants discuss their depressive symptoms with their doctor. If participants consent, a short progress report will be send to their treating physician at the end of the study. At each follow-up, we will ask participants about specific treatment they have received for depression since entering the study (antidepressant medication initiation, discontinuation, change of dose, or psychotherapy) and use of community resources. The Intervention group will receive the Depression SCI. The Control group will receive only usual care for 6 months after randomization; they will be given the Toolkit with a single coaching call upon completion of the final interview, to ensure their access to depression treatment.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Depression self-care', 'InterventionDescription': 'Toolkit and coaching', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression Self-care Intervention (SCI)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in severity of depression symptoms: Centre for Epidemiologic Studies Depression Scale (CES-D)', 'PrimaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in severity of anxiety symptoms: Hospital Anxiety and Depression Scale - Anxiety subscale (HADS-Anxiety)', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'}, {'SecondaryOutcomeMeasure': 'Change in mental and physical health-related quality of life: Short Form health survey (SF-12)', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'}, {'SecondaryOutcomeMeasure': 'Change in activation: Patient Activation Measure (PAM)', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'}, {'SecondaryOutcomeMeasure': 'Change in depression diagnosis: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders - IV Disorders (SCID)', 'SecondaryOutcomeTimeFrame': 'Baseline, 6 months'}, {'SecondaryOutcomeMeasure': 'Change in use of health services: self-report', 'SecondaryOutcomeDescription': 'doctor office and clinic visits, emergency room visits, hospitalizations, psychosocial treatment or support group participation, changes in cancer diagnosis or treatment', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 month, 6 month'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria:\\n\\ncompleted primary cancer treatment (surgery, radiation and/or chemotherapy) for any type of cancer (NB: patients receiving adjuvant therapies will be eligible),\\nbetween 1-10 years post-diagnosis (as suggested by clinicians collaborating on the project),\\nwith moderate depressive symptoms (PHQ-9 score of 8-19).\\n\\nExclusion criteria:\\n\\nmetastatic disease,\\nsuicidal,\\nmoderate-severe cognitive impairment,\\nunable to speak and read in English or French,\\nonly non-melanoma skin cancer (without any other single primary cancer),\\nreceiving ongoing psychological treatment at baseline (because of recent finding that this treatment may negatively modify the effectiveness of the coaching component of the intervention). NB: those who begin psychological treatment during follow-up will not be withdrawn.\\ndose of antidepressant medication changed within last 6 weeks at baseline. NB: those who change dose or treatment during follow-up will not be withdrawn.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': \"St Mary's Research Centre\", 'LocationCity': 'Montreal', 'LocationState': 'Quebec', 'LocationZip': 'H3T1M5', 'LocationCountry': 'Canada'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 32, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02771535', 'OrgStudyIdInfo': {'OrgStudyId': '1027/106'}, 'Organization': {'OrgFullName': 'Universitätsklinikum Hamburg-Eppendorf', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Long-term Efficacy of Metacognitive Training for Depression (D-MCT)', 'OfficialTitle': 'Long-term Efficacy of Metacognitive Training for Depression (D-MCT): a 3-year Follow up'}, 'StatusModule': {'StatusVerifiedDate': 'August 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2016'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2017', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 2017', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 5, 2016', 'StudyFirstSubmitQCDate': 'May 12, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 13, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 2, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 3, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Universitätsklinikum Hamburg-Eppendorf', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Aim of the current study is to investigate the long-term efficacy of Metacognitive Training for Depression (D-MCT) and to explore whether previously observed effects at the 6-month follow-up of a randomized, controlled, assessor-blind, parallel group trial are maintained at the 3-year follow-up.', 'DetailedDescription': 'Dissemination of treatment for depression is still unsatisfying: every second patient does not receive, refuses, or is waiting for treatment. Moreover, with a drop-out rate of almost 25% in routine clinical practice, and a 54% relapse rate for treatment responders within the two years after treatment termination, improving treatment is necessary. Metacognitive Training for depression (D-MCT), a low threshold, easy to administer group intervention was designed to fill this gap. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research. It was positively evaluated with regard to feasibility and acceptance in a non-randomized pilot study. Moreover, efficacy of D-MCT was suggested in a randomized controlled trail (RCT) in comparison to an active control intervention (Jelinek et al., in press). In this trial patients with depressive disorder were completing a psychosomatic outpatient treatment program and were randomly assigned to either D-MCT or general health training. Severity of depression and cognitive biases were assessed at baseline (t0), post treatment (t1) and 6 months (t2) later by raters blind to diagnostic status. Intention-to-treat analyses demonstrated that at the end of treatment, as well as 6 months later, improvement in depression was significantly greater in the D-MCT relative to the health training group at medium effect sizes. A significantly greater number of patients in the D-MCT group were in remission at 6-month follow-up. Moreover, the decrease in cognitive biases and increase in psychological well-being/quality of life was larger in the D-MCT than the health training group over time. Aim of the current study is to investigate the long-term efficacy of D-MCT. For this purpose, an additional 3 year follow-up assessment (t3) is conducted. The Hamilton Depression Rating Scale (HDRS, 17-item version) total score serves as the primary outcome. Self-assessed depression, dysfunctional beliefs, self-esteem, quality of life, and ability to work serve as secondary outcomes.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Unipolar Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '84', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'D-MCT Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: D-MCT']}}, {'ArmGroupLabel': 'Health Training Group', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Health Training']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'D-MCT', 'InterventionDescription': 'Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['D-MCT Group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Metacognitive Training for Depression']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Health Training', 'InterventionDescription': 'Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Health Training Group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Hamilton Depression Rating Scale', 'PrimaryOutcomeDescription': 'Primary outcome is change on the Hamilton Depression Rating Scale (HDRS, 17-item version) from baseline to follow-up (t0 - t3)', 'PrimaryOutcomeTimeFrame': '3 years from baseline (t0) to 3-year follow up (t3)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Self-assessed depression', 'SecondaryOutcomeDescription': 'Change in self-assessed depression as measured by the Beck-Depression Inventory (BDI) from baseline to follow-up (t0 to t3)', 'SecondaryOutcomeTimeFrame': '3 years from baseline (t0) to 3-year follow up (t3)'}, {'SecondaryOutcomeMeasure': 'Dysfunctional beliefs', 'SecondaryOutcomeDescription': 'Change in dysfunctional beliefs as measured by the Dysfunctional Attitude Scale (DAS) from baseline to follow-up (t0 to t3)', 'SecondaryOutcomeTimeFrame': '3 years from baseline (t0) to 3-year follow up (t3)'}, {'SecondaryOutcomeMeasure': 'Dysfunctional metacognitive beliefs', 'SecondaryOutcomeDescription': 'Change in metacognitive beliefs as measured by the Metacognitions Questionnaire (MCQ-30) from baseline to follow-up (t0 to t3)', 'SecondaryOutcomeTimeFrame': '3 years from baseline (t0) to 3-year follow up (t3)'}, {'SecondaryOutcomeMeasure': 'Quality of life', 'SecondaryOutcomeDescription': 'Change in quality of life as measured by the World Health Organization Quality of Life Assessment (WHOQOL-BREF) from baseline to follow-up (t0 to t3)', 'SecondaryOutcomeTimeFrame': '3 years from baseline (t0) to 3-year follow up (t3)'}, {'SecondaryOutcomeMeasure': 'Work status', 'SecondaryOutcomeDescription': 'Work status (full or part-time employment, unemployed, house wife/husband, student, on sick leave, retired) at T3 assessment', 'SecondaryOutcomeTimeFrame': 'at 3-year follow-up (t3)'}, {'SecondaryOutcomeMeasure': 'Self-esteem', 'SecondaryOutcomeDescription': 'Change in self-esteem as measured by the Rosenberg Self-Esteem Scale (RSE) from from baseline to follow-up (t0 to t3)', 'SecondaryOutcomeTimeFrame': '3 years from baseline (t0) to 3-year follow up (t3)'}, {'SecondaryOutcomeMeasure': 'Remission rate', 'SecondaryOutcomeDescription': 'Remission rate at T3 as measured by the Hamilton Depression Rating Scale (HDRS score ≤ 8)', 'SecondaryOutcomeTimeFrame': 'at 3-year follow up (t3)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria for the current study are:\\n\\ninformed consent\\nintention-to-treat-sample of the study Evaluation of Metacognitive Training for Depression (D-MKT) in psychosomatic rehabilitation, DRKS-ID: DRKS00007907 (see Jelinek et al., in press, Psychotherapy and Psychosomatics)\\nage between 18 and 65 years\\ndiagnosis of a single episode or recurrent major depressive disorder (MDD) or dysthymia (verified by the MINI).\\n\\nThe exclusion criteria were:\\n\\nlifetime psychotic symptoms (i.e., hallucinations, delusions, or mania), suicidality (Suicidal Behaviors Questionnaire-Revised ≥ 7), intellectual disability (estimated IQ < 70).', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Lena Jelinek, PD Dr.', 'OverallOfficialAffiliation': 'Universitätsklinikum Hamburg-Eppendorf', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University Medical Center Hamburg Eppendorf', 'LocationCity': 'Hamburg', 'LocationZip': '20246', 'LocationCountry': 'Germany'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25103718', 'ReferenceType': 'background', 'ReferenceCitation': 'Moritz S, Veckenstedt R, Andreou C, Bohn F, Hottenrott B, Leighton L, Köther U, Woodward TS, Treszl A, Menon M, Schneider BC, Pfueller U, Roesch-Ely D. Sustained and \"sleeper\" effects of group metacognitive training for schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2014 Oct;71(10):1103-11. doi: 10.1001/jamapsychiatry.2014.1038.'}, {'ReferencePMID': '27230865', 'ReferenceType': 'background', 'ReferenceCitation': 'Jelinek L, Hauschildt M, Wittekind CE, Schneider BC, Kriston L, Moritz S. Efficacy of Metacognitive Training for Depression: A Randomized Controlled Trial. Psychother Psychosom. 2016;85(4):231-4. doi: 10.1159/000443699. Epub 2016 May 27.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Jelinek L, Otte C, Arlt S, Hauschildt M: Denkverzerrungen erkennen und korrigieren: Eine Machbarkeitsstudie zum Metakognitiven Training bei Depression (D-MKT). [Identifying and correcting cognitive biases: A pilot study on the Metacognitive Training for Depression (D-MCT)]. Zeitschrift Für Psychiatr Psychol Und Psychother 61:1-8, 2013.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 33, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01834534', 'OrgStudyIdInfo': {'OrgStudyId': '1R01MH096699', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH096699&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R01MH096699-01', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH096699-01&Fy=all'}]}, 'Organization': {'OrgFullName': 'University of Michigan', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Telemonitoring Enhanced Support for Depression Self Management', 'OfficialTitle': 'Telemonitoring Enhanced Support for Depression Self Management'}, 'StatusModule': {'StatusVerifiedDate': 'March 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2013'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 29, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 31, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'September 13, 2012', 'StudyFirstSubmitQCDate': 'April 15, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 18, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 6, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 7, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'James Aikens, PhD', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor of Family Medicine', 'ResponsiblePartyInvestigatorAffiliation': 'University of Michigan'}, 'LeadSponsor': {'LeadSponsorName': 'University of Michigan', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The objective of this research is to test the efficacy of \"CarePartners for Depression\" (CP-D) intervention, which was designed to increase between visit monitoring of depression status and enhance self-management.\\n\\n**In order to participate, subjects must be patients at participating clinics: Alcona Health Center, Cherry Street Health Services, Dua Family Practice, Morang Chester.', 'DetailedDescription': 'This project will test a practical intervention that uses low cost technologies to activate depressed patients\\' existing social networks for self-management support. The intervention links patients with a \"CarePartner\" (CP), i.e., a non-household family member or close friend who is willing to support the patient in coordination with the clinician and any existing in-home caregiver (ICG). Through weekly automated telemonitoring, patients report their mood and self-management status, and receive tailored guidance on self-management. The CP receives a corresponding update along with guidance on how to best support the patient\\'s self-management efforts, and the primary care team is notified about clinically urgent situations. The intervention will be tested among depressed primary care patients from clinics serving low-income and underinsured patients, whom the intervention was especially designed to benefit. Specific Aim 1 is to conduct a randomized controlled trial to compare the effectiveness of one year of telemonitoring-supported CP for depression versus usual care (control) on depression severity. Specific Aim 2 is to examine key secondary outcomes (response and remission, impairment, well-being, caregiving burden, healthcare costs) and potential moderators. Specific Aim 3 is to use a mixed-methods approach to enrich our interpretation of the statistical associations, and to discover strategies to enhance the intervention\\'s acceptability, effectiveness, and sustainability. If the intervention proves effective without increasing clinician burden or marginal costs, then its subsequent implementation could yield major public health benefits, especially in medically underserved populations.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '243', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'CarePartners for depression', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': \"For one year, patients receive weekly automated telemonitoring of mood and self-management, while their CarePartners receive weekly reports of the patient's assessment results with tailored instructions on supporting the patient's depression self-management.\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: CarePartners for depression']}}, {'ArmGroupLabel': 'Usual care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Usual medical care.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'CarePartners for depression', 'InterventionDescription': 'Automated telephone calls for depression monitoring and self-management support.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CarePartners for depression']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depressive symptom severity', 'PrimaryOutcomeDescription': 'Patient Health Questionnaire 9 (PHQ-9).', 'PrimaryOutcomeTimeFrame': '12 months after randomization'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depression remission rate', 'SecondaryOutcomeDescription': 'Remission as measured by PHQ-9 <10', 'SecondaryOutcomeTimeFrame': '12 months after randomization'}, {'SecondaryOutcomeMeasure': 'Depression-related functional impairment', 'SecondaryOutcomeDescription': 'Sheehan Disability Scale', 'SecondaryOutcomeTimeFrame': '12 months after randomization'}, {'SecondaryOutcomeMeasure': 'Positive well-being', 'SecondaryOutcomeDescription': 'Positive well-being will be assessed using the REMIT, a 5-item scale of positive affect and other aspects of depression recovery developed by the PI and his colleagues. Reference: Nease DE, Jr., Aikens, JE, Klinkman, MK, Kroenke, K, and Sen, A. Toward a more comprehensive assessment of depression remission: the Remission Evaluation and Mood Inventory Tool (REMIT). Journal of General Hospital Psychiatry. 2011.', 'SecondaryOutcomeTimeFrame': '12 months after randomization'}, {'SecondaryOutcomeMeasure': 'Health care costs', 'SecondaryOutcomeDescription': 'Health care costs will be estimated using data gathered from a variety of patient self-report and site-specific administrative databases.', 'SecondaryOutcomeTimeFrame': '12 months after randomization'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'NOTE: In order to participate, must have received medical care for past year at one of the participating clinics: Alcona Health Center, Cherry Street Health Services, Dua Family Practice, Morang Chester\\n\\nAdditional Inclusion Criteria:\\n\\nat least 2 outpatient primary care visits in the past 2 years, 1 within the past 13 months\\ndepression diagnosis in medical chart problem list or billing record (ICD9 codes: 296.20-.26, .30-.36, 296.4-.9, 298.0, 300.4, 309.0-.1, 309.28, 311.00) during the past 2 years\\ncurrent PHQ >10 (non-mild depressive symptoms)\\nat least 21 years old\\ncomfortable speaking English\\ncan use a touch-tone phone\\ncan identify at least 1 eligible CarePartner\\nnot in palliative care, on transplant waitlist, or <1 year life expectancy\\nfree of major cognitive impairment or psychiatrically unstable\\nnot experiencing domestic abuse or stalking\\n\\nExclusion Criteria:\\n\\nLimited life expectancy (e.g., advanced stage cancer/heart failure/on oxygen/end stage renal disease), receiving palliative care\\nAt risk for domestic abuse, PHQ<10, end stage renal disease, lung cancer, dementia, bipolar disease, schizophrenia, limited life expectancy (advanced stage cancer/heart failure/on oxygen), alcohol problems, receiving palliative care\\nUnable to speak English\\nNot planning to get all or most of care at study site\\nPrimary care physician not affiliated with study site\\nUnable to use telephone to respond to weekly automated self-management support calls\\nUnable to nominate an eligible CP', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '21 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'James E Aikens, Ph.D.', 'OverallOfficialAffiliation': 'University of Michigan', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'John D Piette, Ph.D.', 'OverallOfficialAffiliation': 'University of Michigan', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Alcona Health Centers', 'LocationCity': 'Alpena', 'LocationState': 'Michigan', 'LocationZip': '49707', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Michigan', 'LocationCity': 'Ann Arbor', 'LocationState': 'Michigan', 'LocationZip': '48013', 'LocationCountry': 'United States'}, {'LocationFacility': 'Dua Family Practice', 'LocationCity': 'Canton', 'LocationState': 'Michigan', 'LocationZip': '48187', 'LocationCountry': 'United States'}, {'LocationFacility': 'Morang Chester', 'LocationCity': 'Detroit', 'LocationState': 'Michigan', 'LocationZip': '48224', 'LocationCountry': 'United States'}, {'LocationFacility': 'Hamilton Community Health Network, Inc.', 'LocationCity': 'Flint', 'LocationState': 'Michigan', 'LocationZip': '48505', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cherry Street Health Services', 'LocationCity': 'Grand Rapids', 'LocationState': 'Michigan', 'LocationZip': '49503', 'LocationCountry': 'United States'}, {'LocationFacility': 'Muskegon Family Care', 'LocationCity': 'Muskegon Heights', 'LocationState': 'Michigan', 'LocationZip': '49444', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 34, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02997865', 'OrgStudyIdInfo': {'OrgStudyId': 'R01HL131524', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01HL131524&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01HL131524', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01HL131524&Fy=all'}]}, 'Organization': {'OrgFullName': 'Washington University School of Medicine', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Stepped Care for Depression in Heart Failure', 'OfficialTitle': 'Stepped Care for Depression in Heart Failure', 'Acronym': 'DASH-2'}, 'StatusModule': {'StatusVerifiedDate': 'March 2019', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 17, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'May 2021', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 15, 2016', 'StudyFirstSubmitQCDate': 'December 19, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 20, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 15, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 19, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Washington University School of Medicine', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Heart, Lung, and Blood Institute (NHLBI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study evaluates stepped care for depression in patients with heart failure (HF). The stepped care intervention consists of individualized cognitive behavior therapy (CBT). Half of the participants will receive stepped care and half will receive usual care for depression; all participants will receive heart failure self-care education and support. The primary aims are to determine whether stepped care is superior to usual care for depression, and whether treating depression improves heart failure self-care outcomes.', 'DetailedDescription': 'Depression is associated with poor heart failure self-care. Good self-care practices, including following dietary recommendations, taking prescribed medications, monitoring symptoms, and regular light exercise have been shown to improve quality of life and survival in persons with heart failure.\\n\\nBoth CBT and antidepressant medications have been used in previous studies to treat major depression in patients with heart failure. Participants in the intervention arm in this trial will start with CBT. Those who do not improve very much within the first 5-10 weeks of CBT may also be referred to their own physician to discuss antidepressant medications.\\n\\nHeart failure self-care education and support will be provided after the first 8 weeks of the depression intervention. The study will determine whether people with heart failure benefit more from self-care education and support after their depression has been treated with a stepped care intervention, as compared to usual care for depression as provided by primary care providers.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Heart Failure', 'Depressive Disorder, Major']}, 'KeywordList': {'Keyword': ['heart failure', 'depressive disorder, major', 'cognitive therapy', 'self-care']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '180', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Stepped Care for Depression', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will receive cognitive behavior therapy for depression, plus referral to their own physician for discussion of antidepressant medication if symptoms do not improve within 5-10 weeks. Participants will also receive individually-tailored heart failure self-care education and support.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Stepped care for depression']}}, {'ArmGroupLabel': 'Enhanced Usual Care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': \"Participants will receive individually-tailored heart failure self-care education and support. With the participant's permission, his or her personal physician will be notified about the patient's depression. The participant will be asked to discuss depression treatment options with his or her personal physician.\"}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Stepped care for depression', 'InterventionDescription': \"Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stepped Care for Depression']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Beck Depression Inventory (BDI-II) total score', 'PrimaryOutcomeDescription': 'Self-reported severity of depression', 'PrimaryOutcomeTimeFrame': '16 weeks'}, {'PrimaryOutcomeMeasure': 'Self Care of Heart Failure Index (SCHFI) Maintenance subscale', 'PrimaryOutcomeDescription': 'Self-reported heart failure self-care behaviors', 'PrimaryOutcomeTimeFrame': '16 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Beck Anxiety Inventory', 'SecondaryOutcomeDescription': 'Self-reported severity of anxiety symptoms', 'SecondaryOutcomeTimeFrame': '16 weeks'}, {'SecondaryOutcomeMeasure': 'Kansas City Cardiomyopathy Questionnaire (KCCQ)', 'SecondaryOutcomeDescription': 'Heart failure-related quality of life', 'SecondaryOutcomeTimeFrame': '16 weeks'}, {'SecondaryOutcomeMeasure': 'Hamilton Rating Scale for Depression (HAM-D-17)', 'SecondaryOutcomeDescription': 'Interviewer-rated severity of depression symptoms', 'SecondaryOutcomeTimeFrame': '16 weeks'}, {'SecondaryOutcomeMeasure': 'Actigraphy', 'SecondaryOutcomeDescription': 'Physical activity level', 'SecondaryOutcomeTimeFrame': '16 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nStable, clinically-documented Class I-III heart failure.\\nCurrent major depressive episode.\\nBaseline BDI-II score 14 or greater\\n\\nExclusion Criteria:\\n\\nDementia or other significant cognitive or communication deficits\\nTerminal illness other than HF\\nInsurmountable logistical barriers to participation\\nAge less than 25 years\\nCurrent clinically significant substance abuse, bipolar disorder, schizophrenia, or other psychotic disorder\\nHigh risk of suicide\\nCurrent participation in non-study psychotherapy for depression or other psychiatric conditions\\nInitiation or modification of antidepressant medication treatment within past two months\\nRenal or hepatic conditions that would preclude the use of antidepressants.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '25 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Judith A Skala, PhD, RN', 'CentralContactRole': 'Contact', 'CentralContactPhone': '314-286-1316', 'CentralContactEMail': 'skalaj@wustl.edu'}, {'CentralContactName': 'Kenneth E Freedland, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '314-286-1311', 'CentralContactEMail': 'freedlak@wustl.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kenneth E Freedland, PhD', 'OverallOfficialAffiliation': 'Washington University School of Medicine', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Behavioral Medicine Center at Washington University School of Medicine', 'LocationStatus': 'Recruiting', 'LocationCity': 'Saint Louis', 'LocationState': 'Missouri', 'LocationZip': '63108', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jeanne Heaghney, RN', 'LocationContactRole': 'Contact', 'LocationContactPhone': '314-286-1517', 'LocationContactEMail': 'heaghney@wustl.edu'}, {'LocationContactName': 'Judith Skala, RN, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '3142861316', 'LocationContactEMail': 'skalaj@wustl.edu'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided', 'IPDSharingDescription': 'We may share de-identified data with other researchers after the completion of the study; no specific plans for this have been made yet.'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006333', 'ConditionMeshTerm': 'Heart Failure'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000003865', 'ConditionMeshTerm': 'Depressive Disorder, Major'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafAsFound': 'Depressive Disorder, Major', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8004', 'ConditionBrowseLeafName': 'Heart Failure', 'ConditionBrowseLeafAsFound': 'Heart Failure', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}}, {'Rank': 35, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02712918', 'OrgStudyIdInfo': {'OrgStudyId': 'BATD_16674'}, 'Organization': {'OrgFullName': 'Lovisenberg Diakonale Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Brief Behavioral Activation Treatment for Depression With Inpatients', 'OfficialTitle': 'An Evaluation of Brief Behavioral Activation Treatment for Depression With Moderate to Severely Depressed Inpatients - A Small Randomized Controlled Trial'}, 'StatusModule': {'StatusVerifiedDate': 'March 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2014', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 2014', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 9, 2015', 'StudyFirstSubmitQCDate': 'March 15, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 18, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 15, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 18, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Martin Myhre', 'ResponsiblePartyInvestigatorTitle': 'Learning Disability Nurse/MSc Behavior Analysis', 'ResponsiblePartyInvestigatorAffiliation': 'Lovisenberg Diakonale Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Lovisenberg Diakonale Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Oslo Metropolitan University', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of the current study was to examine Brief Behavioral Activation Treatment for Depressions (BATD) effectiveness, credibility, and acceptability with moderate to severly depressed inpatients. The study is a systematic replication of a randomized controlled trail from 2003, that provided initial support for BATD With inpatients. The current study compared BATD to Treatment as Usual in a randomized controlled trial.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Inpatient', 'Acute', 'Brief Behavioral Activation Treatment for Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '23', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Brief Behavioral Activation Treatment for Depression', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Behavioral treatment of depression. The study utilized the revised version of the Brief Behavioral Activation Treatment for Depression (BATD) protocol from 2011. The treatment was added to treatment as usual. Up to 10 sessions were administered.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Brief Behavioral Activation Treatment for Depression']}}, {'ArmGroupLabel': 'Standard care', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Standard CARE (SC) at the inpatient unit. Mandatory: Therapeutic conversations with psychiatrist, psychologist or M.D, milieu therapy. Optional: Psychosomatic physiotherapy, therapeutic groups, psychopharmacological treatment.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Standard Care']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Brief Behavioral Activation Treatment for Depression', 'InterventionDescription': 'Behavioral treatment of depression which focuses on increasing the Level of positive reinforcement through systematic and goal directed activation of behavior. Goal and values are assessed and used to determine target behaviors.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Brief Behavioral Activation Treatment for Depression']}}, {'InterventionType': 'Other', 'InterventionName': 'Standard Care', 'InterventionDescription': 'Treatment as usual at the ward', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Standard care']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change of Beck`s Depression Inventory-II from baseline', 'PrimaryOutcomeTimeFrame': 'Change from baseline (second day of admission) to discharge from the ward (maximum 21 days, expected average of 10 days).'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Credibility and Expectancies Questionnaire', 'SecondaryOutcomeDescription': 'Only BATD group', 'SecondaryOutcomeTimeFrame': 'Second day of admission. After first sessions of BATD.'}, {'SecondaryOutcomeMeasure': 'Treatment Evaluation Inventory - Short Form', 'SecondaryOutcomeDescription': 'Only BATD group', 'SecondaryOutcomeTimeFrame': 'Prior to discharge from the ward (maximum 21 days, expected average of 10 days)..'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nModerate to severe depression (BDI-II > 28 Points).\\nAdmission length of at least 3 days\\nEvaluated to benefit from depression treatment by unit psychiatrist.\\n\\nExclusion Criteria:\\n\\nCurrent psychotic disorder\\nPreviously diagnosis with psychotic disorder (including Bipolar disorder)', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '11317637', 'ReferenceType': 'background', 'ReferenceCitation': 'Lejuez CW, Hopko DR, Hopko SD. A brief behavioral activation treatment for depression. Treatment manual. Behav Modif. 2001 Apr;25(2):255-86.'}, {'ReferencePMID': '21324944', 'ReferenceType': 'background', 'ReferenceCitation': 'Lejuez CW, Hopko DR, Acierno R, Daughters SB, Pagoto SL. Ten year revision of the brief behavioral activation treatment for depression: revised treatment manual. Behav Modif. 2011 Mar;35(2):111-61. doi: 10.1177/0145445510390929.'}, {'ReferencePMID': '12971122', 'ReferenceType': 'result', 'ReferenceCitation': 'Hopko DR, Lejuez CW, LePage JP, Hopko SD, McNeil DW. A brief behavioral activation treatment for depression. A randomized pilot trial within an inpatient psychiatric hospital. Behav Modif. 2003 Sep;27(4):458-69.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 36, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01114334', 'OrgStudyIdInfo': {'OrgStudyId': 'K23MH082997', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=K23MH082997&Fy=all'}, 'Organization': {'OrgFullName': 'Denver Health and Hospital Authority', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Motivational Interviews for Depression in Primary Care', 'OfficialTitle': 'Motivational Interviews Adapted to Improve Depression Treatment in Primary Care'}, 'StatusModule': {'StatusVerifiedDate': 'May 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2010'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2012', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 29, 2010', 'StudyFirstSubmitQCDate': 'April 30, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 3, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'October 17, 2016', 'ResultsFirstSubmitQCDate': 'March 9, 2017', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'April 20, 2017', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 7, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 6, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Denver Health and Hospital Authority', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The purpose of the study is to determine whether motivational interviewing with guideline-based medical management for depression will significantly improve time to depression recovery and increase the proportion of subjects in recovery compared to guideline-based medical management alone over 9 months.', 'DetailedDescription': 'Setting Denver Health is an integrated healthcare system. During the time period that the trial was conducted, 2010 to 2012, Denver Health comprised eight federally qualified community health facilities serving primarily uninsured and Medicaid patients in Denver, Colorado, USA. The mainstay treatment for depression was antidepressant medication only, as access to specialty mental health counseling or psychiatric services was not readily available at the participating primary care facilities during the time frame of the trial.\\n\\nRandomization and Masking We recruited seven primary care facilities housing 10 independent care teams (clusters). Three facilities had two teams each, and four had one team. Although staff and providers from different facilities and teams attend role-specific training together and may share managers, each team has unique support staff, providers, and patient panels. We used a blocked design to limit the possibility of patients crossing over from a team assigned to one randomization group to one in the other group (contamination). Because of a negative association between minority race/ ethnicity and depression diagnosis and treatment receipt, we stratified the teams by the race/ ethnicity of the respective patient populations at each facility (plurality Hispanic, non-Hispanic black, or non-Hispanic white). Prior to randomization, we blocked eight of 10 teams into four pairs within strata because they: (a) shared the same facility (three facilities with two teams each); or (b) were from closely located neighborhoods (two facilities with one team each).\\n\\nOutcome assessors who obtained written consent, conducted the baseline depression assessment, and collected clinical outcomes were blinded to cluster allocation and were not involved in other study procedures. Patient participants were blinded to group assignment. Participating providers were not blinded.\\n\\nProtocol Change Prior to recruiting patients into the intention-to-treat (ITT) groups, we changed the primary outcome at the trial registration site on 4/29/10 from the outcome specified in the original 2008 protocol, \"adherence to antidepressant medication\", to \"remission from depression.\" However, detecting remission, defined as an event where depressive symptoms fall below a clinically significant level for a prolonged period, entails weekly or bi-weekly outcome assessments (Nierenberg, 2001; Rush et al., 2006). Limited study resources precluded closely spaced outcome assessments over 36 weeks. Therefore, to better understand trajectories of clinical outcome for the primary care patients assigned to teams staffed by providers trained to discuss depression with Motivational Interviewing versus those patients assigned to teams staffed by untrained providers, measures of both continuous depressive symptoms and a binary outcome measure (Patient Health Questionnaire-9 (PHQ-9) score < 5) were calculated for each group at 6, 12, and 36 weeks.\\n\\nPrimary Care Providers In May 2009, the research team emailed 53 providers from 13 primary care teams (eligible clusters) in eight facilities with an invitation to participate in a study of \"training for a new counseling method for treating depression.\" Inclusion criteria included working at least 1.5 days per week in outpatient care, previous experience treating depression, and availability for a one-day baseline MI training on 7/25/09. We obtained consent from providers prior to randomization.\\n\\nPatients During the recruitment phase, the research team called sequential eligible patients 2 to 3 days prior to scheduled visits with participating providers. The team assessed for initial exclusion criteria and invited those not excluded to complete an audio-recorded partial waiver of consent and stage-I depression screen, the Patient Health Questionnaire-2 (PHQ-2). Prior to the visit, a recruiter met patients scoring 2 or higher on either item of the PHQ-2, described the study, obtained written informed consent, and invited consenting patients to complete the PHQ-9.\\n\\nPatients were excluded if they were attending a one-time disability qualification examination, had no personal phone, were homeless, were treated for depression with antidepressant medication within the previous 3 months, were currently in therapy provided by a mental health specialist, had impaired memory, had a life-threatening physical disease, expressed severe suicidal ideation, were pregnant or breastfeeding, or exhibited alcohol/ drug dependence, bipolar disorder or current psychosis assessed with a diagnostic schedule.\\n\\nThe recruiter notified the provider and patient prior to the clinical encounter when patients scored 10 or higher on the PHQ-9, signifying \\'probable major depression\\' . A board-certified psychiatrist, blinded to patient allocation, diagnosed depression and determined additional exclusion criteria. Patients diagnosed with a major depressive episode, not excluded for other reasons, and completing a subsequent baseline telephone interview within 8 days, were enrolled as the Intention-To-Treat (ITT) sample.\\n\\nIntervention - MI with Standard Management of Depression The MI training approach included interactive learning for the core MI skills. An 8-hour classroom training on 7/25/09 consisted of a brief overview of MI, videos and discussion of core MI skills and \"MI Spirit,\" as well as skill-building practice. Providers learned how to use \"OARS\" and summaries to elicit change talk, how to implement the elicit-provide-elicit technique, and how to craft action plans with patients. Providers practiced using 0-10 Ruler questions to assess and increase patient importance and confidence in changing.\\n\\nThe training was designed according to Arkowitz and Burkes\\' (2008) recommendation for a three-component framework when using MI to discuss depression. In this framework, the provider first helps explore the patient\\'s negative emotions through reflective listening. Second, the provider uncovers contributors to the negative emotions. Third, the patient\\'s own ideas about how to handle their negative emotions are elicited.\\n\\nTo optimize treatment integrity, 4-hour refresher sessions were offered after 4 and 12 months. Over the first 14 months, feedback was provided via email and face-to face regarding audio-taped encounters (total two to four feedbacks per provider).\\n\\nControl - Standard Management of Depression Alone All providers randomized to either intervention or to control received a 1-hour slideshow and the \"American Psychiatric Association Practice Guideline for the Treatment of Major Depressive Disorder\" (APA depression guideline) (2010). The resources recommended antidepressant medications and psychotherapy as evidence-based treatments for depression.\\n\\nMeasurements Baseline Descriptors. In addition to demographics, provider information included training (M.D. versus mid-level) and certification (Family Practitioner, General Internist, Physician\\'s Assistant, or Nurse Practitioner), and years of clinical experience. Patient descriptors included generalized anxiety disorder (past 6 months), federal poverty level, and previous suicidal behavior.\\n\\nTreatment Variables. Time spent discussing depression at the index visit was assessed from audio-recorded encounters. Two measures of follow-up over 36 weeks, total primary care visits dichotomized at the median and at least three or more visits with documented discussion of mental health were abstracted from the electronic medical record. Receipt of antidepressant medication and specialty mental health counseling was also determined.\\n\\nStatistical Analysis Missing Data. Total missingness and whether missingness was differential by group or cluster was assessed. Little\\'s likelihood ratio test was used to test the hypothesis that data is Missing Completely at Random (MCAR). To determine plausibility of Missing at Random (MAR), correlations between baseline or auxiliary variables and missingness by group at each time point were calculated.\\n\\nPrior to performing the ITT analyses, Multiple Imputation through Chained Equations (MICE) was conducted to deal with missing data. The Fully Conditional Specification algorithm in the SAS MI procedure was used to generate 30 imputed datasets. The effects of the intervention on depressive symptoms and on remission were determined on each imputed data set. MI repetition results were combined to generate final estimates of parameters and confidence intervals for depressive symptoms. Rubin\\'s rules were used to combine the parameter estimates and errors into a single set of results.\\n\\nTreatment Outcomes. Analyses of treatment outcomes were run by ITT. Generalized linear mixed effects models, adjusted for clustering of patients within care team, were used to examine differences in outcomes by randomization group. Whereas randomization was stratified by class (race/ ethnicity), the interaction between class and treatment group as well as class itself were included in all multivariate analyses.\\n\\nMain Effects. Main outcome analyses were run by ITT utilizing imputed datasets. General linear mixed effects models, or generalized models for a binary outcome, were used to examine whether the group x time interactions for outcomes depressive symptoms and remission were significant. The general linear mixed model assumed unstructured variance-covariance matrices, maximum likelihood (method = ML) estimation, and adjusted for clustering of patients within care teams and repeated measures within patients. Whereas the random effect of clustering patients within care teams on remission in the adjusted model was zero, patients were not clustered within care teams in the generalized model for the binary outcome.\\n\\nModerator hypothesis: A hypothesis concerning moderator variables was included in the Colorado Multiple Institutional Review Board (COMIRB) protocol for the trial. In the protocol approved with a COMIRB stamp on 2/3/10, specific aim #2 was \"ii. Specific Aim #2: Aim 2 is to explore for moderators and mediators of the effect of AMI-TAD on adherence and outcome. We hypothesize that higher baseline patient self-efficacy will differentially increase the effect of AMI-TAD with SCD.\" AMI-TAD is an earlier abbreviated name for the the MI training intervention.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Major Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Cluster Randomized Clinical Trial', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '168', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Guideline-based Medical Management', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': \"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nThe evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Guideline-Based Medical Management']}}, {'ArmGroupLabel': 'Motivational Interview with GBMM', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Motivational Interviewing for Depression combined with guideline-based medical management for depression', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Guideline-Based Medical Management', 'Behavioral: Motivational Interviewing for Depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Guideline-Based Medical Management', 'InterventionDescription': \"We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Guideline-based Medical Management', 'Motivational Interview with GBMM']}, 'InterventionOtherNameList': {'InterventionOtherName': ['GBMM']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Motivational Interviewing for Depression', 'InterventionDescription': \"Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Motivational Interview with GBMM']}, 'InterventionOtherNameList': {'InterventionOtherName': ['MI with GBMM']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression Remission', 'PrimaryOutcomeDescription': 'The primary outcome is depression remission ascertained with the Patient Health Questionnaire-9. A score of less than 5 is considered to represent remission. The secondary clinical outcome is the continuous measure of depressive symptoms.', 'PrimaryOutcomeTimeFrame': '36 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Adherence to Treatment With Antidepressant Medication', 'SecondaryOutcomeDescription': 'Antidepressant Adherence will be measured with Computerized Pharmacy Records. Adherence will be operationalized as \"non-persistence,\" or time to discontinuation. Non-persistence will be considered to have occurred if the days of medication supply from the previous prescription plus a 30-day grace period exceed the number of days between the previous prescription date and the current prescription fill date. Filling no prescriptions, \\'initiation failure,\\' will be treated as non-persistence. Minimally adequate persistence was defined as at least three 30-day fills of an antidepressant medication at a usual dose as defined in the American Psychiatric Association guideline without a 30-day gap in refills. The count of participants receiving minimally adequate persistence with antidepressant medication is reported for each study group.', 'SecondaryOutcomeTimeFrame': '36 weeks'}, {'SecondaryOutcomeMeasure': 'Patient Health Questionnaire-9 Instrument for Assessing Depressive Symptoms', 'SecondaryOutcomeDescription': 'Depressive symptoms were measured with the Patient Health Questionnaire-9 (PHQ-9) instrument. The PHQ-9 is a nine item survey to assess depressive symptoms over the previous 2 weeks. The patient may answer \"not at all\" (scored as a 0) , \"several days\" (scored as a 1), \"more than half the days\" (scored as a 2), or \"nearly every day\" (scored as a 3) for each item. The range in total scores is from 0 (no depressive symptoms or best outcome) to 27 (severe depressive symptoms or worst outcome). For this randomized trial mean total scores are reported.', 'SecondaryOutcomeTimeFrame': '36 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nWomen and men aged 18 or older presenting at one of the seven DHH study clinics with a new treatment episode for depression will be considered for the study.\\nThe PHQ-9 is used to define depression category with a sensitivity and specificity for MDD of at least 88%. Patients must have PHQ-9≥10 to ensure sufficient severity to warrant intervention.\\nA new treatment episode is defined as no treatment with an antidepressant medication for emotional problems over the previous 90 days, nor evidence-based psychotherapy for depression.\\nThe subjects must have major depression as determined by diagnostic schedule.\\n\\nExclusion Criteria:\\n\\nReceipt of an antidepressant medication in the previous 90 days other than a low-dose TCA for pain or Trazodone for sleep (e.g. amitriptyline ≤ 50 mg a day or Trazodone ≤ 100 mg at night).\\nCurrent interpersonal or cognitive behavioral psychotherapy that focuses on depression.\\nFemale subjects who are either pregnant or nursing.\\nSubjects with drug or alcohol dependency or abuse (except for nicotine or caffeine) within the preceding 6 months.\\nHigh risk for suicide.\\nInability to communicate in English.\\nNo personal telephone or homeless.\\nLifetime bipolar disorder.\\nPsychosis.\\nSubjects with a lifetime history of autism, mental retardation, or pervasive developmental disorders.\\nSubjects with uncorrected hypothyroidism or hyperthyroidism.\\nSerious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Robert D Keeley, MD MSPH', 'OverallOfficialAffiliation': 'Denver Health and University of Colorado, Department of Family Medicine', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Denver Health and Hospital Authority', 'LocationCity': 'Denver', 'LocationState': 'Colorado', 'LocationZip': '80204', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided', 'IPDSharingDescription': 'We will be working in the coming year on a plan to share data. We have been able to share data in the past.'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Motivational Interviewing With Guideline-Based Management', 'FlowGroupDescription': 'Intervention – MI with Standard Management of Depression The MI training approach included interactive learning for the core MI skills. An 8-hour classroom training on 7/25/09 consisted of a brief overview of MI, videos and discussion of core MI skills and “MI Spirit,” as well as skill-building practice. At the providers’ request, the research team distributed a pocket-sized, laminated treatment outline to MI trained providers for use at the point of service\\n\\nTo optimize treatment integrity, 4-hour refresher sessions were offered after 4 and 12 months on 11/22/09 and 7/11/10. Over the first 14 months, the assistant trainer provided feedback via email and face-to face regarding audio-taped encounters (total two to four feedbacks per provider). In these sessions, the trainer also summarized MI skills demonstrated during the encounters and listed each patient’s change talk statements. Providers were invited to respond and to choose which MI skill(s) they needed to improve.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Standard Management of Depression', 'FlowGroupDescription': 'All providers randomized to either intervention or to control received a 1-hour slideshow and the “American Psychiatric Association Practice Guideline for the Treatment of Major Depressive Disorder” (APA depression guideline) (Gelenberg et al., 2010). The resources recommended antidepressant medications and psychotherapy as evidence-based treatments for depression.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '88'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '80'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '67'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '58'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '21'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '22'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Motivational Interviewing With Guideline-Based Management', 'BaselineGroupDescription': 'Intervention – MI with Standard Management of Depression The MI training approach included interactive learning for the core MI skills. An 8-hour classroom training on 7/25/09 consisted of a brief overview of MI, videos and discussion of core MI skills and “MI Spirit,” as well as skill-building practice. At the providers’ request, the research team distributed a pocket-sized, laminated treatment outline to MI trained providers for use at the point of service\\n\\nTo optimize treatment integrity, 4-hour refresher sessions were offered after 4 and 12 months on 11/22/09 and 7/11/10. Over the first 14 months, the assistant trainer provided feedback via email and face-to face regarding audio-taped encounters (total two to four feedbacks per provider). In these sessions, the trainer also summarized MI skills demonstrated during the encounters and listed each patient’s change talk statements. Providers were invited to respond and to choose which MI skill(s) they needed to improve.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Standard Management of Depression', 'BaselineGroupDescription': 'All providers randomized to either intervention or to control received a 1-hour slideshow and the “American Psychiatric Association Practice Guideline for the Treatment of Major Depressive Disorder” (APA depression guideline) (Gelenberg et al., 2010). The resources recommended antidepressant medications and psychotherapy as evidence-based treatments for depression.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '88'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '80'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '168'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '82'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '75'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '157'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '11'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '60'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '58'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '118'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '28'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '22'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '50'}]}}]}}]}}, {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '34'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '25'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '59'}]}}, {'BaselineCategoryTitle': 'Not Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '54'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '55'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '109'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '7'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '27'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '32'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '59'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '29'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '31'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '60'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '13'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '18'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '16'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '8'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '24'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '88'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '80'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '168'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Depression Remission', 'OutcomeMeasureDescription': 'The primary outcome is depression remission ascertained with the Patient Health Questionnaire-9. A score of less than 5 is considered to represent remission. The secondary clinical outcome is the continuous measure of depressive symptoms.', 'OutcomeMeasurePopulationDescription': 'We present clinical outcome (remission rate) at 36 weeks for all patient participants entering the study. 58 of 80 subjects assigned to Guideline-Based Medical Management, and 67 of 88 subjects assigned to Motivational Interview with Guideline-Based Medical Management had available data at 36 weeks (end of trial).', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'participants', 'OutcomeMeasureTimeFrame': '36 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Guideline-based Medical Management', 'OutcomeGroupDescription': \"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nThe evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Motivational Interview With GBMM', 'OutcomeGroupDescription': \"Motivational Interviews combined with guideline-based medical management for depression\\n\\nGuideline-Based Medical Management: We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.\\n\\nMotivational Interviewing for Depression: Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or\"}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '58'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '67'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '15'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Adherence to Treatment With Antidepressant Medication', 'OutcomeMeasureDescription': 'Antidepressant Adherence will be measured with Computerized Pharmacy Records. Adherence will be operationalized as \"non-persistence,\" or time to discontinuation. Non-persistence will be considered to have occurred if the days of medication supply from the previous prescription plus a 30-day grace period exceed the number of days between the previous prescription date and the current prescription fill date. Filling no prescriptions, \\'initiation failure,\\' will be treated as non-persistence. Minimally adequate persistence was defined as at least three 30-day fills of an antidepressant medication at a usual dose as defined in the American Psychiatric Association guideline without a 30-day gap in refills. The count of participants receiving minimally adequate persistence with antidepressant medication is reported for each study group.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': '36 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Guideline-based Medical Management', 'OutcomeGroupDescription': \"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nThe evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Motivational Interview With GBMM', 'OutcomeGroupDescription': \"Motivational Interviewing for Depression combined with guideline-based medical management for depression\\n\\nManual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nMotivational Interviewing for Depression: Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.\"}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '80'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '88'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '11'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '15'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Patient Health Questionnaire-9 Instrument for Assessing Depressive Symptoms', 'OutcomeMeasureDescription': 'Depressive symptoms were measured with the Patient Health Questionnaire-9 (PHQ-9) instrument. The PHQ-9 is a nine item survey to assess depressive symptoms over the previous 2 weeks. The patient may answer \"not at all\" (scored as a 0) , \"several days\" (scored as a 1), \"more than half the days\" (scored as a 2), or \"nearly every day\" (scored as a 3) for each item. The range in total scores is from 0 (no depressive symptoms or best outcome) to 27 (severe depressive symptoms or worst outcome). For this randomized trial mean total scores are reported.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': '36 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Guideline-based Medical Management', 'OutcomeGroupDescription': \"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nThe evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Motivational Interview With GBMM', 'OutcomeGroupDescription': \"Motivational Interviewing for Depression combined with guideline-based medical management for depression\\n\\nManual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nMotivational Interviewing for Depression: Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.\"}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '58'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '67'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '11.66', 'OutcomeMeasurementLowerLimit': '10.33', 'OutcomeMeasurementUpperLimit': '13.00'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '9.16', 'OutcomeMeasurementLowerLimit': '7.87', 'OutcomeMeasurementUpperLimit': '10.46'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': 'Up to 36 weeks.', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Guideline-based Medical Management', 'EventGroupDescription': \"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nThe evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications\", 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '80', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '80'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Motivational Interview With GBMM', 'EventGroupDescription': \"Motivational Interviewing for Depression combined with guideline-based medical management for depression\\n\\nManual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nMotivational Interviewing for Depression: Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.\", 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '88', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '88'}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No', 'AgreementRestrictiveAgreement': 'No'}, 'PointOfContact': {'PointOfContactTitle': 'Dr. Robert D. Keeley', 'PointOfContactOrganization': 'Denver Health and University of Colorado Denver', 'PointOfContactEMail': 'robert.keeley@dhha.org', 'PointOfContactPhone': '303-602-8270'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 37, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00555698', 'OrgStudyIdInfo': {'OrgStudyId': '6577'}, 'Organization': {'OrgFullName': 'Ohio State University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Feasibility, Safety and Efficacy of Deep Brain Stimulation for Depression', 'OfficialTitle': 'Feasibility, Safety and Efficacy of Deep Brain Stimulation of the Internal Capsule for Severe and Medically Refractory Major Depression'}, 'StatusModule': {'StatusVerifiedDate': 'March 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2004'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2011', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'February 2011', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 7, 2007', 'StudyFirstSubmitQCDate': 'November 8, 2007', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 9, 2007', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 24, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 28, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator', 'ResponsiblePartyInvestigatorFullName': 'Ali Rezai, MD', 'ResponsiblePartyInvestigatorTitle': 'MD', 'ResponsiblePartyInvestigatorAffiliation': 'Ohio State University'}, 'LeadSponsor': {'LeadSponsorName': 'Ali Rezai, MD', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Medtronic', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'The Cleveland Clinic', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this investigation is to obtain a preliminary indication of the feasibility, safety and efficacy of capsular deep brain stimulation (DBS) as a treatment for intractable depression. Also, to to learn about a new treatment for severe depression that has not improved enough despite long-term treatment with medications and behavior therapy. The new treatment is called deep brain stimulation, or DBS.\\n\\nIn DBS, thin wires are used to carry electric current to parts of the brain that are thought to be involved in producing depression symptoms. Two wires are implanted surgically, and attached to battery packs implanted under the skin of the new chest below your collar bone.', 'DetailedDescription': \"This protocol proposes a pilot/feasibility clinical study of therapeutic benefits of ventral capsule/ventral striatum deep brain stimulation (DBS) as a treatment in ten patients with intractable major depression (MD). Conservative estimates place MD's prevalence at 2.6% to 5.5% in men and 6.0% to 11.8% in women. Most conservative studies estimate a 20% complete refractoriness to medical and psychotherapeutic regimens. Given the prevalence of major depression in the general population, over 3.5 million Americans would be expected to manifest refractory illness if all those with depression received treatment. Study subjects will have MD of disabling severity, intractable to prolonged treatment attempts with conventional medication and pschotherapies. They must also have had electroconvulsive therapy. These refractory patients would be candidates for a destructive/lesioning brain surgery such as a radiofrequency cingulotomy.\\n\\nThese MD patients are analogous to medically intractable Parkinson's disease and tremor patients who until recently underwent similar destructive surgeries such as a pallidotomy or thalamotomy. The use of DBS technology with its inherent advantage of being fully reversible and adjustable has become standard of care for these disabled patients. Studies have demonstrated improved safety and efficacy of DBS over lesioning.\\n\\nRecently, DBS technology has been employed in the lesioning target of the anterior limb of the internal capsule for OCD. These preliminary studies in Europe and now the US, are demonstrating improved outcomes for refractory OCD patients with regard to their OC symptoms as well as depressed mood. This amelioration of mood provides the basis on which anterior internal capsule DBS may help major depression patients.\\n\\nBased on this rationale, we believe that DBS is a viable therapeutic surgical option in this group of severely ill MD patients. The standard DBS stereotactic surgical techniques employed by the CCF team in hundreds of movement disorder patients will be used. The DBS electrodes will be implanted bilaterally in the anterior limb of the internal capsule and connected subcutaneously to subclavicular programmable pulse generators.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['DBS', 'Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Early Phase 1']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '8', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'DBS', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'DBS', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Deep Brain Stimulations for Depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Deep Brain Stimulations for Depression', 'InterventionDescription': 'Deep Brain Stimulations for Depression', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['DBS']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (HDRS)', 'PrimaryOutcomeTimeFrame': 'These scales are administered on each postoperative clinic visit. Visits occur monthly, except during the open continuation phase, when they occur every three months.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Inventory for Depressive Symptoms, Self-report (IDS-SR), Clinical Global Impressions (CGI), Patient Global Impressions (PGI), Global Assessment of Functioning (GAF), Social and Occupational Function Assessment Scale (SOFAS), Quality of LIfe Enjoyment and', 'SecondaryOutcomeTimeFrame': 'These measures will be obtained at baseline, at the end of the initial chronic phase (typically after three months of chronic stimultion), at the end of the open continuation phase (at two years into the study).'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMajor depression, severe, unipolar type, diagnosed by Structured Clinical Interview for DSM-IV (SCID-IV), judged to be of disabling severity\\n24-item Hamilton Depression Rating Scale (HDRS) score of at least 21\\nGlobal Assessment of Function (GAF) score of 45 or less.\\nA recurrent (>4 episodes) or chronic (episode duration >2 years) course and a minimum of 5 years since the onset of the first depressive episode. Major impairment in functioning or potentially severe medical outcomes (repeated hospitalizations, serious suicidal or other self-injurious behavior).\\n\\nFailure to respond to:\\n\\nadequate trials (>6 weeks at the maximum recommended or tolerated dose) of primary antidepressants from at least 3 different classes and;\\nadequate trials (>4 weeks at the usually recommended or maximum tolerated dose) of augmentation/combination of a primary antidepressant using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant) and;\\nan adequate trial of ECT (>6 bilateral treatments) and;\\nan adequate trial of individual psychotherapy (>20 sessions with an experienced psychotherapist).\\nAge 18 - 55 years.\\nAble to comply with the operational and administrative requirements of participation in the study.\\nAble to give written informed consent.\\nEither drug-free or on a stable drug regimen for at least 6 weeks at the time of entry into the study.\\nGood general health.\\n\\nExclusion Criteria:\\n\\nCurrent or past nonaffective psychotic disorder.\\nAny current clinically significant neurological disorder or medical illness affecting brain function, other than motor tics or Gilles de la Tourette syndrome.\\nAny clinically significant abnormality on preoperative magnetic resonance imaging (MRI)\\nAny surgical contraindications to undergoing DBS, including labeled contraindications for DBS and/or inability to undergo presurgical MRI (cardiac pacemaker, pregnancy, metal in body, severe claustrophobia), infection, coagulopathy, inability to undergo an awake operation, significant cardiac or other medical risk factors for surgery.\\nCurrent or unstably remitted substance abuse.\\nPregnancy and women of childbearing age not using effective contraception.\\nHistory of severe personality disorder.\\nImminent risk of suicide (based on the judgment of the investigators).\\nNot able to comply with the operational and administrative requirements of participation in the study (based on the judgment of the investigators).', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '55 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Ali Rezai, MD', 'OverallOfficialAffiliation': 'The Cleveland Clinic', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Cleveland Clinic Foundation', 'LocationCity': 'Cleveland', 'LocationState': 'Ohio', 'LocationZip': '44195', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '16855529', 'ReferenceType': 'background', 'ReferenceCitation': 'Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, Salloway SP, Okun MS, Goodman WK, Rasmussen SA. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology. 2006 Nov;31(11):2384-93. Epub 2006 Jul 19. Erratum in: Neuropsychopharmacology. 2006 Nov;31(11):2394.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 38, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00754936', 'OrgStudyIdInfo': {'OrgStudyId': '0703009061'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH079414-01A1', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH079414-01A1&Fy=all'}]}, 'Organization': {'OrgFullName': 'Weill Medical College of Cornell University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Treatment Response of Geriatric Depression', 'OfficialTitle': 'ERPs, Cognitive Dysfunction and Treatment Response of Geriatric Depression', 'Acronym': 'ERP'}, 'StatusModule': {'StatusVerifiedDate': 'February 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2007', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'September 17, 2008', 'StudyFirstSubmitQCDate': 'September 17, 2008', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 18, 2008', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'February 25, 2019', 'ResultsFirstSubmitQCDate': 'February 25, 2019', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'March 19, 2019', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 25, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 19, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Weill Medical College of Cornell University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}, {'CollaboratorName': 'Forest Laboratories', 'CollaboratorClass': 'INDUSTRY'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': \"The purpose of this study is to examine the relationship between brain electrical activity in elderly depressed patients and response to antidepressant medication treatment. Elderly patients with depression will be treated for 12 weeks with an antidepressant medication commonly used in clinical practice called escitalopram (Lexapro). Brain electrical activity will be assessed using electrophysiological tests. Researchers are interested in whether the brain electrical activity of elderly people with depression before they start the medication can tell us who amongst them will improve with antidepressant treatment and to what extent. They will also determine whether patients' brain electrical activity during the 12 weeks of medication treatment will change in any way and whether this change will be linked with a change in the severity of their depression. Researchers hope that information gained from this study will help to better understand the brain processes associated with depression and its successful treatment.\", 'DetailedDescription': \"This research study will examine how the brain electrical activity of elderly depressed patients is related to how quickly and how well they respond to antidepressant medication treatment. Brain electrical activity will be assessed using electrophysiological tests. Elderly patients with depression will be treated for 12 weeks with an antidepressant medication commonly used in clinical practice called escitalopram (Lexapro). Before they start treatment, patients will be asked questions about their depression to measure how severe it is. They will also be asked to have their brain electrical activity recorded while they perform tests on a computer screen. The questions about their depression and the brain electrical recordings will be repeated regularly during the 12 weeks they will be treated with antidepressant medication. The researchers are interested to see whether the brain electrical activity of elderly people with depression before they start the medication can tell us who amongst them and to what extent will finally improve with treatment with escitalopram (Lexapro). They will also determine whether patients' brain electrical activity, during the 12 weeks they will be receiving the medication treatment, will change in any way and whether this change will be linked with the change in the severity of their depression. It is hoped that information gained from this study will help the investigators to better understand the brain processes associated with depression and its successful treatment.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '106', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Escitalopram', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': '12 week open label with 2 week placebo period (14 weeks total)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Escitalopram']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Escitalopram', 'InterventionDescription': '20 mg by mouth daily', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Escitalopram']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Lexapro']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Montgomery Asberg Depression Rating Scale (Depression Severity)', 'PrimaryOutcomeDescription': 'A published and widely used scale for measuring severity of depression. Montgomery Asberg Depression Rating Scale scores can range from 0-60. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.', 'PrimaryOutcomeTimeFrame': '14 weeks from enrollment (12 weeks from medication start)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Hamilton Depression Rating Scale (Depression Severity)', 'SecondaryOutcomeDescription': 'A published and widely-used scale for rating depression severity, the Hamilton Depression Rating Scale 24 item total scores range from 0-76. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.', 'SecondaryOutcomeTimeFrame': '14 weeks from enrollment (12 weeks from medication start)'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nDiagnosis: Major depression, unipolar without psychotic features (by DSM-IV criteria) -Severity of depression: A 24-Item HDRS above 19 at screening and at baseline -\\nLevel of Executive Dysfunction: Two strata within each age stratum: Stroop Color-Word scores - one half of the sample < 26, one of half ≥ 26.\\nCapacity to provide informed consent.\\n\\nExclusion Criteria:\\n\\nHigh suicide risk, i.e. intent or plan to attempt suicide in near future\\nPresence of any current Axis I psychiatric disorder (other than unipolar major depression or specific phobias) including substance abuse (those with a history of substance abuse must be abstinent for at least 3 months prior to entry)\\nAxis II diagnosis of antisocial personality disorder, mental retardation and pervasive developmental disorder (DSM-IV)\\nHistory of psychiatric disorders such as psychotic depression, primary psychotic disorder, or bipolar spectrum disorder (bipolar disorder and hypomania are exclusions)\\nCognition: MMSE scores below 24 or diagnosis of dementia by DSM-IV\\nAcute or severe medical illness, i.e., delirium, metastatic cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry; or drugs known to cause depression, e.g., reserpine, alpha-methyl-dopa, steroids, sympathomimetics withdrawal\\nPresence of a significant neurological disease such as Parkinson's disease, primary or secondary seizure disorders, intracranial tumors, severe head trauma; neurodegenerative diseases i.e. MS\\nHistory of failure to respond to escitalopram (Lexapro) (20mg/day for 6 weeks or longer) during the current or previous depressive episodes\\nHistory of intolerance to escitalopram (Lexapro) or use of concomitant drugs that may provide reason to believe that escitalopram is contraindicated. Active treatment with fluoxetine at the time of screening\\nPatients' unwillingness or inability to gradually withdraw all other psychotropic medications (except for the following: Low and stable doses of opiates and non-benzodiazepine hypnotics (e.g. zolpidem (5 or 10 mg), zaleplon (5 or 10 mg), or eszopiclone (1 or 2 mg).Low and stable doses of diazepam and other anxiolytics should be tapered at screening; inability to tolerate taper is not an exclusion criteria.\\nInability to perform any of the ADLs (MAI: ADL subscale) even with assistance, e.g. walking with a cane is not an exclusion criterion\\nInability to speak English\\nAphasia\", 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '60 Years', 'MaximumAge': '90 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'George Alexopoulos, MD', 'OverallOfficialAffiliation': 'Weill Medical College of Cornell University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Weill Cornell Medical College-Westchester Division', 'LocationCity': 'White Plains', 'LocationState': 'New York', 'LocationZip': '10605', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': '106 participants enrolled in the study; however, 35 exited during the 2-week washout period and did not start study medication.', 'FlowRecruitmentDetails': 'Overall flow of study participants', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Escitalopram', 'FlowGroupDescription': '12 week open label with 2 week placebo period (14 weeks total)\\n\\nEscitalopram: 20 mg by mouth daily'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '71'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '59'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '12'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '3'}]}}, {'FlowDropWithdrawType': 'Physician Decision', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}]}}, {'FlowDropWithdrawType': 'Withdrawal by Subject', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '2'}]}}, {'FlowDropWithdrawType': 'Side Effects', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '3'}]}}, {'FlowDropWithdrawType': 'Inter-current medical events', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '3'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Escitalopram', 'BaselineGroupDescription': '12 week open label with 2 week placebo period (14 weeks total)\\n\\nEscitalopram: 20 mg by mouth daily'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '71'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '13'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '58'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '71.91', 'BaselineMeasurementSpread': '7.53'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '36'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '35'}]}}]}}]}}, {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}]}}, {'BaselineCategoryTitle': 'Not Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '67'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '66'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '71'}]}}]}}]}}, {'BaselineMeasureTitle': 'Hamilton Depression Rating Scale (HDRS) 24-Item Total Score', 'BaselineMeasureDescription': 'HDRS 24 item: scores can range from 0-76; higher is worse(more depressed)', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'units on a scale', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '23.83', 'BaselineMeasurementSpread': '4.48'}]}}]}}]}}, {'BaselineMeasureTitle': 'Montgomery and Asberg Depression Rating Scale (MADRS) Total Score', 'BaselineMeasureDescription': 'MADRS: scores can range from 0-60; higher is worse(more depressed)', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'units on a scale', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '24.08', 'BaselineMeasurementSpread': '5.74'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Montgomery Asberg Depression Rating Scale (Depression Severity)', 'OutcomeMeasureDescription': 'A published and widely used scale for measuring severity of depression. Montgomery Asberg Depression Rating Scale scores can range from 0-60. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': '14 weeks from enrollment (12 weeks from medication start)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Escitalopram', 'OutcomeGroupDescription': '12 week open label with 2 week placebo period (14 weeks total)\\n\\nEscitalopram: 20 mg by mouth daily'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '71'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '12.23', 'OutcomeMeasurementSpread': '7.67'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Hamilton Depression Rating Scale (Depression Severity)', 'OutcomeMeasureDescription': 'A published and widely-used scale for rating depression severity, the Hamilton Depression Rating Scale 24 item total scores range from 0-76. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': '14 weeks from enrollment (12 weeks from medication start)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Escitalopram', 'OutcomeGroupDescription': '12 week open label with 2 week placebo period (14 weeks total)\\n\\nEscitalopram: 20 mg by mouth daily'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '71'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '11.47', 'OutcomeMeasurementSpread': '6.64'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': '14 weeks', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Escitalopram', 'EventGroupDescription': '12 week open label with 2 week placebo period (14 weeks total)\\n\\nEscitalopram: 20 mg by mouth daily', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '71', 'EventGroupSeriousNumAffected': '3', 'EventGroupSeriousNumAtRisk': '71', 'EventGroupOtherNumAffected': '47', 'EventGroupOtherNumAtRisk': '71'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Hospitalisation', 'SeriousEventOrganSystem': 'Surgical and medical procedures', 'SeriousEventSourceVocabulary': 'MedDRA (21.1)', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '71'}]}}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Abdominal pain upper', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Anxiety', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Arthralgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Burning sensation', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Cerebrovascular accident', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Colitis ulcerative', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Colonoscopy', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Conjunctivitis', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Diarrhoea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '15', 'OtherEventStatsNumAffected': '12', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Dizziness', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Dry mouth', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Epistaxis', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Fall', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '38', 'OtherEventStatsNumAffected': '21', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Fracture', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Gastroenteritis', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Gastroenteritis viral', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Groin infection', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Hyperparathyroidism', 'OtherEventOrganSystem': 'Endocrine disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Micturition urgency', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Night Sweats', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Pollakiuria', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Polymyalgia rheumatica', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Rash', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Sinus headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Sinusitis', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Skin irritation', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Surgery', 'OtherEventOrganSystem': 'Surgical and medical procedures', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Upper gastrointestinal haemorrhage', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Upper respiratory tract infection', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Urinary tract infection', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Vomiting', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}, {'OtherEventTerm': 'Weight decreased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA (21.1)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'George S Alexopoulos', 'PointOfContactOrganization': 'Weill Cornell Medicine', 'PointOfContactEMail': 'gsalexop@med.cornell.edu', 'PointOfContactPhone': '914-997-5767'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000015283', 'InterventionMeshTerm': 'Citalopram'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000017367', 'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'}, {'InterventionAncestorId': 'D000014179', 'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'}, {'InterventionAncestorId': 'D000049990', 'InterventionAncestorTerm': 'Membrane Transport Modulators'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000018490', 'InterventionAncestorTerm': 'Serotonin Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000018687', 'InterventionAncestorTerm': 'Antidepressive Agents, Second-Generation'}, {'InterventionAncestorId': 'D000000928', 'InterventionAncestorTerm': 'Antidepressive Agents'}, {'InterventionAncestorId': 'D000011619', 'InterventionAncestorTerm': 'Psychotropic Drugs'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16566', 'InterventionBrowseLeafName': 'Citalopram', 'InterventionBrowseLeafAsFound': 'Escitalopram', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M5687', 'InterventionBrowseLeafName': 'Dexetimide', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M14095', 'InterventionBrowseLeafName': 'Serotonin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M18232', 'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2828', 'InterventionBrowseLeafName': 'Antidepressive Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M13057', 'InterventionBrowseLeafName': 'Psychotropic Drugs', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr', 'InterventionBrowseBranchName': 'Psychotropic Drugs'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'AnDyAg', 'InterventionBrowseBranchName': 'Anti-Dyskinesia Agents'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M28292', 'ConditionBrowseLeafName': 'Cognitive Dysfunction', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 39, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03892915', 'OrgStudyIdInfo': {'OrgStudyId': '2017-1041'}, 'Organization': {'OrgFullName': 'RAND', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Maternal Depression Treatment in HIV', 'OfficialTitle': 'Depression Care to Improve Adherence to Prevention of Mother-to-Child-Transmission (PMTCT) Care Continuum & Pregnancy Outcomes', 'Acronym': 'M-DEPTH'}, 'StatusModule': {'StatusVerifiedDate': 'September 2019', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 8, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 21, 2019', 'StudyFirstSubmitQCDate': 'March 25, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 27, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'September 9, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 11, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'RAND', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Makerere University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Mildmay Uganda', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Cluster randomized controlled trial to compare the effects of task-shifted, evidence-based depression care vs. usual care on adherence to each step of the prevention of mother-to-child-transmission (PMTCT) care cascade at 8 antenatal care (ANC) clinics in Uganda.', 'DetailedDescription': 'This study is a cluster randomized controlled trial (RCT) to compare the effects of task-shifted, evidence-based depression care vs. usual care on adherence to each step of the PMTCT care cascade at 8 ANC clinics in Uganda. At 4 experimental sites, task-shifted, depression care will include (1) depression screening and psychoeducation, (2) depression diagnosis, and (3) provision of evidence-based problem solving therapy (PST), or antidepressant therapy (ADT) for those with severe and refractory depression (or who decline PST), to be implemented by trained peer mothers and midwife nurses, respectively. The 4 control sites will use usual care services for managing depression, which consist of referrals to a mental health specialist and access to the Family Support Group program (comprehensive, monthly multi-session psychosocial program to enhance pregnancy management and PMTCT adherence). At each site, 50 HIV-positive newly pregnant women (total n=400) who screen positive for potential depression will be enrolled and followed until 18-months post-delivery to assess how depression and depression alleviation relate to primary (adherence to each component of the PMTCT care continuum, maternal virologic suppression) and secondary (infant HIV status; post-natal maternal and child health outcomes) outcomes, as well as processes of depression care (treatment uptake and depression alleviation among clinically depressed patients). A cost-effectiveness analysis will be used to compare the two study arms.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Cluster randomized controlled trial with 4 sites randomly assigned to implement evidence-based depression care in addition to usual care and 4 sites randomly assigned to implement usual care only', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '400', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression Care', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Task-shifted depression care, consisting of (1) depression screening and psychoeducation, (2) depression diagnosis, and (3) evidence-based problem solving therapy (PST) or antidepressant therapy (ADT; for those with severe and refractory depression, or who decline PST), to be implemented by trained peer mothers and midwife nurses in addition to usual care.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Combination Product: evidence-based depression treatment']}}, {'ArmGroupLabel': 'Usual care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Usual care processes for treating depression consist of referrals to mental health specialists and access to the Family Support Group program (a nation wide Ministry of Health program for HIV+ women at public ANC clinics, consisting of monthly sessions designed to provide psychosocial support and education to promote pregnancy management and PMTCT adherence).'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Combination Product', 'InterventionName': 'evidence-based depression treatment', 'InterventionDescription': 'We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression Care']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Rate of maternal HIV viral suppression', 'PrimaryOutcomeDescription': 'Proportion of participants who achieve undetectable HIV viral load as measured by blood assay', 'PrimaryOutcomeTimeFrame': 'One month post pregnancy'}, {'PrimaryOutcomeMeasure': 'Mean maternal antiretroviral (ART) adherence', 'PrimaryOutcomeDescription': 'Group mean proportion of prescribed ART doses taken as measured by pharmacy refill data', 'PrimaryOutcomeTimeFrame': 'From study enrollment to one-month post pregnancy'}, {'PrimaryOutcomeMeasure': 'Rate of prevention of mother-to-child-transmission (PMTCT) care retention', 'PrimaryOutcomeDescription': 'Proportion of participants who continue to attend antenatal care (ANC) visits as measured by chart abstraction', 'PrimaryOutcomeTimeFrame': 'through study completion, an average of 48 weeks'}, {'PrimaryOutcomeMeasure': 'Rate of delivery in health facility', 'PrimaryOutcomeDescription': 'Proportion of participants who delivery their baby of in a health facility as measured by chart abstraction', 'PrimaryOutcomeTimeFrame': 'one month post pregnancy'}, {'PrimaryOutcomeMeasure': 'Rate of infant use of ART', 'PrimaryOutcomeDescription': 'Proportion of delivered infants who receive ART as measured by chart abstraction', 'PrimaryOutcomeTimeFrame': 'First 6 weeks of life'}, {'PrimaryOutcomeMeasure': 'Rate of universal infant feeding', 'PrimaryOutcomeDescription': 'Proportion of delivered infants who receive uniform feeding method (breastfeeding or formula) as documented by self-report', 'PrimaryOutcomeTimeFrame': 'First 6 months of life'}, {'PrimaryOutcomeMeasure': 'Rate of complete infant HIV testing', 'PrimaryOutcomeDescription': 'Proportion of delivered infants who are tested for HIV at all specified intervals, as measured by chart abstraction', 'PrimaryOutcomeTimeFrame': '18 months after birth'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Child HIV status', 'SecondaryOutcomeDescription': 'HIV status of child', 'SecondaryOutcomeTimeFrame': '18 months after birth'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ndetection of pregnancy through 24 weeks gestation (to ensure at least 12 weeks remaining antenatal period for assessing adherence to all stages of PMTCT care cascade)\\nHIV-positive\\npositive screen for potential depression on 2-item Patient Health Questionnaire (PHQ-2>0)\\non ART for at least 4 weeks\\n\\nExclusion Criteria:\\n\\nunstable health (about to start ART or on ART < 4 weeks; active, untreated opportunistic infection)', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Glenn Wagner, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '310-393-0411', 'CentralContactPhoneExt': '7698', 'CentralContactEMail': 'gwagner@rand.org'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Glenn Wagner, PhD', 'OverallOfficialAffiliation': 'RAND', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Makerere University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Kampala', 'LocationCountry': 'Uganda', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Violet Gwokyalya', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'vgwokyalya@musph.ac.ug'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31277180', 'ReferenceType': 'derived', 'ReferenceCitation': 'Wagner GJ, McBain RK, Akena D, Ngo V, Nakigudde J, Nakku J, Chemusto H, Beyeza-Kashesya J, Gwokyalya V, Faherty LJ, Kyohangirwe L, Nabitaka LK, Lukwata H, Linnemayr S, Ghosh-Dastidar B, Businge J, Mukasa B, Wanyenze RK. Maternal depression treatment in HIV (M-DEPTH): Study protocol for a cluster randomized controlled trial. Medicine (Baltimore). 2019 Jul;98(27):e16329. doi: 10.1097/MD.0000000000016329.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Yes', 'IPDSharingDescription': 'We will make the data publicly available in the form of an electronic database for researchers who successfully complete a registration process. Data will be de-identified. We will provide documentation in the form of a codebook in which each variable name and response options are defined. Users must agree to the conditions of use governing access to the public release data. Users must submit brief proposals regarding intended use of the data; the study team will determine the scientific soundness of the proposal, as well as whether adequate data protections in place, as part of the decision for the researcher to be able to access the public use dataset.', 'IPDSharingInfoTypeList': {'IPDSharingInfoType': ['Study Protocol', 'Statistical Analysis Plan (SAP)', 'Informed Consent Form (ICF)']}, 'IPDSharingTimeFrame': 'Following publication of the main paper(s) for this study and the grant end-date.', 'IPDSharingAccessCriteria': 'Users must submit brief proposals regarding intended use of the data; the study team will determine the scientific soundness of the proposal, as well as whether adequate data protections in place, as part of the decision for the researcher to be able to access the public use dataset.'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16833', 'ConditionBrowseLeafName': 'HIV Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2103', 'ConditionBrowseLeafName': 'Acquired Immunodeficiency Syndrome', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}]}}}}}, {'Rank': 40, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00709150', 'OrgStudyIdInfo': {'OrgStudyId': 'R01MH068468', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH068468&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH068468', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH068468&Fy=all'}, {'SecondaryId': 'DSIR 82-SESQ'}]}, 'Organization': {'OrgFullName': 'University of Southern California', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Collaborative Depression Care Management in Treating Depressed Low-income Hispanics With Diabetes', 'OfficialTitle': 'Multifaceted Depression Diabetes Program for Hispanics', 'Acronym': 'MDDP'}, 'StatusModule': {'StatusVerifiedDate': 'July 2013', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2005'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2009', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 2009', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 30, 2008', 'StudyFirstSubmitQCDate': 'June 30, 2008', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 3, 2008', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 25, 2013', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 29, 2013', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Kathleen R. Ell', 'ResponsiblePartyInvestigatorTitle': 'Study Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'University of Southern California'}, 'LeadSponsor': {'LeadSponsorName': 'University of Southern California', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'This study will evaluate the effectiveness of culturally adapted depression treatment for reducing depressive symptoms and improving adherence to diabetes self-care regimens in Hispanics with depression and diabetes.', 'DetailedDescription': \"Diabetes, a disease in which the body does not properly produce or use insulin, is the fifth leading cause of death among Hispanics in the United States. The risk of comorbid depression among diabetics is twice as high as that of the general population, with depression rates among diabetic Hispanics as high as 33%. Symptoms of depression include feelings of sadness, anxiety, and guilt; lack of energy; changes in appetite; and lack of pleasure in previously enjoyed activities. These symptoms can make maintaining good diabetic management and self-care regimens difficult. Fortunately, depression is treatable with forms of psychotherapy and antidepressant medications. However, depression treatment adherence and response rates among the Hispanic population, especially among Hispanics of low socio-economic status, are lower than those of the general population. Depression treatment that is specifically adapted for the Hispanic culture may be best at helping diabetic Hispanics stick to their treatment and self-care plans. This study will evaluate the effectiveness of culturally adapted depression treatment for reducing depressive symptoms and improving adherence to diabetes self-care regimens in low-income Hispanics with depression and diabetes.\\n\\nParticipation in this study will last 18 months. All participants will first undergo baseline assessments that will include a 40-minute interview about personal health and feelings. Eligible participants will then be assigned randomly to receive either collaborative depression care management or enhanced usual care.\\n\\nParticipants assigned to receive collaborative depression care management will first be provided with information about depression treatment. Participants will then have the option of choosing between two depression treatments: counseling or antidepressant medications. Participants who choose to receive treatment with counseling will receive eight weekly 45-minute counseling sessions, conducted either on the phone or at the clinic. During these sessions, participants will undergo structured problem solving therapy (PST) and will learn strategies to manage their depressive symptoms. Participants who choose to receive treatment with antidepressant medication will be prescribed medication by a study doctor and will be monitored for any side effects throughout treatment. Medication treatment may last up to 12 months but will depend upon participants' severity of depression. After completing medication treatment, participants will be offered PST counseling. All participants receiving collaborative depression care management will also receive supportive patient navigation services and maintenance/relapse telephone monitoring.\\n\\nParticipants assigned to enhanced usual care will receive an educational pamphlet on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care. All participants will undergo follow-up phone interviews about their status at Months 6, 12, and 18.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Major Depression', 'Diabetes', 'Hispanics', 'Collaborative Depression Care Management']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 4']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '387', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '1', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients will receive collaborative depression care management.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Collaborative depression care management']}}, {'ArmGroupLabel': '2', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Patients will receive enhanced usual care.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Enhanced usual care']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Collaborative depression care management', 'InterventionDescription': \"Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Enhanced usual care', 'InterventionDescription': \"Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Reduction in symptoms of major depression', 'PrimaryOutcomeTimeFrame': 'Measured at Months 12, 18, and 24'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quality of life', 'SecondaryOutcomeTimeFrame': 'Measured at Months 12, 18, and 24'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMeets criteria for major depression based on a score of greater than 2 for five or more symptoms, including one of the two cardinal depression symptoms and a nine-item depression scale of the Patient Health Questionnaire (PHQ-9) score of greater than 10\\nPatient with diabetes\\nHas attended two community safety net clinics\\n\\nExclusion Criteria:\\n\\nCurrent suicidal ideation\\nScore of 8 or greater on the Alcohol Use Disorders Identification Test (AUDIT)\\nRecent use of lithium or antipsychotic medication', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kathleen R. Ell, DSW', 'OverallOfficialAffiliation': 'University of Southern California', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Southern California School of Social Work', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90089-0411', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '22458987', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ell K, Katon W, Lee PJ, Kapetanovic S, Guterman J, Xie B, Chou CP. Depressive symptom deterioration among predominantly Hispanic diabetes patients in safety net care. Psychosomatics. 2012 Jul-Aug;53(4):347-55. doi: 10.1016/j.psym.2011.12.009. Epub 2012 Mar 27.'}, {'ReferencePMID': '22433755', 'ReferenceType': 'derived', 'ReferenceCitation': 'Hay JW, Katon WJ, Ell K, Lee PJ, Guterman JJ. Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly Hispanics with diabetes. Value Health. 2012 Mar-Apr;15(2):249-54. doi: 10.1016/j.jval.2011.09.008. Epub 2011 Dec 15.'}, {'ReferencePMID': '21774987', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ell K, Katon W, Xie B, Lee PJ, Kapetanovic S, Guterman J, Chou CP. One-year postcollaborative depression care trial outcomes among predominantly Hispanic diabetes safety net patients. Gen Hosp Psychiatry. 2011 Sep-Oct;33(5):436-42. doi: 10.1016/j.genhosppsych.2011.05.018. Epub 2011 Jul 19.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5698', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 41, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02149563', 'OrgStudyIdInfo': {'OrgStudyId': '002'}, 'Organization': {'OrgFullName': 'Meir Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Oxygen Therapy in Depression', 'OfficialTitle': 'Oxygen Therapy in Depression'}, 'StatusModule': {'StatusVerifiedDate': 'March 2015', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2015'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2016', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 2016', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 7, 2014', 'StudyFirstSubmitQCDate': 'May 25, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 29, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 15, 2015', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 17, 2015', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Meir Medical Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The major objective of the present study is to examine the influence of normobaric hyperoxia treatment on the symptoms of patients diagnosed with depression members of Clalit Health Services. The investigators hypothesize that normobaric hyperoxia treatment will improve the symptoms of patients with depression.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression, Normobaric Hyperoxia.']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '200', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Treatment', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'One hundred participants will receive home treatment with oxygen-enriched air (40% O2) through a nasal tube during the night (7 hours) for one month.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: oxygen-enriched air -Normobaric hyperoxia treatment for depression']}}, {'ArmGroupLabel': 'Placebo', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': '100 participants will receive regular air treatment (21% O2) through a nasal tube (identical to the procedure providing 40% O2) for one month', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: oxygen-enriched air -Normobaric hyperoxia treatment for depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'oxygen-enriched air -Normobaric hyperoxia treatment for depression', 'InterventionDescription': 'Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo', 'Treatment']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Oxygen-enriched air provided by oxygen concentrators to improve symptoms of patients with depression.']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Hamilton Rating Scale for Depression (HRSD)-changes in patients' depression.\", 'PrimaryOutcomeDescription': \"HRSD will be used to assess changes in patients' condition. Assessment will be performed at 3 time points: baseline (time zero), 2 weeks and 4 weeks after treatment initiation, by a trained psychiatric nurse blind to the patient's treatment status.\", 'PrimaryOutcomeTimeFrame': 'Baseline (time zero), 2 weeks and 4 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMen and women aged 18-65 years diagnosed with mild to moderate depression.\\n\\nExclusion Criteria:\\n\\nPatients with oxygen saturation below 95%;\\nAn unstable mental (psychiatric) condition\\nA psychiatric condition that requires a change in pharmacotherapy (importantly - medications will not be changed in patients who will be enrolled to the study)\\nAcute or chronic respiratory disease\\nAny severe physical illness\\nSuicidal thoughts or attempts\\nDrug abuse\\nObesity (BMI over 30)\\nInability to cease smoking during night hours while participants are supposed to be using the oxygen/air supplementing machine.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Clalit Health Services in the Southern region', 'LocationStatus': 'Recruiting', 'LocationCity': 'Beer-sheva', 'LocationCountry': 'Israel', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Pesach Shvartzman, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '972-8-6477429'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000018496', 'ConditionMeshTerm': 'Hyperoxia'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000012818', 'ConditionAncestorTerm': 'Signs and Symptoms, Respiratory'}, {'ConditionAncestorId': 'D000012816', 'ConditionAncestorTerm': 'Signs and Symptoms'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M19184', 'ConditionBrowseLeafName': 'Hyperoxia', 'ConditionBrowseLeafAsFound': 'Hyperoxia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14206', 'ConditionBrowseLeafName': 'Signs and Symptoms, Respiratory', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 42, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00282776', 'OrgStudyIdInfo': {'OrgStudyId': 'R01MH071825', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH071825&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH071825', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH071825&Fy=all'}, {'SecondaryId': 'DSIR 82-SEMS', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'National Institute of Mental Health'}]}, 'Organization': {'OrgFullName': 'University of Pittsburgh', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Identification and Therapy of Postpartum Depression', 'OfficialTitle': 'Identification and Therapy of Postpartum Depression'}, 'StatusModule': {'StatusVerifiedDate': 'September 2013', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 2006'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 2012', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 25, 2006', 'StudyFirstSubmitQCDate': 'January 25, 2006', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 27, 2006', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 30, 2013', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 7, 2013', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Katherine Wisner', 'ResponsiblePartyInvestigatorTitle': \"Professor of Psychiatry, Obstetrics and Gynecology and Reproductive Sciences, Epidemiology and Women's Studies\", 'ResponsiblePartyInvestigatorAffiliation': 'University of Pittsburgh'}, 'LeadSponsor': {'LeadSponsorName': 'University of Pittsburgh', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study will evaluate the effectiveness of a telephone-based depression screening and care management program in treating depression in postpartum women.', 'DetailedDescription': \"Depression is a serious illness that can interfere with everyday life. Researchers believe that it is one of the most common complications during and after pregnancy. Depression after pregnancy is called postpartum depression and may be caused by a rapid change in hormone levels during and immediately after pregnancy. Postpartum depression can occur anytime within the first year after childbirth and can negatively affect both mothers and their children. Mothers with postpartum depression may experience low energy, difficulty concentrating, irritability, and inability to meet their children's needs for love and affection. As a result, women with postpartum depression may feel guilty and lose confidence in themselves as parents. Research shows that children of mothers with postpartum depression may have delays in language development, difficulty with emotional bonding to others, behavioral problems, lower activity levels, sleep problems, and distress. This study will evaluate the effectiveness of a telephone-based depression screening and care management program in treating depression in postpartum women.\\n\\nParticipants in this single blind study will be randomly assigned to receive either enhanced treatment as usual or telephone-based care management for the first year postpartum. All participants will have a 90-minute in-home interview upon study entry to assess depressive symptoms, functional status, medical history, and post-pregnancy plans. Participants assigned to care management will receive two calls in the first month postpartum, followed by monthly calls for the remainder of the first postpartum year. During each 10- to 20-minute call, participants will be asked to provide information regarding current depressive symptoms, steps they have taken to seek depression-related care, and any barriers they have encountered in the process. In addition, a care manager will act as an advocate for the participants and assist in obtaining specialized services as necessary throughout the year. Participants assigned to receive enhanced treatment as usual will not receive monthly phone calls or tailored care management. All participants will receive follow-up calls at 3, 6, and 12 months postpartum to assess outcome measures; these calls will last about 30 minutes.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Postpartum Depression', 'Telephone Care Management', 'Screening for Postpartum Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '628', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'TAU', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants will receive treatment as usual', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: TAU']}}, {'ArmGroupLabel': 'DCM', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will receive care management for postpartum depression', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Care Management for Postpartum Depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Care Management for Postpartum Depression', 'InterventionDescription': 'Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['DCM']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'TAU', 'InterventionDescription': 'Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['TAU']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depressive symptoms, social functioning, and health', 'PrimaryOutcomeTimeFrame': 'Measured at Months 3, 6, and 12 postpartum'}, {'PrimaryOutcomeMeasure': 'Preferences for depression treatment', 'PrimaryOutcomeTimeFrame': 'Measured at baseline and Month 12'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n4-6 weeks postpartum\\nEnglish-speaking\\nScore of at least 10 on the Edinburgh Postnatal Depression Scale\\n\\nExclusion Criteria:\\n\\nDSM-IV diagnosis of bipolar disorder or psychotic episode\\nActive substance abuse within 6 months prior to study entry\\nHas not received obstetrical care\\nHistory of a suicide attempt within 6 months of study entry', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Female', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Katherine L. Wisner, MD, RN', 'OverallOfficialAffiliation': 'University of Pittsburgh', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': \"Women's Behavioral HealthCARE Program, Suite 410, 3501 Forbes Ave\", 'LocationCity': 'Pittsburgh', 'LocationState': 'Pennsylvania', 'LocationZip': '15213', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28796940', 'ReferenceType': 'derived', 'ReferenceCitation': 'Wisner KL, Sit DKY, McShea M, Luther JF, Eng HF, Dills JL, Moses-Kolko EL, Wisniewski SR. Telephone-Based Depression Care Management for Postpartum Women: A Randomized Controlled Trial. J Clin Psychiatry. 2017 Nov/Dec;78(9):1369-1375. doi: 10.4088/JCP.15m10563.'}, {'ReferencePMID': '26059839', 'ReferenceType': 'derived', 'ReferenceCitation': 'Clark CT, Sit DK, Driscoll K, Eng HF, Confer AL, Luther JF, Wisniewski SR, Wisner KL. DOES SCREENING WITH THE MDQ AND EPDS IMPROVE IDENTIFICATION OF BIPOLAR DISORDER IN AN OBSTETRICAL SAMPLE? Depress Anxiety. 2015 Jul;32(7):518-26. doi: 10.1002/da.22373. Epub 2015 Jun 8.'}, {'ReferencePMID': '23487258', 'ReferenceType': 'derived', 'ReferenceCitation': 'Wisner KL, Sit DK, McShea MC, Rizzo DM, Zoretich RA, Hughes CL, Eng HF, Luther JF, Wisniewski SR, Costantino ML, Confer AL, Moses-Kolko EL, Famy CS, Hanusa BH. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry. 2013 May;70(5):490-8. doi: 10.1001/jamapsychiatry.2013.87.'}, {'ReferencePMID': '21381158', 'ReferenceType': 'derived', 'ReferenceCitation': 'Sit D, Seltman H, Wisner KL. Seasonal effects on depression risk and suicidal symptoms in postpartum women. Depress Anxiety. 2011 May;28(5):400-5. doi: 10.1002/da.20807. Epub 2011 Mar 4.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000019052', 'ConditionMeshTerm': 'Depression, Postpartum'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000011644', 'ConditionAncestorTerm': 'Puerperal Disorders'}, {'ConditionAncestorId': 'D000011248', 'ConditionAncestorTerm': 'Pregnancy Complications'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M19660', 'ConditionBrowseLeafName': 'Depression, Postpartum', 'ConditionBrowseLeafAsFound': 'Postpartum Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13082', 'ConditionBrowseLeafName': 'Puerperal Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12710', 'ConditionBrowseLeafName': 'Pregnancy Complications', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}}}}, {'Rank': 43, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02691520', 'OrgStudyIdInfo': {'OrgStudyId': 'CR108117'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'NOPRODDEP4001', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Johnson & Johnson Pte Ltd'}]}, 'Organization': {'OrgFullName': 'Johnson & Johnson Pte Ltd', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Epidemiology of Treatment Resistant Depression in Taiwan', 'OfficialTitle': 'Epidemiology of Treatment Resistant Depression in Taiwan'}, 'StatusModule': {'StatusVerifiedDate': 'March 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2015'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'February 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 22, 2016', 'StudyFirstSubmitQCDate': 'February 22, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 25, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 22, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 23, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Johnson & Johnson Pte Ltd', 'LeadSponsorClass': 'INDUSTRY'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Elysia Group', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to assess the epidemiology of Treatment Resistant Depression (TRD) in the nationally insured population in Taiwan including incidence, duration of clinical episodes, and prevalence by age and sex.', 'DetailedDescription': 'This is a retrospective study of approximately one million subjects randomly selected from an anonymized database National Health Insurance Research Database (NHIRD). Participants aged 18 years or older who have had neither a depression diagnosis nor a dispensing of an antidepressant medication in the last four months of 2004 will enter the study when they receive in 2005 a depression diagnosis and a dispensing of an antidepressant medication within 30 days of each other and will be followed up to 8 years or until they have 4 months with neither a depression diagnosis nor a dispensing of an antidepressant medication. Treatment Resistant Depression (TRD) Incidence, TRD prevalence by age and sex and duration of clinical episodes will be estimated.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depressive Disorder, Treatment-Resistant']}, 'KeywordList': {'Keyword': ['Treatment Resistant Depression']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Retrospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '8356', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Taiwan Participants with Treatment Resistant Depression', 'ArmGroupDescription': 'Taiwan participants with Depression will be followed up to 8 years for incidence and duration of treatment resistant depression.'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Incidence Percentage of Participants with Treatment Resistant Depression', 'PrimaryOutcomeDescription': \"The percentage of beneficiaries of Taiwan's health insurance plan who developed treatment resistant depression during 2005\", 'PrimaryOutcomeTimeFrame': 'Approximately 8 Years'}, {'PrimaryOutcomeMeasure': 'Prevalence Percentage of Participants with Treatment Resistant Depression', 'PrimaryOutcomeTimeFrame': 'Approximately 8 Years'}, {'PrimaryOutcomeMeasure': 'Duration of an episode of Depression', 'PrimaryOutcomeDescription': 'Time from onset of depression to cessation of depression visits and medications.', 'PrimaryOutcomeTimeFrame': 'Approximately 8 Years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Healthcare costs', 'SecondaryOutcomeDescription': 'Direct healthcare cost associated with depression treatment will be assessed.', 'SecondaryOutcomeTimeFrame': 'Approximately 8 Years'}, {'SecondaryOutcomeMeasure': 'Number of Participants With Comorbidities', 'SecondaryOutcomeTimeFrame': 'Approximately 8 Years'}, {'SecondaryOutcomeMeasure': 'Medications used by Participants with Treatment Resistant Depression', 'SecondaryOutcomeTimeFrame': 'Approximately 8 Years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nParticipants who have been continuously enrolled in the insurance plan since January 1, 2004 (ignoring breaks of less than 30 days) and have not received an exclusion diagnosis and during the last 4 months of 2004, a) Have not received a diagnosis of depression and b) Have not received a dispensing of an AD medication\\nParticipants with a diagnosis of a depressive disorder including dysthymic disorder (International Classification of Diseases [ICD]-9 codes 296 depression-related, 300.4, 311) and Major Depressive Disorder (ICD-9 296.2, 296.3) will be followed through December 31, 2013\\n\\nExclusion Criteria:\\n\\n- Participants who receive following diagnosis will be excluded, a) Mania, b) Schizophrenia (ICD-9 codes 295), c) Bipolar disorder (ICD-9 codes 296 bipolar-related), D) Dementia (ICD-9 codes 290 or 294); Note: Major depressive disorder (MDD) with psychotic behavior (ICD 296.24 for single episode, ICD 296.34 for recurrent episode) is not an exclusion', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Adults aged 18 and older are randomly sampled from the National Health Insurance Research Database (NHIRD).', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Johnson & Johnson Pte Ltd Clinical Trial', 'OverallOfficialAffiliation': 'Johnson & Johnson Pte Ltd', 'OverallOfficialRole': 'Study Director'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000061218', 'ConditionMeshTerm': 'Depressive Disorder, Treatment-Resistant'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M28370', 'ConditionBrowseLeafName': 'Depressive Disorder, Treatment-Resistant', 'ConditionBrowseLeafAsFound': 'Depressive Disorder, Treatment-Resistant', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 44, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01328639', 'OrgStudyIdInfo': {'OrgStudyId': 'Achord 1101-10'}, 'Organization': {'OrgFullName': 'The Alliance for Canadian Health Outcomes Research in Diabetes', 'OrgClass': 'OTHER'}, 'BriefTitle': 'TeamCare PCN: Collaborative Care for Diabetes and Depression', 'OfficialTitle': 'TeamCare PCN: Collaborative Care for Patients With Diabetes and Depression in Primary Care Networks', 'Acronym': 'TeamCare-PCN'}, 'StatusModule': {'StatusVerifiedDate': 'July 2013', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 2010'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2013', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'January 2013', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 30, 2011', 'StudyFirstSubmitQCDate': 'April 4, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 5, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 9, 2013', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 11, 2013', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Dr. Jeffrey Johnson', 'ResponsiblePartyInvestigatorTitle': 'Professor', 'ResponsiblePartyInvestigatorAffiliation': 'The Alliance for Canadian Health Outcomes Research in Diabetes'}, 'LeadSponsor': {'LeadSponsorName': 'The Alliance for Canadian Health Outcomes Research in Diabetes', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Alberta Health & Wellness', 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': 'Canadian Institutes of Health Research (CIHR)', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Background & Objective: Type 2 diabetes is a complex disease characterized by multiple comorbidities. Depression is one of the most common comorbidities in individuals with diabetes with prevalence rates reaching 30%. Depression complicates diabetes treatment, portends worse outcomes and increases health care costs. One novel approach to managing diabetes with co-morbid depression is a collaborative primary care model involving a multidisciplinary health care team guiding patient-centered care. This model has been tested in the US and showed a significant reduction of depressive symptoms, improved diabetes care and patient-reported outcomes, and saved money. Our aim is to evaluate the implementation of this collaborative care model for type 2 diabetes and comorbid depression within the non-metro Primary Care Network (PCN) setting in Canada.\\n\\nIntervention: The intervention involves three phases: (1) improving depressive symptoms, (2) improving blood sugar, blood pressure and cholesterol, and (3) improving lifestyle behaviours. The intervention is administered by a CM in collaboration with family physicians, psychiatrists, and internists.\\n\\nHypotheses: The TeamCare-PCN intervention will reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours. Furthermore, the investigators anticipate this intervention will be acceptable and implemented in a cost-effective manner in the PCN environment.\\n\\nMethods: The investigators will employ a mixed-methods approach to our evaluation, using a controlled \"on-off\" trial design. Our primary analysis will be based on a multivariable scaled marginal model for the combined outcome of depressive symptoms and medical care. Secondary analyses will assess changes in lifestyle behaviours and patient-reported outcomes.\\n\\nSignificance: Our work will serve as a platform upon which an emerging model of primary care can incorporate an effective and cost-effective depression intervention into the management of individuals with type 2 diabetes, and as a framework for implementing and evaluating similar interventions in individuals with other chronic conditions.', 'DetailedDescription': \"I. Brief Overview The over-arching objectives of this study are to implement and evaluate an evidence-based intervention called TeamCare-PCN for individuals with type-2 diabetes and comorbid depression within primary care networks (PCNs). TeamCare-PCN is based on a proven efficacious and cost-saving collaborative primary care model (Katon et al., 2010) which involves a Care Manager (CM) providing active patient management under the supervision of a family physician and consulting psychiatrists and internists. The goal of the intervention is to achieve remission of depression, reach targets for cardio-metabolic measures, and improve lifestyle behaviours.\\n\\nII. Hypothesis The investigators hypothesize that the TeamCare-PCN intervention will reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours.\\n\\nIII. Setting, Participants, and Sample Size TeamCare-PCN will be conducted in collaboration with 4 PCNs in non-metro Alberta: St. Albert Sturgeon PCN, Leduc/Beaumont/ Devon PCN, Camrose PCN, and Heartland PCN.\\n\\nWe estimate that a minimum total sample size of 120, with 60 in each arm, would provide power of 0.80 to detest a mean difference of 5 points in the PHQ-9, assuming a repeated measures correlation of 0.6, and 2-tailed alpha of 0.05. This sample size also provides more than 80% power (two sided alpha = 0.05) to detect any between-group absolute difference in proportions of 15% or more (e.g., 45% of usual care patients achieve depression remission vs 60% of intervention patients) (Katon et al., 2010). Anticipating a 40% attrition rate, we planned to recruit 168 patients in total across our 4 PCN sites.\\n\\nIV. Participant Recruitment and Allocation Recruiting participants into TeamCare-PCN involves four steps. i) A screening survey accompanied with an endorsement letter from the PCN and a general information letter. Included in the screen is the PHQ-9.\\n\\nii) After potential participants have completed the screening survey and mailed it back to the PCN, staff at the PCN will identify the respondents who are eligible to participate TeamCare-PCN through the responses on the screening survey and by scoring the PHQ-9.\\n\\niii) PCN staff will contact eligible participants through a brief phone interview to confirm all eligibility criteria and schedule an initial assessment visit with the CM at the PCN.\\n\\niv) CM will meet with the participant, and during the initial assessment, the CM will explain the intervention, provide an intervention-specific information letter and obtain a signed written informed consent from the patient to participate in the study.\\n\\nParticipants will be allocated to study groups using an 'on-off' allocation method. Eligible and consenting respondents who book for an initial assessment with the CM during month 1 will be allocated to the intervention arm (On-group). Those who book the initial assessment in month 2 will be allocated to the usual care arm (Off-group). This allocation process will continue until the target sample size is recruited.\\n\\nV. Team Care Depression Intervention for Diabetes\\n\\nA. Patient Management:\\n\\nPatients entering the intervention will have an initial one-hour appointment with the CM. This first visit will include a bio-psychosocial semi-structured assessment (reviewing medical history, previous treatments for depression and diabetes), patient education, potential treatment options (anti-depressant medications and/or psychotherapy) and developing an overall individualized care plan. The intervention will consist of 3 phases; the first focusing on depression management, the second on cardio-metabolic diabetes management, and the third on general lifestyle modifications. The CM will also have weekly meetings with the consulting specialists to review new cases and patient progress, and then make treatment recommendations to the primary care physician.\\n\\nB. Training of Care Managers and Specialists:\\n\\nThe CMs and consulting specialists have already received a 2-day training course on the TeamCare-PCN intervention, including the pharmacotherapy of depression and an introduction to psychotherapeutic techniques (i.e. problem solving, behavioural activation, and motivational interviewing), as well as team interactions, roles and responsibilities. An overview of cardio-metabolic diabetes management, including, glucose control, insulin management, blood pressure management and treatment of high lipid levels based on the developed algorithms, was also provided at the training session. TeamCare-PCN training manuals were developed and used in the training sessions, and retained by the CM.\\n\\nVI. Usual Care All participants in TeamCare-PCN will be actively screened for depression and those allotted to usual care will be identified as such to their family physician. For depression management, patients will receive care from their family physician, without additional active support from the Care Manager.\\n\\nVII. Data Analysis As the initial focus of the intervention is on the management of depressive symptoms, we have considered the PHQ-9 as a main primary outcome, and will assess changes in PHQ-9 scores over 12-months between groups, adjusting for baseline PHQ-9 score, using a mixed effects multivariate model. For our second primary outcome of improvements in global disease control, we will employ a multivariate model that jointly tests the changes in multiple clinical outcomes, namely A1c, LDL cholesterol and systolic blood pressure. Using the same analytic approach as in the recently published RCT of this intervention, we will apply a scaled marginal model (Katon et al., 2010) to simultaneously compare the change in these continuous outcomes at 12 months, adjusting for the baseline status for each variable. In either primary outcome analyses, the models will be estimated iteratively and the potential correlations among and between outcomes within individuals will be handled using generalized-estimating equation (GEE) models for each outcome.\\n\\nFor all analyses the investigators will employ an intention-to-treat framework for our primary analysis, using a last-observation-carried-forward method of imputation for subjects who do not have complete follow-up data for primary or secondary outcomes.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression', 'Depressive Symptoms', 'Type 2 Diabetes']}, 'KeywordList': {'Keyword': ['Collaborative care', 'Diabetes management', 'Depression management', 'Primary care']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '157', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Usual Care', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this arm will be actively screened for depression and will receive the usual standard care for diabetes from their family physicians based on available clinical practice guidelines.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Usual diabetes and depression care']}}, {'ArmGroupLabel': 'TeamCare Depression Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in this arm will be actively screened for depression, and will receive care for depression and diabetes based on the collaborative teamcare model for the management of diabetes and co-morbid depression.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: TeamCare Depression Intervention']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'TeamCare Depression Intervention', 'InterventionDescription': 'The TeamCare-PCN intervention involves a registered nurse Care Manager (CM), who coordinates collaborative team management for patients with diabetes and depression. The goal of the intervention is to reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours. The intervention includes three phases: (1) managing depression and improving depressive symptoms, (2) managing diabetes and controlling blood glucose, blood pressure and cholesterol, and (3) improving lifestyle behaviours such as healthy eating, physical activity and smoking cessation.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['TeamCare Depression Intervention']}, 'InterventionOtherNameList': {'InterventionOtherName': ['TEAMcare']}}, {'InterventionType': 'Other', 'InterventionName': 'Usual diabetes and depression care', 'InterventionDescription': 'Usual care of diabetes and depression involves providing care by the family physician based on usual standards of care and available clinical practice guidelines. Usual care does not involve additional active support from the Care Manager.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Usual Care']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Patient Health Questionnaire-9 items (PHQ-9) score', 'PrimaryOutcomeDescription': 'A remission of depression symptoms is indicated with a PHQ-9 score <10 for a period of three consecutive months.', 'PrimaryOutcomeTimeFrame': 'Baseline, 3-month, 6-month, 9-month, 12-month'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in HbA1c level', 'SecondaryOutcomeDescription': 'Improvement is defined as 10% improvement over baseline', 'SecondaryOutcomeTimeFrame': 'baseline, 6-month, 12-month'}, {'SecondaryOutcomeMeasure': 'Change in total cholesterol level', 'SecondaryOutcomeDescription': 'Improvement is defined as 10% improvement over baseline', 'SecondaryOutcomeTimeFrame': 'baseline, 6-month, 12-month'}, {'SecondaryOutcomeMeasure': 'Change in Systolic blood pressure measurement', 'SecondaryOutcomeDescription': 'Improvement is defined as 10% improvement over baseline', 'SecondaryOutcomeTimeFrame': 'baseline, 6-month, 12-month'}, {'SecondaryOutcomeMeasure': 'Change in self-reported Health Related Quality of Life', 'SecondaryOutcomeDescription': 'Measured by SF-12-V2 and EQ-5D-5L', 'SecondaryOutcomeTimeFrame': 'Baseline, 6-month, 12-month'}, {'SecondaryOutcomeMeasure': 'Change in Diabetes-specific stress', 'SecondaryOutcomeDescription': 'Measured by Problem Areas In Diabetes 5-level questionnaire (PAID-5)', 'SecondaryOutcomeTimeFrame': 'Baseline, 6-month, 12-month'}, {'SecondaryOutcomeMeasure': 'Change in Health behaviours', 'SecondaryOutcomeDescription': 'Includes assessment of smoking behaviours, alcohol consumption, substance use, and physical activity', 'SecondaryOutcomeTimeFrame': 'Baseline, 6-month, 12-month'}, {'SecondaryOutcomeMeasure': 'Change in Self-care management activities', 'SecondaryOutcomeDescription': 'Measured using the Summary of Diabetes Self Care Activities questionnaire (SDSCA)', 'SecondaryOutcomeTimeFrame': 'Baseline, 6-month, 12-month'}, {'SecondaryOutcomeMeasure': 'Change in Satisfaction with care', 'SecondaryOutcomeDescription': 'Measured using the Consumer Assessment of Healthcare Providers and Systems questionnaire (CAHPS), Adult Primary Care 1.0, and the Patient Assessment of Chronic Illness Care questionnaire (PACIC)', 'SecondaryOutcomeTimeFrame': 'Baseline, 12-month'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHave family physician-identified type 2 diabetes\\n18 years of age or older\\nScore >=10 on the PHQ-9\\nSpeak English and have adequate hearing to complete phone interviews\\nBe willing and able to provide written informed consent to participate\\n\\nExclusion Criteria:\\n\\nSevere and/or terminal physical illness\\nSerious and/or severe mental or psychiatric illness\\nPregnant or breastfeeding\\nLive in long term care facility\\nAlready participating in other clinical trials', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jeffrey A Johnson, PhD', 'OverallOfficialAffiliation': 'University of Alberta', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Sumit Majumdar, MD', 'OverallOfficialAffiliation': 'University of Alberta', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Camrose PCN', 'LocationCity': 'Edmonton', 'LocationState': 'Alberta', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Leduc/Beaumont/ Devon PCN', 'LocationCity': 'Edmonton', 'LocationState': 'Alberta', 'LocationCountry': 'Canada'}, {'LocationFacility': 'St. Albert & Sturgeon PCN', 'LocationCity': 'Edmonton', 'LocationState': 'Alberta', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Heartland PCN', 'LocationCity': 'Fort Saskatchewan', 'LocationState': 'Alberta', 'LocationCountry': 'Canada'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '21190455', 'ReferenceType': 'background', 'ReferenceCitation': 'Katon WJ, Lin EH, Von Korff M, Ciechanowski P, Ludman EJ, Young B, Peterson D, Rutter CM, McGregor M, McCulloch D. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010 Dec 30;363(27):2611-20. doi: 10.1056/NEJMoa1003955.'}, {'ReferencePMID': '12687656', 'ReferenceType': 'background', 'ReferenceCitation': 'Jung SH, Ahn C. Sample size estimation for GEE method for comparing slopes in repeated measurements data. Stat Med. 2003 Apr 30;22(8):1305-15.'}, {'ReferencePMID': '15353428', 'ReferenceType': 'background', 'ReferenceCitation': 'Majumdar SR, Rowe BH, Folk D, Johnson JA, Holroyd BH, Morrish DW, Maksymowych WP, Steiner IP, Harley CH, Wirzba BJ, Hanley DA, Blitz S, Russell AS. A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med. 2004 Sep 7;141(5):366-73.'}, {'ReferencePMID': '16488469', 'ReferenceType': 'background', 'ReferenceCitation': 'Rucker D, Rowe BH, Johnson JA, Steiner IP, Russell AS, Hanley DA, Maksymowych WP, Holroyd BR, Harley CH, Morrish DW, Wirzba BJ, Majumdar SR. Educational intervention to reduce falls and fear of falling in patients after fragility fracture: results of a controlled pilot study. Prev Med. 2006 Apr;42(4):316-9. Epub 2006 Feb 20.'}, {'ReferencePMID': '8291818', 'ReferenceType': 'background', 'ReferenceCitation': 'Weingarten SR, Riedinger MS, Conner L, Lee TH, Hoffman I, Johnson B, Ellrodt AG. Practice guidelines and reminders to reduce duration of hospital stay for patients with chest pain. An interventional trial. Ann Intern Med. 1994 Feb 15;120(4):257-63.'}, {'ReferencePMID': '19299058', 'ReferenceType': 'background', 'ReferenceCitation': \"Bell AC, D'Zurilla TJ. Problem-solving therapy for depression: a meta-analysis. Clin Psychol Rev. 2009 Jun;29(4):348-53. doi: 10.1016/j.cpr.2009.02.003. Epub 2009 Feb 26. Review.\"}, {'ReferencePMID': '18591356', 'ReferenceType': 'background', 'ReferenceCitation': 'Arean P, Hegel M, Vannoy S, Fan MY, Unuzter J. Effectiveness of problem-solving therapy for older, primary care patients with depression: results from the IMPACT project. Gerontologist. 2008 Jun;48(3):311-23.'}, {'ReferencePMID': '7873952', 'ReferenceType': 'background', 'ReferenceCitation': 'Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ. 1995 Feb 18;310(6977):441-5.'}, {'ReferencePMID': '17194572', 'ReferenceType': 'background', 'ReferenceCitation': 'Cuijpers P, van Straten A, Warmerdam L. Problem solving therapies for depression: a meta-analysis. Eur Psychiatry. 2007 Jan;22(1):9-15. Epub 2006 Dec 27.'}, {'ReferencePMID': '9583341', 'ReferenceType': 'background', 'ReferenceCitation': 'Gortner ET, Gollan JK, Dobson KS, Jacobson NS. Cognitive-behavioral treatment for depression: relapse prevention. J Consult Clin Psychol. 1998 Apr;66(2):377-84.'}, {'ReferencePMID': '8871414', 'ReferenceType': 'background', 'ReferenceCitation': 'Jacobson NS, Dobson KS, Truax PA, Addis ME, Koerner K, Gollan JK, Gortner E, Prince SE. A component analysis of cognitive-behavioral treatment for depression. J Consult Clin Psychol. 1996 Apr;64(2):295-304.'}, {'ReferencePMID': '10660997', 'ReferenceType': 'background', 'ReferenceCitation': 'Jacobson NS, Gortner ET. Can depression be de-medicalized in the 21st century: scientific revolutions, counter-revolutions and the magnetic field of normal science. Behav Res Ther. 2000 Feb;38(2):103-17.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Rollnick S, Miller W. What is motivational interviewing? Behavioral Cognitive Psychotherapy 23: 325, 1995.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Jacobson N, Martell C, Dimidjian S. Behavioral activation treatment for depression: Returning to contextual roots. Clinical Psychology: Science and Practice 8:255, 2001.'}, {'ReferencePMID': '14516234', 'ReferenceType': 'background', 'ReferenceCitation': 'Burke BL, Arkowitz H, Menchola M. The efficacy of motivational interviewing: a meta-analysis of controlled clinical trials. J Consult Clin Psychol. 2003 Oct;71(5):843-61.'}, {'ReferencePMID': '17059299', 'ReferenceType': 'background', 'ReferenceCitation': \"Butterworth S, Linden A, McClay W, Leo MC. Effect of motivational interviewing-based health coaching on employees' physical and mental health status. J Occup Health Psychol. 2006 Oct;11(4):358-65.\"}, {'ReferencePMID': '15826439', 'ReferenceType': 'background', 'ReferenceCitation': 'Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005 Apr;55(513):305-12. Review.'}, {'ReferencePMID': '12925505', 'ReferenceType': 'background', 'ReferenceCitation': 'Roy J, Lin X, Ryan LM. Scaled marginal models for multiple continuous outcomes. Biostatistics. 2003 Jul;4(3):371-83.'}, {'ReferencePMID': '14578240', 'ReferenceType': 'background', 'ReferenceCitation': 'Majumdar SR, Guirguis LM, Toth EL, Lewanczuk RZ, Lee TK, Johnson JA. Controlled trial of a multifaceted intervention for improving quality of care for rural patients with type 2 diabetes. Diabetes Care. 2003 Nov;26(11):3061-6.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Majumdar SR, Johnson JA, Bowker SL, Booth GL, Dolovich L, Ghali W, Harris SB, Hux JE, Holbrook A, Lee H, Toth EL, Yale J-F. A Canadian consensus for the standardized evaluation of quality improvement interventions in type 2 diabetes: Development of a Quality Indicator Set. Canadian Journal of Diabetes 29:220-229, 2005'}, {'ReferencePMID': '18335281', 'ReferenceType': 'background', 'ReferenceCitation': 'Chew LD, Griffin JM, Partin MR, Noorbaloochi S, Grill JP, Snyder A, Bradley KA, Nugent SM, Baines AD, Vanryn M. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med. 2008 May;23(5):561-6. doi: 10.1007/s11606-008-0520-5. Epub 2008 Mar 12.'}, {'ReferencePMID': '26947212', 'ReferenceType': 'derived', 'ReferenceCitation': 'Johnson JA, Lier DA, Soprovich A, Al Sayah F, Qiu W, Majumdar SR. Cost-Effectiveness Evaluation of Collaborative Care for Diabetes and Depression in Primary Care. Am J Prev Med. 2016 Jul;51(1):e13-20. doi: 10.1016/j.amepre.2016.01.010.'}, {'ReferencePMID': '26303892', 'ReferenceType': 'derived', 'ReferenceCitation': 'Mathe N, Johnson ST, Wozniak LA, Majumdar SR, Johnson JA. Alternation as a form of allocation for quality improvement studies in primary healthcare settings: the on-off study design. Trials. 2015 Aug 25;16:375. doi: 10.1186/s13063-015-0904-x.'}, {'ReferencePMID': '25315205', 'ReferenceType': 'derived', 'ReferenceCitation': 'Johnson JA, Al Sayah F, Wozniak L, Rees S, Soprovich A, Qiu W, Chik CL, Chue P, Florence P, Jacquier J, Lysak P, Opgenorth A, Katon W, Majumdar SR. Collaborative care versus screening and follow-up for patients with diabetes and depressive symptoms: results of a primary care-based comparative effectiveness trial. Diabetes Care. 2014 Dec;37(12):3220-6. doi: 10.2337/dc14-1308. Epub 2014 Oct 14.'}, {'ReferencePMID': '22897901', 'ReferenceType': 'derived', 'ReferenceCitation': 'Johnson JA, Al Sayah F, Wozniak L, Rees S, Soprovich A, Chik CL, Chue P, Florence P, Jacquier J, Lysak P, Opgenorth A, Katon WJ, Majumdar SR. Controlled trial of a collaborative primary care team model for patients with diabetes and depression: rationale and design for a comprehensive evaluation. BMC Health Serv Res. 2012 Aug 16;12:258.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003920', 'ConditionMeshTerm': 'Diabetes Mellitus'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5702', 'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5698', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafAsFound': 'Diabetes', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10222', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M23990', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6445', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 45, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04223115', 'OrgStudyIdInfo': {'OrgStudyId': 'DEPMOM-2020'}, 'Organization': {'OrgFullName': 'University of Turku', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Randomized Controlled Study of Digitalized Cognitive Behavioral Intervention for Antenatal Depression', 'OfficialTitle': 'Randomized Controlled Trial of Digitalized Cognitive Behavioral Therapy With Telephone Coaching for Mothers Suffering From Depression During Pregnancy'}, 'StatusModule': {'StatusVerifiedDate': 'January 2020', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2020', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'January 7, 2020', 'StudyFirstSubmitQCDate': 'January 7, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 10, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 7, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 10, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Andre Sourander', 'ResponsiblePartyInvestigatorTitle': 'Professor, Child Psychiatry', 'ResponsiblePartyInvestigatorAffiliation': 'University of Turku'}, 'LeadSponsor': {'LeadSponsorName': 'University of Turku', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The main objective of the current research project is to evaluate the effectiveness of the digitalized cognitive behavioral therapy program including telephone coaching for antenatal and postnatal depressive symptoms. The participants are screened from the general population of pregnant women, as a part of the routine maternity health care check-ups. Half of the mothers with depressive symptoms will receive the digitalized treatment program, while the other half will receive education about depression in digital form.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression', 'Depression, Postpartum', 'Perinatal Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '400', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Digitalized CBT intervention with phone coaching', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants receive weekly sessions of internet-based CBT, including telephone coaching', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Digitalized CBT with phone coaching']}}, {'ArmGroupLabel': 'Psychoeducation about depression', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants receive psychoeducative material about depression in digitalized form.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Psychoeducation about depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Digitalized CBT with phone coaching', 'InterventionDescription': 'Digitally delivered CBT intervention with weekly phone coaching', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Digitalized CBT intervention with phone coaching']}}, {'InterventionType': 'Other', 'InterventionName': 'Psychoeducation about depression', 'InterventionDescription': 'Psychoeducational material about depression in a digitalized form', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Psychoeducation about depression']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in the Edinburgh Postnatal Depression Scale (EPDS)', 'PrimaryOutcomeDescription': 'EPDS is a ten-item self-report questionnaire originally developed to screen for postpartum depression. The respondents are asked about the symptoms of depression experienced in the previous week. The total score ranges from 0 to 30.', 'PrimaryOutcomeTimeFrame': 'Baseline, 9 weeks after randomization (post-treatment) and 7 months after randomization'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in the World Health Organization Quality of Life (WHOQOL-BREF)', 'SecondaryOutcomeDescription': 'We will use overall QoL items and the domains of psychological QoL and social relationships', 'SecondaryOutcomeTimeFrame': 'Baseline and 7 months after randomization'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nfluent in written and spoken Finnish\\naccess to computer or mobile phone with internet\\nbetween 12 and 24 weeks pregnant\\nscreening and baseline score on the EPDS ≥10 points\\n\\nExclusion Criteria:\\n\\nlifetime history of psychotic disorder (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, psychotic depression)\\nactive suicidal ideation\\nsevere substance abuse or dependence\\nactively ongoing psychotherapy\\ncommenced medication for depression less than 30 days before intake assessment\\nmultiple pregnancy', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '55 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Hanna-Maria Matinolli, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+358 50 5641 814', 'CentralContactEMail': 'hanna-maria.matinolli@utu.fi'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Andre Sourander, Professor', 'OverallOfficialAffiliation': 'University of Turku, Research Center for Child Psychiatry', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Turku', 'LocationCity': 'Turku', 'LocationCountry': 'Finland', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hanna-Maria Matinolli, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+358 50 5641 814', 'LocationContactEMail': 'hanna-maria.matinolli@utu.fi'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000019052', 'ConditionMeshTerm': 'Depression, Postpartum'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000011644', 'ConditionAncestorTerm': 'Puerperal Disorders'}, {'ConditionAncestorId': 'D000011248', 'ConditionAncestorTerm': 'Pregnancy Complications'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M19660', 'ConditionBrowseLeafName': 'Depression, Postpartum', 'ConditionBrowseLeafAsFound': 'Depression, Postpartum', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13082', 'ConditionBrowseLeafName': 'Puerperal Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12710', 'ConditionBrowseLeafName': 'Pregnancy Complications', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}}}}, {'Rank': 46, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01571973', 'OrgStudyIdInfo': {'OrgStudyId': 'SPPsicobio1Lu'}, 'Organization': {'OrgFullName': 'Federal University of São Paulo', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Evaluation of Pharmaceutical Care in Depressed Outpatients', 'OfficialTitle': 'EVALUATION OF THE EFFECTIVENESS OF PHARMACEUTICAL CARE (DÁDER PROGRAM) IN DEPRESSED OUTPATIENTS TREATED WITH PSYCHOTROPIC', 'Acronym': 'depression'}, 'StatusModule': {'StatusVerifiedDate': 'June 2011', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2010'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 2012', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 3, 2012', 'StudyFirstSubmitQCDate': 'April 4, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 5, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'April 4, 2012', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 5, 2012', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Ana Regina Noto', 'ResponsiblePartyInvestigatorTitle': 'Ph.D.', 'ResponsiblePartyInvestigatorAffiliation': 'Federal University of São Paulo'}, 'LeadSponsor': {'LeadSponsorName': 'Federal University of São Paulo', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The study examines whether pharmacotherapeutic follow-up improves outcomes of treatment of depressed outpatients.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['pharmaceutical care', 'depression', 'compliance', \"pharmacist's intervention\", 'Dáder']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '60', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'control group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'outpatients receiving usual care'}, {'ArmGroupLabel': 'intervention group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'outpatients receiving pharmaceutical care or pharmacotherapeutic follow-up by 6 months', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: pharmacotherapeutic follow-up']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'pharmacotherapeutic follow-up', 'InterventionDescription': 'health education adjustment of dose improve compliance replacement of medication', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['intervention group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'depression level', 'PrimaryOutcomeDescription': 'evaluation depression level by Beck scale', 'PrimaryOutcomeTimeFrame': 'six months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'anxiety level', 'SecondaryOutcomeDescription': 'evaluation anxiety level by Beck scale.', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'compliance', 'SecondaryOutcomeDescription': 'evaluation antidepressive treatment compliance by Morisky scale', 'SecondaryOutcomeTimeFrame': '6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nwomen between 18 and 65 years, with diagnostic hypothesis of depression at the beginning of treatment or change in treatment unless 2 months (dosage or substance)\\n\\nExclusion Criteria:\\n\\nrecord of dependence on psychoactive substances, diagnosed schizophrenia,\\nlow education (illiterate) or cognitive impairment evident that compromise the completion of research instruments', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}}, 'AnnotationSection': {'AnnotationModule': {'UnpostedAnnotation': {'UnpostedResponsibleParty': 'Ana Regina Noto, Ph.D., Federal University of São Paulo', 'UnpostedEventList': {'UnpostedEvent': [{'UnpostedEventType': 'Release', 'UnpostedEventDate': 'February 13, 2019'}, {'UnpostedEventType': 'Reset', 'UnpostedEventDate': 'May 10, 2019'}, {'UnpostedEventType': 'Release', 'UnpostedEventDate': 'February 17, 2020'}, {'UnpostedEventType': 'Reset', 'UnpostedEventDate': 'February 27, 2020'}]}}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 47, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02143024', 'OrgStudyIdInfo': {'OrgStudyId': '807849'}, 'Organization': {'OrgFullName': 'University of California, Davis', 'OrgClass': 'OTHER'}, 'BriefTitle': \"A Family-based Primary Care Intervention to Enhance Older Men's Depression Care\", 'OfficialTitle': \"A Family-based Primary Care Intervention to Enhance Older Men's Depression Care\"}, 'StatusModule': {'StatusVerifiedDate': 'January 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 1, 2015', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 19, 2013', 'StudyFirstSubmitQCDate': 'May 16, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 20, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'March 25, 2019', 'ResultsFirstSubmitQCDate': 'January 6, 2020', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'January 18, 2020', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 6, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 18, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of California, Davis', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Washington', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'RAND', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Despite the public health importance of clinical depression, more than 50% of depressed adults receive inadequate or no treatment, with even higher rates of under-treatment in men and minorities. Family members and/or friends often assist older adults in their health care and may help overcome barriers to formal care, yet there is a lack of primary care-based interventions that mobilize family members and friends to improve depression treatment. In partnership with a community-based clinic, this research will address this scientific gap by developing and then testing the feasibility and acceptability of a family-based intervention that can be delivered pragmatically in a primary care setting serving large numbers of older minorities.', 'DetailedDescription': 'The family-based intervention will be tested in a 6 month randomized controlled trial of 24 depressed older men-family member dyads (18 intervention and 6 controls). The purpose of the RCT is to test the acceptability of the intervention, as well as the feasibility of the study methods. Patients from the RCT will be identified from a family practice clinic based on their scores on the PHQ-9 as well as additional inclusion and exclusion criteria. Once they and their family member have agreed to participate, patients will be randomized either to the family based intervention or a usual care control condition augmented by family psychoeducation. The investigators will recruit English and Spanish speaking age 60 and above older men from SJGH who have 1) significant depressive symptoms (i.e. PHQ > 15, 2) have at least one criteria A symptom (depressed mood or anhedonia), 3) depression-related functional impairment) and 4) an adult family member willing to participate in the study. We have chosen a higher cut-off to minimize false positives. We will exclude psychotic, demented or institutionalized men. After enrollment, 24 dyads (i.e. older man and family member) will be randomized one of two groups: intervention or usual care augmented by written psychoeducational materials on depression. Dyads will be randomized to achieve a 2:1 ratio of intervention versus usual care dyads (i.e. 18 intervention and 6 control dyads). To ensure adequate numbers of ethnic minority patients in each arm of the trial, we will conduct a stratified randomization such that each arm of the RCT is 50% English language preferring and 50% Spanish language preferring (i.e. 3 in control and 9 in intervention arm). The research assistant will conduct subject assessment at baseline, 1-month, 3-months and 6 months.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Major Depression']}, 'KeywordList': {'Keyword': ['depression', 'family', 'primary health care']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Randomized controlled trial', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '23', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Family-based depression intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': \"The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Family-based depression intervention']}}, {'ArmGroupLabel': 'Usual care plus educational materials', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Usual care plus educational materials']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Family-based depression intervention', 'InterventionDescription': 'The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Family-based depression intervention']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Usual care plus educational materials', 'InterventionDescription': 'Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Usual care plus educational materials']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depressive Symptoms', 'PrimaryOutcomeDescription': 'Patient Health Questionnaire (PHQ-9) scale; 0-27 scoring units; higher scores indicate more severe depressive symptoms.', 'PrimaryOutcomeTimeFrame': 'baseline, 3 months, and 6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMen, age 50 and above\\nEnglish or Spanish speaking\\nScore of >9 on the PHQ-9\\nNon-demented\\nHave an adult family member or close friend who can participate\\n\\nExclusion Criteria:\\n\\nAdults unable to consent\\nIndividuals who are not yet adults (infants, children, teenagers)\\nPregnant women\\nPrisoners', 'HealthyVolunteers': 'No', 'Gender': 'Male', 'MinimumAge': '50 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Ladson Hinton, MD', 'OverallOfficialAffiliation': 'University of California, Davis', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'San Joaquin General Hospital', 'LocationCity': 'Stockton', 'LocationState': 'California', 'LocationZip': '95231', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowRecruitmentDetails': '45 people were referred to the study. 41 people were assessed, 4 were not assessed for eligibility. 18 were excluded; 10 did not meet inclusion criteria and 8 declined. A total of 23 people were randomized as part of the study.', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Family-based Depression Intervention', 'FlowGroupDescription': \"The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker\\n\\nFamily-based depression intervention: The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.\"}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Usual Care Plus Educational Materials', 'FlowGroupDescription': 'Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.\\n\\nUsual care plus educational materials: Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '15'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '8'}]}}, {'FlowMilestoneType': 'Received Treatment', 'FlowMilestoneComment': 'These people were randomized and received at least 1 session before dropping out of the study.', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '13'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '7'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '13'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '7'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '2'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '1'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'}]}}, {'FlowDropWithdrawType': 'Withdrawal by Subject', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'Randomized participants that received at least 1 session.', 'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Family-based Depression Intervention', 'BaselineGroupDescription': \"The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker\\n\\nFamily-based depression intervention: The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.\"}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Usual Care Plus Educational Materials', 'BaselineGroupDescription': 'Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.\\n\\nUsual care plus educational materials: Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '13'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '7'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '20'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '60.2', 'BaselineMeasurementSpread': '9.6'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '57.4', 'BaselineMeasurementSpread': '4.8'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '59.2', 'BaselineMeasurementSpread': '8.1'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '13'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '7'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '20'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race/Ethnicity, Customized', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Hispanic', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '10'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '12'}]}}]}}, {'BaselineClassTitle': 'African American', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4'}]}}]}}, {'BaselineClassTitle': 'White', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2'}]}}]}}, {'BaselineClassTitle': 'Native American and White', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '13'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '7'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '20'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Depressive Symptoms', 'OutcomeMeasureDescription': 'Patient Health Questionnaire (PHQ-9) scale; 0-27 scoring units; higher scores indicate more severe depressive symptoms.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': 'baseline, 3 months, and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Family-based Depression Intervention', 'OutcomeGroupDescription': \"The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker\\n\\nFamily-based depression intervention: The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Usual Care Plus Educational Materials', 'OutcomeGroupDescription': 'Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.\\n\\nUsual care plus educational materials: Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '13'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '7'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'baseline', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '14.8', 'OutcomeMeasurementSpread': '2.9'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '15.3', 'OutcomeMeasurementSpread': '4.1'}]}}]}}, {'OutcomeClassTitle': '3 months', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '10.1', 'OutcomeMeasurementSpread': '6.6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '13.0', 'OutcomeMeasurementSpread': '7.5'}]}}]}}, {'OutcomeClassTitle': '6 months', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '11.8', 'OutcomeMeasurementSpread': '7.1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '13.3', 'OutcomeMeasurementSpread': '6.3'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '5', 'EventsTimeFrame': 'Adverse events were monitored up until the 6 month visit.', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Family-based Depression Intervention', 'EventGroupDescription': \"The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker\\n\\nFamily-based depression intervention: The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.\", 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '13', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '13', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '13'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Usual Care Plus Educational Materials', 'EventGroupDescription': 'Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.\\n\\nUsual care plus educational materials: Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '7', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '7', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '7'}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Ladson Hinton, MD', 'PointOfContactOrganization': 'UC Davis Department of Psychiatry and Behavioral Sciences', 'PointOfContactEMail': 'lwhinton@ucdavis.edu', 'PointOfContactPhone': '(916) 734-3485'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 48, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03555669', 'OrgStudyIdInfo': {'OrgStudyId': '16-2834'}, 'Organization': {'OrgFullName': 'University of North Carolina, Chapel Hill', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Project SOAR-Mental Health Malawi: Depression and HIV Integration', 'OfficialTitle': 'UNCPM 21609 Project SOAR Mental Health: Evaluation of the Impact of a Depression Treatment Program on Mental Health and HIV Care Outcomes in Malawi'}, 'StatusModule': {'StatusVerifiedDate': 'June 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 24, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 31, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 31, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 1, 2018', 'StudyFirstSubmitQCDate': 'June 1, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 13, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 26, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 27, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of North Carolina, Chapel Hill', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'United States Agency for International Development (USAID)', 'CollaboratorClass': 'FED'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Depression is highly prevalent among people living with HIV (PLHIV) in Malawi and elsewhere in sub-Saharan Africa (SSA). Besides its high prevalence, depression likely represents an important barrier to consistent HIV care engagement and long-term viral suppression. However, the potential for depression treatment to improve HIV care outcomes has received little attention in the region, in part because of limited mental health infrastructure. In this study, the investigators will evaluate the impact of a depression treatment program integrated within existing HIV clinics on depression response, retention in HIV care, and viral suppression. It is expected that this evaluation will yield important evidence on the impact of depression treatment integrated with HIV care for improving HIV care and mental health outcomes in Malawi.', 'DetailedDescription': 'Study population:\\n\\nThe evaluation will abstract screening data for adult (≥18 years old) patients newly initiating antiretroviral therapy (ART) who are screened for depression at the two clinics before and after the integration of the depression treatment program, and additional treatment and outcome data for those patients who screen positive for depression.\\n\\nStudy Size:\\n\\nAcross the two clinics, the investigators expect to abstract depression screening data for approximately 2,300 patients. The investigators expect to abstract further treatment and outcome data for approximately 640 patients who screen positive for mild, moderate, or severe depression.\\n\\nStudy Duration:\\n\\nEvaluation and dissemination activities will last two years.\\n\\nStudy Evaluation:\\n\\nTo evaluate the impact of the mental health treatment program on HIV care outcomes, the investigators will collect data on HIV appointment adherence and viral load at 6 months following ART initiation.\\n\\nTo evaluate the impact of the mental health treatment program on mental health outcomes the investigators will collect data on depression symptoms at baseline through 6 months following ART initiation.\\n\\nStudy Design Overview:\\n\\nThe study will employ a pre-post design in two HIV clinics in Lilongwe to evaluate the impact of integrating the depression treatment program within existing clinic operations on HIV and mental health outcomes. The investigators will use existing medical records and the depression patient registry maintained by the Ministry of Health-run clinics to abstract routinely collected clinical data. Using these data, the investigators will compare mental health and HIV outcomes before and after the integration of the depression treatment program. Depressive symptoms will be measured with the Patient Health Questionnaire 9 (PHQ-9). The PHQ-9 is a self-report questionnaire designed to assess depression through nine questions that come directly from the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) signs and symptoms of major depression. Additionally, the investigators will conduct short qualitative interviews with clinic and Ministry of Health staff about the integration of the depression screening and treatment program and with patients on their understanding of depression and satisfaction with depression screening and treatment.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression', 'HIV/AIDS']}, 'KeywordList': {'Keyword': ['Implementation Science', 'Malawi']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Sequential Assignment', 'DesignInterventionModelDescription': 'The investigators will employ a multiple baseline evaluation design in two clinics to evaluate the impact of depression treatment on HIV outcomes. Patients who screen positive for depression using PHQ-9 during the \"pre\" period will comprise the comparison group, while patients who screen positive during the \"post\" period will comprise the active group.', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '2082', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Screening Phase (Pre) Group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Patients who screen positive on the PHQ-9 for depression during the \"pre\" period will comprise the comparison group. Participants will receive \"standard of care\" depression treatment at the providers discretion.'}, {'ArmGroupLabel': 'Treatment Phase (Post) Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients who screen positive during on the PHQ-9 for depression during the \"post\" period will comprise the active group. Participants will receive the depression treatment intervention in the form of anti-depressants and/or problem solving therapy (PST) based on their PHQ-9 score.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression Treatment']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Depression Treatment', 'InterventionDescription': \"The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Treatment Phase (Post) Group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Proportion of participants who are retained in care', 'PrimaryOutcomeDescription': 'Retention in care is defined as attending sufficient HIV appointments to maintain ART supply through the first 6 months on ART.', 'PrimaryOutcomeTimeFrame': '6 months after ART initiation'}, {'PrimaryOutcomeMeasure': 'Proportion of participants who are virally suppressed', 'PrimaryOutcomeDescription': 'Viral suppression is defined as HIV RNA viral load of <1,000 copies/mL. Viral loads are measured approximately 6 months after ART initiation.', 'PrimaryOutcomeTimeFrame': '6 months after ART initiation'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Proportion of participants who achieve depression remission (PHQ-9 score less than 5)', 'SecondaryOutcomeDescription': 'Depression remission is defined as scoring less than 5 on the PHQ-9 approximately 6 months after ART initiation. The PHQ-9 is a self-report questionnaire designed to assess depression through nine questions that come directly from the DSM-IV signs and symptoms of major depression. The 9 items describe problems associated with depression, and participants must rate how often the patient has been bothered by the problems in the last 2 weeks on a 0-3 scale. The scores are summed for a total depression score, ranging from 0-27, with 0-4 being minimum and indicating no depressive symptoms, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and 20-27 severe depression. Depressive symptoms will be measured with the PHQ-9 at baseline through approximately 6 months after ART initiation.', 'SecondaryOutcomeTimeFrame': '6 months after ART initiation'}, {'SecondaryOutcomeMeasure': 'Proportion of scheduled ART visits attended', 'SecondaryOutcomeDescription': 'ART visit attendance is defined as attending scheduled ART appointments over the first 6 months on ART.', 'SecondaryOutcomeTimeFrame': '6 months after ART initiation'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAdult (≥18 years)\\nHIV-infected\\nNewly initiating antiretroviral treatment at one of the program sites\\nScreened for depression\\n\\nExclusion Criteria:\\n\\n• None', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Brian Pence, PhD, MPH', 'OverallOfficialAffiliation': 'UNC Gillings School of Global Public Health', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Michael Udedi, MBA MPhil', 'OverallOfficialAffiliation': 'Malawi Ministry of Health', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Area 18 Clinic', 'LocationCity': 'Lilongwe', 'LocationCountry': 'Malawi'}, {'LocationFacility': 'Area 25 Clinic', 'LocationCity': 'Lilongwe', 'LocationCountry': 'Malawi'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31242877', 'ReferenceType': 'derived', 'ReferenceCitation': 'Udedi M, Stockton MA, Kulisewa K, Hosseinipour MC, Gaynes BN, Mphonda SM, Pence BW. The effectiveness of depression management for improving HIV care outcomes in Malawi: protocol for a quasi-experimental study. BMC Public Health. 2019 Jun 26;19(1):827. doi: 10.1186/s12889-019-7132-3.'}, {'ReferencePMID': '30064418', 'ReferenceType': 'derived', 'ReferenceCitation': 'Udedi M, Stockton MA, Kulisewa K, Hosseinipour MC, Gaynes BN, Mphonda SM, Mwagomba BM, Mazenga AC, Pence BW. Integrating depression management into HIV primary care in central Malawi: the implementation of a pilot capacity building program. BMC Health Serv Res. 2018 Jul 31;18(1):593. doi: 10.1186/s12913-018-3388-z.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16833', 'ConditionBrowseLeafName': 'HIV Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2103', 'ConditionBrowseLeafName': 'Acquired Immunodeficiency Syndrome', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}]}}}}}, {'Rank': 49, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00183547', 'OrgStudyIdInfo': {'OrgStudyId': 'R34MH071300', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH071300&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R34MH071300', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH071300&Fy=all'}, {'SecondaryId': 'DSIR 84-CTP'}]}, 'Organization': {'OrgFullName': 'Johns Hopkins University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Depression Prevention Program for American Indian Adolescents During and After Pregnancy', 'OfficialTitle': 'Depression Prevention in Pregnant American Indian Teens Using CBT'}, 'StatusModule': {'StatusVerifiedDate': 'December 2008', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2005'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2007', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 2007'}, 'StudyFirstSubmitDate': 'September 13, 2005', 'StudyFirstSubmitQCDate': 'September 13, 2005', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 16, 2005', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'May 28, 2013', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 29, 2013', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyOldNameTitle': 'Golda Ginsburg, PhD', 'ResponsiblePartyOldOrganization': 'Johns Hopkins Center for American Indian Health'}, 'LeadSponsor': {'LeadSponsorName': 'Johns Hopkins University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'This study will determine the effectiveness of the \"Living in Harmony\" depression prevention program in preventing depressive symptoms among pregnant American Indian adolescents during pregnancy and after giving birth.', 'DetailedDescription': 'Pregnancy among reservation-based American Indian adolescents has become increasingly common. Numerous psychosocial and environmental factors have put this population at high risk for pregnancy-related depression. Depression during pregnancy and after giving birth is associated with reduced quality of life for both young mothers and their children. Many reservations lack mental health services; therefore, an inexpensive intervention is needed to prevent depressive symptoms among pregnant adolescents who live on reservations.\\n\\nThe duration of this study will vary for each participant, depending on the time of study entry. Participants will be randomly assigned to receive weekly sessions of either the \"Living in Harmony\" program, consisting of cognitive behavioral therapy (CBT), culturally-relevant education, and support; or general depression-prevention education and support. Participants\\' depressive symptoms will be assessed at study entry, at 4, 12, and 24 weeks after giving birth, and study completion. Interviews and self-report scales will be used to assess participants.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression', 'Pregnancy']}, 'KeywordList': {'Keyword': ['Postpartum Depression', 'Postpartum Period', 'Indians, North American', 'Adolescent', 'Female', 'CBT']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '45'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '1', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': '\"Living in Harmony\" depression prevention program', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: \"Living in Harmony\" depression prevention program']}}, {'ArmGroupLabel': '2', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Depression-prevention education and support', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression-prevention education and support']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': '\"Living in Harmony\" depression prevention program', 'InterventionDescription': 'Weekly therapy sessions consisting of cognitive behavioral therapy (CBT), culturally-relevant education, and support', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Depression-prevention education and support', 'InterventionDescription': 'Weekly therapy sessions offering general depression-prevention education and support', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Postpartum depression', 'PrimaryOutcomeTimeFrame': 'up to 24 weeks postpartum'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAt 28th week or earlier of pregnancy\\nCenter for Epidemiologic Studies-Depression Scale (CES-D) score of 16 or higher\\nIdentified (by others and by self) as an American Indian\\nCurrently live on an American Indian reservation\\nParent or guardian willing to give consent, if applicable\\nWilling and able to comply with all study requirements\\n\\nExclusion Criteria:\\n\\nDiagnosis of major depressive disorder\\nCurrent psychiatric disorder or condition requiring intervention or treatment\\nCurrent participation in another mental or behavioral health study', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Female', 'MinimumAge': '15 Years', 'MaximumAge': '19 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Golda Ginsburg, PhD', 'OverallOfficialAffiliation': 'Johns Hopkins Center for American Indian Health', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Johns Hopkins Center for American Indian Health', 'LocationCity': 'Whiteriver', 'LocationState': 'Arizona', 'LocationZip': '85941', 'LocationCountry': 'United States'}, {'LocationFacility': 'Johns Hopkins Center for American Indian Health', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21205', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M19660', 'ConditionBrowseLeafName': 'Depression, Postpartum', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}}}}, {'Rank': 50, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01896349', 'OrgStudyIdInfo': {'OrgStudyId': 'TIP-120288'}, 'Organization': {'OrgFullName': 'Hospital de Clinicas de Porto Alegre', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Interpersonal Psychotherapy for Treatment Resistant Depression', 'OfficialTitle': 'Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression'}, 'StatusModule': {'StatusVerifiedDate': 'July 2013', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2013'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2014', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'November 2014', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 1, 2013', 'StudyFirstSubmitQCDate': 'July 10, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 11, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 10, 2013', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 11, 2013', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Hospital de Clinicas de Porto Alegre', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to determine whether combination of antidepressant drugs plus interpersonal psychotherapy is superior to antidepressant drugs alone in treatment resistant depression.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Treatment Resistant Depression']}, 'KeywordList': {'Keyword': ['Psychotherapy, Treatment Resistant Depression, depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '74', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'IPT+antidepressant drugs', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Interpersonal Psychotherapy protocol (IPT) consist of 16 sessions of manualized interpersonal psychotherapy for depression. Patients are allowed to reschedule 3 sessions if they miss their appointments.\\n\\nAntidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetin, citalopram, escitalopram, fluvoxamine, venlafaxin, duloxetin, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: IPT+ antidepressant drugs', 'Drug: fluoxetine', 'Drug: sertraline', 'Drug: paroxetine', 'Drug: Citalopram', 'Drug: escitalopram', 'Drug: fluvoxamine', 'Drug: Venlafaxine', 'Drug: Duloxetine', 'Drug: Bupropion', 'Drug: Lithium', 'Drug: Risperidone', 'Drug: tranylcypromine', 'Drug: Imipramine', 'Drug: amitriptyline', 'Drug: Clomipramine', 'Drug: nortriptyline', 'Drug: trazodone', 'Drug: Mirtazapine', 'Drug: sulpiride']}}, {'ArmGroupLabel': 'Antidepressant Drugs', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice.\\n\\nAntidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, venlafaxine, duloxetine, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: fluoxetine', 'Drug: sertraline', 'Drug: paroxetine', 'Drug: Citalopram', 'Drug: escitalopram', 'Drug: fluvoxamine', 'Drug: Venlafaxine', 'Drug: Duloxetine', 'Drug: Bupropion', 'Drug: Lithium', 'Drug: Risperidone', 'Drug: tranylcypromine', 'Drug: Imipramine', 'Drug: amitriptyline', 'Drug: Clomipramine', 'Drug: nortriptyline', 'Drug: trazodone', 'Drug: Mirtazapine', 'Drug: sulpiride']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'IPT+ antidepressant drugs', 'InterventionDescription': '16 sessions of interpersonal psychotherapy plus antidepressant drugs.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['IPT+antidepressant drugs']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Interpersonal Psychotherapy', 'Antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'fluoxetine', 'InterventionDescription': 'Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'sertraline', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'paroxetine', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'Citalopram', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'escitalopram', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'fluvoxamine', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'Venlafaxine', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'Duloxetine', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'Bupropion', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'Lithium', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'Risperidone', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'tranylcypromine', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'Imipramine', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'amitriptyline', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'Clomipramine', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'nortriptyline', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'trazodone', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'Mirtazapine', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}, {'InterventionType': 'Drug', 'InterventionName': 'sulpiride', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs', 'IPT+antidepressant drugs']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Hamilton Depression Scale (HAM-D) - continuous', 'PrimaryOutcomeDescription': 'Score change on Hamilton depression scale from baseline to week 19 and to week 24', 'PrimaryOutcomeTimeFrame': 'End point week 19 and Week 24'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Beck depression Inventory (BDI)', 'SecondaryOutcomeDescription': 'Score change on Beck depression inventory from baseline to week 19 and to week 24', 'SecondaryOutcomeTimeFrame': 'End point week 19 and Week 24'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Clinical Global Impression - Severity Scale (CGI-S) / dichotomous', 'OtherOutcomeTimeFrame': 'Endpoint (week-19) and week 24'}, {'OtherOutcomeMeasure': 'Whoqol brief - World Health Organization Quality of Life Instrument - Short version - Brazilian version', 'OtherOutcomeDescription': 'Score change in Whoqol-breef from baseline to week 19 and week 24', 'OtherOutcomeTimeFrame': 'Endpoint week 19 and week 24'}, {'OtherOutcomeMeasure': 'Biological measures - BDFN, TBARS, TNF-alfa, IL-1, IL-6', 'OtherOutcomeDescription': 'A blood sample will be collected at baseline, week 19 and week 24. Change in serum biomarkers will be evaluated - BDFN (Brain derived neurotrophic factor), TBARS (thiobarbituric acid reactive substance), TNF-alfa (tumor necrosis factor alfa), IL-1 (interleukin-1), IL-6 (interlekin-6) before and after treatment.', 'OtherOutcomeTimeFrame': 'End point week 19 and Week 24'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPrimary diagnose of unipolar treatment resistant depression\\n\\nExclusion Criteria:\\n\\nPatients diagnose of: bipolar disorder, psychosis, high suicide risk, Intellectual disability, illicit drug dependence.\\nCurrently in or having received psychotherapy in the last 4 weeks', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Livia H Souza, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+55 51 98658701', 'CentralContactEMail': 'liviahartmanndesouza@gmail.com'}, {'CentralContactName': 'Marcelo PA Fleck, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+55 51 33598294', 'CentralContactEMail': 'mfleck.voy@terra.com.br'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Marcelo PA Fleck, MD,PhD', 'OverallOfficialAffiliation': 'Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA)', 'LocationStatus': 'Recruiting', 'LocationCity': 'Porto Alegre', 'LocationState': 'RS', 'LocationZip': '90035-003', 'LocationCountry': 'Brazil', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lívia H Souza, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+55 5198658701', 'LocationContactEMail': 'livia.hs@terra.com.br'}, {'LocationContactName': 'Marcelo PA Fleck, MD, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+55 51 33598294', 'LocationContactEMail': 'mfleck.voy@terra.com.br'}, {'LocationContactName': 'Lívia H Souza, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Marcelo PA Fleck, MD, PhD', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Marco Antonio K Caldieraro, MD, MSc', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Lucas Spanemberg, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Edgar A Vares, MD', 'LocationContactRole': 'Sub-Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26799332', 'ReferenceType': 'derived', 'ReferenceCitation': 'Souza LH, Salum GA, Mosqueiro BP, Caldieraro MA, Guerra TA, Fleck MP. Interpersonal psychotherapy as add-on for treatment-resistant depression: A pragmatic randomized controlled trial. J Affect Disord. 2016 Mar 15;193:373-80. doi: 10.1016/j.jad.2016.01.004. Epub 2016 Jan 8.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000068736', 'InterventionMeshTerm': 'Duloxetine Hydrochloride'}, {'InterventionMeshId': 'D000000639', 'InterventionMeshTerm': 'Amitriptyline'}, {'InterventionMeshId': 'D000018967', 'InterventionMeshTerm': 'Risperidone'}, {'InterventionMeshId': 'C000015209', 'InterventionMeshTerm': 'Amitriptyline, perphenazine drug combination'}, {'InterventionMeshId': 'D000013469', 'InterventionMeshTerm': 'Sulpiride'}, {'InterventionMeshId': 'D000078785', 'InterventionMeshTerm': 'Mirtazapine'}, {'InterventionMeshId': 'D000014196', 'InterventionMeshTerm': 'Trazodone'}, {'InterventionMeshId': 'D000016666', 'InterventionMeshTerm': 'Fluvoxamine'}, {'InterventionMeshId': 'D000014191', 'InterventionMeshTerm': 'Tranylcypromine'}, {'InterventionMeshId': 'D000015283', 'InterventionMeshTerm': 'Citalopram'}, {'InterventionMeshId': 'D000016642', 'InterventionMeshTerm': 'Bupropion'}, {'InterventionMeshId': 'D000020280', 'InterventionMeshTerm': 'Sertraline'}, {'InterventionMeshId': 'D000005473', 'InterventionMeshTerm': 'Fluoxetine'}, {'InterventionMeshId': 'D000017374', 'InterventionMeshTerm': 'Paroxetine'}, {'InterventionMeshId': 'D000069470', 'InterventionMeshTerm': 'Venlafaxine Hydrochloride'}, {'InterventionMeshId': 'D000009661', 'InterventionMeshTerm': 'Nortriptyline'}, {'InterventionMeshId': 'D000007099', 'InterventionMeshTerm': 'Imipramine'}, {'InterventionMeshId': 'D000002997', 'InterventionMeshTerm': 'Clomipramine'}, {'InterventionMeshId': 'D000000928', 'InterventionMeshTerm': 'Antidepressive Agents'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000012702', 'InterventionAncestorTerm': 'Serotonin Antagonists'}, {'InterventionAncestorId': 'D000018490', 'InterventionAncestorTerm': 'Serotonin Agents'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000014150', 'InterventionAncestorTerm': 'Antipsychotic Agents'}, {'InterventionAncestorId': 'D000014149', 'InterventionAncestorTerm': 'Tranquilizing Agents'}, {'InterventionAncestorId': 'D000002492', 'InterventionAncestorTerm': 'Central Nervous System Depressants'}, {'InterventionAncestorId': 'D000011619', 'InterventionAncestorTerm': 'Psychotropic Drugs'}, {'InterventionAncestorId': 'D000018492', 'InterventionAncestorTerm': 'Dopamine Antagonists'}, {'InterventionAncestorId': 'D000015259', 'InterventionAncestorTerm': 'Dopamine Agents'}, {'InterventionAncestorId': 'D000017367', 'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'}, {'InterventionAncestorId': 'D000014179', 'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'}, {'InterventionAncestorId': 'D000049990', 'InterventionAncestorTerm': 'Membrane Transport Modulators'}, {'InterventionAncestorId': 'D000018687', 'InterventionAncestorTerm': 'Antidepressive Agents, Second-Generation'}, {'InterventionAncestorId': 'D000018373', 'InterventionAncestorTerm': 'Peripheral Nervous System Agents'}, {'InterventionAncestorId': 'D000018765', 'InterventionAncestorTerm': 'Dopamine Uptake Inhibitors'}, {'InterventionAncestorId': 'D000065690', 'InterventionAncestorTerm': 'Cytochrome P-450 CYP2D6 Inhibitors'}, {'InterventionAncestorId': 'D000065607', 'InterventionAncestorTerm': 'Cytochrome P-450 Enzyme Inhibitors'}, {'InterventionAncestorId': 'D000004791', 'InterventionAncestorTerm': 'Enzyme Inhibitors'}, {'InterventionAncestorId': 'D000068760', 'InterventionAncestorTerm': 'Serotonin and Noradrenaline Reuptake Inhibitors'}, {'InterventionAncestorId': 'D000000700', 'InterventionAncestorTerm': 'Analgesics'}, {'InterventionAncestorId': 'D000018689', 'InterventionAncestorTerm': 'Sensory System Agents'}, {'InterventionAncestorId': 'D000006634', 'InterventionAncestorTerm': 'Histamine H1 Antagonists'}, {'InterventionAncestorId': 'D000006633', 'InterventionAncestorTerm': 'Histamine Antagonists'}, {'InterventionAncestorId': 'D000018494', 'InterventionAncestorTerm': 'Histamine Agents'}, {'InterventionAncestorId': 'D000014151', 'InterventionAncestorTerm': 'Anti-Anxiety Agents'}, {'InterventionAncestorId': 'D000058669', 'InterventionAncestorTerm': 'Adrenergic alpha-2 Receptor Antagonists'}, {'InterventionAncestorId': 'D000000317', 'InterventionAncestorTerm': 'Adrenergic alpha-Antagonists'}, {'InterventionAncestorId': 'D000018674', 'InterventionAncestorTerm': 'Adrenergic Antagonists'}, {'InterventionAncestorId': 'D000018663', 'InterventionAncestorTerm': 'Adrenergic Agents'}, {'InterventionAncestorId': 'D000058830', 'InterventionAncestorTerm': 'Serotonin 5-HT2 Receptor Antagonists'}, {'InterventionAncestorId': 'D000058831', 'InterventionAncestorTerm': 'Serotonin 5-HT3 Receptor Antagonists'}, {'InterventionAncestorId': 'D000000929', 'InterventionAncestorTerm': 'Antidepressive Agents, Tricyclic'}, {'InterventionAncestorId': 'D000018712', 'InterventionAncestorTerm': 'Analgesics, Non-Narcotic'}, {'InterventionAncestorId': 'D000018759', 'InterventionAncestorTerm': 'Adrenergic Uptake Inhibitors'}, {'InterventionAncestorId': 'D000065609', 'InterventionAncestorTerm': 'Cytochrome P-450 CYP1A2 Inhibitors'}, {'InterventionAncestorId': 'D000065689', 'InterventionAncestorTerm': 'Cytochrome P-450 CYP2C19 Inhibitors'}, {'InterventionAncestorId': 'D000008996', 'InterventionAncestorTerm': 'Monoamine Oxidase Inhibitors'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16566', 'InterventionBrowseLeafName': 'Citalopram', 'InterventionBrowseLeafAsFound': 'Citalopram', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M17596', 'InterventionBrowseLeafName': 'Bupropion', 'InterventionBrowseLeafAsFound': 'Bupropion', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M299', 'InterventionBrowseLeafName': 'Duloxetine Hydrochloride', 'InterventionBrowseLeafAsFound': 'Duloxetine', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M17618', 'InterventionBrowseLeafName': 'Fluvoxamine', 'InterventionBrowseLeafAsFound': 'Fluvoxamine', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M5687', 'InterventionBrowseLeafName': 'Dexetimide', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19583', 'InterventionBrowseLeafName': 'Risperidone', 'InterventionBrowseLeafAsFound': 'Risperidone', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M18237', 'InterventionBrowseLeafName': 'Paroxetine', 'InterventionBrowseLeafAsFound': 'Paroxetine', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M15533', 'InterventionBrowseLeafName': 'Trazodone', 'InterventionBrowseLeafAsFound': 'Trazodone', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2558', 'InterventionBrowseLeafName': 'Amitriptyline', 'InterventionBrowseLeafAsFound': 'Amitriptyline', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M191786', 'InterventionBrowseLeafName': 'Amitriptyline, perphenazine drug combination', 'InterventionBrowseLeafAsFound': 'Amitriptyline', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M17605', 'InterventionBrowseLeafName': 'Lithium Carbonate', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20684', 'InterventionBrowseLeafName': 'Sertraline', 'InterventionBrowseLeafAsFound': 'Sertraline', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M7184', 'InterventionBrowseLeafName': 'Fluoxetine', 'InterventionBrowseLeafAsFound': 'Fluoxetine', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M439', 'InterventionBrowseLeafName': 'Venlafaxine Hydrochloride', 'InterventionBrowseLeafAsFound': 'Venlafaxine', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M11180', 'InterventionBrowseLeafName': 'Nortriptyline', 'InterventionBrowseLeafAsFound': 'Nortriptyline', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2828', 'InterventionBrowseLeafName': 'Antidepressive Agents', 'InterventionBrowseLeafAsFound': 'Antidepressant Drug', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2007', 'InterventionBrowseLeafName': 'Mirtazapine', 'InterventionBrowseLeafAsFound': 'Mirtazapine', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M8730', 'InterventionBrowseLeafName': 'Imipramine', 'InterventionBrowseLeafAsFound': 'Imipramine', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M15528', 'InterventionBrowseLeafName': 'Tranylcypromine', 'InterventionBrowseLeafAsFound': 'Tranylcypromine', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M14835', 'InterventionBrowseLeafName': 'Sulpiride', 'InterventionBrowseLeafAsFound': 'Sulpiride', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M4812', 'InterventionBrowseLeafName': 'Clomipramine', 'InterventionBrowseLeafAsFound': 'Clomipramine', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M12037', 'InterventionBrowseLeafName': 'Perphenazine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M14095', 'InterventionBrowseLeafName': 'Serotonin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M15487', 'InterventionBrowseLeafName': 'Antipsychotic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M13057', 'InterventionBrowseLeafName': 'Psychotropic Drugs', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M6056', 'InterventionBrowseLeafName': 'Dopamine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19180', 'InterventionBrowseLeafName': 'Dopamine Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M16545', 'InterventionBrowseLeafName': 'Dopamine Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M18232', 'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M29124', 'InterventionBrowseLeafName': 'Cytochrome P-450 Enzyme Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M11158', 'InterventionBrowseLeafName': 'Norepinephrine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M305', 'InterventionBrowseLeafName': 'Serotonin and Noradrenaline Reuptake Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2613', 'InterventionBrowseLeafName': 'Analgesics', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8293', 'InterventionBrowseLeafName': 'Histamine H1 Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8291', 'InterventionBrowseLeafName': 'Histamine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M219111', 'InterventionBrowseLeafName': 'Histamine phosphate', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8292', 'InterventionBrowseLeafName': 'Histamine Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M15488', 'InterventionBrowseLeafName': 'Anti-Anxiety Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19330', 'InterventionBrowseLeafName': 'Adrenergic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2250', 'InterventionBrowseLeafName': 'Adrenergic alpha-Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19339', 'InterventionBrowseLeafName': 'Adrenergic Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M27833', 'InterventionBrowseLeafName': 'Serotonin 5-HT3 Receptor Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2829', 'InterventionBrowseLeafName': 'Antidepressive Agents, Tricyclic', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19370', 'InterventionBrowseLeafName': 'Analgesics, Non-Narcotic', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M10543', 'InterventionBrowseLeafName': 'Monoamine Oxidase Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr', 'InterventionBrowseBranchName': 'Psychotropic Drugs'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Analg', 'InterventionBrowseBranchName': 'Analgesics'}, {'InterventionBrowseBranchAbbrev': 'CNSDep', 'InterventionBrowseBranchName': 'Central Nervous System Depressants'}, {'InterventionBrowseBranchAbbrev': 'AnDyAg', 'InterventionBrowseBranchName': 'Anti-Dyskinesia Agents'}, {'InterventionBrowseBranchAbbrev': 'CaAg', 'InterventionBrowseBranchName': 'Cardiotonic Agents'}, {'InterventionBrowseBranchAbbrev': 'VaCoAg', 'InterventionBrowseBranchName': 'Vasoconstrictor Agents'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000061218', 'ConditionMeshTerm': 'Depressive Disorder, Treatment-Resistant'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M28370', 'ConditionBrowseLeafName': 'Depressive Disorder, Treatment-Resistant', 'ConditionBrowseLeafAsFound': 'Treatment Resistant Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 51, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01341925', 'OrgStudyIdInfo': {'OrgStudyId': '2011H0033'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R34MH085875-01A2', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R34MH085875-01A2&Fy=all'}]}, 'Organization': {'OrgFullName': 'Ohio State University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Omega-3 and Therapy Study for Depression', 'OfficialTitle': 'Omega-3 Fatty Acids & Psychoeducational Psychotherapy for Childhood Depression', 'Acronym': 'OATS'}, 'StatusModule': {'StatusVerifiedDate': 'March 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2011'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2014', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 2014', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 22, 2011', 'StudyFirstSubmitQCDate': 'April 25, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 26, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 4, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 8, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator', 'ResponsiblePartyInvestigatorFullName': 'L. Eugene Arnold', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Ohio State University'}, 'LeadSponsor': {'LeadSponsorName': 'L. Eugene Arnold', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Childhood depression warrants treatment research; including pharmacological and psychotherapeutic interventions. A recent study found fluoxetine to be the only medication with empirical support for decreasing depression in children, but concerns about treatment-emergent suicidal ideation/behavior led the FDA to mandate black-box warning for use of antidepressants in this age group (Bridge et al, 2007). These worries have prompted interest in alternative therapies including dietary supplements such as omega-3 fatty acids (Ω3).\\n\\nThe current study compares Ω3, psychoeducational psychotherapy (PEP), and their combination to a placebo supplement and active monitoring (AM) in a 12-week trial of 60 children with unipolar depression. Primary goals are to determine: 1) feasibility of a) recruiting 60 participants in 24 months; b) retaining participants over a 12-week trial; and 2) effect sizes for Ω3, PEP, and combination treatment. Secondary goals are to explore response curves over time, mediators and moderators, treatment response across an array of outcome variables, adherence to treatment, and side effects. This pilot study of Ω3, PEP, and combined treatment will provide evidence about whether a larger trial is feasible and justifiable.', 'DetailedDescription': 'Approximately 2 to 4% of children experience either major depressive disorder or dysthymic disorder and 5 to 10% of children and adolescents experience subsyndromal depressive symptoms (Birmaher et al). Due to its prevalence and association with significant functioning deficits, childhood depression warrants treatment research. Treatments include pharmacological and psychotherapeutic interventions. A recent meta-analysis found fluoxetine to be the only medication with empirical support for decreasing depression in children, but concerns about treatment-emergent suicidal ideation/behavior led the FDA to mandate black-box warning for use of antidepressants in this age group (Bridge et al, 2007). These worries have prompted interest in alternative therapies including dietary supplements such as omega-3 fatty acids (Ω3). Research on treatment of mood disorders with Ω3 is promising (Schacter et al, 2005); however, only one RCT has been conducted in children, which was positive (Nemets et al, 2006). Findings from other clinical populations (ADHD, adolescent depression, anxiety and pervasive developmental disorders in children) suggest combination treatments are advantageous (Aman et al., 2009; The MTA Cooperative Group, 1999, 2004; The TADS Team, 2007; Walkup et al., 2008). Little is known about the effectiveness of psychotherapy for children age 12 and under who are clinically depressed. Researchers are beginning to develop and test manual-based individual/family therapies for clinic-referred children with diagnosable depression (Kovacs et al, 2006; Tompson et al, 2007); however, no RCTs have been completed. Prior research supports incorporating psychoeducation about depression, support, and skill building to decrease depressive symptoms (Birmaher et al).\\n\\nThe current study compares Ω3, psychoeducational psychotherapy (PEP), and their combination to a placebo supplement and active monitoring (AM) in a 12-week trial of 60 children with unipolar depression. Primary goals are to determine: 1) feasibility of a) recruiting 60 participants in 24 months; b) retaining participants over a 12-week trial; and 2) effect sizes for Ω3, PEP, and combination treatment. Secondary goals are to explore response curves over time, mediators and moderators, treatment response across an array of outcome variables, adherence to treatment, and side effects. This pilot study of Ω3, PEP, and combined treatment will provide evidence about whether a larger trial is feasible and justifiable.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['childhood depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Factorial Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Quadruple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider', 'Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '73', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Placebo Supplement and No PEP', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Placebo']}}, {'ArmGroupLabel': 'Omega-3 and PEP', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.\\n\\nPsychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Omega-3 Supplementation', 'Behavioral: Psychoeducational Psychotherapy (PEP)']}}, {'ArmGroupLabel': 'Omega-3 and No PEP', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Omega-3 Supplementation']}}, {'ArmGroupLabel': 'Placebo Supplement and PEP', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.\\n\\nPsychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Psychoeducational Psychotherapy (PEP)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Omega-3 Supplementation', 'InterventionDescription': 'The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Omega-3 and No PEP', 'Omega-3 and PEP']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Omega Brite']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Psychoeducational Psychotherapy (PEP)', 'InterventionDescription': \"Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Omega-3 and PEP', 'Placebo Supplement and PEP']}, 'InterventionOtherNameList': {'InterventionOtherName': ['IF-PEP']}}, {'InterventionType': 'Other', 'InterventionName': 'Placebo', 'InterventionDescription': 'The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo Supplement and No PEP']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Pbo']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Childhood Depression Rating Scale - Revised (CDRS-R)', 'PrimaryOutcomeDescription': 'The CDRS-R is a severity scale for depression in children ages 6-17. It has 21 items, each rated on a 1-5 or 1-7 point scale in the direction of increasing severity. Scores can range from 17 to 113, demonstrated to correlate significantly with clinical global ratings of depression and to differentiate clinically defined groups of children. Interrater reliability is adequate (r =.86), as is test-retest reliability over a 4 week interval (r =.81; Poznanski et al, 1984). The CDRS-R will be completed at screen to determine clinical impairment of depressive symptoms necessary for study eligibility and at each subsequent assessment to determine clinical response.', 'PrimaryOutcomeTimeFrame': 'Week prior to randomization and then weeks 2, 4, 6, 9, and 12 post-randomization'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'K-SADS Depression Rating Scale (KDRS)', 'SecondaryOutcomeDescription': 'Depressive symptom severity for worst past episode(s) and current episode (past two weeks) will be assessed using the KDRS at the assessment visits. The KDRS is a 12-item semi-structured interview with depression symptoms rated on a 6-point scale from none to severe. The KDRS has been shown to be a reliable measure of symptom severity.', 'SecondaryOutcomeTimeFrame': 'Week prior to randomization and then weeks 2, 4, 6, 9, and 12 post-randomization'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\naged 7-14 years (boys and girls)\\nDSM-IV-TR diagnosis of major depressive disorder and/or dysthymic disorder as determined by consensus conference\\nChildren\\'s Depression Rating Scale (CDRS-R) score ≥ 40\\nfull scale IQ ≥ 70\\nchild and at least one parent must be able to complete all assessments\\nchild must be able to swallow capsules (training in swallowing will be offered)\\nparent/guardian and child must be willing to have blood drawn from child at two study assessments.\\n\\nExclusion Criteria:\\n\\nmajor medical disorders (eg diabetes, epilepsy, metabolic disorder)\\ninability to communicate in English\\nlack of access via phone\\nautism\\nschizophrenia, or other psychotic states warranting anti-psychotic medication\\nDSM-IV-TR diagnosis of a bipolar disorder\\nactive suicidal concern (e.g., \"I want to kill myself\", a plan for suicide, or an attempt in the past month; however, passive suicidal ideation, such as \"I wish I were dead\" would not exclude)\\nintake in the previous 4 weeks of supplemental Ω3 fatty acids.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '7 Years', 'MaximumAge': '14 Years', 'StdAgeList': {'StdAge': ['Child']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'L E Arnold, MD, MEd', 'OverallOfficialAffiliation': 'Ohio State University', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Mary A Fristad, PhD', 'OverallOfficialAffiliation': 'Ohio State University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Ohio State University Medical Center - Harding Hospital', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43210', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28379964', 'ReferenceType': 'derived', 'ReferenceCitation': 'Christian LM, Young AS, Mitchell AM, Belury MA, Gracious BL, Arnold LE, Fristad MA. Body weight affects ω-3 polyunsaturated fatty acid (PUFA) accumulation in youth following supplementation in post-hoc analyses of a randomized controlled trial. PLoS One. 2017 Apr 5;12(4):e0173087. doi: 10.1371/journal.pone.0173087. eCollection 2017.'}, {'ReferencePMID': '27604240', 'ReferenceType': 'derived', 'ReferenceCitation': 'Young AS, Arnold LE, Wolfson HL, Fristad MA. Psychoeducational Psychotherapy and Omega-3 Supplementation Improve Co-Occurring Behavioral Problems in Youth with Depression: Results from a Pilot RCT. J Abnorm Child Psychol. 2017 Jul;45(5):1025-1037. doi: 10.1007/s10802-016-0203-3.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T415', 'InterventionBrowseLeafName': 'Omega 3 Fatty Acid', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Ot', 'InterventionBrowseBranchName': 'Other Dietary Supplements'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 52, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01200901', 'OrgStudyIdInfo': {'OrgStudyId': 'Nelson AZ-IIT'}, 'Organization': {'OrgFullName': 'University of Cincinnati', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Quetiapine in Melancholic Depression', 'OfficialTitle': 'Quetiapine in Melancholic Depression: an fMRI Study of Treatment-induced Changes in the Neurocircuitry of the Stress Response'}, 'StatusModule': {'StatusVerifiedDate': 'January 2013', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2008'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 2012', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'September 7, 2010', 'StudyFirstSubmitQCDate': 'September 13, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 14, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 16, 2013', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 18, 2013', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Erik Nelson', 'ResponsiblePartyInvestigatorTitle': 'Adjunct Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'University of Cincinnati'}, 'LeadSponsor': {'LeadSponsorName': 'University of Cincinnati', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'In summary, the investigators propose to integrate fMRI assessments within a clinical trial of quetiapine XR in patients with melancholic depression in order to test the predictions that:\\n\\nquetiapine XR treatment will be effective and safe for patients with major depression with melancholic features\\nsuccessful treatment with quetiapine XR will be associated with normalization of limbic areas associated with increased salivary cortisol response to a stressful task as well as normalization on the emotional faces task differences in the melancholic group compared with healthy volunteers.\\nsuccessful treatment with quetiapine XR will be associated with normalization of the salivary cortisol response to the stressful math task (i.e. there will be a diminished post-treatment mean AUC for cortisol secretion after the stress task compared to the pre-treatment AUC values in the patient group)', 'DetailedDescription': 'Patients with major depression (N=20) will be recruited for the 8-week clinical trial of quetiapine XR 100 - 300 mg (flexible dosing). Patients who consent to participate will be referred for an initial fMRI scanning session prior to the initiation of quetiapine XR. Baseline fMRI will be obtained during the index assessment prior to initiating quetiapine XR therapy and then will be re-acquired at the final study visit at 8 weeks (the time of scheduled visits). Ten demographically matched healthy subjects will receive the same fMRI investigations on two occasions in order to provide a healthy baseline comparison to permit interpretation of the patient findings (e.g., whether initial and final fMRI measures in patients are abnormal and to control for any adaptation to the task that may normally occur).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression', 'Healthy']}, 'KeywordList': {'Keyword': ['depression', 'healthy']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 4']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '20', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Melancolic depression patients', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients with major depression will be recruited for the 8-week clinical trial of quetiapine XR 100 - 300 mg (flexible dosing).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Quetiapine']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Quetiapine', 'InterventionDescription': 'quetiapine XR 100 - 300 mg (flexible dosing)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Melancolic depression patients']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Open Label Quetiapine']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'quetiapine XR treatment will be effective and safe for patients with major depression with melancholic features', 'PrimaryOutcomeDescription': 'Patients with major depression (N=20) will be recruited for the 8-week clinical trial of quetiapine XR 100 - 300 mg (flexible dosing). Patients who consent to participate will be referred for an initial fMRI scanning session prior to the initiation of quetiapine XR. Baseline fMRI will be obtained during the index assessment prior to initiating quetiapine XR therapy and then will be re-acquired at the final study visit at 8 weeks (the time of scheduled visits).', 'PrimaryOutcomeTimeFrame': '8 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'normalization of limbic areas associated with increased salivary cortisol response to a stressful task', 'SecondaryOutcomeDescription': 'successful treatment with quetiapine XR will be associated with normalization of limbic areas associated with increased salivary cortisol response to a stressful task as well as normalization on the emotional faces task differences in the melancholic group compared with healthy volunteers.', 'SecondaryOutcomeTimeFrame': '8 Weeks'}, {'SecondaryOutcomeMeasure': 'successful treatment with quetiapine XR will be associated with normalization of the salivary cortisol response to the stressful math task', 'SecondaryOutcomeTimeFrame': '8 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion criteria\\n\\nProvision of written informed consent\\nA diagnosis of major depression with melancholic features by Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV)\\nFemales and males aged 18-65 years\\nFemale patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin (HCG) test at enrollment\\nAble to understand and comply with the requirements of the study\\nSubjects will have a Hamilton Depression Rating Scale, 28-item version (HDRS-28) score of at least 20 at the baseline visit.\\n\\nExclusion criteria\\n\\nPregnancy or lactation\\nPatients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others\\nKnown intolerance or lack of response to quetiapine fumarate, as judged by the investigator\\nUse of any of the following cytochrome P450 3a4 inhibitors in the 14 days preceding enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir\\nUse of any of the following cytochrome P450 inducers in the 14 days preceding enrolment including, but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, and St. John's Wort.\\nAdministration of a depot antipsychotic injection within one dosing interval (for the depot) before randomisation Women using oral contraceptives or other medications that directly affect estrogen or progesterone system in the body.\\nSubjects taking corticosteroids or other medications that directly influence HPA axis function\\nSubjects with certain lifestyle habits (i.e. working night shift) that could affect the function of the HPA axis\\nHistory of substance dependence in the past year or meets criteria for a substance abuse disorder in the past three months.\\nMedical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment\\nUnstable or inadequately treated medical illness (e.g. diabetes, angina pectoris, hypertension) as judged by the investigator\\nParticipation in another drug trial within 4 weeks prior to enrollment into this study\\nAn absolute neutrophil count (ANC) of 1.5 x 109 per liter\\nPatients who have initiated a new psychotherapy or behavioral therapy from a mental health professional in the past 3 months\\nA lifetime DSM-IV history of a psychotic disorder, a bipolar disorder, or dementia.\\nHistory of psychosurgery\\nAxis II disorder\\nHistory of seizures, excluding febrile seizures in childhood.\\nClinically relevant abnormal laboratory results.\\nPatients who have received monoamine oxidase inhibitors, tricyclics, SSRIs, antipsychotics, or lithium within two weeks prior to randomization, or fluoxetine within four weeks prior to randomization.\\nElectroconvulsive therapy (ECT) within three months of start of study\\nHistory of mental retardation.\\nHistory of major neurological illness, including any history of significant head trauma.\\nContraindications to magnetic resonance imaging, including claustrophobia and/or the presence of ferrous material that might make an MRI scan hazardous.\\nPatients will be excluded from the study if they indicate at screening that they know someone who has previously participated in the study.\", 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Erik Nelson, MD', 'OverallOfficialAffiliation': 'University of Cincinnati', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Cincinnati', 'LocationCity': 'Cincinnati', 'LocationState': 'Ohio', 'LocationZip': '45219', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000069348', 'InterventionMeshTerm': 'Quetiapine Fumarate'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000928', 'InterventionAncestorTerm': 'Antidepressive Agents'}, {'InterventionAncestorId': 'D000011619', 'InterventionAncestorTerm': 'Psychotropic Drugs'}, {'InterventionAncestorId': 'D000014150', 'InterventionAncestorTerm': 'Antipsychotic Agents'}, {'InterventionAncestorId': 'D000014149', 'InterventionAncestorTerm': 'Tranquilizing Agents'}, {'InterventionAncestorId': 'D000002492', 'InterventionAncestorTerm': 'Central Nervous System Depressants'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M399', 'InterventionBrowseLeafName': 'Quetiapine Fumarate', 'InterventionBrowseLeafAsFound': 'Quetiapine', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2828', 'InterventionBrowseLeafName': 'Antidepressive Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M13057', 'InterventionBrowseLeafName': 'Psychotropic Drugs', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M15487', 'InterventionBrowseLeafName': 'Antipsychotic Agents', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'CNSDep', 'InterventionBrowseBranchName': 'Central Nervous System Depressants'}, {'InterventionBrowseBranchAbbrev': 'PsychDr', 'InterventionBrowseBranchName': 'Psychotropic Drugs'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 53, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01139060', 'OrgStudyIdInfo': {'OrgStudyId': '5R01MH082995', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=5R01MH082995&Fy=all'}, 'Organization': {'OrgFullName': 'Kaiser Permanente', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Organized Self-Management Support Services for Chronic Depression', 'OfficialTitle': 'Organized Self-Management Support Services for Chronic Depression', 'Acronym': 'Stride'}, 'StatusModule': {'StatusVerifiedDate': 'October 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2013', 'PrimaryCompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 4, 2010', 'StudyFirstSubmitQCDate': 'June 7, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 8, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 11, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 13, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Kaiser Permanente', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Swedish Medical Center', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': \"The purpose is to test the effectiveness of an organized care program for chronic or recurrent depression. Using a two-arm design, the investigators will randomly assign 300 participants with chronic or recurrent depression to one of two conditions: continued usual care (UC); or an 18-month organized treatment program focused on outreach and engagement, including a weekly group self-management training program, monthly visits with a psychotherapist (in-person or by telephone), and optional one-on-one visits with a peer support specialist. All intervention components are intended as adjuncts to any existing depression treatment (usually antidepressant medication) provided by participants' regular providers.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['chronic or recurrent depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '302', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': '18-month organized treatment program focused on outreach and engagement for chronic or recurrent depression', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: organized care program for chronic or recurrent depression']}}, {'ArmGroupLabel': 'Usual Care', 'ArmGroupType': 'No Intervention'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'organized care program for chronic or recurrent depression', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention Group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Evaluate the program's effectiveness, i.e., the effects of the intervention on patient outcomes (depressive symptoms, functional impairment, and disability/lost productivity) and process of care (self-efficacy and self-management behaviors)\", 'PrimaryOutcomeTimeFrame': '18 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Examination of moderators of treatment response', 'SecondaryOutcomeTimeFrame': '18 months'}, {'SecondaryOutcomeMeasure': \"An estimate of the program's costs and effect on the costs of treatment for depression\", 'SecondaryOutcomeTimeFrame': '18 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nall patients will meet criteria for recurrent major depression or dysthymia\\n\\nExclusion Criteria:\\n\\nbipolar disorder or psychotic disorder', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Evette Ludman, PhD', 'OverallOfficialAffiliation': 'Group Health Research Institute', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Group Health Research Insitute', 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationZip': '98101', 'LocationCountry': 'United States'}, {'LocationFacility': 'Swedish Cherry Hill Clinic', 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28726086', 'ReferenceType': 'derived', 'ReferenceCitation': 'Jones SMW, Ludman EJ. Factor Structure and Sensitivity to Change of the Recovery Assessment Scale. J Behav Health Serv Res. 2018 Oct;45(4):690-699. doi: 10.1007/s11414-017-9563-x.'}, {'ReferencePMID': '26278222', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ludman EJ, Simon GE, Grothaus LC, Richards JE, Whiteside U, Stewart C. Organized Self-Management Support Services for Chronic Depressive Symptoms: A Randomized Controlled Trial. Psychiatr Serv. 2016 Jan;67(1):29-36. doi: 10.1176/appi.ps.201400295. Epub 2015 Aug 17.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 54, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03116503', 'OrgStudyIdInfo': {'OrgStudyId': '16-HPNCL-01'}, 'Organization': {'OrgFullName': 'Fondation Lenval', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Bipolarity - Depression in Children and Adolescent Suicide Attempters: Better Diagnosis to Prevent Recurrence', 'OfficialTitle': 'Bipolarity - Depression in Children and Adolescent Suicide Attempters: Better Diagnosis to Prevent Recurrence'}, 'StatusModule': {'StatusVerifiedDate': 'April 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2016', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 21, 2017', 'StudyFirstSubmitQCDate': 'April 11, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 17, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 27, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 30, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Fondation Lenval', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of the study is to describe the number of diagnosis of bipolar depression and comorbid suicidal behavior according to the diagnostic criteria of the DSM-5.', 'DetailedDescription': 'This study is a prospective, routine care, covering pediatric population suicidal (who attempted suicide) and suicide (with suicidal ideas with planning) hospitalized in the pediatric hospital in Nice- Lenval Hospital.\\n\\nThe main objective of the study is to describe the number of diagnosis of bipolar depression and comorbid suicidal behavior according to the diagnostic criteria of the DSM-5.\\n\\nThe secondary objectives are: 1) comparison of the suicide attempt rate of recurrence at 6 months and 12 months among subjects with a diagnosis of mood disorder (depression or bipolar) and subjects with a diagnosis mood disorder; 2) the identification of specific suicidal recurrence risk factors in the diagnosis of mood disorder; 3) comparing the diagnostic evaluation field (ICD-10 criteria) vs standardized assessment (DSM-5 criteria).\\n\\nFor this the investigator propose an observational cohort study, single center, on a trailing 12 months after inclusion.\\n\\nThe topics are selected and included consecutively over a period of 12 months. The inclusion criteria are: 1) children - teenagers age: 6-18 years inclusive; 2) hospitalization for suicide attempt or suicidal ideation with planning in the Pediatric Hospital of Nice Lenval Hospital; 3) French patients; 4) speaking parents 5) affiliation to the social security system.\\n\\nThe criterion for inclusion is not the refusal or failure to realize the Kiddie - SADS with the subject and / or his parents.\\n\\nThe number of subjects to be included is estimated at 100. At baseline: standardized assessment of comorbid psychiatric diagnosis according to DSM-5 Mood disorders according to DSM-IV R criteria for other diagnoses. The investigatorwill use the KIDDIE-SADS, semi-structured interview for diagnostic purposes adapted to the DSM for that assessment.\\n\\nThe patients were distributed into two groups: mood disorder group - group without mood disorder.\\n\\nIn parallel, the field team evaluates blind psychiatric diagnosis according to ICD-10 criteria.\\n\\nThe population included subjects is described: clinicaly - demographic - overall operation - individual and family psychiatric history.\\n\\nThe topics included are reassessed at 6 months and 12 months. At 6 months: occurrence of an attempted suicide or recurrence of suicidal thoughts with planning - overall operation - clinical condition. At 12 months: re standardized diagnostic evaluation with KIDDIE-SADS and re identical clinical evaluation at 6 months.\\n\\nThe recidivism risk factors and recidivism rates are evaluated in both groups. The primary endpoint of the study is the attempt recurrence rate of suicide.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Suicide, Attempted']}, 'KeywordList': {'Keyword': ['Suicide']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignInterventionModelDescription': 'Describe the number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '58', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'bipolar disorder and comorbid depression', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: diagnosis of bipolar disorder and comorbid depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'diagnosis of bipolar disorder and comorbid depression', 'InterventionDescription': 'Evaluation of the number of diagnosis of bipolar disorder and comorbid depression', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['bipolar disorder and comorbid depression']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'diagnosis of bipolar disorder and comorbid depression', 'PrimaryOutcomeDescription': 'Describe the number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.', 'PrimaryOutcomeTimeFrame': 'At baseline during inclusion visit'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'recurrence rates', 'SecondaryOutcomeDescription': 'compare the recurrence rates at 6 and 12 months between bipolar and depressed patients and patients not diagnosed with a mood disorder', 'SecondaryOutcomeTimeFrame': 'comparison between 6 month and 12 month'}, {'SecondaryOutcomeMeasure': 'risk factors for suicidal recidivism', 'SecondaryOutcomeDescription': 'To compare the risk factors for suicidal recidivism between bipolar and depressed patients', 'SecondaryOutcomeTimeFrame': 'At baseline during inclusion visit'}, {'SecondaryOutcomeMeasure': 'comorbid diagnoses', 'SecondaryOutcomeDescription': 'Compare the comorbid diagnoses obtained by the standardized assessment (Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) for mood disorders and DSM-IVR for other diagnoses) vs. field assessment (CIM-10) (Classification internationale des maladies-10)', 'SecondaryOutcomeTimeFrame': 'At baseline during inclusion visit'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nhospitalized at Fondation Lenval/ pediatric hospital of Nice-CHU Lenval for suicide attempt and / or suicidal ideas with planning\\nFrench-speaking patient\\nFrancophone parents\\nAffiliation to asocial security system\\n\\nExclusion Criteria:\\n\\nRefusal or impossibility of carrying out the KIDDIE-SADS questionnaire', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '6 Years', 'MaximumAge': '18 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Nathalie DUGAND, MD', 'OverallOfficialAffiliation': 'Fondation Lenval', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Fondation Lenval, Hôpitaux pédiatriques de Nice CHU Lenval', 'LocationCity': 'Nice', 'LocationZip': '06200', 'LocationCountry': 'France'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000012008', 'ConditionMeshTerm': 'Recurrence'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000013405', 'ConditionMeshTerm': 'Suicide'}, {'ConditionMeshId': 'D000013406', 'ConditionMeshTerm': 'Suicide, Attempted'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000020969', 'ConditionAncestorTerm': 'Disease Attributes'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000016728', 'ConditionAncestorTerm': 'Self-Injurious Behavior'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M13433', 'ConditionBrowseLeafName': 'Recurrence', 'ConditionBrowseLeafAsFound': 'Recurrence', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14774', 'ConditionBrowseLeafName': 'Suicide', 'ConditionBrowseLeafAsFound': 'Suicide', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14775', 'ConditionBrowseLeafName': 'Suicide, Attempted', 'ConditionBrowseLeafAsFound': 'Suicide, Attempted', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21284', 'ConditionBrowseLeafName': 'Disease Attributes', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17672', 'ConditionBrowseLeafName': 'Self-Injurious Behavior', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 55, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02605278', 'OrgStudyIdInfo': {'OrgStudyId': 'PI14/00573'}, 'Organization': {'OrgFullName': 'Jordi Gol i Gurina Foundation', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Multicomponent Program for the Integrated Management of Chronic Pain and Depression in Primary Care', 'OfficialTitle': 'Assessment of a Multicomponent Program for the Integrated Management of Chronic Pain and Depression in Primary Care. Cluster Randomized Clinical Trial', 'Acronym': 'DROP'}, 'StatusModule': {'StatusVerifiedDate': 'September 2015', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2015'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2017', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2017', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'September 28, 2015', 'StudyFirstSubmitQCDate': 'November 13, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 16, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 13, 2015', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 16, 2015', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Jordi Gol i Gurina Foundation', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study evaluates whether the implementation of an integrated clinical program for chronic musculoskeletal pain and depression behave better clinical outcomes than the usual approach in primary care', 'DetailedDescription': 'Chronic musculoskeletal pain and depression are extremely common and relevant pathological conditions, and frequently presented as comorbid processes multiplying the impact on health, worsening the prognosis and complicating the care. The integrated management of both disorders is an opportunity to achieve better clinical outcomes.\\n\\nAIM: To determinate whether the implementation of an integrated clinical program for chronic musculoskeletal pain and depression behave better clinical outcomes than the usual approach in primary care\\n\\nMETHODS\\n\\nDesign: Cluster randomized clinical trials with two arms:\\n\\nIntervention: Integrated program for depression/chronic pain, and\\ncontrol usual care.\\n\\nSettings: Primary Care Centers in Tarragona, Spain. Patients: Adults with moderate/severe musculoskeletal pain (Brief Pain Inventory/pain intensity scale > 4 points), with more than three months of evolution and current diagnostic criteria for major depression episode (DSM-IV).\\n\\nSample: A total sample of 330 patients (165 control arm and 165 intervention arm) divided into 42 clusters of 8 patients. Cluster composition: patients registered with the same doctor.\\n\\nIntervention: Structured program with integrated management for depression/ pain with three main components:\\n\\nOptimized care of major depression,\\nCase Management, and\\nGroup psychoeducational intervention.\\n\\nMeasurements: \"Blind\" interviews at 0, 3, 6 and 12 months.\\n\\nMain outcomes:\\n\\nDepressive symptoms (Hopkins Symptom Checklist-20): Severity, response rate and remission rate.\\nPain symptoms (Brief Pain Inventory). Intensity and interference, response rate.\\nDisability by psychological problems (Sheehan Disability Inventory)\\nQuality of life related to health (EuroQol-5D).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depressive Disorder', 'Musculoskeletal Pain', 'Chronic Pain']}, 'KeywordList': {'Keyword': ['Primary Health Care, Patient Education, Care Managament']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '330', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Clinical program for pain and depression', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Structured program with integrated management for depression and chronic musculoskeletal pain with three main components: 1) Optimized care of major depression on the basis of a Clinical Guideline 2) Care Management, and 3) Group psychoeducational intervention.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Clinical program for pain and depression']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Care as usual', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Control']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Clinical program for pain and depression', 'InterventionDescription': 'Already described', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Clinical program for pain and depression']}, 'InterventionOtherNameList': {'InterventionOtherName': ['DROP Program (Depression and Pain)']}}, {'InterventionType': 'Other', 'InterventionName': 'Control', 'InterventionDescription': 'Care as usual', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression severity', 'PrimaryOutcomeDescription': 'Hopkins Symptoms Checklist-Depression HSCL-20', 'PrimaryOutcomeTimeFrame': '12 months'}, {'PrimaryOutcomeMeasure': 'Pain severity', 'PrimaryOutcomeDescription': 'Brief Pain Inventory BPI', 'PrimaryOutcomeTimeFrame': '12 months'}, {'PrimaryOutcomeMeasure': 'Health Related Quality of Life', 'PrimaryOutcomeDescription': 'EuroQol-5D', 'PrimaryOutcomeTimeFrame': '12 months'}, {'PrimaryOutcomeMeasure': 'Pain Interference', 'PrimaryOutcomeDescription': 'Brief Pain Inventory BPI', 'PrimaryOutcomeTimeFrame': '12 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depression severity', 'SecondaryOutcomeDescription': 'Hopkins Symptoms Checklist-Depression HSCL-20', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Depression severity', 'SecondaryOutcomeDescription': 'Hopkins Symptoms Checklist-Depression HSCL-20', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Pain severity', 'SecondaryOutcomeDescription': 'Brief Pain Inventory BPI', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Pain severity', 'SecondaryOutcomeDescription': 'Brief Pain Inventory BPI', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Health Related Quality of Life', 'SecondaryOutcomeDescription': 'EuroQol-5D', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Health Related Quality of Life', 'SecondaryOutcomeDescription': 'EuroQol-5D', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Pain Interference', 'SecondaryOutcomeDescription': 'Brief Pain Inventory BPI', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Pain Interference', 'SecondaryOutcomeDescription': 'Brief Pain Inventory BPI', 'SecondaryOutcomeTimeFrame': '6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nRegistered patient of a participant doctor\\nChronic musculoskeletal pain moderate to severe (BPI>4), with more than 3 months of duration despite having received analgesic treatment\\nMeeting the diagnostic criteria for major depression (DSM IV) at the time of recruitment.\\n\\nExclusion Criteria:\\n\\nPatients with mental, physical, language limitation or concurrent illness that prevents understanding/participation in the assessments of the study.\\nPatients with serious or terminal illness.\\nPatients whit psychotic disorder, bipolar disorder or dependence disorder.\\nPregnant or lactating patient\\nPatients diagnosed of fibromyalgia or somatization disorder\\nPatient in a process of claim for a work disability\\nIntervention for a joint prothesis planned forn next 12 months.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Enric Aragonès, MD, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '0034680766923', 'CentralContactEMail': 'earagones.tarte.ics@gencat.cat'}, {'CentralContactName': 'Germán López-Cortacans, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '0034627392500', 'CentralContactEMail': 'glopez.tarte.ics@gencat.cat'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Enric Aragonès, MD PhD', 'OverallOfficialAffiliation': 'IDIAP Jordi Gol', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'IDIAP Jordi Gol', 'LocationStatus': 'Recruiting', 'LocationCity': 'Barcelona', 'LocationZip': '08080', 'LocationCountry': 'Spain', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Mariona Pujol, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '003493 482 46 17', 'LocationContactEMail': 'mpujol@idiapjgol.org'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '30986737', 'ReferenceType': 'derived', 'ReferenceCitation': 'Aragonès E, Rambla C, López-Cortacans G, Tomé-Pires C, Sánchez-Rodríguez E, Caballero A, Miró J. Effectiveness of a collaborative care intervention for managing major depression and chronic musculoskeletal pain in primary care: A cluster-randomised controlled trial. J Affect Disord. 2019 Jun 1;252:221-229. doi: 10.1016/j.jad.2019.04.004. Epub 2019 Apr 8.'}, {'ReferencePMID': '27236335', 'ReferenceType': 'derived', 'ReferenceCitation': 'Aragonès E, López-Cortacans G, Caballero A, Piñol JL, Sánchez-Rodríguez E, Rambla C, Tomé-Pires C, Miró J. Evaluation of a multicomponent programme for the management of musculoskeletal pain and depression in primary care: a cluster-randomised clinical trial (the DROP study). BMC Psychiatry. 2016 Mar 16;16:69. doi: 10.1186/s12888-016-0772-2.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000059352', 'ConditionMeshTerm': 'Musculoskeletal Pain'}, {'ConditionMeshId': 'D000059350', 'ConditionMeshTerm': 'Chronic Pain'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000010146', 'ConditionAncestorTerm': 'Pain'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000012816', 'ConditionAncestorTerm': 'Signs and Symptoms'}, {'ConditionAncestorId': 'D000009135', 'ConditionAncestorTerm': 'Muscular Diseases'}, {'ConditionAncestorId': 'D000009140', 'ConditionAncestorTerm': 'Musculoskeletal Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M28029', 'ConditionBrowseLeafName': 'Chronic Pain', 'ConditionBrowseLeafAsFound': 'Chronic Pain', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M28031', 'ConditionBrowseLeafName': 'Musculoskeletal Pain', 'ConditionBrowseLeafAsFound': 'Musculoskeletal Pain', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11649', 'ConditionBrowseLeafName': 'Pain', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10987', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10675', 'ConditionBrowseLeafName': 'Muscular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10680', 'ConditionBrowseLeafName': 'Musculoskeletal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Muscle, Bone, and Cartilage Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}]}}}}}, {'Rank': 56, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02099305', 'OrgStudyIdInfo': {'OrgStudyId': '1-wilcox'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH095855', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH095855&Fy=all'}]}, 'Organization': {'OrgFullName': 'Johns Hopkins University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Randomized, School-based Effectiveness Trial of the Adolescent Depression Awareness Program', 'OfficialTitle': 'Impact of Increasing Adolescent Depression Literacy on Treatment-Seeking Behavior', 'Acronym': 'ADAP'}, 'StatusModule': {'StatusVerifiedDate': 'March 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2012'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'August 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 20, 2014', 'StudyFirstSubmitQCDate': 'March 25, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 28, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'June 8, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 12, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Holly C. wilcox', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Johns Hopkins University'}, 'LeadSponsor': {'LeadSponsorName': 'Johns Hopkins University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The primary goal of the proposed research is to assess the effectiveness of the Adolescent Depression Awareness Program (ADAP), a school-based depression education program, in increasing depression literacy and treatment seeking in high school students. The ADAP intervention will be carried out in approximately 60 schools with over 15,000 students. The following are ADAP Implementation Sites: Baltimore Archdiocese High Schools; New Castle County, Delaware; Washtenaw County, Michigan; and York County, Pennsylvania.', 'DetailedDescription': 'The primary goal of the proposed research is to assess the effectiveness of the Adolescent Depression Awareness Program (ADAP), a school-based depression education program, in increasing depression literacy and treatment seeking. This proposal will have broad reach as the intervention will be carried out in 66 schools with over 15,000 students.\\n\\nThe lifetime prevalence of Major Depressive Disorder (MDD) in the United States is high, ranging from 15% to 17%. Its usual symptom onset occurs early in life, during teen or young adult years. It has been estimated that 8.5% of youth ages 12 to 17 (over 2 million adolescents) experienced at least one Major Depressive Episode in the past year (SAMHSA Office of Applied Studies, 2008). Nearly half (48.3%) of these youth reported severe impairment in at least one of four major role domains (home, school/work, family relationships, or social life). The onset of depression during adolescence is associated with increased risks for educational underachievement, unemployment, early parenthood, substance dependence, anxiety disorders, and recurrent major depression during early adulthood (Fergusson & Woodward, 2002). The most severe consequence of untreated depression is suicide. Psychological autopsy studies of adolescent suicides have reported that upwards of 90% had at least one psychiatric disorder at the time of their death, most notably depression (Marttunen et al., 1990; Brent et al., 1993; Shaffer et al., 1996). From a developmental perspective, the prevention and treatment of depression during adolescence can provide lifelong benefits. Effective treatments for adolescent depression are available (TADS, 2007); however, adolescents in need of treatment are often not recognized by parents, teachers, or peers. The National Comorbidity Study-Replication estimated a median delay of 8 years between the onset of depressive symptoms and receiving treatment (Wang et al., 2006). The early identification of depression leading to effective treatment can help address the morbidity and mortality associated with adolescent depression.\\n\\nDespite the importance of adolescent depression, there have been few large-scale randomized trials investigating the effectiveness of universal interventions targeting depression among adolescents. ADAP is a 3-hour high school-based curriculum, proposed herein to be delivered as part of the standard high school health education curriculum, aimed at improving depression literacy. The mission of ADAP is to educate high school students, teachers, and parents about teenage unipolar and bipolar depression (Hess et al., 2004). The core message of ADAP is that \"depression is a treatable medical illness.\" ADAP was developed in 1999 by a team of psychiatrists and psychiatric nurses from the Johns Hopkins University School of Medicine. In the past decade, ADAP has been implemented in over 85 schools with over 20,000 students throughout the United States. Previously published research evaluating ADAP described a significant improvement in adolescents\\' knowledge about depression after receiving the curriculum using a one group pretest/posttest design (Swartz et al., 2008). Recently, in Tulsa, Oklahoma, comparison schools were included, and it was found that the proportion of students achieving \"depression literacy\" (scoring 80% or higher on our knowledge assessment) more than tripled from pretest to posttest (Leon et al., in review) in the ADAP group. To date, a randomized design has not been employed and the impact of ADAP on treatment seeking behaviors has not been studied. Both of these issues are important to address before ADAP can be routinely integrated into high school health education curricula. The specific aims of this proposal are as follows:\\n\\nSpecific Aim 1: To assess the effectiveness of ADAP, a school-based depression education program, in increasing depression literacy.\\n\\n1.1 To assess depression literacy changes following the intervention, as compared to the standard health education curriculum, with a post-test at 6 weeks post intervention.\\n\\n1.2 To assess the sustainability of depression literacy changes with a post-test at 4 months post ADAP.\\n\\nSpecific Aim 2: To assess whether the ADAP intervention, as compared to the standard health curriculum, has an influence on treatment seeking behaviors in high school students, as measured by an increase in visits to school counselors and self-reported treatment seeking.\\n\\n2.1 To track mental health help-seeking and the receipt of mental health services pre and post ADAP in a subset of schools (28 schools in York County Pennsylvania and St. Francis Indian School on the Rosebud Indian Reservation served by the Indian Health Service).\\n\\n2.2 To track mental health visits to school counselors in aggregate pre and post ADAP in all 66 participating schools.\\n\\nSpecific Aim 3: To identify possible mediators (e.g., fidelity) and moderators of intervention impact (e.g., access to community mental health services, teacher characteristics, school characteristics, parental participation in the community forum; stigma).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Adolescent - Emotional Problem', 'Depression', 'Prevention Harmful Effects']}, 'KeywordList': {'Keyword': ['Adolescent; Depression', 'Early intervention (education)', 'Randomized Controlled Trial', 'Primary Prevention', 'schools', 'Health Literacy', 'Discrimination (Psychology)', 'Mental Health Services']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Factorial Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '17000', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Receive Adolescent Depression Awareness Program (ADAP) intervention', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Adolescent Depression Awareness Program (ADAP)']}}, {'ArmGroupLabel': 'Wait list control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'no intervention'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Adolescent Depression Awareness Program (ADAP)', 'InterventionDescription': 'Depression education curriculum delivered by trained school health education teachers or other school personnel', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}, 'InterventionOtherNameList': {'InterventionOtherName': ['ADAP']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Adolescent Depression Knowledge Questionnaire (ADKQ)', 'PrimaryOutcomeDescription': 'The Adolescent Depression Knowledge Questionnaire (ADKQ) will be used to assess depression literacy', 'PrimaryOutcomeTimeFrame': 'Change from pretest (directly before intervention) to post-test (6 weeks after ADAP). We will see if this is sustained 4 months after ADAP.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Reported and Intended Behaviour Scale (RIBS)', 'SecondaryOutcomeDescription': 'The Reported and Intended Behaviour Scale (RIBS) will be used to assess mental health stigma.', 'SecondaryOutcomeTimeFrame': 'Change from pretest (directly before intervention) to post-test (6 weeks after ADAP). We will see if this is sustained 4 months after ADAP.'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Help-seeking and the receipt of Mental Health Services', 'OtherOutcomeDescription': 'We have designed a web-based survey in RedCAP to assess help-seeking and the receipt of Mental Health Services, barriers and attitudes, and other issues among students in York County, Pennsylvania with parental consent.', 'OtherOutcomeTimeFrame': 'after the ADAP intervention'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nenrolled in one of the participating schools parental consent and student assent is required for the web-based survey\\n\\nExclusion Criteria:\\n\\nnot enrolled in the participating schools', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '12 Years', 'MaximumAge': '18 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Holly C. Wilcox, PhD', 'OverallOfficialAffiliation': 'Associate Professor, Johns Hopkins School of Medicine', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Karen Swartz, MD', 'OverallOfficialAffiliation': 'Johns Hopkins School of Medicine', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Johns Hopkins University', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21205', 'LocationCountry': 'United States'}, {'LocationFacility': 'Johns Hopkins', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21205', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '23790814', 'ReferenceType': 'result', 'ReferenceCitation': 'Ruble AE, Leon PJ, Gilley-Hensley L, Hess SG, Swartz KL. Depression knowledge in high school students: effectiveness of the adolescent depression awareness program. J Affect Disord. 2013 Sep 25;150(3):1025-30. doi: 10.1016/j.jad.2013.05.033. Epub 2013 Jun 18.'}, {'ReferencePMID': '17652614', 'ReferenceType': 'result', 'ReferenceCitation': 'Swartz KL, Kastelic EA, Hess SG, Cox TS, Gonzales LC, Mink SP, DePaulo JR Jr. The effectiveness of a school-based adolescent depression education program. Health Educ Behav. 2010 Feb;37(1):11-22. Epub 2007 Jul 25.'}, {'ReferencePMID': '15625662', 'ReferenceType': 'result', 'ReferenceCitation': \"Hess SG, Cox TS, Gonzales LC, Kastelic EA, Mink SP, Rose LE, Swartz KL. A survey of adolescents' knowledge about depression. Arch Psychiatr Nurs. 2004 Dec;18(6):228-34.\"}, {'ReferencePMID': '30612807', 'ReferenceType': 'derived', 'ReferenceCitation': 'Townsend L, Musci R, Stuart E, Heley K, Beaudry MB, Schweizer B, Ruble A, Swartz K, Wilcox H. Gender Differences in Depression Literacy and Stigma After a Randomized Controlled Evaluation of a Universal Depression Education Program. J Adolesc Health. 2019 Apr;64(4):472-477. doi: 10.1016/j.jadohealth.2018.10.298. Epub 2019 Jan 4.'}, {'ReferencePMID': '29048969', 'ReferenceType': 'derived', 'ReferenceCitation': 'Swartz K, Musci RJ, Beaudry MB, Heley K, Miller L, Alfes C, Townsend L, Thornicroft G, Wilcox HC. School-Based Curriculum to Improve Depression Literacy Among US Secondary School Students: A Randomized Effectiveness Trial. Am J Public Health. 2017 Dec;107(12):1970-1976. doi: 10.2105/AJPH.2017.304088. Epub 2017 Oct 19.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Adolescent Depression Awareness Program (ADAP) website', 'SeeAlsoLinkURL': 'http://www.hopkinsmedicine.org/psychiatry/specialty_areas/moods/ADAP/'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 57, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01790919', 'OrgStudyIdInfo': {'OrgStudyId': 'R34MH094535-01A1', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH094535-01A1&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R34MH094535-01A1', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH094535-01A1&Fy=all'}]}, 'Organization': {'OrgFullName': 'University of California, Berkeley', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Improving Depression Outcome by Enhancing Memory for Cognitive Therapy', 'OfficialTitle': 'Improving Depression Outcome by Enhancing Memory for Cognitive Therapy'}, 'StatusModule': {'StatusVerifiedDate': 'September 2015', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 2013'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 6, 2013', 'StudyFirstSubmitQCDate': 'February 12, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 13, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 16, 2015', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 17, 2015', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Allison Harvey', 'ResponsiblePartyInvestigatorTitle': 'Professor of Clinical Psychology', 'ResponsiblePartyInvestigatorAffiliation': 'University of California, Berkeley'}, 'LeadSponsor': {'LeadSponsorName': 'University of California, Berkeley', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}, {'CollaboratorName': 'Vanderbilt University', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Existing drug and talking therapies for major depressive disorder (MDD) fail to produce complete recovery. This study will determine if substantial improvements to one of the most promising therapies, cognitive therapy (CT), can be achieved by administering a carefully designed procedure to improve memory for the content of CT sessions. This is important because (a) memory deficits are common in MDD patients and (b) each CT therapy session typically covers a complex array of topics and various skills are taught.', 'DetailedDescription': 'Background. Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders and a leading cause of disability worldwide. Existing therapies fail to produce complete recovery. Progress toward improving outcome must include innovations that are safe, powerful, inexpensive and simple (for fast and effective dissemination). The proposed research seeks to test one such innovation. We seek to improve outcome by improving memory for the content of cognitive therapy (CT) sessions. CT is one of the most promising approaches to the treatment of MDD, yet there is room for improvement.\\n\\nWe believe that adding memory enhancing strategies to CT may improve MDD outcome because: (a) MDD is often characterized by memory impairment, (b) there is evidence that the memory impairment is modifiable, (c) CT typically entails the activation of emotion, (d) emotion can impair or bias memory and (e) there is evidence that memory for the content of therapy sessions is poor.\\n\\nAim. To evaluate if a strategy designed to enhance memory for the content of CT sessions improves treatment outcome for MDD. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory. It is hypothesized that CT+Cognitive Support, relative to CT-as-usual, will be associated with improved depression outcome at the end of treatment and 6 months after the completion of treatment.\\n\\nResearch Plan. A small pilot feasibility RCT will be conducted on adults with MDD (n = 48) who will be randomized to one of two groups: (a) CT+Cognitive Support (n = 24) or (b) CT-as-usual (n = 24). Outcome measures will be taken at baseline, end of treatment, and 6 months after treatment. Long-term objective. To provide the pilot data needed to prepare a larger scale intervention study focused on improving outcomes by improving memory for the content of therapy sessions. The outcomes, if positive, will have major public health implications because simple, inexpensive memory enhancing strategies can be readily included as a standard feature in all psychosocial treatments for a broad range of mental illness. Project'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Major Depressive Disorder (MDD)']}, 'KeywordList': {'Keyword': ['Depression, Adults']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '48', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cognitive Therapy plus Cognitive Support', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Cognitive therapy for depression with cognitive support added', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive therapy for depression']}}, {'ArmGroupLabel': 'Cognitive therapy', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Cognitive therapy for depression', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive therapy for depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Cognitive therapy for depression', 'InterventionDescription': 'Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.\\n\\nCognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cognitive Therapy plus Cognitive Support', 'Cognitive therapy']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Inventory of Depressive Symptomatology, Self Report (IDS-SR)', 'PrimaryOutcomeDescription': 'Primary mood outcome', 'PrimaryOutcomeTimeFrame': 'Change in IDS scores from pre-treatment to post-treatment (defined as within 2 weeks of completing the course of treatment, which is 14 sessions) to 6-month followup'}, {'PrimaryOutcomeMeasure': 'Global Assessment of Functioning (GAF)', 'PrimaryOutcomeDescription': 'Primary impairment outcome', 'PrimaryOutcomeTimeFrame': 'Change in GAF scores from pre-treatment to post-treatment (defined as within 2 weeks of completing the course of treatment, which is 14 sessions) to 6-month followup'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Structured Clinical Interview for DSM-IV (SCID)', 'SecondaryOutcomeDescription': 'To determine the presence or absence of current DSM-IV-TR defined episodes of depression', 'SecondaryOutcomeTimeFrame': 'Pre-treatment; Within 2 weeks of completing the course of treatment (14 sessions); 6 month followup'}, {'SecondaryOutcomeMeasure': 'Longitudinal Interval Follow-up Evaluation (LIFE)', 'SecondaryOutcomeDescription': 'Time to relapse or recurrence', 'SecondaryOutcomeTimeFrame': 'Pre-treatment; within 2 weeks of completing the course of treatment (14 sessions); 6-month followup'}, {'SecondaryOutcomeMeasure': 'ACNP defined Response, Remission, Relapse, Recurrence using the IDS, SCID and LIFE', 'SecondaryOutcomeTimeFrame': 'Pre-treatment; within 2 weeks of completing the course of treatment (14 sessions); 6-month followup'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Memory Support Rating Scale (MSRS).', 'OtherOutcomeDescription': 'This is a measure of the use of memory support by treatment providers.', 'OtherOutcomeTimeFrame': 'All patients receive 14 sessions of cognitive therapy for depression. The treatment sessions are video taped. A random subset of 20% of the tapes are selected for MSRS scoring. Average MSRS scores will be compared across the 2 groups.'}, {'OtherOutcomeMeasure': 'Patient Recall Task.', 'OtherOutcomeDescription': \"This is a measure of the content of treatment that patient's remember\", 'OtherOutcomeTimeFrame': 'Completed at the end of Session 7, 14 and at 6 month FU. Patient Recall Task scores will be compared across the two treatment arms and over the three assessment points.'}, {'OtherOutcomeMeasure': 'National Adult Reading Test (NART).', 'OtherOutcomeDescription': 'Estimate of IQ. Used to determine if IQ is a moderator of treatment.', 'OtherOutcomeTimeFrame': 'This measure is taken at baseline (pre-treatment) and will be compared across the two treatment arms'}, {'OtherOutcomeMeasure': 'Episodic Face Naming Task.', 'OtherOutcomeDescription': 'Measure of declarative memory. used to determine if baseline memory is a moderator of treatment outcome.', 'OtherOutcomeTimeFrame': 'This measure is taken at baseline (pre-treatment) and will be compared across the two treatment arms'}, {'OtherOutcomeMeasure': 'Cognitive Therapy Rating Scale (CTRS)', 'OtherOutcomeDescription': 'Measure of the quality of cognitive therapy', 'OtherOutcomeTimeFrame': 'CTRS coding will be conducted on randomly selected recordings of treatment sessions. Average CTRS scores will be compared across the two treatment arms'}, {'OtherOutcomeMeasure': 'Credibility/Expectancy Questionnaire (CEQ)', 'OtherOutcomeDescription': 'A measure of treatment expectancies', 'OtherOutcomeTimeFrame': 'The CEQ scores, measured at the end of the first therapy session, will be compared across the two treatment arms'}, {'OtherOutcomeMeasure': 'Demographics form', 'OtherOutcomeDescription': 'Assesses demographics including age, years of education and chronicity of depression that are used in moderator analysis', 'OtherOutcomeTimeFrame': 'This measure is taken at baseline (pre-treatment) and will be compared across the two treatment arms'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ndiagnosis of major depressive disorder (MDD), first episode, recurrent or chronic, according to DSM-IV-TR criteria\\nscore of 24 or above on the Inventory of Depressive Symptomatology (IDS)-Clinician and 26 or above on the IDS-Self-report\\nolder than 18 years of age\\nif taking medications for mood, medications must be stable for the past 4 weeks\\nable and willing to give informed consent\\n\\nExclusion Criteria:\\n\\nhistory of bipolar disorder\\nhistory of psychosis (including schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, or psychotic organic brain syndrome)\\ncurrent non-psychotic Axis I disorder if it constitutes the principal diagnosis and if it requires treatment other than that offered in the project (including anxiety disorders including active PTSD, somatoform disorders, dissociative disorders, or eating disorders, etc.)\\nhistory of substance dependence in the past six months\\nIQ below 80\\nevidence of any medical disorder or condition that could cause depression or preclude participation in CT\\ncurrent suicide risk sufficient to preclude treatment on an outpatient basis', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'University of California, Berkeley', 'LocationCity': 'Berkeley', 'LocationState': 'California', 'LocationZip': '94720', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '29137655', 'ReferenceType': 'derived', 'ReferenceCitation': 'Harvey AG, Dong L, Lee JY, Gumport NB, Hollon SD, Rabe-Hesketh S, Hein K, Haman K, McNamara ME, Weaver C, Martinez A, Notsu H, Zieve G, Armstrong CC. Can integrating the Memory Support Intervention into cognitive therapy improve depression outcome? Study protocol for a randomized controlled trial. Trials. 2017 Nov 14;18(1):539. doi: 10.1186/s13063-017-2276-x.'}, {'ReferencePMID': '27089159', 'ReferenceType': 'derived', 'ReferenceCitation': 'Harvey AG, Lee J, Smith RL, Gumport NB, Hollon SD, Rabe-Hesketh S, Hein K, Dolsen MR, Haman KL, Kanady JC, Thompson MA, Abrons D. Improving outcome for mental disorders by enhancing memory for treatment. Behav Res Ther. 2016 Jun;81:35-46. doi: 10.1016/j.brat.2016.03.007. Epub 2016 Apr 2.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000003865', 'ConditionMeshTerm': 'Depressive Disorder, Major'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafAsFound': 'Major Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 58, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02521012', 'OrgStudyIdInfo': {'OrgStudyId': 'DepFuDKUH5703453'}, 'Organization': {'OrgFullName': 'Kuopio University Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Follow-up Study With Clinical Vitamin D Supplementation Trial on Patients With Depression (DepFuD)', 'OfficialTitle': 'Follow-up Study With Randomized Clinical Vitamin D Supplementation Trial on Patients With Depression (DepFuD)', 'Acronym': 'DepFuD'}, 'StatusModule': {'StatusVerifiedDate': 'August 2019', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 2015', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'October 2025', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'August 4, 2015', 'StudyFirstSubmitQCDate': 'August 11, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 13, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 29, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 30, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Heimo Viinamaki', 'ResponsiblePartyInvestigatorTitle': 'Professor, Head of Department of Psychiatry', 'ResponsiblePartyInvestigatorAffiliation': 'Kuopio University Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Kuopio University Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': \"Depression affects 350 million people worldwide. In the light of the global disease burden statistics, the efficacy of current treatments for depression appears insufficient. Thus, research on novel treatment interventions and predictors for good treatment response are warranted. Earlier prospective follow-up studies and intervention studies suggest that several bio-psychosocial factors, including high serum concentrations of vitamin D, are related to better treatment outcomes. In this follow-up study with randomized clinical vitamin D supplementation trial on patients with depression, the investigators aim to\\n\\nclarify how a six-month intervention with vitamin D supplementation affects treatment response, recovery, and the biological pathways related to depression. This aims to finding potential sub-groups getting benefits from vitamin D supplementation. In addition, the investigators want to\\ninvestigate and characterize factors related to recovery from depression and working ability in depression patients in the long-term. The investigators are especially interested in the bio-psychosocial factors and the aims include examining both the individual's positive resources.\\n\\nThe trial will start with a six-month double-blinded randomized controlled trial with vitamin D supplementation. The aim is to recruit altogether 3028 patients with non-psychotic, unipolar depression, aged 18-65 years, who are referred to the recruitment sites for treatment for depression. The participants will be randomized to low (10 µg/day) or high (100 µg/day) vitamin D supplementation group. Clinically necessary antidepressant treatments will continue during the intervention as needed. After six months of intervention, the participants will be followed up at 18 months and at 5 years.\\n\\nSeveral measurements will be conducted during the intervention and follow-up period. Participants will fill a variety of clinical questionnaires and questionnaires with background information. All participants give blood samples for biomarker analyses at time points 3, 6, 18 months and 5 years. Clinical interviews of mental disorders (e.g. SCID) and anthropometric measurements (e.g. weight, height, blood pressure) will be carried out.\", 'DetailedDescription': \"Depression affects 350 million people worldwide. In the light of the global disease burden statistics, the efficacy of current treatments for depression appears insufficient. Thus, research on novel treatment interventions and predictors for good treatment response are warranted. Earlier prospective follow-up studies and intervention studies suggest that several bio-psychosocial factors, including high serum concentrations of vitamin D, are related to better treatment outcomes.\\n\\nIn this follow-up study with randomized clinical vitamin D supplementation trial on patients with depression, the investigators aim to\\n\\nclarify how a six-month intervention with vitamin D supplementation affects treatment response, recovery, and the biological pathways related to depression. This aims to finding potential sub-groups getting benefits from vitamin D supplementation. In addition, the investigators want to\\ninvestigate and characterize factors related to recovery from depression and working ability in depression patients in the long-term. The investigators are especially interested in the bio-psychosocial factors and the aims include examining both the individual's positive resources.\\n\\nThe trial will start with a six-month double-blinded randomized controlled trial with vitamin D supplementation. The aim is to recruit altogether 3028 patients with non-psychotic, unipolar depression, aged 18-65 years, who are referred to the recruitment sites for treatment for depression. The participants will be randomized to low (10 µg/day) or high (100 µg/day) vitamin D supplementation group. Clinically necessary antidepressant treatments will continue during the intervention as needed. After six months of intervention, the participants will be followed up at 18 months and at 5 years.\\n\\nSeveral measurements will be conducted during the intervention and follow-up period. Participants will fill a variety of clinical questionnaires and questionnaires with background information. All participants give blood samples for biomarker analyses at time points 3, 6, 18 months and 5 years. Clinical interviews of mental disorders (e.g. SCID) and anthropometric measurements (e.g. weight, height, blood pressure) will be carried out.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression', 'Depressive Disorder']}, 'KeywordList': {'Keyword': ['Depression', 'Depressive symptoms', 'Vitamin D', 'Intervention']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Quadruple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider', 'Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '3028', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Vitamin D 10 micrograms', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Vitamin D supplementation 10 micrograms/day given to depressed individuals, defined as \"reference\"', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Vitamin D 10 micrograms']}}, {'ArmGroupLabel': 'Vitamin D 100 micrograms', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Vitamin D supplementation 100 micrograms/day given to depressed individuals', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Vitamin D 100 micrograms']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Vitamin D 10 micrograms', 'InterventionDescription': 'Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Vitamin D 10 micrograms']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'Vitamin D 100 micrograms', 'InterventionDescription': 'Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Vitamin D 100 micrograms']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores', 'PrimaryOutcomeDescription': 'We are interviewing the patients with depression with MADRS, which has been found to be a practical tool for assessing depressive symptoms in clinical trials. We are especially interest to see the change in scores during the intervention.', 'PrimaryOutcomeTimeFrame': '0, 3 and 6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Beck Depression Inventory (BDI) scores', 'SecondaryOutcomeDescription': 'Participants fill a 21-item Beck Depression Inventory questionnaire and total scores will be calculated. We are especially interested to see if the total scores changes during the intervention.', 'SecondaryOutcomeTimeFrame': '0, 3, 6, 18 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\npatients referred to the recruitment sites for treatment for depression\\nmild, moderate or severe depression,\\nmild, moderate or severe episode of recurrent depression\\n\\nExclusion Criteria:\\n\\nbipolar or psychotic depression\\npsychotic disorder\\nsevere substance abuse\\ndisabilities in senses that affect functioning and severely threat completing the trial\\ndiseases that affect vitamin D metabolism (such as sarcoidosis, hypercalcemia, hypofunction of kidney)\\npregnancy or lactation\\ncurrent use of high dose vitamin D supplementation\\ncurrent use of high dose calcium supplementation', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Heimo Viinamäki, Professor', 'CentralContactRole': 'Contact', 'CentralContactEMail': 'heimo.viinamaki@kuh.fi'}, {'CentralContactName': 'Anu Ruusunen, PhD', 'CentralContactRole': 'Contact', 'CentralContactEMail': 'anu.ruusunen@kuh.fi'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Heimo Viinamaki, Professor', 'OverallOfficialAffiliation': 'Professor, Head of Department', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Kuopio University Hospital, Department of Psychiatry', 'LocationStatus': 'Recruiting', 'LocationCity': 'Kuopio', 'LocationCountry': 'Finland', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ritva Von Koch', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+358447174766', 'LocationContactEMail': 'ritva.vonkoch@kuh.fi'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000014807', 'InterventionMeshTerm': 'Vitamin D'}, {'InterventionMeshId': 'D000004872', 'InterventionMeshTerm': 'Ergocalciferols'}, {'InterventionMeshId': 'D000014815', 'InterventionMeshTerm': 'Vitamins'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000018977', 'InterventionAncestorTerm': 'Micronutrients'}, {'InterventionAncestorId': 'D000078622', 'InterventionAncestorTerm': 'Nutrients'}, {'InterventionAncestorId': 'D000006133', 'InterventionAncestorTerm': 'Growth Substances'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000050071', 'InterventionAncestorTerm': 'Bone Density Conservation Agents'}, {'InterventionAncestorId': 'D000077264', 'InterventionAncestorTerm': 'Calcium-Regulating Hormones and Agents'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16133', 'InterventionBrowseLeafName': 'Vitamin D', 'InterventionBrowseLeafAsFound': 'Vitamin D', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M16141', 'InterventionBrowseLeafName': 'Vitamins', 'InterventionBrowseLeafAsFound': 'Vitamin', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M6609', 'InterventionBrowseLeafName': 'Ergocalciferols', 'InterventionBrowseLeafAsFound': 'Vitamin D', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M15468', 'InterventionBrowseLeafName': 'Trace Elements', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19593', 'InterventionBrowseLeafName': 'Micronutrients', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M1986', 'InterventionBrowseLeafName': 'Nutrients', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3963', 'InterventionBrowseLeafName': 'Calcium', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3980', 'InterventionBrowseLeafName': 'Calcium, Dietary', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8372', 'InterventionBrowseLeafName': 'Hormones', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T440', 'InterventionBrowseLeafName': 'Calciferol', 'InterventionBrowseLeafAsFound': 'Vitamin D', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'T445', 'InterventionBrowseLeafName': 'Ergocalciferol', 'InterventionBrowseLeafAsFound': 'Vitamin D', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'T478', 'InterventionBrowseLeafName': 'Vitamin D2', 'InterventionBrowseLeafAsFound': 'Vitamin D', 'InterventionBrowseLeafRelevance': 'high'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'BDCA', 'InterventionBrowseBranchName': 'Bone Density Conservation Agents'}, {'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Vi', 'InterventionBrowseBranchName': 'Vitamins'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 59, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02069912', 'OrgStudyIdInfo': {'OrgStudyId': 'USCIRB-HS-06-00420'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'CA Health Care Foundation', 'SecondaryIdType': 'Other Grant/Funding Number', 'SecondaryIdDomain': 'California Health Care Foundation'}]}, 'Organization': {'OrgFullName': 'University of Southern California', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Multifaceted Depression and Cardiovascular Program', 'OfficialTitle': 'Multifaceted Depression and Cardiovascular Program for Low-Income Patients', 'Acronym': 'MDCP'}, 'StatusModule': {'StatusVerifiedDate': 'February 2014', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 2006'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2009', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'February 2009', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 20, 2014', 'StudyFirstSubmitQCDate': 'February 20, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 24, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'February 20, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 24, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Kathleen R. Ell', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'University of Southern California'}, 'LeadSponsor': {'LeadSponsorName': 'University of Southern California', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Los Angeles County Department of Public Health', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Implement an evidence-based structured care approach that includes screening; acute treatment and relapse prevention follow-up tailored for public sector clinics and low-income and minority patients.\\nAdapt an evidence-based collaborative care model for primary care, implement the adapted model, evaluate and further refine the model based on the pilot experience, and produce and disseminate a detailed manual for use in public sector clinics.\\nEvaluate Multifaceted Depression and Cardiovascular Program (MDCP) in an open trial to determine: its acceptance by patients, medical providers, and organizational decision-makers; patient depression treatment adherence; its direct cost; and the size and variability of change from baseline in the primary outcome measures: depressive symptoms, functional status, quality of life, health service use, and cardiac status at 6 and 12 month follow-up.', 'DetailedDescription': \"The pilot open trial was conducted to evaluate the effectiveness of a health services quality improvement intervention, Multifaceted Depression and Cardiovascular Program (MDCP), on reduction of major depressive disorder, adherence to recommended cardiac exercise and diet self-care regimens and appointment keeping, blood pressure and low density lipid levels, functional status, quality of life and use of health services among low-income, predominantly Hispanic adults with congestive heart failure (CHF) or other cardiac disease such as coronary artery disease (CAD) in public sector community-based primary care clinics. The study was based on key observations from recent studies: 1) Patients with cardiac conditions are more likely to experience clinically significant depressive symptoms than the general population, with depression being associated with poor cardiac outcomes; 2) depression rates are high among Hispanics with chronic illness; 3) Minority patients are less likely to receive care for depression, but benefit with culturally appropriate care enhancements; and 4) depression co-morbid with cardiac conditions is likely to be persistent. Low-income patient needs, depression illness characteristics, and public care system resources call for a multifaceted, collaborative chronic disease management model of depression care. MDCP is aimed at positively affecting depression and cardiac outcomes by reducing known patient, provider, and system barriers to care.\\n\\nParticipation in this study will last 12 months. All participants will first undergo baseline assessments that will include a 40-minute interview about personal health and feelings. All study participants will receive collaborative depression care management. They will first be provided with information about depression treatment. Participants will then have the option of choosing between two depression treatments: counseling or antidepressant medications. Participants who choose to receive treatment with counseling will receive eight weekly 45-minute counseling sessions, conducted either on the phone or at the clinic. During these sessions, participants will undergo structured problem solving therapy (PST) and will learn strategies to manage their depressive symptoms. Participants who choose to receive treatment with antidepressant medication will be prescribed medication by a study doctor and will be monitored for any side effects throughout treatment. Medication treatment may last up to 12 months but will depend upon participants' severity of depression. After completing medication treatment, participants will be offered PST counseling. All study participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring.\\n\\nAll participants will undergo follow-up phone interviews about their status at months 6 and 12.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression', 'Depressive Disorder', 'Behavioral Symptoms', 'Mood Disorders']}, 'KeywordList': {'Keyword': ['Major Depression', 'Heart Disease', 'Hispanics', 'Collaborative Depression Care Management']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '108', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Collaborative depression care', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'All enrolled patients will receive collaborative depression care management.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Collaborative depression care management']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Collaborative depression care management', 'InterventionDescription': \"Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Collaborative depression care']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depressive symptoms reduction', 'PrimaryOutcomeDescription': 'Achieve minimum a 50% reduction in depressive symptoms from baseline at 6- and 12-month follow-up', 'PrimaryOutcomeTimeFrame': 'Measured at months 6 and 12'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Improvement in quality of life', 'SecondaryOutcomeDescription': 'Change score in quality-of-life 12-item Short-Form Health Survey, Minnesota Living with Heart Failure, Sheehan Disability Scale outcomes', 'SecondaryOutcomeTimeFrame': 'Measured at months 6 and 12'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMeets criteria for clinically significant depression based on a score of ≥ 2 for one of the two cardinal depression symptoms (depressed mood or loss of interest) and a Patient Health Questionnaire-9 total score of ≥ 10\\nPatient with heart disease\\nHas attended Los Angeles County Department of Health Services Comprehensive Health Clinics or the Cardiology Clinic at Los Angeles County+University of Southern California Medical Center\\n\\nExclusion Criteria:\\n\\nCurrent suicidal ideation\\nScore of 8 or greater on the Alcohol Use Disorders Identification Test (AUDIT)\\nRecent use of lithium or antipsychotic medication', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kathleen R Ell, DSW', 'OverallOfficialAffiliation': 'University of Southern California', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Southern California School of Social Work', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90089-0411', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25262042', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ell K, Oh H, Lee PJ, Guterman J. Collaborative health literate depression care among predominantly Hispanic patients with coronary heart disease in safety net care. Psychosomatics. 2014 Nov-Dec;55(6):555-65. doi: 10.1016/j.psym.2014.03.007. Epub 2014 Mar 26.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000004194', 'ConditionMeshTerm': 'Disease'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000019964', 'ConditionMeshTerm': 'Mood Disorders'}, {'ConditionMeshId': 'D000001526', 'ConditionMeshTerm': 'Behavioral Symptoms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafAsFound': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafAsFound': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}}, {'Rank': 60, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00781703', 'OrgStudyIdInfo': {'OrgStudyId': 'PAR-06-039'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH080692', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH080692&Fy=all'}]}, 'Organization': {'OrgFullName': 'HealthPartners Institute', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Evaluation of a Natural Experiment to Improve Statewide Depression Care in Minnesota (MN)', 'OfficialTitle': 'DIAMOND Study: Evaluation of a Natural Experiment to Improve Statewide Depression Care in MN', 'Acronym': 'DIAMOND'}, 'StatusModule': {'StatusVerifiedDate': 'July 2014', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 2008'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'February 2014', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'October 28, 2008', 'StudyFirstSubmitQCDate': 'October 28, 2008', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 29, 2008', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 14, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 15, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'HealthPartners Institute', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': \"The study will evaluate a unique natural experiment that aims to transform the primary care of patients with depression. The experiment's aim is to cause statewide implementation of an evidence-based care model for depression by changing the reimbursement system and by using an established regional collaborative (the Institute for Clinical Systems Improvement) to both facilitate the model's widespread use and certify that medical groups have implemented it. Study hypotheses include the following:\\n\\nNewly treated depressed patients in medical groups that have implemented the new reimbursement and facilitation will report receiving higher rates of best care processes than such patients in these medical groups before implementation.\\nRates of best care practices reported to be received by newly treated depressed patients two years after each medical group implements changes will be maintained at least at the rate reported by patients one year post implementation.\\nNewly treated depressed patients in medical groups that have participated in the new reimbursement and facilitation will have greater improvement in depression symptoms and work productivity and lower healthcare costs than such patients in groups before participation.\\nMedical group measures of priority for improving depression care, capability to manage change, and practice systems will be predictive of more patient-reported best care processes, both at one point in time and in change over time.\", 'DetailedDescription': 'The study will use a multiple baseline across settings with staggered implementation to test the effects of changed reimbursement and facilitated organizational change on the use and sustainability of evidenced-based care processes for patients with depression. The study will also test the effect of the care process changes on changes in depression symptoms, healthcare costs, and work productivity.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Major Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '2631', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'DIAMOND Care Model', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the Patient Health Questionnaire-9 (PHQ9), treatment adjustment as indicated, psychiatric consultation, relapse prevention.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: DIAMOND depression care model']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'DIAMOND depression care model', 'InterventionDescription': 'Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['DIAMOND Care Model']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Rates of best care processes', 'PrimaryOutcomeTimeFrame': 'baseline, 6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Improvement in depression symptoms, work productivity and total healthcare costs', 'SecondaryOutcomeTimeFrame': 'baseline, 3 months, 6 months, 1 year'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nmajor depression\\nPatient Health Questionaire (PHQ-9) > 9\\nprimary care management of depression\\n\\nExclusion Criteria:\\n\\ncomorbid psychiatric conditions', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Leif I Solberg, MD', 'OverallOfficialAffiliation': 'HealthPartners Institute', 'OverallOfficialRole': 'Principal Investigator'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 61, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02207582', 'OrgStudyIdInfo': {'OrgStudyId': 'tRNS in depression'}, 'Organization': {'OrgFullName': 'University of Regensburg', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Prefrontal Transcranial Random Noise Stimulation in Patients With Depression', 'OfficialTitle': 'Prefrontal Transcranial Random Noise Stimulation in Patients With Depression', 'Acronym': 'tRNS-depr'}, 'StatusModule': {'StatusVerifiedDate': 'June 2018', 'OverallStatus': 'Terminated', 'WhyStopped': 'no efficacy', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 14, 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 6, 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 31, 2014', 'StudyFirstSubmitQCDate': 'August 1, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 4, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'June 14, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 18, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Berthold Langguth, MD, Ph.D.', 'ResponsiblePartyInvestigatorTitle': 'MD, PhD', 'ResponsiblePartyInvestigatorAffiliation': 'University of Regensburg'}, 'LeadSponsor': {'LeadSponsorName': 'University of Regensburg', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': \"Transcranial random noise stimulation is used to stimulate the prefrontal cortices in patients with depression. It's a placebo-controlled two-arm study.\", 'DetailedDescription': 'Transcranial random noise stimulation (tRNS) is a non-invasive electric stimulation technique of the brain which was shown to be superior effective in contrast to other electric stimulation such as transcranial direct current stimulation (tDCS). These studies investigated mainly healthy controls and specific tasks. Only one case report is available for depression. Here we stimulate patients with depression with tRNS in a placebo-controlled two-arm design. Stimulation will be done as add-on to standard therapy. Electrodes will be applied over both dorsolateral prefrontal cortices which are standard target points of tDCS and also transcranial magnetic stimulation in depression.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['depression; trns']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '44', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Verum Prefrontal tRNS', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': '2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Verum Prefrontal tRNS']}}, {'ArmGroupLabel': 'Placebo Prefrontal tRNS', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': '2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Placebo Prefrontal tRNS']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Verum Prefrontal tRNS', 'InterventionDescription': '2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Verum Prefrontal tRNS']}}, {'InterventionType': 'Device', 'InterventionName': 'Placebo Prefrontal tRNS', 'InterventionDescription': '2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo Prefrontal tRNS']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (baseline (-day 3) versus end of treatment (day 19))', 'PrimaryOutcomeDescription': 'Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (baseline (-day 3) versus end of treatment (day 19))', 'PrimaryOutcomeTimeFrame': 'day 3; day 19'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in depression severity measured by the Major Depression Inventory over the course of the trial', 'SecondaryOutcomeDescription': 'Change in depression severity measured by the Major Depression Inventory over the course of the trial', 'SecondaryOutcomeTimeFrame': 'day 10; -day 3; day 5; day 12; day 19; day 75'}, {'SecondaryOutcomeMeasure': 'Number of responders (response = decrease of the Hamilton Depression rating scale for at least 50%) (baseline versus end of treatment)', 'SecondaryOutcomeDescription': 'Number of responders (response = decrease of the Hamilton Depression rating scale for at least 50%) (baseline versus end of treatment)', 'SecondaryOutcomeTimeFrame': 'day 3; day 19'}, {'SecondaryOutcomeMeasure': 'Change in the Clinical Global Impression Scale over the course of the trial', 'SecondaryOutcomeDescription': 'Change in the Clinical Global Impression Scale over the course of the trial', 'SecondaryOutcomeTimeFrame': 'day 3; day 5; day 12; day 19; day 75'}, {'SecondaryOutcomeMeasure': 'Change in the Beck Depression Inventory over the course of the trial', 'SecondaryOutcomeDescription': 'Change in the Beck Depression Inventory over the course of the trial', 'SecondaryOutcomeTimeFrame': 'day 3; day 5; day 12; day 19; day 75'}, {'SecondaryOutcomeMeasure': 'Change in alertness, working memory and divided attention over the course of the trial', 'SecondaryOutcomeDescription': 'Change in alertness, working memory and divided attention over the course of the trial', 'SecondaryOutcomeTimeFrame': 'day 3; day 19; day 75'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nepisode of depression (unipolar or bipolar) ( ICD-10)\\nfemale or male between 18 and 70 years old\\nskills to participate in all study procedures\\n18 or more points in the Hamilton rating scale or depression\\nwritten informed consent\\n\\nExclusion Criteria:\\n\\nclinically relevant unstable internal or neurological comorbidity\\nevidence of significant brain malformations or neoplasm, head injury\\ncerebral vascular events\\nneurodegenerative disorders affecting the brain or prior brain surgery\\nmetal objects in and around body that can not be removed\\npregnancy\\nalcohol or drug abuse\\neczema on the head\\nheart pacemaker\\nhigh dose tranquillizers', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '70 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Berthold Langguth', 'OverallOfficialAffiliation': 'University of Regensburg', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Regensburg', 'LocationCity': 'Regensburg', 'LocationZip': '93053', 'LocationCountry': 'Germany'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 62, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01392963', 'OrgStudyIdInfo': {'OrgStudyId': 'CR-11-021'}, 'Organization': {'OrgFullName': 'Seton Healthcare Family', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Treatment of Depression With Botulinum Type A Toxin', 'OfficialTitle': 'The Treatment of Depression With Botulinum Type A Toxin (Botox): A Randomized, Double Blind, Crossover Study'}, 'StatusModule': {'StatusVerifiedDate': 'June 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2011'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2013', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 8, 2011', 'StudyFirstSubmitQCDate': 'July 11, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 13, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'October 3, 2017', 'ResultsFirstSubmitQCDate': 'July 23, 2018', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'July 26, 2018', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 23, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 26, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Seton Healthcare Family', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'Yes', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'A 24-week Randomized, Double-blind study treating people who suffer from depression who also have moderate to severe frown lines in forehead region with Botox injections. Subjects participating will have their photos taken and complete a questionnaire regarding their depression. They will see a psychiatrist at every visit who will assess their depression.', 'DetailedDescription': 'Participants will be assigned to receive either placebo or botulinum toxin injections in the forehead'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['botox', 'depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Crossover Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '30', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Botox, Then Placebo', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: botulinum toxin type A neurotoxin complex', 'Drug: Placebo']}}, {'ArmGroupLabel': 'Placebo, Then Botox', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: botulinum toxin type A neurotoxin complex', 'Drug: Placebo']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'botulinum toxin type A neurotoxin complex', 'InterventionDescription': '29-40 U injection', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Botox, Then Placebo', 'Placebo, Then Botox']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Botox, botulinum toxin type A (BTA)']}}, {'InterventionType': 'Drug', 'InterventionName': 'Placebo', 'InterventionDescription': '29-40 U 0.9% NaCl injection', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Botox, Then Placebo', 'Placebo, Then Botox']}, 'InterventionOtherNameList': {'InterventionOtherName': ['botulinum toxin type A neurotoxin complex matched injection']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change From Baseline in Depression Symptoms on the Hamilton Depression Rating Scale 21 (HDRS-21) AT WEEK 6', 'PrimaryOutcomeDescription': 'HDRS-21 is a validated, clinician-administered depression assessment scale. Possible scores range from 0 - 7 (within normal range or remission) 8-16 (mild depression) 17-23 (moderate depression) 24-52 (severe depression). Change = (Week 6 post injection score - baseline week 0 score).\\n\\nPRIMARY OUTCOME MEASURE IS THE CHANGE IN HDRS-21 SCORE AFTER WEEK 6', 'PrimaryOutcomeTimeFrame': 'baseline and week 6'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change From Baseline (Week 0) in Depression Symptoms on the Hamilton Depression Rating Scale 21 (HDRS-21) at Week 6 (Six Weeks Post Placebo Injection at Week 0) and Week 18 (Six Weeks Post Botox Injection at Week 12)', 'SecondaryOutcomeDescription': 'HDRS-21 is a validated, clinician-administered depression assessment scale. Possible scores range from 0 - 7 (within normal range or remission) 8-16 (mild depression) 17-23 (moderate depression) 24-52 (severe depression). Change = (Week 6/18 score - baseline week 0 score)\\n\\nOutcome measure is the change in HDRS-21 score 6 weeks after injection with placebo (week 0) and Botox (week 12) - HDRS-21 done at week 6 and week 18.', 'SecondaryOutcomeTimeFrame': 'Baseline (Week 0), Week 6, and Week 18'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nMale/Female between the ages of 18 and 65\\n\\nMajor Depression Disorder as defined by DSM IV criteria and diagnosed by a psychiatrist. DSM (Diagnostic and Statistical Manual) IV criteria for depression are: a depressed mood or anhedonia for at least a two week period. This mood must represent a change from the person's normal mood; social, occupational, educational or other important functioning must also be negatively impaired by the change in mood. Major depressive disorder cannot be diagnosed if a person has a history of bipolar disorder or if the depressed mood is better accounted for by substance abuse or a psychotic disorder. In addition, the patient must have 5 of the following symptoms:\\n\\nSignificant weight loss or weight gain.\\nInsomnia or hypersomnia\\nPsychomotor agitation or retardation\\nFeelings of worthlessness or excessive guilt\\nPoor Concentration\\nFatigue or loss of energy\\nSuicidal thoughts\\nHistory of depression for at least 6 months\\nInitial score 14 or higher on initial Hamilton Depression rating scale.\\nMelancholic facial expressions amenable to treatment with Botox. Photos will be taken of potential participants and ranked independently by two investigators, on a scale of 1-10 based on how negative they look, 10 being the highest. Patients with an average score of 6 or above will be included in the study\\n\\nExclusion Criteria:\\n\\nActive substance abuse\\nBipolar Depression\\nSubjects who are pregnant, nursing or trying to become pregnant during study participation\\nSubjects who are currently on more than 3 psychiatric medications at the time of enrollment\\nCurrent medications used to treat depression must be stable for at least 60 days prior to enrollment\\nPrevious Botox treatment\\nThe Principle Investigator has determined that this study is not in the best interest of the subject and therefore the subject will not be enrolled.\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Michelle Magid, MD', 'OverallOfficialAffiliation': 'Seton Healthcare Family', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Seton Mind Institute: Medical Park Tower', 'LocationCity': 'Austin', 'LocationState': 'Texas', 'LocationZip': '78705', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24910934', 'ReferenceType': 'result', 'ReferenceCitation': 'Magid M, Reichenberg JS, Poth PE, Robertson HT, LaViolette AK, Kruger TH, Wollmer MA. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014 Aug;75(8):837-44. doi: 10.4088/JCP.13m08845.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'A total of 101 were screened via telephone, 39 received a face-to-face screening interview, and 30 were enrolled in the study.', 'FlowRecruitmentDetails': 'Participants were recruited from local outpatient psychiatry and primary care practices, and through internet advertisements and media appearances.', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Botox, Then Placebo', 'FlowGroupDescription': 'At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Placebo, Then Botox', 'FlowGroupDescription': 'At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Week 0 (First Intervention)', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '11'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '19'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '11'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '17'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '2'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '0'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'}]}}, {'FlowDropWithdrawType': 'Withdrawal by Subject', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '0'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'}]}}]}}, {'FlowPeriodTitle': 'Week 12 (Second Intervention)', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '11'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '17'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '11'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '17'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '0'}]}}]}}, {'FlowPeriodTitle': 'Week 24 Follow-up', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '11'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '17'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '9'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '17'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '2'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '0'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '2'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Botox, Then Placebo', 'BaselineGroupDescription': 'At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Placebo, Then Botox', 'BaselineGroupDescription': 'At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '11'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '19'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '30'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '11'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '19'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '30'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '11'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '19'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '30'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '11'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '19'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '30'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '11'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '17'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '28'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race and Ethnicity Not Collected', 'BaselineMeasurePopulationDescription': 'Race and Ethnicity were not collected from any participant.', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '0'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '0'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '0'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Change From Baseline in Depression Symptoms on the Hamilton Depression Rating Scale 21 (HDRS-21) AT WEEK 6', 'OutcomeMeasureDescription': 'HDRS-21 is a validated, clinician-administered depression assessment scale. Possible scores range from 0 - 7 (within normal range or remission) 8-16 (mild depression) 17-23 (moderate depression) 24-52 (severe depression). Change = (Week 6 post injection score - baseline week 0 score).\\n\\nPRIMARY OUTCOME MEASURE IS THE CHANGE IN HDRS-21 SCORE AFTER WEEK 6', 'OutcomeMeasurePopulationDescription': 'Participants that completed all study visits were included in the analysis.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': 'baseline and week 6', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Placebo, Then Botox', 'OutcomeGroupDescription': 'At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).\\n\\nbotulinum toxin type A neurotoxin complex: 29-40 U injection\\n\\nPlacebo: 29-40 U 0.9% NaCl injection'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Botox, Then Placebo', 'OutcomeGroupDescription': 'At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '19'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '11'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-0.4', 'OutcomeMeasurementSpread': '4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-12.7', 'OutcomeMeasurementSpread': '4'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisNonInferiorityType': 'Other', 'OutcomeAnalysisPValue': '0.001', 'OutcomeAnalysisStatisticalMethod': 'Mixed Models Analysis'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Change From Baseline (Week 0) in Depression Symptoms on the Hamilton Depression Rating Scale 21 (HDRS-21) at Week 6 (Six Weeks Post Placebo Injection at Week 0) and Week 18 (Six Weeks Post Botox Injection at Week 12)', 'OutcomeMeasureDescription': 'HDRS-21 is a validated, clinician-administered depression assessment scale. Possible scores range from 0 - 7 (within normal range or remission) 8-16 (mild depression) 17-23 (moderate depression) 24-52 (severe depression). Change = (Week 6/18 score - baseline week 0 score)\\n\\nOutcome measure is the change in HDRS-21 score 6 weeks after injection with placebo (week 0) and Botox (week 12) - HDRS-21 done at week 6 and week 18.', 'OutcomeMeasurePopulationDescription': '2 patients in the placebo first group dropped out at crossover and were not included in the 18 week assessment', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': 'Baseline (Week 0), Week 6, and Week 18', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Placebo, Then Botox (Week 6)', 'OutcomeGroupDescription': 'Group received placebo injection at week 0 of study followed by a Botox injection at week 12. HDRS-21 scores were done six weeks after each injection (week 6 and week 18).'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Placebo, Then Botox (Week 18)', 'OutcomeGroupDescription': 'Group received placebo injection at week 0 of study followed by a Botox injection at week 12. HDRS-21 scores were done six weeks after each injection (week 6 and week 18).'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '19'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '17'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-0.4', 'OutcomeMeasurementSpread': '3'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-8.4', 'OutcomeMeasurementSpread': '3'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': '24 weeks', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Botox, Then Placebo', 'EventGroupDescription': 'At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '11', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '11', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '11'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Placebo, Then Botox', 'EventGroupDescription': 'At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '19', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '19', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '19'}]}}, 'MoreInfoModule': {'LimitationsAndCaveats': {}, 'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Katherine Sebastian', 'PointOfContactOrganization': 'Seton Family of Hospitals', 'PointOfContactEMail': 'krsebastian@seton.org', 'PointOfContactPhone': '512-324-9999', 'PointOfContactPhoneExt': '89612'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000001905', 'InterventionMeshTerm': 'Botulinum Toxins'}, {'InterventionMeshId': 'D000019274', 'InterventionMeshTerm': 'Botulinum Toxins, Type A'}, {'InterventionMeshId': 'C000542869', 'InterventionMeshTerm': 'abobotulinumtoxinA'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000065087', 'InterventionAncestorTerm': 'Acetylcholine Release Inhibitors'}, {'InterventionAncestorId': 'D000049990', 'InterventionAncestorTerm': 'Membrane Transport Modulators'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000018678', 'InterventionAncestorTerm': 'Cholinergic Agents'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000009465', 'InterventionAncestorTerm': 'Neuromuscular Agents'}, {'InterventionAncestorId': 'D000018373', 'InterventionAncestorTerm': 'Peripheral Nervous System Agents'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M19841', 'InterventionBrowseLeafName': 'Botulinum Toxins, Type A', 'InterventionBrowseLeafAsFound': 'Botulinum toxin type A', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M258543', 'InterventionBrowseLeafName': 'abobotulinumtoxinA', 'InterventionBrowseLeafAsFound': 'Botulinum toxin type A', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M3765', 'InterventionBrowseLeafName': 'Botulinum Toxins', 'InterventionBrowseLeafAsFound': 'Botulinum toxin', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2054', 'InterventionBrowseLeafName': 'Acetylcholine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19342', 'InterventionBrowseLeafName': 'Cholinergic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'VaDiAg', 'InterventionBrowseBranchName': 'Vasodilator Agents'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 63, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00304915', 'OrgStudyIdInfo': {'OrgStudyId': 'MNT 05-152'}, 'Organization': {'OrgFullName': 'VA Office of Research and Development', 'OrgClass': 'FED'}, 'BriefTitle': 'HIV Translating Initiatives for Depression Into Effective Solutions', 'OfficialTitle': 'HIV Translating Initiatives for Depression Into Effective Solutions', 'Acronym': 'HI-TIDES'}, 'StatusModule': {'StatusVerifiedDate': 'November 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 2007'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2009', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 16, 2006', 'StudyFirstSubmitQCDate': 'March 16, 2006', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 20, 2006', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'September 10, 2014', 'ResultsFirstSubmitQCDate': 'September 10, 2014', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'September 17, 2014', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 10, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 29, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'VA Office of Research and Development', 'LeadSponsorClass': 'FED'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'This study is a randomized trial designed to test and refine a collaborative care model for treating depression in VA patients with HIV.', 'DetailedDescription': \"Background: Depression is the most common mental disorder in HIV infected patients. Despite the availability of efficacious treatments for depression, evidence suggests that it is under-diagnosed and under-treated in routine HIV care. To address this problem, the investigators will adapt and implement a collaborative stepped-care model for depression treatment in HIV clinics. This proposal builds on past success of the TIDES/WAVES programs used in VA primary care. The project (HI-TIDES or HIV Translating Initiatives for Depression into Effective Solutions) will implement the primary care collaborative care model for depression treatment in HIV clinics using evidence-based implementation strategies. Objectives: The objectives of this proposal are to: 1) Develop and evaluate the process of adapting, implementing, and sustaining collaborative care for depression in VA HIV clinics, 2) Compare the quality of depression care and the clinical effectiveness of HI-TIDES to usual care in the HIV clinics, and 3) Evaluate the cost-effectiveness of patients assigned to HI-TIDES relative to patients assigned to usual care in HIV clinics. Methods: The implementation framework for this proposal is primarily informed by the Rogers diffusion of innovation model, Simpson Transfer Model, and the PRECEDE model. The VA and American Psychiatric Association Practice Guidelines inform the stepped care collaborative model intervention as source documents for summarizing the evidence for depression treatment for the general population. An expert panel will be convened to rate the quality of available evidence for depression treatment in the context of HIV. Patients will be recruited from VA HIV clinics: Little Rock, Atlanta, and Houston. The intervention will be randomized at the level of the patient. The investigators expect to recruit a total of 140 intervention and 140 usual care patients. Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in the VA electronic medical record. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager. A formative evaluation will occur during start-up and throughout the implementation of the intervention. A summative evaluation will document the effectiveness and cost-effectiveness of the intervention using an intent to treat analysis plan. Findings: No results at this time. Status: Start-up activities. Impact: The proposed study is highly relevant to the VA and the Veterans it serves for many reasons. First, the majority of VA patients with HIV are not seen in the primary care clinics and therefore will not benefit from VA's efforts in primary care settings to improve depression identification and treatment. Second, in addition to the negative outcomes of depression generally, depression in HIV patients is associated with additional negative outcomes including accelerated HIV disease progression, decreased immune system functioning, and premature death. Third, directly moving collaborative depression care from primary care clinics to HIV clinics is likely to fail for several reasons including the comorbidities associated with depressed HIV patient and the potential for drug-drug interactions. The proposed project will address these gaps and provide effectiveness and cost-effectiveness analyses to inform decisions about larger scale implementation of the HI-TIDES intervention.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['HIV, Depression']}, 'KeywordList': {'Keyword': ['HIV, depression', 'patient care management', 'patient care team']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '249', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Arm 1: Collaborative Care Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received collaborative care intervention.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Collaborative Care Interventions']}}, {'ArmGroupLabel': 'Arm 2: Usual Care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received usual care.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Collaborative Care Interventions', 'InterventionDescription': 'Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Arm 1: Collaborative Care Intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Percentage of Participants With Depression Treatment Response', 'PrimaryOutcomeDescription': 'Depression symptom severity over the past two weeks was measured using the Hopkins Symptom Checklist (SCL-20). The SCL-20 includes the 13-item depression scale plus 7 depression-related items from the Hopkins Symptom Checklist-90-Revised. The items are scored from 0 to 4 and averaged to provide a mean depression severity score from 0 to 4. Depression treatment response at 6-months was defined as a 50% decrease in mean SCL-20 score compared to baseline.', 'PrimaryOutcomeTimeFrame': '6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ncurrent 9-item Patient Health Questionnaire (PHQ-9) score of 10 or more and\\ncurrent treatment in the HIV clinic.\\n\\nExclusion Criteria:\\n\\npatients who do not have access to a telephone,\\npatients with current suicidal ideation,\\npatients with significant cognitive impairment as indicated by a score < 10 on the HIV Dementia Scale, and\\npatients with a chart diagnosis of schizophrenia.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jeffrey M Pyne, MD', 'OverallOfficialAffiliation': 'Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR', 'LocationCity': 'No. Little Rock', 'LocationState': 'Arkansas', 'LocationZip': '72114-1706', 'LocationCountry': 'United States'}, {'LocationFacility': 'Atlanta VA Medical and Rehab Center, Decatur, GA', 'LocationCity': 'Decatur', 'LocationState': 'Georgia', 'LocationZip': '30033', 'LocationCountry': 'United States'}, {'LocationFacility': 'Michael E. DeBakey VA Medical Center, Houston, TX', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '18825515', 'ReferenceType': 'result', 'ReferenceCitation': 'Pyne JM, Asch SM, Lincourt K, Kilbourne AM, Bowman C, Atkinson H, Gifford A. Quality indicators for depression care in HIV patients. AIDS Care. 2008 Oct;20(9):1075-83. doi: 10.1080/09540120701796884. Review.'}, {'ReferencePMID': '19320606', 'ReferenceType': 'result', 'ReferenceCitation': 'Fortney JC, Pyne JM, Smith JL, Curran GM, Otero JM, Enderle MA, McDougall S. Steps for implementing collaborative care programs for depression. Popul Health Manag. 2009 Apr;12(2):69-79.'}, {'ReferencePMID': '19437931', 'ReferenceType': 'result', 'ReferenceCitation': 'Ackerman B, Pyne JM, Fortney JC. Challenges associated with being an off-site depression care manager. J Psychosoc Nurs Ment Health Serv. 2009 Apr;47(4):43-9.'}, {'ReferencePMID': '21220657', 'ReferenceType': 'result', 'ReferenceCitation': 'Pyne JM, Fortney JC, Curran GM, Tripathi S, Atkinson JH, Kilbourne AM, Hagedorn HJ, Rimland D, Rodriguez-Barradas MC, Monson T, Bottonari KA, Asch SM, Gifford AL. Effectiveness of collaborative care for depression in human immunodeficiency virus clinics. Arch Intern Med. 2011 Jan 10;171(1):23-31. doi: 10.1001/archinternmed.2010.395.'}, {'ReferencePMID': '21714689', 'ReferenceType': 'result', 'ReferenceCitation': 'Curran GM, Pyne J, Fortney JC, Gifford A, Asch SM, Rimland D, Rodriguez-Barradas M, Monson TP, Kilbourne AM, Hagedorn H, Atkinson JH. Development and implementation of collaborative care for depression in HIV clinics. AIDS Care. 2011 Dec;23(12):1626-36. doi: 10.1080/09540121.2011.579943. Epub 2011 Jun 30.'}, {'ReferencePMID': '21348556', 'ReferenceType': 'result', 'ReferenceCitation': 'Fortney JC, Pyne JM, Steven CA, Williams JS, Hedrick RG, Lunsford AK, Raney WN, Ackerman BA, Ducker LO, Bonner LM, Smith JL. A Web-based clinical decision support system for depression care management. Am J Manag Care. 2010 Nov;16(11):849-54.'}, {'ReferencePMID': '21826113', 'ReferenceType': 'result', 'ReferenceCitation': 'Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R. Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation. Am J Gastroenterol. 2011 Dec;106(12):2123-32. doi: 10.1038/ajg.2011.252. Epub 2011 Aug 9.'}, {'ReferencePMID': '22310560', 'ReferenceType': 'result', 'ReferenceCitation': 'Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812.'}, {'ReferencePMID': '22536930', 'ReferenceType': 'result', 'ReferenceCitation': 'Bottonari KA, Tripathi SP, Fortney JC, Curran G, Rimland D, Rodriguez-Barradas M, Gifford AL, Pyne JM. Correlates of antiretroviral and antidepressant adherence among depressed HIV-infected patients. AIDS Patient Care STDS. 2012 May;26(5):265-73. doi: 10.1089/apc.2011.0218. Epub 2012 Mar 21.'}, {'ReferencePMID': '26102447', 'ReferenceType': 'result', 'ReferenceCitation': 'Painter JT, Fortney JC, Gifford AL, Rimland D, Monson T, Rodriguez-Barradas MC, Pyne JM. Cost-Effectiveness of Collaborative Care for Depression in HIV Clinics. J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):377-85. doi: 10.1097/QAI.0000000000000732.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'PubMed', 'SeeAlsoLinkURL': 'http://www.ncbi.nlm.nih.gov/pubmed/26126749'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Yes', 'IPDSharingDescription': 'Investigators can request IPD by contacting the PI.'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Arm 1: Collaborative Care Intervention', 'FlowGroupDescription': 'Collaborative Care Intervention: Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in VA electronic medical record. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Arm 2: Usual Care', 'FlowGroupDescription': 'Usual care arm. Usual care will include depression screening with the same 9-item Patient Health Questionnaire (PHQ-9) screener used for Arm 1. The HI-TIDES depression care team will not be a part of the usual care condition.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '123'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '126'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '105'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '110'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '18'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '16'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '11'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '11'}]}}, {'FlowDropWithdrawType': 'Death', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '4'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '5'}]}}, {'FlowDropWithdrawType': 'Withdrawal by Subject', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '3'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Arm 1: Collaborative Care Intervention', 'BaselineGroupDescription': 'Collaborative Care Intervention: Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Arm 2: Usual Care', 'BaselineGroupDescription': 'Usual care arm. Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The HI-TIDES depression care team will not be a part of the usual care condition.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '123'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '126'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '249'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '49.8', 'BaselineMeasurementSpread': '8.7'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '49.8', 'BaselineMeasurementSpread': '10.5'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '49.8', 'BaselineMeasurementSpread': '9.6'}]}}]}}]}}, {'BaselineMeasureTitle': 'Gender', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '7'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '120'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '122'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '242'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '78'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '77'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '155'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '45'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '49'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '94'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Percentage of Participants With Depression Treatment Response', 'OutcomeMeasureDescription': 'Depression symptom severity over the past two weeks was measured using the Hopkins Symptom Checklist (SCL-20). The SCL-20 includes the 13-item depression scale plus 7 depression-related items from the Hopkins Symptom Checklist-90-Revised. The items are scored from 0 to 4 and averaged to provide a mean depression severity score from 0 to 4. Depression treatment response at 6-months was defined as a 50% decrease in mean SCL-20 score compared to baseline.', 'OutcomeMeasurePopulationDescription': 'intent to treat analysis', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'percent response', 'OutcomeMeasureTimeFrame': '6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Arm 1: Collaborative Care Intervention', 'OutcomeGroupDescription': 'Collaborative Care Intervention: Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Arm 2: Usual Care', 'OutcomeGroupDescription': 'Usual care arm. Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The HI-TIDES depression care team will not be a part of the usual care condition.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '123'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '126'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '33.3'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '17.5'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.003', 'OutcomeAnalysisStatisticalMethod': 'Regression, Logistic', 'OutcomeAnalysisParamType': 'Odds Ratio (OR)', 'OutcomeAnalysisParamValue': '2.5', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '1.37', 'OutcomeAnalysisCIUpperLimit': '4.56'}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': '1 year', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Arm 1: Collaborative Care Intervention', 'EventGroupDescription': 'Collaborative Care Intervention: Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '123', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '123'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Arm 2: Usual Care', 'EventGroupDescription': 'Usual care arm. Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The HI-TIDES depression care team will not be a part of the usual care condition.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '126', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '126'}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Dr. Jeff Pyne', 'PointOfContactOrganization': 'Central Arkansas Veterans Healthcare System', 'PointOfContactEMail': 'jmpyne@uams.edu', 'PointOfContactPhone': '501-257-1083'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16833', 'ConditionBrowseLeafName': 'HIV Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2103', 'ConditionBrowseLeafName': 'Acquired Immunodeficiency Syndrome', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}]}}}}}, {'Rank': 64, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00643162', 'OrgStudyIdInfo': {'OrgStudyId': '8648'}, 'Organization': {'OrgFullName': 'Cedars-Sinai Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Combination Lexapro and Massage for Treatment of Depression in Older Adults', 'OfficialTitle': 'Combination Lexapro and Massage for Treatment in Depression in Older Subjects'}, 'StatusModule': {'StatusVerifiedDate': 'May 2019', 'OverallStatus': 'Terminated', 'WhyStopped': 'Interim analysis indicated recruitment was necessary beyond study capabilities.', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2006'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2010', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'February 2010', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 20, 2008', 'StudyFirstSubmitQCDate': 'March 20, 2008', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 26, 2008', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'January 25, 2018', 'ResultsFirstSubmitQCDate': 'May 28, 2019', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'June 18, 2019', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 28, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 18, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Itai Danovitch', 'ResponsiblePartyInvestigatorTitle': 'Chairman, Department of Psychiatry', 'ResponsiblePartyInvestigatorAffiliation': 'Cedars-Sinai Medical Center'}, 'LeadSponsor': {'LeadSponsorName': 'Cedars-Sinai Medical Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Forest Laboratories', 'CollaboratorClass': 'INDUSTRY'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Depression is a common and disabling condition which represents a substantial public health concern, especially with the aging of the population in general. In fact, one to four percent of the older population has major depression. Although medication is the main treatment for depression, studies show that only 50% of patients show a significant response to treatment. The response might actually be less in older subjects, and with more adverse side effects due to changes in the metabolism of the older population as well as drug interaction. For these reasons (changes in metabolism and possible drug interactions) the starting dose of the antidepressant Lexapro will be 5mg, instead of 10mg.\\n\\nTo combat the incomplete response to medication, many combined and augmentation strategies have been developed. Examples of this would be an antidepressant medication plus a neuroleptic medication; or an antidepressant medication plus talk therapy. One non-medication treatment that is being considered is massage therapy. Recent data suggest that massage therapy can be useful for the treatment of depression.\\n\\nThis study proposes to perform a controlled trail to assess the effects of massage therapy on symptoms of depression in older subjects with major depression. All of the subjects will receive Lexapro, which is an FDA approved medication for the treatment of depression. Half of the subjects will receive Swedish massage for one hour, twice a week, and the other half will receive light touch for one hour, twice per week for eight weeks. Standardized rating scales that evaluate depression will be used to evaluate the subjects mood.', 'DetailedDescription': 'Study Design: This will be an open-label, randomized control trial of concomitant massage therapy and escitalopram pharmacotherapy for the treatment of major depression in the elderly. All subjects who meet inclusion/exclusion criteria will receive escitalopram and also be randomized 1:1 (by computer) to Swedish massage or light touch. Escitalopram (5.0 mg/day, PO) will initially be administered for one week followed by an increase in dose to 10 mg/day for the remainder of the study; Massage or touch will be performed twice per week for 8 weeks. Every effort will be made to have non-consecutive massage/touch visits. The massage group will receive Swedish massage for 50 minutes twice per week. In the \"touch\" group, the massage therapist will provide gentle touch to the skin in the same distribution as that of the formal Swedish massage for 50 minutes twice per week. Every effort will be made to have one therapist perform all treatments. All assessments will be obtained prior to the first massage each week.\\nRecruitment and Retention: Subjects will be recruited from our outpatient clinic, attendings, as well as by advertising on radio, television, newspaper and our web site.\\n\\nTreatment\\n\\nMassage: Standard Swedish massage therapy will be employed which includes the systematic manipulation of the soft tissues of the body. It is designed to relax muscles by applying pressure to them against deeper muscles and bones, and rubbing in the same direction as the flow of blood returning to the heart. A routine has been designed whereby the therapist massages different areas of the body in an orderly fashion for specified periods of time. For sham massage (light touch), the massage therapists will provide gentle touch to the skin in the same distribution and duration as that of the formal Swedish massage. As mentioned below, deviations from the structured massage or touch will be recorded in the massage therapist\\'s diary.\\nQuality control for screening and outcome questionnaires: Kappa co-efficients for diagnostic and inter-rater reliability will be determined at six-month intervals. We routinely maintain kappa values of at >0.85.\\n\\nOutcome Measures: Primary outcome measure for this study will be degree of depression as measured by HAM-D. The secondary outcome measures will include quality of life, HAM-A, Beck Depression Inventory. Raters will be blind to treatment cell and test results.\\n\\nQuality control for screening and outcome questionnaires: Kappa co-efficients for diagnostic and inter-rater reliability will be determined at six-month intervals. We routinely maintain kappa values of at >0.85.\\n\\nStatistical Analysis All entries will be blind-verified, and following data entry, results will be checked for obvious outliers and inconsistent values. No single person will have the responsibility for both entry and verification on a given form. Data on computer records will be identifiable by a unique coded identifier to permit matching of records longitudinally. Each record will be logged as it is obtained. An archival record of all data collected, which has passed the above-noted checks, will be maintained on a hard disk. A backup of the archival data will be saved on magnetic tape (DAT tape) and writable CD-ROM archive disks. This copy will be stored in a separate offsite cabinet to ensure the survival of data in case of a natural disaster. A full backup will be made weekly, and stored for at least three months. A CD-ROM backup will be made every three months.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Massage', 'Lexapro', 'Alternative Therapy', 'Anti-depressant']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '17', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Swedish Massage', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Lexapro', 'Behavioral: Massage']}}, {'ArmGroupLabel': 'Light-Touch', 'ArmGroupType': 'Sham Comparator', 'ArmGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Lexapro', 'Behavioral: Light touch']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Lexapro', 'InterventionDescription': '5mg-10mg of lexapro, daily, for 9 weeks for all study participants.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Light-Touch', 'Swedish Massage']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Escitalopram']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Light touch', 'InterventionDescription': 'Light touch twice a week, for 8 weeks', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Light-Touch']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Massage', 'InterventionDescription': 'Massage twice a week, for 8 weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Swedish Massage']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Hamilton Depression Scale (HAM-D) Score', 'PrimaryOutcomeDescription': \"The Hamilton Depression Rating Scale (HAM-D) is a clinician-administered tool used to determine a patient's level of depression before, during, and after treatment. The HAM-D form lists 21 items, but the scoring is based on the first 17 questions. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. The scores from each item are added together to provide a total score. The sum of the scores from the first 17 questions provides an indication for level of depression. 0-7 = normal, 8-13 = mild depression, 14-18 = moderate depression, 19-22=severe depression and ≥ 23=very severe depression.\", 'PrimaryOutcomeTimeFrame': '9 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Beck Depression Inventory Score', 'SecondaryOutcomeDescription': 'The Beck Depression Inventory (BDI) is a series of 21-question, self-report rating inventory developed at a 5th grade reading level that measures characteristic attitudes and symptoms of depression. It was develop to detect, assess and monitor changes in depressive symptoms. For people who have been clinically diagnosed with depression, scores from 0 to 9 represent minimal depressive symptoms, scores of 10 to 16 indicate mild depression, scores of 17 to 29 indicate moderate depression, and scores of 30 to 63 indicate severe depression.', 'SecondaryOutcomeTimeFrame': '9 weeks'}, {'SecondaryOutcomeMeasure': 'Change in Hamilton Anxiety Scale (HAM-A) Score', 'SecondaryOutcomeDescription': \"The Hamilton Depression Rating Scale (HAM-D) is a clinician-administered tool used to determine a patient's level of anxiety before, during, and after treatment. The HAM-A is a 14-item assessment and each item is scored on a 5-point scale, ranging from 0 = not present to 4 = very severe. The sum of the scores is: 0-17 = mild anxiety, 18-24 = moderate anxiety, 25-30 = severe anxiety, and >30 = very severe anxiety.\", 'SecondaryOutcomeTimeFrame': '9 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\n> 60 years of age\\nUnipolar major depression as defined by Structured Clinical Interaction DSM-IV (SCID)\\nHAM-D score of > 17 (21-item scale)]]\\nNot taking antidepressants for at least two weeks, 2 months for fluoxetine and MAOIs]]\\nCapable of giving informed consent.\\n\\nExclusion Criteria:\\n\\nUnable to provide informed consent (e.g. severe cognitive impairment)\\nAcute medical condition or exacerbation of chronic medical condition associated with significant distress (pain, protracted fevers, etc.) and requiring active medical treatment.\\nHigh risk of suicide or violence as assessed by the investigator\\nCurrent or past history of psychosis or bipolar disorder\\nUse of psychotropic medication and/or psychotherapy outside of the study\\n(Exposure to treatment of fluoxetine or MAOIs in the previous two months; chronic use of benzodiazepine and non-benzodiazepine sedatives, antipsychotics, psychostimulants, mood stabilizing agents, codeine, steroids, anti-inflammatory agents.\\nAlternative medicine use in the preceding 30 days (e.g. acupuncture, herbs, etc.)\\nHistory of intolerance to massage or contraindication to massage (e.g. skin lesions that prevent direct contact by the therapist)\\nDiagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression or bipolar disorders;\\nMMSE less than 22\\nAlzheimer's Disease Assessment Scale-Cognitive Subscale ³ greater than 12\\nCurrent drug or alcohol abuse or dependence or history of drug or alcohol abuse or dependence within the past 6 months\\nUnstable medical or neurological conditions that are likely to interfere with the treatment of depression\\nCurrently on psychotropic medications including antidepressants or neuroleptics\\nActive suicidal ideation or other safety issues determined by the clinician to not be suitable for inclusion in the study\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '60 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Itai Danotivtch, Ph.D., M.D.', 'OverallOfficialAffiliation': 'Cedars-Sinai Medical Center', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Cedars-Sinai Medical Center Department of Psychiatry and Behavioral Neurosciences', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90048', 'LocationCountry': 'United States'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': '4 subjects screen failed; 1 subject withdrew consent after screen. Total of 5 subjects were not randomized.', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Swedish Massage', 'FlowGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nMassage: Massage twice a week, for 8 weeks.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Light-Touch', 'FlowGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nLight touch: Light touch twice a week, for 8 weeks'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '7'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '5'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '6'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '4'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '1'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '1'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Withdrawal by Subject', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Swedish Massage', 'BaselineGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nMassage: Massage twice a week, for 8 weeks.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Light-Touch', 'BaselineGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nLight touch: Light touch twice a week, for 8 weeks'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '7'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '5'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '12'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '8'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '8'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4'}]}}]}}]}}, {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}]}}, {'BaselineCategoryTitle': 'Not Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '11'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '10'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineMeasureCalculatePct': 'No', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '7'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '12'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Change in Hamilton Depression Scale (HAM-D) Score', 'OutcomeMeasureDescription': \"The Hamilton Depression Rating Scale (HAM-D) is a clinician-administered tool used to determine a patient's level of depression before, during, and after treatment. The HAM-D form lists 21 items, but the scoring is based on the first 17 questions. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. The scores from each item are added together to provide a total score. The sum of the scores from the first 17 questions provides an indication for level of depression. 0-7 = normal, 8-13 = mild depression, 14-18 = moderate depression, 19-22=severe depression and ≥ 23=very severe depression.\", 'OutcomeMeasurePopulationDescription': 'A 7th Massage subject completed 6 of 7 visits so his data was carried forward to the final visit. Data from the LT subject who terminated early at Visit 3 was not used. An interim analysis was performed, there was one active subject still in the early stages of the protocol, whose data was not included. The interim analysis became final.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': '9 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Swedish Massage', 'OutcomeGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nMassage: Massage twice a week, for 8 weeks.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Light-Touch', 'OutcomeGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nLight touch: Light touch twice a week, for 8 weeks'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '7'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '3'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '13', 'OutcomeMeasurementSpread': '7.4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '10.7', 'OutcomeMeasurementSpread': '4.9'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisNonInferiorityType': 'Other', 'OutcomeAnalysisPValue': '.68', 'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided', 'OutcomeAnalysisParamType': 'Mean Difference (Final Values)', 'OutcomeAnalysisParamValue': '2.3', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisDispersionType': 'Standard Deviation', 'OutcomeAnalysisDispersionValue': '6.15'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Change in Beck Depression Inventory Score', 'OutcomeMeasureDescription': 'The Beck Depression Inventory (BDI) is a series of 21-question, self-report rating inventory developed at a 5th grade reading level that measures characteristic attitudes and symptoms of depression. It was develop to detect, assess and monitor changes in depressive symptoms. For people who have been clinically diagnosed with depression, scores from 0 to 9 represent minimal depressive symptoms, scores of 10 to 16 indicate mild depression, scores of 17 to 29 indicate moderate depression, and scores of 30 to 63 indicate severe depression.', 'OutcomeMeasurePopulationDescription': 'Data was not abstracted since interim analysis recommended study closure', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': '9 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Swedish Massage', 'OutcomeGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nMassage: Massage twice a week, for 8 weeks.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Light-Touch', 'OutcomeGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nLight touch: Light touch twice a week, for 8 weeks'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '7'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '3'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '8.7', 'OutcomeMeasurementSpread': '6.6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '6.3', 'OutcomeMeasurementSpread': '6.3'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Change in Hamilton Anxiety Scale (HAM-A) Score', 'OutcomeMeasureDescription': \"The Hamilton Depression Rating Scale (HAM-D) is a clinician-administered tool used to determine a patient's level of anxiety before, during, and after treatment. The HAM-A is a 14-item assessment and each item is scored on a 5-point scale, ranging from 0 = not present to 4 = very severe. The sum of the scores is: 0-17 = mild anxiety, 18-24 = moderate anxiety, 25-30 = severe anxiety, and >30 = very severe anxiety.\", 'OutcomeMeasurePopulationDescription': 'Data was not abstracted since interim analysis recommended study closure', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': '9 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Swedish Massage', 'OutcomeGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nMassage: Massage twice a week, for 8 weeks.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Light-Touch', 'OutcomeGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nLight touch: Light touch twice a week, for 8 weeks'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '7'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '3'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5.3', 'OutcomeMeasurementSpread': '5.8'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '2.7', 'OutcomeMeasurementSpread': '13.1'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': '1 year', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Swedish Massage', 'EventGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nMassage: Massage twice a week, for 8 weeks.', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '7', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '7', 'EventGroupOtherNumAffected': '1', 'EventGroupOtherNumAtRisk': '7'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Light-Touch', 'EventGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nLight touch: Light touch twice a week, for 8 weeks', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '5', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '5', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '5'}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Cold Symptoms', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'After 2 weeks of taking Lexapro, subject reported symptoms of coughing, sneezing, feeling feverish, fatigue and dizziness and attributed it to a lingering coldAlthough symptoms are not associated with Lexapro, Investigator wanted to report as an AE.', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '7'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Felicia Mayes', 'PointOfContactOrganization': 'Cedars Sinai Medical Center', 'PointOfContactEMail': 'mayesf@cshs.org', 'PointOfContactPhone': '310-423-0825'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000015283', 'InterventionMeshTerm': 'Citalopram'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000017367', 'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'}, {'InterventionAncestorId': 'D000014179', 'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'}, {'InterventionAncestorId': 'D000049990', 'InterventionAncestorTerm': 'Membrane Transport Modulators'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000018490', 'InterventionAncestorTerm': 'Serotonin Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000018687', 'InterventionAncestorTerm': 'Antidepressive Agents, Second-Generation'}, {'InterventionAncestorId': 'D000000928', 'InterventionAncestorTerm': 'Antidepressive Agents'}, {'InterventionAncestorId': 'D000011619', 'InterventionAncestorTerm': 'Psychotropic Drugs'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16566', 'InterventionBrowseLeafName': 'Citalopram', 'InterventionBrowseLeafAsFound': 'Escitalopram', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M5687', 'InterventionBrowseLeafName': 'Dexetimide', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M14095', 'InterventionBrowseLeafName': 'Serotonin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M18232', 'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2828', 'InterventionBrowseLeafName': 'Antidepressive Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M13057', 'InterventionBrowseLeafName': 'Psychotropic Drugs', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr', 'InterventionBrowseBranchName': 'Psychotropic Drugs'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'AnDyAg', 'InterventionBrowseBranchName': 'Anti-Dyskinesia Agents'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 65, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01624402', 'OrgStudyIdInfo': {'OrgStudyId': 'R01MH096685', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH096685&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH096685', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH096685&Fy=all'}]}, 'Organization': {'OrgFullName': 'Weill Medical College of Cornell University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Ecosystem Focused Therapy in Post Stroke Depression', 'OfficialTitle': 'Ecosystem Focused Therapy in Post Stroke Depression'}, 'StatusModule': {'StatusVerifiedDate': 'February 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2012', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 31, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'January 31, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 18, 2012', 'StudyFirstSubmitQCDate': 'June 18, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 20, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'February 5, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 6, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Weill Medical College of Cornell University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': \"Older adults who are stroke survivors can experience many challenges, including depression, cognitive dysfunction, and physical disability. Family members and other caregivers may struggle with helping stroke survivors adjust to life after stroke. This research study involves testing a modified form of problem-solving therapy called Ecosystem Focused Therapy (EFT) to help treat depression in older adult stroke survivors. EFT teaches problem-solving skills to patients to help them cope with problems related to stroke and depression, alters their physical environment to accommodate new needs resulting from stroke, and helps the family or caregiver to assist in the patient's adaptation. In addition this study will compare EFT to an education intervention to see which is more effective in treating depressed stroke survivors.\", 'DetailedDescription': 'We propose to study the efficacy of \"Ecosystem Focused Therapy\" (EFT) in post-stroke depression (PSD), a disorder that afflicts a large number of stroke victims and increases mortality, cognitive impairment, and disability for years after stroke. EFT is a new, home-delivered intervention based on our integrative model of PSD, which originated from our clinical biology and treatment studies in late-life depression. It postulates two main paths to PSD. First, stroke and stroke-repair mechanisms contribute to metabolic changes mediating PSD. Second, a \"psychosocial storm\" stemming both from the patient\\'s sudden disability and the change in the patient\\'s needs and family life add a biological burden to this cascade of depressogenic events. EFT targets the \"psychosocial storm\" of PSD and focuses on the reciprocal interaction between the patient\\'s abilities and the challenges of his/her \"ecosystem\" (family, specialized therapists). EFT follows a structured personalization approach based on the \"model of adaptive functioning\", in which behavior is a function of the person\\'s competence and the demands of the environment. Thus, EFT continuously \"calibrates the environment\" to the PSD patient\\'s competence level and targets the PSD \"psychosocial storm\" through five integrated components: 1) It offers an action-oriented, \"new perspective\" about the patient\\'s recovery. 2) It provides an \"adherence enhancement structure\". 3) It offers a \"problem solving structure\" to the patient focusing on problems, valued by the patient, and pertinent to daily function. 4) It helps the family \"reengineer its goals, involvement, and plans\" to accommodate the patient\\'s disability. 5) It \"coordinates care with specialized therapists\" with the goal to increase patient participation in rehabilitation and social activities.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression', 'Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '151', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Ecosystem Focused Therapy (EFT)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': \"Ecosystem Focused Therapy (EFT) follows a structured personalization approach based on the model of adaptive functioning, in which behavior is a function of the person's competence and the demands of the environment.\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Ecosystem Focused Therapy (EFT)']}}, {'ArmGroupLabel': 'Education on Stroke and Depression (ESD)', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Education on Stroke and Depression (ESD) is home-delivered and imparts education about depression, stroke, and the role of available treatments.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Education on Stroke and Depression (ESD)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Education on Stroke and Depression (ESD)', 'InterventionDescription': \"Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.\\nComprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.\\nConveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.\\nESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy).\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Education on Stroke and Depression (ESD)']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Ecosystem Focused Therapy (EFT)', 'InterventionDescription': \"EFT offers an action-oriented, new perspective about the subject's recovery;\\nIt provides an adherence enhancement structure;\\nIt offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;\\nIt helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;\\nIt coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Ecosystem Focused Therapy (EFT)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression', 'PrimaryOutcomeDescription': 'This research study involves testing a modified form of problem-solving therapy called Ecosystem Focused Therapy (EFT) in reducing depression in older adult stroke survivors.', 'PrimaryOutcomeTimeFrame': '12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAge 50 years and older;\\nDiagnosis of unipolar major depression;\\nMontgomery Asberg Depression Rating Scale score ≥ 18;\\nCapacity to provide written consent for both research assessment and treatment;\\nCommand of English sufficient to participate in assessments and talking therapy.\\n\\nExclusion Criteria:\\n\\nModerately severe to severe dementia (MMSE score < 20);\\nGreater than mild to moderate aphasia (NIH Stroke Scale: Best Language > 1);\\nExpectation to be discharged to a nursing home;\\nPsychotic depression;\\nSuicidal intent or plan.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '50 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'George S. Alexopoulos, M.D.', 'OverallOfficialAffiliation': 'Weill Medical College of Cornell University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'New York Presbyterian Hospital', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10065', 'LocationCountry': 'United States'}, {'LocationFacility': 'Burke Rehabilitation Hospital', 'LocationCity': 'White Plains', 'LocationState': 'New York', 'LocationZip': '10605', 'LocationCountry': 'United States'}, {'LocationFacility': 'Institute of Geriatric Psychiatry', 'LocationCity': 'White Plains', 'LocationState': 'New York', 'LocationZip': '10605', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M20890', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4393', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3786', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4325', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15983', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 66, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01922219', 'OrgStudyIdInfo': {'OrgStudyId': '#6127'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '5K08MH085061', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=5K08MH085061&Fy=all'}]}, 'Organization': {'OrgFullName': 'New York State Psychiatric Institute', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression', 'OfficialTitle': 'Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression'}, 'StatusModule': {'StatusVerifiedDate': 'September 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'August 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 12, 2013', 'StudyFirstSubmitQCDate': 'August 12, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 14, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'December 22, 2016', 'ResultsFirstSubmitQCDate': 'January 10, 2017', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'March 1, 2017', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'September 18, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 19, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'New York State Psychiatric Institute', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this research study is to learn whether specific types of brain imaging and psychological testing can predict how much benefit patients with depression will receive from a well-studied psychotherapy for depression, called cognitive behavioral therapy (CBT), and how the brain imaging and psychological tests change with treatment. We will also be comparing brain scans from this study between individuals suffering from depression and volunteers without depression.\\n\\nThis study offers 14 sessions of one-on-one cognitive-behavioral therapy (CBT) over twelve weeks, administered by an experienced doctoral-level psychologist or psychiatrist.', 'DetailedDescription': 'Major depressive disorder (MDD) affects 13.1 - 14.2 million American adults annually. Cognitive-behavioral therapy (CBT) is a structured psychotherapy that has been demonstrated in multiple studies to be an effective treatment for MDD. Not all patients achieve a full remission from MDD with CBT, however. Mental health clinicians currently lack clinical or biological markers that can reliably predict treatment outcome with CBT for MDD. Developing such markers could greatly improve clinical outcomes, and could facilitate matching of patients to treatments that are likely to help them. A recent functional magnetic resonance imaging (fMRI) study in healthy individuals examined the neural correlates of cognitive strategies to regulate emotional responses to emotional stimuli. The emotional regulation techniques used in this fMRI study map closely onto the cognitive restructuring techniques that are a primary tool used in CBT for MDD. There is evidence that patients with depression may benefit most from a psychotherapy that draws on their existing strengths. We therefore propose to examine the neural representations of emotion regulation as a predictor of treatment outcome with CBT for MDD. We will recruit subjects with MDD in a current major depressive episode. Research participants will complete baseline psychological and biological assessments, including MRI and functional MRI imaging. Following scanning, subjects will receive 14 sessions of individual CBT for depression over 12 weeks, administered by an experienced psychiatrist or psychologist. Baseline assessments will be examined as predictors of treatment outcome with CBT for depression.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Major Depressive Disorder']}, 'KeywordList': {'Keyword': ['depression', 'cognitive therapy', 'cognitive behavioral therapy', 'CBT', 'psychotherapy', 'MDD', 'major depressive disorder', 'MRI', 'fMRI']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '37', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cognitive Behavioral Therapy', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive Behavioral Therapy']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Cognitive Behavioral Therapy', 'InterventionDescription': '14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cognitive Behavioral Therapy']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Remitters as Assessed by Post-treatment Beck Depression Inventory Less Than or Equal to 10', 'PrimaryOutcomeDescription': 'The primary outcome of this study is remission from depression at the conclusion of 12 weeks of cognitive behavioral therapy for depression. This will be assessed using the Beck Depression Inventory, a self-report questionnaire of symptoms of depression that will be administered at every treatment visit. Remission is defined by a final Beck Depression Inventory score less than or equal to 10.', 'PrimaryOutcomeTimeFrame': '12 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Post-Treatment Beck Depression Inventory', 'SecondaryOutcomeDescription': \"The Beck Depression Inventory is a self-report measure of depression severity that is a well-characterized scale with excellent psychometric properties and is frequently used in research studies of depression.\\n\\nThe scale measures symptoms related to sadness, pessimism, past failure, loss of pleasure, guilty feelings, punishment feelings, self-dislike, self-criticalness, suicidal thoughts or wishes, crying, agitation, loss of interest, indecisiveness, worthlessness, loss of energy, changes in sleeping pattern, irritability, changes in appetite, concentration difficulty, tiredness or fatigue, and loss of interest in sex.\\n\\nWe report the total score on the BDI, which has a range of 0 to 63. Higher values represent greater severity of depression. The following score interpretations are provided in the scale's manual:\\n\\n0-9 minimal depression 10-18 mild depression 19-29 moderate depression 30-63 severe depression\", 'SecondaryOutcomeTimeFrame': 'Post-Treatment, up to 12 weeks'}, {'SecondaryOutcomeMeasure': 'Final Score on the Hamilton Depression Rating Scale', 'SecondaryOutcomeDescription': 'Final score on the Hamilton Depression Rating Scale (HDRS) was calculated for 37 patients who were treated with Cognitive Behavioral Therapy.\\n\\nThe 17-item HDRS is a clinician-administered scale that quantifies depression severity, and includes items assessing mood, suicidal thinking, insomnia, feelings of guilt, work and activities, somatic symptoms, and insight. It is a well-characterized scale with excellent psychometric properties. The total score is the sum of the individual scores of the 17 scale items. Higher scores indicate greater depression severity. When using this outcome measure, we covary for baseline HDRS scores. Published norms for interpretation of the 17-item HDRS use a different version of the scale with a total possible score of 52, and are listed below. Interpretation is comparable (but not identical) with the 17-item HDRS version used in this study, which has a maximum score is 51.\\n\\nNone: 0-7 Mild: 8-13 Moderate: 14-19 Severe: 20-25 Very Severe: 26-52', 'SecondaryOutcomeTimeFrame': 'Post-Treatment, up to 12 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nIn a current major depressive episode\\nIf currently on medications, lack of benefit after an adequate trial. If currently on medications, willing and able to tolerate a medication washout.\\nAbility to provide an informed consent\\nFor healthy volunteers, no current or past history of depression\\n\\nExclusion Criteria:\\n\\nUnstable medical conditions\\nCurrent alcohol or substance abuse or dependence\\nCurrent or past history of other major psychiatric disorders such as Bipolar disorder, schizophrenia, or other psychotic illnesses (Anxiety in depressed participants is okay)\\nFor females, current pregnancy\\nDementia or neurological disease or head trauma with evidence of cognitive impairment\\nCurrently taking fluoxetine\\nContraindication to CBT\\nPresence of metal in body\\nClaustrophobia\\nWeight > 350 pounds', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jeffrey M Miller, M.D.', 'OverallOfficialAffiliation': 'New York State Psychiatric Institute', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'New York State Psychiatric Institute', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10032', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Cognitive Behavioral Therapy', 'FlowGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).\\n\\nCognitive Behavioral Therapy: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '37'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '28'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '9'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Cognitive Behavioral Therapy', 'BaselineGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).\\n\\nCognitive Behavioral Therapy: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '37'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '36'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '36', 'BaselineMeasurementSpread': '11.1'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '24'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '13'}]}}]}}]}}, {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '6'}]}}, {'BaselineCategoryTitle': 'Not Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '27'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '22'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '37'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Remitters as Assessed by Post-treatment Beck Depression Inventory Less Than or Equal to 10', 'OutcomeMeasureDescription': 'The primary outcome of this study is remission from depression at the conclusion of 12 weeks of cognitive behavioral therapy for depression. This will be assessed using the Beck Depression Inventory, a self-report questionnaire of symptoms of depression that will be administered at every treatment visit. Remission is defined by a final Beck Depression Inventory score less than or equal to 10.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': '12 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Cognitive Behavioral Therapy', 'OutcomeGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).\\n\\nCognitive Behavioral Therapy: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '37'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '13'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Post-Treatment Beck Depression Inventory', 'OutcomeMeasureDescription': \"The Beck Depression Inventory is a self-report measure of depression severity that is a well-characterized scale with excellent psychometric properties and is frequently used in research studies of depression.\\n\\nThe scale measures symptoms related to sadness, pessimism, past failure, loss of pleasure, guilty feelings, punishment feelings, self-dislike, self-criticalness, suicidal thoughts or wishes, crying, agitation, loss of interest, indecisiveness, worthlessness, loss of energy, changes in sleeping pattern, irritability, changes in appetite, concentration difficulty, tiredness or fatigue, and loss of interest in sex.\\n\\nWe report the total score on the BDI, which has a range of 0 to 63. Higher values represent greater severity of depression. The following score interpretations are provided in the scale's manual:\\n\\n0-9 minimal depression 10-18 mild depression 19-29 moderate depression 30-63 severe depression\", 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'Score on a scale', 'OutcomeMeasureTimeFrame': 'Post-Treatment, up to 12 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Cognitive Behavioral Therapy', 'OutcomeGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).\\n\\nCognitive Behavioral Therapy: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '37'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '15.4', 'OutcomeMeasurementSpread': '9.5'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Final Score on the Hamilton Depression Rating Scale', 'OutcomeMeasureDescription': 'Final score on the Hamilton Depression Rating Scale (HDRS) was calculated for 37 patients who were treated with Cognitive Behavioral Therapy.\\n\\nThe 17-item HDRS is a clinician-administered scale that quantifies depression severity, and includes items assessing mood, suicidal thinking, insomnia, feelings of guilt, work and activities, somatic symptoms, and insight. It is a well-characterized scale with excellent psychometric properties. The total score is the sum of the individual scores of the 17 scale items. Higher scores indicate greater depression severity. When using this outcome measure, we covary for baseline HDRS scores. Published norms for interpretation of the 17-item HDRS use a different version of the scale with a total possible score of 52, and are listed below. Interpretation is comparable (but not identical) with the 17-item HDRS version used in this study, which has a maximum score is 51.\\n\\nNone: 0-7 Mild: 8-13 Moderate: 14-19 Severe: 20-25 Very Severe: 26-52', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': 'Post-Treatment, up to 12 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Cognitive Behavioral Therapy', 'OutcomeGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).\\n\\nCognitive Behavioral Therapy: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '37'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '13.41', 'OutcomeMeasurementSpread': '6.61'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Cognitive Behavioral Therapy', 'EventGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).\\n\\nCognitive Behavioral Therapy: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '37', 'EventGroupOtherNumAffected': '1', 'EventGroupOtherNumAtRisk': '37'}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Knee Pain during MRI', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'During an MRI, a subject developed mild unilateral knee pain similar to pain she had experienced in the past, and subsequently developed some stiffness and swelling in this knee. The IRB concluded that the event was neither serious nor study related.', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '37'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Jeffrey Miller, M.D.', 'PointOfContactOrganization': 'NYSPI', 'PointOfContactEMail': 'jm2233@cumc.columbia.edu', 'PointOfContactPhone': '646-774-7613'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000003865', 'ConditionMeshTerm': 'Depressive Disorder, Major'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafAsFound': 'Major Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 67, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03941106', 'OrgStudyIdInfo': {'OrgStudyId': 'CNIG18may-0001'}, 'Organization': {'OrgFullName': 'Institute of Mental Health, Singapore', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Accelerated Transcranial Magnetic Stimulation (aTBS) to Treat Depression', 'OfficialTitle': 'A Pilot Study of Intermittent Accelerated Burst Transcranial Magnetic Stimulation (aTBS) to Treat Depression: a Randomized, Single-blind, Delayed-start Trial'}, 'StatusModule': {'StatusVerifiedDate': 'April 2019', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 1, 2019', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 1, 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'May 1, 2021', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 7, 2019', 'StudyFirstSubmitQCDate': 'May 5, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 7, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 8, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 10, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Institute of Mental Health, Singapore', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The primary aims of this study are to investigate the efficacy of L DLPFC accelerated TMS (aTMS) in patients with depression in Singapore and to assess the whether a 1-week course of treatment is as effective as a 4-week course of non-accelerated treatment and if additional aTMS or different aTMS treatments will be more efficacious in non-responders to initial aTMS treatment.', 'DetailedDescription': \"Repetitive transcranial magnetic stimulation (TMS) is a technique for stimulating brain activity using transient magnetic field to induce an electrical current in the brain producing firing of focal groups of brain cells. TMS is beginning to emerge in routine clinical practice as a treatment for depression. The predominant hypothesis is that depressed patients benefit from left sided high-frequency TMS (LHF-TMS) over the left dorsolateral prefrontal cortex (DLPFC)(1). A major limitation of rTMS is the large amount of time taken for a standard protocol (38 minutes a day for 20-30 working days). The optimal type and duration of TMS is still uncertain , as is the optimal strategy for continuing or changing type of rTMS if there is poor initial response.(1) One potential strategy to improve the acceptability of rTMS is to compress or accelerate the administration of rTMS (aTMS) by administering multiple sessions of rTMS over a shorter period of time to have equivalent efficacy in shorter period of time. Various studies of aTMS (2-9) have been safely conducted with anywhere from 2 (3) to 10 (2) sessions of rTMS a day for a total of 9 (5) - 20 (4, 7) sessions of TMS over 2 (2) to 9 (8) days. These studies showed that aTMS was safe and efficacious, with no significant side effects reported and a high level of patient acceptability and significant improvements in subjects' depression after the aTMS. However, there is no data on whether subjects who do not response to aTMS will benefit from more of the same TMS or from changing the mode of rTMS. The only study investigating this issue investigated normal rTMS, not aTMS, and did not find a significant difference in response to different forms of rTMS in initial non-responders (10). Our own observations and some preliminary evidence suggest that there may be a delayed response to TMS in some patients (11, 12). Thus, instead of the usual practice of giving 4-6 weeks stimulation (every weekday) and assessing for response at the end of the stimulation period, the same outcome may be achieved by giving a shorter period of stimulation (eg 1 weeks), waiting 2-4 weeks, then assessing response and the need for further TMS treatment. Further, giving more than 1 treatment per day has been shown to be effective (13) and may lead to more efficient treatment, i.e. fewer days to response and less requirement for patient attendance at the treatment centre (2-9).\\n\\nThis pilot study will contribute to existing knowledge by being possibly the first group in South East Asia to investigate the immediate and delayed efficacy of aTMS in the local population (i.e. in an Asian setting) as well as whether continuing or changing the type of rTMS is more efficacious in subjects who do not respond to initial aTMS.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['rTMS, depression, accelerated']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Sequential Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '60', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Left aTMS', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Accelerated repetitive transcranial magnetic stimulation']}}, {'ArmGroupLabel': 'Right aTMS', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Accelerated repetitive transcranial magnetic stimulation']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Accelerated repetitive transcranial magnetic stimulation', 'InterventionDescription': 'Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Left aTMS', 'Right aTMS']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Remission as assessed by The Montgomery-Åsberg Depression Rating Scale (MADRS)', 'PrimaryOutcomeDescription': 'The MADRS is a 0-60 point scale to measure depression severity with a higher number indicating more severe depression. Remission from depression is defined as 10 or less. Moderate to severe depression is defined as 20 or more.', 'PrimaryOutcomeTimeFrame': '3 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Remission as assessed by The Montgomery-Åsberg Depression Rating Scale (MADRS)', 'SecondaryOutcomeDescription': 'A MADRS score of 10 or less.', 'SecondaryOutcomeTimeFrame': '6 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAge ≥21 years.\\nDSM-V diagnosis of current Major Depressive Episode.\\nMontgomery-Asberg Depression Rating Scale score of 20 or more.\\nAble to give informed consent.\\n\\nExclusion Criteria:\\n\\nDSM-V psychotic disorder.\\nDrug or alcohol abuse or dependence (preceding 3 months).\\nInadequate response to ECT (current episode of depression).\\nRapid clinical response required, e.g. high suicide risk.\\nSignificant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy.\\nMetal in the cranium, skull defects, pacemaker, cochlear implant, medication pump or other electronic device.\\nPregnancy.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '21 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Phern-Chern Tor, MBBS', 'CentralContactRole': 'Contact', 'CentralContactPhone': '65-63892000', 'CentralContactEMail': 'phern_chern_tor@imh.com.sg'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26909825', 'ReferenceType': 'background', 'ReferenceCitation': 'Tor PC, Gálvez V, Goldstein J, George D, Loo CK. Pilot Study of Accelerated Low-Frequency Right-Sided Transcranial Magnetic Stimulation for Treatment-Resistant Depression. J ECT. 2016 Sep;32(3):180-2. doi: 10.1097/YCT.0000000000000306.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 68, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01773629', 'OrgStudyIdInfo': {'OrgStudyId': '2010-38-LGH'}, 'Organization': {'OrgFullName': 'Lancaster General Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Care Managers for Perinatal Depression (CMPD)', 'OfficialTitle': 'Care Managers for Perinatal Depression (CMPD)', 'Acronym': 'CMPD'}, 'StatusModule': {'StatusVerifiedDate': 'January 2014', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2010'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2013', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2013', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 16, 2013', 'StudyFirstSubmitQCDate': 'January 18, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 23, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 29, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 30, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Lancaster General Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Pennsylvania', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Robert Wood Johnson Foundation', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The investigators will evaluate effects of introducing the care manager on:\\n\\nPatient receipt of timely diagnosis and initiation of treatment for major depression (diagnosis within 2 weeks of screening and treatment within 1 month of diagnosis); and\\nPatient continuity of care for depression across the transition of care from pregnancy to postpartum (within 4 months postpartum).', 'DetailedDescription': 'The first two specific research aims of this proposed randomized study will evaluate the benefits of introducing site specific care managers into established multi-component enhancements of perinatal depression care. The four study sites are members of the IMPLICIT perinatal quality improvement network and provide prenatal care to a diverse population of low income minority women using a common set of care processes within diverse practice models including Obstetric, Family Medicine, and Nurse Practitioner/Midwifery settings. The established processes of care include evidence based screening, diagnosis, treatment protocols and quality improvement care teams.\\n\\nThe investigators will evaluate effects of introducing the care manager on:\\n\\nPatient receipt of timely diagnosis and initiation of treatment for major depression (diagnosis within 2 weeks of screening and treatment within 1 month of diagnosis); and\\nPatient continuity of care for depression across the transition of care from pregnancy to postpartum (within 4 months postpartum).\\n\\nFor the third and fourth specific research aims we will conduct supplementary econometric and qualitative analyses to aid in understanding the provider and system context in which this intervention is implemented across the four study sites. Results of this evaluation will be used to understand for whom and in which systems of care this model is most successful as well as the costs of delivering this intervention.\\n\\nSpecifically the investigators will:\\n\\nEmploy econometric techniques to quantify the costs of implementing and maintaining the IMPLICIT collaborative care maternal depression intervention; and\\nDevelop institutional ethnographies of the four study sites and identify factors associated with relative success in implementing perinatal depression care managers and improving timely diagnosis, initiation, and continuity of depression care.\\n\\nAchieving these aims will provide the foundation for dissemination of this innovative approach to perinatal depression care delivery throughout the entire growing IMPLICIT network which now extends across the northeast and mid-Atlantic regions of the US; sites which provide perinatal care for low income minority women in urban, rural, and suburban communities. These sites include prenatal practices in the Robert Wood Johnson Foundation Aligning Forces for Quality initiative, the Healthy York County Coalition which is partnering with us to disseminate this work in their region.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression', 'Pregnancy']}, 'KeywordList': {'Keyword': ['Depression', 'Pregnancy', 'Postpartum', 'Perinatal']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '194', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Intervention']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a \"perinatal depression champion\" for a timely formal diagnostic interview.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Control']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Intervention', 'InterventionDescription': 'Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}}, {'InterventionType': 'Other', 'InterventionName': 'Control', 'InterventionDescription': 'Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a \"perinatal depression champion\" for a timely formal diagnostic interview.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Diagnosis of major depression within 2 weeks of screening', 'PrimaryOutcomeDescription': 'Patient receipt of timely diagnosis for major depression during perinatal period.', 'PrimaryOutcomeTimeFrame': '2 weeks after screening'}, {'PrimaryOutcomeMeasure': 'Treatment of major depression within 1 month of diagnosis', 'PrimaryOutcomeDescription': 'Patient receipt of timely initiation of treatment for major depression during the perinatal period.', 'PrimaryOutcomeTimeFrame': '1 month'}, {'PrimaryOutcomeMeasure': 'Transition of care from pregnancy to postpartum', 'PrimaryOutcomeDescription': 'Patient continuity of care for depression across the transition of care from pregnancy to postpartum within 4 months postpartum.', 'PrimaryOutcomeTimeFrame': '4 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quantify the costs of implementing a care manager', 'SecondaryOutcomeDescription': 'Employ econometric techniques to quantify the costs of implementing and maintaining the care manager for managing perinatal depression.', 'SecondaryOutcomeTimeFrame': '3 years'}, {'SecondaryOutcomeMeasure': 'Qualitative assessment of success in implementation of perinatal depression care management process.', 'SecondaryOutcomeDescription': 'Develop institutional ethnographies of the study sites and identify factors associated with relative success in implementing perinatal depression care managers and improving timely diagnosis, initiation, and continuity of depression care. Qualitative measures include efficacy of core implementation group, commitment of implementation group, commitment of user group and readiness to change.', 'SecondaryOutcomeTimeFrame': '3 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nFemale\\nCurrent pregnancy or experienced pregnancy in the past 6 weeks\\nScore >= 12 on PHQ9\\n\\nExclusion Criteria:\\n\\n< age 13\\nMental illness\\nPrimary language other than English or Spanish', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '13 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Stephen Ratcliffe, MD, MSPH', 'OverallOfficialAffiliation': 'Lancaster General Hospital', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Ian M Bennett, MD, PhD', 'OverallOfficialAffiliation': 'University of Pennsylvania', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Donna Cohen, MD, MS', 'OverallOfficialAffiliation': 'Lancaster General Hospital', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Michael A Horst, PhD, MPHS, MS', 'OverallOfficialAffiliation': 'Lancaster General Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Downtown Family Medicine', 'LocationCity': 'Lancaster', 'LocationState': 'Pennsylvania', 'LocationZip': '17604', 'LocationCountry': 'United States'}, {'LocationFacility': 'Southeast Lancaster Health Services', 'LocationCity': 'Lancaster', 'LocationState': 'Pennsylvania', 'LocationZip': '17608', 'LocationCountry': 'United States'}, {'LocationFacility': 'Broad Street Health Center', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19122', 'LocationCountry': 'United States'}, {'LocationFacility': 'Haddington Health Center', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19139', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 69, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03283254', 'OrgStudyIdInfo': {'OrgStudyId': '7428'}, 'Organization': {'OrgFullName': 'New York State Psychiatric Institute', 'OrgClass': 'OTHER'}, 'BriefTitle': 'PREPP: Preventing Postpartum Depression', 'OfficialTitle': 'Preventing Postpartum Depression: A Dyadic Approach Adjunctive to Obstetric Care', 'Acronym': 'PREPP'}, 'StatusModule': {'StatusVerifiedDate': 'June 2019', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 17, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 20, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'August 10, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'August 14, 2017', 'StudyFirstSubmitQCDate': 'September 12, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 14, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 6, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 10, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Catherine Monk', 'ResponsiblePartyInvestigatorTitle': 'Professor of Medical Psychology', 'ResponsiblePartyInvestigatorAffiliation': 'New York State Psychiatric Institute'}, 'LeadSponsor': {'LeadSponsorName': 'New York State Psychiatric Institute', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"The primary aim of this study is to determine if a behavioral intervention targeting maternal caregiving of young infants can increase infant sleep and reduce fuss/cry behavior, and thereby (1) reduce the incidence and/or severity of postpartum maternal depression and (2) improve the quality of the mother-infant interaction and subsequent child development. Specifically, the study team will investigate: (1) the effectiveness of the intervention compared to usual care; (2) if the effects of the intervention can be detected in the assessments of the quality of mother-infant interaction; (3) if there are prenatal and/or postnatal biomarkers that can help identify infants whose behavior is more likely to play a role in their mothers' depression; (4) if these markers differentiate which infants will be most responsive to the intervention(s); and (5), if assessments of brain function at birth and at 4-6 weeks of age provide biological nodal points for identifying the effects of the intervention on infant brain development. Participants will be recruited during their 2nd trimester, and will be randomly separated into one of two groups: a group that receives coaching in parenting techniques (4 in-person coaching sessions and 1 phone session) or one that receives treatment as usual.\", 'DetailedDescription': \"Of the nearly 4 million mothers delivering live births each year in the United States, approximately 560,000 — or 14% — will develop major or minor depression within the first four months postpartum, when the rate peaks. This number dwarfs prevalence rates for gestational diabetes (2-5%) and is comparable to preterm birth (11.4%). Postpartum depression (PPD) has substantial consequences: poorer maternal quality of life, significant emotional suffering, and suicide risk. PPD predicts diminished mother-infant bonding, and poor outcomes in social-emotional and, in some groups, cognitive development. PPD is undertreated in part because women are reluctant to seek treatment due to the stigma associated with mental health care, logistical barriers to at-tending added health care appointments, and disinclination to take medications while breastfeeding. Of preventive interventions, few embed services in obstetrical care or leverage the unique mother-infant dyadic orientation of the childbearing period. The investigators developed a novel intervention based on the conceptualization of maternal depression as a potential disorder of the mother-infant dyad, and one that can be approached through psychological and behavioral changes in the mother — commencing before birth — that affect her and the child. PREPP (Practical Resources for Effective Postpartum Parenting) enrolls distressed pregnant women at risk for PPD, spans late pregnancy to the 6 week postpartum check up, comprises four in-person 'coaching' sessions adjunctive to obstetrical (OB) prenatal and postnatal appointments, one phone session, and imparts (a) mindfulness and self-reflection skills, (b) parenting skills, and (c) psycho-education.\\n\\nThe primary aim of this study is to determine if a behavioral intervention targeting maternal caregiving of young infants can increase infant sleep and reduce fuss/cry behavior, and thereby (1) reduce the incidence and/or severity of postpartum maternal depression and (2) improve the quality of the mother-infant interaction and subsequent child development.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Postpartum Depression']}, 'KeywordList': {'Keyword': ['Postpartum Depression Treatment']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Two groups: One receives PREPP prevention intervention and the other group receives Enhanced Treatment as Usual (psychoeducation about Postpartum Depression, referral and monitoring)', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignMaskingDescription': 'The person administering the outcome measures is blind to participant group.', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '300', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Practical Resources for Effective Postpartum (PREPP)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'A psychotherapeutic preventive intervention that involves psychoeducation and cognitive behavioral techniques.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Practical Resources for Effective Postpartum Parenting']}}, {'ArmGroupLabel': 'Enhanced Treatment as Usual', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Psychoeducation about Postpartum Depression, referral to treatment in the community and monitoring', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Enhanced Treatment As Usual']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Practical Resources for Effective Postpartum Parenting', 'InterventionDescription': 'A preventive psychotherapy intervention for Postpartum Depression', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Practical Resources for Effective Postpartum (PREPP)']}, 'InterventionOtherNameList': {'InterventionOtherName': ['PREPP']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Enhanced Treatment As Usual', 'InterventionDescription': 'Psychoeducation about Postpartum Depression, referral to treatment in the community, clinical monitoring', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Enhanced Treatment as Usual']}, 'InterventionOtherNameList': {'InterventionOtherName': ['ETAU']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Postpartum Depression Symptoms', 'PrimaryOutcomeDescription': 'Postpartum Depression Symptoms measured by Edinburgh Postnatal Depression Scale', 'PrimaryOutcomeTimeFrame': '6-16 weeks postpartum'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Improved Sleep', 'SecondaryOutcomeDescription': 'Improved self-report of sleep quality on Pittsburgh Sleep Quality Index and improved sleep shown on actigraphy monitor', 'SecondaryOutcomeTimeFrame': '3rd trimester of pregnancy - 16 weeks postpartum'}, {'SecondaryOutcomeMeasure': 'Infant Behavior', 'SecondaryOutcomeDescription': 'Cry behavior and sleep behavior measured by The Baby Day Diary', 'SecondaryOutcomeTimeFrame': '6 & 16 weeks postpartum'}, {'SecondaryOutcomeMeasure': 'Greater infant left frontal EEG power reflecting sleep spindle activity', 'SecondaryOutcomeDescription': 'More positive perceptions and objective assessments of maternal postpartum sleep efficiency will be mediated by greater infant left frontal EEG power reflecting sleep spindle activity and associated longer average durations of infant nocturnal sleep per maternal report and actigraphy.', 'SecondaryOutcomeTimeFrame': 'Newborn-6 weeks postpartum'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHealthy pregnant women between 18-45 years old (based on self report)\\nA score of ≥21 on the Predictive Index of Postnatal Depression (PIPD), indicating risk for developing postpartum depression\\nA healthy, singleton pregnancy (based on self report)\\nEnglish speaking (based on self report)\\nReceiving standard prenatal care (based on self report)\\n\\nExclusion Criteria:\\n\\nMulti-fetal pregnancy (based on self-report)\\nSmoking, illicit drug use, or alcohol use during pregnancy (based on self-report)\\nAcute medical illness or significant pregnancy complication (based on self-report)\\nCurrently in weekly, individual psychotherapy, including psychopharmacology (based on self report)\\nPsychotic d/o; Bipolar I; Major Depressive d/o (based on M.I.N.I.)', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '45 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Elizabeth Werner, Ph.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '6463191008', 'CentralContactEMail': 'ew150@cumc.columbia.edu'}, {'CentralContactName': 'Catherine Monk, Ph.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '917-543-6031', 'CentralContactEMail': 'cem31@cumc.columbia.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Catherine Monk, Ph.D.', 'OverallOfficialAffiliation': 'Columbia University', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Elizabeth Werner, Ph.D.', 'OverallOfficialAffiliation': 'Columbia University', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Elizabeth Werner', 'LocationStatus': 'Recruiting', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10032', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Elizabeth Werner, Ph.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '646-774-8945', 'LocationContactEMail': 'ew150@cumc.columbia.edu'}, {'LocationContactName': 'Catherine Monk, Ph.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '646-774-8941', 'LocationContactEMail': 'cem31@cumc.columbia.edu'}, {'LocationContactName': 'Catherine Monk, PhD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Yes', 'IPDSharingDescription': 'De-identified data may be made available to other researchers.', 'IPDSharingInfoTypeList': {'IPDSharingInfoType': ['Study Protocol', 'Informed Consent Form (ICF)']}, 'IPDSharingTimeFrame': 'After the completion of the study', 'IPDSharingAccessCriteria': 'Permission of the PI'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000019052', 'ConditionMeshTerm': 'Depression, Postpartum'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000011644', 'ConditionAncestorTerm': 'Puerperal Disorders'}, {'ConditionAncestorId': 'D000011248', 'ConditionAncestorTerm': 'Pregnancy Complications'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M19660', 'ConditionBrowseLeafName': 'Depression, Postpartum', 'ConditionBrowseLeafAsFound': 'Postpartum Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13082', 'ConditionBrowseLeafName': 'Puerperal Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12710', 'ConditionBrowseLeafName': 'Pregnancy Complications', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}}}}, {'Rank': 70, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01238614', 'OrgStudyIdInfo': {'OrgStudyId': 'MLM-CHICA-K-MD'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'K22LM009160', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=K22LM009160&Fy=all'}]}, 'Organization': {'OrgFullName': 'Indiana University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Universal Screening for Maternal Depression With the CHICA System', 'OfficialTitle': 'Universal Screening for Maternal Depression With the CHICA System'}, 'StatusModule': {'StatusVerifiedDate': 'November 2010', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 2007'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2009', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 2010', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 9, 2010', 'StudyFirstSubmitQCDate': 'November 9, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 10, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 9, 2010', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 10, 2010', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyOldNameTitle': 'Paul Biondich', 'ResponsiblePartyOldOrganization': 'IUPUI'}, 'LeadSponsor': {'LeadSponsorName': 'Indiana University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Library of Medicine (NLM)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The CHICA system is a clinical decision support system that uses adaptive turnaround documents to provide point-of-care information to clinicians. We will be studying whether it can help in the diagnosis and referral of mothers with maternal depression.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Maternal Depression']}, 'KeywordList': {'Keyword': ['maternal depression', 'clinical decision support']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Factorial Assignment', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '3250', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'PSF-JIT', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Mothers in this arm receive prescreening questions and clinicians receive just-in-time handouts to aid in diagnosis.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: CHICA PSF plus JIT']}}, {'ArmGroupLabel': 'PSF', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Mothers in this arm receive screening questions on the prescreener form', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: CHICA maternal depression PSF']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Mothers in this arm receive no maternal depression CHICA additional care', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Control']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'CHICA PSF plus JIT', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['PSF-JIT']}}, {'InterventionType': 'Other', 'InterventionName': 'CHICA maternal depression PSF', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['PSF']}}, {'InterventionType': 'Other', 'InterventionName': 'Control', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Percent of mothers screening positive for maternal depression.', 'PrimaryOutcomeTimeFrame': \"1 year after child's birth\"}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Percent of mothers diagnosed with maternal depression', 'SecondaryOutcomeTimeFrame': \"one year after child's birth\"}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAll families of patients age 0 to 15 months\\n\\nExclusion Criteria:\\n\\nNone', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'CHSR', 'LocationCity': 'Indianapolis', 'LocationState': 'Indiana', 'LocationZip': '46202', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 71, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00556140', 'OrgStudyIdInfo': {'OrgStudyId': '2003-P-000990'}, 'Organization': {'OrgFullName': 'Massachusetts General Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression', 'OfficialTitle': 'The Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Acute Treatment of Psychotic Major Depression: Efficacy and Tolerability', 'Acronym': 'Abilify'}, 'StatusModule': {'StatusVerifiedDate': 'July 2012', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2003'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2008', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'January 2008', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 8, 2007', 'StudyFirstSubmitQCDate': 'November 8, 2007', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 9, 2007', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'June 1, 2012', 'ResultsFirstSubmitQCDate': 'July 11, 2012', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 20, 2012', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 11, 2012', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 20, 2012', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'John D. Matthews', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Massachusetts General Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Massachusetts General Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Bristol-Myers Squibb', 'CollaboratorClass': 'INDUSTRY'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Psychotic Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 3']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '16', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Major Depression with Psychotic Features', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Aripiprazole']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Aripiprazole', 'InterventionDescription': 'Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.\\n\\nAripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.\\n\\nYou will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Major Depression with Psychotic Features']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Abilify']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression and Psychosis Response Rate', 'PrimaryOutcomeDescription': 'This response rate refers to the percentage of patients who experienced a 50 percent or greater reduction in symptoms. Specifically, this refers to a 50 percent reduction in Hamilton Depression Rating Scale 17 (HAM-D-17) scores from baseline and no psychotic symptoms as measured by the Structured Clinical Interview for DMS-IV psychosis module. HAM-D-17 scores range from 0-50 with a score of >23 considered severely depressed and <7 to be mildly to not at all depressed.', 'PrimaryOutcomeTimeFrame': 'Baseline and 7 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depression and Psychosis Remission Rate', 'SecondaryOutcomeDescription': 'This remission rate refers to a Hamilton Depression Rating Scale 17 (HAM-D-17) score of 7 or less and no psychotic symptoms as measured by the Structured Clinical Interview for DMS-IV psychosis module. HAM-D-17 scores range from 0-50 with a score of >23 considered severely depressed and <7 to be mildly to not at all depressed.', 'SecondaryOutcomeTimeFrame': 'Baseline and 7 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nMen and women aged 18-80 years, inclusive.\\nDrug-free outpatients or inpatients meeting DSM-IV criteria for major depression with psychotic features.\\nInpatients who undergo a 5-7 day washout period of their medication while concurrently beginning one of the approved SSRI's and abilify.\\nHAM-D-24 score > 16.\\n\\nExclusion Criteria:\\n\\nPregnant women and women of child bearing potential not using a medically accepted means of contraception (oral contraceptives are allowed).\\nWomen who are breast-feeding.\\nPatients meeting DSM-IV criteria for major depression without psychotic features, or psychosis without major depression at the screen visit.\\nPatients with serious suicidal risk.\\nPatients with a history of seizure disorder; unstable physical disorders (cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic); or any physical disorder judged to significantly affect central nervous system function.\\nPatients meeting criteria for the following DSM-IV diagnoses: organic mental disorders; substance use disorders, including alcohol, active within the last 6 months; bipolar disorder; schizoaffective disorder; or antisocial personality disorder.\\nPatients who are currently taking an antidepressant, antipsychotic, or mood stabilizing drug and who are responding to one or all of these medications. If patients are not responding to these medications, they may go through a washout period of at least one week under the supervision of a study doctor before entering into this study.\\nPatients who are not able to read and understand the consent form, or who are not capable of understanding or giving informed consent to the procedures of the study\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Matthews D John, MD', 'OverallOfficialAffiliation': 'Massachusetts General Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Massachusetts General Hospital', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02114', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '19142112', 'ReferenceType': 'derived', 'ReferenceCitation': 'Matthews JD, Siefert C, Dording C, Denninger JW, Park L, van Nieuwenhuizen AO, Sklarsky K, Hilliker S, Homberger C, Rooney K, Fava M. An open study of aripiprazole and escitalopram for psychotic major depressive disorder. J Clin Psychopharmacol. 2009 Feb;29(1):73-6. doi: 10.1097/JCP.0b013e318193dfb4.'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'All participants enrolled in the study were given aripiprazole and escitalopram.', 'FlowRecruitmentDetails': 'Recruitment ran from Sept. 13, 2004 to Aug. 9, 2006 from the Massachusetts General Psychiatry Inpatient and Outpatient clinics.', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Major Depression With Psychotic Features', 'FlowGroupDescription': 'All patients received aripiprazole 10 milligrams and escitalopram 10 milligrams as starting doses. These doses were increased to 20 milligrams and 30 milligrams, respectively. These increases occurred over a period of 7 weeks.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '16'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '13'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '3'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Major Depression With Psychotic Features', 'BaselineGroupDescription': 'All patients received aripiprazole 10 milligrams and escitalopram 10 milligrams as starting doses. These doses were increased to 20 milligrams and 30 milligrams, respectively. These increases occurred over a period of 7 weeks.'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '16'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '16'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '41.8', 'BaselineMeasurementSpread': '12.9'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '6'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '10'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '16'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Depression and Psychosis Response Rate', 'OutcomeMeasureDescription': 'This response rate refers to the percentage of patients who experienced a 50 percent or greater reduction in symptoms. Specifically, this refers to a 50 percent reduction in Hamilton Depression Rating Scale 17 (HAM-D-17) scores from baseline and no psychotic symptoms as measured by the Structured Clinical Interview for DMS-IV psychosis module. HAM-D-17 scores range from 0-50 with a score of >23 considered severely depressed and <7 to be mildly to not at all depressed.', 'OutcomeMeasurePopulationDescription': 'For the 3 participants who did not complete the study, the \"last observation carried forward\" technique was used to replace missing data for them.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'percent of participants', 'OutcomeMeasureTimeFrame': 'Baseline and 7 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Major Depression With Psychotic Features', 'OutcomeGroupDescription': 'All patients received aripiprazole 10 milligrams and escitalopram 10 milligrams as starting doses. These doses were increased to 20 milligrams and 30 milligrams, respectively. These increases occurred over a period of 7 weeks.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '16'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '62.5', 'OutcomeMeasurementSpread': '8.3'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Depression and Psychosis Remission Rate', 'OutcomeMeasureDescription': 'This remission rate refers to a Hamilton Depression Rating Scale 17 (HAM-D-17) score of 7 or less and no psychotic symptoms as measured by the Structured Clinical Interview for DMS-IV psychosis module. HAM-D-17 scores range from 0-50 with a score of >23 considered severely depressed and <7 to be mildly to not at all depressed.', 'OutcomeMeasurePopulationDescription': 'For the 3 participants who did not complete the study, the \"last observation carried forward\" technique was used to replace missing data for them.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'percent of participants', 'OutcomeMeasureTimeFrame': 'Baseline and 7 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Major Depression With Psychotic Features', 'OutcomeGroupDescription': 'All patients received aripiprazole 10 milligrams and escitalopram 10 milligrams as starting doses. These doses were increased to 20 milligrams and 30 milligrams, respectively. These increases occurred over a period of 7 weeks.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '16'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '50'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '5', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Major Depression With Psychotic Features', 'EventGroupDescription': 'All patients received aripiprazole 10 milligrams and escitalopram 10 milligrams as starting doses. These doses were increased to 20 milligrams and 30 milligrams, respectively. These increases occurred over a period of 7 weeks.', 'EventGroupSeriousNumAffected': '2', 'EventGroupSeriousNumAtRisk': '16', 'EventGroupOtherNumAffected': '16', 'EventGroupOtherNumAtRisk': '16'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Orthostatic hypotension', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': '1 subject had a severe orthostatic drop in her blood pressure requiring an ED visit while on aripiprazole 15mg a day, escitalopram 10 mg a day, and propanolol 10 mg 3 times a day.', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '16'}]}}, {'SeriousEventTerm': 'worsening of major depression with psychotic features', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': '1 subject had to be hospitalized for worsening of major depression with psychotic features.', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '16'}]}}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Akathisia', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '10', 'OtherEventStatsNumAffected': '10', 'OtherEventStatsNumAtRisk': '16'}]}}, {'OtherEventTerm': 'Gastrointestinal distress', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '16'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '16'}]}}, {'OtherEventTerm': 'Sedation', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '16'}]}}, {'OtherEventTerm': 'Body aches', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '16'}]}}]}}, 'MoreInfoModule': {'LimitationsAndCaveats': {}, 'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Dr. John Matthews', 'PointOfContactOrganization': 'Massachusetts General Hospital', 'PointOfContactEMail': 'jmatthews@partners.org', 'PointOfContactPhone': '617-724-0847'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000068180', 'InterventionMeshTerm': 'Aripiprazole'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000928', 'InterventionAncestorTerm': 'Antidepressive Agents'}, {'InterventionAncestorId': 'D000011619', 'InterventionAncestorTerm': 'Psychotropic Drugs'}, {'InterventionAncestorId': 'D000014150', 'InterventionAncestorTerm': 'Antipsychotic Agents'}, {'InterventionAncestorId': 'D000014149', 'InterventionAncestorTerm': 'Tranquilizing Agents'}, {'InterventionAncestorId': 'D000002492', 'InterventionAncestorTerm': 'Central Nervous System Depressants'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000018491', 'InterventionAncestorTerm': 'Dopamine Agonists'}, {'InterventionAncestorId': 'D000015259', 'InterventionAncestorTerm': 'Dopamine Agents'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000058825', 'InterventionAncestorTerm': 'Serotonin 5-HT1 Receptor Agonists'}, {'InterventionAncestorId': 'D000017366', 'InterventionAncestorTerm': 'Serotonin Receptor Agonists'}, {'InterventionAncestorId': 'D000018490', 'InterventionAncestorTerm': 'Serotonin Agents'}, {'InterventionAncestorId': 'D000058830', 'InterventionAncestorTerm': 'Serotonin 5-HT2 Receptor Antagonists'}, {'InterventionAncestorId': 'D000012702', 'InterventionAncestorTerm': 'Serotonin Antagonists'}, {'InterventionAncestorId': 'D000065127', 'InterventionAncestorTerm': 'Dopamine D2 Receptor Antagonists'}, {'InterventionAncestorId': 'D000018492', 'InterventionAncestorTerm': 'Dopamine Antagonists'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M229', 'InterventionBrowseLeafName': 'Aripiprazole', 'InterventionBrowseLeafAsFound': 'Aripiprazole', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2828', 'InterventionBrowseLeafName': 'Antidepressive Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M13057', 'InterventionBrowseLeafName': 'Psychotropic Drugs', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M15487', 'InterventionBrowseLeafName': 'Antipsychotic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M6056', 'InterventionBrowseLeafName': 'Dopamine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19179', 'InterventionBrowseLeafName': 'Dopamine Agonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M16545', 'InterventionBrowseLeafName': 'Dopamine Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M14095', 'InterventionBrowseLeafName': 'Serotonin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M18231', 'InterventionBrowseLeafName': 'Serotonin Receptor Agonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19180', 'InterventionBrowseLeafName': 'Dopamine Antagonists', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'CNSDep', 'InterventionBrowseBranchName': 'Central Nervous System Depressants'}, {'InterventionBrowseBranchAbbrev': 'PsychDr', 'InterventionBrowseBranchName': 'Psychotropic Drugs'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'CaAg', 'InterventionBrowseBranchName': 'Cardiotonic Agents'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000001523', 'ConditionMeshTerm': 'Mental Disorders'}, {'ConditionMeshId': 'D000011618', 'ConditionMeshTerm': 'Psychotic Disorders'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000019967', 'ConditionAncestorTerm': 'Schizophrenia Spectrum and Other Psychotic Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafAsFound': 'Psychotic', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafAsFound': 'Psychotic', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13959', 'ConditionBrowseLeafName': 'Schizophrenia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20422', 'ConditionBrowseLeafName': 'Schizophrenia Spectrum and Other Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 72, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03056183', 'OrgStudyIdInfo': {'OrgStudyId': 'Pro00045116'}, 'Organization': {'OrgFullName': 'Cedars-Sinai Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Care Transitions for Patients With Depression', 'OfficialTitle': 'Care Transitions for Medically Ill Patients With Depression'}, 'StatusModule': {'StatusVerifiedDate': 'July 2019', 'OverallStatus': 'Withdrawn', 'WhyStopped': 'not funded', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 1, 2019', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2019', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2021', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 14, 2017', 'StudyFirstSubmitQCDate': 'February 14, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 17, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 27, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 30, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Waguih William IsHak, MD, FAPA', 'ResponsiblePartyInvestigatorTitle': 'Vice Chair, Education and Research', 'ResponsiblePartyInvestigatorAffiliation': 'Cedars-Sinai Medical Center'}, 'LeadSponsor': {'LeadSponsorName': 'Cedars-Sinai Medical Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"Aim 1: To collect data on a Depression Care Transition (DCT) program's association with self-care behaviors as measured by medication adherence and clinic visit attendance, after discharge. Hypothesis 1: Compared with usual care, patients who receive the DCT intervention will have significantly greater medication adherence and clinic visit attendance, at 30, 90, and 365 days after discharge.\\n\\nAim 2: To collect data on DCT's association with clinical/health outcomes as measured by depression severity, functional status, and overall physical and mental health, after discharge. Hypothesis 2: Compared with usual care, patients who receive the DCT intervention will have significantly larger improvements in depression severity, functional status, and overall physical & mental health at 30, 90, and 365 days after discharge.\\n\\nAim 3: To collect data on DCT's association with utilization outcomes as measured by readmissions, length of subsequent hospital stays, and cost of care, after discharge. Hypothesis 3: Compared with usual care, patients who receive the DCT intervention will have significantly lower hospital readmissions, shortened length of subsequent hospital stays and lower cost of care, at 30, 90, and 365 days of discharge.\\n\\nLeading the research team are a psychiatrist (Dr. IsHak - PI) and a hospitalist (Dr. Nuckols - Co-I) with an advanced and well-established track record of health services research/scholarship in the fields of depression, outcome measurement, and economic implications of improving the quality and safety of health care.\", 'DetailedDescription': \"This study will contribute to advancing the science of continuity of care delivery for depressed medical inpatients by collecting data on the impact of a modified evidence-based care transition model on clinical/health and utilization outcomes of depression in medically ill inpatients. The study could generate evidence to support the inpatient application of the USPSTF guidelines for screening adults for depression through staff-assisted depression care systems including follow-up and continuity of care. This study will add to the existing outpatient evidence for identification and treatment of depression in improving outcomes (Simon et al., 2001;O'Connor et al., 2013), the crucial aspect of inpatient evidence for depression identification, treatment, and continuity of care/care transitions in improving clinical/health and utilization outcomes.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '0', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Treatment Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients in the Depression Care Transitions intervention will have a Transitional Care Social Worker who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression Care Transitions (DCT)']}}, {'ArmGroupLabel': 'Control Group - Standard of Care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'To be followed per standard of care and data from their medical records will be reviewed.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Depression Care Transitions (DCT)', 'InterventionDescription': 'DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Treatment Group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Transitional Care', 'PrimaryOutcomeDescription': 'Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.', 'PrimaryOutcomeTimeFrame': '365 days'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depression Surveys', 'SecondaryOutcomeDescription': 'All patients who are admitted to CSMC are screened for depression using the PHQ instrument (Kroenke, Spitzer, & Williams, 2001). Patients are asked two questions about frequent occurrence of cardinal depressive symptoms - sadness and anhedonia - and provide yes/no answers to the intake nurse (PHQ-2). If patients answer, \"yes\" to either question, they are administered the complete PHQ-9 instrument. Per the CSMC depression screening protocol, if patients score >12 on the PHQ-9, a social worker evaluation, and notification of the admitting physician and psychiatry, will take place. The subjects will be identified through the psychiatrist who will discuss the risks and benefits of study participation, and assess the patient\\'s interest in the study.', 'SecondaryOutcomeTimeFrame': '365 days'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nParticipants older than the age of 18, admitted to Cedars-Sinai Medical Center, English speaking, and answers \"yes\" to either question on the PHQ-2 instrument.\\n\\nExclusion Criteria:\\n\\nParticipants under the age of 18, non-English speaking, and does not answer \"yes\" to either question on the PHQ-2 instrument.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Waguih IsHak, MD', 'OverallOfficialAffiliation': 'Cedars-Sinai Medical Center', 'OverallOfficialRole': 'Principal Investigator'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 73, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02874027', 'OrgStudyIdInfo': {'OrgStudyId': 'xhechun2'}, 'Organization': {'OrgFullName': 'General Hospital of Ningxia Medical University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Clinical Research on the Relationship Between Depression and Gut Microbiota in TBI Patients', 'OfficialTitle': 'The Clinical Research on the Relationship Between Depression and Gut Microbiota in TBI Patients'}, 'StatusModule': {'StatusVerifiedDate': 'August 2016', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 2016'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2017', 'PrimaryCompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'August 17, 2016', 'StudyFirstSubmitQCDate': 'August 17, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 22, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 21, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 23, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'General Hospital of Ningxia Medical University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Microbiome studies may be highlighted as crucial in the development of depression for TBI patients. The microbiota-gut-brain connection may further provide an opportunity for microbiota manipulation to treat the TBI patients with depression.This study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not and focus the study on the potential of the host-microbiota interaction in regulating depression.', 'DetailedDescription': 'Neuroscientists are probing the connections between intestinal microbes and brain development. The general scaffolding of the brain-gut-enteric microbiota axis includes the central nervous system (CNS), the neuroendocrine and neuroimmune systems,the sympathetic and parasympathetic arms of the autonomic nervous system (ANS),the enteric nervous system (ENS), and of course the intestinal microbiota. These components interact to form a complex reflex network with afferent fibers that project to integrative CNS structures and efferent projections to the smooth muscle. Gut microbiota regulates intestinal and extraintestinal homeostasis. Accumulating evidence suggests that the gut microbiota may also regulate brain function and behavior. Results from animal models indicate that disturbances in the composition and functionality of some microbiota members are associated with neurophysiological disorders, strengthening the idea of a microbiota-gut-brain axis and the role of microbiota as a\"peacekeeper\" in the brain health. It is now clear that the gut-brain communication is bidirectional. On one hand, changes in the microbial community affect behavior. On the other hand, perturbations in behavior alter the composition of the gut microbiota. Since changes in the composition of the gut microbiota are associated with the behavioral and cognitive alterations, a healthy microbiota community is essential for a normal regulation of the microbiota-gut-brain axis. Among the potential factors regulating the axis, microbial metabolites may be the major mediators. Seven million traumatic brain injuries (TBIs) occur each year in the many countries. One of the most common sequelae in patients exposed to TBI is post-traumatic brain syndrome, which is especially common following mild TBI. And the common one is depression.Depression is governed by the intricate interplay between sleep wake homeostasis and circadian rhythms in the body. These rhythms are largely controlled by the suprachiasmatic nucleus (SCN) of the anterior hypothalamus. Clock genes form the molecular machinery of this circadian system, operating via autoregulatory feedback loops.\\n\\nAmong the vertebrate peripheral tissues that express circadian rhythms is the gastrointestinal system, which exhibit circadian rhythms in gene expression (including clock genes), motility and secretion in vivo and in vitro. These rhythms depend upon a patent molecular clock and they are also coordinated by SCN input via the sympathetic nervous system.\\n\\nThe emerging role of the gut microbiome as an important modulator of gastrointestinal function has recently included the role of circadian rhythms. Recent studies have suggested that microbial signaling plays a critical role in homeostatic maintenance of intestinal function along with the host circadian mechanism.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Traumatic Brain Injury With Brief Loss of Consciousness']}, 'KeywordList': {'Keyword': ['gut microbiota', 'depression', 'gut-brain axis', 'circadian rhythm', 'Traumatic Brain Injury']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case Control']}}, 'EnrollmentInfo': {'EnrollmentCount': '50', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'TBI Patients with depression', 'ArmGroupDescription': 'All the patients should be diagnosed by CCMD－3(evaluation of depression)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: The TBI patients with depression']}}, {'ArmGroupLabel': 'TBI Patients without depression', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: The TBI patients with depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'The TBI patients with depression', 'InterventionDescription': 'The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['TBI Patients with depression', 'TBI Patients without depression']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'the relationship between depression and circadian rhythm of patients with TBI', 'PrimaryOutcomeTimeFrame': 'From three months to six months after traumatic brain injury'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'the relationship between gut microbiota and circadian rhythm of patients with TBI', 'SecondaryOutcomeTimeFrame': 'From three months to six months after traumatic brain injury'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nThe mild TBI (mTBI) patients (a short loss of consciousness (<30 min), and/or a short post-traumatic amnesia (PTA) (< 24 h), a Glasgow Coma Scale (GCS) score between 13 and 15)\\nclinical diagnosis of depression\\n\\nExclusion Criteria:\\n\\nthe moderate and severe TBI patients.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '60 Years', 'StdAgeList': {'StdAge': ['Adult']}, 'StudyPopulation': 'The number of patients is 25 and the health people is 25.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Xia hechun, Bachelor', 'CentralContactRole': 'Contact', 'CentralContactPhone': '8613995109559', 'CentralContactEMail': 'xhechun@aliyun.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Xia Hechun, Bachelor', 'OverallOfficialAffiliation': 'General Hospital of Ningxia Medical University', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'General Hospital of Ningxia Medical University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Yinchuan', 'LocationState': 'Ningxia', 'LocationZip': '750004', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Xia Hechun, Bachelor', 'LocationContactRole': 'Contact', 'LocationContactPhone': '8613995109559', 'LocationContactEMail': 'Xhechun@aliyun.com'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001930', 'ConditionMeshTerm': 'Brain Injuries'}, {'ConditionMeshId': 'D000070642', 'ConditionMeshTerm': 'Brain Injuries, Traumatic'}, {'ConditionMeshId': 'D000014474', 'ConditionMeshTerm': 'Unconsciousness'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000006259', 'ConditionAncestorTerm': 'Craniocerebral Trauma'}, {'ConditionAncestorId': 'D000020196', 'ConditionAncestorTerm': 'Trauma, Nervous System'}, {'ConditionAncestorId': 'D000014947', 'ConditionAncestorTerm': 'Wounds and Injuries'}, {'ConditionAncestorId': 'D000003244', 'ConditionAncestorTerm': 'Consciousness Disorders'}, {'ConditionAncestorId': 'D000019954', 'ConditionAncestorTerm': 'Neurobehavioral Manifestations'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000012816', 'ConditionAncestorTerm': 'Signs and Symptoms'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M3789', 'ConditionBrowseLeafName': 'Brain Injuries', 'ConditionBrowseLeafAsFound': 'Brain Injury', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M628', 'ConditionBrowseLeafName': 'Brain Injuries, Traumatic', 'ConditionBrowseLeafAsFound': 'Traumatic Brain Injury', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15807', 'ConditionBrowseLeafName': 'Unconsciousness', 'ConditionBrowseLeafAsFound': 'Loss of Consciousness', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3786', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4325', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16268', 'ConditionBrowseLeafName': 'Wounds and Injuries', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7932', 'ConditionBrowseLeafName': 'Craniocerebral Trauma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20607', 'ConditionBrowseLeafName': 'Trauma, Nervous System', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5051', 'ConditionBrowseLeafName': 'Consciousness Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20410', 'ConditionBrowseLeafName': 'Neurobehavioral Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10987', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC26', 'ConditionBrowseBranchName': 'Wounds and Injuries'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 74, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03928132', 'OrgStudyIdInfo': {'OrgStudyId': '384530'}, 'Organization': {'OrgFullName': 'CHU de Quebec-Universite Laval', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Integrating Sex and Gender Into CPD for Depression/Diabetes', 'OfficialTitle': 'Integrating Sex and Gender Considerations Into a Continuing Professional Development Activity on Diabetes and Depression: Protocol for a Non-Randomized Controlled Trial', 'Acronym': 'INCluDED'}, 'StatusModule': {'StatusVerifiedDate': 'April 2019', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 1, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 29, 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'March 31, 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 23, 2019', 'StudyFirstSubmitQCDate': 'April 24, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 25, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 25, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 26, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'CHU de Quebec-Universite Laval', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Canadian Institutes of Health Research (CIHR)', 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': 'Chaire Claire-Bonenfant-Femmes, Savoir et Société', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Institut du Savoir Montfort', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"People with type 2 diabetes are twice as likely to experience depression as nondiabetic individuals, and depression in turn increases the risk of diabetes. Clinical care for patients for either condition usually fails to consider the impact of sex and gender on tests, diagnosis and treatment, and evidence on these impacts is limited. The investigators aim to assess the impact of a continuing professional education activity (CPD) on diabetes and depression that includes considerations of sex and gender on the clinical behaviours of French-speaking healthcare professionals in Canada.\\n\\nIn a non-randomised controlled trial, the investigators are assessing the impacts of two CPD activities on depression and diabetes, one that includes considerations of sex and gender, and an identical one that omits sex and gender considerations, on French-speaking healthcare professionals' self-reported clinical behaviors regarding sex and gender considerations post-intervention and at 3 months. Data collection will occur in three distinct locations in Canada. Project development, data collection and analysis and dissemination of results will all integrate considerations of sex and gender. The process of creating a CPD activity that integrates considerations of sex and gender could be scaled up to other CPD activities in other clinical subjects and in other minority languages.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Health Knowledge, Attitudes, Practice']}, 'KeywordList': {'Keyword': ['Diabetes and depression', 'Continuing professional development', 'Continuing medical education', 'Sex and gender', 'Minority languages', 'Knowledge translation']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'A non-randomized controlled trial', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignMaskingDescription': 'Health professionals will self-select their attendance at one or other of the interventions (control or experimental CPD activity) without knowing that they are different (one including sex and gender considerations, the other excluding them).', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '90', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'CPD Workshop on Depression and Diabetes', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will include considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: CPD Workshop on Depression and Diabetes']}}, {'ArmGroupLabel': 'CPD Workshop on Depression and Diabetes II', 'ArmGroupType': 'Sham Comparator', 'ArmGroupDescription': 'Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will exclude considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: CPD Workshop on Depression and Diabetes']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'CPD Workshop on Depression and Diabetes', 'InterventionDescription': '2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CPD Workshop on Depression and Diabetes', 'CPD Workshop on Depression and Diabetes II']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Immediate clinical behavioural intention, as measured by CPD-REACTION questionnaire', 'PrimaryOutcomeDescription': 'Clinical behavioural intention to integrate considerations of sex and gender into the diagnosis and treatment of depression and diabetes, using the validated CPD-REACTION scale. CPD=continuing professional development, REACTION=a theoRy-basEd instrument to assess the impACT of continuing professional development activities on professional behavIOr chaNge. A 12-item Likert-type scale (i.e., Strongly disagree = 1, Strongly agree = 7; Never = 1, Always = 7, etc.) evaluates 5 constructs: 1) intention; 2) social influence; 3) beliefs about capabilities; 4) moral norms; and 5) beliefs about consequences. Sociodemographic questions are asked on sex, age (10 age ranges), province, rural/urban/semi-rural practice, and language of consultation. Mean, standard deviation, median and frequencies are calculated to summarize participant characteristics and questionnaire item responses. Construct scores are obtained by calculating the mean score for the items.', 'PrimaryOutcomeTimeFrame': 'Immediately following the intervention'}, {'PrimaryOutcomeMeasure': 'Change from immediate clinical behavioural intention at 3 months, as measured by CPD-REACTION questionnaire', 'PrimaryOutcomeDescription': 'Evolution of clinical behavioural intention to integrate considerations of sex and gender into the diagnosis and treatment of depression and diabetes, using the validated CPD-REACTION scale, after a 3-month period.', 'PrimaryOutcomeTimeFrame': '3 months after the intervention'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Acceptability Questionnaire', 'SecondaryOutcomeDescription': '1) Participants rate acceptability of workshop with the following 9 items: organization, clarity, mastery of subject by trainer, exercises and discussion, presentation of sex and gender data, group interaction, overall quality, organization and quality of discussions and presentations, quality of documents distributed (Poor, Acceptable, Good, Very Good, or Excellent); 2) Participants rate the workshop length (too short, just right, too long); 3) Participants rate their confidence in incorporating the notions presented in the workshop in their management of Type 2 Diabetes (with or without depression) (scale of 1-10, 1=very little confidence, 10=very confident) both before and after the workshop; 4) Participants describe what changes they will make in their practice following the workshop; 5) Participants describe what they liked most and 6) least about the workshop; 7) Participants are asked if they thought the presentation was biased (yes/no) and if yes, are asked for details.', 'SecondaryOutcomeTimeFrame': 'Immediately following the intervention.'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nFrench-speaking health professionals (in practice and in training).', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'France Légaré, MD, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+1 (418) 821-9481', 'CentralContactEMail': 'france.legare@fmed.ulaval.ca'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'France Légaré, MD, PhD', 'OverallOfficialAffiliation': 'CERSSPUL', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'CERSSPL', 'LocationStatus': 'Recruiting', 'LocationCity': 'Québec', 'LocationState': 'Quebec', 'LocationCountry': 'Canada', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'France Légaré, MD, PhD', 'LocationContactRole': 'Contact'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': 'Aggregate anonymous data only in the form of published results.'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5698', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 75, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03247764', 'OrgStudyIdInfo': {'OrgStudyId': 'Regist-EP and DP'}, 'Organization': {'OrgFullName': 'Shanghai Zhongshan Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Registration Study on Depression in Patients With Epilepsy', 'OfficialTitle': 'A Registration Study on Diagnosis and Treatment for Comorbid Depression in Patients With Epilepsy From the East China'}, 'StatusModule': {'StatusVerifiedDate': 'August 2017', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 8, 2017', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 30, 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'August 3, 2017', 'StudyFirstSubmitQCDate': 'August 8, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 14, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 8, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 14, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Shanghai Zhongshan Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The prevalence of comorbid depression in patients with epilepsy is as high as 30-50%. The depressive symptoms severely affect seizure severity and quality of life in patients with epilepsy. The aim of this study is to register the diagnosis and treatment for depression in patients with epilepsy from the East China, determining the incidence rate of comorbid depression in patients with epilepsy and the choices for the antidepressant treatment. At the same time, neuroimaging data such as brain MRI and blood sample will be collected to analyze some biomarkers for the comorbidity of epilepsy and depression.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Epilepsy', 'Depression']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'Yes', 'TargetDuration': '6 Months', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '1200', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'patients with epilepsy and depression', 'ArmGroupDescription': 'Patients with comorbidity of epilepsy and depression will be asked to use antidepressants such as selective serotonin reuptake inhibitor(SSRIs) or xylaria nigripes and followed up', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: SSRIs or xylaria nigripes']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'SSRIs or xylaria nigripes', 'InterventionDescription': \"Patients with comorbidity of epilepsy and depression will be used SSRIs or xylaria nigripes as antidepressants after discussing with them. They will still be followed up if they don't want to use any antidepressants.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with epilepsy and depression']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Comparing the efficacy of using SSRIs with using xylaria nigripes on depressive symptoms in patients with epilepsy and depression', 'PrimaryOutcomeDescription': 'The reduction rate of Hamilton Depression Rating Scale (HAMD) score will be used to assess the change of depressive symptoms', 'PrimaryOutcomeTimeFrame': '6 month'}, {'PrimaryOutcomeMeasure': 'The safety of using SSRIs and xylaria nigripes in patients with epilepsy', 'PrimaryOutcomeDescription': 'The changes of seizure frequencies will be assessed', 'PrimaryOutcomeTimeFrame': '6 month'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'The rate of antidepressant treatment in patients with comorbidity of epilepsy and depression', 'SecondaryOutcomeTimeFrame': '6 month'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAt least 1 or more seizures with evidences demonstrated by EEG\\n\\nExclusion Criteria:\\n\\nSevere psychotic symptoms such as hallucination and delusions\\nProgressive central nervous system diseases such as acute stroke, brain malignant tumors, encephalitis, and Parkinson's disease etc.\\nSevere cardiac, pulmonary, hepatic, and renal diseases\\nSevere cognitive dysfunctions and physical disabilities\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'All patients with epilepsy who meet the inclusion and exclusion criteria will be asked to fill out PHQ-9 scale to screen depression', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Weifeng Peng, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '8602164041990', 'CentralContactPhoneExt': '2976', 'CentralContactEMail': 'peng.weifeng@zs-hospital.sh.cn'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000004827', 'ConditionMeshTerm': 'Epilepsy'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6566', 'ConditionBrowseLeafName': 'Epilepsy', 'ConditionBrowseLeafAsFound': 'Epilepsy', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3786', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4325', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 76, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02366429', 'OrgStudyIdInfo': {'OrgStudyId': '20141959311'}, 'Organization': {'OrgFullName': 'Karolinska Institutet', 'OrgClass': 'OTHER'}, 'BriefTitle': 'ICBT for Antenatal Depression', 'OfficialTitle': 'Psychological Treatment Via the Internet for Antenatal Depression'}, 'StatusModule': {'StatusVerifiedDate': 'September 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 2015'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 12, 2015', 'StudyFirstSubmitQCDate': 'February 18, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 19, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 2, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 5, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Viktor Kaldo', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Karolinska Institutet'}, 'LeadSponsor': {'LeadSponsorName': 'Karolinska Institutet', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Randomized controlled trial evaluating an Internet-delivered Cognitive Behavioral Therapy (ICBT) adapted for pregnant women suffering from antenatal depression. The ICBT-program will be added to treatment as usual (TAU) and compared to TAU only.\\n\\nParticipants (n=60) are recruited from all over Sweden (only Swedish citizens can participate) and are assessed and treated on a distance via a secure web platform and telephone.', 'DetailedDescription': \"In order to evaluate feasibility and effectiveness of an ICBT-program for antenatal depression that will be used in a larger clinical trial, the current RCT (n=60) will be performed and act as a pilot for the main study.\\n\\nParticipants will all be receiving the regular treatment (TAU) provided at their antenatal clinic and other health care instances. Half of them will be randomized to an add-on of a previously established 10-week long ICBT-program for depression in general, now adapted for pregnant women. The other half will receive TAU during 10 weeks and then freely decide if they want to participate in the pregnancy-adapted ICBT-program (only possible if 10 or more weeks left till estimated delivery date), start the regular ICBT-program for depression within 2-6 weeks post-partum, or decline ICBT-treatment. The participants in this study will be recruited from all over Sweden via internet, advertisements and information at antenatal clinics. A web-based screening questionnaire will form the basis for a first assessment and review of inclusion criteria, followed by a structured telephone interview where diagnoses (SCID-1 for depression, adjusted for DSM 5, and M.I.N.I. for other diagnoses and assessment of suicide risk) and suitability will be assessed, a CGI-rating will be performed, and the final decision on inclusion will be made.\\n\\nLevel of depression pre- and post-treatment will be assessed with MADRS-S filled out via the internet-treatment platform together with the other self-rating measures used in the main study. A questionnaire where the participants evaluate the content of the adapted ICBT-program and their own use and perceived benefit of the treatment methods will also be given at post-treatment and during treatment.\\n\\nStructured telephone interview will be held at post-treatment, primarily to assess the content of TAU, to administer CGI and a standardized version for MADRS-S (designed to replace missing questionnaire data), and to make a qualitative evaluation of the participants view of the adapted ICBT-program.\\n\\nThe estimated effect of ICBT compared to TAU is 0.8 (Cohen's d) and with 60 participants and some attrition this will result in a statistical power of 80% for this initial, smaller RCT.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Antenatal Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '60', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'ICBT', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Internet-based CBT for antenatal depression', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: ICBT for antenatal depression']}}, {'ArmGroupLabel': 'TAU', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Treatment as usual provided at antenatal clinics and other health care instances', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: TAU']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'ICBT for antenatal depression', 'InterventionDescription': 'Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['ICBT']}}, {'InterventionType': 'Other', 'InterventionName': 'TAU', 'InterventionDescription': 'Treatment as usual provided at antenatal clinics and other health care instances', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['TAU']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Self-rated depression measured by Montgomery Asberg Depression Rating Scale', 'PrimaryOutcomeDescription': 'Depression measured by Montgomery Asberg Depression Rating Scale (MADRS-S), a 9-item self-rated measure of change in depression severity. It also screens for suicidality.', 'PrimaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Self-rated antenatal depression Edinburgh Postnatal Depression Scale', 'SecondaryOutcomeDescription': 'Edinburgh Postnatal Depression Scale (EPDS; Cox, Holden & Sagovsky, 1987)', 'SecondaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'}, {'SecondaryOutcomeMeasure': 'Self-rated function Work and Social Adjustment Scale', 'SecondaryOutcomeDescription': 'Work and Social Adjustment Scale (WSAS; Zahra et al., 2014)', 'SecondaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'}, {'SecondaryOutcomeMeasure': 'Self-rated Insomnia Insomnia Severity Index', 'SecondaryOutcomeDescription': 'Insomnia Severity Index (ISI; Bastien, Vallieres & Morin, 2001)', 'SecondaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'}, {'SecondaryOutcomeMeasure': 'Self-rated function/quality of life Euroqol', 'SecondaryOutcomeDescription': 'Euroqol (EQ-5D ; Hinz et al., 2006),', 'SecondaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'}, {'SecondaryOutcomeMeasure': 'Self-rated anxiety and worry GAD-7', 'SecondaryOutcomeDescription': 'GAD-7(Beard, & Björgvinsson, 2014)', 'SecondaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'}, {'SecondaryOutcomeMeasure': 'Expert rating of overall disease burden Clinical Global Impression - Severity scale', 'SecondaryOutcomeDescription': 'Clinical Global Impression - Severity scale (CGI-S; Guy, 2000)', 'SecondaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\npregnant female > 18 years old at gestational week 11-28\\nverified moderate depression according to SCID-I with or without concomitant anxiety disorder\\nable to understand the Swedish language orally and in written\\nable to use the internet for the ICBT\\ncurrently in contact with an antenatal clinic to receive regular care\\n\\nExclusion Criteria:\\n\\nknown drug or alcohol abuse\\nserious somatic disorder or psychiatric disorder such as psychosis, bipolar disorder, severe personality disorder, autism or mental retardation and severe melancholic or psychotic depression,\\nhaving started or changed medication with SSRI, SNRI or mood-stabilizers within 3 weeks,\\naccording to psychiatric assessment have a high suicide risk will be excluded from the study. These women will be helped to receive necessary psychiatric treatment as usual.', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '55 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Internetpsykiatrienehten (Internet Psychiatry Unit), Psykiatri Sydväst, SLSO', 'LocationCity': 'Stockholm', 'LocationCountry': 'Sweden'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28628768', 'ReferenceType': 'derived', 'ReferenceCitation': 'Forsell E, Bendix M, Holländare F, Szymanska von Schultz B, Nasiell J, Blomdahl-Wetterholm M, Eriksson C, Kvarned S, Lindau van der Linden J, Söderberg E, Jokinen J, Wide K, Kaldo V. Internet delivered cognitive behavior therapy for antenatal depression: A randomised controlled trial. J Affect Disord. 2017 Oct 15;221:56-64. doi: 10.1016/j.jad.2017.06.013. Epub 2017 Jun 13.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Related Info', 'SeeAlsoLinkURL': 'http://www.internetpsykiatri.se'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 77, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02122406', 'OrgStudyIdInfo': {'OrgStudyId': '31748\\\\2009 progetto lorhen'}, 'Organization': {'OrgFullName': 'University of Pavia', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Depression and Anxiety in Rheumatoid Arthritis', 'OfficialTitle': 'Depression and Anxiety in Rheumatoid Arthritis: Prevalence and Relation With Disease Activity', 'Acronym': 'DEAR'}, 'StatusModule': {'StatusVerifiedDate': 'August 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 22, 2014', 'StudyFirstSubmitQCDate': 'April 23, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 24, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'May 10, 2016', 'ResultsFirstSubmitQCDate': 'August 16, 2016', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'October 10, 2016', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 16, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 10, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Vittorio Grosso', 'ResponsiblePartyInvestigatorTitle': 'MD', 'ResponsiblePartyInvestigatorAffiliation': 'University of Pavia'}, 'LeadSponsor': {'LeadSponsorName': 'University of Pavia', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The primary endpoint of this study is to evaluate the prevalence of anxiety and depressive disorders, and their relationship with disease activity, in patients with rheumatoid arthritis treated with biological drugs', 'DetailedDescription': 'The prevalence of anxiety and depressive disorders will be assesed with the HADS questionnaire at the time of the visit'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Rheumatoid Arthritis', 'Depression', 'Anxiety']}, 'KeywordList': {'Keyword': ['Rheumatoid Arthritis', 'Depression', 'Anxiety', 'DAS28', 'HADS']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'EnrollmentInfo': {'EnrollmentCount': '200', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Patients RA-BIO', 'ArmGroupDescription': 'Patients with rheumatoid arthritis treated with biological drugs (infliximab, adalimumab, etanercept, abatacept, tocilizumab, golimumab, certolizumab, rituximab)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Hospital Anxiety and Depression Scale (HADS) questionnaire']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Hospital Anxiety and Depression Scale (HADS) questionnaire', 'InterventionDescription': 'Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Patients RA-BIO']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Hospital Anxiety and Depression Scale (HADS)', 'PrimaryOutcomeDescription': 'Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.', 'PrimaryOutcomeTimeFrame': '1 day of enrollement'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nage >18 years\\ndiagnosis of rheumatoid arthritis according to 2010 Classification American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Criteria\\nbeing able to compile questionnaire\\ncurrent treatment with biological disease-modifying antirheumatic drug\\n\\nExclusion Criteria:\\n\\nCurrent treatment for anxiety or depressive disorder', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Adult patients with rheumatoid arthritis currently treated with biological drugs.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Roberto Caporali, MD', 'OverallOfficialAffiliation': 'University of Pavia', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'IRCCS policlinico San Matteo - Reparto di Reumatologia', 'LocationCity': 'Pavia', 'LocationState': 'PV', 'LocationZip': '27100', 'LocationCountry': 'Italy'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Patients RA-BIO', 'FlowGroupDescription': 'Patients with rheumatoid arthritis treated with biological drugs'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '200'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '200'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Patients RA-BIO', 'BaselineGroupDescription': 'Patients with rheumatoid arthritis treated with biological drugs'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '200'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Median', 'BaselineMeasureDispersionType': 'Inter-Quartile Range', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '62.35', 'BaselineMeasurementLowerLimit': '54.09', 'BaselineMeasurementUpperLimit': '76.03'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '171'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '29'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Italy', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '200'}]}}]}}]}}, {'BaselineMeasureTitle': 'Disease Duration', 'BaselineMeasureParamType': 'Median', 'BaselineMeasureDispersionType': 'Inter-Quartile Range', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '11.24', 'BaselineMeasurementLowerLimit': '7.29', 'BaselineMeasurementUpperLimit': '19.46'}]}}]}}]}}, {'BaselineMeasureTitle': 'Disease Activity Score on 28 joints (DAS28)', 'BaselineMeasureDescription': 'The Disease Activity Score 28 (DAS28) is a combined index that measures the disease activity in patients with Rheumatoid Arthritis. It is based on the assessment of the number of swollen and tender joints and measure of the ESR.\\n\\nLower values indicate lower disease activity levels. It ranges from 0.49 to 9.35.', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'units on a scale', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3.01', 'BaselineMeasurementSpread': '1.07'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Hospital Anxiety and Depression Scale (HADS)', 'OutcomeMeasureDescription': 'Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'participants', 'OutcomeMeasureTimeFrame': '1 day of enrollement', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Patients RA-BIO', 'OutcomeGroupDescription': 'Patients with rheumatoid arthritis treated with biological drugs'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '200'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'HEALTHY', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '107'}]}}]}}, {'OutcomeClassTitle': 'ANXIETY', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '46'}]}}]}}, {'OutcomeClassTitle': 'DEPRESSION', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '20'}]}}]}}, {'OutcomeClassTitle': 'ANXIETY/DEPRESSION', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '27'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': 'at the time of the visit', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Patients RA-BIO', 'EventGroupDescription': 'Patients with rheumatoid arthritis treated with biological drugs', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '200', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '200'}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No', 'AgreementRestrictiveAgreement': 'No'}, 'PointOfContact': {'PointOfContactTitle': 'Vittorio Grosso MD', 'PointOfContactOrganization': 'University of Pavia', 'PointOfContactEMail': 'vittorio.grosso@gmail.com', 'PointOfContactPhone': '+393332605945'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001168', 'ConditionMeshTerm': 'Arthritis'}, {'ConditionMeshId': 'D000001172', 'ConditionMeshTerm': 'Arthritis, Rheumatoid'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000001008', 'ConditionMeshTerm': 'Anxiety Disorders'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000007592', 'ConditionAncestorTerm': 'Joint Diseases'}, {'ConditionAncestorId': 'D000009140', 'ConditionAncestorTerm': 'Musculoskeletal Diseases'}, {'ConditionAncestorId': 'D000012216', 'ConditionAncestorTerm': 'Rheumatic Diseases'}, {'ConditionAncestorId': 'D000003240', 'ConditionAncestorTerm': 'Connective Tissue Diseases'}, {'ConditionAncestorId': 'D000001327', 'ConditionAncestorTerm': 'Autoimmune Diseases'}, {'ConditionAncestorId': 'D000007154', 'ConditionAncestorTerm': 'Immune System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M2905', 'ConditionBrowseLeafName': 'Anxiety Disorders', 'ConditionBrowseLeafAsFound': 'Anxiety', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3057', 'ConditionBrowseLeafName': 'Arthritis', 'ConditionBrowseLeafAsFound': 'Arthritis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3061', 'ConditionBrowseLeafName': 'Arthritis, Rheumatoid', 'ConditionBrowseLeafAsFound': 'Rheumatoid Arthritis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9204', 'ConditionBrowseLeafName': 'Joint Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10680', 'ConditionBrowseLeafName': 'Musculoskeletal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13628', 'ConditionBrowseLeafName': 'Rheumatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4906', 'ConditionBrowseLeafName': 'Collagen Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5047', 'ConditionBrowseLeafName': 'Connective Tissue Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3210', 'ConditionBrowseLeafName': 'Autoimmune Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8783', 'ConditionBrowseLeafName': 'Immune System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Muscle, Bone, and Cartilage Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}]}}}}}, {'Rank': 78, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02375308', 'OrgStudyIdInfo': {'OrgStudyId': 'UTubingen'}, 'Organization': {'OrgFullName': 'University Hospital Tuebingen', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Efficacy of Cognitive Behavioral to Hypnotherapeutic Treatment of Depression', 'OfficialTitle': 'Efficacy of Activation-focussed Cognitive Treatment of Depression (ACDT) to Hypnotherapeutic Treatment of Depression (HDT) in Mild to Moderate Major Depression'}, 'StatusModule': {'StatusVerifiedDate': 'September 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2015'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2017', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 28, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 24, 2015', 'StudyFirstSubmitQCDate': 'February 27, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 2, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 21, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 25, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Anil Batra', 'ResponsiblePartyInvestigatorTitle': 'Efficacy of Activation-focussed Cognitive Treatment of Depression (ACDT) to Hypnotherapeutic Treatment of Depression (HDT) in Mild to Moderate Major Depression', 'ResponsiblePartyInvestigatorAffiliation': 'University Hospital Tuebingen'}, 'LeadSponsor': {'LeadSponsorName': 'University Hospital Tuebingen', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The purpose of the study is to compare the efficacy of an Hypnotherapeutic Treatment of Depression to Cognitive Behavioral Treatment of Depression in patients with mild to moderate Major Depressive Episodes.', 'DetailedDescription': \"Cognitive Behavioral Therapy (CBT) is considered to be an effective psychological treatment of mild to moderate Major Depressive Episodes. Effective treatments, however, show a reduction of depressive symptoms only up to 50 % (Luty et al., 2007) which is one reason for the modification of the well-established CBT in the last years. Following the 'third wave' approaches of CBT, e.g. Emotion-Focussed Therapy or Mindfulness-Based Cognitive Therapy, techniques like meditation or the use of systemic or Gestalt techniques within CBT has been applied. Within this context, Hypnotherapy-based strategies can also show an improvement of the current state of the art in depression psychotherapy. However, only few studies conducted randomised controlled trials to study the efficacy of hypnosis for depression as e.g. the comparison of cognitive hypnotherapy to CBT-alone (e.g. Alladin and Alibhai, 2007). With the present study, the efficacy of the Hypnotherapeutic Treatment of Depression (HDT) will be compared to the CBT-based Activation-focussed Cognitive Treatment of Depression (ACDT). Both treatments are individually administered and includes 20 sessions. We expect HDT not being inferior to ACDT in the reduction of depressive symptoms after six months of treatment.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Major Depressive Disorder']}, 'KeywordList': {'Keyword': ['Hypnotherapy; Cognitive Behavioral Therapy; Efficacy']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '153', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Hypnotherapeutic Treatment', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'HDT (Hypnotherapeutic Treatment of Depression) focuses on the hypnotic activation and strengthening of individual resources, the use of regression techniques to rebuild positive and negative experiences and the development of positive imaginations for the future.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: HDT']}}, {'ArmGroupLabel': 'Cognitive Behavioral Treatment', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'ACDT (Activation-focussed Cognitive Treatment of Depression) focuses on psychoeducation, behavior activation, the use of cognitive techniques, and the improvement of social skills.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: ACDT']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'HDT', 'InterventionDescription': '20 sessions, individual psychotherapy', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Hypnotherapeutic Treatment']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Hypnotherapeutic Treatment of Depression']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'ACDT', 'InterventionDescription': '20 sessions, individual psychotherapy', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cognitive Behavioral Treatment']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Cognitive Behavioral Therapy (CBT) of Depression']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Montgomery-Åsberg Depression Rating Scale (MADRS)', 'PrimaryOutcomeDescription': 'Clinician-rating of depressive symptoms, Primary outcome', 'PrimaryOutcomeTimeFrame': 'Change from Baseline in MADRS to end of treatment (20 sessions in 20-24 weeks)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'QIDS: Quick Inventory of Depressive Symptomatology - Clinician Rating (QIDS-C16)', 'SecondaryOutcomeDescription': 'Clinician-rating of depressive symptoms', 'SecondaryOutcomeTimeFrame': 'Change from Baseline to end of therapy and follow-ups (six and 12 months after end of treatment)'}, {'SecondaryOutcomeMeasure': 'Patient Health Questionnaire (PHQ-9)', 'SecondaryOutcomeDescription': 'Self-report of depressive symptoms', 'SecondaryOutcomeTimeFrame': 'Change from Baseline to end of therapy and follow-ups (six and 12 months after end of treatment)'}, {'SecondaryOutcomeMeasure': 'Montgomery-Åsberg Depression Rating Scale (MADRS)', 'SecondaryOutcomeDescription': 'Incidence of response rate (symptom reduction > 60%)', 'SecondaryOutcomeTimeFrame': 'six and 12 months after end of treatment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nDSM-5 (Diagnostic and Statistical Manual) criteria for current mild to moderate Major Depressive Episode (MDE)\\nInformed consent\\nFluent in German\\nTime for weekly therapy sessions\\nStable antidepressant medication since three months\\n\\nExclusion Criteria:\\n\\nA history of lifetime bipolar disorder, psychotic symptoms\\nA diagnosis of a chronic Major Depressive Disorder (total duration of two years and more)\\nFulfilling the DSM-5 criteria for current severe MDE or scores in MADRS >/= 35 or QIDSC16 (Quick Inventory of Depressive Symptomatology) >/= 16\\nRemission of current MDE since more than four weeks prior to inclusion assessment\\nAcute risk for suicide\\nSevere cognitive impairment (confirmed suspicion with Mini-Mental-State-Test > 25)\\nA dominating primary diagnosis of another axis I disorder including anxiety disorders (e.g. Panic disorder, Posttraumatic Stress Disorder, Anorexia nervosa, Borderline personality disorder), or any severe substance-related abuse or dependence disorder\\nA physical illness which would interfere with regular psychotherapy sessions\\nOutpatient psychotherapy during the last 12 months', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '70 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Anil Batra, Prof.', 'OverallOfficialAffiliation': 'University Hospital Tuebingen', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Prof. Dr. A. Batra/ Dr. Kristina Fuhr, University Department for Psychiatry and Psychotherapie', 'LocationCity': 'Tuebingen', 'LocationZip': '72076', 'LocationCountry': 'Germany'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '17541109', 'ReferenceType': 'background', 'ReferenceCitation': 'Luty SE, Carter JD, McKenzie JM, Rae AM, Frampton CM, Mulder RT, Joyce PR. Randomised controlled trial of interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatry. 2007 Jun;190:496-502.'}, {'ReferencePMID': '17365072', 'ReferenceType': 'background', 'ReferenceCitation': 'Alladin A, Alibhai A. Cognitive hypnotherapy for depression: an empirical investigation. Int J Clin Exp Hypn. 2007 Apr;55(2):147-66.'}, {'ReferencePMID': '29196478', 'ReferenceType': 'derived', 'ReferenceCitation': 'Fuhr K, Schweizer C, Meisner C, Batra A. Efficacy of hypnotherapy compared to cognitive-behavioural therapy for mild-to-moderate depression: study protocol of a randomised-controlled rater-blind trial (WIKI-D). BMJ Open. 2017 Dec 1;7(11):e016978. doi: 10.1136/bmjopen-2017-016978.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000003865', 'ConditionMeshTerm': 'Depressive Disorder, Major'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafAsFound': 'Major Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 79, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02021578', 'OrgStudyIdInfo': {'OrgStudyId': '8482529'}, 'Organization': {'OrgFullName': 'Vanderbilt University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Family Depression Prevention Program', 'OfficialTitle': 'Family Cognitive Behavioral Prevention of Depression in Youth and Parents', 'Acronym': 'FDP'}, 'StatusModule': {'StatusVerifiedDate': 'February 2020', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2021', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 19, 2013', 'StudyFirstSubmitQCDate': 'December 19, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 27, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'February 5, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 6, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Judith Garber', 'ResponsiblePartyInvestigatorTitle': 'Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Vanderbilt University'}, 'LeadSponsor': {'LeadSponsorName': 'Vanderbilt University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'San Diego State University', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The primary aim is to prevent depression in youth and parents in a single, integrated family intervention.\\n\\nHypothesis 1a: Children in the Family Depression Prevention (FDP) program will have significantly fewer onsets of depressive episodes and lower levels of anxious/depressive symptoms as compared to children in the Written Information (WI) condition.\\n\\nHypothesis 1b: In parents, the amount of time in a depressive episode will be significantly lower for those in the FDP program as compared to those in the WI condition.', 'DetailedDescription': 'Depression is a major public health problem affecting over 15 million U.S. adults annually and is especially prevalent in those of parenting age. Offspring of depressed parents are at increased risk of depression and therefore are a critical target for preventive interventions. The current study aims to reduce the rate of depression in parents and their children by adopting an innovative, family-based approach to simultaneously preventing depression in at-risk youth and in their affected parents. The rationale for this approach is based on (a) a conceptual model that integrates parenting processes, stress (particularly that which is associated with parental depression), and children\\'s self-regulatory skills in the face of stress, (b) evidence that depression runs in families, (c) promising results from family- and child-focused depression prevention programs, (d) evidence that in adults, cognitive-behavioral therapy (CBT) reduces both depressive episodes and their recurrence, and (e) growing consensus among scientists, clinicians, and policymakers on the need for family-based models of healthcare. This 5- year, two-site randomized controlled trial will test a Family Depression Prevention (FDP) program for children (ages 9-15) and their parents with depressive disorders (past or current). This \"dual prevention\" approach is a novel synthesis of existing evidence-based intervention techniques drawn from child prevention and adult treatment models. Participating families (N=300) will be randomized to either FDP (12 weekly + 3 monthly sessions) or a written information comparison (WI) condition. All parents and children will be evaluated at pre- and post-intervention, and at 6-, 12-, 18-, and 24-months from baseline.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Mood disorder']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '300', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Family Cognitive Behavioral Prevention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'A family cognitive behavioral program for parents and children. Parents learn parenting skills and cognitive behavioral techniques for managing depression. Children learn coping skills.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Family Cognitive Behavioral Prevention']}}, {'ArmGroupLabel': 'Written Information', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Families receive written materials about depression and the effects of parental depression on children.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Written information']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Family Cognitive Behavioral Prevention', 'InterventionDescription': 'Parent training and cognitive behavioral intervention with parents. Coping skills training with children.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Family Cognitive Behavioral Prevention']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Cognitive behavioral intervention', 'Coping skills training', 'Parent training']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Written information', 'InterventionDescription': 'Reading materials about depression', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Written Information']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Psychoeducation', 'Self-help']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'In children, the primary outcome is onset of a depressive episode. In parents, the primary outcome is time in a depressive episode.', 'PrimaryOutcomeDescription': 'For child participants, we will assess time to onset of a depressive disorder (e.g., Major Depressive Episode; persistent depressive disorder) using a semi-structured clinical interview, the Longitudinal Interval Follow-up Evaluation (LIFE).\\n\\nFor parent participants, we also will use the LIFE to measure the amount of time in a depressive episode during the assessment interval.', 'PrimaryOutcomeTimeFrame': 'up to two years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Parents: Patient Health Questionnaire - 9 (PHQ-9)', 'SecondaryOutcomeDescription': 'Parent participants: The PHQ-9 measures 9 symptoms of depression on a 4-point scale. Scores can range from 0 to 36.', 'SecondaryOutcomeTimeFrame': 'past two weeks'}, {'SecondaryOutcomeMeasure': 'Children: Youth Self-report (YSR) anxiety/depression subscale', 'SecondaryOutcomeDescription': 'Children will complete the YSR, which is a self-report checklist containing 112 items scored on a 3-point scale.', 'SecondaryOutcomeTimeFrame': 'six months'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nParent with a current or history of a depressive disorder within child's life\\nChildren ages 9.0 to 15.6 years old\\n\\nExclusion Criteria:\\n\\nBipolar I (parent or child)\\nSchizophrenia (parent or child)\\nCurrent alcohol or drug abuse (parent or child)\\nConduct disorder; developmental disability (child)\\nCurrent diagnosis of a depressive disorder (child)\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '9 Years', 'MaximumAge': '15 Years', 'StdAgeList': {'StdAge': ['Child']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Judy Garber, PhD', 'OverallOfficialAffiliation': 'Vanderbilt University', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Bruce Compas, PhD', 'OverallOfficialAffiliation': 'Vanderbilt University', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Robin Weersing, PhD', 'OverallOfficialAffiliation': 'San Diego State University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'San Diego State University', 'LocationStatus': 'Recruiting', 'LocationCity': 'San Diego', 'LocationState': 'California', 'LocationZip': '92120-4913', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Robin Weersing, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '619-594-8892', 'LocationContactEMail': 'robin.weersing@mail.sdsu.edu'}, {'LocationContactName': 'Robin Weersing, PhD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Vanderbilt University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37203-5721', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Judy Garber, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '615-343-0595', 'LocationContactEMail': 'jgarber.vanderbilt@gmail.com'}, {'LocationContactName': 'Bruce Compas, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '615-322-8306', 'LocationContactEMail': 'Bruce.Compas@Vanderbilt.edu'}, {'LocationContactName': 'Judy Garber, PhD', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Bruce Compas, PhD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '19968378', 'ReferenceType': 'background', 'ReferenceCitation': 'Compas BE, Forehand R, Keller G, Champion JE, Rakow A, Reeslund KL, McKee L, Fear JM, Colletti CJ, Hardcastle E, Merchant MJ, Roberts L, Potts J, Garai E, Coffelt N, Roland E, Sterba SK, Cole DA. Randomized controlled trial of a family cognitive-behavioral preventive intervention for children of depressed parents. J Consult Clin Psychol. 2009 Dec;77(6):1007-20. doi: 10.1037/a0016930.'}, {'ReferencePMID': '20873898', 'ReferenceType': 'background', 'ReferenceCitation': 'Compas BE, Champion JE, Forehand R, Cole DA, Reeslund KL, Fear J, Hardcastle EJ, Keller G, Rakow A, Garai E, Merchant MJ, Roberts L. Coping and parenting: Mediators of 12-month outcomes of a family group cognitive-behavioral preventive intervention with families of depressed parents. J Consult Clin Psychol. 2010 Oct;78(5):623-34. doi: 10.1037/a0020459.'}, {'ReferencePMID': '21707137', 'ReferenceType': 'background', 'ReferenceCitation': 'Compas BE, Forehand R, Thigpen JC, Keller G, Hardcastle EJ, Cole DA, Potts J, Watson KH, Rakow A, Colletti C, Reeslund K, Fear J, Garai E, McKee L, Merchant MJ, Roberts L. Family group cognitive-behavioral preventive intervention for families of depressed parents: 18- and 24-month outcomes. J Consult Clin Psychol. 2011 Aug;79(4):488-99. doi: 10.1037/a0024254.'}, {'ReferencePMID': '19491183', 'ReferenceType': 'background', 'ReferenceCitation': \"Garber J, Clarke GN, Weersing VR, Beardslee WR, Brent DA, Gladstone TR, DeBar LL, Lynch FL, D'Angelo E, Hollon SD, Shamseddeen W, Iyengar S. Prevention of depression in at-risk adolescents: a randomized controlled trial. JAMA. 2009 Jun 3;301(21):2215-24. doi: 10.1001/jama.2009.788.\"}, {'ReferencePMID': '24005242', 'ReferenceType': 'background', 'ReferenceCitation': 'Beardslee WR, Brent DA, Weersing VR, Clarke GN, Porta G, Hollon SD, Gladstone TR, Gallop R, Lynch FL, Iyengar S, DeBar L, Garber J. Prevention of depression in at-risk adolescents: longer-term effects. JAMA Psychiatry. 2013 Nov;70(11):1161-70. doi: 10.1001/jamapsychiatry.2013.295.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 80, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01379027', 'OrgStudyIdInfo': {'OrgStudyId': '1R01MH087505', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH087505&Fy=all'}, 'Organization': {'OrgFullName': 'Kaiser Permanente', 'OrgClass': 'OTHER'}, 'BriefTitle': 'MoodHelper: Internet Cognitive Behavioral Therapy (CBT) for Depression', 'OfficialTitle': 'Internet CBT for Depression: Comparing Pure, Guided, and Stepped Care'}, 'StatusModule': {'StatusVerifiedDate': 'March 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 2011'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 10, 2011', 'StudyFirstSubmitQCDate': 'June 22, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 23, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 6, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 8, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Kaiser Permanente', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Oregon Health and Science University', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Evidence-based treatments (EBTs) for mental health conditions are often not available to persons needing them in the community. Our aim is to test a novel Internet intervention that has the promise of eventually improving the Reach and Implementation of mental health EBTs, speeding the translation of research successes into improved community care.', 'DetailedDescription': 'Evidence-based treatments (EBTs) for depression are often not available to persons needing them; this is particularly true of psychotherapies. Even when available, EBTs are often poorly delivered at less-than-optimal quality. High direct and indirect costs also limit the availability of EBTs. Together these barriers contribute to suboptimal treatment of depression in the community. In a preliminary step toward addressing these quality shortcomings, the investigators propose to conduct a blended efficacy- effectiveness randomized controlled trial (RCT) of high fidelity, Internet-delivered cognitive behavioral therapy (CBT) for depression, extending our previous research to maximize treatment availability and quality as well as to reduce costs. Over a 36-month recruitment period, the investigators will enroll 1,800 adults seeking care for depression from 3 rural healthcare clinics, 3 safety net federally qualified healthcare centers (FQHCs), and 2 non-profit HMOs. Participants will be randomized to: (a) a treatment as usual (TAU) control condition, typically antidepressants and/or psychosocial services; (b) TAU plus Pure self-help Internet CBT for depression, consisting of access to the Internet site without any contact with therapists; (c) TAU plus Guided self-help Internet CBT, consisting of access to the Internet site plus brief, periodic telephone contacts with therapists; or (d) a Stepped-Care Internet CBT condition, starting with TAU + Pure self-help CBT and progressing to Guided self-help CBT if adequate progress is not observed early on. Participants will be followed for one year. The primary hypothesis for which the study is powered is that Guided self-help CBT will result in greater depression symptom improvement than Pure self-help CBT. The investigators also expect secondary analyses to reveal this pattern of results: Guided CBT > Pure CBT > TAU. The investigators will conduct cost-effectiveness analyses (CEA), as the investigators project substantial differences in the direct costs of each study arm. The investigators will also examine TAU healthcare utilization (medications, visits, etc) from electronic medical records (EMR), billing systems, and participant report. The investigators hypothesize that cost per depression free days (DFDs) and quality- adjusted life years (QALYs) will be lowest for Pure CBT, relative to Guided and Stepped-Care CBT and TAU. The investigators also hypothesize that cost per unit of improvement in QALYs and DFDs will be better for Stepped-Care compared to Guided CBT. Additional aims include exploratory examination of secondary outcomes, and predictors and moderators of outcomes among the interventions. The investigators also will collect quantitative and qualitative data on patient, provider, and organizational factors that may impede or facilitate implementation of these interventions, to help prepare for future dissemination efforts. Finally, in this reapplication the investigators have added a non-research Reach Estimation Phase to better estimate acceptance and retention rates under conditions that closely match real-world dissemination'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Website intervention', 'CBT']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Factorial Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '1816', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'a treatment as usual (TAU) control condition', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Participants will receive recruitment information, go on the study website to enroll and complete assessments over the study web site but will not receive the study intervention.'}, {'ArmGroupLabel': 'Pure self-help Internet CBT for depression', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will receive TAU plus access to the study website for the self-help Internet CBT for depression, consisting of access to the Internet site without any contact with therapist', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Pure self-help Internet CBT for depression']}}, {'ArmGroupLabel': 'Guided self-help Internet CBT', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will receive TAU plus Guided self-help Internet CBT, consisting of access to the Internet site plus brief, periodic telephone contacts with therapists', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Guided self-help Internet CBT']}}, {'ArmGroupLabel': 'Stepped-Care Internet CBT condition', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'This consists of a Stepped-Care Internet CBT condition, starting with TAU + Pure self-help CBT and progressing to Guided self-help CBT if adequate progress is not observed early on', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Stepped-Care Internet CBT condition']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Pure self-help Internet CBT for depression', 'InterventionDescription': 'Internet, CBT, Depression', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Pure self-help Internet CBT for depression']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Guided self-help Internet CBT', 'InterventionDescription': 'CBT, Depression, Website intervention, coaching', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Guided self-help Internet CBT']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Stepped-Care Internet CBT condition', 'InterventionDescription': 'Depression CBT, Internet intervention', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stepped-Care Internet CBT condition']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The primary hypothesis for which the study is powered is that Guided self-help CBT will result in greater depression symptom improvement than Pure self-help CBT.', 'PrimaryOutcomeDescription': \"We'll enroll 1,800 adults with depression from 3 rural healthcare clinics, 3 safety net federally qualified healthcare centers and 2 non-profit HMO. Participants will be randomized to: TAU only (b) TAU plus Pure self-help Internet CBT for depression (G-CBT), (c) TAU plus G-CBT, plus brief, periodic therapist telephone contacts; or (d) a Stepped-Care Internet CBT condition, starting with TAU + Pure self-help CBT and progressing to Guided self-help CBT if adequate progress is not observed early on. Participants will be followed for one year.\", 'PrimaryOutcomeTimeFrame': 'assessment measure is administered at baseline and each follow-up, at 5, 10, 15, 25, and 50 weeks after enrollment'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'secondary analyses will examine healthcare utilization for any signs of shifts in amount or mix of TAU services by study condition.', 'SecondaryOutcomeDescription': 'We will conduct cost-effectiveness analyses, examine TAU healthcare utilization from EMR, participant report and collect quantitative and qualitative data on patient, provider, and organizational factors that may impede or facilitate implementation of these interventions and we have added a non-research Reach Estimation Phase to better estimate acceptance and retention rates under conditions that closely match real-world dissemination', 'SecondaryOutcomeTimeFrame': 'assessment measure is administered at baseline and each follow-up, at 5, 10, 15, 25, and 50 weeks after enrollment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nParticipants must have a score ≥ 10 on the self-report Patient Health Questionnaire (PHQ-8), indicative of clinically significant, moderate depression.\\nParticipants must identify their primary healthcare provider in one of the 8 performance sites, and give permission to contact him or her for the purpose of periodic progress reports as well as a referral contact in case any emergent crises are detected.\\nParticipant must be 18 years of age have access to a computer with internet and a working email address.\\nParticipants must also indicate they are planning to continue receiving services from one of the performance site clinics/organizations for at least the next 6 months', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Greg N Clarke, PhD', 'OverallOfficialAffiliation': 'Kaiser Permanente', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Kaiser Permanente Center for Health Research', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97227', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 81, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04008719', 'OrgStudyIdInfo': {'OrgStudyId': 'D17-P02'}, 'Organization': {'OrgFullName': 'Centre Hospitalier St Anne', 'OrgClass': 'OTHER'}, 'BriefTitle': 'ATtention Test and Executive Functions After STroke to Predict Depression.', 'OfficialTitle': 'Predictivity of Attention Test and Executive Functions After Stroke to Predict Depression 3 Months After Stroke.', 'Acronym': 'ATTEST-Depress'}, 'StatusModule': {'StatusVerifiedDate': 'July 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 16, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 16, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'August 16, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 27, 2017', 'StudyFirstSubmitQCDate': 'July 3, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 5, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 4, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 8, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Centre Hospitalier St Anne', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to determine whether cognitive function evaluation (sustained attention, executive functions, working memory) during acute post-stroke is predictive of a 3 months post-stroke depression.', 'DetailedDescription': \"Baseline visit: after neurologic stability, 14 days or less after stroke and before discharge.\\n\\nFirst assessment :\\n\\nNeurologic data: morphologic data (MRI of the brain), stroke severity (NIHSScore), aphasia assessment (Boston Diagnostic Aphasia Examination) if NIHS verbal score ≥1, hemineglect assessment (Bells test).\\nPersonal data assessment :\\n\\ni. Socio demographic : age, gender, marital status, employment, level of education ii. Medical history: medical treatments, psychiatric and non psychiatric history.\\n\\nc. Psychiatric assessment i. Mini International Neuropsychiatric Interview - depression ii. Beck Depression Inventory iii. Clinical Global Impression iv. Standardized Assessment of Personality - Abbreviated Scale (SAPAS) v. Fageström-C vi. Alcohol Use Disorders Identification Test (AUDIT-C) d. Cognitive assessment: i. Verbal memory : Dubois's five words ii. Clock drawing test iii. D2test (computerized) iv. Verbal fluency (Cardebat) v. Working memory (digit span WAIS 3) vi. Brixton (computerized)\\n\\nAssessment 3 months after the first assessment. Phone call and psychiatric assessment: MINI depression, Beck Depression Inventory. Barthel index and Quality of Life assessment.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Post-stroke Depression']}, 'KeywordList': {'Keyword': ['Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '69', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Patients', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Assessments are made by a psychiatrist', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Thymic history', 'Other: Evaluation of the psychiatric disorders', 'Other: Cognitive evaluation']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Thymic history', 'InterventionDescription': 'This interview concerns mainly the nature of the previous psychiatric and psychological care', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Patients']}}, {'InterventionType': 'Other', 'InterventionName': 'Evaluation of the psychiatric disorders', 'InterventionDescription': 'Mini International Neuropsychiatric Interview for the positive diagnosis of depression - under the MINI score of depression.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Patients']}}, {'InterventionType': 'Other', 'InterventionName': 'Cognitive evaluation', 'InterventionDescription': \"They will be held consecutively to the patient's bedside interview on the same day. Some tests will be computerized, others will be in paper form.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Patients']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Post stroke depression', 'PrimaryOutcomeDescription': 'Whether or not a post-stroke depression occurs. occurrence of post-stroke depression assessed with Mini International Neuropsychiatric Interview (MINI), subscale depression .', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Post-stroke depression population characterization', 'SecondaryOutcomeDescription': 'Age, gender, marital status, occupation, level of education, laterality of stroke,and medical and psychiatric history will be collected during the inclusion interview and cognitive tests', 'SecondaryOutcomeTimeFrame': '1 day'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAge 18 or more\\nIschemic or hemorragic stroke, diagnosed with radiology : cerebral CT or MRI, 14 days or less after stroke\\nSigned Consent\\nSocial insurance regime affiliation\\n\\nExclusion Criteria:\\n\\nDeath\\nNo possibility of follow-up\\nNo French-speaker : insufficient command of French\\nDeprivation of liberty : judicial or administrative decision\\nD2 test assessment impossibility\\nAphasia with major disorder of the understanding (Boston <8)\\nAntidepressant treatment during stroke\\nDepression during stroke\\nprotected people', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Philip GORWOOD, MD, PhD', 'OverallOfficialAffiliation': 'CHSA', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Neurology service', 'LocationCity': 'Paris', 'LocationZip': '75014', 'LocationCountry': 'France'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M20890', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4393', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3786', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4325', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15983', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 82, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03990792', 'OrgStudyIdInfo': {'OrgStudyId': 'PI15/00401'}, 'Organization': {'OrgFullName': 'The Mediterranean Institute for the Advance of Biotechnology and Health Research', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Personalized Prevention of Depression in Primary Care', 'OfficialTitle': 'Preventing the Onset of Depression Through a Personalized Intervention Based on ICTs, Risk Prediction Algorithms and Decision Support Systems for Patients and GPs: the e-predictD Study'}, 'StatusModule': {'StatusVerifiedDate': 'February 2020', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 1, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2021', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 17, 2019', 'StudyFirstSubmitQCDate': 'June 17, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 19, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 11, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 13, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Juan Ángel Bellón', 'ResponsiblePartyInvestigatorTitle': 'PhD, Medicine', 'ResponsiblePartyInvestigatorAffiliation': 'Andalusian Health Service'}, 'LeadSponsor': {'LeadSponsorName': 'The Mediterranean Institute for the Advance of Biotechnology and Health Research', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Preventive Services and Health Promotion Research Network', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Institute of Biomedical Research in Málaga (IBIMA)', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Andalusian Regional Ministry of Health', 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': 'European Regional Development Fund (FEDER)', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'University of Malaga', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The main goal is to design, develop and evaluate a personalized intervention to prevent the onset of depression based on Information and Communications Technology (ICTs), risk predictive algorithms and decision support systems (DSS) for patients and general practitioners (GPs). The specific goals are 1) to design and develop a DSS, called e-predictD-DSS, to elaborate personalized plans to prevent depression; 2) to design and develop an ICT solution that integrates the DSS on the web, a mobile application (App), the risk predictive algorithm, different intervention modules and a monitoring-feedback system; 3) to evaluate the usability and adherence of primary care patients and their GPs with the e-predictD intervention; 4) to evaluate the effectiveness of the e-predictD intervention to reduce the incidence of major depression, depression and anxiety symptoms and the probability of major depression next year; 5) to evaluate the cost-effectiveness and cost-utility of the e-predictD intervention to prevent depression.\\n\\nMethods: This is a randomized controlled trial with allocation by cluster (GPs), simple blind, two parallel arms (e-predictD vs \"active m-Health control\") and 1 year follow-up including 720 patients (360 in each arm) and 72 GPs (36 in each arm). Patients will be free of major depression at baseline and aged between 18 and 55 years old. Primary outcome will be the incidence of major depression at 12 months measured by CIDI. As secondary outcomes: depressive and anxiety symptomatology measured by PHQ-9 and GAD-7 and the risk probability of depression measured by predictD algorithm, as well as cost-effectiveness and cost-utility. The e-predictD intervention is multi-component and it is based on a DSS that helps the patients to elaborate their own personalized depression prevention plans, which the patient approves, and implements, and the system monitors offering feedback to the patient and to the GPs. It is an e-Health intervention because it is based on a web and m-Health because it is also implemented on the patient\\'s smartphones through an App. In addition, it integrates a risk algorithm of depression, which is already validated (the predictD algorithm). It also includes an initial GP-patient interview and a specific training for the GP. Finally, a map of potentially useful local community resources to prevent depression will be integrated into the DSS.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Primary Prevention', 'Primary Health Care', 'Randomized controlled trial', 'mHealth', 'App']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Triple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '720', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'e-predictD intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'In this arm, patients will receive a personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS) for patients and General Practitioners (GPs).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: e-predictD intervention']}}, {'ArmGroupLabel': 'm-Health control', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'In this arm, patients will continue receiving the usual care from their GPs. In addition, they will use an App with the same appearance as the e-predictD App but it will only send weekly messages about physical and mental health management. This intervention is not personalized and does not include GP training and GP-patient interview.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Brief psychoeducational intervention']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'e-predictD intervention', 'InterventionDescription': \"The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps patients to develop their own personalized plans to prevent (PPP) depression; 3) eight intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the patient. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Patients will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6 and 9 months. The intervention also includes an initial and single 15-minute face-to-face GP-patient interview.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['e-predictD intervention']}}, {'InterventionType': 'Other', 'InterventionName': 'Brief psychoeducational intervention', 'InterventionDescription': 'The intervention consists of an App that weekly send brief psychoeducational messages about physical and mental health (depression, anxiety, sleep hygiene, physical activity, etc.)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['m-Health control']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Incidence of major depression measured by the Composite International Diagnostic Interview (CIDI)', 'PrimaryOutcomeDescription': 'Composite International Diagnostic Interview (CIDI) is a structured diagnostic interview that provides current diagnoses of major depression', 'PrimaryOutcomeTimeFrame': '12 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depressive symptoms measured by the Patient Health Questionnaire-9 (PHQ-9)', 'SecondaryOutcomeDescription': \"The Patient Health Questionnaire-9 (PHQ-9) measures symptoms of depression through 9 items, each of which is scored 0 ('not at all') to 3 ('nearly every day'). Low scores are equivalent to less symptoms of depression, the scale range is 0 to 27 (9 items)\", 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Anxious symptoms measured by the General Anxiety Questionnaire (GAD-7)', 'SecondaryOutcomeDescription': \"The General Anxiety Questionnaire (GAD-7) measures generalized anxiety disorder through 7 items, each of which is scored 0 ('not at all') to 3 ('nearly every day'). Low scores are equivalent to less symptoms of anxiety, the scale range is 0 to 21 (7 items)\", 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Probability of depression (predictD risk algorithm)', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'Cost-effectiveness and cost-utility', 'SecondaryOutcomeTimeFrame': '12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPHQ-9 <10 at baseline\\nModerate-high risk of depression (predictD risk algorithm score ≥ 10%)\\n\\nExclusion Criteria:\\n\\nNot have a smartphone and internet for personal use\\nUnable to speak Spanish\\nDocumented terminal illness\\nDocumented cognitive impairment\\nLimiting sensory disorder (e.g. deafness)\\nDocumented serious mental illness (psychosis, bipolar, addictions, etc.)', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '55 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Sonia Conejo-Cerón, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+34 951031417', 'CentralContactEMail': 'soniafundacionimabis@hotmail.com'}, {'CentralContactName': 'Patricia Moreno-Peral, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+34 951031347', 'CentralContactEMail': 'predictmalaga@hotmail.com'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Juan M. Mendive', 'LocationStatus': 'Recruiting', 'LocationCity': 'Barcelona', 'LocationCountry': 'Spain', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Juan M. Mendive, PhD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'María Isabel Ballesta Rodríguez', 'LocationStatus': 'Recruiting', 'LocationCity': 'Jaén', 'LocationCountry': 'Spain', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'María Isabel Ballesta Rodríguez, PhD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Antonina Rodríguez Bayón', 'LocationStatus': 'Recruiting', 'LocationCity': 'Linares', 'LocationCountry': 'Spain', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Antonina Rodríguez Bayón, PhD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Juan Á Bellón', 'LocationStatus': 'Recruiting', 'LocationCity': 'Málaga', 'LocationCountry': 'Spain', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Juan Á Bellón, PhD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Emiliano Rodríguez', 'LocationStatus': 'Recruiting', 'LocationCity': 'Salamanca', 'LocationCountry': 'Spain', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Emiliano Rodríguez, PhD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Yolanda López del Hoyo', 'LocationStatus': 'Recruiting', 'LocationCity': 'Zaragoza', 'LocationCountry': 'Spain', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yolanda López del Hoyo, PhD', 'LocationContactRole': 'Contact'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 83, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02021669', 'OrgStudyIdInfo': {'OrgStudyId': '201309002'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01HL117805', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01HL117805&Fy=all'}]}, 'Organization': {'OrgFullName': 'Washington University School of Medicine', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Omega-3 for Depression and Other Cardiac Risk Factors - 2', 'OfficialTitle': 'Omega-3 for Depression and Other Cardiac Risk Factors-2', 'Acronym': 'Omega-3(2)'}, 'StatusModule': {'StatusVerifiedDate': 'August 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 14, 2014', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 13, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 13, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'December 19, 2013', 'StudyFirstSubmitQCDate': 'December 19, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 27, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'July 12, 2019', 'ResultsFirstSubmitQCDate': 'July 12, 2019', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 6, 2019', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 23, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 4, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Washington University School of Medicine', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Heart, Lung, and Blood Institute (NHLBI)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to determine whether antidepressant augmentation with two grams of EPA omega-3 per day is superior to antidepressant therapy alone for major depression in patients with coronary heart disease (CHD).', 'DetailedDescription': 'Depression increases the risk for cardiac morbidity and mortality 2-4 fold in patients with coronary heart disease (CHD). Recent clinical trials have tested standard treatments for comorbid depression in patients with CHD, and some have evaluated their effects on cardiac morbidity and mortality. Most of these trials have shown that standard treatments have only modest effects on depression and have produced relatively small differences between the intervention and control condition. Consequently, they have been unable to determine whether effective treatment of depression can improve cardiac outcomes. Low dietary intake and low plasma phospholipid or erythrocyte levels of two omega-3 fatty acids(FAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are associated with depression and other cardiac risk markers. There is growing evidence from small psychiatric trials that the efficacy of standard antidepressants can be improved by coadministration of an omega-3 FA formulation containing at least 1 gram of EPA. The purpose of the proposed research is to determine whether antidepressant augmentation with this omega-3 formulation is superior to antidepressant therapy alone for major depression in patients with CHD. The proposed study is a randomized, placebo-controlled, double-blind clinical trial. Consenting patients with established coronary heart disease who meet the Diagnostic Statistical Manual (DSM)-5 criteria for a major depressive episode will undergo a baseline evaluation and then be randomly assigned to receive either 50 mg/day of sertraline plus omega-3 FA or 50 mg/day of sertraline plus placebo for 10 weeks. At baseline and after 10 weeks, participants will complete assessments of depression, 24 hour ambulatory ECG monitoring to measure 24 hour heart rate and heart rate variability, and blood draws to measure procoagulant and proinflammatory markers and blood levels of EPA, DHA, other omega-3 FAs, and the omega-6 FAs. If sertraline plus this omega-3 formulation significantly reduces depression compared to sertraline plus placebo, and if it improves or at least does not worsen other cardiovascular risk markers, this study will provide a strong basis for proposing a multicenter clinical trial of sertraline augmented with omega-3 to determine whether treatment of depression can improve survival in patients with CHD and depression.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Antidepressive agents', 'Coronary disease', 'Depression', 'Depressive disorder', 'Fatty Acids, Omega-3']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Quadruple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider', 'Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '144', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Omega-3 supplement', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Omega-3 supplement']}}, {'ArmGroupLabel': 'Placebo', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Placebo']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Omega-3 supplement', 'InterventionDescription': 'Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Omega-3 supplement']}, 'InterventionOtherNameList': {'InterventionOtherName': ['EPA Plus Minami Nutrition']}}, {'InterventionType': 'Drug', 'InterventionName': 'Placebo', 'InterventionDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Beck Depression Inventory-II (BDI-II)', 'PrimaryOutcomeDescription': 'The BDI-II is a 21-item self-report inventory of depression symptoms. The minimum and maximum values for the BDI-II are (0-63). For both instruments, the higher the scores, the greater the severity of depression.', 'PrimaryOutcomeTimeFrame': 'Change from baseline to 10 weeks (post-treatment)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Hamilton Depression Rating Scale (HAM-D, 17)', 'SecondaryOutcomeDescription': 'The HAM-D, 17 is a 17-item, observer-rated measure of depression symptoms. The minimum and maximum values for the HAM-D, (0-52). For both instruments, the higher the scores, the greater the severity of depression.', 'SecondaryOutcomeTimeFrame': 'Change from baseline to 10 weeks (post-treatment)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nDocumented coronary heart disease\\nDiagnosis of major depression based on structured interview\\n\\nExclusion Criteria:\\n\\nModerate to severe cognitive impairment\\nMeets DSM-5 criteria for depressive disorder due to a general medical condition or medication\\nMajor Axis I psychiatric disorder other than unipolar depression or an anxiety disorder, a high risk of suicide, or current substance abuse other than tobacco;\\nNot expected to survive one year or physically unable to tolerate the study protocol\\nKnown sensitivity to sertraline or omega-3, or an allergy to fish oil or shellfish\\nTaking an antidepressant or an omega-3 supplement at baseline\\nExempted by their cardiologist or primary care physician\\nRefuses to provide informed consent\\nParticipating in a competing protocol or trial', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '25 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Robert M Carney, PhD', 'OverallOfficialAffiliation': 'Washington University School of Medicine', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Washington University Medical Center', 'LocationCity': 'Saint Louis', 'LocationState': 'Missouri', 'LocationZip': '63108', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31163106', 'ReferenceType': 'derived', 'ReferenceCitation': 'Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. A Randomized Placebo-Controlled Trial of Omega-3 and Sertraline in Depressed Patients With or at Risk for Coronary Heart Disease. J Clin Psychiatry. 2019 Jun 4;80(4). pii: 19m12742. doi: 10.4088/JCP.19m12742.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Omega-3 Supplement', 'FlowGroupDescription': 'Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks\\n\\nOmega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Placebo', 'FlowGroupDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.\\n\\nPlacebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '71'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '73'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '64'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '70'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '7'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '3'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Omega-3 Supplement', 'BaselineGroupDescription': 'Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks\\n\\nOmega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Placebo', 'BaselineGroupDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.\\n\\nPlacebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '71'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '73'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '144'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '49'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '46'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '95'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '22'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '27'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '49'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '58.5', 'BaselineMeasurementSpread': '9.6'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '60.5', 'BaselineMeasurementSpread': '9.3'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '59.6', 'BaselineMeasurementSpread': '9.4'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '26'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '30'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '56'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '45'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '43'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '88'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '21'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '27'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '48'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '44'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '45'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '89'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '71'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '73'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '144'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Beck Depression Inventory-II (BDI-II)', 'OutcomeMeasureDescription': 'The BDI-II is a 21-item self-report inventory of depression symptoms. The minimum and maximum values for the BDI-II are (0-63). For both instruments, the higher the scores, the greater the severity of depression.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'score on a scale', 'OutcomeMeasureTimeFrame': 'Change from baseline to 10 weeks (post-treatment)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Omega-3 Supplement', 'OutcomeGroupDescription': 'Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks\\n\\nOmega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Placebo', 'OutcomeGroupDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.\\n\\nPlacebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '71'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '73'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '29.9', 'OutcomeMeasurementSpread': '9.0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '29.1', 'OutcomeMeasurementSpread': '8.8'}]}}]}}, {'OutcomeClassTitle': 'Post Treatment (10 Weeks)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '11.0', 'OutcomeMeasurementSpread': '9.9'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '9.1', 'OutcomeMeasurementSpread': '7.7'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Hamilton Depression Rating Scale (HAM-D, 17)', 'OutcomeMeasureDescription': 'The HAM-D, 17 is a 17-item, observer-rated measure of depression symptoms. The minimum and maximum values for the HAM-D, (0-52). For both instruments, the higher the scores, the greater the severity of depression.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'score on a scale', 'OutcomeMeasureTimeFrame': 'Change from baseline to 10 weeks (post-treatment)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Omega-3 Supplement', 'OutcomeGroupDescription': 'Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks\\n\\nOmega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Placebo', 'OutcomeGroupDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.\\n\\nPlacebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '71'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '73'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '17.4', 'OutcomeMeasurementSpread': '5.4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '17.0', 'OutcomeMeasurementSpread': '5.0'}]}}]}}, {'OutcomeClassTitle': 'Post Treatment (10 Weeks)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '7.1', 'OutcomeMeasurementSpread': '7.0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '6.2', 'OutcomeMeasurementSpread': '5.5'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': 'Each participant was followed for fourteen weeks (ten weeks of treatment plus a final call 4 weeks after the end of treatment)', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Omega-3 Supplement', 'EventGroupDescription': 'Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks\\n\\nOmega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '71', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '71', 'EventGroupOtherNumAffected': '35', 'EventGroupOtherNumAtRisk': '71'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Placebo', 'EventGroupDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.\\n\\nPlacebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '73', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '73', 'EventGroupOtherNumAffected': '32', 'EventGroupOtherNumAtRisk': '73'}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '15', 'OtherEventStatsNumAffected': '15', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '11', 'OtherEventStatsNumAffected': '11', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Diarrhea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '7', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '15', 'OtherEventStatsNumAffected': '15', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Constipation', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Increased flatulence', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Increased sleepiness', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '8', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Dizziness', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Insomnia', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Hand Tremors', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Decreased sexual interest/performance', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Less emotionally responsive', 'OtherEventOrganSystem': 'Social circumstances', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Headaches', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Increased anxiety', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Agitation', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Increased sweating', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Decreased appetite', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Bad taste in mouth', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '73'}]}}, {'OtherEventTerm': 'Burping', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '71'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '73'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes', 'AgreementRestrictiveAgreement': 'No'}, 'PointOfContact': {'PointOfContactTitle': 'Robert M. Carney, Ph.D', 'PointOfContactOrganization': 'Washington University School of Medicine', 'PointOfContactEMail': 'carneyr@wustl.edu', 'PointOfContactPhone': '314-286-1305'}}}, 'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'Prot_SAP_ICF', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'Yes', 'LargeDocHasICF': 'Yes', 'LargeDocLabel': 'Study Protocol, Statistical Analysis Plan, and Informed Consent Form', 'LargeDocDate': 'May 22, 2018', 'LargeDocUploadDate': '10/19/2018 11:05', 'LargeDocFilename': 'Prot_SAP_ICF_000.pdf'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T415', 'InterventionBrowseLeafName': 'Omega 3 Fatty Acid', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Ot', 'InterventionBrowseBranchName': 'Other Dietary Supplements'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5129', 'ConditionBrowseLeafName': 'Coronary Artery Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5132', 'ConditionBrowseLeafName': 'Coronary Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}}, {'Rank': 84, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01527981', 'OrgStudyIdInfo': {'OrgStudyId': 'MGHBMED2172010'}, 'Organization': {'OrgFullName': 'Massachusetts General Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Cognitive Behavioral Therapy (CBT) for Adherence and Depression in Type 1 Diabetes', 'OfficialTitle': 'CBT for Adherence and Depression in Type 1 Diabetes'}, 'StatusModule': {'StatusVerifiedDate': 'February 2012', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2008'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2010', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 2010', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 31, 2012', 'StudyFirstSubmitQCDate': 'February 3, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 7, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'February 3, 2012', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 7, 2012', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Steven A. Safren', 'ResponsiblePartyInvestigatorTitle': 'Director, Behavioral Medicine', 'ResponsiblePartyInvestigatorAffiliation': 'Massachusetts General Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Massachusetts General Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study is a pilot behavioral intervention trial, designed to initially examine cognitive behavioral therapy for medical adherence and depression (CBT-AD) in patients with depression and poorly controlled type 1 diabetes.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression', 'Type 1 Diabetes']}, 'KeywordList': {'Keyword': ['Depression', 'Diabetes', 'Adherence', 'Medication', 'Glucose', 'Insulin']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '9', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'CBT-AD', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants received weekly one-hour CBT-AD sessions focusing on diabetes self-care and depression for approximately 10 sessions. Participants also had meetings with a registered dietitian and a nurse educator, focusing on nutritional management of diabetes and diabetes self-care education, respectively.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive behavioral therapy for adherence and depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Cognitive behavioral therapy for adherence and depression', 'InterventionDescription': \"Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CBT-AD']}, 'InterventionOtherNameList': {'InterventionOtherName': ['CBT-AD']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Changes in glucose monitoring', 'PrimaryOutcomeDescription': \"We used electronic glucometers to measure participants' adherence to prescribed glucose self-monitoring, which record each time glucose was measured and the glucose level of each measurement.\", 'PrimaryOutcomeTimeFrame': 'Baseline assessment; 4, 8, and 12 months post-intervention assessments'}, {'PrimaryOutcomeMeasure': 'Changes in insulin adherence', 'PrimaryOutcomeDescription': \"We assessed adherence to participants' self-administered insulin through a self-report questionnaire.\", 'PrimaryOutcomeTimeFrame': 'Baseline assessment; 4, 8, and 12 months post-intervention assessments'}, {'PrimaryOutcomeMeasure': 'Changes in depression severity', 'PrimaryOutcomeDescription': \"Participants' depression severity was measured by clinician-administered measures (Montgomery-Asberg Depression Rating Scale) and self-report measures (Center for Epidemiological Studies Depression Scale). Clinician-delivered measures were administered at baseline and follow-up assessments by assessors blinded to participants' randomization status.\", 'PrimaryOutcomeTimeFrame': 'Baseline assessment; 4, 8, and 12 months post-intervention assessments'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Changes in hemoglobin A1C', 'SecondaryOutcomeDescription': 'We measured participants hemoglobin A1C by means of a blood draw and laboratory test.', 'SecondaryOutcomeTimeFrame': 'Baseline assessment; 4, 8, and 12 months post-intervention assessment'}, {'SecondaryOutcomeMeasure': 'Changes in glucose levels', 'SecondaryOutcomeDescription': 'We measured participants self-monitored glucose levels using electronic glucometers, which record the glucose level of each measurement.', 'SecondaryOutcomeTimeFrame': 'Baseline assessment; 4, 8, and 12 months post-intervention assessment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nDiagnosis of type 1 diabetes that is poorly controlled (HbA1C greater than or equal to 8.0%) despite treatment with insulin.\\nDiagnosis of major depression and/or dysthymia, or current subclinical symptoms of depression in spite of being treated with antidepressants.\\nAge 18-80.\\nIf on an antidepressant, stable for two months. Oral hypoglycemic medications stable for 2 months, and insulin prescription stable for 2 months (if prescribed).\\n\\nExclusion Criteria:\\n\\nActive or untreated major mental illness that would interfere with participation (e.g., untreated psychosis), untreated/unstable bipolar disorder, eating disorder, mental retardation, dementia, or active suicidality.\\nUnable or unwilling to provide informed consent.\\nHistory of or current CBT for depression.\\nCurrently on dialysis.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Steven A Safren, Ph.D.', 'OverallOfficialAffiliation': 'Massachusetts General Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Massachusetts General Hospital', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02114', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '22943030', 'ReferenceType': 'derived', 'ReferenceCitation': 'Markowitz SM, Carper MM, Gonzalez JS, Delahanty LM, Safren SA. Cognitive-behavioral therapy for the treatment of depression and adherence in patients with type 1 diabetes: pilot data and feasibility. Prim Care Companion CNS Disord. 2012;14(2). pii: PCC.11m01220. doi: 10.4088/PCC.11m01220. Epub 2012 Mar 15.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003920', 'ConditionMeshTerm': 'Diabetes Mellitus'}, {'ConditionMeshId': 'D000003922', 'ConditionMeshTerm': 'Diabetes Mellitus, Type 1'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000001327', 'ConditionAncestorTerm': 'Autoimmune Diseases'}, {'ConditionAncestorId': 'D000007154', 'ConditionAncestorTerm': 'Immune System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5698', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafAsFound': 'Diabetes', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5700', 'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 1', 'ConditionBrowseLeafAsFound': 'Type 1 Diabetes', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10222', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M23990', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6445', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3210', 'ConditionBrowseLeafName': 'Autoimmune Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8783', 'ConditionBrowseLeafName': 'Immune System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}]}}}}}, {'Rank': 85, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00868699', 'OrgStudyIdInfo': {'OrgStudyId': 'D1050236'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'EUDRACT No. 2008-007457-13'}]}, 'Organization': {'OrgFullName': 'Sunovion', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)', 'OfficialTitle': 'A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression'}, 'StatusModule': {'StatusVerifiedDate': 'March 2014', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'February 2012', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 23, 2009', 'StudyFirstSubmitQCDate': 'March 24, 2009', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 25, 2009', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'February 14, 2013', 'ResultsFirstSubmitQCDate': 'May 28, 2013', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'July 2, 2013', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 31, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 17, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Sunovion', 'LeadSponsorClass': 'INDUSTRY'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Bipolar Depression']}, 'KeywordList': {'Keyword': ['Bipolar I, Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '505', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'lurasidone low arm', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: lurasidone']}}, {'ArmGroupLabel': 'Placebo', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Placebo']}}, {'ArmGroupLabel': 'lurasidone high arm', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: lurasidone']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'lurasidone', 'InterventionDescription': 'lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['lurasidone high arm']}}, {'InterventionType': 'Drug', 'InterventionName': 'lurasidone', 'InterventionDescription': 'lurasidone 20 mg/day for Days 1-7', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['lurasidone low arm']}}, {'InterventionType': 'Drug', 'InterventionName': 'Placebo', 'InterventionDescription': 'Placebo Comparator', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)', 'PrimaryOutcomeDescription': \"Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression.\\n\\nThe MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.\\n\\nThe MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.\", 'PrimaryOutcomeTimeFrame': 'Baseline to Week 6'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)', 'SecondaryOutcomeDescription': \"Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression.\\n\\nThe CGI depression score ranges from a minimum of 0 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.\", 'SecondaryOutcomeTimeFrame': 'Baseline to Week 6'}, {'SecondaryOutcomeMeasure': 'Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score', 'SecondaryOutcomeDescription': \"Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of depression.\\n\\nThe SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.\\n\\nThe SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items.\", 'SecondaryOutcomeTimeFrame': 'Baseline to Week 6'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nSubject is diagnosed with bipolar I disorder, most resent episode depressed\\nSubject must have a lifetime history of at least one bipolar manic or mixed episode\\n\\nExclusion Criteria:\\n\\nHistory of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode\\nSubject has been hospitalized for a manic or mixed episode within 60 days prior to randomization\\nImminent risk of suicide or injury to self, others, or property', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Medical Director, MD', 'OverallOfficialAffiliation': 'Sunovion', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Synergy Escondido,710 East Grand Ave.', 'LocationCity': 'Escondido', 'LocationState': 'California', 'LocationZip': '92025', 'LocationCountry': 'United States'}, {'LocationFacility': 'Collaborative Neuroscience Network Inc.,12772 Valley View Street,Suite 3', 'LocationCity': 'Garden Grove', 'LocationState': 'California', 'LocationZip': '92645', 'LocationCountry': 'United States'}, {'LocationFacility': 'Excell Research, Inc,3998 Vista Way,Suite 100', 'LocationCity': 'Oceanside', 'LocationState': 'California', 'LocationZip': '92056', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of California at Irvine Medical Center', 'LocationCity': 'Orange', 'LocationState': 'California', 'LocationZip': '92868', 'LocationCountry': 'United States'}, {'LocationFacility': 'California Neuropsychopharmacology,CNRI - Los Angeles LLC,8309 Telegraph Road', 'LocationCity': 'Pico Rivera', 'LocationState': 'California', 'LocationZip': '90660', 'LocationCountry': 'United States'}, {'LocationFacility': 'California Neuropsychopharmacology Clinical Research Institute, LLC,466 26th Street,6th Floor', 'LocationCity': 'San Diego', 'LocationState': 'California', 'LocationZip': '92102', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Colorado', 'LocationCity': 'Aurora', 'LocationState': 'Colorado', 'LocationZip': '80045', 'LocationCountry': 'United States'}, {'LocationFacility': 'Florida Clinical Research Center, LLC,3914 State Road 64 East', 'LocationCity': 'Bradenton', 'LocationState': 'Florida', 'LocationZip': '34208', 'LocationCountry': 'United States'}, {'LocationFacility': 'Florida Clinical Research Center, LLC,2300 Maitland Center Parkway,Suite 230', 'LocationCity': 'Maitland', 'LocationState': 'Florida', 'LocationZip': '32751', 'LocationCountry': 'United States'}, {'LocationFacility': 'Depression and Anxiety Disorders Research Institute', 'LocationCity': 'Tampa', 'LocationState': 'Florida', 'LocationZip': '33613', 'LocationCountry': 'United States'}, {'LocationFacility': 'Janus Center for Psychiatric Research,5601 Corporate Way,Suite 103', 'LocationCity': 'West Palm Beach', 'LocationState': 'Florida', 'LocationZip': '33407', 'LocationCountry': 'United States'}, {'LocationFacility': 'American Medical Research Inc.,1200 Harger Road Suite 415', 'LocationCity': 'Oak Brook', 'LocationState': 'Illinois', 'LocationZip': '60523', 'LocationCountry': 'United States'}, {'LocationFacility': 'Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340', 'LocationCity': 'Lake Charles', 'LocationState': 'Louisiana', 'LocationZip': '70601', 'LocationCountry': 'United States'}, {'LocationFacility': 'Sheppard Pratt Health System,6501 North Charles Street', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21285', 'LocationCountry': 'United States'}, {'LocationFacility': 'Albuquerque Neuroscience Inc., 101 Hospital Loop, NE, Suite 209', 'LocationCity': 'Albuquerque', 'LocationState': 'New Mexico', 'LocationZip': '87109', 'LocationCountry': 'United States'}, {'LocationFacility': 'Neurobehavioral Research, Inc.', 'LocationCity': 'Cedarhurst', 'LocationState': 'New York', 'LocationZip': '11516', 'LocationCountry': 'United States'}, {'LocationFacility': 'Finger Lakes Clinical Research', 'LocationCity': 'Rochester', 'LocationState': 'New York', 'LocationZip': '14618', 'LocationCountry': 'United States'}, {'LocationFacility': 'Richard H. Weisler., M.D., P.A., & Associates,700 Spring Forest Road,Suite 125', 'LocationCity': 'Raleigh', 'LocationState': 'North Carolina', 'LocationZip': '27609', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mood Disorders Program-UHCMC', 'LocationCity': 'Cleveland', 'LocationState': 'Ohio', 'LocationZip': '44106', 'LocationCountry': 'United States'}, {'LocationFacility': 'MetroHealth System', 'LocationCity': 'Cleveland', 'LocationState': 'Ohio', 'LocationZip': '44122', 'LocationCountry': 'United States'}, {'LocationFacility': 'CRI Worldwide, LLC', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19139', 'LocationCountry': 'United States'}, {'LocationFacility': 'FutureSearch Clinical Trials, LLC.,4200 Marathon Blvd.,Suite 200', 'LocationCity': 'Austin', 'LocationState': 'Texas', 'LocationZip': '78756', 'LocationCountry': 'United States'}, {'LocationFacility': 'Medical Services Prague s.r.o.', 'LocationCity': 'Kolejni 429-5', 'LocationState': 'Praha', 'LocationCountry': 'Czech Republic'}, {'LocationFacility': 'Psychiatricka ambulance', 'LocationCity': 'Brno - mesto', 'LocationZip': '602 00', 'LocationCountry': 'Czech Republic'}, {'LocationFacility': 'BIALBI s.r.o., Psychiatricke Oddeleni', 'LocationCity': 'Litomerice', 'LocationCountry': 'Czech Republic'}, {'LocationFacility': 'Clintrial, s.r.o.', 'LocationCity': 'Praha', 'LocationZip': '10 100 00', 'LocationCountry': 'Czech Republic'}, {'LocationFacility': 'Hopital Caremeau, Service de Psychiatrie A', 'LocationCity': 'Nimes Cedex', 'LocationZip': '30 30029', 'LocationCountry': 'France'}, {'LocationFacility': 'Zans Ritter, Marcel', 'LocationCity': 'Orvault', 'LocationZip': '44700', 'LocationCountry': 'France'}, {'LocationFacility': 'S V Medical College', 'LocationCity': 'Tirupati', 'LocationState': 'Andh Prad', 'LocationZip': '517507', 'LocationCountry': 'India'}, {'LocationFacility': 'Vijayawada Institute of Mental Health and Neurosciences, Psychiatry', 'LocationCity': 'Vijaywada', 'LocationState': 'Andh Prad', 'LocationZip': '520002', 'LocationCountry': 'India'}, {'LocationFacility': 'Samvedna Hospitals', 'LocationCity': 'Ahmedabad', 'LocationState': 'Gujarat', 'LocationZip': '380006', 'LocationCountry': 'India'}, {'LocationFacility': 'Seth K M School of P G Medicine & Research', 'LocationCity': 'Ahmedabad', 'LocationState': 'Gujarat', 'LocationZip': '380006', 'LocationCountry': 'India'}, {'LocationFacility': 'Mental Illness Treatment Rehabilitationi Foundation', 'LocationCity': 'Ahmedabad', 'LocationState': 'Gujarat', 'LocationZip': '380013', 'LocationCountry': 'India'}, {'LocationFacility': 'Spandana Nursing Home', 'LocationCity': 'Bangalore', 'LocationState': 'Karna', 'LocationZip': '560010', 'LocationCountry': 'India'}, {'LocationFacility': 'Sujata Birla Hospital & Research Centre', 'LocationCity': 'Nashik', 'LocationState': 'Mahara', 'LocationZip': '422101', 'LocationCountry': 'India'}, {'LocationFacility': 'R.K. Yadav Memorial Mental Health & De-Addiction Hospital', 'LocationCity': 'Jaipur', 'LocationState': 'Rajasthan', 'LocationZip': '302021', 'LocationCountry': 'India'}, {'LocationFacility': 'Manobal Med. Research Centre', 'LocationCity': 'Lucknow', 'LocationState': 'Uttar Prad', 'LocationZip': '226006', 'LocationCountry': 'India'}, {'LocationFacility': 'Spitalul Clinic de Urgenta Militar Central', 'LocationCity': 'Bucdresti', 'LocationZip': '010825', 'LocationCountry': 'Romania'}, {'LocationFacility': 'Spitalul Clinic de Psihaiatrie Prof. Dr. Alexandru Obregia', 'LocationCity': 'Bucuresti', 'LocationZip': '041914', 'LocationCountry': 'Romania'}, {'LocationFacility': 'Spitalul Clinic Judetean de Urgenta Cluj', 'LocationCity': 'Cluj-Napoca', 'LocationZip': '400012', 'LocationCountry': 'Romania'}, {'LocationFacility': 'Spitalul Clinic de Neuropsihiatrie Craiova', 'LocationCity': 'Craiova', 'LocationZip': '200620', 'LocationCountry': 'Romania'}, {'LocationFacility': 'Spitalul Clinic de Neurologie si Psihiatrie Oradea', 'LocationCity': 'Oradea', 'LocationZip': '410154', 'LocationCountry': 'Romania'}, {'LocationFacility': 'City Psychiatric Hospital #2 of St. Nikolay Chudotvorets', 'LocationCity': 'St. Petersburg', 'LocationZip': '190121', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Bekhterev Scientific Research Psychoneurological Institute', 'LocationCity': 'St. Petersburg', 'LocationZip': '193019', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Psychoneurology Dispensary #4', 'LocationCity': 'St. Petersburg', 'LocationZip': '197110', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Cape Trial Centre', 'LocationCity': 'Cape Town, W. Cape', 'LocationZip': '7530', 'LocationCountry': 'South Africa'}, {'LocationFacility': 'Paarl Medical Centre', 'LocationCity': 'Paarl, W. Cape', 'LocationZip': '7646', 'LocationCountry': 'South Africa'}, {'LocationFacility': 'Clinika', 'LocationCity': 'Port Elizabeth, E. Cape', 'LocationZip': '6000', 'LocationCountry': 'South Africa'}, {'LocationFacility': 'Dey Clinic', 'LocationCity': 'Pretoria, Gauteng', 'LocationZip': '0181', 'LocationCountry': 'South Africa'}, {'LocationFacility': 'Vereeniging Medi-Clinic', 'LocationCity': 'Vereeniging, Free State', 'LocationZip': '1941', 'LocationCountry': 'South Africa'}, {'LocationFacility': 'Chair of Psychiatry and Medical Psychology', 'LocationCity': 'Donetsk', 'LocationZip': '83008', 'LocationCountry': 'Ukraine'}, {'LocationFacility': 'Reg. Psychiatric Hospital', 'LocationCity': 'Odessa', 'LocationCountry': 'Ukraine'}, {'LocationFacility': 'Reg Cl.Ps.H.n.a.O.F. Malstev, Fem.Ac. Gen. Ps.D.5B', 'LocationCity': 'Poltava', 'LocationZip': '36006', 'LocationCountry': 'Ukraine'}, {'LocationFacility': 'CRI Cl.Psych.Hosp. #1, Fem. Psych. Dept. #2, Male I', 'LocationCity': 'Simferopol', 'LocationZip': '95006', 'LocationCountry': 'Ukraine'}, {'LocationFacility': 'Reg. Psych. Hosp.n.a.O.Yuschenko, Dept #21', 'LocationCity': 'Vinnitsia', 'LocationZip': '21018', 'LocationCountry': 'Ukraine'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24170180', 'ReferenceType': 'result', 'ReferenceCitation': 'Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, Sachs G. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014 Feb;171(2):160-8. doi: 10.1176/appi.ajp.2013.13070984.'}, {'ReferencePMID': '30102967', 'ReferenceType': 'derived', 'ReferenceCitation': 'Raison CL, Pikalov A, Siu C, Tsai J, Koblan K, Loebel A. C-reactive protein and response to lurasidone in patients with bipolar depression. Brain Behav Immun. 2018 Oct;73:717-724. doi: 10.1016/j.bbi.2018.08.009. Epub 2018 Aug 10.'}, {'ReferencePMID': '27529375', 'ReferenceType': 'derived', 'ReferenceCitation': 'Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies. J Clin Psychiatry. 2016 Oct;77(10):e1324-e1331. doi: 10.4088/JCP.15m10261.'}, {'ReferencePMID': '27215976', 'ReferenceType': 'derived', 'ReferenceCitation': 'Rajagopalan K, Bacci ED, Ng-Mak D, Wyrwich K, Pikalov A, Loebel A. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. BMC Psychiatry. 2016 May 23;16:157. doi: 10.1186/s12888-016-0865-y.'}, {'ReferencePMID': '26730454', 'ReferenceType': 'derived', 'ReferenceCitation': 'Chapel S, Chiu YY, Hsu J, Cucchiaro J, Loebel A. Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis. Clin Ther. 2016 Jan 1;38(1):4-15. doi: 10.1016/j.clinthera.2015.11.013. Epub 2015 Dec 22.'}, {'ReferencePMID': '26363720', 'ReferenceType': 'derived', 'ReferenceCitation': 'Loebel A, Siu C, Rajagopalan K, Pikalov A, Cucchiaro J, Ketter TA. Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study. J Affect Disord. 2015 Nov 1;186:376-82. doi: 10.1016/j.jad.2015.07.033. Epub 2015 Aug 5.'}, {'ReferencePMID': '25844756', 'ReferenceType': 'derived', 'ReferenceCitation': 'McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015 Apr;76(4):398-405. doi: 10.4088/JCP.14m09410.'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowRecruitmentDetails': '4/29/09 to 2/1/12', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Placebo', 'FlowGroupDescription': 'Placebo : Placebo Comparator'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Lurasidone High Arm', 'FlowGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day'}, {'FlowGroupId': 'FG002', 'FlowGroupTitle': 'Lurasidone Low Arm', 'FlowGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '170'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '169'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '166'}]}}, {'FlowMilestoneType': 'Intent-to-Treat Population', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '162'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '162'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '161'}]}}, {'FlowMilestoneType': 'Safety Population', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '168'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '167'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '164'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '127'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '124'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '123'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '43'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '45'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '43'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'Intent-to-treat population is analyzed.', 'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Placebo', 'BaselineGroupDescription': 'Placebo : Placebo Comparator'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Lurasidone High Arm', 'BaselineGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Lurasidone Low Arm', 'BaselineGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day'}, {'BaselineGroupId': 'BG003', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '162'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '162'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '161'}, {'BaselineDenomCountGroupId': 'BG003', 'BaselineDenomCountValue': '485'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '3'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '159'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '159'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '155'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '473'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '9'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '41.2', 'BaselineMeasurementSpread': '12.45'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '42.0', 'BaselineMeasurementSpread': '12.35'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '41.3', 'BaselineMeasurementSpread': '12.31'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '41.5', 'BaselineMeasurementSpread': '12.35'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '87'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '98'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '91'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '276'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '75'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '64'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '70'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '209'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'France', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '13'}]}}]}}, {'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '58'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '70'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '67'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '195'}]}}]}}, {'BaselineClassTitle': 'Czech Republic', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '19'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '19'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '17'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '55'}]}}]}}, {'BaselineClassTitle': 'Ukraine', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '16'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '17'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '16'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '49'}]}}]}}, {'BaselineClassTitle': 'Romania', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '9'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '15'}]}}]}}, {'BaselineClassTitle': 'South Africa', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '18'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '17'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '19'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '54'}]}}]}}, {'BaselineClassTitle': 'Russian Federation', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '10'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '10'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '11'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '31'}]}}]}}, {'BaselineClassTitle': 'India', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '27'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '23'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '23'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '73'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)', 'OutcomeMeasureDescription': \"Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression.\\n\\nThe MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.\\n\\nThe MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.\", 'OutcomeMeasurePopulationDescription': 'Intent-to-treat population is analyzed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Least Squares Mean', 'OutcomeMeasureDispersionType': 'Standard Error', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': 'Baseline to Week 6', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Placebo', 'OutcomeGroupDescription': 'Placebo : Placebo Comparator'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Lurasidone High Arm', 'OutcomeGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Lurasidone Low Arm', 'OutcomeGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '162'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '162'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '161'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-10.7', 'OutcomeMeasurementSpread': '0.83'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-15.4', 'OutcomeMeasurementSpread': '0.83'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '-15.4', 'OutcomeMeasurementSpread': '0.83'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG002']}, 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '<0.001', 'OutcomeAnalysisStatisticalMethod': 'Mixed Models Analysis', 'OutcomeAnalysisParamType': 'Mean Difference (Final Values)', 'OutcomeAnalysisParamValue': '-4.6', 'OutcomeAnalysisDispersionType': 'Standard Error of the mean', 'OutcomeAnalysisDispersionValue': '1.17', 'OutcomeAnalysisEstimateComment': 'A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '<0.001', 'OutcomeAnalysisStatisticalMethod': 'Mixed Models Analysis', 'OutcomeAnalysisParamType': 'Mean Difference (Final Values)', 'OutcomeAnalysisParamValue': '-4.6', 'OutcomeAnalysisDispersionType': 'Standard Error of the mean', 'OutcomeAnalysisDispersionValue': '1.17', 'OutcomeAnalysisEstimateComment': 'A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)', 'OutcomeMeasureDescription': \"Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression.\\n\\nThe CGI depression score ranges from a minimum of 0 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.\", 'OutcomeMeasurePopulationDescription': 'Intent-to-treat population is analyzed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Least Squares Mean', 'OutcomeMeasureDispersionType': 'Standard Error', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': 'Baseline to Week 6', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Placebo', 'OutcomeGroupDescription': 'Placebo : Placebo Comparator'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Lurasidone High Arm', 'OutcomeGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Lurasidone Low Arm', 'OutcomeGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '162'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '162'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '161'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-1.14', 'OutcomeMeasurementSpread': '0.102'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-1.71', 'OutcomeMeasurementSpread': '0.101'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '-1.83', 'OutcomeMeasurementSpread': '0.102'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG002']}, 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '<0.001', 'OutcomeAnalysisStatisticalMethod': 'Mixed Models Analysis', 'OutcomeAnalysisParamType': 'Mean Difference (Final Values)', 'OutcomeAnalysisParamValue': '-0.69', 'OutcomeAnalysisDispersionType': 'Standard Error of the mean', 'OutcomeAnalysisDispersionValue': '0.143', 'OutcomeAnalysisEstimateComment': 'A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '<0.001', 'OutcomeAnalysisStatisticalMethod': 'Mixed Models Analysis', 'OutcomeAnalysisParamType': 'Mean Difference (Final Values)', 'OutcomeAnalysisParamValue': '-0.57', 'OutcomeAnalysisDispersionType': 'Standard Error of the mean', 'OutcomeAnalysisDispersionValue': '0.143', 'OutcomeAnalysisEstimateComment': 'A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score', 'OutcomeMeasureDescription': \"Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of depression.\\n\\nThe SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.\\n\\nThe SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items.\", 'OutcomeMeasurePopulationDescription': 'Intent-to-treat population is analyzed. Number of participants in table is not consistent with intent-to-treat population because: if one or more items are missing at a study visit, as can occur when a subject opts out of the work/school item because it does not apply, the authors of the scale recommend setting the total score to missing', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Least Squares Mean', 'OutcomeMeasureDispersionType': 'Standard Error', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': 'Baseline to Week 6', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Placebo', 'OutcomeGroupDescription': 'Placebo : Placebo Comparator'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Lurasidone High Arm', 'OutcomeGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Lurasidone Low Arm', 'OutcomeGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '100'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '105'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '88'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-6.3', 'OutcomeMeasurementSpread': '0.77'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-9.8', 'OutcomeMeasurementSpread': '0.73'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '-9.5', 'OutcomeMeasurementSpread': '0.81'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG002']}, 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.003', 'OutcomeAnalysisStatisticalMethod': 'ANCOVA', 'OutcomeAnalysisParamType': 'Mean Difference (Final Values)', 'OutcomeAnalysisParamValue': '-3.1', 'OutcomeAnalysisDispersionType': 'Standard Error of the mean', 'OutcomeAnalysisDispersionValue': '1.05', 'OutcomeAnalysisEstimateComment': 'A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '<0.001', 'OutcomeAnalysisStatisticalMethod': 'ANCOVA', 'OutcomeAnalysisParamType': 'Mean Difference (Final Values)', 'OutcomeAnalysisParamValue': '-3.5', 'OutcomeAnalysisDispersionType': 'Standard Error of the mean', 'OutcomeAnalysisDispersionValue': '1.01', 'OutcomeAnalysisEstimateComment': 'A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.'}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '5', 'EventsTimeFrame': 'April 29,2009 - February 1, 2012', 'EventsDescription': 'Safety population is analyzed.', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Placebo', 'EventGroupDescription': 'Placebo : Placebo Comparator', 'EventGroupSeriousNumAffected': '1', 'EventGroupSeriousNumAtRisk': '168', 'EventGroupOtherNumAffected': '56', 'EventGroupOtherNumAtRisk': '168'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Lurasidone High Arm', 'EventGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day', 'EventGroupSeriousNumAffected': '5', 'EventGroupSeriousNumAtRisk': '167', 'EventGroupOtherNumAffected': '65', 'EventGroupOtherNumAtRisk': '167'}, {'EventGroupId': 'EG002', 'EventGroupTitle': 'Lurasidone Low Arm', 'EventGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day', 'EventGroupSeriousNumAffected': '3', 'EventGroupSeriousNumAtRisk': '164', 'EventGroupOtherNumAffected': '57', 'EventGroupOtherNumAtRisk': '164'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Depression', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventSourceVocabulary': 'MeDRA 14.1', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '168'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '167'}, {'SeriousEventStatsGroupId': 'EG002', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '164'}]}}, {'SeriousEventTerm': 'Panic Attack', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventSourceVocabulary': 'MeDRA 14.1', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '168'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '167'}, {'SeriousEventStatsGroupId': 'EG002', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '164'}]}}, {'SeriousEventTerm': 'Foot Fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MeDRA 14.1', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '168'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '167'}, {'SeriousEventStatsGroupId': 'EG002', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '164'}]}}, {'SeriousEventTerm': 'Restless Leg Syndrome', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MeDRA 14.1', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '168'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '167'}, {'SeriousEventStatsGroupId': 'EG002', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '164'}]}}, {'SeriousEventTerm': 'HIV Infection', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MeDRA 14.1', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '168'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '167'}, {'SeriousEventStatsGroupId': 'EG002', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '164'}]}}, {'SeriousEventTerm': 'Subcutaneous Absceses', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MeDRA 14.1', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '168'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '167'}, {'SeriousEventStatsGroupId': 'EG002', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '164'}]}}, {'SeriousEventTerm': 'Duodenal Ulcer', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MeDRA 14.1', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '168'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '167'}, {'SeriousEventStatsGroupId': 'EG002', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '164'}]}}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MeDRA 14.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '87', 'OtherEventStatsNumAffected': '13', 'OtherEventStatsNumAtRisk': '168'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '38', 'OtherEventStatsNumAffected': '29', 'OtherEventStatsNumAtRisk': '167'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '24', 'OtherEventStatsNumAffected': '17', 'OtherEventStatsNumAtRisk': '164'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MeDRA 14.1', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '25', 'OtherEventStatsNumAffected': '20', 'OtherEventStatsNumAtRisk': '168'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '16', 'OtherEventStatsNumAffected': '15', 'OtherEventStatsNumAtRisk': '167'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '36', 'OtherEventStatsNumAffected': '23', 'OtherEventStatsNumAtRisk': '164'}]}}, {'OtherEventTerm': 'Akathisia', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MeDRA 14.1', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '168'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '23', 'OtherEventStatsNumAffected': '18', 'OtherEventStatsNumAtRisk': '167'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '18', 'OtherEventStatsNumAffected': '13', 'OtherEventStatsNumAtRisk': '164'}]}}, {'OtherEventTerm': 'Insomnia', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MeDRA 14.1', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '19', 'OtherEventStatsNumAffected': '14', 'OtherEventStatsNumAtRisk': '168'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '16', 'OtherEventStatsNumAffected': '11', 'OtherEventStatsNumAtRisk': '167'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '12', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '164'}]}}, {'OtherEventTerm': 'Somnolence', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MeDRA 14.1', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '7', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '168'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '11', 'OtherEventStatsNumAtRisk': '167'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '7', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '164'}]}}, {'OtherEventTerm': 'Sedation', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MeDRA 14.1', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '168'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '12', 'OtherEventStatsNumAtRisk': '167'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '164'}]}}, {'OtherEventTerm': 'Dizziness', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MeDRA 14.1', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '13', 'OtherEventStatsNumAtRisk': '168'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '12', 'OtherEventStatsNumAffected': '10', 'OtherEventStatsNumAtRisk': '167'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '164'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No', 'AgreementRestrictionType': 'OTHER', 'AgreementRestrictiveAgreement': 'Yes', 'AgreementOtherDetails': 'In addition to the <60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.'}, 'PointOfContact': {'PointOfContactTitle': 'Medical Director, CNS', 'PointOfContactOrganization': 'Sunovion', 'PointOfContactPhone': '1-866-503-6351'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000069056', 'InterventionMeshTerm': 'Lurasidone Hydrochloride'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000014150', 'InterventionAncestorTerm': 'Antipsychotic Agents'}, {'InterventionAncestorId': 'D000014149', 'InterventionAncestorTerm': 'Tranquilizing Agents'}, {'InterventionAncestorId': 'D000002492', 'InterventionAncestorTerm': 'Central Nervous System Depressants'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000011619', 'InterventionAncestorTerm': 'Psychotropic Drugs'}, {'InterventionAncestorId': 'D000058669', 'InterventionAncestorTerm': 'Adrenergic alpha-2 Receptor Antagonists'}, {'InterventionAncestorId': 'D000000317', 'InterventionAncestorTerm': 'Adrenergic alpha-Antagonists'}, {'InterventionAncestorId': 'D000018674', 'InterventionAncestorTerm': 'Adrenergic Antagonists'}, {'InterventionAncestorId': 'D000018663', 'InterventionAncestorTerm': 'Adrenergic Agents'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000058830', 'InterventionAncestorTerm': 'Serotonin 5-HT2 Receptor Antagonists'}, {'InterventionAncestorId': 'D000012702', 'InterventionAncestorTerm': 'Serotonin Antagonists'}, {'InterventionAncestorId': 'D000018490', 'InterventionAncestorTerm': 'Serotonin Agents'}, {'InterventionAncestorId': 'D000065127', 'InterventionAncestorTerm': 'Dopamine D2 Receptor Antagonists'}, {'InterventionAncestorId': 'D000018492', 'InterventionAncestorTerm': 'Dopamine Antagonists'}, {'InterventionAncestorId': 'D000015259', 'InterventionAncestorTerm': 'Dopamine Agents'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M348', 'InterventionBrowseLeafName': 'Lurasidone Hydrochloride', 'InterventionBrowseLeafAsFound': 'Lurasidone', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M15487', 'InterventionBrowseLeafName': 'Antipsychotic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M13057', 'InterventionBrowseLeafName': 'Psychotropic Drugs', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19330', 'InterventionBrowseLeafName': 'Adrenergic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2250', 'InterventionBrowseLeafName': 'Adrenergic alpha-Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19339', 'InterventionBrowseLeafName': 'Adrenergic Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M14095', 'InterventionBrowseLeafName': 'Serotonin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M6056', 'InterventionBrowseLeafName': 'Dopamine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19180', 'InterventionBrowseLeafName': 'Dopamine Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M16545', 'InterventionBrowseLeafName': 'Dopamine Agents', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'CNSDep', 'InterventionBrowseBranchName': 'Central Nervous System Depressants'}, {'InterventionBrowseBranchAbbrev': 'PsychDr', 'InterventionBrowseBranchName': 'Psychotropic Drugs'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'CaAg', 'InterventionBrowseBranchName': 'Cardiotonic Agents'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000001714', 'ConditionMeshTerm': 'Bipolar Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000068105', 'ConditionAncestorTerm': 'Bipolar and Related Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3578', 'ConditionBrowseLeafName': 'Bipolar Disorder', 'ConditionBrowseLeafAsFound': 'Bipolar Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M226', 'ConditionBrowseLeafName': 'Bipolar and Related Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 86, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02429674', 'OrgStudyIdInfo': {'OrgStudyId': '#7089'}, 'Organization': {'OrgFullName': 'New York State Psychiatric Institute', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Efficacy of a Depression Intervention for Adolescents With Depression and Sleep Disturbances', 'OfficialTitle': 'The Efficacy of a Depression Intervention for Adolescents With Depression and Sleep Disturbances'}, 'StatusModule': {'StatusVerifiedDate': 'January 2020', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 2015'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 2021', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 22, 2015', 'StudyFirstSubmitQCDate': 'April 24, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 29, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 27, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 29, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Eleanor McGlinchey', 'ResponsiblePartyInvestigatorTitle': 'Assistant Professor of Clinical Psychology in Psychiatry', 'ResponsiblePartyInvestigatorAffiliation': 'New York State Psychiatric Institute'}, 'LeadSponsor': {'LeadSponsorName': 'New York State Psychiatric Institute', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The focus of this study is on identifying how Interpersonal Psychotherapy for Adolescents (IPT-A) with depression works to change sleep and related biological markers found in saliva, namely cortisol and pro-inflammatory cytokine levels. The long-term goal of this project is to understand the biological mechanisms of recovery from depression in order to assist in selecting and guiding personalized psychotherapeutic interventions with the highest likelihood of success for individual adolescents with depression.', 'DetailedDescription': \"The primary aim of this project is to examine whether adolescent depression and the associated symptoms of sleep disturbance are best treated using an empirically supported psychotherapy that is augmented with a sleep improvement module. Twenty adolescents (ages 12-17) who meet criteria for major depressive disorder, dysthymic disorder, depressive disorder not otherwise specified, or adjustment disorder with depressed mood and also report elevated levels of sleep disturbance will receive Interpersonal Psychotherapy for Depressed Adolescents (IPT-A) with an adjunctive sleep module that is integrated throughout the treatment. Identifying the best approach to treating both the adolescent's depression and the commonly associated symptom of sleep disturbance will have significant implications for the long-term outcomes of depressed adolescents. Moreover, identifying unique symptom and biological profiles at the outset of treatment may enable doctors to predict treatment outcome.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Adolescence']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '20', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'TranS-C and IPT-A', 'ArmGroupType': 'Other', 'ArmGroupDescription': '12 sessions of weekly outpatient psychotherapy for adolescent depression.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: TranS-C and IPT-A']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'TranS-C and IPT-A', 'InterventionDescription': \"The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['TranS-C and IPT-A']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Transdiagnostic Sleep and Circadian treatment and IPT-A']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Change from Baseline in Depression symptom score on the Children's Depression Rating Scale (CDRS)\", 'PrimaryOutcomeDescription': 'Reduction in depression symptoms', 'PrimaryOutcomeTimeFrame': 'Week 12'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change from Baseline in sleep using actigraphy estimated sleep variables', 'SecondaryOutcomeDescription': 'Reduction in sleep difficulties and increase in sleep duration', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Change from baseline in Cytokine levels found in saliva', 'SecondaryOutcomeDescription': 'Reduction in inflammatory markers', 'SecondaryOutcomeTimeFrame': 'Week 12'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\noutpatient participant\\nparent or legally authorized representative must provide consent and assent by the participant\\nDiagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-V) criteria for a depressive disorder\\nClinical Global Assessment Scale (C-GAS) < 65\\nQuick Inventory of Depression Symptoms - Self Report 16 (QIDS-SR16) over 8 and less than 24.\\nEnglish speaking\\nsignificant sleep complaints\\n\\nExclusion Criteria:\\n\\nco-morbid psychiatric diagnosis of bipolar disorder, psychosis, autism spectrum disorder, intellectual development disorder, conduct disorder or substance abuse disorder\\nany condition or illness such as uncontrolled seizure disorder, uncontrolled diabetes, or any other conditions that represent as an inappropriate risk to the participant and/or could confound the interpretation of the study\\ncurrently in active evidence-based psychotherapy for the same condition\\ncurrently taking medication for a psychiatric diagnosis that is not a stable dose (4 weeks on the same dose).\\ncurrently considered at risk for suicide in the opinion of the study doctor, has made a suicide attempt in the past 4 months, or is currently reporting active suicidal ideation.\\nhistory of alcohol or other substance abuse as defined by DSM-V within the last 6 months.\\nevidence from clinical diagnosis or report by youth or parent of sleep apnea, restless legs or periodic limb movements during sleep\\nsleep treatment that might confound the interpretation of sleep outcomes.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '12 Years', 'MaximumAge': '17 Years', 'StdAgeList': {'StdAge': ['Child']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Eleanor McGlinchey, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '646 774-5859', 'CentralContactEMail': 'mcglinc@nyspi.columbia.edu'}, {'CentralContactName': 'Amir Levine, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '646-774-7331', 'CentralContactEMail': 'alevine@nyspi.columbia.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Eleanor L McGlinchey, Ph.D.', 'OverallOfficialAffiliation': 'New York State Psychiatric Institute', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Pediatric Anxiety and Mood Research Clinic, New York State Psychiatric Institute', 'LocationStatus': 'Recruiting', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10032', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Eleanor McGlinchey, Ph.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '646-774-5859', 'LocationContactEMail': 'mcglinc@nyspi.columbia.edu'}, {'LocationContactName': 'Eleanor L McGlinchey, Ph.D.', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Laura Mufson, Ph.D.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Amir Levine, M.D.', 'LocationContactRole': 'Sub-Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020920', 'ConditionMeshTerm': 'Dyssomnias'}, {'ConditionMeshId': 'D000012893', 'ConditionMeshTerm': 'Sleep Wake Disorders'}, {'ConditionMeshId': 'D000020447', 'ConditionMeshTerm': 'Parasomnias'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000012816', 'ConditionAncestorTerm': 'Signs and Symptoms'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14279', 'ConditionBrowseLeafName': 'Sleep Wake Disorders', 'ConditionBrowseLeafAsFound': 'Sleep Disturbance', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21239', 'ConditionBrowseLeafName': 'Dyssomnias', 'ConditionBrowseLeafAsFound': 'Sleep Disturbance', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M20826', 'ConditionBrowseLeafName': 'Parasomnias', 'ConditionBrowseLeafAsFound': 'Sleep Disturbance', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10987', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 87, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01685294', 'OrgStudyIdInfo': {'OrgStudyId': '1R01MH095230-01', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH095230-01&Fy=all'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH095230', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH095230&Fy=all'}]}, 'Organization': {'OrgFullName': 'Brown University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression', 'OfficialTitle': 'Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression'}, 'StatusModule': {'StatusVerifiedDate': 'January 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 2011'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2014', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 2014', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 29, 2012', 'StudyFirstSubmitQCDate': 'September 11, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 14, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 12, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 13, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Dr. Jennifer Johnson', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor (Research), Department of Psychiatry and Human Behavior', 'ResponsiblePartyInvestigatorAffiliation': 'Brown University'}, 'LeadSponsor': {'LeadSponsorName': 'Brown University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'This study will examine the effects of a first-line treatment for major depressive disorder (MDD), interpersonal psychotherapy (IPT), among men and women prisoners.', 'DetailedDescription': 'The purpose of this 3-year randomized trial is to promote uptake of evidence-based treatment in criminal justice settings by conducting a fully-powered randomized effectiveness study that collects pilot implementation data, including cost-effectiveness data. Group IPT will be compared to treatment as usual (TAU) in a sample of 90 male and 90 female prisoners with MDD from 4 institutions, allowing us to explore gender effects.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Major Depressive Disorder']}, 'KeywordList': {'Keyword': ['Major Depressive Disorder (MDD)', 'Suicidality', 'Incarcerated Populations', 'Prisons', 'Interpersonal Psychotherapy (IPT)']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '181', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Treatment as Usual (TAU)', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Standard prison mental health treatment instead of the research groups, including individual therapy, medication, etc.'}, {'ArmGroupLabel': 'Group Interpersonal Psychotherapy (IPT) for Depression + TAU', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will receive Group IPT for Depression + TAU.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Group IPT for Depression + TAU']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Group IPT for Depression + TAU', 'InterventionDescription': 'Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group Interpersonal Psychotherapy (IPT) for Depression + TAU']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change from Baseline in Hamilton Rating Scale for Depression (HRSD) at 3 Months', 'PrimaryOutcomeTimeFrame': '3 Months from Baseline'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change from Baseline in Suicidality at 3 Months', 'SecondaryOutcomeDescription': 'Suicidality as measured by the Beck Scale for Suicide Ideation.', 'SecondaryOutcomeTimeFrame': '3 Months from Baseline'}, {'SecondaryOutcomeMeasure': 'Change from Baseline in In-Prison Functioning at 3 Months', 'SecondaryOutcomeDescription': 'In-prison functioning will be assessed by the number of correctional programs enrolled/completed and disciplinary/incident reports (measured by the Timeline Followback); aggression/victimization (measured by the Conflict Tactics Scale 2); social support (measured by the Multidimensional Scale of Perceived Social Support and the UCLA Loneliness Scale)', 'SecondaryOutcomeTimeFrame': '3 Months from Baseline'}, {'SecondaryOutcomeMeasure': 'Change from Baseline in Hamilton Rating Scale for Depression (HRSD) at 6 Months', 'SecondaryOutcomeTimeFrame': '6 Months from Baseline'}, {'SecondaryOutcomeMeasure': 'Change from Baseline in Suicidality at 6 Months', 'SecondaryOutcomeDescription': 'Suicidality as measured by the Beck Scale for Suicide Ideation.', 'SecondaryOutcomeTimeFrame': '6 Months from Baseline'}, {'SecondaryOutcomeMeasure': 'Change from Baseline in In-Prison Functioning at 6 Months', 'SecondaryOutcomeDescription': 'In-prison functioning will be assessed by the number of correctional programs enrolled/completed and disciplinary/incident reports (measured by the Timeline Followback); aggression/victimization (measured by the Conflict Tactics Scale 2); social support (measured by the Multidimensional Scale of Perceived Social Support and the UCLA Loneliness Scale)', 'SecondaryOutcomeTimeFrame': '6 Months from Baseline'}, {'SecondaryOutcomeMeasure': 'Cost-effectiveness', 'SecondaryOutcomeDescription': 'Cost-effectiveness based on costs of IPT and TAU, improvements in HRSD scores, LIFE scores, and cost-offsets, including medical costs, programs completed, fewer fights, fewer suicide attempts, and reduced length of incarceration due to more \"good time.\"', 'SecondaryOutcomeTimeFrame': '6 months post-baseline'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMeet all DSM-IV criteria for primary (non-substance induced) major depressive disorder\\nExpectation of at least 6 months of incarceration at baseline interview\\nIncarcerated for at least 4 weeks\\n\\nExclusion Criteria:\\n\\nLifetime:\\n\\nBipolar disorder\\nPsychotic disorder\\nAre imminently suicidal\\nCannot understand English well enough to understand the consent form or assessment instruments when read aloud', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jennifer E. Johnson, Ph.D.', 'OverallOfficialAffiliation': 'Brown University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Massachusetts Correctional Institute - Old Colony Correctional Center', 'LocationCity': 'Bridgewater', 'LocationState': 'Massachusetts', 'LocationZip': '02324', 'LocationCountry': 'United States'}, {'LocationFacility': 'Massachusetts Correctional Institution - Framingham', 'LocationCity': 'Framingham', 'LocationState': 'Massachusetts', 'LocationZip': '01702', 'LocationCountry': 'United States'}, {'LocationFacility': 'South Middlesex Correctional Center', 'LocationCity': 'Framingham', 'LocationState': 'Massachusetts', 'LocationZip': '01702', 'LocationCountry': 'United States'}, {'LocationFacility': 'Massachusetts Correctional Institution - Norfolk', 'LocationCity': 'Norfolk', 'LocationState': 'Massachusetts', 'LocationZip': '02056', 'LocationCountry': 'United States'}, {'LocationFacility': \"Adult Correctional Institution - Men's & Women's Medium & Minimum Security Facilities\", 'LocationCity': 'Cranston', 'LocationState': 'Rhode Island', 'LocationZip': '02920', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '30857489', 'ReferenceType': 'derived', 'ReferenceCitation': 'Felton JW, Hailemariam M, Richie F, Reddy MK, Edukere S, Zlotnick C, Johnson JE. Preliminary efficacy and mediators of interpersonal psychotherapy for reducing posttraumatic stress symptoms in an incarcerated population. Psychother Res. 2020 Feb;30(2):239-250. doi: 10.1080/10503307.2019.1587192. Epub 2019 Mar 11.'}, {'ReferencePMID': '30714749', 'ReferenceType': 'derived', 'ReferenceCitation': 'Johnson JE, Stout RL, Miller TR, Zlotnick C, Cerbo LA, Andrade JT, Nargiso J, Bonner J, Wiltsey-Stirman S. Randomized cost-effectiveness trial of group interpersonal psychotherapy (IPT) for prisoners with major depression. J Consult Clin Psychol. 2019 Apr;87(4):392-406. doi: 10.1037/ccp0000379. Epub 2019 Feb 4.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000003865', 'ConditionMeshTerm': 'Depressive Disorder, Major'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafAsFound': 'Major Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 88, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02943876', 'OrgStudyIdInfo': {'OrgStudyId': '10015082'}, 'Organization': {'OrgFullName': 'University of Calgary', 'OrgClass': 'OTHER'}, 'BriefTitle': \"The Impact of Disclosing Personalized Depression Risk Information on High-risk Individuals' Outcomes\", 'OfficialTitle': \"The Impact of Disclosing Personalized Depression Risk Information on High-risk Individuals' Outcomes\"}, 'StatusModule': {'StatusVerifiedDate': 'May 2019', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 1, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2019', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2019', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'October 21, 2016', 'StudyFirstSubmitQCDate': 'October 21, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 25, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'May 15, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 16, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'JianLi Wang', 'ResponsiblePartyInvestigatorTitle': 'Professor', 'ResponsiblePartyInvestigatorAffiliation': 'University of Calgary'}, 'LeadSponsor': {'LeadSponsorName': 'University of Calgary', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Canadian Institutes of Health Research (CIHR)', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"Major depressive episode (MDE) is one of the most prevalent and disabling form of mental illness in the general population. Despite increased mental health services and antidepressants use in the past 10 years, there has been no measurable change in the prevalence of MDE in the Canadian general population, which motivates the search for additional strategies for reducing the burden of MDE. One strategy that has been successful in the fields of oncology, cardiology and diabetes is early identification and prevention - identifying people who are at high risk and taking preventive actions to lower the risk so as to prevent symptoms from progressing into a MDE. As multivariable risk prediction algorithms are used to estimate an individual's risk (probability) of future disease, they can play an important role in the process of early identification. The proposed study stems from a project funded by an operating grant from the Canadian Institutes of Health Research (CIHR). With the CIHR support, the team developed and validated sex-specific prediction algorithms for MDE. As risk prediction is at very early stage in psychiatry and MDE is still highly stigmatized, to facilitate the future implementation of the developed risk prediction algorithms, the proposed study seeks to answer the following research questions: (1) Does disclosure of personalized depression risk information promote high-risk individuals to take preventive actions? (2) Will disclosure of personalized depression risk information negatively affect high-risk people's mental health status in terms of increased psychological distress? To answer the questions, the investigators planned to conduct a randomized controlled trial (RCT) with an embedded qualitative component. The proposed study will develop an evidence base for guiding the disclosure of personalized risk information and understanding the process of risk communication and consumer empowerment, contributing to the advancement of early prevention of MDE in Canada.\", 'DetailedDescription': 'Rationale: The proposed study stems from a CIHR project and is driven by the results of knowledge translation (KT) activities. The investigators developed the first sex-specific risk prediction models for major depressive episode (MDE) using data from over 10,000 Canadians. The models include age, personal and family history of MDE, childhood trauma, and predictors that may change over time. Using the models, individuals can answer the question: what is my risk of having a MDE in the next 4 years? Knowing this personalized risk information may assist health professionals in communicating with patients and planning preventive actions; disclosing the information may also empower consumers to actively engage in self-help. In the past 5 years, the KT activities with over 500 stakeholders informed that the investigators need to clearly delineate the benefits (enhanced risk perceptions and self-help) and potential risk (increased psychological distress and impaired function) of disclosing the information before implementing the tools.\\n\\nThe goal of this study is to produce evidence about the benefits and potential risks associated with risk disclosure (i.e., the expected outputs). The primary objectives are to compare those who do and do not receive personalized depression risk information in (1) accuracy of risk perceptions, the use of self-help strategies, and (2) changes in psychological distress and functional measures over one year among those who are at high risk of MDE. The secondary objective is to examine the differential impacts of the disclosure on the outcomes by demographics and levels of baseline risk. To achieve these objectives, the investigators propose a 3-year randomized controlled trial (RCT) with an embedded qualitative component.\\n\\nThe proposed study will be a RCT with an embedded qualitative component. The RCT will have one interventional arm (receiving personalized depression risk information) and one control arm. The personalized depression risk will be generated using the sex-specific prediction algorithms for MDE that we developed in Canadians aged 18+ years old. Because the prediction algorithms are sex-specific, the investigators propose to recruit 350 men and 350 women at baseline. After baseline assessment for eligibility, participants will be randomized into intervention and control groups, in men and women separately. To obtain in-depth information about how the personalized depression risk information is processed by participants and how the information affects them emotionally, the research team will conduct qualitative interviews 1 month after the personalized risk information is disclosed. To understand how the personalized risk information affect participants\\' health behaviors, the investigators will conduct another round of qualitative interviews at 12-month.\\n\\nRecruitment: The target population of future preventive studies are high risk individuals in the general population, who reside in different regions across the country. For the proposed study, a feasible approach for recruiting eligible participants is the random digit dialing method (RDD). In the past 10 years, we have used the RDD for recruitment in CIHR-funded longitudinal studies and an ongoing national RCT funded by the Movember Foundation. Recruitment, screening and baseline assessment will be done by a telephone interview firm identified through a competitive bidding process.\\n\\nA random sample of land line and cell phone numbers will be selected. When a household is reached, the person who is 18+ years will be assessed for eligibility. If a household has 2+ persons aged 18+ years, one will be randomly selected. The interviewers will explain the study objectives and procedures and answer questions. Potential participants will be ensured about confidentiality, that participation is voluntary and that they may withdraw at any time. Oral consent will be obtained before assessment of eligibility. Outcome measures will be assessed at baseline, 6 and 12-month.\\n\\nBaseline Assessment and Randomization Screening: Once a potentially eligible participant is identified, the interviewer will confirm the participant\\'s age and administer the World Health Organization\\'s Composite International Diagnostic Interview - Short Form for Major Depression (CIDI-SFMD) and the sex-specific prediction algorithms. Interviewees who are in a MDE or are below the risk thresholds based on the risk calculators, will be excluded. Individuals with MDE will be encouraged to contact family doctors and information about local mental health resources will be provided. For those who are at low risk, the web site of the sex-specific risk prediction algorithms (www.predictingdepression.com) will be provided so they may monitor their risk in the future.\\n\\nBaseline assessment: In eligible participants, the interviewer will administer the Non-specific Psychological Distress Scale (K10), Self-help Strategy Use Scale (SSUS), and ask questions about absenteeism and perceived risk of MDE. Our pilot study showed that the screening and baseline assessment take 20 to 25 minutes.\\n\\nRandomization will be carried out in men and in women separately. Eligible participants who complete the baseline telephone interview will be randomized into intervention and control groups. The randomization will be conducted and managed by the project coordinator affiliated with the project. 350 random numbers (between 0 and 1) will first be generated for men and women separately using Excel (\"RAND()\") for 350 study identification numbers (ID), ranging from 1 to 350. The 350 random numbers will then be sorted at the descending order and categorized into 2 equal groups:\\n\\nthe ID numbers in the first group (n = 175) will be allocated to the control group\\nthe ID numbers in the second group (n = 175) will be allocated to the intervention group\\n\\nIntervention and Control: For the participants in the intervention group, the personalized risk will be disclosed and the interviewer will inform them that they will be contacted again at 6 months and 12 months. The interest in receiving such personalized depression information has been confirmed by our recent pilot study using the same sampling method. The team\\'s pilot data (n = 200) showed that 100% of high-risk individuals were interested in knowing their risks. Participants in the intervention group will also be informed that some may be contacted in one month for a 30-minute qualitative interview. A package including the following materials will be mailed to intervention participants: (1) thank-you letter, (2) a website containing general information about MDE, and self-help strategies. (3) $20 incentive as appreciation of their participation. For participants in the control group, the project coordinator will inform them that they will be contacted again at 6 and 12 months. Their personal risks will be provided at the 12-month interview. The control group participants will receive the same package as those in the intervention group.\\n\\nBlinding and follow-up assessments: The telephone interviewers will securely transfer encrypted baseline data to the PI on a bi-weekly basis. The group assignment data will be transferred in a separate file. The follow-up assessments will be conducted at the telephone interview laboratory at the Mathison Mental Health Research & Education Center. One month before the scheduled follow-up interviews, letters will be sent to participants to remind them of the upcoming interview. After the 12-month interview, participants\\' group status will be linked with interview data by study ID numbers.\\n\\nOver the study period, investigators will be blinded to participants\\' group status. The interviewers who conduct randomization, will not be involved in follow-up interviews. The interviewers who conduct the follow-up interviews in Calgary will not have access to participants\\' group status. Given the description of study objectives, participants may know their group status. Therefore, it is possible that some participants in the control group may try to find more information about personalized depression risk. At the follow-up assessments, the research staff will ask if they have used any risk prediction tools over the study period. At the follow-up assessments, if participants develop a MDE, they will be encouraged to contact family doctors and information about local mental health resources will be provided.\\n\\nQualitative Interviews: To obtain in-depth information about how disclosing personalized depression risk affects participants\\' decision processes, mental health and health behaviors, the investigators will conduct two rounds of qualitative interviews via telephone, 1 month after these participants receive the personalized depression risk and at 12 months. Each will include a initial random sub-sample of 20 men and 20 women from the intervention group. The qualitative interviews strengthen this study as the researchers will use the findings to \"triangulate\" our quantitative results and to guide interpretation of the quantitative results. The interviews will be audio recorded. Qualitative interviews will be transcribed verbatim then analyzed inductively for themes. As per Berg themes will be chosen to \"reflect all relevant aspects of the messages.\" The analysis will follow the interpretive practices of constant comparison and attempt to uncover patterns both within and between interviews. Nvivo 10 software will be used to support thematic analysis. It is expected to achieve theoretical saturation with the initial sample. However, if new themes continue to emerge in final interviews, more interviews will be conducted until no new themes emerge.\\n\\nRisk and mitigation: The investigators acknowledge concerns about the changes in response rates in telephone surveys due to cell phone use and telemarketing. Including eligible participants across the country will enhance the generalizability of the study. Given the vast geographic area of Canada, RDD is the only feasible method. The goal of this study is to recruit participants for a RCT, rather than selecting a representative sample. In a RCT, selection bias is not a serious concern as long as the bias is the same across the intervention and control groups. To mitigate the risk, the interviewers will also access the validated cellphone database. However the use of cellphone numbers is associated with increased costs. Another potential risk of the proposed study is attrition which may incur selection bias. The population-based cohort studies on mental disorders in the workplace, conducted in our lab, showed that we could achieve 77% response rate at one year follow-up without any financial incentives. The strategies for reducing attrition will include appropriately designed introductory scripts, a minimum of nine call back attempts spaced over weekdays and times of day and provision of $20 incentive for each completed interview. Finally, those deemed low risk but who go on to develop MDE will be excluded from the RCT at the screening stage, which is a limitation. the investigators have planned to provide the risk prediction algorithms so that they can monitor their risks in the future.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['risk prediction', 'risk score', 'accuracy of risk perception', 'self-help', 'psychological distress']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Triple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '700', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Serves as a control group, receiving generic information about depression and self-help.'}, {'ArmGroupLabel': 'Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Serves as an intervention group, receiving personalized depression risk information determined by the sex-specific risk calculators, and generic information about depression and self-help.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: personalized depression risk information']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'personalized depression risk information', 'InterventionDescription': \"The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in psychological distress', 'PrimaryOutcomeDescription': 'Psychological distress will be measured by the Non-Specific Psychological Distress (K10), a 10-item screening scale intended to yield a global measure of distress based on questions about anxiety and depressive symptoms that a person has experienced in the most recent 4 week period.', 'PrimaryOutcomeTimeFrame': 'baseline, 6-month, 12-month'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in self-management strategy use', 'SecondaryOutcomeDescription': 'It will be measured by self-management strategy use scale (SSUS) was developed and validated by Morgan and Jorm', 'SecondaryOutcomeTimeFrame': 'Baseline, 6-month, 12-month'}, {'SecondaryOutcomeMeasure': 'Accuracy of risk perception', 'SecondaryOutcomeDescription': '\"How likely are you to get depression in the next 4 years?\" The answer can range from 0 to 100, where 0=certain not to happen and 100=certain to happen', 'SecondaryOutcomeTimeFrame': 'baseline, 6- and 12-month follow-up assessment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ndid not have a MDE at baseline,\\naged 18+ years old,\\nat high risk of MDE based on the algorithms (predicted risk of 6.5%+ for men and of 11.2%+ for women),\\nagreement to be contacted for follow-up assessments, and\\nno language barriers to English or French.\\n\\nExclusion Criteria:\\n\\n-', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'JianLi Wang, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '403-210-8653', 'CentralContactEMail': 'jlwang@ucalgary.ca'}, {'CentralContactName': 'Erin Jones', 'CentralContactRole': 'Contact', 'CentralContactPhone': '402-210-6839', 'CentralContactEMail': 'emjones@ucalgary.ca'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'JianLi Wang, PhD', 'OverallOfficialAffiliation': 'University of Calgary', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Mathison Centre for Mental Health Research and Education', 'LocationStatus': 'Recruiting', 'LocationCity': 'Calgary', 'LocationState': 'Alberta', 'LocationZip': 'T2N 4Z6', 'LocationCountry': 'Canada', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'JianLi Wang, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '403-210-8653', 'LocationContactEMail': 'jlwang@ucalgary.ca'}, {'LocationContactName': 'Erin Jones', 'LocationContactRole': 'Contact', 'LocationContactPhone': '403-210-6839', 'LocationContactEMail': 'emjones@ucalgary.ca'}, {'LocationContactName': 'Scott B Patten, MD, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Raymond W Lam, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Bonnie Lashewicz, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'David Hodgins, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Kendall Ho, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Erin Michalak, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Mark Attridge, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Zul Merali, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Norbert Schmitz, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Alice Aiken, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Alain Marchand, PhD', 'LocationContactRole': 'Sub-Investigator'}]}}, {'LocationFacility': 'JianLi Wang', 'LocationStatus': 'Recruiting', 'LocationCity': 'Calgary', 'LocationState': 'Alberta', 'LocationZip': 'T3A 6B3', 'LocationCountry': 'Canada', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'JianLi Wang, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '4039913738', 'LocationContactEMail': 'jlwang@ucalgary.ca'}, {'LocationContactName': 'Erin Jones', 'LocationContactRole': 'Contact', 'LocationContactPhone': '403-2106839', 'LocationContactEMail': 'emjones@ucalgary.ca'}, {'LocationContactName': 'Scott Patten, MD, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Glenda MacQueen, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Bonnie Lashewicz, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Douglas Manuel, MD, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Norbert Schmitz, PhD', 'LocationContactRole': 'Sub-Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31533691', 'ReferenceType': 'derived', 'ReferenceCitation': 'Wang J, MacQueen G, Patten S, Manuel D, Lashewicz B, Schmitz N. A randomized controlled trial to examine the impacts of disclosing personalized depression risk information on the outcomes of individuals who are at high risk of developing major depression: a research protocol. BMC Psychiatry. 2019 Sep 18;19(1):285. doi: 10.1186/s12888-019-2270-9.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 89, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03268434', 'OrgStudyIdInfo': {'OrgStudyId': 'LJ05207'}, 'Organization': {'OrgFullName': 'Universitätsklinikum Hamburg-Eppendorf', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care', 'OfficialTitle': 'Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Psychiatric-psychotherapeutic Care: Randomized Controlled Trial'}, 'StatusModule': {'StatusVerifiedDate': 'September 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 10, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 22, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 24, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 3, 2017', 'StudyFirstSubmitQCDate': 'August 28, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 31, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'September 26, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 27, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Universitätsklinikum Hamburg-Eppendorf', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Asklepios Kliniken Hamburg GmbH', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Aim of the current study is to investigate the acceptance and efficacy of Metacognitive Training for Depression (D-MCT) compared to cognitive remediation in outpatients with major depressive disorders in a randomized, controlled, assessor-blind, group trial.', 'DetailedDescription': 'Evidence-based treatments for depression include pharmacological and psychological interventions. Within psychological interventions, cognitive behavioral therapy (CBT) is one of the most extensively researched evidence-based approaches for depression (Cuijpers, 2015). However, even if optimal treatment and access to services were available to all patients, the burden of depression would be reduced by only 30% (Andrews et al., 2004). Moreover, as depression represents the disorder with the highest drop-out rates during CBT treatment (36.4%) (Fernandez et al., 2015), and a relapse rate of 54% for treatment responders within the two years after treatment termination (Vittengl et al., 2007), it is pivotal to improve treatment for depression. It has been argued that this is less a question of developing novel psychological treatments as of determining how existing treatments may be improved (Cuijpers, 2015) and better disseminated to increase retention rates and to use the waiting phase to rise interest in therapy (Fernandez et al., 2015). Due to hopelessness and the discouraging character of the disorder, this poses a particular challenge.\\n\\nTo meet this aim, Metacognitive Training for Depression (D-MCT) has been developed as a low-threshold, highly standardized and yet easy to administer group concept for the treatment of depression. It is conceptualized as a variant of CBT that adopts a metacognitive perspective focusing on the modification of cognitive biases, and is compatible with a general CBT treatment approach. Use of standardized presentations reduces time needed for preparation and administration of the training; moreover, this \"packaging\" increases the accessibility of D-MCT to a wide range of health care providers, and encourages standardization across therapists. The training seeks to enable group members to recognize and correct the often automatic and unconscious thought patterns that accompany depression. To this end, it attempts to challenge cognitive biases through the use of creative and engaging exercises supported by a multimedia presentation (e.g., insight based on \"aha\" effects rather than psychoeducation) and to encourage patients to take a metacognitive perspective (\"think about one\\'s thinking\"). The training is highly flexible with regard to depth and intensity. Patients do not need to (but may) discuss their own problems, and can still experience how cognitive biases work and influence one\\'s mood in a playful atmosphere. The training is conceptualized as an open group: New patients can join the group in every session. Thus, the threshold for administration of and participation in this intervention is low.\\n\\nThe general structure of and exercises in D-MCT were inspired by Metacognitive Training for psychosis (Moritz et al., 2014); however, contents were modified upon to suit the specific problems of individuals with depression. Beside depressive thought patterns already targeted in CBT (e.g., overgeneralization, \"mind reading\"), a number of general cognitive biases, which have been identified by basic cognitive research, form the core of D-MCT (e.g., mood-congruent memory (Mathews and MacLeod, 2005)). Finally, as in Metacognitive Therapy (MCT) sensu Adrian Wells (Wells, 2011) dysfunctional coping strategies (i.e., thought suppression, rumination as problem-solving) are challenged. D-MCT thus blends established elements from CBT and MCT as well as newly developed and evidence-based exercises in one coherent metacognitive approach.\\n\\nD-MCT was positively evaluated with regard to feasibility and acceptance in a non-randomized pilot study (Jelinek et al., 2013). Moreover, efficacy of D-MCT was suggested in a randomized controlled trail (RCT) in comparison to an active control intervention (Jelinek et al., 2016). In this trial patients with depressive disorder were completing a psychosomatic outpatient treatment program and were randomly assigned to either D-MCT or general health training. Severity of depression and cognitive biases were assessed at baseline (t0), post treatment (t1) and 6 months (t2) later by raters blind to diagnostic status. Intention-to-treat analyses demonstrated that at the end of treatment, as well as 6 months later, improvement in depression was significantly greater in the D-MCT relative to the health training group at medium effect sizes. A significantly greater number of patients in the D-MCT group were in remission at 6-month follow-up. Moreover, the decrease in cognitive biases and increase in psychological well-being/quality of life was larger in the D-MCT than the health training group over time. Patients\\' subjective appraisal of D-MCT was also positive (Jelinek et al., 2017).\\n\\nAim of the current study is to investigate the acceptance and efficacy of D-MCT in outpatients.The Hamilton Depression Rating Scale (HDRS, 17-item version) total score as well as the Quick Inventory of Depressive Symptomatology (QIDS) serve as primary outcome. Self-assessed depression, dysfunctional beliefs, self-esteem, quality of life, rumination, remission rate as well as neuropsychological functioning serve as secondary outcomes.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Unipolar Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Metacognition', 'CBT', 'D-MCT', 'cognitive bias']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignMaskingDescription': 'Double Blind (Investigator, Outcome Assessor)', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '86', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'D-MCT Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: D-MCT']}}, {'ArmGroupLabel': 'Cognitive remediation', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory.The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance.; 8 sessions (60min), once a week over a period of 8 weeks', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive remediation']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'D-MCT', 'InterventionDescription': 'Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['D-MCT Group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Metacognitive Training for Depression']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Cognitive remediation', 'InterventionDescription': 'A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory. The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance; 8 sessions (60min), once a week over a period of 8 weeks', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cognitive remediation']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Quick Inventory of Depressive Symptomatology (QIDS)', 'PrimaryOutcomeDescription': 'Primary outcome is change on the Quick Inventory of Depressive Symptomatology (QIDS) from baseline to follow-up (t0 - t2)', 'PrimaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Hamilton Depression Rating Scale', 'SecondaryOutcomeDescription': 'Change on the Hamilton Depression Rating Scale (HDRS, 17-item version) from baseline to follow-up (t0 - t2)', 'SecondaryOutcomeTimeFrame': '[Time Frame: eight months from baseline (t0) to 6-months follow up (t2)]'}, {'SecondaryOutcomeMeasure': 'Self-assessed depression', 'SecondaryOutcomeDescription': 'Change in self-assessed depression as measured by the Patient Health Questionnaire (PHQ-9) from baseline to follow-up (t0 to t2)', 'SecondaryOutcomeTimeFrame': '[Time Frame: eight months from baseline (t0) to 6-months follow up (t2)]'}, {'SecondaryOutcomeMeasure': 'Quick Inventory of Depressive Symptomatology (QIDS)', 'SecondaryOutcomeDescription': 'Change on the Quick Inventory of Depressive Symptomatology (QIDS) from baseline to post intervention assessment (t0 - t1)', 'SecondaryOutcomeTimeFrame': 'from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks]'}, {'SecondaryOutcomeMeasure': 'Hamilton Depression Rating Scale', 'SecondaryOutcomeDescription': 'Change on the Hamilton Depression Rating Scale from baseline to post intervention assessment (t0 - t1)', 'SecondaryOutcomeTimeFrame': 'from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks]'}, {'SecondaryOutcomeMeasure': 'Patient Health Questionnaire (PHQ-9)', 'SecondaryOutcomeDescription': 'Change on the Patient Health Questionnaire (PHQ-9) from baseline to post intervention assessment (t0 - t1)', 'SecondaryOutcomeTimeFrame': 'from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks]'}, {'SecondaryOutcomeMeasure': 'Dysfunctional beliefs', 'SecondaryOutcomeDescription': 'Change in dysfunctional beliefs as measured by the Dysfunctional Attitude Scale (DAS) from baseline to follow-up (t0 to t2)', 'SecondaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2'}, {'SecondaryOutcomeMeasure': 'Quality of life', 'SecondaryOutcomeDescription': 'Change in quality of life as measured by the World Health Organization Quality of Life Assessment (WHOQOL-BREF) from baseline to follow-up (t0 to t2)', 'SecondaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2)'}, {'SecondaryOutcomeMeasure': 'Dysfunctional metacognitive beliefs', 'SecondaryOutcomeDescription': 'Change in metacognitive beliefs as measured by the Metacognitions Questionnaire (MCQ-30) from baseline to follow-up (t0 to t2)', 'SecondaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2)'}, {'SecondaryOutcomeMeasure': 'Rumination', 'SecondaryOutcomeDescription': 'Rumination measured by the Ruminative Response Scale (RRS) from baseline to follow-up (t0 to t2)', 'SecondaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2)'}, {'SecondaryOutcomeMeasure': 'Self-esteem', 'SecondaryOutcomeDescription': 'Change in self-esteem as measured by the Rosenberg Self-Esteem Scale (RSE) from from baseline to follow-up (t0 to t2)', 'SecondaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2)'}, {'SecondaryOutcomeMeasure': 'Remission rate', 'SecondaryOutcomeDescription': 'Remission rate at T2 as measured by the Hamilton Depression Rating Scale (HDRS score ≤ 8)', 'SecondaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2)'}, {'SecondaryOutcomeMeasure': 'Information processing', 'SecondaryOutcomeDescription': 'Information processing as measured by the Trail-Making Test A (TMT-A) from baseline to post treatment assessment (t0 to t1)', 'SecondaryOutcomeTimeFrame': 'from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks]'}, {'SecondaryOutcomeMeasure': 'Subjective appraisal of the training', 'SecondaryOutcomeDescription': 'Subjective appraisal of the training after each session as well as at post treatment and follow up assessment (for questionnaire see Jelinek et al., 2017)', 'SecondaryOutcomeTimeFrame': 'each week (session data) [time frame: 8 weeks] and six months from post treatment assessment (t1) to 6 months follow up (t1 to t2) [time frame: 6 months]'}, {'SecondaryOutcomeMeasure': 'Executive functioning', 'SecondaryOutcomeDescription': 'Executive functions as measured by the Trail-Making Test B (TMT-B) from baseline to post treatment assessment (t0 to t1)', 'SecondaryOutcomeTimeFrame': 'from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks]'}, {'SecondaryOutcomeMeasure': 'Verbal memory', 'SecondaryOutcomeDescription': 'Memory functioning as measured by Rivermead Behavioral Memory Test from baseline to post treatment assessment (t0 to t1)', 'SecondaryOutcomeTimeFrame': 'from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks]'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ninformed consent\\nage between 18 and 70 years\\ndiagnosis of a single Episode or recurrent Major depressive disorder (MDD) or dysthymia (verified by the MINI)\\n\\nExclusion Criteria:\\n\\nlifetime psychotic symptoms (i.e., hallucinations, delusions, or mania), suicidality (Suicidal Behaviors Questionnaire-Revised ≥ 7), intellectual disability (estimated IQ < 70) or dementia.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '70 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Marion Hagemann-Goebel, Dr.', 'OverallOfficialAffiliation': 'Asklepios Klinik Nord-Ochsenzoll', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Asklepios Klinik Nord-Ochsenzoll', 'LocationCity': 'Hamburg', 'LocationZip': '22419', 'LocationCountry': 'Germany'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25103718', 'ReferenceType': 'background', 'ReferenceCitation': 'Moritz S, Veckenstedt R, Andreou C, Bohn F, Hottenrott B, Leighton L, Köther U, Woodward TS, Treszl A, Menon M, Schneider BC, Pfueller U, Roesch-Ely D. Sustained and \"sleeper\" effects of group metacognitive training for schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2014 Oct;71(10):1103-11. doi: 10.1001/jamapsychiatry.2014.1038.'}, {'ReferencePMID': '27230865', 'ReferenceType': 'background', 'ReferenceCitation': 'Jelinek L, Hauschildt M, Wittekind CE, Schneider BC, Kriston L, Moritz S. Efficacy of Metacognitive Training for Depression: A Randomized Controlled Trial. Psychother Psychosom. 2016;85(4):231-4. doi: 10.1159/000443699. Epub 2016 May 27.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Jelinek L, Otte C, Arlt S, & Hauschildt M. Denkverzerrungen erkennen und korrigieren: Eine Machbarkeitsstudie zum Metakognitiven Training bei Depressionen (D-MKT). [Identifying and correcting cognitive biases: A Pilot study on the Metacognitive Training for Depression (D-MCT)] Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 61, 247-254, 2013.'}, {'ReferencePMID': '28628763', 'ReferenceType': 'background', 'ReferenceCitation': \"Jelinek L, Moritz S, Hauschildt M. Patients' perspectives on treatment with Metacognitive Training for Depression (D-MCT): Results on acceptability. J Affect Disord. 2017 Oct 15;221:17-24. doi: 10.1016/j.jad.2017.06.003. Epub 2017 Jun 7.\"}, {'ReferencePMID': '15172947', 'ReferenceType': 'background', 'ReferenceCitation': 'Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry. 2004 Jun;184:526-33.'}, {'ReferencePMID': '25415495', 'ReferenceType': 'background', 'ReferenceCitation': 'Cuijpers P. Psychotherapies for adult depression: recent developments. Curr Opin Psychiatry. 2015 Jan;28(1):24-9. doi: 10.1097/YCO.0000000000000121. Review.'}, {'ReferencePMID': '26302248', 'ReferenceType': 'background', 'ReferenceCitation': 'Fernandez E, Salem D, Swift JK, Ramtahal N. Meta-analysis of dropout from cognitive behavioral therapy: Magnitude, timing, and moderators. J Consult Clin Psychol. 2015 Dec;83(6):1108-22. doi: 10.1037/ccp0000044. Epub 2015 Aug 24.'}, {'ReferencePMID': '17716086', 'ReferenceType': 'background', 'ReferenceCitation': 'Mathews A, MacLeod C. Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol. 2005;1:167-95. Review.'}, {'ReferencePMID': '17563164', 'ReferenceType': 'background', 'ReferenceCitation': \"Vittengl JR, Clark LA, Dunn TW, Jarrett RB. Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects. J Consult Clin Psychol. 2007 Jun;75(3):475-88.\"}, {'ReferenceType': 'background', 'ReferenceCitation': 'Wells, A., 2011. Metacognitive Therapy for anxiety and depression. The Guilford Press, New York.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 90, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01862913', 'OrgStudyIdInfo': {'OrgStudyId': 'FONDECYT Nº11121637'}, 'Organization': {'OrgFullName': 'University of Chile', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Computer-Assisted Cognitive-Behavioral Therapy for Adolescent Depression', 'OfficialTitle': 'Computer-Assisted Cognitive-Behavioral Therapy for Adolescent Depression in Primary Care Clinics in Santiago, Chile (YPSA-M): A Randomized Controlled Trial', 'Acronym': 'YPSA-M'}, 'StatusModule': {'StatusVerifiedDate': 'November 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2013'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 20, 2013', 'StudyFirstSubmitQCDate': 'May 22, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 27, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 8, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 10, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Vania Martínez-Nahuel', 'ResponsiblePartyInvestigatorTitle': 'Dr.med.', 'ResponsiblePartyInvestigatorAffiliation': 'University of Chile'}, 'LeadSponsor': {'LeadSponsorName': 'University of Chile', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Background: Most adolescents suffering depression are treated in primary care clinics. Cognitive-behavior therapy (CBT) is effective in the treatment of adolescent depression. The availability of appropriately trained CBT therapist may be limited, especially in primary care clinics. One way to increase the availability of CBT is to use computer-assisted CBT (c-CBT). It can be effective in the treatment of adults, although the outcomes in adolescents remain unclear.\\n\\nPurpose: The purpose of this study is to determine whether a computer-assisted cognitive-behavioral therapy is effective for the treatment of depression in adolescents between 15 and 19 years of age in 4 primary care clinics in Santiago, Chile.\\n\\nStudy design: A two-arm single-blind (outcomes assessor) randomized controlled trial will be carried out with 216 adolescents. The efficacy, the adherence, and acceptability of the computerized-assisted cognitive behavioral therapy will be evaluated.', 'DetailedDescription': \"This is a two-arm, single-blind (blinded only to outcome assessor), individually randomized controlled trial, which will compare the efficacy of computer-assisted CBT versus usual treatment for depression in adolescents in primary care clinics in Santiago, Chile.\\n\\nGeneral aim To carry out a randomized controlled trial to compare the efficacy of a computer-assisted CBT intervention versus usual care to treat depression in adolescents in primary care clinics in Santiago, Chile.\\n\\nSpecific aims\\n\\nTo compare the level of depressive symptoms of adolescents suffering depression treated with computer-assisted CBT versus usual care in primary care clinics.\\nTo compare the level of dysfunctional thoughts, strategies for solving problems, and health-related quality of life (HRQoL) of adolescents suffering depression treated with computer-assisted CBT versus usual care in primary care clinics.\\nTo compare adolescents' adherence to computer-assisted CBT versus usual care in primary care clinics.\\nTo compare adolescents' satisfaction with computer-assisted CBT versus usual care in primary care clinics.\\n\\nHypotheses\\n\\nAdolescents receiving the intervention will achieve lower scores (difference in mean of at least 0.4 standard deviations) in the depression questionnaire than those receiving the usual care, four months after randomization.\\nAdolescents receiving the intervention would have fewer dysfunctional thoughts than those receiving the usual care, four months after randomization.\\nAdolescents receiving the intervention would be better at solving problems than those receiving the usual care, four months after randomization.\\nAdolescents receiving the intervention would have better HRQoL than those receiving the usual care, four months after randomization.\\nSymptomatic improvements achieved at four months after randomization will be maintained at six months after randomization.\\n\\nSetting and population Adolescents between 15 and 19 years of age attending four primary care clinics located in Puente Alto, a low-income municipality of Santiago, Chile, with a large adolescent population.\\n\\nTraining of primary care center professionals Before the start of recruitment, professionals in the four participating primary care centers will receive a special training session from the principal investigator to assist with the correct identification, diagnosis, and treatment of patients with depression, according to the AUGE Clinical Guidelines for Depression. There will also be a refresher session 6 months after the start of recruitment.\\n\\nRecruitment Adolescents eligible for the study will be identified by health professionals of the four primary care clinics, as well as by psychologists and counselors of nearby schools, who will be informed of the study, trained to identify potential cases of depression among their students, and instructed to refer any adolescent who seems to have depression symptoms to the primary care clinics for further evaluation and possible participation in the study, according to inclusion and exclusion criteria.\\n\\nGroup assignment Those adolescents who at baseline assessment meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to the intervention arm or to the control arm. Blocked (size of four), stratified randomization will be used. Stratification will be implemented regarding sex and severity of depression (mild, moderate, and severe) according to BDI score. Randomization will be generated using web-based random allocation algorithms. Allocation concealment will be carried out by keeping treatment assignment in numbered sealed envelopes in a central place; the envelopes will be opened by individuals who do not participate in the recruitment process.\\n\\nData collection All participants will be assessed at baseline and at four and six months after randomization. The instruments that will be used are all self-report questionnaires, which will be completed on paper by the participants. Trained psychologists who are blind to the group assignments will be present to assist the adolescents if necessary.\\n\\nData management After the participants have completed the questionnaires, the data will entered into a secure platform, without identifying information (each participant will be assigned an ID number). The original copies of the instruments will be filed and stored, under lock and key, in the principal investigator's office, along with the list linking the participants' names and ID numbers. Only two research assistants, in charge of data entry, and the statistician will have access to the database.\\n\\nData analysis Data and presentation of the results will be in accordance with CONSORT guidelines for randomized clinical trials, with the primary comparative analysis being conducted on an intention-to-treat basis. Initially, we will conduct descriptive analysis to assess the balance between the two groups. The primary analysis will employ multivariable linear regression to investigate differences in mean symptom scores (primary outcome measure) between groups at four months after randomization, adjusting for baseline outcome variable if imbalances are identified. Sensitivity analysis making different assumptions will be conducted to investigate the potential effects of missing data. Similar analyses will be conducted for the secondary outcome measures.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['depression', 'adolescents']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '216', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Computer-assisted CBT', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Usual medical treatment in accordance with a decision algorithm based on the \"Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile\".\\nEight sessions of a computer-assisted cognitive-behavioral therapy. Trained psychologists administer this program in face to face meetings.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Computer-assisted cognitive-behavioral therapy']}}, {'ArmGroupLabel': 'Usual care treatment', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': '- Usual psychological and medical treatment in accordance with a decision algorithm based on the \"Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile\".', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Usual care treatment']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Computer-assisted cognitive-behavioral therapy', 'InterventionDescription': \"The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Computer-assisted CBT']}}, {'InterventionType': 'Other', 'InterventionName': 'Usual care treatment', 'InterventionDescription': 'The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Usual care treatment']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change from baseline in Beck Depression Inventory (BDI) at 4 months', 'PrimaryOutcomeTimeFrame': 'Baseline and 4 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Change from baseline in Children's Automatic Thought Questionnaire (CATS)\", 'SecondaryOutcomeTimeFrame': 'Baseline, 4 months, and 6 months'}, {'SecondaryOutcomeMeasure': 'Change from baseline in Social Problem Solving Inventory-Revised Short Form (SPSI-RS)', 'SecondaryOutcomeTimeFrame': 'Baseline, 4 months, and 6 months'}, {'SecondaryOutcomeMeasure': 'Change from baseline in KIDSCREEN-27', 'SecondaryOutcomeDescription': 'Health-related quality of life questionnaire', 'SecondaryOutcomeTimeFrame': 'Baseline, 4 months, and 6 months'}, {'SecondaryOutcomeMeasure': 'Change from baseline in Beck Depression Inventory (BDI) at 6 months', 'SecondaryOutcomeTimeFrame': 'Baseline and 6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nBeck Depression Inventory > o = 10\\nMeets diagnostic criteria of a depressive disorder according Kiddie Sads Present and Lifetime Version interview (K-SADS-PL)\\nParent or caregiver giving informed consent and adolescent giving informed assent\\n\\nExclusion Criteria:\\n\\nSuicidal risk requiring in-patient care\\nBipolar Disorder\\nCurrent substance dependence\\nCurrent alcohol dependence\\nCurrent psychosis\\nLow intellectual abilities\\nCurrent treatment with antidepressant and/or psychotherapy', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '15 Years', 'MaximumAge': '19 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Vania Martínez-Nahuel, Dr.med.', 'OverallOfficialAffiliation': 'University of Chile', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'CESFAM Bernardo Leighton, CESFAM Cardenal Raúl Silva Henríquez, CESFAM Padre Manuel Villaseca, CESFAM San Gerónimo', 'LocationCity': 'Santiago', 'LocationCountry': 'Chile'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31417440', 'ReferenceType': 'derived', 'ReferenceCitation': 'Martínez V, Rojas G, Martínez P, Gaete J, Zitko P, Vöhringer PA, Araya R. Computer-Assisted Cognitive-Behavioral Therapy to Treat Adolescents With Depression in Primary Health Care Centers in Santiago, Chile: A Randomized Controlled Trial. Front Psychiatry. 2019 Jul 30;10:552. doi: 10.3389/fpsyt.2019.00552. eCollection 2019.'}, {'ReferencePMID': '25091593', 'ReferenceType': 'derived', 'ReferenceCitation': 'Martínez V, Martínez P, Vöhringer PA, Araya R, Rojas G. Computer-assisted cognitive-behavioral therapy for adolescent depression in primary care clinics in Santiago, Chile (YPSA-M): study protocol for a randomized controlled trial. Trials. 2014 Aug 5;15:309. doi: 10.1186/1745-6215-15-309.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 91, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01634022', 'OrgStudyIdInfo': {'OrgStudyId': '2004P002819'}, 'Organization': {'OrgFullName': 'Massachusetts General Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effectiveness of Acupuncture for Depressed Patients Not Taking Antidepressant Medications', 'OfficialTitle': 'Effectiveness of Acupuncture on Treating Major Depressive Disorder'}, 'StatusModule': {'StatusVerifiedDate': 'July 2012', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2005'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2011', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 2011', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 15, 2012', 'StudyFirstSubmitQCDate': 'July 2, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 6, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 2, 2012', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 6, 2012', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Albert Yeung', 'ResponsiblePartyInvestigatorTitle': 'Director of Primary Care Research, Depression Clinical and Research Program', 'ResponsiblePartyInvestigatorAffiliation': 'Massachusetts General Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Massachusetts General Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Acupuncture is a popular complementary/alternative therapy that has been in use for thousands of years for the treatment of various medical and psychiatric conditions, including Major Depressive Disorder (MDD). In this study, the investigators applied the investigators acupuncture-treatment-for-depression protocol, based on Traditional Chinese Medicine (TCM) principles for treating MDD, to depressed patients not taking any antidepressant medications (a protocol that the investigators previously piloted as a medication augmentation therapy for partial responders with MDD).\\n\\nThe investigators specifically investigated the efficacy, safety, and tolerability of this TCM-based protocol for such patients, as well as potential differences in outcomes between weekly vs. twice-weekly treatment. The investigators hypothesized that acupuncture monotherapy would be associated with a response rate of at least 50%, which the investigators defined as a decrease in depressive symptoms from the beginning to the end of the study of 50% or more, and that the response would be greater among patients who received acupuncture 2 times per week (vs. 1 time per week). The investigators also hypothesized that acupuncture would be associated with minimal side effects.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Acupuncture', 'Antidepressant', 'Monotherapy', 'Depression', 'Alternative treatments']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '64', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Acupuncture', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Adults with depression who are not currently taking an antidepressant medication.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Acupuncture']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'Acupuncture', 'InterventionDescription': '5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (−) to GV24.5 (+).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Acupuncture']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in scores on the Hamilton Depression Rating Scale, 17 items (HAM-D-17)', 'PrimaryOutcomeDescription': \"The HAM-D-17 is a clinician-rated assessment (structured interview) of patients' depressive symptoms. Questions focus on depressive symptoms during the past 7 days, and higher cumulative scores (possible responses to each item range from 0-4 or 0-2) indicate more severe depression.\", 'PrimaryOutcomeTimeFrame': 'Baseline and all acupuncture sessions (weekly) for 8 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Response to treatment, defined as a 50% or greater improvement in HAM-D-17 score compared to baseline', 'SecondaryOutcomeDescription': '(See primary outcome measure description.)', 'SecondaryOutcomeTimeFrame': 'Baseline and all acupuncture sessions (weekly) for 8 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHas current or past DSM-IV MDD diagnosis based on SCID; AND current 17-Hamilton Rating Scale for Depression (BRSD) score of 14 or above\\nAge between 18-65\\nNo treatment with antidepressant(s) in the past 3 months\\nIf patient has received psychotherapy, no initiation or termination of therapy in the past 3 months.\\n\\nExclusion Criteria:\\n\\nPatients with primary diagnosis other than Major Depressive Disorder, or any history of psychosis or mania.\\nConditions that could make it difficult to conclusively determine that depressive symptoms were the result of MDD and not some other condition, including substance abuse or dependence within the last 6 months, medical conditions that could produce depression, including epilepsy, history of an abnormal EEG, severe head trauma, or stroke.\\nSerious uncontrolled medical conditions [e.g. poorly controlled diabetes, severe congestive heart failure], or other medical conditions that have not been stable for at least 3 months.\\nElectroconvulsive therapy (ECT) during the last year.\\nCurrent active suicidal or self-injurious potential necessitating immediate treatment.\\nCurrently receiving concomitant Acupuncture Treatment, or any Acupuncture treatment in the past three months.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Albert Yeung, MD, ScD', 'OverallOfficialAffiliation': 'Depression Clinical and Research Program, Massachusetts General Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Depression Clinical and Research Program, Massachusetts General Hospital', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02114', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '22521855', 'ReferenceType': 'result', 'ReferenceCitation': 'Mischoulon D, Brill CD, Ameral VE, Fava M, Yeung AS. A pilot study of acupuncture monotherapy in patients with major depressive disorder. J Affect Disord. 2012 Dec 10;141(2-3):469-73. doi: 10.1016/j.jad.2012.03.023. Epub 2012 Apr 21.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 92, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01583400', 'OrgStudyIdInfo': {'OrgStudyId': 'CPHS#22616, W&P-PCMH-01'}, 'Organization': {'OrgFullName': 'Dartmouth-Hitchcock Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial', 'OfficialTitle': 'Development and Evaluation of Enhanced Digital Health Coaching Program for Depressive Symptoms to Support Collaborative Depression Treatment in Primary Care: The RESPECT-D-E (Enhanced) Trial'}, 'StatusModule': {'StatusVerifiedDate': 'September 2014', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2011'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2013', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 2013', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 12, 2012', 'StudyFirstSubmitQCDate': 'April 20, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 24, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 17, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 18, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Mark T. Hegel', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Dartmouth-Hitchcock Medical Center'}, 'LeadSponsor': {'LeadSponsorName': 'Dartmouth-Hitchcock Medical Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Johnson & Johnson', 'CollaboratorClass': 'INDUSTRY'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': \"Primary care physicians have emerged as the predominant mental health care providers for diagnosing and treating depression. The majority of patients with mood disorders receive treatment in the primary care setting, within which approximately 10-30% of all patients present with a depressive disorder. Comprehensive 'Collaborative Care' models of depression management significantly improve depression outcomes and health-related quality of life. Core features of these programs include use of a trained depression care manager to closely coordinate with primary care clinicians, support treatment recommendations, provide patient education, conduct patient follow-up to ensure adequate treatment, and manage as-needed access to psychiatrists for patients with more complex presentations. Evidence based Collaborative Care models do not currently weave in the use of web-based or mobile technologies. These technologies offer unique features that may make collaborative depression care more effective. The digital health coaching program for depressive symptoms enhanced during Phase I of the current project is a web-based tool featuring video, text, links and graphics which provide patients with education, self-management techniques, tailored feedback, and tools for tracking treatment progress. The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a collaborative depression management model for primary care. The primary objective of this project is to compare the efficacy of an enhanced Collaborative Care model for depression (RESPECT-D-E) to the standard model (RESPECT-D) for patients with minor and major depression and dysthymic disorder. This study will be a randomized controlled trial with 150 participants who are receiving antidepressant medication treatment in the primary care setting. The primary objectives are: reduction in subject reported depressive symptoms, improvement in subject reported health related quality of life and improvement in subject adherence to treatment regimen as demonstrated by self-report measures and clinician-administered assessment. The investigators hypothesize that compared to RESPECT-D at 12 weeks, participants randomized to RESPECT-D-E will demonstrate: a greater reduction in depressive symptoms, a greater improvement in health-related quality of life and a greater satisfaction with quality of depression care received.\", 'DetailedDescription': \"The National Comorbidity Survey suggests a lifetime prevalence of 17% and 1-year prevalence of 10% for major depression. Within primary care, approximately 10-30% of patients present with a depressive disorder. Over the past decade, primary care physicians have emerged as the predominant mental health care providers insofar as diagnosing and treating depression, with the majority of patients with mood disorders receiving treatment in a primary care setting.\\n\\nComprehensive 'Collaborative Care' models of depression management in primary care significantly improve depression outcomes and health-related quality of life. Core features of these programs include use of a trained depression care manager to closely coordinate with primary care clinicians, provision of specific treatment recommendations/guidelines, patient education, appropriate follow-up by the depression care manager to ensure adequate treatment, as-needed access to psychiatrists for patients with more complex presentations, and, occasionally, on-site psychotherapy. For example, the IMPACT study of primary care patients with late-life depression found that a Collaborative Care program doubled the effectiveness of depression treatment and improved functional outcomes at 3 months, 6 months and 1 year compared to usual care. The RESPECT-D phone-based Collaborative Care program similarly had increases at 3 and 6 months in depression response, remission, and satisfaction with care, compared to usual care.\\n\\nNonetheless, evidence based Collaborative Care leaves room for improvement. In both IMPACT and RESPECT-D, 40% to 50% of intervention participants failed to achieve a clinically meaningful depression treatment effect. Evidence based Collaborative Care models do not currently weave in the use of web-based or mobile technologies. These technologies offer unique features that may make collaborative depression care more effective. The enhanced digital health coaching program for depressive symptoms is a web-based tool featuring video, text and graphics which provides patients with education, self-management techniques, tailored feedback, and tools for tracking treatment progress. Incorporating a digital health coaching program for depressive symptoms into the flow of collaborative depression care and testing its impact is an important next step for the field.\\n\\nThe RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression by the primary care provider, with a centrally based care manager providing telephone support for patients. The essential components of this Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient.\\n\\nRESPECT-D-E (Enhanced) intervention is Collaborative Care depression treatment in primary care including care manager (the elements of RESPECT-D) plus patient access to on-line coaching, education, and symptom, side effect and medication adherence tracking which is automatically fed back to the Care Manager.\\n\\nThe primary objective of this project is to compare the efficacy of an enhanced Collaborative Care model for depression (RESPECT-D-E) to the standard model (RESPECT-D) in primary care patients with minor and major depression and dysthymic disorder .\\n\\nThe RESEPCT-D-E trial is a randomized, 12-week prospective 2-arm, comparative clinical effectiveness study. Primary care patients (N=150) with major or minor depressive disorder, or dysthymia and currently taking antidepressant medication will be randomly assigned to either Collaborative Care treatment for depression (RESPECT-D) or RESPECT-D plus a digital health coaching program for depressive symptoms intervention (RESPECT-D-E). Patients will be assessed at baseline, 4 weeks, 8 weeks, and 12 weeks using self-report and clinician -administered rating scales including the Hopkins Symptom Checklist and Hamilton Depression Rating Scale. Intervention participants will receive access to the online depression coach as well as the elements of standard Collaborative Care (RESPECT-D). The primary objectives are: reduction in depressive symptoms, improvement in health related quality of life and improvement in adherence to treatment regimen.\\n\\nThe secondary objectives of the RESPECT-D-E trial are to: Evaluate the program impact on overall health, work productivity, and medical costs; Assess the usability of the enhanced digital health coaching program for depressive symptoms tool; Assess the program's impact on overall satisfaction with care.\\n\\nHypotheses: Compared to RESPECT-D at 12 weeks, participants randomized to RESPECT-D-E will demonstrate: H1.1a: a greater reduction in depressive symptoms, as measured by the clinician administered Hamilton Depression Rating Scale (HAM-D); H1.1b: a greater reduction in depressive symptoms, as measured by the self-report Hopkins Symptom Checklist Depression Scale (HSCL-20); H1.1c: a greater improvement in health related quality of life, as measured by the Mental Component Summary score from the Medical Outcomes Study Short Form (SF-36); H1.1d: a greater satisfaction with quality of depression care received.\\n\\nHypothesis 1.2: Compared to RESPECT-D at 4, 8, and 12 weeks, participants randomized to RESPECT-D-E will demonstrate: H1.2a: more frequent contact with the depression care manager and primary care provider, as measured by depression care manager treatment logs and medical record review; H1.2b: greater adherence to their antidepressant regimen, as measured by participant self-report; H1.2c: greater exposure to depression counseling, as measured by participant self-report.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depressive Disorder, Major', 'Depressive Disorder, Minor', 'Dysthymic Disorder']}, 'KeywordList': {'Keyword': ['Depressive Disorder, Major', 'Depressive Disorder, Minor', 'Dysthymic Disorder']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '131', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'RESPECT-D', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'The RESPECT-D Model: Collaborative Care depression treatment within primary care including care manager', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: RESPECT-D']}}, {'ArmGroupLabel': 'RESPECT-D-E', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'RESPECT-D-E: Collaborative Care depression treatment within primary care including care manager plus on-line coaching, education and symptom, side effect and, medication adherence tracking with the digital health coaching program for depressive symptoms.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: RESPECT-D-E (Enhanced)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'RESPECT-D', 'InterventionDescription': 'The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['RESPECT-D']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Collaborative Care Treatment for Depression in Primary Care']}}, {'InterventionType': 'Other', 'InterventionName': 'RESPECT-D-E (Enhanced)', 'InterventionDescription': 'The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['RESPECT-D-E']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Enhanced Collaborative Care Treatment for Depression in Primary Care', 'Digital Health Coaching Program for Depressive Symptoms']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Score of Hamilton Rating Scale for Depression (HAM-D)', 'PrimaryOutcomeDescription': '17-item assessment rated during a clinical interview', 'PrimaryOutcomeTimeFrame': '12 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Score of Hopkins Symptom Checklist-20 (HSCL-20)', 'SecondaryOutcomeDescription': 'Self-report measure of depressive symptom severity', 'SecondaryOutcomeTimeFrame': '12 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMales and Females, ages 18 and older who are self-reporting generally good health.\\nNewly started on an antidepressant medication, switched to a different antidepressant medication or prescribed an increased dosage of antidepressant medication within the past 2 weeks.\\nA Hamilton Depression Rating Scale (HAM-D) score of greater than 10.\\nA Patient Health Questionnaire (PHQ-9) score of 10 or greater, with endorsement of depressed mood or anhedonia, and endorsement of impaired daily function.\\nMeets diagnostic criteria for Major Depressive Disorder, persistent Minor Depressive Disorder (i.e., > 1 month duration), or Dysthymic Disorder via a structured interview with the PRIME-MD.\\nAble to read, understand, and sign the Informed Consent in English.\\nWilling and able to comply with study requirements.\\nWell-versed in using a personal computer and the internet and must have easy access to a computer connected to the internet everyday (both weekdays and weekends).\\nEnrollment in Surescripts Pharmacy benefit plan\\nCurrently under care with a Provider in Family Medicine at Cheshire Medical Center / Dartmouth-Hitchcock Keene\\n\\nExclusion Criteria:\\n\\nSubjects must not have a major psychiatric co-morbid condition (schizophrenia, bipolar affective disorder, obsessive-compulsive disorder, PTSD, or a depressive disorder with psychotic features, as determined from chart review and patient report).\\nSubjects must not have a substance use disorder or dependence as assessed by: CAGE Alcohol Dependence Questionnaire score >3\\nSubjects must not have a history of treatment -resistant depression as defined by the following: Psychiatric hospitalization within the past year; More than 2 clinically ineffective antidepressant medication trials, of adequate duration and adequate dose, within the current depressive episode; Any history of Electroconvulsive Therapy (ECT); A trial of Monoamine Oxidase inhibitor (MAO) within the past year.\\nSubjects must not report being actively suicidal\\nSubjects must score 4 or greater on the Callahan Six-Item Cognitive Screening assessment\\nSubjects must not be diagnosed with a terminal or near terminal medical illness such that their primary care provider has estimated the patient has less than 6 months to live.\\nSubjects reporting any medical condition that would make it unsafe to participate in a research study.\\nParticipation in any other clinical research study within the past 30 days.\\nParticipation in any on-line depression-related coaching or lifestyle improvement program within the past 5 years.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Mark T. Hegel, PhD', 'OverallOfficialAffiliation': 'Dartmouth-Hitchcock Medical Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Family Medicine Clinics, Cheshire Medical Center (DH-Keene)', 'LocationCity': 'Keene', 'LocationState': 'New Hampshire', 'LocationZip': '03431', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '15345600', 'ReferenceType': 'background', 'ReferenceCitation': 'Dietrich AJ, Oxman TE, Williams JW Jr, Schulberg HC, Bruce ML, Lee PW, Barry S, Raue PJ, Lefever JJ, Heo M, Rost K, Kroenke K, Gerrity M, Nutting PA. Re-engineering systems for the treatment of depression in primary care: cluster randomised controlled trial. BMJ. 2004 Sep 11;329(7466):602. Epub 2004 Sep 2.'}, {'ReferencePMID': '16428253', 'ReferenceType': 'background', 'ReferenceCitation': 'Hunkeler EM, Katon W, Tang L, Williams JW Jr, Kroenke K, Lin EH, Harpole LH, Arean P, Levine S, Grypma LM, Hargreaves WA, Unützer J. Long term outcomes from the IMPACT randomised trial for depressed elderly patients in primary care. BMJ. 2006 Feb 4;332(7536):259-63. Epub 2006 Jan 20.'}, {'ReferencePMID': '7897786', 'ReferenceType': 'background', 'ReferenceCitation': 'Katon W, Von Korff M, Lin E, Walker E, Simon GE, Bush T, Robinson P, Russo J. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA. 1995 Apr 5;273(13):1026-31.'}, {'ReferencePMID': '15466678', 'ReferenceType': 'background', 'ReferenceCitation': 'Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J, Ciechanowski P, Walker E, Bush T. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004 Oct;61(10):1042-9.'}, {'ReferencePMID': '10591288', 'ReferenceType': 'background', 'ReferenceCitation': 'Katon W, Von Korff M, Lin E, Simon G, Walker E, Unützer J, Bush T, Russo J, Ludman E. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry. 1999 Dec;56(12):1109-15.'}, {'ReferencePMID': '19898985', 'ReferenceType': 'background', 'ReferenceCitation': 'Torrey WC, Drake RE. Practicing shared decision making in the outpatient psychiatric care of adults with severe mental illnesses: redesigning care for the future. Community Ment Health J. 2010 Oct;46(5):433-40. doi: 10.1007/s10597-009-9265-9. Epub 2009 Nov 8.'}, {'ReferencePMID': '12472325', 'ReferenceType': 'background', 'ReferenceCitation': 'Unützer J, Katon W, Callahan CM, Williams JW Jr, Hunkeler E, Harpole L, Hoffing M, Della Penna RD, Noël PH, Lin EH, Areán PA, Hegel MT, Tang L, Belin TR, Oishi S, Langston C; IMPACT Investigators. Improving Mood-Promoting Access to Collaborative Treatment. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002 Dec 11;288(22):2836-45.'}, {'ReferencePMID': '8864145', 'ReferenceType': 'background', 'ReferenceCitation': 'Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl. 1996 Jun;(30):17-30.'}, {'ReferencePMID': '10512600', 'ReferenceType': 'background', 'ReferenceCitation': 'McQuaid JR, Stein MB, Laffaye C, McCahill ME. Depression in a primary care clinic: the prevalence and impact of an unrecognized disorder. J Affect Disord. 1999 Sep;55(1):1-10.'}, {'ReferencePMID': '8712797', 'ReferenceType': 'background', 'ReferenceCitation': 'Norquist GS, Regier DA. The epidemiology of psychiatric disorders and the de facto mental health care system. Annu Rev Med. 1996;47:473-9. Review.'}, {'ReferencePMID': '7665808', 'ReferenceType': 'background', 'ReferenceCitation': 'Stein MB, Kirk P, Prabhu V, Grott M, Terepa M. Mixed anxiety-depression in a primary-care clinic. J Affect Disord. 1995 May 17;34(2):79-84.'}, {'ReferencePMID': '12954939', 'ReferenceType': 'background', 'ReferenceCitation': \"Weilburg JB, O'Leary KM, Meigs JB, Hennen J, Stafford RS. Evaluation of the adequacy of outpatient antidepressant treatment. Psychiatr Serv. 2003 Sep;54(9):1233-9.\"}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000004194', 'ConditionMeshTerm': 'Disease'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000003865', 'ConditionMeshTerm': 'Depressive Disorder, Major'}, {'ConditionMeshId': 'D000019263', 'ConditionMeshTerm': 'Dysthymic Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafAsFound': 'Depressive Disorder, Major', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M19831', 'ConditionBrowseLeafName': 'Dysthymic Disorder', 'ConditionBrowseLeafAsFound': 'Dysthymic Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 93, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01027559', 'OrgStudyIdInfo': {'OrgStudyId': '081348'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH064821', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH064821&Fy=all'}, {'SecondaryId': '2R01MH064821-05A2', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=2R01MH064821-05A2&Fy=all'}, {'SecondaryId': 'DDTR A3-NSI', 'SecondaryIdType': 'Other Grant/Funding Number', 'SecondaryIdDomain': 'National Institute of Mental Health'}]}, 'Organization': {'OrgFullName': 'Washington University School of Medicine', 'OrgClass': 'OTHER'}, 'BriefTitle': 'fMRI Study of Treatment Changes in Major Depression', 'OfficialTitle': 'fMRI Studies of Emotional Circuitry in Major Depression: Treatment Changes'}, 'StatusModule': {'StatusVerifiedDate': 'June 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2014', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'January 2014', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'December 4, 2009', 'StudyFirstSubmitQCDate': 'December 4, 2009', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 8, 2009', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'June 15, 2016', 'ResultsFirstSubmitQCDate': 'May 11, 2018', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'June 13, 2018', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 18, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 17, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Washington University School of Medicine', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The overall purposes of this research are to determine if Cognitive Behavioral Therapy (CBT) has the same healing effect on the brain for people with depression as traditional antidepressants do, and in comparison to healthy controls with no history of depression, to find out more about the causes of depression including differences in the extent of problems caused by depression. We hypothesize that CBT will have the same healing effect on the brain as antidepressants; that differences in brain activations created by the various tasks and genetic differences will help us understand differences in the type and severity of symptoms among the depressed subjects.', 'DetailedDescription': 'The overall purposes of this research are to determine if Cognitive Behavioral Therapy (CBT) has the same healing effect on the brain for people with depression as traditional antidepressants do, to find out more about the causes of depression and why people differ in the extent of problems caused by depression, and to determine if certain differences in genes within populations are related to clinical symptoms.Genes we are examining for this study are COMT, BDNF, and 5-HTT long arm and short arm, as well as future genes that may be discovered to play a role in depression at a later time, and will be determined by examining saliva and blood samples. We are primarily studying depression by functional Magnetic Resonance Imaging (fMRI) which allows us to identify certain parts of the brain that show how the brain works in controlling negative feelings. Participants will be imaged while performing different tasks that are believed to activate emotional circuitry of the brain. Comparisons of activation patterns across these tasks will be used to characterize the cognitive mechanisms supported by different cortical regions, and to determine patterns of functional brain deficits in subjects with depression. Comparisons will also be made between changes that occur after treatment with an approved antidepressant and treatment with CBT.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Major Depression', 'Treatment']}, 'KeywordList': {'Keyword': ['Major Depression', 'Functional Magnetic Resonance Imaging', 'Emotional Circuitry', 'Cognitive Behavioral Therapy']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Other', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '97', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depressed Group: CBT', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive Behavioral Therapy']}}, {'ArmGroupLabel': 'Healthy Control Group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.'}, {'ArmGroupLabel': 'Depressed Group: SRT', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Depressed participants randomized to receive the antidepressant sertraline (SRT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Sertraline']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Sertraline', 'InterventionDescription': 'Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depressed Group: SRT']}, 'InterventionOtherNameList': {'InterventionOtherName': ['SRT']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Cognitive Behavioral Therapy', 'InterventionDescription': 'Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depressed Group: CBT']}, 'InterventionOtherNameList': {'InterventionOtherName': ['CBT']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Blood Oxygen-level Dependent Activations During an Emotional Distractor Task Between fMRI Scans of Depressed Participants in the CBT Group and Control Participants.', 'PrimaryOutcomeDescription': 'MRI imaging was completed on 50 participants (26 depressed who were randomized to the CBT group and 24 controls) for this analysis, including fMRI scans to evaluate regional brain activation in depression during an emotional distractor task. Image data from their baseline visit was processed and analyzed to show differences in blood oxygen-level dependent (BOLD) activations between depressed participants in the CBT group and control participants in a priori regions (amygdala and dorsolateral prefrontal cortex) during the task. The specified regions were masked on the images, and voxel-wise comparisons (ANOVAs) were performed to determine differences in activations between groups within these masked regions Positive values reflect a BOLD activation in that region; negative reflects a BOLD de-activation in that region.', 'PrimaryOutcomeTimeFrame': 'baseline visit and 8-week follow-up'}, {'PrimaryOutcomeMeasure': 'Hamilton Depression Rating Scale Score at Baseline and 12 Weeks', 'PrimaryOutcomeDescription': 'The patient was rated by a research team member among 17 dimensions/items pertaining to depression symptoms experienced over the last week. Each item is scored from 0 (=absent), up to 2 or 4 (depending on the item). The maximum total score on the assessment, indicating the most severe depression, would be 52. A total score of 0-7 is considered to be normal. Total scores of 20 or higher indicate moderate, severe, or very severe depression. A 50% or greater drop in Hamilton Depression Rating Scale signifies response to treatment.', 'PrimaryOutcomeTimeFrame': 'Baseline and 12 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'DEPRESSED GROUP:\\n\\nInclusion criteria:\\n\\nAge 18-50\\nDSM-IV criteria for major depressive disorder (MDD)\\nMinimum Hamilton Rating Scale for Depression (HAMD) score > 18\\nRight handed\\nCapacity to give informed consent and follow study procedures\\nEnglish speaking\\n\\nExclusion criteria:\\n\\nCannot give informed consent\\nSignificant handicaps (e.g. visual or hearing loss, mental retardation) that would interfere with testing procedures\\nDoes not speak English\\nKnown primary neurological disorders\\nAny other factor that in the investigators judgment may affect patient safety or compliance (e.g. distance greater than 100 miles from clinic)\\nMRI contraindications e.g. foreign metallic implants, pacemaker\\nKnown allergy or hypersensitivity to sertraline\\nActive suicidality\\nSevere or unstable medical illness or conditions or drugs that may cause depression\\nAny of the following diagnosed by DSM-IV: alcohol or substance abuse disorder, schizophrenia or other psychotic disorder, bipolar disorder, psychotic features of depression, current obsessive compulsive disorder (OCD) or panic disorder. In general, subjects with a history of other Axis I disorders prior to their depression will be excluded.\\nCurrent episode has failed to respond to adequate trials of two prior antidepressants for at least 6 weeks at therapeutic doses.\\nTreatment with sertraline for at least one month in past 3 months.\\nCurrent use of psychotropic prescription or nonprescription drugs or herbals (e.g. hypericum) except for limited use of certain hypnotics.\\nCurrent psychotherapy\\nTreatment with psychotropic drugs or drugs that affect the CNS such as beta-blockers or mood stabilizers.\\n\\nCONTROL GROUP:\\n\\nInclusion criteria:\\n\\nAge 18-50\\nNo history of MDD\\nHAMD score < 7\\nRight handed\\nCapacity to give informed consent and follow study procedures\\nEnglish speaking\\n\\nExclusion criteria:\\n\\nCannot give informed consent\\nSignificant handicaps (e.g. visual or hearing loss, mental retardation) that would interfere with testing procedures\\nDoes not speak English\\nKnown primary neurological disorders\\nAny other factor that in the investigators judgment may affect patient safety or compliance (e.g. distance greater than 100 miles from clinic)\\nMRI contraindications e.g. foreign metallic implants, pacemaker\\nSevere or unstable medical illness or conditions or drugs that may cause depression\\nAny of the following diagnosed by DSM-IV: alcohol or substance abuse disorder, schizophrenia or other psychotic disorder, bipolar disorder, major depression, OCD or panic disorder.\\nCurrent use of psychotropic prescription or nonprescription drugs or herbals (e.g. hypericum) except for limited use of certain hypnotics.\\nTreatment with psychotropic drugs or drugs that affect the CNS such as beta-blockers or mood stabilizers.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '50 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Yvette I Sheline, MD', 'OverallOfficialAffiliation': 'University of Pennsylvania', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Charles Conway, MD', 'OverallOfficialAffiliation': 'Washington University School of Medicine', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Washington University', 'LocationCity': 'Saint Louis', 'LocationState': 'Missouri', 'LocationZip': '63110', 'LocationCountry': 'United States'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'Prior to being assigned to a group, 6 depressed participants dropped from the study before being assigned to treatment type.', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Depressed Group: CBT', 'FlowGroupDescription': 'Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nCognitive Behavioral Therapy: Visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and HAMD administration will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Healthy Control Group', 'FlowGroupDescription': 'Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.'}, {'FlowGroupId': 'FG002', 'FlowGroupTitle': 'Depressed Group: Sertraline', 'FlowGroupDescription': 'Depressed participants randomized to receive sertraline (SRT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nSertraline: Visits will involve dispensing medication, side effects assessment and HAMD administration occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '26'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '34'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '31'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '20'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '26'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '22'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '6'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '8'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '9'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'A total of 97 participants enrolled in the study (63 depressed and 34 controls). Of the 63 depressed participants enrolled in the study, 57 (26 CBT and 31 SRT) were assigned to a treatment group and completed at least some study-related activities. Six depressed participants dropped from the study before being assigned to treatment type.', 'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Depressed Group: CBT', 'BaselineGroupDescription': 'Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nCognitive Behavioral Therapy: Visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and HAMD administration will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Depressed Group: SRT', 'BaselineGroupDescription': 'Depressed participants randomized to receive sertraline (SRT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nSertraline: Visits will involve dispensing medication, side effects assessment and HAMD administration occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Healthy Control Group', 'BaselineGroupDescription': 'Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.'}, {'BaselineGroupId': 'BG003', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '26'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '31'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '34'}, {'BaselineDenomCountGroupId': 'BG003', 'BaselineDenomCountValue': '91'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Full Range', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '31.54', 'BaselineMeasurementLowerLimit': '18', 'BaselineMeasurementUpperLimit': '48'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '33.29', 'BaselineMeasurementLowerLimit': '19', 'BaselineMeasurementUpperLimit': '49'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '31.64', 'BaselineMeasurementLowerLimit': '18', 'BaselineMeasurementUpperLimit': '48'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '32.16', 'BaselineMeasurementLowerLimit': '18', 'BaselineMeasurementUpperLimit': '49'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex/Gender, Customized', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Female', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '19'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '26'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '28'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '77'}]}}]}}, {'BaselineClassTitle': 'Male', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '7'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '19'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '26'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '31'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '34'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '91'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Blood Oxygen-level Dependent Activations During an Emotional Distractor Task Between fMRI Scans of Depressed Participants in the CBT Group and Control Participants.', 'OutcomeMeasureDescription': 'MRI imaging was completed on 50 participants (26 depressed who were randomized to the CBT group and 24 controls) for this analysis, including fMRI scans to evaluate regional brain activation in depression during an emotional distractor task. Image data from their baseline visit was processed and analyzed to show differences in blood oxygen-level dependent (BOLD) activations between depressed participants in the CBT group and control participants in a priori regions (amygdala and dorsolateral prefrontal cortex) during the task. The specified regions were masked on the images, and voxel-wise comparisons (ANOVAs) were performed to determine differences in activations between groups within these masked regions Positive values reflect a BOLD activation in that region; negative reflects a BOLD de-activation in that region.', 'OutcomeMeasurePopulationDescription': 'fMRI data from a total of 26 depressed participants randomized to receive CBT and 24 control participants was analyzed. The primary aim was to compare depressed and control participants to evaluate regional brain activation during an emotional task, both at baseline and 8-week follow-up. The primary regions analyzed were the amygdala and DLPFC.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'Voxels', 'OutcomeMeasureTimeFrame': 'baseline visit and 8-week follow-up', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Depressed Group', 'OutcomeGroupDescription': 'Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.\\n\\nCognitive Behavioral Therapy: Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Healthy Control Group', 'OutcomeGroupDescription': 'Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '26'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '24'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Amygdala - baseline', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-18.74', 'OutcomeMeasurementSpread': '98.45'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '2.71', 'OutcomeMeasurementSpread': '141.09'}]}}]}}, {'OutcomeClassTitle': 'DLPFC - baseline', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '316.24', 'OutcomeMeasurementSpread': '199.83'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '411.2', 'OutcomeMeasurementSpread': '241.53'}]}}]}}, {'OutcomeClassTitle': 'Amygdala - Time 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-16.82', 'OutcomeMeasurementSpread': '108.55'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-46.06', 'OutcomeMeasurementSpread': '97.10'}]}}]}}, {'OutcomeClassTitle': 'DLPFC - Time 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '403.72', 'OutcomeMeasurementSpread': '248.02'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '421.51', 'OutcomeMeasurementSpread': '231.33'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Hamilton Depression Rating Scale Score at Baseline and 12 Weeks', 'OutcomeMeasureDescription': 'The patient was rated by a research team member among 17 dimensions/items pertaining to depression symptoms experienced over the last week. Each item is scored from 0 (=absent), up to 2 or 4 (depending on the item). The maximum total score on the assessment, indicating the most severe depression, would be 52. A total score of 0-7 is considered to be normal. Total scores of 20 or higher indicate moderate, severe, or very severe depression. A 50% or greater drop in Hamilton Depression Rating Scale signifies response to treatment.', 'OutcomeMeasurePopulationDescription': 'Numbers may differ from Participant Flow but these are the totals of those participants who had data at this time point for the Hamilton Depression Rating Scale.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': 'Baseline and 12 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Depressed Group: CBT', 'OutcomeGroupDescription': 'Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nCognitive Behavioral Therapy: Visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and HAMD administration will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Healthy Control Group', 'OutcomeGroupDescription': 'Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Depressed Group: Sertraline', 'OutcomeGroupDescription': 'Depressed participants randomized to receive sertraline (SRT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nSertraline: Visits will involve dispensing medication, side effects assessment and Hamilton Depression Rating Scale (HAMD) administration occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '18'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '15'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '14'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '19.94', 'OutcomeMeasurementSpread': '5.23'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1.38', 'OutcomeMeasurementSpread': '1.33'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '20.79', 'OutcomeMeasurementSpread': '3.98'}]}}]}}, {'OutcomeClassTitle': 'Week 12', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5.94', 'OutcomeMeasurementSpread': '6.08'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1.07', 'OutcomeMeasurementSpread': '1.33'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '4.43', 'OutcomeMeasurementSpread': '5.37'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '5', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Depressed Group: CBT', 'EventGroupDescription': 'Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nCognitive Behavioral Therapy: Visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and HAMD administration will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '26', 'EventGroupOtherNumAffected': '7', 'EventGroupOtherNumAtRisk': '26'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Healthy Control Group', 'EventGroupDescription': 'Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '34', 'EventGroupOtherNumAffected': '2', 'EventGroupOtherNumAtRisk': '34'}, {'EventGroupId': 'EG002', 'EventGroupTitle': 'Depressed Group: SSRI (Selective Serotonin Re-Uptake Inhibitor', 'EventGroupDescription': 'Depressed participants randomized to receive setraline (SRT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nSertraline: Visits will involve dispensing medication, side effects assessment and HAMD administration occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '31', 'EventGroupOtherNumAffected': '21', 'EventGroupOtherNumAtRisk': '31'}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Constipation', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Sedation/Drowsiness', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '17', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Excitement/Weakness', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '12', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Nausea/Vomitting', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '10', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Stomach/Abdominal Pain', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Irritability', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Muscle Twitching', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Tremor', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Decreased Appetite', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Increased Appetite', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Weight Gain', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Insomnia', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Dry Mouth', 'OtherEventOrganSystem': 'Immune system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '10', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Decreased Libido', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Malaise', 'OtherEventOrganSystem': 'Immune system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Impaired Mentation', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Hyperventilation', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Dizziness/Faintness', 'OtherEventOrganSystem': 'Ear and labyrinth disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Sexual Dysfunction', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Diarrhea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Nasal Congestion', 'OtherEventOrganSystem': 'Immune system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Excessive Sweating', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Back Pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventNotes': 'Back pain/stiffness from taking part in the MRI scan', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Chest Pain', 'OtherEventOrganSystem': 'Vascular disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Panic', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Slurred Speech', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Difficulty Hearing/Tinnitus', 'OtherEventOrganSystem': 'Ear and labyrinth disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Increased Libido', 'OtherEventOrganSystem': 'Vascular disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Syncope', 'OtherEventOrganSystem': 'Vascular disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Blurred Vision', 'OtherEventOrganSystem': 'Eye disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Increased Salivation', 'OtherEventOrganSystem': 'General disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Tachycardia/Palpitations', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Menstrual Irregularity', 'OtherEventOrganSystem': 'Reproductive system and breast disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Weight Loss', 'OtherEventOrganSystem': 'General disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '31'}]}}, {'OtherEventTerm': 'Abnormal Muscle Tone/Movements', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '26'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '34'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '31'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No', 'AgreementRestrictiveAgreement': 'No'}, 'PointOfContact': {'PointOfContactTitle': 'Dr. Yvette Sheline', 'PointOfContactOrganization': 'University of Pennsylvania', 'PointOfContactEMail': 'sheline@pennmedicine.upenn.edu', 'PointOfContactPhone': '215-573-0082'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000020280', 'InterventionMeshTerm': 'Sertraline'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000928', 'InterventionAncestorTerm': 'Antidepressive Agents'}, {'InterventionAncestorId': 'D000011619', 'InterventionAncestorTerm': 'Psychotropic Drugs'}, {'InterventionAncestorId': 'D000017367', 'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'}, {'InterventionAncestorId': 'D000014179', 'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'}, {'InterventionAncestorId': 'D000049990', 'InterventionAncestorTerm': 'Membrane Transport Modulators'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000018490', 'InterventionAncestorTerm': 'Serotonin Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M20684', 'InterventionBrowseLeafName': 'Sertraline', 'InterventionBrowseLeafAsFound': 'Sertraline', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2828', 'InterventionBrowseLeafName': 'Antidepressive Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M13057', 'InterventionBrowseLeafName': 'Psychotropic Drugs', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M14095', 'InterventionBrowseLeafName': 'Serotonin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M18232', 'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr', 'InterventionBrowseBranchName': 'Psychotropic Drugs'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}, {'ConditionMeshId': 'D000003865', 'ConditionMeshTerm': 'Depressive Disorder, Major'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5643', 'ConditionBrowseLeafName': 'Depressive Disorder, Major', 'ConditionBrowseLeafAsFound': 'Major Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 94, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03988985', 'OrgStudyIdInfo': {'OrgStudyId': 'UHHamburgEppendorfGetFeedback'}, 'Organization': {'OrgFullName': 'Universitätsklinikum Hamburg-Eppendorf', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Enhancing the Clinical Effectiveness of Depression Screening Using Patient-targeted Feedback in General Practices', 'OfficialTitle': 'Enhancing the Clinical Effectiveness of Depression Screening Using Patient-targeted Feedback in General Practices: The GET.FEEDBACK.GP Multicentre Randomized Controlled Trial'}, 'StatusModule': {'StatusVerifiedDate': 'September 2019', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 17, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 18, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'April 28, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 4, 2019', 'StudyFirstSubmitQCDate': 'June 15, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 18, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'September 5, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 6, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Universitätsklinikum Hamburg-Eppendorf', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Federal Joint Committee, Germany', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"The multi-center GET.FEEDBACK.GP randomized controlled trial is designed based on patients' needs and preferences. In order to evaluate the effect of feedback in the broader setting of primary care, a total of 1076 primary care patients with elevated levels of depression (PHQ-9 score ≥ 10) will be randomized into three groups who either receive a) patient-targeted and physician-targeted feedback of depression screening results, b) a physician-targeted feedback of depression screening results only, or c) no feedback of screening results. The primary study outcome is depression severity after 6 months, secondary outcomes include the patients' behavior and cognitions after the screening, depression care according to German guideline recommendations and the health economic evaluation.\", 'DetailedDescription': \"Major depression is one of the most significant clinical disorders. In primary care, every sixth patient suffers from increased depression level, which is associated with higher risk of suicide, increased risk of onset and progression of chronic physical conditions. Still, depression is under recognized and undertreated in primary care. Moreover, evidence regarding the efficacy of depression screening in primary care is insufficient to draw clear conclusions. Our previous mono-center depression screening trial in cardiac patients, provides first evidence that written patient-targeted feedback improves depression severity, encourages greater patient participation and engagement in mental health. To amplify these effects, the multi-center GET.FEEDBACK.GP randomized controlled trial is now designed based on patients' needs and preferences. In order to evaluate the effect of feedback in the broader setting of primary care, a total of 1076 primary care patients with elevated levels of depression (PHQ-9 score ≥ 10) will be randomized into three groups who either receive a) patient-targeted and physician-targeted feedback of depression screening results, b) a physician-targeted feedback of depression screening results only, or c) no feedback of screening results. The primary study outcome is depression severity after 6 months, secondary outcomes include the patients' behavior and cognitions after the screening, depression care according to German guideline recommendations and the health economic evaluation.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Depression', 'Screening', 'Primary Care', 'General Practice', 'Feedback']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Factorial Assignment', 'DesignPrimaryPurpose': 'Screening', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '1074', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'PATIENT-GP-FEEDBACK', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Using a randomized-controlled study design one third of the patients and their attending general practitioner will receive feedback after depression screening. The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Patient-targeted feedback', 'Other: GP-targeted feedback']}}, {'ArmGroupLabel': 'GP-FEEDBACK', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Using a randomized-controlled study design in one third of the cases only the attending general practitioner will receive feedback after depression screening. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: GP-targeted feedback']}}, {'ArmGroupLabel': 'NO-FEEDBACK', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Using a randomized-controlled study design one third of the patients and their attending general practitioner will not receive any feedback.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Patient-targeted feedback', 'InterventionDescription': 'The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['PATIENT-GP-FEEDBACK']}}, {'InterventionType': 'Other', 'InterventionName': 'GP-targeted feedback', 'InterventionDescription': 'The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['GP-FEEDBACK', 'PATIENT-GP-FEEDBACK']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression severity (Questionnaire: Patient Health Questionnaire-9)', 'PrimaryOutcomeDescription': 'Level of depression severity six months after screening (Patient Health Questionnaire-9)', 'PrimaryOutcomeTimeFrame': 'Six months after screening'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depression severity (Questionnaire: Patient Health Questionnaire-9)', 'SecondaryOutcomeDescription': 'Level of depression severity one and twelve months after screening (Questionnaire: Patient Health Questionnaire-9)', 'SecondaryOutcomeTimeFrame': 'One and twelve months after screening'}, {'SecondaryOutcomeMeasure': 'Depression treatment', 'SecondaryOutcomeDescription': 'Proportion of patients treated according to German Guideline based recommendations', 'SecondaryOutcomeTimeFrame': 'Six and twelve months after screening'}, {'SecondaryOutcomeMeasure': 'Health economic Evaluation (Questionnaire: Client Sociodemographic and Service Receipt Inventory)', 'SecondaryOutcomeDescription': 'Direct and indirect health costs (Client Sociodemographic and Service Receipt Inventory)', 'SecondaryOutcomeTimeFrame': 'Six and twelve months after screening'}, {'SecondaryOutcomeMeasure': 'Quality-adjusted life years (Questionnaire: EuroQol-5D)', 'SecondaryOutcomeDescription': 'Quality-adjusted years of life and quality of life (EuroQol-5D)', 'SecondaryOutcomeTimeFrame': 'Six and twelve months after screening'}, {'SecondaryOutcomeMeasure': 'Anxiety (Questionnaire: Generalized Anxiety Disorder-7)', 'SecondaryOutcomeDescription': 'Level of anxiety severity one, six and twelve months after screening', 'SecondaryOutcomeTimeFrame': 'One, six and twelve months after screening'}, {'SecondaryOutcomeMeasure': 'Somatic symptom severity (Questionnaire: Somatic Symptom Scale-8)', 'SecondaryOutcomeDescription': 'Level of somatic symptom severity one, six and twelve months after screening', 'SecondaryOutcomeTimeFrame': 'One, six and twelve months after screening'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nGender: male, female, diverse\\nMaximum Age: no maximum age\\nAttendance in primary care with medical consultation\\nAge ≥ 18 years;\\nSufficient language skills;\\nInformed consent\\nPatient Health Questionnaire-9 > 9 points\\n\\nExclusion Criteria:\\n\\nLife threatening health status;\\nSevere somatic or/and psychological disorder that needs urgent treatment;\\nKnown diagnosis of a depressive disorder\\nCurrent depression treatment\\nAcute suicidal tendency;\\nSevere cognitive or/and visual difficulties;\\nNot being able to fill out questionnaires\\nNo contact details', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Sebastian Kohlmann, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+49 40 7410 54321', 'CentralContactEMail': 's.kohlmann@uke.de'}, {'CentralContactName': 'Bernd Löwe, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+49 40 7410 53992', 'CentralContactEMail': 'b.loewe@uke.de'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Bernd Löwe, MD', 'OverallOfficialAffiliation': 'Director of the Department of Psychosomatic Medicine and Psychotherapy', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Technical University of Munich - Medical Faculty', 'LocationStatus': 'Recruiting', 'LocationCity': 'Munich', 'LocationState': 'Bavaria', 'LocationZip': '80333', 'LocationCountry': 'Germany', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Antonius Schneider, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+49 89 / 6146589-11', 'LocationContactEMail': 'antonius.schneider@tum.de'}, {'LocationContactName': 'Klaus Linde, MD', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'Klaus.Linde@mri.tum.de'}]}}, {'LocationFacility': 'University Medical Center Hamburg', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hamburg', 'LocationZip': '20246', 'LocationCountry': 'Germany', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Bernd Löwe, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+49 40-7410-59733', 'LocationContactEMail': 'b.loewe@uke.de'}, {'LocationContactName': 'Sebastian Kohlmann, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+49 40-7410-54321', 'LocationContactEMail': 's.kohlmann@uke.de'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 95, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01633996', 'OrgStudyIdInfo': {'OrgStudyId': '2002-P-001899'}, 'Organization': {'OrgFullName': 'Massachusetts General Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effectiveness of Acupuncture for Depressed Patients Taking Antidepressant Medications', 'OfficialTitle': 'Effectiveness of Acupuncture Augmentation on Treatment Resistant Depressed Patients'}, 'StatusModule': {'StatusVerifiedDate': 'July 2012', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 2007'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2010', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 2010', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 15, 2012', 'StudyFirstSubmitQCDate': 'July 2, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 6, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 2, 2012', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 6, 2012', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Albert Yeung', 'ResponsiblePartyInvestigatorTitle': 'Director of Primary Care Research, Depression Clinical and Research Program', 'ResponsiblePartyInvestigatorAffiliation': 'Massachusetts General Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Massachusetts General Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': \"In this research study, the investigators piloted a uniform acupuncture treatment protocol among adults with depression who were taking an antidepressant medication that was providing only partial or no symptom alleviation. The study's aims were evaluate the efficacy, safety, and tolerability of acupuncture augmentation treatment among this population. The investigators hypothesized that acupuncture as an augmentation treatment would be associated with a response rate of at least 50%, which the investigators defined as a decrease in depressive symptoms from the beginning to the end of the study of 50% or more, and that the response would be greater among patients who received acupuncture 2 times per week (vs. 1 time per week). The investigators also hypothesized that acupuncture would be associated with minimal side effects.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Acupuncture', 'Antidepressant', 'Augmentation', 'Depression']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '45', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Acupuncture', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'All participants received open acupuncture augmentation treatment per the uniform acupuncture treatment protocol that we developed according to Traditional Chinese Medicine (TCM) principles for treating depression (see Intervention Description).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Acupuncture']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'Acupuncture', 'InterventionDescription': 'Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Acupuncture']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Response to acupuncture augmentation treatment, defined as a change in scores on the Hamilton Depression Rating Scale, 17 items (HAM-D-17) from baseline to endpoint.', 'PrimaryOutcomeDescription': 'The HAM-D-17 is a clinician-rated measure of patient depressive symptoms (structured interview). Higher cumulative scores indicate more severe depression. A 50% or greater reduction in HAM-D-17 from baseline to endpoint was considered representative of our hypothesized acupuncture-augmentation response rate of at least 50%.', 'PrimaryOutcomeTimeFrame': 'Baseline and all acupuncture sessions (weekly) for 8 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Evidence of acupuncture augmentation's tolerability and acceptability, as determined clinically by the participant and study doctor.\", 'SecondaryOutcomeTimeFrame': 'Once per acupuncture session (weekly) for 8 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAges 18-65\\nA HAM-D-17 score of >= 14\\nPartial or nonresponse to a standard antidepressant (monotherapy or combination) at an adequate dose over the past 8 or more weeks (natural agents such as omega-3 fatty acids, St John's wort, SAMe, and folic acid, were allowed as antidepressants)\\nConcurrent psychotherapy was allowed, provided that it was not initiated within the 3 months prior to study entry.\\n\\nExclusion Criteria:\\n\\nA primary diagnosis other than major depressive disorder, or any history of psychosis or mania\\nConditions that could make it difficult to conclusively determine that depressive symptoms were the result of major depression and not some other condition, including any form of substance abuse or dependence within the last 6 months, other medical conditions that could be the basis of a depression (including epilepsy, history of an abnormal EEG, severe head trauma, or stroke)\\nSerious uncontrolled medical conditions (e.g. poorly controlled diabetes, severe congestive heart failure), or other medical conditions that had not been stable for at least 3 months\\nHaving had electroconvulsive therapy (ECT) during the past year\\nCurrent active suicidal or self-injurious potential necessitating immediate treatment.\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Albert Yeung, MD, ScD', 'OverallOfficialAffiliation': 'Depression Clinical and Research Program, Massachusetts General Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Depression Clinical and Research Program, Massachusetts General Hospital', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02114', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '20692042', 'ReferenceType': 'result', 'ReferenceCitation': 'Yeung AS, Ameral VE, Chuzi SE, Fava M, Mischoulon D. A pilot study of acupuncture augmentation therapy in antidepressant partial and non-responders with major depressive disorder. J Affect Disord. 2011 Apr;130(1-2):285-9. doi: 10.1016/j.jad.2010.07.025. Epub 2010 Aug 6.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 96, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02261818', 'OrgStudyIdInfo': {'OrgStudyId': 'K23MH100705', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=K23MH100705&Fy=all'}, 'Organization': {'OrgFullName': 'Johns Hopkins University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Using Peer Mentors to Deliver Depression Care', 'OfficialTitle': 'Phase 1 Study of Using Peers to Deliver Depression Care to Older Adults'}, 'StatusModule': {'StatusVerifiedDate': 'August 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 1, 2014', 'StudyFirstSubmitQCDate': 'October 9, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 10, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'March 7, 2017', 'ResultsFirstSubmitQCDate': 'August 24, 2017', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'October 2, 2017', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 24, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 2, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Jin Hui Joo', 'ResponsiblePartyInvestigatorTitle': 'Primary Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Johns Hopkins University'}, 'LeadSponsor': {'LeadSponsorName': 'Johns Hopkins University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Can peer mentors be integrated into depression care to older adults with mental health professional supervision? We will assess whether peer mentors who are lay persons who are in recovery from depression can provide depression care services to older adults with depression. Older adults who are 50 and older will be screened for depression in the clinic and community. Those who meet criteria will be paired with a peer mentor for 8 meetings. Peer mentors will audiorecord their meetings with the patient and the recordings will be analyzed to assess what kinds of communication and behaviors the peer mentors engage in and what among those communications may be associated with relieving depression. The peer mentor will be trained and supervised by a psychiatrist and they will form a team to provide the depression care to the older adult. The study aims to relieve depressive symptoms and engage older adults in care. Both older adults and peer mentors wil be interviewed after the study to assess the strengths and weaknesses of peer mentor delivery of depression care. A manual will be developed describing the process and procedures of the study.', 'DetailedDescription': \"Recruitment of peer mentors. We will recruit peer mentors from a community organization who are in recovery and are recommended by the organization and have had basic training in supportive listening and experience working with persons in the community in need of mental health support. We will recruit 10 peer mentors, striving for a balance of men and women, and accounting for attrition, so that at least 5 peer mentors will participate in the project. The study doctor will meet and interview interested peers to screen for eligibility criteria, motivation and aptitude. Persons who do not meet criteria for continued participation in the study will be referred to other volunteer opportunities when appropriate.\\n\\nRecruitment of patients. Twenty patient participants will be recruited through the internal medicine and psychiatry clinics at Johns Hopkins Bayview Medical Center as well as the community. A research assistant will screen patients for depressive symptoms with the Patient Health Questionnaire-9 (PHQ-9). Patients meeting eligibility criteria will give written informed consent. Eligible patients will be scheduled for another appointment to meet with the study doctor in a private room at offices in the clinical campus.\\n\\nTraining of peer mentors. The PI and research assistant will conduct 5 sessions totaling 20 hours of training for the peer mentors. Training will refine the peer mentor's social support behaviors, which include the use of effective communication skills, rapport building, active listening, and sharing of experiential knowledge, and expression of empathy. Issues of cultural interviewing, cultural competence, patient confidentiality, DSM-IV diagnosis, differentiation of peer and professional roles and patient safety will be addressed. Knowledge regarding how mental health and illness presents itself in old age and the specific developmental problems older adults face will be provided. Training will include review of written materials, lectures, discussion of case studies and role play. Upon completion of the training, peer mentors will be assessed for mental health knowledge and interpersonal skills and those who pass muster will be matched with patients.\\n\\nThe peer mentor role: Activities of the peer mentor with the patient will be structured by the following principles which are derived from important elements of both peer support and psychotherapy and our preliminary work:\\n\\nPrinciples to structure peer mentor interactions with patients\\n\\nEstablish a working relationship\\nEstablish goals of meetings with patient\\nProvide active listening, empathy, reciprocity, mutual respect, provision of emotional support Provide support and encourage work toward patient-identified goals to relieve depression\\nWork on patient-identified goals by engaging multiple techniques as appropriate: sharing appropriate coping strategies eg. positive thinking, experiential knowledge, problem solving, consideration of different perspectives.\\nProvide psychoeducation. Discuss the kinds of depression services available, medications, psychotherapy Acknowledge socioeconomic contributors to depression\\nProvide information on community resources\\nConnect to professional clinical services if appropriate The psychiatrist role: Peer mentors will meet with the candidate who is a psychiatrist on a weekly basis. The psychiatrist will provide: (1) clinical leadership and structure by reinforcing the principles of the peer-patient meetings; and (2) supervision and coaching which will involve encouragement, continuing education, training and skill enhancement for the peer mentor. The psychiatrist will guide the peer mentor to ensure that a positive social experience is being provided and to manage the patient in a way that ensures the realization of the patient's goal. The peer mentor will share impressions of patient progress and receive any guidance needed from the psychiatrist.\\n\\nStudy procedures. After patient consent is obtained, the psychiatrist will meet with the patient for a clinical interview so that the psychiatrist can form an impression of the patient and provide relevant guidance to the peer mentor. The patient will then be matched with a peer mentor. The peer mentor will contact the patient by telephone to schedule a meeting and meet with the peer mentor at his home or in the clinic. The peer mentor will meet the patient weekly for 8 one-hour sessions. The peer mentors will meet individually on a weekly basis with the psychiatrist during the study period in a collaborative and supervisory effort regarding the care of the patient Data Analysis. Analysis will involve both quantitative and qualitative methods. We will identify measured factors related to engagement and depression response and remission so that we can understand how the delivery model may need to be tailored or modified. This analysis will consider depression response and remission and engagement as dependent variables, with other variables as predictors or effect modifiers. We will also carry out debriefing interviews with peers and patients in order to look for themes that will call attention to factors that are most salient to patients and peers.\\n\\nQuantitative analysis. Influential variables will be identified in the statistical models according to association with the dependent variables, namely 1) engagement in depression care defined as two or more sessions attended with the peer mentor, and 2) decrease in depressive symptoms which will be treated as a continuous variable.\\n\\nQualitative analysis. We will collect qualitative data to obtain the perspective of peer mentors and patients themselves regarding study processes and mediators from their point of view. Two semi-structured interviews with patients and peer mentors will be conducted by the PI at 4 weeks and upon completion of the study. The purpose will be to obtain feedback regarding positive and negative aspects of the peer delivery model which will provide perspectives different from the expert and valuable for that reason.\\n\\nANALYSIS OF PROCESS We will analyze the process of the peer mentor-patient interactions by 1) conducting an interaction analysis which will provide quantitative associations between communication elements and outcomes to determine which elements are salient to the effectiveness of the peer delivery model, and 2) conducting a qualitative analysis of the voice recordings to assess how the peer mentors implement the critical elements and how patients respond to them. The analyses of process will serve to determine the content of the training for peer mentors, the activities peers will perform with patients and manual development.\\n\\nThe Roter Interaction Analysis System (RIAS) is a widely used system for interaction assessment in medical contexts. The RIAS has demonstrated predictive validity to patient satisfaction, patient recall, and improvements in levels of emotional distress. Combined with quantitative process and outcome measures of care, statistical analysis can establish associations between specific communicative thematic categories and patient outcomes.\\n\\nData Analysis. We will evaluate the specific interactions between peer and patient employing the RIAS to investigate the specific interactions that are associated with engagement and depression response and remission so that we can refine the training required for peers and develop measures tapping effective interaction strategies. We will also carry out open-ended interviews with patients that complement the RIAS analysis to assess how the peer mentors implement the critical elements and how patients respond.\\n\\nQuantitative analysis. The voice recordings to be analyzed with the RIAS in Phase 2 are obtained from two sources: (1) 28 voice recordings of peer mentor-patient interactions were obtained in our preliminary work and (2) 160 voice recordings of peer mentor-patient interactions will be obtained in the pilot study proposed in this application. The PI will work with Dr. Roter's laboratory for consultation where coding, reliability testing, and data entry into an SPSS file will occur. We will draw upon our conceptual model as well as incorporate the results of the quantitative and qualitative analysis regarding mediators to construct peer mentor and patient communication profiles which will then be linked to outcomes. Those elements which are associated with outcomes should be the focus of peer mentor training and be integrated into the manual. We will use linear regression to assess the presence, strength, and statistical associations between RIAS categories and outcomes.\\n\\nQualitative analysis. The goal of qualitative analysis of the voice recordings will be to enrich the inferences we make using RIAS data to capture the nuances of what is occurring in the peer mentor-patient relationship. The PI and the research assistant will listen to the voice recordings of peer mentor-patient interactions at weeks 1, 4, and 8. They will mark and transcribe sections in the voice recordings that show how interaction elements such as affective exchange take place between the peer mentor and patient, and those sections that provide examples of variations in the methods the peer mentors use and the responses of the patients. The transcriptions will be coded and analyzed for themes. This analysis will contextualize the results of the RIAS analysis and provide knowledge about peer mentor communication and behavior.\\n\\nManual development: Knowledge obtained from the study will be developed into a manual which will form the basis for a larger peer mentor study.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['depression', 'aging', 'health services']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '30', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Meetings with peer mentors', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Meetings with peer mentors']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Meetings with peer mentors', 'InterventionDescription': 'Peer mentors provide social support to address depressive symptoms', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Meetings with peer mentors']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression With PHQ-9', 'PrimaryOutcomeDescription': 'PHQ-9 will be used to assess depression. The maximum score is 27. The scale is interpreted as follows: 0-4 no depression, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe.', 'PrimaryOutcomeTimeFrame': 'at 8 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPeer mentors: Inclusion criteria:\\n\\n50 years and older,\\nable to give informed consent;\\nreceived basic training in behavioral health,\\nhistory of depression.-\\n\\nPatients:\\n\\n50 years and older;\\nclinically significant depression (defined above);\\nable to communicate in English;\\nwilling to give informed consent\\n\\nExclusion Criteria:\\n\\nPeer mentors: Exclusion criteria:\\n\\nmeet current diagnostic criteria for Minor or Major Depressive Disorder;\\nmeet current diagnostic criteria for a psychotic disorder;\\nmeet current diagnostic criteria for substance abuse or dependence.\\n\\nPatients:\\n\\nmeet diagnostic criteria for mania or hypomania;\\nmeet diagnostic criteria for psychotic syndrome;\\nmeet diagnostic criteria for alcohol abuse or dependence;\\nacutely suicidal or psychotic; and,\\na score on the Mini-Mental State Examination (MMSE) <24.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '50 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jin Hui Joo, MA MA', 'OverallOfficialAffiliation': 'Johns Hopkins University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Johns Hopkins Bayview Medical Center', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21224', 'LocationCountry': 'United States'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'No pre-study details.', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Meetings With Peer Mentors', 'FlowGroupDescription': 'Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.\\n\\nMeetings with peer mentors: Peer mentors provide peer support to address depressive symptoms'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '30'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '27'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '3'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselinePopulationDescription': '30 participants', 'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Meetings With Peer Mentors', 'BaselineGroupDescription': 'Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.\\n\\nMeetings with peer mentors: Peer mentors provide social support to address depressive symptoms'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '30'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '30'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '68.9', 'BaselineMeasurementSpread': '6.6'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '23'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '7'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '30'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Depression With PHQ-9', 'OutcomeMeasureDescription': 'PHQ-9 will be used to assess depression. The maximum score is 27. The scale is interpreted as follows: 0-4 no depression, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe.', 'OutcomeMeasurePopulationDescription': 'Patient participants', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale', 'OutcomeMeasureTimeFrame': 'at 8 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Meetings With Peer Mentors', 'OutcomeGroupDescription': 'Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.\\n\\nMeetings with peer mentors: Peer mentors provide social support to address depressive symptoms'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '27'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '7.7', 'OutcomeMeasurementSpread': '7.7'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': 'Over 8 weeks', 'EventsDescription': 'No adverse events', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Meetings With Peer Mentors', 'EventGroupDescription': 'Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.\\n\\nMeetings with peer mentors: Peer mentors provide social support to address depressive symptoms', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '30', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '30'}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No', 'AgreementRestrictiveAgreement': 'No'}, 'PointOfContact': {'PointOfContactTitle': 'Dr Jin Hui Joo', 'PointOfContactOrganization': 'Johns Hopkins University', 'PointOfContactEMail': 'jjoo1@jhmi.edu', 'PointOfContactPhone': '4105502282', 'PointOfContactPhoneExt': '410'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 97, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01783652', 'OrgStudyIdInfo': {'OrgStudyId': 'catch_it_2013'}, 'Organization': {'OrgFullName': 'The University of Hong Kong', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Adapted and Translated, Adolescent Depression, Internet Intervention', 'OfficialTitle': 'Adaptation of a U.S. Internet Tool to Prevent Depression and Addiction in Hong Kong Adolescents'}, 'StatusModule': {'StatusVerifiedDate': 'July 2014', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2013'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2015', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'July 2015', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'January 31, 2013', 'StudyFirstSubmitQCDate': 'February 4, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 5, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 10, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 11, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'The University of Hong Kong', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Objectives :\\n\\nThe key objective of this study is to develop new interventions that addresses the diverse needs and circumstances of Hong Kong adolescents with depressive symptoms in community settings. Collaboration between medical professionals and social workers may prevent the occurrence of depression and misguided attempts to self-treat with alcohol and / or drugs in our adolescents.\\n\\nMethods :\\n\\nTo address this intervention gap in the United States, Dr. Van Voorhees, a research collaborator of Dr. Chim and Dr. Ip, developed and conducted a phase 2 clinical trial of a primary care internet-based depression prevention intervention (CATCH-IT, Competent Adulthood Transition with Cognitive Behavioral Humanistic and Interpersonal training). It has been observed clinically that the strategy could reduce depressed mood, increased social support and reduced depressive episodes at 12 month follow-up.\\n\\nThe investigators now propose to study if an adaptation of the CATCH-IT website for Hong Kong Chinese adolescents may lead to significant reductions in depressed mood. In this pilot trial, the investigators propose to test the efficacy of the Adapted and Translated version of CATCH-IT (AT-CATCH) against the placebo approach in preventing the onset of depressive episodes in a group of adolescents (aged 13-17) who have depressive symptoms, but have not developed depression yet.The case group will have access to the AT-CATCH website while the control group will only be allow to use the anti-smoking website.\\n\\nThe investigators hypothesize that compared to youth in the control group, youth assigned to the AT-CATCH group will have a lower hazard ratio of major depressive episodes and decreased alcohol / drug use frequency over 2 years. Moreover, compared to youth in the control group, youth in the AT-CATCH program will demonstrate a steeper slope of improved symptoms through growth curve analysis and fewer depressed days over the study period.', 'DetailedDescription': \"Although efficacious psychological and pharmacological treatments for adolescent depression have been demonstrated, any single approach only helps about 50-75% of those treated. Furthermore, adolescents have low rates of care seeking, and many primary care patients find group therapy to be the least acceptable treatment for depression. Limited supply of mental health specialists make face-to-face counseling difficult to implement, hence the internet is a promising modality for the delivery of preventive interventions. Therefore, prevention of depression in at-risk adolescents may be more cost-effective and less distressing than allowing for the depressive symptoms to become more severe.\\n\\nKey issues - international level:\\n\\nAs proposed by the World Health Organization (WHO) and National Institute of Mental Health (NIMH), prevention of mental disorders has become a major health need (9), and a primary care internet-based depression prevention intervention strategy should be developed. Such care has already been provided for depression in the U.S. by Dr. Van Voorhees, suggesting the intervention must:\\n\\nhave broad reach into at-risk populations;\\nwork outside of traditional mental health systems;\\nuse new technologies;\\nbuild on previous clinical trials;\\nreduce identified disorders/enhance functional outcomes;\\ninclude families; and\\nbe personalized\\n\\nKey issues - local level Developing new interventions that incorporate the diverse needs and circumstances of Hong Kong adolescents with depressive symptoms in community settings is our key strategic objective. While it is ideal to have a series of primary care physician consultations for at-risk adolescents, this is not available and too expensive for the lower socioeconomic class. This lack is apparent in both the East and the West. The U.S. has built up a new cost-effective prevention strategy for depression in primary care system; however, such a strategy may not be able to be incorporated into the public health sector. Hence, the collaboration between physicians and social workers will be used for this study.\\n\\nInclusion criteria:\\n\\n138 adolescent participants (ages 13 to 21) who experience a moderately elevated level of depressive symptoms on the CES-D scale (score 16-34) will be recruited to join the study. Participants may or may not have had a past history of depression, anxiety and/or substance abuse.\\n\\nOutcome measures to compare between 2 groups:\\n\\ni) depressive episodes and symptoms Assessment of adolescent depression by the Centre of Epidemiological Studies Depression Scale (CES-D) and Depression Anxiety Stress Scale (DASS) are a standard diagnostic test for assessment of adolescent's depression. The scores of both groups would be measured and compared in 3 follow-ups to study the effect and its sustainability of the website intervention.\\n\\nii) use of alcohol and drugs Assessment of drinking and drug use behavior of adolescents by CRAFFT Screening Test, which includes questions regarding alcohol and drug use situations in the past 12 months, and additional assessment for those who show a significant problem. There are 6 questions covering road safety, drug-use habits, and influences of using drugs or alcohol.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Adolescent - Emotional Problem']}, 'KeywordList': {'Keyword': ['Adolescent depression', 'internet intervention']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '138', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Study participants in the intervention group will be given access to an anti-depression website and have four telephone follow-up within the 1-year study period.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Intervention group']}}, {'ArmGroupLabel': 'Control group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Study participants in the control group will not received any depression-related service other than an interactive anti-smoking website provided by the University of Hong Kong.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Intervention group', 'InterventionDescription': 'Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression symptoms', 'PrimaryOutcomeDescription': 'Centre for Epidemiological Studies Depression Scale (CES-D) : at baseline, 3 months, 6 months and 12 months', 'PrimaryOutcomeTimeFrame': '12 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depression measurement', 'SecondaryOutcomeDescription': 'Depression Anxiety Stress Scale (DASS) : at baseline, 3 months, 6 months and 12 months', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'alcohol abuse', 'SecondaryOutcomeDescription': 'CRAFFT Screening Test : at baseline, 3 months, 6 months, and 12 months', 'SecondaryOutcomeTimeFrame': '12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nage 13 to 21\\nexperience a moderately elevated level of depressive symptoms on the CES-D scale (score 16-34)\\nmay or may not have had a past history of depression, anxiety and/or substance abuse\\n\\nExclusion Criteria:\\n\\ncurrently diagnosed with depression, schizophrenia, or bipolar affective disorder ;\\ncurrently taking antidepressants or psychotropic medication ;\\nCES-D score equal or higher than 35, or a proved serious medical illness that causes significant disability or dysfunction ;\\nexhibit significant reading impairment, mental retardation, developmental disabilities\\nserious imminent suicidal risk or other conditions that may require immediate psychiatric hospitalization\\nhave extreme, current drug / alcohol abuse (greater than or equal to 2 on the CRAFFT)', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '13 Years', 'MaximumAge': '21 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'David Chim, Dr.', 'OverallOfficialAffiliation': 'The University of Hong Kong', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'The University of Hong Kong', 'LocationCity': 'Hong Kong', 'LocationState': 'Hong Kong', 'LocationCountry': 'China'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17683', 'ConditionBrowseLeafName': 'Behavior, Addictive', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 98, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04278456', 'OrgStudyIdInfo': {'OrgStudyId': 'EBYU 88'}, 'Organization': {'OrgFullName': 'Erzincan University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Postpartum Depression', 'OfficialTitle': 'The Effect of the Anesthesia Modality Used in Women Giving Birth Under Caesarian Section on Postpartum Depression and/or Postoperative Melatonin Levels'}, 'StatusModule': {'StatusVerifiedDate': 'February 2020', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 21, 2020', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 21, 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'July 21, 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 18, 2020', 'StudyFirstSubmitQCDate': 'February 18, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 20, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 18, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 20, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'REMZIYE AYSENUR NALBANT', 'ResponsiblePartyInvestigatorTitle': 'MD', 'ResponsiblePartyInvestigatorAffiliation': 'Erzincan University'}, 'LeadSponsor': {'LeadSponsorName': 'Erzincan University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Our aim was to diagnose and initiate early treatment for postpartum depression by detecting the changes of melatonin levels in c-sections with different antesthesia modalities.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Postpartum Depression', 'Melatonin']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'Yes', 'TargetDuration': '1 Week', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'blood samples'}, 'EnrollmentInfo': {'EnrollmentCount': '300', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'general anesthesia', 'ArmGroupDescription': 'c-section with general anesthesia', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: postpartum depression']}}, {'ArmGroupLabel': 'spinal anesthesia', 'ArmGroupDescription': 'c-section with spinal anesthesia', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: postpartum depression']}}, {'ArmGroupLabel': 'epidural anesthesia', 'ArmGroupDescription': 'c-section with epidural anesthesia', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: postpartum depression']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'postpartum depression', 'InterventionDescription': 'melatonin levels in c-sections with different anesthesia modalities.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['epidural anesthesia', 'general anesthesia', 'spinal anesthesia']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'edinburgh depression scale', 'PrimaryOutcomeDescription': 'below 12 is associated with depression', 'PrimaryOutcomeTimeFrame': '5 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\npregnant women c-section (using general or regional anesthesia) aged between 18-45 years\\n\\nExclusion Criteria:\\n\\nage under 18 or above 45, history of smoking, a diagnosis with mental retardation, psychiatric patients, use of antipsychotics or antidepressants, patients with sleeping disorders, hormone replacement theraphy patients.', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'GenderBased': 'Yes', 'GenderDescription': 'aged between 18-45 years', 'MinimumAge': '18 Years', 'MaximumAge': '45 Years', 'StdAgeList': {'StdAge': ['Adult']}, 'StudyPopulation': 'pregnant women that will give birth by c-section (using general or regional anesthesia) aged between 18-45 years will be included to our study', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'DİDEM ONK', 'CentralContactRole': 'Contact', 'CentralContactPhone': '05053856322', 'CentralContactEMail': 'd.hesapdar@gmail.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Remziye Ayşenur NALBANT', 'OverallOfficialAffiliation': 'ERZİNCAN', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Erzincan Byu', 'LocationStatus': 'Recruiting', 'LocationCity': 'Erzincan', 'LocationCountry': 'Turkey', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'DİDEM ONK', 'LocationContactRole': 'Contact', 'LocationContactPhone': '05053856322', 'LocationContactEMail': 'd.hesapdar@gmail.com'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24835540', 'ReferenceType': 'result', 'ReferenceCitation': 'Andersen LP, Werner MU, Rosenberg J, Gögenur I. A systematic review of peri-operative melatonin. Anaesthesia. 2014 Oct;69(10):1163-71. doi: 10.1111/anae.12717. Epub 2014 May 19. Review.'}, {'ReferencePMID': '24015137', 'ReferenceType': 'result', 'ReferenceCitation': 'Maitra S, Baidya DK, Khanna P. Melatonin in perioperative medicine: Current perspective. Saudi J Anaesth. 2013 Jul;7(3):315-21. doi: 10.4103/1658-354X.115316. Review.'}, {'ReferencePMID': '26697084', 'ReferenceType': 'result', 'ReferenceCitation': 'Dianatkhah M, Ghaeli P, Hajhossein Talasaz A, Karimi A, Salehiomran A, Bina P, Jalali A, Ghaffary S, Shahmansouri N, Vejdani S. Evaluating the Potential Effect of Melatonin on the post-Cardiac Surgery Sleep Disorder. J Tehran Heart Cent. 2015 Jul 3;10(3):122-8.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000019052', 'ConditionMeshTerm': 'Depression, Postpartum'}, {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000011644', 'ConditionAncestorTerm': 'Puerperal Disorders'}, {'ConditionAncestorId': 'D000011248', 'ConditionAncestorTerm': 'Pregnancy Complications'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M19660', 'ConditionBrowseLeafName': 'Depression, Postpartum', 'ConditionBrowseLeafAsFound': 'Postpartum Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13082', 'ConditionBrowseLeafName': 'Puerperal Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12710', 'ConditionBrowseLeafName': 'Pregnancy Complications', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}}}}, {'Rank': 99, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04165681', 'OrgStudyIdInfo': {'OrgStudyId': 'Limbix Spark 01'}, 'Organization': {'OrgFullName': 'Limbix Health, Inc.', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'A Mobile and Virtual Reality Intervention for Adolescent Depression', 'OfficialTitle': 'Evaluating the Feasibility of Limbix Spark: a Cognitive Behavioral Therapy Based Mobile and Virtual Reality Intervention for Adolescent Depression'}, 'StatusModule': {'StatusVerifiedDate': 'November 2019', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 12, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'March 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 11, 2019', 'StudyFirstSubmitQCDate': 'November 13, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 18, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'November 13, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 18, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Limbix Health, Inc.', 'LeadSponsorClass': 'INDUSTRY'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Depression, the most common mental health disorder among adolescents, is a critical health problem within the US. In this study, the feasibility, acceptability, and preliminary efficacy of Limbix Spark, a cognitive behavioral therapy (CBT)- based mobile app + virtual reality (VR) program for helping adolescents live well with depression will be investigated. This program is specifically designed around behavioral activation theory, the idea that completing activities that make a patient feel pleasure or provide a sense of mastery are effective in reducing symptoms of depression. The program involves the use of both VR and a mobile app that include CBT components like psychological assessments, psychoeducation, and skills training. 30 participants aged 12-21 years old with mild to severe depressive symptoms and smartphone access will be enrolled in this study. The primary efficacy outcome measures will be depressive symptoms with anxiety symptoms, functional outcomes, and dimensional scales of positive and negative affect and behavioral activation serving as secondary outcome measures. Qualitative and quantitative feedback on the use of the VR + mobile app (ease of use, comfort, willingness to use again) will be assessed using questionnaires. Engagement and adherence to the program will be assessed by assessing VR and app usage.', 'DetailedDescription': \"Depression, the most common mental health disorder among adolescents, is a major public health concern with significant personal, societal, and economic burdens, particularly as incidence rates are increasing. Effective care for adolescent depression is limited due to lack of access to care, increasingly long waitlists, stigma surrounding mental health, and ineffectiveness of pharmaceutical options. There is an urgent need for accessible, cost-effective, and evidence-based treatment options for adolescents with depression.\\n\\nThe development of effective digital health programs for adolescents is a key strategy to reduce the personal, familiar and societal burden of depression. Such programs provide an innovative way to deliver resources in a cost-effective, accessible fashion. Cognitive-behavioral therapy (CBT) is effective in the prevention and treatment of depression in children and adolescents. Digital forms of CBT have also been shown to be efficacious in the treatment of anxiety and depressive symptoms in youth, however. adherence to such programs in clinical trials and particularly in real world evidence evaluations is low. Virtual reality (VR) holds promise as a way to enhance adherence to and the efficacy of digital CBT for depression.\\n\\nTo address the need for effective, accessible, and engaging treatments for adolescent depression, the objective of this project is to evaluate the feasibility, acceptability, and preliminary evidence of efficacy of Limbix Spark: a 5 week CBT-based mobile + VR self-guided program. Limbix Spark is specifically designed to implement behavioral activation, a CBT skill, which involves completing self-monitored activities that provide a sense of pleasure or mastery in order to reduce depressive symptoms and improve functional outcomes. VR allows adolescents to complete such activities in virtual environments as a potential stepping stone to engaging in similar experiences in the real world.\\n\\n30 participants aged 12-21 years old with mild to severe depressive symptoms and with smart phone access will be enrolled. During a baseline visit, participants or participants' legal guardians, will be asked to provide written informed consent and potential participants under 18 will be asked to provide written assent after study procedures are explained and any questions are answered by study staff in accordance with good clinical practice (GCP) and human subjects research guidelines.\\n\\nAfter consent, all eligible participants will be assigned to complete the 5-week Limbix Spark program. Participants and their legal guardian if under 18 will first complete baseline assessments, including the Patient Health Questionnaire (PHQ-8) Generalized Anxiety Disorder scale (GAD-7), the Positive and Negative Affective Schedule (PANAS-C), the Behavioral Activation for Depression Scale-Short Form (BADS-SF), 20-item Short Form Survey (SF-20), Mood and Feelings Questionnaire Short Parent version (MFQ-PS). Participants will then receive VR equipment, and receive an initial orientation to the Limbix Spark program. Program orientation will include training on how to set up and use the VR headset and how to download and use the mobile app.\\n\\nThe 5 modules in the Limbix Spark program are meant to be completed weekly, however, participants will be allowed to progress through the program at their own pace. Each module contains VR and mobile app components and is expected to take no more than 60 minutes to complete, with no more than approximately 25 min per module of VR content. Modules do not need to be completed in a single session and can be completed over the course of several days. During the program, weekly PHQ-8 assessments will be completed within the mobile app.\\n\\nAt the post-intervention site visit, participants and their legal guardian if under 18 will complete post-program assessments, including the PHQ-8, GAD-7, PANAS-C, MFQ-PS, SF-20, and BADS-SF, as well as a questionnaire about their thoughts and experiences with the Spark program. Participants will also complete a qualitative interview to further understand their experience with the program.\\n\\nOne month after the post-intervention site visit, participants will be sent a 1-month follow up questionnaires via email, including the PHQ-8, GAD-7, PANAS-C, MFQ-PS, SF-20, and BADS-SF, as well as a questionnaire about their thoughts and experiences with the Spark program.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}, 'KeywordList': {'Keyword': ['Adolescence', 'Cognitive Behavioral Therapy', 'Virtual Reality', 'Depression', 'Behavioral Activation']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Other', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '30', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Limbix Spark', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'A 5 week mobile + virtual reality CBT-based program', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Limbix Spark']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Limbix Spark', 'InterventionDescription': '5-week, self-guided mobile + VR CBT-based program for adolescent depression', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Limbix Spark']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Adherence to program', 'PrimaryOutcomeDescription': '% of enrolled participants completing all sessions at post treatment', 'PrimaryOutcomeTimeFrame': 'Post treatment (5 weeks)'}, {'PrimaryOutcomeMeasure': 'Change in depression post treatment', 'PrimaryOutcomeDescription': 'Change in depressive symptoms measured by Personal Health Questionnaire (PHQ-8) (min: 0; max: 24, with higher score indicating more severe depression).', 'PrimaryOutcomeTimeFrame': 'Change from Baseline to Post treatment (5 weeks)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in depression at one month follow up', 'SecondaryOutcomeDescription': 'Change in depressive symptoms measured by Personal Health Questionnaire (PHQ-8) (min: 0; max: 24, with higher score indicating more severe depression).', 'SecondaryOutcomeTimeFrame': 'Change from Baseline to 1 month follow up (9 weeks)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nScore of 10 or greater on Patient Health Questionnaire (PHQ-8)\\nEnglish fluency and literacy\\nAccess to a smart phone\\nPatient willing to provide informed consent/assent and have parent/guardian willing to provide informed consent if under 18.\\n\\nExclusion Criteria:\\n\\nSeizure disorder or other neurological disorder\\nPrior diagnosis of or receiving treatment for substance use disorder, bipolar disorder, or psychosis\\nSignificant vision or hearing impairment\\nHospitalized or received residential/inpatient treatment for a suicide attempt or self-harming behaviors within the past 3 months\\nCurrent diagnosis of a reading/learning or intellectual disability.\\nReceiving treatment (including but not limited to medication or psychotherapy) for a cognitive disorder, including attention deficit hyperactivity disorder (ADHD).\\nAre currently participating in a treatment study.\\nPregnancy\\nHistory of significant motion sickness', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '12 Years', 'MaximumAge': '21 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Jessica Lake, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '1-888-546-2495', 'CentralContactPhoneExt': '708', 'CentralContactEMail': 'jessica@limbix.com'}, {'CentralContactName': 'Aarthi Padmanabhan, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '1-888-546-2495', 'CentralContactPhoneExt': '703', 'CentralContactEMail': 'aarthi@limbix.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jessica Lake, PhD', 'OverallOfficialAffiliation': 'Director of Research', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Limbix Health, Inc.', 'LocationStatus': 'Recruiting', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90266-2558', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jessica Lake, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '888-546-2495', 'LocationContactPhoneExt': '708', 'LocationContactEMail': 'jessica@limbix.com'}, {'LocationContactName': 'Aarthi Padmanabhan, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '1-888-546-2495', 'LocationContactPhoneExt': '703', 'LocationContactEMail': 'aarthi@limbix.com'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 100, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02310529', 'OrgStudyIdInfo': {'OrgStudyId': 'PILL-IPT'}, 'Organization': {'OrgFullName': 'Pakistan Institute of Living and Learning', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Interpersonal Psychotherapy for Maternal Depression', 'OfficialTitle': 'Randomized Control Trial of an Interpersonal Psychotherapy for Maternal Depression'}, 'StatusModule': {'StatusVerifiedDate': 'August 2015', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'January 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 15, 2014', 'StudyFirstSubmitQCDate': 'December 5, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 8, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 15, 2015', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 18, 2015', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Pakistan Institute of Living and Learning', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': \"Depression related to pregnancy frequently presents postpartum depression, which has deteriorating and lasting negative effects, not only on infant and child well being but also on mother's and father's mental health (Nancy K et al 2009). It is therefore important to introduce interventions aiming to improve mental health of mothers that could minimize the risk of diseases, and have positive effect child's on physical and psychological developmental wellbeing.\\n\\nTherefore, this project has been designed to assess the effectiveness of Interpersonal Psychotherapy for Postnatal Depression in Pakistan.\", 'DetailedDescription': \"Prevalence of depression in the postnatal period is 10% to 17 % in western world ( O 'Hara and Swain 1996; Josseffson et al 2001; Yoshida et al 2001) and 23% to 36% in the developing world (Rahman et al 2003; Patel et al 2002; Husain et al 2006).\\n\\nIn developed countries, studies indicate that maternal depression is associated with long-term emotional, cognitive and behavioral problem in children. There is evidence of link between maternal psychopathology to physical health of child. Research evidence also indicates that long-term negative impact of postnatal depression is on the mother's mental health, on infant's development and on the marital relationship (Reay, Fisher, Robertson, Adams and Owen 2005).\\n\\nbecause of high prevalence of maternal depression in low income countries like Pakistan, the present study is designed to test the effectiveness of Interpersonal Psychotherapy for women with maternal depression. The participants will be recruited from Civil hospital Karachi and also from three different communities. total 50 participants will be recruited and randomized to 2 groups: either intervention or TAU group. Assessment will be done on baseline, after completion of intervention and 3 months after completion of intervention. Assessment will include Edinburg Postnatal depression scale, Patient Health Questionnaire-9, Generalized Anxiety Disorder-7 and Rosenberg Self Esteem scale. Participants in intervention group will receive 12 sessions of Interpersonal Psychotherapy (IPT)\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Maternal Depression']}, 'KeywordList': {'Keyword': ['Maternal depression', 'Interpersonal Psycotherapy']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '50', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Interpersonal Psychotherapy', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group). IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected. Intervention will be delivered by trained clinical psychologists.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Interpersonal Psychotherapy']}}, {'ArmGroupLabel': 'Treatment as usual', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': \"Patients including in this group will be taking only treatment as usual (in Pakistan it means that participants attending in outpatients' clinic at regular intervals and may or may not be taking prescribed medication).\"}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Interpersonal Psychotherapy', 'InterventionDescription': 'Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group).IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected.\\n\\nIntervention will be delivered by trained clinical psychologists.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Interpersonal Psychotherapy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['IPT']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Edinberg Postnatal Depression Scale (EPDS) To test the feasibility and acceptability of interpersonal psychotherapy in women suffering from postnatal depression.', 'PrimaryOutcomeDescription': 'EPDS will be used to assess depression', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Patient Health Questionnaire-9 (PHQ-9)', 'SecondaryOutcomeDescription': 'PHQ-9 will be used to assess severity of depression', 'SecondaryOutcomeTimeFrame': '3 and 6 Months'}, {'SecondaryOutcomeMeasure': 'Generalized Anxiety Disorder-7 (GAD-7)', 'SecondaryOutcomeDescription': 'GAD-7 will be used to assess severity of anxiety', 'SecondaryOutcomeTimeFrame': '3 and 6 Months'}, {'SecondaryOutcomeMeasure': 'Rosenberg Self Esteem Scale (RSES)', 'SecondaryOutcomeDescription': 'This scale will ne used to assess self esteem', 'SecondaryOutcomeTimeFrame': '3 and 6 Months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMothers age 18 years and above older with child below 3 years of age\\nMeet the criteria for mild to moderate depressive symptoms on (EPDS (cut off score above 10) and\\nWere resident of trial catchment area were included in the study.\\n\\nExclusion Criteria:\\n\\nMothers who were suffering from severe depression, with diagnosed learning or physical disability or\\nAny major psychiatric illness other than maternal depression, with Alcohol and substance dependent or\\nActively suicidal were excluded from the study.', 'HealthyVolunteers': 'No', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '45 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Dr. Nusrat Husain', 'OverallOfficialAffiliation': 'PILL', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Civil hospital Karachi', 'LocationCity': 'Karachi', 'LocationState': 'Sindh', 'LocationZip': '72000', 'LocationCountry': 'Pakistan'}, {'LocationFacility': 'Bilal Colony', 'LocationCity': 'Karachi', 'LocationState': 'Sindh', 'LocationCountry': 'Pakistan'}, {'LocationFacility': 'Yousuf Goth', 'LocationCity': 'Karachi', 'LocationState': 'Sindh', 'LocationCountry': 'Pakistan'}, {'LocationFacility': 'Bhitaiabad', 'LocationCity': 'Karachi', 'LocationState': 'Sind', 'LocationCountry': 'Pakistan'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Organizational Website', 'SeeAlsoLinkURL': 'http://pill.org.pk'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'}, {'ConditionMeshId': 'D000003866', 'ConditionMeshTerm': 'Depressive Disorder'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000019964', 'ConditionAncestorTerm': 'Mood Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafAsFound': 'Depression', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20419', 'ConditionBrowseLeafName': 'Mood Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}]}}\n"
     ]
    }
   ],
   "source": [
    "kw_search = 'depression'\n",
    "r_format = 'json'\n",
    "min_rnk = '1' \n",
    "max_rnk = '100'\n",
    "parameters = {\"expr\": kw_search, \"fmt\": r_format, \"min_rnk\": min_rnk, 'max_rnk': max_rnk}\n",
    "\n",
    "# Make a get request with the parameters.\n",
    "response = requests.get(\"https://clinicaltrials.gov/api/query/full_studies?\", params=parameters)\n",
    "# Print the content of the response (the data the server returned)\n",
    "print(response.json())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "json_response = response.json()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'FullStudiesResponse': {'APIVrs': '1.01.02',\n",
       "  'DataVrs': '2020:04:21 21:56:06.523',\n",
       "  'Expression': 'depression',\n",
       "  'NStudiesAvail': 336905,\n",
       "  'NStudiesFound': 20868,\n",
       "  'MinRank': 1,\n",
       "  'MaxRank': 100,\n",
       "  'NStudiesReturned': 100,\n",
       "  'FullStudies': [{'Rank': 1,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01083628',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '68556-35551-01'},\n",
       "       'Organization': {'OrgFullName': 'University of California, San Francisco',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Text Messaging and Cognitive Behavioral Therapy for Depression',\n",
       "       'OfficialTitle': 'Automated Text Messaging to Increase Engagement in Cognitive Behavioral Therapy (CBT) for Depression',\n",
       "       'Acronym': 'HealthySMS'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2019',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2014'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2016',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'April 2017',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'February 19, 2010',\n",
       "       'StudyFirstSubmitQCDate': 'March 8, 2010',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 10, 2010',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'December 21, 2018',\n",
       "       'ResultsFirstSubmitQCDate': 'July 2, 2019',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 12, 2019',\n",
       "        'ResultsFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'July 2, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 12, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of California, San Francisco',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study aims to asses whether adding automated text messaging to group cognitive behavioral therapy for depression increases engagement which may lead to improved outcomes.',\n",
       "       'DetailedDescription': \"Background: Cognitive Behavioral Therapy (CBT) for depression is efficacious, but effectiveness is limited when implemented in low-income settings due to engagement difficulties including nonadherence with skill-building homework and early discontinuation of treatment. Automated messaging can be used in clinical settings to increase dosage of depression treatment and encourage sustained engagement with psychotherapy.\\n\\nObjectives: The aim of this study was to test whether a text messaging adjunct (mood monitoring text messages, treatment-related text messages, and a clinician dashboard to display patient data) increases engagement and improves clinical outcomes in a group CBT treatment for depression. Specifically, the investigators aim to assess whether the text messaging adjunct led to an increase in group therapy sessions attended, an increase in duration of therapy attended, and reductions in Patient Health Questionnaire-9 item (PHQ-9) symptoms compared with the control condition of standard group CBT in a sample of low-income Spanish speaking Latino patients.\\n\\nMethods: Patients in an outpatient behavioral health clinic were assigned to standard group CBT for depression (control condition; n=40) or the same treatment with the addition of a text messaging adjunct (n=45). The adjunct consisted of a daily mood monitoring message, a daily message reiterating the theme of that week's content, and medication and appointment reminders. Mood data and qualitative responses were sent to a Web-based platform (HealthySMS) for review by the therapist and displayed in session as a tool for teaching CBT skills.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['mhealth',\n",
       "         'depression',\n",
       "         'latinos',\n",
       "         'text messaging',\n",
       "         'CBT',\n",
       "         'SMS']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '85',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Group CBT for Depression with MoodText'\",\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Group cognitive behavioral therapy utilizing the BRIGHT manual for depression along with automated text messaging for mood monitoring and reminder of session content',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Group CBT for Depression with MoodText']}},\n",
       "         {'ArmGroupLabel': 'Group CBT for Depression',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Standard group cognitive behavioral therapy utilizing the BRIGHT manual for depression',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Group CBT for Depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Group CBT for Depression with MoodText',\n",
       "          'InterventionDescription': 'Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Group CBT for Depression with MoodText'\"]},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Group CBT for Depression with HealthySMS']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Group CBT for Depression',\n",
       "          'InterventionDescription': 'Standard group CBT for depression using BRIGHT manual',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group CBT for Depression']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'PHQ-9 Depression Symptoms',\n",
       "          'PrimaryOutcomeDescription': 'The PHQ-9 (Patient Health Questionnaire - 9) is commonly used to screen for depression and to monitor progression of depressive symptoms over time. The scores represent the following depression severity: 0-4: minimal depression, 5-9: mild depression, 10-14: moderate depression, 15-19: moderately severe, 20-27: severe. A score of 10 is often recommended as the cut-off score for diagnosing an episode of depression that may require treatment.',\n",
       "          'PrimaryOutcomeTimeFrame': '16 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Attendance',\n",
       "          'SecondaryOutcomeDescription': 'Number of sessions attended',\n",
       "          'SecondaryOutcomeTimeFrame': '16 weeks'},\n",
       "         {'SecondaryOutcomeMeasure': 'Duration of Therapy Attended',\n",
       "          'SecondaryOutcomeDescription': 'Number of weeks until patients dropped out of therapy',\n",
       "          'SecondaryOutcomeTimeFrame': '16 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nParticipation in CBT group at San Francisco General Hospital\\n\\nExclusion Criteria:\\n\\nActive suicidality\\nActive and severe psychosis',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '100 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Adrian Aguilera, Ph.D.',\n",
       "          'OverallOfficialAffiliation': 'University of California, San Francisco',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'San Francisco General Hospital',\n",
       "          'LocationCity': 'San Francisco',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '94110',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Latino Mental Health Research Program',\n",
       "          'SeeAlsoLinkURL': 'http://medschool.ucsf.edu/latino/'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Group CBT With Text Messaging Adjunct',\n",
       "          'FlowGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Group CBT for Depression',\n",
       "          'FlowGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '45'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '40'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '45'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '40'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '0'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '0'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Group CBT With Text Messaging Adjunct',\n",
       "          'BaselineGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Group CBT for Depression',\n",
       "          'BaselineGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '45'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '40'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '85'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '45'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '40'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '85'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '51.71',\n",
       "                   'BaselineMeasurementSpread': '11.55'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '51.83',\n",
       "                   'BaselineMeasurementSpread': '11.73'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '51.75',\n",
       "                   'BaselineMeasurementSpread': '11.62'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '38'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '29'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '67'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '7'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '11'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '18'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '45'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '40'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '85'}]}},\n",
       "               {'BaselineCategoryTitle': 'Not Hispanic or Latino',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '45'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '40'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '85'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'PHQ-9',\n",
       "          'BaselineMeasureDescription': 'The PHQ-9 (Patient Health Questionnaire - 9) is commonly used to screen for depression and to monitor progression of depressive symptoms over time. The scores represent the following depression severity: 0-4: minimal depression, 5-9: mild depression, 10-14: moderate depression, 15-19: moderately severe, 20-27: severe. A score of 10 is often recommended as the cut-off score for diagnosing an episode of depression that may require treatment.',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '13.36',\n",
       "                   'BaselineMeasurementSpread': '5.96'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '13.13',\n",
       "                   'BaselineMeasurementSpread': '4.99'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '13.25',\n",
       "                   'BaselineMeasurementSpread': '5.68'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'PHQ-9 Depression Symptoms',\n",
       "          'OutcomeMeasureDescription': 'The PHQ-9 (Patient Health Questionnaire - 9) is commonly used to screen for depression and to monitor progression of depressive symptoms over time. The scores represent the following depression severity: 0-4: minimal depression, 5-9: mild depression, 10-14: moderate depression, 15-19: moderately severe, 20-27: severe. A score of 10 is often recommended as the cut-off score for diagnosing an episode of depression that may require treatment.',\n",
       "          'OutcomeMeasurePopulationDescription': 'The number of participants analyzed in this intention-to-treat analyses represents the number of participants that provided PHQ-9 scores at the end of the study period, at 16 weeks. Because the PHQ-9 was filled in during psychotherapy sessions, this number is smaller than the original sample (n=44, n=38) due to patient drop-out of psychotherapy.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': '16 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Group CBT With Text Messaging Adjunct',\n",
       "             'OutcomeGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Group CBT for Depression',\n",
       "             'OutcomeGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '18'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '9'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '6',\n",
       "                   'OutcomeMeasurementSpread': '4.2'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '12.67',\n",
       "                   'OutcomeMeasurementSpread': '6.4'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Attendance',\n",
       "          'OutcomeMeasureDescription': 'Number of sessions attended',\n",
       "          'OutcomeMeasurePopulationDescription': 'For the attendance analyses, 3 patients (1 in the intervention and 2 in the control) were excluded, because the study ended before these patients had been offered 16 sessions of psychotherapy.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Median',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'sessions',\n",
       "          'OutcomeMeasureTimeFrame': '16 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Group CBT With Text Messaging Adjunct',\n",
       "             'OutcomeGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Group CBT for Depression',\n",
       "             'OutcomeGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '44'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '38'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '6',\n",
       "                   'OutcomeMeasurementSpread': '2.3'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '2.5',\n",
       "                   'OutcomeMeasurementSpread': '1.4'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Duration of Therapy Attended',\n",
       "          'OutcomeMeasureDescription': 'Number of weeks until patients dropped out of therapy',\n",
       "          'OutcomeMeasurePopulationDescription': 'For the duration of therapy analyses, 3 patients (1 in the intervention and 2 in the control) were excluded, because the study ended before these patients had been offered 16 sessions of psychotherapy.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Median',\n",
       "          'OutcomeMeasureDispersionType': 'Full Range',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'weeks',\n",
       "          'OutcomeMeasureTimeFrame': '16 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Group CBT With Text Messaging Adjunct',\n",
       "             'OutcomeGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Group CBT for Depression',\n",
       "             'OutcomeGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '44'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '38'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '13.5',\n",
       "                   'OutcomeMeasurementLowerLimit': '1',\n",
       "                   'OutcomeMeasurementUpperLimit': '16'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '3',\n",
       "                   'OutcomeMeasurementLowerLimit': '1',\n",
       "                   'OutcomeMeasurementUpperLimit': '16'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Group CBT With Text Messaging Adjunct',\n",
       "          'EventGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '45',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '45'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Group CBT for Depression',\n",
       "          'EventGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '40',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '40'}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
       "        'AgreementRestrictiveAgreement': 'No'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Dr. Adrian Aguilera',\n",
       "        'PointOfContactOrganization': 'University of California, Berkeley',\n",
       "        'PointOfContactEMail': 'aguila@berkeley.edu',\n",
       "        'PointOfContactPhone': '510-642-8564'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 2,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01979302',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'R01MH082425',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH082425&Fy=all'},\n",
       "       'Organization': {'OrgFullName': 'Weill Medical College of Cornell University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Effectiveness of a Depression Care Management Initiative in Home Healthcare',\n",
       "       'OfficialTitle': 'Effectiveness of a Depression Care Management Initiative in Home Healthcare'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2014',\n",
       "       'OverallStatus': 'Unknown status',\n",
       "       'LastKnownStatus': 'Active, not recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2009'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2013',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'September 26, 2013',\n",
       "       'StudyFirstSubmitQCDate': 'November 1, 2013',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 8, 2013',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 9, 2014',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 10, 2014',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Weill Medical College of Cornell University',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Depression in older home healthcare patients occurs very often, is typically not treated appropriately, and leads to poor health outcomes. This study tests an intervention, called \"Depression Care for Patients at Home\" or the Depression CAREPATH, designed to help home healthcare nurses work with the patients, their family, and their doctors in managing depression treat depression according to clinical guidelines and to manage its treatment over time. Patient outcomes, measured at 3, 6, and 12 months, include guideline-consistent changes in depression treatment and reduction in depressive symptoms.',\n",
       "       'DetailedDescription': 'The goal of this research is to improve depression treatment and outcomes among elderly home healthcare patients. Homecare nursing is a major source of health care for a large and growing number of medically ill or injured older adults who are homebound by illness or disability. Clinically significant depression is twice as prevalent in this patient population compared to similarly aged primary care patients. Depression can be effectively treated in older adults, and treatment guidelines have been developed to help physicians make treatment decisions for their depressed older patients. However, medical home healthcare patients rarely receive guideline-consistent treatment for depression. This research tests the effectiveness of an intervention, Depression Care for Patients at Home\" (CAREPATH), on two outcomes: 1. Depression treatment (i.e., initiate treatment or have a change in treatment that is consistent with guidelines), and 2. Depressive symptoms (i.e., reduction in depressive symptoms over time). The CAREPATH protocol was designed in partnership with home healthcare providers. It includes the major elements of depression care management models that have proven effective in primary care but restructures these elements to fit the clinical needs of home healthcare patients and for consistency with home healthcare practice. The intervention itself is designed to be ecologically sensitive to maximize the feasibility and generalizability of the program. The CAREPATH Intervention is being tested within six home healthcare agencies located in Vermont/New Hampshire, New York, Pennsylvania, Michigan, Florida, and Arkansas. The design includes randomization of ~20 teams of nurses to CAREPATH or usual care. The impact of CAREPATH on depression treatment is tested with all eligible patients (N~600) using data collected routinely by all agencies as these are the kinds of data that agencies typically use for quality assurance. Depressive symptoms outcomes are tested using the Hamilton Depression Rating Scale (HDRS) collected by researcher staff from (N=300) patients who consent to in-person baseline and telephone follow-up interviews at 12, 24, and 52 weeks.\\n\\nData Plan: H1 Depression Treatment : Patients of CAREPATH home nurses with clinically significant depressive symptoms will be more likely to receive a \"guideline-based step\" in their treatment of depression than patients of nurses providing usual care. This analysis will be tested using the merged administrative data set. A mixed-effects logistic regression analyses will compare patients in the intervention and usual care groups on change in depression treatment received. The primary independent variable (a fixed effect) is group and the dependent variable is change (from start-of-care to discharge to guideline consistent treatment received (yes/no). The structure of these data from this cluster randomized trial involves three level mixed-effects models in which patients are nested within nurse and nurse within team supervisor. These analyses will be preceded by mixed-effects models that compare groups on sociodemographic and clinical variables. Those variables that differ significantly will be included as covariates in the primary analysis that examines the intervention effect (described above).\\n\\nH2 Depressive Symptoms: Patients of CAREPATH home nurses with clinically significant depressive symptoms will have greater reduction in depressive symptomatology (HDRS change from baseline) by 3, 6 and 12 months of the baseline interview than patients receiving usual care. This analysis will be tested using data collected from patient research interviews. A mixed-effects linear regression analyses will compare patients in the intervention and usual care groups on change in severity of depressive symptoms from baseline. Covariates in the model will be selected as described in H1.\\n\\nD9.3 Exploratory Analyses: . S1. Different Outcomes:. Whether the intervention reduces the risk of poor outcomes as measured by Medicare\\'s \"Outcome-Based Quality Indicators\" (OBQI) and targeted adverse events, including: decline in activities of daily living, discharge to hospital, and/or falls. This analysis will be tested using the merged administrative data set. Mixed-effects analyses will be conducted on the following OBQI outcomes and adverse events. Mixed-effects linear regression will be used for the continuous measures (e.g., ADL decline) whereas mixed-effects logistic regression analyses will be used on binary outcomes (e.g., fall). The choice of covariates and the structure of the data will conform to that described for H1. We anticipate that some of these exploratory analyses will be sufficiently power for statistical tests (e.g., decline in ADL), yet others (e.g., adverse fall events) will be examined for the direction and magnitude of effects rather than statistical significance.\\n\\nS2 Patient Characteristics as Moderators: Whether the effects of the intervention on patient outcomes and quality of care differ by depression severity, patient location (e.g., rural vs. urban), race/ethnicity (White, Black, Hispanic, Native American), availability of social support (caregiver), health status, or cognitive impairment. Separate models will examine each patient characteristic as a moderator using mixed-effects linear or logistic regression analyses. The independent variables will include intervention and the respective hypothesized mediating (from post baseline) or moderating (from baseline) effects (described below). Initially the main effects will be tested. Then subsequent models will examine the incremental contribution of the interaction of intervention with each of the hypothesized moderating effects.\\n\\nD10 POWER ANALYSIS Power analyses for the primary hypotheses were conducted based on the following assumptions about sample size: 5 agencies; 4 nurse teams per agency, 5 nurses per team, and 5 patients subjects per nurse. These assumptions result in a patient sample size of 500 patients (5*4*5*5). We estimate that the number of patients who consent to research interviews will be about half of the patients who are eligible based in the agency\\'s database data (i.e., 60% participation at baseline; 85% of baseline patients eligible for follow-up). Thus the number of patients in the agency\\'s database that could be included in analyses using the this source of data will be at least 1,000.\\n\\nOther assumptions for the power analyses included a two-tailed alpha = 0.05, 12 and 24 week follow-up assessments for each subject, and an attrition rate of 15%. This rate is based on our six month follow-up rates as well as our experience with other samples of community-dwelling frail elders (e.g., home care patients), where we have found that obtaining the first interview is far more difficult than following older adults overtime once they have met and talked with us. Because computer algorithms are not readily available for conducting power analyses for three-level mixed-effects models, power estimates for testing H1 and H2 are based on simulations described below, that involved 1000 simulation runs for each combination of specifications.\\n\\nH1 Depression Treatment: The simulations considered two intraclass correlations reflecting variations in level 1 (subject-level intraclass correlation within nurse) and level 2 (nurse-level intraclass correlation within team). Statistical power to detect the hypothesized effects with the anticipated sample size, will exceed >80%.\\n\\nH2 Depressive Symptoms: Power analyses was conducted based on simulation using Mixed-effects models for level 1 and level 2 level random intercepts 3-level linear mixed effects regression model. We hypothesized medium intervention effects (Cohen\\'s d) with a standardized group mean difference in HDRS change from the baseline: 0.5 and 0.6. (These correspond to differences in HDRS changes = 3.43, and 4.11 based on an estimated residual standard deviation = 6.85 of HAM-D changes from the TRIAD study.) The table shows that power to detect effect size > 0.5 is adequate (>80%).'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Geriatric Depression',\n",
       "         'Depression Care Management',\n",
       "         'home healthcare',\n",
       "         'nurse training intervention']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '310',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression CAREPATH',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Patients receiving care from Nurses trained in depression care management',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression CAREPATH']}},\n",
       "         {'ArmGroupLabel': 'Usual Care',\n",
       "          'ArmGroupType': 'Other',\n",
       "          'ArmGroupDescription': 'Patients under the care of nurses who were trained in depression assessment and usual care',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Usual Care']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Depression CAREPATH',\n",
       "          'InterventionDescription': 'Nurses receive training and agency support in depression assessment and depression care management',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression CAREPATH']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Usual Care',\n",
       "          'InterventionDescription': 'Nurses receive training in depression assessment and review of usual care procedures.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Usual Care']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression Severity',\n",
       "          'PrimaryOutcomeDescription': 'Assessment of depression severity using the Hamilton Depression Rating Scale',\n",
       "          'PrimaryOutcomeTimeFrame': '2 week'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Guideline Consistent change in depression treatment',\n",
       "          'SecondaryOutcomeDescription': 'Patient home healthcare records reviewed for evidence that patients received a change in depression treatment (e.g., antidepressant initiation, dose change, augmentation, switch)',\n",
       "          'SecondaryOutcomeTimeFrame': '60 Days'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nNew home healthcare patient\\nAge 65 years or older\\nDepressed Mood or Anhedonia recorded by visiting nurse\\nEnglish or Spanish speaking\\n\\nExclusion Criteria:\\n\\nHigh suicide risk, i.e. intent or plan to attempt suicide in near future as defined by the suicide risk assessment.\\nSignificant Cognitive Impairment: Mini-mental Status Exam below 20\\nSevere hearing impairment or aphasic\\nLife expectancy less than 6 months (CMS 485)',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Martha L Bruce, PhD, MPH',\n",
       "          'OverallOfficialAffiliation': 'Weill Medical College of Cornell University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Weill Cornell Medical College, Westchester Division',\n",
       "          'LocationCity': 'White Plains',\n",
       "          'LocationState': 'New York',\n",
       "          'LocationZip': '10605',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '21716043',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Bruce ML, Sheeran T, Raue PJ, Reilly CF, Greenberg RL, Pomerantz JC, Meyers BS, Weinberger MI, Johnston CL. Depression care for patients at home (Depression CAREPATH): intervention development and implementation, part 1. Home Healthc Nurse. 2011 Jul-Aug;29(7):416-26. doi: 10.1097/NHH.0b013e31821fe9f7.'},\n",
       "         {'ReferencePMID': '21881429',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Bruce ML, Raue PJ, Sheeran T, Reilly C, Pomerantz JC, Meyers BS, Weinberger MI, Zukowski D. Depression Care for Patients at Home (Depression CAREPATH): home care depression care management protocol, part 2. Home Healthc Nurse. 2011 Sep;29(8):480-9. doi: 10.1097/NHH.0b013e318229d75b.'},\n",
       "         {'ReferencePMID': '27739067',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Bruce ML, Lohman MC, Greenberg RL, Bao Y, Raue PJ. Integrating Depression Care Management into Medicare Home Health Reduces Risk of 30- and 60-Day Hospitalization: The Depression Care for Patients at Home Cluster-Randomized Trial. J Am Geriatr Soc. 2016 Nov;64(11):2196-2203. doi: 10.1111/jgs.14440. Epub 2016 Oct 14.'},\n",
       "         {'ReferencePMID': '25384017',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Bruce ML, Raue PJ, Reilly CF, Greenberg RL, Meyers BS, Banerjee S, Pickett YR, Sheeran TF, Ghesquiere A, Zukowski DM, Rosas VH, McLaughlin J, Pledger L, Doyle J, Joachim P, Leon AC. Clinical effectiveness of integrating depression care management into medicare home health: the Depression CAREPATH Randomized trial. JAMA Intern Med. 2015 Jan;175(1):55-64. doi: 10.1001/jamainternmed.2014.5835.'}]},\n",
       "       'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Website describing Depression CAREPATH protocol and offering free nurse e-training in depression care management as well as depression assessment using the 9-item Patient Health Questionnaire with older adults',\n",
       "          'SeeAlsoLinkURL': 'http://mentalhealthtrainingnetwork.org/'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 3,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01453790',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '214808'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '214808-7',\n",
       "          'SecondaryIdType': 'Other Identifier',\n",
       "          'SecondaryIdDomain': 'UC Davis'}]},\n",
       "       'Organization': {'OrgFullName': 'University of California, Davis',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Parent Specific Depression Education and Motivation',\n",
       "       'OfficialTitle': 'Effectiveness of Parent Specific Depression Education and Motivation on Intent to Seek Follow-Up Care for Potential Depression Symptoms'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'June 2012',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'April 2011'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2011',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'January 2012',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'October 11, 2011',\n",
       "       'StudyFirstSubmitQCDate': 'October 13, 2011',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 18, 2011',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'May 24, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 30, 2017',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of California, Davis',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': \"Children's Miracle Network\",\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This project is an investigator-initiated, randomized-controlled trial of the effectiveness of written and verbal parent-specific depression education and motivational advice in increasing participants self-disclosed intention to seek follow-up care for possible depression symptoms. The control condition is written and verbal general depression education and advice. Hypothesis: the office-based experimental intervention of written and verbal parent-specific depression and emotional health education and motivational advice increases intention to seek follow-up services for emotional health or depression, when compared to written and verbal general depression education and advice.',\n",
       "       'DetailedDescription': 'Maternal depression is a common problem, debilitating for mothers and affecting parenting practices with negative effects on the behavior, development, and physical health of children. The value of identifying and treating maternal depression for child development and well-being is well documented. Unfortunately, there are multiple barriers to the recognition and treatment of maternal depression. This is particularly problematic in younger women, as they are less often seen for health care. The overall objective of this project is to test whether the uptake of follow-up recommendations for potential depression by mothers identified by screening in clinical settings is improved by parent-specific targetting of depression education and motivational advice.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depressive Symptoms']},\n",
       "       'KeywordList': {'Keyword': ['depression',\n",
       "         'treatment',\n",
       "         'motivation to seek follow up']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Triple',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Investigator',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '104',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Parent-Specific Depression Education-Motivation',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Mothers receive depression education (verbal and written) with messages targeted to parent status which are drawn from previous research. They also receive motivational messages at 2 days via telephone.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Parent-Specific Depression Education and Motivation']}},\n",
       "         {'ArmGroupLabel': 'General Depression Education',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Mothers receive general depression education (verbal and written) which are drawn from previous research. They also receive attention control telephone calls at 2 days.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: General Depression Education-Motivation']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Parent-Specific Depression Education and Motivation',\n",
       "          'InterventionDescription': 'Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Parent-Specific Depression Education-Motivation']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'General Depression Education-Motivation',\n",
       "          'InterventionDescription': 'General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['General Depression Education']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression Follow-Up Care Seeking',\n",
       "          'PrimaryOutcomeDescription': \"Mothers' self-reported attempts at obtaining follow-up services for emotional health or depression.\",\n",
       "          'PrimaryOutcomeTimeFrame': 'at 2 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Intention to Seek Depression Follow-Up Care',\n",
       "          'SecondaryOutcomeDescription': 'Three item scale measure of intention to seek care (any) for follow-up of positive depression screen.',\n",
       "          'SecondaryOutcomeTimeFrame': 'at 2 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nParent of a child between the ages of 2 days and 12 years who is a patient of the UC Davis Pediatric Clinic.\\nPrimary, female caregiver\\nFeeling down, depressed, or hopeless or little interest or pleasure in doing things.\\nNot currently receiving care from a mental health practitioner.\\nComfortable speaking English without an interpreter.\\n\\nExclusion Criteria:\\n\\nParent of a child younger than 2 days or older than 12 years.\\nDad, Foster parent, or other short term guardian.\\nCurrently in treatment with a mental health practitioner.\\nLimited English Proficiency',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Female',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'UC Davis Medical Center, General Pediatrics',\n",
       "          'LocationCity': 'Sacramento',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '95817',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25906700',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Fernandez y Garcia E, Joseph J, Wilson MD, Hinton L, Simon G, Ludman E, Scott F, Kravitz RL. Pediatric-based intervention to motivate mothers to seek follow-up for depression screens: The Motivating Our Mothers (MOM) trial. Acad Pediatr. 2015 May-Jun;15(3):311-8. doi: 10.1016/j.acap.2014.11.008.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 4,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01402206',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'Madrs 2010'},\n",
       "       'Organization': {'OrgFullName': 'Göteborg University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Management of Depression in Primary Care',\n",
       "       'OfficialTitle': 'Management of Depression in Primary Health Care: a Controlled Trial on the Effectiveness of Regular, Structured, Patient-centered Visits'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'August 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'March 2010'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2013',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2014',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 27, 2011',\n",
       "       'StudyFirstSubmitQCDate': 'July 25, 2011',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 26, 2011',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'August 15, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 16, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Göteborg University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Vastra Gotaland Region',\n",
       "          'CollaboratorClass': 'OTHER_GOV'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Most people in Sweden with mild to moderate depression are treated in primary care, but follow-up is unstructured, and we know little about whether structured, follow-up would affect the prognosis for depression and working life. The purpose of this study is to determine the effectiveness of regular, structured, patient-centered visits on mild to moderate depression.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Intervention',\n",
       "         'Primary health care']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '258',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Structured patient visits',\n",
       "          'ArmGroupType': 'Other',\n",
       "          'ArmGroupDescription': 'Participants in the intervention group visit their general practitioner at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Structured patient-centered follow up of depression']}},\n",
       "         {'ArmGroupLabel': 'Treatment as usual',\n",
       "          'ArmGroupType': 'Other',\n",
       "          'ArmGroupDescription': 'The control group receives treatment as usual by general practitioner (no intervention).',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Structured patient-centered follow up of depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Structured patient-centered follow up of depression',\n",
       "          'InterventionDescription': 'All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.\\n\\nThe control group receives treatment as usual (no intervention).',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Structured patient visits',\n",
       "            'Treatment as usual']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['MADRS/MADRS-S depression rating scale']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Depressive symptoms',\n",
       "          'PrimaryOutcomeDescription': 'Depressive symptoms will be assessed using the Beck Depression Inventory (BDI-II), a self-administered questionnaire that measures the symptoms and severity of the depression.',\n",
       "          'PrimaryOutcomeTimeFrame': '3, 6 and 12 months.'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Quality of life',\n",
       "          'SecondaryOutcomeDescription': \"Each patient's quality of life will be assessed using the EuroQoL-5D questionnaire that measures five dimensions of quality of life\",\n",
       "          'SecondaryOutcomeTimeFrame': '3, 6 and 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Prescriptions for antidepressants',\n",
       "          'SecondaryOutcomeDescription': 'Information on Antidepressant use will be collected from patient records from start of the study and the 12-month follow-up period',\n",
       "          'SecondaryOutcomeTimeFrame': '12-month follow-up period'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Activity/work ability',\n",
       "          'SecondaryOutcomeDescription': \"Will be measured by Work Ability Index (WAI) and the Karaseks Job Strain Model Questionnaire. The Work Ability Index is used for evaluating people's work capacity and Karaseks Job Strain Model Questionnaire is used for evaluating Demands-Control in work place\",\n",
       "          'SecondaryOutcomeTimeFrame': '12-month follow-up period'},\n",
       "         {'SecondaryOutcomeMeasure': 'sick-listing data',\n",
       "          'SecondaryOutcomeDescription': 'Data on sick-listing is derived from primary care record fom baseline to 3 months follow up and from patient interview from 3 to 12 months',\n",
       "          'SecondaryOutcomeTimeFrame': '12 month follow up'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria\\n\\nAge 18 years and up\\nAttends a participating primary health care center in the region\\nDiagnosis of mild/moderate depressive disorder (new episode)\\nNo change in possible antidepressant maintenance therapy during the preceding 1 month\\nProvided written informed consent\\n\\nExclusion criteria\\n\\nAntidepressant medication initiated or changed during the preceding 1 month\\nPatient diagnosed with major depressive disorder (BDI-II >28)\\nPatients diagnosed of severe mental psychiatric disorder (i.e. bipolar disorder, antisocial personality disorder, psychosis, substance use disorder or other serious mental disorder)\\nSuicidal ideation or intentions\\nInability to speak and understand Swedish language well enough to take part in the activities required in the study.\\nCognitive impairment that makes it impossible to take part in the activities required in the study\\nDoes not provide written informed consent to participation in the study',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '20 Years',\n",
       "       'MaximumAge': '75 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Cecila Björkelund, Professor',\n",
       "          'OverallOfficialAffiliation': 'Göteborg University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'University of Gothenburg',\n",
       "          'LocationCity': 'Gothenburg',\n",
       "          'LocationCountry': 'Sweden'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28103816',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Wikberg C, Westman J, Petersson EL, Larsson ME, André M, Eggertsen R, Thorn J, Ågren H, Björkelund C. Use of a self-rating scale to monitor depression severity in recurrent GP consultations in primary care - does it really make a difference? A randomised controlled study. BMC Fam Pract. 2017 Jan 19;18(1):6. doi: 10.1186/s12875-016-0578-9.'}]},\n",
       "       'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Our homepage at University of Gothenburg (in swedish)',\n",
       "          'SeeAlsoLinkURL': 'http://www.medicine.gu.se/avdelningar/samhallsmedicin_folkhalsa/allmanmedicin/'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 5,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01096316',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '37061-G'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R01MH085668',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH085668&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'University of Washington',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Depression Attention for Women Now (The DAWN Study)',\n",
       "       'OfficialTitle': 'Reducing Disparities and Improving Care for Depression in OB-GYN Clinics: Depression Attention for Women Now (The DAWN Study)',\n",
       "       'Acronym': 'DAWN'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'January 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'November 2009'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'May 2015',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'March 25, 2010',\n",
       "       'StudyFirstSubmitQCDate': 'March 29, 2010',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 31, 2010',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'June 27, 2014',\n",
       "       'ResultsFirstSubmitQCDate': 'August 25, 2014',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 27, 2014',\n",
       "        'ResultsFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'January 6, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 4, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Jurgen Unutzer',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Professor and Chair, Psychiatry & Behavioral Sciences',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Washington'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Washington',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Major depressive disorder (MDD) is a common disabling illness that disproportionately affects women, with prevalence rates two times those of men. In addition to suffering, MDD has been shown to have a marked effect on social and vocational functioning, with increased disability, lost productivity, and excess mortality. Women with MDD have an increased prevalence of comorbid anxiety disorders and medical conditions.\\n\\nOur model of care utilizes a social worker as a depression care manager (DCM) to support both patients and physicians in optimizing care in the OB-GYN clinical setting. This intervention will be compared to usual care for depression.',\n",
       "       'DetailedDescription': 'A large number of women receive their routine care in OB-GYN clinics, including a disproportionate percentage of low-income and minority women. For many of these women, OG-GYNs are the only provider they see on a regular basis. OB-GYNs take care of women across their lifespan, addressing gynecologic, health care maintenance, pregnancy and primary care concerns in their everyday practices. There are multiple aspects of OG-GYN care that are uniquely suited for detection and treatment of depression, but there are also significant barriers to such care that must be addressed.\\n\\nIn this randomized controlled trial, we are testing this depression care management program for women attending two OB-GYN clinics in the University of Washington health care system. Our research aims to test the hypothesis that a depression care management intervention, integrated into the OB-GYN clinic setting, will improve treatment outcomes for depression, functional outcomes, and satisfaction with depression care. The results of our research will greatly impact clinical care by satisfying an unmet need for effective depression services for women seen in OB-GYN clinical settings.\\n\\nThe study compares a depression care management intervention, delivered by a depression care manager, to usual care for depression in the clinics. The primary aims of the study are to evaluate, compared to usual care, a depression intervention consisting of enhanced education, engagement, and depression care management (with a choice of antidepressant medication monitoring and/or provision of brief psychotherapy).'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depressive Disorder']},\n",
       "       'KeywordList': {'Keyword': ['mood disorders',\n",
       "         'depressive disorder',\n",
       "         'women',\n",
       "         'depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '205',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:\\n\\nenhanced education of patients and providers\\nengagement of patients\\ndepression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression Care Management']}},\n",
       "         {'ArmGroupLabel': 'Usual Care',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Depression Care Management',\n",
       "          'InterventionDescription': \"The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Study Intervention']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression Treatment Outcome',\n",
       "          'PrimaryOutcomeDescription': 'Impact of the intervention on depression treatment outcomes, including change in depressive symptoms and treatment response. In particular, the depression scale from the Hopkins Symptom Checklist 20 (SCL-20) was used to assess depression severity at the assessments. The SCL-20 ranges from 0 (no depression) to 4 (severe depression),',\n",
       "          'PrimaryOutcomeTimeFrame': '12 months'},\n",
       "         {'PrimaryOutcomeMeasure': 'Functional Outcome',\n",
       "          'PrimaryOutcomeDescription': 'Impact of the intervention on functional outcomes of patients. Functional impairment was measured using the Sheehan Disability Scale. The Sheehan disability scale is the average of 3 items assessing impairment in social, work and family responsibilities. Each item is rated 0 (no impairment) to 10 (totally impaired) and the 3 ratings are averaged for the Sheehan disability scale reported below.',\n",
       "          'PrimaryOutcomeTimeFrame': '12 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quality of Depression Care Indicators',\n",
       "          'SecondaryOutcomeDescription': 'Intervention impact on quality of depression care indicators and satisfaction with depression care. Number of participants receiving 4 or more mental health visits are reported. Receiving 4 or more mental health visits has previously been used in depression randomized control trials as a measure of the quality of depression treatment received by a patient',\n",
       "          'SecondaryOutcomeTimeFrame': '12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Potential Facilitators and Barriers to Sustainability',\n",
       "          'SecondaryOutcomeDescription': \"Providers' and administrators' perceived barriers and facilitators to continue providing the intervention after study end.\",\n",
       "          'SecondaryOutcomeTimeFrame': '18 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPHQ-9 score ≥10 for Major Depressive Disorder (with 1 cardinal symptom) and/or ≥10 for Dysthymia (with 1 cardinal symptom)\\nMINI confirmation of PHQ-9 diagnoses\\nAccess to a telephone\\nEnglish-speaking\\n\\nExclusion Criteria:\\n\\nHigh suicide risk (PHQ-9 response)\\n≥2 prior suicide attempts\\nLifetime history of schizophrenia or bipolar disorder (MINI response)\\nSubstance abuse/dependence within the previous 3 months (CAGE-AID)\\nCurrent severe intimate partner violence\\nCurrently seeing a psychiatrist',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Female',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jurgen Unutzer, MD, MPH, MA',\n",
       "          'OverallOfficialAffiliation': 'University of Washington',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': \"Women's Clinic at Harborview Medical Center\",\n",
       "          'LocationCity': 'Seattle',\n",
       "          'LocationState': 'Washington',\n",
       "          'LocationZip': '98104',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': \"Women's Health Care Center at University of Washington Medical Center (Roosevelt Clinic)\",\n",
       "          'LocationCity': 'Seattle',\n",
       "          'LocationState': 'Washington',\n",
       "          'LocationZip': '98195',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24807320',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Melville JL, Reed SD, Russo J, Croicu CA, Ludman E, LaRocco-Cockburn A, Katon W. Improving care for depression in obstetrics and gynecology: a randomized controlled trial. Obstet Gynecol. 2014 Jun;123(6):1237-46. doi: 10.1097/AOG.0000000000000231.'},\n",
       "         {'ReferencePMID': '23969800',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Cerimele JM, Vanderlip ER, Croicu CA, Melville JL, Russo J, Reed SD, Katon W. Presenting symptoms of women with depression in an obstetrics and gynecology setting. Obstet Gynecol. 2013 Aug;122(2 Pt 1):313-8. doi: 10.1097/AOG.0b013e31829999ee.'},\n",
       "         {'ReferencePMID': '23939510',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'LaRocco-Cockburn A, Reed SD, Melville J, Croicu C, Russo JE, Inspektor M, Edmondson E, Katon W. Improving depression treatment for women: integrating a collaborative care depression intervention into OB-GYN care. Contemp Clin Trials. 2013 Nov;36(2):362-70. doi: 10.1016/j.cct.2013.08.001. Epub 2013 Aug 9. Erratum in: Contemp Clin Trials. 2014 Jan;37(1):166.'}]}}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Intervention',\n",
       "          'FlowGroupDescription': 'The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:\\n\\nenhanced education of patients and providers\\nengagement of patients\\ndepression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation.\\n\\nDepression Care Management: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST,'},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Usual Care',\n",
       "          'FlowGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '102'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '103'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '87'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '94'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '15'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '9'}]}}]},\n",
       "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '15'},\n",
       "               {'FlowReasonGroupId': 'FG001',\n",
       "                'FlowReasonNumSubjects': '9'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'Baseline data from the intervention arms were examined for statistically significant differences using t tests, chi squares and logistic regression analyses.',\n",
       "       'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Intervention',\n",
       "          'BaselineGroupDescription': 'The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:\\n\\nenhanced education of patients and providers\\nengagement of patients\\ndepression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation.\\n\\nDepression Care Management: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST,'},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Usual Care',\n",
       "          'BaselineGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '102'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '103'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '205'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '39.47',\n",
       "                   'BaselineMeasurementSpread': '12.11'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '38.59',\n",
       "                   'BaselineMeasurementSpread': '12.10'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '39.02',\n",
       "                   'BaselineMeasurementSpread': '12.09'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '102'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '103'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '205'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Depression Treatment Outcome',\n",
       "          'OutcomeMeasureDescription': 'Impact of the intervention on depression treatment outcomes, including change in depressive symptoms and treatment response. In particular, the depression scale from the Hopkins Symptom Checklist 20 (SCL-20) was used to assess depression severity at the assessments. The SCL-20 ranges from 0 (no depression) to 4 (severe depression),',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': '12 months',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Intervention',\n",
       "             'OutcomeGroupDescription': 'The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:\\n\\nenhanced education of patients and providers\\nengagement of patients\\ndepression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation.\\n\\nDepression Care Management: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST,'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Usual Care',\n",
       "             'OutcomeGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '102'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '103'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '0.96',\n",
       "                   'OutcomeMeasurementSpread': '0.65'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '1.33',\n",
       "                   'OutcomeMeasurementSpread': '0.75'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Functional Outcome',\n",
       "          'OutcomeMeasureDescription': 'Impact of the intervention on functional outcomes of patients. Functional impairment was measured using the Sheehan Disability Scale. The Sheehan disability scale is the average of 3 items assessing impairment in social, work and family responsibilities. Each item is rated 0 (no impairment) to 10 (totally impaired) and the 3 ratings are averaged for the Sheehan disability scale reported below.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': '12 months',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Intervention',\n",
       "             'OutcomeGroupDescription': 'The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:\\n\\nenhanced education of patients and providers\\nengagement of patients\\ndepression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation.\\n\\nDepression Care Management: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST,'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Usual Care',\n",
       "             'OutcomeGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '102'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '103'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '3.69',\n",
       "                   'OutcomeMeasurementSpread': '2.70'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '4.03',\n",
       "                   'OutcomeMeasurementSpread': '2.70'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Quality of Depression Care Indicators',\n",
       "          'OutcomeMeasureDescription': 'Intervention impact on quality of depression care indicators and satisfaction with depression care. Number of participants receiving 4 or more mental health visits are reported. Receiving 4 or more mental health visits has previously been used in depression randomized control trials as a measure of the quality of depression treatment received by a patient',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Number',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'participants',\n",
       "          'OutcomeMeasureTimeFrame': '12 months',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Intervention',\n",
       "             'OutcomeGroupDescription': 'The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:\\n\\nenhanced education of patients and providers\\nengagement of patients\\ndepression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation.\\n\\nDepression Care Management: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST,'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Usual Care',\n",
       "             'OutcomeGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '102'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '103'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '67'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '28'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Potential Facilitators and Barriers to Sustainability',\n",
       "          'OutcomeMeasureDescription': \"Providers' and administrators' perceived barriers and facilitators to continue providing the intervention after study end.\",\n",
       "          'OutcomeMeasureReportingStatus': 'Not Posted',\n",
       "          'OutcomeMeasureTimeFrame': '18 months'}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Intervention',\n",
       "          'EventGroupDescription': \"The intervention will integrate care between a depression care manager(DCM), consulting study team (psychiatry OB-GYN physician) and OB-GYN clinic providers.\\n\\nDepression Care Management: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). The DCM in a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the 12-month intervention. Patients choose either medication or Problem-Solving Treatment. Depressive symptoms are assessed at each visit with the PHQ-9. Patients with inadequate response after 4 to 8 weeks to the first choice will switch or combine treatments. DCMs partcipate in weekly caseload review with a psychiatrist and Ob-Gyn physician who make treatment recommendations that the DCM then communicates to the patient's own Ob-Gyn physician who writes all prescriptions.\",\n",
       "          'EventGroupSeriousNumAffected': '1',\n",
       "          'EventGroupSeriousNumAtRisk': '102',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '102'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Usual Care',\n",
       "          'EventGroupDescription': 'Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.',\n",
       "          'EventGroupSeriousNumAffected': '1',\n",
       "          'EventGroupSeriousNumAtRisk': '103',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '103'}]},\n",
       "       'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Psychiatric ER visits or hospitalization',\n",
       "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
       "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
       "          'SeriousEventNotes': 'We assessed at each objective follow-up all psychiatric emergency room visits and psychiatric hospitalizations. These were also spontaneously sent to us via EMR if the ER visit or hospitalization occurred in the University hospitals',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '1',\n",
       "             'SeriousEventStatsNumAffected': '1',\n",
       "             'SeriousEventStatsNumAtRisk': '102'},\n",
       "            {'SeriousEventStatsGroupId': 'EG001',\n",
       "             'SeriousEventStatsNumEvents': '1',\n",
       "             'SeriousEventStatsNumAffected': '1',\n",
       "             'SeriousEventStatsNumAtRisk': '103'}]}}]}},\n",
       "      'MoreInfoModule': {'LimitationsAndCaveats': {},\n",
       "       'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Jurgen Unutzer MD MPH MA, Professor and Chair',\n",
       "        'PointOfContactOrganization': 'Dept Psychiatry & Behavioral Sciences University of Washington',\n",
       "        'PointOfContactEMail': 'unutzer@uw.edu',\n",
       "        'PointOfContactPhone': '206-543-3752'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 6,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04218214',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '2017-0716'},\n",
       "       'Organization': {'OrgFullName': 'RAND', 'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Mixed Methods Implementation Evaluation of an Integrated Depression and Microfinance Program for Women in Vietnam',\n",
       "       'OfficialTitle': 'LIFE-DM Implementation Study: A Mixed Methods Implementation Evaluation of an Integrated Depression and Microfinance Program for Women in Vietnam',\n",
       "       'Acronym': 'LIFE-DM'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'November 2019',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'December 7, 2017',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2018',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'March 31, 2019',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'May 11, 2018',\n",
       "       'StudyFirstSubmitQCDate': 'January 2, 2020',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 6, 2020',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'January 2, 2020',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 6, 2020',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Victoria K. Ngo, PhD',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'RAND'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'RAND', 'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Grand Challenges Canada',\n",
       "          'CollaboratorClass': 'OTHER'},\n",
       "         {'CollaboratorName': 'Basic Needs Vietnam',\n",
       "          'CollaboratorClass': 'UNKNOWN'},\n",
       "         {'CollaboratorName': 'Danang Psychiatric Hospital',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This is an implementation project to develop a model to support implementation of LIFE-DM, an evidence-based practice (EBP) program that integrates depression management with microfinance services to address both poverty and depression among low-income women in Vietnam. This evaluation is a mixed methods study that will 1) describe the development of community-partnered implementation process, 2) study the effectiveness of the training and implementation support plan on provider and patient outcomes, and 3) identify factors that impact implementation success.',\n",
       "       'DetailedDescription': 'Livelihood Integration for Effective Depression Management (LIFE-DM) aims to address the dual challenges of poverty and depression faced by women in Vietnam by integrating evidence-based treatment for depression management and microfinance services. With funding from NIMH, the investigators established initial evidence for the effectiveness of LIFE-DM in reducing depression and improving functioning, social support, self-efficacy, and income at six months. These treatment effects were maintained at twelve months, suggesting that the LIFE-DM program may be an effective strategy to break the cycle of depression and poverty in low-income women.\\n\\nFor the Grand Challenges of Canada (GCC) Transition to Scale Grant, the investigators developed a model to scale up the program in the public health and social system across two provinces, Danang and Thua Thien Hue through 1) the training of local trainers from the psychiatric hospital to support local implementation, 2) development of a supervision model, and 3) use of a learning collaborative.\\n\\nTo evaluate the success of the model, the investigators will conduct a mixed methods implementation study that will assess implementation and patient outcomes according to the RE-AIM framework, as well as identify barriers and facilitators to implementation.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['depression', 'poverty']}},\n",
       "      'DesignModule': {'StudyType': 'Observational',\n",
       "       'PatientRegistry': 'Yes',\n",
       "       'TargetDuration': '6 Months',\n",
       "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
       "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '141',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'LIFE-DM Group',\n",
       "          'ArmGroupDescription': \"The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and microfinance loans of 2 million VND. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union.\",\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)',\n",
       "          'InterventionDescription': \"Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['LIFE-DM Group']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Livelihood Integration for Effective Depression Management',\n",
       "            'behavior activation',\n",
       "            'problem solving',\n",
       "            'microfinance']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Provider Adoption of LIFE-DM and Depression Care - Count',\n",
       "          'PrimaryOutcomeDescription': 'Delivery of LIFE-DM and depression care components (Counts of depression care components delivered - # of screening, assessment, LIFEDM, individual therapy, medication, loans)',\n",
       "          'PrimaryOutcomeTimeFrame': 'one year'},\n",
       "         {'PrimaryOutcomeMeasure': 'Provider Adoption of LIFE-DM and Depression Care - Percentage',\n",
       "          'PrimaryOutcomeDescription': 'Delivery of LIFE-DM and depression care components (% of depression care components delivered - screening, assessment, LIFEDM, individual therapy, medication, loans based on eligible cases)',\n",
       "          'PrimaryOutcomeTimeFrame': 'one year'},\n",
       "         {'PrimaryOutcomeMeasure': 'Patient Depression Scores (PHQ) Change from Baseline to 6 month',\n",
       "          'PrimaryOutcomeDescription': 'Patients will be assessed for depression using self-reported depression measure (PHQ). The Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders. The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as \"0\" (not at all) to \"3\" (nearly every day). Total scores are used and they range from 0 to 27, with PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively.',\n",
       "          'PrimaryOutcomeTimeFrame': '0, 6 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Provider Participation',\n",
       "          'SecondaryOutcomeDescription': 'Provider Participation in Training Activities (Count / % of workshop attendance, supervision meetings, and learning collaborative meetings)',\n",
       "          'SecondaryOutcomeTimeFrame': '0-12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Provider Implementation Quality',\n",
       "          'SecondaryOutcomeDescription': 'Supervisor Rated LIFE-DM session adherence and quality. Supervision of groups involve observation of group facilitation by supervisors, who provide adherence and quality ratings of sessions. Each item is assessed on a 4 point scale - 0 (did not do), 1 (delivered but poor), 2 (average), and 3 (excellent). The items are averaged to provide a session specific score of adherence and quality. Session adherence / quality scores are used to compute provider level adherence and quality averages. Each supervisor was expected to provide ratings for a minimum of 3 assessments out of the 12 group sessions. These session ratings are used to compute the average adherence and quality score for each provider.',\n",
       "          'SecondaryOutcomeTimeFrame': 'throughout the study implementation period, about 1 year'},\n",
       "         {'SecondaryOutcomeMeasure': 'Implementation Barriers and Facilitators',\n",
       "          'SecondaryOutcomeDescription': 'Qualitative Interviews of Providers and Program Staff to Assess Barriers and Facilitators of Implementation',\n",
       "          'SecondaryOutcomeTimeFrame': 'one year'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Patient Functioning',\n",
       "          'SecondaryOutcomeDescription': 'Patient - SF-12 - Change in functioning from baseline to 6 months. The SF-12 Health Survey is a 12-item subset of the SF-36v2™ that measures the same eight domains of health (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health). It is a brief, reliable measure of overall health status. Scores are calibrated so that 50 is the average score or norm. This norm-based score allows comparison among the three surveys and across the more than 19,000 studies published in the past 20 years',\n",
       "          'SecondaryOutcomeTimeFrame': '0 and 6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Patient Family Functioning',\n",
       "          'SecondaryOutcomeDescription': \"Patient - McMaster Family Functioning Scale - Change from baseline to 6 months. This is a 12 item scale (on a 4 point scale). the average score across items is used to determine the degree of problematic family functioning. A score of 2.00 or above indicates problematic family functioning. The higher the score, the more problematic the family member perceives the family's overall functioning.\",\n",
       "          'SecondaryOutcomeTimeFrame': '0 and 6 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ndepression - based on Patient Health Questionnaire Total Score = > 9\\nlow-income\\nfemale\\nages 18 - 60\\n\\nExclusion Criteria:\\n\\npsychosis risk\\nmania risk\\nsubstance abuse risk\\nhigh suicide risk\\nphysical disabilities\\nsignificant cognitive impairments',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Female',\n",
       "       'GenderBased': 'Yes',\n",
       "       'GenderDescription': 'Female',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '60 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult']},\n",
       "       'StudyPopulation': 'Study participants are recruited from community health clinics that are implementing LIFE-DM and depression care services in the GCC funded transition to scale grant. These participants are 18-60 years old, have elevated depressive symptoms (PHQ 9 > 9), have economic disadvantage, and are interested in participating in an integrated depression and livelihood program. Patients with severe mental illness, such as psychosis, mania, substance abuse, or high risk of suicide are also excluded and referred to psychiatric hospital for higher level of care. Those who have disabilities, significant cognitive impairments, and chronic illness that may interfere with their ability to participate in group therapy are also excluded and referred to other more individualized support.',\n",
       "       'SamplingMethod': 'Non-Probability Sample'},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Victoria Ngo, PhD',\n",
       "          'OverallOfficialAffiliation': 'RAND',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Commune Health Stations',\n",
       "          'LocationCity': 'Huế',\n",
       "          'LocationState': 'Thua Thien Hue',\n",
       "          'LocationCountry': 'Vietnam'},\n",
       "         {'LocationFacility': 'Commune Health Stations',\n",
       "          'LocationCity': 'Da Nang',\n",
       "          'LocationCountry': 'Vietnam'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 7,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02239367',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '1401014663'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'P30MH085943',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=P30MH085943&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'Weill Medical College of Cornell University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Depression Decision Aid: Feasibility Pilot',\n",
       "       'OfficialTitle': 'Electronic Depression Decision Aid for Nurses in Primary Care: Development and Implementation in a Diverse Low-Income Population'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'January 2017',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'May 30, 2014',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 13, 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'April 13, 2015',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'September 4, 2014',\n",
       "       'StudyFirstSubmitQCDate': 'September 10, 2014',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 12, 2014',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'January 23, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 25, 2017',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Weill Medical College of Cornell University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The goal of this proposed pilot study is to test the feasibility and acceptability of a Depression Decision Aid (DDA) protocol integrated into the Electronic Health Record (EHR) and used by nurses with depressed ambulatory care patients. The Depression Decision Aid protocol is a streamlined adaptation of an in-person Shared Decision-Making (SDM) intervention, and its goal is to increase patient involvement in clinically appropriate treatment decision-making as a way of strengthening treatment engagement and outcomes. The protocol guides ambulatory care nurses in helping depressed patients (Patient Health Questionnaire-9 [PHQ-9] >10) develop informed treatment preferences through a process of education and values clarification. We will target patients in the general medical clinic, whether currently receiving depression treatment or not, because depression is highly prevalent but often poorly managed in this population.',\n",
       "       'DetailedDescription': \"The aims of this project are to evaluate the acceptability and feasibility of an electronic Depression Decision Aid protocol with nurses and patients using questionnaire and administrative data.\\n\\nOne to two nurses will deliver the Decision Aid protocol to 40 low-income patients (aged 21 and over) scoring >10 via routine PHQ-9 screening. Consenting nurses will be assessed regarding their satisfaction with the protocol following its use with each patient subject. Nurse fidelity to the protocol will be evaluated via their documentation of protocol use in the EHR. Consenting patient subjects will be assessed at baseline; week 1 to determine their decision about depression treatment, satisfaction with the decision-making process; and week 12 to determine treatment initiation or change, treatment adherence, and depressive status. Medical records will also be examined for documentation of medication prescription and other depression treatments.\\n\\nThe study will test the following hypothesis concerning the Depression Decision Aid protocol:\\n\\n1. Feasibility and Acceptability: a) At least 85% of each nurse's intervention sessions will meet fidelity standards via Electronic Health Record (EHR) data; b) Nurses will report high levels of satisfaction with the Decision Aid; c) Patients will report high levels of satisfaction with the decision-making process;\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '18',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression Decision Aid protocol',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention. Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower the elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression Decision Aid']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Depression Decision Aid',\n",
       "          'InterventionDescription': 'The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression Decision Aid protocol']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Shared Decision Making']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Use of Depression Decision Aid protocol',\n",
       "          'PrimaryOutcomeDescription': \"The number of nurse's intervention sessions based on Electronic Health Record data\",\n",
       "          'PrimaryOutcomeTimeFrame': '12 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Satisfaction with the Decision Aid Measure',\n",
       "          'SecondaryOutcomeDescription': 'The Nurse Satisfaction Scale includes a measure of usefulness, clarity, ease of use, and feasibility in terms of timing when using the Decision Aid.',\n",
       "          'SecondaryOutcomeTimeFrame': '12 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n21 years and older\\nMedical outpatient presenting to the Lincoln Hospital ambulatory care clinic or geriatric sub-specialty clinic\\nScreen positive for depression (Patient Health Questionnaire-9 score of 10 or greater)\\n\\nExclusion Criteria:\\n\\nPresence of significant alcohol or substance abuse, psychotic disorder, or bipolar disorder\\nHigh suicide risk\\nCognitive impairment: Mini Mental Status Exam (MMSE) score less than 24.\\nAcute or severe medical illness (ie. delirium, metastatic cancer, decompensated cardiac, liver, or kidney failure, major surgery, stroke, or myocardial infarction during the three months prior to entry.\\nInability to speak English or Spanish\\nAphasia interfering with communication',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '21 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Patrick J Raue, Ph.D.',\n",
       "          'OverallOfficialAffiliation': 'Weill Medical College of Cornell University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Lincoln Hospital- the New York City Health and Hospitals Corporation (HHC)',\n",
       "          'LocationCity': 'Bronx',\n",
       "          'LocationState': 'New York',\n",
       "          'LocationZip': '10451',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 8,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02378272',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'RS 1938-2013'},\n",
       "       'Organization': {'OrgFullName': 'Göteborg University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Care Manager - Coordinating Care for Person Centered Management of Depression in Primary Care',\n",
       "       'OfficialTitle': 'RCT on Care Manager Organization for Management of Mild-moderate Depression in the Primary Care Setting, Sweden',\n",
       "       'Acronym': 'PRIM-CARE'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'April 2019',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'December 2014'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 31, 2017',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 31, 2018',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'February 2, 2015',\n",
       "       'StudyFirstSubmitQCDate': 'March 3, 2015',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 4, 2015',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'April 25, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 29, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Göteborg University',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': \"The aim of the project is to explore if a complementary addition of a care manager for depression treatment in the primary care setting has positive effects concerning reduction of the patients' depressive symptoms as well as improvement of daily function and quality of life in a short- and long-term perspective compared with the traditional Swedish primary care organization. The aim is also to evaluate the care manager function in a health economic perspective.\\n\\nThe specific aims are to develop and evaluate an evidence-based care manager program for patients with mild to moderate depression and to compare the evidence-based care manager program to treatment as usual (TAU) in terms of their short- and long-term effects on symptom remission, treatment adherence, care satisfaction, and self-efficacy as well as to perform a cost - effectiveness analysis of the care manager program, i.e. to evaluate the effects of the program on patients' health in relation to the running costs of the program.\",\n",
       "       'DetailedDescription': \"Methods The research questions will be tested in a randomised controlled trial with follow ups 3 and 6 months in the primary care setting in cooperation between universities of Gothenburg, Karolinska Institute and primary care centres (PCC) of regions/county councils of Västra Götaland, and Dalarna.\\n\\nDesign A cluster randomized controlled trial of two groups (intervention and control). Randomization will be at the level of the primary care centers (PCCs).\\n\\nPopulation of study Patients aged 18 and up that visit one of 20 different urban and rural PCCs.\\n\\nRandomization All PCCs in the participating regions without employed onsite mental health professionals are invited to participate in the study. Around twenty practices will be matched into 10 blocks by depression treatment practices, thereafter 1 practice from each block will be randomly assigned to receive the care manager intervention program.\\n\\nIntervention At the intervention practices, a district nurse will apply around 15-25% of working time as care coordinator for management of care for the patients with depression. Before patient recruitment begins, physicians and the nurse/district nurse (care manager) will participate in sessions for training in providing clinical services (patient information and education on patient's preferred treatment, assessment of patient's depressive symptoms and regular telephone contacts, follow up visits etc).\\n\\nRecruitment of patients and Data collection Patients aged 18 and up that visit primary health care centres and are diagnosed by the General Practitioner (GP) with light/medium depression disorder according to PRIME-MD (4). The patients will be monitored up to 6 months after inclusion in the study by an individual interview (first visit, 3 and 6 months).\\n\\nAll parameters will be assessed at baseline and 3 and 6 months; prescription of antidepressants, number of days of labour lost, socio-demographic and economic variables, alcohol consumption, physical activity, and ethnicity. BDI-II, EuroQoL-5D, Work Ability Instrument (WAI) Karasek Job strain Model , medication, other treatment (psychological, counselling, or other).\\n\\nFor somatic health reasons, also blood pressure and p-glucose will be monitored, and blood samples for bio-bank storage.\\n\\nOutcome criteria Change in: depression symptoms (BDI-II), work ability index (WAI), Job strain (Karasek), EQ-5D, QALYs from baseline to 3 and 6 months. Amount of sick listing (days, %), days of labour lost.\\n\\nStatistical analysis Analysis of covariance, controlling for baseline value, will be used to estimate the overall treatment effectiveness (difference in score) at final follow-up. Subgroup analysis by gender as well as age adjustments will also be performed.\\n\\nPower calculation The primary variable is the level of depression (as measured by the BDI-II) and analyzed in an ANCOVA model with repeated measures. In order to detect an effect of 3 units in the difference between the two groups, with a power of 80% and a significance level of 10% (two-sided) about 200 patients is needed in each group (9). The underlying assumption is a standard deviation in the group of 10 units, a within-subject correlation of 0.4, and a within-cluster-correlation of 0.1, i.e. a design effect of 1.9 to correct for having a cluster analysis.\\n\\nCost-effectiveness analysis A cost- effectiveness analysis (CEA) with quality-adjusted life years (QALY) as measure of effect will be performed.\\n\\nThe region Västra Götaland has proclaimed interest in the study, and financially supports the study.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Care Manager',\n",
       "         'Primary Care',\n",
       "         'Depressive symptoms',\n",
       "         'quality of life',\n",
       "         'return to work']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '376',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Care manager for depression',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'A district nurse will apply around 15-25% of working time as care coordinator (care manager for depression) at PCC for management of care for all recruited patients with depression',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: care manager for depression']}},\n",
       "         {'ArmGroupLabel': 'Treatment As Usual',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Management of recruited patients with depression continued as usually applied at PCC'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'care manager for depression',\n",
       "          'InterventionDescription': \"District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Care manager for depression']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change of level of depression (Self-reported level of depressive symptoms measured by Beck Depression Inventory II)',\n",
       "          'PrimaryOutcomeDescription': 'Self-reported level of depressive symptoms measured by Beck Depression Inventory II',\n",
       "          'PrimaryOutcomeTimeFrame': '0- 6 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Sick-listing (Amount of sick-listing days during 0-6 months observation period)',\n",
       "          'SecondaryOutcomeDescription': 'Amount of sick-listing days during 0-6 months observation period',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change of level of job strain (Perception of job strain measured by Karasek Job Strain Model)',\n",
       "          'SecondaryOutcomeDescription': 'Perception of job strain measured by Karasek Job Strain Model',\n",
       "          'SecondaryOutcomeTimeFrame': '0-6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change of level of Quality of Life (Self-reported level of perceived Quality of Life measured by EQ-5D)',\n",
       "          'SecondaryOutcomeDescription': 'Self-reported level of perceived Quality of Life measured by EQ-5D',\n",
       "          'SecondaryOutcomeTimeFrame': '0- 6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change of level of Work Ability (Self-reported level of perceived work ability measured by Work Ability Index)',\n",
       "          'SecondaryOutcomeDescription': 'Self-reported level of perceived work ability measured by Work Ability Index',\n",
       "          'SecondaryOutcomeTimeFrame': '0 - 6 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ndiagnosed mild-moderate depression,\\n18 years an up,\\nattending primary care center\\n\\nExclusion Criteria:\\n\\nschizophrenia,\\nabuse/addiction,\\npsychosis,\\nbipolar syndrome,\\nsuicidal ideation or earlier suicide attempt,\\nongoing deep depression,\\ngeneralized anxiety syndrome,\\nnot communicable in Swedish',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Cecilia Björkelund',\n",
       "          'OverallOfficialAffiliation': 'Göteborg University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Department of Primary Health Care, Sahlgrenska Academy',\n",
       "          'LocationCity': 'Gothenburg',\n",
       "          'LocationState': 'Region Västra Götaland',\n",
       "          'LocationZip': '40530',\n",
       "          'LocationCountry': 'Sweden'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '29426288',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Björkelund C, Svenningsson I, Hange D, Udo C, Petersson EL, Ariai N, Nejati S, Wessman C, Wikberg C, André M, Wallin L, Westman J. Clinical effectiveness of care managers in collaborative care for patients with depression in Swedish primary health care: a pragmatic cluster randomized controlled trial. BMC Fam Pract. 2018 Feb 9;19(1):28. doi: 10.1186/s12875-018-0711-z.'},\n",
       "         {'ReferencePMID': '30420353',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Holst A, Ginter A, Björkelund C, Hange D, Petersson EL, Svenningsson I, Westman J, André M, Wikberg C, Wallin L, Möller C, Svensson M. Cost-effectiveness of a care manager collaborative care programme for patients with depression in primary care: economic evaluation of a pragmatic randomised controlled study. BMJ Open. 2018 Nov 12;8(11):e024741. doi: 10.1136/bmjopen-2018-024741.'},\n",
       "         {'ReferencePMID': '31351444',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Svenningsson I, Petersson EL, Udo C, Westman J, Björkelund C, Wallin L. Process evaluation of a cluster randomised intervention in Swedish primary care: using care managers in collaborative care to improve care quality for patients with depression. BMC Fam Pract. 2019 Jul 27;20(1):108. doi: 10.1186/s12875-019-0998-4.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'T6054',\n",
       "          'ConditionBrowseLeafName': 'Quality of Life',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 9,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01277432',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'CRE-2010-281'},\n",
       "       'Organization': {'OrgFullName': 'Chinese University of Hong Kong',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Prevalence Study of Depression in Chinese Patients With Type 2 Diabetes (HK13)',\n",
       "       'OfficialTitle': 'A Multicentre Study to Investigate the Prevalence and Factors Associated With Depression in Chinese Patients With Type 2 Diabetes',\n",
       "       'Acronym': 'DD2'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'August 2015',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'July 2010'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'February 2015',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'January 14, 2011',\n",
       "       'StudyFirstSubmitQCDate': 'January 14, 2011',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 17, 2011',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'August 20, 2015',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 24, 2015',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Juliana Chan',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Professor Chan',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Chinese University of Hong Kong'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Chinese University of Hong Kong',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Asia Diabetes Foundation',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': \"The investigators aim to:\\n\\nEstimate the prevalence of depression in a consecutive cohort of Chinese patients diagnosed with Type 2 Diabetes (T2D) living in areas of China with different socioeconomical affluence\\nExamine patients' awareness of the frequent coexistence of these 2 conditions\\nAnalyze the associations between depression and T2D, in particularly the role of metabolic control, socioeconomical status and cognitive-psychological-behavioral factors\\nTo document the predisposing, precipitating and perpetuating factors for depression and their interrelationships in Chinese type 2 diabetic patients\",\n",
       "       'DetailedDescription': 'Overall objectives of this multicentre study are to document;\\n\\nthe prevalence and diagnosis rates of depression in type 2 diabetic (T2D) patients attending 7 centres in 4 major cities in China including Hong Kong (HK), Shanghai (SH), Guangzhou (GZ) and Beijing (BJ)\\nthe predisposing, precipitating and perpetuating factors for depression and their interrelationships in Chinese T2D patients\\n\\nThis study includes two phases. In the phase I pilot study, the investigators shall confirm and compare the validity of Patient Health Questionnaire (PHQ-9) and Clinical Epidemiological Scale for Depression (CESD) in predicting depression in Chinese T2D patients using the SCID as a gold standard. Other questionaires which measure personal and external factors, diabetes associated distress and anxiety, quality of life, mental wellness, self efficacy, health-related behavior and compliance will also be used to document possible predisposing, precipitating and perpetuating factors for depression in diabetes. These results will be used to select a set of tools which are most informative in the evaluation of depression and mental wellness in T2D patients based on their predictions for health behavior, compliance and metabolic control. A random sample of 100 T2D patients will be recruited from 3 Diabetes Centres in GZ, BJ and HK who will complete a full set of questionnaires and structured clinical assessments using a web-based electronic portal. In each of the three centres, all patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ>10 and/or CES>16) and a random sample of 20 subjects with no or mild symptoms will undergo face-to-face interview by psychiatrists using the following instruments: SCID, BDI, SSI-28 (somatization), Coping (Brief Cope 28, Chinese version).\\n\\nIn Phase II, the investigators shall use a subset of the most informative questionaires to document the rates of depression (diagnosed and undiagnosed) and cognitive-psychological-behavioral factors in a consecutive cohort of Chinese patients with T2D and its associations with metabolic control and psychological behavioral factors. In each of the 7 participating centres in HK, SH, BJ and GZ, 500 consecutive patients will undergo comprehensive clinical assessments for risk factors, complications and medications the JADE (Joint Asia Diabetes Evaluation) e-portal, giving a total of 3500 patients.\\n\\nThis survey which documents the rate of depression in T2D patients using similar methodologies will provide a comprehensive data set for exploratory analysis of the multicausality and heterogeneity of clinical presentation and risk factors in Chinese populations. Once this cohort is established and subject to availability of future funding, they can be followed up prospectively to validate and discover risk factors for new onset of depression. Apart from raising awareness, these data are essential in our design of care models and interventions to tailor the unmet needs of these patients. Data from this study will also provide insights into the effects of rapid acculturation and migration on the double burden of diabetes and depression in Chinese populations.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Diabetes',\n",
       "         'Depression']},\n",
       "       'KeywordList': {'Keyword': ['Diabetes', 'Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Observational',\n",
       "       'PatientRegistry': 'No',\n",
       "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
       "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '3218',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Psychiatrist interview',\n",
       "          'ArmGroupDescription': \"All patients will receive the same assessments as the 'active comparator' arm, but in addition those patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ>10 and/or CES>16) and a random sample of subjects with no or mild symptoms will also undergo a face-to-face interview by a trained clinician or psychiatrist using the following instruments:\\n\\nMINI\\nSSI-28 (somatization)\",\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Psychiatrist Interview']}},\n",
       "         {'ArmGroupLabel': 'Depression screening',\n",
       "          'ArmGroupDescription': 'All study participants will undergo a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal.\\n\\nAll patients will also undergo detailed psychological and behavioral assessments using validated questionnaires.\\n\\nSeveral specialist questionnaires will also be conducted with all patients, including those on depression, self care and quality of life;\\n\\nPatient Health Questionnaire (PHQ-9)\\nDepression Anxiety and Stress Scale (DASS-21)\\nDiabetes Distress Scale (DDS-17)\\nLife events questions (Inter-Heart Study)\\nDiabetes Empowerment Scale (C-DES 20)\\nSummary of Diabetes Self Care Activities (SDSCA-15)\\nEuroqol-5D (EQ-5D)',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression screening - control']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Psychiatrist Interview',\n",
       "          'InterventionDescription': 'Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:\\n\\nMINI\\nSSI-28 (somatization)',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Psychiatrist interview']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Depression screening - control',\n",
       "          'InterventionDescription': 'All study participants will undergo;\\n\\na comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal\\na detailed psychological and behavioral assessments using validated questionnaires\\nseveral specialist questionnaires on depression, self care and quality of life',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression screening']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression and psychological well-being',\n",
       "          'PrimaryOutcomeDescription': 'Depression (PHQ-9, CESD)\\nDepression Anxiety and Stress Scale (DASS-21)\\nDiabetes Stress Scale (DSS-17)',\n",
       "          'PrimaryOutcomeTimeFrame': '1 year'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Percentage of patients who attain 2 or more of the 'ABC' targets\",\n",
       "          'SecondaryOutcomeDescription': 'Percentage of patients who attain 2 or more of the following 3 targets:\\n\\nHbA1c <7%\\nBP <130/80 mmHg\\nLDL cholesterol <2.6 mmol/L',\n",
       "          'SecondaryOutcomeTimeFrame': '1 year'},\n",
       "         {'SecondaryOutcomeMeasure': 'Self care and Efficacy',\n",
       "          'SecondaryOutcomeDescription': 'Diabetes Empowerment Scale (C-DES)\\nSummary of Diabetes Self Care Activities (SDSCA-15)',\n",
       "          'SecondaryOutcomeTimeFrame': '1 year'},\n",
       "         {'SecondaryOutcomeMeasure': 'Quality of life',\n",
       "          'SecondaryOutcomeDescription': 'Using EuroQol-5D (EQ-5D) tool',\n",
       "          'SecondaryOutcomeTimeFrame': '1 year'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients diagnosed with type 2 diabetes\\nAged ≥25 and <75 years inclusive\\nChinese ethnicity\\n\\nExclusion Criteria:\\n\\nPatients with mental/physical handicap and/or difficulty in communication such as deafness, mental retardation\\nPatients with disabling diseases or reduced life expectancy such as severe heart failure, stroke, respiratory diseases, or late stages of cancer\\nPatients diagnosed with type 1 diabetes, defined as presentation with diabetic ketoacidosis or unprovoked ketosis or requirement of continuous insulin requirement within 12 months of diagnosis',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '25 Years',\n",
       "       'MaximumAge': '75 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
       "       'StudyPopulation': 'Tertiary Hospitals and community centre',\n",
       "       'SamplingMethod': 'Probability Sample'},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Juliana Chan, MD',\n",
       "          'OverallOfficialAffiliation': 'Chinese University of Hong Kong',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': '1st Affiliated Hosp, Peking University',\n",
       "          'LocationCity': 'Beijing',\n",
       "          'LocationCountry': 'China'},\n",
       "         {'LocationFacility': 'China-Japan Friendship Hospital',\n",
       "          'LocationCity': 'Beijing',\n",
       "          'LocationCountry': 'China'},\n",
       "         {'LocationFacility': 'Peking Union Hospital',\n",
       "          'LocationCity': 'Beijing',\n",
       "          'LocationCountry': 'China'},\n",
       "         {'LocationFacility': \"Peking University People's Hospital\",\n",
       "          'LocationCity': 'Bejing',\n",
       "          'LocationCountry': 'China'},\n",
       "         {'LocationFacility': 'Third Affiliated Hospital of Sun Yat-Sen University',\n",
       "          'LocationCity': 'Guangzhou',\n",
       "          'LocationCountry': 'China'},\n",
       "         {'LocationFacility': \"Shanghai Sixth People's Hospital\",\n",
       "          'LocationCity': 'Shanghai',\n",
       "          'LocationCountry': 'China'},\n",
       "         {'LocationFacility': 'YCK Diabetes Assessment Centre, Prince of Wales Hospital',\n",
       "          'LocationCity': 'Shatin',\n",
       "          'LocationCountry': 'Hong Kong'}]}},\n",
       "      'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Works of the Asia Diabetes Foundation',\n",
       "          'SeeAlsoLinkURL': 'http://www.adf.org.hk'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003920',\n",
       "          'ConditionMeshTerm': 'Diabetes Mellitus'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000044882',\n",
       "          'ConditionAncestorTerm': 'Glucose Metabolism Disorders'},\n",
       "         {'ConditionAncestorId': 'D000008659',\n",
       "          'ConditionAncestorTerm': 'Metabolic Diseases'},\n",
       "         {'ConditionAncestorId': 'D000004700',\n",
       "          'ConditionAncestorTerm': 'Endocrine System Diseases'},\n",
       "         {'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5702',\n",
       "          'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5698',\n",
       "          'ConditionBrowseLeafName': 'Diabetes Mellitus',\n",
       "          'ConditionBrowseLeafAsFound': 'Diabetes',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M10222',\n",
       "          'ConditionBrowseLeafName': 'Metabolic Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M23990',\n",
       "          'ConditionBrowseLeafName': 'Glucose Metabolism Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M6445',\n",
       "          'ConditionBrowseLeafName': 'Endocrine System Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18',\n",
       "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC19',\n",
       "          'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
       "   {'Rank': 10,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02232854',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '1130230'},\n",
       "       'Organization': {'OrgFullName': 'University of Chile',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Training and Supervision Program for Depression Management',\n",
       "       'OfficialTitle': 'Comprehensive Technology-Assisted Training and Supervision Program to Enhance Depression Management in Primary Care'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'October 2017',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'April 2014',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2016',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'June 2016',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'August 7, 2014',\n",
       "       'StudyFirstSubmitQCDate': 'September 2, 2014',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 5, 2014',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'October 24, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 25, 2017',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Graciela Rojas Castillo',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Dr.med. Psychyatrist',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Chile'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Chile',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'According to the literature the management of depressive disorders at primary care level is not always consistent with guidelines. The main objective of this study is to test whether a Comprehensive Technology-Assisted Training and Supervision Program will improve depression management in Primary Health Care clinics in Santiago, Chile.',\n",
       "       'DetailedDescription': 'A cluster randomized controlled clinical trial will be conducted in four Primary Health Care (PHC) clinics in Santiago, Chile.\\n\\nThe sample selection of the PHC clinics will be performed in two steps. Firstly, two urban municipalities of Santiago Metropolitan Region, Chile, will be randomly selected if they work with the Faculty of Medicine of the U.Chile and have at least two PHC.Municipalities with a high Human Development Index, high percentage of immigrants and older population, and Psychiatry residents working in PHC , will be excluded.Secondly in each selected municipalities,two PHC will be randomly selected for the active and control arm.\\n\\nTo detect a difference of 20%, in a one-sided model, with an alpha of 5% and power of 80%, 152 depressed persons, 76 to each group, will be required for the study. A design effect of 2.42 was estimated. After applying the design effect the sample needed increased to 368 depressed persons. Considering a retention rate of approximately 85%, 434 depressed cases will be needed required for the study, hence 109 cases in each of the 4 primary health care clinics.\\n\\nAnalysis and presentation of the results will be in accordance with CONSORT guidelines for randomized clinical trials, with the primary comparative analysis being conducted on an intention to treat basis and due emphasis placed on confidence intervals for the between-arm comparisons.\\n\\nInitially descriptive analysis to assess the balance between two groups will be conducted. The primary analysis will employ multilevel multivariable lineal regression to investigate differences in the PHQ-9 scores between groups at 3 and 6 months after randomization, adjusting for baseline outcome variable scores. Sensitivity analysis making different assumptions will be conducted to investigate the potential effects of missing data. Similar analysis will be done for the secondary outcomes measures.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '256',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression training/supervision program',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'A complex intervention, which will include:\\n\\nPrimary Health Care team training in depression\\nA focus group, after training\\nTelephone monitoring of patients\\nWeb-based supervision of clinicians',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression training/supervision program']}},\n",
       "         {'ArmGroupLabel': 'Usual Care',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Patients in the control group will receive all the interventions that are guaranteed for persons with depression in Chile: treatment in Primary Health Care clinics with the Primary Health Care team and referral to the regional specialized psychiatric service.'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Depression training/supervision program',\n",
       "          'InterventionDescription': 'The intervention will be composed of:\\n\\nTraining of Primary Health Care teams to ensure compliance to the \"Clinical Guidelines of the Ministry of Health for the Treatment of Depression\". Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.\\nAfter the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.\\nPrimary Health Care clinics\\' trained administrative staff will contact patients from a call-center to support treatment adherence.\\nPsychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients\\' progress, and their response to treatment.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression training/supervision program']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change from Baseline Depressive Symptomatology at 3 months',\n",
       "          'PrimaryOutcomeDescription': 'Depressive symptomatology measured with the Patient Health Questionnaire - Nine Item (PHQ-9) at 3 months after patient recruitment.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline , 3 months'},\n",
       "         {'PrimaryOutcomeMeasure': 'Change from Baseline Depressive Symptomatology at 6 months',\n",
       "          'PrimaryOutcomeDescription': 'Depressive symptomatology measured with the Patient Health Questionnaire - Nine Item (PHQ-9) at 6 months after patient recruitment.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline, 6 months.'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Adherence to depression treatment at patient's level\",\n",
       "          'SecondaryOutcomeTimeFrame': '3 and 6 months after baseline.'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change from Baseline Quality of life at 3 and 6 months',\n",
       "          'SecondaryOutcomeDescription': \"Quality of life at patient's level measured with the Health Survey, Short form (SF-36), at 3 months and 6 months after patient recruitment.\",\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline , 3 months, 6 months.'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change from Baseline Clinical Outcomes at 3 and 6 months',\n",
       "          'SecondaryOutcomeDescription': \"Clinical outcomes at patient's level measured with the Outcome Questionnaire-45.2 (OQ-45.2), at 3 months and 6 months after patient recruitment.\",\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline , 3 months, 6 months.'},\n",
       "         {'SecondaryOutcomeMeasure': \"Use of Health Care services at patient's level\",\n",
       "          'SecondaryOutcomeDescription': \"Use of Health Care services at patient's level measured with and ad-hoc built questionnaire.\",\n",
       "          'SecondaryOutcomeTimeFrame': '3 and 6 months after baseline'},\n",
       "         {'SecondaryOutcomeMeasure': 'Rate of treated depressed cases at Primary Care team level',\n",
       "          'SecondaryOutcomeTimeFrame': '12 months before randomization and 12 months after.'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nsigning written informed consent\\nage between 18-65 years\\ncurrent depressive episode, according to the Mini-International Neuropsychiatric Interview (MINI)\\n\\nExclusion Criteria:\\n\\ncurrent depression treatment\\nno access to telephone',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'CESFAM Garín',\n",
       "          'LocationCity': 'Quinta Normal',\n",
       "          'LocationState': 'Santiago',\n",
       "          'LocationCountry': 'Chile'},\n",
       "         {'LocationFacility': 'CESFAM Lo Franco',\n",
       "          'LocationCity': 'Quinta Normal',\n",
       "          'LocationState': 'Santiago',\n",
       "          'LocationCountry': 'Chile'},\n",
       "         {'LocationFacility': 'CESFAM Barros Luco',\n",
       "          'LocationCity': 'San Miguel',\n",
       "          'LocationState': 'Santiago',\n",
       "          'LocationCountry': 'Chile'},\n",
       "         {'LocationFacility': 'CESFAM Recreo',\n",
       "          'LocationCity': 'San Miguel',\n",
       "          'LocationState': 'Santiago',\n",
       "          'LocationCountry': 'Chile'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26201546',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Rojas G, Martínez P, Vöhringer PA, Martínez V, Castro-Lara A, Fritsch R. Comprehensive technology-assisted training and supervision program to enhance depression management in primary care in Santiago, Chile: study protocol for a cluster randomized controlled trial. Trials. 2015 Jul 24;16:311. doi: 10.1186/s13063-015-0845-4.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 11,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01152307',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'CSR-DQ1-002'},\n",
       "       'Organization': {'OrgFullName': 'University of Massachusetts, Boston',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Measuring Quality of Decisions About Treatment of Depression',\n",
       "       'OfficialTitle': 'Measuring Quality of Decisions About Treatment of Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2012',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'June 2010'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2010',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2010',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 22, 2010',\n",
       "       'StudyFirstSubmitQCDate': 'June 25, 2010',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 29, 2010',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'June 12, 2012',\n",
       "       'ResultsFirstSubmitQCDate': 'July 13, 2012',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 20, 2012',\n",
       "        'ResultsFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 13, 2012',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 20, 2012',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Carol Cosenza',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Project Manager',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Massachusetts, Boston'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Massachusetts, Boston',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Foundation for Informed Medical Decision Making',\n",
       "          'CollaboratorClass': 'OTHER'},\n",
       "         {'CollaboratorName': 'Massachusetts General Hospital',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of this randomized controlled trial is to examine the impact of a patient decision aid on the quality of decisions about managing symptoms of depression. In particular, we will examine whether the decision aid increases knowledge about depression/managing depression symptoms and concordance between goals and treatment choices.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Depressive disorder',\n",
       "         'Decision Making',\n",
       "         'Decision Aids',\n",
       "         'Decision Quality Instrument']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '405',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Decision Aid',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Group receiving the decision aid (DVD/booklet)',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: DVD/Booklet: Coping with Symptoms of Depression']}},\n",
       "         {'ArmGroupLabel': 'Control',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Group not receiving the decision aid (DVD/booklet)'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'DVD/Booklet: Coping with Symptoms of Depression',\n",
       "          'InterventionDescription': 'DVD and booklet that provides information about treatment choices for depression symptoms',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Decision Aid']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Decision aids',\n",
       "            'Shared decision making programs']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression Knowledge',\n",
       "          'PrimaryOutcomeDescription': 'Total knowledge score from factual questions about depression and methods for managing depression symptoms. Score is the percent of knowledge items answered correctly (0 - 100%).',\n",
       "          'PrimaryOutcomeTimeFrame': '2 weeks, on average'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Value Concordance',\n",
       "          'SecondaryOutcomeDescription': \"Measure of how concordant respondents' actual decisions about treatment for their depression are with their stated beliefs\",\n",
       "          'SecondaryOutcomeTimeFrame': '2 weeks, on average'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAged 18+\\nIn the last 12 months, talked to a health care provider about starting or stopping a treatment (prescription medicine for depression or counseling)\\n\\nExclusion Criteria:\\n\\nnone',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Patricia M Gallagher, PhD',\n",
       "          'OverallOfficialAffiliation': 'Center for Survey Research, University of Massachusetts, Boston',\n",
       "          'OverallOfficialRole': 'Study Director'},\n",
       "         {'OverallOfficialName': 'Karen R Sepucha, PhD',\n",
       "          'OverallOfficialAffiliation': 'Massachusetts General Hospital',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Center for Survey Research - University of Massachusetts Boston',\n",
       "          'LocationCity': 'Boston',\n",
       "          'LocationState': 'Massachusetts',\n",
       "          'LocationZip': '02125',\n",
       "          'LocationCountry': 'United States'}]}}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'Eligible patients received a mailed survey and were randomly selected to receive a DVD or no DVD and booklet about depression.',\n",
       "       'FlowRecruitmentDetails': 'Patients were recruited through online and newspaper ads by the Center for Survey Research in 17 cities: Atlanta, Baltimore, Boston, Chicago, Dallas-Ft. Worth, Denver, Detroit, Ft. Myers, Houston, Los Angeles, Minneapolis, New York, Phoenix, Portland, Raleigh-Durham, San Francisco, Washington, D.C. August 5, 2010-Jan 10, 2011.',\n",
       "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Decision Aid',\n",
       "          'FlowGroupDescription': 'Group receiving the decision aid (DVD/booklet)'},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Control',\n",
       "          'FlowGroupDescription': 'Group not receiving the decision aid (DVD/booklet)'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '191'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '214'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '191'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '214'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '0'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '0'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Decision Aid',\n",
       "          'BaselineGroupDescription': 'Group receiving the decision aid (DVD/booklet)'},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Control',\n",
       "          'BaselineGroupDescription': 'Group not receiving the decision aid (DVD/booklet)'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '191'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '214'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '405'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '186'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '209'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '395'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '10'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Age Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '39.5',\n",
       "                   'BaselineMeasurementSpread': '13.4'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '43.5',\n",
       "                   'BaselineMeasurementSpread': '16.8'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '42',\n",
       "                   'BaselineMeasurementSpread': '15.4'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '122'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '144'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '266'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '69'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '70'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '139'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '191'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '214'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '405'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Depression Knowledge',\n",
       "          'OutcomeMeasureDescription': 'Total knowledge score from factual questions about depression and methods for managing depression symptoms. Score is the percent of knowledge items answered correctly (0 - 100%).',\n",
       "          'OutcomeMeasurePopulationDescription': 'Participants were randomized to receive the DVD and booklet.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'percent of correct responses',\n",
       "          'OutcomeMeasureTimeFrame': '2 weeks, on average',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Decision Aid',\n",
       "             'OutcomeGroupDescription': 'Group receiving the decision aid (DVD/booklet)'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Control',\n",
       "             'OutcomeGroupDescription': 'Group not receiving the decision aid (DVD/booklet)'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '191'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '214'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '67.0',\n",
       "                   'OutcomeMeasurementSpread': '14.1'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '63.6',\n",
       "                   'OutcomeMeasurementSpread': '12.5'}]}}]}}]},\n",
       "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
       "               'OG001']},\n",
       "             'OutcomeAnalysisGroupDescription': 'We tested for a difference in the mean total knowledge score between the decision aid and control groups using independent t-test (2 sided). With 100 patients in each arm, the study had more than 90% power to detect a 10% difference in knowledge assuming a common standard deviation of 18%.',\n",
       "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
       "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
       "             'OutcomeAnalysisPValue': '0.01',\n",
       "             'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided',\n",
       "             'OutcomeAnalysisParamType': 'Mean Difference (Net)',\n",
       "             'OutcomeAnalysisParamValue': '3.42',\n",
       "             'OutcomeAnalysisCIPctValue': '95',\n",
       "             'OutcomeAnalysisCINumSides': '2-Sided',\n",
       "             'OutcomeAnalysisCILowerLimit': '0.76',\n",
       "             'OutcomeAnalysisCIUpperLimit': '6.09',\n",
       "             'OutcomeAnalysisDispersionType': 'Standard Deviation',\n",
       "             'OutcomeAnalysisDispersionValue': '1.6'}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Value Concordance',\n",
       "          'OutcomeMeasureDescription': \"Measure of how concordant respondents' actual decisions about treatment for their depression are with their stated beliefs\",\n",
       "          'OutcomeMeasureReportingStatus': 'Not Posted',\n",
       "          'OutcomeMeasureTimeFrame': '2 weeks, on average'}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventsTimeFrame': 'August 5, 2010 through January 10, 2011.',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Decision Aid',\n",
       "          'EventGroupDescription': 'Group receiving the decision aid (DVD/booklet)',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '191',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '191'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Control',\n",
       "          'EventGroupDescription': 'Group not receiving the decision aid (DVD/booklet)',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '214',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '214'}]}},\n",
       "      'MoreInfoModule': {'LimitationsAndCaveats': {},\n",
       "       'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
       "        'AgreementRestrictiveAgreement': 'No'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Dr. Karen Sepucha',\n",
       "        'PointOfContactOrganization': 'Massachusetts General Hospital',\n",
       "        'PointOfContactEMail': 'ksepucha@partners.org',\n",
       "        'PointOfContactPhone': '617-724-3350'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 12,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01342536',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '2011-0109, 2011-0234'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MD005905-01A1',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MD005905-01A1&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'University of Wisconsin, Madison',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'African American Depression Intervention Trial (AADI)',\n",
       "       'OfficialTitle': 'A Culturally Adapted Depression Intervention for African American Adults',\n",
       "       'Acronym': 'AADI'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'May 2019',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'December 14, 2011',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2018',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'June 2018',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'April 25, 2011',\n",
       "       'StudyFirstSubmitQCDate': 'April 26, 2011',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 27, 2011',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'May 6, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 8, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Wisconsin, Madison',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute on Minority Health and Health Disparities (NIMHD)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Primary Aim 1: Examine effectiveness of the Oh Happy Day Class (OHDC) compared to the Coping With Depression (CWD)in increasing retention, adherence, engagement, satisfaction, and treatment-seeking. The investigators hypothesize the OHDC compared to the CWD will result in greater increases in: 1a. retention, 1b. adherence, 1c. engagement, and 1d. satisfaction at the middle and end of the intervention, and 2.e. greater increase in treatment-seeking 3-, 6-, 9-, and 12- months post-intervention. Outcome measures: logs: attendance, homework completion, class-participation level; Client Satisfaction Inventory; and Cornell Service Index. Primary Aim 2: Examine effectiveness of the OHDC in reducing symptoms of depression at the middle and immediate end of the intervention, and 3-, 6-, 9-, and 12- months post-intervention. The investigators hypothesize the OHDC will result in greater reduction in depressive symptoms compared to the CWD at 3-months post-intervention. Outcome measures: Center for Epidemiologic Studies Depression Scale and Quick Inventory of Depression Symptoms. Secondary Aim 3: Examine the effectiveness of the OHDC in improving self-reports of mental and physical health status and reducing self-reports of perceived disability. The investigators hypothesize the OHDC compared to the CWD will result in greater self-report of: 3a. improved mental and physical health status, and 3b. reduced self-report of disability at the immediate end of the intervention and 3-,6-, 9-, 12- months post-intervention. Outcome measures: SF-12 Health Survey, and World Health Organization Disability Assessment Schedule.\\n\\nPublic Health Impact: Based on CAI research, the OHDC has the potential to be four times more effective than the CWD. If our hypotheses are proven, the OHDC will be the first evidence-based culturally adapted depression intervention designed specifically for African American men and women between the ages of 30-60.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Major Depressive Disorder']},\n",
       "       'KeywordList': {'Keyword': ['Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 3']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '160',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'lifestyle counseling (OHDC)',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Oh Happy Day Class (OHDC) is a culturally-specific, 12-week cognitive behavioral group counseling intervention designed for African American adults experiencing depression',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)']}},\n",
       "         {'ArmGroupLabel': 'lifestyle counseling (CWD)',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Coping with Depression Course (CWD) is a 8-week cognitive behavioral group counseling depression intervention',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)',\n",
       "          'InterventionDescription': 'The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.\\n\\nThe CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.\\n\\nArms: lifestyle counseling (OHDC), lifestyle counseling (CWD)',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['lifestyle counseling (CWD)',\n",
       "            'lifestyle counseling (OHDC)']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Center for Epidemiologic Studies Depression Scale (CES-D)',\n",
       "          'PrimaryOutcomeDescription': 'Center for Epidemiologic Studies Depression Scale (CES-D). The CES-D scale is a 20-item self-report inventory developed by NIMH to assess the frequency and severity of depression symptoms in the past week. Respondents indicate how often each symptom was experienced during the past week on a four-point scale from \"Rarely or none of the time (0)\", \"Some or a little of the time (1)\", \"Occasionally or a moderate amount of the time (2)\", or \"Most or all of the time (3)\". Item scores are summed for analyses, with a possible range 0-60. A standard cutoff score of 16 indicates depressive symptoms.',\n",
       "          'PrimaryOutcomeTimeFrame': 'up to 4 years'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quick Inventory of Depressive Symptomatology (QIDS)',\n",
       "          'SecondaryOutcomeDescription': 'The 16-item Quick Inventory of Depressive Symptomatology (QIDS) using DSM-IV criteria assesses depressive symptom severity and symptom change. The QIDS has a clinician-rated and self-report format. Studies show high internal consistency for the QIDS-CR (0.85) and QIDS-SR(0.86). Scores range from 0-27 and higher scores suggest higher severity. The QIDS also has high concurrent validity with the SF-12.',\n",
       "          'SecondaryOutcomeTimeFrame': 'up to 4 years'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nInclusion criteria. Self-identified African-American men and women, between the ages of 30 to 60, with symptoms of depression as evidenced by data from the Composite International Diagnostic Interview 2.1 (CIDI). Although age of inclusion is broad, our pilot studies have shown positive outcomes with mixed aged groups\\n\\nExclusion Criteria:\\n\\nExclusion criteria. Individuals will be excluded from the study if they have: (1) self-reported alcohol or other drug abuse/dependence, (2) major psychotic illnesses, such as schizophrenia as evidenced by results of the CIDI, (3) self-reported changes in antidepressants (dosage or type) less than 6 weeks prior to participating in the study, (4) self-report of current psychotherapy treatment, or (5) self-report of current suicidal ideations (our psychiatrist will conduct additional suicide risk assessment and facilitate referral for appropriate care.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '30 Years',\n",
       "       'MaximumAge': '60 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Earlise C Ward, Ph.D.',\n",
       "          'OverallOfficialAffiliation': 'University of Wisconsin, Madison',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Mental Health Center of Dane County',\n",
       "          'LocationCity': 'Madison',\n",
       "          'LocationState': 'Wisconsin',\n",
       "          'LocationZip': '53703',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Milwaukee Health Services, INC',\n",
       "          'LocationCity': 'Milwaukee',\n",
       "          'LocationState': 'Wisconsin',\n",
       "          'LocationZip': '53216',\n",
       "          'LocationCountry': 'United States'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000003865',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder, Major'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafAsFound': 'Major Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 13,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01014312',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'P30MH085943-02',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=P30MH085943-02&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'P30MH085943-02',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=P30MH085943-02&Fy=all'},\n",
       "         {'SecondaryId': 'P30MH085943',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=P30MH085943&Fy=all'},\n",
       "         {'SecondaryId': 'DATR A4-GPC',\n",
       "          'SecondaryIdType': 'Other Identifier',\n",
       "          'SecondaryIdDomain': 'National Institute of Mental Health'}]},\n",
       "       'Organization': {'OrgFullName': 'Weill Medical College of Cornell University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Treatment for Depressed Primary Care Patients',\n",
       "       'OfficialTitle': 'Community-Based Depression Care Management for Elderly Primary Care Patients'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'February 2017',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'September 1, 2009',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 30, 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'April 30, 2015',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'November 3, 2009',\n",
       "       'StudyFirstSubmitQCDate': 'November 13, 2009',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 16, 2009',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'February 17, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 23, 2017',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Weill Medical College of Cornell University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This research study develop a collaborative depression care management model (C-DCM) that encourages collaboration between primary care physicians (PCPs) and trained social workers employed by community-based, public and nonprofit mental health clinics.',\n",
       "       'DetailedDescription': 'Major depression affects 5%-9% of older primary care patients, is often chronic or recurrent and disabling, and leads to frequent use of medical services. Most depressed elders are treated by primary care physicians (PCPs) and prior research has shown that collaboration between primary care physicians and depression care managers is effective in treating depression. The challenge has been in securing third-party reimbursement for such services.\\n\\nThis research study will address this barrier by developing a collaborative depression care management model (C-DCM) that encourages collaboration between PCPs and trained social workers employed by community-based, public and nonprofit mental health clinics. In addition to developing C-DCM, a total of 112 primary care outpatients will participate in this study to test whether C-DCM is more effective than the standard of care in decreasing the severity of depression and disability experienced by older adults. Each subject will be randomized into either Usual Care or C-DCM. All subjects will be assessed at Baseline and at 2 and 4 months while the C-DCM subjects will also meet with social worker depression case managers bi-weekly over four months. If shown effective, C-DCM may bring to bear an available, yet untapped resource in the care of depressed elders.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '11',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression Care Management (DCM)',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants will receive Depression Care Management.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression Care Management (DCM)']}},\n",
       "         {'ArmGroupLabel': 'Enhanced Care',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': \"Participants will receive the standard of care from their primary care physicians enhanced by a summary of the study's diagnostic interview.\",\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Enhanced Care']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Depression Care Management (DCM)',\n",
       "          'InterventionDescription': \"Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression Care Management (DCM)']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Enhanced Care',\n",
       "          'InterventionDescription': \"Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Enhanced Care']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Reduction in severity of depression over 16 weeks as measured by the Montgomery Asberg Depression Rating Scale (MADRS).',\n",
       "          'PrimaryOutcomeTimeFrame': 'Measured at Baseline, 8 weeks, and 16 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Reduction in disability over 16 weeks as measured by the World Health Organization Disability Scale (WHODAS).',\n",
       "          'SecondaryOutcomeTimeFrame': 'Measured at Baseline, 8 weeks, and 16 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAge 60 years and older: This study focuses on the clinical complexities of late-life depression and its treatment. Family Services of Westchester (our partner community mental health agency) offers geriatric mental health counseling services to adults age 60 and older.\\nDiagnosis of unipolar major depression\\nMADRS score >=18: Depression of such severity in primary care patients requires treatment.\\nCANE score >0: Reflects the presence of at least one unmet need in the domains of housing, self-care, safety, finances, benefits, legal matters, transportation, etc. and thus need for social services.\\nCapacity to provide written consent for both research assessment and depression care management: PCPs will be asked to clinically evaluate prospective participants' capacity to consent and document it in their medical record.\\nWorking knowledge of English: Command in English sufficient for comprehending questionnaires of the study and/or for understanding the DCM therapists. English does not have to be the subject's first language.\\n\\nExclusion Criteria:\\n\\nPsychotic depression: This will be determined by the Structured Clinical Interview for DSM Disorders(SCID) assessment; presence of delusions and or hallucinations. This is a severe disorder typically referred for treatment to mental health specialists.\\nActive suicidal ideation: This will be determined by the SCID and MADRS assessments. Older patients at these levels of risk for self-harm typically are referred to mental health specialists.\\nAntisocial personality by Diagnostic and Statistical Manual of Mental Disorders (DSM)IV: This disorder will possibly interfere with adherence to research procedures and treatment.\\nSignificant Cognitive Impairment (MMSE score <24) or clinical diagnosis of dementia by DSM-IV: These conditions may limit the patient's ability to participate in treatment and require social service interventions exceeding those available through the proposed depression care management models.\\nCurrent participation in specialist psychiatric care: Such patients will require the development of collaborative arrangements for depression care management which differ from those being tested in this study.\\nAcute or severe medical illness: i.e., delirium, metastatic cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry; or drugs often causing depression, e.g., steroids, reserpine, alpha-methyl-dopa, tamoxifen, vincristine.\",\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '60 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jo Anne Sirey, Ph.D.',\n",
       "          'OverallOfficialAffiliation': 'Weill Medical College of Cornell University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'George S. Alexopoulos, M.D.',\n",
       "          'OverallOfficialAffiliation': 'Weill Medical College of Cornell University',\n",
       "          'OverallOfficialRole': 'Study Director'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Westchester Medical Group Practices',\n",
       "          'LocationCity': 'White Plains',\n",
       "          'LocationState': 'New York',\n",
       "          'LocationZip': '10605',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 14,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01013220',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'R01MH076227',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH076227&Fy=all'},\n",
       "       'Organization': {'OrgFullName': 'Florida State University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Depression Management at the Workplace',\n",
       "       'OfficialTitle': 'Influencing Employer Purchasing Behavior',\n",
       "       'Acronym': 'DMW'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'December 2014',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2009'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2014',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'September 2014',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'November 12, 2009',\n",
       "       'StudyFirstSubmitQCDate': 'November 12, 2009',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 13, 2009',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'December 15, 2014',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 16, 2014',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Florida State University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Colorado Business Group on Health',\n",
       "          'CollaboratorClass': 'OTHER'},\n",
       "         {'CollaboratorName': 'University of South Florida',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': \"Randomized trials demonstrate that depression management products can improve clinical and organizational outcomes sufficiently for selected employers to realize a return on investment. Rather than usual care marketing which uses voltage-enhanced promises to sell voltage-diminished products, the investigators designed an evidence-based (EB) intervention to encourage employers to purchase a depression management product that offers the type, intensity and duration of care shown to provide clinical and organizational value. In an RCT designed to examine employer benefit purchasing behavior of depression products in 360 employer members of over 20 regional business coalitions, the research team proposes: (a) to compare the impact of evidence-based (EB) to usual care (UC) presentations on employer benefit purchasing behavior, and (b) to identify mediators and organizational moderators of intervention impact on employer benefit purchasing behavior.\\n\\nThis study addresses what policy analysts argue is one of the most pivotal problems in the translation of evidence-based care to 'real world' settings: whether purchasers can be influenced to buy health care products on the basis of value rather than cost. In the likely event that EB > UC, the study will provide encouragement to use an evidence-based approach to market new health care products to private payers on the basis of the product's clinical and organizational value. UC may achieve comparable outcomes to EB if the limiting factors in benefit purchasing are organizational, purchasing group and vendor constraints that no intervention can meaningfully modify. Support for this scenario would encourage the targeted marketing of new products to coalition members with empirically identified organizational, purchasing group and vendor characteristics, using usual care strategies.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['depression',\n",
       "         'depression care management',\n",
       "         'financing',\n",
       "         'absenteeism',\n",
       "         'presenteeism',\n",
       "         'employer decisions to purchase health care benefits']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '293',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression Product Detailing',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Employers receive education on how to purchase high quality depression management products to improve the quality of depression treatment depressed employees receive. Materials delivered in this arm of the study are available at www.caremanagementfordepression.org',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression Product Detailing']}},\n",
       "         {'ArmGroupLabel': 'Depression HEDIS Detailing',\n",
       "          'ArmGroupType': 'Placebo Comparator',\n",
       "          'ArmGroupDescription': 'Employers receive education on how to obtain and use HEDIS depression indicators to encourage health plans to improve the quality of depression treatment depressed employees receive',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression HEDIS detailing']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Depression Product Detailing',\n",
       "          'InterventionDescription': 'two hour academic detailing of depression management products to employees with responsibility for purchasing health care benefits\\ntechnical assistance in purchasing high quality depression management products',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression Product Detailing']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Depression HEDIS detailing',\n",
       "          'InterventionDescription': 'academic detailing to employees responsible for purchasing health care benefits on how to use HEDIS indicators for depression to assure their depressed employees receive high quality care for the condition\\ntechnical assistance',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression HEDIS Detailing']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'employer purchase of depression management product',\n",
       "          'PrimaryOutcomeTimeFrame': 'two years after intervention'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'fidelity of depression management model purchased to evidence-based models',\n",
       "          'SecondaryOutcomeTimeFrame': 'two years after intervention'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nCoalitions who belong to the National Business Coalition on Health are eligible if:\\n\\nthey have 30+ employer purchasers/affiliates as members\\nthey act as more than purchasing agents\\n(3)they did not participate in the research team's preliminary studies on this topic.\\n\\nEmployers of participating coalitions are eligible if:\\n\\nthey are a public or private organization providing health care benefits to 100+ domestic employees\\nthey have not purchased a depression management product in the past two years.\\n\\nExclusion Criteria:\\n\\nNone\",\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kathryn Rost, PhD',\n",
       "          'OverallOfficialAffiliation': 'Florida State University, College of Medicine',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Colorado Business Group on Health',\n",
       "          'LocationCity': 'Denver',\n",
       "          'LocationState': 'Colorado',\n",
       "          'LocationZip': '80226',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25519705',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Rost KM, Meng H, Xu S. Work productivity loss from depression: evidence from an employer survey. BMC Health Serv Res. 2014 Dec 18;14:597. doi: 10.1186/s12913-014-0597-y.'}]},\n",
       "       'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'materials for academic detailing of depression management products',\n",
       "          'SeeAlsoLinkURL': 'http://www.caremanagementfordepression.org'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 15,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03983291',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'Version 1.1'},\n",
       "       'Organization': {'OrgFullName': 'Zentrum für Angst und Depressionsbehandlung Zürich',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'FaReWell Depression - Facial Exercise Program to Treat Depression',\n",
       "       'OfficialTitle': 'Facial Rehabilitation of Wellbeing in Depression: a Randomized Controled Trial of a Facial Physiotherapeutic Exercise Program in the Treatment of Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'June 2019',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'June 1, 2019',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 15, 2020',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'May 31, 2020',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'June 10, 2019',\n",
       "       'StudyFirstSubmitQCDate': 'June 10, 2019',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 12, 2019',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'June 11, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 14, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Zentrum für Angst und Depressionsbehandlung Zürich',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study investigates if a physiotherapeutic exercise program designed to relax facial muscles associated with the expression of negative emotions and to activate and strengthen facial muscles associated with the expression of positive emotions can reduce the symptoms of depression and improve wellbeing and quality of life in the affected patients.',\n",
       "       'DetailedDescription': 'Activity of the facial musculature expresses emotions, but also generates proprioceptive signals to the emotional brain that maintain and reinforce the expressed emotions. This has been described by Charles Darwin and William James in the facial feedback hypothesis.\\n\\nStudies have shown that interruption of facial feedback by the injection of botulinum toxin into the corrugator and procerus muscles, which express negative emotions like sadness, anger, and fear, can reduce the symptoms of depression.\\n\\nIn the present study we investigate, if similar effects can be achieved by a relaxing massage of these and other muscles that are associated with the expression of negative emotions and if strengthening exercises of muscles that express positive emotions, the zygomaticus and orbicularis oculi muscles, can contribute to the rehabilitation of positive emotionality in depression. After instruction by a physiotherapist, participants will practice the exercises daily for 15 minutes.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignInterventionModelDescription': 'For six weeks one arm receives the FaReWell Depression intervention and one arm receives a control resting intervention. The former arm continues on the FaReWell Depression intervention while the latter arm is switched to the FaReWell Depression intervention for another six weeks.',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '40',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'FaReWell Depression',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Physiotherapeutic exercises for the relaxation of facial muscles associated with the expression of negative emotions and for the activation and strengthening of facial muscles associated with the expression of positive emotions 15 minutes daily',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: FaReWell Depression']}},\n",
       "         {'ArmGroupLabel': 'Resting exercise',\n",
       "          'ArmGroupType': 'Placebo Comparator',\n",
       "          'ArmGroupDescription': 'Resting 15 minutes daily',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: FaReWell Depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'FaReWell Depression',\n",
       "          'InterventionDescription': 'Facial massage and force exercise',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['FaReWell Depression',\n",
       "            'Resting exercise']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Montgomery-Asberg Depression Rating Scale (MADRS)',\n",
       "          'PrimaryOutcomeDescription': 'The Montgomery-Asberg Depression Rating Scale (MADRS) is an expert rating scale with 10 items for the measurement of the severity of depressive symptoms. Change in depression severity is measured as change in the total score of the scale (0-60 points).',\n",
       "          'PrimaryOutcomeTimeFrame': '6 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Montgomery-Asberg Depression Rating Scale (MADRS)',\n",
       "          'SecondaryOutcomeDescription': 'The Montgomery-Asberg Depression Rating Scale (MADRS) is an expert rating scale with 10 items for the measurement of the severity of depressive symptoms. Change in depression severity is measured as change in the total score of the scale (0-60 points).',\n",
       "          'SecondaryOutcomeTimeFrame': '3, 9, 12 weeks'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Patient-Health-Questionnaire-9 (PHQ-9)',\n",
       "          'SecondaryOutcomeDescription': 'The Patient-Health-Questionnaire-9 (PHQ-9) is a self-rating scale with 9 items for the measurement of the severity of depressive symptoms. Change in depression severity is measured as change in the total score of the scale (0-27 points).',\n",
       "          'SecondaryOutcomeTimeFrame': '3, 6, 9, 12 weeks'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Snaith-Hamilton-Pleasure-Scale (SHAPS-D)',\n",
       "          'SecondaryOutcomeDescription': 'The Snaith-Hamilton-Pleasure-Scale (SHAPS-D) is a self-rating scale with 14 items for the measurement of pleasure. Change in anhedonia (inability to experience pleasure) is measured as change in the total score of the scale (0-14 points).',\n",
       "          'SecondaryOutcomeTimeFrame': '3, 6, 9, 12 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMild to moderate unipolar depression\\nStable treatment for at least 6 weeks\\n\\nExclusion Criteria:\\n\\nOrganic mental disorders\\nMental disorders due to psychoactive substance use\\nSchizophrenia and other psychotic disorders\\nPrevious cosmetic procedures (botulinum toxin, fillers, lifting)\\nFacial palsy\\nFacial skin disorders',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Patricia Waldvogel, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '+41 44 3866600',\n",
       "          'CentralContactEMail': 'PWaldvogel@zadz.ch'},\n",
       "         {'CentralContactName': 'Axel Wollmer, MD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '+49 151 53136738',\n",
       "          'CentralContactEMail': 'axel.wollmer@unibas.ch'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Patricia Waldvogel, PhD',\n",
       "          'OverallOfficialAffiliation': 'Zentrum für Angst und Depressionsbehandlung Zürich',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Zentrum für Angst- und Depressionsbehandlung',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Zürich',\n",
       "          'LocationZip': '8008',\n",
       "          'LocationCountry': 'Switzerland',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Patricia Waldvogel, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '+41 44 3866600',\n",
       "             'LocationContactEMail': 'PWaldvogel@zadz.ch'}]}}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M19673',\n",
       "          'ConditionBrowseLeafName': 'Facies',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
       "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}},\n",
       "   {'Rank': 16,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01794598',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '5132'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '5132-03-8R0ER',\n",
       "          'SecondaryIdType': 'Other Identifier',\n",
       "          'SecondaryIdDomain': 'Duke legacy protocol ID'}]},\n",
       "       'Organization': {'OrgFullName': 'Duke University', 'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Preliminary Study Examining Heart Failure Patients Responses to Depression Education',\n",
       "       'OfficialTitle': 'HF-ACTION Depression Education Substudy'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'February 2013',\n",
       "       'OverallStatus': 'Terminated',\n",
       "       'WhyStopped': 'Terminated',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'May 2004'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2006',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2006',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'February 17, 2012',\n",
       "       'StudyFirstSubmitQCDate': 'February 15, 2013',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 20, 2013',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'September 19, 2014',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 22, 2014',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Duke University',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Purpose of the Study: The significant impact of depression on the poor prognosis and functional restrain, recognition and successful treatment of depression in patients with Chronic Heart Failure (CHF) may result in improvement of overall outcome of those patients. However, depression comorbid with CHF has been overlooked in the real practice. Therefore, the investigators are proposing a study to 1) assess the prognostic impact of depression in patients with stable CHF who have been managed as outpatients, and 2) assess whether provision of depression education to CHF patients will improve the care of depression.\\n\\nPatients with chronic heart failure are enrolled into this study with a half of them are randomly assigned to receive a packet of depression education materials and then other half not. Participants and investigators both are blinded to the assignment. All the participants are provided a toll free phone number to contact the research team as needed. Depressive symptoms and patients knowledge of depression are assessed at baseline prior to randomization and at 1-month and 6-month following the enrollment.\\n\\nResponses of the study participants, such as change of depressive symptoms, and requests for psychiatric help are examined between two groups.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Chronic Heart Failure']},\n",
       "       'KeywordList': {'Keyword': ['Heart failure',\n",
       "         'depression',\n",
       "         'depression care education']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Triple',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Investigator',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '270',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Educational materials',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Receiving educational materials of depression care',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Receiving educational material of depression care']}},\n",
       "         {'ArmGroupLabel': 'No educational materials',\n",
       "          'ArmGroupType': 'Sham Comparator',\n",
       "          'ArmGroupDescription': 'Receiving an envelope but no inclusion of educational materials of depression care',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Receiving educational material of depression care']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Receiving educational material of depression care',\n",
       "          'InterventionDescription': 'The educational material provides patients about depression management',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Educational materials',\n",
       "            'No educational materials']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in recognition of study participant to depression care',\n",
       "          'PrimaryOutcomeDescription': 'To assess whether the provision of depression education materials will increase knowledge of the impact depression has on Congestive Heart Failure patients. This will be measured through study participants completion of a questionnaire to record their views on depression and depression care in a non-psychiatric setting.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline, 1 month and 6 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in response of study participant to depression care',\n",
       "          'SecondaryOutcomeDescription': 'Response of participants to depression care was measured by use of the Beck Depression Inventory scale (BDI), PHQ-9 (the 9 items of the depression scale of the Patient Health Questionnaire) and an anxiety questionnaire and a toll-free contact number to access free psychiatric consultants at the coordinating center. A contact log was kept documenting subject ID, reason for call, number of contacts and duration of the call.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 1 month, and 6 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nInclusion Criteria\\n\\nLVEF ≤ 35%.\\nNYHA class II, III, or IV heart failure for the previous three months despite a minimum of 6 weeks of treatment.\\nMust be on optimal heart failure therapy according to AHA/ACC and HFSA heart failure guidelines, including treatment with ACEI and beta-blocker therapy, or have documented rationale for variation, including intolerance, contraindication, patient preference, or personal physician's judgment.\\n\\nExclusion Criteria:\\n\\nAge less than 18.\\nCurrently pregnant or intending to become pregnant in the next year.\\nCardiovascular procedure or hospitalization for any reason planned in the next 6 months.\\nExpectation of receiving a cardiac transplant in the next six months.\\nUnable to provide the study consent.\\nParticipation another clinical trial(s) that may interfere with follow-up or data collection for this study, or that may affect cardiovascular mortality.\",\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Wei Jiang, MD',\n",
       "          'OverallOfficialAffiliation': 'Duke University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006333',\n",
       "          'ConditionMeshTerm': 'Heart Failure'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000006331',\n",
       "          'ConditionAncestorTerm': 'Heart Diseases'},\n",
       "         {'ConditionAncestorId': 'D000002318',\n",
       "          'ConditionAncestorTerm': 'Cardiovascular Diseases'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M8004',\n",
       "          'ConditionBrowseLeafName': 'Heart Failure',\n",
       "          'ConditionBrowseLeafAsFound': 'Heart Failure',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M8002',\n",
       "          'ConditionBrowseLeafName': 'Heart Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC14',\n",
       "          'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}},\n",
       "   {'Rank': 17,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00930293',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'R01MH085874',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH085874&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH085874',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH085874&Fy=all'},\n",
       "         {'SecondaryId': 'MH085874-01'},\n",
       "         {'SecondaryId': 'PRO08070009'},\n",
       "         {'SecondaryId': 'PCC: DSIR 84-CT'}]},\n",
       "       'Organization': {'OrgFullName': 'University of Pittsburgh',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety',\n",
       "       'OfficialTitle': 'Personalizing Treatment of Depression Complicated by Panic Features-Pilot Study'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'January 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'July 2009'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2012',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'June 2012',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 26, 2009',\n",
       "       'StudyFirstSubmitQCDate': 'June 26, 2009',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 30, 2009',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'December 19, 2013',\n",
       "       'ResultsFirstSubmitQCDate': 'January 7, 2016',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'February 9, 2016',\n",
       "        'ResultsFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'January 7, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 9, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Jill Cyranowski',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Associate Professor of Psychiatry and Psychology',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Pittsburgh'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Pittsburgh',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study will examine the feasibility and efficacy of a personalized psychotherapy treatment for people with depression and co-occurring anxiety.',\n",
       "       'DetailedDescription': \"Approximately one half of all depressed psychiatric patients also meet the criteria for an anxiety disorder. Compared to people with only depression, people with both depression and panic features experience poorer psychological and social functioning, a greater risk of suicide, less response to medication and therapy treatment, and a greater risk of recurring symptoms. Because people with depression and co-occurring anxiety features do not achieve full symptom remission with either medication or therapy alone, this study will use a treatment that combines the two. A commonly used type of depression medication called a selective serotonin reuptake inhibitor (SSRI) will be combined with a specialized therapy developed to address depression with co-occurring symptoms of panic, anxiety, and avoidance. This study will also test a computer-based method of assessing mood and anxiety symptom profiles and outcomes to determine whether participants find this method acceptable and clinicians find it useful.\\n\\nParticipation in this study will last 20 weeks, with follow-up visits occurring 4 and 8 months after starting. Participants will be randomly assigned to receive either an individualized therapy for depression and anxiety, called interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS), or a standard therapy for depression, called brief supportive psychotherapy (BSP). All participants will complete up to 16 therapy sessions and receive a standard SSRI treatment with the medication citalopram hydrobromide. During the IPT-PS treatment, a study therapist will examine regular computer updates of depression and anxiety scores for participants and talk to them about identifying and addressing life stressors that trigger symptoms. During the BSP treatment, a study therapist will encourage participants to arrive at their own solutions by emphasizing the participants' strengths and examining what has worked in the past.\\n\\nParticipants will complete assessments weekly during the 20 weeks of the study intervention and at 4- and 8-month follow-up visits. These assessments will include self-report questionnaires about symptoms, medication side effects, and treatment adherence; vital sign and weight measurements; and a clinical interview. Regular assessments of medication effectiveness and side effects will occur every 1 to 4 weeks. Starting at the second study visit, participants will also complete monthly computer-based questionnaires about depression and anxiety symptoms.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression',\n",
       "         'Anxiety']},\n",
       "       'KeywordList': {'Keyword': ['Interpersonal Psychotherapy']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '50',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Personalized Depression Care',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication (citalopram) treatment.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)',\n",
       "            'Drug: Citalopram hydrobromide']}},\n",
       "         {'ArmGroupLabel': 'Standard Depression Care',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication (citalopram) treatment.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Brief Supportive Psychotherapy (BSP)',\n",
       "            'Drug: Citalopram hydrobromide']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)',\n",
       "          'InterventionDescription': '16 weekly IPT-PS sessions, each lasting approximately 45 minutes',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Personalized Depression Care']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Brief Supportive Psychotherapy (BSP)',\n",
       "          'InterventionDescription': '16 weekly BPS sessions, each lasting approximately 45 minutes',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Standard Depression Care']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Citalopram hydrobromide',\n",
       "          'InterventionDescription': 'A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Personalized Depression Care',\n",
       "            'Standard Depression Care']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Celexa']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Number of Participants Meeting Depression Remission Criteria',\n",
       "          'PrimaryOutcomeDescription': 'Depression remission defined as 3 consecutive weeks of HRSD-17 scores that on average, < or = 7',\n",
       "          'PrimaryOutcomeTimeFrame': 'Measured at baseline and weekly for up to 20 weeks of acute treatment'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Weeks to Depression Remission',\n",
       "          'SecondaryOutcomeDescription': 'Kaplan-Meier survival analyses to determine time to depression remission (defined as average HRSD-17 score < or = 7 for three consecutive weeks).\\n\\nAnalyses run with the full intent to treat sample (censoring patients who dropped out at time of termination)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Measured at baseline and weekly for up to 20 weeks of treatment'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nCurrently in an episode of nonpsychotic major depression, as defined by the DSM-IV and documented by both the Structured Clinical Interview for Axis I, DSM-IV Disorders (SCID) and by a rating of greater than 15 on the 25-item Hamilton Rating Scale for Depression (HRSD)\\nPanic spectrum risk category of at least 7, as defined by the Panic-Agoraphobic Spectrum Self-Report (PAS-SR), last month version\\nNot currently receiving effective treatment\\nParticipants with suicidal ideation are eligible as long as outpatient treatment is deemed safe.\\n\\nExclusion Criteria:\\n\\nHistory of manic or hypomanic episode(s)\\nHistory of schizophrenia or schizoaffective disorder\\nMood disorder due to a general medical condition or induced by substance use\\nPresence of psychosis\\nCurrent pregnancy or plans to become pregnant\\nCurrent primary diagnosis of anorexia nervosa or bulimia nervosa (this does not include an eating disorder not otherwise specified [NOS])\\nCurrent primary diagnosis of severe obsessive-compulsive disorder (OCD), as determined by clinician evaluation of symptom severity and temporal onset of symptoms\\nDrug or alcohol abuse or dependence within the past 3 months (participants with episodic abuse related to mood episodes will not be excluded)\\nSatisfies full DSM-IV criteria for antisocial personality disorder, as determined by SCID-II evaluation\\nRequires inpatient treatment because of suicidal risk or psychotic symptoms (current suicidal thinking or parasuicidal behavior is not exclusionary if, in clinician judgment, it can be managed on an outpatient basis)\\n\\nAny of the following medical conditions:\\n\\nAn index episode that is secondary to the effect of medically prescribed drugs, i.e., reserpine, antihistamines, etc.\\nPresence of significant uncontrolled medical illness including cardiovascular disorder, kidney or liver disease, epilepsy, untreated hypertension, or unstabilized endocrine disease (stable medical conditions such as well-controlled diabetes or HIV positive status are not exclusionary provided the participant meets other inclusion and exclusion criteria)\\nCurrent treatment with a pharmacologic, over-the-counter, or herbal therapy for depression or anxiety (unless the participant wishes to discontinue an ineffective treatment)\\nHistory of poor or failed treatment response to an adequate dose and duration of citalopram',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jill M. Cyranowski, PhD',\n",
       "          'OverallOfficialAffiliation': 'University of Pittsburgh',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Western Psychiatric Institute and Clinic',\n",
       "          'LocationCity': 'Pittsburgh',\n",
       "          'LocationState': 'Pennsylvania',\n",
       "          'LocationZip': '15213',\n",
       "          'LocationCountry': 'United States'}]}}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Personalized Depression Care',\n",
       "          'FlowGroupDescription': 'Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.\\n\\nInterpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Standard Depression Care',\n",
       "          'FlowGroupDescription': 'Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.\\n\\nBrief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '24'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '26'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '17'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '19'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '7'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '7'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Personalized Depression Care',\n",
       "          'BaselineGroupDescription': 'Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.\\n\\nInterpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Standard Depression Care',\n",
       "          'BaselineGroupDescription': 'Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.\\n\\nBrief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '24'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '26'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '50'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '30.37',\n",
       "                   'BaselineMeasurementSpread': '11.41'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '31.09',\n",
       "                   'BaselineMeasurementSpread': '10.27'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '30.74',\n",
       "                   'BaselineMeasurementSpread': '10.72'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '24'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '26'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '50'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '19'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '18'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '37'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '8'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '13'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '24'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '26'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '50'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Number of Participants Meeting Depression Remission Criteria',\n",
       "          'OutcomeMeasureDescription': 'Depression remission defined as 3 consecutive weeks of HRSD-17 scores that on average, < or = 7',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Number',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'participants',\n",
       "          'OutcomeMeasureTimeFrame': 'Measured at baseline and weekly for up to 20 weeks of acute treatment',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Personalized Depression Care',\n",
       "             'OutcomeGroupDescription': 'Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.\\n\\nInterpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Standard Depression Care',\n",
       "             'OutcomeGroupDescription': 'Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.\\n\\nBrief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '24'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '26'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '10'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '15'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Weeks to Depression Remission',\n",
       "          'OutcomeMeasureDescription': 'Kaplan-Meier survival analyses to determine time to depression remission (defined as average HRSD-17 score < or = 7 for three consecutive weeks).\\n\\nAnalyses run with the full intent to treat sample (censoring patients who dropped out at time of termination)',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'weeks',\n",
       "          'OutcomeMeasureTimeFrame': 'Measured at baseline and weekly for up to 20 weeks of treatment',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Personalized Depression Care',\n",
       "             'OutcomeGroupDescription': 'Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.\\n\\nInterpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Standard Depression Care',\n",
       "             'OutcomeGroupDescription': 'Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.\\n\\nBrief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '24'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '26'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '13.99',\n",
       "                   'OutcomeMeasurementSpread': '1.47'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '11.59',\n",
       "                   'OutcomeMeasurementSpread': '1.31'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Personalized Depression Care',\n",
       "          'EventGroupDescription': 'Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.\\n\\nInterpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '24',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '24'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Standard Depression Care',\n",
       "          'EventGroupDescription': 'Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.\\n\\nBrief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes\\n\\nCitalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '26',\n",
       "          'EventGroupOtherNumAffected': '1',\n",
       "          'EventGroupOtherNumAtRisk': '26'}]},\n",
       "       'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Unexplained Visual Disturbance',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '0',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '24'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '26'}]}}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Jill M. Cyranowski, PhD',\n",
       "        'PointOfContactOrganization': 'University of Pittsburgh',\n",
       "        'PointOfContactEMail': 'cyranowskijm@upmc.edu',\n",
       "        'PointOfContactPhone': '412-246-5588'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000003909',\n",
       "          'InterventionMeshTerm': 'Dexetimide'},\n",
       "         {'InterventionMeshId': 'D000015283',\n",
       "          'InterventionMeshTerm': 'Citalopram'}]},\n",
       "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000017367',\n",
       "          'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000014179',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000049990',\n",
       "          'InterventionAncestorTerm': 'Membrane Transport Modulators'},\n",
       "         {'InterventionAncestorId': 'D000045504',\n",
       "          'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "         {'InterventionAncestorId': 'D000018377',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Agents'},\n",
       "         {'InterventionAncestorId': 'D000018490',\n",
       "          'InterventionAncestorTerm': 'Serotonin Agents'},\n",
       "         {'InterventionAncestorId': 'D000045505',\n",
       "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'},\n",
       "         {'InterventionAncestorId': 'D000018687',\n",
       "          'InterventionAncestorTerm': 'Antidepressive Agents, Second-Generation'},\n",
       "         {'InterventionAncestorId': 'D000000928',\n",
       "          'InterventionAncestorTerm': 'Antidepressive Agents'},\n",
       "         {'InterventionAncestorId': 'D000011619',\n",
       "          'InterventionAncestorTerm': 'Psychotropic Drugs'},\n",
       "         {'InterventionAncestorId': 'D000000978',\n",
       "          'InterventionAncestorTerm': 'Antiparkinson Agents'},\n",
       "         {'InterventionAncestorId': 'D000018726',\n",
       "          'InterventionAncestorTerm': 'Anti-Dyskinesia Agents'},\n",
       "         {'InterventionAncestorId': 'D000010276',\n",
       "          'InterventionAncestorTerm': 'Parasympatholytics'},\n",
       "         {'InterventionAncestorId': 'D000001337',\n",
       "          'InterventionAncestorTerm': 'Autonomic Agents'},\n",
       "         {'InterventionAncestorId': 'D000018373',\n",
       "          'InterventionAncestorTerm': 'Peripheral Nervous System Agents'},\n",
       "         {'InterventionAncestorId': 'D000018727',\n",
       "          'InterventionAncestorTerm': 'Muscarinic Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000018680',\n",
       "          'InterventionAncestorTerm': 'Cholinergic Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000018678',\n",
       "          'InterventionAncestorTerm': 'Cholinergic Agents'}]},\n",
       "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16566',\n",
       "          'InterventionBrowseLeafName': 'Citalopram',\n",
       "          'InterventionBrowseLeafAsFound': 'Citalopram Hydrobromide',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M5687',\n",
       "          'InterventionBrowseLeafName': 'Dexetimide',\n",
       "          'InterventionBrowseLeafAsFound': 'Citalopram Hydrobromide',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M14095',\n",
       "          'InterventionBrowseLeafName': 'Serotonin',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M18232',\n",
       "          'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19088',\n",
       "          'InterventionBrowseLeafName': 'Neurotransmitter Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M2828',\n",
       "          'InterventionBrowseLeafName': 'Antidepressive Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M13057',\n",
       "          'InterventionBrowseLeafName': 'Psychotropic Drugs',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M2876',\n",
       "          'InterventionBrowseLeafName': 'Antiparkinson Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M11772',\n",
       "          'InterventionBrowseLeafName': 'Parasympatholytics',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19385',\n",
       "          'InterventionBrowseLeafName': 'Muscarinic Antagonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19344',\n",
       "          'InterventionBrowseLeafName': 'Cholinergic Antagonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19342',\n",
       "          'InterventionBrowseLeafName': 'Cholinergic Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr',\n",
       "          'InterventionBrowseBranchName': 'Psychotropic Drugs'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'AnDyAg',\n",
       "          'InterventionBrowseBranchName': 'Anti-Dyskinesia Agents'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M2905',\n",
       "          'ConditionBrowseLeafName': 'Anxiety Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 18,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00105833',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'MHI 20-020'},\n",
       "       'Organization': {'OrgFullName': 'VA Office of Research and Development',\n",
       "        'OrgClass': 'FED'},\n",
       "       'BriefTitle': 'Improving Outcomes of Depression in Primary Care',\n",
       "       'OfficialTitle': 'Improving Outcomes of Depression in Primary Care',\n",
       "       'Acronym': 'DEP-PC'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2009',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'July 2002'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2004',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2008',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'March 16, 2005',\n",
       "       'StudyFirstSubmitQCDate': 'March 16, 2005',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 17, 2005',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'April 6, 2015',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 7, 2015',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'US Department of Veterans Affairs',\n",
       "        'LeadSponsorClass': 'FED'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Depression is common in primary care settings, and associated with substantial physical and psychosocial impairment and increased healthcare utilization. Despite efforts to educate primary care providers, depression is often undetected or undertreated in primary care settings. The main objective of this study was to determine the impact of a low-intensity, care management intervention on depression treatment outcomes of patients in a VA primary care setting.',\n",
       "       'DetailedDescription': 'OBJECTIVE(S): The primary objective of the study was to determine the impact of a low-intensity, care management intervention on depression treatment outcomes of patients in a VA primary care setting. Secondary objectives were to determine the extent to which primary care clinicians adhere to major depression treatment guidelines, the extent to which the intervention impacts healthcare utilization, and to examine the impact of provider and patient covariates (including pain and adherence) on depression treatment response PLAN: Randomized controlled trial. METHODS: All clinicians first participated in the MacArthur Depression Education Program (DEP). After stratification by discipline and site, clinicians were randomized to receive the Depression Decision Support (DDS) intervention versus usual care (which included an on-site mental health team). Patients were nested within clinician intervention status. DDS intervention clinicians received serial reports of depression severity scores and other clinical data for their enrolled patients. The DDS care manager made one telephone contact with each intervention patient, and invited patients to attend a depression group education session. The DDS team monitored patient depression severity over time, and targeted additional time and effort towards patients not showing improvement. Additional DDS intervention included making further recommendations to primary care clinicians, and in some cases, a one-time consultation with the DDS psychiatrist.\\n\\nPotential subjects were identified from lists of patients due for appointments with primary care clinicians, and were contacted for telephone screening. Patients were enrolled if they had Patient Health Questionnaire (PHQ-9) scores >10 or a Hopkins Symptom Checklist (SCL-20) score of > 1.0 at a subsequent in-person interview. There were no restrictions by age or sex. Patients were excluded if they had psychotic symptoms, dementia, serious suicidal ideation, very severe depression (PHQ-9 >25), or had been treated by mental health clinicians within the previous six months. The intervention lasted 12 months. Depression symptom severity (SCL-20) and health related quality of life (SF-36V) at 6 and 12-months were primary outcomes. Primary analyses employed mixed-model repeated measure analyses of covariance, which include a random effect for clinician and fixed effects for time and intervention status.\\n\\nFINDINGS TO DATE: Five Portland VA clinic sites and 41 clinicians participated. 3,103 patients were screened, and 402 patients were enrolled. Three hundred seventy-five met final eligibility criteria. There were no adverse events. SCL-20 scores improved in both groups over 12 months (slope: -.382; 95% CI -.488, -.276), but there was no effect of the intervention on SCL-20 or Short Form-36V compared to usual care. There was greater initial improvement in PHQ-9 for intervention patients (p=.030); however, this effect diminished over time. At 12 months, intervention patients reported greater satisfaction (p=.002), and were more likely to have received antidepressants. To date, 10 manuscripts supported by the project have been published. One manuscript examining associations between stressful live events and depression outcomes has been submitted for publication.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '400',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Arm 1',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Multifaceted collaborative intervention for depression based in primary care',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Collaborative Care - Depression Decision Support (DDS)']}},\n",
       "         {'ArmGroupLabel': 'Arm 2',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Treatment as usual'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Collaborative Care - Depression Decision Support (DDS)',\n",
       "          'InterventionDescription': 'Multifaceted collaborative intervention for depression based in primary care',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Arm 1']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Depression Decision Support (DDS)']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Symptom Checklist SCL-20 score',\n",
       "          'PrimaryOutcomeTimeFrame': 'SCL-20 score over 12 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPrimary care patients of eligible providers with depression (Patient Health Questionnaire [PHQ-9] depression scores of 10 to 25 or Hopkins Symptom Checklist-20 [SCL-20] scores >= 1.0)\\n\\nExclusion Criteria:\\n\\nPatients who had received treatment from mental health specialists within the previous 6 months; who had received a diagnosis of psychotic disorder, dementia, or bipolar disorder; or who were considered to be terminally ill',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Steven K. Dobscha, MD',\n",
       "          'OverallOfficialAffiliation': 'VA Portland Health Care System, Portland, OR',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Martha S. Gerrity, MD MPH PhD',\n",
       "          'OverallOfficialAffiliation': 'VA Portland Health Care System, Portland, OR',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'VA Portland Health Care System, Portland, OR',\n",
       "          'LocationCity': 'Portland',\n",
       "          'LocationState': 'Oregon',\n",
       "          'LocationZip': '97239',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '18071900',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Snyder K, Dobscha SK, Ganzini L, Hoffman WF, Delorit MA. Clinical outcomes of integrated psychiatric and general medical care. Community Ment Health J. 2008 Jun;44(3):147-54. Epub 2007 Dec 11.'},\n",
       "         {'ReferencePMID': '17336659',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Williams JW Jr, Gerrity M, Holsinger T, Dobscha S, Gaynes B, Dietrich A. Systematic review of multifaceted interventions to improve depression care. Gen Hosp Psychiatry. 2007 Mar-Apr;29(2):91-116. Review.'},\n",
       "         {'ReferencePMID': '17250493',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Dobscha SK, Corson K, Pruitt S, Crutchfield M, Gerrity MS. Measuring depression and pain with home health monitors. Telemed J E Health. 2006 Dec;12(6):702-6.'},\n",
       "         {'ReferencePMID': '17015865',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Dobscha SK, Corson K, Hickam DH, Perrin NA, Kraemer DF, Gerrity MS. Depression decision support in primary care: a cluster randomized trial. Ann Intern Med. 2006 Oct 3;145(7):477-87.'},\n",
       "         {'ReferencePMID': '17634781',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Gerrity MS, Corson K, Dobscha SK. Screening for posttraumatic stress disorder in VA primary care patients with depression symptoms. J Gen Intern Med. 2007 Sep;22(9):1321-4. Epub 2007 Jul 17.'},\n",
       "         {'ReferencePMID': '18071094',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Dobscha SK, Corson K, Gerrity MS. Depression treatment preferences of VA primary care patients. Psychosomatics. 2007 Nov-Dec;48(6):482-8.'},\n",
       "         {'ReferencePMID': '17029000',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Dobscha SK, Winterbottom LM, Snodgrass LS. Reducing drug costs at a Veterans Affairs hospital by increasing market-share of generic fluoxetine. Community Ment Health J. 2007 Feb;43(1):75-84. Epub 2006 Sep 22.'},\n",
       "         {'ReferencePMID': '15609737',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Corson K, Gerrity MS, Dobscha SK. Screening for depression and suicidality in a VA primary care setting: 2 items are better than 1 item. Am J Manag Care. 2004 Nov;10(11 Pt 2):839-45.'},\n",
       "         {'ReferencePMID': '15785225',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Dobscha SK, Corson K, Solodky J, Gerrity MS. Use of videoconferencing for depression research: enrollment, retention, and patient satisfaction. Telemed J E Health. 2005 Feb;11(1):84-9.'},\n",
       "         {'ReferencePMID': '12556600',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Dobscha SK, Anderson TA, Hoffman WF, Winterbottom LM, Turner EH, Snodgrass LS, Hauser P. Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center. Psychiatr Serv. 2003 Feb;54(2):195-200.'},\n",
       "         {'ReferencePMID': '12850654',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Dobscha SK, Gerrity MS, Corson K, Bahr A, Cuilwik NM. Measuring adherence to depression treatment guidelines in a VA primary care clinic. Gen Hosp Psychiatry. 2003 Jul-Aug;25(4):230-7.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 19,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03811041',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '29BRC18.0221'},\n",
       "       'Organization': {'OrgFullName': 'University Hospital, Brest',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Adolescent Depression Associated With Parental Depression',\n",
       "       'OfficialTitle': 'Adolescent Depression Associated With Parental Depression : Screening, Prevalence and Secondary Prevention From the Meeting of Depressed Parents on Primary Care',\n",
       "       'Acronym': 'AdoDesP'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2020',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'March 28, 2019',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 28, 2021',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'March 28, 2022',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'January 15, 2019',\n",
       "       'StudyFirstSubmitQCDate': 'January 17, 2019',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 22, 2019',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'March 26, 2020',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 27, 2020',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University Hospital, Brest',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Depression is difficult to identify, prevent and treat in adolescents because of complex and stigmatized multiform symptoms and pathways of care.\\n\\nIn children the existence of a parental depression is a significant and recognized risk factor for the development of a depression. It is regularly reported that 30% of adolescents of depressed parents have depression themselves. General Practitioners (GP) have significant access to the depression of adults, potentially parents of teenagers. In fact, 20% of patients in the regular active file of one GP have depression. The primary health care system could provide indirect but voluminous and unprecedented access to the identification of adolescent depression at an early stage from the encounter of depressed parents.\\n\\nThe difficulties of articulation between primary care (PC) and mental health devices are demonstrated. They disrupt the care pathways of adolescents detected in PC, prevention, and may even disturb early detection of depression. An organized joint between the PC and a specialized mental health service for adolescents (\"Maison Des Adolescents\" MDA) could promote the process of screening and preventing depression of adolescents of depressed parents encountered in PC.\\n\\nIn addition, if the effects of parental depression on adolescents are established, they remain complex and interactive. They vary by age and sex of the child but also the sex of the parent. A concomitant study of adolescent and parent depression will provide data to analyze the prevalence of depressed parent adolescent depression and to define risk or protection factors.\\n\\nAdoDesP study is a cluster randomised trial (randomisation of the GPs) which compare a group of adolescent with PC articulated with mental health service (MDA) and an other group without articulation (routine cares).\\n\\nA third group of depressed adolescents will be constituted to analyse parental depression of depressed adolescents.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Diagnostic',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '1068',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'PC articulated with MDA',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM).Finally, the patient will be oriented to the MDA of Brest and will meet again the GP at 6 and 12 month to answers the same tests.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: MDA']}},\n",
       "         {'ArmGroupLabel': 'Routine cares',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM). Finally, the patient will be oriented to the routine cares and will meet again the GP at 6 and 12 month to answers the same tests.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Routine Cares']}},\n",
       "         {'ArmGroupLabel': 'Parental depression',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Parental depression will be studied. Depressed adolescent encountered in MDA of Marseille for confirmation of depression with 3 tests : ADRS, CDI and PedsQL. If positive, the parent will come to the MDA for a screening test of depression (HSCL25). Parents and adolescent are seen only once.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Parental depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'MDA',\n",
       "          'InterventionDescription': 'Depressed adolescents of depressed parents will be oriented to the MDA of Brest for depression cares.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['PC articulated with MDA']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Routine Cares',\n",
       "          'InterventionDescription': 'Depressed adolescents of depressed parents will be oriented to routine cares for depression cares.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Routine cares']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Parental depression',\n",
       "          'InterventionDescription': 'Parents of depressed adolescents will be met for a screening test of depression.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Parental depression']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Changes in adolescents' depression intensity\",\n",
       "          'PrimaryOutcomeDescription': 'The depression intensity will be evaluated by Child DepressionInventory (CDI)scale at Day 0, Months 6 and 12 and the investigators will compare its evolution between group 1 and 2. Each of the 27 items is scored 0, 1 or 2 and the total score is the sum of all items. Score between 0 and 9 mean minor depression, 10 to 18 is mild depression, 19 to 29 is moderate depression and 30 to 63 is for the severe depressions.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Day 0, Month6 and Month12'},\n",
       "         {'PrimaryOutcomeMeasure': \"Changes in adolescents' quality of live\",\n",
       "          'PrimaryOutcomeDescription': 'The quality of live will be evaluated by Pediatric Quality of Life InventoryTM (PedsQL) scale at Day 0, Months 6 and 12 and the investigators will compare its evolution between group 1 and 2. 3 scores will be calculated : psychosocial health summary score (average score of 15 items), physical health summary score (average score of 8 items) and the total score (average score of all items). Scores are between 0 and 100% and the higher scores indicate better Health-Related Quality of Life.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Day 0, Month6 and Month12'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Prevalence of adolescent depression with depressed parent',\n",
       "          'SecondaryOutcomeDescription': 'With group 1 and 2, the investigators will calculate de prevalence of adolescent depression when a parent is depressed. Adolescent depression will be assessed by Adolescent Depression Rating Scale (ADRS). This scale is composed of 8 true (1)/false(0) questions. The score is the sum of all item. An adolescent is consider depressed when his score is higher than 4.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Day 0'},\n",
       "         {'SecondaryOutcomeMeasure': 'Prevalence of parental depression with depressed adolescent',\n",
       "          'SecondaryOutcomeDescription': 'With group 3, the investigators will calculate de prevalence of parental depression when a adolescent is depressed. Parental depression will be assessed by Hopkins Symptom Checklist (HSCL25). This scale is composed of 25 questions with 4 answers (1-4). The score is the average score of the 25 items. The parent is considered depressed when the score is higher or equal to 1.75.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Day 0'},\n",
       "         {'SecondaryOutcomeMeasure': 'Risk and protection factors',\n",
       "          'SecondaryOutcomeDescription': 'With the 3 groups, the investigators will isolate risk and protection factors for adolescent of depressed parents and for parents of depressed adolescents. Sociodemographics informations will be used and protective or risk factors may be highlighted from the study of some of the medico-psychological and social characteristics of families.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Day 0'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nParents of groups 1 and 2 :\\n\\nMajor patient consulting his GP\\nDepressed patient\\nParent of adolescent aged between 11 and 18 years old\\n\\nAdolescents of groups 1 and 2 :\\n\\nAged more than 11 and less than 18 years old\\nParent included in the study and whose depression is confirmed by HSCL25 scale\\n\\nParents of group 3 :\\n\\nParent of depressed adolescent under care at the MDA of Marseille, included in the study and whose depression is confirmed by HSCL25 scale\\n\\nAdolescents of group 3 :\\n\\nAged more than 11 and less than 18 years old\\nDepressed patient\\nUnder care at the MDA of Marseille since less than 1 month\\n\\nExclusion Criteria:\\n\\nParents of groups 1, 2 and 3 :\\n\\nMinor patient\\nEnable to give his consent\\nPatient with guardianship or curatorship\\nNon consenting patient\\nPregnant or nursing mother\\n\\nAdolescents of groups 1 and 2 :\\n\\nAged < 11 or ≥18\\nParent whose depression isn't confirmed by HSCL25 scale\\nNon consenting adolescent\\nPregnant or nursing mother\\n\\nAdolescent of group 3 :\\n\\nAged < 11 or ≥18\\nNon depressed adolescent\\nNon consenting patient\\nPregnant or nursing mother\",\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '11 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Guillaume BRONSARD, Pr',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '0298015010',\n",
       "          'CentralContactEMail': 'guillaume.bronsard@chu-brest.fr'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Dr Andro-De-Schotten',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Brest',\n",
       "          'LocationZip': '29200',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Anne-Cécile ANDRO-DE-SCHOTTEN, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr GLOANEC',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Brest',\n",
       "          'LocationZip': '29200',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Isabelle GLOANEC, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr MOUDEN',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Brest',\n",
       "          'LocationZip': '29200',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jean-Hervé MOUDEN, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Phan',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Brest',\n",
       "          'LocationZip': '29200',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Thi Xuân-Mai PHAN, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Volant-Le-Berre',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Brest',\n",
       "          'LocationZip': '29200',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Charlotte VOLANT-LE-BERRE, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Wauters',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Brest',\n",
       "          'LocationZip': '29200',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Thomas WAUTERS, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr CAMILLERI',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Gouesnou',\n",
       "          'LocationZip': '29850',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Claire CAMILLERI, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Magueres',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Gouesnou',\n",
       "          'LocationZip': '29850',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Catherine MAGUERES, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Ben Yahmed',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Guipavas',\n",
       "          'LocationZip': '29490',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Khalil BEN YAHMED, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Le Grignou',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Guissény',\n",
       "          'LocationZip': '29880',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Caroline LE GRIGNOU, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': \"Dr Ac'h\",\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Landerneau',\n",
       "          'LocationZip': '29800',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': \"Sylvie AC'H, Dr\",\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Le Goff',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Landerneau',\n",
       "          'LocationZip': '29800',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Delphine LE GOFF, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Monnier',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Landerneau',\n",
       "          'LocationZip': '29800',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Brigitte MONNIER, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr PITMAN',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Landivisiau',\n",
       "          'LocationZip': '29400',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Roberto PITMAN, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Beck-Robert',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Lanmeur',\n",
       "          'LocationZip': '29260',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Emilie BECK-ROBERT, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Crenn-Corvez',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Lanmeur',\n",
       "          'LocationZip': '29260',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hélène CRENN-CORVEZ, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr CHIRON',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Le Relecq-Kerhuon',\n",
       "          'LocationZip': '29480',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Benoit CHIRON, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr CONNAN',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Le Relecq-Kerhuon',\n",
       "          'LocationZip': '29480',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Elodie CONNAN, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Cazuguel',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Locmaria-Plouzané',\n",
       "          'LocationZip': '29280',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yann CAZUGUEL, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Gasnier',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Ploudalmezeau',\n",
       "          'LocationZip': '29830',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Anne-laure GASNIER, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr Coat-Gourio',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Plougastel-Daoulas',\n",
       "          'LocationZip': '29470',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Christine COAT-GOURIO, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Dr MAZE',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Saint-Renan',\n",
       "          'LocationZip': '29290',\n",
       "          'LocationCountry': 'France',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Maryline MAZE, Dr',\n",
       "             'LocationContactRole': 'Contact'}]}}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'Yes',\n",
       "       'IPDSharingDescription': 'All collected data that underlie results in a publication',\n",
       "       'IPDSharingInfoTypeList': {'IPDSharingInfoType': ['Study Protocol']},\n",
       "       'IPDSharingTimeFrame': 'Data will be available beginning 3 years and ending fifteen years following the final study report completion',\n",
       "       'IPDSharingAccessCriteria': 'Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M10890',\n",
       "          'ConditionBrowseLeafName': 'Neoplasm Metastasis',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC04',\n",
       "          'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
       "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}},\n",
       "   {'Rank': 20,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01143896',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'SDP 10-044'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '10-05',\n",
       "          'SecondaryIdType': 'Other Identifier',\n",
       "          'SecondaryIdDomain': 'VA Central IRB'}]},\n",
       "       'Organization': {'OrgFullName': 'VA Office of Research and Development',\n",
       "        'OrgClass': 'FED'},\n",
       "       'BriefTitle': 'Hepatitis C Translating Initiatives for Depression Into Effective Solutions',\n",
       "       'OfficialTitle': 'Hepatitis C Translating Initiatives for Depression Into Solutions',\n",
       "       'Acronym': 'HEPTIDES'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'April 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'February 2012'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2014',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'November 2015',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 11, 2010',\n",
       "       'StudyFirstSubmitQCDate': 'June 11, 2010',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 14, 2010',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'January 4, 2016',\n",
       "       'ResultsFirstSubmitQCDate': 'March 11, 2016',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'April 11, 2016',\n",
       "        'ResultsFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'April 12, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 16, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'VA Office of Research and Development',\n",
       "        'LeadSponsorClass': 'FED'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Chronic infection with hepatitis C (CHC) is a common and expensive condition, and it disproportionately affects Veterans. Treatment with antiviral therapy reduces liver disease progression and improves health related quality of life. However, ~70% of Veterans with CHC are considered ineligible for antiviral treatment. Most of these patients are excluded due to the presence of co-existing depression and substance use. The proposed project will adapt and adopt an evidence-based collaborative depression care model in CHC clinics. By removing the leading contraindication for antiviral treatment, this project will potentially yield benefits that go far beyond the obvious quality of life benefit from antidepressant therapy itself.',\n",
       "       'DetailedDescription': 'Project Background and Rationale: Depression is highly prevalent, yet under-diagnosed and under-treated in CHC. Treatment models that increase collaborative management of depression by mental health and physical health clinicians can improve quality and outcomes, and collaborative care models have been identified as the best-practice for depression in VA primary care settings. However, the antiviral treatment for CHC patients may not benefit from the existing primary care-mental health integration because the antiviral treatment is time-limited and conducted in specialty clinics. Although there is little evidence evaluating the effects of collaborative depression care in specialty settings, QUERI HIV-hepatitis initiated one of the first such efforts that effectively implemented collaborative depression care in HIV clinics. Built on this experience, an intensive yet focused collaborative care model in CHC clinics may be effective in improving not only depression but also CHC care. This proposed study, \"Hepatitis-Translating Initiatives for Depression into Effective Solutions (HEP-TIDES)\" will target this issue.\\n\\nProject Objectives: The proposal has three overarching primary aims and one exploratory aim. The primary aims are (1) adapt and adopt the collaborative care model for improving depression care in specialty CHC care settings, (2) compare the effectiveness of HEP-TIDES to usual care in improving CHC care, and (3) compare the effectiveness of HEP-TIDES to usual care in improving depression care. The exploratory aim is to evaluate the cost-effectiveness of HEP-TIDES versus usual care.\\n\\nProject Methods: HEP-TIDES is a multi-site, multi-method implementation project. HEP-TIDES will use evidence-based quality improvement (EBQI) methods to adapt and implement depression screening and the collaborative care model for depression in the CHC clinics at 4 disparate VA facilities (aim 1). HEP-TIDES will involve CHC and mental health providers working with an off-site depression care team comprised of a depression care nurse manager, pharmacist, and a psychiatrist. The purpose of the team will be to support CHC and mental health clinicians in delivering evidence-based stepped-care depression treatment. The adapted model will also take into account the substance use disorders among CHC patients. HEP-TIDES implementation will be assessed using a formative evaluation of the implementation process and a summative evaluation of a randomized controlled implementation trial of collaborative depression care in 242 patients (aims 2 and 3).'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Hepatitis C',\n",
       "         'Depression']},\n",
       "       'KeywordList': {'Keyword': ['Hepatitis C',\n",
       "         'Depression',\n",
       "         'Collaborative care',\n",
       "         'Antiviral treatment']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '309',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Arm 1: Depression Collaborative Care',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\",\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression collaborative care model']}},\n",
       "         {'ArmGroupLabel': 'Arm 2: Usual Care',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Depression collaborative care model',\n",
       "          'InterventionDescription': \"The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Arm 1: Depression Collaborative Care']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment',\n",
       "          'PrimaryOutcomeDescription': 'Antiviral treatment initiation was measured dichotomously by assigning a value of 1 if the patient received at least one prescription of interferon within 12 months of enrollment, and a value of 0 otherwise.',\n",
       "          'PrimaryOutcomeTimeFrame': '12 months'},\n",
       "         {'PrimaryOutcomeMeasure': 'Depression Care: Treatment Response',\n",
       "          'PrimaryOutcomeDescription': 'Depression outcomes were assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Depression treatment response was defined as a 50% or greater decrease in the mean SCL-20 score compared with baseline.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline and 12 months'},\n",
       "         {'PrimaryOutcomeMeasure': 'Depression Care: Depression Remission',\n",
       "          'PrimaryOutcomeDescription': 'Depression outcomes were assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Remission was defined as an item mean SCL-20 score of less than 0.5.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline and 12 months'},\n",
       "         {'PrimaryOutcomeMeasure': 'Depression Care: Change From Baseline in Number of Depression Free Days (DFDs) at 12 Months',\n",
       "          'PrimaryOutcomeDescription': 'The change in Depression Free Days was assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Depression-free days (DFDs) were calculated using an SCL-20 score of less than 0.5 for depression-free and 2.0 or higher for fully symptomatic, and scores in between were assigned a linear proportional value.',\n",
       "          'PrimaryOutcomeTimeFrame': 'From Baseline to 12 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quality of Hepatitis C Care: Quality Indicators: Proportion of QIs Received',\n",
       "          'SecondaryOutcomeDescription': 'Quality of CHC Indicator Measure is based on a Delphi panel-derived list of quality indicators (QI) in CHC care. The list spans the following domains of care, i.e., CHC-specific function of care (diagnosis, specialty evaluation, treatment, etc); general function of care (diagnosis, treatment, follow-up); and mode of care (encounter, medication, immunization, counseling, etc). Adherence to a given QI is scored as 1 if there is evidence in the patient EMR for the indicator being satisfied. The quality of CHC care at the patient level is calculated by dividing the number of QIs for which that individual received the indicated care by the number of QIs for which the individual is eligible for during the length of time the patient is enrolled in the HEP-TIDES 12-month study timeframe.',\n",
       "          'SecondaryOutcomeTimeFrame': '12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Medication Adherence: Medication Possession Ratio',\n",
       "          'SecondaryOutcomeDescription': \"Medication adherence was measured using the Medication Possession Ratio (MPR) calculation: Pharmacy refill data was used to calculate a medication possession ratio (MPR), by dividing the number of days supply of a medication received by the number of day's supply the patient needed to be able to take the medication continuously. An MPR closer to 1.0 indicates better adherence and has been associated with lower rates of hospital admission in veterans and greater symptom improvement.\",\n",
       "          'SecondaryOutcomeTimeFrame': '12 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nconfirmed untreated infection (positive HCV RNA test)\\ncurrent PHQ-9 score of 10 or more\\ncurrent treatment in the CHC clinic\\n\\nExclusion Criteria:\\n\\nnon-Veterans\\npatients who do not have access to a telephone\\npatients with current suicidal ideation\\npatients with significant cognitive impairment as indicated by a score > 10 on the Blessed Orientation Memory and Concentration Test\\npatients with a chart diagnosis of schizophrenia\\npatients with a chart diagnosis of bipolar disorder who have been hospitalized for a mental health condition within the last 12 months',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '99 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Fasiha Kanwal, MBBS MD',\n",
       "          'OverallOfficialAffiliation': 'Michael E. DeBakey VA Medical Center, Houston, TX',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Jeffrey M. Pyne, MD',\n",
       "          'OverallOfficialAffiliation': 'Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Brian Dieckgraefe, MD',\n",
       "          'OverallOfficialAffiliation': 'St. Louis VA Medical Center John Cochran Division, St. Louis, MO',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Matthew Goetz, MD',\n",
       "          'OverallOfficialAffiliation': 'VA Greater Los Angeles Healthcare System',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock',\n",
       "          'LocationCity': 'Little Rock',\n",
       "          'LocationState': 'Arkansas',\n",
       "          'LocationZip': '72205-5484',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'VA Greater Los Angeles Healthcare System, West Los Angeles, CA',\n",
       "          'LocationCity': 'West Los Angeles',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '90073',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'St. Louis VA Medical Center John Cochran Division, St. Louis, MO',\n",
       "          'LocationCity': 'St Louis',\n",
       "          'LocationState': 'Missouri',\n",
       "          'LocationZip': '63106',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Michael E. DeBakey VA Medical Center, Houston, TX',\n",
       "          'LocationCity': 'Houston',\n",
       "          'LocationState': 'Texas',\n",
       "          'LocationZip': '77030',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25952310',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Pyne JM. Expanding the Scope of Integrated Behavioral Health Care for Patients With Hepatitis C Virus. Clin Gastroenterol Hepatol. 2015 Nov;13(11):2015-6. doi: 10.1016/j.cgh.2015.04.174. Epub 2015 May 5.'},\n",
       "         {'ReferencePMID': '26429337',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Zuchowski JL, Hamilton AB, Pyne JM, Clark JA, Naik AD, Smith DL, Kanwal F. Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment. BMC Gastroenterol. 2015 Oct 1;15:124. doi: 10.1186/s12876-015-0356-5.'},\n",
       "         {'ReferencePMID': '27364808',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Kanwal F, Pyne JM, Tavakoli-Tabasi S, Nicholson S, Dieckgraefe B, Storay E, Bidwell Goetz M, Smith DL, Sansgiry S, Gifford A, Asch SM. Collaborative Care for Depression in Chronic Hepatitis C Clinics. Psychiatr Serv. 2016 Oct 1;67(10):1076-1082. Epub 2016 Jul 1.'}]}}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowRecruitmentDetails': 'We recruited a total of 309 patients from CHC clinics at 4 VAs (Houston, St Louis, Little Rock, and Los Angeles) between April 2012 and September 2013. Of these, 292 patients completed baseline interviews. Follow-up data-collection interviews were completed for 263 (90.1%) participants at 6-months and 242 (78.3%) participants at 12-months.',\n",
       "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Arm 1: Depression Collaborative Care',\n",
       "          'FlowGroupDescription': \"Depression collaborative care model: The depression collaborative care arm will include a stepped-care model. The five steps are expected to include symptom and self-management monitoring by depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM will provide education about depression and depression treatment options, assess the patient's treatment preferences and barriers, assess the patient's current depression severity and mental health comorbidity, initiate a self-management plan, and assess treatment adherence. The DCM will use the alcohol screening and brief intervention. The DCM will also screen for street drug use and will recommend referral of participants who are using street drugs to the local substance abuse treatment programs.\"},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Arm 2: Usual Care',\n",
       "          'FlowGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '156'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '153'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '114'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '128'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '42'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '25'}]}}]},\n",
       "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Did not complete Baseline Interview',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '5'},\n",
       "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '4'}]}},\n",
       "            {'FlowDropWithdrawType': 'Lost to Follow-up',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '18'},\n",
       "               {'FlowReasonGroupId': 'FG001',\n",
       "                'FlowReasonNumSubjects': '13'}]}},\n",
       "            {'FlowDropWithdrawType': 'Withdrawal by Subject',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '13'},\n",
       "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '5'}]}},\n",
       "            {'FlowDropWithdrawType': 'Death',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '6'},\n",
       "               {'FlowReasonGroupId': 'FG001',\n",
       "                'FlowReasonNumSubjects': '3'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'A total of 292 participants completed baseline interviews.',\n",
       "       'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Arm 1: Depression Collaborative Care',\n",
       "          'BaselineGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\"},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Arm 2: Usual Care',\n",
       "          'BaselineGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '145'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '147'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '292'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '59',\n",
       "                   'BaselineMeasurementSpread': '5.8'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '59',\n",
       "                   'BaselineMeasurementSpread': '5.2'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '59',\n",
       "                   'BaselineMeasurementSpread': '5.5'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '6'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '6'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '12'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '139'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '141'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '280'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Race/Ethnicity, Customized',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'White Non-Hispanic',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '59'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '41'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '100'}]}}]}},\n",
       "            {'BaselineClassTitle': 'Black or African American',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '72'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '91'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '163'}]}}]}},\n",
       "            {'BaselineClassTitle': 'Other',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '14'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '15'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '29'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '145'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '147'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '292'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Marital Status',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Single, Never Married',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '45'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '68'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '113'}]}}]}},\n",
       "            {'BaselineClassTitle': 'Married',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '14'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '16'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '30'}]}}]}},\n",
       "            {'BaselineClassTitle': 'Other (divorced, widowed, separated, no response)',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '86'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '63'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '149'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Annual Income',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Less than $20,000',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '60'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '57'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '117'}]}}]}},\n",
       "            {'BaselineClassTitle': 'Over $20,000',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '43'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '41'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '84'}]}}]}},\n",
       "            {'BaselineClassTitle': \"Don't Know/Refused\",\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '42'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '49'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '91'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'History of Mood Disorders',\n",
       "          'BaselineMeasureDescription': 'In the last 6 months, did you receive care for personal or emotional problems, feeling down, worried or anxious, or alcohol or drug problem?',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Yes',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '65'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '67'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '132'}]}}]}},\n",
       "            {'BaselineClassTitle': 'No',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '80'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '78'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '158'}]}}]}},\n",
       "            {'BaselineClassTitle': \"Don't Know/Refused\",\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '2'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '2'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Taking antidepressant meds at baseline',\n",
       "          'BaselineMeasureDescription': 'Do you have a current prescription for any anti-depressant medications, such as prozac or lexapro?',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Yes',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '71'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '67'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '138'}]}}]}},\n",
       "            {'BaselineClassTitle': 'No',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '71'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '79'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '150'}]}}]}},\n",
       "            {'BaselineClassTitle': \"Don't Know/Refused\",\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '3'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '1'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '4'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment',\n",
       "          'OutcomeMeasureDescription': 'Antiviral treatment initiation was measured dichotomously by assigning a value of 1 if the patient received at least one prescription of interferon within 12 months of enrollment, and a value of 0 otherwise.',\n",
       "          'OutcomeMeasurePopulationDescription': 'intent to treat',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Number',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'participants',\n",
       "          'OutcomeMeasureTimeFrame': '12 months',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Arm 1: Depression Collaborative Care',\n",
       "             'OutcomeGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\"},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Arm 2: Usual Care',\n",
       "             'OutcomeGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '114'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '128'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '11'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '7'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Quality of Hepatitis C Care: Quality Indicators: Proportion of QIs Received',\n",
       "          'OutcomeMeasureDescription': 'Quality of CHC Indicator Measure is based on a Delphi panel-derived list of quality indicators (QI) in CHC care. The list spans the following domains of care, i.e., CHC-specific function of care (diagnosis, specialty evaluation, treatment, etc); general function of care (diagnosis, treatment, follow-up); and mode of care (encounter, medication, immunization, counseling, etc). Adherence to a given QI is scored as 1 if there is evidence in the patient EMR for the indicator being satisfied. The quality of CHC care at the patient level is calculated by dividing the number of QIs for which that individual received the indicated care by the number of QIs for which the individual is eligible for during the length of time the patient is enrolled in the HEP-TIDES 12-month study timeframe.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'proportion of QIs met',\n",
       "          'OutcomeMeasureTimeFrame': '12 months',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Arm 1: Depression Collaborative Care',\n",
       "             'OutcomeGroupDescription': \"Depression collaborative care model: The depression collaborative care arm will include a stepped-care model. The five steps are expected to include symptom and self-management monitoring by depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM will provide education about depression and depression treatment options, assess the patient's treatment preferences and barriers, assess the patient's current depression severity and mental health comorbidity, initiate a self-management plan, and assess treatment adherence. The DCM will use the alcohol screening and brief intervention. The DCM will also screen for street drug use and will recommend referral of participants who are using street drugs to the local substance abuse treatment programs.\"},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Arm 2: Usual Care',\n",
       "             'OutcomeGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '114'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '128'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '.89',\n",
       "                   'OutcomeMeasurementSpread': '.16'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '.83',\n",
       "                   'OutcomeMeasurementSpread': '.19'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Medication Adherence: Medication Possession Ratio',\n",
       "          'OutcomeMeasureDescription': \"Medication adherence was measured using the Medication Possession Ratio (MPR) calculation: Pharmacy refill data was used to calculate a medication possession ratio (MPR), by dividing the number of days supply of a medication received by the number of day's supply the patient needed to be able to take the medication continuously. An MPR closer to 1.0 indicates better adherence and has been associated with lower rates of hospital admission in veterans and greater symptom improvement.\",\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'medication posession ratio',\n",
       "          'OutcomeMeasureTimeFrame': '12 months',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Arm 1: Depression Collaborative Care',\n",
       "             'OutcomeGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\"},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Arm 2: Usual Care',\n",
       "             'OutcomeGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '114'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '128'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '.83',\n",
       "                   'OutcomeMeasurementSpread': '.20'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '.78',\n",
       "                   'OutcomeMeasurementSpread': '.24'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Depression Care: Treatment Response',\n",
       "          'OutcomeMeasureDescription': 'Depression outcomes were assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Depression treatment response was defined as a 50% or greater decrease in the mean SCL-20 score compared with baseline.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Number',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'participants',\n",
       "          'OutcomeMeasureTimeFrame': 'Baseline and 12 months',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Arm 1: Depression Collaborative Care',\n",
       "             'OutcomeGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\"},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Arm 2: Usual Care',\n",
       "             'OutcomeGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '114'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '128'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '36'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '19'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Depression Care: Depression Remission',\n",
       "          'OutcomeMeasureDescription': 'Depression outcomes were assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Remission was defined as an item mean SCL-20 score of less than 0.5.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Number',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'participants',\n",
       "          'OutcomeMeasureTimeFrame': 'Baseline and 12 months',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Arm 1: Depression Collaborative Care',\n",
       "             'OutcomeGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\"},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Arm 2: Usual Care',\n",
       "             'OutcomeGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '114'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '128'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '22'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '9'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Depression Care: Change From Baseline in Number of Depression Free Days (DFDs) at 12 Months',\n",
       "          'OutcomeMeasureDescription': 'The change in Depression Free Days was assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Depression-free days (DFDs) were calculated using an SCL-20 score of less than 0.5 for depression-free and 2.0 or higher for fully symptomatic, and scores in between were assigned a linear proportional value.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'Depression Free Days (DFDs)',\n",
       "          'OutcomeMeasureTimeFrame': 'From Baseline to 12 months',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Arm 1: Depression Collaborative Care',\n",
       "             'OutcomeGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\"},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Arm 2: Usual Care',\n",
       "             'OutcomeGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '114'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '128'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '118.74',\n",
       "                   'OutcomeMeasurementSpread': '106.68'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '109.30',\n",
       "                   'OutcomeMeasurementSpread': '117.88'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventsTimeFrame': '12 months',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Arm 1: Depression Collaborative Care',\n",
       "          'EventGroupDescription': \"Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.\",\n",
       "          'EventGroupSeriousNumAffected': '6',\n",
       "          'EventGroupSeriousNumAtRisk': '145',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '145'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Arm 2: Usual Care',\n",
       "          'EventGroupDescription': 'Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.',\n",
       "          'EventGroupSeriousNumAffected': '3',\n",
       "          'EventGroupSeriousNumAtRisk': '147',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '147'}]},\n",
       "       'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Death (IRB determined unrelated to the study)',\n",
       "          'SeriousEventOrganSystem': 'General disorders',\n",
       "          'SeriousEventAssessmentType': 'Non-systematic Assessment',\n",
       "          'SeriousEventNotes': 'Specific cause of death unavailable',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '6',\n",
       "             'SeriousEventStatsNumAffected': '6',\n",
       "             'SeriousEventStatsNumAtRisk': '145'},\n",
       "            {'SeriousEventStatsGroupId': 'EG001',\n",
       "             'SeriousEventStatsNumEvents': '3',\n",
       "             'SeriousEventStatsNumAffected': '3',\n",
       "             'SeriousEventStatsNumAtRisk': '147'}]}}]}},\n",
       "      'MoreInfoModule': {'LimitationsAndCaveats': {},\n",
       "       'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Fasiha Kanwal, MD, MSHS',\n",
       "        'PointOfContactOrganization': 'Michael E. DeBakey VA Medical Center',\n",
       "        'PointOfContactEMail': 'Fasiha.Kanwal@va.gov',\n",
       "        'PointOfContactPhone': '(713) 440-4495'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006506',\n",
       "          'ConditionMeshTerm': 'Hepatitis A'},\n",
       "         {'ConditionMeshId': 'D000006526', 'ConditionMeshTerm': 'Hepatitis C'},\n",
       "         {'ConditionMeshId': 'D000006505', 'ConditionMeshTerm': 'Hepatitis'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000008107',\n",
       "          'ConditionAncestorTerm': 'Liver Diseases'},\n",
       "         {'ConditionAncestorId': 'D000004066',\n",
       "          'ConditionAncestorTerm': 'Digestive System Diseases'},\n",
       "         {'ConditionAncestorId': 'D000006525',\n",
       "          'ConditionAncestorTerm': 'Hepatitis, Viral, Human'},\n",
       "         {'ConditionAncestorId': 'D000014777',\n",
       "          'ConditionAncestorTerm': 'Virus Diseases'},\n",
       "         {'ConditionAncestorId': 'D000004769',\n",
       "          'ConditionAncestorTerm': 'Enterovirus Infections'},\n",
       "         {'ConditionAncestorId': 'D000010850',\n",
       "          'ConditionAncestorTerm': 'Picornaviridae Infections'},\n",
       "         {'ConditionAncestorId': 'D000012327',\n",
       "          'ConditionAncestorTerm': 'RNA Virus Infections'},\n",
       "         {'ConditionAncestorId': 'D000018178',\n",
       "          'ConditionAncestorTerm': 'Flaviviridae Infections'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M8174',\n",
       "          'ConditionBrowseLeafName': 'Hepatitis',\n",
       "          'ConditionBrowseLeafAsFound': 'Hepatitis',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M8175',\n",
       "          'ConditionBrowseLeafName': 'Hepatitis A',\n",
       "          'ConditionBrowseLeafAsFound': 'Hepatitis',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M8194',\n",
       "          'ConditionBrowseLeafName': 'Hepatitis C',\n",
       "          'ConditionBrowseLeafAsFound': 'Hepatitis C',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M9690',\n",
       "          'ConditionBrowseLeafName': 'Liver Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M7466',\n",
       "          'ConditionBrowseLeafName': 'Gastrointestinal Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5838',\n",
       "          'ConditionBrowseLeafName': 'Digestive System Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M8193',\n",
       "          'ConditionBrowseLeafName': 'Hepatitis, Viral, Human',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M16105',\n",
       "          'ConditionBrowseLeafName': 'Virus Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M8866',\n",
       "          'ConditionBrowseLeafName': 'Infection',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M4951',\n",
       "          'ConditionBrowseLeafName': 'Communicable Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M6513',\n",
       "          'ConditionBrowseLeafName': 'Enterovirus Infections',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M12328',\n",
       "          'ConditionBrowseLeafName': 'Picornaviridae Infections',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13732',\n",
       "          'ConditionBrowseLeafName': 'RNA Virus Infections',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M18907',\n",
       "          'ConditionBrowseLeafName': 'Flaviviridae Infections',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC06',\n",
       "          'ConditionBrowseBranchName': 'Digestive System Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC02',\n",
       "          'ConditionBrowseBranchName': 'Viral Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC01',\n",
       "          'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}]}}}}},\n",
       "   {'Rank': 21,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03062215',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'CAiCBT'},\n",
       "       'Organization': {'OrgFullName': 'Silver Cloud Health',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Efficacy of a Culturally Adapted Cognitive Behavioural Internet-delivered Treatment for Depression',\n",
       "       'OfficialTitle': 'Assessing the Efficacy of a Culturally Adapted Cognitive Behavioural Internet-delivered Treatment for Depression: Protocol for a Randomised Controlled Trial',\n",
       "       'Acronym': 'CAiCBT'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'September 2018',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'August 2, 2016',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 1, 2018',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'June 1, 2018',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'February 14, 2017',\n",
       "       'StudyFirstSubmitQCDate': 'February 20, 2017',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 23, 2017',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'September 7, 2018',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 10, 2018',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Silver Cloud Health',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Irish Research Council',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The study seeks to evaluate the efficacy of a culturally adapted internet-delivered treatment for depression in Colombia. The research involves two studies: (a) the cultural adaptation of the Space from Depression cognitive-behavioural internet-delivered programme, and (b) the implementation of the culturally adapted intervention using a randomised controlled trial methodology. The study will be a first contribution of a culturally adapted low-intensity internet-delivered intervention with Latin Americans.',\n",
       "       'DetailedDescription': 'Depression is the principal cause of disability in the world. High rates of prevalence of depression in general populations and college students have been found worldwide and in various cultural groups. For instance, a 12-month prevalence rate has been estimated in the U.S. at 9.5% and in Europe at 8.5% of the population. In Colombia, 12-month prevalence is between 6.2% and 12.1%. The Colombian National Mental Health Survey has estimated point prevalence of mild to moderate depressive symptoms at 15.6% and severe depressive symptoms at 4.2% of adults. On the other hand, there are significant barriers for accessing mental health services in Colombia. About 50% of the population does not have access to health services, while the majority of the population with mental health problems do not have adequate mental health insurance coverage.\\n\\nAlthough low-intensity interventions for depression have been developed in western high-income countries and these interventions therefore have been influenced by their specific cultural context (for example, Ireland, UK, Australia), it is important to consider how cultural context may impact on the adaptation for use in LMICs such as Colombia. The authors argue that cultural aspects need to be taken into consideration when translating and adapting interventions to help guarantee similar results to what have been achieved in high-income countries.\\n\\nGeneral method Aims and Hypothesis: We aim to assess the efficacy of a culturally adapted cognitive behavioural internet-delivered treatment for college students with depressive symptoms in Colombia. In line with other studies in high-income countries (HICs), and using an already established intervention, we hypothesise that the culturally adapted Space from Depression programme will be efficacious, with significant changes within the treatment group and differences post-treatment between the active treatment and the waiting list control group.\\n\\nThe study is a mixed method approach utilising in study 1, quantitative and qualitative methods to assist in the cultural adaptation of the Space from Depression intervention and in study 2 a randomised control design to examine the efficacy of the culturally-adapted intervention.\\n\\nProcedure The programme Space from Depression will be culturally adapted for a Colombian population using cultural sensitivity and ecological validity frameworks, including principles from cross-cultural assessment research. (Study 1). Once the programme is culturally adapted, it will be tested using a randomised controlled trial methodology (Study 2).'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Culturally adapted psychotherapy',\n",
       "         'Internet-delivered treatment',\n",
       "         'Depression',\n",
       "         'Latin America']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '127',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Space from depression',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions depression. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page. Also, users have a supporter, who will give feedback asynchronously (D Richards et al., 2015). Research on the SilverCloud interventions has yielded significant clinical outcomes (D Richards et al., 2015).',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Space from Depression']}},\n",
       "         {'ArmGroupLabel': 'Control Group',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Waiting list'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Space from Depression',\n",
       "          'InterventionDescription': 'Space from Depression programme (Yo puedo sentirme Bien -Spanish version) consists of seven modules of cognitive-behavioural therapy. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Space from depression']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Yo puedo sentirme bien']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Patient Health Questionnaire -9',\n",
       "          'PrimaryOutcomeDescription': 'depression symptoms',\n",
       "          'PrimaryOutcomeTimeFrame': '6 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Generalised Anxiety Disorder 7',\n",
       "          'SecondaryOutcomeDescription': 'anxiety symptoms',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months'}]},\n",
       "       'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Satisfaction with Treatment Questionnaire',\n",
       "          'OtherOutcomeDescription': 'Patient satisfaction',\n",
       "          'OtherOutcomeTimeFrame': '2 months'},\n",
       "         {'OtherOutcomeMeasure': 'Helpful Aspects of Therapy Questionnaire',\n",
       "          'OtherOutcomeDescription': 'Significant events',\n",
       "          'OtherOutcomeTimeFrame': 'weekly for 7 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n18 years old and above\\nMild to moderately severe depressive symptoms: (PHQ-9 score 10-19)\\n\\nExclusion Criteria:\\n\\nSevere depressive symptoms >19 on PHQ-9\\nSuicidal ideation or intent: Score of 2 or above on PHQ-9 question 9\\nPsychosis\\nCurrently in psychological treatment for depression\\nOn medication for less than 1 month\\nAlcohol or drugs misuse\\nPrevious diagnosis of an organic mental health disorder\\nDepression preceding or coinciding a diagnosed medical condition',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '80 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Derek Richards, PhD',\n",
       "          'OverallOfficialAffiliation': 'Trinity College Dublin',\n",
       "          'OverallOfficialRole': 'Study Director'},\n",
       "         {'OverallOfficialName': 'Alicia Salamanca, MSc',\n",
       "          'OverallOfficialAffiliation': 'Trinity College Dublin',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'University Los Andes',\n",
       "          'LocationCity': 'Bogota',\n",
       "          'LocationCountry': 'Colombia'},\n",
       "         {'LocationFacility': 'University of Bucaramanga',\n",
       "          'LocationCity': 'Bucaramanga',\n",
       "          'LocationCountry': 'Colombia'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '11581110',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Ayuso-Mateos JL, Vázquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P, Wilkinson C, Lasa L, Page H, Dunn G, Wilkinson G; ODIN Group. Depressive disorders in Europe: prevalence figures from the ODIN study. Br J Psychiatry. 2001 Oct;179:308-16.'},\n",
       "         {'ReferencePMID': '15939839',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):617-27. Erratum in: Arch Gen Psychiatry. 2005 Jul;62(7):709. Merikangas, Kathleen R [added].'},\n",
       "         {'ReferencePMID': '21791035',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, Levinson D, Matschinger H, Mora ME, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011 Jul 26;9:90. doi: 10.1186/1741-7015-9-90.'},\n",
       "         {'ReferencePMID': '15173149',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, Angermeyer MC, Bernert S, de Girolamo G, Morosini P, Polidori G, Kikkawa T, Kawakami N, Ono Y, Takeshima T, Uda H, Karam EG, Fayyad JA, Karam AN, Mneimneh ZN, Medina-Mora ME, Borges G, Lara C, de Graaf R, Ormel J, Gureje O, Shen Y, Huang Y, Zhang M, Alonso J, Haro JM, Vilagut G, Bromet EJ, Gluzman S, Webb C, Kessler RC, Merikangas KR, Anthony JC, Von Korff MR, Wang PS, Brugha TS, Aguilar-Gaxiola S, Lee S, Heeringa S, Pennell BE, Zaslavsky AM, Ustun TB, Chatterji S; WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004 Jun 2;291(21):2581-90.'},\n",
       "         {'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Bernal, Sáez-Santiago E. Culturally centered psychosocial interventions. Journal of Community Psychology. 2006;34(2):121.'},\n",
       "         {'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Richards D, Timulak L, Hevey D. A comparison of two online cognitive-behavioural interventions for symptoms of depression in a student population: The role of therapist responsiveness. Counselling & Psychotherapy Research. 2013;13(3):184-93.'},\n",
       "         {'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Ministry of Health. National Mental Health survey. Bogota, Colombia: Ministry of Health; 2015. Report No.: 978-958-8903-19-4.'},\n",
       "         {'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Rodriguez J. La atención de Salud Mental en América Latina y el caribe. Rev Psiquiatr Urug. 2007;71(2):117-24.'},\n",
       "         {'ReferencePMID': '21787063',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Merz EL, Malcarne VL, Roesch SC, Riley N, Sadler GR. A multigroup confirmatory factor analysis of the Patient Health Questionnaire-9 among English- and Spanish-speaking Latinas. Cultur Divers Ethnic Minor Psychol. 2011 Jul;17(3):309-316. doi: 10.1037/a0023883.'},\n",
       "         {'ReferencePMID': '11556941',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.'},\n",
       "         {'ReferencePMID': '10568646',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999 Nov 10;282(18):1737-44.'},\n",
       "         {'ReferencePMID': '17874169',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med. 2007 Nov;22(11):1596-602. Epub 2007 Sep 14.'},\n",
       "         {'ReferencePMID': '26523885',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': \"Richards D, Timulak L, O'Brien E, Hayes C, Vigano N, Sharry J, Doherty G. A randomized controlled trial of an internet-delivered treatment: Its potential as a low-intensity community intervention for adults with symptoms of depression. Behav Res Ther. 2015 Dec;75:20-31. doi: 10.1016/j.brat.2015.10.005. Epub 2015 Oct 21.\"},\n",
       "         {'ReferencePMID': '16717171',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7.'},\n",
       "         {'ReferencePMID': '20089179',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'García-Campayo J, Zamorano E, Ruiz MA, Pardo A, Pérez-Páramo M, López-Gómez V, Freire O, Rejas J. Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool. Health Qual Life Outcomes. 2010 Jan 20;8:8. doi: 10.1186/1477-7525-8-8.'},\n",
       "         {'ReferencePMID': '3191302',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Llewelyn SP. Psychological therapy as viewed by clients and therapists. Br J Clin Psychol. 1988 Sep;27(3):223-37.'},\n",
       "         {'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Elliott R, Slatick E, Urman M. Qualitative change process research on psychotherapy: Alternative strategies. Psychological Test and Assessment Modeling. 2001;43(3):69.'},\n",
       "         {'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Richards D, Timulak L. Satisfaction with therapist-delivered vs. self-administered online cognitive behavioural treatments for depression symptoms in college students. British Journal of Guidance & Counselling. 2013;41(2):193-207.'},\n",
       "         {'ReferencePMID': '32003749',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Salamanca-Sanabria A, Richards D, Timulak L, Connell S, Mojica Perilla M, Parra-Villa Y, Castro-Camacho L. A Culturally Adapted Cognitive Behavioral Internet-Delivered Intervention for Depressive Symptoms: Randomized Controlled Trial. JMIR Ment Health. 2020 Jan 31;7(1):e13392. doi: 10.2196/13392.'},\n",
       "         {'ReferencePMID': '29482586',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Salamanca-Sanabria A, Richards D, Timulak L, Castro-Camacho L, Mojica-Perilla M, Parra-Villa Y. Assessing the efficacy of a culturally adapted cognitive behavioural internet-delivered treatment for depression: protocol for a randomised controlled trial. BMC Psychiatry. 2018 Feb 27;18(1):53. doi: 10.1186/s12888-018-1634-x.'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 22,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01159041',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '1R01MH082861',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH082861&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH082856-01A2',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH082856-01A2&Fy=all'},\n",
       "         {'SecondaryId': 'R01MH082861-01A2',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH082861-01A2&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'Boston University Charles River Campus',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Systems of Support Study for Childhood Depression',\n",
       "       'OfficialTitle': 'Evaluation of Family Focused Treatment for Childhood Depression',\n",
       "       'Acronym': 'SOS'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'January 2018',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2010'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 31, 2016',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'July 7, 2010',\n",
       "       'StudyFirstSubmitQCDate': 'July 7, 2010',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 9, 2010',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'January 22, 2018',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 24, 2018',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Martha C. Tompson',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Associate Professor',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Boston University Charles River Campus'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Boston University Charles River Campus',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of California, Los Angeles',\n",
       "          'CollaboratorClass': 'OTHER'},\n",
       "         {'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study is designed to compare two treatments for depression in pre-adolescent (7-13 year old) children. A family-focused treatment will be compared to an individual child-focused treatment in this 14-week intervention.',\n",
       "       'DetailedDescription': 'Childhood-onset depression is an impairing and often recurrent and persistent disorder that impacts current and later development resulting in high personal, social, and economic costs. Despite the costs of early-onset depression, the emphasis in current practice parameters on an initial course of psychosocial treatment, and extensive research on adolescent depression, we currently lack randomized controlled trials evaluating psychosocial treatments for children with depressive disorders.\\n\\nThe present proposal aims to address this gap in knowledge regarding optimal psychosocial treatment strategies for children suffering from depressive disorders. We propose a 2-site randomized controlled trial to evaluate the efficacy of Family Focused Treatment (FFT), as compared to an individual client-centered psychotherapy (IP) modeled after \"usual\" community care. FFT adopts an interpersonal model for understanding how depressive symptoms are maintained, emphasizes developing family skills/strategies for altering interpersonal processes, and works on building a family environment that supports recovery and enhances stress resistance and resilience. This approach may be particularly appropriate to the developmental needs of depressed children, given their dependence on parents, the potential of FFT to address the needs of multiple family members, and our data supporting benefits on depression, functioning, and other co-occurring symptoms.\\n\\nThe proposed project will enroll 140 children (ages 8-12) with depressive disorders. Children will be randomly assigned to receive a 14-week trial of either FFT or IP. At study entry, immediately post-treatment, and at a 9-month post-treatment follow-up all participants will undergo intensive evaluation of clinical state and psychosocial and family functioning.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression, children, adolescent, family']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '134',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Family Focused Treatment (FFT)',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': '15 session family-based treatment emphasizing improving relationship skills to combat depression symptoms and support recovery.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Family Focused Treatment (FFT)']}},\n",
       "         {'ArmGroupLabel': 'Individual Treatment (IP)',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': '15 session individually-based treatment to assist children in understanding the causes of their symptoms.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Individual Treatment (IP)']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Family Focused Treatment (FFT)',\n",
       "          'InterventionDescription': 'FFT is designed to specifically address the developmental needs of school-aged children and their parents through an emphasis on fostering positive and supportive parent-child interactions that scaffold the development of a positive self, to help parents provide the child additional positive feedback on his/her developmentally appropriate achievements, and to enhance family and child coping. This treatment is conducted with the child and his/her parent(s) and includes education about depression, communication training, relationship enhancement, and problem-solving.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Family Focused Treatment (FFT)']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Individual Treatment (IP)',\n",
       "          'InterventionDescription': \"The goals of the treatment are to foster the therapeutic relationship, to provide a supportive and empathic setting where the child can come to better understand his/her emotions/feelings and address issues underlying current symptoms. Therapeutic goals will be addressed through reflection and clarification of feelings/emotions and understanding the child's perception of the context of depressed feelings.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Individual Treatment (IP)']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Adequate Depression Treatment Response',\n",
       "          'PrimaryOutcomeDescription': \"50% improvement on Children's Depression Rating Scale-Revised\",\n",
       "          'PrimaryOutcomeTimeFrame': '3 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Interviewer-rated Depression Severity',\n",
       "          'SecondaryOutcomeDescription': \"Children's Depression Rating Scale-Revised (CDRS-R) measures depression severity over the past two weeks. The 17-item CDRS-R has total scores ranging from 17 to 113 with scores of 40 or greater considered indicative of a depression diagnosis. Used in pharmacological and psychosocial treatment studies, it provides comparability across studies.\",\n",
       "          'SecondaryOutcomeTimeFrame': '3 Months'},\n",
       "         {'SecondaryOutcomeMeasure': \"Children's Self-Report of Depression Symptoms\",\n",
       "          'SecondaryOutcomeDescription': 'Child Depression Inventory (CDI) is a 27-item self-report measure. Scores range from 0 to 54 with higher scores reflecting higher levels of symptoms.',\n",
       "          'SecondaryOutcomeTimeFrame': '3 Months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ncurrent Depressive Disorder\\nages 7-13 years\\nliving with at least one biological parent willing to participate\\n\\nExclusion Criteria:\\n\\nthought disturbance\\nsevere conduct disorders\\nunstable on antidepressant medications\\ncontinuation in current non-study treatment\\nnon-English speaking',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '7 Years',\n",
       "       'MaximumAge': '13 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child']}},\n",
       "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'UCLA Semel Institute for Neuroscience and Human Behavior',\n",
       "          'LocationCity': 'Los Angeles',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '90095',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Boston University',\n",
       "          'LocationCity': 'Boston',\n",
       "          'LocationState': 'Massachusetts',\n",
       "          'LocationZip': '02215',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '17953128',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Tompson MC, Pierre CB, Haber FM, Fogler JM, Groff AR, Asarnow JR. Family-focused treatment for childhood-onset depressive disorders: results of an open trial. Clin Child Psychol Psychiatry. 2007 Jul;12(3):403-20.'},\n",
       "         {'ReferencePMID': '22537731',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Tompson MC, Boger KD, Asarnow JR. Enhancing the developmental appropriateness of treatment for depression in youth: integrating the family in treatment. Child Adolesc Psychiatr Clin N Am. 2012 Apr;21(2):345-84. doi: 10.1016/j.chc.2012.01.003. Epub 2012 Mar 17. Review.'},\n",
       "         {'ReferencePMID': '28545757',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Tompson MC, Sugar CA, Langer DA, Asarnow JR. A Randomized Clinical Trial Comparing Family-Focused Treatment and Individual Supportive Therapy for Depression in Childhood and Early Adolescence. J Am Acad Child Adolesc Psychiatry. 2017 Jun;56(6):515-523. doi: 10.1016/j.jaac.2017.03.018. Epub 2017 Apr 7.'},\n",
       "         {'ReferencePMID': '28966545',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Tompson MC, Langer DA, Hughes JL, Asarnow JR. Family-Focused Treatment for Childhood Depression: Model and Case Illustrations. Cogn Behav Pract. 2017 Aug;24(3):269-287. doi: 10.1016/j.cbpra.2016.06.003.'},\n",
       "         {'ReferencePMID': '31840263',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Asarnow JR, Tompson MC, Klomhaus AM, Babeva K, Langer DA, Sugar CA. Randomized controlled trial of family-focused treatment for child depression compared to individual psychotherapy: one-year outcomes. J Child Psychol Psychiatry. 2019 Dec 15. doi: 10.1111/jcpp.13162. [Epub ahead of print]'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 23,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02030782',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'HS009908'},\n",
       "       'Organization': {'OrgFullName': 'Agency for Healthcare Research and Quality (AHRQ)',\n",
       "        'OrgClass': 'FED'},\n",
       "       'BriefTitle': 'Youth Partners in Care: Depression and Quality Improvement',\n",
       "       'OfficialTitle': 'Youth Partners in Care: Depression & Quality Improvement',\n",
       "       'Acronym': 'YPIC'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'December 2008',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'October 1999'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2003',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2003',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'January 19, 2012',\n",
       "       'StudyFirstSubmitQCDate': 'January 7, 2014',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 9, 2014',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'January 7, 2014',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 9, 2014',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Agency for Healthcare Research and Quality (AHRQ)',\n",
       "        'LeadSponsorClass': 'FED'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'RAND',\n",
       "          'CollaboratorClass': 'OTHER'},\n",
       "         {'CollaboratorName': 'Kaiser Permanente',\n",
       "          'CollaboratorClass': 'OTHER'},\n",
       "         {'CollaboratorName': 'University of Pittsburgh',\n",
       "          'CollaboratorClass': 'OTHER'},\n",
       "         {'CollaboratorName': 'Venice Family Clinic',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This randomized effectiveness trial evaluates a quality improvement intervention aimed at providing access to evidence-based depression treatments (particularly cognitive-behavior therapy for depression and or pharmacotherapy) through primary care for youth ages 13-21, as compared to enhanced usual care. The major hypothesis is that the quality improvement intervention will be associated with improved outcomes, relative to enhanced usual care.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['depression',\n",
       "         'quality improvement',\n",
       "         'treatment',\n",
       "         'adolescents']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '418',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Usual Care',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Patients received usual care through primary care, enhanced by provider education regarding depression evaluation and management (1-2 hour training, plus study manual)',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Usual Care']}},\n",
       "         {'ArmGroupLabel': 'Quality Improvement for Depression',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Quality Improvement (QI) for depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Quality Improvement (QI) for depression',\n",
       "          'InterventionDescription': 'Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Quality Improvement for Depression']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Usual Care',\n",
       "          'InterventionDescription': 'Usual care enhanced by provider education regarding depression evaluation and management',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Usual Care']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Self-reported depressive symptoms on the CES-D (Center for Epidemiologic Studies Depression Scale)',\n",
       "          'PrimaryOutcomeTimeFrame': '6-months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'mental health related quality of life as assessed using self-report on the Medical Outcomes Study Short Form 12 Health Survey.',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months, with follow up at 12 and 18 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'satisfaction with care',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months with follow up at 12 and 18 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Rates of mental health care, counseling/psychotherapy, and medication treatment.',\n",
       "          'SecondaryOutcomeDescription': 'Youth self report on the study version of the Service Assessment for Children & Adolescents provided measures of rates of mental health care(dichotomous indicator of whether any mental health treatment received), counseling/psychotherapy (dichotomous indicator of whether counseling/psychotherapy was received, number of counseling/psychotherapy sessions), and medication treatment (dichotomous indicator of whether youth received any medication treatment for mental health problems). These measures were obtained using .',\n",
       "          'SecondaryOutcomeTimeFrame': '6-months with follow-up at 12 and 18 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMet either of two criteria: 1) endorsed \"stem items\" for major depression or dysthymia from the 12-month Composite International Diagnostic Interview(CIDI-12,2.1) modified slightly to conform to diagnostic criteria for adolescents, 1-week or more of past-month depressive symptoms, and a total Center for Epidemiological Studies- Depression Scale(CES-D)40 score ≥ 16, or 2) CES-D score ≥ 24.\\nAge 13-21\\nPresented at primary care clinic\\n\\nExclusion Criteria:\\n\\nnot English-speaking\\nprovider not in study\\nsibling already in study\\ncompleted eligibility screener previously',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '13 Years',\n",
       "       'MaximumAge': '21 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child', 'Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Joan R Asarnow, PhD',\n",
       "          'OverallOfficialAffiliation': 'University of California, Los Angeles',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'University of California',\n",
       "          'LocationCity': 'Los Angeles',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '90024',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Kaiser Permanente Los Angeles Medical Center',\n",
       "          'LocationCity': 'Los Angeles',\n",
       "          'LocationState': 'California',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Venice Family Clinic',\n",
       "          'LocationCity': 'Venice',\n",
       "          'LocationState': 'California',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Ventura County Medical Center',\n",
       "          'LocationCity': 'Ventura',\n",
       "          'LocationState': 'California',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'University of Pittsburgh',\n",
       "          'LocationCity': 'Pittsburgh',\n",
       "          'LocationState': 'Pennsylvania',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '12222079',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Asarnow JR, Jaycox LH, Anderson M. Depression among youth in primary care models for delivering mental health services. Child Adolesc Psychiatr Clin N Am. 2002 Jul;11(3):477-97, viii.'},\n",
       "         {'ReferencePMID': '11430853',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Wells KB, Kataoka SH, Asarnow JR. Affective disorders in children and adolescents: addressing unmet need in primary care settings. Biol Psychiatry. 2001 Jun 15;49(12):1111-20. Review.'},\n",
       "         {'ReferencePMID': '19651711',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Asarnow JR, Jaycox LH, Tang L, Duan N, LaBorde AP, Zeledon LR, Anderson M, Murray PJ, Landon C, Rea MM, Wells KB. Long-term benefits of short-term quality improvement interventions for depressed youths in primary care. Am J Psychiatry. 2009 Sep;166(9):1002-10. doi: 10.1176/appi.ajp.2009.08121909. Epub 2009 Aug 3.'},\n",
       "         {'ReferencePMID': '15657324',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Asarnow JR, Jaycox LH, Duan N, LaBorde AP, Rea MM, Murray P, Anderson M, Landon C, Tang L, Wells KB. Effectiveness of a quality improvement intervention for adolescent depression in primary care clinics: a randomized controlled trial. JAMA. 2005 Jan 19;293(3):311-9.'},\n",
       "         {'ReferencePMID': '16502131',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': \"Jaycox LH, Asarnow JR, Sherbourne CD, Rea MM, LaBorde AP, Wells KB. Adolescent primary care patients' preferences for depression treatment. Adm Policy Ment Health. 2006 Mar;33(2):198-207.\"},\n",
       "         {'ReferencePMID': '16310125',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Asarnow JR, Jaycox LH, Duan N, LaBorde AP, Rea MM, Tang L, Anderson M, Murray P, Landon C, Tang B, Huizar DP, Wells KB. Depression and role impairment among adolescents in primary care clinics. J Adolesc Health. 2005 Dec;37(6):477-83.'},\n",
       "         {'ReferencePMID': '19797376',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Ngo VK, Asarnow JR, Lange J, Jaycox LH, Rea MM, Landon C, Tang L, Miranda J. Outcomes for youths from racial-ethnic minority groups in a quality improvement intervention for depression treatment. Psychiatr Serv. 2009 Oct;60(10):1357-64. doi: 10.1176/ps.2009.60.10.1357.'},\n",
       "         {'ReferencePMID': '18937226',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Tang L, Duan N, Klap R, Asarnow JR, Belin TR. Applying permutation tests with adjustment for covariates and attrition weights to randomized trials of health-services interventions. Stat Med. 2009 Jan 15;28(1):65-74. doi: 10.1002/sim.3453.'},\n",
       "         {'ReferencePMID': '18018807',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Goldstein RB, Asarnow JR, Jaycox LH, Shoptaw S, Murray PJ. Correlates of \"non-problematic\" and \"problematic\" substance use among depressed adolescents in primary care. J Addict Dis. 2007;26(3):39-52.'},\n",
       "         {'ReferencePMID': '17658983',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Fordwood SR, Asarnow JR, Huizar DP, Reise SP. Suicide attempts among depressed adolescents in primary care. J Clin Child Adolesc Psychol. 2007 Jul-Sep;36(3):392-404.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 24,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00755235',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'R21MH082924',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R21MH082924&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R21MH082924',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R21MH082924&Fy=all'},\n",
       "         {'SecondaryId': 'DSIR 82-SEDR'}]},\n",
       "       'Organization': {'OrgFullName': 'Kaiser Permanente',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Feasibility of Depression Care Management by E-mail',\n",
       "       'OfficialTitle': 'Pilot Trial of Depression Care Management by Electronic Secure Messaging'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'October 2017',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'April 2009'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2010',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'April 2010',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'September 17, 2008',\n",
       "       'StudyFirstSubmitQCDate': 'September 17, 2008',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 18, 2008',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'July 22, 2011',\n",
       "       'ResultsFirstSubmitQCDate': 'May 31, 2012',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'June 1, 2012',\n",
       "        'ResultsFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'October 11, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 13, 2017',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Kaiser Permanente',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study will test whether an electronic system that monitors and sends messages to help people with depression could be feasible, acceptable, and potentially effective as a treatment.',\n",
       "       'DetailedDescription': 'Symptoms of depression, such as persistent sadness, problems sleeping, and inability to feel pleasure, interfere with the daily lives of more than 20 million Americans. Previous research indicates that telephone care management systems improve the quality and outcomes of depression care, but are too expensive to be used widely. Using secure messaging over e-mail would be more cost effective than telephone care. This study will examine whether a secure messaging care management program would be feasible, based on whether participants are willing to sign up for and continue with the program, and whether the program has a positive effect on those participants enrolled in the program.\\n\\nPotential participants for this study will be contacted via e-mail, with a follow-up telephone call if they do not respond to the e-mail message. Only people who have used e-mails in the past year and who are starting antidepressant treatment will be contacted. The percentage of people contacted who enroll will be recorded.\\n\\nParticipation in this study will last 6 months. Participants will be randomly assigned to receive either a secure messaging care management program, based on effective telephone management programs, or their usual care with no intervention. Those receiving the secure messaging program will receive an initial welcome message and monitoring messages approximately 2, 6, and 10 weeks after treatment has begun. The monitoring messages will include structured assessments of depression severity, medication adherence, medication side effects, and barriers to continuing treatment. Participants who do not respond to monitoring messages will receive up to two e-mailed reminders. Care managers will analyze the results of monitoring messages, provide feedback and recommendations to physicians, coordinate physician follow-ups, and facilitate emergency care or specialty referrals. Care managers will also provide patients with motivation, based on semi-scripted protocols, and education concerning their disorder and treatment. Measures of the success of the study will be taken at enrollment and after 6 months of participation. Specific measurements will include the response rate of recruitment e-mails, response rate for follow-up data collection, proportion of those in the secure messaging program who complete the monitoring assessments, effects of the program on antidepressant treatment, and effects of the program on patient satisfaction.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Primary care',\n",
       "         'Effectiveness',\n",
       "         'Care management']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '208',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '1',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants will receive depression care management by secure messaging.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression care management by secure messaging']}},\n",
       "         {'ArmGroupLabel': '2',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Participants will receive their usual care, with no additional education or care management services.'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Depression care management by secure messaging',\n",
       "          'InterventionDescription': \"Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['online messaging',\n",
       "            'email']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': '20-Item Symptom Checklist Depression Scale',\n",
       "          'PrimaryOutcomeDescription': '20-item depression severity scalse adapted from longer SCL-90. Mean score ranges from 0 to 4 with scores above 1.5 indicating moderate depression.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Measured at baseline and after 6 months of treatment'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Treatment Satisfaction',\n",
       "          'SecondaryOutcomeDescription': 'Single item seven point scale ranging from \"very satisfied\" to \"very dissatisfied\"',\n",
       "          'SecondaryOutcomeTimeFrame': 'Measured after 6 months of treatment'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatient at Capitol Hill or Rainier clinics of Group Health Cooperative in Seattle\\nNew prescription of an antidepressant, defined by an interval of at least 180 days since a previous antidepressant prescription\\nIndication of depression, defined by a visit diagnosis of major depressive disorder (Internal Classification of Diseases 9th Revision [ICD9] codes 296.2x or 296.3x) within 30 days of the first prescription\\nHas used secure messaging, or e-mailing, at least twice in the last 12 months\\n\\nExclusion Criteria:\\n\\nAny diagnosis of psychotic disorder or bipolar disorder in the prior 2 years\\nAny prescription for mood stabilizer or antipsychotic medication in the prior 2 years',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Gregory E. Simon, MD, MPH',\n",
       "          'OverallOfficialAffiliation': 'Group Health Cooperative Center for Health Studies',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Group Health Cooperative Center for Health Studies',\n",
       "          'LocationCity': 'Seattle',\n",
       "          'LocationState': 'Washington',\n",
       "          'LocationZip': '98101',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '21384219',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Simon GE, Ralston JD, Savarino J, Pabiniak C, Wentzel C, Operskalski BH. Randomized trial of depression follow-up care by online messaging. J Gen Intern Med. 2011 Jul;26(7):698-704. doi: 10.1007/s11606-011-1679-8. Epub 2011 Mar 8.'}]}}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Secure Messaging Care Management',\n",
       "          'FlowGroupDescription': 'Participants will receive depression care management by secure messaging.'},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Usual Care',\n",
       "          'FlowGroupDescription': 'Participants will receive their usual care, with no additional education or care management services.'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '106'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '102'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '104'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '93'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '2'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '9'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Secure Messaging Care Management',\n",
       "          'BaselineGroupDescription': 'Participants will receive depression care management by secure messaging.'},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Usual Care',\n",
       "          'BaselineGroupDescription': 'Participants will receive their usual care, with no additional education or care management services.'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '106'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '102'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '208'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '96'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '94'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '190'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '10'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '8'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '18'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '48',\n",
       "                   'BaselineMeasurementSpread': '9'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '48',\n",
       "                   'BaselineMeasurementSpread': '10'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '48',\n",
       "                   'BaselineMeasurementSpread': '9'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '76'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '74'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '150'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '30'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '28'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '58'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '106'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '102'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '208'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': '20-Item Symptom Checklist Depression Scale',\n",
       "          'OutcomeMeasureDescription': '20-item depression severity scalse adapted from longer SCL-90. Mean score ranges from 0 to 4 with scores above 1.5 indicating moderate depression.',\n",
       "          'OutcomeMeasurePopulationDescription': 'Analysis included all participants participating in outcome assessment',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'Measured at baseline and after 6 months of treatment',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Secure Messaging Care Management',\n",
       "             'OutcomeGroupDescription': 'Participants will receive depression care management by secure messaging.'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Usual Care',\n",
       "             'OutcomeGroupDescription': 'Participants will receive their usual care, with no additional education or care management services.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '104'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '93'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '0.95',\n",
       "                   'OutcomeMeasurementSpread': '0.71'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '1.17',\n",
       "                   'OutcomeMeasurementSpread': '0.81'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Treatment Satisfaction',\n",
       "          'OutcomeMeasureDescription': 'Single item seven point scale ranging from \"very satisfied\" to \"very dissatisfied\"',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Number',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'participants',\n",
       "          'OutcomeMeasureTimeFrame': 'Measured after 6 months of treatment',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Secure Messaging Care Management',\n",
       "             'OutcomeGroupDescription': 'Participants will receive depression care management by secure messaging.'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Usual Care',\n",
       "             'OutcomeGroupDescription': 'Participants will receive their usual care, with no additional education or care management services.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '104'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '93'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Very Satisfied',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '56'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '31'}]}}]}},\n",
       "            {'OutcomeClassTitle': 'Less than very satisfied',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '48'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '62'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '1',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Secure Messaging Care Management',\n",
       "          'EventGroupDescription': 'Participants will receive depression care management by secure messaging.',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '104',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '104'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Usual Care',\n",
       "          'EventGroupDescription': 'Participants will receive their usual care, with no additional education or care management services.',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '93',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '93'}]},\n",
       "       'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Suicide attempt',\n",
       "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
       "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '104'},\n",
       "            {'SeriousEventStatsGroupId': 'EG001',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '93'}]}}]}},\n",
       "      'MoreInfoModule': {'LimitationsAndCaveats': {},\n",
       "       'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
       "        'AgreementRestrictiveAgreement': 'No'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Gregory Simon, Principal Investigator',\n",
       "        'PointOfContactOrganization': 'Group Health Research Institute',\n",
       "        'PointOfContactEMail': 'simon.g@ghc.org',\n",
       "        'PointOfContactPhone': '206-287-2979'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 25,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02335554',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '81RR-2R'},\n",
       "       'Organization': {'OrgFullName': 'Oregon Center for Applied Science, Inc.',\n",
       "        'OrgClass': 'INDUSTRY'},\n",
       "       'BriefTitle': 'Internet Program for Workers With Subthreshold Depression',\n",
       "       'OfficialTitle': 'Multimedia Internet-Based Program for Workers With Subthreshold Depression',\n",
       "       'Acronym': 'WorkDep'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'January 2015',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'August 2012'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2013',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'June 2013',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'January 7, 2015',\n",
       "       'StudyFirstSubmitQCDate': 'January 8, 2015',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 9, 2015',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'January 9, 2015',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 12, 2015',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Oregon Center for Applied Science, Inc.',\n",
       "        'LeadSponsorClass': 'INDUSTRY'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Depression is one of the most prevalent mental disorders to afflict adults. It seriously impacts role functioning and often takes a recurrent or chronic course. Because most adults who suffer from depression never receive treatment, there is a critical need to develop interventions that can be easily implemented and widely disseminated. Interventions that reduce the performance-impairing symptoms of subclinical depression and prevent the onset of major depression can improve employee well-being, while reducing healthcare costs and improving productivity. This project produced a mobile-web program to activate cognitive behavioral skills in workers with subthreshold depression, reduce depression symptoms, improve functioning in the workplace, and potentially reduce the risk for escalation to full-syndrome depression.',\n",
       "       'DetailedDescription': 'The responsive mobile-web MoodHacker app was designed to: (a) educate users about depression; (b) educate users about the logistics and benefits of mood and activity monitoring; (c) promote daily mood and activity monitoring; (d) help users increase their positive activity engagement; (e) help users decrease negative thinking and increase positive thinking; and (f) promote daily practice of the skills taught.\\n\\nProgram content was adapted from the Coping with Depression group therapy course [18], enhanced with mindfulness-based [22] and other evidence-based positive psychology strategies [23-25]. Content for the application was refined based on input from experts in the field who had extensive experience working with adult employees at risk for depression. Additional program modifications were made based on data from individual interviews and iterative user testing with the population of interest during the formative and production phases of the project.\\n\\nThe MoodHacker user experience is structured around twelve learning objectives delivered through daily emails, in-app messaging, and in the \"Articles & Videos\" library. Daily emails (Figure 1) are sent to engage users in program content, provide sequenced guidance through the learning objectives in the articles and whiteboard-style videos, give tips for getting the most out of MoodHacker, and prompt the user to track their mood and activities daily. Users are encouraged to view the articles and videos as ordered, but viewing is not restricted, and users can view content according to their interest. The emails, articles and videos promote practice of the featured cognitive and behavioral skills outside the app experience.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Subthreshold',\n",
       "         'Employees',\n",
       "         'Internet',\n",
       "         'Mobile',\n",
       "         'cognitive-behavioral']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '300',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'MoodHacker',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants in the treatment condition were emailed a link to the MoodHacker mobile-web app and instructed to use the program for the next six weeks. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: MoodHacker']}},\n",
       "         {'ArmGroupLabel': 'Alternative Care',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Alternative care participants were emailed and encouraged to browse links to vetted online information about depression. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline and were given access to the MoodHacker program after the 10-week assessment',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Alternative Care']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'MoodHacker',\n",
       "          'InterventionDescription': 'Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['MoodHacker']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Internet program for workers with subthreshold depression']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Alternative Care',\n",
       "          'InterventionDescription': 'Online information about depression from government and other trusted sources to educate users about depression.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Alternative Care']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression symptoms as assessed by the Patient Health Questionnaire-9 (PHQ-9)',\n",
       "          'PrimaryOutcomeDescription': 'Depressive symptomatology was assessed at each assessment point using the self-reported Patient Health Questionnaire-9 scale to assess the nine DSM-IV major depression symptoms. The PHQ-9 is a self-report version of the Primary Care Evaluation of Mental Disorders (PRIME-MD) and has been shown to be a reliable and valid brief depression assessment tool.',\n",
       "          'PrimaryOutcomeTimeFrame': '10 week follow-up'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Activation of positive self-care and life-choice behaviors',\n",
       "          'SecondaryOutcomeDescription': 'How actively individuals are taking care of themselves, including making positive life choices, was expected to increase as a result of the intervention. Behavioral activation was measured using the Behavioral Activation for Depression Scale Short Form (BADS). This scale consists of 9 items.',\n",
       "          'SecondaryOutcomeTimeFrame': '6-week posttest and 10-week follow-up'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in negative thinking',\n",
       "          'SecondaryOutcomeDescription': 'Change in negative thinking was assessed using the Automatic Thoughts Questionnaire - Revised scale Short Form (ATQ-R-SF). A 12-item adaptation of the ATQ-R instrument asked respondents to rate how many times over the past week they have had thoughts that are consistent with 12 negative self-statements.',\n",
       "          'SecondaryOutcomeTimeFrame': '6-week posttest and 10-week follow-up'},\n",
       "         {'SecondaryOutcomeMeasure': 'Knowledge about depression',\n",
       "          'SecondaryOutcomeDescription': 'Treatment participants were assessed for an increase in knowledge about depression. The scale consisted of 14 multiple-choice items based on the 12 learning objectives addressed in the MoodHacker articles and videos.',\n",
       "          'SecondaryOutcomeTimeFrame': '6-week posttest and 10-week follow-up'},\n",
       "         {'SecondaryOutcomeMeasure': 'Worker productivity as assessed by the Work Limitations Questionnaire',\n",
       "          'SecondaryOutcomeDescription': \"Worker productivity was assessed using the Work Limitations Questionnaire (WLQ). The WLQ Short Form consists of 10 items divided into four subscales measuring the degree to which a person was limited in their job's (1) time demands; (2) physical demands; (3) mental demands; and (4) output demands.\",\n",
       "          'SecondaryOutcomeTimeFrame': '6-week posttest and 10-week follow-up'},\n",
       "         {'SecondaryOutcomeMeasure': 'Worksite outcomes as assessed by the Workplace Outcomes Suite',\n",
       "          'SecondaryOutcomeDescription': 'Worksite outcomes were also assessed using the Workplace Outcomes Suite (WOS). The WOS is designed as an open-access instrument to facilitate empirical research on Employee Assistance Program (EAP) interventions. The suite contains five 5-item scales that assess: absenteeism, presenteeism, work engagement, life satisfaction, and workplace distress.',\n",
       "          'SecondaryOutcomeTimeFrame': '6-week posttest and 10-week follow-up'},\n",
       "         {'SecondaryOutcomeMeasure': 'User satisfaction as assessed by the System Usability Scale',\n",
       "          'SecondaryOutcomeDescription': 'Treatment participants completed the System Usability Scale, which is a quantitative measure of program ease of use. The scale includes 10 items. Users were asked to what degree they agreed or disagreed with program use and satisfaction statements on a 6-point scale (1=strongly disagree; 6=strongly agree).',\n",
       "          'SecondaryOutcomeTimeFrame': '6 week posttest'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n18 years or older\\nmild-to-moderate depressive symptoms as measured by the PHQ-9 (score of 10-19)\\nnot currently suicidal or meeting criteria for bipolar or schizo-affective disorder\\nemployed at least part-time\\nEnglish speaking\\naccess to a high-speed internet connection\\n\\nExclusion Criteria:\\n\\nyounger than 18 years old\\nsevere depressive symptoms as measured by the PHQ-9 (score of 20+)\\ncurrently suicidal or meeting criteria for bipolar or schizo-affective disorder\\nemployed less than part-time or unemployed\\nnot English speaking\\nno access to a high-speed internet connection',\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '85 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Amy J Birney, MPH, MCHES',\n",
       "          'OverallOfficialAffiliation': 'Oregon Center for Applied Science',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26813737',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Birney AJ, Gunn R, Russell JK, Ary DV. MoodHacker Mobile Web App With Email for Adults to Self-Manage Mild-to-Moderate Depression: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2016 Jan 26;4(1):e8. doi: 10.2196/mhealth.4231.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 26,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02069301',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '5R34MH094648-02',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=5R34MH094648-02&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '5R34MH094648-02',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=5R34MH094648-02&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'RAND', 'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Evaluation of an Integrated Microfinance and Depression Care Program for Women',\n",
       "       'OfficialTitle': 'Development of an Integrated Microfinance and Depression Care Program for Women',\n",
       "       'Acronym': 'LIFE-DM'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'November 2017',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'February 2014',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'September 2016',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'February 10, 2014',\n",
       "       'StudyFirstSubmitQCDate': 'February 19, 2014',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 24, 2014',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'November 28, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 30, 2017',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Victoria K. Ngo, PhD',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Behavior Scientist',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'RAND'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'RAND', 'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'},\n",
       "         {'CollaboratorName': 'Danang Psychiatric Hospital',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The study evaluates LIFE-DM, an integrated microfinance and collaborative care intervention by comparing it to enhanced treatment as usual (national guideline antidepressant care and referral to microfinance resources) in Vietnam. Intervention effects at baseline, 6 month, and 12 month follow-up on patient outcomes, including depression, anxiety, quality of life, functioning, self-efficacy, satisfaction, and income will be compared across the two conditions.',\n",
       "       'DetailedDescription': 'Depression is one of the largest contributors to the world\\'s health burden. Prior work in the Partners in Care study has shown that evidence-based service delivery programs for depression can improve health outcomes in depressed patients, and especially in minorities, largely overcoming disparities in outcomes from care between whites and minorities. Effective treatments exist, but they do not reach many depressed individuals, especially in resource-poor communities--ethnic minorities, rural residents in the United States, and individuals in most of the developing world.\\n\\nWomen, in particular, are at risk for depression and poverty. Integrating programs that treat depression and address livelihood concerns may improve engagement in depression treatment and improve mental health and functioning for patients in low-resource settings. The proposed study would integrate depression care with existing \"microfinance\" programs, which provide poverty-alleviation services including small loans, savings programs, and vocational training to women.\\n\\nThis project will (1) conduct qualitative studies of barriers and facilitators of women\\'s successful use of existing depression care and microfinance programs; (2) adapt and integrate the depression care and microfinance services; (3) train Women\\'s Union facilitators to deliver the integrated depression care and microfinance program; and conduct evaluation of LIFE-DM program to assess acceptability, feasibility, and preliminary effectiveness. The non-randomized control trial compares the integrated microfinance and collaborative care intervention with enhanced treatment as usual (national guideline antidepressant care and referral to microfinance resources) at the Women\\'s Union in Danang city in Vietnam.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Behavior Activation',\n",
       "         'Problem solving therapy',\n",
       "         'Depression Treatment',\n",
       "         'depression care integration',\n",
       "         'microfinance',\n",
       "         'livelihood']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '166',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Integrated Depression/Microfinance Group',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'LIFE-DM is a Depression and Microfinance integrated program using behavior activation and problem solving therapy applied to both depression and livelihood. Livelihood support include microfinance loans, personal finance, and income-generation skills.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Integrated Depression/Microfinance Group',\n",
       "            'Other: Treatment as Usual',\n",
       "            'Other: Livelihood Support']}},\n",
       "         {'ArmGroupLabel': 'Treatment as Usual',\n",
       "          'ArmGroupType': 'Other',\n",
       "          'ArmGroupDescription': 'Currently treatment as usual in this province includes national guidelines for antidepressant care for depression and referral for microfinance/livelihood programs',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Treatment as Usual']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Integrated Depression/Microfinance Group',\n",
       "          'InterventionDescription': 'LIFE-DM Integrated Depression and Microfinance group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Integrated Depression/Microfinance Group']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['LIFE-DM Group']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Treatment as Usual',\n",
       "          'InterventionDescription': 'National Guideline for antidepressant care',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Integrated Depression/Microfinance Group',\n",
       "            'Treatment as Usual']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Guideline antidepressant care',\n",
       "            'Fluoxetine, Amitrytaline',\n",
       "            'other antidepressants']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Livelihood Support',\n",
       "          'InterventionDescription': 'Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Integrated Depression/Microfinance Group']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Microfinance loans']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Depression Score from the Patient Health Questionnaire',\n",
       "          'PrimaryOutcomeDescription': 'The PHQ-9 is a nine-item validated tool measuring depressive symptoms based on DSM-IV criteria. The answers are rated on a scale from zero (not at all) to three (nearly every day). Total scores range from 0-27, subdivided into five categories of depression severity: 1 to 4 is minimal; 5 to 9 is mild; 10 to 14 is moderate; 15 to 19 is moderate-severe; and 20 and above is severe. The PHQ-9 has been widely used internationally including in Vietnam.',\n",
       "          'PrimaryOutcomeTimeFrame': '0, 6, 12 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Quality of Life Score from Quality of Life and Enjoyment and Satisfaction Questionnaire',\n",
       "          'SecondaryOutcomeDescription': 'The Quality of Life Enjoyment and Satisfaction Questionnaire is a self-report measure designed to enable investigators to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning. The summary scores were found to be reliable and valid measures of these dimensions in a group of depressed outpatients. The Q-LES-Q measures were related to, but not redundant with, measures of overall severity of illness or severity of depression within this sample. These findings suggest that the Q-LES-Q measures may be sensitive to important differences among depressed patients that are not detected by the measures usually employed.',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Self-Efficacy Score from Self Efficacy Survey',\n",
       "          'SecondaryOutcomeDescription': 'Items were developed to assess effectiveness of a goal-setting and planning intervention (Macleod et al., 2008). Self-efficacy is assessed via 4-items that measure locus of control, materials and skills to complete goals, confidence, and optimism. Self-efficacy is rated on a 9-point scale from 1 (\"Not at all\") to 9 (\"To a great extent\").',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Social Support Index from Medical Outcome Study Social Support Survey',\n",
       "          'SecondaryOutcomeDescription': 'A brief, multidimensional, selfadministered, social support survey that was developed for patients in the Medical Outcomes Study (MOS), a two-year study of patients with chronic conditions. This survey was designed to be comprehensive in terms of recent thinking about the various dimensions of social support.',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in health and mental health functioning scores from Medical Outcomes Study Short Form Health Survey (SF-12)',\n",
       "          'SecondaryOutcomeDescription': 'The SF-12v2 is a 12-item survey that measures the same eight domains of health. The domains scores are summarized into two composite scores: Physical Component Summary and Mental Component Summary scores. The survey is a brief, reliable measure of overall health status. It is useful in large population health surveys and has been used in Vietnamese populations.',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Anxiety Symptom Score from Generalized Anxiety Disorder (GAD-7) Scale',\n",
       "          'SecondaryOutcomeDescription': 'The GAD-7 is a 7-item anxiety scale used for screening and assessing symptom severity of GAD. GAD and depression symptoms frequently occurred together, but factor analysis confirmed them as distinct dimensions, and they had independent effects on functional impairment and disability. Self-report and interviewer-administered versions of GAD-7 were in good agreement.',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Behavior Activation Score from the Behavior Activation for Depression Scale Short Form (BADS-SF)',\n",
       "          'SecondaryOutcomeDescription': 'The abbreviated BADS-SF is a nine-item scale measuring factors expected to change as a function of behavioral activation, including activation and avoidance',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in household wealth indicators from Economic Well-Being Inventory',\n",
       "          'SecondaryOutcomeDescription': 'The economic well-being inventory collect various indicators of self-reported household wealth: housing materials, land ownership, home ownership, and selling and purchasing of assets such as livestock and durable goods (car, bicycle, radio, TV), as well as income, savings, and debt. This economic well-being inventory was used in the Danang Household Mental Health Survey.',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in number and type of income generating activities from the Employment and business Activities Questionnaire',\n",
       "          'SecondaryOutcomeDescription': 'We developed questionnaire to measure income generating activities, which include questions about participation and number of hours in types of employment and income generating activities in Low-Income countries, including formal salaried employment, farming and planting food, selling goods and services, property rentals, etc.',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Treatment Acceptability Score from Help-Seeking Behavior Questionnaire',\n",
       "          'SecondaryOutcomeDescription': \"This measure consists of items that assesses 1) resources in the community, 2) participant's help seeking history, 3) perceived effectiveness, and 4) acceptability of a variety of strategies used for depression care.\",\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Depression Stigma Score from the Depression Stigma Questionnaire',\n",
       "          'SecondaryOutcomeDescription': '18 item questionnaire about perceived and personal stigma related to depression.',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Social Capital Score from Social Capital Assessment Tool',\n",
       "          'SecondaryOutcomeDescription': 'The short version of the Adapted Social Capital Assessment Tool (SASCAT) is a nine-item tool measures the structural (quantity of social relationships) and cognitive (quality of social relationships) components of social capital as well as citizenship. The measure derived from the Adapted Social Capital Assessment Tool (A-SCAT) (Harpham et al., 2002). The measures has been used in many international settings, including developing countries.',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Total Score Client Service Satisfaction Questionnaire',\n",
       "          'SecondaryOutcomeDescription': 'A standardized measure with strong psychometric properties that could be used to assess general satisfaction across varied health and human services. The CSQ Scales® (CSQ) measure may be used to assess client satisfaction with mental health services, as a program evaluation tool, or to assess client satisfaction within and across programs (intra- or inter-program) and demographic groups.',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Number of Participants Demonstrating Mental Health Literacy with Depression Vignette',\n",
       "          'SecondaryOutcomeDescription': 'Vignette describes someone with the minimal number of symptoms necessary for major depression (according to DSM description). Respondents were asked an open-ended question, ``What would you say, if anything, is wrong with Mary?\\'\\' Only answers including \" depression \" are considered a correct response.',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Number of Participants with Depression Diagnosis - MINI International Neuropsychiatric Interview, Version 6.0 (MINI)',\n",
       "          'SecondaryOutcomeDescription': 'The MINI is a brief structured psychiatric interview used to diagnose for multiple axis I DSM-IV mental disorders. In this study, the MINI is used to assess for major depressive episodes. Using DSM-IV criteria (at least 5 symptoms of depression over a 2 week period; endorsement of depressed mood or anhedonia were necessary for diagnosis) the interviewers can distinguish between past, current, and recurrent episodes of depression. The MINI is a reliable and valid alternative to the longer Structured Clinical Interview for Diagnostic. The MINI has been used widely in developing countries and administered by non-mental health providers.',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 6, 12 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ndepression, low-income\\n\\nExclusion Criteria:\\n\\npsychosis, mania, substance abuse, high suicide risk, physical disabilities, significant cognitive impairments',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Female',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '55 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Victoria K Ngo, PhD',\n",
       "          'OverallOfficialAffiliation': 'RAND',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Hoa Cuong Bac Commune Health Station',\n",
       "          'LocationCity': 'Da Nang',\n",
       "          'LocationCountry': 'Vietnam'},\n",
       "         {'LocationFacility': 'Hoa Cuong Nam Commune Health Station',\n",
       "          'LocationCity': 'Da Nang',\n",
       "          'LocationCountry': 'Vietnam'},\n",
       "         {'LocationFacility': 'Hoa Hiep Nam Commune Health Station',\n",
       "          'LocationCity': 'Da Nang',\n",
       "          'LocationCountry': 'Vietnam'},\n",
       "         {'LocationFacility': 'Hoa Minh Commune Health Station',\n",
       "          'LocationCity': 'Da Nang',\n",
       "          'LocationCountry': 'Vietnam'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25568593',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Ngo VK, Weiss B, Lam T, Dang T, Nguyen T, Nguyen MH. The Vietnam Multicomponent Collaborative Care for Depression Program: Development of Depression Care for Low- and Middle-Income Nations. J Cogn Psychother. 2014;28(3):156-167.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000005473',\n",
       "          'InterventionMeshTerm': 'Fluoxetine'},\n",
       "         {'InterventionMeshId': 'D000000928',\n",
       "          'InterventionMeshTerm': 'Antidepressive Agents'}]},\n",
       "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000017367',\n",
       "          'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000014179',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000049990',\n",
       "          'InterventionAncestorTerm': 'Membrane Transport Modulators'},\n",
       "         {'InterventionAncestorId': 'D000045504',\n",
       "          'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "         {'InterventionAncestorId': 'D000018377',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Agents'},\n",
       "         {'InterventionAncestorId': 'D000018490',\n",
       "          'InterventionAncestorTerm': 'Serotonin Agents'},\n",
       "         {'InterventionAncestorId': 'D000045505',\n",
       "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'},\n",
       "         {'InterventionAncestorId': 'D000018687',\n",
       "          'InterventionAncestorTerm': 'Antidepressive Agents, Second-Generation'},\n",
       "         {'InterventionAncestorId': 'D000011619',\n",
       "          'InterventionAncestorTerm': 'Psychotropic Drugs'},\n",
       "         {'InterventionAncestorId': 'D000065690',\n",
       "          'InterventionAncestorTerm': 'Cytochrome P-450 CYP2D6 Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000065607',\n",
       "          'InterventionAncestorTerm': 'Cytochrome P-450 Enzyme Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000004791',\n",
       "          'InterventionAncestorTerm': 'Enzyme Inhibitors'}]},\n",
       "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M7184',\n",
       "          'InterventionBrowseLeafName': 'Fluoxetine',\n",
       "          'InterventionBrowseLeafAsFound': 'Fluoxetine',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M2828',\n",
       "          'InterventionBrowseLeafName': 'Antidepressive Agents',\n",
       "          'InterventionBrowseLeafAsFound': 'Antidepressant',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M14095',\n",
       "          'InterventionBrowseLeafName': 'Serotonin',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M18232',\n",
       "          'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19088',\n",
       "          'InterventionBrowseLeafName': 'Neurotransmitter Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M13057',\n",
       "          'InterventionBrowseLeafName': 'Psychotropic Drugs',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M29124',\n",
       "          'InterventionBrowseLeafName': 'Cytochrome P-450 Enzyme Inhibitors',\n",
       "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr',\n",
       "          'InterventionBrowseBranchName': 'Psychotropic Drugs'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 27,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03887390',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '120560'},\n",
       "       'Organization': {'OrgFullName': 'Laval University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Depression Medication Choice Decision Aid',\n",
       "       'OfficialTitle': 'Implementation of the Depression Medication Choice Decision Aid in a Canadian Context: A Feasibility Trial'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2020',\n",
       "       'OverallStatus': 'Terminated',\n",
       "       'WhyStopped': 'First the study failed to recruit the required sample size. Second, we no longer have acess to the clinics, due to the coronavirus outbreak',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'July 22, 2019',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 28, 2020',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'March 20, 2020',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'March 12, 2019',\n",
       "       'StudyFirstSubmitQCDate': 'March 21, 2019',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 25, 2019',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'March 20, 2020',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 24, 2020',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Annie Leblanc',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Associate Professor',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Laval University'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Laval University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Réseau-1 Québec',\n",
       "          'CollaboratorClass': 'UNKNOWN'},\n",
       "         {'CollaboratorName': 'CERSSPL', 'CollaboratorClass': 'UNKNOWN'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The quality of care for patients facing depression, one of the most prevalent chronic diseases, needs improvement. Despite its high incidence, depression remains sub-optimally managed, particularly in primary care, where most patients suffering from depression receive care. Successfully treated depressive patients can potentially improve their burden of disease and significantly improve their quality of life, but not without the best treatment adapted to their contexts, preferences, and expectations. Clinical research provides essential knowledge for the delivery of quality care which is unfortunately seldom applied in daily practice.\\n\\nOne of the preferred methods for overcoming this lack of quality of care is shared decision making: a collaborative process between a clinician and patient that relies on the consideration of scientific evidence, in addition to the values and preferences of the patient. The use of decision aids supports this process by presenting scientific information in an accessible manner while focusing on patient-centered discussion. We developed and rigorously evaluated, in the United States, a decision aid regarding pharmaceutical treatment options for depression, Depression Medication Choice, to be used by health professionals and patients during clinical encounters. The integration and impact of Depression Medication Choice, in primary care practices in a Canadian context is unknown.\\n\\nThe specific objectives of this study are threefold: (i) Evaluate the potential impact of the use of Depression Medication Choice by health professionals and patients during clinical encounters on measures of the quality of the decisional process and on health issues important to the patient and health professional; (ii) Document the processes and optimal measures to take to successfully realize projects on a larger scale; and (iii) Evaluate the feasibility of performing patient-centered studies in a realistic context, minimally disturbing to the study environment, in the primary care context in Quebec, Canada.\\n\\nOnce completed, the estimated potential impact of this decision aid and shared decision making in primary care in a Canadian context will have been measured, progressing toward high-quality patient-centered care. Moreover, it will be possible to optimally perform future studies in realistic contexts while minimizing the burden on the clinics, their health professionals, and their patients.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Decision Aid',\n",
       "         'Shared Decision Making',\n",
       "         'Primary Care',\n",
       "         'Comparative Effectiveness Research']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignInterventionModelDescription': 'This is a mixed-method feasibility study centered on a pilot clinical trial in family medicine groups in Quebec, Canada, accompanied by a realistic qualitative evaluation of process.',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)',\n",
       "         'DesignMaskingDescription': 'Patients will be randomly assigned to one of two groups (intervention or usual care) using a computer-generated sequence. Due to the nature of the study, patients, health professionals, and members of the research team cannot be masked to the allocation.'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '3', 'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Usual Care',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Participants in this arm will receive care as usual.'},\n",
       "         {'ArmGroupLabel': 'Depression Medication Choice',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants in this arm will have the Depression Medication Choice decision aid be made available to their clinician to be used during their clinical encounter.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression Medication Choice']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Depression Medication Choice',\n",
       "          'InterventionDescription': 'The Depression Medication Choice tool is a series of cards emphasizing issues that are important for the patient and the health care professional when choosing antidepressants: weight change, sexual issues, sleep, cost, side effects, and stopping approach. The Depression Medication Choice tool uses clear language and is designed to improve the understanding of patients regarding the different attributes of antidepressants, and for use during clinical encounters.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression Medication Choice']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Changes in decisional conflict assessed by the Decisional Conflict Scale (DCS)',\n",
       "          'PrimaryOutcomeDescription': 'Participants and clinicians will complete a Decisional Conflict Scale so that their level of decisional conflict may be measured. This measure, validated in French, comprises 16-items grouped into factors impacting the feeling of comfort toward making the decision. Scores range from 0 (no decisional conflict) to 100 (extremely high decisional conflict). A participant version as well as a clinician version of the DCS will be used.',\n",
       "          'PrimaryOutcomeTimeFrame': \"Immediately following each participant's first clinical encounter and every subsequent scheduled visit for the approximate 6-month study intervention duration\"}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Participant engagement assessed by the Observing Patient Involvement in Decision Making instrument (OPTION) and video recordings',\n",
       "          'SecondaryOutcomeDescription': 'The level to which the clinicians engage the participants in decision making will be evaluated via the 12-item OPTION scale, an observational measurement scored 0 to 100 percent. Independent reviewers will assess the level of engagement using video recordings of the clinical encounters.',\n",
       "          'SecondaryOutcomeTimeFrame': \"At each participant's scheduled clinical encounter, for up to 6 months post-recruitment\"},\n",
       "         {'SecondaryOutcomeMeasure': 'Changes in severity of symptoms assessed by the Patient Health Questionnaire (PHQ-9)',\n",
       "          'SecondaryOutcomeDescription': 'Participants will complete the PHQ-9, a severity of depression measurement using a 4-point Likert-type scale. Scores range between 0 and 27 and correspond to depression severity. Depression severity may be: none-minimal (0 to 4), mild (5 to 9), moderate (10-14), moderately severe (15-19), or severe (20-27).',\n",
       "          'SecondaryOutcomeTimeFrame': \"Immediately prior to each participant's first clinical encounter and every subsequent scheduled visit for the approximate 6-month study intervention duration\"},\n",
       "         {'SecondaryOutcomeMeasure': 'Decision making preference assessed by questionnaire',\n",
       "          'SecondaryOutcomeDescription': \"Participants will be asked to answer a single question with a 5-point Likert-type scale to rate their decision making preferences. Lower values indicate participants' preference for making decisions themselves while higher values indicate a preference for their doctor to make the decision for them. An intermediate value indicates participants' preference for shared decision making.\",\n",
       "          'SecondaryOutcomeTimeFrame': \"Immediately prior to each participant's first clinical encounter\"},\n",
       "         {'SecondaryOutcomeMeasure': 'Global quality of life assessed by questionnaire',\n",
       "          'SecondaryOutcomeDescription': 'Participants will be asked to answer a single question with a 10-point Likert-type scale to rate their quality of life. The question is scored from 1 (very bad) to 10 (very good).',\n",
       "          'SecondaryOutcomeTimeFrame': 'Immediately prior to the first clinical encounter'},\n",
       "         {'SecondaryOutcomeMeasure': \"Changes in medication adherence assessed by participants' pharmacy records\",\n",
       "          'SecondaryOutcomeDescription': 'The following data will be extracted for the duration of trial participation: new prescriptions filled and the associated renewal dates as well as the types of medication (depression-related).',\n",
       "          'SecondaryOutcomeTimeFrame': 'Following the approximate 6-month study intervention completion'},\n",
       "         {'SecondaryOutcomeMeasure': 'Fidelity to the intervention delivery',\n",
       "          'SecondaryOutcomeDescription': 'Independent reviewers will evaluate the fidelity with which the Depression Medication Choice tool is used during the clinical encounters via video observation. The control of fidelity list is specific to the Depression Medication Choice tool. This will also allow us to validate the contamination level of the clinicians who will navigate between both groups.',\n",
       "          'SecondaryOutcomeTimeFrame': 'The entire duration of the discussion between the clinician and participant regarding depression medication during each scheduled visit for the approximate 6-month study intervention duration'},\n",
       "         {'SecondaryOutcomeMeasure': 'Changes in knowledge assessed by questionnaire',\n",
       "          'SecondaryOutcomeDescription': 'Participants will be asked to complete a questionnaire assessing their knowledge of the illness (depression) and the advantages and disadvantages of 15 pharmacological treatments. Participants may choose to answer true, false, or unsure. Correct answeres are are given a score of 1 and incorrect answers (or if a participant answered \"unsure\") is given a score of 0. A mean knowledge score is calculated from the totaled items for comparison.',\n",
       "          'SecondaryOutcomeTimeFrame': \"Immediately following each participant's clinical encounter and every subsequent visit for the approximate 6-month study intervention duration\"},\n",
       "         {'SecondaryOutcomeMeasure': 'Changes in satisfaction and acceptability by questionnaire',\n",
       "          'SecondaryOutcomeDescription': 'Participants and clinicians will be asked to rate their level of satisfaction and acceptability of the decision aid by completing a 5-question questionnaire. The 7-point Likert-type scale is scored from 5 to 35 with higher values corresponding to higher levels of satisfaction and acceptability.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Immediately following the first clinical encounter and every subsequent visit for the approximate 6-month study intervention duration'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAlready have or receive a depression diagnosis (according to the treating clinician)\\nSpeak English of French\\nHave no major obstacles providing clear written consent\\nDiscuss the possibility of taking antidepressants during the clinical encounter',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Annie LeBlanc, PhD',\n",
       "          'OverallOfficialAffiliation': 'Laval University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Groupe de médecine de famille universitaire Maizerets',\n",
       "          'LocationCity': 'Québec',\n",
       "          'LocationZip': 'G1J 2G1',\n",
       "          'LocationCountry': 'Canada'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26414670',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'LeBlanc A, Herrin J, Williams MD, Inselman JW, Branda ME, Shah ND, Heim EM, Dick SR, Linzer M, Boehm DH, Dall-Winther KM, Matthews MR, Yost KJ, Shepel KK, Montori VM. Shared Decision Making for Antidepressants in Primary Care: A Cluster Randomized Trial. JAMA Intern Med. 2015 Nov;175(11):1761-70. doi: 10.1001/jamainternmed.2015.5214.'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 28,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02491034',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '2015-0336'},\n",
       "       'Organization': {'OrgFullName': 'The University of Texas at Arlington',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'DESEO: DEpression Screening and Education: Options to Reduce Barriers to Treatment',\n",
       "       'OfficialTitle': 'DESEO: DEpression Screening and Education: Options to Reduce Barriers to Treatment',\n",
       "       'Acronym': 'DESEO'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2018',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2015',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 30, 2017',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'September 30, 2017',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'July 2, 2015',\n",
       "       'StudyFirstSubmitQCDate': 'July 6, 2015',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 7, 2015',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 6, 2018',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 10, 2018',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'The University of Texas at Arlington',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Texas Southwestern Medical Center',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of this project is to implement a Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement. This project will be conducted at one community health center whose patient population is majority Hispanic.',\n",
       "       'DetailedDescription': 'Barriers to depression treatment among Hispanic populations include persistent stigma, inadequate doctor patient communication (DPC) and resultant sub-optimal use of anti-depressant medications. Stigma is primarily perpetuated due to inadequate disease literacy and cultural factors. Common concerns about depression treatments among Hispanics include fears about the addictive and harmful properties of antidepressants, worries about taking too many pills, and the stigma attached to taking psychotropic medications.\\n\\nPrimary care settings often are the gateway to identifying undiagnosed or untreated mental health disorders, particularly for people with comorbid physical health conditions. Hispanics, in particular, are more likely to receive mental health care in primary care settings. Recent recommendations from the U.S. Preventive Services Task Force are that primary care providers screen adult patients for depression only if systems are in place to ensure adequate treatment and follow-up.\\n\\nProject Purpose, Goals and Objectives Purpose: The purpose of this project is to implement a Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement. This project will be conducted at one community health center whose patient population is majority Hispanic.\\n\\nGoal #1: Patients who screen positive for depression will engage in the Depression Education Intervention (DEI) (two sessions) with a trained Depression Educator.\\n\\nObjectives:\\n\\nTo increase knowledge of depression (signs/symptoms, causes, risk factors, treatment, cultural beliefs, and its role in chronic disease) among Hispanics in a primary care setting as measured by changes in scores from pre- to post- DEI on the Knowledge of Depression-MCQ scale.\\nTo reduce perceived cultural stigma about depression and its treatment through a culturally and linguistically appropriate educational intervention as measured by changes in scores from pre- to post- DEI on the Stigma Checklist for Latinos in Primary Care.\\nTo increase engagement in depression treatment in primary care by Hispanic patients as measured by the iPad Depression Screening application, which will record the treatment decision after the diagnosis and measure the number of patients engaged in depression treatment of any kind (pharmacotherapy, counseling, other behavioral intervention) at the time of the DEI and one month after completion of the DEI.\\n\\nGoal #2: In order to identify patients with depression, all adult primary care patients will be screened for depression utilizing the 9-item Patient Health Questionnaire (PHQ-9) via the iPad Depression Screening application.\\n\\nObjectives:\\n\\nTo systematically screen all adult primary care patients with an iPad Depression Screening application as measured by number of patients screened compared to the number eligible for screening.\\nTo increase provider detection of depression in patients through the proper use and interpretation of the PHQ-9 as measured by depression diagnoses recorded in the EHR.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Hispanics',\n",
       "         'Stigma',\n",
       "         'Barriers to Treatment']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '350',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention',\n",
       "          'ArmGroupType': 'Other',\n",
       "          'ArmGroupDescription': 'Depression Education Intervention',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression Education Intervention']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Depression Education Intervention',\n",
       "          'InterventionDescription': 'Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The number of Hispanic patients diagnosed with depression who went on to begin depression treatment.',\n",
       "          'PrimaryOutcomeTimeFrame': 'One month post DEI'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAdult primary care patients\\n\\nExclusion Criteria:\\n\\nprevious diagnosis of depression and currently in treatment',\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Katherine Sanchez, PhD',\n",
       "          'OverallOfficialAffiliation': 'The University of Texas at Arlington',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31638915',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Sanchez K, Killian MO, Eghaneyan BH, Cabassa LJ, Trivedi MH. Culturally adapted depression education and engagement in treatment among Hispanics in primary care: outcomes from a pilot feasibility study. BMC Fam Pract. 2019 Oct 21;20(1):140. doi: 10.1186/s12875-019-1031-7.'},\n",
       "         {'ReferencePMID': '29788998',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Lopez V, Sanchez K, Killian MO, Eghaneyan BH. Depression screening and education: an examination of mental health literacy and stigma in a sample of Hispanic women. BMC Public Health. 2018 May 22;18(1):646. doi: 10.1186/s12889-018-5516-4.'},\n",
       "         {'ReferencePMID': '27473569',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Sanchez K, Eghaneyan BH, Trivedi MH. Depression Screening and Education: Options to Reduce Barriers to Treatment (DESEO): protocol for an educational intervention study. BMC Health Serv Res. 2016 Jul 29;16:322. doi: 10.1186/s12913-016-1575-3.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 29,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01887639',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'NIS-NAR-XXX-2013/1'},\n",
       "       'Organization': {'OrgFullName': 'AstraZeneca', 'OrgClass': 'INDUSTRY'},\n",
       "       'BriefTitle': 'Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial',\n",
       "       'OfficialTitle': 'Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial: PANTHER Study',\n",
       "       'Acronym': 'PANTHER'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2015',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'September 2013'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2014',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'September 2014',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 25, 2013',\n",
       "       'StudyFirstSubmitQCDate': 'June 25, 2013',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 27, 2013',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 29, 2015',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 30, 2015',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'AstraZeneca',\n",
       "        'LeadSponsorClass': 'INDUSTRY'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'A non interventional, descriptive, longitudinal cohort study is designed, trying to obtain local data about the prevalence of non remitted depressed patients after an antidepressant treatment, and to get information about sociodemographic and clinical characteristics of these patients as well as features of their treatments and compare them with those of the patients that achieve remission. Also the effect of patient´s expectation in the treatment outcome will be examined.',\n",
       "       'DetailedDescription': 'A non interventional, descriptive, longitudinal cohort study is designed, trying to obtain local data about the prevalence of non remitted depressed patients after an antidepressant treatment, and to get information about sociodemographic and clinical characteristics of these patients as well as features of their treatments and compare them with those of the patients that achieve remission. Also the effect of patient´s expectation in the treatment outcome will be examined.\\n\\nNon psychotic depressed patients that are initiating an antidepressant treatment will be recruited. Socio demographic and clinical features will be recorded as well as their expectations before the treatment. Severity of depression and treatment characteristics will be recorded after 4 to 8 weeks of drug treatment at an adequate dose. Variables will be compared between the patients that will achieve remission and those that do not.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Non-psychotic Unipolar Major Depression']},\n",
       "       'KeywordList': {'Keyword': ['Non-psychotic unipolar major depression',\n",
       "         'Resistant depression']}},\n",
       "      'DesignModule': {'StudyType': 'Observational',\n",
       "       'PatientRegistry': 'Yes',\n",
       "       'TargetDuration': '12 Weeks',\n",
       "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
       "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '200',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Unipolar major depression',\n",
       "          'ArmGroupDescription': 'Outpatients Individuals between 18 and 75 years old with a current episode of non-psychotic unipolar major depression that are treated with an antidepressant drug according to physician´s current and usual practice.'}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Percentage of patients with unipolar major depression that do not achieve remission after one antidepressant treatment.',\n",
       "          'PrimaryOutcomeDescription': 'Non psychotic depressed patients that are initiating an antidepressant treatment will be recruited. Socio demographic and clinical features will be recorded as well as their expectations before the treatment. Severity of depression and treatment characteristics will be recorded after drug treatment at an adequate dose. Variables will be compared between the patients that will achieve remission and those that do not.',\n",
       "          'PrimaryOutcomeTimeFrame': '12 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Clinical, therapeutic and socio-demographic characteristics of resistant depression patients and comparisson of them with the characteristics of the sample of depressed patients in remission.',\n",
       "          'SecondaryOutcomeDescription': 'Description of the clinical (Clinical history, episode features, BDI and HAM D17 scores), therapeutic (Type of drug, dose used, treatment period, adherence, presence and type of psychosocial therapy) and socio-demographic (age, gender, civil status, employment status, cohabitation, health insurance) characteristics of resistant depression patients and to compare them with the characteristics of the sample of depressed patients in remission.',\n",
       "          'SecondaryOutcomeTimeFrame': '12 weeks'},\n",
       "         {'SecondaryOutcomeMeasure': 'Comparison of the depression severity change assessed by the physician with the evaluation done by the patient',\n",
       "          'SecondaryOutcomeDescription': 'Comparison of the depression severity change assessed by the physician with the evaluation done by the patient by means of the BDI.',\n",
       "          'SecondaryOutcomeTimeFrame': '12 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nFemale and male aged 18 to 75 years old. Outpatients with a current episode of non-psychotic unipolar major depression according to the DSM IV-TR.\\n\\nSeverity of illness assessed by means of a score ≥ 14 in the HAM D17 Have not been medicated for the current depression episode with an antidepressant Provision of subject informed consent\\n\\nExclusion Criteria:\\n\\nPatients participating in any clinical trial, the subject cannot take part in this study.\\n\\nThe individual has participated in the last 3 months (including this study) or is participating in a clinical trial.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '75 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
       "       'StudyPopulation': 'Individuals between 18 and 75 years old that have non-psychotic unipolar major depression and have not been treated for the current episode.',\n",
       "       'SamplingMethod': 'Non-Probability Sample'},\n",
       "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Research Site',\n",
       "          'LocationCity': 'Buenos Aires',\n",
       "          'LocationCountry': 'Argentina'},\n",
       "         {'LocationFacility': 'Research Site',\n",
       "          'LocationCity': 'Caba',\n",
       "          'LocationCountry': 'Argentina'},\n",
       "         {'LocationFacility': 'Research Site',\n",
       "          'LocationCity': 'Chaco',\n",
       "          'LocationCountry': 'Argentina'},\n",
       "         {'LocationFacility': 'Research Site',\n",
       "          'LocationCity': 'Cordoba',\n",
       "          'LocationCountry': 'Argentina'},\n",
       "         {'LocationFacility': 'Research Site',\n",
       "          'LocationCity': 'Rosario',\n",
       "          'LocationCountry': 'Argentina'},\n",
       "         {'LocationFacility': 'Research Site',\n",
       "          'LocationCity': 'San Salvador de Jujuy',\n",
       "          'LocationCountry': 'Argentina'},\n",
       "         {'LocationFacility': 'Research Site',\n",
       "          'LocationCity': 'Santa Fe',\n",
       "          'LocationCountry': 'Argentina'},\n",
       "         {'LocationFacility': 'Research Site',\n",
       "          'LocationCity': 'Tucuman',\n",
       "          'LocationCountry': 'Argentina'}]}},\n",
       "      'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Synopsis',\n",
       "          'SeeAlsoLinkURL': 'http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1832&filename=NIS-NAR-XXX-2013-1_AZ_Synopsis.pdf'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000003865',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder, Major'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafAsFound': 'Major Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 30,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01128764',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'R34MH083092',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH083092&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R34MH083092',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH083092&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'Brown University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Integrated Treatment for Comorbid Depression and Obesity in Adolescents',\n",
       "       'OfficialTitle': 'Integrated Treatment for Comorbid Depression and Obesity in Adolescents'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2014',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'December 2009'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2013',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2013',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'May 21, 2010',\n",
       "       'StudyFirstSubmitQCDate': 'May 21, 2010',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 24, 2010',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 28, 2014',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 29, 2014',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Anthony Spirito',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Professor',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'National Institute of Mental Health (NIMH)'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Brown University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Lifetime prevalence of major depression is estimated at 28% by age 18 (Lewinsohn et al., 1999), with higher cumulative rates in females (35%) than males (19%). Approximately 17% of children and adolescents in the United States are obese as defined by a BMI above the 95th percentile, with more than 30% falling between the 85th and 95th percentiles (Ogden et al., 2008). Overweight children and adolescents are at increased risk for type 2 diabetes (Pinhas-Hamiel et al., 1996) and overwhelming risk for adult obesity (Guo et al., 1994). There is a substantial percentage of adolescents who are both overweight and depressed with estimates from clinical samples averaging 25%. Treatment of teens with comorbid medical and psychiatric conditions such as overweight/obesity and depression has received little to no attention in the psychosocial treatment research literature. Due to the large number of adolescents who are both depressed and overweight, developing a behavioral treatment that addresses both problems simultaneously has important public health significance. The purpose of this proposal is to combine treatments for depression and overweight to address these co-occurring conditions in one intervention. The long-term objectives of this research are to develop efficient and effective treatments for co-occurring physical and emotional disorders. The research program will be divided into 3 major phases: a development phase (Stage 1a), a pilot study phase (Stage 1b), and a revision phase. During the development phase (Stage 1a), a treatment for overweight teens and CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating. As part of this phase, we will adapt existing intervention manuals and therapist training materials, and gain some initial clinical experience with the intervention via an open trial with 6 teens. During the randomized pilot study phase (Stage 1b), the integrated intervention will be compared to a control group receiving CBT treatment for depression alone (N=40 in total). During the pilot phase, the feasibility and acceptability of administering the program will be assessed. In addition, we will compare change in depressed mood at end of treatment and 6 month follow-up periods across the two groups. During the revision phase, the intervention manual will be further developed and refined, based on experiences and observations made during the development and pilot study phases.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression',\n",
       "         'Overweight']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 1']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '36',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'CBT for depression and healthy lifestyle plus exercise',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: CBT for depression and healthy lifestyle plus exercise']}},\n",
       "         {'ArmGroupLabel': 'CBT for depression',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'CBT for depression only',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: CBT for depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'CBT for depression and healthy lifestyle plus exercise',\n",
       "          'InterventionDescription': 'CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CBT for depression and healthy lifestyle plus exercise']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'CBT for depression',\n",
       "          'InterventionDescription': 'Standard CBT treatment for depressed teens that addresses depression using CBT techniques only',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CBT for depression']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'depressed mood',\n",
       "          'PrimaryOutcomeTimeFrame': 'baseline, posttreatment , 6 month follow-up'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'weight',\n",
       "          'SecondaryOutcomeTimeFrame': 'baseline, posttreatment, 6 month foll-up'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAdolescents must: 1) be between the ages of 12 and 18 years (18 year olds must still be in high school and living at home); 2) be at or above the 85th percentile with reference to age and gender-specific Body Mass Index (BMI); 3) have at least one parent available to participate in the treatment protocol; 4) speak English; 5) agree to study participation and random assignment; and 6) be available for follow-up. In order to meet the depressed mood criterion, adolescents must have a primary diagnosis of major depressive disorder (single or recurrent), based on the KSADS-PL with a CGI-Severity ≥ 3 for depression and CDRS ≥ 36. Participants must be healthy, as established by their primary care physician, in order to participate in the exercise program -\\n\\nExclusion Criteria:\\n\\nAdolescents will be excluded if: 1) they are currently receiving psychotherapy or participating in another weight loss program (only can have been in a weight loss program in the past); 2) they have a medical condition that would interfere with the prescribed dietary plan or participation in physical activity; 3) they are developmentally delayed such that the intervention materials will not be appropriate; 4) they are actively suicidal at intake; 5) they have not been on a stable dose of a psychostimulant for 6 months to ensure that a recently prescribed psychostimulant is not contributing to weight loss; 6) teens on an SSRI will not be allowed to participate due to potential effects of medication on weight loss; 7) they have a substance abuse or dependence diagnosis; or 8) they have failed a medication or psychotherapy trial for depression in the past.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '12 Years',\n",
       "       'MaximumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child', 'Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Anthony Spirito, PhD',\n",
       "          'OverallOfficialAffiliation': 'Brown University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Elissa Jelalian, PhD',\n",
       "          'OverallOfficialAffiliation': 'Brown University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Brown University',\n",
       "          'LocationCity': 'Providence',\n",
       "          'LocationState': 'Rhode Island',\n",
       "          'LocationZip': '02912',\n",
       "          'LocationCountry': 'United States'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000050177',\n",
       "          'ConditionMeshTerm': 'Overweight'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001835',\n",
       "          'ConditionAncestorTerm': 'Body Weight'},\n",
       "         {'ConditionAncestorId': 'D000012816',\n",
       "          'ConditionAncestorTerm': 'Signs and Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M11284',\n",
       "          'ConditionBrowseLeafName': 'Obesity',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M24773',\n",
       "          'ConditionBrowseLeafName': 'Overweight',\n",
       "          'ConditionBrowseLeafAsFound': 'Overweight',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3696',\n",
       "          'ConditionBrowseLeafName': 'Body Weight',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18',\n",
       "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
       "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
       "   {'Rank': 31,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02890615',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'SMHC 16-15'},\n",
       "       'Organization': {'OrgFullName': 'McGill University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'CanDirect: Effectiveness of a Telephone-supported Depression Self-care Intervention for Cancer Survivors',\n",
       "       'OfficialTitle': 'Effectiveness of a Telephone-supported Depression Self-care Intervention for Cancer Survivors',\n",
       "       'Acronym': 'CanDirect'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'February 2020',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'July 2016'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2019',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'June 2019',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'August 24, 2016',\n",
       "       'StudyFirstSubmitQCDate': 'August 31, 2016',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 7, 2016',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'February 18, 2020',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 19, 2020',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Jane McCusker, MD DrPH',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Professor Emerita and Full Professor Post-Retirement',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'McGill University'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'McGill University',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {},\n",
       "      'DescriptionModule': {'BriefSummary': 'Depressive symptoms are common in cancer survivors; 15% or more of cancer patients, even 1 year after diagnosis, experience depressive symptoms that can have a negative impact on their quality of life. Canadian care guidelines for cancer survivors recommend supporting the active engagement of survivors in their self-care.\\n\\nThis study is an evaluation of the effect of a depression self-care program which includes a self-care toolkit and support in the form of regular telephone calls from a self-care coach.\\n\\nThe toolkit contains tools that help cancer survivors:\\n\\nLearn new information to better understand depression. This can help people feel that they are not alone, and that their experience is not abnormal. Better understanding a condition also helps people feel more confident in their communications with health care professionals and can make it easier to share their experience with family and friends.\\nLearn and practice new coping skills. This can help people feel confident that they can engage in the behaviours that have been shown to be beneficial for mood, e.g. restructuring thoughts, problem solving, and planning pleasant activities.\\n\\nPeople eligible for the study are aged 18 and over, 1-10 years post-diagnosis, have completed primary cancer treatment (chemotherapy, radiation therapy or surgery) for any type of cancer, and have moderate depressive symptoms (as measured by a Patient Health Questionnaire (PHQ-9) score of 8-19). Recruitment will be conducted at cancer care centres in Montreal and at the Princess Margaret Cancer Centre in Toronto, and via community cancer support groups in Quebec and Ontario. Each participant enrolled in the study will receive the self-care toolkit (half will receive the toolkit and support calls at the start of the study, and half will receive the toolkit at the end), and will be followed for 6 months.\\n\\nThis proposed self-care program is innovative in its approach to the treatment of depression and has the potential to significantly improve the quality of life for Canadian cancer survivors with persistent depressive symptoms. The results of the study will determine whether the supported depression self-care program for cancer survivors is effective. The program is designed to be sustainable and widely applicable as it involves minimal costs, and the coaching can be delivered by telephone by volunteers in hospital and community settings. Investigators will work with clinical stakeholders and patient representatives to ensure that deliverables are relevant to the target population. Specific deliverables (in both French and English) include: a toolkit with a manual describing its use; a manual detailing coaching procedures; reports for decision makers and community cancer care groups; and short summaries for stakeholder groups.',\n",
       "       'DetailedDescription': 'This pragmatic randomized controlled superiority trial aims to assess the effectiveness of a telephone-supported depression SCI in cancer survivors with moderate depressive symptoms when given in addition to usual care, in comparison to usual care only. Because of the pragmatic nature of this trial, members of both groups will continue to receive \"usual care\" for their depression, which may vary widely depending on local resources and medical practice. At each follow-up, participants are asked about specific treatment they have received for depression since entering the study (antidepressant medication initiation, discontinuation, change of dose, or psychotherapy) and their participation in community support groups and related activities; investigators will explore whether this care mediates the effects of the intervention. The study includes safeguards for participants who become suicidal or severely depressed during the study.\\n\\nResearch questions\\n\\nAmong cancer survivors in the post-treatment phase who have moderate to moderately-severe depressive symptoms [Patient Health Questionnaire (PHQ-9) score 8-19]:\\n\\nPrimary research question: What is the effect of a telephone-supported depression self-care intervention (SCI) plus usual care compared to usual care only (control group CTL) on the primary outcome - severity of depression symptoms as measured by the Centre for Epidemiologic Studies Depression Scale (CES-D) 6 months after randomization? Hypothesis: Participants who receive the SCI will have better 6 month primary outcomes than those randomized to the Control group.\\n\\nSecondary questions:\\n\\nWhat are the effects of the SCI on: CES-D score at 3 months; depression diagnosis at 6 months; and mental health related quality of life, activation, severity of anxiety symptoms at 3 and 6 months, and use of health services over 6 months? Hypothesis: Participants who receive the SCI will have better health outcomes and lower use of health services than those randomized to the Control group.\\n\\nAre the effects of the SCI on the primary outcome modified by 5 primary baseline patient characteristics [major depression diagnosis; antidepressant medication; activation; recruitment source (clinical vs community); and level of education ] or by 9 secondary patient characteristics [cancer type, ongoing adjuvant cancer treatment (yes, no), years from cancer diagnosis (quartiles), severity of anxiety (as measured by the Hospital Anxiety and Depression Scale - Anxiety subscale (HADS-A)), physical health-related quality of life (as measured by the Physical Component Summary (PCS) of the Short Form Health Survey (SF-12)) (quartiles), sex, age (quartiles), family support for self-management (quartiles), province of residence (Quebec, Ontario)].\\n\\nHypothesis and support Effect moderators (or modifiers) represent variables e.g. patient characteristics, measured at baseline, that interact with treatment to change outcome for each sub-group. These specify for whom treatment is most effective and can improve power in subsequent trials by better selection of study groups for stratification. In selecting those potential modifiers/moderators that will be pre-specified for testing, investigators followed consensus criteria for assessment of these factors. Pinctus proposes 5 criteria for systematic reviews of randomized controlled trials confirming moderator effects: 1) was the analysis a priori; 2) was selection of factors for analysis clinically plausible and either theory-based or evidence-based; 3) were moderators measured prior to randomization; 4) adequate quality of measurement; 5) explicit test of the interaction between moderator and treatment. For meta-analyses exploring moderator effects, criteria 1 and 2 are not required.\\n\\nInvestigators will analyze 5 possible moderators using sub-group analyses:\\n\\nMajor depression They hypothesize that the intervention will be more effective among participants with a diagnosis of major depression (measured through the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders Disorders - Major Depressive Syndrome in the Mood Disorders Module (SCID)) than those without. A meta-analysis of psychosocial interventions in cancer populations found that studies in which patients were pre-selected for higher levels of distress found greater effectiveness of the intervention. A meta-analysis of depression self-care interventions also reported greater effectiveness in patients with major depression, although only in univariate analysis.\\n\\nAntidepressant medication Investigators hypothesize that the intervention will be more effective among participants with baseline antidepressant medication than those without. A meta-analysis found that the combination of psychotherapy and pharmacotherapy is more effective in the treatment of depression than psychotherapy alone.\\n\\nActivation Investigators hypothesize that the intervention will be more effective among participants with higher baseline activation than those with lower levels. As there is no accepted cut-point on the Patient Activation Measure (PAM) scale, higher activation will be defined as a PAM score in the highest quartile. In a randomized controlled trial of the depression self-care intervention among primary care patients with chronic physical conditions, investigators found that coaching was more effective among patients with higher baseline self-efficacy (one component of activation).\\n\\nRecruitment source Investigators hypothesize that the intervention will be more effective among participants recruited from community settings than from clinical settings. A meta-analysis of depression self-care interventions also reported lower effectiveness in patients studied in clinical settings, although only in univariate analysis. Participants recruited from community settings in this study (e.g., from community groups and social media) will already be selected to be more motivated to participate actively in the intervention.\\n\\nLevel of education Investigators hypothesize that the intervention will be more effective among participants with higher education, defined as some education beyond high school (e.g, diploma or university), compared with those with only high school or less education. Investigators are not aware of evidence supporting this hypothesis, but the use of paper and pencil and electronic tools will be more familiar to those with a higher level of education.\\n\\nIn addition to these 5 hypothesized moderators, investigators propose to examine the following 9 secondary potential baseline moderators, each with a maximum of 4 categories:\\n\\ncancer type, ongoing adjuvant cancer treatment (yes, no), years from cancer diagnosis (quartiles), severity of anxiety (HADS), physical health-related quality of life (PCS) (quartiles), sex, age (quartiles), family support for self-management (quartiles), province of residence (Quebec, Ontario).\\n\\nIn the Intervention group, is greater adherence to the SCI (e.g., use of self-care tools, completion of written exercises and mood monitoring, goal setting, greater number of coaching contacts) associated with better primary and secondary outcomes? Hypothesis: Participants who adhere to the SCI, particularly those who actively engage with the Cognitive behavioural therapy (CBT)-based tools will have greater reductions in depressive symptoms, diagnoses, and severity of anxiety symptoms, and greater increases in activation and quality of life.\\nEconomic analysis:\\n\\nAn economic analysis of the SCI is beyond the scope of this study. In the current study, investigators collect patient-reported data on use of health services and request additional (optional) consent for linkage to health care administrative data (the Ontario Health Insurance Plan (OHIP) Claims database and the Discharge Abstract Database (DAD)). They plan to seek additional funding for analyses of these use of services and administrative data for a future study on impact of the SCI on use of services. They will only extract use of services data for patients who consent to this optional element, and only for a period 12 months before and 12 months after the date of enrolment in the present trial. Patients who consent to use of their administrative data are asked to provide their OHIP number to allow researchers to extract the required data.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Survivors', 'Self Care']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Supportive Care',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '246',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression Self-care Intervention (SCI)',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': \"Intervention group participants will receive the Depression Self-Care Toolkit for Cancer Survivors and will be supported by telephone by a coach who will help to activate them, guide them through the materials, help in selecting appropriate tools, and provide positive reinforcement. Coach contacts will be made every week for 3 months followed by 3 monthly contacts, up to a maximum of 15 contacts, lasting 10-20 minutes each.\\n\\nThe coach uses a stepped approach (i.e. educate about depression, initiate mood monitoring, determine participant's goals with respect to reducing depressive symptoms, and help with the use of specific tools). A suggested script is provided for the coach as a framework for each call. Tailoring of the SCI to different participants will be based on problems, depressive symptoms (from the PHQ-9), or concerns a participant may raise during the call.\",\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression self-care']}},\n",
       "         {'ArmGroupLabel': 'Control group',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Members of both groups will continue to receive \"usual care\" for their depression. We will not interfere with usual care beyond recommending that participants discuss their depressive symptoms with their doctor. If participants consent, a short progress report will be send to their treating physician at the end of the study. At each follow-up, we will ask participants about specific treatment they have received for depression since entering the study (antidepressant medication initiation, discontinuation, change of dose, or psychotherapy) and use of community resources. The Intervention group will receive the Depression SCI. The Control group will receive only usual care for 6 months after randomization; they will be given the Toolkit with a single coaching call upon completion of the final interview, to ensure their access to depression treatment.'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Depression self-care',\n",
       "          'InterventionDescription': 'Toolkit and coaching',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression Self-care Intervention (SCI)']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in severity of depression symptoms: Centre for Epidemiologic Studies Depression Scale (CES-D)',\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in severity of anxiety symptoms: Hospital Anxiety and Depression Scale - Anxiety subscale (HADS-Anxiety)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in mental and physical health-related quality of life: Short Form health survey (SF-12)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in activation: Patient Activation Measure (PAM)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in depression diagnosis: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders - IV Disorders (SCID)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in use of health services: self-report',\n",
       "          'SecondaryOutcomeDescription': 'doctor office and clinic visits, emergency room visits, hospitalizations, psychosocial treatment or support group participation, changes in cancer diagnosis or treatment',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 3 month, 6 month'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria:\\n\\ncompleted primary cancer treatment (surgery, radiation and/or chemotherapy) for any type of cancer (NB: patients receiving adjuvant therapies will be eligible),\\nbetween 1-10 years post-diagnosis (as suggested by clinicians collaborating on the project),\\nwith moderate depressive symptoms (PHQ-9 score of 8-19).\\n\\nExclusion criteria:\\n\\nmetastatic disease,\\nsuicidal,\\nmoderate-severe cognitive impairment,\\nunable to speak and read in English or French,\\nonly non-melanoma skin cancer (without any other single primary cancer),\\nreceiving ongoing psychological treatment at baseline (because of recent finding that this treatment may negatively modify the effectiveness of the coaching component of the intervention). NB: those who begin psychological treatment during follow-up will not be withdrawn.\\ndose of antidepressant medication changed within last 6 weeks at baseline. NB: those who change dose or treatment during follow-up will not be withdrawn.',\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': \"St Mary's Research Centre\",\n",
       "          'LocationCity': 'Montreal',\n",
       "          'LocationState': 'Quebec',\n",
       "          'LocationZip': 'H3T1M5',\n",
       "          'LocationCountry': 'Canada'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 32,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02771535',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '1027/106'},\n",
       "       'Organization': {'OrgFullName': 'Universitätsklinikum Hamburg-Eppendorf',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Long-term Efficacy of Metacognitive Training for Depression (D-MCT)',\n",
       "       'OfficialTitle': 'Long-term Efficacy of Metacognitive Training for Depression (D-MCT): a 3-year Follow up'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'August 2017',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'March 2016'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2017',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'May 2017',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'April 5, 2016',\n",
       "       'StudyFirstSubmitQCDate': 'May 12, 2016',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 13, 2016',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'August 2, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 3, 2017',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Universitätsklinikum Hamburg-Eppendorf',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Aim of the current study is to investigate the long-term efficacy of Metacognitive Training for Depression (D-MCT) and to explore whether previously observed effects at the 6-month follow-up of a randomized, controlled, assessor-blind, parallel group trial are maintained at the 3-year follow-up.',\n",
       "       'DetailedDescription': 'Dissemination of treatment for depression is still unsatisfying: every second patient does not receive, refuses, or is waiting for treatment. Moreover, with a drop-out rate of almost 25% in routine clinical practice, and a 54% relapse rate for treatment responders within the two years after treatment termination, improving treatment is necessary. Metacognitive Training for depression (D-MCT), a low threshold, easy to administer group intervention was designed to fill this gap. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research. It was positively evaluated with regard to feasibility and acceptance in a non-randomized pilot study. Moreover, efficacy of D-MCT was suggested in a randomized controlled trail (RCT) in comparison to an active control intervention (Jelinek et al., in press). In this trial patients with depressive disorder were completing a psychosomatic outpatient treatment program and were randomly assigned to either D-MCT or general health training. Severity of depression and cognitive biases were assessed at baseline (t0), post treatment (t1) and 6 months (t2) later by raters blind to diagnostic status. Intention-to-treat analyses demonstrated that at the end of treatment, as well as 6 months later, improvement in depression was significantly greater in the D-MCT relative to the health training group at medium effect sizes. A significantly greater number of patients in the D-MCT group were in remission at 6-month follow-up. Moreover, the decrease in cognitive biases and increase in psychological well-being/quality of life was larger in the D-MCT than the health training group over time. Aim of the current study is to investigate the long-term efficacy of D-MCT. For this purpose, an additional 3 year follow-up assessment (t3) is conducted. The Hamilton Depression Rating Scale (HDRS, 17-item version) total score serves as the primary outcome. Self-assessed depression, dysfunctional beliefs, self-esteem, quality of life, and ability to work serve as secondary outcomes.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Unipolar Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '84',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'D-MCT Group',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: D-MCT']}},\n",
       "         {'ArmGroupLabel': 'Health Training Group',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Health Training']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'D-MCT',\n",
       "          'InterventionDescription': 'Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['D-MCT Group']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Metacognitive Training for Depression']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Health Training',\n",
       "          'InterventionDescription': 'Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Health Training Group']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Hamilton Depression Rating Scale',\n",
       "          'PrimaryOutcomeDescription': 'Primary outcome is change on the Hamilton Depression Rating Scale (HDRS, 17-item version) from baseline to follow-up (t0 - t3)',\n",
       "          'PrimaryOutcomeTimeFrame': '3 years from baseline (t0) to 3-year follow up (t3)'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Self-assessed depression',\n",
       "          'SecondaryOutcomeDescription': 'Change in self-assessed depression as measured by the Beck-Depression Inventory (BDI) from baseline to follow-up (t0 to t3)',\n",
       "          'SecondaryOutcomeTimeFrame': '3 years from baseline (t0) to 3-year follow up (t3)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Dysfunctional beliefs',\n",
       "          'SecondaryOutcomeDescription': 'Change in dysfunctional beliefs as measured by the Dysfunctional Attitude Scale (DAS) from baseline to follow-up (t0 to t3)',\n",
       "          'SecondaryOutcomeTimeFrame': '3 years from baseline (t0) to 3-year follow up (t3)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Dysfunctional metacognitive beliefs',\n",
       "          'SecondaryOutcomeDescription': 'Change in metacognitive beliefs as measured by the Metacognitions Questionnaire (MCQ-30) from baseline to follow-up (t0 to t3)',\n",
       "          'SecondaryOutcomeTimeFrame': '3 years from baseline (t0) to 3-year follow up (t3)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Quality of life',\n",
       "          'SecondaryOutcomeDescription': 'Change in quality of life as measured by the World Health Organization Quality of Life Assessment (WHOQOL-BREF) from baseline to follow-up (t0 to t3)',\n",
       "          'SecondaryOutcomeTimeFrame': '3 years from baseline (t0) to 3-year follow up (t3)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Work status',\n",
       "          'SecondaryOutcomeDescription': 'Work status (full or part-time employment, unemployed, house wife/husband, student, on sick leave, retired) at T3 assessment',\n",
       "          'SecondaryOutcomeTimeFrame': 'at 3-year follow-up (t3)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Self-esteem',\n",
       "          'SecondaryOutcomeDescription': 'Change in self-esteem as measured by the Rosenberg Self-Esteem Scale (RSE) from from baseline to follow-up (t0 to t3)',\n",
       "          'SecondaryOutcomeTimeFrame': '3 years from baseline (t0) to 3-year follow up (t3)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Remission rate',\n",
       "          'SecondaryOutcomeDescription': 'Remission rate at T3 as measured by the Hamilton Depression Rating Scale (HDRS score ≤ 8)',\n",
       "          'SecondaryOutcomeTimeFrame': 'at 3-year follow up (t3)'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria for the current study are:\\n\\ninformed consent\\nintention-to-treat-sample of the study Evaluation of Metacognitive Training for Depression (D-MKT) in psychosomatic rehabilitation, DRKS-ID: DRKS00007907 (see Jelinek et al., in press, Psychotherapy and Psychosomatics)\\nage between 18 and 65 years\\ndiagnosis of a single episode or recurrent major depressive disorder (MDD) or dysthymia (verified by the MINI).\\n\\nThe exclusion criteria were:\\n\\nlifetime psychotic symptoms (i.e., hallucinations, delusions, or mania), suicidality (Suicidal Behaviors Questionnaire-Revised ≥ 7), intellectual disability (estimated IQ < 70).',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Lena Jelinek, PD Dr.',\n",
       "          'OverallOfficialAffiliation': 'Universitätsklinikum Hamburg-Eppendorf',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'University Medical Center Hamburg Eppendorf',\n",
       "          'LocationCity': 'Hamburg',\n",
       "          'LocationZip': '20246',\n",
       "          'LocationCountry': 'Germany'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25103718',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Moritz S, Veckenstedt R, Andreou C, Bohn F, Hottenrott B, Leighton L, Köther U, Woodward TS, Treszl A, Menon M, Schneider BC, Pfueller U, Roesch-Ely D. Sustained and \"sleeper\" effects of group metacognitive training for schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2014 Oct;71(10):1103-11. doi: 10.1001/jamapsychiatry.2014.1038.'},\n",
       "         {'ReferencePMID': '27230865',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Jelinek L, Hauschildt M, Wittekind CE, Schneider BC, Kriston L, Moritz S. Efficacy of Metacognitive Training for Depression: A Randomized Controlled Trial. Psychother Psychosom. 2016;85(4):231-4. doi: 10.1159/000443699. Epub 2016 May 27.'},\n",
       "         {'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Jelinek L, Otte C, Arlt S, Hauschildt M: Denkverzerrungen erkennen und korrigieren: Eine Machbarkeitsstudie zum Metakognitiven Training bei Depression (D-MKT). [Identifying and correcting cognitive biases: A pilot study on the Metacognitive Training for Depression (D-MCT)]. Zeitschrift Für Psychiatr Psychol Und Psychother 61:1-8, 2013.'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 33,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01834534',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '1R01MH096699',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH096699&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R01MH096699-01',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH096699-01&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'University of Michigan',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Telemonitoring Enhanced Support for Depression Self Management',\n",
       "       'OfficialTitle': 'Telemonitoring Enhanced Support for Depression Self Management'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2019',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'September 2013'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 29, 2018',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'October 31, 2018',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'September 13, 2012',\n",
       "       'StudyFirstSubmitQCDate': 'April 15, 2013',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 18, 2013',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'March 6, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 7, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'James Aikens, PhD',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Associate Professor of Family Medicine',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Michigan'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Michigan',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The objective of this research is to test the efficacy of \"CarePartners for Depression\" (CP-D) intervention, which was designed to increase between visit monitoring of depression status and enhance self-management.\\n\\n**In order to participate, subjects must be patients at participating clinics: Alcona Health Center, Cherry Street Health Services, Dua Family Practice, Morang Chester.',\n",
       "       'DetailedDescription': 'This project will test a practical intervention that uses low cost technologies to activate depressed patients\\' existing social networks for self-management support. The intervention links patients with a \"CarePartner\" (CP), i.e., a non-household family member or close friend who is willing to support the patient in coordination with the clinician and any existing in-home caregiver (ICG). Through weekly automated telemonitoring, patients report their mood and self-management status, and receive tailored guidance on self-management. The CP receives a corresponding update along with guidance on how to best support the patient\\'s self-management efforts, and the primary care team is notified about clinically urgent situations. The intervention will be tested among depressed primary care patients from clinics serving low-income and underinsured patients, whom the intervention was especially designed to benefit. Specific Aim 1 is to conduct a randomized controlled trial to compare the effectiveness of one year of telemonitoring-supported CP for depression versus usual care (control) on depression severity. Specific Aim 2 is to examine key secondary outcomes (response and remission, impairment, well-being, caregiving burden, healthcare costs) and potential moderators. Specific Aim 3 is to use a mixed-methods approach to enrich our interpretation of the statistical associations, and to discover strategies to enhance the intervention\\'s acceptability, effectiveness, and sustainability. If the intervention proves effective without increasing clinician burden or marginal costs, then its subsequent implementation could yield major public health benefits, especially in medically underserved populations.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '243',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'CarePartners for depression',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': \"For one year, patients receive weekly automated telemonitoring of mood and self-management, while their CarePartners receive weekly reports of the patient's assessment results with tailored instructions on supporting the patient's depression self-management.\",\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: CarePartners for depression']}},\n",
       "         {'ArmGroupLabel': 'Usual care',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Usual medical care.'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'CarePartners for depression',\n",
       "          'InterventionDescription': 'Automated telephone calls for depression monitoring and self-management support.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CarePartners for depression']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depressive symptom severity',\n",
       "          'PrimaryOutcomeDescription': 'Patient Health Questionnaire 9 (PHQ-9).',\n",
       "          'PrimaryOutcomeTimeFrame': '12 months after randomization'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depression remission rate',\n",
       "          'SecondaryOutcomeDescription': 'Remission as measured by PHQ-9 <10',\n",
       "          'SecondaryOutcomeTimeFrame': '12 months after randomization'},\n",
       "         {'SecondaryOutcomeMeasure': 'Depression-related functional impairment',\n",
       "          'SecondaryOutcomeDescription': 'Sheehan Disability Scale',\n",
       "          'SecondaryOutcomeTimeFrame': '12 months after randomization'},\n",
       "         {'SecondaryOutcomeMeasure': 'Positive well-being',\n",
       "          'SecondaryOutcomeDescription': 'Positive well-being will be assessed using the REMIT, a 5-item scale of positive affect and other aspects of depression recovery developed by the PI and his colleagues. Reference: Nease DE, Jr., Aikens, JE, Klinkman, MK, Kroenke, K, and Sen, A. Toward a more comprehensive assessment of depression remission: the Remission Evaluation and Mood Inventory Tool (REMIT). Journal of General Hospital Psychiatry. 2011.',\n",
       "          'SecondaryOutcomeTimeFrame': '12 months after randomization'},\n",
       "         {'SecondaryOutcomeMeasure': 'Health care costs',\n",
       "          'SecondaryOutcomeDescription': 'Health care costs will be estimated using data gathered from a variety of patient self-report and site-specific administrative databases.',\n",
       "          'SecondaryOutcomeTimeFrame': '12 months after randomization'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'NOTE: In order to participate, must have received medical care for past year at one of the participating clinics: Alcona Health Center, Cherry Street Health Services, Dua Family Practice, Morang Chester\\n\\nAdditional Inclusion Criteria:\\n\\nat least 2 outpatient primary care visits in the past 2 years, 1 within the past 13 months\\ndepression diagnosis in medical chart problem list or billing record (ICD9 codes: 296.20-.26, .30-.36, 296.4-.9, 298.0, 300.4, 309.0-.1, 309.28, 311.00) during the past 2 years\\ncurrent PHQ >10 (non-mild depressive symptoms)\\nat least 21 years old\\ncomfortable speaking English\\ncan use a touch-tone phone\\ncan identify at least 1 eligible CarePartner\\nnot in palliative care, on transplant waitlist, or <1 year life expectancy\\nfree of major cognitive impairment or psychiatrically unstable\\nnot experiencing domestic abuse or stalking\\n\\nExclusion Criteria:\\n\\nLimited life expectancy (e.g., advanced stage cancer/heart failure/on oxygen/end stage renal disease), receiving palliative care\\nAt risk for domestic abuse, PHQ<10, end stage renal disease, lung cancer, dementia, bipolar disease, schizophrenia, limited life expectancy (advanced stage cancer/heart failure/on oxygen), alcohol problems, receiving palliative care\\nUnable to speak English\\nNot planning to get all or most of care at study site\\nPrimary care physician not affiliated with study site\\nUnable to use telephone to respond to weekly automated self-management support calls\\nUnable to nominate an eligible CP',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '21 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'James E Aikens, Ph.D.',\n",
       "          'OverallOfficialAffiliation': 'University of Michigan',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'John D Piette, Ph.D.',\n",
       "          'OverallOfficialAffiliation': 'University of Michigan',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Alcona Health Centers',\n",
       "          'LocationCity': 'Alpena',\n",
       "          'LocationState': 'Michigan',\n",
       "          'LocationZip': '49707',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'University of Michigan',\n",
       "          'LocationCity': 'Ann Arbor',\n",
       "          'LocationState': 'Michigan',\n",
       "          'LocationZip': '48013',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Dua Family Practice',\n",
       "          'LocationCity': 'Canton',\n",
       "          'LocationState': 'Michigan',\n",
       "          'LocationZip': '48187',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Morang Chester',\n",
       "          'LocationCity': 'Detroit',\n",
       "          'LocationState': 'Michigan',\n",
       "          'LocationZip': '48224',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Hamilton Community Health Network, Inc.',\n",
       "          'LocationCity': 'Flint',\n",
       "          'LocationState': 'Michigan',\n",
       "          'LocationZip': '48505',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Cherry Street Health Services',\n",
       "          'LocationCity': 'Grand Rapids',\n",
       "          'LocationState': 'Michigan',\n",
       "          'LocationZip': '49503',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Muskegon Family Care',\n",
       "          'LocationCity': 'Muskegon Heights',\n",
       "          'LocationState': 'Michigan',\n",
       "          'LocationZip': '49444',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 34,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02997865',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'R01HL131524',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01HL131524&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01HL131524',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01HL131524&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'Washington University School of Medicine',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Stepped Care for Depression in Heart Failure',\n",
       "       'OfficialTitle': 'Stepped Care for Depression in Heart Failure',\n",
       "       'Acronym': 'DASH-2'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2019',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'February 17, 2017',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2021',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'May 2021',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'December 15, 2016',\n",
       "       'StudyFirstSubmitQCDate': 'December 19, 2016',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 20, 2016',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'March 15, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 19, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Washington University School of Medicine',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Heart, Lung, and Blood Institute (NHLBI)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study evaluates stepped care for depression in patients with heart failure (HF). The stepped care intervention consists of individualized cognitive behavior therapy (CBT). Half of the participants will receive stepped care and half will receive usual care for depression; all participants will receive heart failure self-care education and support. The primary aims are to determine whether stepped care is superior to usual care for depression, and whether treating depression improves heart failure self-care outcomes.',\n",
       "       'DetailedDescription': 'Depression is associated with poor heart failure self-care. Good self-care practices, including following dietary recommendations, taking prescribed medications, monitoring symptoms, and regular light exercise have been shown to improve quality of life and survival in persons with heart failure.\\n\\nBoth CBT and antidepressant medications have been used in previous studies to treat major depression in patients with heart failure. Participants in the intervention arm in this trial will start with CBT. Those who do not improve very much within the first 5-10 weeks of CBT may also be referred to their own physician to discuss antidepressant medications.\\n\\nHeart failure self-care education and support will be provided after the first 8 weeks of the depression intervention. The study will determine whether people with heart failure benefit more from self-care education and support after their depression has been treated with a stepped care intervention, as compared to usual care for depression as provided by primary care providers.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Heart Failure',\n",
       "         'Depressive Disorder, Major']},\n",
       "       'KeywordList': {'Keyword': ['heart failure',\n",
       "         'depressive disorder, major',\n",
       "         'cognitive therapy',\n",
       "         'self-care']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '180',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Stepped Care for Depression',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants will receive cognitive behavior therapy for depression, plus referral to their own physician for discussion of antidepressant medication if symptoms do not improve within 5-10 weeks. Participants will also receive individually-tailored heart failure self-care education and support.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Stepped care for depression']}},\n",
       "         {'ArmGroupLabel': 'Enhanced Usual Care',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': \"Participants will receive individually-tailored heart failure self-care education and support. With the participant's permission, his or her personal physician will be notified about the patient's depression. The participant will be asked to discuss depression treatment options with his or her personal physician.\"}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Stepped care for depression',\n",
       "          'InterventionDescription': \"Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stepped Care for Depression']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Beck Depression Inventory (BDI-II) total score',\n",
       "          'PrimaryOutcomeDescription': 'Self-reported severity of depression',\n",
       "          'PrimaryOutcomeTimeFrame': '16 weeks'},\n",
       "         {'PrimaryOutcomeMeasure': 'Self Care of Heart Failure Index (SCHFI) Maintenance subscale',\n",
       "          'PrimaryOutcomeDescription': 'Self-reported heart failure self-care behaviors',\n",
       "          'PrimaryOutcomeTimeFrame': '16 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Beck Anxiety Inventory',\n",
       "          'SecondaryOutcomeDescription': 'Self-reported severity of anxiety symptoms',\n",
       "          'SecondaryOutcomeTimeFrame': '16 weeks'},\n",
       "         {'SecondaryOutcomeMeasure': 'Kansas City Cardiomyopathy Questionnaire (KCCQ)',\n",
       "          'SecondaryOutcomeDescription': 'Heart failure-related quality of life',\n",
       "          'SecondaryOutcomeTimeFrame': '16 weeks'},\n",
       "         {'SecondaryOutcomeMeasure': 'Hamilton Rating Scale for Depression (HAM-D-17)',\n",
       "          'SecondaryOutcomeDescription': 'Interviewer-rated severity of depression symptoms',\n",
       "          'SecondaryOutcomeTimeFrame': '16 weeks'},\n",
       "         {'SecondaryOutcomeMeasure': 'Actigraphy',\n",
       "          'SecondaryOutcomeDescription': 'Physical activity level',\n",
       "          'SecondaryOutcomeTimeFrame': '16 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nStable, clinically-documented Class I-III heart failure.\\nCurrent major depressive episode.\\nBaseline BDI-II score 14 or greater\\n\\nExclusion Criteria:\\n\\nDementia or other significant cognitive or communication deficits\\nTerminal illness other than HF\\nInsurmountable logistical barriers to participation\\nAge less than 25 years\\nCurrent clinically significant substance abuse, bipolar disorder, schizophrenia, or other psychotic disorder\\nHigh risk of suicide\\nCurrent participation in non-study psychotherapy for depression or other psychiatric conditions\\nInitiation or modification of antidepressant medication treatment within past two months\\nRenal or hepatic conditions that would preclude the use of antidepressants.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '25 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Judith A Skala, PhD, RN',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '314-286-1316',\n",
       "          'CentralContactEMail': 'skalaj@wustl.edu'},\n",
       "         {'CentralContactName': 'Kenneth E Freedland, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '314-286-1311',\n",
       "          'CentralContactEMail': 'freedlak@wustl.edu'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kenneth E Freedland, PhD',\n",
       "          'OverallOfficialAffiliation': 'Washington University School of Medicine',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Behavioral Medicine Center at Washington University School of Medicine',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Saint Louis',\n",
       "          'LocationState': 'Missouri',\n",
       "          'LocationZip': '63108',\n",
       "          'LocationCountry': 'United States',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jeanne Heaghney, RN',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '314-286-1517',\n",
       "             'LocationContactEMail': 'heaghney@wustl.edu'},\n",
       "            {'LocationContactName': 'Judith Skala, RN, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '3142861316',\n",
       "             'LocationContactEMail': 'skalaj@wustl.edu'}]}}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'Undecided',\n",
       "       'IPDSharingDescription': 'We may share de-identified data with other researchers after the completion of the study; no specific plans for this have been made yet.'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006333',\n",
       "          'ConditionMeshTerm': 'Heart Failure'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000003865',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder, Major'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000006331',\n",
       "          'ConditionAncestorTerm': 'Heart Diseases'},\n",
       "         {'ConditionAncestorId': 'D000002318',\n",
       "          'ConditionAncestorTerm': 'Cardiovascular Diseases'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M8004',\n",
       "          'ConditionBrowseLeafName': 'Heart Failure',\n",
       "          'ConditionBrowseLeafAsFound': 'Heart Failure',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M8002',\n",
       "          'ConditionBrowseLeafName': 'Heart Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC14',\n",
       "          'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}},\n",
       "   {'Rank': 35,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02712918',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'BATD_16674'},\n",
       "       'Organization': {'OrgFullName': 'Lovisenberg Diakonale Hospital',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Brief Behavioral Activation Treatment for Depression With Inpatients',\n",
       "       'OfficialTitle': 'An Evaluation of Brief Behavioral Activation Treatment for Depression With Moderate to Severely Depressed Inpatients - A Small Randomized Controlled Trial'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2014'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2014',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'October 2014',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'March 9, 2015',\n",
       "       'StudyFirstSubmitQCDate': 'March 15, 2016',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 18, 2016',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'March 15, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 18, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Martin Myhre',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Learning Disability Nurse/MSc Behavior Analysis',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Lovisenberg Diakonale Hospital'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Lovisenberg Diakonale Hospital',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Oslo Metropolitan University',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of the current study was to examine Brief Behavioral Activation Treatment for Depressions (BATD) effectiveness, credibility, and acceptability with moderate to severly depressed inpatients. The study is a systematic replication of a randomized controlled trail from 2003, that provided initial support for BATD With inpatients. The current study compared BATD to Treatment as Usual in a randomized controlled trial.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Inpatient',\n",
       "         'Acute',\n",
       "         'Brief Behavioral Activation Treatment for Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '23',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Brief Behavioral Activation Treatment for Depression',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Behavioral treatment of depression. The study utilized the revised version of the Brief Behavioral Activation Treatment for Depression (BATD) protocol from 2011. The treatment was added to treatment as usual. Up to 10 sessions were administered.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Brief Behavioral Activation Treatment for Depression']}},\n",
       "         {'ArmGroupLabel': 'Standard care',\n",
       "          'ArmGroupType': 'Placebo Comparator',\n",
       "          'ArmGroupDescription': 'Standard CARE (SC) at the inpatient unit. Mandatory: Therapeutic conversations with psychiatrist, psychologist or M.D, milieu therapy. Optional: Psychosomatic physiotherapy, therapeutic groups, psychopharmacological treatment.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Standard Care']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Brief Behavioral Activation Treatment for Depression',\n",
       "          'InterventionDescription': 'Behavioral treatment of depression which focuses on increasing the Level of positive reinforcement through systematic and goal directed activation of behavior. Goal and values are assessed and used to determine target behaviors.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Brief Behavioral Activation Treatment for Depression']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Standard Care',\n",
       "          'InterventionDescription': 'Treatment as usual at the ward',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Standard care']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change of Beck`s Depression Inventory-II from baseline',\n",
       "          'PrimaryOutcomeTimeFrame': 'Change from baseline (second day of admission) to discharge from the ward (maximum 21 days, expected average of 10 days).'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Credibility and Expectancies Questionnaire',\n",
       "          'SecondaryOutcomeDescription': 'Only BATD group',\n",
       "          'SecondaryOutcomeTimeFrame': 'Second day of admission. After first sessions of BATD.'},\n",
       "         {'SecondaryOutcomeMeasure': 'Treatment Evaluation Inventory - Short Form',\n",
       "          'SecondaryOutcomeDescription': 'Only BATD group',\n",
       "          'SecondaryOutcomeTimeFrame': 'Prior to discharge from the ward (maximum 21 days, expected average of 10 days)..'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nModerate to severe depression (BDI-II > 28 Points).\\nAdmission length of at least 3 days\\nEvaluated to benefit from depression treatment by unit psychiatrist.\\n\\nExclusion Criteria:\\n\\nCurrent psychotic disorder\\nPreviously diagnosis with psychotic disorder (including Bipolar disorder)',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '11317637',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Lejuez CW, Hopko DR, Hopko SD. A brief behavioral activation treatment for depression. Treatment manual. Behav Modif. 2001 Apr;25(2):255-86.'},\n",
       "         {'ReferencePMID': '21324944',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Lejuez CW, Hopko DR, Acierno R, Daughters SB, Pagoto SL. Ten year revision of the brief behavioral activation treatment for depression: revised treatment manual. Behav Modif. 2011 Mar;35(2):111-61. doi: 10.1177/0145445510390929.'},\n",
       "         {'ReferencePMID': '12971122',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Hopko DR, Lejuez CW, LePage JP, Hopko SD, McNeil DW. A brief behavioral activation treatment for depression. A randomized pilot trial within an inpatient psychiatric hospital. Behav Modif. 2003 Sep;27(4):458-69.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 36,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01114334',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'K23MH082997',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=K23MH082997&Fy=all'},\n",
       "       'Organization': {'OrgFullName': 'Denver Health and Hospital Authority',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Motivational Interviews for Depression in Primary Care',\n",
       "       'OfficialTitle': 'Motivational Interviews Adapted to Improve Depression Treatment in Primary Care'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'May 2018',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'April 2010'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2012',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2012',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'April 29, 2010',\n",
       "       'StudyFirstSubmitQCDate': 'April 30, 2010',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 3, 2010',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'October 17, 2016',\n",
       "       'ResultsFirstSubmitQCDate': 'March 9, 2017',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'April 20, 2017',\n",
       "        'ResultsFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'May 7, 2018',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 6, 2018',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Denver Health and Hospital Authority',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of the study is to determine whether motivational interviewing with guideline-based medical management for depression will significantly improve time to depression recovery and increase the proportion of subjects in recovery compared to guideline-based medical management alone over 9 months.',\n",
       "       'DetailedDescription': 'Setting Denver Health is an integrated healthcare system. During the time period that the trial was conducted, 2010 to 2012, Denver Health comprised eight federally qualified community health facilities serving primarily uninsured and Medicaid patients in Denver, Colorado, USA. The mainstay treatment for depression was antidepressant medication only, as access to specialty mental health counseling or psychiatric services was not readily available at the participating primary care facilities during the time frame of the trial.\\n\\nRandomization and Masking We recruited seven primary care facilities housing 10 independent care teams (clusters). Three facilities had two teams each, and four had one team. Although staff and providers from different facilities and teams attend role-specific training together and may share managers, each team has unique support staff, providers, and patient panels. We used a blocked design to limit the possibility of patients crossing over from a team assigned to one randomization group to one in the other group (contamination). Because of a negative association between minority race/ ethnicity and depression diagnosis and treatment receipt, we stratified the teams by the race/ ethnicity of the respective patient populations at each facility (plurality Hispanic, non-Hispanic black, or non-Hispanic white). Prior to randomization, we blocked eight of 10 teams into four pairs within strata because they: (a) shared the same facility (three facilities with two teams each); or (b) were from closely located neighborhoods (two facilities with one team each).\\n\\nOutcome assessors who obtained written consent, conducted the baseline depression assessment, and collected clinical outcomes were blinded to cluster allocation and were not involved in other study procedures. Patient participants were blinded to group assignment. Participating providers were not blinded.\\n\\nProtocol Change Prior to recruiting patients into the intention-to-treat (ITT) groups, we changed the primary outcome at the trial registration site on 4/29/10 from the outcome specified in the original 2008 protocol, \"adherence to antidepressant medication\", to \"remission from depression.\" However, detecting remission, defined as an event where depressive symptoms fall below a clinically significant level for a prolonged period, entails weekly or bi-weekly outcome assessments (Nierenberg, 2001; Rush et al., 2006). Limited study resources precluded closely spaced outcome assessments over 36 weeks. Therefore, to better understand trajectories of clinical outcome for the primary care patients assigned to teams staffed by providers trained to discuss depression with Motivational Interviewing versus those patients assigned to teams staffed by untrained providers, measures of both continuous depressive symptoms and a binary outcome measure (Patient Health Questionnaire-9 (PHQ-9) score < 5) were calculated for each group at 6, 12, and 36 weeks.\\n\\nPrimary Care Providers In May 2009, the research team emailed 53 providers from 13 primary care teams (eligible clusters) in eight facilities with an invitation to participate in a study of \"training for a new counseling method for treating depression.\" Inclusion criteria included working at least 1.5 days per week in outpatient care, previous experience treating depression, and availability for a one-day baseline MI training on 7/25/09. We obtained consent from providers prior to randomization.\\n\\nPatients During the recruitment phase, the research team called sequential eligible patients 2 to 3 days prior to scheduled visits with participating providers. The team assessed for initial exclusion criteria and invited those not excluded to complete an audio-recorded partial waiver of consent and stage-I depression screen, the Patient Health Questionnaire-2 (PHQ-2). Prior to the visit, a recruiter met patients scoring 2 or higher on either item of the PHQ-2, described the study, obtained written informed consent, and invited consenting patients to complete the PHQ-9.\\n\\nPatients were excluded if they were attending a one-time disability qualification examination, had no personal phone, were homeless, were treated for depression with antidepressant medication within the previous 3 months, were currently in therapy provided by a mental health specialist, had impaired memory, had a life-threatening physical disease, expressed severe suicidal ideation, were pregnant or breastfeeding, or exhibited alcohol/ drug dependence, bipolar disorder or current psychosis assessed with a diagnostic schedule.\\n\\nThe recruiter notified the provider and patient prior to the clinical encounter when patients scored 10 or higher on the PHQ-9, signifying \\'probable major depression\\' . A board-certified psychiatrist, blinded to patient allocation, diagnosed depression and determined additional exclusion criteria. Patients diagnosed with a major depressive episode, not excluded for other reasons, and completing a subsequent baseline telephone interview within 8 days, were enrolled as the Intention-To-Treat (ITT) sample.\\n\\nIntervention - MI with Standard Management of Depression The MI training approach included interactive learning for the core MI skills. An 8-hour classroom training on 7/25/09 consisted of a brief overview of MI, videos and discussion of core MI skills and \"MI Spirit,\" as well as skill-building practice. Providers learned how to use \"OARS\" and summaries to elicit change talk, how to implement the elicit-provide-elicit technique, and how to craft action plans with patients. Providers practiced using 0-10 Ruler questions to assess and increase patient importance and confidence in changing.\\n\\nThe training was designed according to Arkowitz and Burkes\\' (2008) recommendation for a three-component framework when using MI to discuss depression. In this framework, the provider first helps explore the patient\\'s negative emotions through reflective listening. Second, the provider uncovers contributors to the negative emotions. Third, the patient\\'s own ideas about how to handle their negative emotions are elicited.\\n\\nTo optimize treatment integrity, 4-hour refresher sessions were offered after 4 and 12 months. Over the first 14 months, feedback was provided via email and face-to face regarding audio-taped encounters (total two to four feedbacks per provider).\\n\\nControl - Standard Management of Depression Alone All providers randomized to either intervention or to control received a 1-hour slideshow and the \"American Psychiatric Association Practice Guideline for the Treatment of Major Depressive Disorder\" (APA depression guideline) (2010). The resources recommended antidepressant medications and psychotherapy as evidence-based treatments for depression.\\n\\nMeasurements Baseline Descriptors. In addition to demographics, provider information included training (M.D. versus mid-level) and certification (Family Practitioner, General Internist, Physician\\'s Assistant, or Nurse Practitioner), and years of clinical experience. Patient descriptors included generalized anxiety disorder (past 6 months), federal poverty level, and previous suicidal behavior.\\n\\nTreatment Variables. Time spent discussing depression at the index visit was assessed from audio-recorded encounters. Two measures of follow-up over 36 weeks, total primary care visits dichotomized at the median and at least three or more visits with documented discussion of mental health were abstracted from the electronic medical record. Receipt of antidepressant medication and specialty mental health counseling was also determined.\\n\\nStatistical Analysis Missing Data. Total missingness and whether missingness was differential by group or cluster was assessed. Little\\'s likelihood ratio test was used to test the hypothesis that data is Missing Completely at Random (MCAR). To determine plausibility of Missing at Random (MAR), correlations between baseline or auxiliary variables and missingness by group at each time point were calculated.\\n\\nPrior to performing the ITT analyses, Multiple Imputation through Chained Equations (MICE) was conducted to deal with missing data. The Fully Conditional Specification algorithm in the SAS MI procedure was used to generate 30 imputed datasets. The effects of the intervention on depressive symptoms and on remission were determined on each imputed data set. MI repetition results were combined to generate final estimates of parameters and confidence intervals for depressive symptoms. Rubin\\'s rules were used to combine the parameter estimates and errors into a single set of results.\\n\\nTreatment Outcomes. Analyses of treatment outcomes were run by ITT. Generalized linear mixed effects models, adjusted for clustering of patients within care team, were used to examine differences in outcomes by randomization group. Whereas randomization was stratified by class (race/ ethnicity), the interaction between class and treatment group as well as class itself were included in all multivariate analyses.\\n\\nMain Effects. Main outcome analyses were run by ITT utilizing imputed datasets. General linear mixed effects models, or generalized models for a binary outcome, were used to examine whether the group x time interactions for outcomes depressive symptoms and remission were significant. The general linear mixed model assumed unstructured variance-covariance matrices, maximum likelihood (method = ML) estimation, and adjusted for clustering of patients within care teams and repeated measures within patients. Whereas the random effect of clustering patients within care teams on remission in the adjusted model was zero, patients were not clustered within care teams in the generalized model for the binary outcome.\\n\\nModerator hypothesis: A hypothesis concerning moderator variables was included in the Colorado Multiple Institutional Review Board (COMIRB) protocol for the trial. In the protocol approved with a COMIRB stamp on 2/3/10, specific aim #2 was \"ii. Specific Aim #2: Aim 2 is to explore for moderators and mediators of the effect of AMI-TAD on adherence and outcome. We hypothesize that higher baseline patient self-efficacy will differentially increase the effect of AMI-TAD with SCD.\" AMI-TAD is an earlier abbreviated name for the the MI training intervention.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Major Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignInterventionModelDescription': 'Cluster Randomized Clinical Trial',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '168',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Guideline-based Medical Management',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': \"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nThe evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications\",\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Guideline-Based Medical Management']}},\n",
       "         {'ArmGroupLabel': 'Motivational Interview with GBMM',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Motivational Interviewing for Depression combined with guideline-based medical management for depression',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Guideline-Based Medical Management',\n",
       "            'Behavioral: Motivational Interviewing for Depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Guideline-Based Medical Management',\n",
       "          'InterventionDescription': \"We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Guideline-based Medical Management',\n",
       "            'Motivational Interview with GBMM']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['GBMM']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Motivational Interviewing for Depression',\n",
       "          'InterventionDescription': \"Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Motivational Interview with GBMM']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['MI with GBMM']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression Remission',\n",
       "          'PrimaryOutcomeDescription': 'The primary outcome is depression remission ascertained with the Patient Health Questionnaire-9. A score of less than 5 is considered to represent remission. The secondary clinical outcome is the continuous measure of depressive symptoms.',\n",
       "          'PrimaryOutcomeTimeFrame': '36 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Adherence to Treatment With Antidepressant Medication',\n",
       "          'SecondaryOutcomeDescription': 'Antidepressant Adherence will be measured with Computerized Pharmacy Records. Adherence will be operationalized as \"non-persistence,\" or time to discontinuation. Non-persistence will be considered to have occurred if the days of medication supply from the previous prescription plus a 30-day grace period exceed the number of days between the previous prescription date and the current prescription fill date. Filling no prescriptions, \\'initiation failure,\\' will be treated as non-persistence. Minimally adequate persistence was defined as at least three 30-day fills of an antidepressant medication at a usual dose as defined in the American Psychiatric Association guideline without a 30-day gap in refills. The count of participants receiving minimally adequate persistence with antidepressant medication is reported for each study group.',\n",
       "          'SecondaryOutcomeTimeFrame': '36 weeks'},\n",
       "         {'SecondaryOutcomeMeasure': 'Patient Health Questionnaire-9 Instrument for Assessing Depressive Symptoms',\n",
       "          'SecondaryOutcomeDescription': 'Depressive symptoms were measured with the Patient Health Questionnaire-9 (PHQ-9) instrument. The PHQ-9 is a nine item survey to assess depressive symptoms over the previous 2 weeks. The patient may answer \"not at all\" (scored as a 0) , \"several days\" (scored as a 1), \"more than half the days\" (scored as a 2), or \"nearly every day\" (scored as a 3) for each item. The range in total scores is from 0 (no depressive symptoms or best outcome) to 27 (severe depressive symptoms or worst outcome). For this randomized trial mean total scores are reported.',\n",
       "          'SecondaryOutcomeTimeFrame': '36 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nWomen and men aged 18 or older presenting at one of the seven DHH study clinics with a new treatment episode for depression will be considered for the study.\\nThe PHQ-9 is used to define depression category with a sensitivity and specificity for MDD of at least 88%. Patients must have PHQ-9≥10 to ensure sufficient severity to warrant intervention.\\nA new treatment episode is defined as no treatment with an antidepressant medication for emotional problems over the previous 90 days, nor evidence-based psychotherapy for depression.\\nThe subjects must have major depression as determined by diagnostic schedule.\\n\\nExclusion Criteria:\\n\\nReceipt of an antidepressant medication in the previous 90 days other than a low-dose TCA for pain or Trazodone for sleep (e.g. amitriptyline ≤ 50 mg a day or Trazodone ≤ 100 mg at night).\\nCurrent interpersonal or cognitive behavioral psychotherapy that focuses on depression.\\nFemale subjects who are either pregnant or nursing.\\nSubjects with drug or alcohol dependency or abuse (except for nicotine or caffeine) within the preceding 6 months.\\nHigh risk for suicide.\\nInability to communicate in English.\\nNo personal telephone or homeless.\\nLifetime bipolar disorder.\\nPsychosis.\\nSubjects with a lifetime history of autism, mental retardation, or pervasive developmental disorders.\\nSubjects with uncorrected hypothyroidism or hyperthyroidism.\\nSerious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Robert D Keeley, MD MSPH',\n",
       "          'OverallOfficialAffiliation': 'Denver Health and University of Colorado, Department of Family Medicine',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Denver Health and Hospital Authority',\n",
       "          'LocationCity': 'Denver',\n",
       "          'LocationState': 'Colorado',\n",
       "          'LocationZip': '80204',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'Undecided',\n",
       "       'IPDSharingDescription': 'We will be working in the coming year on a plan to share data. We have been able to share data in the past.'}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Motivational Interviewing With Guideline-Based Management',\n",
       "          'FlowGroupDescription': 'Intervention – MI with Standard Management of Depression The MI training approach included interactive learning for the core MI skills. An 8-hour classroom training on 7/25/09 consisted of a brief overview of MI, videos and discussion of core MI skills and “MI Spirit,” as well as skill-building practice. At the providers’ request, the research team distributed a pocket-sized, laminated treatment outline to MI trained providers for use at the point of service\\n\\nTo optimize treatment integrity, 4-hour refresher sessions were offered after 4 and 12 months on 11/22/09 and 7/11/10. Over the first 14 months, the assistant trainer provided feedback via email and face-to face regarding audio-taped encounters (total two to four feedbacks per provider). In these sessions, the trainer also summarized MI skills demonstrated during the encounters and listed each patient’s change talk statements. Providers were invited to respond and to choose which MI skill(s) they needed to improve.'},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Standard Management of Depression',\n",
       "          'FlowGroupDescription': 'All providers randomized to either intervention or to control received a 1-hour slideshow and the “American Psychiatric Association Practice Guideline for the Treatment of Major Depressive Disorder” (APA depression guideline) (Gelenberg et al., 2010). The resources recommended antidepressant medications and psychotherapy as evidence-based treatments for depression.'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '88'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '80'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '67'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '58'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '21'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '22'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Motivational Interviewing With Guideline-Based Management',\n",
       "          'BaselineGroupDescription': 'Intervention – MI with Standard Management of Depression The MI training approach included interactive learning for the core MI skills. An 8-hour classroom training on 7/25/09 consisted of a brief overview of MI, videos and discussion of core MI skills and “MI Spirit,” as well as skill-building practice. At the providers’ request, the research team distributed a pocket-sized, laminated treatment outline to MI trained providers for use at the point of service\\n\\nTo optimize treatment integrity, 4-hour refresher sessions were offered after 4 and 12 months on 11/22/09 and 7/11/10. Over the first 14 months, the assistant trainer provided feedback via email and face-to face regarding audio-taped encounters (total two to four feedbacks per provider). In these sessions, the trainer also summarized MI skills demonstrated during the encounters and listed each patient’s change talk statements. Providers were invited to respond and to choose which MI skill(s) they needed to improve.'},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Standard Management of Depression',\n",
       "          'BaselineGroupDescription': 'All providers randomized to either intervention or to control received a 1-hour slideshow and the “American Psychiatric Association Practice Guideline for the Treatment of Major Depressive Disorder” (APA depression guideline) (Gelenberg et al., 2010). The resources recommended antidepressant medications and psychotherapy as evidence-based treatments for depression.'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '88'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '80'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '168'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '82'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '75'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '157'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '6'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '11'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '60'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '58'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '118'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '28'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '22'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '50'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '34'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '25'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '59'}]}},\n",
       "               {'BaselineCategoryTitle': 'Not Hispanic or Latino',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '54'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '55'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '109'}]}},\n",
       "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Race (NIH/OMB)',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '3'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '4'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '7'}]}},\n",
       "               {'BaselineCategoryTitle': 'Asian',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Black or African American',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '27'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '32'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '59'}]}},\n",
       "               {'BaselineCategoryTitle': 'White',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '29'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '31'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '60'}]}},\n",
       "               {'BaselineCategoryTitle': 'More than one race',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '13'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '18'}]}},\n",
       "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '16'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '8'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '24'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '88'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '80'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '168'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Depression Remission',\n",
       "          'OutcomeMeasureDescription': 'The primary outcome is depression remission ascertained with the Patient Health Questionnaire-9. A score of less than 5 is considered to represent remission. The secondary clinical outcome is the continuous measure of depressive symptoms.',\n",
       "          'OutcomeMeasurePopulationDescription': 'We present clinical outcome (remission rate) at 36 weeks for all patient participants entering the study. 58 of 80 subjects assigned to Guideline-Based Medical Management, and 67 of 88 subjects assigned to Motivational Interview with Guideline-Based Medical Management had available data at 36 weeks (end of trial).',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Number',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'participants',\n",
       "          'OutcomeMeasureTimeFrame': '36 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Guideline-based Medical Management',\n",
       "             'OutcomeGroupDescription': \"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nThe evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications\"},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Motivational Interview With GBMM',\n",
       "             'OutcomeGroupDescription': \"Motivational Interviews combined with guideline-based medical management for depression\\n\\nGuideline-Based Medical Management: We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.\\n\\nMotivational Interviewing for Depression: Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or\"}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '58'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '67'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '4'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '15'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Adherence to Treatment With Antidepressant Medication',\n",
       "          'OutcomeMeasureDescription': 'Antidepressant Adherence will be measured with Computerized Pharmacy Records. Adherence will be operationalized as \"non-persistence,\" or time to discontinuation. Non-persistence will be considered to have occurred if the days of medication supply from the previous prescription plus a 30-day grace period exceed the number of days between the previous prescription date and the current prescription fill date. Filling no prescriptions, \\'initiation failure,\\' will be treated as non-persistence. Minimally adequate persistence was defined as at least three 30-day fills of an antidepressant medication at a usual dose as defined in the American Psychiatric Association guideline without a 30-day gap in refills. The count of participants receiving minimally adequate persistence with antidepressant medication is reported for each study group.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Count of Participants',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'Participants',\n",
       "          'OutcomeMeasureTimeFrame': '36 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Guideline-based Medical Management',\n",
       "             'OutcomeGroupDescription': \"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nThe evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications\"},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Motivational Interview With GBMM',\n",
       "             'OutcomeGroupDescription': \"Motivational Interviewing for Depression combined with guideline-based medical management for depression\\n\\nManual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nMotivational Interviewing for Depression: Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.\"}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '80'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '88'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '11'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '15'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Patient Health Questionnaire-9 Instrument for Assessing Depressive Symptoms',\n",
       "          'OutcomeMeasureDescription': 'Depressive symptoms were measured with the Patient Health Questionnaire-9 (PHQ-9) instrument. The PHQ-9 is a nine item survey to assess depressive symptoms over the previous 2 weeks. The patient may answer \"not at all\" (scored as a 0) , \"several days\" (scored as a 1), \"more than half the days\" (scored as a 2), or \"nearly every day\" (scored as a 3) for each item. The range in total scores is from 0 (no depressive symptoms or best outcome) to 27 (severe depressive symptoms or worst outcome). For this randomized trial mean total scores are reported.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': '95% Confidence Interval',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': '36 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Guideline-based Medical Management',\n",
       "             'OutcomeGroupDescription': \"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nThe evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications\"},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Motivational Interview With GBMM',\n",
       "             'OutcomeGroupDescription': \"Motivational Interviewing for Depression combined with guideline-based medical management for depression\\n\\nManual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nMotivational Interviewing for Depression: Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.\"}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '58'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '67'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '11.66',\n",
       "                   'OutcomeMeasurementLowerLimit': '10.33',\n",
       "                   'OutcomeMeasurementUpperLimit': '13.00'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '9.16',\n",
       "                   'OutcomeMeasurementLowerLimit': '7.87',\n",
       "                   'OutcomeMeasurementUpperLimit': '10.46'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventsTimeFrame': 'Up to 36 weeks.',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Guideline-based Medical Management',\n",
       "          'EventGroupDescription': \"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nThe evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications\",\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '80',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '80'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Motivational Interview With GBMM',\n",
       "          'EventGroupDescription': \"Motivational Interviewing for Depression combined with guideline-based medical management for depression\\n\\nManual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.\\n\\nMotivational Interviewing for Depression: Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.\",\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '88',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '88'}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
       "        'AgreementRestrictiveAgreement': 'No'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Dr. Robert D. Keeley',\n",
       "        'PointOfContactOrganization': 'Denver Health and University of Colorado Denver',\n",
       "        'PointOfContactEMail': 'robert.keeley@dhha.org',\n",
       "        'PointOfContactPhone': '303-602-8270'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 37,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00555698',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '6577'},\n",
       "       'Organization': {'OrgFullName': 'Ohio State University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Feasibility, Safety and Efficacy of Deep Brain Stimulation for Depression',\n",
       "       'OfficialTitle': 'Feasibility, Safety and Efficacy of Deep Brain Stimulation of the Internal Capsule for Severe and Medically Refractory Major Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2017',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2004'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2011',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'February 2011',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'November 7, 2007',\n",
       "       'StudyFirstSubmitQCDate': 'November 8, 2007',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 9, 2007',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'March 24, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 28, 2017',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Ali Rezai, MD',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'MD',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Ohio State University'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Ali Rezai, MD',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Medtronic',\n",
       "          'CollaboratorClass': 'INDUSTRY'},\n",
       "         {'CollaboratorName': 'The Cleveland Clinic',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of this investigation is to obtain a preliminary indication of the feasibility, safety and efficacy of capsular deep brain stimulation (DBS) as a treatment for intractable depression. Also, to to learn about a new treatment for severe depression that has not improved enough despite long-term treatment with medications and behavior therapy. The new treatment is called deep brain stimulation, or DBS.\\n\\nIn DBS, thin wires are used to carry electric current to parts of the brain that are thought to be involved in producing depression symptoms. Two wires are implanted surgically, and attached to battery packs implanted under the skin of the new chest below your collar bone.',\n",
       "       'DetailedDescription': \"This protocol proposes a pilot/feasibility clinical study of therapeutic benefits of ventral capsule/ventral striatum deep brain stimulation (DBS) as a treatment in ten patients with intractable major depression (MD). Conservative estimates place MD's prevalence at 2.6% to 5.5% in men and 6.0% to 11.8% in women. Most conservative studies estimate a 20% complete refractoriness to medical and psychotherapeutic regimens. Given the prevalence of major depression in the general population, over 3.5 million Americans would be expected to manifest refractory illness if all those with depression received treatment. Study subjects will have MD of disabling severity, intractable to prolonged treatment attempts with conventional medication and pschotherapies. They must also have had electroconvulsive therapy. These refractory patients would be candidates for a destructive/lesioning brain surgery such as a radiofrequency cingulotomy.\\n\\nThese MD patients are analogous to medically intractable Parkinson's disease and tremor patients who until recently underwent similar destructive surgeries such as a pallidotomy or thalamotomy. The use of DBS technology with its inherent advantage of being fully reversible and adjustable has become standard of care for these disabled patients. Studies have demonstrated improved safety and efficacy of DBS over lesioning.\\n\\nRecently, DBS technology has been employed in the lesioning target of the anterior limb of the internal capsule for OCD. These preliminary studies in Europe and now the US, are demonstrating improved outcomes for refractory OCD patients with regard to their OC symptoms as well as depressed mood. This amelioration of mood provides the basis on which anterior internal capsule DBS may help major depression patients.\\n\\nBased on this rationale, we believe that DBS is a viable therapeutic surgical option in this group of severely ill MD patients. The standard DBS stereotactic surgical techniques employed by the CCF team in hundreds of movement disorder patients will be used. The DBS electrodes will be implanted bilaterally in the anterior limb of the internal capsule and connected subcutaneously to subclavicular programmable pulse generators.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['DBS', 'Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Early Phase 1']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '8', 'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'DBS',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'DBS',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Deep Brain Stimulations for Depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
       "          'InterventionName': 'Deep Brain Stimulations for Depression',\n",
       "          'InterventionDescription': 'Deep Brain Stimulations for Depression',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['DBS']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (HDRS)',\n",
       "          'PrimaryOutcomeTimeFrame': 'These scales are administered on each postoperative clinic visit. Visits occur monthly, except during the open continuation phase, when they occur every three months.'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Inventory for Depressive Symptoms, Self-report (IDS-SR), Clinical Global Impressions (CGI), Patient Global Impressions (PGI), Global Assessment of Functioning (GAF), Social and Occupational Function Assessment Scale (SOFAS), Quality of LIfe Enjoyment and',\n",
       "          'SecondaryOutcomeTimeFrame': 'These measures will be obtained at baseline, at the end of the initial chronic phase (typically after three months of chronic stimultion), at the end of the open continuation phase (at two years into the study).'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMajor depression, severe, unipolar type, diagnosed by Structured Clinical Interview for DSM-IV (SCID-IV), judged to be of disabling severity\\n24-item Hamilton Depression Rating Scale (HDRS) score of at least 21\\nGlobal Assessment of Function (GAF) score of 45 or less.\\nA recurrent (>4 episodes) or chronic (episode duration >2 years) course and a minimum of 5 years since the onset of the first depressive episode. Major impairment in functioning or potentially severe medical outcomes (repeated hospitalizations, serious suicidal or other self-injurious behavior).\\n\\nFailure to respond to:\\n\\nadequate trials (>6 weeks at the maximum recommended or tolerated dose) of primary antidepressants from at least 3 different classes and;\\nadequate trials (>4 weeks at the usually recommended or maximum tolerated dose) of augmentation/combination of a primary antidepressant using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant) and;\\nan adequate trial of ECT (>6 bilateral treatments) and;\\nan adequate trial of individual psychotherapy (>20 sessions with an experienced psychotherapist).\\nAge 18 - 55 years.\\nAble to comply with the operational and administrative requirements of participation in the study.\\nAble to give written informed consent.\\nEither drug-free or on a stable drug regimen for at least 6 weeks at the time of entry into the study.\\nGood general health.\\n\\nExclusion Criteria:\\n\\nCurrent or past nonaffective psychotic disorder.\\nAny current clinically significant neurological disorder or medical illness affecting brain function, other than motor tics or Gilles de la Tourette syndrome.\\nAny clinically significant abnormality on preoperative magnetic resonance imaging (MRI)\\nAny surgical contraindications to undergoing DBS, including labeled contraindications for DBS and/or inability to undergo presurgical MRI (cardiac pacemaker, pregnancy, metal in body, severe claustrophobia), infection, coagulopathy, inability to undergo an awake operation, significant cardiac or other medical risk factors for surgery.\\nCurrent or unstably remitted substance abuse.\\nPregnancy and women of childbearing age not using effective contraception.\\nHistory of severe personality disorder.\\nImminent risk of suicide (based on the judgment of the investigators).\\nNot able to comply with the operational and administrative requirements of participation in the study (based on the judgment of the investigators).',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '55 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Ali Rezai, MD',\n",
       "          'OverallOfficialAffiliation': 'The Cleveland Clinic',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Cleveland Clinic Foundation',\n",
       "          'LocationCity': 'Cleveland',\n",
       "          'LocationState': 'Ohio',\n",
       "          'LocationZip': '44195',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '16855529',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, Salloway SP, Okun MS, Goodman WK, Rasmussen SA. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology. 2006 Nov;31(11):2384-93. Epub 2006 Jul 19. Erratum in: Neuropsychopharmacology. 2006 Nov;31(11):2394.'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 38,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00754936',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '0703009061'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH079414-01A1',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH079414-01A1&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'Weill Medical College of Cornell University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Treatment Response of Geriatric Depression',\n",
       "       'OfficialTitle': 'ERPs, Cognitive Dysfunction and Treatment Response of Geriatric Depression',\n",
       "       'Acronym': 'ERP'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'February 2019',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'May 2007', 'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'May 2015',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'September 17, 2008',\n",
       "       'StudyFirstSubmitQCDate': 'September 17, 2008',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 18, 2008',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'February 25, 2019',\n",
       "       'ResultsFirstSubmitQCDate': 'February 25, 2019',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'March 19, 2019',\n",
       "        'ResultsFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'February 25, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 19, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Weill Medical College of Cornell University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'},\n",
       "         {'CollaboratorName': 'Forest Laboratories',\n",
       "          'CollaboratorClass': 'INDUSTRY'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': \"The purpose of this study is to examine the relationship between brain electrical activity in elderly depressed patients and response to antidepressant medication treatment. Elderly patients with depression will be treated for 12 weeks with an antidepressant medication commonly used in clinical practice called escitalopram (Lexapro). Brain electrical activity will be assessed using electrophysiological tests. Researchers are interested in whether the brain electrical activity of elderly people with depression before they start the medication can tell us who amongst them will improve with antidepressant treatment and to what extent. They will also determine whether patients' brain electrical activity during the 12 weeks of medication treatment will change in any way and whether this change will be linked with a change in the severity of their depression. Researchers hope that information gained from this study will help to better understand the brain processes associated with depression and its successful treatment.\",\n",
       "       'DetailedDescription': \"This research study will examine how the brain electrical activity of elderly depressed patients is related to how quickly and how well they respond to antidepressant medication treatment. Brain electrical activity will be assessed using electrophysiological tests. Elderly patients with depression will be treated for 12 weeks with an antidepressant medication commonly used in clinical practice called escitalopram (Lexapro). Before they start treatment, patients will be asked questions about their depression to measure how severe it is. They will also be asked to have their brain electrical activity recorded while they perform tests on a computer screen. The questions about their depression and the brain electrical recordings will be repeated regularly during the 12 weeks they will be treated with antidepressant medication. The researchers are interested to see whether the brain electrical activity of elderly people with depression before they start the medication can tell us who amongst them and to what extent will finally improve with treatment with escitalopram (Lexapro). They will also determine whether patients' brain electrical activity, during the 12 weeks they will be receiving the medication treatment, will change in any way and whether this change will be linked with the change in the severity of their depression. It is hoped that information gained from this study will help the investigators to better understand the brain processes associated with depression and its successful treatment.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '106',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Escitalopram',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': '12 week open label with 2 week placebo period (14 weeks total)',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Escitalopram']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Escitalopram',\n",
       "          'InterventionDescription': '20 mg by mouth daily',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Escitalopram']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Lexapro']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Montgomery Asberg Depression Rating Scale (Depression Severity)',\n",
       "          'PrimaryOutcomeDescription': 'A published and widely used scale for measuring severity of depression. Montgomery Asberg Depression Rating Scale scores can range from 0-60. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.',\n",
       "          'PrimaryOutcomeTimeFrame': '14 weeks from enrollment (12 weeks from medication start)'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Hamilton Depression Rating Scale (Depression Severity)',\n",
       "          'SecondaryOutcomeDescription': 'A published and widely-used scale for rating depression severity, the Hamilton Depression Rating Scale 24 item total scores range from 0-76. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.',\n",
       "          'SecondaryOutcomeTimeFrame': '14 weeks from enrollment (12 weeks from medication start)'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nDiagnosis: Major depression, unipolar without psychotic features (by DSM-IV criteria) -Severity of depression: A 24-Item HDRS above 19 at screening and at baseline -\\nLevel of Executive Dysfunction: Two strata within each age stratum: Stroop Color-Word scores - one half of the sample < 26, one of half ≥ 26.\\nCapacity to provide informed consent.\\n\\nExclusion Criteria:\\n\\nHigh suicide risk, i.e. intent or plan to attempt suicide in near future\\nPresence of any current Axis I psychiatric disorder (other than unipolar major depression or specific phobias) including substance abuse (those with a history of substance abuse must be abstinent for at least 3 months prior to entry)\\nAxis II diagnosis of antisocial personality disorder, mental retardation and pervasive developmental disorder (DSM-IV)\\nHistory of psychiatric disorders such as psychotic depression, primary psychotic disorder, or bipolar spectrum disorder (bipolar disorder and hypomania are exclusions)\\nCognition: MMSE scores below 24 or diagnosis of dementia by DSM-IV\\nAcute or severe medical illness, i.e., delirium, metastatic cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry; or drugs known to cause depression, e.g., reserpine, alpha-methyl-dopa, steroids, sympathomimetics withdrawal\\nPresence of a significant neurological disease such as Parkinson's disease, primary or secondary seizure disorders, intracranial tumors, severe head trauma; neurodegenerative diseases i.e. MS\\nHistory of failure to respond to escitalopram (Lexapro) (20mg/day for 6 weeks or longer) during the current or previous depressive episodes\\nHistory of intolerance to escitalopram (Lexapro) or use of concomitant drugs that may provide reason to believe that escitalopram is contraindicated. Active treatment with fluoxetine at the time of screening\\nPatients' unwillingness or inability to gradually withdraw all other psychotropic medications (except for the following: Low and stable doses of opiates and non-benzodiazepine hypnotics (e.g. zolpidem (5 or 10 mg), zaleplon (5 or 10 mg), or eszopiclone (1 or 2 mg).Low and stable doses of diazepam and other anxiolytics should be tapered at screening; inability to tolerate taper is not an exclusion criteria.\\nInability to perform any of the ADLs (MAI: ADL subscale) even with assistance, e.g. walking with a cane is not an exclusion criterion\\nInability to speak English\\nAphasia\",\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '60 Years',\n",
       "       'MaximumAge': '90 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'George Alexopoulos, MD',\n",
       "          'OverallOfficialAffiliation': 'Weill Medical College of Cornell University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Weill Cornell Medical College-Westchester Division',\n",
       "          'LocationCity': 'White Plains',\n",
       "          'LocationState': 'New York',\n",
       "          'LocationZip': '10605',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': '106 participants enrolled in the study; however, 35 exited during the 2-week washout period and did not start study medication.',\n",
       "       'FlowRecruitmentDetails': 'Overall flow of study participants',\n",
       "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Escitalopram',\n",
       "          'FlowGroupDescription': '12 week open label with 2 week placebo period (14 weeks total)\\n\\nEscitalopram: 20 mg by mouth daily'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '71'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '59'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '12'}]}}]},\n",
       "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '3'}]}},\n",
       "            {'FlowDropWithdrawType': 'Physician Decision',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '1'}]}},\n",
       "            {'FlowDropWithdrawType': 'Withdrawal by Subject',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '2'}]}},\n",
       "            {'FlowDropWithdrawType': 'Side Effects',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '3'}]}},\n",
       "            {'FlowDropWithdrawType': 'Inter-current medical events',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '3'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Escitalopram',\n",
       "          'BaselineGroupDescription': '12 week open label with 2 week placebo period (14 weeks total)\\n\\nEscitalopram: 20 mg by mouth daily'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '71'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '13'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '58'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '71.91',\n",
       "                   'BaselineMeasurementSpread': '7.53'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '36'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '35'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '4'}]}},\n",
       "               {'BaselineCategoryTitle': 'Not Hispanic or Latino',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '67'}]}},\n",
       "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Race (NIH/OMB)',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Asian',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '1'}]}},\n",
       "               {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Black or African American',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '4'}]}},\n",
       "               {'BaselineCategoryTitle': 'White',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '66'}]}},\n",
       "               {'BaselineCategoryTitle': 'More than one race',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '71'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Hamilton Depression Rating Scale (HDRS) 24-Item Total Score',\n",
       "          'BaselineMeasureDescription': 'HDRS 24 item: scores can range from 0-76; higher is worse(more depressed)',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '23.83',\n",
       "                   'BaselineMeasurementSpread': '4.48'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Montgomery and Asberg Depression Rating Scale (MADRS) Total Score',\n",
       "          'BaselineMeasureDescription': 'MADRS: scores can range from 0-60; higher is worse(more depressed)',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '24.08',\n",
       "                   'BaselineMeasurementSpread': '5.74'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Montgomery Asberg Depression Rating Scale (Depression Severity)',\n",
       "          'OutcomeMeasureDescription': 'A published and widely used scale for measuring severity of depression. Montgomery Asberg Depression Rating Scale scores can range from 0-60. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': '14 weeks from enrollment (12 weeks from medication start)',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Escitalopram',\n",
       "             'OutcomeGroupDescription': '12 week open label with 2 week placebo period (14 weeks total)\\n\\nEscitalopram: 20 mg by mouth daily'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '71'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '12.23',\n",
       "                   'OutcomeMeasurementSpread': '7.67'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Hamilton Depression Rating Scale (Depression Severity)',\n",
       "          'OutcomeMeasureDescription': 'A published and widely-used scale for rating depression severity, the Hamilton Depression Rating Scale 24 item total scores range from 0-76. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': '14 weeks from enrollment (12 weeks from medication start)',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Escitalopram',\n",
       "             'OutcomeGroupDescription': '12 week open label with 2 week placebo period (14 weeks total)\\n\\nEscitalopram: 20 mg by mouth daily'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '71'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '11.47',\n",
       "                   'OutcomeMeasurementSpread': '6.64'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventsTimeFrame': '14 weeks',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Escitalopram',\n",
       "          'EventGroupDescription': '12 week open label with 2 week placebo period (14 weeks total)\\n\\nEscitalopram: 20 mg by mouth daily',\n",
       "          'EventGroupDeathsNumAffected': '0',\n",
       "          'EventGroupDeathsNumAtRisk': '71',\n",
       "          'EventGroupSeriousNumAffected': '3',\n",
       "          'EventGroupSeriousNumAtRisk': '71',\n",
       "          'EventGroupOtherNumAffected': '47',\n",
       "          'EventGroupOtherNumAtRisk': '71'}]},\n",
       "       'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Hospitalisation',\n",
       "          'SeriousEventOrganSystem': 'Surgical and medical procedures',\n",
       "          'SeriousEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '3',\n",
       "             'SeriousEventStatsNumAffected': '3',\n",
       "             'SeriousEventStatsNumAtRisk': '71'}]}}]},\n",
       "       'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Abdominal pain upper',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Anxiety',\n",
       "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Arthralgia',\n",
       "          'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Burning sensation',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Cerebrovascular accident',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Colitis ulcerative',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Colonoscopy',\n",
       "          'OtherEventOrganSystem': 'Investigations',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Conjunctivitis',\n",
       "          'OtherEventOrganSystem': 'Infections and infestations',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Diarrhoea',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '15',\n",
       "             'OtherEventStatsNumAffected': '12',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Dizziness',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Dry mouth',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Epistaxis',\n",
       "          'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Fall',\n",
       "          'OtherEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '38',\n",
       "             'OtherEventStatsNumAffected': '21',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Fracture',\n",
       "          'OtherEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Gastroenteritis',\n",
       "          'OtherEventOrganSystem': 'Infections and infestations',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Gastroenteritis viral',\n",
       "          'OtherEventOrganSystem': 'Infections and infestations',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Groin infection',\n",
       "          'OtherEventOrganSystem': 'Infections and infestations',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Hyperparathyroidism',\n",
       "          'OtherEventOrganSystem': 'Endocrine disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Micturition urgency',\n",
       "          'OtherEventOrganSystem': 'Renal and urinary disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Nausea',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Night Sweats',\n",
       "          'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Pollakiuria',\n",
       "          'OtherEventOrganSystem': 'Renal and urinary disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Polymyalgia rheumatica',\n",
       "          'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Rash',\n",
       "          'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Sinus headache',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Sinusitis',\n",
       "          'OtherEventOrganSystem': 'Infections and infestations',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Skin irritation',\n",
       "          'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Surgery',\n",
       "          'OtherEventOrganSystem': 'Surgical and medical procedures',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Upper gastrointestinal haemorrhage',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Upper respiratory tract infection',\n",
       "          'OtherEventOrganSystem': 'Infections and infestations',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Urinary tract infection',\n",
       "          'OtherEventOrganSystem': 'Infections and infestations',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Vomiting',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}},\n",
       "         {'OtherEventTerm': 'Weight decreased',\n",
       "          'OtherEventOrganSystem': 'Investigations',\n",
       "          'OtherEventSourceVocabulary': 'MedDRA (21.1)',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'}]}}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'George S Alexopoulos',\n",
       "        'PointOfContactOrganization': 'Weill Cornell Medicine',\n",
       "        'PointOfContactEMail': 'gsalexop@med.cornell.edu',\n",
       "        'PointOfContactPhone': '914-997-5767'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000015283',\n",
       "          'InterventionMeshTerm': 'Citalopram'}]},\n",
       "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000017367',\n",
       "          'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000014179',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000049990',\n",
       "          'InterventionAncestorTerm': 'Membrane Transport Modulators'},\n",
       "         {'InterventionAncestorId': 'D000045504',\n",
       "          'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "         {'InterventionAncestorId': 'D000018377',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Agents'},\n",
       "         {'InterventionAncestorId': 'D000018490',\n",
       "          'InterventionAncestorTerm': 'Serotonin Agents'},\n",
       "         {'InterventionAncestorId': 'D000045505',\n",
       "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'},\n",
       "         {'InterventionAncestorId': 'D000018687',\n",
       "          'InterventionAncestorTerm': 'Antidepressive Agents, Second-Generation'},\n",
       "         {'InterventionAncestorId': 'D000000928',\n",
       "          'InterventionAncestorTerm': 'Antidepressive Agents'},\n",
       "         {'InterventionAncestorId': 'D000011619',\n",
       "          'InterventionAncestorTerm': 'Psychotropic Drugs'}]},\n",
       "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16566',\n",
       "          'InterventionBrowseLeafName': 'Citalopram',\n",
       "          'InterventionBrowseLeafAsFound': 'Escitalopram',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M5687',\n",
       "          'InterventionBrowseLeafName': 'Dexetimide',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M14095',\n",
       "          'InterventionBrowseLeafName': 'Serotonin',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M18232',\n",
       "          'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19088',\n",
       "          'InterventionBrowseLeafName': 'Neurotransmitter Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M2828',\n",
       "          'InterventionBrowseLeafName': 'Antidepressive Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M13057',\n",
       "          'InterventionBrowseLeafName': 'Psychotropic Drugs',\n",
       "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr',\n",
       "          'InterventionBrowseBranchName': 'Psychotropic Drugs'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'AnDyAg',\n",
       "          'InterventionBrowseBranchName': 'Anti-Dyskinesia Agents'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M28292',\n",
       "          'ConditionBrowseLeafName': 'Cognitive Dysfunction',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 39,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03892915',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '2017-1041'},\n",
       "       'Organization': {'OrgFullName': 'RAND', 'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Maternal Depression Treatment in HIV',\n",
       "       'OfficialTitle': 'Depression Care to Improve Adherence to Prevention of Mother-to-Child-Transmission (PMTCT) Care Continuum & Pregnancy Outcomes',\n",
       "       'Acronym': 'M-DEPTH'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'September 2019',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'July 8, 2019',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2022',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2022',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'March 21, 2019',\n",
       "       'StudyFirstSubmitQCDate': 'March 25, 2019',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 27, 2019',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'September 9, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 11, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'RAND', 'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Makerere University',\n",
       "          'CollaboratorClass': 'OTHER'},\n",
       "         {'CollaboratorName': 'Mildmay Uganda',\n",
       "          'CollaboratorClass': 'UNKNOWN'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Cluster randomized controlled trial to compare the effects of task-shifted, evidence-based depression care vs. usual care on adherence to each step of the prevention of mother-to-child-transmission (PMTCT) care cascade at 8 antenatal care (ANC) clinics in Uganda.',\n",
       "       'DetailedDescription': 'This study is a cluster randomized controlled trial (RCT) to compare the effects of task-shifted, evidence-based depression care vs. usual care on adherence to each step of the PMTCT care cascade at 8 ANC clinics in Uganda. At 4 experimental sites, task-shifted, depression care will include (1) depression screening and psychoeducation, (2) depression diagnosis, and (3) provision of evidence-based problem solving therapy (PST), or antidepressant therapy (ADT) for those with severe and refractory depression (or who decline PST), to be implemented by trained peer mothers and midwife nurses, respectively. The 4 control sites will use usual care services for managing depression, which consist of referrals to a mental health specialist and access to the Family Support Group program (comprehensive, monthly multi-session psychosocial program to enhance pregnancy management and PMTCT adherence). At each site, 50 HIV-positive newly pregnant women (total n=400) who screen positive for potential depression will be enrolled and followed until 18-months post-delivery to assess how depression and depression alleviation relate to primary (adherence to each component of the PMTCT care continuum, maternal virologic suppression) and secondary (infant HIV status; post-natal maternal and child health outcomes) outcomes, as well as processes of depression care (treatment uptake and depression alleviation among clinically depressed patients). A cost-effectiveness analysis will be used to compare the two study arms.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 2', 'Phase 3']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignInterventionModelDescription': 'Cluster randomized controlled trial with 4 sites randomly assigned to implement evidence-based depression care in addition to usual care and 4 sites randomly assigned to implement usual care only',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '400',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depression Care',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Task-shifted depression care, consisting of (1) depression screening and psychoeducation, (2) depression diagnosis, and (3) evidence-based problem solving therapy (PST) or antidepressant therapy (ADT; for those with severe and refractory depression, or who decline PST), to be implemented by trained peer mothers and midwife nurses in addition to usual care.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Combination Product: evidence-based depression treatment']}},\n",
       "         {'ArmGroupLabel': 'Usual care',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Usual care processes for treating depression consist of referrals to mental health specialists and access to the Family Support Group program (a nation wide Ministry of Health program for HIV+ women at public ANC clinics, consisting of monthly sessions designed to provide psychosocial support and education to promote pregnancy management and PMTCT adherence).'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Combination Product',\n",
       "          'InterventionName': 'evidence-based depression treatment',\n",
       "          'InterventionDescription': 'We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depression Care']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Rate of maternal HIV viral suppression',\n",
       "          'PrimaryOutcomeDescription': 'Proportion of participants who achieve undetectable HIV viral load as measured by blood assay',\n",
       "          'PrimaryOutcomeTimeFrame': 'One month post pregnancy'},\n",
       "         {'PrimaryOutcomeMeasure': 'Mean maternal antiretroviral (ART) adherence',\n",
       "          'PrimaryOutcomeDescription': 'Group mean proportion of prescribed ART doses taken as measured by pharmacy refill data',\n",
       "          'PrimaryOutcomeTimeFrame': 'From study enrollment to one-month post pregnancy'},\n",
       "         {'PrimaryOutcomeMeasure': 'Rate of prevention of mother-to-child-transmission (PMTCT) care retention',\n",
       "          'PrimaryOutcomeDescription': 'Proportion of participants who continue to attend antenatal care (ANC) visits as measured by chart abstraction',\n",
       "          'PrimaryOutcomeTimeFrame': 'through study completion, an average of 48 weeks'},\n",
       "         {'PrimaryOutcomeMeasure': 'Rate of delivery in health facility',\n",
       "          'PrimaryOutcomeDescription': 'Proportion of participants who delivery their baby of in a health facility as measured by chart abstraction',\n",
       "          'PrimaryOutcomeTimeFrame': 'one month post pregnancy'},\n",
       "         {'PrimaryOutcomeMeasure': 'Rate of infant use of ART',\n",
       "          'PrimaryOutcomeDescription': 'Proportion of delivered infants who receive ART as measured by chart abstraction',\n",
       "          'PrimaryOutcomeTimeFrame': 'First 6 weeks of life'},\n",
       "         {'PrimaryOutcomeMeasure': 'Rate of universal infant feeding',\n",
       "          'PrimaryOutcomeDescription': 'Proportion of delivered infants who receive uniform feeding method (breastfeeding or formula) as documented by self-report',\n",
       "          'PrimaryOutcomeTimeFrame': 'First 6 months of life'},\n",
       "         {'PrimaryOutcomeMeasure': 'Rate of complete infant HIV testing',\n",
       "          'PrimaryOutcomeDescription': 'Proportion of delivered infants who are tested for HIV at all specified intervals, as measured by chart abstraction',\n",
       "          'PrimaryOutcomeTimeFrame': '18 months after birth'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Child HIV status',\n",
       "          'SecondaryOutcomeDescription': 'HIV status of child',\n",
       "          'SecondaryOutcomeTimeFrame': '18 months after birth'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ndetection of pregnancy through 24 weeks gestation (to ensure at least 12 weeks remaining antenatal period for assessing adherence to all stages of PMTCT care cascade)\\nHIV-positive\\npositive screen for potential depression on 2-item Patient Health Questionnaire (PHQ-2>0)\\non ART for at least 4 weeks\\n\\nExclusion Criteria:\\n\\nunstable health (about to start ART or on ART < 4 weeks; active, untreated opportunistic infection)',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Female',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Glenn Wagner, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '310-393-0411',\n",
       "          'CentralContactPhoneExt': '7698',\n",
       "          'CentralContactEMail': 'gwagner@rand.org'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Glenn Wagner, PhD',\n",
       "          'OverallOfficialAffiliation': 'RAND',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Makerere University',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Kampala',\n",
       "          'LocationCountry': 'Uganda',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Violet Gwokyalya',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactEMail': 'vgwokyalya@musph.ac.ug'}]}}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31277180',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Wagner GJ, McBain RK, Akena D, Ngo V, Nakigudde J, Nakku J, Chemusto H, Beyeza-Kashesya J, Gwokyalya V, Faherty LJ, Kyohangirwe L, Nabitaka LK, Lukwata H, Linnemayr S, Ghosh-Dastidar B, Businge J, Mukasa B, Wanyenze RK. Maternal depression treatment in HIV (M-DEPTH): Study protocol for a cluster randomized controlled trial. Medicine (Baltimore). 2019 Jul;98(27):e16329. doi: 10.1097/MD.0000000000016329.'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'Yes',\n",
       "       'IPDSharingDescription': 'We will make the data publicly available in the form of an electronic database for researchers who successfully complete a registration process. Data will be de-identified. We will provide documentation in the form of a codebook in which each variable name and response options are defined. Users must agree to the conditions of use governing access to the public release data. Users must submit brief proposals regarding intended use of the data; the study team will determine the scientific soundness of the proposal, as well as whether adequate data protections in place, as part of the decision for the researcher to be able to access the public use dataset.',\n",
       "       'IPDSharingInfoTypeList': {'IPDSharingInfoType': ['Study Protocol',\n",
       "         'Statistical Analysis Plan (SAP)',\n",
       "         'Informed Consent Form (ICF)']},\n",
       "       'IPDSharingTimeFrame': 'Following publication of the main paper(s) for this study and the grant end-date.',\n",
       "       'IPDSharingAccessCriteria': 'Users must submit brief proposals regarding intended use of the data; the study team will determine the scientific soundness of the proposal, as well as whether adequate data protections in place, as part of the decision for the researcher to be able to access the public use dataset.'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M16833',\n",
       "          'ConditionBrowseLeafName': 'HIV Infections',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M2103',\n",
       "          'ConditionBrowseLeafName': 'Acquired Immunodeficiency Syndrome',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC02',\n",
       "          'ConditionBrowseBranchName': 'Viral Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC20',\n",
       "          'ConditionBrowseBranchName': 'Immune System Diseases'}]}}}}},\n",
       "   {'Rank': 40,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00709150',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'R01MH068468',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH068468&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH068468',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH068468&Fy=all'},\n",
       "         {'SecondaryId': 'DSIR 82-SESQ'}]},\n",
       "       'Organization': {'OrgFullName': 'University of Southern California',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Collaborative Depression Care Management in Treating Depressed Low-income Hispanics With Diabetes',\n",
       "       'OfficialTitle': 'Multifaceted Depression Diabetes Program for Hispanics',\n",
       "       'Acronym': 'MDDP'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2013',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'March 2005'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2009',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'September 2009',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 30, 2008',\n",
       "       'StudyFirstSubmitQCDate': 'June 30, 2008',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 3, 2008',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 25, 2013',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 29, 2013',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Kathleen R. Ell',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Study Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Southern California'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Southern California',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study will evaluate the effectiveness of culturally adapted depression treatment for reducing depressive symptoms and improving adherence to diabetes self-care regimens in Hispanics with depression and diabetes.',\n",
       "       'DetailedDescription': \"Diabetes, a disease in which the body does not properly produce or use insulin, is the fifth leading cause of death among Hispanics in the United States. The risk of comorbid depression among diabetics is twice as high as that of the general population, with depression rates among diabetic Hispanics as high as 33%. Symptoms of depression include feelings of sadness, anxiety, and guilt; lack of energy; changes in appetite; and lack of pleasure in previously enjoyed activities. These symptoms can make maintaining good diabetic management and self-care regimens difficult. Fortunately, depression is treatable with forms of psychotherapy and antidepressant medications. However, depression treatment adherence and response rates among the Hispanic population, especially among Hispanics of low socio-economic status, are lower than those of the general population. Depression treatment that is specifically adapted for the Hispanic culture may be best at helping diabetic Hispanics stick to their treatment and self-care plans. This study will evaluate the effectiveness of culturally adapted depression treatment for reducing depressive symptoms and improving adherence to diabetes self-care regimens in low-income Hispanics with depression and diabetes.\\n\\nParticipation in this study will last 18 months. All participants will first undergo baseline assessments that will include a 40-minute interview about personal health and feelings. Eligible participants will then be assigned randomly to receive either collaborative depression care management or enhanced usual care.\\n\\nParticipants assigned to receive collaborative depression care management will first be provided with information about depression treatment. Participants will then have the option of choosing between two depression treatments: counseling or antidepressant medications. Participants who choose to receive treatment with counseling will receive eight weekly 45-minute counseling sessions, conducted either on the phone or at the clinic. During these sessions, participants will undergo structured problem solving therapy (PST) and will learn strategies to manage their depressive symptoms. Participants who choose to receive treatment with antidepressant medication will be prescribed medication by a study doctor and will be monitored for any side effects throughout treatment. Medication treatment may last up to 12 months but will depend upon participants' severity of depression. After completing medication treatment, participants will be offered PST counseling. All participants receiving collaborative depression care management will also receive supportive patient navigation services and maintenance/relapse telephone monitoring.\\n\\nParticipants assigned to enhanced usual care will receive an educational pamphlet on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care. All participants will undergo follow-up phone interviews about their status at Months 6, 12, and 18.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Major Depression',\n",
       "         'Diabetes',\n",
       "         'Hispanics',\n",
       "         'Collaborative Depression Care Management']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 4']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '387',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '1',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Patients will receive collaborative depression care management.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Collaborative depression care management']}},\n",
       "         {'ArmGroupLabel': '2',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Patients will receive enhanced usual care.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Enhanced usual care']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Collaborative depression care management',\n",
       "          'InterventionDescription': \"Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Enhanced usual care',\n",
       "          'InterventionDescription': \"Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Reduction in symptoms of major depression',\n",
       "          'PrimaryOutcomeTimeFrame': 'Measured at Months 12, 18, and 24'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quality of life',\n",
       "          'SecondaryOutcomeTimeFrame': 'Measured at Months 12, 18, and 24'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMeets criteria for major depression based on a score of greater than 2 for five or more symptoms, including one of the two cardinal depression symptoms and a nine-item depression scale of the Patient Health Questionnaire (PHQ-9) score of greater than 10\\nPatient with diabetes\\nHas attended two community safety net clinics\\n\\nExclusion Criteria:\\n\\nCurrent suicidal ideation\\nScore of 8 or greater on the Alcohol Use Disorders Identification Test (AUDIT)\\nRecent use of lithium or antipsychotic medication',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kathleen R. Ell, DSW',\n",
       "          'OverallOfficialAffiliation': 'University of Southern California',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'University of Southern California School of Social Work',\n",
       "          'LocationCity': 'Los Angeles',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '90089-0411',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '22458987',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Ell K, Katon W, Lee PJ, Kapetanovic S, Guterman J, Xie B, Chou CP. Depressive symptom deterioration among predominantly Hispanic diabetes patients in safety net care. Psychosomatics. 2012 Jul-Aug;53(4):347-55. doi: 10.1016/j.psym.2011.12.009. Epub 2012 Mar 27.'},\n",
       "         {'ReferencePMID': '22433755',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Hay JW, Katon WJ, Ell K, Lee PJ, Guterman JJ. Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly Hispanics with diabetes. Value Health. 2012 Mar-Apr;15(2):249-54. doi: 10.1016/j.jval.2011.09.008. Epub 2011 Dec 15.'},\n",
       "         {'ReferencePMID': '21774987',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Ell K, Katon W, Xie B, Lee PJ, Kapetanovic S, Guterman J, Chou CP. One-year postcollaborative depression care trial outcomes among predominantly Hispanic diabetes safety net patients. Gen Hosp Psychiatry. 2011 Sep-Oct;33(5):436-42. doi: 10.1016/j.genhosppsych.2011.05.018. Epub 2011 Jul 19.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5698',\n",
       "          'ConditionBrowseLeafName': 'Diabetes Mellitus',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18',\n",
       "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC19',\n",
       "          'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
       "   {'Rank': 41,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02149563',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '002'},\n",
       "       'Organization': {'OrgFullName': 'Meir Medical Center',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Oxygen Therapy in Depression',\n",
       "       'OfficialTitle': 'Oxygen Therapy in Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2015',\n",
       "       'OverallStatus': 'Unknown status',\n",
       "       'LastKnownStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2015'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2016',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'September 2016',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'April 7, 2014',\n",
       "       'StudyFirstSubmitQCDate': 'May 25, 2014',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 29, 2014',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'March 15, 2015',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 17, 2015',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Meir Medical Center',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The major objective of the present study is to examine the influence of normobaric hyperoxia treatment on the symptoms of patients diagnosed with depression members of Clalit Health Services. The investigators hypothesize that normobaric hyperoxia treatment will improve the symptoms of patients with depression.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression, Normobaric Hyperoxia.']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Investigator']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '200',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Treatment',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'One hundred participants will receive home treatment with oxygen-enriched air (40% O2) through a nasal tube during the night (7 hours) for one month.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: oxygen-enriched air -Normobaric hyperoxia treatment for depression']}},\n",
       "         {'ArmGroupLabel': 'Placebo',\n",
       "          'ArmGroupType': 'Placebo Comparator',\n",
       "          'ArmGroupDescription': '100 participants will receive regular air treatment (21% O2) through a nasal tube (identical to the procedure providing 40% O2) for one month',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: oxygen-enriched air -Normobaric hyperoxia treatment for depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
       "          'InterventionName': 'oxygen-enriched air -Normobaric hyperoxia treatment for depression',\n",
       "          'InterventionDescription': 'Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo',\n",
       "            'Treatment']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Oxygen-enriched air provided by oxygen concentrators to improve symptoms of patients with depression.']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Hamilton Rating Scale for Depression (HRSD)-changes in patients' depression.\",\n",
       "          'PrimaryOutcomeDescription': \"HRSD will be used to assess changes in patients' condition. Assessment will be performed at 3 time points: baseline (time zero), 2 weeks and 4 weeks after treatment initiation, by a trained psychiatric nurse blind to the patient's treatment status.\",\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline (time zero), 2 weeks and 4 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMen and women aged 18-65 years diagnosed with mild to moderate depression.\\n\\nExclusion Criteria:\\n\\nPatients with oxygen saturation below 95%;\\nAn unstable mental (psychiatric) condition\\nA psychiatric condition that requires a change in pharmacotherapy (importantly - medications will not be changed in patients who will be enrolled to the study)\\nAcute or chronic respiratory disease\\nAny severe physical illness\\nSuicidal thoughts or attempts\\nDrug abuse\\nObesity (BMI over 30)\\nInability to cease smoking during night hours while participants are supposed to be using the oxygen/air supplementing machine.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Clalit Health Services in the Southern region',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Beer-sheva',\n",
       "          'LocationCountry': 'Israel',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Pesach Shvartzman, M.D.',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '972-8-6477429'}]}}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000018496',\n",
       "          'ConditionMeshTerm': 'Hyperoxia'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000012818',\n",
       "          'ConditionAncestorTerm': 'Signs and Symptoms, Respiratory'},\n",
       "         {'ConditionAncestorId': 'D000012816',\n",
       "          'ConditionAncestorTerm': 'Signs and Symptoms'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M19184',\n",
       "          'ConditionBrowseLeafName': 'Hyperoxia',\n",
       "          'ConditionBrowseLeafAsFound': 'Hyperoxia',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M14206',\n",
       "          'ConditionBrowseLeafName': 'Signs and Symptoms, Respiratory',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
       "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}},\n",
       "   {'Rank': 42,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00282776',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'R01MH071825',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH071825&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH071825',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH071825&Fy=all'},\n",
       "         {'SecondaryId': 'DSIR 82-SEMS',\n",
       "          'SecondaryIdType': 'Other Identifier',\n",
       "          'SecondaryIdDomain': 'National Institute of Mental Health'}]},\n",
       "       'Organization': {'OrgFullName': 'University of Pittsburgh',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Identification and Therapy of Postpartum Depression',\n",
       "       'OfficialTitle': 'Identification and Therapy of Postpartum Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'September 2013',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'August 2006'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2012',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'March 2012',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'January 25, 2006',\n",
       "       'StudyFirstSubmitQCDate': 'January 25, 2006',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 27, 2006',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'September 30, 2013',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 7, 2013',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Katherine Wisner',\n",
       "        'ResponsiblePartyInvestigatorTitle': \"Professor of Psychiatry, Obstetrics and Gynecology and Reproductive Sciences, Epidemiology and Women's Studies\",\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Pittsburgh'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Pittsburgh',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study will evaluate the effectiveness of a telephone-based depression screening and care management program in treating depression in postpartum women.',\n",
       "       'DetailedDescription': \"Depression is a serious illness that can interfere with everyday life. Researchers believe that it is one of the most common complications during and after pregnancy. Depression after pregnancy is called postpartum depression and may be caused by a rapid change in hormone levels during and immediately after pregnancy. Postpartum depression can occur anytime within the first year after childbirth and can negatively affect both mothers and their children. Mothers with postpartum depression may experience low energy, difficulty concentrating, irritability, and inability to meet their children's needs for love and affection. As a result, women with postpartum depression may feel guilty and lose confidence in themselves as parents. Research shows that children of mothers with postpartum depression may have delays in language development, difficulty with emotional bonding to others, behavioral problems, lower activity levels, sleep problems, and distress. This study will evaluate the effectiveness of a telephone-based depression screening and care management program in treating depression in postpartum women.\\n\\nParticipants in this single blind study will be randomly assigned to receive either enhanced treatment as usual or telephone-based care management for the first year postpartum. All participants will have a 90-minute in-home interview upon study entry to assess depressive symptoms, functional status, medical history, and post-pregnancy plans. Participants assigned to care management will receive two calls in the first month postpartum, followed by monthly calls for the remainder of the first postpartum year. During each 10- to 20-minute call, participants will be asked to provide information regarding current depressive symptoms, steps they have taken to seek depression-related care, and any barriers they have encountered in the process. In addition, a care manager will act as an advocate for the participants and assist in obtaining specialized services as necessary throughout the year. Participants assigned to receive enhanced treatment as usual will not receive monthly phone calls or tailored care management. All participants will receive follow-up calls at 3, 6, and 12 months postpartum to assess outcome measures; these calls will last about 30 minutes.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Postpartum Depression',\n",
       "         'Telephone Care Management',\n",
       "         'Screening for Postpartum Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 3']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '628',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'TAU',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Participants will receive treatment as usual',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: TAU']}},\n",
       "         {'ArmGroupLabel': 'DCM',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants will receive care management for postpartum depression',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Care Management for Postpartum Depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Care Management for Postpartum Depression',\n",
       "          'InterventionDescription': 'Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['DCM']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'TAU',\n",
       "          'InterventionDescription': 'Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['TAU']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depressive symptoms, social functioning, and health',\n",
       "          'PrimaryOutcomeTimeFrame': 'Measured at Months 3, 6, and 12 postpartum'},\n",
       "         {'PrimaryOutcomeMeasure': 'Preferences for depression treatment',\n",
       "          'PrimaryOutcomeTimeFrame': 'Measured at baseline and Month 12'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n4-6 weeks postpartum\\nEnglish-speaking\\nScore of at least 10 on the Edinburgh Postnatal Depression Scale\\n\\nExclusion Criteria:\\n\\nDSM-IV diagnosis of bipolar disorder or psychotic episode\\nActive substance abuse within 6 months prior to study entry\\nHas not received obstetrical care\\nHistory of a suicide attempt within 6 months of study entry',\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'Female',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Katherine L. Wisner, MD, RN',\n",
       "          'OverallOfficialAffiliation': 'University of Pittsburgh',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': \"Women's Behavioral HealthCARE Program, Suite 410, 3501 Forbes Ave\",\n",
       "          'LocationCity': 'Pittsburgh',\n",
       "          'LocationState': 'Pennsylvania',\n",
       "          'LocationZip': '15213',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28796940',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Wisner KL, Sit DKY, McShea M, Luther JF, Eng HF, Dills JL, Moses-Kolko EL, Wisniewski SR. Telephone-Based Depression Care Management for Postpartum Women: A Randomized Controlled Trial. J Clin Psychiatry. 2017 Nov/Dec;78(9):1369-1375. doi: 10.4088/JCP.15m10563.'},\n",
       "         {'ReferencePMID': '26059839',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Clark CT, Sit DK, Driscoll K, Eng HF, Confer AL, Luther JF, Wisniewski SR, Wisner KL. DOES SCREENING WITH THE MDQ AND EPDS IMPROVE IDENTIFICATION OF BIPOLAR DISORDER IN AN OBSTETRICAL SAMPLE? Depress Anxiety. 2015 Jul;32(7):518-26. doi: 10.1002/da.22373. Epub 2015 Jun 8.'},\n",
       "         {'ReferencePMID': '23487258',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Wisner KL, Sit DK, McShea MC, Rizzo DM, Zoretich RA, Hughes CL, Eng HF, Luther JF, Wisniewski SR, Costantino ML, Confer AL, Moses-Kolko EL, Famy CS, Hanusa BH. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry. 2013 May;70(5):490-8. doi: 10.1001/jamapsychiatry.2013.87.'},\n",
       "         {'ReferencePMID': '21381158',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Sit D, Seltman H, Wisner KL. Seasonal effects on depression risk and suicidal symptoms in postpartum women. Depress Anxiety. 2011 May;28(5):400-5. doi: 10.1002/da.20807. Epub 2011 Mar 4.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000019052',\n",
       "          'ConditionMeshTerm': 'Depression, Postpartum'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000011644',\n",
       "          'ConditionAncestorTerm': 'Puerperal Disorders'},\n",
       "         {'ConditionAncestorId': 'D000011248',\n",
       "          'ConditionAncestorTerm': 'Pregnancy Complications'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M19660',\n",
       "          'ConditionBrowseLeafName': 'Depression, Postpartum',\n",
       "          'ConditionBrowseLeafAsFound': 'Postpartum Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13082',\n",
       "          'ConditionBrowseLeafName': 'Puerperal Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M12710',\n",
       "          'ConditionBrowseLeafName': 'Pregnancy Complications',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXS',\n",
       "          'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}}}},\n",
       "   {'Rank': 43,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02691520',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'CR108117'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'NOPRODDEP4001',\n",
       "          'SecondaryIdType': 'Other Identifier',\n",
       "          'SecondaryIdDomain': 'Johnson & Johnson Pte Ltd'}]},\n",
       "       'Organization': {'OrgFullName': 'Johnson & Johnson Pte Ltd',\n",
       "        'OrgClass': 'INDUSTRY'},\n",
       "       'BriefTitle': 'Epidemiology of Treatment Resistant Depression in Taiwan',\n",
       "       'OfficialTitle': 'Epidemiology of Treatment Resistant Depression in Taiwan'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'September 2015'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2016',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'February 2016',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'February 22, 2016',\n",
       "       'StudyFirstSubmitQCDate': 'February 22, 2016',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 25, 2016',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'March 22, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 23, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Johnson & Johnson Pte Ltd',\n",
       "        'LeadSponsorClass': 'INDUSTRY'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Elysia Group',\n",
       "          'CollaboratorClass': 'UNKNOWN'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of this study is to assess the epidemiology of Treatment Resistant Depression (TRD) in the nationally insured population in Taiwan including incidence, duration of clinical episodes, and prevalence by age and sex.',\n",
       "       'DetailedDescription': 'This is a retrospective study of approximately one million subjects randomly selected from an anonymized database National Health Insurance Research Database (NHIRD). Participants aged 18 years or older who have had neither a depression diagnosis nor a dispensing of an antidepressant medication in the last four months of 2004 will enter the study when they receive in 2005 a depression diagnosis and a dispensing of an antidepressant medication within 30 days of each other and will be followed up to 8 years or until they have 4 months with neither a depression diagnosis nor a dispensing of an antidepressant medication. Treatment Resistant Depression (TRD) Incidence, TRD prevalence by age and sex and duration of clinical episodes will be estimated.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depressive Disorder, Treatment-Resistant']},\n",
       "       'KeywordList': {'Keyword': ['Treatment Resistant Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Observational',\n",
       "       'PatientRegistry': 'No',\n",
       "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
       "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Retrospective']}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '8356',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Taiwan Participants with Treatment Resistant Depression',\n",
       "          'ArmGroupDescription': 'Taiwan participants with Depression will be followed up to 8 years for incidence and duration of treatment resistant depression.'}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Incidence Percentage of Participants with Treatment Resistant Depression',\n",
       "          'PrimaryOutcomeDescription': \"The percentage of beneficiaries of Taiwan's health insurance plan who developed treatment resistant depression during 2005\",\n",
       "          'PrimaryOutcomeTimeFrame': 'Approximately 8 Years'},\n",
       "         {'PrimaryOutcomeMeasure': 'Prevalence Percentage of Participants with Treatment Resistant Depression',\n",
       "          'PrimaryOutcomeTimeFrame': 'Approximately 8 Years'},\n",
       "         {'PrimaryOutcomeMeasure': 'Duration of an episode of Depression',\n",
       "          'PrimaryOutcomeDescription': 'Time from onset of depression to cessation of depression visits and medications.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Approximately 8 Years'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Healthcare costs',\n",
       "          'SecondaryOutcomeDescription': 'Direct healthcare cost associated with depression treatment will be assessed.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Approximately 8 Years'},\n",
       "         {'SecondaryOutcomeMeasure': 'Number of Participants With Comorbidities',\n",
       "          'SecondaryOutcomeTimeFrame': 'Approximately 8 Years'},\n",
       "         {'SecondaryOutcomeMeasure': 'Medications used by Participants with Treatment Resistant Depression',\n",
       "          'SecondaryOutcomeTimeFrame': 'Approximately 8 Years'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nParticipants who have been continuously enrolled in the insurance plan since January 1, 2004 (ignoring breaks of less than 30 days) and have not received an exclusion diagnosis and during the last 4 months of 2004, a) Have not received a diagnosis of depression and b) Have not received a dispensing of an AD medication\\nParticipants with a diagnosis of a depressive disorder including dysthymic disorder (International Classification of Diseases [ICD]-9 codes 296 depression-related, 300.4, 311) and Major Depressive Disorder (ICD-9 296.2, 296.3) will be followed through December 31, 2013\\n\\nExclusion Criteria:\\n\\n- Participants who receive following diagnosis will be excluded, a) Mania, b) Schizophrenia (ICD-9 codes 295), c) Bipolar disorder (ICD-9 codes 296 bipolar-related), D) Dementia (ICD-9 codes 290 or 294); Note: Major depressive disorder (MDD) with psychotic behavior (ICD 296.24 for single episode, ICD 296.34 for recurrent episode) is not an exclusion',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
       "       'StudyPopulation': 'Adults aged 18 and older are randomly sampled from the National Health Insurance Research Database (NHIRD).',\n",
       "       'SamplingMethod': 'Probability Sample'},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Johnson & Johnson Pte Ltd Clinical Trial',\n",
       "          'OverallOfficialAffiliation': 'Johnson & Johnson Pte Ltd',\n",
       "          'OverallOfficialRole': 'Study Director'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000061218',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder, Treatment-Resistant'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M28370',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Treatment-Resistant',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder, Treatment-Resistant',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 44,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01328639',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'Achord 1101-10'},\n",
       "       'Organization': {'OrgFullName': 'The Alliance for Canadian Health Outcomes Research in Diabetes',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'TeamCare PCN: Collaborative Care for Diabetes and Depression',\n",
       "       'OfficialTitle': 'TeamCare PCN: Collaborative Care for Patients With Diabetes and Depression in Primary Care Networks',\n",
       "       'Acronym': 'TeamCare-PCN'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2013',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'November 2010'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2013',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'January 2013',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'March 30, 2011',\n",
       "       'StudyFirstSubmitQCDate': 'April 4, 2011',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 5, 2011',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 9, 2013',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 11, 2013',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Dr. Jeffrey Johnson',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Professor',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'The Alliance for Canadian Health Outcomes Research in Diabetes'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'The Alliance for Canadian Health Outcomes Research in Diabetes',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Alberta Health & Wellness',\n",
       "          'CollaboratorClass': 'OTHER_GOV'},\n",
       "         {'CollaboratorName': 'Canadian Institutes of Health Research (CIHR)',\n",
       "          'CollaboratorClass': 'OTHER_GOV'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Background & Objective: Type 2 diabetes is a complex disease characterized by multiple comorbidities. Depression is one of the most common comorbidities in individuals with diabetes with prevalence rates reaching 30%. Depression complicates diabetes treatment, portends worse outcomes and increases health care costs. One novel approach to managing diabetes with co-morbid depression is a collaborative primary care model involving a multidisciplinary health care team guiding patient-centered care. This model has been tested in the US and showed a significant reduction of depressive symptoms, improved diabetes care and patient-reported outcomes, and saved money. Our aim is to evaluate the implementation of this collaborative care model for type 2 diabetes and comorbid depression within the non-metro Primary Care Network (PCN) setting in Canada.\\n\\nIntervention: The intervention involves three phases: (1) improving depressive symptoms, (2) improving blood sugar, blood pressure and cholesterol, and (3) improving lifestyle behaviours. The intervention is administered by a CM in collaboration with family physicians, psychiatrists, and internists.\\n\\nHypotheses: The TeamCare-PCN intervention will reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours. Furthermore, the investigators anticipate this intervention will be acceptable and implemented in a cost-effective manner in the PCN environment.\\n\\nMethods: The investigators will employ a mixed-methods approach to our evaluation, using a controlled \"on-off\" trial design. Our primary analysis will be based on a multivariable scaled marginal model for the combined outcome of depressive symptoms and medical care. Secondary analyses will assess changes in lifestyle behaviours and patient-reported outcomes.\\n\\nSignificance: Our work will serve as a platform upon which an emerging model of primary care can incorporate an effective and cost-effective depression intervention into the management of individuals with type 2 diabetes, and as a framework for implementing and evaluating similar interventions in individuals with other chronic conditions.',\n",
       "       'DetailedDescription': \"I. Brief Overview The over-arching objectives of this study are to implement and evaluate an evidence-based intervention called TeamCare-PCN for individuals with type-2 diabetes and comorbid depression within primary care networks (PCNs). TeamCare-PCN is based on a proven efficacious and cost-saving collaborative primary care model (Katon et al., 2010) which involves a Care Manager (CM) providing active patient management under the supervision of a family physician and consulting psychiatrists and internists. The goal of the intervention is to achieve remission of depression, reach targets for cardio-metabolic measures, and improve lifestyle behaviours.\\n\\nII. Hypothesis The investigators hypothesize that the TeamCare-PCN intervention will reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours.\\n\\nIII. Setting, Participants, and Sample Size TeamCare-PCN will be conducted in collaboration with 4 PCNs in non-metro Alberta: St. Albert Sturgeon PCN, Leduc/Beaumont/ Devon PCN, Camrose PCN, and Heartland PCN.\\n\\nWe estimate that a minimum total sample size of 120, with 60 in each arm, would provide power of 0.80 to detest a mean difference of 5 points in the PHQ-9, assuming a repeated measures correlation of 0.6, and 2-tailed alpha of 0.05. This sample size also provides more than 80% power (two sided alpha = 0.05) to detect any between-group absolute difference in proportions of 15% or more (e.g., 45% of usual care patients achieve depression remission vs 60% of intervention patients) (Katon et al., 2010). Anticipating a 40% attrition rate, we planned to recruit 168 patients in total across our 4 PCN sites.\\n\\nIV. Participant Recruitment and Allocation Recruiting participants into TeamCare-PCN involves four steps. i) A screening survey accompanied with an endorsement letter from the PCN and a general information letter. Included in the screen is the PHQ-9.\\n\\nii) After potential participants have completed the screening survey and mailed it back to the PCN, staff at the PCN will identify the respondents who are eligible to participate TeamCare-PCN through the responses on the screening survey and by scoring the PHQ-9.\\n\\niii) PCN staff will contact eligible participants through a brief phone interview to confirm all eligibility criteria and schedule an initial assessment visit with the CM at the PCN.\\n\\niv) CM will meet with the participant, and during the initial assessment, the CM will explain the intervention, provide an intervention-specific information letter and obtain a signed written informed consent from the patient to participate in the study.\\n\\nParticipants will be allocated to study groups using an 'on-off' allocation method. Eligible and consenting respondents who book for an initial assessment with the CM during month 1 will be allocated to the intervention arm (On-group). Those who book the initial assessment in month 2 will be allocated to the usual care arm (Off-group). This allocation process will continue until the target sample size is recruited.\\n\\nV. Team Care Depression Intervention for Diabetes\\n\\nA. Patient Management:\\n\\nPatients entering the intervention will have an initial one-hour appointment with the CM. This first visit will include a bio-psychosocial semi-structured assessment (reviewing medical history, previous treatments for depression and diabetes), patient education, potential treatment options (anti-depressant medications and/or psychotherapy) and developing an overall individualized care plan. The intervention will consist of 3 phases; the first focusing on depression management, the second on cardio-metabolic diabetes management, and the third on general lifestyle modifications. The CM will also have weekly meetings with the consulting specialists to review new cases and patient progress, and then make treatment recommendations to the primary care physician.\\n\\nB. Training of Care Managers and Specialists:\\n\\nThe CMs and consulting specialists have already received a 2-day training course on the TeamCare-PCN intervention, including the pharmacotherapy of depression and an introduction to psychotherapeutic techniques (i.e. problem solving, behavioural activation, and motivational interviewing), as well as team interactions, roles and responsibilities. An overview of cardio-metabolic diabetes management, including, glucose control, insulin management, blood pressure management and treatment of high lipid levels based on the developed algorithms, was also provided at the training session. TeamCare-PCN training manuals were developed and used in the training sessions, and retained by the CM.\\n\\nVI. Usual Care All participants in TeamCare-PCN will be actively screened for depression and those allotted to usual care will be identified as such to their family physician. For depression management, patients will receive care from their family physician, without additional active support from the Care Manager.\\n\\nVII. Data Analysis As the initial focus of the intervention is on the management of depressive symptoms, we have considered the PHQ-9 as a main primary outcome, and will assess changes in PHQ-9 scores over 12-months between groups, adjusting for baseline PHQ-9 score, using a mixed effects multivariate model. For our second primary outcome of improvements in global disease control, we will employ a multivariate model that jointly tests the changes in multiple clinical outcomes, namely A1c, LDL cholesterol and systolic blood pressure. Using the same analytic approach as in the recently published RCT of this intervention, we will apply a scaled marginal model (Katon et al., 2010) to simultaneously compare the change in these continuous outcomes at 12 months, adjusting for the baseline status for each variable. In either primary outcome analyses, the models will be estimated iteratively and the potential correlations among and between outcomes within individuals will be handled using generalized-estimating equation (GEE) models for each outcome.\\n\\nFor all analyses the investigators will employ an intention-to-treat framework for our primary analysis, using a last-observation-carried-forward method of imputation for subjects who do not have complete follow-up data for primary or secondary outcomes.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression',\n",
       "         'Depressive Symptoms',\n",
       "         'Type 2 Diabetes']},\n",
       "       'KeywordList': {'Keyword': ['Collaborative care',\n",
       "         'Diabetes management',\n",
       "         'Depression management',\n",
       "         'Primary care']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '157',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Usual Care',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Participants in this arm will be actively screened for depression and will receive the usual standard care for diabetes from their family physicians based on available clinical practice guidelines.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Usual diabetes and depression care']}},\n",
       "         {'ArmGroupLabel': 'TeamCare Depression Intervention',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants in this arm will be actively screened for depression, and will receive care for depression and diabetes based on the collaborative teamcare model for the management of diabetes and co-morbid depression.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: TeamCare Depression Intervention']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'TeamCare Depression Intervention',\n",
       "          'InterventionDescription': 'The TeamCare-PCN intervention involves a registered nurse Care Manager (CM), who coordinates collaborative team management for patients with diabetes and depression. The goal of the intervention is to reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours. The intervention includes three phases: (1) managing depression and improving depressive symptoms, (2) managing diabetes and controlling blood glucose, blood pressure and cholesterol, and (3) improving lifestyle behaviours such as healthy eating, physical activity and smoking cessation.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['TeamCare Depression Intervention']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['TEAMcare']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Usual diabetes and depression care',\n",
       "          'InterventionDescription': 'Usual care of diabetes and depression involves providing care by the family physician based on usual standards of care and available clinical practice guidelines. Usual care does not involve additional active support from the Care Manager.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Usual Care']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Patient Health Questionnaire-9 items (PHQ-9) score',\n",
       "          'PrimaryOutcomeDescription': 'A remission of depression symptoms is indicated with a PHQ-9 score <10 for a period of three consecutive months.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline, 3-month, 6-month, 9-month, 12-month'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in HbA1c level',\n",
       "          'SecondaryOutcomeDescription': 'Improvement is defined as 10% improvement over baseline',\n",
       "          'SecondaryOutcomeTimeFrame': 'baseline, 6-month, 12-month'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in total cholesterol level',\n",
       "          'SecondaryOutcomeDescription': 'Improvement is defined as 10% improvement over baseline',\n",
       "          'SecondaryOutcomeTimeFrame': 'baseline, 6-month, 12-month'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Systolic blood pressure measurement',\n",
       "          'SecondaryOutcomeDescription': 'Improvement is defined as 10% improvement over baseline',\n",
       "          'SecondaryOutcomeTimeFrame': 'baseline, 6-month, 12-month'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in self-reported Health Related Quality of Life',\n",
       "          'SecondaryOutcomeDescription': 'Measured by SF-12-V2 and EQ-5D-5L',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 6-month, 12-month'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Diabetes-specific stress',\n",
       "          'SecondaryOutcomeDescription': 'Measured by Problem Areas In Diabetes 5-level questionnaire (PAID-5)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 6-month, 12-month'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Health behaviours',\n",
       "          'SecondaryOutcomeDescription': 'Includes assessment of smoking behaviours, alcohol consumption, substance use, and physical activity',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 6-month, 12-month'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Self-care management activities',\n",
       "          'SecondaryOutcomeDescription': 'Measured using the Summary of Diabetes Self Care Activities questionnaire (SDSCA)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 6-month, 12-month'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Satisfaction with care',\n",
       "          'SecondaryOutcomeDescription': 'Measured using the Consumer Assessment of Healthcare Providers and Systems questionnaire (CAHPS), Adult Primary Care 1.0, and the Patient Assessment of Chronic Illness Care questionnaire (PACIC)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 12-month'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHave family physician-identified type 2 diabetes\\n18 years of age or older\\nScore >=10 on the PHQ-9\\nSpeak English and have adequate hearing to complete phone interviews\\nBe willing and able to provide written informed consent to participate\\n\\nExclusion Criteria:\\n\\nSevere and/or terminal physical illness\\nSerious and/or severe mental or psychiatric illness\\nPregnant or breastfeeding\\nLive in long term care facility\\nAlready participating in other clinical trials',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jeffrey A Johnson, PhD',\n",
       "          'OverallOfficialAffiliation': 'University of Alberta',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Sumit Majumdar, MD',\n",
       "          'OverallOfficialAffiliation': 'University of Alberta',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Camrose PCN',\n",
       "          'LocationCity': 'Edmonton',\n",
       "          'LocationState': 'Alberta',\n",
       "          'LocationCountry': 'Canada'},\n",
       "         {'LocationFacility': 'Leduc/Beaumont/ Devon PCN',\n",
       "          'LocationCity': 'Edmonton',\n",
       "          'LocationState': 'Alberta',\n",
       "          'LocationCountry': 'Canada'},\n",
       "         {'LocationFacility': 'St. Albert & Sturgeon PCN',\n",
       "          'LocationCity': 'Edmonton',\n",
       "          'LocationState': 'Alberta',\n",
       "          'LocationCountry': 'Canada'},\n",
       "         {'LocationFacility': 'Heartland PCN',\n",
       "          'LocationCity': 'Fort Saskatchewan',\n",
       "          'LocationState': 'Alberta',\n",
       "          'LocationCountry': 'Canada'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '21190455',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Katon WJ, Lin EH, Von Korff M, Ciechanowski P, Ludman EJ, Young B, Peterson D, Rutter CM, McGregor M, McCulloch D. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010 Dec 30;363(27):2611-20. doi: 10.1056/NEJMoa1003955.'},\n",
       "         {'ReferencePMID': '12687656',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Jung SH, Ahn C. Sample size estimation for GEE method for comparing slopes in repeated measurements data. Stat Med. 2003 Apr 30;22(8):1305-15.'},\n",
       "         {'ReferencePMID': '15353428',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Majumdar SR, Rowe BH, Folk D, Johnson JA, Holroyd BH, Morrish DW, Maksymowych WP, Steiner IP, Harley CH, Wirzba BJ, Hanley DA, Blitz S, Russell AS. A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med. 2004 Sep 7;141(5):366-73.'},\n",
       "         {'ReferencePMID': '16488469',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Rucker D, Rowe BH, Johnson JA, Steiner IP, Russell AS, Hanley DA, Maksymowych WP, Holroyd BR, Harley CH, Morrish DW, Wirzba BJ, Majumdar SR. Educational intervention to reduce falls and fear of falling in patients after fragility fracture: results of a controlled pilot study. Prev Med. 2006 Apr;42(4):316-9. Epub 2006 Feb 20.'},\n",
       "         {'ReferencePMID': '8291818',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Weingarten SR, Riedinger MS, Conner L, Lee TH, Hoffman I, Johnson B, Ellrodt AG. Practice guidelines and reminders to reduce duration of hospital stay for patients with chest pain. An interventional trial. Ann Intern Med. 1994 Feb 15;120(4):257-63.'},\n",
       "         {'ReferencePMID': '19299058',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': \"Bell AC, D'Zurilla TJ. Problem-solving therapy for depression: a meta-analysis. Clin Psychol Rev. 2009 Jun;29(4):348-53. doi: 10.1016/j.cpr.2009.02.003. Epub 2009 Feb 26. Review.\"},\n",
       "         {'ReferencePMID': '18591356',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Arean P, Hegel M, Vannoy S, Fan MY, Unuzter J. Effectiveness of problem-solving therapy for older, primary care patients with depression: results from the IMPACT project. Gerontologist. 2008 Jun;48(3):311-23.'},\n",
       "         {'ReferencePMID': '7873952',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ. 1995 Feb 18;310(6977):441-5.'},\n",
       "         {'ReferencePMID': '17194572',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Cuijpers P, van Straten A, Warmerdam L. Problem solving therapies for depression: a meta-analysis. Eur Psychiatry. 2007 Jan;22(1):9-15. Epub 2006 Dec 27.'},\n",
       "         {'ReferencePMID': '9583341',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Gortner ET, Gollan JK, Dobson KS, Jacobson NS. Cognitive-behavioral treatment for depression: relapse prevention. J Consult Clin Psychol. 1998 Apr;66(2):377-84.'},\n",
       "         {'ReferencePMID': '8871414',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Jacobson NS, Dobson KS, Truax PA, Addis ME, Koerner K, Gollan JK, Gortner E, Prince SE. A component analysis of cognitive-behavioral treatment for depression. J Consult Clin Psychol. 1996 Apr;64(2):295-304.'},\n",
       "         {'ReferencePMID': '10660997',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Jacobson NS, Gortner ET. Can depression be de-medicalized in the 21st century: scientific revolutions, counter-revolutions and the magnetic field of normal science. Behav Res Ther. 2000 Feb;38(2):103-17.'},\n",
       "         {'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Rollnick S, Miller W. What is motivational interviewing? Behavioral Cognitive Psychotherapy 23: 325, 1995.'},\n",
       "         {'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Jacobson N, Martell C, Dimidjian S. Behavioral activation treatment for depression: Returning to contextual roots. Clinical Psychology: Science and Practice 8:255, 2001.'},\n",
       "         {'ReferencePMID': '14516234',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Burke BL, Arkowitz H, Menchola M. The efficacy of motivational interviewing: a meta-analysis of controlled clinical trials. J Consult Clin Psychol. 2003 Oct;71(5):843-61.'},\n",
       "         {'ReferencePMID': '17059299',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': \"Butterworth S, Linden A, McClay W, Leo MC. Effect of motivational interviewing-based health coaching on employees' physical and mental health status. J Occup Health Psychol. 2006 Oct;11(4):358-65.\"},\n",
       "         {'ReferencePMID': '15826439',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005 Apr;55(513):305-12. Review.'},\n",
       "         {'ReferencePMID': '12925505',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Roy J, Lin X, Ryan LM. Scaled marginal models for multiple continuous outcomes. Biostatistics. 2003 Jul;4(3):371-83.'},\n",
       "         {'ReferencePMID': '14578240',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Majumdar SR, Guirguis LM, Toth EL, Lewanczuk RZ, Lee TK, Johnson JA. Controlled trial of a multifaceted intervention for improving quality of care for rural patients with type 2 diabetes. Diabetes Care. 2003 Nov;26(11):3061-6.'},\n",
       "         {'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Majumdar SR, Johnson JA, Bowker SL, Booth GL, Dolovich L, Ghali W, Harris SB, Hux JE, Holbrook A, Lee H, Toth EL, Yale J-F. A Canadian consensus for the standardized evaluation of quality improvement interventions in type 2 diabetes: Development of a Quality Indicator Set. Canadian Journal of Diabetes 29:220-229, 2005'},\n",
       "         {'ReferencePMID': '18335281',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Chew LD, Griffin JM, Partin MR, Noorbaloochi S, Grill JP, Snyder A, Bradley KA, Nugent SM, Baines AD, Vanryn M. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med. 2008 May;23(5):561-6. doi: 10.1007/s11606-008-0520-5. Epub 2008 Mar 12.'},\n",
       "         {'ReferencePMID': '26947212',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Johnson JA, Lier DA, Soprovich A, Al Sayah F, Qiu W, Majumdar SR. Cost-Effectiveness Evaluation of Collaborative Care for Diabetes and Depression in Primary Care. Am J Prev Med. 2016 Jul;51(1):e13-20. doi: 10.1016/j.amepre.2016.01.010.'},\n",
       "         {'ReferencePMID': '26303892',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Mathe N, Johnson ST, Wozniak LA, Majumdar SR, Johnson JA. Alternation as a form of allocation for quality improvement studies in primary healthcare settings: the on-off study design. Trials. 2015 Aug 25;16:375. doi: 10.1186/s13063-015-0904-x.'},\n",
       "         {'ReferencePMID': '25315205',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Johnson JA, Al Sayah F, Wozniak L, Rees S, Soprovich A, Qiu W, Chik CL, Chue P, Florence P, Jacquier J, Lysak P, Opgenorth A, Katon W, Majumdar SR. Collaborative care versus screening and follow-up for patients with diabetes and depressive symptoms: results of a primary care-based comparative effectiveness trial. Diabetes Care. 2014 Dec;37(12):3220-6. doi: 10.2337/dc14-1308. Epub 2014 Oct 14.'},\n",
       "         {'ReferencePMID': '22897901',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Johnson JA, Al Sayah F, Wozniak L, Rees S, Soprovich A, Chik CL, Chue P, Florence P, Jacquier J, Lysak P, Opgenorth A, Katon WJ, Majumdar SR. Controlled trial of a collaborative primary care team model for patients with diabetes and depression: rationale and design for a comprehensive evaluation. BMC Health Serv Res. 2012 Aug 16;12:258.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003920',\n",
       "          'ConditionMeshTerm': 'Diabetes Mellitus'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000044882',\n",
       "          'ConditionAncestorTerm': 'Glucose Metabolism Disorders'},\n",
       "         {'ConditionAncestorId': 'D000008659',\n",
       "          'ConditionAncestorTerm': 'Metabolic Diseases'},\n",
       "         {'ConditionAncestorId': 'D000004700',\n",
       "          'ConditionAncestorTerm': 'Endocrine System Diseases'},\n",
       "         {'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5702',\n",
       "          'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5698',\n",
       "          'ConditionBrowseLeafName': 'Diabetes Mellitus',\n",
       "          'ConditionBrowseLeafAsFound': 'Diabetes',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M10222',\n",
       "          'ConditionBrowseLeafName': 'Metabolic Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M23990',\n",
       "          'ConditionBrowseLeafName': 'Glucose Metabolism Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M6445',\n",
       "          'ConditionBrowseLeafName': 'Endocrine System Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18',\n",
       "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC19',\n",
       "          'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
       "   {'Rank': 45,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04223115',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'DEPMOM-2020'},\n",
       "       'Organization': {'OrgFullName': 'University of Turku',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'A Randomized Controlled Study of Digitalized Cognitive Behavioral Intervention for Antenatal Depression',\n",
       "       'OfficialTitle': 'Randomized Controlled Trial of Digitalized Cognitive Behavioral Therapy With Telephone Coaching for Mothers Suffering From Depression During Pregnancy'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'January 2020',\n",
       "       'OverallStatus': 'Not yet recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2020',\n",
       "        'StartDateType': 'Anticipated'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2021',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'June 2023',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'January 7, 2020',\n",
       "       'StudyFirstSubmitQCDate': 'January 7, 2020',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 10, 2020',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'January 7, 2020',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 10, 2020',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Andre Sourander',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Professor, Child Psychiatry',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Turku'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Turku',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The main objective of the current research project is to evaluate the effectiveness of the digitalized cognitive behavioral therapy program including telephone coaching for antenatal and postnatal depressive symptoms. The participants are screened from the general population of pregnant women, as a part of the routine maternity health care check-ups. Half of the mothers with depressive symptoms will receive the digitalized treatment program, while the other half will receive education about depression in digital form.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression',\n",
       "         'Depression, Postpartum',\n",
       "         'Perinatal Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '400',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Digitalized CBT intervention with phone coaching',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants receive weekly sessions of internet-based CBT, including telephone coaching',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Digitalized CBT with phone coaching']}},\n",
       "         {'ArmGroupLabel': 'Psychoeducation about depression',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Participants receive psychoeducative material about depression in digitalized form.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Psychoeducation about depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Digitalized CBT with phone coaching',\n",
       "          'InterventionDescription': 'Digitally delivered CBT intervention with weekly phone coaching',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Digitalized CBT intervention with phone coaching']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Psychoeducation about depression',\n",
       "          'InterventionDescription': 'Psychoeducational material about depression in a digitalized form',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Psychoeducation about depression']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in the Edinburgh Postnatal Depression Scale (EPDS)',\n",
       "          'PrimaryOutcomeDescription': 'EPDS is a ten-item self-report questionnaire originally developed to screen for postpartum depression. The respondents are asked about the symptoms of depression experienced in the previous week. The total score ranges from 0 to 30.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline, 9 weeks after randomization (post-treatment) and 7 months after randomization'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in the World Health Organization Quality of Life (WHOQOL-BREF)',\n",
       "          'SecondaryOutcomeDescription': 'We will use overall QoL items and the domains of psychological QoL and social relationships',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline and 7 months after randomization'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nfluent in written and spoken Finnish\\naccess to computer or mobile phone with internet\\nbetween 12 and 24 weeks pregnant\\nscreening and baseline score on the EPDS ≥10 points\\n\\nExclusion Criteria:\\n\\nlifetime history of psychotic disorder (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, psychotic depression)\\nactive suicidal ideation\\nsevere substance abuse or dependence\\nactively ongoing psychotherapy\\ncommenced medication for depression less than 30 days before intake assessment\\nmultiple pregnancy',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Female',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '55 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Hanna-Maria Matinolli, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '+358 50 5641 814',\n",
       "          'CentralContactEMail': 'hanna-maria.matinolli@utu.fi'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Andre Sourander, Professor',\n",
       "          'OverallOfficialAffiliation': 'University of Turku, Research Center for Child Psychiatry',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'University of Turku',\n",
       "          'LocationCity': 'Turku',\n",
       "          'LocationCountry': 'Finland',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hanna-Maria Matinolli, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '+358 50 5641 814',\n",
       "             'LocationContactEMail': 'hanna-maria.matinolli@utu.fi'}]}}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000019052',\n",
       "          'ConditionMeshTerm': 'Depression, Postpartum'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000011644',\n",
       "          'ConditionAncestorTerm': 'Puerperal Disorders'},\n",
       "         {'ConditionAncestorId': 'D000011248',\n",
       "          'ConditionAncestorTerm': 'Pregnancy Complications'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M19660',\n",
       "          'ConditionBrowseLeafName': 'Depression, Postpartum',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression, Postpartum',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13082',\n",
       "          'ConditionBrowseLeafName': 'Puerperal Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M12710',\n",
       "          'ConditionBrowseLeafName': 'Pregnancy Complications',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXS',\n",
       "          'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}}}},\n",
       "   {'Rank': 46,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01571973',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'SPPsicobio1Lu'},\n",
       "       'Organization': {'OrgFullName': 'Federal University of São Paulo',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Evaluation of Pharmaceutical Care in Depressed Outpatients',\n",
       "       'OfficialTitle': 'EVALUATION OF THE EFFECTIVENESS OF PHARMACEUTICAL CARE (DÁDER PROGRAM) IN DEPRESSED OUTPATIENTS TREATED WITH PSYCHOTROPIC',\n",
       "       'Acronym': 'depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'June 2011',\n",
       "       'OverallStatus': 'Unknown status',\n",
       "       'LastKnownStatus': 'Active, not recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'March 2010'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2012',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'May 2012',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'April 3, 2012',\n",
       "       'StudyFirstSubmitQCDate': 'April 4, 2012',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 5, 2012',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'April 4, 2012',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 5, 2012',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Ana Regina Noto',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Ph.D.',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Federal University of São Paulo'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Federal University of São Paulo',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The study examines whether pharmacotherapeutic follow-up improves outcomes of treatment of depressed outpatients.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['pharmaceutical care',\n",
       "         'depression',\n",
       "         'compliance',\n",
       "         \"pharmacist's intervention\",\n",
       "         'Dáder']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Supportive Care',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '60',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'control group',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'outpatients receiving usual care'},\n",
       "         {'ArmGroupLabel': 'intervention group',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'outpatients receiving pharmaceutical care or pharmacotherapeutic follow-up by 6 months',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: pharmacotherapeutic follow-up']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Procedure',\n",
       "          'InterventionName': 'pharmacotherapeutic follow-up',\n",
       "          'InterventionDescription': 'health education adjustment of dose improve compliance replacement of medication',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['intervention group']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'depression level',\n",
       "          'PrimaryOutcomeDescription': 'evaluation depression level by Beck scale',\n",
       "          'PrimaryOutcomeTimeFrame': 'six months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'anxiety level',\n",
       "          'SecondaryOutcomeDescription': 'evaluation anxiety level by Beck scale.',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'compliance',\n",
       "          'SecondaryOutcomeDescription': 'evaluation antidepressive treatment compliance by Morisky scale',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nwomen between 18 and 65 years, with diagnostic hypothesis of depression at the beginning of treatment or change in treatment unless 2 months (dosage or substance)\\n\\nExclusion Criteria:\\n\\nrecord of dependence on psychoactive substances, diagnosed schizophrenia,\\nlow education (illiterate) or cognitive impairment evident that compromise the completion of research instruments',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Female',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}},\n",
       "     'AnnotationSection': {'AnnotationModule': {'UnpostedAnnotation': {'UnpostedResponsibleParty': 'Ana Regina Noto, Ph.D., Federal University of São Paulo',\n",
       "        'UnpostedEventList': {'UnpostedEvent': [{'UnpostedEventType': 'Release',\n",
       "           'UnpostedEventDate': 'February 13, 2019'},\n",
       "          {'UnpostedEventType': 'Reset', 'UnpostedEventDate': 'May 10, 2019'},\n",
       "          {'UnpostedEventType': 'Release',\n",
       "           'UnpostedEventDate': 'February 17, 2020'},\n",
       "          {'UnpostedEventType': 'Reset',\n",
       "           'UnpostedEventDate': 'February 27, 2020'}]}}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 47,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02143024',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '807849'},\n",
       "       'Organization': {'OrgFullName': 'University of California, Davis',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': \"A Family-based Primary Care Intervention to Enhance Older Men's Depression Care\",\n",
       "       'OfficialTitle': \"A Family-based Primary Care Intervention to Enhance Older Men's Depression Care\"},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'January 2020',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'November 1, 2015',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2016',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 31, 2016',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 19, 2013',\n",
       "       'StudyFirstSubmitQCDate': 'May 16, 2014',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 20, 2014',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'March 25, 2019',\n",
       "       'ResultsFirstSubmitQCDate': 'January 6, 2020',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'January 18, 2020',\n",
       "        'ResultsFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'January 6, 2020',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 18, 2020',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of California, Davis',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Washington',\n",
       "          'CollaboratorClass': 'OTHER'},\n",
       "         {'CollaboratorName': 'RAND', 'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Despite the public health importance of clinical depression, more than 50% of depressed adults receive inadequate or no treatment, with even higher rates of under-treatment in men and minorities. Family members and/or friends often assist older adults in their health care and may help overcome barriers to formal care, yet there is a lack of primary care-based interventions that mobilize family members and friends to improve depression treatment. In partnership with a community-based clinic, this research will address this scientific gap by developing and then testing the feasibility and acceptability of a family-based intervention that can be delivered pragmatically in a primary care setting serving large numbers of older minorities.',\n",
       "       'DetailedDescription': 'The family-based intervention will be tested in a 6 month randomized controlled trial of 24 depressed older men-family member dyads (18 intervention and 6 controls). The purpose of the RCT is to test the acceptability of the intervention, as well as the feasibility of the study methods. Patients from the RCT will be identified from a family practice clinic based on their scores on the PHQ-9 as well as additional inclusion and exclusion criteria. Once they and their family member have agreed to participate, patients will be randomized either to the family based intervention or a usual care control condition augmented by family psychoeducation. The investigators will recruit English and Spanish speaking age 60 and above older men from SJGH who have 1) significant depressive symptoms (i.e. PHQ > 15, 2) have at least one criteria A symptom (depressed mood or anhedonia), 3) depression-related functional impairment) and 4) an adult family member willing to participate in the study. We have chosen a higher cut-off to minimize false positives. We will exclude psychotic, demented or institutionalized men. After enrollment, 24 dyads (i.e. older man and family member) will be randomized one of two groups: intervention or usual care augmented by written psychoeducational materials on depression. Dyads will be randomized to achieve a 2:1 ratio of intervention versus usual care dyads (i.e. 18 intervention and 6 control dyads). To ensure adequate numbers of ethnic minority patients in each arm of the trial, we will conduct a stratified randomization such that each arm of the RCT is 50% English language preferring and 50% Spanish language preferring (i.e. 3 in control and 9 in intervention arm). The research assistant will conduct subject assessment at baseline, 1-month, 3-months and 6 months.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Major Depression']},\n",
       "       'KeywordList': {'Keyword': ['depression',\n",
       "         'family',\n",
       "         'primary health care']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignInterventionModelDescription': 'Randomized controlled trial',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '23',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Family-based depression intervention',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': \"The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker\",\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Family-based depression intervention']}},\n",
       "         {'ArmGroupLabel': 'Usual care plus educational materials',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Usual care plus educational materials']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Family-based depression intervention',\n",
       "          'InterventionDescription': 'The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Family-based depression intervention']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Usual care plus educational materials',\n",
       "          'InterventionDescription': 'Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Usual care plus educational materials']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depressive Symptoms',\n",
       "          'PrimaryOutcomeDescription': 'Patient Health Questionnaire (PHQ-9) scale; 0-27 scoring units; higher scores indicate more severe depressive symptoms.',\n",
       "          'PrimaryOutcomeTimeFrame': 'baseline, 3 months, and 6 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMen, age 50 and above\\nEnglish or Spanish speaking\\nScore of >9 on the PHQ-9\\nNon-demented\\nHave an adult family member or close friend who can participate\\n\\nExclusion Criteria:\\n\\nAdults unable to consent\\nIndividuals who are not yet adults (infants, children, teenagers)\\nPregnant women\\nPrisoners',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Male',\n",
       "       'MinimumAge': '50 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Ladson Hinton, MD',\n",
       "          'OverallOfficialAffiliation': 'University of California, Davis',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'San Joaquin General Hospital',\n",
       "          'LocationCity': 'Stockton',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '95231',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowRecruitmentDetails': '45 people were referred to the study. 41 people were assessed, 4 were not assessed for eligibility. 18 were excluded; 10 did not meet inclusion criteria and 8 declined. A total of 23 people were randomized as part of the study.',\n",
       "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Family-based Depression Intervention',\n",
       "          'FlowGroupDescription': \"The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker\\n\\nFamily-based depression intervention: The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.\"},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Usual Care Plus Educational Materials',\n",
       "          'FlowGroupDescription': 'Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.\\n\\nUsual care plus educational materials: Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '15'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '8'}]}},\n",
       "            {'FlowMilestoneType': 'Received Treatment',\n",
       "             'FlowMilestoneComment': 'These people were randomized and received at least 1 session before dropping out of the study.',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '13'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '7'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '13'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '7'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '2'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '1'}]}}]},\n",
       "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '1'},\n",
       "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'}]}},\n",
       "            {'FlowDropWithdrawType': 'Withdrawal by Subject',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '1'},\n",
       "               {'FlowReasonGroupId': 'FG001',\n",
       "                'FlowReasonNumSubjects': '0'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'Randomized participants that received at least 1 session.',\n",
       "       'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Family-based Depression Intervention',\n",
       "          'BaselineGroupDescription': \"The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker\\n\\nFamily-based depression intervention: The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.\"},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Usual Care Plus Educational Materials',\n",
       "          'BaselineGroupDescription': 'Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.\\n\\nUsual care plus educational materials: Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '13'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '7'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '20'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '60.2',\n",
       "                   'BaselineMeasurementSpread': '9.6'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '57.4',\n",
       "                   'BaselineMeasurementSpread': '4.8'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '59.2',\n",
       "                   'BaselineMeasurementSpread': '8.1'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '13'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '7'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '20'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Race/Ethnicity, Customized',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Hispanic',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '10'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '2'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '12'}]}}]}},\n",
       "            {'BaselineClassTitle': 'African American',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '1'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '3'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '4'}]}}]}},\n",
       "            {'BaselineClassTitle': 'White',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '1'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '1'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '2'}]}}]}},\n",
       "            {'BaselineClassTitle': 'Native American and White',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '1'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '1'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '2'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '13'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '7'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '20'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Depressive Symptoms',\n",
       "          'OutcomeMeasureDescription': 'Patient Health Questionnaire (PHQ-9) scale; 0-27 scoring units; higher scores indicate more severe depressive symptoms.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'baseline, 3 months, and 6 months',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Family-based Depression Intervention',\n",
       "             'OutcomeGroupDescription': \"The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker\\n\\nFamily-based depression intervention: The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.\"},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Usual Care Plus Educational Materials',\n",
       "             'OutcomeGroupDescription': 'Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.\\n\\nUsual care plus educational materials: Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '13'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '7'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'baseline',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '14.8',\n",
       "                   'OutcomeMeasurementSpread': '2.9'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '15.3',\n",
       "                   'OutcomeMeasurementSpread': '4.1'}]}}]}},\n",
       "            {'OutcomeClassTitle': '3 months',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '10.1',\n",
       "                   'OutcomeMeasurementSpread': '6.6'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '13.0',\n",
       "                   'OutcomeMeasurementSpread': '7.5'}]}}]}},\n",
       "            {'OutcomeClassTitle': '6 months',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '11.8',\n",
       "                   'OutcomeMeasurementSpread': '7.1'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '13.3',\n",
       "                   'OutcomeMeasurementSpread': '6.3'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '5',\n",
       "       'EventsTimeFrame': 'Adverse events were monitored up until the 6 month visit.',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Family-based Depression Intervention',\n",
       "          'EventGroupDescription': \"The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker\\n\\nFamily-based depression intervention: The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.\",\n",
       "          'EventGroupDeathsNumAffected': '0',\n",
       "          'EventGroupDeathsNumAtRisk': '13',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '13',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '13'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Usual Care Plus Educational Materials',\n",
       "          'EventGroupDescription': 'Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.\\n\\nUsual care plus educational materials: Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.',\n",
       "          'EventGroupDeathsNumAffected': '0',\n",
       "          'EventGroupDeathsNumAtRisk': '7',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '7',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '7'}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Ladson Hinton, MD',\n",
       "        'PointOfContactOrganization': 'UC Davis Department of Psychiatry and Behavioral Sciences',\n",
       "        'PointOfContactEMail': 'lwhinton@ucdavis.edu',\n",
       "        'PointOfContactPhone': '(916) 734-3485'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 48,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03555669',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '16-2834'},\n",
       "       'Organization': {'OrgFullName': 'University of North Carolina, Chapel Hill',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Project SOAR-Mental Health Malawi: Depression and HIV Integration',\n",
       "       'OfficialTitle': 'UNCPM 21609 Project SOAR Mental Health: Evaluation of the Impact of a Depression Treatment Program on Mental Health and HIV Care Outcomes in Malawi'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'June 2019',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'April 24, 2017',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 31, 2019',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'May 31, 2019',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 1, 2018',\n",
       "       'StudyFirstSubmitQCDate': 'June 1, 2018',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 13, 2018',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'June 26, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 27, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of North Carolina, Chapel Hill',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'United States Agency for International Development (USAID)',\n",
       "          'CollaboratorClass': 'FED'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Depression is highly prevalent among people living with HIV (PLHIV) in Malawi and elsewhere in sub-Saharan Africa (SSA). Besides its high prevalence, depression likely represents an important barrier to consistent HIV care engagement and long-term viral suppression. However, the potential for depression treatment to improve HIV care outcomes has received little attention in the region, in part because of limited mental health infrastructure. In this study, the investigators will evaluate the impact of a depression treatment program integrated within existing HIV clinics on depression response, retention in HIV care, and viral suppression. It is expected that this evaluation will yield important evidence on the impact of depression treatment integrated with HIV care for improving HIV care and mental health outcomes in Malawi.',\n",
       "       'DetailedDescription': 'Study population:\\n\\nThe evaluation will abstract screening data for adult (≥18 years old) patients newly initiating antiretroviral therapy (ART) who are screened for depression at the two clinics before and after the integration of the depression treatment program, and additional treatment and outcome data for those patients who screen positive for depression.\\n\\nStudy Size:\\n\\nAcross the two clinics, the investigators expect to abstract depression screening data for approximately 2,300 patients. The investigators expect to abstract further treatment and outcome data for approximately 640 patients who screen positive for mild, moderate, or severe depression.\\n\\nStudy Duration:\\n\\nEvaluation and dissemination activities will last two years.\\n\\nStudy Evaluation:\\n\\nTo evaluate the impact of the mental health treatment program on HIV care outcomes, the investigators will collect data on HIV appointment adherence and viral load at 6 months following ART initiation.\\n\\nTo evaluate the impact of the mental health treatment program on mental health outcomes the investigators will collect data on depression symptoms at baseline through 6 months following ART initiation.\\n\\nStudy Design Overview:\\n\\nThe study will employ a pre-post design in two HIV clinics in Lilongwe to evaluate the impact of integrating the depression treatment program within existing clinic operations on HIV and mental health outcomes. The investigators will use existing medical records and the depression patient registry maintained by the Ministry of Health-run clinics to abstract routinely collected clinical data. Using these data, the investigators will compare mental health and HIV outcomes before and after the integration of the depression treatment program. Depressive symptoms will be measured with the Patient Health Questionnaire 9 (PHQ-9). The PHQ-9 is a self-report questionnaire designed to assess depression through nine questions that come directly from the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) signs and symptoms of major depression. Additionally, the investigators will conduct short qualitative interviews with clinic and Ministry of Health staff about the integration of the depression screening and treatment program and with patients on their understanding of depression and satisfaction with depression screening and treatment.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression',\n",
       "         'HIV/AIDS']},\n",
       "       'KeywordList': {'Keyword': ['Implementation Science', 'Malawi']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
       "        'DesignInterventionModel': 'Sequential Assignment',\n",
       "        'DesignInterventionModelDescription': 'The investigators will employ a multiple baseline evaluation design in two clinics to evaluate the impact of depression treatment on HIV outcomes. Patients who screen positive for depression using PHQ-9 during the \"pre\" period will comprise the comparison group, while patients who screen positive during the \"post\" period will comprise the active group.',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '2082',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Screening Phase (Pre) Group',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Patients who screen positive on the PHQ-9 for depression during the \"pre\" period will comprise the comparison group. Participants will receive \"standard of care\" depression treatment at the providers discretion.'},\n",
       "         {'ArmGroupLabel': 'Treatment Phase (Post) Group',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Patients who screen positive during on the PHQ-9 for depression during the \"post\" period will comprise the active group. Participants will receive the depression treatment intervention in the form of anti-depressants and/or problem solving therapy (PST) based on their PHQ-9 score.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Depression Treatment']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Depression Treatment',\n",
       "          'InterventionDescription': \"The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Treatment Phase (Post) Group']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Proportion of participants who are retained in care',\n",
       "          'PrimaryOutcomeDescription': 'Retention in care is defined as attending sufficient HIV appointments to maintain ART supply through the first 6 months on ART.',\n",
       "          'PrimaryOutcomeTimeFrame': '6 months after ART initiation'},\n",
       "         {'PrimaryOutcomeMeasure': 'Proportion of participants who are virally suppressed',\n",
       "          'PrimaryOutcomeDescription': 'Viral suppression is defined as HIV RNA viral load of <1,000 copies/mL. Viral loads are measured approximately 6 months after ART initiation.',\n",
       "          'PrimaryOutcomeTimeFrame': '6 months after ART initiation'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Proportion of participants who achieve depression remission (PHQ-9 score less than 5)',\n",
       "          'SecondaryOutcomeDescription': 'Depression remission is defined as scoring less than 5 on the PHQ-9 approximately 6 months after ART initiation. The PHQ-9 is a self-report questionnaire designed to assess depression through nine questions that come directly from the DSM-IV signs and symptoms of major depression. The 9 items describe problems associated with depression, and participants must rate how often the patient has been bothered by the problems in the last 2 weeks on a 0-3 scale. The scores are summed for a total depression score, ranging from 0-27, with 0-4 being minimum and indicating no depressive symptoms, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and 20-27 severe depression. Depressive symptoms will be measured with the PHQ-9 at baseline through approximately 6 months after ART initiation.',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months after ART initiation'},\n",
       "         {'SecondaryOutcomeMeasure': 'Proportion of scheduled ART visits attended',\n",
       "          'SecondaryOutcomeDescription': 'ART visit attendance is defined as attending scheduled ART appointments over the first 6 months on ART.',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months after ART initiation'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAdult (≥18 years)\\nHIV-infected\\nNewly initiating antiretroviral treatment at one of the program sites\\nScreened for depression\\n\\nExclusion Criteria:\\n\\n• None',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Brian Pence, PhD, MPH',\n",
       "          'OverallOfficialAffiliation': 'UNC Gillings School of Global Public Health',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Michael Udedi, MBA MPhil',\n",
       "          'OverallOfficialAffiliation': 'Malawi Ministry of Health',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Area 18 Clinic',\n",
       "          'LocationCity': 'Lilongwe',\n",
       "          'LocationCountry': 'Malawi'},\n",
       "         {'LocationFacility': 'Area 25 Clinic',\n",
       "          'LocationCity': 'Lilongwe',\n",
       "          'LocationCountry': 'Malawi'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31242877',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Udedi M, Stockton MA, Kulisewa K, Hosseinipour MC, Gaynes BN, Mphonda SM, Pence BW. The effectiveness of depression management for improving HIV care outcomes in Malawi: protocol for a quasi-experimental study. BMC Public Health. 2019 Jun 26;19(1):827. doi: 10.1186/s12889-019-7132-3.'},\n",
       "         {'ReferencePMID': '30064418',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Udedi M, Stockton MA, Kulisewa K, Hosseinipour MC, Gaynes BN, Mphonda SM, Mwagomba BM, Mazenga AC, Pence BW. Integrating depression management into HIV primary care in central Malawi: the implementation of a pilot capacity building program. BMC Health Serv Res. 2018 Jul 31;18(1):593. doi: 10.1186/s12913-018-3388-z.'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M16833',\n",
       "          'ConditionBrowseLeafName': 'HIV Infections',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M2103',\n",
       "          'ConditionBrowseLeafName': 'Acquired Immunodeficiency Syndrome',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC02',\n",
       "          'ConditionBrowseBranchName': 'Viral Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC20',\n",
       "          'ConditionBrowseBranchName': 'Immune System Diseases'}]}}}}},\n",
       "   {'Rank': 49,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00183547',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'R34MH071300',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH071300&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R34MH071300',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH071300&Fy=all'},\n",
       "         {'SecondaryId': 'DSIR 84-CTP'}]},\n",
       "       'Organization': {'OrgFullName': 'Johns Hopkins University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Depression Prevention Program for American Indian Adolescents During and After Pregnancy',\n",
       "       'OfficialTitle': 'Depression Prevention in Pregnant American Indian Teens Using CBT'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'December 2008',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2005'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2007',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'September 2007'},\n",
       "       'StudyFirstSubmitDate': 'September 13, 2005',\n",
       "       'StudyFirstSubmitQCDate': 'September 13, 2005',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 16, 2005',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'May 28, 2013',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 29, 2013',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyOldNameTitle': 'Golda Ginsburg, PhD',\n",
       "        'ResponsiblePartyOldOrganization': 'Johns Hopkins Center for American Indian Health'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Johns Hopkins University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study will determine the effectiveness of the \"Living in Harmony\" depression prevention program in preventing depressive symptoms among pregnant American Indian adolescents during pregnancy and after giving birth.',\n",
       "       'DetailedDescription': 'Pregnancy among reservation-based American Indian adolescents has become increasingly common. Numerous psychosocial and environmental factors have put this population at high risk for pregnancy-related depression. Depression during pregnancy and after giving birth is associated with reduced quality of life for both young mothers and their children. Many reservations lack mental health services; therefore, an inexpensive intervention is needed to prevent depressive symptoms among pregnant adolescents who live on reservations.\\n\\nThe duration of this study will vary for each participant, depending on the time of study entry. Participants will be randomly assigned to receive weekly sessions of either the \"Living in Harmony\" program, consisting of cognitive behavioral therapy (CBT), culturally-relevant education, and support; or general depression-prevention education and support. Participants\\' depressive symptoms will be assessed at study entry, at 4, 12, and 24 weeks after giving birth, and study completion. Interviews and self-report scales will be used to assess participants.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression',\n",
       "         'Pregnancy']},\n",
       "       'KeywordList': {'Keyword': ['Postpartum Depression',\n",
       "         'Postpartum Period',\n",
       "         'Indians, North American',\n",
       "         'Adolescent',\n",
       "         'Female',\n",
       "         'CBT']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Prevention',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '45'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '1',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': '\"Living in Harmony\" depression prevention program',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: \"Living in Harmony\" depression prevention program']}},\n",
       "         {'ArmGroupLabel': '2',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Depression-prevention education and support',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression-prevention education and support']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': '\"Living in Harmony\" depression prevention program',\n",
       "          'InterventionDescription': 'Weekly therapy sessions consisting of cognitive behavioral therapy (CBT), culturally-relevant education, and support',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Depression-prevention education and support',\n",
       "          'InterventionDescription': 'Weekly therapy sessions offering general depression-prevention education and support',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Postpartum depression',\n",
       "          'PrimaryOutcomeTimeFrame': 'up to 24 weeks postpartum'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAt 28th week or earlier of pregnancy\\nCenter for Epidemiologic Studies-Depression Scale (CES-D) score of 16 or higher\\nIdentified (by others and by self) as an American Indian\\nCurrently live on an American Indian reservation\\nParent or guardian willing to give consent, if applicable\\nWilling and able to comply with all study requirements\\n\\nExclusion Criteria:\\n\\nDiagnosis of major depressive disorder\\nCurrent psychiatric disorder or condition requiring intervention or treatment\\nCurrent participation in another mental or behavioral health study',\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'Female',\n",
       "       'MinimumAge': '15 Years',\n",
       "       'MaximumAge': '19 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child', 'Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Golda Ginsburg, PhD',\n",
       "          'OverallOfficialAffiliation': 'Johns Hopkins Center for American Indian Health',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Johns Hopkins Center for American Indian Health',\n",
       "          'LocationCity': 'Whiteriver',\n",
       "          'LocationState': 'Arizona',\n",
       "          'LocationZip': '85941',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Johns Hopkins Center for American Indian Health',\n",
       "          'LocationCity': 'Baltimore',\n",
       "          'LocationState': 'Maryland',\n",
       "          'LocationZip': '21205',\n",
       "          'LocationCountry': 'United States'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M19660',\n",
       "          'ConditionBrowseLeafName': 'Depression, Postpartum',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXS',\n",
       "          'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}}}},\n",
       "   {'Rank': 50,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01896349',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'TIP-120288'},\n",
       "       'Organization': {'OrgFullName': 'Hospital de Clinicas de Porto Alegre',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Interpersonal Psychotherapy for Treatment Resistant Depression',\n",
       "       'OfficialTitle': 'Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2013',\n",
       "       'OverallStatus': 'Unknown status',\n",
       "       'LastKnownStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'April 2013'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2014',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'November 2014',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'July 1, 2013',\n",
       "       'StudyFirstSubmitQCDate': 'July 10, 2013',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 11, 2013',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 10, 2013',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 11, 2013',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Hospital de Clinicas de Porto Alegre',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of this study is to determine whether combination of antidepressant drugs plus interpersonal psychotherapy is superior to antidepressant drugs alone in treatment resistant depression.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Treatment Resistant Depression']},\n",
       "       'KeywordList': {'Keyword': ['Psychotherapy, Treatment Resistant Depression, depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '74',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'IPT+antidepressant drugs',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Interpersonal Psychotherapy protocol (IPT) consist of 16 sessions of manualized interpersonal psychotherapy for depression. Patients are allowed to reschedule 3 sessions if they miss their appointments.\\n\\nAntidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetin, citalopram, escitalopram, fluvoxamine, venlafaxin, duloxetin, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: IPT+ antidepressant drugs',\n",
       "            'Drug: fluoxetine',\n",
       "            'Drug: sertraline',\n",
       "            'Drug: paroxetine',\n",
       "            'Drug: Citalopram',\n",
       "            'Drug: escitalopram',\n",
       "            'Drug: fluvoxamine',\n",
       "            'Drug: Venlafaxine',\n",
       "            'Drug: Duloxetine',\n",
       "            'Drug: Bupropion',\n",
       "            'Drug: Lithium',\n",
       "            'Drug: Risperidone',\n",
       "            'Drug: tranylcypromine',\n",
       "            'Drug: Imipramine',\n",
       "            'Drug: amitriptyline',\n",
       "            'Drug: Clomipramine',\n",
       "            'Drug: nortriptyline',\n",
       "            'Drug: trazodone',\n",
       "            'Drug: Mirtazapine',\n",
       "            'Drug: sulpiride']}},\n",
       "         {'ArmGroupLabel': 'Antidepressant Drugs',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice.\\n\\nAntidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, venlafaxine, duloxetine, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: fluoxetine',\n",
       "            'Drug: sertraline',\n",
       "            'Drug: paroxetine',\n",
       "            'Drug: Citalopram',\n",
       "            'Drug: escitalopram',\n",
       "            'Drug: fluvoxamine',\n",
       "            'Drug: Venlafaxine',\n",
       "            'Drug: Duloxetine',\n",
       "            'Drug: Bupropion',\n",
       "            'Drug: Lithium',\n",
       "            'Drug: Risperidone',\n",
       "            'Drug: tranylcypromine',\n",
       "            'Drug: Imipramine',\n",
       "            'Drug: amitriptyline',\n",
       "            'Drug: Clomipramine',\n",
       "            'Drug: nortriptyline',\n",
       "            'Drug: trazodone',\n",
       "            'Drug: Mirtazapine',\n",
       "            'Drug: sulpiride']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'IPT+ antidepressant drugs',\n",
       "          'InterventionDescription': '16 sessions of interpersonal psychotherapy plus antidepressant drugs.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['IPT+antidepressant drugs']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Interpersonal Psychotherapy',\n",
       "            'Antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'fluoxetine',\n",
       "          'InterventionDescription': 'Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'sertraline',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'paroxetine',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Citalopram',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'escitalopram',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'fluvoxamine',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Venlafaxine',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Duloxetine',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Bupropion',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Lithium',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Risperidone',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'tranylcypromine',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Imipramine',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'amitriptyline',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Clomipramine',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'nortriptyline',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'trazodone',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Mirtazapine',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'sulpiride',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Antidepressant Drugs',\n",
       "            'IPT+antidepressant drugs']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Hamilton Depression Scale (HAM-D) - continuous',\n",
       "          'PrimaryOutcomeDescription': 'Score change on Hamilton depression scale from baseline to week 19 and to week 24',\n",
       "          'PrimaryOutcomeTimeFrame': 'End point week 19 and Week 24'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Beck depression Inventory (BDI)',\n",
       "          'SecondaryOutcomeDescription': 'Score change on Beck depression inventory from baseline to week 19 and to week 24',\n",
       "          'SecondaryOutcomeTimeFrame': 'End point week 19 and Week 24'}]},\n",
       "       'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Clinical Global Impression - Severity Scale (CGI-S) / dichotomous',\n",
       "          'OtherOutcomeTimeFrame': 'Endpoint (week-19) and week 24'},\n",
       "         {'OtherOutcomeMeasure': 'Whoqol brief - World Health Organization Quality of Life Instrument - Short version - Brazilian version',\n",
       "          'OtherOutcomeDescription': 'Score change in Whoqol-breef from baseline to week 19 and week 24',\n",
       "          'OtherOutcomeTimeFrame': 'Endpoint week 19 and week 24'},\n",
       "         {'OtherOutcomeMeasure': 'Biological measures - BDFN, TBARS, TNF-alfa, IL-1, IL-6',\n",
       "          'OtherOutcomeDescription': 'A blood sample will be collected at baseline, week 19 and week 24. Change in serum biomarkers will be evaluated - BDFN (Brain derived neurotrophic factor), TBARS (thiobarbituric acid reactive substance), TNF-alfa (tumor necrosis factor alfa), IL-1 (interleukin-1), IL-6 (interlekin-6) before and after treatment.',\n",
       "          'OtherOutcomeTimeFrame': 'End point week 19 and Week 24'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPrimary diagnose of unipolar treatment resistant depression\\n\\nExclusion Criteria:\\n\\nPatients diagnose of: bipolar disorder, psychosis, high suicide risk, Intellectual disability, illicit drug dependence.\\nCurrently in or having received psychotherapy in the last 4 weeks',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Livia H Souza, MD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '+55 51 98658701',\n",
       "          'CentralContactEMail': 'liviahartmanndesouza@gmail.com'},\n",
       "         {'CentralContactName': 'Marcelo PA Fleck, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '+55 51 33598294',\n",
       "          'CentralContactEMail': 'mfleck.voy@terra.com.br'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Marcelo PA Fleck, MD,PhD',\n",
       "          'OverallOfficialAffiliation': 'Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA)',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Porto Alegre',\n",
       "          'LocationState': 'RS',\n",
       "          'LocationZip': '90035-003',\n",
       "          'LocationCountry': 'Brazil',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lívia H Souza, MD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '+55 5198658701',\n",
       "             'LocationContactEMail': 'livia.hs@terra.com.br'},\n",
       "            {'LocationContactName': 'Marcelo PA Fleck, MD, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '+55 51 33598294',\n",
       "             'LocationContactEMail': 'mfleck.voy@terra.com.br'},\n",
       "            {'LocationContactName': 'Lívia H Souza, MD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Marcelo PA Fleck, MD, PhD',\n",
       "             'LocationContactRole': 'Principal Investigator'},\n",
       "            {'LocationContactName': 'Marco Antonio K Caldieraro, MD, MSc',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Lucas Spanemberg, MD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Edgar A Vares, MD',\n",
       "             'LocationContactRole': 'Sub-Investigator'}]}}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26799332',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Souza LH, Salum GA, Mosqueiro BP, Caldieraro MA, Guerra TA, Fleck MP. Interpersonal psychotherapy as add-on for treatment-resistant depression: A pragmatic randomized controlled trial. J Affect Disord. 2016 Mar 15;193:373-80. doi: 10.1016/j.jad.2016.01.004. Epub 2016 Jan 8.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000068736',\n",
       "          'InterventionMeshTerm': 'Duloxetine Hydrochloride'},\n",
       "         {'InterventionMeshId': 'D000000639',\n",
       "          'InterventionMeshTerm': 'Amitriptyline'},\n",
       "         {'InterventionMeshId': 'D000018967',\n",
       "          'InterventionMeshTerm': 'Risperidone'},\n",
       "         {'InterventionMeshId': 'C000015209',\n",
       "          'InterventionMeshTerm': 'Amitriptyline, perphenazine drug combination'},\n",
       "         {'InterventionMeshId': 'D000013469',\n",
       "          'InterventionMeshTerm': 'Sulpiride'},\n",
       "         {'InterventionMeshId': 'D000078785',\n",
       "          'InterventionMeshTerm': 'Mirtazapine'},\n",
       "         {'InterventionMeshId': 'D000014196',\n",
       "          'InterventionMeshTerm': 'Trazodone'},\n",
       "         {'InterventionMeshId': 'D000016666',\n",
       "          'InterventionMeshTerm': 'Fluvoxamine'},\n",
       "         {'InterventionMeshId': 'D000014191',\n",
       "          'InterventionMeshTerm': 'Tranylcypromine'},\n",
       "         {'InterventionMeshId': 'D000015283',\n",
       "          'InterventionMeshTerm': 'Citalopram'},\n",
       "         {'InterventionMeshId': 'D000016642',\n",
       "          'InterventionMeshTerm': 'Bupropion'},\n",
       "         {'InterventionMeshId': 'D000020280',\n",
       "          'InterventionMeshTerm': 'Sertraline'},\n",
       "         {'InterventionMeshId': 'D000005473',\n",
       "          'InterventionMeshTerm': 'Fluoxetine'},\n",
       "         {'InterventionMeshId': 'D000017374',\n",
       "          'InterventionMeshTerm': 'Paroxetine'},\n",
       "         {'InterventionMeshId': 'D000069470',\n",
       "          'InterventionMeshTerm': 'Venlafaxine Hydrochloride'},\n",
       "         {'InterventionMeshId': 'D000009661',\n",
       "          'InterventionMeshTerm': 'Nortriptyline'},\n",
       "         {'InterventionMeshId': 'D000007099',\n",
       "          'InterventionMeshTerm': 'Imipramine'},\n",
       "         {'InterventionMeshId': 'D000002997',\n",
       "          'InterventionMeshTerm': 'Clomipramine'},\n",
       "         {'InterventionMeshId': 'D000000928',\n",
       "          'InterventionMeshTerm': 'Antidepressive Agents'}]},\n",
       "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000012702',\n",
       "          'InterventionAncestorTerm': 'Serotonin Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000018490',\n",
       "          'InterventionAncestorTerm': 'Serotonin Agents'},\n",
       "         {'InterventionAncestorId': 'D000018377',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Agents'},\n",
       "         {'InterventionAncestorId': 'D000045504',\n",
       "          'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "         {'InterventionAncestorId': 'D000045505',\n",
       "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'},\n",
       "         {'InterventionAncestorId': 'D000014150',\n",
       "          'InterventionAncestorTerm': 'Antipsychotic Agents'},\n",
       "         {'InterventionAncestorId': 'D000014149',\n",
       "          'InterventionAncestorTerm': 'Tranquilizing Agents'},\n",
       "         {'InterventionAncestorId': 'D000002492',\n",
       "          'InterventionAncestorTerm': 'Central Nervous System Depressants'},\n",
       "         {'InterventionAncestorId': 'D000011619',\n",
       "          'InterventionAncestorTerm': 'Psychotropic Drugs'},\n",
       "         {'InterventionAncestorId': 'D000018492',\n",
       "          'InterventionAncestorTerm': 'Dopamine Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000015259',\n",
       "          'InterventionAncestorTerm': 'Dopamine Agents'},\n",
       "         {'InterventionAncestorId': 'D000017367',\n",
       "          'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000014179',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000049990',\n",
       "          'InterventionAncestorTerm': 'Membrane Transport Modulators'},\n",
       "         {'InterventionAncestorId': 'D000018687',\n",
       "          'InterventionAncestorTerm': 'Antidepressive Agents, Second-Generation'},\n",
       "         {'InterventionAncestorId': 'D000018373',\n",
       "          'InterventionAncestorTerm': 'Peripheral Nervous System Agents'},\n",
       "         {'InterventionAncestorId': 'D000018765',\n",
       "          'InterventionAncestorTerm': 'Dopamine Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000065690',\n",
       "          'InterventionAncestorTerm': 'Cytochrome P-450 CYP2D6 Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000065607',\n",
       "          'InterventionAncestorTerm': 'Cytochrome P-450 Enzyme Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000004791',\n",
       "          'InterventionAncestorTerm': 'Enzyme Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000068760',\n",
       "          'InterventionAncestorTerm': 'Serotonin and Noradrenaline Reuptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000000700',\n",
       "          'InterventionAncestorTerm': 'Analgesics'},\n",
       "         {'InterventionAncestorId': 'D000018689',\n",
       "          'InterventionAncestorTerm': 'Sensory System Agents'},\n",
       "         {'InterventionAncestorId': 'D000006634',\n",
       "          'InterventionAncestorTerm': 'Histamine H1 Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000006633',\n",
       "          'InterventionAncestorTerm': 'Histamine Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000018494',\n",
       "          'InterventionAncestorTerm': 'Histamine Agents'},\n",
       "         {'InterventionAncestorId': 'D000014151',\n",
       "          'InterventionAncestorTerm': 'Anti-Anxiety Agents'},\n",
       "         {'InterventionAncestorId': 'D000058669',\n",
       "          'InterventionAncestorTerm': 'Adrenergic alpha-2 Receptor Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000000317',\n",
       "          'InterventionAncestorTerm': 'Adrenergic alpha-Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000018674',\n",
       "          'InterventionAncestorTerm': 'Adrenergic Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000018663',\n",
       "          'InterventionAncestorTerm': 'Adrenergic Agents'},\n",
       "         {'InterventionAncestorId': 'D000058830',\n",
       "          'InterventionAncestorTerm': 'Serotonin 5-HT2 Receptor Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000058831',\n",
       "          'InterventionAncestorTerm': 'Serotonin 5-HT3 Receptor Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000000929',\n",
       "          'InterventionAncestorTerm': 'Antidepressive Agents, Tricyclic'},\n",
       "         {'InterventionAncestorId': 'D000018712',\n",
       "          'InterventionAncestorTerm': 'Analgesics, Non-Narcotic'},\n",
       "         {'InterventionAncestorId': 'D000018759',\n",
       "          'InterventionAncestorTerm': 'Adrenergic Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000065609',\n",
       "          'InterventionAncestorTerm': 'Cytochrome P-450 CYP1A2 Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000065689',\n",
       "          'InterventionAncestorTerm': 'Cytochrome P-450 CYP2C19 Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000008996',\n",
       "          'InterventionAncestorTerm': 'Monoamine Oxidase Inhibitors'}]},\n",
       "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16566',\n",
       "          'InterventionBrowseLeafName': 'Citalopram',\n",
       "          'InterventionBrowseLeafAsFound': 'Citalopram',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M17596',\n",
       "          'InterventionBrowseLeafName': 'Bupropion',\n",
       "          'InterventionBrowseLeafAsFound': 'Bupropion',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M299',\n",
       "          'InterventionBrowseLeafName': 'Duloxetine Hydrochloride',\n",
       "          'InterventionBrowseLeafAsFound': 'Duloxetine',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M17618',\n",
       "          'InterventionBrowseLeafName': 'Fluvoxamine',\n",
       "          'InterventionBrowseLeafAsFound': 'Fluvoxamine',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M5687',\n",
       "          'InterventionBrowseLeafName': 'Dexetimide',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19583',\n",
       "          'InterventionBrowseLeafName': 'Risperidone',\n",
       "          'InterventionBrowseLeafAsFound': 'Risperidone',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M18237',\n",
       "          'InterventionBrowseLeafName': 'Paroxetine',\n",
       "          'InterventionBrowseLeafAsFound': 'Paroxetine',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M15533',\n",
       "          'InterventionBrowseLeafName': 'Trazodone',\n",
       "          'InterventionBrowseLeafAsFound': 'Trazodone',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M2558',\n",
       "          'InterventionBrowseLeafName': 'Amitriptyline',\n",
       "          'InterventionBrowseLeafAsFound': 'Amitriptyline',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M191786',\n",
       "          'InterventionBrowseLeafName': 'Amitriptyline, perphenazine drug combination',\n",
       "          'InterventionBrowseLeafAsFound': 'Amitriptyline',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M17605',\n",
       "          'InterventionBrowseLeafName': 'Lithium Carbonate',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M20684',\n",
       "          'InterventionBrowseLeafName': 'Sertraline',\n",
       "          'InterventionBrowseLeafAsFound': 'Sertraline',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M7184',\n",
       "          'InterventionBrowseLeafName': 'Fluoxetine',\n",
       "          'InterventionBrowseLeafAsFound': 'Fluoxetine',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M439',\n",
       "          'InterventionBrowseLeafName': 'Venlafaxine Hydrochloride',\n",
       "          'InterventionBrowseLeafAsFound': 'Venlafaxine',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M11180',\n",
       "          'InterventionBrowseLeafName': 'Nortriptyline',\n",
       "          'InterventionBrowseLeafAsFound': 'Nortriptyline',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M2828',\n",
       "          'InterventionBrowseLeafName': 'Antidepressive Agents',\n",
       "          'InterventionBrowseLeafAsFound': 'Antidepressant Drug',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M2007',\n",
       "          'InterventionBrowseLeafName': 'Mirtazapine',\n",
       "          'InterventionBrowseLeafAsFound': 'Mirtazapine',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M8730',\n",
       "          'InterventionBrowseLeafName': 'Imipramine',\n",
       "          'InterventionBrowseLeafAsFound': 'Imipramine',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M15528',\n",
       "          'InterventionBrowseLeafName': 'Tranylcypromine',\n",
       "          'InterventionBrowseLeafAsFound': 'Tranylcypromine',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M14835',\n",
       "          'InterventionBrowseLeafName': 'Sulpiride',\n",
       "          'InterventionBrowseLeafAsFound': 'Sulpiride',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M4812',\n",
       "          'InterventionBrowseLeafName': 'Clomipramine',\n",
       "          'InterventionBrowseLeafAsFound': 'Clomipramine',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M12037',\n",
       "          'InterventionBrowseLeafName': 'Perphenazine',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M14095',\n",
       "          'InterventionBrowseLeafName': 'Serotonin',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19088',\n",
       "          'InterventionBrowseLeafName': 'Neurotransmitter Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M15487',\n",
       "          'InterventionBrowseLeafName': 'Antipsychotic Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M13057',\n",
       "          'InterventionBrowseLeafName': 'Psychotropic Drugs',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M6056',\n",
       "          'InterventionBrowseLeafName': 'Dopamine',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19180',\n",
       "          'InterventionBrowseLeafName': 'Dopamine Antagonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M16545',\n",
       "          'InterventionBrowseLeafName': 'Dopamine Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M18232',\n",
       "          'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M29124',\n",
       "          'InterventionBrowseLeafName': 'Cytochrome P-450 Enzyme Inhibitors',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M11158',\n",
       "          'InterventionBrowseLeafName': 'Norepinephrine',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M305',\n",
       "          'InterventionBrowseLeafName': 'Serotonin and Noradrenaline Reuptake Inhibitors',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M2613',\n",
       "          'InterventionBrowseLeafName': 'Analgesics',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M8293',\n",
       "          'InterventionBrowseLeafName': 'Histamine H1 Antagonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M8291',\n",
       "          'InterventionBrowseLeafName': 'Histamine',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M219111',\n",
       "          'InterventionBrowseLeafName': 'Histamine phosphate',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M8292',\n",
       "          'InterventionBrowseLeafName': 'Histamine Antagonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M15488',\n",
       "          'InterventionBrowseLeafName': 'Anti-Anxiety Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19330',\n",
       "          'InterventionBrowseLeafName': 'Adrenergic Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M2250',\n",
       "          'InterventionBrowseLeafName': 'Adrenergic alpha-Antagonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19339',\n",
       "          'InterventionBrowseLeafName': 'Adrenergic Antagonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M27833',\n",
       "          'InterventionBrowseLeafName': 'Serotonin 5-HT3 Receptor Antagonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M2829',\n",
       "          'InterventionBrowseLeafName': 'Antidepressive Agents, Tricyclic',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19370',\n",
       "          'InterventionBrowseLeafName': 'Analgesics, Non-Narcotic',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M10543',\n",
       "          'InterventionBrowseLeafName': 'Monoamine Oxidase Inhibitors',\n",
       "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr',\n",
       "          'InterventionBrowseBranchName': 'Psychotropic Drugs'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'Analg',\n",
       "          'InterventionBrowseBranchName': 'Analgesics'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'CNSDep',\n",
       "          'InterventionBrowseBranchName': 'Central Nervous System Depressants'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'AnDyAg',\n",
       "          'InterventionBrowseBranchName': 'Anti-Dyskinesia Agents'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'CaAg',\n",
       "          'InterventionBrowseBranchName': 'Cardiotonic Agents'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'VaCoAg',\n",
       "          'InterventionBrowseBranchName': 'Vasoconstrictor Agents'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000061218',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder, Treatment-Resistant'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M28370',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Treatment-Resistant',\n",
       "          'ConditionBrowseLeafAsFound': 'Treatment Resistant Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 51,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01341925',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '2011H0033'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R34MH085875-01A2',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R34MH085875-01A2&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'Ohio State University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Omega-3 and Therapy Study for Depression',\n",
       "       'OfficialTitle': 'Omega-3 Fatty Acids & Psychoeducational Psychotherapy for Childhood Depression',\n",
       "       'Acronym': 'OATS'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'September 2011'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2014',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'September 2014',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'April 22, 2011',\n",
       "       'StudyFirstSubmitQCDate': 'April 25, 2011',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 26, 2011',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'March 4, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 8, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'L. Eugene Arnold',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Ohio State University'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'L. Eugene Arnold',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Childhood depression warrants treatment research; including pharmacological and psychotherapeutic interventions. A recent study found fluoxetine to be the only medication with empirical support for decreasing depression in children, but concerns about treatment-emergent suicidal ideation/behavior led the FDA to mandate black-box warning for use of antidepressants in this age group (Bridge et al, 2007). These worries have prompted interest in alternative therapies including dietary supplements such as omega-3 fatty acids (Ω3).\\n\\nThe current study compares Ω3, psychoeducational psychotherapy (PEP), and their combination to a placebo supplement and active monitoring (AM) in a 12-week trial of 60 children with unipolar depression. Primary goals are to determine: 1) feasibility of a) recruiting 60 participants in 24 months; b) retaining participants over a 12-week trial; and 2) effect sizes for Ω3, PEP, and combination treatment. Secondary goals are to explore response curves over time, mediators and moderators, treatment response across an array of outcome variables, adherence to treatment, and side effects. This pilot study of Ω3, PEP, and combined treatment will provide evidence about whether a larger trial is feasible and justifiable.',\n",
       "       'DetailedDescription': 'Approximately 2 to 4% of children experience either major depressive disorder or dysthymic disorder and 5 to 10% of children and adolescents experience subsyndromal depressive symptoms (Birmaher et al). Due to its prevalence and association with significant functioning deficits, childhood depression warrants treatment research. Treatments include pharmacological and psychotherapeutic interventions. A recent meta-analysis found fluoxetine to be the only medication with empirical support for decreasing depression in children, but concerns about treatment-emergent suicidal ideation/behavior led the FDA to mandate black-box warning for use of antidepressants in this age group (Bridge et al, 2007). These worries have prompted interest in alternative therapies including dietary supplements such as omega-3 fatty acids (Ω3). Research on treatment of mood disorders with Ω3 is promising (Schacter et al, 2005); however, only one RCT has been conducted in children, which was positive (Nemets et al, 2006). Findings from other clinical populations (ADHD, adolescent depression, anxiety and pervasive developmental disorders in children) suggest combination treatments are advantageous (Aman et al., 2009; The MTA Cooperative Group, 1999, 2004; The TADS Team, 2007; Walkup et al., 2008). Little is known about the effectiveness of psychotherapy for children age 12 and under who are clinically depressed. Researchers are beginning to develop and test manual-based individual/family therapies for clinic-referred children with diagnosable depression (Kovacs et al, 2006; Tompson et al, 2007); however, no RCTs have been completed. Prior research supports incorporating psychoeducation about depression, support, and skill building to decrease depressive symptoms (Birmaher et al).\\n\\nThe current study compares Ω3, psychoeducational psychotherapy (PEP), and their combination to a placebo supplement and active monitoring (AM) in a 12-week trial of 60 children with unipolar depression. Primary goals are to determine: 1) feasibility of a) recruiting 60 participants in 24 months; b) retaining participants over a 12-week trial; and 2) effect sizes for Ω3, PEP, and combination treatment. Secondary goals are to explore response curves over time, mediators and moderators, treatment response across an array of outcome variables, adherence to treatment, and side effects. This pilot study of Ω3, PEP, and combined treatment will provide evidence about whether a larger trial is feasible and justifiable.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['childhood depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 1']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Factorial Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Quadruple',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Care Provider',\n",
       "           'Investigator',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '73',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Placebo Supplement and No PEP',\n",
       "          'ArmGroupType': 'Placebo Comparator',\n",
       "          'ArmGroupDescription': 'Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Placebo']}},\n",
       "         {'ArmGroupLabel': 'Omega-3 and PEP',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.\\n\\nPsychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Omega-3 Supplementation',\n",
       "            'Behavioral: Psychoeducational Psychotherapy (PEP)']}},\n",
       "         {'ArmGroupLabel': 'Omega-3 and No PEP',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Omega-3 Supplementation']}},\n",
       "         {'ArmGroupLabel': 'Placebo Supplement and PEP',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.\\n\\nPsychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Psychoeducational Psychotherapy (PEP)']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Omega-3 Supplementation',\n",
       "          'InterventionDescription': 'The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Omega-3 and No PEP',\n",
       "            'Omega-3 and PEP']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Omega Brite']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Psychoeducational Psychotherapy (PEP)',\n",
       "          'InterventionDescription': \"Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Omega-3 and PEP',\n",
       "            'Placebo Supplement and PEP']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['IF-PEP']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Placebo',\n",
       "          'InterventionDescription': 'The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo Supplement and No PEP']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Pbo']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Childhood Depression Rating Scale - Revised (CDRS-R)',\n",
       "          'PrimaryOutcomeDescription': 'The CDRS-R is a severity scale for depression in children ages 6-17. It has 21 items, each rated on a 1-5 or 1-7 point scale in the direction of increasing severity. Scores can range from 17 to 113, demonstrated to correlate significantly with clinical global ratings of depression and to differentiate clinically defined groups of children. Interrater reliability is adequate (r =.86), as is test-retest reliability over a 4 week interval (r =.81; Poznanski et al, 1984). The CDRS-R will be completed at screen to determine clinical impairment of depressive symptoms necessary for study eligibility and at each subsequent assessment to determine clinical response.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Week prior to randomization and then weeks 2, 4, 6, 9, and 12 post-randomization'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'K-SADS Depression Rating Scale (KDRS)',\n",
       "          'SecondaryOutcomeDescription': 'Depressive symptom severity for worst past episode(s) and current episode (past two weeks) will be assessed using the KDRS at the assessment visits. The KDRS is a 12-item semi-structured interview with depression symptoms rated on a 6-point scale from none to severe. The KDRS has been shown to be a reliable measure of symptom severity.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Week prior to randomization and then weeks 2, 4, 6, 9, and 12 post-randomization'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\naged 7-14 years (boys and girls)\\nDSM-IV-TR diagnosis of major depressive disorder and/or dysthymic disorder as determined by consensus conference\\nChildren\\'s Depression Rating Scale (CDRS-R) score ≥ 40\\nfull scale IQ ≥ 70\\nchild and at least one parent must be able to complete all assessments\\nchild must be able to swallow capsules (training in swallowing will be offered)\\nparent/guardian and child must be willing to have blood drawn from child at two study assessments.\\n\\nExclusion Criteria:\\n\\nmajor medical disorders (eg diabetes, epilepsy, metabolic disorder)\\ninability to communicate in English\\nlack of access via phone\\nautism\\nschizophrenia, or other psychotic states warranting anti-psychotic medication\\nDSM-IV-TR diagnosis of a bipolar disorder\\nactive suicidal concern (e.g., \"I want to kill myself\", a plan for suicide, or an attempt in the past month; however, passive suicidal ideation, such as \"I wish I were dead\" would not exclude)\\nintake in the previous 4 weeks of supplemental Ω3 fatty acids.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '7 Years',\n",
       "       'MaximumAge': '14 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'L E Arnold, MD, MEd',\n",
       "          'OverallOfficialAffiliation': 'Ohio State University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Mary A Fristad, PhD',\n",
       "          'OverallOfficialAffiliation': 'Ohio State University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Ohio State University Medical Center - Harding Hospital',\n",
       "          'LocationCity': 'Columbus',\n",
       "          'LocationState': 'Ohio',\n",
       "          'LocationZip': '43210',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28379964',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Christian LM, Young AS, Mitchell AM, Belury MA, Gracious BL, Arnold LE, Fristad MA. Body weight affects ω-3 polyunsaturated fatty acid (PUFA) accumulation in youth following supplementation in post-hoc analyses of a randomized controlled trial. PLoS One. 2017 Apr 5;12(4):e0173087. doi: 10.1371/journal.pone.0173087. eCollection 2017.'},\n",
       "         {'ReferencePMID': '27604240',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Young AS, Arnold LE, Wolfson HL, Fristad MA. Psychoeducational Psychotherapy and Omega-3 Supplementation Improve Co-Occurring Behavioral Problems in Youth with Depression: Results from a Pilot RCT. J Abnorm Child Psychol. 2017 Jul;45(5):1025-1037. doi: 10.1007/s10802-016-0203-3.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T415',\n",
       "          'InterventionBrowseLeafName': 'Omega 3 Fatty Acid',\n",
       "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Ot',\n",
       "          'InterventionBrowseBranchName': 'Other Dietary Supplements'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 52,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01200901',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'Nelson AZ-IIT'},\n",
       "       'Organization': {'OrgFullName': 'University of Cincinnati',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Quetiapine in Melancholic Depression',\n",
       "       'OfficialTitle': 'Quetiapine in Melancholic Depression: an fMRI Study of Treatment-induced Changes in the Neurocircuitry of the Stress Response'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'January 2013',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'September 2008'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2012',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'September 2012',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'September 7, 2010',\n",
       "       'StudyFirstSubmitQCDate': 'September 13, 2010',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 14, 2010',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'January 16, 2013',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 18, 2013',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Erik Nelson',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Adjunct Associate Professor',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Cincinnati'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Cincinnati',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'In summary, the investigators propose to integrate fMRI assessments within a clinical trial of quetiapine XR in patients with melancholic depression in order to test the predictions that:\\n\\nquetiapine XR treatment will be effective and safe for patients with major depression with melancholic features\\nsuccessful treatment with quetiapine XR will be associated with normalization of limbic areas associated with increased salivary cortisol response to a stressful task as well as normalization on the emotional faces task differences in the melancholic group compared with healthy volunteers.\\nsuccessful treatment with quetiapine XR will be associated with normalization of the salivary cortisol response to the stressful math task (i.e. there will be a diminished post-treatment mean AUC for cortisol secretion after the stress task compared to the pre-treatment AUC values in the patient group)',\n",
       "       'DetailedDescription': 'Patients with major depression (N=20) will be recruited for the 8-week clinical trial of quetiapine XR 100 - 300 mg (flexible dosing). Patients who consent to participate will be referred for an initial fMRI scanning session prior to the initiation of quetiapine XR. Baseline fMRI will be obtained during the index assessment prior to initiating quetiapine XR therapy and then will be re-acquired at the final study visit at 8 weeks (the time of scheduled visits). Ten demographically matched healthy subjects will receive the same fMRI investigations on two occasions in order to provide a healthy baseline comparison to permit interpretation of the patient findings (e.g., whether initial and final fMRI measures in patients are abnormal and to control for any adaptation to the task that may normally occur).'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression',\n",
       "         'Healthy']},\n",
       "       'KeywordList': {'Keyword': ['depression', 'healthy']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 4']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '20',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Melancolic depression patients',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Patients with major depression will be recruited for the 8-week clinical trial of quetiapine XR 100 - 300 mg (flexible dosing).',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Quetiapine']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Quetiapine',\n",
       "          'InterventionDescription': 'quetiapine XR 100 - 300 mg (flexible dosing)',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Melancolic depression patients']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Open Label Quetiapine']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'quetiapine XR treatment will be effective and safe for patients with major depression with melancholic features',\n",
       "          'PrimaryOutcomeDescription': 'Patients with major depression (N=20) will be recruited for the 8-week clinical trial of quetiapine XR 100 - 300 mg (flexible dosing). Patients who consent to participate will be referred for an initial fMRI scanning session prior to the initiation of quetiapine XR. Baseline fMRI will be obtained during the index assessment prior to initiating quetiapine XR therapy and then will be re-acquired at the final study visit at 8 weeks (the time of scheduled visits).',\n",
       "          'PrimaryOutcomeTimeFrame': '8 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'normalization of limbic areas associated with increased salivary cortisol response to a stressful task',\n",
       "          'SecondaryOutcomeDescription': 'successful treatment with quetiapine XR will be associated with normalization of limbic areas associated with increased salivary cortisol response to a stressful task as well as normalization on the emotional faces task differences in the melancholic group compared with healthy volunteers.',\n",
       "          'SecondaryOutcomeTimeFrame': '8 Weeks'},\n",
       "         {'SecondaryOutcomeMeasure': 'successful treatment with quetiapine XR will be associated with normalization of the salivary cortisol response to the stressful math task',\n",
       "          'SecondaryOutcomeTimeFrame': '8 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion criteria\\n\\nProvision of written informed consent\\nA diagnosis of major depression with melancholic features by Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV)\\nFemales and males aged 18-65 years\\nFemale patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin (HCG) test at enrollment\\nAble to understand and comply with the requirements of the study\\nSubjects will have a Hamilton Depression Rating Scale, 28-item version (HDRS-28) score of at least 20 at the baseline visit.\\n\\nExclusion criteria\\n\\nPregnancy or lactation\\nPatients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others\\nKnown intolerance or lack of response to quetiapine fumarate, as judged by the investigator\\nUse of any of the following cytochrome P450 3a4 inhibitors in the 14 days preceding enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir\\nUse of any of the following cytochrome P450 inducers in the 14 days preceding enrolment including, but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, and St. John's Wort.\\nAdministration of a depot antipsychotic injection within one dosing interval (for the depot) before randomisation Women using oral contraceptives or other medications that directly affect estrogen or progesterone system in the body.\\nSubjects taking corticosteroids or other medications that directly influence HPA axis function\\nSubjects with certain lifestyle habits (i.e. working night shift) that could affect the function of the HPA axis\\nHistory of substance dependence in the past year or meets criteria for a substance abuse disorder in the past three months.\\nMedical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment\\nUnstable or inadequately treated medical illness (e.g. diabetes, angina pectoris, hypertension) as judged by the investigator\\nParticipation in another drug trial within 4 weeks prior to enrollment into this study\\nAn absolute neutrophil count (ANC) of 1.5 x 109 per liter\\nPatients who have initiated a new psychotherapy or behavioral therapy from a mental health professional in the past 3 months\\nA lifetime DSM-IV history of a psychotic disorder, a bipolar disorder, or dementia.\\nHistory of psychosurgery\\nAxis II disorder\\nHistory of seizures, excluding febrile seizures in childhood.\\nClinically relevant abnormal laboratory results.\\nPatients who have received monoamine oxidase inhibitors, tricyclics, SSRIs, antipsychotics, or lithium within two weeks prior to randomization, or fluoxetine within four weeks prior to randomization.\\nElectroconvulsive therapy (ECT) within three months of start of study\\nHistory of mental retardation.\\nHistory of major neurological illness, including any history of significant head trauma.\\nContraindications to magnetic resonance imaging, including claustrophobia and/or the presence of ferrous material that might make an MRI scan hazardous.\\nPatients will be excluded from the study if they indicate at screening that they know someone who has previously participated in the study.\",\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Erik Nelson, MD',\n",
       "          'OverallOfficialAffiliation': 'University of Cincinnati',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'University of Cincinnati',\n",
       "          'LocationCity': 'Cincinnati',\n",
       "          'LocationState': 'Ohio',\n",
       "          'LocationZip': '45219',\n",
       "          'LocationCountry': 'United States'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000069348',\n",
       "          'InterventionMeshTerm': 'Quetiapine Fumarate'}]},\n",
       "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000928',\n",
       "          'InterventionAncestorTerm': 'Antidepressive Agents'},\n",
       "         {'InterventionAncestorId': 'D000011619',\n",
       "          'InterventionAncestorTerm': 'Psychotropic Drugs'},\n",
       "         {'InterventionAncestorId': 'D000014150',\n",
       "          'InterventionAncestorTerm': 'Antipsychotic Agents'},\n",
       "         {'InterventionAncestorId': 'D000014149',\n",
       "          'InterventionAncestorTerm': 'Tranquilizing Agents'},\n",
       "         {'InterventionAncestorId': 'D000002492',\n",
       "          'InterventionAncestorTerm': 'Central Nervous System Depressants'},\n",
       "         {'InterventionAncestorId': 'D000045505',\n",
       "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]},\n",
       "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M399',\n",
       "          'InterventionBrowseLeafName': 'Quetiapine Fumarate',\n",
       "          'InterventionBrowseLeafAsFound': 'Quetiapine',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M2828',\n",
       "          'InterventionBrowseLeafName': 'Antidepressive Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M13057',\n",
       "          'InterventionBrowseLeafName': 'Psychotropic Drugs',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M15487',\n",
       "          'InterventionBrowseLeafName': 'Antipsychotic Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'CNSDep',\n",
       "          'InterventionBrowseBranchName': 'Central Nervous System Depressants'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'PsychDr',\n",
       "          'InterventionBrowseBranchName': 'Psychotropic Drugs'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 53,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01139060',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '5R01MH082995',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=5R01MH082995&Fy=all'},\n",
       "       'Organization': {'OrgFullName': 'Kaiser Permanente',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Organized Self-Management Support Services for Chronic Depression',\n",
       "       'OfficialTitle': 'Organized Self-Management Support Services for Chronic Depression',\n",
       "       'Acronym': 'Stride'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'October 2017',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'August 2009'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2013',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 4, 2010',\n",
       "       'StudyFirstSubmitQCDate': 'June 7, 2010',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 8, 2010',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'October 11, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 13, 2017',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Kaiser Permanente',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Swedish Medical Center',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': \"The purpose is to test the effectiveness of an organized care program for chronic or recurrent depression. Using a two-arm design, the investigators will randomly assign 300 participants with chronic or recurrent depression to one of two conditions: continued usual care (UC); or an 18-month organized treatment program focused on outreach and engagement, including a weekly group self-management training program, monthly visits with a psychotherapist (in-person or by telephone), and optional one-on-one visits with a peer support specialist. All intervention components are intended as adjuncts to any existing depression treatment (usually antidepressant medication) provided by participants' regular providers.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['chronic or recurrent depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 3']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '302',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention Group',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': '18-month organized treatment program focused on outreach and engagement for chronic or recurrent depression',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: organized care program for chronic or recurrent depression']}},\n",
       "         {'ArmGroupLabel': 'Usual Care', 'ArmGroupType': 'No Intervention'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'organized care program for chronic or recurrent depression',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention Group']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Evaluate the program's effectiveness, i.e., the effects of the intervention on patient outcomes (depressive symptoms, functional impairment, and disability/lost productivity) and process of care (self-efficacy and self-management behaviors)\",\n",
       "          'PrimaryOutcomeTimeFrame': '18 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Examination of moderators of treatment response',\n",
       "          'SecondaryOutcomeTimeFrame': '18 months'},\n",
       "         {'SecondaryOutcomeMeasure': \"An estimate of the program's costs and effect on the costs of treatment for depression\",\n",
       "          'SecondaryOutcomeTimeFrame': '18 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nall patients will meet criteria for recurrent major depression or dysthymia\\n\\nExclusion Criteria:\\n\\nbipolar disorder or psychotic disorder',\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Evette Ludman, PhD',\n",
       "          'OverallOfficialAffiliation': 'Group Health Research Institute',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Group Health Research Insitute',\n",
       "          'LocationCity': 'Seattle',\n",
       "          'LocationState': 'Washington',\n",
       "          'LocationZip': '98101',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Swedish Cherry Hill Clinic',\n",
       "          'LocationCity': 'Seattle',\n",
       "          'LocationState': 'Washington',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28726086',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Jones SMW, Ludman EJ. Factor Structure and Sensitivity to Change of the Recovery Assessment Scale. J Behav Health Serv Res. 2018 Oct;45(4):690-699. doi: 10.1007/s11414-017-9563-x.'},\n",
       "         {'ReferencePMID': '26278222',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Ludman EJ, Simon GE, Grothaus LC, Richards JE, Whiteside U, Stewart C. Organized Self-Management Support Services for Chronic Depressive Symptoms: A Randomized Controlled Trial. Psychiatr Serv. 2016 Jan;67(1):29-36. doi: 10.1176/appi.ps.201400295. Epub 2015 Aug 17.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 54,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03116503',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '16-HPNCL-01'},\n",
       "       'Organization': {'OrgFullName': 'Fondation Lenval',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Bipolarity - Depression in Children and Adolescent Suicide Attempters: Better Diagnosis to Prevent Recurrence',\n",
       "       'OfficialTitle': 'Bipolarity - Depression in Children and Adolescent Suicide Attempters: Better Diagnosis to Prevent Recurrence'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'April 2017',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'June 2016',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2018',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'June 2018',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'February 21, 2017',\n",
       "       'StudyFirstSubmitQCDate': 'April 11, 2017',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 17, 2017',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'July 27, 2018',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 30, 2018',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Fondation Lenval',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of the study is to describe the number of diagnosis of bipolar depression and comorbid suicidal behavior according to the diagnostic criteria of the DSM-5.',\n",
       "       'DetailedDescription': 'This study is a prospective, routine care, covering pediatric population suicidal (who attempted suicide) and suicide (with suicidal ideas with planning) hospitalized in the pediatric hospital in Nice- Lenval Hospital.\\n\\nThe main objective of the study is to describe the number of diagnosis of bipolar depression and comorbid suicidal behavior according to the diagnostic criteria of the DSM-5.\\n\\nThe secondary objectives are: 1) comparison of the suicide attempt rate of recurrence at 6 months and 12 months among subjects with a diagnosis of mood disorder (depression or bipolar) and subjects with a diagnosis mood disorder; 2) the identification of specific suicidal recurrence risk factors in the diagnosis of mood disorder; 3) comparing the diagnostic evaluation field (ICD-10 criteria) vs standardized assessment (DSM-5 criteria).\\n\\nFor this the investigator propose an observational cohort study, single center, on a trailing 12 months after inclusion.\\n\\nThe topics are selected and included consecutively over a period of 12 months. The inclusion criteria are: 1) children - teenagers age: 6-18 years inclusive; 2) hospitalization for suicide attempt or suicidal ideation with planning in the Pediatric Hospital of Nice Lenval Hospital; 3) French patients; 4) speaking parents 5) affiliation to the social security system.\\n\\nThe criterion for inclusion is not the refusal or failure to realize the Kiddie - SADS with the subject and / or his parents.\\n\\nThe number of subjects to be included is estimated at 100. At baseline: standardized assessment of comorbid psychiatric diagnosis according to DSM-5 Mood disorders according to DSM-IV R criteria for other diagnoses. The investigatorwill use the KIDDIE-SADS, semi-structured interview for diagnostic purposes adapted to the DSM for that assessment.\\n\\nThe patients were distributed into two groups: mood disorder group - group without mood disorder.\\n\\nIn parallel, the field team evaluates blind psychiatric diagnosis according to ICD-10 criteria.\\n\\nThe population included subjects is described: clinicaly - demographic - overall operation - individual and family psychiatric history.\\n\\nThe topics included are reassessed at 6 months and 12 months. At 6 months: occurrence of an attempted suicide or recurrence of suicidal thoughts with planning - overall operation - clinical condition. At 12 months: re standardized diagnostic evaluation with KIDDIE-SADS and re identical clinical evaluation at 6 months.\\n\\nThe recidivism risk factors and recidivism rates are evaluated in both groups. The primary endpoint of the study is the attempt recurrence rate of suicide.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Suicide, Attempted']},\n",
       "       'KeywordList': {'Keyword': ['Suicide']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignInterventionModelDescription': 'Describe the number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.',\n",
       "        'DesignPrimaryPurpose': 'Screening',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '58',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'bipolar disorder and comorbid depression',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: diagnosis of bipolar disorder and comorbid depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'diagnosis of bipolar disorder and comorbid depression',\n",
       "          'InterventionDescription': 'Evaluation of the number of diagnosis of bipolar disorder and comorbid depression',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['bipolar disorder and comorbid depression']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'diagnosis of bipolar disorder and comorbid depression',\n",
       "          'PrimaryOutcomeDescription': 'Describe the number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.',\n",
       "          'PrimaryOutcomeTimeFrame': 'At baseline during inclusion visit'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'recurrence rates',\n",
       "          'SecondaryOutcomeDescription': 'compare the recurrence rates at 6 and 12 months between bipolar and depressed patients and patients not diagnosed with a mood disorder',\n",
       "          'SecondaryOutcomeTimeFrame': 'comparison between 6 month and 12 month'},\n",
       "         {'SecondaryOutcomeMeasure': 'risk factors for suicidal recidivism',\n",
       "          'SecondaryOutcomeDescription': 'To compare the risk factors for suicidal recidivism between bipolar and depressed patients',\n",
       "          'SecondaryOutcomeTimeFrame': 'At baseline during inclusion visit'},\n",
       "         {'SecondaryOutcomeMeasure': 'comorbid diagnoses',\n",
       "          'SecondaryOutcomeDescription': 'Compare the comorbid diagnoses obtained by the standardized assessment (Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) for mood disorders and DSM-IVR for other diagnoses) vs. field assessment (CIM-10) (Classification internationale des maladies-10)',\n",
       "          'SecondaryOutcomeTimeFrame': 'At baseline during inclusion visit'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nhospitalized at Fondation Lenval/ pediatric hospital of Nice-CHU Lenval for suicide attempt and / or suicidal ideas with planning\\nFrench-speaking patient\\nFrancophone parents\\nAffiliation to asocial security system\\n\\nExclusion Criteria:\\n\\nRefusal or impossibility of carrying out the KIDDIE-SADS questionnaire',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '6 Years',\n",
       "       'MaximumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child', 'Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Nathalie DUGAND, MD',\n",
       "          'OverallOfficialAffiliation': 'Fondation Lenval',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Fondation Lenval, Hôpitaux pédiatriques de Nice CHU Lenval',\n",
       "          'LocationCity': 'Nice',\n",
       "          'LocationZip': '06200',\n",
       "          'LocationCountry': 'France'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000012008',\n",
       "          'ConditionMeshTerm': 'Recurrence'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000013405', 'ConditionMeshTerm': 'Suicide'},\n",
       "         {'ConditionMeshId': 'D000013406',\n",
       "          'ConditionMeshTerm': 'Suicide, Attempted'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000020969',\n",
       "          'ConditionAncestorTerm': 'Disease Attributes'},\n",
       "         {'ConditionAncestorId': 'D000010335',\n",
       "          'ConditionAncestorTerm': 'Pathologic Processes'},\n",
       "         {'ConditionAncestorId': 'D000016728',\n",
       "          'ConditionAncestorTerm': 'Self-Injurious Behavior'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M13433',\n",
       "          'ConditionBrowseLeafName': 'Recurrence',\n",
       "          'ConditionBrowseLeafAsFound': 'Recurrence',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M14774',\n",
       "          'ConditionBrowseLeafName': 'Suicide',\n",
       "          'ConditionBrowseLeafAsFound': 'Suicide',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M14775',\n",
       "          'ConditionBrowseLeafName': 'Suicide, Attempted',\n",
       "          'ConditionBrowseLeafAsFound': 'Suicide, Attempted',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M21284',\n",
       "          'ConditionBrowseLeafName': 'Disease Attributes',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M17672',\n",
       "          'ConditionBrowseLeafName': 'Self-Injurious Behavior',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23',\n",
       "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
       "   {'Rank': 55,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02605278',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'PI14/00573'},\n",
       "       'Organization': {'OrgFullName': 'Jordi Gol i Gurina Foundation',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Multicomponent Program for the Integrated Management of Chronic Pain and Depression in Primary Care',\n",
       "       'OfficialTitle': 'Assessment of a Multicomponent Program for the Integrated Management of Chronic Pain and Depression in Primary Care. Cluster Randomized Clinical Trial',\n",
       "       'Acronym': 'DROP'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'September 2015',\n",
       "       'OverallStatus': 'Unknown status',\n",
       "       'LastKnownStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2015'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2017',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2017',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'September 28, 2015',\n",
       "       'StudyFirstSubmitQCDate': 'November 13, 2015',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 16, 2015',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'November 13, 2015',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 16, 2015',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Jordi Gol i Gurina Foundation',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study evaluates whether the implementation of an integrated clinical program for chronic musculoskeletal pain and depression behave better clinical outcomes than the usual approach in primary care',\n",
       "       'DetailedDescription': 'Chronic musculoskeletal pain and depression are extremely common and relevant pathological conditions, and frequently presented as comorbid processes multiplying the impact on health, worsening the prognosis and complicating the care. The integrated management of both disorders is an opportunity to achieve better clinical outcomes.\\n\\nAIM: To determinate whether the implementation of an integrated clinical program for chronic musculoskeletal pain and depression behave better clinical outcomes than the usual approach in primary care\\n\\nMETHODS\\n\\nDesign: Cluster randomized clinical trials with two arms:\\n\\nIntervention: Integrated program for depression/chronic pain, and\\ncontrol usual care.\\n\\nSettings: Primary Care Centers in Tarragona, Spain. Patients: Adults with moderate/severe musculoskeletal pain (Brief Pain Inventory/pain intensity scale > 4 points), with more than three months of evolution and current diagnostic criteria for major depression episode (DSM-IV).\\n\\nSample: A total sample of 330 patients (165 control arm and 165 intervention arm) divided into 42 clusters of 8 patients. Cluster composition: patients registered with the same doctor.\\n\\nIntervention: Structured program with integrated management for depression/ pain with three main components:\\n\\nOptimized care of major depression,\\nCase Management, and\\nGroup psychoeducational intervention.\\n\\nMeasurements: \"Blind\" interviews at 0, 3, 6 and 12 months.\\n\\nMain outcomes:\\n\\nDepressive symptoms (Hopkins Symptom Checklist-20): Severity, response rate and remission rate.\\nPain symptoms (Brief Pain Inventory). Intensity and interference, response rate.\\nDisability by psychological problems (Sheehan Disability Inventory)\\nQuality of life related to health (EuroQol-5D).'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depressive Disorder',\n",
       "         'Musculoskeletal Pain',\n",
       "         'Chronic Pain']},\n",
       "       'KeywordList': {'Keyword': ['Primary Health Care, Patient Education, Care Managament']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '330',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Clinical program for pain and depression',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Structured program with integrated management for depression and chronic musculoskeletal pain with three main components: 1) Optimized care of major depression on the basis of a Clinical Guideline 2) Care Management, and 3) Group psychoeducational intervention.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Clinical program for pain and depression']}},\n",
       "         {'ArmGroupLabel': 'Control',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Care as usual',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Control']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Clinical program for pain and depression',\n",
       "          'InterventionDescription': 'Already described',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Clinical program for pain and depression']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['DROP Program (Depression and Pain)']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Control',\n",
       "          'InterventionDescription': 'Care as usual',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression severity',\n",
       "          'PrimaryOutcomeDescription': 'Hopkins Symptoms Checklist-Depression HSCL-20',\n",
       "          'PrimaryOutcomeTimeFrame': '12 months'},\n",
       "         {'PrimaryOutcomeMeasure': 'Pain severity',\n",
       "          'PrimaryOutcomeDescription': 'Brief Pain Inventory BPI',\n",
       "          'PrimaryOutcomeTimeFrame': '12 months'},\n",
       "         {'PrimaryOutcomeMeasure': 'Health Related Quality of Life',\n",
       "          'PrimaryOutcomeDescription': 'EuroQol-5D',\n",
       "          'PrimaryOutcomeTimeFrame': '12 months'},\n",
       "         {'PrimaryOutcomeMeasure': 'Pain Interference',\n",
       "          'PrimaryOutcomeDescription': 'Brief Pain Inventory BPI',\n",
       "          'PrimaryOutcomeTimeFrame': '12 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depression severity',\n",
       "          'SecondaryOutcomeDescription': 'Hopkins Symptoms Checklist-Depression HSCL-20',\n",
       "          'SecondaryOutcomeTimeFrame': '3 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Depression severity',\n",
       "          'SecondaryOutcomeDescription': 'Hopkins Symptoms Checklist-Depression HSCL-20',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Pain severity',\n",
       "          'SecondaryOutcomeDescription': 'Brief Pain Inventory BPI',\n",
       "          'SecondaryOutcomeTimeFrame': '3 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Pain severity',\n",
       "          'SecondaryOutcomeDescription': 'Brief Pain Inventory BPI',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Health Related Quality of Life',\n",
       "          'SecondaryOutcomeDescription': 'EuroQol-5D',\n",
       "          'SecondaryOutcomeTimeFrame': '3 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Health Related Quality of Life',\n",
       "          'SecondaryOutcomeDescription': 'EuroQol-5D',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Pain Interference',\n",
       "          'SecondaryOutcomeDescription': 'Brief Pain Inventory BPI',\n",
       "          'SecondaryOutcomeTimeFrame': '3 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Pain Interference',\n",
       "          'SecondaryOutcomeDescription': 'Brief Pain Inventory BPI',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nRegistered patient of a participant doctor\\nChronic musculoskeletal pain moderate to severe (BPI>4), with more than 3 months of duration despite having received analgesic treatment\\nMeeting the diagnostic criteria for major depression (DSM IV) at the time of recruitment.\\n\\nExclusion Criteria:\\n\\nPatients with mental, physical, language limitation or concurrent illness that prevents understanding/participation in the assessments of the study.\\nPatients with serious or terminal illness.\\nPatients whit psychotic disorder, bipolar disorder or dependence disorder.\\nPregnant or lactating patient\\nPatients diagnosed of fibromyalgia or somatization disorder\\nPatient in a process of claim for a work disability\\nIntervention for a joint prothesis planned forn next 12 months.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '80 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Enric Aragonès, MD, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '0034680766923',\n",
       "          'CentralContactEMail': 'earagones.tarte.ics@gencat.cat'},\n",
       "         {'CentralContactName': 'Germán López-Cortacans, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '0034627392500',\n",
       "          'CentralContactEMail': 'glopez.tarte.ics@gencat.cat'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Enric Aragonès, MD PhD',\n",
       "          'OverallOfficialAffiliation': 'IDIAP Jordi Gol',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'IDIAP Jordi Gol',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Barcelona',\n",
       "          'LocationZip': '08080',\n",
       "          'LocationCountry': 'Spain',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Mariona Pujol, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '003493 482 46 17',\n",
       "             'LocationContactEMail': 'mpujol@idiapjgol.org'}]}}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '30986737',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Aragonès E, Rambla C, López-Cortacans G, Tomé-Pires C, Sánchez-Rodríguez E, Caballero A, Miró J. Effectiveness of a collaborative care intervention for managing major depression and chronic musculoskeletal pain in primary care: A cluster-randomised controlled trial. J Affect Disord. 2019 Jun 1;252:221-229. doi: 10.1016/j.jad.2019.04.004. Epub 2019 Apr 8.'},\n",
       "         {'ReferencePMID': '27236335',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Aragonès E, López-Cortacans G, Caballero A, Piñol JL, Sánchez-Rodríguez E, Rambla C, Tomé-Pires C, Miró J. Evaluation of a multicomponent programme for the management of musculoskeletal pain and depression in primary care: a cluster-randomised clinical trial (the DROP study). BMC Psychiatry. 2016 Mar 16;16:69. doi: 10.1186/s12888-016-0772-2.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000059352',\n",
       "          'ConditionMeshTerm': 'Musculoskeletal Pain'},\n",
       "         {'ConditionMeshId': 'D000059350',\n",
       "          'ConditionMeshTerm': 'Chronic Pain'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000010146',\n",
       "          'ConditionAncestorTerm': 'Pain'},\n",
       "         {'ConditionAncestorId': 'D000009461',\n",
       "          'ConditionAncestorTerm': 'Neurologic Manifestations'},\n",
       "         {'ConditionAncestorId': 'D000012816',\n",
       "          'ConditionAncestorTerm': 'Signs and Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000009135',\n",
       "          'ConditionAncestorTerm': 'Muscular Diseases'},\n",
       "         {'ConditionAncestorId': 'D000009140',\n",
       "          'ConditionAncestorTerm': 'Musculoskeletal Diseases'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M28029',\n",
       "          'ConditionBrowseLeafName': 'Chronic Pain',\n",
       "          'ConditionBrowseLeafAsFound': 'Chronic Pain',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M28031',\n",
       "          'ConditionBrowseLeafName': 'Musculoskeletal Pain',\n",
       "          'ConditionBrowseLeafAsFound': 'Musculoskeletal Pain',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M11649',\n",
       "          'ConditionBrowseLeafName': 'Pain',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M10987',\n",
       "          'ConditionBrowseLeafName': 'Neurologic Manifestations',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M10675',\n",
       "          'ConditionBrowseLeafName': 'Muscular Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M10680',\n",
       "          'ConditionBrowseLeafName': 'Musculoskeletal Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
       "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC05',\n",
       "          'ConditionBrowseBranchName': 'Muscle, Bone, and Cartilage Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC10',\n",
       "          'ConditionBrowseBranchName': 'Nervous System Diseases'}]}}}}},\n",
       "   {'Rank': 56,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02099305',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '1-wilcox'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH095855',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH095855&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'Johns Hopkins University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Randomized, School-based Effectiveness Trial of the Adolescent Depression Awareness Program',\n",
       "       'OfficialTitle': 'Impact of Increasing Adolescent Depression Literacy on Treatment-Seeking Behavior',\n",
       "       'Acronym': 'ADAP'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'September 2012'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'August 2015',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'March 20, 2014',\n",
       "       'StudyFirstSubmitQCDate': 'March 25, 2014',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 28, 2014',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'June 8, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 12, 2017',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Holly C. wilcox',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Associate Professor',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Johns Hopkins University'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Johns Hopkins University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The primary goal of the proposed research is to assess the effectiveness of the Adolescent Depression Awareness Program (ADAP), a school-based depression education program, in increasing depression literacy and treatment seeking in high school students. The ADAP intervention will be carried out in approximately 60 schools with over 15,000 students. The following are ADAP Implementation Sites: Baltimore Archdiocese High Schools; New Castle County, Delaware; Washtenaw County, Michigan; and York County, Pennsylvania.',\n",
       "       'DetailedDescription': 'The primary goal of the proposed research is to assess the effectiveness of the Adolescent Depression Awareness Program (ADAP), a school-based depression education program, in increasing depression literacy and treatment seeking. This proposal will have broad reach as the intervention will be carried out in 66 schools with over 15,000 students.\\n\\nThe lifetime prevalence of Major Depressive Disorder (MDD) in the United States is high, ranging from 15% to 17%. Its usual symptom onset occurs early in life, during teen or young adult years. It has been estimated that 8.5% of youth ages 12 to 17 (over 2 million adolescents) experienced at least one Major Depressive Episode in the past year (SAMHSA Office of Applied Studies, 2008). Nearly half (48.3%) of these youth reported severe impairment in at least one of four major role domains (home, school/work, family relationships, or social life). The onset of depression during adolescence is associated with increased risks for educational underachievement, unemployment, early parenthood, substance dependence, anxiety disorders, and recurrent major depression during early adulthood (Fergusson & Woodward, 2002). The most severe consequence of untreated depression is suicide. Psychological autopsy studies of adolescent suicides have reported that upwards of 90% had at least one psychiatric disorder at the time of their death, most notably depression (Marttunen et al., 1990; Brent et al., 1993; Shaffer et al., 1996). From a developmental perspective, the prevention and treatment of depression during adolescence can provide lifelong benefits. Effective treatments for adolescent depression are available (TADS, 2007); however, adolescents in need of treatment are often not recognized by parents, teachers, or peers. The National Comorbidity Study-Replication estimated a median delay of 8 years between the onset of depressive symptoms and receiving treatment (Wang et al., 2006). The early identification of depression leading to effective treatment can help address the morbidity and mortality associated with adolescent depression.\\n\\nDespite the importance of adolescent depression, there have been few large-scale randomized trials investigating the effectiveness of universal interventions targeting depression among adolescents. ADAP is a 3-hour high school-based curriculum, proposed herein to be delivered as part of the standard high school health education curriculum, aimed at improving depression literacy. The mission of ADAP is to educate high school students, teachers, and parents about teenage unipolar and bipolar depression (Hess et al., 2004). The core message of ADAP is that \"depression is a treatable medical illness.\" ADAP was developed in 1999 by a team of psychiatrists and psychiatric nurses from the Johns Hopkins University School of Medicine. In the past decade, ADAP has been implemented in over 85 schools with over 20,000 students throughout the United States. Previously published research evaluating ADAP described a significant improvement in adolescents\\' knowledge about depression after receiving the curriculum using a one group pretest/posttest design (Swartz et al., 2008). Recently, in Tulsa, Oklahoma, comparison schools were included, and it was found that the proportion of students achieving \"depression literacy\" (scoring 80% or higher on our knowledge assessment) more than tripled from pretest to posttest (Leon et al., in review) in the ADAP group. To date, a randomized design has not been employed and the impact of ADAP on treatment seeking behaviors has not been studied. Both of these issues are important to address before ADAP can be routinely integrated into high school health education curricula. The specific aims of this proposal are as follows:\\n\\nSpecific Aim 1: To assess the effectiveness of ADAP, a school-based depression education program, in increasing depression literacy.\\n\\n1.1 To assess depression literacy changes following the intervention, as compared to the standard health education curriculum, with a post-test at 6 weeks post intervention.\\n\\n1.2 To assess the sustainability of depression literacy changes with a post-test at 4 months post ADAP.\\n\\nSpecific Aim 2: To assess whether the ADAP intervention, as compared to the standard health curriculum, has an influence on treatment seeking behaviors in high school students, as measured by an increase in visits to school counselors and self-reported treatment seeking.\\n\\n2.1 To track mental health help-seeking and the receipt of mental health services pre and post ADAP in a subset of schools (28 schools in York County Pennsylvania and St. Francis Indian School on the Rosebud Indian Reservation served by the Indian Health Service).\\n\\n2.2 To track mental health visits to school counselors in aggregate pre and post ADAP in all 66 participating schools.\\n\\nSpecific Aim 3: To identify possible mediators (e.g., fidelity) and moderators of intervention impact (e.g., access to community mental health services, teacher characteristics, school characteristics, parental participation in the community forum; stigma).'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Adolescent - Emotional Problem',\n",
       "         'Depression',\n",
       "         'Prevention Harmful Effects']},\n",
       "       'KeywordList': {'Keyword': ['Adolescent; Depression',\n",
       "         'Early intervention (education)',\n",
       "         'Randomized Controlled Trial',\n",
       "         'Primary Prevention',\n",
       "         'schools',\n",
       "         'Health Literacy',\n",
       "         'Discrimination (Psychology)',\n",
       "         'Mental Health Services']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Factorial Assignment',\n",
       "        'DesignPrimaryPurpose': 'Prevention',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '17000',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Receive Adolescent Depression Awareness Program (ADAP) intervention',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Adolescent Depression Awareness Program (ADAP)']}},\n",
       "         {'ArmGroupLabel': 'Wait list control',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'no intervention'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Adolescent Depression Awareness Program (ADAP)',\n",
       "          'InterventionDescription': 'Depression education curriculum delivered by trained school health education teachers or other school personnel',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['ADAP']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Adolescent Depression Knowledge Questionnaire (ADKQ)',\n",
       "          'PrimaryOutcomeDescription': 'The Adolescent Depression Knowledge Questionnaire (ADKQ) will be used to assess depression literacy',\n",
       "          'PrimaryOutcomeTimeFrame': 'Change from pretest (directly before intervention) to post-test (6 weeks after ADAP). We will see if this is sustained 4 months after ADAP.'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Reported and Intended Behaviour Scale (RIBS)',\n",
       "          'SecondaryOutcomeDescription': 'The Reported and Intended Behaviour Scale (RIBS) will be used to assess mental health stigma.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Change from pretest (directly before intervention) to post-test (6 weeks after ADAP). We will see if this is sustained 4 months after ADAP.'}]},\n",
       "       'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Help-seeking and the receipt of Mental Health Services',\n",
       "          'OtherOutcomeDescription': 'We have designed a web-based survey in RedCAP to assess help-seeking and the receipt of Mental Health Services, barriers and attitudes, and other issues among students in York County, Pennsylvania with parental consent.',\n",
       "          'OtherOutcomeTimeFrame': 'after the ADAP intervention'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nenrolled in one of the participating schools parental consent and student assent is required for the web-based survey\\n\\nExclusion Criteria:\\n\\nnot enrolled in the participating schools',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '12 Years',\n",
       "       'MaximumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child', 'Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Holly C. Wilcox, PhD',\n",
       "          'OverallOfficialAffiliation': 'Associate Professor, Johns Hopkins School of Medicine',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Karen Swartz, MD',\n",
       "          'OverallOfficialAffiliation': 'Johns Hopkins School of Medicine',\n",
       "          'OverallOfficialRole': 'Study Chair'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Johns Hopkins University',\n",
       "          'LocationCity': 'Baltimore',\n",
       "          'LocationState': 'Maryland',\n",
       "          'LocationZip': '21205',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Johns Hopkins',\n",
       "          'LocationCity': 'Baltimore',\n",
       "          'LocationState': 'Maryland',\n",
       "          'LocationZip': '21205',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '23790814',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Ruble AE, Leon PJ, Gilley-Hensley L, Hess SG, Swartz KL. Depression knowledge in high school students: effectiveness of the adolescent depression awareness program. J Affect Disord. 2013 Sep 25;150(3):1025-30. doi: 10.1016/j.jad.2013.05.033. Epub 2013 Jun 18.'},\n",
       "         {'ReferencePMID': '17652614',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Swartz KL, Kastelic EA, Hess SG, Cox TS, Gonzales LC, Mink SP, DePaulo JR Jr. The effectiveness of a school-based adolescent depression education program. Health Educ Behav. 2010 Feb;37(1):11-22. Epub 2007 Jul 25.'},\n",
       "         {'ReferencePMID': '15625662',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': \"Hess SG, Cox TS, Gonzales LC, Kastelic EA, Mink SP, Rose LE, Swartz KL. A survey of adolescents' knowledge about depression. Arch Psychiatr Nurs. 2004 Dec;18(6):228-34.\"},\n",
       "         {'ReferencePMID': '30612807',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Townsend L, Musci R, Stuart E, Heley K, Beaudry MB, Schweizer B, Ruble A, Swartz K, Wilcox H. Gender Differences in Depression Literacy and Stigma After a Randomized Controlled Evaluation of a Universal Depression Education Program. J Adolesc Health. 2019 Apr;64(4):472-477. doi: 10.1016/j.jadohealth.2018.10.298. Epub 2019 Jan 4.'},\n",
       "         {'ReferencePMID': '29048969',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Swartz K, Musci RJ, Beaudry MB, Heley K, Miller L, Alfes C, Townsend L, Thornicroft G, Wilcox HC. School-Based Curriculum to Improve Depression Literacy Among US Secondary School Students: A Randomized Effectiveness Trial. Am J Public Health. 2017 Dec;107(12):1970-1976. doi: 10.2105/AJPH.2017.304088. Epub 2017 Oct 19.'}]},\n",
       "       'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Adolescent Depression Awareness Program (ADAP) website',\n",
       "          'SeeAlsoLinkURL': 'http://www.hopkinsmedicine.org/psychiatry/specialty_areas/moods/ADAP/'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 57,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01790919',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'R34MH094535-01A1',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH094535-01A1&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R34MH094535-01A1',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH094535-01A1&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'University of California, Berkeley',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Improving Depression Outcome by Enhancing Memory for Cognitive Therapy',\n",
       "       'OfficialTitle': 'Improving Depression Outcome by Enhancing Memory for Cognitive Therapy'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'September 2015',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'February 2013'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'March 2015',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'February 6, 2013',\n",
       "       'StudyFirstSubmitQCDate': 'February 12, 2013',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 13, 2013',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'September 16, 2015',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 17, 2015',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Allison Harvey',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Professor of Clinical Psychology',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of California, Berkeley'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of California, Berkeley',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'},\n",
       "         {'CollaboratorName': 'Vanderbilt University',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Existing drug and talking therapies for major depressive disorder (MDD) fail to produce complete recovery. This study will determine if substantial improvements to one of the most promising therapies, cognitive therapy (CT), can be achieved by administering a carefully designed procedure to improve memory for the content of CT sessions. This is important because (a) memory deficits are common in MDD patients and (b) each CT therapy session typically covers a complex array of topics and various skills are taught.',\n",
       "       'DetailedDescription': 'Background. Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders and a leading cause of disability worldwide. Existing therapies fail to produce complete recovery. Progress toward improving outcome must include innovations that are safe, powerful, inexpensive and simple (for fast and effective dissemination). The proposed research seeks to test one such innovation. We seek to improve outcome by improving memory for the content of cognitive therapy (CT) sessions. CT is one of the most promising approaches to the treatment of MDD, yet there is room for improvement.\\n\\nWe believe that adding memory enhancing strategies to CT may improve MDD outcome because: (a) MDD is often characterized by memory impairment, (b) there is evidence that the memory impairment is modifiable, (c) CT typically entails the activation of emotion, (d) emotion can impair or bias memory and (e) there is evidence that memory for the content of therapy sessions is poor.\\n\\nAim. To evaluate if a strategy designed to enhance memory for the content of CT sessions improves treatment outcome for MDD. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory. It is hypothesized that CT+Cognitive Support, relative to CT-as-usual, will be associated with improved depression outcome at the end of treatment and 6 months after the completion of treatment.\\n\\nResearch Plan. A small pilot feasibility RCT will be conducted on adults with MDD (n = 48) who will be randomized to one of two groups: (a) CT+Cognitive Support (n = 24) or (b) CT-as-usual (n = 24). Outcome measures will be taken at baseline, end of treatment, and 6 months after treatment. Long-term objective. To provide the pilot data needed to prepare a larger scale intervention study focused on improving outcomes by improving memory for the content of therapy sessions. The outcomes, if positive, will have major public health implications because simple, inexpensive memory enhancing strategies can be readily included as a standard feature in all psychosocial treatments for a broad range of mental illness. Project'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Major Depressive Disorder (MDD)']},\n",
       "       'KeywordList': {'Keyword': ['Depression, Adults']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 2']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '48',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cognitive Therapy plus Cognitive Support',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Cognitive therapy for depression with cognitive support added',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive therapy for depression']}},\n",
       "         {'ArmGroupLabel': 'Cognitive therapy',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Cognitive therapy for depression',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive therapy for depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Cognitive therapy for depression',\n",
       "          'InterventionDescription': 'Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.\\n\\nCognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cognitive Therapy plus Cognitive Support',\n",
       "            'Cognitive therapy']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Inventory of Depressive Symptomatology, Self Report (IDS-SR)',\n",
       "          'PrimaryOutcomeDescription': 'Primary mood outcome',\n",
       "          'PrimaryOutcomeTimeFrame': 'Change in IDS scores from pre-treatment to post-treatment (defined as within 2 weeks of completing the course of treatment, which is 14 sessions) to 6-month followup'},\n",
       "         {'PrimaryOutcomeMeasure': 'Global Assessment of Functioning (GAF)',\n",
       "          'PrimaryOutcomeDescription': 'Primary impairment outcome',\n",
       "          'PrimaryOutcomeTimeFrame': 'Change in GAF scores from pre-treatment to post-treatment (defined as within 2 weeks of completing the course of treatment, which is 14 sessions) to 6-month followup'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Structured Clinical Interview for DSM-IV (SCID)',\n",
       "          'SecondaryOutcomeDescription': 'To determine the presence or absence of current DSM-IV-TR defined episodes of depression',\n",
       "          'SecondaryOutcomeTimeFrame': 'Pre-treatment; Within 2 weeks of completing the course of treatment (14 sessions); 6 month followup'},\n",
       "         {'SecondaryOutcomeMeasure': 'Longitudinal Interval Follow-up Evaluation (LIFE)',\n",
       "          'SecondaryOutcomeDescription': 'Time to relapse or recurrence',\n",
       "          'SecondaryOutcomeTimeFrame': 'Pre-treatment; within 2 weeks of completing the course of treatment (14 sessions); 6-month followup'},\n",
       "         {'SecondaryOutcomeMeasure': 'ACNP defined Response, Remission, Relapse, Recurrence using the IDS, SCID and LIFE',\n",
       "          'SecondaryOutcomeTimeFrame': 'Pre-treatment; within 2 weeks of completing the course of treatment (14 sessions); 6-month followup'}]},\n",
       "       'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Memory Support Rating Scale (MSRS).',\n",
       "          'OtherOutcomeDescription': 'This is a measure of the use of memory support by treatment providers.',\n",
       "          'OtherOutcomeTimeFrame': 'All patients receive 14 sessions of cognitive therapy for depression. The treatment sessions are video taped. A random subset of 20% of the tapes are selected for MSRS scoring. Average MSRS scores will be compared across the 2 groups.'},\n",
       "         {'OtherOutcomeMeasure': 'Patient Recall Task.',\n",
       "          'OtherOutcomeDescription': \"This is a measure of the content of treatment that patient's remember\",\n",
       "          'OtherOutcomeTimeFrame': 'Completed at the end of Session 7, 14 and at 6 month FU. Patient Recall Task scores will be compared across the two treatment arms and over the three assessment points.'},\n",
       "         {'OtherOutcomeMeasure': 'National Adult Reading Test (NART).',\n",
       "          'OtherOutcomeDescription': 'Estimate of IQ. Used to determine if IQ is a moderator of treatment.',\n",
       "          'OtherOutcomeTimeFrame': 'This measure is taken at baseline (pre-treatment) and will be compared across the two treatment arms'},\n",
       "         {'OtherOutcomeMeasure': 'Episodic Face Naming Task.',\n",
       "          'OtherOutcomeDescription': 'Measure of declarative memory. used to determine if baseline memory is a moderator of treatment outcome.',\n",
       "          'OtherOutcomeTimeFrame': 'This measure is taken at baseline (pre-treatment) and will be compared across the two treatment arms'},\n",
       "         {'OtherOutcomeMeasure': 'Cognitive Therapy Rating Scale (CTRS)',\n",
       "          'OtherOutcomeDescription': 'Measure of the quality of cognitive therapy',\n",
       "          'OtherOutcomeTimeFrame': 'CTRS coding will be conducted on randomly selected recordings of treatment sessions. Average CTRS scores will be compared across the two treatment arms'},\n",
       "         {'OtherOutcomeMeasure': 'Credibility/Expectancy Questionnaire (CEQ)',\n",
       "          'OtherOutcomeDescription': 'A measure of treatment expectancies',\n",
       "          'OtherOutcomeTimeFrame': 'The CEQ scores, measured at the end of the first therapy session, will be compared across the two treatment arms'},\n",
       "         {'OtherOutcomeMeasure': 'Demographics form',\n",
       "          'OtherOutcomeDescription': 'Assesses demographics including age, years of education and chronicity of depression that are used in moderator analysis',\n",
       "          'OtherOutcomeTimeFrame': 'This measure is taken at baseline (pre-treatment) and will be compared across the two treatment arms'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ndiagnosis of major depressive disorder (MDD), first episode, recurrent or chronic, according to DSM-IV-TR criteria\\nscore of 24 or above on the Inventory of Depressive Symptomatology (IDS)-Clinician and 26 or above on the IDS-Self-report\\nolder than 18 years of age\\nif taking medications for mood, medications must be stable for the past 4 weeks\\nable and willing to give informed consent\\n\\nExclusion Criteria:\\n\\nhistory of bipolar disorder\\nhistory of psychosis (including schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, or psychotic organic brain syndrome)\\ncurrent non-psychotic Axis I disorder if it constitutes the principal diagnosis and if it requires treatment other than that offered in the project (including anxiety disorders including active PTSD, somatoform disorders, dissociative disorders, or eating disorders, etc.)\\nhistory of substance dependence in the past six months\\nIQ below 80\\nevidence of any medical disorder or condition that could cause depression or preclude participation in CT\\ncurrent suicide risk sufficient to preclude treatment on an outpatient basis',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'University of California, Berkeley',\n",
       "          'LocationCity': 'Berkeley',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '94720',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '29137655',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Harvey AG, Dong L, Lee JY, Gumport NB, Hollon SD, Rabe-Hesketh S, Hein K, Haman K, McNamara ME, Weaver C, Martinez A, Notsu H, Zieve G, Armstrong CC. Can integrating the Memory Support Intervention into cognitive therapy improve depression outcome? Study protocol for a randomized controlled trial. Trials. 2017 Nov 14;18(1):539. doi: 10.1186/s13063-017-2276-x.'},\n",
       "         {'ReferencePMID': '27089159',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Harvey AG, Lee J, Smith RL, Gumport NB, Hollon SD, Rabe-Hesketh S, Hein K, Dolsen MR, Haman KL, Kanady JC, Thompson MA, Abrons D. Improving outcome for mental disorders by enhancing memory for treatment. Behav Res Ther. 2016 Jun;81:35-46. doi: 10.1016/j.brat.2016.03.007. Epub 2016 Apr 2.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000003865',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder, Major'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafAsFound': 'Major Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 58,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02521012',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'DepFuDKUH5703453'},\n",
       "       'Organization': {'OrgFullName': 'Kuopio University Hospital',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Follow-up Study With Clinical Vitamin D Supplementation Trial on Patients With Depression (DepFuD)',\n",
       "       'OfficialTitle': 'Follow-up Study With Randomized Clinical Vitamin D Supplementation Trial on Patients With Depression (DepFuD)',\n",
       "       'Acronym': 'DepFuD'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'August 2019',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'November 2015',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2020',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'October 2025',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'August 4, 2015',\n",
       "       'StudyFirstSubmitQCDate': 'August 11, 2015',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 13, 2015',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'August 29, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 30, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Heimo Viinamaki',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Professor, Head of Department of Psychiatry',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Kuopio University Hospital'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Kuopio University Hospital',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': \"Depression affects 350 million people worldwide. In the light of the global disease burden statistics, the efficacy of current treatments for depression appears insufficient. Thus, research on novel treatment interventions and predictors for good treatment response are warranted. Earlier prospective follow-up studies and intervention studies suggest that several bio-psychosocial factors, including high serum concentrations of vitamin D, are related to better treatment outcomes. In this follow-up study with randomized clinical vitamin D supplementation trial on patients with depression, the investigators aim to\\n\\nclarify how a six-month intervention with vitamin D supplementation affects treatment response, recovery, and the biological pathways related to depression. This aims to finding potential sub-groups getting benefits from vitamin D supplementation. In addition, the investigators want to\\ninvestigate and characterize factors related to recovery from depression and working ability in depression patients in the long-term. The investigators are especially interested in the bio-psychosocial factors and the aims include examining both the individual's positive resources.\\n\\nThe trial will start with a six-month double-blinded randomized controlled trial with vitamin D supplementation. The aim is to recruit altogether 3028 patients with non-psychotic, unipolar depression, aged 18-65 years, who are referred to the recruitment sites for treatment for depression. The participants will be randomized to low (10 µg/day) or high (100 µg/day) vitamin D supplementation group. Clinically necessary antidepressant treatments will continue during the intervention as needed. After six months of intervention, the participants will be followed up at 18 months and at 5 years.\\n\\nSeveral measurements will be conducted during the intervention and follow-up period. Participants will fill a variety of clinical questionnaires and questionnaires with background information. All participants give blood samples for biomarker analyses at time points 3, 6, 18 months and 5 years. Clinical interviews of mental disorders (e.g. SCID) and anthropometric measurements (e.g. weight, height, blood pressure) will be carried out.\",\n",
       "       'DetailedDescription': \"Depression affects 350 million people worldwide. In the light of the global disease burden statistics, the efficacy of current treatments for depression appears insufficient. Thus, research on novel treatment interventions and predictors for good treatment response are warranted. Earlier prospective follow-up studies and intervention studies suggest that several bio-psychosocial factors, including high serum concentrations of vitamin D, are related to better treatment outcomes.\\n\\nIn this follow-up study with randomized clinical vitamin D supplementation trial on patients with depression, the investigators aim to\\n\\nclarify how a six-month intervention with vitamin D supplementation affects treatment response, recovery, and the biological pathways related to depression. This aims to finding potential sub-groups getting benefits from vitamin D supplementation. In addition, the investigators want to\\ninvestigate and characterize factors related to recovery from depression and working ability in depression patients in the long-term. The investigators are especially interested in the bio-psychosocial factors and the aims include examining both the individual's positive resources.\\n\\nThe trial will start with a six-month double-blinded randomized controlled trial with vitamin D supplementation. The aim is to recruit altogether 3028 patients with non-psychotic, unipolar depression, aged 18-65 years, who are referred to the recruitment sites for treatment for depression. The participants will be randomized to low (10 µg/day) or high (100 µg/day) vitamin D supplementation group. Clinically necessary antidepressant treatments will continue during the intervention as needed. After six months of intervention, the participants will be followed up at 18 months and at 5 years.\\n\\nSeveral measurements will be conducted during the intervention and follow-up period. Participants will fill a variety of clinical questionnaires and questionnaires with background information. All participants give blood samples for biomarker analyses at time points 3, 6, 18 months and 5 years. Clinical interviews of mental disorders (e.g. SCID) and anthropometric measurements (e.g. weight, height, blood pressure) will be carried out.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression',\n",
       "         'Depressive Disorder']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Depressive symptoms',\n",
       "         'Vitamin D',\n",
       "         'Intervention']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Quadruple',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Care Provider',\n",
       "           'Investigator',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '3028',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Vitamin D 10 micrograms',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Vitamin D supplementation 10 micrograms/day given to depressed individuals, defined as \"reference\"',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Vitamin D 10 micrograms']}},\n",
       "         {'ArmGroupLabel': 'Vitamin D 100 micrograms',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Vitamin D supplementation 100 micrograms/day given to depressed individuals',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Vitamin D 100 micrograms']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement',\n",
       "          'InterventionName': 'Vitamin D 10 micrograms',\n",
       "          'InterventionDescription': 'Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Vitamin D 10 micrograms']}},\n",
       "         {'InterventionType': 'Dietary Supplement',\n",
       "          'InterventionName': 'Vitamin D 100 micrograms',\n",
       "          'InterventionDescription': 'Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Vitamin D 100 micrograms']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores',\n",
       "          'PrimaryOutcomeDescription': 'We are interviewing the patients with depression with MADRS, which has been found to be a practical tool for assessing depressive symptoms in clinical trials. We are especially interest to see the change in scores during the intervention.',\n",
       "          'PrimaryOutcomeTimeFrame': '0, 3 and 6 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Beck Depression Inventory (BDI) scores',\n",
       "          'SecondaryOutcomeDescription': 'Participants fill a 21-item Beck Depression Inventory questionnaire and total scores will be calculated. We are especially interested to see if the total scores changes during the intervention.',\n",
       "          'SecondaryOutcomeTimeFrame': '0, 3, 6, 18 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\npatients referred to the recruitment sites for treatment for depression\\nmild, moderate or severe depression,\\nmild, moderate or severe episode of recurrent depression\\n\\nExclusion Criteria:\\n\\nbipolar or psychotic depression\\npsychotic disorder\\nsevere substance abuse\\ndisabilities in senses that affect functioning and severely threat completing the trial\\ndiseases that affect vitamin D metabolism (such as sarcoidosis, hypercalcemia, hypofunction of kidney)\\npregnancy or lactation\\ncurrent use of high dose vitamin D supplementation\\ncurrent use of high dose calcium supplementation',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Heimo Viinamäki, Professor',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactEMail': 'heimo.viinamaki@kuh.fi'},\n",
       "         {'CentralContactName': 'Anu Ruusunen, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactEMail': 'anu.ruusunen@kuh.fi'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Heimo Viinamaki, Professor',\n",
       "          'OverallOfficialAffiliation': 'Professor, Head of Department',\n",
       "          'OverallOfficialRole': 'Study Chair'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Kuopio University Hospital, Department of Psychiatry',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Kuopio',\n",
       "          'LocationCountry': 'Finland',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ritva Von Koch',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '+358447174766',\n",
       "             'LocationContactEMail': 'ritva.vonkoch@kuh.fi'}]}}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000014807',\n",
       "          'InterventionMeshTerm': 'Vitamin D'},\n",
       "         {'InterventionMeshId': 'D000004872',\n",
       "          'InterventionMeshTerm': 'Ergocalciferols'},\n",
       "         {'InterventionMeshId': 'D000014815',\n",
       "          'InterventionMeshTerm': 'Vitamins'}]},\n",
       "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000018977',\n",
       "          'InterventionAncestorTerm': 'Micronutrients'},\n",
       "         {'InterventionAncestorId': 'D000078622',\n",
       "          'InterventionAncestorTerm': 'Nutrients'},\n",
       "         {'InterventionAncestorId': 'D000006133',\n",
       "          'InterventionAncestorTerm': 'Growth Substances'},\n",
       "         {'InterventionAncestorId': 'D000045505',\n",
       "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'},\n",
       "         {'InterventionAncestorId': 'D000050071',\n",
       "          'InterventionAncestorTerm': 'Bone Density Conservation Agents'},\n",
       "         {'InterventionAncestorId': 'D000077264',\n",
       "          'InterventionAncestorTerm': 'Calcium-Regulating Hormones and Agents'}]},\n",
       "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16133',\n",
       "          'InterventionBrowseLeafName': 'Vitamin D',\n",
       "          'InterventionBrowseLeafAsFound': 'Vitamin D',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M16141',\n",
       "          'InterventionBrowseLeafName': 'Vitamins',\n",
       "          'InterventionBrowseLeafAsFound': 'Vitamin',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M6609',\n",
       "          'InterventionBrowseLeafName': 'Ergocalciferols',\n",
       "          'InterventionBrowseLeafAsFound': 'Vitamin D',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M15468',\n",
       "          'InterventionBrowseLeafName': 'Trace Elements',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19593',\n",
       "          'InterventionBrowseLeafName': 'Micronutrients',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M1986',\n",
       "          'InterventionBrowseLeafName': 'Nutrients',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M3963',\n",
       "          'InterventionBrowseLeafName': 'Calcium',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M3980',\n",
       "          'InterventionBrowseLeafName': 'Calcium, Dietary',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M8372',\n",
       "          'InterventionBrowseLeafName': 'Hormones',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'T440',\n",
       "          'InterventionBrowseLeafName': 'Calciferol',\n",
       "          'InterventionBrowseLeafAsFound': 'Vitamin D',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'T445',\n",
       "          'InterventionBrowseLeafName': 'Ergocalciferol',\n",
       "          'InterventionBrowseLeafAsFound': 'Vitamin D',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'T478',\n",
       "          'InterventionBrowseLeafName': 'Vitamin D2',\n",
       "          'InterventionBrowseLeafAsFound': 'Vitamin D',\n",
       "          'InterventionBrowseLeafRelevance': 'high'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'BDCA',\n",
       "          'InterventionBrowseBranchName': 'Bone Density Conservation Agents'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'Micro',\n",
       "          'InterventionBrowseBranchName': 'Micronutrients'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'Vi',\n",
       "          'InterventionBrowseBranchName': 'Vitamins'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 59,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02069912',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'USCIRB-HS-06-00420'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'CA Health Care Foundation',\n",
       "          'SecondaryIdType': 'Other Grant/Funding Number',\n",
       "          'SecondaryIdDomain': 'California Health Care Foundation'}]},\n",
       "       'Organization': {'OrgFullName': 'University of Southern California',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Multifaceted Depression and Cardiovascular Program',\n",
       "       'OfficialTitle': 'Multifaceted Depression and Cardiovascular Program for Low-Income Patients',\n",
       "       'Acronym': 'MDCP'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'February 2014',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'November 2006'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2009',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'February 2009',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'February 20, 2014',\n",
       "       'StudyFirstSubmitQCDate': 'February 20, 2014',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 24, 2014',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'February 20, 2014',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 24, 2014',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Kathleen R. Ell',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Southern California'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Southern California',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Los Angeles County Department of Public Health',\n",
       "          'CollaboratorClass': 'OTHER_GOV'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Implement an evidence-based structured care approach that includes screening; acute treatment and relapse prevention follow-up tailored for public sector clinics and low-income and minority patients.\\nAdapt an evidence-based collaborative care model for primary care, implement the adapted model, evaluate and further refine the model based on the pilot experience, and produce and disseminate a detailed manual for use in public sector clinics.\\nEvaluate Multifaceted Depression and Cardiovascular Program (MDCP) in an open trial to determine: its acceptance by patients, medical providers, and organizational decision-makers; patient depression treatment adherence; its direct cost; and the size and variability of change from baseline in the primary outcome measures: depressive symptoms, functional status, quality of life, health service use, and cardiac status at 6 and 12 month follow-up.',\n",
       "       'DetailedDescription': \"The pilot open trial was conducted to evaluate the effectiveness of a health services quality improvement intervention, Multifaceted Depression and Cardiovascular Program (MDCP), on reduction of major depressive disorder, adherence to recommended cardiac exercise and diet self-care regimens and appointment keeping, blood pressure and low density lipid levels, functional status, quality of life and use of health services among low-income, predominantly Hispanic adults with congestive heart failure (CHF) or other cardiac disease such as coronary artery disease (CAD) in public sector community-based primary care clinics. The study was based on key observations from recent studies: 1) Patients with cardiac conditions are more likely to experience clinically significant depressive symptoms than the general population, with depression being associated with poor cardiac outcomes; 2) depression rates are high among Hispanics with chronic illness; 3) Minority patients are less likely to receive care for depression, but benefit with culturally appropriate care enhancements; and 4) depression co-morbid with cardiac conditions is likely to be persistent. Low-income patient needs, depression illness characteristics, and public care system resources call for a multifaceted, collaborative chronic disease management model of depression care. MDCP is aimed at positively affecting depression and cardiac outcomes by reducing known patient, provider, and system barriers to care.\\n\\nParticipation in this study will last 12 months. All participants will first undergo baseline assessments that will include a 40-minute interview about personal health and feelings. All study participants will receive collaborative depression care management. They will first be provided with information about depression treatment. Participants will then have the option of choosing between two depression treatments: counseling or antidepressant medications. Participants who choose to receive treatment with counseling will receive eight weekly 45-minute counseling sessions, conducted either on the phone or at the clinic. During these sessions, participants will undergo structured problem solving therapy (PST) and will learn strategies to manage their depressive symptoms. Participants who choose to receive treatment with antidepressant medication will be prescribed medication by a study doctor and will be monitored for any side effects throughout treatment. Medication treatment may last up to 12 months but will depend upon participants' severity of depression. After completing medication treatment, participants will be offered PST counseling. All study participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring.\\n\\nAll participants will undergo follow-up phone interviews about their status at months 6 and 12.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression',\n",
       "         'Depressive Disorder',\n",
       "         'Behavioral Symptoms',\n",
       "         'Mood Disorders']},\n",
       "       'KeywordList': {'Keyword': ['Major Depression',\n",
       "         'Heart Disease',\n",
       "         'Hispanics',\n",
       "         'Collaborative Depression Care Management']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '108',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Collaborative depression care',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'All enrolled patients will receive collaborative depression care management.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Collaborative depression care management']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Collaborative depression care management',\n",
       "          'InterventionDescription': \"Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Collaborative depression care']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depressive symptoms reduction',\n",
       "          'PrimaryOutcomeDescription': 'Achieve minimum a 50% reduction in depressive symptoms from baseline at 6- and 12-month follow-up',\n",
       "          'PrimaryOutcomeTimeFrame': 'Measured at months 6 and 12'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Improvement in quality of life',\n",
       "          'SecondaryOutcomeDescription': 'Change score in quality-of-life 12-item Short-Form Health Survey, Minnesota Living with Heart Failure, Sheehan Disability Scale outcomes',\n",
       "          'SecondaryOutcomeTimeFrame': 'Measured at months 6 and 12'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMeets criteria for clinically significant depression based on a score of ≥ 2 for one of the two cardinal depression symptoms (depressed mood or loss of interest) and a Patient Health Questionnaire-9 total score of ≥ 10\\nPatient with heart disease\\nHas attended Los Angeles County Department of Health Services Comprehensive Health Clinics or the Cardiology Clinic at Los Angeles County+University of Southern California Medical Center\\n\\nExclusion Criteria:\\n\\nCurrent suicidal ideation\\nScore of 8 or greater on the Alcohol Use Disorders Identification Test (AUDIT)\\nRecent use of lithium or antipsychotic medication',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kathleen R Ell, DSW',\n",
       "          'OverallOfficialAffiliation': 'University of Southern California',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'University of Southern California School of Social Work',\n",
       "          'LocationCity': 'Los Angeles',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '90089-0411',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25262042',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Ell K, Oh H, Lee PJ, Guterman J. Collaborative health literate depression care among predominantly Hispanic patients with coronary heart disease in safety net care. Psychosomatics. 2014 Nov-Dec;55(6):555-65. doi: 10.1016/j.psym.2014.03.007. Epub 2014 Mar 26.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000004194',\n",
       "          'ConditionMeshTerm': 'Disease'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000019964',\n",
       "          'ConditionMeshTerm': 'Mood Disorders'},\n",
       "         {'ConditionMeshId': 'D000001526',\n",
       "          'ConditionMeshTerm': 'Behavioral Symptoms'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010335',\n",
       "          'ConditionAncestorTerm': 'Pathologic Processes'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafAsFound': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M8002',\n",
       "          'ConditionBrowseLeafName': 'Heart Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafAsFound': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC14',\n",
       "          'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}},\n",
       "   {'Rank': 60,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00781703',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'PAR-06-039'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH080692',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH080692&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'HealthPartners Institute',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Evaluation of a Natural Experiment to Improve Statewide Depression Care in Minnesota (MN)',\n",
       "       'OfficialTitle': 'DIAMOND Study: Evaluation of a Natural Experiment to Improve Statewide Depression Care in MN',\n",
       "       'Acronym': 'DIAMOND'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2014',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'February 2008'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2012',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'February 2014',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'October 28, 2008',\n",
       "       'StudyFirstSubmitQCDate': 'October 28, 2008',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 29, 2008',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 14, 2014',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 15, 2014',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'HealthPartners Institute',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': \"The study will evaluate a unique natural experiment that aims to transform the primary care of patients with depression. The experiment's aim is to cause statewide implementation of an evidence-based care model for depression by changing the reimbursement system and by using an established regional collaborative (the Institute for Clinical Systems Improvement) to both facilitate the model's widespread use and certify that medical groups have implemented it. Study hypotheses include the following:\\n\\nNewly treated depressed patients in medical groups that have implemented the new reimbursement and facilitation will report receiving higher rates of best care processes than such patients in these medical groups before implementation.\\nRates of best care practices reported to be received by newly treated depressed patients two years after each medical group implements changes will be maintained at least at the rate reported by patients one year post implementation.\\nNewly treated depressed patients in medical groups that have participated in the new reimbursement and facilitation will have greater improvement in depression symptoms and work productivity and lower healthcare costs than such patients in groups before participation.\\nMedical group measures of priority for improving depression care, capability to manage change, and practice systems will be predictive of more patient-reported best care processes, both at one point in time and in change over time.\",\n",
       "       'DetailedDescription': 'The study will use a multiple baseline across settings with staggered implementation to test the effects of changed reimbursement and facilitated organizational change on the use and sustainability of evidenced-based care processes for patients with depression. The study will also test the effect of the care process changes on changes in depression symptoms, healthcare costs, and work productivity.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Major Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '2631',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'DIAMOND Care Model',\n",
       "          'ArmGroupType': 'Other',\n",
       "          'ArmGroupDescription': 'Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the Patient Health Questionnaire-9 (PHQ9), treatment adjustment as indicated, psychiatric consultation, relapse prevention.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: DIAMOND depression care model']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'DIAMOND depression care model',\n",
       "          'InterventionDescription': 'Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['DIAMOND Care Model']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Rates of best care processes',\n",
       "          'PrimaryOutcomeTimeFrame': 'baseline, 6 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Improvement in depression symptoms, work productivity and total healthcare costs',\n",
       "          'SecondaryOutcomeTimeFrame': 'baseline, 3 months, 6 months, 1 year'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nmajor depression\\nPatient Health Questionaire (PHQ-9) > 9\\nprimary care management of depression\\n\\nExclusion Criteria:\\n\\ncomorbid psychiatric conditions',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Leif I Solberg, MD',\n",
       "          'OverallOfficialAffiliation': 'HealthPartners Institute',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 61,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02207582',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'tRNS in depression'},\n",
       "       'Organization': {'OrgFullName': 'University of Regensburg',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Prefrontal Transcranial Random Noise Stimulation in Patients With Depression',\n",
       "       'OfficialTitle': 'Prefrontal Transcranial Random Noise Stimulation in Patients With Depression',\n",
       "       'Acronym': 'tRNS-depr'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'June 2018',\n",
       "       'OverallStatus': 'Terminated',\n",
       "       'WhyStopped': 'no efficacy',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'July 2014'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 14, 2016',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 6, 2016',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'July 31, 2014',\n",
       "       'StudyFirstSubmitQCDate': 'August 1, 2014',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 4, 2014',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'June 14, 2018',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 18, 2018',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Berthold Langguth, MD, Ph.D.',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'MD, PhD',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Regensburg'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Regensburg',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': \"Transcranial random noise stimulation is used to stimulate the prefrontal cortices in patients with depression. It's a placebo-controlled two-arm study.\",\n",
       "       'DetailedDescription': 'Transcranial random noise stimulation (tRNS) is a non-invasive electric stimulation technique of the brain which was shown to be superior effective in contrast to other electric stimulation such as transcranial direct current stimulation (tDCS). These studies investigated mainly healthy controls and specific tasks. Only one case report is available for depression. Here we stimulate patients with depression with tRNS in a placebo-controlled two-arm design. Stimulation will be done as add-on to standard therapy. Electrodes will be applied over both dorsolateral prefrontal cortices which are standard target points of tDCS and also transcranial magnetic stimulation in depression.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['depression; trns']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '44',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Verum Prefrontal tRNS',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': '2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Verum Prefrontal tRNS']}},\n",
       "         {'ArmGroupLabel': 'Placebo Prefrontal tRNS',\n",
       "          'ArmGroupType': 'Placebo Comparator',\n",
       "          'ArmGroupDescription': '2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Placebo Prefrontal tRNS']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
       "          'InterventionName': 'Verum Prefrontal tRNS',\n",
       "          'InterventionDescription': '2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Verum Prefrontal tRNS']}},\n",
       "         {'InterventionType': 'Device',\n",
       "          'InterventionName': 'Placebo Prefrontal tRNS',\n",
       "          'InterventionDescription': '2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo Prefrontal tRNS']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (baseline (-day 3) versus end of treatment (day 19))',\n",
       "          'PrimaryOutcomeDescription': 'Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (baseline (-day 3) versus end of treatment (day 19))',\n",
       "          'PrimaryOutcomeTimeFrame': 'day 3; day 19'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in depression severity measured by the Major Depression Inventory over the course of the trial',\n",
       "          'SecondaryOutcomeDescription': 'Change in depression severity measured by the Major Depression Inventory over the course of the trial',\n",
       "          'SecondaryOutcomeTimeFrame': 'day 10; -day 3; day 5; day 12; day 19; day 75'},\n",
       "         {'SecondaryOutcomeMeasure': 'Number of responders (response = decrease of the Hamilton Depression rating scale for at least 50%) (baseline versus end of treatment)',\n",
       "          'SecondaryOutcomeDescription': 'Number of responders (response = decrease of the Hamilton Depression rating scale for at least 50%) (baseline versus end of treatment)',\n",
       "          'SecondaryOutcomeTimeFrame': 'day 3; day 19'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in the Clinical Global Impression Scale over the course of the trial',\n",
       "          'SecondaryOutcomeDescription': 'Change in the Clinical Global Impression Scale over the course of the trial',\n",
       "          'SecondaryOutcomeTimeFrame': 'day 3; day 5; day 12; day 19; day 75'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in the Beck Depression Inventory over the course of the trial',\n",
       "          'SecondaryOutcomeDescription': 'Change in the Beck Depression Inventory over the course of the trial',\n",
       "          'SecondaryOutcomeTimeFrame': 'day 3; day 5; day 12; day 19; day 75'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in alertness, working memory and divided attention over the course of the trial',\n",
       "          'SecondaryOutcomeDescription': 'Change in alertness, working memory and divided attention over the course of the trial',\n",
       "          'SecondaryOutcomeTimeFrame': 'day 3; day 19; day 75'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nepisode of depression (unipolar or bipolar) ( ICD-10)\\nfemale or male between 18 and 70 years old\\nskills to participate in all study procedures\\n18 or more points in the Hamilton rating scale or depression\\nwritten informed consent\\n\\nExclusion Criteria:\\n\\nclinically relevant unstable internal or neurological comorbidity\\nevidence of significant brain malformations or neoplasm, head injury\\ncerebral vascular events\\nneurodegenerative disorders affecting the brain or prior brain surgery\\nmetal objects in and around body that can not be removed\\npregnancy\\nalcohol or drug abuse\\neczema on the head\\nheart pacemaker\\nhigh dose tranquillizers',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '70 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Berthold Langguth',\n",
       "          'OverallOfficialAffiliation': 'University of Regensburg',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'University of Regensburg',\n",
       "          'LocationCity': 'Regensburg',\n",
       "          'LocationZip': '93053',\n",
       "          'LocationCountry': 'Germany'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 62,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01392963',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'CR-11-021'},\n",
       "       'Organization': {'OrgFullName': 'Seton Healthcare Family',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'The Treatment of Depression With Botulinum Type A Toxin',\n",
       "       'OfficialTitle': 'The Treatment of Depression With Botulinum Type A Toxin (Botox): A Randomized, Double Blind, Crossover Study'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'June 2018',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'July 2011'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2012',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'June 2013',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'July 8, 2011',\n",
       "       'StudyFirstSubmitQCDate': 'July 11, 2011',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 13, 2011',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'October 3, 2017',\n",
       "       'ResultsFirstSubmitQCDate': 'July 23, 2018',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'July 26, 2018',\n",
       "        'ResultsFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'July 23, 2018',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 26, 2018',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Seton Healthcare Family',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "       'IsFDARegulatedDrug': 'Yes',\n",
       "       'IsFDARegulatedDevice': 'No',\n",
       "       'IsUSExport': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'A 24-week Randomized, Double-blind study treating people who suffer from depression who also have moderate to severe frown lines in forehead region with Botox injections. Subjects participating will have their photos taken and complete a questionnaire regarding their depression. They will see a psychiatrist at every visit who will assess their depression.',\n",
       "       'DetailedDescription': 'Participants will be assigned to receive either placebo or botulinum toxin injections in the forehead'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['botox', 'depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 2']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Crossover Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Investigator']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '30',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Botox, Then Placebo',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: botulinum toxin type A neurotoxin complex',\n",
       "            'Drug: Placebo']}},\n",
       "         {'ArmGroupLabel': 'Placebo, Then Botox',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: botulinum toxin type A neurotoxin complex',\n",
       "            'Drug: Placebo']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
       "          'InterventionName': 'botulinum toxin type A neurotoxin complex',\n",
       "          'InterventionDescription': '29-40 U injection',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Botox, Then Placebo',\n",
       "            'Placebo, Then Botox']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Botox, botulinum toxin type A (BTA)']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Placebo',\n",
       "          'InterventionDescription': '29-40 U 0.9% NaCl injection',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Botox, Then Placebo',\n",
       "            'Placebo, Then Botox']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['botulinum toxin type A neurotoxin complex matched injection']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change From Baseline in Depression Symptoms on the Hamilton Depression Rating Scale 21 (HDRS-21) AT WEEK 6',\n",
       "          'PrimaryOutcomeDescription': 'HDRS-21 is a validated, clinician-administered depression assessment scale. Possible scores range from 0 - 7 (within normal range or remission) 8-16 (mild depression) 17-23 (moderate depression) 24-52 (severe depression). Change = (Week 6 post injection score - baseline week 0 score).\\n\\nPRIMARY OUTCOME MEASURE IS THE CHANGE IN HDRS-21 SCORE AFTER WEEK 6',\n",
       "          'PrimaryOutcomeTimeFrame': 'baseline and week 6'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change From Baseline (Week 0) in Depression Symptoms on the Hamilton Depression Rating Scale 21 (HDRS-21) at Week 6 (Six Weeks Post Placebo Injection at Week 0) and Week 18 (Six Weeks Post Botox Injection at Week 12)',\n",
       "          'SecondaryOutcomeDescription': 'HDRS-21 is a validated, clinician-administered depression assessment scale. Possible scores range from 0 - 7 (within normal range or remission) 8-16 (mild depression) 17-23 (moderate depression) 24-52 (severe depression). Change = (Week 6/18 score - baseline week 0 score)\\n\\nOutcome measure is the change in HDRS-21 score 6 weeks after injection with placebo (week 0) and Botox (week 12) - HDRS-21 done at week 6 and week 18.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline (Week 0), Week 6, and Week 18'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nMale/Female between the ages of 18 and 65\\n\\nMajor Depression Disorder as defined by DSM IV criteria and diagnosed by a psychiatrist. DSM (Diagnostic and Statistical Manual) IV criteria for depression are: a depressed mood or anhedonia for at least a two week period. This mood must represent a change from the person's normal mood; social, occupational, educational or other important functioning must also be negatively impaired by the change in mood. Major depressive disorder cannot be diagnosed if a person has a history of bipolar disorder or if the depressed mood is better accounted for by substance abuse or a psychotic disorder. In addition, the patient must have 5 of the following symptoms:\\n\\nSignificant weight loss or weight gain.\\nInsomnia or hypersomnia\\nPsychomotor agitation or retardation\\nFeelings of worthlessness or excessive guilt\\nPoor Concentration\\nFatigue or loss of energy\\nSuicidal thoughts\\nHistory of depression for at least 6 months\\nInitial score 14 or higher on initial Hamilton Depression rating scale.\\nMelancholic facial expressions amenable to treatment with Botox. Photos will be taken of potential participants and ranked independently by two investigators, on a scale of 1-10 based on how negative they look, 10 being the highest. Patients with an average score of 6 or above will be included in the study\\n\\nExclusion Criteria:\\n\\nActive substance abuse\\nBipolar Depression\\nSubjects who are pregnant, nursing or trying to become pregnant during study participation\\nSubjects who are currently on more than 3 psychiatric medications at the time of enrollment\\nCurrent medications used to treat depression must be stable for at least 60 days prior to enrollment\\nPrevious Botox treatment\\nThe Principle Investigator has determined that this study is not in the best interest of the subject and therefore the subject will not be enrolled.\",\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Michelle Magid, MD',\n",
       "          'OverallOfficialAffiliation': 'Seton Healthcare Family',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Seton Mind Institute: Medical Park Tower',\n",
       "          'LocationCity': 'Austin',\n",
       "          'LocationState': 'Texas',\n",
       "          'LocationZip': '78705',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24910934',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Magid M, Reichenberg JS, Poth PE, Robertson HT, LaViolette AK, Kruger TH, Wollmer MA. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014 Aug;75(8):837-44. doi: 10.4088/JCP.13m08845.'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'A total of 101 were screened via telephone, 39 received a face-to-face screening interview, and 30 were enrolled in the study.',\n",
       "       'FlowRecruitmentDetails': 'Participants were recruited from local outpatient psychiatry and primary care practices, and through internet advertisements and media appearances.',\n",
       "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Botox, Then Placebo',\n",
       "          'FlowGroupDescription': 'At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).'},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Placebo, Then Botox',\n",
       "          'FlowGroupDescription': 'At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Week 0 (First Intervention)',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '11'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '19'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '11'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '17'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '0'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '2'}]}}]},\n",
       "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '0'},\n",
       "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'}]}},\n",
       "            {'FlowDropWithdrawType': 'Withdrawal by Subject',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '0'},\n",
       "               {'FlowReasonGroupId': 'FG001',\n",
       "                'FlowReasonNumSubjects': '1'}]}}]}},\n",
       "         {'FlowPeriodTitle': 'Week 12 (Second Intervention)',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '11'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '17'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '11'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '17'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '0'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '0'}]}}]}},\n",
       "         {'FlowPeriodTitle': 'Week 24 Follow-up',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '11'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '17'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '9'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '17'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '2'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '0'}]}}]},\n",
       "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '2'},\n",
       "               {'FlowReasonGroupId': 'FG001',\n",
       "                'FlowReasonNumSubjects': '0'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Botox, Then Placebo',\n",
       "          'BaselineGroupDescription': 'At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).'},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Placebo, Then Botox',\n",
       "          'BaselineGroupDescription': 'At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '11'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '19'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '30'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
       "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
       "                   'BaselineClassDenomCountValue': '11'},\n",
       "                  {'BaselineClassDenomCountGroupId': 'BG001',\n",
       "                   'BaselineClassDenomCountValue': '19'},\n",
       "                  {'BaselineClassDenomCountGroupId': 'BG002',\n",
       "                   'BaselineClassDenomCountValue': '30'}]}}]},\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '11'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '19'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '30'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
       "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
       "                   'BaselineClassDenomCountValue': '11'},\n",
       "                  {'BaselineClassDenomCountGroupId': 'BG001',\n",
       "                   'BaselineClassDenomCountValue': '19'},\n",
       "                  {'BaselineClassDenomCountGroupId': 'BG002',\n",
       "                   'BaselineClassDenomCountValue': '30'}]}}]},\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '11'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '17'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '28'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '2'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '2'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Race and Ethnicity Not Collected',\n",
       "          'BaselineMeasurePopulationDescription': 'Race and Ethnicity were not collected from any participant.',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants',\n",
       "                'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000',\n",
       "                   'BaselineClassDenomCountValue': '0'},\n",
       "                  {'BaselineClassDenomCountGroupId': 'BG001',\n",
       "                   'BaselineClassDenomCountValue': '0'},\n",
       "                  {'BaselineClassDenomCountGroupId': 'BG002',\n",
       "                   'BaselineClassDenomCountValue': '0'}]}}]},\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Change From Baseline in Depression Symptoms on the Hamilton Depression Rating Scale 21 (HDRS-21) AT WEEK 6',\n",
       "          'OutcomeMeasureDescription': 'HDRS-21 is a validated, clinician-administered depression assessment scale. Possible scores range from 0 - 7 (within normal range or remission) 8-16 (mild depression) 17-23 (moderate depression) 24-52 (severe depression). Change = (Week 6 post injection score - baseline week 0 score).\\n\\nPRIMARY OUTCOME MEASURE IS THE CHANGE IN HDRS-21 SCORE AFTER WEEK 6',\n",
       "          'OutcomeMeasurePopulationDescription': 'Participants that completed all study visits were included in the analysis.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'baseline and week 6',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Placebo, Then Botox',\n",
       "             'OutcomeGroupDescription': 'At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).\\n\\nbotulinum toxin type A neurotoxin complex: 29-40 U injection\\n\\nPlacebo: 29-40 U 0.9% NaCl injection'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Botox, Then Placebo',\n",
       "             'OutcomeGroupDescription': 'At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '19'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '11'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '-0.4',\n",
       "                   'OutcomeMeasurementSpread': '4'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '-12.7',\n",
       "                   'OutcomeMeasurementSpread': '4'}]}}]}}]},\n",
       "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
       "               'OG001']},\n",
       "             'OutcomeAnalysisNonInferiorityType': 'Other',\n",
       "             'OutcomeAnalysisPValue': '0.001',\n",
       "             'OutcomeAnalysisStatisticalMethod': 'Mixed Models Analysis'}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Change From Baseline (Week 0) in Depression Symptoms on the Hamilton Depression Rating Scale 21 (HDRS-21) at Week 6 (Six Weeks Post Placebo Injection at Week 0) and Week 18 (Six Weeks Post Botox Injection at Week 12)',\n",
       "          'OutcomeMeasureDescription': 'HDRS-21 is a validated, clinician-administered depression assessment scale. Possible scores range from 0 - 7 (within normal range or remission) 8-16 (mild depression) 17-23 (moderate depression) 24-52 (severe depression). Change = (Week 6/18 score - baseline week 0 score)\\n\\nOutcome measure is the change in HDRS-21 score 6 weeks after injection with placebo (week 0) and Botox (week 12) - HDRS-21 done at week 6 and week 18.',\n",
       "          'OutcomeMeasurePopulationDescription': '2 patients in the placebo first group dropped out at crossover and were not included in the 18 week assessment',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'Baseline (Week 0), Week 6, and Week 18',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Placebo, Then Botox (Week 6)',\n",
       "             'OutcomeGroupDescription': 'Group received placebo injection at week 0 of study followed by a Botox injection at week 12. HDRS-21 scores were done six weeks after each injection (week 6 and week 18).'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Placebo, Then Botox (Week 18)',\n",
       "             'OutcomeGroupDescription': 'Group received placebo injection at week 0 of study followed by a Botox injection at week 12. HDRS-21 scores were done six weeks after each injection (week 6 and week 18).'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '19'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '17'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '-0.4',\n",
       "                   'OutcomeMeasurementSpread': '3'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '-8.4',\n",
       "                   'OutcomeMeasurementSpread': '3'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventsTimeFrame': '24 weeks',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Botox, Then Placebo',\n",
       "          'EventGroupDescription': 'At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).',\n",
       "          'EventGroupDeathsNumAffected': '0',\n",
       "          'EventGroupDeathsNumAtRisk': '11',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '11',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '11'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Placebo, Then Botox',\n",
       "          'EventGroupDescription': 'At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).',\n",
       "          'EventGroupDeathsNumAffected': '0',\n",
       "          'EventGroupDeathsNumAtRisk': '19',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '19',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '19'}]}},\n",
       "      'MoreInfoModule': {'LimitationsAndCaveats': {},\n",
       "       'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Katherine Sebastian',\n",
       "        'PointOfContactOrganization': 'Seton Family of Hospitals',\n",
       "        'PointOfContactEMail': 'krsebastian@seton.org',\n",
       "        'PointOfContactPhone': '512-324-9999',\n",
       "        'PointOfContactPhoneExt': '89612'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000001905',\n",
       "          'InterventionMeshTerm': 'Botulinum Toxins'},\n",
       "         {'InterventionMeshId': 'D000019274',\n",
       "          'InterventionMeshTerm': 'Botulinum Toxins, Type A'},\n",
       "         {'InterventionMeshId': 'C000542869',\n",
       "          'InterventionMeshTerm': 'abobotulinumtoxinA'}]},\n",
       "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000065087',\n",
       "          'InterventionAncestorTerm': 'Acetylcholine Release Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000049990',\n",
       "          'InterventionAncestorTerm': 'Membrane Transport Modulators'},\n",
       "         {'InterventionAncestorId': 'D000045504',\n",
       "          'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "         {'InterventionAncestorId': 'D000018678',\n",
       "          'InterventionAncestorTerm': 'Cholinergic Agents'},\n",
       "         {'InterventionAncestorId': 'D000018377',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Agents'},\n",
       "         {'InterventionAncestorId': 'D000045505',\n",
       "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'},\n",
       "         {'InterventionAncestorId': 'D000009465',\n",
       "          'InterventionAncestorTerm': 'Neuromuscular Agents'},\n",
       "         {'InterventionAncestorId': 'D000018373',\n",
       "          'InterventionAncestorTerm': 'Peripheral Nervous System Agents'}]},\n",
       "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M19841',\n",
       "          'InterventionBrowseLeafName': 'Botulinum Toxins, Type A',\n",
       "          'InterventionBrowseLeafAsFound': 'Botulinum toxin type A',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M258543',\n",
       "          'InterventionBrowseLeafName': 'abobotulinumtoxinA',\n",
       "          'InterventionBrowseLeafAsFound': 'Botulinum toxin type A',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M3765',\n",
       "          'InterventionBrowseLeafName': 'Botulinum Toxins',\n",
       "          'InterventionBrowseLeafAsFound': 'Botulinum toxin',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M2054',\n",
       "          'InterventionBrowseLeafName': 'Acetylcholine',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19342',\n",
       "          'InterventionBrowseLeafName': 'Cholinergic Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19088',\n",
       "          'InterventionBrowseLeafName': 'Neurotransmitter Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'VaDiAg',\n",
       "          'InterventionBrowseBranchName': 'Vasodilator Agents'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 63,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00304915',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'MNT 05-152'},\n",
       "       'Organization': {'OrgFullName': 'VA Office of Research and Development',\n",
       "        'OrgClass': 'FED'},\n",
       "       'BriefTitle': 'HIV Translating Initiatives for Depression Into Effective Solutions',\n",
       "       'OfficialTitle': 'HIV Translating Initiatives for Depression Into Effective Solutions',\n",
       "       'Acronym': 'HI-TIDES'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'November 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'February 2007'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2009',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'November 2016',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'March 16, 2006',\n",
       "       'StudyFirstSubmitQCDate': 'March 16, 2006',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 20, 2006',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'September 10, 2014',\n",
       "       'ResultsFirstSubmitQCDate': 'September 10, 2014',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'September 17, 2014',\n",
       "        'ResultsFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'November 10, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 29, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'VA Office of Research and Development',\n",
       "        'LeadSponsorClass': 'FED'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study is a randomized trial designed to test and refine a collaborative care model for treating depression in VA patients with HIV.',\n",
       "       'DetailedDescription': \"Background: Depression is the most common mental disorder in HIV infected patients. Despite the availability of efficacious treatments for depression, evidence suggests that it is under-diagnosed and under-treated in routine HIV care. To address this problem, the investigators will adapt and implement a collaborative stepped-care model for depression treatment in HIV clinics. This proposal builds on past success of the TIDES/WAVES programs used in VA primary care. The project (HI-TIDES or HIV Translating Initiatives for Depression into Effective Solutions) will implement the primary care collaborative care model for depression treatment in HIV clinics using evidence-based implementation strategies. Objectives: The objectives of this proposal are to: 1) Develop and evaluate the process of adapting, implementing, and sustaining collaborative care for depression in VA HIV clinics, 2) Compare the quality of depression care and the clinical effectiveness of HI-TIDES to usual care in the HIV clinics, and 3) Evaluate the cost-effectiveness of patients assigned to HI-TIDES relative to patients assigned to usual care in HIV clinics. Methods: The implementation framework for this proposal is primarily informed by the Rogers diffusion of innovation model, Simpson Transfer Model, and the PRECEDE model. The VA and American Psychiatric Association Practice Guidelines inform the stepped care collaborative model intervention as source documents for summarizing the evidence for depression treatment for the general population. An expert panel will be convened to rate the quality of available evidence for depression treatment in the context of HIV. Patients will be recruited from VA HIV clinics: Little Rock, Atlanta, and Houston. The intervention will be randomized at the level of the patient. The investigators expect to recruit a total of 140 intervention and 140 usual care patients. Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in the VA electronic medical record. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager. A formative evaluation will occur during start-up and throughout the implementation of the intervention. A summative evaluation will document the effectiveness and cost-effectiveness of the intervention using an intent to treat analysis plan. Findings: No results at this time. Status: Start-up activities. Impact: The proposed study is highly relevant to the VA and the Veterans it serves for many reasons. First, the majority of VA patients with HIV are not seen in the primary care clinics and therefore will not benefit from VA's efforts in primary care settings to improve depression identification and treatment. Second, in addition to the negative outcomes of depression generally, depression in HIV patients is associated with additional negative outcomes including accelerated HIV disease progression, decreased immune system functioning, and premature death. Third, directly moving collaborative depression care from primary care clinics to HIV clinics is likely to fail for several reasons including the comorbidities associated with depressed HIV patient and the potential for drug-drug interactions. The proposed project will address these gaps and provide effectiveness and cost-effectiveness analyses to inform decisions about larger scale implementation of the HI-TIDES intervention.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['HIV, Depression']},\n",
       "       'KeywordList': {'Keyword': ['HIV, depression',\n",
       "         'patient care management',\n",
       "         'patient care team']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '249',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Arm 1: Collaborative Care Intervention',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received collaborative care intervention.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Collaborative Care Interventions']}},\n",
       "         {'ArmGroupLabel': 'Arm 2: Usual Care',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received usual care.'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Collaborative Care Interventions',\n",
       "          'InterventionDescription': 'Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Arm 1: Collaborative Care Intervention']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Percentage of Participants With Depression Treatment Response',\n",
       "          'PrimaryOutcomeDescription': 'Depression symptom severity over the past two weeks was measured using the Hopkins Symptom Checklist (SCL-20). The SCL-20 includes the 13-item depression scale plus 7 depression-related items from the Hopkins Symptom Checklist-90-Revised. The items are scored from 0 to 4 and averaged to provide a mean depression severity score from 0 to 4. Depression treatment response at 6-months was defined as a 50% decrease in mean SCL-20 score compared to baseline.',\n",
       "          'PrimaryOutcomeTimeFrame': '6 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ncurrent 9-item Patient Health Questionnaire (PHQ-9) score of 10 or more and\\ncurrent treatment in the HIV clinic.\\n\\nExclusion Criteria:\\n\\npatients who do not have access to a telephone,\\npatients with current suicidal ideation,\\npatients with significant cognitive impairment as indicated by a score < 10 on the HIV Dementia Scale, and\\npatients with a chart diagnosis of schizophrenia.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '75 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jeffrey M Pyne, MD',\n",
       "          'OverallOfficialAffiliation': 'Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR',\n",
       "          'LocationCity': 'No. Little Rock',\n",
       "          'LocationState': 'Arkansas',\n",
       "          'LocationZip': '72114-1706',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Atlanta VA Medical and Rehab Center, Decatur, GA',\n",
       "          'LocationCity': 'Decatur',\n",
       "          'LocationState': 'Georgia',\n",
       "          'LocationZip': '30033',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Michael E. DeBakey VA Medical Center, Houston, TX',\n",
       "          'LocationCity': 'Houston',\n",
       "          'LocationState': 'Texas',\n",
       "          'LocationZip': '77030',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '18825515',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Pyne JM, Asch SM, Lincourt K, Kilbourne AM, Bowman C, Atkinson H, Gifford A. Quality indicators for depression care in HIV patients. AIDS Care. 2008 Oct;20(9):1075-83. doi: 10.1080/09540120701796884. Review.'},\n",
       "         {'ReferencePMID': '19320606',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Fortney JC, Pyne JM, Smith JL, Curran GM, Otero JM, Enderle MA, McDougall S. Steps for implementing collaborative care programs for depression. Popul Health Manag. 2009 Apr;12(2):69-79.'},\n",
       "         {'ReferencePMID': '19437931',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Ackerman B, Pyne JM, Fortney JC. Challenges associated with being an off-site depression care manager. J Psychosoc Nurs Ment Health Serv. 2009 Apr;47(4):43-9.'},\n",
       "         {'ReferencePMID': '21220657',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Pyne JM, Fortney JC, Curran GM, Tripathi S, Atkinson JH, Kilbourne AM, Hagedorn HJ, Rimland D, Rodriguez-Barradas MC, Monson T, Bottonari KA, Asch SM, Gifford AL. Effectiveness of collaborative care for depression in human immunodeficiency virus clinics. Arch Intern Med. 2011 Jan 10;171(1):23-31. doi: 10.1001/archinternmed.2010.395.'},\n",
       "         {'ReferencePMID': '21714689',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Curran GM, Pyne J, Fortney JC, Gifford A, Asch SM, Rimland D, Rodriguez-Barradas M, Monson TP, Kilbourne AM, Hagedorn H, Atkinson JH. Development and implementation of collaborative care for depression in HIV clinics. AIDS Care. 2011 Dec;23(12):1626-36. doi: 10.1080/09540121.2011.579943. Epub 2011 Jun 30.'},\n",
       "         {'ReferencePMID': '21348556',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Fortney JC, Pyne JM, Steven CA, Williams JS, Hedrick RG, Lunsford AK, Raney WN, Ackerman BA, Ducker LO, Bonner LM, Smith JL. A Web-based clinical decision support system for depression care management. Am J Manag Care. 2010 Nov;16(11):849-54.'},\n",
       "         {'ReferencePMID': '21826113',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R. Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation. Am J Gastroenterol. 2011 Dec;106(12):2123-32. doi: 10.1038/ajg.2011.252. Epub 2011 Aug 9.'},\n",
       "         {'ReferencePMID': '22310560',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812.'},\n",
       "         {'ReferencePMID': '22536930',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Bottonari KA, Tripathi SP, Fortney JC, Curran G, Rimland D, Rodriguez-Barradas M, Gifford AL, Pyne JM. Correlates of antiretroviral and antidepressant adherence among depressed HIV-infected patients. AIDS Patient Care STDS. 2012 May;26(5):265-73. doi: 10.1089/apc.2011.0218. Epub 2012 Mar 21.'},\n",
       "         {'ReferencePMID': '26102447',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Painter JT, Fortney JC, Gifford AL, Rimland D, Monson T, Rodriguez-Barradas MC, Pyne JM. Cost-Effectiveness of Collaborative Care for Depression in HIV Clinics. J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):377-85. doi: 10.1097/QAI.0000000000000732.'}]},\n",
       "       'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'PubMed',\n",
       "          'SeeAlsoLinkURL': 'http://www.ncbi.nlm.nih.gov/pubmed/26126749'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'Yes',\n",
       "       'IPDSharingDescription': 'Investigators can request IPD by contacting the PI.'}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Arm 1: Collaborative Care Intervention',\n",
       "          'FlowGroupDescription': 'Collaborative Care Intervention: Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in VA electronic medical record. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.'},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Arm 2: Usual Care',\n",
       "          'FlowGroupDescription': 'Usual care arm. Usual care will include depression screening with the same 9-item Patient Health Questionnaire (PHQ-9) screener used for Arm 1. The HI-TIDES depression care team will not be a part of the usual care condition.'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '123'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '126'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '105'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '110'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '18'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '16'}]}}]},\n",
       "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '11'},\n",
       "               {'FlowReasonGroupId': 'FG001',\n",
       "                'FlowReasonNumSubjects': '11'}]}},\n",
       "            {'FlowDropWithdrawType': 'Death',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '4'},\n",
       "               {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '5'}]}},\n",
       "            {'FlowDropWithdrawType': 'Withdrawal by Subject',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '3'},\n",
       "               {'FlowReasonGroupId': 'FG001',\n",
       "                'FlowReasonNumSubjects': '0'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Arm 1: Collaborative Care Intervention',\n",
       "          'BaselineGroupDescription': 'Collaborative Care Intervention: Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.'},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Arm 2: Usual Care',\n",
       "          'BaselineGroupDescription': 'Usual care arm. Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The HI-TIDES depression care team will not be a part of the usual care condition.'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '123'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '126'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '249'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '49.8',\n",
       "                   'BaselineMeasurementSpread': '8.7'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '49.8',\n",
       "                   'BaselineMeasurementSpread': '10.5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '49.8',\n",
       "                   'BaselineMeasurementSpread': '9.6'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Gender',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '3'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '4'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '7'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '120'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '122'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '242'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Race (NIH/OMB)',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Asian',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Black or African American',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '78'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '77'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '155'}]}},\n",
       "               {'BaselineCategoryTitle': 'White',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '45'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '49'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '94'}]}},\n",
       "               {'BaselineCategoryTitle': 'More than one race',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Percentage of Participants With Depression Treatment Response',\n",
       "          'OutcomeMeasureDescription': 'Depression symptom severity over the past two weeks was measured using the Hopkins Symptom Checklist (SCL-20). The SCL-20 includes the 13-item depression scale plus 7 depression-related items from the Hopkins Symptom Checklist-90-Revised. The items are scored from 0 to 4 and averaged to provide a mean depression severity score from 0 to 4. Depression treatment response at 6-months was defined as a 50% decrease in mean SCL-20 score compared to baseline.',\n",
       "          'OutcomeMeasurePopulationDescription': 'intent to treat analysis',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Number',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'percent response',\n",
       "          'OutcomeMeasureTimeFrame': '6 months',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Arm 1: Collaborative Care Intervention',\n",
       "             'OutcomeGroupDescription': 'Collaborative Care Intervention: Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Arm 2: Usual Care',\n",
       "             'OutcomeGroupDescription': 'Usual care arm. Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The HI-TIDES depression care team will not be a part of the usual care condition.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '123'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '126'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '33.3'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '17.5'}]}}]}}]},\n",
       "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
       "               'OG001']},\n",
       "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
       "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
       "             'OutcomeAnalysisPValue': '0.003',\n",
       "             'OutcomeAnalysisStatisticalMethod': 'Regression, Logistic',\n",
       "             'OutcomeAnalysisParamType': 'Odds Ratio (OR)',\n",
       "             'OutcomeAnalysisParamValue': '2.5',\n",
       "             'OutcomeAnalysisCIPctValue': '95',\n",
       "             'OutcomeAnalysisCINumSides': '2-Sided',\n",
       "             'OutcomeAnalysisCILowerLimit': '1.37',\n",
       "             'OutcomeAnalysisCIUpperLimit': '4.56'}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventsTimeFrame': '1 year',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Arm 1: Collaborative Care Intervention',\n",
       "          'EventGroupDescription': 'Collaborative Care Intervention: Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '123',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '123'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Arm 2: Usual Care',\n",
       "          'EventGroupDescription': 'Usual care arm. Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The HI-TIDES depression care team will not be a part of the usual care condition.',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '126',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '126'}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Dr. Jeff Pyne',\n",
       "        'PointOfContactOrganization': 'Central Arkansas Veterans Healthcare System',\n",
       "        'PointOfContactEMail': 'jmpyne@uams.edu',\n",
       "        'PointOfContactPhone': '501-257-1083'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M16833',\n",
       "          'ConditionBrowseLeafName': 'HIV Infections',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M2103',\n",
       "          'ConditionBrowseLeafName': 'Acquired Immunodeficiency Syndrome',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC02',\n",
       "          'ConditionBrowseBranchName': 'Viral Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC20',\n",
       "          'ConditionBrowseBranchName': 'Immune System Diseases'}]}}}}},\n",
       "   {'Rank': 64,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00643162',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '8648'},\n",
       "       'Organization': {'OrgFullName': 'Cedars-Sinai Medical Center',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Combination Lexapro and Massage for Treatment of Depression in Older Adults',\n",
       "       'OfficialTitle': 'Combination Lexapro and Massage for Treatment in Depression in Older Subjects'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'May 2019',\n",
       "       'OverallStatus': 'Terminated',\n",
       "       'WhyStopped': 'Interim analysis indicated recruitment was necessary beyond study capabilities.',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'June 2006'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2010',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'February 2010',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'March 20, 2008',\n",
       "       'StudyFirstSubmitQCDate': 'March 20, 2008',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 26, 2008',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'January 25, 2018',\n",
       "       'ResultsFirstSubmitQCDate': 'May 28, 2019',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'June 18, 2019',\n",
       "        'ResultsFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'May 28, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 18, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Itai Danovitch',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Chairman, Department of Psychiatry',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Cedars-Sinai Medical Center'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Cedars-Sinai Medical Center',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Forest Laboratories',\n",
       "          'CollaboratorClass': 'INDUSTRY'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Depression is a common and disabling condition which represents a substantial public health concern, especially with the aging of the population in general. In fact, one to four percent of the older population has major depression. Although medication is the main treatment for depression, studies show that only 50% of patients show a significant response to treatment. The response might actually be less in older subjects, and with more adverse side effects due to changes in the metabolism of the older population as well as drug interaction. For these reasons (changes in metabolism and possible drug interactions) the starting dose of the antidepressant Lexapro will be 5mg, instead of 10mg.\\n\\nTo combat the incomplete response to medication, many combined and augmentation strategies have been developed. Examples of this would be an antidepressant medication plus a neuroleptic medication; or an antidepressant medication plus talk therapy. One non-medication treatment that is being considered is massage therapy. Recent data suggest that massage therapy can be useful for the treatment of depression.\\n\\nThis study proposes to perform a controlled trail to assess the effects of massage therapy on symptoms of depression in older subjects with major depression. All of the subjects will receive Lexapro, which is an FDA approved medication for the treatment of depression. Half of the subjects will receive Swedish massage for one hour, twice a week, and the other half will receive light touch for one hour, twice per week for eight weeks. Standardized rating scales that evaluate depression will be used to evaluate the subjects mood.',\n",
       "       'DetailedDescription': 'Study Design: This will be an open-label, randomized control trial of concomitant massage therapy and escitalopram pharmacotherapy for the treatment of major depression in the elderly. All subjects who meet inclusion/exclusion criteria will receive escitalopram and also be randomized 1:1 (by computer) to Swedish massage or light touch. Escitalopram (5.0 mg/day, PO) will initially be administered for one week followed by an increase in dose to 10 mg/day for the remainder of the study; Massage or touch will be performed twice per week for 8 weeks. Every effort will be made to have non-consecutive massage/touch visits. The massage group will receive Swedish massage for 50 minutes twice per week. In the \"touch\" group, the massage therapist will provide gentle touch to the skin in the same distribution as that of the formal Swedish massage for 50 minutes twice per week. Every effort will be made to have one therapist perform all treatments. All assessments will be obtained prior to the first massage each week.\\nRecruitment and Retention: Subjects will be recruited from our outpatient clinic, attendings, as well as by advertising on radio, television, newspaper and our web site.\\n\\nTreatment\\n\\nMassage: Standard Swedish massage therapy will be employed which includes the systematic manipulation of the soft tissues of the body. It is designed to relax muscles by applying pressure to them against deeper muscles and bones, and rubbing in the same direction as the flow of blood returning to the heart. A routine has been designed whereby the therapist massages different areas of the body in an orderly fashion for specified periods of time. For sham massage (light touch), the massage therapists will provide gentle touch to the skin in the same distribution and duration as that of the formal Swedish massage. As mentioned below, deviations from the structured massage or touch will be recorded in the massage therapist\\'s diary.\\nQuality control for screening and outcome questionnaires: Kappa co-efficients for diagnostic and inter-rater reliability will be determined at six-month intervals. We routinely maintain kappa values of at >0.85.\\n\\nOutcome Measures: Primary outcome measure for this study will be degree of depression as measured by HAM-D. The secondary outcome measures will include quality of life, HAM-A, Beck Depression Inventory. Raters will be blind to treatment cell and test results.\\n\\nQuality control for screening and outcome questionnaires: Kappa co-efficients for diagnostic and inter-rater reliability will be determined at six-month intervals. We routinely maintain kappa values of at >0.85.\\n\\nStatistical Analysis All entries will be blind-verified, and following data entry, results will be checked for obvious outliers and inconsistent values. No single person will have the responsibility for both entry and verification on a given form. Data on computer records will be identifiable by a unique coded identifier to permit matching of records longitudinally. Each record will be logged as it is obtained. An archival record of all data collected, which has passed the above-noted checks, will be maintained on a hard disk. A backup of the archival data will be saved on magnetic tape (DAT tape) and writable CD-ROM archive disks. This copy will be stored in a separate offsite cabinet to ensure the survival of data in case of a natural disaster. A full backup will be made weekly, and stored for at least three months. A CD-ROM backup will be made every three months.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Massage',\n",
       "         'Lexapro',\n",
       "         'Alternative Therapy',\n",
       "         'Anti-depressant']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '17',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Swedish Massage',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Lexapro',\n",
       "            'Behavioral: Massage']}},\n",
       "         {'ArmGroupLabel': 'Light-Touch',\n",
       "          'ArmGroupType': 'Sham Comparator',\n",
       "          'ArmGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Lexapro',\n",
       "            'Behavioral: Light touch']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Lexapro',\n",
       "          'InterventionDescription': '5mg-10mg of lexapro, daily, for 9 weeks for all study participants.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Light-Touch',\n",
       "            'Swedish Massage']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Escitalopram']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Light touch',\n",
       "          'InterventionDescription': 'Light touch twice a week, for 8 weeks',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Light-Touch']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Massage',\n",
       "          'InterventionDescription': 'Massage twice a week, for 8 weeks.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Swedish Massage']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Hamilton Depression Scale (HAM-D) Score',\n",
       "          'PrimaryOutcomeDescription': \"The Hamilton Depression Rating Scale (HAM-D) is a clinician-administered tool used to determine a patient's level of depression before, during, and after treatment. The HAM-D form lists 21 items, but the scoring is based on the first 17 questions. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. The scores from each item are added together to provide a total score. The sum of the scores from the first 17 questions provides an indication for level of depression. 0-7 = normal, 8-13 = mild depression, 14-18 = moderate depression, 19-22=severe depression and ≥ 23=very severe depression.\",\n",
       "          'PrimaryOutcomeTimeFrame': '9 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Beck Depression Inventory Score',\n",
       "          'SecondaryOutcomeDescription': 'The Beck Depression Inventory (BDI) is a series of 21-question, self-report rating inventory developed at a 5th grade reading level that measures characteristic attitudes and symptoms of depression. It was develop to detect, assess and monitor changes in depressive symptoms. For people who have been clinically diagnosed with depression, scores from 0 to 9 represent minimal depressive symptoms, scores of 10 to 16 indicate mild depression, scores of 17 to 29 indicate moderate depression, and scores of 30 to 63 indicate severe depression.',\n",
       "          'SecondaryOutcomeTimeFrame': '9 weeks'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change in Hamilton Anxiety Scale (HAM-A) Score',\n",
       "          'SecondaryOutcomeDescription': \"The Hamilton Depression Rating Scale (HAM-D) is a clinician-administered tool used to determine a patient's level of anxiety before, during, and after treatment. The HAM-A is a 14-item assessment and each item is scored on a 5-point scale, ranging from 0 = not present to 4 = very severe. The sum of the scores is: 0-17 = mild anxiety, 18-24 = moderate anxiety, 25-30 = severe anxiety, and >30 = very severe anxiety.\",\n",
       "          'SecondaryOutcomeTimeFrame': '9 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\n> 60 years of age\\nUnipolar major depression as defined by Structured Clinical Interaction DSM-IV (SCID)\\nHAM-D score of > 17 (21-item scale)]]\\nNot taking antidepressants for at least two weeks, 2 months for fluoxetine and MAOIs]]\\nCapable of giving informed consent.\\n\\nExclusion Criteria:\\n\\nUnable to provide informed consent (e.g. severe cognitive impairment)\\nAcute medical condition or exacerbation of chronic medical condition associated with significant distress (pain, protracted fevers, etc.) and requiring active medical treatment.\\nHigh risk of suicide or violence as assessed by the investigator\\nCurrent or past history of psychosis or bipolar disorder\\nUse of psychotropic medication and/or psychotherapy outside of the study\\n(Exposure to treatment of fluoxetine or MAOIs in the previous two months; chronic use of benzodiazepine and non-benzodiazepine sedatives, antipsychotics, psychostimulants, mood stabilizing agents, codeine, steroids, anti-inflammatory agents.\\nAlternative medicine use in the preceding 30 days (e.g. acupuncture, herbs, etc.)\\nHistory of intolerance to massage or contraindication to massage (e.g. skin lesions that prevent direct contact by the therapist)\\nDiagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression or bipolar disorders;\\nMMSE less than 22\\nAlzheimer's Disease Assessment Scale-Cognitive Subscale ³ greater than 12\\nCurrent drug or alcohol abuse or dependence or history of drug or alcohol abuse or dependence within the past 6 months\\nUnstable medical or neurological conditions that are likely to interfere with the treatment of depression\\nCurrently on psychotropic medications including antidepressants or neuroleptics\\nActive suicidal ideation or other safety issues determined by the clinician to not be suitable for inclusion in the study\",\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '60 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Itai Danotivtch, Ph.D., M.D.',\n",
       "          'OverallOfficialAffiliation': 'Cedars-Sinai Medical Center',\n",
       "          'OverallOfficialRole': 'Study Chair'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Cedars-Sinai Medical Center Department of Psychiatry and Behavioral Neurosciences',\n",
       "          'LocationCity': 'Los Angeles',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '90048',\n",
       "          'LocationCountry': 'United States'}]}}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': '4 subjects screen failed; 1 subject withdrew consent after screen. Total of 5 subjects were not randomized.',\n",
       "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Swedish Massage',\n",
       "          'FlowGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nMassage: Massage twice a week, for 8 weeks.'},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Light-Touch',\n",
       "          'FlowGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nLight touch: Light touch twice a week, for 8 weeks'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '7'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '5'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '6'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '4'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '1'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '1'}]}}]},\n",
       "          'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Withdrawal by Subject',\n",
       "             'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000',\n",
       "                'FlowReasonNumSubjects': '1'},\n",
       "               {'FlowReasonGroupId': 'FG001',\n",
       "                'FlowReasonNumSubjects': '1'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Swedish Massage',\n",
       "          'BaselineGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nMassage: Massage twice a week, for 8 weeks.'},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Light-Touch',\n",
       "          'BaselineGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nLight touch: Light touch twice a week, for 8 weeks'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '7'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '5'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '12'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '3'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '8'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '2'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '2'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '4'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '3'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '8'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '4'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '4'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '1'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '1'}]}},\n",
       "               {'BaselineCategoryTitle': 'Not Hispanic or Latino',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '6'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '11'}]}},\n",
       "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Race (NIH/OMB)',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Asian',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Black or African American',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '1'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '1'}]}},\n",
       "               {'BaselineCategoryTitle': 'White',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '6'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '4'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '10'}]}},\n",
       "               {'BaselineCategoryTitle': 'More than one race',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '1'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '1'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineMeasureCalculatePct': 'No',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '7'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '12'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Change in Hamilton Depression Scale (HAM-D) Score',\n",
       "          'OutcomeMeasureDescription': \"The Hamilton Depression Rating Scale (HAM-D) is a clinician-administered tool used to determine a patient's level of depression before, during, and after treatment. The HAM-D form lists 21 items, but the scoring is based on the first 17 questions. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. The scores from each item are added together to provide a total score. The sum of the scores from the first 17 questions provides an indication for level of depression. 0-7 = normal, 8-13 = mild depression, 14-18 = moderate depression, 19-22=severe depression and ≥ 23=very severe depression.\",\n",
       "          'OutcomeMeasurePopulationDescription': 'A 7th Massage subject completed 6 of 7 visits so his data was carried forward to the final visit. Data from the LT subject who terminated early at Visit 3 was not used. An interim analysis was performed, there was one active subject still in the early stages of the protocol, whose data was not included. The interim analysis became final.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': '9 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Swedish Massage',\n",
       "             'OutcomeGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nMassage: Massage twice a week, for 8 weeks.'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Light-Touch',\n",
       "             'OutcomeGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nLight touch: Light touch twice a week, for 8 weeks'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '7'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '3'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '13',\n",
       "                   'OutcomeMeasurementSpread': '7.4'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '10.7',\n",
       "                   'OutcomeMeasurementSpread': '4.9'}]}}]}}]},\n",
       "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
       "               'OG001']},\n",
       "             'OutcomeAnalysisNonInferiorityType': 'Other',\n",
       "             'OutcomeAnalysisPValue': '.68',\n",
       "             'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided',\n",
       "             'OutcomeAnalysisParamType': 'Mean Difference (Final Values)',\n",
       "             'OutcomeAnalysisParamValue': '2.3',\n",
       "             'OutcomeAnalysisCINumSides': '2-Sided',\n",
       "             'OutcomeAnalysisDispersionType': 'Standard Deviation',\n",
       "             'OutcomeAnalysisDispersionValue': '6.15'}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Change in Beck Depression Inventory Score',\n",
       "          'OutcomeMeasureDescription': 'The Beck Depression Inventory (BDI) is a series of 21-question, self-report rating inventory developed at a 5th grade reading level that measures characteristic attitudes and symptoms of depression. It was develop to detect, assess and monitor changes in depressive symptoms. For people who have been clinically diagnosed with depression, scores from 0 to 9 represent minimal depressive symptoms, scores of 10 to 16 indicate mild depression, scores of 17 to 29 indicate moderate depression, and scores of 30 to 63 indicate severe depression.',\n",
       "          'OutcomeMeasurePopulationDescription': 'Data was not abstracted since interim analysis recommended study closure',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': '9 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Swedish Massage',\n",
       "             'OutcomeGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nMassage: Massage twice a week, for 8 weeks.'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Light-Touch',\n",
       "             'OutcomeGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nLight touch: Light touch twice a week, for 8 weeks'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '7'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '3'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '8.7',\n",
       "                   'OutcomeMeasurementSpread': '6.6'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '6.3',\n",
       "                   'OutcomeMeasurementSpread': '6.3'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Change in Hamilton Anxiety Scale (HAM-A) Score',\n",
       "          'OutcomeMeasureDescription': \"The Hamilton Depression Rating Scale (HAM-D) is a clinician-administered tool used to determine a patient's level of anxiety before, during, and after treatment. The HAM-A is a 14-item assessment and each item is scored on a 5-point scale, ranging from 0 = not present to 4 = very severe. The sum of the scores is: 0-17 = mild anxiety, 18-24 = moderate anxiety, 25-30 = severe anxiety, and >30 = very severe anxiety.\",\n",
       "          'OutcomeMeasurePopulationDescription': 'Data was not abstracted since interim analysis recommended study closure',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': '9 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Swedish Massage',\n",
       "             'OutcomeGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nMassage: Massage twice a week, for 8 weeks.'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Light-Touch',\n",
       "             'OutcomeGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nLight touch: Light touch twice a week, for 8 weeks'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '7'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '3'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '5.3',\n",
       "                   'OutcomeMeasurementSpread': '5.8'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '2.7',\n",
       "                   'OutcomeMeasurementSpread': '13.1'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventsTimeFrame': '1 year',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Swedish Massage',\n",
       "          'EventGroupDescription': 'Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nMassage: Massage twice a week, for 8 weeks.',\n",
       "          'EventGroupDeathsNumAffected': '0',\n",
       "          'EventGroupDeathsNumAtRisk': '7',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '7',\n",
       "          'EventGroupOtherNumAffected': '1',\n",
       "          'EventGroupOtherNumAtRisk': '7'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Light-Touch',\n",
       "          'EventGroupDescription': 'Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.\\n\\nLexapro: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.\\n\\nLight touch: Light touch twice a week, for 8 weeks',\n",
       "          'EventGroupDeathsNumAffected': '0',\n",
       "          'EventGroupDeathsNumAtRisk': '5',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '5',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '5'}]},\n",
       "       'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Cold Symptoms',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventNotes': 'After 2 weeks of taking Lexapro, subject reported symptoms of coughing, sneezing, feeling feverish, fatigue and dizziness and attributed it to a lingering coldAlthough symptoms are not associated with Lexapro, Investigator wanted to report as an AE.',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '7'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '0',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '5'}]}}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Felicia Mayes',\n",
       "        'PointOfContactOrganization': 'Cedars Sinai Medical Center',\n",
       "        'PointOfContactEMail': 'mayesf@cshs.org',\n",
       "        'PointOfContactPhone': '310-423-0825'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000015283',\n",
       "          'InterventionMeshTerm': 'Citalopram'}]},\n",
       "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000017367',\n",
       "          'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000014179',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000049990',\n",
       "          'InterventionAncestorTerm': 'Membrane Transport Modulators'},\n",
       "         {'InterventionAncestorId': 'D000045504',\n",
       "          'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "         {'InterventionAncestorId': 'D000018377',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Agents'},\n",
       "         {'InterventionAncestorId': 'D000018490',\n",
       "          'InterventionAncestorTerm': 'Serotonin Agents'},\n",
       "         {'InterventionAncestorId': 'D000045505',\n",
       "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'},\n",
       "         {'InterventionAncestorId': 'D000018687',\n",
       "          'InterventionAncestorTerm': 'Antidepressive Agents, Second-Generation'},\n",
       "         {'InterventionAncestorId': 'D000000928',\n",
       "          'InterventionAncestorTerm': 'Antidepressive Agents'},\n",
       "         {'InterventionAncestorId': 'D000011619',\n",
       "          'InterventionAncestorTerm': 'Psychotropic Drugs'}]},\n",
       "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M16566',\n",
       "          'InterventionBrowseLeafName': 'Citalopram',\n",
       "          'InterventionBrowseLeafAsFound': 'Escitalopram',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M5687',\n",
       "          'InterventionBrowseLeafName': 'Dexetimide',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M14095',\n",
       "          'InterventionBrowseLeafName': 'Serotonin',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M18232',\n",
       "          'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19088',\n",
       "          'InterventionBrowseLeafName': 'Neurotransmitter Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M2828',\n",
       "          'InterventionBrowseLeafName': 'Antidepressive Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M13057',\n",
       "          'InterventionBrowseLeafName': 'Psychotropic Drugs',\n",
       "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr',\n",
       "          'InterventionBrowseBranchName': 'Psychotropic Drugs'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'AnDyAg',\n",
       "          'InterventionBrowseBranchName': 'Anti-Dyskinesia Agents'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 65,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01624402',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'R01MH096685',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH096685&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH096685',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH096685&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'Weill Medical College of Cornell University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Ecosystem Focused Therapy in Post Stroke Depression',\n",
       "       'OfficialTitle': 'Ecosystem Focused Therapy in Post Stroke Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'February 2019',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'March 2012',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 31, 2019',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'January 31, 2019',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 18, 2012',\n",
       "       'StudyFirstSubmitQCDate': 'June 18, 2012',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 20, 2012',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'February 5, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 6, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Weill Medical College of Cornell University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': \"Older adults who are stroke survivors can experience many challenges, including depression, cognitive dysfunction, and physical disability. Family members and other caregivers may struggle with helping stroke survivors adjust to life after stroke. This research study involves testing a modified form of problem-solving therapy called Ecosystem Focused Therapy (EFT) to help treat depression in older adult stroke survivors. EFT teaches problem-solving skills to patients to help them cope with problems related to stroke and depression, alters their physical environment to accommodate new needs resulting from stroke, and helps the family or caregiver to assist in the patient's adaptation. In addition this study will compare EFT to an education intervention to see which is more effective in treating depressed stroke survivors.\",\n",
       "       'DetailedDescription': 'We propose to study the efficacy of \"Ecosystem Focused Therapy\" (EFT) in post-stroke depression (PSD), a disorder that afflicts a large number of stroke victims and increases mortality, cognitive impairment, and disability for years after stroke. EFT is a new, home-delivered intervention based on our integrative model of PSD, which originated from our clinical biology and treatment studies in late-life depression. It postulates two main paths to PSD. First, stroke and stroke-repair mechanisms contribute to metabolic changes mediating PSD. Second, a \"psychosocial storm\" stemming both from the patient\\'s sudden disability and the change in the patient\\'s needs and family life add a biological burden to this cascade of depressogenic events. EFT targets the \"psychosocial storm\" of PSD and focuses on the reciprocal interaction between the patient\\'s abilities and the challenges of his/her \"ecosystem\" (family, specialized therapists). EFT follows a structured personalization approach based on the \"model of adaptive functioning\", in which behavior is a function of the person\\'s competence and the demands of the environment. Thus, EFT continuously \"calibrates the environment\" to the PSD patient\\'s competence level and targets the PSD \"psychosocial storm\" through five integrated components: 1) It offers an action-oriented, \"new perspective\" about the patient\\'s recovery. 2) It provides an \"adherence enhancement structure\". 3) It offers a \"problem solving structure\" to the patient focusing on problems, valued by the patient, and pertinent to daily function. 4) It helps the family \"reengineer its goals, involvement, and plans\" to accommodate the patient\\'s disability. 5) It \"coordinates care with specialized therapists\" with the goal to increase patient participation in rehabilitation and social activities.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression',\n",
       "         'Stroke']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '151',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Ecosystem Focused Therapy (EFT)',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': \"Ecosystem Focused Therapy (EFT) follows a structured personalization approach based on the model of adaptive functioning, in which behavior is a function of the person's competence and the demands of the environment.\",\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Ecosystem Focused Therapy (EFT)']}},\n",
       "         {'ArmGroupLabel': 'Education on Stroke and Depression (ESD)',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Education on Stroke and Depression (ESD) is home-delivered and imparts education about depression, stroke, and the role of available treatments.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Education on Stroke and Depression (ESD)']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Education on Stroke and Depression (ESD)',\n",
       "          'InterventionDescription': \"Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.\\nComprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.\\nConveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.\\nESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy).\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Education on Stroke and Depression (ESD)']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Ecosystem Focused Therapy (EFT)',\n",
       "          'InterventionDescription': \"EFT offers an action-oriented, new perspective about the subject's recovery;\\nIt provides an adherence enhancement structure;\\nIt offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;\\nIt helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;\\nIt coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Ecosystem Focused Therapy (EFT)']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression',\n",
       "          'PrimaryOutcomeDescription': 'This research study involves testing a modified form of problem-solving therapy called Ecosystem Focused Therapy (EFT) in reducing depression in older adult stroke survivors.',\n",
       "          'PrimaryOutcomeTimeFrame': '12 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAge 50 years and older;\\nDiagnosis of unipolar major depression;\\nMontgomery Asberg Depression Rating Scale score ≥ 18;\\nCapacity to provide written consent for both research assessment and treatment;\\nCommand of English sufficient to participate in assessments and talking therapy.\\n\\nExclusion Criteria:\\n\\nModerately severe to severe dementia (MMSE score < 20);\\nGreater than mild to moderate aphasia (NIH Stroke Scale: Best Language > 1);\\nExpectation to be discharged to a nursing home;\\nPsychotic depression;\\nSuicidal intent or plan.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '50 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'George S. Alexopoulos, M.D.',\n",
       "          'OverallOfficialAffiliation': 'Weill Medical College of Cornell University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'New York Presbyterian Hospital',\n",
       "          'LocationCity': 'New York',\n",
       "          'LocationState': 'New York',\n",
       "          'LocationZip': '10065',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Burke Rehabilitation Hospital',\n",
       "          'LocationCity': 'White Plains',\n",
       "          'LocationState': 'New York',\n",
       "          'LocationZip': '10605',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Institute of Geriatric Psychiatry',\n",
       "          'LocationCity': 'White Plains',\n",
       "          'LocationState': 'New York',\n",
       "          'LocationZip': '10605',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521',\n",
       "          'ConditionMeshTerm': 'Stroke'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561',\n",
       "          'ConditionAncestorTerm': 'Cerebrovascular Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001927',\n",
       "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
       "         {'ConditionAncestorId': 'D000002493',\n",
       "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
       "         {'ConditionAncestorId': 'D000009422',\n",
       "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
       "         {'ConditionAncestorId': 'D000014652',\n",
       "          'ConditionAncestorTerm': 'Vascular Diseases'},\n",
       "         {'ConditionAncestorId': 'D000002318',\n",
       "          'ConditionAncestorTerm': 'Cardiovascular Diseases'},\n",
       "         {'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M20890',\n",
       "          'ConditionBrowseLeafName': 'Stroke',\n",
       "          'ConditionBrowseLeafAsFound': 'Stroke',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M4393',\n",
       "          'ConditionBrowseLeafName': 'Cerebrovascular Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3786',\n",
       "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M4325',\n",
       "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M15983',\n",
       "          'ConditionBrowseLeafName': 'Vascular Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
       "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC14',\n",
       "          'ConditionBrowseBranchName': 'Heart and Blood Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
       "   {'Rank': 66,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01922219',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '#6127'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '5K08MH085061',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=5K08MH085061&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'New York State Psychiatric Institute',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression',\n",
       "       'OfficialTitle': 'Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'September 2017',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'December 2009'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'August 2015',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'August 12, 2013',\n",
       "       'StudyFirstSubmitQCDate': 'August 12, 2013',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 14, 2013',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'December 22, 2016',\n",
       "       'ResultsFirstSubmitQCDate': 'January 10, 2017',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'March 1, 2017',\n",
       "        'ResultsFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'September 18, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 19, 2017',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'New York State Psychiatric Institute',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of this research study is to learn whether specific types of brain imaging and psychological testing can predict how much benefit patients with depression will receive from a well-studied psychotherapy for depression, called cognitive behavioral therapy (CBT), and how the brain imaging and psychological tests change with treatment. We will also be comparing brain scans from this study between individuals suffering from depression and volunteers without depression.\\n\\nThis study offers 14 sessions of one-on-one cognitive-behavioral therapy (CBT) over twelve weeks, administered by an experienced doctoral-level psychologist or psychiatrist.',\n",
       "       'DetailedDescription': 'Major depressive disorder (MDD) affects 13.1 - 14.2 million American adults annually. Cognitive-behavioral therapy (CBT) is a structured psychotherapy that has been demonstrated in multiple studies to be an effective treatment for MDD. Not all patients achieve a full remission from MDD with CBT, however. Mental health clinicians currently lack clinical or biological markers that can reliably predict treatment outcome with CBT for MDD. Developing such markers could greatly improve clinical outcomes, and could facilitate matching of patients to treatments that are likely to help them. A recent functional magnetic resonance imaging (fMRI) study in healthy individuals examined the neural correlates of cognitive strategies to regulate emotional responses to emotional stimuli. The emotional regulation techniques used in this fMRI study map closely onto the cognitive restructuring techniques that are a primary tool used in CBT for MDD. There is evidence that patients with depression may benefit most from a psychotherapy that draws on their existing strengths. We therefore propose to examine the neural representations of emotion regulation as a predictor of treatment outcome with CBT for MDD. We will recruit subjects with MDD in a current major depressive episode. Research participants will complete baseline psychological and biological assessments, including MRI and functional MRI imaging. Following scanning, subjects will receive 14 sessions of individual CBT for depression over 12 weeks, administered by an experienced psychiatrist or psychologist. Baseline assessments will be examined as predictors of treatment outcome with CBT for depression.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Major Depressive Disorder']},\n",
       "       'KeywordList': {'Keyword': ['depression',\n",
       "         'cognitive therapy',\n",
       "         'cognitive behavioral therapy',\n",
       "         'CBT',\n",
       "         'psychotherapy',\n",
       "         'MDD',\n",
       "         'major depressive disorder',\n",
       "         'MRI',\n",
       "         'fMRI']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '37',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cognitive Behavioral Therapy',\n",
       "          'ArmGroupType': 'Other',\n",
       "          'ArmGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive Behavioral Therapy']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Cognitive Behavioral Therapy',\n",
       "          'InterventionDescription': '14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cognitive Behavioral Therapy']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Remitters as Assessed by Post-treatment Beck Depression Inventory Less Than or Equal to 10',\n",
       "          'PrimaryOutcomeDescription': 'The primary outcome of this study is remission from depression at the conclusion of 12 weeks of cognitive behavioral therapy for depression. This will be assessed using the Beck Depression Inventory, a self-report questionnaire of symptoms of depression that will be administered at every treatment visit. Remission is defined by a final Beck Depression Inventory score less than or equal to 10.',\n",
       "          'PrimaryOutcomeTimeFrame': '12 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Post-Treatment Beck Depression Inventory',\n",
       "          'SecondaryOutcomeDescription': \"The Beck Depression Inventory is a self-report measure of depression severity that is a well-characterized scale with excellent psychometric properties and is frequently used in research studies of depression.\\n\\nThe scale measures symptoms related to sadness, pessimism, past failure, loss of pleasure, guilty feelings, punishment feelings, self-dislike, self-criticalness, suicidal thoughts or wishes, crying, agitation, loss of interest, indecisiveness, worthlessness, loss of energy, changes in sleeping pattern, irritability, changes in appetite, concentration difficulty, tiredness or fatigue, and loss of interest in sex.\\n\\nWe report the total score on the BDI, which has a range of 0 to 63. Higher values represent greater severity of depression. The following score interpretations are provided in the scale's manual:\\n\\n0-9 minimal depression 10-18 mild depression 19-29 moderate depression 30-63 severe depression\",\n",
       "          'SecondaryOutcomeTimeFrame': 'Post-Treatment, up to 12 weeks'},\n",
       "         {'SecondaryOutcomeMeasure': 'Final Score on the Hamilton Depression Rating Scale',\n",
       "          'SecondaryOutcomeDescription': 'Final score on the Hamilton Depression Rating Scale (HDRS) was calculated for 37 patients who were treated with Cognitive Behavioral Therapy.\\n\\nThe 17-item HDRS is a clinician-administered scale that quantifies depression severity, and includes items assessing mood, suicidal thinking, insomnia, feelings of guilt, work and activities, somatic symptoms, and insight. It is a well-characterized scale with excellent psychometric properties. The total score is the sum of the individual scores of the 17 scale items. Higher scores indicate greater depression severity. When using this outcome measure, we covary for baseline HDRS scores. Published norms for interpretation of the 17-item HDRS use a different version of the scale with a total possible score of 52, and are listed below. Interpretation is comparable (but not identical) with the 17-item HDRS version used in this study, which has a maximum score is 51.\\n\\nNone: 0-7 Mild: 8-13 Moderate: 14-19 Severe: 20-25 Very Severe: 26-52',\n",
       "          'SecondaryOutcomeTimeFrame': 'Post-Treatment, up to 12 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nIn a current major depressive episode\\nIf currently on medications, lack of benefit after an adequate trial. If currently on medications, willing and able to tolerate a medication washout.\\nAbility to provide an informed consent\\nFor healthy volunteers, no current or past history of depression\\n\\nExclusion Criteria:\\n\\nUnstable medical conditions\\nCurrent alcohol or substance abuse or dependence\\nCurrent or past history of other major psychiatric disorders such as Bipolar disorder, schizophrenia, or other psychotic illnesses (Anxiety in depressed participants is okay)\\nFor females, current pregnancy\\nDementia or neurological disease or head trauma with evidence of cognitive impairment\\nCurrently taking fluoxetine\\nContraindication to CBT\\nPresence of metal in body\\nClaustrophobia\\nWeight > 350 pounds',\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jeffrey M Miller, M.D.',\n",
       "          'OverallOfficialAffiliation': 'New York State Psychiatric Institute',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'New York State Psychiatric Institute',\n",
       "          'LocationCity': 'New York',\n",
       "          'LocationState': 'New York',\n",
       "          'LocationZip': '10032',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Cognitive Behavioral Therapy',\n",
       "          'FlowGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).\\n\\nCognitive Behavioral Therapy: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '37'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '28'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '9'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Cognitive Behavioral Therapy',\n",
       "          'BaselineGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).\\n\\nCognitive Behavioral Therapy: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '37'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '36'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '1'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '36',\n",
       "                   'BaselineMeasurementSpread': '11.1'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '24'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '13'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '6'}]}},\n",
       "               {'BaselineCategoryTitle': 'Not Hispanic or Latino',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '27'}]}},\n",
       "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '4'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Race (NIH/OMB)',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Asian',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '4'}]}},\n",
       "               {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Black or African American',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '3'}]}},\n",
       "               {'BaselineCategoryTitle': 'White',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '22'}]}},\n",
       "               {'BaselineCategoryTitle': 'More than one race',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '3'}]}},\n",
       "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '5'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '37'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Remitters as Assessed by Post-treatment Beck Depression Inventory Less Than or Equal to 10',\n",
       "          'OutcomeMeasureDescription': 'The primary outcome of this study is remission from depression at the conclusion of 12 weeks of cognitive behavioral therapy for depression. This will be assessed using the Beck Depression Inventory, a self-report questionnaire of symptoms of depression that will be administered at every treatment visit. Remission is defined by a final Beck Depression Inventory score less than or equal to 10.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Count of Participants',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'Participants',\n",
       "          'OutcomeMeasureTimeFrame': '12 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Cognitive Behavioral Therapy',\n",
       "             'OutcomeGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).\\n\\nCognitive Behavioral Therapy: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '37'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '13'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Post-Treatment Beck Depression Inventory',\n",
       "          'OutcomeMeasureDescription': \"The Beck Depression Inventory is a self-report measure of depression severity that is a well-characterized scale with excellent psychometric properties and is frequently used in research studies of depression.\\n\\nThe scale measures symptoms related to sadness, pessimism, past failure, loss of pleasure, guilty feelings, punishment feelings, self-dislike, self-criticalness, suicidal thoughts or wishes, crying, agitation, loss of interest, indecisiveness, worthlessness, loss of energy, changes in sleeping pattern, irritability, changes in appetite, concentration difficulty, tiredness or fatigue, and loss of interest in sex.\\n\\nWe report the total score on the BDI, which has a range of 0 to 63. Higher values represent greater severity of depression. The following score interpretations are provided in the scale's manual:\\n\\n0-9 minimal depression 10-18 mild depression 19-29 moderate depression 30-63 severe depression\",\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'Score on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'Post-Treatment, up to 12 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Cognitive Behavioral Therapy',\n",
       "             'OutcomeGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).\\n\\nCognitive Behavioral Therapy: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '37'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '15.4',\n",
       "                   'OutcomeMeasurementSpread': '9.5'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Final Score on the Hamilton Depression Rating Scale',\n",
       "          'OutcomeMeasureDescription': 'Final score on the Hamilton Depression Rating Scale (HDRS) was calculated for 37 patients who were treated with Cognitive Behavioral Therapy.\\n\\nThe 17-item HDRS is a clinician-administered scale that quantifies depression severity, and includes items assessing mood, suicidal thinking, insomnia, feelings of guilt, work and activities, somatic symptoms, and insight. It is a well-characterized scale with excellent psychometric properties. The total score is the sum of the individual scores of the 17 scale items. Higher scores indicate greater depression severity. When using this outcome measure, we covary for baseline HDRS scores. Published norms for interpretation of the 17-item HDRS use a different version of the scale with a total possible score of 52, and are listed below. Interpretation is comparable (but not identical) with the 17-item HDRS version used in this study, which has a maximum score is 51.\\n\\nNone: 0-7 Mild: 8-13 Moderate: 14-19 Severe: 20-25 Very Severe: 26-52',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'Post-Treatment, up to 12 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Cognitive Behavioral Therapy',\n",
       "             'OutcomeGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).\\n\\nCognitive Behavioral Therapy: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '37'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '13.41',\n",
       "                   'OutcomeMeasurementSpread': '6.61'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Cognitive Behavioral Therapy',\n",
       "          'EventGroupDescription': 'Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).\\n\\nCognitive Behavioral Therapy: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '37',\n",
       "          'EventGroupOtherNumAffected': '1',\n",
       "          'EventGroupOtherNumAtRisk': '37'}]},\n",
       "       'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Knee Pain during MRI',\n",
       "          'OtherEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
       "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
       "          'OtherEventNotes': 'During an MRI, a subject developed mild unilateral knee pain similar to pain she had experienced in the past, and subsequently developed some stiffness and swelling in this knee. The IRB concluded that the event was neither serious nor study related.',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '37'}]}}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Jeffrey Miller, M.D.',\n",
       "        'PointOfContactOrganization': 'NYSPI',\n",
       "        'PointOfContactEMail': 'jm2233@cumc.columbia.edu',\n",
       "        'PointOfContactPhone': '646-774-7613'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000003865',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder, Major'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafAsFound': 'Major Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 67,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03941106',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'CNIG18may-0001'},\n",
       "       'Organization': {'OrgFullName': 'Institute of Mental Health, Singapore',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Accelerated Transcranial Magnetic Stimulation (aTBS) to Treat Depression',\n",
       "       'OfficialTitle': 'A Pilot Study of Intermittent Accelerated Burst Transcranial Magnetic Stimulation (aTBS) to Treat Depression: a Randomized, Single-blind, Delayed-start Trial'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'April 2019',\n",
       "       'OverallStatus': 'Not yet recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'July 1, 2019',\n",
       "        'StartDateType': 'Anticipated'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 1, 2021',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'May 1, 2021',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'April 7, 2019',\n",
       "       'StudyFirstSubmitQCDate': 'May 5, 2019',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 7, 2019',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'May 8, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 10, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Institute of Mental Health, Singapore',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The primary aims of this study are to investigate the efficacy of L DLPFC accelerated TMS (aTMS) in patients with depression in Singapore and to assess the whether a 1-week course of treatment is as effective as a 4-week course of non-accelerated treatment and if additional aTMS or different aTMS treatments will be more efficacious in non-responders to initial aTMS treatment.',\n",
       "       'DetailedDescription': \"Repetitive transcranial magnetic stimulation (TMS) is a technique for stimulating brain activity using transient magnetic field to induce an electrical current in the brain producing firing of focal groups of brain cells. TMS is beginning to emerge in routine clinical practice as a treatment for depression. The predominant hypothesis is that depressed patients benefit from left sided high-frequency TMS (LHF-TMS) over the left dorsolateral prefrontal cortex (DLPFC)(1). A major limitation of rTMS is the large amount of time taken for a standard protocol (38 minutes a day for 20-30 working days). The optimal type and duration of TMS is still uncertain , as is the optimal strategy for continuing or changing type of rTMS if there is poor initial response.(1) One potential strategy to improve the acceptability of rTMS is to compress or accelerate the administration of rTMS (aTMS) by administering multiple sessions of rTMS over a shorter period of time to have equivalent efficacy in shorter period of time. Various studies of aTMS (2-9) have been safely conducted with anywhere from 2 (3) to 10 (2) sessions of rTMS a day for a total of 9 (5) - 20 (4, 7) sessions of TMS over 2 (2) to 9 (8) days. These studies showed that aTMS was safe and efficacious, with no significant side effects reported and a high level of patient acceptability and significant improvements in subjects' depression after the aTMS. However, there is no data on whether subjects who do not response to aTMS will benefit from more of the same TMS or from changing the mode of rTMS. The only study investigating this issue investigated normal rTMS, not aTMS, and did not find a significant difference in response to different forms of rTMS in initial non-responders (10). Our own observations and some preliminary evidence suggest that there may be a delayed response to TMS in some patients (11, 12). Thus, instead of the usual practice of giving 4-6 weeks stimulation (every weekday) and assessing for response at the end of the stimulation period, the same outcome may be achieved by giving a shorter period of stimulation (eg 1 weeks), waiting 2-4 weeks, then assessing response and the need for further TMS treatment. Further, giving more than 1 treatment per day has been shown to be effective (13) and may lead to more efficient treatment, i.e. fewer days to response and less requirement for patient attendance at the treatment centre (2-9).\\n\\nThis pilot study will contribute to existing knowledge by being possibly the first group in South East Asia to investigate the immediate and delayed efficacy of aTMS in the local population (i.e. in an Asian setting) as well as whether continuing or changing the type of rTMS is more efficacious in subjects who do not respond to initial aTMS.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['rTMS, depression, accelerated']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Sequential Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '60',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Left aTMS',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Accelerated repetitive transcranial magnetic stimulation']}},\n",
       "         {'ArmGroupLabel': 'Right aTMS',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Accelerated repetitive transcranial magnetic stimulation']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Device',\n",
       "          'InterventionName': 'Accelerated repetitive transcranial magnetic stimulation',\n",
       "          'InterventionDescription': 'Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Left aTMS',\n",
       "            'Right aTMS']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Remission as assessed by The Montgomery-Åsberg Depression Rating Scale (MADRS)',\n",
       "          'PrimaryOutcomeDescription': 'The MADRS is a 0-60 point scale to measure depression severity with a higher number indicating more severe depression. Remission from depression is defined as 10 or less. Moderate to severe depression is defined as 20 or more.',\n",
       "          'PrimaryOutcomeTimeFrame': '3 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Remission as assessed by The Montgomery-Åsberg Depression Rating Scale (MADRS)',\n",
       "          'SecondaryOutcomeDescription': 'A MADRS score of 10 or less.',\n",
       "          'SecondaryOutcomeTimeFrame': '6 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAge ≥21 years.\\nDSM-V diagnosis of current Major Depressive Episode.\\nMontgomery-Asberg Depression Rating Scale score of 20 or more.\\nAble to give informed consent.\\n\\nExclusion Criteria:\\n\\nDSM-V psychotic disorder.\\nDrug or alcohol abuse or dependence (preceding 3 months).\\nInadequate response to ECT (current episode of depression).\\nRapid clinical response required, e.g. high suicide risk.\\nSignificant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy.\\nMetal in the cranium, skull defects, pacemaker, cochlear implant, medication pump or other electronic device.\\nPregnancy.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '21 Years',\n",
       "       'MaximumAge': '85 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Phern-Chern Tor, MBBS',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '65-63892000',\n",
       "          'CentralContactEMail': 'phern_chern_tor@imh.com.sg'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26909825',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Tor PC, Gálvez V, Goldstein J, George D, Loo CK. Pilot Study of Accelerated Low-Frequency Right-Sided Transcranial Magnetic Stimulation for Treatment-Resistant Depression. J ECT. 2016 Sep;32(3):180-2. doi: 10.1097/YCT.0000000000000306.'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 68,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01773629',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '2010-38-LGH'},\n",
       "       'Organization': {'OrgFullName': 'Lancaster General Hospital',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Care Managers for Perinatal Depression (CMPD)',\n",
       "       'OfficialTitle': 'Care Managers for Perinatal Depression (CMPD)',\n",
       "       'Acronym': 'CMPD'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'January 2014',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'September 2010'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2013',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2013',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'January 16, 2013',\n",
       "       'StudyFirstSubmitQCDate': 'January 18, 2013',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 23, 2013',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'January 29, 2014',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 30, 2014',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Lancaster General Hospital',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Pennsylvania',\n",
       "          'CollaboratorClass': 'OTHER'},\n",
       "         {'CollaboratorName': 'Robert Wood Johnson Foundation',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The investigators will evaluate effects of introducing the care manager on:\\n\\nPatient receipt of timely diagnosis and initiation of treatment for major depression (diagnosis within 2 weeks of screening and treatment within 1 month of diagnosis); and\\nPatient continuity of care for depression across the transition of care from pregnancy to postpartum (within 4 months postpartum).',\n",
       "       'DetailedDescription': 'The first two specific research aims of this proposed randomized study will evaluate the benefits of introducing site specific care managers into established multi-component enhancements of perinatal depression care. The four study sites are members of the IMPLICIT perinatal quality improvement network and provide prenatal care to a diverse population of low income minority women using a common set of care processes within diverse practice models including Obstetric, Family Medicine, and Nurse Practitioner/Midwifery settings. The established processes of care include evidence based screening, diagnosis, treatment protocols and quality improvement care teams.\\n\\nThe investigators will evaluate effects of introducing the care manager on:\\n\\nPatient receipt of timely diagnosis and initiation of treatment for major depression (diagnosis within 2 weeks of screening and treatment within 1 month of diagnosis); and\\nPatient continuity of care for depression across the transition of care from pregnancy to postpartum (within 4 months postpartum).\\n\\nFor the third and fourth specific research aims we will conduct supplementary econometric and qualitative analyses to aid in understanding the provider and system context in which this intervention is implemented across the four study sites. Results of this evaluation will be used to understand for whom and in which systems of care this model is most successful as well as the costs of delivering this intervention.\\n\\nSpecifically the investigators will:\\n\\nEmploy econometric techniques to quantify the costs of implementing and maintaining the IMPLICIT collaborative care maternal depression intervention; and\\nDevelop institutional ethnographies of the four study sites and identify factors associated with relative success in implementing perinatal depression care managers and improving timely diagnosis, initiation, and continuity of depression care.\\n\\nAchieving these aims will provide the foundation for dissemination of this innovative approach to perinatal depression care delivery throughout the entire growing IMPLICIT network which now extends across the northeast and mid-Atlantic regions of the US; sites which provide perinatal care for low income minority women in urban, rural, and suburban communities. These sites include prenatal practices in the Robert Wood Johnson Foundation Aligning Forces for Quality initiative, the Healthy York County Coalition which is partnering with us to disseminate this work in their region.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression',\n",
       "         'Pregnancy']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Pregnancy',\n",
       "         'Postpartum',\n",
       "         'Perinatal']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '194',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Intervention']}},\n",
       "         {'ArmGroupLabel': 'Control',\n",
       "          'ArmGroupType': 'Other',\n",
       "          'ArmGroupDescription': 'Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a \"perinatal depression champion\" for a timely formal diagnostic interview.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Control']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Intervention',\n",
       "          'InterventionDescription': 'Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Control',\n",
       "          'InterventionDescription': 'Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a \"perinatal depression champion\" for a timely formal diagnostic interview.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Diagnosis of major depression within 2 weeks of screening',\n",
       "          'PrimaryOutcomeDescription': 'Patient receipt of timely diagnosis for major depression during perinatal period.',\n",
       "          'PrimaryOutcomeTimeFrame': '2 weeks after screening'},\n",
       "         {'PrimaryOutcomeMeasure': 'Treatment of major depression within 1 month of diagnosis',\n",
       "          'PrimaryOutcomeDescription': 'Patient receipt of timely initiation of treatment for major depression during the perinatal period.',\n",
       "          'PrimaryOutcomeTimeFrame': '1 month'},\n",
       "         {'PrimaryOutcomeMeasure': 'Transition of care from pregnancy to postpartum',\n",
       "          'PrimaryOutcomeDescription': 'Patient continuity of care for depression across the transition of care from pregnancy to postpartum within 4 months postpartum.',\n",
       "          'PrimaryOutcomeTimeFrame': '4 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quantify the costs of implementing a care manager',\n",
       "          'SecondaryOutcomeDescription': 'Employ econometric techniques to quantify the costs of implementing and maintaining the care manager for managing perinatal depression.',\n",
       "          'SecondaryOutcomeTimeFrame': '3 years'},\n",
       "         {'SecondaryOutcomeMeasure': 'Qualitative assessment of success in implementation of perinatal depression care management process.',\n",
       "          'SecondaryOutcomeDescription': 'Develop institutional ethnographies of the study sites and identify factors associated with relative success in implementing perinatal depression care managers and improving timely diagnosis, initiation, and continuity of depression care. Qualitative measures include efficacy of core implementation group, commitment of implementation group, commitment of user group and readiness to change.',\n",
       "          'SecondaryOutcomeTimeFrame': '3 years'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nFemale\\nCurrent pregnancy or experienced pregnancy in the past 6 weeks\\nScore >= 12 on PHQ9\\n\\nExclusion Criteria:\\n\\n< age 13\\nMental illness\\nPrimary language other than English or Spanish',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Female',\n",
       "       'MinimumAge': '13 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Stephen Ratcliffe, MD, MSPH',\n",
       "          'OverallOfficialAffiliation': 'Lancaster General Hospital',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Ian M Bennett, MD, PhD',\n",
       "          'OverallOfficialAffiliation': 'University of Pennsylvania',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Donna Cohen, MD, MS',\n",
       "          'OverallOfficialAffiliation': 'Lancaster General Hospital',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Michael A Horst, PhD, MPHS, MS',\n",
       "          'OverallOfficialAffiliation': 'Lancaster General Hospital',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Downtown Family Medicine',\n",
       "          'LocationCity': 'Lancaster',\n",
       "          'LocationState': 'Pennsylvania',\n",
       "          'LocationZip': '17604',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Southeast Lancaster Health Services',\n",
       "          'LocationCity': 'Lancaster',\n",
       "          'LocationState': 'Pennsylvania',\n",
       "          'LocationZip': '17608',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Broad Street Health Center',\n",
       "          'LocationCity': 'Philadelphia',\n",
       "          'LocationState': 'Pennsylvania',\n",
       "          'LocationZip': '19122',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Haddington Health Center',\n",
       "          'LocationCity': 'Philadelphia',\n",
       "          'LocationState': 'Pennsylvania',\n",
       "          'LocationZip': '19139',\n",
       "          'LocationCountry': 'United States'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 69,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03283254',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '7428'},\n",
       "       'Organization': {'OrgFullName': 'New York State Psychiatric Institute',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'PREPP: Preventing Postpartum Depression',\n",
       "       'OfficialTitle': 'Preventing Postpartum Depression: A Dyadic Approach Adjunctive to Obstetric Care',\n",
       "       'Acronym': 'PREPP'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'June 2019',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'October 17, 2017',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 20, 2022',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'August 10, 2022',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'August 14, 2017',\n",
       "       'StudyFirstSubmitQCDate': 'September 12, 2017',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 14, 2017',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'June 6, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 10, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Catherine Monk',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Professor of Medical Psychology',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'New York State Psychiatric Institute'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'New York State Psychiatric Institute',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': \"The primary aim of this study is to determine if a behavioral intervention targeting maternal caregiving of young infants can increase infant sleep and reduce fuss/cry behavior, and thereby (1) reduce the incidence and/or severity of postpartum maternal depression and (2) improve the quality of the mother-infant interaction and subsequent child development. Specifically, the study team will investigate: (1) the effectiveness of the intervention compared to usual care; (2) if the effects of the intervention can be detected in the assessments of the quality of mother-infant interaction; (3) if there are prenatal and/or postnatal biomarkers that can help identify infants whose behavior is more likely to play a role in their mothers' depression; (4) if these markers differentiate which infants will be most responsive to the intervention(s); and (5), if assessments of brain function at birth and at 4-6 weeks of age provide biological nodal points for identifying the effects of the intervention on infant brain development. Participants will be recruited during their 2nd trimester, and will be randomly separated into one of two groups: a group that receives coaching in parenting techniques (4 in-person coaching sessions and 1 phone session) or one that receives treatment as usual.\",\n",
       "       'DetailedDescription': \"Of the nearly 4 million mothers delivering live births each year in the United States, approximately 560,000 — or 14% — will develop major or minor depression within the first four months postpartum, when the rate peaks. This number dwarfs prevalence rates for gestational diabetes (2-5%) and is comparable to preterm birth (11.4%). Postpartum depression (PPD) has substantial consequences: poorer maternal quality of life, significant emotional suffering, and suicide risk. PPD predicts diminished mother-infant bonding, and poor outcomes in social-emotional and, in some groups, cognitive development. PPD is undertreated in part because women are reluctant to seek treatment due to the stigma associated with mental health care, logistical barriers to at-tending added health care appointments, and disinclination to take medications while breastfeeding. Of preventive interventions, few embed services in obstetrical care or leverage the unique mother-infant dyadic orientation of the childbearing period. The investigators developed a novel intervention based on the conceptualization of maternal depression as a potential disorder of the mother-infant dyad, and one that can be approached through psychological and behavioral changes in the mother — commencing before birth — that affect her and the child. PREPP (Practical Resources for Effective Postpartum Parenting) enrolls distressed pregnant women at risk for PPD, spans late pregnancy to the 6 week postpartum check up, comprises four in-person 'coaching' sessions adjunctive to obstetrical (OB) prenatal and postnatal appointments, one phone session, and imparts (a) mindfulness and self-reflection skills, (b) parenting skills, and (c) psycho-education.\\n\\nThe primary aim of this study is to determine if a behavioral intervention targeting maternal caregiving of young infants can increase infant sleep and reduce fuss/cry behavior, and thereby (1) reduce the incidence and/or severity of postpartum maternal depression and (2) improve the quality of the mother-infant interaction and subsequent child development.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Postpartum Depression']},\n",
       "       'KeywordList': {'Keyword': ['Postpartum Depression Treatment']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignInterventionModelDescription': 'Two groups: One receives PREPP prevention intervention and the other group receives Enhanced Treatment as Usual (psychoeducation about Postpartum Depression, referral and monitoring)',\n",
       "        'DesignPrimaryPurpose': 'Prevention',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignMaskingDescription': 'The person administering the outcome measures is blind to participant group.',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '300',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Practical Resources for Effective Postpartum (PREPP)',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'A psychotherapeutic preventive intervention that involves psychoeducation and cognitive behavioral techniques.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Practical Resources for Effective Postpartum Parenting']}},\n",
       "         {'ArmGroupLabel': 'Enhanced Treatment as Usual',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Psychoeducation about Postpartum Depression, referral to treatment in the community and monitoring',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Enhanced Treatment As Usual']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Practical Resources for Effective Postpartum Parenting',\n",
       "          'InterventionDescription': 'A preventive psychotherapy intervention for Postpartum Depression',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Practical Resources for Effective Postpartum (PREPP)']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['PREPP']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Enhanced Treatment As Usual',\n",
       "          'InterventionDescription': 'Psychoeducation about Postpartum Depression, referral to treatment in the community, clinical monitoring',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Enhanced Treatment as Usual']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['ETAU']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Postpartum Depression Symptoms',\n",
       "          'PrimaryOutcomeDescription': 'Postpartum Depression Symptoms measured by Edinburgh Postnatal Depression Scale',\n",
       "          'PrimaryOutcomeTimeFrame': '6-16 weeks postpartum'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Improved Sleep',\n",
       "          'SecondaryOutcomeDescription': 'Improved self-report of sleep quality on Pittsburgh Sleep Quality Index and improved sleep shown on actigraphy monitor',\n",
       "          'SecondaryOutcomeTimeFrame': '3rd trimester of pregnancy - 16 weeks postpartum'},\n",
       "         {'SecondaryOutcomeMeasure': 'Infant Behavior',\n",
       "          'SecondaryOutcomeDescription': 'Cry behavior and sleep behavior measured by The Baby Day Diary',\n",
       "          'SecondaryOutcomeTimeFrame': '6 & 16 weeks postpartum'},\n",
       "         {'SecondaryOutcomeMeasure': 'Greater infant left frontal EEG power reflecting sleep spindle activity',\n",
       "          'SecondaryOutcomeDescription': 'More positive perceptions and objective assessments of maternal postpartum sleep efficiency will be mediated by greater infant left frontal EEG power reflecting sleep spindle activity and associated longer average durations of infant nocturnal sleep per maternal report and actigraphy.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Newborn-6 weeks postpartum'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHealthy pregnant women between 18-45 years old (based on self report)\\nA score of ≥21 on the Predictive Index of Postnatal Depression (PIPD), indicating risk for developing postpartum depression\\nA healthy, singleton pregnancy (based on self report)\\nEnglish speaking (based on self report)\\nReceiving standard prenatal care (based on self report)\\n\\nExclusion Criteria:\\n\\nMulti-fetal pregnancy (based on self-report)\\nSmoking, illicit drug use, or alcohol use during pregnancy (based on self-report)\\nAcute medical illness or significant pregnancy complication (based on self-report)\\nCurrently in weekly, individual psychotherapy, including psychopharmacology (based on self report)\\nPsychotic d/o; Bipolar I; Major Depressive d/o (based on M.I.N.I.)',\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'Female',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '45 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Elizabeth Werner, Ph.D.',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '6463191008',\n",
       "          'CentralContactEMail': 'ew150@cumc.columbia.edu'},\n",
       "         {'CentralContactName': 'Catherine Monk, Ph.D.',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '917-543-6031',\n",
       "          'CentralContactEMail': 'cem31@cumc.columbia.edu'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Catherine Monk, Ph.D.',\n",
       "          'OverallOfficialAffiliation': 'Columbia University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Elizabeth Werner, Ph.D.',\n",
       "          'OverallOfficialAffiliation': 'Columbia University',\n",
       "          'OverallOfficialRole': 'Study Director'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Elizabeth Werner',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'New York',\n",
       "          'LocationState': 'New York',\n",
       "          'LocationZip': '10032',\n",
       "          'LocationCountry': 'United States',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Elizabeth Werner, Ph.D.',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '646-774-8945',\n",
       "             'LocationContactEMail': 'ew150@cumc.columbia.edu'},\n",
       "            {'LocationContactName': 'Catherine Monk, Ph.D.',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '646-774-8941',\n",
       "             'LocationContactEMail': 'cem31@cumc.columbia.edu'},\n",
       "            {'LocationContactName': 'Catherine Monk, PhD',\n",
       "             'LocationContactRole': 'Principal Investigator'}]}}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'Yes',\n",
       "       'IPDSharingDescription': 'De-identified data may be made available to other researchers.',\n",
       "       'IPDSharingInfoTypeList': {'IPDSharingInfoType': ['Study Protocol',\n",
       "         'Informed Consent Form (ICF)']},\n",
       "       'IPDSharingTimeFrame': 'After the completion of the study',\n",
       "       'IPDSharingAccessCriteria': 'Permission of the PI'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000019052',\n",
       "          'ConditionMeshTerm': 'Depression, Postpartum'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000011644',\n",
       "          'ConditionAncestorTerm': 'Puerperal Disorders'},\n",
       "         {'ConditionAncestorId': 'D000011248',\n",
       "          'ConditionAncestorTerm': 'Pregnancy Complications'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M19660',\n",
       "          'ConditionBrowseLeafName': 'Depression, Postpartum',\n",
       "          'ConditionBrowseLeafAsFound': 'Postpartum Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13082',\n",
       "          'ConditionBrowseLeafName': 'Puerperal Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M12710',\n",
       "          'ConditionBrowseLeafName': 'Pregnancy Complications',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXS',\n",
       "          'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}}}},\n",
       "   {'Rank': 70,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01238614',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'MLM-CHICA-K-MD'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'K22LM009160',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=K22LM009160&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'Indiana University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Universal Screening for Maternal Depression With the CHICA System',\n",
       "       'OfficialTitle': 'Universal Screening for Maternal Depression With the CHICA System'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'November 2010',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'October 2007'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2009',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'September 2010',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'November 9, 2010',\n",
       "       'StudyFirstSubmitQCDate': 'November 9, 2010',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 10, 2010',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'November 9, 2010',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 10, 2010',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyOldNameTitle': 'Paul Biondich',\n",
       "        'ResponsiblePartyOldOrganization': 'IUPUI'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Indiana University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Library of Medicine (NLM)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The CHICA system is a clinical decision support system that uses adaptive turnaround documents to provide point-of-care information to clinicians. We will be studying whether it can help in the diagnosis and referral of mothers with maternal depression.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Maternal Depression']},\n",
       "       'KeywordList': {'Keyword': ['maternal depression',\n",
       "         'clinical decision support']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Factorial Assignment',\n",
       "        'DesignPrimaryPurpose': 'Screening',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '3250',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'PSF-JIT',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Mothers in this arm receive prescreening questions and clinicians receive just-in-time handouts to aid in diagnosis.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: CHICA PSF plus JIT']}},\n",
       "         {'ArmGroupLabel': 'PSF',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Mothers in this arm receive screening questions on the prescreener form',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: CHICA maternal depression PSF']}},\n",
       "         {'ArmGroupLabel': 'Control',\n",
       "          'ArmGroupType': 'Placebo Comparator',\n",
       "          'ArmGroupDescription': 'Mothers in this arm receive no maternal depression CHICA additional care',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Control']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'CHICA PSF plus JIT',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['PSF-JIT']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'CHICA maternal depression PSF',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['PSF']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Control',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Percent of mothers screening positive for maternal depression.',\n",
       "          'PrimaryOutcomeTimeFrame': \"1 year after child's birth\"}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Percent of mothers diagnosed with maternal depression',\n",
       "          'SecondaryOutcomeTimeFrame': \"one year after child's birth\"}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAll families of patients age 0 to 15 months\\n\\nExclusion Criteria:\\n\\nNone',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Female',\n",
       "       'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'CHSR',\n",
       "          'LocationCity': 'Indianapolis',\n",
       "          'LocationState': 'Indiana',\n",
       "          'LocationZip': '46202',\n",
       "          'LocationCountry': 'United States'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 71,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00556140',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '2003-P-000990'},\n",
       "       'Organization': {'OrgFullName': 'Massachusetts General Hospital',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression',\n",
       "       'OfficialTitle': 'The Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Acute Treatment of Psychotic Major Depression: Efficacy and Tolerability',\n",
       "       'Acronym': 'Abilify'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2012',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'June 2003'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2008',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'January 2008',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'November 8, 2007',\n",
       "       'StudyFirstSubmitQCDate': 'November 8, 2007',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 9, 2007',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'June 1, 2012',\n",
       "       'ResultsFirstSubmitQCDate': 'July 11, 2012',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 20, 2012',\n",
       "        'ResultsFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 11, 2012',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 20, 2012',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'John D. Matthews',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Massachusetts General Hospital'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Massachusetts General Hospital',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Bristol-Myers Squibb',\n",
       "          'CollaboratorClass': 'INDUSTRY'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Psychotic Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 3']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '16',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Major Depression with Psychotic Features',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Aripiprazole']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Aripiprazole',\n",
       "          'InterventionDescription': 'Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.\\n\\nAripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.\\n\\nYou will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Major Depression with Psychotic Features']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Abilify']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression and Psychosis Response Rate',\n",
       "          'PrimaryOutcomeDescription': 'This response rate refers to the percentage of patients who experienced a 50 percent or greater reduction in symptoms. Specifically, this refers to a 50 percent reduction in Hamilton Depression Rating Scale 17 (HAM-D-17) scores from baseline and no psychotic symptoms as measured by the Structured Clinical Interview for DMS-IV psychosis module. HAM-D-17 scores range from 0-50 with a score of >23 considered severely depressed and <7 to be mildly to not at all depressed.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline and 7 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depression and Psychosis Remission Rate',\n",
       "          'SecondaryOutcomeDescription': 'This remission rate refers to a Hamilton Depression Rating Scale 17 (HAM-D-17) score of 7 or less and no psychotic symptoms as measured by the Structured Clinical Interview for DMS-IV psychosis module. HAM-D-17 scores range from 0-50 with a score of >23 considered severely depressed and <7 to be mildly to not at all depressed.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline and 7 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nMen and women aged 18-80 years, inclusive.\\nDrug-free outpatients or inpatients meeting DSM-IV criteria for major depression with psychotic features.\\nInpatients who undergo a 5-7 day washout period of their medication while concurrently beginning one of the approved SSRI's and abilify.\\nHAM-D-24 score > 16.\\n\\nExclusion Criteria:\\n\\nPregnant women and women of child bearing potential not using a medically accepted means of contraception (oral contraceptives are allowed).\\nWomen who are breast-feeding.\\nPatients meeting DSM-IV criteria for major depression without psychotic features, or psychosis without major depression at the screen visit.\\nPatients with serious suicidal risk.\\nPatients with a history of seizure disorder; unstable physical disorders (cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic); or any physical disorder judged to significantly affect central nervous system function.\\nPatients meeting criteria for the following DSM-IV diagnoses: organic mental disorders; substance use disorders, including alcohol, active within the last 6 months; bipolar disorder; schizoaffective disorder; or antisocial personality disorder.\\nPatients who are currently taking an antidepressant, antipsychotic, or mood stabilizing drug and who are responding to one or all of these medications. If patients are not responding to these medications, they may go through a washout period of at least one week under the supervision of a study doctor before entering into this study.\\nPatients who are not able to read and understand the consent form, or who are not capable of understanding or giving informed consent to the procedures of the study\",\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '80 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Matthews D John, MD',\n",
       "          'OverallOfficialAffiliation': 'Massachusetts General Hospital',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Massachusetts General Hospital',\n",
       "          'LocationCity': 'Boston',\n",
       "          'LocationState': 'Massachusetts',\n",
       "          'LocationZip': '02114',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '19142112',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Matthews JD, Siefert C, Dording C, Denninger JW, Park L, van Nieuwenhuizen AO, Sklarsky K, Hilliker S, Homberger C, Rooney K, Fava M. An open study of aripiprazole and escitalopram for psychotic major depressive disorder. J Clin Psychopharmacol. 2009 Feb;29(1):73-6. doi: 10.1097/JCP.0b013e318193dfb4.'}]}}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'All participants enrolled in the study were given aripiprazole and escitalopram.',\n",
       "       'FlowRecruitmentDetails': 'Recruitment ran from Sept. 13, 2004 to Aug. 9, 2006 from the Massachusetts General Psychiatry Inpatient and Outpatient clinics.',\n",
       "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Major Depression With Psychotic Features',\n",
       "          'FlowGroupDescription': 'All patients received aripiprazole 10 milligrams and escitalopram 10 milligrams as starting doses. These doses were increased to 20 milligrams and 30 milligrams, respectively. These increases occurred over a period of 7 weeks.'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '16'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '13'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '3'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Major Depression With Psychotic Features',\n",
       "          'BaselineGroupDescription': 'All patients received aripiprazole 10 milligrams and escitalopram 10 milligrams as starting doses. These doses were increased to 20 milligrams and 30 milligrams, respectively. These increases occurred over a period of 7 weeks.'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '16'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '16'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Age Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '41.8',\n",
       "                   'BaselineMeasurementSpread': '12.9'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '6'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '10'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '16'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Depression and Psychosis Response Rate',\n",
       "          'OutcomeMeasureDescription': 'This response rate refers to the percentage of patients who experienced a 50 percent or greater reduction in symptoms. Specifically, this refers to a 50 percent reduction in Hamilton Depression Rating Scale 17 (HAM-D-17) scores from baseline and no psychotic symptoms as measured by the Structured Clinical Interview for DMS-IV psychosis module. HAM-D-17 scores range from 0-50 with a score of >23 considered severely depressed and <7 to be mildly to not at all depressed.',\n",
       "          'OutcomeMeasurePopulationDescription': 'For the 3 participants who did not complete the study, the \"last observation carried forward\" technique was used to replace missing data for them.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Number',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'percent of participants',\n",
       "          'OutcomeMeasureTimeFrame': 'Baseline and 7 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Major Depression With Psychotic Features',\n",
       "             'OutcomeGroupDescription': 'All patients received aripiprazole 10 milligrams and escitalopram 10 milligrams as starting doses. These doses were increased to 20 milligrams and 30 milligrams, respectively. These increases occurred over a period of 7 weeks.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '16'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '62.5',\n",
       "                   'OutcomeMeasurementSpread': '8.3'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Depression and Psychosis Remission Rate',\n",
       "          'OutcomeMeasureDescription': 'This remission rate refers to a Hamilton Depression Rating Scale 17 (HAM-D-17) score of 7 or less and no psychotic symptoms as measured by the Structured Clinical Interview for DMS-IV psychosis module. HAM-D-17 scores range from 0-50 with a score of >23 considered severely depressed and <7 to be mildly to not at all depressed.',\n",
       "          'OutcomeMeasurePopulationDescription': 'For the 3 participants who did not complete the study, the \"last observation carried forward\" technique was used to replace missing data for them.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Number',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'percent of participants',\n",
       "          'OutcomeMeasureTimeFrame': 'Baseline and 7 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Major Depression With Psychotic Features',\n",
       "             'OutcomeGroupDescription': 'All patients received aripiprazole 10 milligrams and escitalopram 10 milligrams as starting doses. These doses were increased to 20 milligrams and 30 milligrams, respectively. These increases occurred over a period of 7 weeks.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '16'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '50'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '5',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Major Depression With Psychotic Features',\n",
       "          'EventGroupDescription': 'All patients received aripiprazole 10 milligrams and escitalopram 10 milligrams as starting doses. These doses were increased to 20 milligrams and 30 milligrams, respectively. These increases occurred over a period of 7 weeks.',\n",
       "          'EventGroupSeriousNumAffected': '2',\n",
       "          'EventGroupSeriousNumAtRisk': '16',\n",
       "          'EventGroupOtherNumAffected': '16',\n",
       "          'EventGroupOtherNumAtRisk': '16'}]},\n",
       "       'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Orthostatic hypotension',\n",
       "          'SeriousEventOrganSystem': 'Vascular disorders',\n",
       "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
       "          'SeriousEventNotes': '1 subject had a severe orthostatic drop in her blood pressure requiring an ED visit while on aripiprazole 15mg a day, escitalopram 10 mg a day, and propanolol 10 mg 3 times a day.',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '1',\n",
       "             'SeriousEventStatsNumAffected': '1',\n",
       "             'SeriousEventStatsNumAtRisk': '16'}]}},\n",
       "         {'SeriousEventTerm': 'worsening of major depression with psychotic features',\n",
       "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
       "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
       "          'SeriousEventNotes': '1 subject had to be hospitalized for worsening of major depression with psychotic features.',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '1',\n",
       "             'SeriousEventStatsNumAffected': '1',\n",
       "             'SeriousEventStatsNumAtRisk': '16'}]}}]},\n",
       "       'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Akathisia',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '10',\n",
       "             'OtherEventStatsNumAffected': '10',\n",
       "             'OtherEventStatsNumAtRisk': '16'}]}},\n",
       "         {'OtherEventTerm': 'Gastrointestinal distress',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '4',\n",
       "             'OtherEventStatsNumAffected': '4',\n",
       "             'OtherEventStatsNumAtRisk': '16'}]}},\n",
       "         {'OtherEventTerm': 'Fatigue',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '16'}]}},\n",
       "         {'OtherEventTerm': 'Sedation',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '16'}]}},\n",
       "         {'OtherEventTerm': 'Body aches',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '16'}]}}]}},\n",
       "      'MoreInfoModule': {'LimitationsAndCaveats': {},\n",
       "       'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Dr. John Matthews',\n",
       "        'PointOfContactOrganization': 'Massachusetts General Hospital',\n",
       "        'PointOfContactEMail': 'jmatthews@partners.org',\n",
       "        'PointOfContactPhone': '617-724-0847'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000068180',\n",
       "          'InterventionMeshTerm': 'Aripiprazole'}]},\n",
       "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000928',\n",
       "          'InterventionAncestorTerm': 'Antidepressive Agents'},\n",
       "         {'InterventionAncestorId': 'D000011619',\n",
       "          'InterventionAncestorTerm': 'Psychotropic Drugs'},\n",
       "         {'InterventionAncestorId': 'D000014150',\n",
       "          'InterventionAncestorTerm': 'Antipsychotic Agents'},\n",
       "         {'InterventionAncestorId': 'D000014149',\n",
       "          'InterventionAncestorTerm': 'Tranquilizing Agents'},\n",
       "         {'InterventionAncestorId': 'D000002492',\n",
       "          'InterventionAncestorTerm': 'Central Nervous System Depressants'},\n",
       "         {'InterventionAncestorId': 'D000045505',\n",
       "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'},\n",
       "         {'InterventionAncestorId': 'D000018491',\n",
       "          'InterventionAncestorTerm': 'Dopamine Agonists'},\n",
       "         {'InterventionAncestorId': 'D000015259',\n",
       "          'InterventionAncestorTerm': 'Dopamine Agents'},\n",
       "         {'InterventionAncestorId': 'D000018377',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Agents'},\n",
       "         {'InterventionAncestorId': 'D000045504',\n",
       "          'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "         {'InterventionAncestorId': 'D000058825',\n",
       "          'InterventionAncestorTerm': 'Serotonin 5-HT1 Receptor Agonists'},\n",
       "         {'InterventionAncestorId': 'D000017366',\n",
       "          'InterventionAncestorTerm': 'Serotonin Receptor Agonists'},\n",
       "         {'InterventionAncestorId': 'D000018490',\n",
       "          'InterventionAncestorTerm': 'Serotonin Agents'},\n",
       "         {'InterventionAncestorId': 'D000058830',\n",
       "          'InterventionAncestorTerm': 'Serotonin 5-HT2 Receptor Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000012702',\n",
       "          'InterventionAncestorTerm': 'Serotonin Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000065127',\n",
       "          'InterventionAncestorTerm': 'Dopamine D2 Receptor Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000018492',\n",
       "          'InterventionAncestorTerm': 'Dopamine Antagonists'}]},\n",
       "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M229',\n",
       "          'InterventionBrowseLeafName': 'Aripiprazole',\n",
       "          'InterventionBrowseLeafAsFound': 'Aripiprazole',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M2828',\n",
       "          'InterventionBrowseLeafName': 'Antidepressive Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M13057',\n",
       "          'InterventionBrowseLeafName': 'Psychotropic Drugs',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M15487',\n",
       "          'InterventionBrowseLeafName': 'Antipsychotic Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M6056',\n",
       "          'InterventionBrowseLeafName': 'Dopamine',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19179',\n",
       "          'InterventionBrowseLeafName': 'Dopamine Agonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M16545',\n",
       "          'InterventionBrowseLeafName': 'Dopamine Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19088',\n",
       "          'InterventionBrowseLeafName': 'Neurotransmitter Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M14095',\n",
       "          'InterventionBrowseLeafName': 'Serotonin',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M18231',\n",
       "          'InterventionBrowseLeafName': 'Serotonin Receptor Agonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19180',\n",
       "          'InterventionBrowseLeafName': 'Dopamine Antagonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'CNSDep',\n",
       "          'InterventionBrowseBranchName': 'Central Nervous System Depressants'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'PsychDr',\n",
       "          'InterventionBrowseBranchName': 'Psychotropic Drugs'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'CaAg',\n",
       "          'InterventionBrowseBranchName': 'Cardiotonic Agents'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000001523',\n",
       "          'ConditionMeshTerm': 'Mental Disorders'},\n",
       "         {'ConditionMeshId': 'D000011618',\n",
       "          'ConditionMeshTerm': 'Psychotic Disorders'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000019967',\n",
       "          'ConditionAncestorTerm': 'Schizophrenia Spectrum and Other Psychotic Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafAsFound': 'Psychotic',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafAsFound': 'Psychotic',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13959',\n",
       "          'ConditionBrowseLeafName': 'Schizophrenia',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20422',\n",
       "          'ConditionBrowseLeafName': 'Schizophrenia Spectrum and Other Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 72,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03056183',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'Pro00045116'},\n",
       "       'Organization': {'OrgFullName': 'Cedars-Sinai Medical Center',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Care Transitions for Patients With Depression',\n",
       "       'OfficialTitle': 'Care Transitions for Medically Ill Patients With Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2019',\n",
       "       'OverallStatus': 'Withdrawn',\n",
       "       'WhyStopped': 'not funded',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 1, 2019',\n",
       "        'StartDateType': 'Anticipated'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2019',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 31, 2021',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'February 14, 2017',\n",
       "       'StudyFirstSubmitQCDate': 'February 14, 2017',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 17, 2017',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'July 27, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 30, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Waguih William IsHak, MD, FAPA',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Vice Chair, Education and Research',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Cedars-Sinai Medical Center'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Cedars-Sinai Medical Center',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': \"Aim 1: To collect data on a Depression Care Transition (DCT) program's association with self-care behaviors as measured by medication adherence and clinic visit attendance, after discharge. Hypothesis 1: Compared with usual care, patients who receive the DCT intervention will have significantly greater medication adherence and clinic visit attendance, at 30, 90, and 365 days after discharge.\\n\\nAim 2: To collect data on DCT's association with clinical/health outcomes as measured by depression severity, functional status, and overall physical and mental health, after discharge. Hypothesis 2: Compared with usual care, patients who receive the DCT intervention will have significantly larger improvements in depression severity, functional status, and overall physical & mental health at 30, 90, and 365 days after discharge.\\n\\nAim 3: To collect data on DCT's association with utilization outcomes as measured by readmissions, length of subsequent hospital stays, and cost of care, after discharge. Hypothesis 3: Compared with usual care, patients who receive the DCT intervention will have significantly lower hospital readmissions, shortened length of subsequent hospital stays and lower cost of care, at 30, 90, and 365 days of discharge.\\n\\nLeading the research team are a psychiatrist (Dr. IsHak - PI) and a hospitalist (Dr. Nuckols - Co-I) with an advanced and well-established track record of health services research/scholarship in the fields of depression, outcome measurement, and economic implications of improving the quality and safety of health care.\",\n",
       "       'DetailedDescription': \"This study will contribute to advancing the science of continuity of care delivery for depressed medical inpatients by collecting data on the impact of a modified evidence-based care transition model on clinical/health and utilization outcomes of depression in medically ill inpatients. The study could generate evidence to support the inpatient application of the USPSTF guidelines for screening adults for depression through staff-assisted depression care systems including follow-up and continuity of care. This study will add to the existing outpatient evidence for identification and treatment of depression in improving outcomes (Simon et al., 2001;O'Connor et al., 2013), the crucial aspect of inpatient evidence for depression identification, treatment, and continuity of care/care transitions in improving clinical/health and utilization outcomes.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '0', 'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Treatment Group',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Patients in the Depression Care Transitions intervention will have a Transitional Care Social Worker who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Depression Care Transitions (DCT)']}},\n",
       "         {'ArmGroupLabel': 'Control Group - Standard of Care',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'To be followed per standard of care and data from their medical records will be reviewed.'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Depression Care Transitions (DCT)',\n",
       "          'InterventionDescription': 'DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Treatment Group']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Transitional Care',\n",
       "          'PrimaryOutcomeDescription': 'Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.',\n",
       "          'PrimaryOutcomeTimeFrame': '365 days'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depression Surveys',\n",
       "          'SecondaryOutcomeDescription': 'All patients who are admitted to CSMC are screened for depression using the PHQ instrument (Kroenke, Spitzer, & Williams, 2001). Patients are asked two questions about frequent occurrence of cardinal depressive symptoms - sadness and anhedonia - and provide yes/no answers to the intake nurse (PHQ-2). If patients answer, \"yes\" to either question, they are administered the complete PHQ-9 instrument. Per the CSMC depression screening protocol, if patients score >12 on the PHQ-9, a social worker evaluation, and notification of the admitting physician and psychiatry, will take place. The subjects will be identified through the psychiatrist who will discuss the risks and benefits of study participation, and assess the patient\\'s interest in the study.',\n",
       "          'SecondaryOutcomeTimeFrame': '365 days'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nParticipants older than the age of 18, admitted to Cedars-Sinai Medical Center, English speaking, and answers \"yes\" to either question on the PHQ-2 instrument.\\n\\nExclusion Criteria:\\n\\nParticipants under the age of 18, non-English speaking, and does not answer \"yes\" to either question on the PHQ-2 instrument.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Waguih IsHak, MD',\n",
       "          'OverallOfficialAffiliation': 'Cedars-Sinai Medical Center',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 73,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02874027',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'xhechun2'},\n",
       "       'Organization': {'OrgFullName': 'General Hospital of Ningxia Medical University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'The Clinical Research on the Relationship Between Depression and Gut Microbiota in TBI Patients',\n",
       "       'OfficialTitle': 'The Clinical Research on the Relationship Between Depression and Gut Microbiota in TBI Patients'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'August 2016',\n",
       "       'OverallStatus': 'Unknown status',\n",
       "       'LastKnownStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'August 2016'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2017',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'August 17, 2016',\n",
       "       'StudyFirstSubmitQCDate': 'August 17, 2016',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 22, 2016',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'August 21, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 23, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'General Hospital of Ningxia Medical University',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Microbiome studies may be highlighted as crucial in the development of depression for TBI patients. The microbiota-gut-brain connection may further provide an opportunity for microbiota manipulation to treat the TBI patients with depression.This study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not and focus the study on the potential of the host-microbiota interaction in regulating depression.',\n",
       "       'DetailedDescription': 'Neuroscientists are probing the connections between intestinal microbes and brain development. The general scaffolding of the brain-gut-enteric microbiota axis includes the central nervous system (CNS), the neuroendocrine and neuroimmune systems,the sympathetic and parasympathetic arms of the autonomic nervous system (ANS),the enteric nervous system (ENS), and of course the intestinal microbiota. These components interact to form a complex reflex network with afferent fibers that project to integrative CNS structures and efferent projections to the smooth muscle. Gut microbiota regulates intestinal and extraintestinal homeostasis. Accumulating evidence suggests that the gut microbiota may also regulate brain function and behavior. Results from animal models indicate that disturbances in the composition and functionality of some microbiota members are associated with neurophysiological disorders, strengthening the idea of a microbiota-gut-brain axis and the role of microbiota as a\"peacekeeper\" in the brain health. It is now clear that the gut-brain communication is bidirectional. On one hand, changes in the microbial community affect behavior. On the other hand, perturbations in behavior alter the composition of the gut microbiota. Since changes in the composition of the gut microbiota are associated with the behavioral and cognitive alterations, a healthy microbiota community is essential for a normal regulation of the microbiota-gut-brain axis. Among the potential factors regulating the axis, microbial metabolites may be the major mediators. Seven million traumatic brain injuries (TBIs) occur each year in the many countries. One of the most common sequelae in patients exposed to TBI is post-traumatic brain syndrome, which is especially common following mild TBI. And the common one is depression.Depression is governed by the intricate interplay between sleep wake homeostasis and circadian rhythms in the body. These rhythms are largely controlled by the suprachiasmatic nucleus (SCN) of the anterior hypothalamus. Clock genes form the molecular machinery of this circadian system, operating via autoregulatory feedback loops.\\n\\nAmong the vertebrate peripheral tissues that express circadian rhythms is the gastrointestinal system, which exhibit circadian rhythms in gene expression (including clock genes), motility and secretion in vivo and in vitro. These rhythms depend upon a patent molecular clock and they are also coordinated by SCN input via the sympathetic nervous system.\\n\\nThe emerging role of the gut microbiome as an important modulator of gastrointestinal function has recently included the role of circadian rhythms. Recent studies have suggested that microbial signaling plays a critical role in homeostatic maintenance of intestinal function along with the host circadian mechanism.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Traumatic Brain Injury With Brief Loss of Consciousness']},\n",
       "       'KeywordList': {'Keyword': ['gut microbiota',\n",
       "         'depression',\n",
       "         'gut-brain axis',\n",
       "         'circadian rhythm',\n",
       "         'Traumatic Brain Injury']}},\n",
       "      'DesignModule': {'StudyType': 'Observational',\n",
       "       'PatientRegistry': 'No',\n",
       "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case Control']}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '50',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'TBI Patients with depression',\n",
       "          'ArmGroupDescription': 'All the patients should be diagnosed by CCMD－3(evaluation of depression)',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: The TBI patients with depression']}},\n",
       "         {'ArmGroupLabel': 'TBI Patients without depression',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: The TBI patients with depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'The TBI patients with depression',\n",
       "          'InterventionDescription': 'The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['TBI Patients with depression',\n",
       "            'TBI Patients without depression']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'the relationship between depression and circadian rhythm of patients with TBI',\n",
       "          'PrimaryOutcomeTimeFrame': 'From three months to six months after traumatic brain injury'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'the relationship between gut microbiota and circadian rhythm of patients with TBI',\n",
       "          'SecondaryOutcomeTimeFrame': 'From three months to six months after traumatic brain injury'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nThe mild TBI (mTBI) patients (a short loss of consciousness (<30 min), and/or a short post-traumatic amnesia (PTA) (< 24 h), a Glasgow Coma Scale (GCS) score between 13 and 15)\\nclinical diagnosis of depression\\n\\nExclusion Criteria:\\n\\nthe moderate and severe TBI patients.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '60 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult']},\n",
       "       'StudyPopulation': 'The number of patients is 25 and the health people is 25.',\n",
       "       'SamplingMethod': 'Probability Sample'},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Xia hechun, Bachelor',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '8613995109559',\n",
       "          'CentralContactEMail': 'xhechun@aliyun.com'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Xia Hechun, Bachelor',\n",
       "          'OverallOfficialAffiliation': 'General Hospital of Ningxia Medical University',\n",
       "          'OverallOfficialRole': 'Study Director'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'General Hospital of Ningxia Medical University',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Yinchuan',\n",
       "          'LocationState': 'Ningxia',\n",
       "          'LocationZip': '750004',\n",
       "          'LocationCountry': 'China',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Xia Hechun, Bachelor',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '8613995109559',\n",
       "             'LocationContactEMail': 'Xhechun@aliyun.com'}]}}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001930',\n",
       "          'ConditionMeshTerm': 'Brain Injuries'},\n",
       "         {'ConditionMeshId': 'D000070642',\n",
       "          'ConditionMeshTerm': 'Brain Injuries, Traumatic'},\n",
       "         {'ConditionMeshId': 'D000014474',\n",
       "          'ConditionMeshTerm': 'Unconsciousness'},\n",
       "         {'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000001927',\n",
       "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
       "         {'ConditionAncestorId': 'D000002493',\n",
       "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
       "         {'ConditionAncestorId': 'D000009422',\n",
       "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
       "         {'ConditionAncestorId': 'D000006259',\n",
       "          'ConditionAncestorTerm': 'Craniocerebral Trauma'},\n",
       "         {'ConditionAncestorId': 'D000020196',\n",
       "          'ConditionAncestorTerm': 'Trauma, Nervous System'},\n",
       "         {'ConditionAncestorId': 'D000014947',\n",
       "          'ConditionAncestorTerm': 'Wounds and Injuries'},\n",
       "         {'ConditionAncestorId': 'D000003244',\n",
       "          'ConditionAncestorTerm': 'Consciousness Disorders'},\n",
       "         {'ConditionAncestorId': 'D000019954',\n",
       "          'ConditionAncestorTerm': 'Neurobehavioral Manifestations'},\n",
       "         {'ConditionAncestorId': 'D000009461',\n",
       "          'ConditionAncestorTerm': 'Neurologic Manifestations'},\n",
       "         {'ConditionAncestorId': 'D000012816',\n",
       "          'ConditionAncestorTerm': 'Signs and Symptoms'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M3789',\n",
       "          'ConditionBrowseLeafName': 'Brain Injuries',\n",
       "          'ConditionBrowseLeafAsFound': 'Brain Injury',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M628',\n",
       "          'ConditionBrowseLeafName': 'Brain Injuries, Traumatic',\n",
       "          'ConditionBrowseLeafAsFound': 'Traumatic Brain Injury',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M15807',\n",
       "          'ConditionBrowseLeafName': 'Unconsciousness',\n",
       "          'ConditionBrowseLeafAsFound': 'Loss of Consciousness',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3786',\n",
       "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M4325',\n",
       "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M16268',\n",
       "          'ConditionBrowseLeafName': 'Wounds and Injuries',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M7932',\n",
       "          'ConditionBrowseLeafName': 'Craniocerebral Trauma',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20607',\n",
       "          'ConditionBrowseLeafName': 'Trauma, Nervous System',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5051',\n",
       "          'ConditionBrowseLeafName': 'Consciousness Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20410',\n",
       "          'ConditionBrowseLeafName': 'Neurobehavioral Manifestations',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M10987',\n",
       "          'ConditionBrowseLeafName': 'Neurologic Manifestations',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
       "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC26',\n",
       "          'ConditionBrowseBranchName': 'Wounds and Injuries'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
       "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}},\n",
       "   {'Rank': 74,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03928132',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '384530'},\n",
       "       'Organization': {'OrgFullName': 'CHU de Quebec-Universite Laval',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Integrating Sex and Gender Into CPD for Depression/Diabetes',\n",
       "       'OfficialTitle': 'Integrating Sex and Gender Considerations Into a Continuing Professional Development Activity on Diabetes and Depression: Protocol for a Non-Randomized Controlled Trial',\n",
       "       'Acronym': 'INCluDED'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'April 2019',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'April 1, 2017',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 29, 2020',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'March 31, 2020',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'April 23, 2019',\n",
       "       'StudyFirstSubmitQCDate': 'April 24, 2019',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 25, 2019',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'April 25, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 26, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'CHU de Quebec-Universite Laval',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Canadian Institutes of Health Research (CIHR)',\n",
       "          'CollaboratorClass': 'OTHER_GOV'},\n",
       "         {'CollaboratorName': 'Chaire Claire-Bonenfant-Femmes, Savoir et Société',\n",
       "          'CollaboratorClass': 'UNKNOWN'},\n",
       "         {'CollaboratorName': 'Institut du Savoir Montfort',\n",
       "          'CollaboratorClass': 'UNKNOWN'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': \"People with type 2 diabetes are twice as likely to experience depression as nondiabetic individuals, and depression in turn increases the risk of diabetes. Clinical care for patients for either condition usually fails to consider the impact of sex and gender on tests, diagnosis and treatment, and evidence on these impacts is limited. The investigators aim to assess the impact of a continuing professional education activity (CPD) on diabetes and depression that includes considerations of sex and gender on the clinical behaviours of French-speaking healthcare professionals in Canada.\\n\\nIn a non-randomised controlled trial, the investigators are assessing the impacts of two CPD activities on depression and diabetes, one that includes considerations of sex and gender, and an identical one that omits sex and gender considerations, on French-speaking healthcare professionals' self-reported clinical behaviors regarding sex and gender considerations post-intervention and at 3 months. Data collection will occur in three distinct locations in Canada. Project development, data collection and analysis and dissemination of results will all integrate considerations of sex and gender. The process of creating a CPD activity that integrates considerations of sex and gender could be scaled up to other CPD activities in other clinical subjects and in other minority languages.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Health Knowledge, Attitudes, Practice']},\n",
       "       'KeywordList': {'Keyword': ['Diabetes and depression',\n",
       "         'Continuing professional development',\n",
       "         'Continuing medical education',\n",
       "         'Sex and gender',\n",
       "         'Minority languages',\n",
       "         'Knowledge translation']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignInterventionModelDescription': 'A non-randomized controlled trial',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignMaskingDescription': 'Health professionals will self-select their attendance at one or other of the interventions (control or experimental CPD activity) without knowing that they are different (one including sex and gender considerations, the other excluding them).',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '90',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'CPD Workshop on Depression and Diabetes',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will include considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: CPD Workshop on Depression and Diabetes']}},\n",
       "         {'ArmGroupLabel': 'CPD Workshop on Depression and Diabetes II',\n",
       "          'ArmGroupType': 'Sham Comparator',\n",
       "          'ArmGroupDescription': 'Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will exclude considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: CPD Workshop on Depression and Diabetes']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'CPD Workshop on Depression and Diabetes',\n",
       "          'InterventionDescription': '2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CPD Workshop on Depression and Diabetes',\n",
       "            'CPD Workshop on Depression and Diabetes II']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Immediate clinical behavioural intention, as measured by CPD-REACTION questionnaire',\n",
       "          'PrimaryOutcomeDescription': 'Clinical behavioural intention to integrate considerations of sex and gender into the diagnosis and treatment of depression and diabetes, using the validated CPD-REACTION scale. CPD=continuing professional development, REACTION=a theoRy-basEd instrument to assess the impACT of continuing professional development activities on professional behavIOr chaNge. A 12-item Likert-type scale (i.e., Strongly disagree = 1, Strongly agree = 7; Never = 1, Always = 7, etc.) evaluates 5 constructs: 1) intention; 2) social influence; 3) beliefs about capabilities; 4) moral norms; and 5) beliefs about consequences. Sociodemographic questions are asked on sex, age (10 age ranges), province, rural/urban/semi-rural practice, and language of consultation. Mean, standard deviation, median and frequencies are calculated to summarize participant characteristics and questionnaire item responses. Construct scores are obtained by calculating the mean score for the items.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Immediately following the intervention'},\n",
       "         {'PrimaryOutcomeMeasure': 'Change from immediate clinical behavioural intention at 3 months, as measured by CPD-REACTION questionnaire',\n",
       "          'PrimaryOutcomeDescription': 'Evolution of clinical behavioural intention to integrate considerations of sex and gender into the diagnosis and treatment of depression and diabetes, using the validated CPD-REACTION scale, after a 3-month period.',\n",
       "          'PrimaryOutcomeTimeFrame': '3 months after the intervention'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Acceptability Questionnaire',\n",
       "          'SecondaryOutcomeDescription': '1) Participants rate acceptability of workshop with the following 9 items: organization, clarity, mastery of subject by trainer, exercises and discussion, presentation of sex and gender data, group interaction, overall quality, organization and quality of discussions and presentations, quality of documents distributed (Poor, Acceptable, Good, Very Good, or Excellent); 2) Participants rate the workshop length (too short, just right, too long); 3) Participants rate their confidence in incorporating the notions presented in the workshop in their management of Type 2 Diabetes (with or without depression) (scale of 1-10, 1=very little confidence, 10=very confident) both before and after the workshop; 4) Participants describe what changes they will make in their practice following the workshop; 5) Participants describe what they liked most and 6) least about the workshop; 7) Participants are asked if they thought the presentation was biased (yes/no) and if yes, are asked for details.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Immediately following the intervention.'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nFrench-speaking health professionals (in practice and in training).',\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'France Légaré, MD, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '+1 (418) 821-9481',\n",
       "          'CentralContactEMail': 'france.legare@fmed.ulaval.ca'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'France Légaré, MD, PhD',\n",
       "          'OverallOfficialAffiliation': 'CERSSPUL',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'CERSSPL',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Québec',\n",
       "          'LocationState': 'Quebec',\n",
       "          'LocationCountry': 'Canada',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'France Légaré, MD, PhD',\n",
       "             'LocationContactRole': 'Contact'}]}}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No',\n",
       "       'IPDSharingDescription': 'Aggregate anonymous data only in the form of published results.'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5698',\n",
       "          'ConditionBrowseLeafName': 'Diabetes Mellitus',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18',\n",
       "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC19',\n",
       "          'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
       "   {'Rank': 75,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03247764',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'Regist-EP and DP'},\n",
       "       'Organization': {'OrgFullName': 'Shanghai Zhongshan Hospital',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'A Registration Study on Depression in Patients With Epilepsy',\n",
       "       'OfficialTitle': 'A Registration Study on Diagnosis and Treatment for Comorbid Depression in Patients With Epilepsy From the East China'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'August 2017',\n",
       "       'OverallStatus': 'Not yet recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'October 8, 2017',\n",
       "        'StartDateType': 'Anticipated'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 30, 2020',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 31, 2020',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'August 3, 2017',\n",
       "       'StudyFirstSubmitQCDate': 'August 8, 2017',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 14, 2017',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'August 8, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 14, 2017',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Shanghai Zhongshan Hospital',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The prevalence of comorbid depression in patients with epilepsy is as high as 30-50%. The depressive symptoms severely affect seizure severity and quality of life in patients with epilepsy. The aim of this study is to register the diagnosis and treatment for depression in patients with epilepsy from the East China, determining the incidence rate of comorbid depression in patients with epilepsy and the choices for the antidepressant treatment. At the same time, neuroimaging data such as brain MRI and blood sample will be collected to analyze some biomarkers for the comorbidity of epilepsy and depression.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Epilepsy',\n",
       "         'Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Observational',\n",
       "       'PatientRegistry': 'Yes',\n",
       "       'TargetDuration': '6 Months',\n",
       "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']},\n",
       "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '1200',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'patients with epilepsy and depression',\n",
       "          'ArmGroupDescription': 'Patients with comorbidity of epilepsy and depression will be asked to use antidepressants such as selective serotonin reuptake inhibitor(SSRIs) or xylaria nigripes and followed up',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: SSRIs or xylaria nigripes']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
       "          'InterventionName': 'SSRIs or xylaria nigripes',\n",
       "          'InterventionDescription': \"Patients with comorbidity of epilepsy and depression will be used SSRIs or xylaria nigripes as antidepressants after discussing with them. They will still be followed up if they don't want to use any antidepressants.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with epilepsy and depression']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Comparing the efficacy of using SSRIs with using xylaria nigripes on depressive symptoms in patients with epilepsy and depression',\n",
       "          'PrimaryOutcomeDescription': 'The reduction rate of Hamilton Depression Rating Scale (HAMD) score will be used to assess the change of depressive symptoms',\n",
       "          'PrimaryOutcomeTimeFrame': '6 month'},\n",
       "         {'PrimaryOutcomeMeasure': 'The safety of using SSRIs and xylaria nigripes in patients with epilepsy',\n",
       "          'PrimaryOutcomeDescription': 'The changes of seizure frequencies will be assessed',\n",
       "          'PrimaryOutcomeTimeFrame': '6 month'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'The rate of antidepressant treatment in patients with comorbidity of epilepsy and depression',\n",
       "          'SecondaryOutcomeTimeFrame': '6 month'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAt least 1 or more seizures with evidences demonstrated by EEG\\n\\nExclusion Criteria:\\n\\nSevere psychotic symptoms such as hallucination and delusions\\nProgressive central nervous system diseases such as acute stroke, brain malignant tumors, encephalitis, and Parkinson's disease etc.\\nSevere cardiac, pulmonary, hepatic, and renal diseases\\nSevere cognitive dysfunctions and physical disabilities\",\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '75 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
       "       'StudyPopulation': 'All patients with epilepsy who meet the inclusion and exclusion criteria will be asked to fill out PHQ-9 scale to screen depression',\n",
       "       'SamplingMethod': 'Probability Sample'},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Weifeng Peng, MD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '8602164041990',\n",
       "          'CentralContactPhoneExt': '2976',\n",
       "          'CentralContactEMail': 'peng.weifeng@zs-hospital.sh.cn'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000004827',\n",
       "          'ConditionMeshTerm': 'Epilepsy'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001927',\n",
       "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
       "         {'ConditionAncestorId': 'D000002493',\n",
       "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
       "         {'ConditionAncestorId': 'D000009422',\n",
       "          'ConditionAncestorTerm': 'Nervous System Diseases'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6566',\n",
       "          'ConditionBrowseLeafName': 'Epilepsy',\n",
       "          'ConditionBrowseLeafAsFound': 'Epilepsy',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3786',\n",
       "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M4325',\n",
       "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
       "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
       "   {'Rank': 76,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02366429',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '20141959311'},\n",
       "       'Organization': {'OrgFullName': 'Karolinska Institutet',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'ICBT for Antenatal Depression',\n",
       "       'OfficialTitle': 'Psychological Treatment Via the Internet for Antenatal Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'September 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'February 2015'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2016',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'March 2016',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'February 12, 2015',\n",
       "       'StudyFirstSubmitQCDate': 'February 18, 2015',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 19, 2015',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'September 2, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 5, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Viktor Kaldo',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Karolinska Institutet'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Karolinska Institutet',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Randomized controlled trial evaluating an Internet-delivered Cognitive Behavioral Therapy (ICBT) adapted for pregnant women suffering from antenatal depression. The ICBT-program will be added to treatment as usual (TAU) and compared to TAU only.\\n\\nParticipants (n=60) are recruited from all over Sweden (only Swedish citizens can participate) and are assessed and treated on a distance via a secure web platform and telephone.',\n",
       "       'DetailedDescription': \"In order to evaluate feasibility and effectiveness of an ICBT-program for antenatal depression that will be used in a larger clinical trial, the current RCT (n=60) will be performed and act as a pilot for the main study.\\n\\nParticipants will all be receiving the regular treatment (TAU) provided at their antenatal clinic and other health care instances. Half of them will be randomized to an add-on of a previously established 10-week long ICBT-program for depression in general, now adapted for pregnant women. The other half will receive TAU during 10 weeks and then freely decide if they want to participate in the pregnancy-adapted ICBT-program (only possible if 10 or more weeks left till estimated delivery date), start the regular ICBT-program for depression within 2-6 weeks post-partum, or decline ICBT-treatment. The participants in this study will be recruited from all over Sweden via internet, advertisements and information at antenatal clinics. A web-based screening questionnaire will form the basis for a first assessment and review of inclusion criteria, followed by a structured telephone interview where diagnoses (SCID-1 for depression, adjusted for DSM 5, and M.I.N.I. for other diagnoses and assessment of suicide risk) and suitability will be assessed, a CGI-rating will be performed, and the final decision on inclusion will be made.\\n\\nLevel of depression pre- and post-treatment will be assessed with MADRS-S filled out via the internet-treatment platform together with the other self-rating measures used in the main study. A questionnaire where the participants evaluate the content of the adapted ICBT-program and their own use and perceived benefit of the treatment methods will also be given at post-treatment and during treatment.\\n\\nStructured telephone interview will be held at post-treatment, primarily to assess the content of TAU, to administer CGI and a standardized version for MADRS-S (designed to replace missing questionnaire data), and to make a qualitative evaluation of the participants view of the adapted ICBT-program.\\n\\nThe estimated effect of ICBT compared to TAU is 0.8 (Cohen's d) and with 60 participants and some attrition this will result in a statistical power of 80% for this initial, smaller RCT.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Antenatal Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '60',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'ICBT',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Internet-based CBT for antenatal depression',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: ICBT for antenatal depression']}},\n",
       "         {'ArmGroupLabel': 'TAU',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Treatment as usual provided at antenatal clinics and other health care instances',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: TAU']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'ICBT for antenatal depression',\n",
       "          'InterventionDescription': 'Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['ICBT']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'TAU',\n",
       "          'InterventionDescription': 'Treatment as usual provided at antenatal clinics and other health care instances',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['TAU']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Self-rated depression measured by Montgomery Asberg Depression Rating Scale',\n",
       "          'PrimaryOutcomeDescription': 'Depression measured by Montgomery Asberg Depression Rating Scale (MADRS-S), a 9-item self-rated measure of change in depression severity. It also screens for suicidality.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Self-rated antenatal depression Edinburgh Postnatal Depression Scale',\n",
       "          'SecondaryOutcomeDescription': 'Edinburgh Postnatal Depression Scale (EPDS; Cox, Holden & Sagovsky, 1987)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'},\n",
       "         {'SecondaryOutcomeMeasure': 'Self-rated function Work and Social Adjustment Scale',\n",
       "          'SecondaryOutcomeDescription': 'Work and Social Adjustment Scale (WSAS; Zahra et al., 2014)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'},\n",
       "         {'SecondaryOutcomeMeasure': 'Self-rated Insomnia Insomnia Severity Index',\n",
       "          'SecondaryOutcomeDescription': 'Insomnia Severity Index (ISI; Bastien, Vallieres & Morin, 2001)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'},\n",
       "         {'SecondaryOutcomeMeasure': 'Self-rated function/quality of life Euroqol',\n",
       "          'SecondaryOutcomeDescription': 'Euroqol (EQ-5D ; Hinz et al., 2006),',\n",
       "          'SecondaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'},\n",
       "         {'SecondaryOutcomeMeasure': 'Self-rated anxiety and worry GAD-7',\n",
       "          'SecondaryOutcomeDescription': 'GAD-7(Beard, & Björgvinsson, 2014)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'},\n",
       "         {'SecondaryOutcomeMeasure': 'Expert rating of overall disease burden Clinical Global Impression - Severity scale',\n",
       "          'SecondaryOutcomeDescription': 'Clinical Global Impression - Severity scale (CGI-S; Guy, 2000)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Change from baseline to post-treatment (after 10 weeks) and to 3-4 weeks post-partum'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\npregnant female > 18 years old at gestational week 11-28\\nverified moderate depression according to SCID-I with or without concomitant anxiety disorder\\nable to understand the Swedish language orally and in written\\nable to use the internet for the ICBT\\ncurrently in contact with an antenatal clinic to receive regular care\\n\\nExclusion Criteria:\\n\\nknown drug or alcohol abuse\\nserious somatic disorder or psychiatric disorder such as psychosis, bipolar disorder, severe personality disorder, autism or mental retardation and severe melancholic or psychotic depression,\\nhaving started or changed medication with SSRI, SNRI or mood-stabilizers within 3 weeks,\\naccording to psychiatric assessment have a high suicide risk will be excluded from the study. These women will be helped to receive necessary psychiatric treatment as usual.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Female',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '55 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult']}},\n",
       "      'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Internetpsykiatrienehten (Internet Psychiatry Unit), Psykiatri Sydväst, SLSO',\n",
       "          'LocationCity': 'Stockholm',\n",
       "          'LocationCountry': 'Sweden'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28628768',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Forsell E, Bendix M, Holländare F, Szymanska von Schultz B, Nasiell J, Blomdahl-Wetterholm M, Eriksson C, Kvarned S, Lindau van der Linden J, Söderberg E, Jokinen J, Wide K, Kaldo V. Internet delivered cognitive behavior therapy for antenatal depression: A randomised controlled trial. J Affect Disord. 2017 Oct 15;221:56-64. doi: 10.1016/j.jad.2017.06.013. Epub 2017 Jun 13.'}]},\n",
       "       'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Related Info',\n",
       "          'SeeAlsoLinkURL': 'http://www.internetpsykiatri.se'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 77,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02122406',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '31748\\\\2009 progetto lorhen'},\n",
       "       'Organization': {'OrgFullName': 'University of Pavia',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Depression and Anxiety in Rheumatoid Arthritis',\n",
       "       'OfficialTitle': 'Depression and Anxiety in Rheumatoid Arthritis: Prevalence and Relation With Disease Activity',\n",
       "       'Acronym': 'DEAR'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'August 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2014'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2015',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'April 22, 2014',\n",
       "       'StudyFirstSubmitQCDate': 'April 23, 2014',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 24, 2014',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'May 10, 2016',\n",
       "       'ResultsFirstSubmitQCDate': 'August 16, 2016',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'October 10, 2016',\n",
       "        'ResultsFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'August 16, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 10, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Vittorio Grosso',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'MD',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Pavia'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Pavia',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The primary endpoint of this study is to evaluate the prevalence of anxiety and depressive disorders, and their relationship with disease activity, in patients with rheumatoid arthritis treated with biological drugs',\n",
       "       'DetailedDescription': 'The prevalence of anxiety and depressive disorders will be assesed with the HADS questionnaire at the time of the visit'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Rheumatoid Arthritis',\n",
       "         'Depression',\n",
       "         'Anxiety']},\n",
       "       'KeywordList': {'Keyword': ['Rheumatoid Arthritis',\n",
       "         'Depression',\n",
       "         'Anxiety',\n",
       "         'DAS28',\n",
       "         'HADS']}},\n",
       "      'DesignModule': {'StudyType': 'Observational',\n",
       "       'PatientRegistry': 'No',\n",
       "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
       "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '200',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Patients RA-BIO',\n",
       "          'ArmGroupDescription': 'Patients with rheumatoid arthritis treated with biological drugs (infliximab, adalimumab, etanercept, abatacept, tocilizumab, golimumab, certolizumab, rituximab)',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Hospital Anxiety and Depression Scale (HADS) questionnaire']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Hospital Anxiety and Depression Scale (HADS) questionnaire',\n",
       "          'InterventionDescription': 'Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Patients RA-BIO']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Hospital Anxiety and Depression Scale (HADS)',\n",
       "          'PrimaryOutcomeDescription': 'Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.',\n",
       "          'PrimaryOutcomeTimeFrame': '1 day of enrollement'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nage >18 years\\ndiagnosis of rheumatoid arthritis according to 2010 Classification American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Criteria\\nbeing able to compile questionnaire\\ncurrent treatment with biological disease-modifying antirheumatic drug\\n\\nExclusion Criteria:\\n\\nCurrent treatment for anxiety or depressive disorder',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
       "       'StudyPopulation': 'Adult patients with rheumatoid arthritis currently treated with biological drugs.',\n",
       "       'SamplingMethod': 'Non-Probability Sample'},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Roberto Caporali, MD',\n",
       "          'OverallOfficialAffiliation': 'University of Pavia',\n",
       "          'OverallOfficialRole': 'Study Director'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'IRCCS policlinico San Matteo - Reparto di Reumatologia',\n",
       "          'LocationCity': 'Pavia',\n",
       "          'LocationState': 'PV',\n",
       "          'LocationZip': '27100',\n",
       "          'LocationCountry': 'Italy'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Patients RA-BIO',\n",
       "          'FlowGroupDescription': 'Patients with rheumatoid arthritis treated with biological drugs'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '200'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '200'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '0'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Patients RA-BIO',\n",
       "          'BaselineGroupDescription': 'Patients with rheumatoid arthritis treated with biological drugs'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '200'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Median',\n",
       "          'BaselineMeasureDispersionType': 'Inter-Quartile Range',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '62.35',\n",
       "                   'BaselineMeasurementLowerLimit': '54.09',\n",
       "                   'BaselineMeasurementUpperLimit': '76.03'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '171'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '29'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Italy',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '200'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Disease Duration',\n",
       "          'BaselineMeasureParamType': 'Median',\n",
       "          'BaselineMeasureDispersionType': 'Inter-Quartile Range',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '11.24',\n",
       "                   'BaselineMeasurementLowerLimit': '7.29',\n",
       "                   'BaselineMeasurementUpperLimit': '19.46'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Disease Activity Score on 28 joints (DAS28)',\n",
       "          'BaselineMeasureDescription': 'The Disease Activity Score 28 (DAS28) is a combined index that measures the disease activity in patients with Rheumatoid Arthritis. It is based on the assessment of the number of swollen and tender joints and measure of the ESR.\\n\\nLower values indicate lower disease activity levels. It ranges from 0.49 to 9.35.',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '3.01',\n",
       "                   'BaselineMeasurementSpread': '1.07'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Hospital Anxiety and Depression Scale (HADS)',\n",
       "          'OutcomeMeasureDescription': 'Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Number',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'participants',\n",
       "          'OutcomeMeasureTimeFrame': '1 day of enrollement',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Patients RA-BIO',\n",
       "             'OutcomeGroupDescription': 'Patients with rheumatoid arthritis treated with biological drugs'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '200'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'HEALTHY',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '107'}]}}]}},\n",
       "            {'OutcomeClassTitle': 'ANXIETY',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '46'}]}}]}},\n",
       "            {'OutcomeClassTitle': 'DEPRESSION',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '20'}]}}]}},\n",
       "            {'OutcomeClassTitle': 'ANXIETY/DEPRESSION',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '27'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventsTimeFrame': 'at the time of the visit',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Patients RA-BIO',\n",
       "          'EventGroupDescription': 'Patients with rheumatoid arthritis treated with biological drugs',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '200',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '200'}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
       "        'AgreementRestrictiveAgreement': 'No'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Vittorio Grosso MD',\n",
       "        'PointOfContactOrganization': 'University of Pavia',\n",
       "        'PointOfContactEMail': 'vittorio.grosso@gmail.com',\n",
       "        'PointOfContactPhone': '+393332605945'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001168',\n",
       "          'ConditionMeshTerm': 'Arthritis'},\n",
       "         {'ConditionMeshId': 'D000001172',\n",
       "          'ConditionMeshTerm': 'Arthritis, Rheumatoid'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000001008',\n",
       "          'ConditionMeshTerm': 'Anxiety Disorders'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000007592',\n",
       "          'ConditionAncestorTerm': 'Joint Diseases'},\n",
       "         {'ConditionAncestorId': 'D000009140',\n",
       "          'ConditionAncestorTerm': 'Musculoskeletal Diseases'},\n",
       "         {'ConditionAncestorId': 'D000012216',\n",
       "          'ConditionAncestorTerm': 'Rheumatic Diseases'},\n",
       "         {'ConditionAncestorId': 'D000003240',\n",
       "          'ConditionAncestorTerm': 'Connective Tissue Diseases'},\n",
       "         {'ConditionAncestorId': 'D000001327',\n",
       "          'ConditionAncestorTerm': 'Autoimmune Diseases'},\n",
       "         {'ConditionAncestorId': 'D000007154',\n",
       "          'ConditionAncestorTerm': 'Immune System Diseases'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M2905',\n",
       "          'ConditionBrowseLeafName': 'Anxiety Disorders',\n",
       "          'ConditionBrowseLeafAsFound': 'Anxiety',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3057',\n",
       "          'ConditionBrowseLeafName': 'Arthritis',\n",
       "          'ConditionBrowseLeafAsFound': 'Arthritis',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3061',\n",
       "          'ConditionBrowseLeafName': 'Arthritis, Rheumatoid',\n",
       "          'ConditionBrowseLeafAsFound': 'Rheumatoid Arthritis',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M9204',\n",
       "          'ConditionBrowseLeafName': 'Joint Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M10680',\n",
       "          'ConditionBrowseLeafName': 'Musculoskeletal Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13628',\n",
       "          'ConditionBrowseLeafName': 'Rheumatic Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M4906',\n",
       "          'ConditionBrowseLeafName': 'Collagen Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5047',\n",
       "          'ConditionBrowseLeafName': 'Connective Tissue Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3210',\n",
       "          'ConditionBrowseLeafName': 'Autoimmune Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M8783',\n",
       "          'ConditionBrowseLeafName': 'Immune System Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC05',\n",
       "          'ConditionBrowseBranchName': 'Muscle, Bone, and Cartilage Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC17',\n",
       "          'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC20',\n",
       "          'ConditionBrowseBranchName': 'Immune System Diseases'}]}}}}},\n",
       "   {'Rank': 78,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02375308',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'UTubingen'},\n",
       "       'Organization': {'OrgFullName': 'University Hospital Tuebingen',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Efficacy of Cognitive Behavioral to Hypnotherapeutic Treatment of Depression',\n",
       "       'OfficialTitle': 'Efficacy of Activation-focussed Cognitive Treatment of Depression (ACDT) to Hypnotherapeutic Treatment of Depression (HDT) in Mild to Moderate Major Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'September 2018',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'April 2015'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2017',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'June 28, 2018',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'February 24, 2015',\n",
       "       'StudyFirstSubmitQCDate': 'February 27, 2015',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 2, 2015',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'September 21, 2018',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 25, 2018',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Anil Batra',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Efficacy of Activation-focussed Cognitive Treatment of Depression (ACDT) to Hypnotherapeutic Treatment of Depression (HDT) in Mild to Moderate Major Depression',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University Hospital Tuebingen'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University Hospital Tuebingen',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of the study is to compare the efficacy of an Hypnotherapeutic Treatment of Depression to Cognitive Behavioral Treatment of Depression in patients with mild to moderate Major Depressive Episodes.',\n",
       "       'DetailedDescription': \"Cognitive Behavioral Therapy (CBT) is considered to be an effective psychological treatment of mild to moderate Major Depressive Episodes. Effective treatments, however, show a reduction of depressive symptoms only up to 50 % (Luty et al., 2007) which is one reason for the modification of the well-established CBT in the last years. Following the 'third wave' approaches of CBT, e.g. Emotion-Focussed Therapy or Mindfulness-Based Cognitive Therapy, techniques like meditation or the use of systemic or Gestalt techniques within CBT has been applied. Within this context, Hypnotherapy-based strategies can also show an improvement of the current state of the art in depression psychotherapy. However, only few studies conducted randomised controlled trials to study the efficacy of hypnosis for depression as e.g. the comparison of cognitive hypnotherapy to CBT-alone (e.g. Alladin and Alibhai, 2007). With the present study, the efficacy of the Hypnotherapeutic Treatment of Depression (HDT) will be compared to the CBT-based Activation-focussed Cognitive Treatment of Depression (ACDT). Both treatments are individually administered and includes 20 sessions. We expect HDT not being inferior to ACDT in the reduction of depressive symptoms after six months of treatment.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Major Depressive Disorder']},\n",
       "       'KeywordList': {'Keyword': ['Hypnotherapy; Cognitive Behavioral Therapy; Efficacy']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '153',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Hypnotherapeutic Treatment',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'HDT (Hypnotherapeutic Treatment of Depression) focuses on the hypnotic activation and strengthening of individual resources, the use of regression techniques to rebuild positive and negative experiences and the development of positive imaginations for the future.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: HDT']}},\n",
       "         {'ArmGroupLabel': 'Cognitive Behavioral Treatment',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'ACDT (Activation-focussed Cognitive Treatment of Depression) focuses on psychoeducation, behavior activation, the use of cognitive techniques, and the improvement of social skills.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: ACDT']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'HDT',\n",
       "          'InterventionDescription': '20 sessions, individual psychotherapy',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Hypnotherapeutic Treatment']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Hypnotherapeutic Treatment of Depression']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'ACDT',\n",
       "          'InterventionDescription': '20 sessions, individual psychotherapy',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cognitive Behavioral Treatment']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Cognitive Behavioral Therapy (CBT) of Depression']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Montgomery-Åsberg Depression Rating Scale (MADRS)',\n",
       "          'PrimaryOutcomeDescription': 'Clinician-rating of depressive symptoms, Primary outcome',\n",
       "          'PrimaryOutcomeTimeFrame': 'Change from Baseline in MADRS to end of treatment (20 sessions in 20-24 weeks)'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'QIDS: Quick Inventory of Depressive Symptomatology - Clinician Rating (QIDS-C16)',\n",
       "          'SecondaryOutcomeDescription': 'Clinician-rating of depressive symptoms',\n",
       "          'SecondaryOutcomeTimeFrame': 'Change from Baseline to end of therapy and follow-ups (six and 12 months after end of treatment)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Patient Health Questionnaire (PHQ-9)',\n",
       "          'SecondaryOutcomeDescription': 'Self-report of depressive symptoms',\n",
       "          'SecondaryOutcomeTimeFrame': 'Change from Baseline to end of therapy and follow-ups (six and 12 months after end of treatment)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Montgomery-Åsberg Depression Rating Scale (MADRS)',\n",
       "          'SecondaryOutcomeDescription': 'Incidence of response rate (symptom reduction > 60%)',\n",
       "          'SecondaryOutcomeTimeFrame': 'six and 12 months after end of treatment'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nDSM-5 (Diagnostic and Statistical Manual) criteria for current mild to moderate Major Depressive Episode (MDE)\\nInformed consent\\nFluent in German\\nTime for weekly therapy sessions\\nStable antidepressant medication since three months\\n\\nExclusion Criteria:\\n\\nA history of lifetime bipolar disorder, psychotic symptoms\\nA diagnosis of a chronic Major Depressive Disorder (total duration of two years and more)\\nFulfilling the DSM-5 criteria for current severe MDE or scores in MADRS >/= 35 or QIDSC16 (Quick Inventory of Depressive Symptomatology) >/= 16\\nRemission of current MDE since more than four weeks prior to inclusion assessment\\nAcute risk for suicide\\nSevere cognitive impairment (confirmed suspicion with Mini-Mental-State-Test > 25)\\nA dominating primary diagnosis of another axis I disorder including anxiety disorders (e.g. Panic disorder, Posttraumatic Stress Disorder, Anorexia nervosa, Borderline personality disorder), or any severe substance-related abuse or dependence disorder\\nA physical illness which would interfere with regular psychotherapy sessions\\nOutpatient psychotherapy during the last 12 months',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '70 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Anil Batra, Prof.',\n",
       "          'OverallOfficialAffiliation': 'University Hospital Tuebingen',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Prof. Dr. A. Batra/ Dr. Kristina Fuhr, University Department for Psychiatry and Psychotherapie',\n",
       "          'LocationCity': 'Tuebingen',\n",
       "          'LocationZip': '72076',\n",
       "          'LocationCountry': 'Germany'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '17541109',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Luty SE, Carter JD, McKenzie JM, Rae AM, Frampton CM, Mulder RT, Joyce PR. Randomised controlled trial of interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatry. 2007 Jun;190:496-502.'},\n",
       "         {'ReferencePMID': '17365072',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Alladin A, Alibhai A. Cognitive hypnotherapy for depression: an empirical investigation. Int J Clin Exp Hypn. 2007 Apr;55(2):147-66.'},\n",
       "         {'ReferencePMID': '29196478',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Fuhr K, Schweizer C, Meisner C, Batra A. Efficacy of hypnotherapy compared to cognitive-behavioural therapy for mild-to-moderate depression: study protocol of a randomised-controlled rater-blind trial (WIKI-D). BMJ Open. 2017 Dec 1;7(11):e016978. doi: 10.1136/bmjopen-2017-016978.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000003865',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder, Major'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafAsFound': 'Major Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 79,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02021578',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '8482529'},\n",
       "       'Organization': {'OrgFullName': 'Vanderbilt University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'A Family Depression Prevention Program',\n",
       "       'OfficialTitle': 'Family Cognitive Behavioral Prevention of Depression in Youth and Parents',\n",
       "       'Acronym': 'FDP'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'February 2020',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'December 2014'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2021',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2021',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'December 19, 2013',\n",
       "       'StudyFirstSubmitQCDate': 'December 19, 2013',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 27, 2013',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'February 5, 2020',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 6, 2020',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Judith Garber',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Professor',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Vanderbilt University'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Vanderbilt University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'San Diego State University',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The primary aim is to prevent depression in youth and parents in a single, integrated family intervention.\\n\\nHypothesis 1a: Children in the Family Depression Prevention (FDP) program will have significantly fewer onsets of depressive episodes and lower levels of anxious/depressive symptoms as compared to children in the Written Information (WI) condition.\\n\\nHypothesis 1b: In parents, the amount of time in a depressive episode will be significantly lower for those in the FDP program as compared to those in the WI condition.',\n",
       "       'DetailedDescription': 'Depression is a major public health problem affecting over 15 million U.S. adults annually and is especially prevalent in those of parenting age. Offspring of depressed parents are at increased risk of depression and therefore are a critical target for preventive interventions. The current study aims to reduce the rate of depression in parents and their children by adopting an innovative, family-based approach to simultaneously preventing depression in at-risk youth and in their affected parents. The rationale for this approach is based on (a) a conceptual model that integrates parenting processes, stress (particularly that which is associated with parental depression), and children\\'s self-regulatory skills in the face of stress, (b) evidence that depression runs in families, (c) promising results from family- and child-focused depression prevention programs, (d) evidence that in adults, cognitive-behavioral therapy (CBT) reduces both depressive episodes and their recurrence, and (e) growing consensus among scientists, clinicians, and policymakers on the need for family-based models of healthcare. This 5- year, two-site randomized controlled trial will test a Family Depression Prevention (FDP) program for children (ages 9-15) and their parents with depressive disorders (past or current). This \"dual prevention\" approach is a novel synthesis of existing evidence-based intervention techniques drawn from child prevention and adult treatment models. Participating families (N=300) will be randomized to either FDP (12 weekly + 3 monthly sessions) or a written information comparison (WI) condition. All parents and children will be evaluated at pre- and post-intervention, and at 6-, 12-, 18-, and 24-months from baseline.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression', 'Mood disorder']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Prevention',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '300',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Family Cognitive Behavioral Prevention',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'A family cognitive behavioral program for parents and children. Parents learn parenting skills and cognitive behavioral techniques for managing depression. Children learn coping skills.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Family Cognitive Behavioral Prevention']}},\n",
       "         {'ArmGroupLabel': 'Written Information',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Families receive written materials about depression and the effects of parental depression on children.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Written information']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Family Cognitive Behavioral Prevention',\n",
       "          'InterventionDescription': 'Parent training and cognitive behavioral intervention with parents. Coping skills training with children.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Family Cognitive Behavioral Prevention']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Cognitive behavioral intervention',\n",
       "            'Coping skills training',\n",
       "            'Parent training']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Written information',\n",
       "          'InterventionDescription': 'Reading materials about depression',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Written Information']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Psychoeducation',\n",
       "            'Self-help']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'In children, the primary outcome is onset of a depressive episode. In parents, the primary outcome is time in a depressive episode.',\n",
       "          'PrimaryOutcomeDescription': 'For child participants, we will assess time to onset of a depressive disorder (e.g., Major Depressive Episode; persistent depressive disorder) using a semi-structured clinical interview, the Longitudinal Interval Follow-up Evaluation (LIFE).\\n\\nFor parent participants, we also will use the LIFE to measure the amount of time in a depressive episode during the assessment interval.',\n",
       "          'PrimaryOutcomeTimeFrame': 'up to two years'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Parents: Patient Health Questionnaire - 9 (PHQ-9)',\n",
       "          'SecondaryOutcomeDescription': 'Parent participants: The PHQ-9 measures 9 symptoms of depression on a 4-point scale. Scores can range from 0 to 36.',\n",
       "          'SecondaryOutcomeTimeFrame': 'past two weeks'},\n",
       "         {'SecondaryOutcomeMeasure': 'Children: Youth Self-report (YSR) anxiety/depression subscale',\n",
       "          'SecondaryOutcomeDescription': 'Children will complete the YSR, which is a self-report checklist containing 112 items scored on a 3-point scale.',\n",
       "          'SecondaryOutcomeTimeFrame': 'six months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nParent with a current or history of a depressive disorder within child's life\\nChildren ages 9.0 to 15.6 years old\\n\\nExclusion Criteria:\\n\\nBipolar I (parent or child)\\nSchizophrenia (parent or child)\\nCurrent alcohol or drug abuse (parent or child)\\nConduct disorder; developmental disability (child)\\nCurrent diagnosis of a depressive disorder (child)\",\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '9 Years',\n",
       "       'MaximumAge': '15 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Judy Garber, PhD',\n",
       "          'OverallOfficialAffiliation': 'Vanderbilt University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Bruce Compas, PhD',\n",
       "          'OverallOfficialAffiliation': 'Vanderbilt University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Robin Weersing, PhD',\n",
       "          'OverallOfficialAffiliation': 'San Diego State University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'San Diego State University',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'San Diego',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '92120-4913',\n",
       "          'LocationCountry': 'United States',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Robin Weersing, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '619-594-8892',\n",
       "             'LocationContactEMail': 'robin.weersing@mail.sdsu.edu'},\n",
       "            {'LocationContactName': 'Robin Weersing, PhD',\n",
       "             'LocationContactRole': 'Principal Investigator'}]}},\n",
       "         {'LocationFacility': 'Vanderbilt University',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Nashville',\n",
       "          'LocationState': 'Tennessee',\n",
       "          'LocationZip': '37203-5721',\n",
       "          'LocationCountry': 'United States',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Judy Garber, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '615-343-0595',\n",
       "             'LocationContactEMail': 'jgarber.vanderbilt@gmail.com'},\n",
       "            {'LocationContactName': 'Bruce Compas, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '615-322-8306',\n",
       "             'LocationContactEMail': 'Bruce.Compas@Vanderbilt.edu'},\n",
       "            {'LocationContactName': 'Judy Garber, PhD',\n",
       "             'LocationContactRole': 'Principal Investigator'},\n",
       "            {'LocationContactName': 'Bruce Compas, PhD',\n",
       "             'LocationContactRole': 'Principal Investigator'}]}}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '19968378',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Compas BE, Forehand R, Keller G, Champion JE, Rakow A, Reeslund KL, McKee L, Fear JM, Colletti CJ, Hardcastle E, Merchant MJ, Roberts L, Potts J, Garai E, Coffelt N, Roland E, Sterba SK, Cole DA. Randomized controlled trial of a family cognitive-behavioral preventive intervention for children of depressed parents. J Consult Clin Psychol. 2009 Dec;77(6):1007-20. doi: 10.1037/a0016930.'},\n",
       "         {'ReferencePMID': '20873898',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Compas BE, Champion JE, Forehand R, Cole DA, Reeslund KL, Fear J, Hardcastle EJ, Keller G, Rakow A, Garai E, Merchant MJ, Roberts L. Coping and parenting: Mediators of 12-month outcomes of a family group cognitive-behavioral preventive intervention with families of depressed parents. J Consult Clin Psychol. 2010 Oct;78(5):623-34. doi: 10.1037/a0020459.'},\n",
       "         {'ReferencePMID': '21707137',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Compas BE, Forehand R, Thigpen JC, Keller G, Hardcastle EJ, Cole DA, Potts J, Watson KH, Rakow A, Colletti C, Reeslund K, Fear J, Garai E, McKee L, Merchant MJ, Roberts L. Family group cognitive-behavioral preventive intervention for families of depressed parents: 18- and 24-month outcomes. J Consult Clin Psychol. 2011 Aug;79(4):488-99. doi: 10.1037/a0024254.'},\n",
       "         {'ReferencePMID': '19491183',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': \"Garber J, Clarke GN, Weersing VR, Beardslee WR, Brent DA, Gladstone TR, DeBar LL, Lynch FL, D'Angelo E, Hollon SD, Shamseddeen W, Iyengar S. Prevention of depression in at-risk adolescents: a randomized controlled trial. JAMA. 2009 Jun 3;301(21):2215-24. doi: 10.1001/jama.2009.788.\"},\n",
       "         {'ReferencePMID': '24005242',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Beardslee WR, Brent DA, Weersing VR, Clarke GN, Porta G, Hollon SD, Gladstone TR, Gallop R, Lynch FL, Iyengar S, DeBar L, Garber J. Prevention of depression in at-risk adolescents: longer-term effects. JAMA Psychiatry. 2013 Nov;70(11):1161-70. doi: 10.1001/jamapsychiatry.2013.295.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 80,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01379027',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '1R01MH087505',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH087505&Fy=all'},\n",
       "       'Organization': {'OrgFullName': 'Kaiser Permanente',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'MoodHelper: Internet Cognitive Behavioral Therapy (CBT) for Depression',\n",
       "       'OfficialTitle': 'Internet CBT for Depression: Comparing Pure, Guided, and Stepped Care'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2018',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'October 2011'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2016',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2016',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 10, 2011',\n",
       "       'StudyFirstSubmitQCDate': 'June 22, 2011',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 23, 2011',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'March 6, 2018',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 8, 2018',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Kaiser Permanente',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Oregon Health and Science University',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Evidence-based treatments (EBTs) for mental health conditions are often not available to persons needing them in the community. Our aim is to test a novel Internet intervention that has the promise of eventually improving the Reach and Implementation of mental health EBTs, speeding the translation of research successes into improved community care.',\n",
       "       'DetailedDescription': 'Evidence-based treatments (EBTs) for depression are often not available to persons needing them; this is particularly true of psychotherapies. Even when available, EBTs are often poorly delivered at less-than-optimal quality. High direct and indirect costs also limit the availability of EBTs. Together these barriers contribute to suboptimal treatment of depression in the community. In a preliminary step toward addressing these quality shortcomings, the investigators propose to conduct a blended efficacy- effectiveness randomized controlled trial (RCT) of high fidelity, Internet-delivered cognitive behavioral therapy (CBT) for depression, extending our previous research to maximize treatment availability and quality as well as to reduce costs. Over a 36-month recruitment period, the investigators will enroll 1,800 adults seeking care for depression from 3 rural healthcare clinics, 3 safety net federally qualified healthcare centers (FQHCs), and 2 non-profit HMOs. Participants will be randomized to: (a) a treatment as usual (TAU) control condition, typically antidepressants and/or psychosocial services; (b) TAU plus Pure self-help Internet CBT for depression, consisting of access to the Internet site without any contact with therapists; (c) TAU plus Guided self-help Internet CBT, consisting of access to the Internet site plus brief, periodic telephone contacts with therapists; or (d) a Stepped-Care Internet CBT condition, starting with TAU + Pure self-help CBT and progressing to Guided self-help CBT if adequate progress is not observed early on. Participants will be followed for one year. The primary hypothesis for which the study is powered is that Guided self-help CBT will result in greater depression symptom improvement than Pure self-help CBT. The investigators also expect secondary analyses to reveal this pattern of results: Guided CBT > Pure CBT > TAU. The investigators will conduct cost-effectiveness analyses (CEA), as the investigators project substantial differences in the direct costs of each study arm. The investigators will also examine TAU healthcare utilization (medications, visits, etc) from electronic medical records (EMR), billing systems, and participant report. The investigators hypothesize that cost per depression free days (DFDs) and quality- adjusted life years (QALYs) will be lowest for Pure CBT, relative to Guided and Stepped-Care CBT and TAU. The investigators also hypothesize that cost per unit of improvement in QALYs and DFDs will be better for Stepped-Care compared to Guided CBT. Additional aims include exploratory examination of secondary outcomes, and predictors and moderators of outcomes among the interventions. The investigators also will collect quantitative and qualitative data on patient, provider, and organizational factors that may impede or facilitate implementation of these interventions, to help prepare for future dissemination efforts. Finally, in this reapplication the investigators have added a non-research Reach Estimation Phase to better estimate acceptance and retention rates under conditions that closely match real-world dissemination'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Website intervention',\n",
       "         'CBT']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Factorial Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '1816',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'a treatment as usual (TAU) control condition',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Participants will receive recruitment information, go on the study website to enroll and complete assessments over the study web site but will not receive the study intervention.'},\n",
       "         {'ArmGroupLabel': 'Pure self-help Internet CBT for depression',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants will receive TAU plus access to the study website for the self-help Internet CBT for depression, consisting of access to the Internet site without any contact with therapist',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Pure self-help Internet CBT for depression']}},\n",
       "         {'ArmGroupLabel': 'Guided self-help Internet CBT',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants will receive TAU plus Guided self-help Internet CBT, consisting of access to the Internet site plus brief, periodic telephone contacts with therapists',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Guided self-help Internet CBT']}},\n",
       "         {'ArmGroupLabel': 'Stepped-Care Internet CBT condition',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'This consists of a Stepped-Care Internet CBT condition, starting with TAU + Pure self-help CBT and progressing to Guided self-help CBT if adequate progress is not observed early on',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Stepped-Care Internet CBT condition']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Pure self-help Internet CBT for depression',\n",
       "          'InterventionDescription': 'Internet, CBT, Depression',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Pure self-help Internet CBT for depression']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Guided self-help Internet CBT',\n",
       "          'InterventionDescription': 'CBT, Depression, Website intervention, coaching',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Guided self-help Internet CBT']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Stepped-Care Internet CBT condition',\n",
       "          'InterventionDescription': 'Depression CBT, Internet intervention',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stepped-Care Internet CBT condition']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The primary hypothesis for which the study is powered is that Guided self-help CBT will result in greater depression symptom improvement than Pure self-help CBT.',\n",
       "          'PrimaryOutcomeDescription': \"We'll enroll 1,800 adults with depression from 3 rural healthcare clinics, 3 safety net federally qualified healthcare centers and 2 non-profit HMO. Participants will be randomized to: TAU only (b) TAU plus Pure self-help Internet CBT for depression (G-CBT), (c) TAU plus G-CBT, plus brief, periodic therapist telephone contacts; or (d) a Stepped-Care Internet CBT condition, starting with TAU + Pure self-help CBT and progressing to Guided self-help CBT if adequate progress is not observed early on. Participants will be followed for one year.\",\n",
       "          'PrimaryOutcomeTimeFrame': 'assessment measure is administered at baseline and each follow-up, at 5, 10, 15, 25, and 50 weeks after enrollment'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'secondary analyses will examine healthcare utilization for any signs of shifts in amount or mix of TAU services by study condition.',\n",
       "          'SecondaryOutcomeDescription': 'We will conduct cost-effectiveness analyses, examine TAU healthcare utilization from EMR, participant report and collect quantitative and qualitative data on patient, provider, and organizational factors that may impede or facilitate implementation of these interventions and we have added a non-research Reach Estimation Phase to better estimate acceptance and retention rates under conditions that closely match real-world dissemination',\n",
       "          'SecondaryOutcomeTimeFrame': 'assessment measure is administered at baseline and each follow-up, at 5, 10, 15, 25, and 50 weeks after enrollment'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nParticipants must have a score ≥ 10 on the self-report Patient Health Questionnaire (PHQ-8), indicative of clinically significant, moderate depression.\\nParticipants must identify their primary healthcare provider in one of the 8 performance sites, and give permission to contact him or her for the purpose of periodic progress reports as well as a referral contact in case any emergent crises are detected.\\nParticipant must be 18 years of age have access to a computer with internet and a working email address.\\nParticipants must also indicate they are planning to continue receiving services from one of the performance site clinics/organizations for at least the next 6 months',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Greg N Clarke, PhD',\n",
       "          'OverallOfficialAffiliation': 'Kaiser Permanente',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Kaiser Permanente Center for Health Research',\n",
       "          'LocationCity': 'Portland',\n",
       "          'LocationState': 'Oregon',\n",
       "          'LocationZip': '97227',\n",
       "          'LocationCountry': 'United States'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 81,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04008719',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'D17-P02'},\n",
       "       'Organization': {'OrgFullName': 'Centre Hospitalier St Anne',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'ATtention Test and Executive Functions After STroke to Predict Depression.',\n",
       "       'OfficialTitle': 'Predictivity of Attention Test and Executive Functions After Stroke to Predict Depression 3 Months After Stroke.',\n",
       "       'Acronym': 'ATTEST-Depress'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2019',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'May 16, 2017',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 16, 2018',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'August 16, 2018',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'April 27, 2017',\n",
       "       'StudyFirstSubmitQCDate': 'July 3, 2019',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 5, 2019',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'July 4, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 8, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Centre Hospitalier St Anne',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of this study is to determine whether cognitive function evaluation (sustained attention, executive functions, working memory) during acute post-stroke is predictive of a 3 months post-stroke depression.',\n",
       "       'DetailedDescription': \"Baseline visit: after neurologic stability, 14 days or less after stroke and before discharge.\\n\\nFirst assessment :\\n\\nNeurologic data: morphologic data (MRI of the brain), stroke severity (NIHSScore), aphasia assessment (Boston Diagnostic Aphasia Examination) if NIHS verbal score ≥1, hemineglect assessment (Bells test).\\nPersonal data assessment :\\n\\ni. Socio demographic : age, gender, marital status, employment, level of education ii. Medical history: medical treatments, psychiatric and non psychiatric history.\\n\\nc. Psychiatric assessment i. Mini International Neuropsychiatric Interview - depression ii. Beck Depression Inventory iii. Clinical Global Impression iv. Standardized Assessment of Personality - Abbreviated Scale (SAPAS) v. Fageström-C vi. Alcohol Use Disorders Identification Test (AUDIT-C) d. Cognitive assessment: i. Verbal memory : Dubois's five words ii. Clock drawing test iii. D2test (computerized) iv. Verbal fluency (Cardebat) v. Working memory (digit span WAIS 3) vi. Brixton (computerized)\\n\\nAssessment 3 months after the first assessment. Phone call and psychiatric assessment: MINI depression, Beck Depression Inventory. Barthel index and Quality of Life assessment.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Post-stroke Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Screening',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '69',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Patients',\n",
       "          'ArmGroupType': 'Other',\n",
       "          'ArmGroupDescription': 'Assessments are made by a psychiatrist',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Thymic history',\n",
       "            'Other: Evaluation of the psychiatric disorders',\n",
       "            'Other: Cognitive evaluation']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Thymic history',\n",
       "          'InterventionDescription': 'This interview concerns mainly the nature of the previous psychiatric and psychological care',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Patients']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Evaluation of the psychiatric disorders',\n",
       "          'InterventionDescription': 'Mini International Neuropsychiatric Interview for the positive diagnosis of depression - under the MINI score of depression.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Patients']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Cognitive evaluation',\n",
       "          'InterventionDescription': \"They will be held consecutively to the patient's bedside interview on the same day. Some tests will be computerized, others will be in paper form.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Patients']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Post stroke depression',\n",
       "          'PrimaryOutcomeDescription': 'Whether or not a post-stroke depression occurs. occurrence of post-stroke depression assessed with Mini International Neuropsychiatric Interview (MINI), subscale depression .',\n",
       "          'PrimaryOutcomeTimeFrame': '3 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Post-stroke depression population characterization',\n",
       "          'SecondaryOutcomeDescription': 'Age, gender, marital status, occupation, level of education, laterality of stroke,and medical and psychiatric history will be collected during the inclusion interview and cognitive tests',\n",
       "          'SecondaryOutcomeTimeFrame': '1 day'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAge 18 or more\\nIschemic or hemorragic stroke, diagnosed with radiology : cerebral CT or MRI, 14 days or less after stroke\\nSigned Consent\\nSocial insurance regime affiliation\\n\\nExclusion Criteria:\\n\\nDeath\\nNo possibility of follow-up\\nNo French-speaker : insufficient command of French\\nDeprivation of liberty : judicial or administrative decision\\nD2 test assessment impossibility\\nAphasia with major disorder of the understanding (Boston <8)\\nAntidepressant treatment during stroke\\nDepression during stroke\\nprotected people',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Philip GORWOOD, MD, PhD',\n",
       "          'OverallOfficialAffiliation': 'CHSA',\n",
       "          'OverallOfficialRole': 'Study Director'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Neurology service',\n",
       "          'LocationCity': 'Paris',\n",
       "          'LocationZip': '75014',\n",
       "          'LocationCountry': 'France'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521',\n",
       "          'ConditionMeshTerm': 'Stroke'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561',\n",
       "          'ConditionAncestorTerm': 'Cerebrovascular Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001927',\n",
       "          'ConditionAncestorTerm': 'Brain Diseases'},\n",
       "         {'ConditionAncestorId': 'D000002493',\n",
       "          'ConditionAncestorTerm': 'Central Nervous System Diseases'},\n",
       "         {'ConditionAncestorId': 'D000009422',\n",
       "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
       "         {'ConditionAncestorId': 'D000014652',\n",
       "          'ConditionAncestorTerm': 'Vascular Diseases'},\n",
       "         {'ConditionAncestorId': 'D000002318',\n",
       "          'ConditionAncestorTerm': 'Cardiovascular Diseases'},\n",
       "         {'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M20890',\n",
       "          'ConditionBrowseLeafName': 'Stroke',\n",
       "          'ConditionBrowseLeafAsFound': 'Stroke',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M4393',\n",
       "          'ConditionBrowseLeafName': 'Cerebrovascular Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3786',\n",
       "          'ConditionBrowseLeafName': 'Brain Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M4325',\n",
       "          'ConditionBrowseLeafName': 'Central Nervous System Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M15983',\n",
       "          'ConditionBrowseLeafName': 'Vascular Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10',\n",
       "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC14',\n",
       "          'ConditionBrowseBranchName': 'Heart and Blood Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}},\n",
       "   {'Rank': 82,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03990792',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'PI15/00401'},\n",
       "       'Organization': {'OrgFullName': 'The Mediterranean Institute for the Advance of Biotechnology and Health Research',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Personalized Prevention of Depression in Primary Care',\n",
       "       'OfficialTitle': 'Preventing the Onset of Depression Through a Personalized Intervention Based on ICTs, Risk Prediction Algorithms and Decision Support Systems for Patients and GPs: the e-predictD Study'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'February 2020',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'February 1, 2020',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2021',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2021',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'June 17, 2019',\n",
       "       'StudyFirstSubmitQCDate': 'June 17, 2019',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 19, 2019',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'February 11, 2020',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 13, 2020',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Juan Ángel Bellón',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'PhD, Medicine',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Andalusian Health Service'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'The Mediterranean Institute for the Advance of Biotechnology and Health Research',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Preventive Services and Health Promotion Research Network',\n",
       "          'CollaboratorClass': 'OTHER'},\n",
       "         {'CollaboratorName': 'Institute of Biomedical Research in Málaga (IBIMA)',\n",
       "          'CollaboratorClass': 'UNKNOWN'},\n",
       "         {'CollaboratorName': 'Andalusian Regional Ministry of Health',\n",
       "          'CollaboratorClass': 'OTHER_GOV'},\n",
       "         {'CollaboratorName': 'European Regional Development Fund (FEDER)',\n",
       "          'CollaboratorClass': 'UNKNOWN'},\n",
       "         {'CollaboratorName': 'University of Malaga',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The main goal is to design, develop and evaluate a personalized intervention to prevent the onset of depression based on Information and Communications Technology (ICTs), risk predictive algorithms and decision support systems (DSS) for patients and general practitioners (GPs). The specific goals are 1) to design and develop a DSS, called e-predictD-DSS, to elaborate personalized plans to prevent depression; 2) to design and develop an ICT solution that integrates the DSS on the web, a mobile application (App), the risk predictive algorithm, different intervention modules and a monitoring-feedback system; 3) to evaluate the usability and adherence of primary care patients and their GPs with the e-predictD intervention; 4) to evaluate the effectiveness of the e-predictD intervention to reduce the incidence of major depression, depression and anxiety symptoms and the probability of major depression next year; 5) to evaluate the cost-effectiveness and cost-utility of the e-predictD intervention to prevent depression.\\n\\nMethods: This is a randomized controlled trial with allocation by cluster (GPs), simple blind, two parallel arms (e-predictD vs \"active m-Health control\") and 1 year follow-up including 720 patients (360 in each arm) and 72 GPs (36 in each arm). Patients will be free of major depression at baseline and aged between 18 and 55 years old. Primary outcome will be the incidence of major depression at 12 months measured by CIDI. As secondary outcomes: depressive and anxiety symptomatology measured by PHQ-9 and GAD-7 and the risk probability of depression measured by predictD algorithm, as well as cost-effectiveness and cost-utility. The e-predictD intervention is multi-component and it is based on a DSS that helps the patients to elaborate their own personalized depression prevention plans, which the patient approves, and implements, and the system monitors offering feedback to the patient and to the GPs. It is an e-Health intervention because it is based on a web and m-Health because it is also implemented on the patient\\'s smartphones through an App. In addition, it integrates a risk algorithm of depression, which is already validated (the predictD algorithm). It also includes an initial GP-patient interview and a specific training for the GP. Finally, a map of potentially useful local community resources to prevent depression will be integrated into the DSS.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Primary Prevention',\n",
       "         'Primary Health Care',\n",
       "         'Randomized controlled trial',\n",
       "         'mHealth',\n",
       "         'App']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Prevention',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Triple',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Investigator',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '720',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'e-predictD intervention',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'In this arm, patients will receive a personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS) for patients and General Practitioners (GPs).',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: e-predictD intervention']}},\n",
       "         {'ArmGroupLabel': 'm-Health control',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'In this arm, patients will continue receiving the usual care from their GPs. In addition, they will use an App with the same appearance as the e-predictD App but it will only send weekly messages about physical and mental health management. This intervention is not personalized and does not include GP training and GP-patient interview.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Brief psychoeducational intervention']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'e-predictD intervention',\n",
       "          'InterventionDescription': \"The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps patients to develop their own personalized plans to prevent (PPP) depression; 3) eight intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the patient. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Patients will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6 and 9 months. The intervention also includes an initial and single 15-minute face-to-face GP-patient interview.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['e-predictD intervention']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Brief psychoeducational intervention',\n",
       "          'InterventionDescription': 'The intervention consists of an App that weekly send brief psychoeducational messages about physical and mental health (depression, anxiety, sleep hygiene, physical activity, etc.)',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['m-Health control']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Incidence of major depression measured by the Composite International Diagnostic Interview (CIDI)',\n",
       "          'PrimaryOutcomeDescription': 'Composite International Diagnostic Interview (CIDI) is a structured diagnostic interview that provides current diagnoses of major depression',\n",
       "          'PrimaryOutcomeTimeFrame': '12 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depressive symptoms measured by the Patient Health Questionnaire-9 (PHQ-9)',\n",
       "          'SecondaryOutcomeDescription': \"The Patient Health Questionnaire-9 (PHQ-9) measures symptoms of depression through 9 items, each of which is scored 0 ('not at all') to 3 ('nearly every day'). Low scores are equivalent to less symptoms of depression, the scale range is 0 to 27 (9 items)\",\n",
       "          'SecondaryOutcomeTimeFrame': '12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Anxious symptoms measured by the General Anxiety Questionnaire (GAD-7)',\n",
       "          'SecondaryOutcomeDescription': \"The General Anxiety Questionnaire (GAD-7) measures generalized anxiety disorder through 7 items, each of which is scored 0 ('not at all') to 3 ('nearly every day'). Low scores are equivalent to less symptoms of anxiety, the scale range is 0 to 21 (7 items)\",\n",
       "          'SecondaryOutcomeTimeFrame': '12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Probability of depression (predictD risk algorithm)',\n",
       "          'SecondaryOutcomeTimeFrame': '12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Cost-effectiveness and cost-utility',\n",
       "          'SecondaryOutcomeTimeFrame': '12 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPHQ-9 <10 at baseline\\nModerate-high risk of depression (predictD risk algorithm score ≥ 10%)\\n\\nExclusion Criteria:\\n\\nNot have a smartphone and internet for personal use\\nUnable to speak Spanish\\nDocumented terminal illness\\nDocumented cognitive impairment\\nLimiting sensory disorder (e.g. deafness)\\nDocumented serious mental illness (psychosis, bipolar, addictions, etc.)',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '55 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Sonia Conejo-Cerón, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '+34 951031417',\n",
       "          'CentralContactEMail': 'soniafundacionimabis@hotmail.com'},\n",
       "         {'CentralContactName': 'Patricia Moreno-Peral, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '+34 951031347',\n",
       "          'CentralContactEMail': 'predictmalaga@hotmail.com'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Juan M. Mendive',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Barcelona',\n",
       "          'LocationCountry': 'Spain',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Juan M. Mendive, PhD',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'María Isabel Ballesta Rodríguez',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Jaén',\n",
       "          'LocationCountry': 'Spain',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'María Isabel Ballesta Rodríguez, PhD',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Antonina Rodríguez Bayón',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Linares',\n",
       "          'LocationCountry': 'Spain',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Antonina Rodríguez Bayón, PhD',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Juan Á Bellón',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Málaga',\n",
       "          'LocationCountry': 'Spain',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Juan Á Bellón, PhD',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Emiliano Rodríguez',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Salamanca',\n",
       "          'LocationCountry': 'Spain',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Emiliano Rodríguez, PhD',\n",
       "             'LocationContactRole': 'Contact'}]}},\n",
       "         {'LocationFacility': 'Yolanda López del Hoyo',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Zaragoza',\n",
       "          'LocationCountry': 'Spain',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yolanda López del Hoyo, PhD',\n",
       "             'LocationContactRole': 'Contact'}]}}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 83,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02021669',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '201309002'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01HL117805',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01HL117805&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'Washington University School of Medicine',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Omega-3 for Depression and Other Cardiac Risk Factors - 2',\n",
       "       'OfficialTitle': 'Omega-3 for Depression and Other Cardiac Risk Factors-2',\n",
       "       'Acronym': 'Omega-3(2)'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'August 2019',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'May 14, 2014',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 13, 2018',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'September 13, 2018',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'December 19, 2013',\n",
       "       'StudyFirstSubmitQCDate': 'December 19, 2013',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 27, 2013',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'July 12, 2019',\n",
       "       'ResultsFirstSubmitQCDate': 'July 12, 2019',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 6, 2019',\n",
       "        'ResultsFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'August 23, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 4, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Washington University School of Medicine',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Heart, Lung, and Blood Institute (NHLBI)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to determine whether antidepressant augmentation with two grams of EPA omega-3 per day is superior to antidepressant therapy alone for major depression in patients with coronary heart disease (CHD).',\n",
       "       'DetailedDescription': 'Depression increases the risk for cardiac morbidity and mortality 2-4 fold in patients with coronary heart disease (CHD). Recent clinical trials have tested standard treatments for comorbid depression in patients with CHD, and some have evaluated their effects on cardiac morbidity and mortality. Most of these trials have shown that standard treatments have only modest effects on depression and have produced relatively small differences between the intervention and control condition. Consequently, they have been unable to determine whether effective treatment of depression can improve cardiac outcomes. Low dietary intake and low plasma phospholipid or erythrocyte levels of two omega-3 fatty acids(FAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are associated with depression and other cardiac risk markers. There is growing evidence from small psychiatric trials that the efficacy of standard antidepressants can be improved by coadministration of an omega-3 FA formulation containing at least 1 gram of EPA. The purpose of the proposed research is to determine whether antidepressant augmentation with this omega-3 formulation is superior to antidepressant therapy alone for major depression in patients with CHD. The proposed study is a randomized, placebo-controlled, double-blind clinical trial. Consenting patients with established coronary heart disease who meet the Diagnostic Statistical Manual (DSM)-5 criteria for a major depressive episode will undergo a baseline evaluation and then be randomly assigned to receive either 50 mg/day of sertraline plus omega-3 FA or 50 mg/day of sertraline plus placebo for 10 weeks. At baseline and after 10 weeks, participants will complete assessments of depression, 24 hour ambulatory ECG monitoring to measure 24 hour heart rate and heart rate variability, and blood draws to measure procoagulant and proinflammatory markers and blood levels of EPA, DHA, other omega-3 FAs, and the omega-6 FAs. If sertraline plus this omega-3 formulation significantly reduces depression compared to sertraline plus placebo, and if it improves or at least does not worsen other cardiovascular risk markers, this study will provide a strong basis for proposing a multicenter clinical trial of sertraline augmented with omega-3 to determine whether treatment of depression can improve survival in patients with CHD and depression.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Antidepressive agents',\n",
       "         'Coronary disease',\n",
       "         'Depression',\n",
       "         'Depressive disorder',\n",
       "         'Fatty Acids, Omega-3']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 2']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Quadruple',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Care Provider',\n",
       "           'Investigator',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '144',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Omega-3 supplement',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Omega-3 supplement']}},\n",
       "         {'ArmGroupLabel': 'Placebo',\n",
       "          'ArmGroupType': 'Placebo Comparator',\n",
       "          'ArmGroupDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Placebo']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Omega-3 supplement',\n",
       "          'InterventionDescription': 'Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Omega-3 supplement']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['EPA Plus Minami Nutrition']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Placebo',\n",
       "          'InterventionDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Beck Depression Inventory-II (BDI-II)',\n",
       "          'PrimaryOutcomeDescription': 'The BDI-II is a 21-item self-report inventory of depression symptoms. The minimum and maximum values for the BDI-II are (0-63). For both instruments, the higher the scores, the greater the severity of depression.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Change from baseline to 10 weeks (post-treatment)'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Hamilton Depression Rating Scale (HAM-D, 17)',\n",
       "          'SecondaryOutcomeDescription': 'The HAM-D, 17 is a 17-item, observer-rated measure of depression symptoms. The minimum and maximum values for the HAM-D, (0-52). For both instruments, the higher the scores, the greater the severity of depression.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Change from baseline to 10 weeks (post-treatment)'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nDocumented coronary heart disease\\nDiagnosis of major depression based on structured interview\\n\\nExclusion Criteria:\\n\\nModerate to severe cognitive impairment\\nMeets DSM-5 criteria for depressive disorder due to a general medical condition or medication\\nMajor Axis I psychiatric disorder other than unipolar depression or an anxiety disorder, a high risk of suicide, or current substance abuse other than tobacco;\\nNot expected to survive one year or physically unable to tolerate the study protocol\\nKnown sensitivity to sertraline or omega-3, or an allergy to fish oil or shellfish\\nTaking an antidepressant or an omega-3 supplement at baseline\\nExempted by their cardiologist or primary care physician\\nRefuses to provide informed consent\\nParticipating in a competing protocol or trial',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '25 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Robert M Carney, PhD',\n",
       "          'OverallOfficialAffiliation': 'Washington University School of Medicine',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Washington University Medical Center',\n",
       "          'LocationCity': 'Saint Louis',\n",
       "          'LocationState': 'Missouri',\n",
       "          'LocationZip': '63108',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31163106',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. A Randomized Placebo-Controlled Trial of Omega-3 and Sertraline in Depressed Patients With or at Risk for Coronary Heart Disease. J Clin Psychiatry. 2019 Jun 4;80(4). pii: 19m12742. doi: 10.4088/JCP.19m12742.'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Omega-3 Supplement',\n",
       "          'FlowGroupDescription': 'Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks\\n\\nOmega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks'},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Placebo',\n",
       "          'FlowGroupDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.\\n\\nPlacebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '71'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '73'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '64'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '70'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '7'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '3'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Omega-3 Supplement',\n",
       "          'BaselineGroupDescription': 'Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks\\n\\nOmega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks'},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Placebo',\n",
       "          'BaselineGroupDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.\\n\\nPlacebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '71'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '73'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '144'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '49'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '46'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '95'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '22'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '27'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '49'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '58.5',\n",
       "                   'BaselineMeasurementSpread': '9.6'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '60.5',\n",
       "                   'BaselineMeasurementSpread': '9.3'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '59.6',\n",
       "                   'BaselineMeasurementSpread': '9.4'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '26'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '30'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '56'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '45'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '43'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '88'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Race (NIH/OMB)',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '2'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '2'}]}},\n",
       "               {'BaselineCategoryTitle': 'Asian',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '1'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '1'}]}},\n",
       "               {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Black or African American',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '21'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '27'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '48'}]}},\n",
       "               {'BaselineCategoryTitle': 'White',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '44'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '45'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '89'}]}},\n",
       "               {'BaselineCategoryTitle': 'More than one race',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '3'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '1'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '4'}]}},\n",
       "               {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '71'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '73'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '144'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Beck Depression Inventory-II (BDI-II)',\n",
       "          'OutcomeMeasureDescription': 'The BDI-II is a 21-item self-report inventory of depression symptoms. The minimum and maximum values for the BDI-II are (0-63). For both instruments, the higher the scores, the greater the severity of depression.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'score on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'Change from baseline to 10 weeks (post-treatment)',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Omega-3 Supplement',\n",
       "             'OutcomeGroupDescription': 'Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks\\n\\nOmega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Placebo',\n",
       "             'OutcomeGroupDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.\\n\\nPlacebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '71'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '73'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '29.9',\n",
       "                   'OutcomeMeasurementSpread': '9.0'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '29.1',\n",
       "                   'OutcomeMeasurementSpread': '8.8'}]}}]}},\n",
       "            {'OutcomeClassTitle': 'Post Treatment (10 Weeks)',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '11.0',\n",
       "                   'OutcomeMeasurementSpread': '9.9'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '9.1',\n",
       "                   'OutcomeMeasurementSpread': '7.7'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Hamilton Depression Rating Scale (HAM-D, 17)',\n",
       "          'OutcomeMeasureDescription': 'The HAM-D, 17 is a 17-item, observer-rated measure of depression symptoms. The minimum and maximum values for the HAM-D, (0-52). For both instruments, the higher the scores, the greater the severity of depression.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'score on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'Change from baseline to 10 weeks (post-treatment)',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Omega-3 Supplement',\n",
       "             'OutcomeGroupDescription': 'Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks\\n\\nOmega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Placebo',\n",
       "             'OutcomeGroupDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.\\n\\nPlacebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '71'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '73'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '17.4',\n",
       "                   'OutcomeMeasurementSpread': '5.4'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '17.0',\n",
       "                   'OutcomeMeasurementSpread': '5.0'}]}}]}},\n",
       "            {'OutcomeClassTitle': 'Post Treatment (10 Weeks)',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '7.1',\n",
       "                   'OutcomeMeasurementSpread': '7.0'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '6.2',\n",
       "                   'OutcomeMeasurementSpread': '5.5'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventsTimeFrame': 'Each participant was followed for fourteen weeks (ten weeks of treatment plus a final call 4 weeks after the end of treatment)',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Omega-3 Supplement',\n",
       "          'EventGroupDescription': 'Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks\\n\\nOmega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks',\n",
       "          'EventGroupDeathsNumAffected': '0',\n",
       "          'EventGroupDeathsNumAtRisk': '71',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '71',\n",
       "          'EventGroupOtherNumAffected': '35',\n",
       "          'EventGroupOtherNumAtRisk': '71'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Placebo',\n",
       "          'EventGroupDescription': 'Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.\\n\\nPlacebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.',\n",
       "          'EventGroupDeathsNumAffected': '0',\n",
       "          'EventGroupDeathsNumAtRisk': '73',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '73',\n",
       "          'EventGroupOtherNumAffected': '32',\n",
       "          'EventGroupOtherNumAtRisk': '73'}]},\n",
       "       'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Nausea',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '15',\n",
       "             'OtherEventStatsNumAffected': '15',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '11',\n",
       "             'OtherEventStatsNumAffected': '11',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Diarrhea',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '7',\n",
       "             'OtherEventStatsNumAffected': '7',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '15',\n",
       "             'OtherEventStatsNumAffected': '15',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Constipation',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '4',\n",
       "             'OtherEventStatsNumAffected': '4',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Increased flatulence',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Increased sleepiness',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '8',\n",
       "             'OtherEventStatsNumAffected': '8',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '5',\n",
       "             'OtherEventStatsNumAffected': '5',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Fatigue',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '4',\n",
       "             'OtherEventStatsNumAffected': '4',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Dizziness',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Insomnia',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '0',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Hand Tremors',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Decreased sexual interest/performance',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Less emotionally responsive',\n",
       "          'OtherEventOrganSystem': 'Social circumstances',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Headaches',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '6',\n",
       "             'OtherEventStatsNumAffected': '6',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Increased anxiety',\n",
       "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Agitation',\n",
       "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Increased sweating',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Decreased appetite',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Bad taste in mouth',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '1',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}},\n",
       "         {'OtherEventTerm': 'Burping',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '2',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '71'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '0',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '73'}]}}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes',\n",
       "        'AgreementRestrictiveAgreement': 'No'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Robert M. Carney, Ph.D',\n",
       "        'PointOfContactOrganization': 'Washington University School of Medicine',\n",
       "        'PointOfContactEMail': 'carneyr@wustl.edu',\n",
       "        'PointOfContactPhone': '314-286-1305'}}},\n",
       "     'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'Prot_SAP_ICF',\n",
       "          'LargeDocHasProtocol': 'Yes',\n",
       "          'LargeDocHasSAP': 'Yes',\n",
       "          'LargeDocHasICF': 'Yes',\n",
       "          'LargeDocLabel': 'Study Protocol, Statistical Analysis Plan, and Informed Consent Form',\n",
       "          'LargeDocDate': 'May 22, 2018',\n",
       "          'LargeDocUploadDate': '10/19/2018 11:05',\n",
       "          'LargeDocFilename': 'Prot_SAP_ICF_000.pdf'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T415',\n",
       "          'InterventionBrowseLeafName': 'Omega 3 Fatty Acid',\n",
       "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Ot',\n",
       "          'InterventionBrowseBranchName': 'Other Dietary Supplements'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5129',\n",
       "          'ConditionBrowseLeafName': 'Coronary Artery Disease',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5132',\n",
       "          'ConditionBrowseLeafName': 'Coronary Disease',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC14',\n",
       "          'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}},\n",
       "   {'Rank': 84,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01527981',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'MGHBMED2172010'},\n",
       "       'Organization': {'OrgFullName': 'Massachusetts General Hospital',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Cognitive Behavioral Therapy (CBT) for Adherence and Depression in Type 1 Diabetes',\n",
       "       'OfficialTitle': 'CBT for Adherence and Depression in Type 1 Diabetes'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'February 2012',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'March 2008'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2010',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'November 2010',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'January 31, 2012',\n",
       "       'StudyFirstSubmitQCDate': 'February 3, 2012',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 7, 2012',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'February 3, 2012',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 7, 2012',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Steven A. Safren',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Director, Behavioral Medicine',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Massachusetts General Hospital'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Massachusetts General Hospital',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study is a pilot behavioral intervention trial, designed to initially examine cognitive behavioral therapy for medical adherence and depression (CBT-AD) in patients with depression and poorly controlled type 1 diabetes.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression',\n",
       "         'Type 1 Diabetes']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Diabetes',\n",
       "         'Adherence',\n",
       "         'Medication',\n",
       "         'Glucose',\n",
       "         'Insulin']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 2']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '9', 'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'CBT-AD',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants received weekly one-hour CBT-AD sessions focusing on diabetes self-care and depression for approximately 10 sessions. Participants also had meetings with a registered dietitian and a nurse educator, focusing on nutritional management of diabetes and diabetes self-care education, respectively.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive behavioral therapy for adherence and depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Cognitive behavioral therapy for adherence and depression',\n",
       "          'InterventionDescription': \"Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CBT-AD']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['CBT-AD']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Changes in glucose monitoring',\n",
       "          'PrimaryOutcomeDescription': \"We used electronic glucometers to measure participants' adherence to prescribed glucose self-monitoring, which record each time glucose was measured and the glucose level of each measurement.\",\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline assessment; 4, 8, and 12 months post-intervention assessments'},\n",
       "         {'PrimaryOutcomeMeasure': 'Changes in insulin adherence',\n",
       "          'PrimaryOutcomeDescription': \"We assessed adherence to participants' self-administered insulin through a self-report questionnaire.\",\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline assessment; 4, 8, and 12 months post-intervention assessments'},\n",
       "         {'PrimaryOutcomeMeasure': 'Changes in depression severity',\n",
       "          'PrimaryOutcomeDescription': \"Participants' depression severity was measured by clinician-administered measures (Montgomery-Asberg Depression Rating Scale) and self-report measures (Center for Epidemiological Studies Depression Scale). Clinician-delivered measures were administered at baseline and follow-up assessments by assessors blinded to participants' randomization status.\",\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline assessment; 4, 8, and 12 months post-intervention assessments'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Changes in hemoglobin A1C',\n",
       "          'SecondaryOutcomeDescription': 'We measured participants hemoglobin A1C by means of a blood draw and laboratory test.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline assessment; 4, 8, and 12 months post-intervention assessment'},\n",
       "         {'SecondaryOutcomeMeasure': 'Changes in glucose levels',\n",
       "          'SecondaryOutcomeDescription': 'We measured participants self-monitored glucose levels using electronic glucometers, which record the glucose level of each measurement.',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline assessment; 4, 8, and 12 months post-intervention assessment'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nDiagnosis of type 1 diabetes that is poorly controlled (HbA1C greater than or equal to 8.0%) despite treatment with insulin.\\nDiagnosis of major depression and/or dysthymia, or current subclinical symptoms of depression in spite of being treated with antidepressants.\\nAge 18-80.\\nIf on an antidepressant, stable for two months. Oral hypoglycemic medications stable for 2 months, and insulin prescription stable for 2 months (if prescribed).\\n\\nExclusion Criteria:\\n\\nActive or untreated major mental illness that would interfere with participation (e.g., untreated psychosis), untreated/unstable bipolar disorder, eating disorder, mental retardation, dementia, or active suicidality.\\nUnable or unwilling to provide informed consent.\\nHistory of or current CBT for depression.\\nCurrently on dialysis.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '80 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Steven A Safren, Ph.D.',\n",
       "          'OverallOfficialAffiliation': 'Massachusetts General Hospital',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Massachusetts General Hospital',\n",
       "          'LocationCity': 'Boston',\n",
       "          'LocationState': 'Massachusetts',\n",
       "          'LocationZip': '02114',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '22943030',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Markowitz SM, Carper MM, Gonzalez JS, Delahanty LM, Safren SA. Cognitive-behavioral therapy for the treatment of depression and adherence in patients with type 1 diabetes: pilot data and feasibility. Prim Care Companion CNS Disord. 2012;14(2). pii: PCC.11m01220. doi: 10.4088/PCC.11m01220. Epub 2012 Mar 15.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003920',\n",
       "          'ConditionMeshTerm': 'Diabetes Mellitus'},\n",
       "         {'ConditionMeshId': 'D000003922',\n",
       "          'ConditionMeshTerm': 'Diabetes Mellitus, Type 1'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000044882',\n",
       "          'ConditionAncestorTerm': 'Glucose Metabolism Disorders'},\n",
       "         {'ConditionAncestorId': 'D000008659',\n",
       "          'ConditionAncestorTerm': 'Metabolic Diseases'},\n",
       "         {'ConditionAncestorId': 'D000004700',\n",
       "          'ConditionAncestorTerm': 'Endocrine System Diseases'},\n",
       "         {'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001327',\n",
       "          'ConditionAncestorTerm': 'Autoimmune Diseases'},\n",
       "         {'ConditionAncestorId': 'D000007154',\n",
       "          'ConditionAncestorTerm': 'Immune System Diseases'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5698',\n",
       "          'ConditionBrowseLeafName': 'Diabetes Mellitus',\n",
       "          'ConditionBrowseLeafAsFound': 'Diabetes',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5700',\n",
       "          'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 1',\n",
       "          'ConditionBrowseLeafAsFound': 'Type 1 Diabetes',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M10222',\n",
       "          'ConditionBrowseLeafName': 'Metabolic Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M23990',\n",
       "          'ConditionBrowseLeafName': 'Glucose Metabolism Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M6445',\n",
       "          'ConditionBrowseLeafName': 'Endocrine System Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3210',\n",
       "          'ConditionBrowseLeafName': 'Autoimmune Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M8783',\n",
       "          'ConditionBrowseLeafName': 'Immune System Diseases',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18',\n",
       "          'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC19',\n",
       "          'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC20',\n",
       "          'ConditionBrowseBranchName': 'Immune System Diseases'}]}}}}},\n",
       "   {'Rank': 85,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00868699',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'D1050236'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'EUDRACT No. 2008-007457-13'}]},\n",
       "       'Organization': {'OrgFullName': 'Sunovion', 'OrgClass': 'INDUSTRY'},\n",
       "       'BriefTitle': 'Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)',\n",
       "       'OfficialTitle': 'A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'March 2014',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'April 2009'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2012',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'February 2012',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'March 23, 2009',\n",
       "       'StudyFirstSubmitQCDate': 'March 24, 2009',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 25, 2009',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'February 14, 2013',\n",
       "       'ResultsFirstSubmitQCDate': 'May 28, 2013',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'July 2, 2013',\n",
       "        'ResultsFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'March 31, 2014',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 17, 2014',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Sunovion',\n",
       "        'LeadSponsorClass': 'INDUSTRY'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Bipolar Depression']},\n",
       "       'KeywordList': {'Keyword': ['Bipolar I, Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 3']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Investigator']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '505',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'lurasidone low arm',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: lurasidone']}},\n",
       "         {'ArmGroupLabel': 'Placebo',\n",
       "          'ArmGroupType': 'Placebo Comparator',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Placebo']}},\n",
       "         {'ArmGroupLabel': 'lurasidone high arm',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: lurasidone']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
       "          'InterventionName': 'lurasidone',\n",
       "          'InterventionDescription': 'lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['lurasidone high arm']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'lurasidone',\n",
       "          'InterventionDescription': 'lurasidone 20 mg/day for Days 1-7',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['lurasidone low arm']}},\n",
       "         {'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Placebo',\n",
       "          'InterventionDescription': 'Placebo Comparator',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)',\n",
       "          'PrimaryOutcomeDescription': \"Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression.\\n\\nThe MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.\\n\\nThe MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.\",\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline to Week 6'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)',\n",
       "          'SecondaryOutcomeDescription': \"Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression.\\n\\nThe CGI depression score ranges from a minimum of 0 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.\",\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline to Week 6'},\n",
       "         {'SecondaryOutcomeMeasure': 'Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score',\n",
       "          'SecondaryOutcomeDescription': \"Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of depression.\\n\\nThe SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.\\n\\nThe SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items.\",\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline to Week 6'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nSubject is diagnosed with bipolar I disorder, most resent episode depressed\\nSubject must have a lifetime history of at least one bipolar manic or mixed episode\\n\\nExclusion Criteria:\\n\\nHistory of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode\\nSubject has been hospitalized for a manic or mixed episode within 60 days prior to randomization\\nImminent risk of suicide or injury to self, others, or property',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '75 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Medical Director, MD',\n",
       "          'OverallOfficialAffiliation': 'Sunovion',\n",
       "          'OverallOfficialRole': 'Study Director'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Synergy Escondido,710 East Grand Ave.',\n",
       "          'LocationCity': 'Escondido',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '92025',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Collaborative Neuroscience Network Inc.,12772 Valley View Street,Suite 3',\n",
       "          'LocationCity': 'Garden Grove',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '92645',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Excell Research, Inc,3998 Vista Way,Suite 100',\n",
       "          'LocationCity': 'Oceanside',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '92056',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'University of California at Irvine Medical Center',\n",
       "          'LocationCity': 'Orange',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '92868',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'California Neuropsychopharmacology,CNRI - Los Angeles LLC,8309 Telegraph Road',\n",
       "          'LocationCity': 'Pico Rivera',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '90660',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'California Neuropsychopharmacology Clinical Research Institute, LLC,466 26th Street,6th Floor',\n",
       "          'LocationCity': 'San Diego',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '92102',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'University of Colorado',\n",
       "          'LocationCity': 'Aurora',\n",
       "          'LocationState': 'Colorado',\n",
       "          'LocationZip': '80045',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Florida Clinical Research Center, LLC,3914 State Road 64 East',\n",
       "          'LocationCity': 'Bradenton',\n",
       "          'LocationState': 'Florida',\n",
       "          'LocationZip': '34208',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Florida Clinical Research Center, LLC,2300 Maitland Center Parkway,Suite 230',\n",
       "          'LocationCity': 'Maitland',\n",
       "          'LocationState': 'Florida',\n",
       "          'LocationZip': '32751',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Depression and Anxiety Disorders Research Institute',\n",
       "          'LocationCity': 'Tampa',\n",
       "          'LocationState': 'Florida',\n",
       "          'LocationZip': '33613',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Janus Center for Psychiatric Research,5601 Corporate Way,Suite 103',\n",
       "          'LocationCity': 'West Palm Beach',\n",
       "          'LocationState': 'Florida',\n",
       "          'LocationZip': '33407',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'American Medical Research Inc.,1200 Harger Road Suite 415',\n",
       "          'LocationCity': 'Oak Brook',\n",
       "          'LocationState': 'Illinois',\n",
       "          'LocationZip': '60523',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340',\n",
       "          'LocationCity': 'Lake Charles',\n",
       "          'LocationState': 'Louisiana',\n",
       "          'LocationZip': '70601',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Sheppard Pratt Health System,6501 North Charles Street',\n",
       "          'LocationCity': 'Baltimore',\n",
       "          'LocationState': 'Maryland',\n",
       "          'LocationZip': '21285',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Albuquerque Neuroscience Inc., 101 Hospital Loop, NE, Suite 209',\n",
       "          'LocationCity': 'Albuquerque',\n",
       "          'LocationState': 'New Mexico',\n",
       "          'LocationZip': '87109',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Neurobehavioral Research, Inc.',\n",
       "          'LocationCity': 'Cedarhurst',\n",
       "          'LocationState': 'New York',\n",
       "          'LocationZip': '11516',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Finger Lakes Clinical Research',\n",
       "          'LocationCity': 'Rochester',\n",
       "          'LocationState': 'New York',\n",
       "          'LocationZip': '14618',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Richard H. Weisler., M.D., P.A., & Associates,700 Spring Forest Road,Suite 125',\n",
       "          'LocationCity': 'Raleigh',\n",
       "          'LocationState': 'North Carolina',\n",
       "          'LocationZip': '27609',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Mood Disorders Program-UHCMC',\n",
       "          'LocationCity': 'Cleveland',\n",
       "          'LocationState': 'Ohio',\n",
       "          'LocationZip': '44106',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'MetroHealth System',\n",
       "          'LocationCity': 'Cleveland',\n",
       "          'LocationState': 'Ohio',\n",
       "          'LocationZip': '44122',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'CRI Worldwide, LLC',\n",
       "          'LocationCity': 'Philadelphia',\n",
       "          'LocationState': 'Pennsylvania',\n",
       "          'LocationZip': '19139',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'FutureSearch Clinical Trials, LLC.,4200 Marathon Blvd.,Suite 200',\n",
       "          'LocationCity': 'Austin',\n",
       "          'LocationState': 'Texas',\n",
       "          'LocationZip': '78756',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Medical Services Prague s.r.o.',\n",
       "          'LocationCity': 'Kolejni 429-5',\n",
       "          'LocationState': 'Praha',\n",
       "          'LocationCountry': 'Czech Republic'},\n",
       "         {'LocationFacility': 'Psychiatricka ambulance',\n",
       "          'LocationCity': 'Brno - mesto',\n",
       "          'LocationZip': '602 00',\n",
       "          'LocationCountry': 'Czech Republic'},\n",
       "         {'LocationFacility': 'BIALBI s.r.o., Psychiatricke Oddeleni',\n",
       "          'LocationCity': 'Litomerice',\n",
       "          'LocationCountry': 'Czech Republic'},\n",
       "         {'LocationFacility': 'Clintrial, s.r.o.',\n",
       "          'LocationCity': 'Praha',\n",
       "          'LocationZip': '10 100 00',\n",
       "          'LocationCountry': 'Czech Republic'},\n",
       "         {'LocationFacility': 'Hopital Caremeau, Service de Psychiatrie A',\n",
       "          'LocationCity': 'Nimes Cedex',\n",
       "          'LocationZip': '30 30029',\n",
       "          'LocationCountry': 'France'},\n",
       "         {'LocationFacility': 'Zans Ritter, Marcel',\n",
       "          'LocationCity': 'Orvault',\n",
       "          'LocationZip': '44700',\n",
       "          'LocationCountry': 'France'},\n",
       "         {'LocationFacility': 'S V Medical College',\n",
       "          'LocationCity': 'Tirupati',\n",
       "          'LocationState': 'Andh Prad',\n",
       "          'LocationZip': '517507',\n",
       "          'LocationCountry': 'India'},\n",
       "         {'LocationFacility': 'Vijayawada Institute of Mental Health and Neurosciences, Psychiatry',\n",
       "          'LocationCity': 'Vijaywada',\n",
       "          'LocationState': 'Andh Prad',\n",
       "          'LocationZip': '520002',\n",
       "          'LocationCountry': 'India'},\n",
       "         {'LocationFacility': 'Samvedna Hospitals',\n",
       "          'LocationCity': 'Ahmedabad',\n",
       "          'LocationState': 'Gujarat',\n",
       "          'LocationZip': '380006',\n",
       "          'LocationCountry': 'India'},\n",
       "         {'LocationFacility': 'Seth K M School of P G Medicine & Research',\n",
       "          'LocationCity': 'Ahmedabad',\n",
       "          'LocationState': 'Gujarat',\n",
       "          'LocationZip': '380006',\n",
       "          'LocationCountry': 'India'},\n",
       "         {'LocationFacility': 'Mental Illness Treatment Rehabilitationi Foundation',\n",
       "          'LocationCity': 'Ahmedabad',\n",
       "          'LocationState': 'Gujarat',\n",
       "          'LocationZip': '380013',\n",
       "          'LocationCountry': 'India'},\n",
       "         {'LocationFacility': 'Spandana Nursing Home',\n",
       "          'LocationCity': 'Bangalore',\n",
       "          'LocationState': 'Karna',\n",
       "          'LocationZip': '560010',\n",
       "          'LocationCountry': 'India'},\n",
       "         {'LocationFacility': 'Sujata Birla Hospital & Research Centre',\n",
       "          'LocationCity': 'Nashik',\n",
       "          'LocationState': 'Mahara',\n",
       "          'LocationZip': '422101',\n",
       "          'LocationCountry': 'India'},\n",
       "         {'LocationFacility': 'R.K. Yadav Memorial Mental Health & De-Addiction Hospital',\n",
       "          'LocationCity': 'Jaipur',\n",
       "          'LocationState': 'Rajasthan',\n",
       "          'LocationZip': '302021',\n",
       "          'LocationCountry': 'India'},\n",
       "         {'LocationFacility': 'Manobal Med. Research Centre',\n",
       "          'LocationCity': 'Lucknow',\n",
       "          'LocationState': 'Uttar Prad',\n",
       "          'LocationZip': '226006',\n",
       "          'LocationCountry': 'India'},\n",
       "         {'LocationFacility': 'Spitalul Clinic de Urgenta Militar Central',\n",
       "          'LocationCity': 'Bucdresti',\n",
       "          'LocationZip': '010825',\n",
       "          'LocationCountry': 'Romania'},\n",
       "         {'LocationFacility': 'Spitalul Clinic de Psihaiatrie Prof. Dr. Alexandru Obregia',\n",
       "          'LocationCity': 'Bucuresti',\n",
       "          'LocationZip': '041914',\n",
       "          'LocationCountry': 'Romania'},\n",
       "         {'LocationFacility': 'Spitalul Clinic Judetean de Urgenta Cluj',\n",
       "          'LocationCity': 'Cluj-Napoca',\n",
       "          'LocationZip': '400012',\n",
       "          'LocationCountry': 'Romania'},\n",
       "         {'LocationFacility': 'Spitalul Clinic de Neuropsihiatrie Craiova',\n",
       "          'LocationCity': 'Craiova',\n",
       "          'LocationZip': '200620',\n",
       "          'LocationCountry': 'Romania'},\n",
       "         {'LocationFacility': 'Spitalul Clinic de Neurologie si Psihiatrie Oradea',\n",
       "          'LocationCity': 'Oradea',\n",
       "          'LocationZip': '410154',\n",
       "          'LocationCountry': 'Romania'},\n",
       "         {'LocationFacility': 'City Psychiatric Hospital #2 of St. Nikolay Chudotvorets',\n",
       "          'LocationCity': 'St. Petersburg',\n",
       "          'LocationZip': '190121',\n",
       "          'LocationCountry': 'Russian Federation'},\n",
       "         {'LocationFacility': 'Bekhterev Scientific Research Psychoneurological Institute',\n",
       "          'LocationCity': 'St. Petersburg',\n",
       "          'LocationZip': '193019',\n",
       "          'LocationCountry': 'Russian Federation'},\n",
       "         {'LocationFacility': 'Psychoneurology Dispensary #4',\n",
       "          'LocationCity': 'St. Petersburg',\n",
       "          'LocationZip': '197110',\n",
       "          'LocationCountry': 'Russian Federation'},\n",
       "         {'LocationFacility': 'Cape Trial Centre',\n",
       "          'LocationCity': 'Cape Town, W. Cape',\n",
       "          'LocationZip': '7530',\n",
       "          'LocationCountry': 'South Africa'},\n",
       "         {'LocationFacility': 'Paarl Medical Centre',\n",
       "          'LocationCity': 'Paarl, W. Cape',\n",
       "          'LocationZip': '7646',\n",
       "          'LocationCountry': 'South Africa'},\n",
       "         {'LocationFacility': 'Clinika',\n",
       "          'LocationCity': 'Port Elizabeth, E. Cape',\n",
       "          'LocationZip': '6000',\n",
       "          'LocationCountry': 'South Africa'},\n",
       "         {'LocationFacility': 'Dey Clinic',\n",
       "          'LocationCity': 'Pretoria, Gauteng',\n",
       "          'LocationZip': '0181',\n",
       "          'LocationCountry': 'South Africa'},\n",
       "         {'LocationFacility': 'Vereeniging Medi-Clinic',\n",
       "          'LocationCity': 'Vereeniging, Free State',\n",
       "          'LocationZip': '1941',\n",
       "          'LocationCountry': 'South Africa'},\n",
       "         {'LocationFacility': 'Chair of Psychiatry and Medical Psychology',\n",
       "          'LocationCity': 'Donetsk',\n",
       "          'LocationZip': '83008',\n",
       "          'LocationCountry': 'Ukraine'},\n",
       "         {'LocationFacility': 'Reg. Psychiatric Hospital',\n",
       "          'LocationCity': 'Odessa',\n",
       "          'LocationCountry': 'Ukraine'},\n",
       "         {'LocationFacility': 'Reg Cl.Ps.H.n.a.O.F. Malstev, Fem.Ac. Gen. Ps.D.5B',\n",
       "          'LocationCity': 'Poltava',\n",
       "          'LocationZip': '36006',\n",
       "          'LocationCountry': 'Ukraine'},\n",
       "         {'LocationFacility': 'CRI Cl.Psych.Hosp. #1, Fem. Psych. Dept. #2, Male I',\n",
       "          'LocationCity': 'Simferopol',\n",
       "          'LocationZip': '95006',\n",
       "          'LocationCountry': 'Ukraine'},\n",
       "         {'LocationFacility': 'Reg. Psych. Hosp.n.a.O.Yuschenko, Dept #21',\n",
       "          'LocationCity': 'Vinnitsia',\n",
       "          'LocationZip': '21018',\n",
       "          'LocationCountry': 'Ukraine'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24170180',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, Sachs G. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014 Feb;171(2):160-8. doi: 10.1176/appi.ajp.2013.13070984.'},\n",
       "         {'ReferencePMID': '30102967',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Raison CL, Pikalov A, Siu C, Tsai J, Koblan K, Loebel A. C-reactive protein and response to lurasidone in patients with bipolar depression. Brain Behav Immun. 2018 Oct;73:717-724. doi: 10.1016/j.bbi.2018.08.009. Epub 2018 Aug 10.'},\n",
       "         {'ReferencePMID': '27529375',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies. J Clin Psychiatry. 2016 Oct;77(10):e1324-e1331. doi: 10.4088/JCP.15m10261.'},\n",
       "         {'ReferencePMID': '27215976',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Rajagopalan K, Bacci ED, Ng-Mak D, Wyrwich K, Pikalov A, Loebel A. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. BMC Psychiatry. 2016 May 23;16:157. doi: 10.1186/s12888-016-0865-y.'},\n",
       "         {'ReferencePMID': '26730454',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Chapel S, Chiu YY, Hsu J, Cucchiaro J, Loebel A. Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis. Clin Ther. 2016 Jan 1;38(1):4-15. doi: 10.1016/j.clinthera.2015.11.013. Epub 2015 Dec 22.'},\n",
       "         {'ReferencePMID': '26363720',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Loebel A, Siu C, Rajagopalan K, Pikalov A, Cucchiaro J, Ketter TA. Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study. J Affect Disord. 2015 Nov 1;186:376-82. doi: 10.1016/j.jad.2015.07.033. Epub 2015 Aug 5.'},\n",
       "         {'ReferencePMID': '25844756',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015 Apr;76(4):398-405. doi: 10.4088/JCP.14m09410.'}]}}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowRecruitmentDetails': '4/29/09 to 2/1/12',\n",
       "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Placebo',\n",
       "          'FlowGroupDescription': 'Placebo : Placebo Comparator'},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Lurasidone High Arm',\n",
       "          'FlowGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day'},\n",
       "         {'FlowGroupId': 'FG002',\n",
       "          'FlowGroupTitle': 'Lurasidone Low Arm',\n",
       "          'FlowGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '170'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '169'},\n",
       "               {'FlowAchievementGroupId': 'FG002',\n",
       "                'FlowAchievementNumSubjects': '166'}]}},\n",
       "            {'FlowMilestoneType': 'Intent-to-Treat Population',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '162'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '162'},\n",
       "               {'FlowAchievementGroupId': 'FG002',\n",
       "                'FlowAchievementNumSubjects': '161'}]}},\n",
       "            {'FlowMilestoneType': 'Safety Population',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '168'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '167'},\n",
       "               {'FlowAchievementGroupId': 'FG002',\n",
       "                'FlowAchievementNumSubjects': '164'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '127'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '124'},\n",
       "               {'FlowAchievementGroupId': 'FG002',\n",
       "                'FlowAchievementNumSubjects': '123'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '43'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '45'},\n",
       "               {'FlowAchievementGroupId': 'FG002',\n",
       "                'FlowAchievementNumSubjects': '43'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'Intent-to-treat population is analyzed.',\n",
       "       'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Placebo',\n",
       "          'BaselineGroupDescription': 'Placebo : Placebo Comparator'},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Lurasidone High Arm',\n",
       "          'BaselineGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Lurasidone Low Arm',\n",
       "          'BaselineGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day'},\n",
       "         {'BaselineGroupId': 'BG003',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '162'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '162'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '161'},\n",
       "            {'BaselineDenomCountGroupId': 'BG003',\n",
       "             'BaselineDenomCountValue': '485'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '0'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '3'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '3'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '159'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '159'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '155'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '473'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '3'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '3'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '3'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '9'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '41.2',\n",
       "                   'BaselineMeasurementSpread': '12.45'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '42.0',\n",
       "                   'BaselineMeasurementSpread': '12.35'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '41.3',\n",
       "                   'BaselineMeasurementSpread': '12.31'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '41.5',\n",
       "                   'BaselineMeasurementSpread': '12.35'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '87'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '98'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '91'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '276'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '75'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '64'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '70'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '209'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'France',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '4'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '4'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '13'}]}}]}},\n",
       "            {'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '58'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '70'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '67'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '195'}]}}]}},\n",
       "            {'BaselineClassTitle': 'Czech Republic',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '19'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '19'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '17'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '55'}]}}]}},\n",
       "            {'BaselineClassTitle': 'Ukraine',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '16'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '17'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '16'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '49'}]}}]}},\n",
       "            {'BaselineClassTitle': 'Romania',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '9'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '2'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '4'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '15'}]}}]}},\n",
       "            {'BaselineClassTitle': 'South Africa',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '18'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '17'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '19'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '54'}]}}]}},\n",
       "            {'BaselineClassTitle': 'Russian Federation',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '10'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '10'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '11'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '31'}]}}]}},\n",
       "            {'BaselineClassTitle': 'India',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '27'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '23'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '23'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '73'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)',\n",
       "          'OutcomeMeasureDescription': \"Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression.\\n\\nThe MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.\\n\\nThe MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.\",\n",
       "          'OutcomeMeasurePopulationDescription': 'Intent-to-treat population is analyzed.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Least Squares Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'Baseline to Week 6',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Placebo',\n",
       "             'OutcomeGroupDescription': 'Placebo : Placebo Comparator'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Lurasidone High Arm',\n",
       "             'OutcomeGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day'},\n",
       "            {'OutcomeGroupId': 'OG002',\n",
       "             'OutcomeGroupTitle': 'Lurasidone Low Arm',\n",
       "             'OutcomeGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '162'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '162'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG002',\n",
       "                'OutcomeDenomCountValue': '161'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '-10.7',\n",
       "                   'OutcomeMeasurementSpread': '0.83'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '-15.4',\n",
       "                   'OutcomeMeasurementSpread': '0.83'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
       "                   'OutcomeMeasurementValue': '-15.4',\n",
       "                   'OutcomeMeasurementSpread': '0.83'}]}}]}}]},\n",
       "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
       "               'OG002']},\n",
       "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
       "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
       "             'OutcomeAnalysisPValue': '<0.001',\n",
       "             'OutcomeAnalysisStatisticalMethod': 'Mixed Models Analysis',\n",
       "             'OutcomeAnalysisParamType': 'Mean Difference (Final Values)',\n",
       "             'OutcomeAnalysisParamValue': '-4.6',\n",
       "             'OutcomeAnalysisDispersionType': 'Standard Error of the mean',\n",
       "             'OutcomeAnalysisDispersionValue': '1.17',\n",
       "             'OutcomeAnalysisEstimateComment': 'A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.'},\n",
       "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
       "               'OG001']},\n",
       "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
       "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
       "             'OutcomeAnalysisPValue': '<0.001',\n",
       "             'OutcomeAnalysisStatisticalMethod': 'Mixed Models Analysis',\n",
       "             'OutcomeAnalysisParamType': 'Mean Difference (Final Values)',\n",
       "             'OutcomeAnalysisParamValue': '-4.6',\n",
       "             'OutcomeAnalysisDispersionType': 'Standard Error of the mean',\n",
       "             'OutcomeAnalysisDispersionValue': '1.17',\n",
       "             'OutcomeAnalysisEstimateComment': 'A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.'}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)',\n",
       "          'OutcomeMeasureDescription': \"Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression.\\n\\nThe CGI depression score ranges from a minimum of 0 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.\",\n",
       "          'OutcomeMeasurePopulationDescription': 'Intent-to-treat population is analyzed.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Least Squares Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'Baseline to Week 6',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Placebo',\n",
       "             'OutcomeGroupDescription': 'Placebo : Placebo Comparator'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Lurasidone High Arm',\n",
       "             'OutcomeGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day'},\n",
       "            {'OutcomeGroupId': 'OG002',\n",
       "             'OutcomeGroupTitle': 'Lurasidone Low Arm',\n",
       "             'OutcomeGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '162'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '162'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG002',\n",
       "                'OutcomeDenomCountValue': '161'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '-1.14',\n",
       "                   'OutcomeMeasurementSpread': '0.102'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '-1.71',\n",
       "                   'OutcomeMeasurementSpread': '0.101'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
       "                   'OutcomeMeasurementValue': '-1.83',\n",
       "                   'OutcomeMeasurementSpread': '0.102'}]}}]}}]},\n",
       "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
       "               'OG002']},\n",
       "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
       "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
       "             'OutcomeAnalysisPValue': '<0.001',\n",
       "             'OutcomeAnalysisStatisticalMethod': 'Mixed Models Analysis',\n",
       "             'OutcomeAnalysisParamType': 'Mean Difference (Final Values)',\n",
       "             'OutcomeAnalysisParamValue': '-0.69',\n",
       "             'OutcomeAnalysisDispersionType': 'Standard Error of the mean',\n",
       "             'OutcomeAnalysisDispersionValue': '0.143',\n",
       "             'OutcomeAnalysisEstimateComment': 'A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.'},\n",
       "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
       "               'OG001']},\n",
       "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
       "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
       "             'OutcomeAnalysisPValue': '<0.001',\n",
       "             'OutcomeAnalysisStatisticalMethod': 'Mixed Models Analysis',\n",
       "             'OutcomeAnalysisParamType': 'Mean Difference (Final Values)',\n",
       "             'OutcomeAnalysisParamValue': '-0.57',\n",
       "             'OutcomeAnalysisDispersionType': 'Standard Error of the mean',\n",
       "             'OutcomeAnalysisDispersionValue': '0.143',\n",
       "             'OutcomeAnalysisEstimateComment': 'A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.'}]}},\n",
       "         {'OutcomeMeasureType': 'Secondary',\n",
       "          'OutcomeMeasureTitle': 'Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score',\n",
       "          'OutcomeMeasureDescription': \"Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of depression.\\n\\nThe SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.\\n\\nThe SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items.\",\n",
       "          'OutcomeMeasurePopulationDescription': 'Intent-to-treat population is analyzed. Number of participants in table is not consistent with intent-to-treat population because: if one or more items are missing at a study visit, as can occur when a subject opts out of the work/school item because it does not apply, the authors of the scale recommend setting the total score to missing',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Least Squares Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Error',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'Baseline to Week 6',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Placebo',\n",
       "             'OutcomeGroupDescription': 'Placebo : Placebo Comparator'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Lurasidone High Arm',\n",
       "             'OutcomeGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day'},\n",
       "            {'OutcomeGroupId': 'OG002',\n",
       "             'OutcomeGroupTitle': 'Lurasidone Low Arm',\n",
       "             'OutcomeGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '100'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '105'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG002',\n",
       "                'OutcomeDenomCountValue': '88'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '-6.3',\n",
       "                   'OutcomeMeasurementSpread': '0.77'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '-9.8',\n",
       "                   'OutcomeMeasurementSpread': '0.73'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
       "                   'OutcomeMeasurementValue': '-9.5',\n",
       "                   'OutcomeMeasurementSpread': '0.81'}]}}]}}]},\n",
       "          'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
       "               'OG002']},\n",
       "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
       "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
       "             'OutcomeAnalysisPValue': '0.003',\n",
       "             'OutcomeAnalysisStatisticalMethod': 'ANCOVA',\n",
       "             'OutcomeAnalysisParamType': 'Mean Difference (Final Values)',\n",
       "             'OutcomeAnalysisParamValue': '-3.1',\n",
       "             'OutcomeAnalysisDispersionType': 'Standard Error of the mean',\n",
       "             'OutcomeAnalysisDispersionValue': '1.05',\n",
       "             'OutcomeAnalysisEstimateComment': 'A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.'},\n",
       "            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000',\n",
       "               'OG001']},\n",
       "             'OutcomeAnalysisTestedNonInferiority': 'No',\n",
       "             'OutcomeAnalysisNonInferiorityType': 'Superiority or Other',\n",
       "             'OutcomeAnalysisPValue': '<0.001',\n",
       "             'OutcomeAnalysisStatisticalMethod': 'ANCOVA',\n",
       "             'OutcomeAnalysisParamType': 'Mean Difference (Final Values)',\n",
       "             'OutcomeAnalysisParamValue': '-3.5',\n",
       "             'OutcomeAnalysisDispersionType': 'Standard Error of the mean',\n",
       "             'OutcomeAnalysisDispersionValue': '1.01',\n",
       "             'OutcomeAnalysisEstimateComment': 'A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.'}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '5',\n",
       "       'EventsTimeFrame': 'April 29,2009 - February 1, 2012',\n",
       "       'EventsDescription': 'Safety population is analyzed.',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Placebo',\n",
       "          'EventGroupDescription': 'Placebo : Placebo Comparator',\n",
       "          'EventGroupSeriousNumAffected': '1',\n",
       "          'EventGroupSeriousNumAtRisk': '168',\n",
       "          'EventGroupOtherNumAffected': '56',\n",
       "          'EventGroupOtherNumAtRisk': '168'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Lurasidone High Arm',\n",
       "          'EventGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day',\n",
       "          'EventGroupSeriousNumAffected': '5',\n",
       "          'EventGroupSeriousNumAtRisk': '167',\n",
       "          'EventGroupOtherNumAffected': '65',\n",
       "          'EventGroupOtherNumAtRisk': '167'},\n",
       "         {'EventGroupId': 'EG002',\n",
       "          'EventGroupTitle': 'Lurasidone Low Arm',\n",
       "          'EventGroupDescription': 'lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day',\n",
       "          'EventGroupSeriousNumAffected': '3',\n",
       "          'EventGroupSeriousNumAtRisk': '164',\n",
       "          'EventGroupOtherNumAffected': '57',\n",
       "          'EventGroupOtherNumAtRisk': '164'}]},\n",
       "       'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Depression',\n",
       "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
       "          'SeriousEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '168'},\n",
       "            {'SeriousEventStatsGroupId': 'EG001',\n",
       "             'SeriousEventStatsNumEvents': '2',\n",
       "             'SeriousEventStatsNumAffected': '2',\n",
       "             'SeriousEventStatsNumAtRisk': '167'},\n",
       "            {'SeriousEventStatsGroupId': 'EG002',\n",
       "             'SeriousEventStatsNumEvents': '2',\n",
       "             'SeriousEventStatsNumAffected': '2',\n",
       "             'SeriousEventStatsNumAtRisk': '164'}]}},\n",
       "         {'SeriousEventTerm': 'Panic Attack',\n",
       "          'SeriousEventOrganSystem': 'Psychiatric disorders',\n",
       "          'SeriousEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '168'},\n",
       "            {'SeriousEventStatsGroupId': 'EG001',\n",
       "             'SeriousEventStatsNumEvents': '1',\n",
       "             'SeriousEventStatsNumAffected': '1',\n",
       "             'SeriousEventStatsNumAtRisk': '167'},\n",
       "            {'SeriousEventStatsGroupId': 'EG002',\n",
       "             'SeriousEventStatsNumEvents': '1',\n",
       "             'SeriousEventStatsNumAffected': '1',\n",
       "             'SeriousEventStatsNumAtRisk': '164'}]}},\n",
       "         {'SeriousEventTerm': 'Foot Fracture',\n",
       "          'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
       "          'SeriousEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '168'},\n",
       "            {'SeriousEventStatsGroupId': 'EG001',\n",
       "             'SeriousEventStatsNumEvents': '1',\n",
       "             'SeriousEventStatsNumAffected': '1',\n",
       "             'SeriousEventStatsNumAtRisk': '167'},\n",
       "            {'SeriousEventStatsGroupId': 'EG002',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '164'}]}},\n",
       "         {'SeriousEventTerm': 'Restless Leg Syndrome',\n",
       "          'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications',\n",
       "          'SeriousEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '168'},\n",
       "            {'SeriousEventStatsGroupId': 'EG001',\n",
       "             'SeriousEventStatsNumEvents': '1',\n",
       "             'SeriousEventStatsNumAffected': '1',\n",
       "             'SeriousEventStatsNumAtRisk': '167'},\n",
       "            {'SeriousEventStatsGroupId': 'EG002',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '164'}]}},\n",
       "         {'SeriousEventTerm': 'HIV Infection',\n",
       "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
       "          'SeriousEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '168'},\n",
       "            {'SeriousEventStatsGroupId': 'EG001',\n",
       "             'SeriousEventStatsNumEvents': '1',\n",
       "             'SeriousEventStatsNumAffected': '1',\n",
       "             'SeriousEventStatsNumAtRisk': '167'},\n",
       "            {'SeriousEventStatsGroupId': 'EG002',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '164'}]}},\n",
       "         {'SeriousEventTerm': 'Subcutaneous Absceses',\n",
       "          'SeriousEventOrganSystem': 'Infections and infestations',\n",
       "          'SeriousEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '168'},\n",
       "            {'SeriousEventStatsGroupId': 'EG001',\n",
       "             'SeriousEventStatsNumEvents': '1',\n",
       "             'SeriousEventStatsNumAffected': '1',\n",
       "             'SeriousEventStatsNumAtRisk': '167'},\n",
       "            {'SeriousEventStatsGroupId': 'EG002',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '164'}]}},\n",
       "         {'SeriousEventTerm': 'Duodenal Ulcer',\n",
       "          'SeriousEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'SeriousEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'SeriousEventAssessmentType': 'Systematic Assessment',\n",
       "          'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000',\n",
       "             'SeriousEventStatsNumEvents': '1',\n",
       "             'SeriousEventStatsNumAffected': '1',\n",
       "             'SeriousEventStatsNumAtRisk': '168'},\n",
       "            {'SeriousEventStatsGroupId': 'EG001',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '167'},\n",
       "            {'SeriousEventStatsGroupId': 'EG002',\n",
       "             'SeriousEventStatsNumEvents': '0',\n",
       "             'SeriousEventStatsNumAffected': '0',\n",
       "             'SeriousEventStatsNumAtRisk': '164'}]}}]},\n",
       "       'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Nausea',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'OtherEventAssessmentType': 'Non-systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '87',\n",
       "             'OtherEventStatsNumAffected': '13',\n",
       "             'OtherEventStatsNumAtRisk': '168'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '38',\n",
       "             'OtherEventStatsNumAffected': '29',\n",
       "             'OtherEventStatsNumAtRisk': '167'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumEvents': '24',\n",
       "             'OtherEventStatsNumAffected': '17',\n",
       "             'OtherEventStatsNumAtRisk': '164'}]}},\n",
       "         {'OtherEventTerm': 'Headache',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '25',\n",
       "             'OtherEventStatsNumAffected': '20',\n",
       "             'OtherEventStatsNumAtRisk': '168'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '16',\n",
       "             'OtherEventStatsNumAffected': '15',\n",
       "             'OtherEventStatsNumAtRisk': '167'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumEvents': '36',\n",
       "             'OtherEventStatsNumAffected': '23',\n",
       "             'OtherEventStatsNumAtRisk': '164'}]}},\n",
       "         {'OtherEventTerm': 'Akathisia',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '6',\n",
       "             'OtherEventStatsNumAffected': '4',\n",
       "             'OtherEventStatsNumAtRisk': '168'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '23',\n",
       "             'OtherEventStatsNumAffected': '18',\n",
       "             'OtherEventStatsNumAtRisk': '167'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumEvents': '18',\n",
       "             'OtherEventStatsNumAffected': '13',\n",
       "             'OtherEventStatsNumAtRisk': '164'}]}},\n",
       "         {'OtherEventTerm': 'Insomnia',\n",
       "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
       "          'OtherEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '19',\n",
       "             'OtherEventStatsNumAffected': '14',\n",
       "             'OtherEventStatsNumAtRisk': '168'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '16',\n",
       "             'OtherEventStatsNumAffected': '11',\n",
       "             'OtherEventStatsNumAtRisk': '167'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumEvents': '12',\n",
       "             'OtherEventStatsNumAffected': '8',\n",
       "             'OtherEventStatsNumAtRisk': '164'}]}},\n",
       "         {'OtherEventTerm': 'Somnolence',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '7',\n",
       "             'OtherEventStatsNumAffected': '7',\n",
       "             'OtherEventStatsNumAtRisk': '168'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '13',\n",
       "             'OtherEventStatsNumAffected': '11',\n",
       "             'OtherEventStatsNumAtRisk': '167'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumEvents': '7',\n",
       "             'OtherEventStatsNumAffected': '7',\n",
       "             'OtherEventStatsNumAtRisk': '164'}]}},\n",
       "         {'OtherEventTerm': 'Sedation',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '3',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '168'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '13',\n",
       "             'OtherEventStatsNumAffected': '12',\n",
       "             'OtherEventStatsNumAtRisk': '167'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumEvents': '6',\n",
       "             'OtherEventStatsNumAffected': '5',\n",
       "             'OtherEventStatsNumAtRisk': '164'}]}},\n",
       "         {'OtherEventTerm': 'Dizziness',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventSourceVocabulary': 'MeDRA 14.1',\n",
       "          'OtherEventAssessmentType': 'Systematic Assessment',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumEvents': '13',\n",
       "             'OtherEventStatsNumAffected': '13',\n",
       "             'OtherEventStatsNumAtRisk': '168'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumEvents': '12',\n",
       "             'OtherEventStatsNumAffected': '10',\n",
       "             'OtherEventStatsNumAtRisk': '167'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumEvents': '5',\n",
       "             'OtherEventStatsNumAffected': '4',\n",
       "             'OtherEventStatsNumAtRisk': '164'}]}}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
       "        'AgreementRestrictionType': 'OTHER',\n",
       "        'AgreementRestrictiveAgreement': 'Yes',\n",
       "        'AgreementOtherDetails': 'In addition to the <60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Medical Director, CNS',\n",
       "        'PointOfContactOrganization': 'Sunovion',\n",
       "        'PointOfContactPhone': '1-866-503-6351'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000069056',\n",
       "          'InterventionMeshTerm': 'Lurasidone Hydrochloride'}]},\n",
       "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000014150',\n",
       "          'InterventionAncestorTerm': 'Antipsychotic Agents'},\n",
       "         {'InterventionAncestorId': 'D000014149',\n",
       "          'InterventionAncestorTerm': 'Tranquilizing Agents'},\n",
       "         {'InterventionAncestorId': 'D000002492',\n",
       "          'InterventionAncestorTerm': 'Central Nervous System Depressants'},\n",
       "         {'InterventionAncestorId': 'D000045505',\n",
       "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'},\n",
       "         {'InterventionAncestorId': 'D000011619',\n",
       "          'InterventionAncestorTerm': 'Psychotropic Drugs'},\n",
       "         {'InterventionAncestorId': 'D000058669',\n",
       "          'InterventionAncestorTerm': 'Adrenergic alpha-2 Receptor Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000000317',\n",
       "          'InterventionAncestorTerm': 'Adrenergic alpha-Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000018674',\n",
       "          'InterventionAncestorTerm': 'Adrenergic Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000018663',\n",
       "          'InterventionAncestorTerm': 'Adrenergic Agents'},\n",
       "         {'InterventionAncestorId': 'D000018377',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Agents'},\n",
       "         {'InterventionAncestorId': 'D000045504',\n",
       "          'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "         {'InterventionAncestorId': 'D000058830',\n",
       "          'InterventionAncestorTerm': 'Serotonin 5-HT2 Receptor Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000012702',\n",
       "          'InterventionAncestorTerm': 'Serotonin Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000018490',\n",
       "          'InterventionAncestorTerm': 'Serotonin Agents'},\n",
       "         {'InterventionAncestorId': 'D000065127',\n",
       "          'InterventionAncestorTerm': 'Dopamine D2 Receptor Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000018492',\n",
       "          'InterventionAncestorTerm': 'Dopamine Antagonists'},\n",
       "         {'InterventionAncestorId': 'D000015259',\n",
       "          'InterventionAncestorTerm': 'Dopamine Agents'}]},\n",
       "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M348',\n",
       "          'InterventionBrowseLeafName': 'Lurasidone Hydrochloride',\n",
       "          'InterventionBrowseLeafAsFound': 'Lurasidone',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M15487',\n",
       "          'InterventionBrowseLeafName': 'Antipsychotic Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M13057',\n",
       "          'InterventionBrowseLeafName': 'Psychotropic Drugs',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19330',\n",
       "          'InterventionBrowseLeafName': 'Adrenergic Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M2250',\n",
       "          'InterventionBrowseLeafName': 'Adrenergic alpha-Antagonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19339',\n",
       "          'InterventionBrowseLeafName': 'Adrenergic Antagonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19088',\n",
       "          'InterventionBrowseLeafName': 'Neurotransmitter Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M14095',\n",
       "          'InterventionBrowseLeafName': 'Serotonin',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M6056',\n",
       "          'InterventionBrowseLeafName': 'Dopamine',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19180',\n",
       "          'InterventionBrowseLeafName': 'Dopamine Antagonists',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M16545',\n",
       "          'InterventionBrowseLeafName': 'Dopamine Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'CNSDep',\n",
       "          'InterventionBrowseBranchName': 'Central Nervous System Depressants'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'PsychDr',\n",
       "          'InterventionBrowseBranchName': 'Psychotropic Drugs'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'CaAg',\n",
       "          'InterventionBrowseBranchName': 'Cardiotonic Agents'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000001714',\n",
       "          'ConditionMeshTerm': 'Bipolar Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000068105',\n",
       "          'ConditionAncestorTerm': 'Bipolar and Related Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3578',\n",
       "          'ConditionBrowseLeafName': 'Bipolar Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Bipolar Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M226',\n",
       "          'ConditionBrowseLeafName': 'Bipolar and Related Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 86,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02429674',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '#7089'},\n",
       "       'Organization': {'OrgFullName': 'New York State Psychiatric Institute',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'The Efficacy of a Depression Intervention for Adolescents With Depression and Sleep Disturbances',\n",
       "       'OfficialTitle': 'The Efficacy of a Depression Intervention for Adolescents With Depression and Sleep Disturbances'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'January 2020',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'February 2015'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2021',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'June 2021',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'April 22, 2015',\n",
       "       'StudyFirstSubmitQCDate': 'April 24, 2015',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 29, 2015',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'January 27, 2020',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 29, 2020',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Eleanor McGlinchey',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Assistant Professor of Clinical Psychology in Psychiatry',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'New York State Psychiatric Institute'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'New York State Psychiatric Institute',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The focus of this study is on identifying how Interpersonal Psychotherapy for Adolescents (IPT-A) with depression works to change sleep and related biological markers found in saliva, namely cortisol and pro-inflammatory cytokine levels. The long-term goal of this project is to understand the biological mechanisms of recovery from depression in order to assist in selecting and guiding personalized psychotherapeutic interventions with the highest likelihood of success for individual adolescents with depression.',\n",
       "       'DetailedDescription': \"The primary aim of this project is to examine whether adolescent depression and the associated symptoms of sleep disturbance are best treated using an empirically supported psychotherapy that is augmented with a sleep improvement module. Twenty adolescents (ages 12-17) who meet criteria for major depressive disorder, dysthymic disorder, depressive disorder not otherwise specified, or adjustment disorder with depressed mood and also report elevated levels of sleep disturbance will receive Interpersonal Psychotherapy for Depressed Adolescents (IPT-A) with an adjunctive sleep module that is integrated throughout the treatment. Identifying the best approach to treating both the adolescent's depression and the commonly associated symptom of sleep disturbance will have significant implications for the long-term outcomes of depressed adolescents. Moreover, identifying unique symptom and biological profiles at the outset of treatment may enable doctors to predict treatment outcome.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression', 'Adolescence']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '20',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'TranS-C and IPT-A',\n",
       "          'ArmGroupType': 'Other',\n",
       "          'ArmGroupDescription': '12 sessions of weekly outpatient psychotherapy for adolescent depression.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: TranS-C and IPT-A']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'TranS-C and IPT-A',\n",
       "          'InterventionDescription': \"The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['TranS-C and IPT-A']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Transdiagnostic Sleep and Circadian treatment and IPT-A']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Change from Baseline in Depression symptom score on the Children's Depression Rating Scale (CDRS)\",\n",
       "          'PrimaryOutcomeDescription': 'Reduction in depression symptoms',\n",
       "          'PrimaryOutcomeTimeFrame': 'Week 12'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change from Baseline in sleep using actigraphy estimated sleep variables',\n",
       "          'SecondaryOutcomeDescription': 'Reduction in sleep difficulties and increase in sleep duration',\n",
       "          'SecondaryOutcomeTimeFrame': 'Week 12'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change from baseline in Cytokine levels found in saliva',\n",
       "          'SecondaryOutcomeDescription': 'Reduction in inflammatory markers',\n",
       "          'SecondaryOutcomeTimeFrame': 'Week 12'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\noutpatient participant\\nparent or legally authorized representative must provide consent and assent by the participant\\nDiagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-V) criteria for a depressive disorder\\nClinical Global Assessment Scale (C-GAS) < 65\\nQuick Inventory of Depression Symptoms - Self Report 16 (QIDS-SR16) over 8 and less than 24.\\nEnglish speaking\\nsignificant sleep complaints\\n\\nExclusion Criteria:\\n\\nco-morbid psychiatric diagnosis of bipolar disorder, psychosis, autism spectrum disorder, intellectual development disorder, conduct disorder or substance abuse disorder\\nany condition or illness such as uncontrolled seizure disorder, uncontrolled diabetes, or any other conditions that represent as an inappropriate risk to the participant and/or could confound the interpretation of the study\\ncurrently in active evidence-based psychotherapy for the same condition\\ncurrently taking medication for a psychiatric diagnosis that is not a stable dose (4 weeks on the same dose).\\ncurrently considered at risk for suicide in the opinion of the study doctor, has made a suicide attempt in the past 4 months, or is currently reporting active suicidal ideation.\\nhistory of alcohol or other substance abuse as defined by DSM-V within the last 6 months.\\nevidence from clinical diagnosis or report by youth or parent of sleep apnea, restless legs or periodic limb movements during sleep\\nsleep treatment that might confound the interpretation of sleep outcomes.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '12 Years',\n",
       "       'MaximumAge': '17 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Eleanor McGlinchey, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '646 774-5859',\n",
       "          'CentralContactEMail': 'mcglinc@nyspi.columbia.edu'},\n",
       "         {'CentralContactName': 'Amir Levine, MD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '646-774-7331',\n",
       "          'CentralContactEMail': 'alevine@nyspi.columbia.edu'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Eleanor L McGlinchey, Ph.D.',\n",
       "          'OverallOfficialAffiliation': 'New York State Psychiatric Institute',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Pediatric Anxiety and Mood Research Clinic, New York State Psychiatric Institute',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'New York',\n",
       "          'LocationState': 'New York',\n",
       "          'LocationZip': '10032',\n",
       "          'LocationCountry': 'United States',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Eleanor McGlinchey, Ph.D.',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '646-774-5859',\n",
       "             'LocationContactEMail': 'mcglinc@nyspi.columbia.edu'},\n",
       "            {'LocationContactName': 'Eleanor L McGlinchey, Ph.D.',\n",
       "             'LocationContactRole': 'Principal Investigator'},\n",
       "            {'LocationContactName': 'Laura Mufson, Ph.D.',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Amir Levine, M.D.',\n",
       "             'LocationContactRole': 'Sub-Investigator'}]}}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020920',\n",
       "          'ConditionMeshTerm': 'Dyssomnias'},\n",
       "         {'ConditionMeshId': 'D000012893',\n",
       "          'ConditionMeshTerm': 'Sleep Wake Disorders'},\n",
       "         {'ConditionMeshId': 'D000020447', 'ConditionMeshTerm': 'Parasomnias'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000009422',\n",
       "          'ConditionAncestorTerm': 'Nervous System Diseases'},\n",
       "         {'ConditionAncestorId': 'D000009461',\n",
       "          'ConditionAncestorTerm': 'Neurologic Manifestations'},\n",
       "         {'ConditionAncestorId': 'D000012816',\n",
       "          'ConditionAncestorTerm': 'Signs and Symptoms'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M14279',\n",
       "          'ConditionBrowseLeafName': 'Sleep Wake Disorders',\n",
       "          'ConditionBrowseLeafAsFound': 'Sleep Disturbance',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M21239',\n",
       "          'ConditionBrowseLeafName': 'Dyssomnias',\n",
       "          'ConditionBrowseLeafAsFound': 'Sleep Disturbance',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M20826',\n",
       "          'ConditionBrowseLeafName': 'Parasomnias',\n",
       "          'ConditionBrowseLeafAsFound': 'Sleep Disturbance',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M10987',\n",
       "          'ConditionBrowseLeafName': 'Neurologic Manifestations',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC10',\n",
       "          'ConditionBrowseBranchName': 'Nervous System Diseases'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BC23',\n",
       "          'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}},\n",
       "   {'Rank': 87,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01685294',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '1R01MH095230-01',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH095230-01&Fy=all'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH095230',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH095230&Fy=all'}]},\n",
       "       'Organization': {'OrgFullName': 'Brown University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression',\n",
       "       'OfficialTitle': 'Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'January 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'December 2011'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2014',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'October 2014',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'August 29, 2012',\n",
       "       'StudyFirstSubmitQCDate': 'September 11, 2012',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 14, 2012',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'January 12, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 13, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Dr. Jennifer Johnson',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Associate Professor (Research), Department of Psychiatry and Human Behavior',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Brown University'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Brown University',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': 'This study will examine the effects of a first-line treatment for major depressive disorder (MDD), interpersonal psychotherapy (IPT), among men and women prisoners.',\n",
       "       'DetailedDescription': 'The purpose of this 3-year randomized trial is to promote uptake of evidence-based treatment in criminal justice settings by conducting a fully-powered randomized effectiveness study that collects pilot implementation data, including cost-effectiveness data. Group IPT will be compared to treatment as usual (TAU) in a sample of 90 male and 90 female prisoners with MDD from 4 institutions, allowing us to explore gender effects.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Major Depressive Disorder']},\n",
       "       'KeywordList': {'Keyword': ['Major Depressive Disorder (MDD)',\n",
       "         'Suicidality',\n",
       "         'Incarcerated Populations',\n",
       "         'Prisons',\n",
       "         'Interpersonal Psychotherapy (IPT)']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Phase 3']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '181',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Treatment as Usual (TAU)',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Standard prison mental health treatment instead of the research groups, including individual therapy, medication, etc.'},\n",
       "         {'ArmGroupLabel': 'Group Interpersonal Psychotherapy (IPT) for Depression + TAU',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Participants will receive Group IPT for Depression + TAU.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Group IPT for Depression + TAU']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Group IPT for Depression + TAU',\n",
       "          'InterventionDescription': 'Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group Interpersonal Psychotherapy (IPT) for Depression + TAU']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change from Baseline in Hamilton Rating Scale for Depression (HRSD) at 3 Months',\n",
       "          'PrimaryOutcomeTimeFrame': '3 Months from Baseline'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change from Baseline in Suicidality at 3 Months',\n",
       "          'SecondaryOutcomeDescription': 'Suicidality as measured by the Beck Scale for Suicide Ideation.',\n",
       "          'SecondaryOutcomeTimeFrame': '3 Months from Baseline'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change from Baseline in In-Prison Functioning at 3 Months',\n",
       "          'SecondaryOutcomeDescription': 'In-prison functioning will be assessed by the number of correctional programs enrolled/completed and disciplinary/incident reports (measured by the Timeline Followback); aggression/victimization (measured by the Conflict Tactics Scale 2); social support (measured by the Multidimensional Scale of Perceived Social Support and the UCLA Loneliness Scale)',\n",
       "          'SecondaryOutcomeTimeFrame': '3 Months from Baseline'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change from Baseline in Hamilton Rating Scale for Depression (HRSD) at 6 Months',\n",
       "          'SecondaryOutcomeTimeFrame': '6 Months from Baseline'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change from Baseline in Suicidality at 6 Months',\n",
       "          'SecondaryOutcomeDescription': 'Suicidality as measured by the Beck Scale for Suicide Ideation.',\n",
       "          'SecondaryOutcomeTimeFrame': '6 Months from Baseline'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change from Baseline in In-Prison Functioning at 6 Months',\n",
       "          'SecondaryOutcomeDescription': 'In-prison functioning will be assessed by the number of correctional programs enrolled/completed and disciplinary/incident reports (measured by the Timeline Followback); aggression/victimization (measured by the Conflict Tactics Scale 2); social support (measured by the Multidimensional Scale of Perceived Social Support and the UCLA Loneliness Scale)',\n",
       "          'SecondaryOutcomeTimeFrame': '6 Months from Baseline'},\n",
       "         {'SecondaryOutcomeMeasure': 'Cost-effectiveness',\n",
       "          'SecondaryOutcomeDescription': 'Cost-effectiveness based on costs of IPT and TAU, improvements in HRSD scores, LIFE scores, and cost-offsets, including medical costs, programs completed, fewer fights, fewer suicide attempts, and reduced length of incarceration due to more \"good time.\"',\n",
       "          'SecondaryOutcomeTimeFrame': '6 months post-baseline'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMeet all DSM-IV criteria for primary (non-substance induced) major depressive disorder\\nExpectation of at least 6 months of incarceration at baseline interview\\nIncarcerated for at least 4 weeks\\n\\nExclusion Criteria:\\n\\nLifetime:\\n\\nBipolar disorder\\nPsychotic disorder\\nAre imminently suicidal\\nCannot understand English well enough to understand the consent form or assessment instruments when read aloud',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jennifer E. Johnson, Ph.D.',\n",
       "          'OverallOfficialAffiliation': 'Brown University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Massachusetts Correctional Institute - Old Colony Correctional Center',\n",
       "          'LocationCity': 'Bridgewater',\n",
       "          'LocationState': 'Massachusetts',\n",
       "          'LocationZip': '02324',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Massachusetts Correctional Institution - Framingham',\n",
       "          'LocationCity': 'Framingham',\n",
       "          'LocationState': 'Massachusetts',\n",
       "          'LocationZip': '01702',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'South Middlesex Correctional Center',\n",
       "          'LocationCity': 'Framingham',\n",
       "          'LocationState': 'Massachusetts',\n",
       "          'LocationZip': '01702',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': 'Massachusetts Correctional Institution - Norfolk',\n",
       "          'LocationCity': 'Norfolk',\n",
       "          'LocationState': 'Massachusetts',\n",
       "          'LocationZip': '02056',\n",
       "          'LocationCountry': 'United States'},\n",
       "         {'LocationFacility': \"Adult Correctional Institution - Men's & Women's Medium & Minimum Security Facilities\",\n",
       "          'LocationCity': 'Cranston',\n",
       "          'LocationState': 'Rhode Island',\n",
       "          'LocationZip': '02920',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '30857489',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Felton JW, Hailemariam M, Richie F, Reddy MK, Edukere S, Zlotnick C, Johnson JE. Preliminary efficacy and mediators of interpersonal psychotherapy for reducing posttraumatic stress symptoms in an incarcerated population. Psychother Res. 2020 Feb;30(2):239-250. doi: 10.1080/10503307.2019.1587192. Epub 2019 Mar 11.'},\n",
       "         {'ReferencePMID': '30714749',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Johnson JE, Stout RL, Miller TR, Zlotnick C, Cerbo LA, Andrade JT, Nargiso J, Bonner J, Wiltsey-Stirman S. Randomized cost-effectiveness trial of group interpersonal psychotherapy (IPT) for prisoners with major depression. J Consult Clin Psychol. 2019 Apr;87(4):392-406. doi: 10.1037/ccp0000379. Epub 2019 Feb 4.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000003865',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder, Major'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafAsFound': 'Major Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 88,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02943876',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '10015082'},\n",
       "       'Organization': {'OrgFullName': 'University of Calgary',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': \"The Impact of Disclosing Personalized Depression Risk Information on High-risk Individuals' Outcomes\",\n",
       "       'OfficialTitle': \"The Impact of Disclosing Personalized Depression Risk Information on High-risk Individuals' Outcomes\"},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'May 2019',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'May 1, 2017',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2019',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'December 2019',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'October 21, 2016',\n",
       "       'StudyFirstSubmitQCDate': 'October 21, 2016',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 25, 2016',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'May 15, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 16, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'JianLi Wang',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Professor',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Calgary'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Calgary',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Canadian Institutes of Health Research (CIHR)',\n",
       "          'CollaboratorClass': 'OTHER_GOV'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': \"Major depressive episode (MDE) is one of the most prevalent and disabling form of mental illness in the general population. Despite increased mental health services and antidepressants use in the past 10 years, there has been no measurable change in the prevalence of MDE in the Canadian general population, which motivates the search for additional strategies for reducing the burden of MDE. One strategy that has been successful in the fields of oncology, cardiology and diabetes is early identification and prevention - identifying people who are at high risk and taking preventive actions to lower the risk so as to prevent symptoms from progressing into a MDE. As multivariable risk prediction algorithms are used to estimate an individual's risk (probability) of future disease, they can play an important role in the process of early identification. The proposed study stems from a project funded by an operating grant from the Canadian Institutes of Health Research (CIHR). With the CIHR support, the team developed and validated sex-specific prediction algorithms for MDE. As risk prediction is at very early stage in psychiatry and MDE is still highly stigmatized, to facilitate the future implementation of the developed risk prediction algorithms, the proposed study seeks to answer the following research questions: (1) Does disclosure of personalized depression risk information promote high-risk individuals to take preventive actions? (2) Will disclosure of personalized depression risk information negatively affect high-risk people's mental health status in terms of increased psychological distress? To answer the questions, the investigators planned to conduct a randomized controlled trial (RCT) with an embedded qualitative component. The proposed study will develop an evidence base for guiding the disclosure of personalized risk information and understanding the process of risk communication and consumer empowerment, contributing to the advancement of early prevention of MDE in Canada.\",\n",
       "       'DetailedDescription': 'Rationale: The proposed study stems from a CIHR project and is driven by the results of knowledge translation (KT) activities. The investigators developed the first sex-specific risk prediction models for major depressive episode (MDE) using data from over 10,000 Canadians. The models include age, personal and family history of MDE, childhood trauma, and predictors that may change over time. Using the models, individuals can answer the question: what is my risk of having a MDE in the next 4 years? Knowing this personalized risk information may assist health professionals in communicating with patients and planning preventive actions; disclosing the information may also empower consumers to actively engage in self-help. In the past 5 years, the KT activities with over 500 stakeholders informed that the investigators need to clearly delineate the benefits (enhanced risk perceptions and self-help) and potential risk (increased psychological distress and impaired function) of disclosing the information before implementing the tools.\\n\\nThe goal of this study is to produce evidence about the benefits and potential risks associated with risk disclosure (i.e., the expected outputs). The primary objectives are to compare those who do and do not receive personalized depression risk information in (1) accuracy of risk perceptions, the use of self-help strategies, and (2) changes in psychological distress and functional measures over one year among those who are at high risk of MDE. The secondary objective is to examine the differential impacts of the disclosure on the outcomes by demographics and levels of baseline risk. To achieve these objectives, the investigators propose a 3-year randomized controlled trial (RCT) with an embedded qualitative component.\\n\\nThe proposed study will be a RCT with an embedded qualitative component. The RCT will have one interventional arm (receiving personalized depression risk information) and one control arm. The personalized depression risk will be generated using the sex-specific prediction algorithms for MDE that we developed in Canadians aged 18+ years old. Because the prediction algorithms are sex-specific, the investigators propose to recruit 350 men and 350 women at baseline. After baseline assessment for eligibility, participants will be randomized into intervention and control groups, in men and women separately. To obtain in-depth information about how the personalized depression risk information is processed by participants and how the information affects them emotionally, the research team will conduct qualitative interviews 1 month after the personalized risk information is disclosed. To understand how the personalized risk information affect participants\\' health behaviors, the investigators will conduct another round of qualitative interviews at 12-month.\\n\\nRecruitment: The target population of future preventive studies are high risk individuals in the general population, who reside in different regions across the country. For the proposed study, a feasible approach for recruiting eligible participants is the random digit dialing method (RDD). In the past 10 years, we have used the RDD for recruitment in CIHR-funded longitudinal studies and an ongoing national RCT funded by the Movember Foundation. Recruitment, screening and baseline assessment will be done by a telephone interview firm identified through a competitive bidding process.\\n\\nA random sample of land line and cell phone numbers will be selected. When a household is reached, the person who is 18+ years will be assessed for eligibility. If a household has 2+ persons aged 18+ years, one will be randomly selected. The interviewers will explain the study objectives and procedures and answer questions. Potential participants will be ensured about confidentiality, that participation is voluntary and that they may withdraw at any time. Oral consent will be obtained before assessment of eligibility. Outcome measures will be assessed at baseline, 6 and 12-month.\\n\\nBaseline Assessment and Randomization Screening: Once a potentially eligible participant is identified, the interviewer will confirm the participant\\'s age and administer the World Health Organization\\'s Composite International Diagnostic Interview - Short Form for Major Depression (CIDI-SFMD) and the sex-specific prediction algorithms. Interviewees who are in a MDE or are below the risk thresholds based on the risk calculators, will be excluded. Individuals with MDE will be encouraged to contact family doctors and information about local mental health resources will be provided. For those who are at low risk, the web site of the sex-specific risk prediction algorithms (www.predictingdepression.com) will be provided so they may monitor their risk in the future.\\n\\nBaseline assessment: In eligible participants, the interviewer will administer the Non-specific Psychological Distress Scale (K10), Self-help Strategy Use Scale (SSUS), and ask questions about absenteeism and perceived risk of MDE. Our pilot study showed that the screening and baseline assessment take 20 to 25 minutes.\\n\\nRandomization will be carried out in men and in women separately. Eligible participants who complete the baseline telephone interview will be randomized into intervention and control groups. The randomization will be conducted and managed by the project coordinator affiliated with the project. 350 random numbers (between 0 and 1) will first be generated for men and women separately using Excel (\"RAND()\") for 350 study identification numbers (ID), ranging from 1 to 350. The 350 random numbers will then be sorted at the descending order and categorized into 2 equal groups:\\n\\nthe ID numbers in the first group (n = 175) will be allocated to the control group\\nthe ID numbers in the second group (n = 175) will be allocated to the intervention group\\n\\nIntervention and Control: For the participants in the intervention group, the personalized risk will be disclosed and the interviewer will inform them that they will be contacted again at 6 months and 12 months. The interest in receiving such personalized depression information has been confirmed by our recent pilot study using the same sampling method. The team\\'s pilot data (n = 200) showed that 100% of high-risk individuals were interested in knowing their risks. Participants in the intervention group will also be informed that some may be contacted in one month for a 30-minute qualitative interview. A package including the following materials will be mailed to intervention participants: (1) thank-you letter, (2) a website containing general information about MDE, and self-help strategies. (3) $20 incentive as appreciation of their participation. For participants in the control group, the project coordinator will inform them that they will be contacted again at 6 and 12 months. Their personal risks will be provided at the 12-month interview. The control group participants will receive the same package as those in the intervention group.\\n\\nBlinding and follow-up assessments: The telephone interviewers will securely transfer encrypted baseline data to the PI on a bi-weekly basis. The group assignment data will be transferred in a separate file. The follow-up assessments will be conducted at the telephone interview laboratory at the Mathison Mental Health Research & Education Center. One month before the scheduled follow-up interviews, letters will be sent to participants to remind them of the upcoming interview. After the 12-month interview, participants\\' group status will be linked with interview data by study ID numbers.\\n\\nOver the study period, investigators will be blinded to participants\\' group status. The interviewers who conduct randomization, will not be involved in follow-up interviews. The interviewers who conduct the follow-up interviews in Calgary will not have access to participants\\' group status. Given the description of study objectives, participants may know their group status. Therefore, it is possible that some participants in the control group may try to find more information about personalized depression risk. At the follow-up assessments, the research staff will ask if they have used any risk prediction tools over the study period. At the follow-up assessments, if participants develop a MDE, they will be encouraged to contact family doctors and information about local mental health resources will be provided.\\n\\nQualitative Interviews: To obtain in-depth information about how disclosing personalized depression risk affects participants\\' decision processes, mental health and health behaviors, the investigators will conduct two rounds of qualitative interviews via telephone, 1 month after these participants receive the personalized depression risk and at 12 months. Each will include a initial random sub-sample of 20 men and 20 women from the intervention group. The qualitative interviews strengthen this study as the researchers will use the findings to \"triangulate\" our quantitative results and to guide interpretation of the quantitative results. The interviews will be audio recorded. Qualitative interviews will be transcribed verbatim then analyzed inductively for themes. As per Berg themes will be chosen to \"reflect all relevant aspects of the messages.\" The analysis will follow the interpretive practices of constant comparison and attempt to uncover patterns both within and between interviews. Nvivo 10 software will be used to support thematic analysis. It is expected to achieve theoretical saturation with the initial sample. However, if new themes continue to emerge in final interviews, more interviews will be conducted until no new themes emerge.\\n\\nRisk and mitigation: The investigators acknowledge concerns about the changes in response rates in telephone surveys due to cell phone use and telemarketing. Including eligible participants across the country will enhance the generalizability of the study. Given the vast geographic area of Canada, RDD is the only feasible method. The goal of this study is to recruit participants for a RCT, rather than selecting a representative sample. In a RCT, selection bias is not a serious concern as long as the bias is the same across the intervention and control groups. To mitigate the risk, the interviewers will also access the validated cellphone database. However the use of cellphone numbers is associated with increased costs. Another potential risk of the proposed study is attrition which may incur selection bias. The population-based cohort studies on mental disorders in the workplace, conducted in our lab, showed that we could achieve 77% response rate at one year follow-up without any financial incentives. The strategies for reducing attrition will include appropriately designed introductory scripts, a minimum of nine call back attempts spaced over weekdays and times of day and provision of $20 incentive for each completed interview. Finally, those deemed low risk but who go on to develop MDE will be excluded from the RCT at the screening stage, which is a limitation. the investigators have planned to provide the risk prediction algorithms so that they can monitor their risks in the future.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['risk prediction',\n",
       "         'risk score',\n",
       "         'accuracy of risk perception',\n",
       "         'self-help',\n",
       "         'psychological distress']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Prevention',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Triple',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant',\n",
       "           'Investigator',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '700',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Control',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Serves as a control group, receiving generic information about depression and self-help.'},\n",
       "         {'ArmGroupLabel': 'Intervention',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Serves as an intervention group, receiving personalized depression risk information determined by the sex-specific risk calculators, and generic information about depression and self-help.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: personalized depression risk information']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'personalized depression risk information',\n",
       "          'InterventionDescription': \"The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in psychological distress',\n",
       "          'PrimaryOutcomeDescription': 'Psychological distress will be measured by the Non-Specific Psychological Distress (K10), a 10-item screening scale intended to yield a global measure of distress based on questions about anxiety and depressive symptoms that a person has experienced in the most recent 4 week period.',\n",
       "          'PrimaryOutcomeTimeFrame': 'baseline, 6-month, 12-month'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in self-management strategy use',\n",
       "          'SecondaryOutcomeDescription': 'It will be measured by self-management strategy use scale (SSUS) was developed and validated by Morgan and Jorm',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 6-month, 12-month'},\n",
       "         {'SecondaryOutcomeMeasure': 'Accuracy of risk perception',\n",
       "          'SecondaryOutcomeDescription': '\"How likely are you to get depression in the next 4 years?\" The answer can range from 0 to 100, where 0=certain not to happen and 100=certain to happen',\n",
       "          'SecondaryOutcomeTimeFrame': 'baseline, 6- and 12-month follow-up assessment'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ndid not have a MDE at baseline,\\naged 18+ years old,\\nat high risk of MDE based on the algorithms (predicted risk of 6.5%+ for men and of 11.2%+ for women),\\nagreement to be contacted for follow-up assessments, and\\nno language barriers to English or French.\\n\\nExclusion Criteria:\\n\\n-',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'JianLi Wang, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '403-210-8653',\n",
       "          'CentralContactEMail': 'jlwang@ucalgary.ca'},\n",
       "         {'CentralContactName': 'Erin Jones',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '402-210-6839',\n",
       "          'CentralContactEMail': 'emjones@ucalgary.ca'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'JianLi Wang, PhD',\n",
       "          'OverallOfficialAffiliation': 'University of Calgary',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Mathison Centre for Mental Health Research and Education',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Calgary',\n",
       "          'LocationState': 'Alberta',\n",
       "          'LocationZip': 'T2N 4Z6',\n",
       "          'LocationCountry': 'Canada',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'JianLi Wang, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '403-210-8653',\n",
       "             'LocationContactEMail': 'jlwang@ucalgary.ca'},\n",
       "            {'LocationContactName': 'Erin Jones',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '403-210-6839',\n",
       "             'LocationContactEMail': 'emjones@ucalgary.ca'},\n",
       "            {'LocationContactName': 'Scott B Patten, MD, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Raymond W Lam, MD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Bonnie Lashewicz, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'David Hodgins, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Kendall Ho, MD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Erin Michalak, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Mark Attridge, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Zul Merali, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Norbert Schmitz, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Alice Aiken, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Alain Marchand, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'}]}},\n",
       "         {'LocationFacility': 'JianLi Wang',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Calgary',\n",
       "          'LocationState': 'Alberta',\n",
       "          'LocationZip': 'T3A 6B3',\n",
       "          'LocationCountry': 'Canada',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'JianLi Wang, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '4039913738',\n",
       "             'LocationContactEMail': 'jlwang@ucalgary.ca'},\n",
       "            {'LocationContactName': 'Erin Jones',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '403-2106839',\n",
       "             'LocationContactEMail': 'emjones@ucalgary.ca'},\n",
       "            {'LocationContactName': 'Scott Patten, MD, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Glenda MacQueen, MD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Bonnie Lashewicz, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Douglas Manuel, MD, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'},\n",
       "            {'LocationContactName': 'Norbert Schmitz, PhD',\n",
       "             'LocationContactRole': 'Sub-Investigator'}]}}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31533691',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Wang J, MacQueen G, Patten S, Manuel D, Lashewicz B, Schmitz N. A randomized controlled trial to examine the impacts of disclosing personalized depression risk information on the outcomes of individuals who are at high risk of developing major depression: a research protocol. BMC Psychiatry. 2019 Sep 18;19(1):285. doi: 10.1186/s12888-019-2270-9.'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 89,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03268434',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'LJ05207'},\n",
       "       'Organization': {'OrgFullName': 'Universitätsklinikum Hamburg-Eppendorf',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care',\n",
       "       'OfficialTitle': 'Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Psychiatric-psychotherapeutic Care: Randomized Controlled Trial'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'September 2019',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'October 10, 2017',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 22, 2019',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'September 24, 2019',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'August 3, 2017',\n",
       "       'StudyFirstSubmitQCDate': 'August 28, 2017',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 31, 2017',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'September 26, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 27, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Universitätsklinikum Hamburg-Eppendorf',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Asklepios Kliniken Hamburg GmbH',\n",
       "          'CollaboratorClass': 'OTHER'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Aim of the current study is to investigate the acceptance and efficacy of Metacognitive Training for Depression (D-MCT) compared to cognitive remediation in outpatients with major depressive disorders in a randomized, controlled, assessor-blind, group trial.',\n",
       "       'DetailedDescription': 'Evidence-based treatments for depression include pharmacological and psychological interventions. Within psychological interventions, cognitive behavioral therapy (CBT) is one of the most extensively researched evidence-based approaches for depression (Cuijpers, 2015). However, even if optimal treatment and access to services were available to all patients, the burden of depression would be reduced by only 30% (Andrews et al., 2004). Moreover, as depression represents the disorder with the highest drop-out rates during CBT treatment (36.4%) (Fernandez et al., 2015), and a relapse rate of 54% for treatment responders within the two years after treatment termination (Vittengl et al., 2007), it is pivotal to improve treatment for depression. It has been argued that this is less a question of developing novel psychological treatments as of determining how existing treatments may be improved (Cuijpers, 2015) and better disseminated to increase retention rates and to use the waiting phase to rise interest in therapy (Fernandez et al., 2015). Due to hopelessness and the discouraging character of the disorder, this poses a particular challenge.\\n\\nTo meet this aim, Metacognitive Training for Depression (D-MCT) has been developed as a low-threshold, highly standardized and yet easy to administer group concept for the treatment of depression. It is conceptualized as a variant of CBT that adopts a metacognitive perspective focusing on the modification of cognitive biases, and is compatible with a general CBT treatment approach. Use of standardized presentations reduces time needed for preparation and administration of the training; moreover, this \"packaging\" increases the accessibility of D-MCT to a wide range of health care providers, and encourages standardization across therapists. The training seeks to enable group members to recognize and correct the often automatic and unconscious thought patterns that accompany depression. To this end, it attempts to challenge cognitive biases through the use of creative and engaging exercises supported by a multimedia presentation (e.g., insight based on \"aha\" effects rather than psychoeducation) and to encourage patients to take a metacognitive perspective (\"think about one\\'s thinking\"). The training is highly flexible with regard to depth and intensity. Patients do not need to (but may) discuss their own problems, and can still experience how cognitive biases work and influence one\\'s mood in a playful atmosphere. The training is conceptualized as an open group: New patients can join the group in every session. Thus, the threshold for administration of and participation in this intervention is low.\\n\\nThe general structure of and exercises in D-MCT were inspired by Metacognitive Training for psychosis (Moritz et al., 2014); however, contents were modified upon to suit the specific problems of individuals with depression. Beside depressive thought patterns already targeted in CBT (e.g., overgeneralization, \"mind reading\"), a number of general cognitive biases, which have been identified by basic cognitive research, form the core of D-MCT (e.g., mood-congruent memory (Mathews and MacLeod, 2005)). Finally, as in Metacognitive Therapy (MCT) sensu Adrian Wells (Wells, 2011) dysfunctional coping strategies (i.e., thought suppression, rumination as problem-solving) are challenged. D-MCT thus blends established elements from CBT and MCT as well as newly developed and evidence-based exercises in one coherent metacognitive approach.\\n\\nD-MCT was positively evaluated with regard to feasibility and acceptance in a non-randomized pilot study (Jelinek et al., 2013). Moreover, efficacy of D-MCT was suggested in a randomized controlled trail (RCT) in comparison to an active control intervention (Jelinek et al., 2016). In this trial patients with depressive disorder were completing a psychosomatic outpatient treatment program and were randomly assigned to either D-MCT or general health training. Severity of depression and cognitive biases were assessed at baseline (t0), post treatment (t1) and 6 months (t2) later by raters blind to diagnostic status. Intention-to-treat analyses demonstrated that at the end of treatment, as well as 6 months later, improvement in depression was significantly greater in the D-MCT relative to the health training group at medium effect sizes. A significantly greater number of patients in the D-MCT group were in remission at 6-month follow-up. Moreover, the decrease in cognitive biases and increase in psychological well-being/quality of life was larger in the D-MCT than the health training group over time. Patients\\' subjective appraisal of D-MCT was also positive (Jelinek et al., 2017).\\n\\nAim of the current study is to investigate the acceptance and efficacy of D-MCT in outpatients.The Hamilton Depression Rating Scale (HDRS, 17-item version) total score as well as the Quick Inventory of Depressive Symptomatology (QIDS) serve as primary outcome. Self-assessed depression, dysfunctional beliefs, self-esteem, quality of life, rumination, remission rate as well as neuropsychological functioning serve as secondary outcomes.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Unipolar Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Metacognition',\n",
       "         'CBT',\n",
       "         'D-MCT',\n",
       "         'cognitive bias']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Double',\n",
       "         'DesignMaskingDescription': 'Double Blind (Investigator, Outcome Assessor)',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator',\n",
       "           'Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '86',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'D-MCT Group',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: D-MCT']}},\n",
       "         {'ArmGroupLabel': 'Cognitive remediation',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory.The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance.; 8 sessions (60min), once a week over a period of 8 weeks',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive remediation']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'D-MCT',\n",
       "          'InterventionDescription': 'Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['D-MCT Group']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Metacognitive Training for Depression']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Cognitive remediation',\n",
       "          'InterventionDescription': 'A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory. The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance; 8 sessions (60min), once a week over a period of 8 weeks',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cognitive remediation']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Quick Inventory of Depressive Symptomatology (QIDS)',\n",
       "          'PrimaryOutcomeDescription': 'Primary outcome is change on the Quick Inventory of Depressive Symptomatology (QIDS) from baseline to follow-up (t0 - t2)',\n",
       "          'PrimaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2)'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Hamilton Depression Rating Scale',\n",
       "          'SecondaryOutcomeDescription': 'Change on the Hamilton Depression Rating Scale (HDRS, 17-item version) from baseline to follow-up (t0 - t2)',\n",
       "          'SecondaryOutcomeTimeFrame': '[Time Frame: eight months from baseline (t0) to 6-months follow up (t2)]'},\n",
       "         {'SecondaryOutcomeMeasure': 'Self-assessed depression',\n",
       "          'SecondaryOutcomeDescription': 'Change in self-assessed depression as measured by the Patient Health Questionnaire (PHQ-9) from baseline to follow-up (t0 to t2)',\n",
       "          'SecondaryOutcomeTimeFrame': '[Time Frame: eight months from baseline (t0) to 6-months follow up (t2)]'},\n",
       "         {'SecondaryOutcomeMeasure': 'Quick Inventory of Depressive Symptomatology (QIDS)',\n",
       "          'SecondaryOutcomeDescription': 'Change on the Quick Inventory of Depressive Symptomatology (QIDS) from baseline to post intervention assessment (t0 - t1)',\n",
       "          'SecondaryOutcomeTimeFrame': 'from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks]'},\n",
       "         {'SecondaryOutcomeMeasure': 'Hamilton Depression Rating Scale',\n",
       "          'SecondaryOutcomeDescription': 'Change on the Hamilton Depression Rating Scale from baseline to post intervention assessment (t0 - t1)',\n",
       "          'SecondaryOutcomeTimeFrame': 'from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks]'},\n",
       "         {'SecondaryOutcomeMeasure': 'Patient Health Questionnaire (PHQ-9)',\n",
       "          'SecondaryOutcomeDescription': 'Change on the Patient Health Questionnaire (PHQ-9) from baseline to post intervention assessment (t0 - t1)',\n",
       "          'SecondaryOutcomeTimeFrame': 'from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks]'},\n",
       "         {'SecondaryOutcomeMeasure': 'Dysfunctional beliefs',\n",
       "          'SecondaryOutcomeDescription': 'Change in dysfunctional beliefs as measured by the Dysfunctional Attitude Scale (DAS) from baseline to follow-up (t0 to t2)',\n",
       "          'SecondaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2'},\n",
       "         {'SecondaryOutcomeMeasure': 'Quality of life',\n",
       "          'SecondaryOutcomeDescription': 'Change in quality of life as measured by the World Health Organization Quality of Life Assessment (WHOQOL-BREF) from baseline to follow-up (t0 to t2)',\n",
       "          'SecondaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Dysfunctional metacognitive beliefs',\n",
       "          'SecondaryOutcomeDescription': 'Change in metacognitive beliefs as measured by the Metacognitions Questionnaire (MCQ-30) from baseline to follow-up (t0 to t2)',\n",
       "          'SecondaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Rumination',\n",
       "          'SecondaryOutcomeDescription': 'Rumination measured by the Ruminative Response Scale (RRS) from baseline to follow-up (t0 to t2)',\n",
       "          'SecondaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Self-esteem',\n",
       "          'SecondaryOutcomeDescription': 'Change in self-esteem as measured by the Rosenberg Self-Esteem Scale (RSE) from from baseline to follow-up (t0 to t2)',\n",
       "          'SecondaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Remission rate',\n",
       "          'SecondaryOutcomeDescription': 'Remission rate at T2 as measured by the Hamilton Depression Rating Scale (HDRS score ≤ 8)',\n",
       "          'SecondaryOutcomeTimeFrame': 'eight months from baseline (t0) to 6-months follow up (t2)'},\n",
       "         {'SecondaryOutcomeMeasure': 'Information processing',\n",
       "          'SecondaryOutcomeDescription': 'Information processing as measured by the Trail-Making Test A (TMT-A) from baseline to post treatment assessment (t0 to t1)',\n",
       "          'SecondaryOutcomeTimeFrame': 'from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks]'},\n",
       "         {'SecondaryOutcomeMeasure': 'Subjective appraisal of the training',\n",
       "          'SecondaryOutcomeDescription': 'Subjective appraisal of the training after each session as well as at post treatment and follow up assessment (for questionnaire see Jelinek et al., 2017)',\n",
       "          'SecondaryOutcomeTimeFrame': 'each week (session data) [time frame: 8 weeks] and six months from post treatment assessment (t1) to 6 months follow up (t1 to t2) [time frame: 6 months]'},\n",
       "         {'SecondaryOutcomeMeasure': 'Executive functioning',\n",
       "          'SecondaryOutcomeDescription': 'Executive functions as measured by the Trail-Making Test B (TMT-B) from baseline to post treatment assessment (t0 to t1)',\n",
       "          'SecondaryOutcomeTimeFrame': 'from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks]'},\n",
       "         {'SecondaryOutcomeMeasure': 'Verbal memory',\n",
       "          'SecondaryOutcomeDescription': 'Memory functioning as measured by Rivermead Behavioral Memory Test from baseline to post treatment assessment (t0 to t1)',\n",
       "          'SecondaryOutcomeTimeFrame': 'from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks]'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ninformed consent\\nage between 18 and 70 years\\ndiagnosis of a single Episode or recurrent Major depressive disorder (MDD) or dysthymia (verified by the MINI)\\n\\nExclusion Criteria:\\n\\nlifetime psychotic symptoms (i.e., hallucinations, delusions, or mania), suicidality (Suicidal Behaviors Questionnaire-Revised ≥ 7), intellectual disability (estimated IQ < 70) or dementia.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '70 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Marion Hagemann-Goebel, Dr.',\n",
       "          'OverallOfficialAffiliation': 'Asklepios Klinik Nord-Ochsenzoll',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Asklepios Klinik Nord-Ochsenzoll',\n",
       "          'LocationCity': 'Hamburg',\n",
       "          'LocationZip': '22419',\n",
       "          'LocationCountry': 'Germany'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25103718',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Moritz S, Veckenstedt R, Andreou C, Bohn F, Hottenrott B, Leighton L, Köther U, Woodward TS, Treszl A, Menon M, Schneider BC, Pfueller U, Roesch-Ely D. Sustained and \"sleeper\" effects of group metacognitive training for schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2014 Oct;71(10):1103-11. doi: 10.1001/jamapsychiatry.2014.1038.'},\n",
       "         {'ReferencePMID': '27230865',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Jelinek L, Hauschildt M, Wittekind CE, Schneider BC, Kriston L, Moritz S. Efficacy of Metacognitive Training for Depression: A Randomized Controlled Trial. Psychother Psychosom. 2016;85(4):231-4. doi: 10.1159/000443699. Epub 2016 May 27.'},\n",
       "         {'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Jelinek L, Otte C, Arlt S, & Hauschildt M. Denkverzerrungen erkennen und korrigieren: Eine Machbarkeitsstudie zum Metakognitiven Training bei Depressionen (D-MKT). [Identifying and correcting cognitive biases: A Pilot study on the Metacognitive Training for Depression (D-MCT)] Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 61, 247-254, 2013.'},\n",
       "         {'ReferencePMID': '28628763',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': \"Jelinek L, Moritz S, Hauschildt M. Patients' perspectives on treatment with Metacognitive Training for Depression (D-MCT): Results on acceptability. J Affect Disord. 2017 Oct 15;221:17-24. doi: 10.1016/j.jad.2017.06.003. Epub 2017 Jun 7.\"},\n",
       "         {'ReferencePMID': '15172947',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry. 2004 Jun;184:526-33.'},\n",
       "         {'ReferencePMID': '25415495',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Cuijpers P. Psychotherapies for adult depression: recent developments. Curr Opin Psychiatry. 2015 Jan;28(1):24-9. doi: 10.1097/YCO.0000000000000121. Review.'},\n",
       "         {'ReferencePMID': '26302248',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Fernandez E, Salem D, Swift JK, Ramtahal N. Meta-analysis of dropout from cognitive behavioral therapy: Magnitude, timing, and moderators. J Consult Clin Psychol. 2015 Dec;83(6):1108-22. doi: 10.1037/ccp0000044. Epub 2015 Aug 24.'},\n",
       "         {'ReferencePMID': '17716086',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Mathews A, MacLeod C. Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol. 2005;1:167-95. Review.'},\n",
       "         {'ReferencePMID': '17563164',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': \"Vittengl JR, Clark LA, Dunn TW, Jarrett RB. Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects. J Consult Clin Psychol. 2007 Jun;75(3):475-88.\"},\n",
       "         {'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Wells, A., 2011. Metacognitive Therapy for anxiety and depression. The Guilford Press, New York.'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 90,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01862913',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'FONDECYT Nº11121637'},\n",
       "       'Organization': {'OrgFullName': 'University of Chile',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Computer-Assisted Cognitive-Behavioral Therapy for Adolescent Depression',\n",
       "       'OfficialTitle': 'Computer-Assisted Cognitive-Behavioral Therapy for Adolescent Depression in Primary Care Clinics in Santiago, Chile (YPSA-M): A Randomized Controlled Trial',\n",
       "       'Acronym': 'YPSA-M'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'November 2016',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'June 2013'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2016',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'June 2016',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'May 20, 2013',\n",
       "       'StudyFirstSubmitQCDate': 'May 22, 2013',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 27, 2013',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'November 8, 2016',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 10, 2016',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Vania Martínez-Nahuel',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Dr.med.',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'University of Chile'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'University of Chile',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Background: Most adolescents suffering depression are treated in primary care clinics. Cognitive-behavior therapy (CBT) is effective in the treatment of adolescent depression. The availability of appropriately trained CBT therapist may be limited, especially in primary care clinics. One way to increase the availability of CBT is to use computer-assisted CBT (c-CBT). It can be effective in the treatment of adults, although the outcomes in adolescents remain unclear.\\n\\nPurpose: The purpose of this study is to determine whether a computer-assisted cognitive-behavioral therapy is effective for the treatment of depression in adolescents between 15 and 19 years of age in 4 primary care clinics in Santiago, Chile.\\n\\nStudy design: A two-arm single-blind (outcomes assessor) randomized controlled trial will be carried out with 216 adolescents. The efficacy, the adherence, and acceptability of the computerized-assisted cognitive behavioral therapy will be evaluated.',\n",
       "       'DetailedDescription': \"This is a two-arm, single-blind (blinded only to outcome assessor), individually randomized controlled trial, which will compare the efficacy of computer-assisted CBT versus usual treatment for depression in adolescents in primary care clinics in Santiago, Chile.\\n\\nGeneral aim To carry out a randomized controlled trial to compare the efficacy of a computer-assisted CBT intervention versus usual care to treat depression in adolescents in primary care clinics in Santiago, Chile.\\n\\nSpecific aims\\n\\nTo compare the level of depressive symptoms of adolescents suffering depression treated with computer-assisted CBT versus usual care in primary care clinics.\\nTo compare the level of dysfunctional thoughts, strategies for solving problems, and health-related quality of life (HRQoL) of adolescents suffering depression treated with computer-assisted CBT versus usual care in primary care clinics.\\nTo compare adolescents' adherence to computer-assisted CBT versus usual care in primary care clinics.\\nTo compare adolescents' satisfaction with computer-assisted CBT versus usual care in primary care clinics.\\n\\nHypotheses\\n\\nAdolescents receiving the intervention will achieve lower scores (difference in mean of at least 0.4 standard deviations) in the depression questionnaire than those receiving the usual care, four months after randomization.\\nAdolescents receiving the intervention would have fewer dysfunctional thoughts than those receiving the usual care, four months after randomization.\\nAdolescents receiving the intervention would be better at solving problems than those receiving the usual care, four months after randomization.\\nAdolescents receiving the intervention would have better HRQoL than those receiving the usual care, four months after randomization.\\nSymptomatic improvements achieved at four months after randomization will be maintained at six months after randomization.\\n\\nSetting and population Adolescents between 15 and 19 years of age attending four primary care clinics located in Puente Alto, a low-income municipality of Santiago, Chile, with a large adolescent population.\\n\\nTraining of primary care center professionals Before the start of recruitment, professionals in the four participating primary care centers will receive a special training session from the principal investigator to assist with the correct identification, diagnosis, and treatment of patients with depression, according to the AUGE Clinical Guidelines for Depression. There will also be a refresher session 6 months after the start of recruitment.\\n\\nRecruitment Adolescents eligible for the study will be identified by health professionals of the four primary care clinics, as well as by psychologists and counselors of nearby schools, who will be informed of the study, trained to identify potential cases of depression among their students, and instructed to refer any adolescent who seems to have depression symptoms to the primary care clinics for further evaluation and possible participation in the study, according to inclusion and exclusion criteria.\\n\\nGroup assignment Those adolescents who at baseline assessment meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to the intervention arm or to the control arm. Blocked (size of four), stratified randomization will be used. Stratification will be implemented regarding sex and severity of depression (mild, moderate, and severe) according to BDI score. Randomization will be generated using web-based random allocation algorithms. Allocation concealment will be carried out by keeping treatment assignment in numbered sealed envelopes in a central place; the envelopes will be opened by individuals who do not participate in the recruitment process.\\n\\nData collection All participants will be assessed at baseline and at four and six months after randomization. The instruments that will be used are all self-report questionnaires, which will be completed on paper by the participants. Trained psychologists who are blind to the group assignments will be present to assist the adolescents if necessary.\\n\\nData management After the participants have completed the questionnaires, the data will entered into a secure platform, without identifying information (each participant will be assigned an ID number). The original copies of the instruments will be filed and stored, under lock and key, in the principal investigator's office, along with the list linking the participants' names and ID numbers. Only two research assistants, in charge of data entry, and the statistician will have access to the database.\\n\\nData analysis Data and presentation of the results will be in accordance with CONSORT guidelines for randomized clinical trials, with the primary comparative analysis being conducted on an intention-to-treat basis. Initially, we will conduct descriptive analysis to assess the balance between the two groups. The primary analysis will employ multivariable linear regression to investigate differences in mean symptom scores (primary outcome measure) between groups at four months after randomization, adjusting for baseline outcome variable if imbalances are identified. Sensitivity analysis making different assumptions will be conducted to investigate the potential effects of missing data. Similar analyses will be conducted for the secondary outcome measures.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['depression', 'adolescents']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '216',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Computer-assisted CBT',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Usual medical treatment in accordance with a decision algorithm based on the \"Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile\".\\nEight sessions of a computer-assisted cognitive-behavioral therapy. Trained psychologists administer this program in face to face meetings.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Computer-assisted cognitive-behavioral therapy']}},\n",
       "         {'ArmGroupLabel': 'Usual care treatment',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': '- Usual psychological and medical treatment in accordance with a decision algorithm based on the \"Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile\".',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Usual care treatment']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Computer-assisted cognitive-behavioral therapy',\n",
       "          'InterventionDescription': \"The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.\",\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Computer-assisted CBT']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'Usual care treatment',\n",
       "          'InterventionDescription': 'The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Usual care treatment']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change from baseline in Beck Depression Inventory (BDI) at 4 months',\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline and 4 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Change from baseline in Children's Automatic Thought Questionnaire (CATS)\",\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 4 months, and 6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change from baseline in Social Problem Solving Inventory-Revised Short Form (SPSI-RS)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 4 months, and 6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change from baseline in KIDSCREEN-27',\n",
       "          'SecondaryOutcomeDescription': 'Health-related quality of life questionnaire',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline, 4 months, and 6 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Change from baseline in Beck Depression Inventory (BDI) at 6 months',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline and 6 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nBeck Depression Inventory > o = 10\\nMeets diagnostic criteria of a depressive disorder according Kiddie Sads Present and Lifetime Version interview (K-SADS-PL)\\nParent or caregiver giving informed consent and adolescent giving informed assent\\n\\nExclusion Criteria:\\n\\nSuicidal risk requiring in-patient care\\nBipolar Disorder\\nCurrent substance dependence\\nCurrent alcohol dependence\\nCurrent psychosis\\nLow intellectual abilities\\nCurrent treatment with antidepressant and/or psychotherapy',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '15 Years',\n",
       "       'MaximumAge': '19 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child', 'Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Vania Martínez-Nahuel, Dr.med.',\n",
       "          'OverallOfficialAffiliation': 'University of Chile',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'CESFAM Bernardo Leighton, CESFAM Cardenal Raúl Silva Henríquez, CESFAM Padre Manuel Villaseca, CESFAM San Gerónimo',\n",
       "          'LocationCity': 'Santiago',\n",
       "          'LocationCountry': 'Chile'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31417440',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Martínez V, Rojas G, Martínez P, Gaete J, Zitko P, Vöhringer PA, Araya R. Computer-Assisted Cognitive-Behavioral Therapy to Treat Adolescents With Depression in Primary Health Care Centers in Santiago, Chile: A Randomized Controlled Trial. Front Psychiatry. 2019 Jul 30;10:552. doi: 10.3389/fpsyt.2019.00552. eCollection 2019.'},\n",
       "         {'ReferencePMID': '25091593',\n",
       "          'ReferenceType': 'derived',\n",
       "          'ReferenceCitation': 'Martínez V, Martínez P, Vöhringer PA, Araya R, Rojas G. Computer-assisted cognitive-behavioral therapy for adolescent depression in primary care clinics in Santiago, Chile (YPSA-M): study protocol for a randomized controlled trial. Trials. 2014 Aug 5;15:309. doi: 10.1186/1745-6215-15-309.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 91,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01634022',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '2004P002819'},\n",
       "       'Organization': {'OrgFullName': 'Massachusetts General Hospital',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Effectiveness of Acupuncture for Depressed Patients Not Taking Antidepressant Medications',\n",
       "       'OfficialTitle': 'Effectiveness of Acupuncture on Treating Major Depressive Disorder'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2012',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'May 2005'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2011',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'November 2011',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 15, 2012',\n",
       "       'StudyFirstSubmitQCDate': 'July 2, 2012',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 6, 2012',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 2, 2012',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 6, 2012',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Albert Yeung',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Director of Primary Care Research, Depression Clinical and Research Program',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Massachusetts General Hospital'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Massachusetts General Hospital',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Acupuncture is a popular complementary/alternative therapy that has been in use for thousands of years for the treatment of various medical and psychiatric conditions, including Major Depressive Disorder (MDD). In this study, the investigators applied the investigators acupuncture-treatment-for-depression protocol, based on Traditional Chinese Medicine (TCM) principles for treating MDD, to depressed patients not taking any antidepressant medications (a protocol that the investigators previously piloted as a medication augmentation therapy for partial responders with MDD).\\n\\nThe investigators specifically investigated the efficacy, safety, and tolerability of this TCM-based protocol for such patients, as well as potential differences in outcomes between weekly vs. twice-weekly treatment. The investigators hypothesized that acupuncture monotherapy would be associated with a response rate of at least 50%, which the investigators defined as a decrease in depressive symptoms from the beginning to the end of the study of 50% or more, and that the response would be greater among patients who received acupuncture 2 times per week (vs. 1 time per week). The investigators also hypothesized that acupuncture would be associated with minimal side effects.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Acupuncture',\n",
       "         'Antidepressant',\n",
       "         'Monotherapy',\n",
       "         'Depression',\n",
       "         'Alternative treatments']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '64',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Acupuncture',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Adults with depression who are not currently taking an antidepressant medication.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Acupuncture']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Procedure',\n",
       "          'InterventionName': 'Acupuncture',\n",
       "          'InterventionDescription': '5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (−) to GV24.5 (+).',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Acupuncture']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in scores on the Hamilton Depression Rating Scale, 17 items (HAM-D-17)',\n",
       "          'PrimaryOutcomeDescription': \"The HAM-D-17 is a clinician-rated assessment (structured interview) of patients' depressive symptoms. Questions focus on depressive symptoms during the past 7 days, and higher cumulative scores (possible responses to each item range from 0-4 or 0-2) indicate more severe depression.\",\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline and all acupuncture sessions (weekly) for 8 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Response to treatment, defined as a 50% or greater improvement in HAM-D-17 score compared to baseline',\n",
       "          'SecondaryOutcomeDescription': '(See primary outcome measure description.)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Baseline and all acupuncture sessions (weekly) for 8 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHas current or past DSM-IV MDD diagnosis based on SCID; AND current 17-Hamilton Rating Scale for Depression (BRSD) score of 14 or above\\nAge between 18-65\\nNo treatment with antidepressant(s) in the past 3 months\\nIf patient has received psychotherapy, no initiation or termination of therapy in the past 3 months.\\n\\nExclusion Criteria:\\n\\nPatients with primary diagnosis other than Major Depressive Disorder, or any history of psychosis or mania.\\nConditions that could make it difficult to conclusively determine that depressive symptoms were the result of MDD and not some other condition, including substance abuse or dependence within the last 6 months, medical conditions that could produce depression, including epilepsy, history of an abnormal EEG, severe head trauma, or stroke.\\nSerious uncontrolled medical conditions [e.g. poorly controlled diabetes, severe congestive heart failure], or other medical conditions that have not been stable for at least 3 months.\\nElectroconvulsive therapy (ECT) during the last year.\\nCurrent active suicidal or self-injurious potential necessitating immediate treatment.\\nCurrently receiving concomitant Acupuncture Treatment, or any Acupuncture treatment in the past three months.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Albert Yeung, MD, ScD',\n",
       "          'OverallOfficialAffiliation': 'Depression Clinical and Research Program, Massachusetts General Hospital',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Depression Clinical and Research Program, Massachusetts General Hospital',\n",
       "          'LocationCity': 'Boston',\n",
       "          'LocationState': 'Massachusetts',\n",
       "          'LocationZip': '02114',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '22521855',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Mischoulon D, Brill CD, Ameral VE, Fava M, Yeung AS. A pilot study of acupuncture monotherapy in patients with major depressive disorder. J Affect Disord. 2012 Dec 10;141(2-3):469-73. doi: 10.1016/j.jad.2012.03.023. Epub 2012 Apr 21.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 92,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01583400',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'CPHS#22616, W&P-PCMH-01'},\n",
       "       'Organization': {'OrgFullName': 'Dartmouth-Hitchcock Medical Center',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial',\n",
       "       'OfficialTitle': 'Development and Evaluation of Enhanced Digital Health Coaching Program for Depressive Symptoms to Support Collaborative Depression Treatment in Primary Care: The RESPECT-D-E (Enhanced) Trial'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'September 2014',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'September 2011'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2013',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'October 2013',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'April 12, 2012',\n",
       "       'StudyFirstSubmitQCDate': 'April 20, 2012',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 24, 2012',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'September 17, 2014',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 18, 2014',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Mark T. Hegel',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Associate Professor',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Dartmouth-Hitchcock Medical Center'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Dartmouth-Hitchcock Medical Center',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Johnson & Johnson',\n",
       "          'CollaboratorClass': 'INDUSTRY'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes'},\n",
       "      'DescriptionModule': {'BriefSummary': \"Primary care physicians have emerged as the predominant mental health care providers for diagnosing and treating depression. The majority of patients with mood disorders receive treatment in the primary care setting, within which approximately 10-30% of all patients present with a depressive disorder. Comprehensive 'Collaborative Care' models of depression management significantly improve depression outcomes and health-related quality of life. Core features of these programs include use of a trained depression care manager to closely coordinate with primary care clinicians, support treatment recommendations, provide patient education, conduct patient follow-up to ensure adequate treatment, and manage as-needed access to psychiatrists for patients with more complex presentations. Evidence based Collaborative Care models do not currently weave in the use of web-based or mobile technologies. These technologies offer unique features that may make collaborative depression care more effective. The digital health coaching program for depressive symptoms enhanced during Phase I of the current project is a web-based tool featuring video, text, links and graphics which provide patients with education, self-management techniques, tailored feedback, and tools for tracking treatment progress. The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a collaborative depression management model for primary care. The primary objective of this project is to compare the efficacy of an enhanced Collaborative Care model for depression (RESPECT-D-E) to the standard model (RESPECT-D) for patients with minor and major depression and dysthymic disorder. This study will be a randomized controlled trial with 150 participants who are receiving antidepressant medication treatment in the primary care setting. The primary objectives are: reduction in subject reported depressive symptoms, improvement in subject reported health related quality of life and improvement in subject adherence to treatment regimen as demonstrated by self-report measures and clinician-administered assessment. The investigators hypothesize that compared to RESPECT-D at 12 weeks, participants randomized to RESPECT-D-E will demonstrate: a greater reduction in depressive symptoms, a greater improvement in health-related quality of life and a greater satisfaction with quality of depression care received.\",\n",
       "       'DetailedDescription': \"The National Comorbidity Survey suggests a lifetime prevalence of 17% and 1-year prevalence of 10% for major depression. Within primary care, approximately 10-30% of patients present with a depressive disorder. Over the past decade, primary care physicians have emerged as the predominant mental health care providers insofar as diagnosing and treating depression, with the majority of patients with mood disorders receiving treatment in a primary care setting.\\n\\nComprehensive 'Collaborative Care' models of depression management in primary care significantly improve depression outcomes and health-related quality of life. Core features of these programs include use of a trained depression care manager to closely coordinate with primary care clinicians, provision of specific treatment recommendations/guidelines, patient education, appropriate follow-up by the depression care manager to ensure adequate treatment, as-needed access to psychiatrists for patients with more complex presentations, and, occasionally, on-site psychotherapy. For example, the IMPACT study of primary care patients with late-life depression found that a Collaborative Care program doubled the effectiveness of depression treatment and improved functional outcomes at 3 months, 6 months and 1 year compared to usual care. The RESPECT-D phone-based Collaborative Care program similarly had increases at 3 and 6 months in depression response, remission, and satisfaction with care, compared to usual care.\\n\\nNonetheless, evidence based Collaborative Care leaves room for improvement. In both IMPACT and RESPECT-D, 40% to 50% of intervention participants failed to achieve a clinically meaningful depression treatment effect. Evidence based Collaborative Care models do not currently weave in the use of web-based or mobile technologies. These technologies offer unique features that may make collaborative depression care more effective. The enhanced digital health coaching program for depressive symptoms is a web-based tool featuring video, text and graphics which provides patients with education, self-management techniques, tailored feedback, and tools for tracking treatment progress. Incorporating a digital health coaching program for depressive symptoms into the flow of collaborative depression care and testing its impact is an important next step for the field.\\n\\nThe RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression by the primary care provider, with a centrally based care manager providing telephone support for patients. The essential components of this Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient.\\n\\nRESPECT-D-E (Enhanced) intervention is Collaborative Care depression treatment in primary care including care manager (the elements of RESPECT-D) plus patient access to on-line coaching, education, and symptom, side effect and medication adherence tracking which is automatically fed back to the Care Manager.\\n\\nThe primary objective of this project is to compare the efficacy of an enhanced Collaborative Care model for depression (RESPECT-D-E) to the standard model (RESPECT-D) in primary care patients with minor and major depression and dysthymic disorder .\\n\\nThe RESEPCT-D-E trial is a randomized, 12-week prospective 2-arm, comparative clinical effectiveness study. Primary care patients (N=150) with major or minor depressive disorder, or dysthymia and currently taking antidepressant medication will be randomly assigned to either Collaborative Care treatment for depression (RESPECT-D) or RESPECT-D plus a digital health coaching program for depressive symptoms intervention (RESPECT-D-E). Patients will be assessed at baseline, 4 weeks, 8 weeks, and 12 weeks using self-report and clinician -administered rating scales including the Hopkins Symptom Checklist and Hamilton Depression Rating Scale. Intervention participants will receive access to the online depression coach as well as the elements of standard Collaborative Care (RESPECT-D). The primary objectives are: reduction in depressive symptoms, improvement in health related quality of life and improvement in adherence to treatment regimen.\\n\\nThe secondary objectives of the RESPECT-D-E trial are to: Evaluate the program impact on overall health, work productivity, and medical costs; Assess the usability of the enhanced digital health coaching program for depressive symptoms tool; Assess the program's impact on overall satisfaction with care.\\n\\nHypotheses: Compared to RESPECT-D at 12 weeks, participants randomized to RESPECT-D-E will demonstrate: H1.1a: a greater reduction in depressive symptoms, as measured by the clinician administered Hamilton Depression Rating Scale (HAM-D); H1.1b: a greater reduction in depressive symptoms, as measured by the self-report Hopkins Symptom Checklist Depression Scale (HSCL-20); H1.1c: a greater improvement in health related quality of life, as measured by the Mental Component Summary score from the Medical Outcomes Study Short Form (SF-36); H1.1d: a greater satisfaction with quality of depression care received.\\n\\nHypothesis 1.2: Compared to RESPECT-D at 4, 8, and 12 weeks, participants randomized to RESPECT-D-E will demonstrate: H1.2a: more frequent contact with the depression care manager and primary care provider, as measured by depression care manager treatment logs and medical record review; H1.2b: greater adherence to their antidepressant regimen, as measured by participant self-report; H1.2c: greater exposure to depression counseling, as measured by participant self-report.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depressive Disorder, Major',\n",
       "         'Depressive Disorder, Minor',\n",
       "         'Dysthymic Disorder']},\n",
       "       'KeywordList': {'Keyword': ['Depressive Disorder, Major',\n",
       "         'Depressive Disorder, Minor',\n",
       "         'Dysthymic Disorder']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '131',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'RESPECT-D',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'The RESPECT-D Model: Collaborative Care depression treatment within primary care including care manager',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: RESPECT-D']}},\n",
       "         {'ArmGroupLabel': 'RESPECT-D-E',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'RESPECT-D-E: Collaborative Care depression treatment within primary care including care manager plus on-line coaching, education and symptom, side effect and, medication adherence tracking with the digital health coaching program for depressive symptoms.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: RESPECT-D-E (Enhanced)']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'RESPECT-D',\n",
       "          'InterventionDescription': 'The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['RESPECT-D']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Collaborative Care Treatment for Depression in Primary Care']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'RESPECT-D-E (Enhanced)',\n",
       "          'InterventionDescription': 'The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['RESPECT-D-E']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['Enhanced Collaborative Care Treatment for Depression in Primary Care',\n",
       "            'Digital Health Coaching Program for Depressive Symptoms']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Score of Hamilton Rating Scale for Depression (HAM-D)',\n",
       "          'PrimaryOutcomeDescription': '17-item assessment rated during a clinical interview',\n",
       "          'PrimaryOutcomeTimeFrame': '12 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Score of Hopkins Symptom Checklist-20 (HSCL-20)',\n",
       "          'SecondaryOutcomeDescription': 'Self-report measure of depressive symptom severity',\n",
       "          'SecondaryOutcomeTimeFrame': '12 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMales and Females, ages 18 and older who are self-reporting generally good health.\\nNewly started on an antidepressant medication, switched to a different antidepressant medication or prescribed an increased dosage of antidepressant medication within the past 2 weeks.\\nA Hamilton Depression Rating Scale (HAM-D) score of greater than 10.\\nA Patient Health Questionnaire (PHQ-9) score of 10 or greater, with endorsement of depressed mood or anhedonia, and endorsement of impaired daily function.\\nMeets diagnostic criteria for Major Depressive Disorder, persistent Minor Depressive Disorder (i.e., > 1 month duration), or Dysthymic Disorder via a structured interview with the PRIME-MD.\\nAble to read, understand, and sign the Informed Consent in English.\\nWilling and able to comply with study requirements.\\nWell-versed in using a personal computer and the internet and must have easy access to a computer connected to the internet everyday (both weekdays and weekends).\\nEnrollment in Surescripts Pharmacy benefit plan\\nCurrently under care with a Provider in Family Medicine at Cheshire Medical Center / Dartmouth-Hitchcock Keene\\n\\nExclusion Criteria:\\n\\nSubjects must not have a major psychiatric co-morbid condition (schizophrenia, bipolar affective disorder, obsessive-compulsive disorder, PTSD, or a depressive disorder with psychotic features, as determined from chart review and patient report).\\nSubjects must not have a substance use disorder or dependence as assessed by: CAGE Alcohol Dependence Questionnaire score >3\\nSubjects must not have a history of treatment -resistant depression as defined by the following: Psychiatric hospitalization within the past year; More than 2 clinically ineffective antidepressant medication trials, of adequate duration and adequate dose, within the current depressive episode; Any history of Electroconvulsive Therapy (ECT); A trial of Monoamine Oxidase inhibitor (MAO) within the past year.\\nSubjects must not report being actively suicidal\\nSubjects must score 4 or greater on the Callahan Six-Item Cognitive Screening assessment\\nSubjects must not be diagnosed with a terminal or near terminal medical illness such that their primary care provider has estimated the patient has less than 6 months to live.\\nSubjects reporting any medical condition that would make it unsafe to participate in a research study.\\nParticipation in any other clinical research study within the past 30 days.\\nParticipation in any on-line depression-related coaching or lifestyle improvement program within the past 5 years.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Mark T. Hegel, PhD',\n",
       "          'OverallOfficialAffiliation': 'Dartmouth-Hitchcock Medical Center',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Family Medicine Clinics, Cheshire Medical Center (DH-Keene)',\n",
       "          'LocationCity': 'Keene',\n",
       "          'LocationState': 'New Hampshire',\n",
       "          'LocationZip': '03431',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '15345600',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Dietrich AJ, Oxman TE, Williams JW Jr, Schulberg HC, Bruce ML, Lee PW, Barry S, Raue PJ, Lefever JJ, Heo M, Rost K, Kroenke K, Gerrity M, Nutting PA. Re-engineering systems for the treatment of depression in primary care: cluster randomised controlled trial. BMJ. 2004 Sep 11;329(7466):602. Epub 2004 Sep 2.'},\n",
       "         {'ReferencePMID': '16428253',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Hunkeler EM, Katon W, Tang L, Williams JW Jr, Kroenke K, Lin EH, Harpole LH, Arean P, Levine S, Grypma LM, Hargreaves WA, Unützer J. Long term outcomes from the IMPACT randomised trial for depressed elderly patients in primary care. BMJ. 2006 Feb 4;332(7536):259-63. Epub 2006 Jan 20.'},\n",
       "         {'ReferencePMID': '7897786',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Katon W, Von Korff M, Lin E, Walker E, Simon GE, Bush T, Robinson P, Russo J. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA. 1995 Apr 5;273(13):1026-31.'},\n",
       "         {'ReferencePMID': '15466678',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J, Ciechanowski P, Walker E, Bush T. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004 Oct;61(10):1042-9.'},\n",
       "         {'ReferencePMID': '10591288',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Katon W, Von Korff M, Lin E, Simon G, Walker E, Unützer J, Bush T, Russo J, Ludman E. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry. 1999 Dec;56(12):1109-15.'},\n",
       "         {'ReferencePMID': '19898985',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Torrey WC, Drake RE. Practicing shared decision making in the outpatient psychiatric care of adults with severe mental illnesses: redesigning care for the future. Community Ment Health J. 2010 Oct;46(5):433-40. doi: 10.1007/s10597-009-9265-9. Epub 2009 Nov 8.'},\n",
       "         {'ReferencePMID': '12472325',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Unützer J, Katon W, Callahan CM, Williams JW Jr, Hunkeler E, Harpole L, Hoffing M, Della Penna RD, Noël PH, Lin EH, Areán PA, Hegel MT, Tang L, Belin TR, Oishi S, Langston C; IMPACT Investigators. Improving Mood-Promoting Access to Collaborative Treatment. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002 Dec 11;288(22):2836-45.'},\n",
       "         {'ReferencePMID': '8864145',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl. 1996 Jun;(30):17-30.'},\n",
       "         {'ReferencePMID': '10512600',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'McQuaid JR, Stein MB, Laffaye C, McCahill ME. Depression in a primary care clinic: the prevalence and impact of an unrecognized disorder. J Affect Disord. 1999 Sep;55(1):1-10.'},\n",
       "         {'ReferencePMID': '8712797',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Norquist GS, Regier DA. The epidemiology of psychiatric disorders and the de facto mental health care system. Annu Rev Med. 1996;47:473-9. Review.'},\n",
       "         {'ReferencePMID': '7665808',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': 'Stein MB, Kirk P, Prabhu V, Grott M, Terepa M. Mixed anxiety-depression in a primary-care clinic. J Affect Disord. 1995 May 17;34(2):79-84.'},\n",
       "         {'ReferencePMID': '12954939',\n",
       "          'ReferenceType': 'background',\n",
       "          'ReferenceCitation': \"Weilburg JB, O'Leary KM, Meigs JB, Hennen J, Stafford RS. Evaluation of the adequacy of outpatient antidepressant treatment. Psychiatr Serv. 2003 Sep;54(9):1233-9.\"}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000004194',\n",
       "          'ConditionMeshTerm': 'Disease'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000003865',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder, Major'},\n",
       "         {'ConditionMeshId': 'D000019263',\n",
       "          'ConditionMeshTerm': 'Dysthymic Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010335',\n",
       "          'ConditionAncestorTerm': 'Pathologic Processes'},\n",
       "         {'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafAsFound': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M19831',\n",
       "          'ConditionBrowseLeafName': 'Dysthymic Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Dysthymic Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 93,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01027559',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '081348'},\n",
       "       'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01MH064821',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH064821&Fy=all'},\n",
       "         {'SecondaryId': '2R01MH064821-05A2',\n",
       "          'SecondaryIdType': 'U.S. NIH Grant/Contract',\n",
       "          'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=2R01MH064821-05A2&Fy=all'},\n",
       "         {'SecondaryId': 'DDTR A3-NSI',\n",
       "          'SecondaryIdType': 'Other Grant/Funding Number',\n",
       "          'SecondaryIdDomain': 'National Institute of Mental Health'}]},\n",
       "       'Organization': {'OrgFullName': 'Washington University School of Medicine',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'fMRI Study of Treatment Changes in Major Depression',\n",
       "       'OfficialTitle': 'fMRI Studies of Emotional Circuitry in Major Depression: Treatment Changes'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'June 2018',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'February 2009'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2014',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'January 2014',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'December 4, 2009',\n",
       "       'StudyFirstSubmitQCDate': 'December 4, 2009',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 8, 2009',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'June 15, 2016',\n",
       "       'ResultsFirstSubmitQCDate': 'May 11, 2018',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'June 13, 2018',\n",
       "        'ResultsFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'June 18, 2018',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 17, 2018',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Washington University School of Medicine',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Mental Health (NIMH)',\n",
       "          'CollaboratorClass': 'NIH'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'The overall purposes of this research are to determine if Cognitive Behavioral Therapy (CBT) has the same healing effect on the brain for people with depression as traditional antidepressants do, and in comparison to healthy controls with no history of depression, to find out more about the causes of depression including differences in the extent of problems caused by depression. We hypothesize that CBT will have the same healing effect on the brain as antidepressants; that differences in brain activations created by the various tasks and genetic differences will help us understand differences in the type and severity of symptoms among the depressed subjects.',\n",
       "       'DetailedDescription': 'The overall purposes of this research are to determine if Cognitive Behavioral Therapy (CBT) has the same healing effect on the brain for people with depression as traditional antidepressants do, to find out more about the causes of depression and why people differ in the extent of problems caused by depression, and to determine if certain differences in genes within populations are related to clinical symptoms.Genes we are examining for this study are COMT, BDNF, and 5-HTT long arm and short arm, as well as future genes that may be discovered to play a role in depression at a later time, and will be determined by examining saliva and blood samples. We are primarily studying depression by functional Magnetic Resonance Imaging (fMRI) which allows us to identify certain parts of the brain that show how the brain works in controlling negative feelings. Participants will be imaged while performing different tasks that are believed to activate emotional circuitry of the brain. Comparisons of activation patterns across these tasks will be used to characterize the cognitive mechanisms supported by different cortical regions, and to determine patterns of functional brain deficits in subjects with depression. Comparisons will also be made between changes that occur after treatment with an approved antidepressant and treatment with CBT.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Major Depression',\n",
       "         'Treatment']},\n",
       "       'KeywordList': {'Keyword': ['Major Depression',\n",
       "         'Functional Magnetic Resonance Imaging',\n",
       "         'Emotional Circuitry',\n",
       "         'Cognitive Behavioral Therapy']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Other',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '97',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Depressed Group: CBT',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive Behavioral Therapy']}},\n",
       "         {'ArmGroupLabel': 'Healthy Control Group',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.'},\n",
       "         {'ArmGroupLabel': 'Depressed Group: SRT',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Depressed participants randomized to receive the antidepressant sertraline (SRT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Sertraline']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Drug',\n",
       "          'InterventionName': 'Sertraline',\n",
       "          'InterventionDescription': 'Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depressed Group: SRT']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['SRT']}},\n",
       "         {'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Cognitive Behavioral Therapy',\n",
       "          'InterventionDescription': 'Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Depressed Group: CBT']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['CBT']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Blood Oxygen-level Dependent Activations During an Emotional Distractor Task Between fMRI Scans of Depressed Participants in the CBT Group and Control Participants.',\n",
       "          'PrimaryOutcomeDescription': 'MRI imaging was completed on 50 participants (26 depressed who were randomized to the CBT group and 24 controls) for this analysis, including fMRI scans to evaluate regional brain activation in depression during an emotional distractor task. Image data from their baseline visit was processed and analyzed to show differences in blood oxygen-level dependent (BOLD) activations between depressed participants in the CBT group and control participants in a priori regions (amygdala and dorsolateral prefrontal cortex) during the task. The specified regions were masked on the images, and voxel-wise comparisons (ANOVAs) were performed to determine differences in activations between groups within these masked regions Positive values reflect a BOLD activation in that region; negative reflects a BOLD de-activation in that region.',\n",
       "          'PrimaryOutcomeTimeFrame': 'baseline visit and 8-week follow-up'},\n",
       "         {'PrimaryOutcomeMeasure': 'Hamilton Depression Rating Scale Score at Baseline and 12 Weeks',\n",
       "          'PrimaryOutcomeDescription': 'The patient was rated by a research team member among 17 dimensions/items pertaining to depression symptoms experienced over the last week. Each item is scored from 0 (=absent), up to 2 or 4 (depending on the item). The maximum total score on the assessment, indicating the most severe depression, would be 52. A total score of 0-7 is considered to be normal. Total scores of 20 or higher indicate moderate, severe, or very severe depression. A 50% or greater drop in Hamilton Depression Rating Scale signifies response to treatment.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline and 12 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'DEPRESSED GROUP:\\n\\nInclusion criteria:\\n\\nAge 18-50\\nDSM-IV criteria for major depressive disorder (MDD)\\nMinimum Hamilton Rating Scale for Depression (HAMD) score > 18\\nRight handed\\nCapacity to give informed consent and follow study procedures\\nEnglish speaking\\n\\nExclusion criteria:\\n\\nCannot give informed consent\\nSignificant handicaps (e.g. visual or hearing loss, mental retardation) that would interfere with testing procedures\\nDoes not speak English\\nKnown primary neurological disorders\\nAny other factor that in the investigators judgment may affect patient safety or compliance (e.g. distance greater than 100 miles from clinic)\\nMRI contraindications e.g. foreign metallic implants, pacemaker\\nKnown allergy or hypersensitivity to sertraline\\nActive suicidality\\nSevere or unstable medical illness or conditions or drugs that may cause depression\\nAny of the following diagnosed by DSM-IV: alcohol or substance abuse disorder, schizophrenia or other psychotic disorder, bipolar disorder, psychotic features of depression, current obsessive compulsive disorder (OCD) or panic disorder. In general, subjects with a history of other Axis I disorders prior to their depression will be excluded.\\nCurrent episode has failed to respond to adequate trials of two prior antidepressants for at least 6 weeks at therapeutic doses.\\nTreatment with sertraline for at least one month in past 3 months.\\nCurrent use of psychotropic prescription or nonprescription drugs or herbals (e.g. hypericum) except for limited use of certain hypnotics.\\nCurrent psychotherapy\\nTreatment with psychotropic drugs or drugs that affect the CNS such as beta-blockers or mood stabilizers.\\n\\nCONTROL GROUP:\\n\\nInclusion criteria:\\n\\nAge 18-50\\nNo history of MDD\\nHAMD score < 7\\nRight handed\\nCapacity to give informed consent and follow study procedures\\nEnglish speaking\\n\\nExclusion criteria:\\n\\nCannot give informed consent\\nSignificant handicaps (e.g. visual or hearing loss, mental retardation) that would interfere with testing procedures\\nDoes not speak English\\nKnown primary neurological disorders\\nAny other factor that in the investigators judgment may affect patient safety or compliance (e.g. distance greater than 100 miles from clinic)\\nMRI contraindications e.g. foreign metallic implants, pacemaker\\nSevere or unstable medical illness or conditions or drugs that may cause depression\\nAny of the following diagnosed by DSM-IV: alcohol or substance abuse disorder, schizophrenia or other psychotic disorder, bipolar disorder, major depression, OCD or panic disorder.\\nCurrent use of psychotropic prescription or nonprescription drugs or herbals (e.g. hypericum) except for limited use of certain hypnotics.\\nTreatment with psychotropic drugs or drugs that affect the CNS such as beta-blockers or mood stabilizers.',\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '50 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Yvette I Sheline, MD',\n",
       "          'OverallOfficialAffiliation': 'University of Pennsylvania',\n",
       "          'OverallOfficialRole': 'Principal Investigator'},\n",
       "         {'OverallOfficialName': 'Charles Conway, MD',\n",
       "          'OverallOfficialAffiliation': 'Washington University School of Medicine',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Washington University',\n",
       "          'LocationCity': 'Saint Louis',\n",
       "          'LocationState': 'Missouri',\n",
       "          'LocationZip': '63110',\n",
       "          'LocationCountry': 'United States'}]}}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'Prior to being assigned to a group, 6 depressed participants dropped from the study before being assigned to treatment type.',\n",
       "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Depressed Group: CBT',\n",
       "          'FlowGroupDescription': 'Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nCognitive Behavioral Therapy: Visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and HAMD administration will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84.'},\n",
       "         {'FlowGroupId': 'FG001',\n",
       "          'FlowGroupTitle': 'Healthy Control Group',\n",
       "          'FlowGroupDescription': 'Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.'},\n",
       "         {'FlowGroupId': 'FG002',\n",
       "          'FlowGroupTitle': 'Depressed Group: Sertraline',\n",
       "          'FlowGroupDescription': 'Depressed participants randomized to receive sertraline (SRT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nSertraline: Visits will involve dispensing medication, side effects assessment and HAMD administration occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response.'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '26'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '34'},\n",
       "               {'FlowAchievementGroupId': 'FG002',\n",
       "                'FlowAchievementNumSubjects': '31'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '20'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '26'},\n",
       "               {'FlowAchievementGroupId': 'FG002',\n",
       "                'FlowAchievementNumSubjects': '22'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '6'},\n",
       "               {'FlowAchievementGroupId': 'FG001',\n",
       "                'FlowAchievementNumSubjects': '8'},\n",
       "               {'FlowAchievementGroupId': 'FG002',\n",
       "                'FlowAchievementNumSubjects': '9'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselinePopulationDescription': 'A total of 97 participants enrolled in the study (63 depressed and 34 controls). Of the 63 depressed participants enrolled in the study, 57 (26 CBT and 31 SRT) were assigned to a treatment group and completed at least some study-related activities. Six depressed participants dropped from the study before being assigned to treatment type.',\n",
       "       'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Depressed Group: CBT',\n",
       "          'BaselineGroupDescription': 'Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nCognitive Behavioral Therapy: Visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and HAMD administration will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84.'},\n",
       "         {'BaselineGroupId': 'BG001',\n",
       "          'BaselineGroupTitle': 'Depressed Group: SRT',\n",
       "          'BaselineGroupDescription': 'Depressed participants randomized to receive sertraline (SRT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nSertraline: Visits will involve dispensing medication, side effects assessment and HAMD administration occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response.'},\n",
       "         {'BaselineGroupId': 'BG002',\n",
       "          'BaselineGroupTitle': 'Healthy Control Group',\n",
       "          'BaselineGroupDescription': 'Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.'},\n",
       "         {'BaselineGroupId': 'BG003',\n",
       "          'BaselineGroupTitle': 'Total',\n",
       "          'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '26'},\n",
       "            {'BaselineDenomCountGroupId': 'BG001',\n",
       "             'BaselineDenomCountValue': '31'},\n",
       "            {'BaselineDenomCountGroupId': 'BG002',\n",
       "             'BaselineDenomCountValue': '34'},\n",
       "            {'BaselineDenomCountGroupId': 'BG003',\n",
       "             'BaselineDenomCountValue': '91'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Full Range',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '31.54',\n",
       "                   'BaselineMeasurementLowerLimit': '18',\n",
       "                   'BaselineMeasurementUpperLimit': '48'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '33.29',\n",
       "                   'BaselineMeasurementLowerLimit': '19',\n",
       "                   'BaselineMeasurementUpperLimit': '49'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '31.64',\n",
       "                   'BaselineMeasurementLowerLimit': '18',\n",
       "                   'BaselineMeasurementUpperLimit': '48'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '32.16',\n",
       "                   'BaselineMeasurementLowerLimit': '18',\n",
       "                   'BaselineMeasurementUpperLimit': '49'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex/Gender, Customized',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Female',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '19'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '26'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '28'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '77'}]}}]}},\n",
       "            {'BaselineClassTitle': 'Male',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '7'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '5'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '19'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Number',\n",
       "          'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '26'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG001',\n",
       "                   'BaselineMeasurementValue': '31'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG002',\n",
       "                   'BaselineMeasurementValue': '34'},\n",
       "                  {'BaselineMeasurementGroupId': 'BG003',\n",
       "                   'BaselineMeasurementValue': '91'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Blood Oxygen-level Dependent Activations During an Emotional Distractor Task Between fMRI Scans of Depressed Participants in the CBT Group and Control Participants.',\n",
       "          'OutcomeMeasureDescription': 'MRI imaging was completed on 50 participants (26 depressed who were randomized to the CBT group and 24 controls) for this analysis, including fMRI scans to evaluate regional brain activation in depression during an emotional distractor task. Image data from their baseline visit was processed and analyzed to show differences in blood oxygen-level dependent (BOLD) activations between depressed participants in the CBT group and control participants in a priori regions (amygdala and dorsolateral prefrontal cortex) during the task. The specified regions were masked on the images, and voxel-wise comparisons (ANOVAs) were performed to determine differences in activations between groups within these masked regions Positive values reflect a BOLD activation in that region; negative reflects a BOLD de-activation in that region.',\n",
       "          'OutcomeMeasurePopulationDescription': 'fMRI data from a total of 26 depressed participants randomized to receive CBT and 24 control participants was analyzed. The primary aim was to compare depressed and control participants to evaluate regional brain activation during an emotional task, both at baseline and 8-week follow-up. The primary regions analyzed were the amygdala and DLPFC.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'Voxels',\n",
       "          'OutcomeMeasureTimeFrame': 'baseline visit and 8-week follow-up',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Depressed Group',\n",
       "             'OutcomeGroupDescription': 'Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.\\n\\nCognitive Behavioral Therapy: Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Healthy Control Group',\n",
       "             'OutcomeGroupDescription': 'Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '26'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '24'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Amygdala - baseline',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '-18.74',\n",
       "                   'OutcomeMeasurementSpread': '98.45'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '2.71',\n",
       "                   'OutcomeMeasurementSpread': '141.09'}]}}]}},\n",
       "            {'OutcomeClassTitle': 'DLPFC - baseline',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '316.24',\n",
       "                   'OutcomeMeasurementSpread': '199.83'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '411.2',\n",
       "                   'OutcomeMeasurementSpread': '241.53'}]}}]}},\n",
       "            {'OutcomeClassTitle': 'Amygdala - Time 2',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '-16.82',\n",
       "                   'OutcomeMeasurementSpread': '108.55'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '-46.06',\n",
       "                   'OutcomeMeasurementSpread': '97.10'}]}}]}},\n",
       "            {'OutcomeClassTitle': 'DLPFC - Time 2',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '403.72',\n",
       "                   'OutcomeMeasurementSpread': '248.02'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '421.51',\n",
       "                   'OutcomeMeasurementSpread': '231.33'}]}}]}}]}},\n",
       "         {'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Hamilton Depression Rating Scale Score at Baseline and 12 Weeks',\n",
       "          'OutcomeMeasureDescription': 'The patient was rated by a research team member among 17 dimensions/items pertaining to depression symptoms experienced over the last week. Each item is scored from 0 (=absent), up to 2 or 4 (depending on the item). The maximum total score on the assessment, indicating the most severe depression, would be 52. A total score of 0-7 is considered to be normal. Total scores of 20 or higher indicate moderate, severe, or very severe depression. A 50% or greater drop in Hamilton Depression Rating Scale signifies response to treatment.',\n",
       "          'OutcomeMeasurePopulationDescription': 'Numbers may differ from Participant Flow but these are the totals of those participants who had data at this time point for the Hamilton Depression Rating Scale.',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'Baseline and 12 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Depressed Group: CBT',\n",
       "             'OutcomeGroupDescription': 'Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nCognitive Behavioral Therapy: Visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and HAMD administration will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84.'},\n",
       "            {'OutcomeGroupId': 'OG001',\n",
       "             'OutcomeGroupTitle': 'Healthy Control Group',\n",
       "             'OutcomeGroupDescription': 'Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.'},\n",
       "            {'OutcomeGroupId': 'OG002',\n",
       "             'OutcomeGroupTitle': 'Depressed Group: Sertraline',\n",
       "             'OutcomeGroupDescription': 'Depressed participants randomized to receive sertraline (SRT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nSertraline: Visits will involve dispensing medication, side effects assessment and Hamilton Depression Rating Scale (HAMD) administration occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response.'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '18'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG001',\n",
       "                'OutcomeDenomCountValue': '15'},\n",
       "               {'OutcomeDenomCountGroupId': 'OG002',\n",
       "                'OutcomeDenomCountValue': '14'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '19.94',\n",
       "                   'OutcomeMeasurementSpread': '5.23'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '1.38',\n",
       "                   'OutcomeMeasurementSpread': '1.33'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
       "                   'OutcomeMeasurementValue': '20.79',\n",
       "                   'OutcomeMeasurementSpread': '3.98'}]}}]}},\n",
       "            {'OutcomeClassTitle': 'Week 12',\n",
       "             'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '5.94',\n",
       "                   'OutcomeMeasurementSpread': '6.08'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                   'OutcomeMeasurementValue': '1.07',\n",
       "                   'OutcomeMeasurementSpread': '1.33'},\n",
       "                  {'OutcomeMeasurementGroupId': 'OG002',\n",
       "                   'OutcomeMeasurementValue': '4.43',\n",
       "                   'OutcomeMeasurementSpread': '5.37'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '5',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Depressed Group: CBT',\n",
       "          'EventGroupDescription': 'Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nCognitive Behavioral Therapy: Visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and HAMD administration will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84.',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '26',\n",
       "          'EventGroupOtherNumAffected': '7',\n",
       "          'EventGroupOtherNumAtRisk': '26'},\n",
       "         {'EventGroupId': 'EG001',\n",
       "          'EventGroupTitle': 'Healthy Control Group',\n",
       "          'EventGroupDescription': 'Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '34',\n",
       "          'EventGroupOtherNumAffected': '2',\n",
       "          'EventGroupOtherNumAtRisk': '34'},\n",
       "         {'EventGroupId': 'EG002',\n",
       "          'EventGroupTitle': 'Depressed Group: SSRI (Selective Serotonin Re-Uptake Inhibitor',\n",
       "          'EventGroupDescription': 'Depressed participants randomized to receive setraline (SRT) for treatment. fMRI scan session occurs immediately prior to starting treatment, and a second fMRI scan will occur following 12 weeks of therapy.\\n\\nSertraline: Visits will involve dispensing medication, side effects assessment and HAMD administration occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response.',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '31',\n",
       "          'EventGroupOtherNumAffected': '21',\n",
       "          'EventGroupOtherNumAtRisk': '31'}]},\n",
       "       'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Constipation',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '6',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Sedation/Drowsiness',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '4',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '17',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Excitement/Weakness',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '5',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Headache',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '12',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Nausea/Vomitting',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '10',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Stomach/Abdominal Pain',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '5',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Irritability',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '5',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '8',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Muscle Twitching',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '8',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Tremor',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '4',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Decreased Appetite',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '8',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Increased Appetite',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '5',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Weight Gain',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '5',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Insomnia',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '7',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Dry Mouth',\n",
       "          'OtherEventOrganSystem': 'Immune system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '10',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Decreased Libido',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '7',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Malaise',\n",
       "          'OtherEventOrganSystem': 'Immune system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '5',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Impaired Mentation',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '4',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Hyperventilation',\n",
       "          'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '4',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Dizziness/Faintness',\n",
       "          'OtherEventOrganSystem': 'Ear and labyrinth disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '8',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Sexual Dysfunction',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '6',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Diarrhea',\n",
       "          'OtherEventOrganSystem': 'Gastrointestinal disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '5',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Nasal Congestion',\n",
       "          'OtherEventOrganSystem': 'Immune system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '8',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Excessive Sweating',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '4',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Back Pain',\n",
       "          'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
       "          'OtherEventNotes': 'Back pain/stiffness from taking part in the MRI scan',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Chest Pain',\n",
       "          'OtherEventOrganSystem': 'Vascular disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Panic',\n",
       "          'OtherEventOrganSystem': 'Psychiatric disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Slurred Speech',\n",
       "          'OtherEventOrganSystem': 'Nervous system disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '1',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Difficulty Hearing/Tinnitus',\n",
       "          'OtherEventOrganSystem': 'Ear and labyrinth disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Increased Libido',\n",
       "          'OtherEventOrganSystem': 'Vascular disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Syncope',\n",
       "          'OtherEventOrganSystem': 'Vascular disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Blurred Vision',\n",
       "          'OtherEventOrganSystem': 'Eye disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Increased Salivation',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Tachycardia/Palpitations',\n",
       "          'OtherEventOrganSystem': 'Cardiac disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Menstrual Irregularity',\n",
       "          'OtherEventOrganSystem': 'Reproductive system and breast disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Weight Loss',\n",
       "          'OtherEventOrganSystem': 'General disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '3',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}},\n",
       "         {'OtherEventTerm': 'Abnormal Muscle Tone/Movements',\n",
       "          'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders',\n",
       "          'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '26'},\n",
       "            {'OtherEventStatsGroupId': 'EG001',\n",
       "             'OtherEventStatsNumAffected': '0',\n",
       "             'OtherEventStatsNumAtRisk': '34'},\n",
       "            {'OtherEventStatsGroupId': 'EG002',\n",
       "             'OtherEventStatsNumAffected': '2',\n",
       "             'OtherEventStatsNumAtRisk': '31'}]}}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
       "        'AgreementRestrictiveAgreement': 'No'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Dr. Yvette Sheline',\n",
       "        'PointOfContactOrganization': 'University of Pennsylvania',\n",
       "        'PointOfContactEMail': 'sheline@pennmedicine.upenn.edu',\n",
       "        'PointOfContactPhone': '215-573-0082'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000020280',\n",
       "          'InterventionMeshTerm': 'Sertraline'}]},\n",
       "       'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000928',\n",
       "          'InterventionAncestorTerm': 'Antidepressive Agents'},\n",
       "         {'InterventionAncestorId': 'D000011619',\n",
       "          'InterventionAncestorTerm': 'Psychotropic Drugs'},\n",
       "         {'InterventionAncestorId': 'D000017367',\n",
       "          'InterventionAncestorTerm': 'Serotonin Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000014179',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Uptake Inhibitors'},\n",
       "         {'InterventionAncestorId': 'D000049990',\n",
       "          'InterventionAncestorTerm': 'Membrane Transport Modulators'},\n",
       "         {'InterventionAncestorId': 'D000045504',\n",
       "          'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "         {'InterventionAncestorId': 'D000018377',\n",
       "          'InterventionAncestorTerm': 'Neurotransmitter Agents'},\n",
       "         {'InterventionAncestorId': 'D000018490',\n",
       "          'InterventionAncestorTerm': 'Serotonin Agents'},\n",
       "         {'InterventionAncestorId': 'D000045505',\n",
       "          'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]},\n",
       "       'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M20684',\n",
       "          'InterventionBrowseLeafName': 'Sertraline',\n",
       "          'InterventionBrowseLeafAsFound': 'Sertraline',\n",
       "          'InterventionBrowseLeafRelevance': 'high'},\n",
       "         {'InterventionBrowseLeafId': 'M2828',\n",
       "          'InterventionBrowseLeafName': 'Antidepressive Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M13057',\n",
       "          'InterventionBrowseLeafName': 'Psychotropic Drugs',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M14095',\n",
       "          'InterventionBrowseLeafName': 'Serotonin',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M18232',\n",
       "          'InterventionBrowseLeafName': 'Serotonin Uptake Inhibitors',\n",
       "          'InterventionBrowseLeafRelevance': 'low'},\n",
       "         {'InterventionBrowseLeafId': 'M19088',\n",
       "          'InterventionBrowseLeafName': 'Neurotransmitter Agents',\n",
       "          'InterventionBrowseLeafRelevance': 'low'}]},\n",
       "       'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr',\n",
       "          'InterventionBrowseBranchName': 'Psychotropic Drugs'},\n",
       "         {'InterventionBrowseBranchAbbrev': 'All',\n",
       "          'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'},\n",
       "         {'ConditionMeshId': 'D000003865',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder, Major'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5643',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder, Major',\n",
       "          'ConditionBrowseLeafAsFound': 'Major Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 94,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03988985',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'UHHamburgEppendorfGetFeedback'},\n",
       "       'Organization': {'OrgFullName': 'Universitätsklinikum Hamburg-Eppendorf',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Enhancing the Clinical Effectiveness of Depression Screening Using Patient-targeted Feedback in General Practices',\n",
       "       'OfficialTitle': 'Enhancing the Clinical Effectiveness of Depression Screening Using Patient-targeted Feedback in General Practices: The GET.FEEDBACK.GP Multicentre Randomized Controlled Trial'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'September 2019',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'July 17, 2019',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 18, 2022',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'April 28, 2022',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'June 4, 2019',\n",
       "       'StudyFirstSubmitQCDate': 'June 15, 2019',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 18, 2019',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'September 5, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 6, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Universitätsklinikum Hamburg-Eppendorf',\n",
       "        'LeadSponsorClass': 'OTHER'},\n",
       "       'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Federal Joint Committee, Germany',\n",
       "          'CollaboratorClass': 'UNKNOWN'}]}},\n",
       "      'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': \"The multi-center GET.FEEDBACK.GP randomized controlled trial is designed based on patients' needs and preferences. In order to evaluate the effect of feedback in the broader setting of primary care, a total of 1076 primary care patients with elevated levels of depression (PHQ-9 score ≥ 10) will be randomized into three groups who either receive a) patient-targeted and physician-targeted feedback of depression screening results, b) a physician-targeted feedback of depression screening results only, or c) no feedback of screening results. The primary study outcome is depression severity after 6 months, secondary outcomes include the patients' behavior and cognitions after the screening, depression care according to German guideline recommendations and the health economic evaluation.\",\n",
       "       'DetailedDescription': \"Major depression is one of the most significant clinical disorders. In primary care, every sixth patient suffers from increased depression level, which is associated with higher risk of suicide, increased risk of onset and progression of chronic physical conditions. Still, depression is under recognized and undertreated in primary care. Moreover, evidence regarding the efficacy of depression screening in primary care is insufficient to draw clear conclusions. Our previous mono-center depression screening trial in cardiac patients, provides first evidence that written patient-targeted feedback improves depression severity, encourages greater patient participation and engagement in mental health. To amplify these effects, the multi-center GET.FEEDBACK.GP randomized controlled trial is now designed based on patients' needs and preferences. In order to evaluate the effect of feedback in the broader setting of primary care, a total of 1076 primary care patients with elevated levels of depression (PHQ-9 score ≥ 10) will be randomized into three groups who either receive a) patient-targeted and physician-targeted feedback of depression screening results, b) a physician-targeted feedback of depression screening results only, or c) no feedback of screening results. The primary study outcome is depression severity after 6 months, secondary outcomes include the patients' behavior and cognitions after the screening, depression care according to German guideline recommendations and the health economic evaluation.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Depression',\n",
       "         'Screening',\n",
       "         'Primary Care',\n",
       "         'General Practice',\n",
       "         'Feedback']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Factorial Assignment',\n",
       "        'DesignPrimaryPurpose': 'Screening',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '1074',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'PATIENT-GP-FEEDBACK',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Using a randomized-controlled study design one third of the patients and their attending general practitioner will receive feedback after depression screening. The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Patient-targeted feedback',\n",
       "            'Other: GP-targeted feedback']}},\n",
       "         {'ArmGroupLabel': 'GP-FEEDBACK',\n",
       "          'ArmGroupType': 'Active Comparator',\n",
       "          'ArmGroupDescription': 'Using a randomized-controlled study design in one third of the cases only the attending general practitioner will receive feedback after depression screening. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: GP-targeted feedback']}},\n",
       "         {'ArmGroupLabel': 'NO-FEEDBACK',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Using a randomized-controlled study design one third of the patients and their attending general practitioner will not receive any feedback.'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Patient-targeted feedback',\n",
       "          'InterventionDescription': 'The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['PATIENT-GP-FEEDBACK']}},\n",
       "         {'InterventionType': 'Other',\n",
       "          'InterventionName': 'GP-targeted feedback',\n",
       "          'InterventionDescription': 'The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['GP-FEEDBACK',\n",
       "            'PATIENT-GP-FEEDBACK']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression severity (Questionnaire: Patient Health Questionnaire-9)',\n",
       "          'PrimaryOutcomeDescription': 'Level of depression severity six months after screening (Patient Health Questionnaire-9)',\n",
       "          'PrimaryOutcomeTimeFrame': 'Six months after screening'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depression severity (Questionnaire: Patient Health Questionnaire-9)',\n",
       "          'SecondaryOutcomeDescription': 'Level of depression severity one and twelve months after screening (Questionnaire: Patient Health Questionnaire-9)',\n",
       "          'SecondaryOutcomeTimeFrame': 'One and twelve months after screening'},\n",
       "         {'SecondaryOutcomeMeasure': 'Depression treatment',\n",
       "          'SecondaryOutcomeDescription': 'Proportion of patients treated according to German Guideline based recommendations',\n",
       "          'SecondaryOutcomeTimeFrame': 'Six and twelve months after screening'},\n",
       "         {'SecondaryOutcomeMeasure': 'Health economic Evaluation (Questionnaire: Client Sociodemographic and Service Receipt Inventory)',\n",
       "          'SecondaryOutcomeDescription': 'Direct and indirect health costs (Client Sociodemographic and Service Receipt Inventory)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Six and twelve months after screening'},\n",
       "         {'SecondaryOutcomeMeasure': 'Quality-adjusted life years (Questionnaire: EuroQol-5D)',\n",
       "          'SecondaryOutcomeDescription': 'Quality-adjusted years of life and quality of life (EuroQol-5D)',\n",
       "          'SecondaryOutcomeTimeFrame': 'Six and twelve months after screening'},\n",
       "         {'SecondaryOutcomeMeasure': 'Anxiety (Questionnaire: Generalized Anxiety Disorder-7)',\n",
       "          'SecondaryOutcomeDescription': 'Level of anxiety severity one, six and twelve months after screening',\n",
       "          'SecondaryOutcomeTimeFrame': 'One, six and twelve months after screening'},\n",
       "         {'SecondaryOutcomeMeasure': 'Somatic symptom severity (Questionnaire: Somatic Symptom Scale-8)',\n",
       "          'SecondaryOutcomeDescription': 'Level of somatic symptom severity one, six and twelve months after screening',\n",
       "          'SecondaryOutcomeTimeFrame': 'One, six and twelve months after screening'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nGender: male, female, diverse\\nMaximum Age: no maximum age\\nAttendance in primary care with medical consultation\\nAge ≥ 18 years;\\nSufficient language skills;\\nInformed consent\\nPatient Health Questionnaire-9 > 9 points\\n\\nExclusion Criteria:\\n\\nLife threatening health status;\\nSevere somatic or/and psychological disorder that needs urgent treatment;\\nKnown diagnosis of a depressive disorder\\nCurrent depression treatment\\nAcute suicidal tendency;\\nSevere cognitive or/and visual difficulties;\\nNot being able to fill out questionnaires\\nNo contact details',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Sebastian Kohlmann, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '+49 40 7410 54321',\n",
       "          'CentralContactEMail': 's.kohlmann@uke.de'},\n",
       "         {'CentralContactName': 'Bernd Löwe, MD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '+49 40 7410 53992',\n",
       "          'CentralContactEMail': 'b.loewe@uke.de'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Bernd Löwe, MD',\n",
       "          'OverallOfficialAffiliation': 'Director of the Department of Psychosomatic Medicine and Psychotherapy',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Technical University of Munich - Medical Faculty',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Munich',\n",
       "          'LocationState': 'Bavaria',\n",
       "          'LocationZip': '80333',\n",
       "          'LocationCountry': 'Germany',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Antonius Schneider, MD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '+49 89 / 6146589-11',\n",
       "             'LocationContactEMail': 'antonius.schneider@tum.de'},\n",
       "            {'LocationContactName': 'Klaus Linde, MD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactEMail': 'Klaus.Linde@mri.tum.de'}]}},\n",
       "         {'LocationFacility': 'University Medical Center Hamburg',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Hamburg',\n",
       "          'LocationZip': '20246',\n",
       "          'LocationCountry': 'Germany',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Bernd Löwe, MD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '+49 40-7410-59733',\n",
       "             'LocationContactEMail': 'b.loewe@uke.de'},\n",
       "            {'LocationContactName': 'Sebastian Kohlmann, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '+49 40-7410-54321',\n",
       "             'LocationContactEMail': 's.kohlmann@uke.de'}]}}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 95,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01633996',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': '2002-P-001899'},\n",
       "       'Organization': {'OrgFullName': 'Massachusetts General Hospital',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Effectiveness of Acupuncture for Depressed Patients Taking Antidepressant Medications',\n",
       "       'OfficialTitle': 'Effectiveness of Acupuncture Augmentation on Treatment Resistant Depressed Patients'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2012',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'August 2007'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2010',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'April 2010',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'June 15, 2012',\n",
       "       'StudyFirstSubmitQCDate': 'July 2, 2012',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 6, 2012',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 2, 2012',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 6, 2012',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Albert Yeung',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Director of Primary Care Research, Depression Clinical and Research Program',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Massachusetts General Hospital'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Massachusetts General Hospital',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': \"In this research study, the investigators piloted a uniform acupuncture treatment protocol among adults with depression who were taking an antidepressant medication that was providing only partial or no symptom alleviation. The study's aims were evaluate the efficacy, safety, and tolerability of acupuncture augmentation treatment among this population. The investigators hypothesized that acupuncture as an augmentation treatment would be associated with a response rate of at least 50%, which the investigators defined as a decrease in depressive symptoms from the beginning to the end of the study of 50% or more, and that the response would be greater among patients who received acupuncture 2 times per week (vs. 1 time per week). The investigators also hypothesized that acupuncture would be associated with minimal side effects.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Acupuncture',\n",
       "         'Antidepressant',\n",
       "         'Augmentation',\n",
       "         'Depression']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '45',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Acupuncture',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'All participants received open acupuncture augmentation treatment per the uniform acupuncture treatment protocol that we developed according to Traditional Chinese Medicine (TCM) principles for treating depression (see Intervention Description).',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Acupuncture']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Procedure',\n",
       "          'InterventionName': 'Acupuncture',\n",
       "          'InterventionDescription': 'Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Acupuncture']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Response to acupuncture augmentation treatment, defined as a change in scores on the Hamilton Depression Rating Scale, 17 items (HAM-D-17) from baseline to endpoint.',\n",
       "          'PrimaryOutcomeDescription': 'The HAM-D-17 is a clinician-rated measure of patient depressive symptoms (structured interview). Higher cumulative scores indicate more severe depression. A 50% or greater reduction in HAM-D-17 from baseline to endpoint was considered representative of our hypothesized acupuncture-augmentation response rate of at least 50%.',\n",
       "          'PrimaryOutcomeTimeFrame': 'Baseline and all acupuncture sessions (weekly) for 8 weeks'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"Evidence of acupuncture augmentation's tolerability and acceptability, as determined clinically by the participant and study doctor.\",\n",
       "          'SecondaryOutcomeTimeFrame': 'Once per acupuncture session (weekly) for 8 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAges 18-65\\nA HAM-D-17 score of >= 14\\nPartial or nonresponse to a standard antidepressant (monotherapy or combination) at an adequate dose over the past 8 or more weeks (natural agents such as omega-3 fatty acids, St John's wort, SAMe, and folic acid, were allowed as antidepressants)\\nConcurrent psychotherapy was allowed, provided that it was not initiated within the 3 months prior to study entry.\\n\\nExclusion Criteria:\\n\\nA primary diagnosis other than major depressive disorder, or any history of psychosis or mania\\nConditions that could make it difficult to conclusively determine that depressive symptoms were the result of major depression and not some other condition, including any form of substance abuse or dependence within the last 6 months, other medical conditions that could be the basis of a depression (including epilepsy, history of an abnormal EEG, severe head trauma, or stroke)\\nSerious uncontrolled medical conditions (e.g. poorly controlled diabetes, severe congestive heart failure), or other medical conditions that had not been stable for at least 3 months\\nHaving had electroconvulsive therapy (ECT) during the past year\\nCurrent active suicidal or self-injurious potential necessitating immediate treatment.\",\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '65 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Albert Yeung, MD, ScD',\n",
       "          'OverallOfficialAffiliation': 'Depression Clinical and Research Program, Massachusetts General Hospital',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Depression Clinical and Research Program, Massachusetts General Hospital',\n",
       "          'LocationCity': 'Boston',\n",
       "          'LocationState': 'Massachusetts',\n",
       "          'LocationZip': '02114',\n",
       "          'LocationCountry': 'United States'}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '20692042',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Yeung AS, Ameral VE, Chuzi SE, Fava M, Mischoulon D. A pilot study of acupuncture augmentation therapy in antidepressant partial and non-responders with major depressive disorder. J Affect Disord. 2011 Apr;130(1-2):285-9. doi: 10.1016/j.jad.2010.07.025. Epub 2010 Aug 6.'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 96,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02261818',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'K23MH100705',\n",
       "        'OrgStudyIdType': 'U.S. NIH Grant/Contract',\n",
       "        'OrgStudyIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=K23MH100705&Fy=all'},\n",
       "       'Organization': {'OrgFullName': 'Johns Hopkins University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Using Peer Mentors to Deliver Depression Care',\n",
       "       'OfficialTitle': 'Phase 1 Study of Using Peers to Deliver Depression Care to Older Adults'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'August 2017',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'April 2014'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'May 2015',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'August 1, 2014',\n",
       "       'StudyFirstSubmitQCDate': 'October 9, 2014',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 10, 2014',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'ResultsFirstSubmitDate': 'March 7, 2017',\n",
       "       'ResultsFirstSubmitQCDate': 'August 24, 2017',\n",
       "       'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'October 2, 2017',\n",
       "        'ResultsFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'August 24, 2017',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 2, 2017',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'Jin Hui Joo',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'Primary Investigator',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Johns Hopkins University'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Johns Hopkins University',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Can peer mentors be integrated into depression care to older adults with mental health professional supervision? We will assess whether peer mentors who are lay persons who are in recovery from depression can provide depression care services to older adults with depression. Older adults who are 50 and older will be screened for depression in the clinic and community. Those who meet criteria will be paired with a peer mentor for 8 meetings. Peer mentors will audiorecord their meetings with the patient and the recordings will be analyzed to assess what kinds of communication and behaviors the peer mentors engage in and what among those communications may be associated with relieving depression. The peer mentor will be trained and supervised by a psychiatrist and they will form a team to provide the depression care to the older adult. The study aims to relieve depressive symptoms and engage older adults in care. Both older adults and peer mentors wil be interviewed after the study to assess the strengths and weaknesses of peer mentor delivery of depression care. A manual will be developed describing the process and procedures of the study.',\n",
       "       'DetailedDescription': \"Recruitment of peer mentors. We will recruit peer mentors from a community organization who are in recovery and are recommended by the organization and have had basic training in supportive listening and experience working with persons in the community in need of mental health support. We will recruit 10 peer mentors, striving for a balance of men and women, and accounting for attrition, so that at least 5 peer mentors will participate in the project. The study doctor will meet and interview interested peers to screen for eligibility criteria, motivation and aptitude. Persons who do not meet criteria for continued participation in the study will be referred to other volunteer opportunities when appropriate.\\n\\nRecruitment of patients. Twenty patient participants will be recruited through the internal medicine and psychiatry clinics at Johns Hopkins Bayview Medical Center as well as the community. A research assistant will screen patients for depressive symptoms with the Patient Health Questionnaire-9 (PHQ-9). Patients meeting eligibility criteria will give written informed consent. Eligible patients will be scheduled for another appointment to meet with the study doctor in a private room at offices in the clinical campus.\\n\\nTraining of peer mentors. The PI and research assistant will conduct 5 sessions totaling 20 hours of training for the peer mentors. Training will refine the peer mentor's social support behaviors, which include the use of effective communication skills, rapport building, active listening, and sharing of experiential knowledge, and expression of empathy. Issues of cultural interviewing, cultural competence, patient confidentiality, DSM-IV diagnosis, differentiation of peer and professional roles and patient safety will be addressed. Knowledge regarding how mental health and illness presents itself in old age and the specific developmental problems older adults face will be provided. Training will include review of written materials, lectures, discussion of case studies and role play. Upon completion of the training, peer mentors will be assessed for mental health knowledge and interpersonal skills and those who pass muster will be matched with patients.\\n\\nThe peer mentor role: Activities of the peer mentor with the patient will be structured by the following principles which are derived from important elements of both peer support and psychotherapy and our preliminary work:\\n\\nPrinciples to structure peer mentor interactions with patients\\n\\nEstablish a working relationship\\nEstablish goals of meetings with patient\\nProvide active listening, empathy, reciprocity, mutual respect, provision of emotional support Provide support and encourage work toward patient-identified goals to relieve depression\\nWork on patient-identified goals by engaging multiple techniques as appropriate: sharing appropriate coping strategies eg. positive thinking, experiential knowledge, problem solving, consideration of different perspectives.\\nProvide psychoeducation. Discuss the kinds of depression services available, medications, psychotherapy Acknowledge socioeconomic contributors to depression\\nProvide information on community resources\\nConnect to professional clinical services if appropriate The psychiatrist role: Peer mentors will meet with the candidate who is a psychiatrist on a weekly basis. The psychiatrist will provide: (1) clinical leadership and structure by reinforcing the principles of the peer-patient meetings; and (2) supervision and coaching which will involve encouragement, continuing education, training and skill enhancement for the peer mentor. The psychiatrist will guide the peer mentor to ensure that a positive social experience is being provided and to manage the patient in a way that ensures the realization of the patient's goal. The peer mentor will share impressions of patient progress and receive any guidance needed from the psychiatrist.\\n\\nStudy procedures. After patient consent is obtained, the psychiatrist will meet with the patient for a clinical interview so that the psychiatrist can form an impression of the patient and provide relevant guidance to the peer mentor. The patient will then be matched with a peer mentor. The peer mentor will contact the patient by telephone to schedule a meeting and meet with the peer mentor at his home or in the clinic. The peer mentor will meet the patient weekly for 8 one-hour sessions. The peer mentors will meet individually on a weekly basis with the psychiatrist during the study period in a collaborative and supervisory effort regarding the care of the patient Data Analysis. Analysis will involve both quantitative and qualitative methods. We will identify measured factors related to engagement and depression response and remission so that we can understand how the delivery model may need to be tailored or modified. This analysis will consider depression response and remission and engagement as dependent variables, with other variables as predictors or effect modifiers. We will also carry out debriefing interviews with peers and patients in order to look for themes that will call attention to factors that are most salient to patients and peers.\\n\\nQuantitative analysis. Influential variables will be identified in the statistical models according to association with the dependent variables, namely 1) engagement in depression care defined as two or more sessions attended with the peer mentor, and 2) decrease in depressive symptoms which will be treated as a continuous variable.\\n\\nQualitative analysis. We will collect qualitative data to obtain the perspective of peer mentors and patients themselves regarding study processes and mediators from their point of view. Two semi-structured interviews with patients and peer mentors will be conducted by the PI at 4 weeks and upon completion of the study. The purpose will be to obtain feedback regarding positive and negative aspects of the peer delivery model which will provide perspectives different from the expert and valuable for that reason.\\n\\nANALYSIS OF PROCESS We will analyze the process of the peer mentor-patient interactions by 1) conducting an interaction analysis which will provide quantitative associations between communication elements and outcomes to determine which elements are salient to the effectiveness of the peer delivery model, and 2) conducting a qualitative analysis of the voice recordings to assess how the peer mentors implement the critical elements and how patients respond to them. The analyses of process will serve to determine the content of the training for peer mentors, the activities peers will perform with patients and manual development.\\n\\nThe Roter Interaction Analysis System (RIAS) is a widely used system for interaction assessment in medical contexts. The RIAS has demonstrated predictive validity to patient satisfaction, patient recall, and improvements in levels of emotional distress. Combined with quantitative process and outcome measures of care, statistical analysis can establish associations between specific communicative thematic categories and patient outcomes.\\n\\nData Analysis. We will evaluate the specific interactions between peer and patient employing the RIAS to investigate the specific interactions that are associated with engagement and depression response and remission so that we can refine the training required for peers and develop measures tapping effective interaction strategies. We will also carry out open-ended interviews with patients that complement the RIAS analysis to assess how the peer mentors implement the critical elements and how patients respond.\\n\\nQuantitative analysis. The voice recordings to be analyzed with the RIAS in Phase 2 are obtained from two sources: (1) 28 voice recordings of peer mentor-patient interactions were obtained in our preliminary work and (2) 160 voice recordings of peer mentor-patient interactions will be obtained in the pilot study proposed in this application. The PI will work with Dr. Roter's laboratory for consultation where coding, reliability testing, and data entry into an SPSS file will occur. We will draw upon our conceptual model as well as incorporate the results of the quantitative and qualitative analysis regarding mediators to construct peer mentor and patient communication profiles which will then be linked to outcomes. Those elements which are associated with outcomes should be the focus of peer mentor training and be integrated into the manual. We will use linear regression to assess the presence, strength, and statistical associations between RIAS categories and outcomes.\\n\\nQualitative analysis. The goal of qualitative analysis of the voice recordings will be to enrich the inferences we make using RIAS data to capture the nuances of what is occurring in the peer mentor-patient relationship. The PI and the research assistant will listen to the voice recordings of peer mentor-patient interactions at weeks 1, 4, and 8. They will mark and transcribe sections in the voice recordings that show how interaction elements such as affective exchange take place between the peer mentor and patient, and those sections that provide examples of variations in the methods the peer mentors use and the responses of the patients. The transcriptions will be coded and analyzed for themes. This analysis will contextualize the results of the RIAS analysis and provide knowledge about peer mentor communication and behavior.\\n\\nManual development: Knowledge obtained from the study will be developed into a manual which will form the basis for a larger peer mentor study.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['depression', 'aging', 'health services']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Health Services Research',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '30',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Meetings with peer mentors',\n",
       "          'ArmGroupType': 'Other',\n",
       "          'ArmGroupDescription': 'Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Meetings with peer mentors']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Meetings with peer mentors',\n",
       "          'InterventionDescription': 'Peer mentors provide social support to address depressive symptoms',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Meetings with peer mentors']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression With PHQ-9',\n",
       "          'PrimaryOutcomeDescription': 'PHQ-9 will be used to assess depression. The maximum score is 27. The scale is interpreted as follows: 0-4 no depression, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe.',\n",
       "          'PrimaryOutcomeTimeFrame': 'at 8 weeks'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPeer mentors: Inclusion criteria:\\n\\n50 years and older,\\nable to give informed consent;\\nreceived basic training in behavioral health,\\nhistory of depression.-\\n\\nPatients:\\n\\n50 years and older;\\nclinically significant depression (defined above);\\nable to communicate in English;\\nwilling to give informed consent\\n\\nExclusion Criteria:\\n\\nPeer mentors: Exclusion criteria:\\n\\nmeet current diagnostic criteria for Minor or Major Depressive Disorder;\\nmeet current diagnostic criteria for a psychotic disorder;\\nmeet current diagnostic criteria for substance abuse or dependence.\\n\\nPatients:\\n\\nmeet diagnostic criteria for mania or hypomania;\\nmeet diagnostic criteria for psychotic syndrome;\\nmeet diagnostic criteria for alcohol abuse or dependence;\\nacutely suicidal or psychotic; and,\\na score on the Mini-Mental State Examination (MMSE) <24.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '50 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jin Hui Joo, MA MA',\n",
       "          'OverallOfficialAffiliation': 'Johns Hopkins University',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Johns Hopkins Bayview Medical Center',\n",
       "          'LocationCity': 'Baltimore',\n",
       "          'LocationState': 'Maryland',\n",
       "          'LocationZip': '21224',\n",
       "          'LocationCountry': 'United States'}]}}},\n",
       "     'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'No pre-study details.',\n",
       "       'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "          'FlowGroupTitle': 'Meetings With Peer Mentors',\n",
       "          'FlowGroupDescription': 'Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.\\n\\nMeetings with peer mentors: Peer mentors provide peer support to address depressive symptoms'}]},\n",
       "       'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "          'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '30'}]}},\n",
       "            {'FlowMilestoneType': 'COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '27'}]}},\n",
       "            {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "             'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "                'FlowAchievementNumSubjects': '3'}]}}]}}]}},\n",
       "      'BaselineCharacteristicsModule': {'BaselinePopulationDescription': '30 participants',\n",
       "       'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "          'BaselineGroupTitle': 'Meetings With Peer Mentors',\n",
       "          'BaselineGroupDescription': 'Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.\\n\\nMeetings with peer mentors: Peer mentors provide social support to address depressive symptoms'}]},\n",
       "       'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "          'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "             'BaselineDenomCountValue': '30'}]}}]},\n",
       "       'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '0'}]}},\n",
       "               {'BaselineCategoryTitle': '>=65 years',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '30'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Age, Continuous',\n",
       "          'BaselineMeasureParamType': 'Mean',\n",
       "          'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "          'BaselineMeasureUnitOfMeasure': 'years',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '68.9',\n",
       "                   'BaselineMeasurementSpread': '6.6'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '23'}]}},\n",
       "               {'BaselineCategoryTitle': 'Male',\n",
       "                'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '7'}]}}]}}]}},\n",
       "         {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "          'BaselineMeasureParamType': 'Count of Participants',\n",
       "          'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "          'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "             'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                   'BaselineMeasurementValue': '30'}]}}]}}]}}]}},\n",
       "      'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "          'OutcomeMeasureTitle': 'Depression With PHQ-9',\n",
       "          'OutcomeMeasureDescription': 'PHQ-9 will be used to assess depression. The maximum score is 27. The scale is interpreted as follows: 0-4 no depression, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe.',\n",
       "          'OutcomeMeasurePopulationDescription': 'Patient participants',\n",
       "          'OutcomeMeasureReportingStatus': 'Posted',\n",
       "          'OutcomeMeasureParamType': 'Mean',\n",
       "          'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "          'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "          'OutcomeMeasureTimeFrame': 'at 8 weeks',\n",
       "          'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "             'OutcomeGroupTitle': 'Meetings With Peer Mentors',\n",
       "             'OutcomeGroupDescription': 'Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.\\n\\nMeetings with peer mentors: Peer mentors provide social support to address depressive symptoms'}]},\n",
       "          'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "             'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "                'OutcomeDenomCountValue': '27'}]}}]},\n",
       "          'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                   'OutcomeMeasurementValue': '7.7',\n",
       "                   'OutcomeMeasurementSpread': '7.7'}]}}]}}]}}]}},\n",
       "      'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "       'EventsTimeFrame': 'Over 8 weeks',\n",
       "       'EventsDescription': 'No adverse events',\n",
       "       'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "          'EventGroupTitle': 'Meetings With Peer Mentors',\n",
       "          'EventGroupDescription': 'Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.\\n\\nMeetings with peer mentors: Peer mentors provide social support to address depressive symptoms',\n",
       "          'EventGroupSeriousNumAffected': '0',\n",
       "          'EventGroupSeriousNumAtRisk': '30',\n",
       "          'EventGroupOtherNumAffected': '0',\n",
       "          'EventGroupOtherNumAtRisk': '30'}]}},\n",
       "      'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
       "        'AgreementRestrictiveAgreement': 'No'},\n",
       "       'PointOfContact': {'PointOfContactTitle': 'Dr Jin Hui Joo',\n",
       "        'PointOfContactOrganization': 'Johns Hopkins University',\n",
       "        'PointOfContactEMail': 'jjoo1@jhmi.edu',\n",
       "        'PointOfContactPhone': '4105502282',\n",
       "        'PointOfContactPhoneExt': '410'}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 97,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01783652',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'catch_it_2013'},\n",
       "       'Organization': {'OrgFullName': 'The University of Hong Kong',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Adapted and Translated, Adolescent Depression, Internet Intervention',\n",
       "       'OfficialTitle': 'Adaptation of a U.S. Internet Tool to Prevent Depression and Addiction in Hong Kong Adolescents'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'July 2014',\n",
       "       'OverallStatus': 'Unknown status',\n",
       "       'LastKnownStatus': 'Active, not recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'January 2013'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2015',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'July 2015',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'January 31, 2013',\n",
       "       'StudyFirstSubmitQCDate': 'February 4, 2013',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 5, 2013',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'July 10, 2014',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 11, 2014',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'The University of Hong Kong',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Objectives :\\n\\nThe key objective of this study is to develop new interventions that addresses the diverse needs and circumstances of Hong Kong adolescents with depressive symptoms in community settings. Collaboration between medical professionals and social workers may prevent the occurrence of depression and misguided attempts to self-treat with alcohol and / or drugs in our adolescents.\\n\\nMethods :\\n\\nTo address this intervention gap in the United States, Dr. Van Voorhees, a research collaborator of Dr. Chim and Dr. Ip, developed and conducted a phase 2 clinical trial of a primary care internet-based depression prevention intervention (CATCH-IT, Competent Adulthood Transition with Cognitive Behavioral Humanistic and Interpersonal training). It has been observed clinically that the strategy could reduce depressed mood, increased social support and reduced depressive episodes at 12 month follow-up.\\n\\nThe investigators now propose to study if an adaptation of the CATCH-IT website for Hong Kong Chinese adolescents may lead to significant reductions in depressed mood. In this pilot trial, the investigators propose to test the efficacy of the Adapted and Translated version of CATCH-IT (AT-CATCH) against the placebo approach in preventing the onset of depressive episodes in a group of adolescents (aged 13-17) who have depressive symptoms, but have not developed depression yet.The case group will have access to the AT-CATCH website while the control group will only be allow to use the anti-smoking website.\\n\\nThe investigators hypothesize that compared to youth in the control group, youth assigned to the AT-CATCH group will have a lower hazard ratio of major depressive episodes and decreased alcohol / drug use frequency over 2 years. Moreover, compared to youth in the control group, youth in the AT-CATCH program will demonstrate a steeper slope of improved symptoms through growth curve analysis and fewer depressed days over the study period.',\n",
       "       'DetailedDescription': \"Although efficacious psychological and pharmacological treatments for adolescent depression have been demonstrated, any single approach only helps about 50-75% of those treated. Furthermore, adolescents have low rates of care seeking, and many primary care patients find group therapy to be the least acceptable treatment for depression. Limited supply of mental health specialists make face-to-face counseling difficult to implement, hence the internet is a promising modality for the delivery of preventive interventions. Therefore, prevention of depression in at-risk adolescents may be more cost-effective and less distressing than allowing for the depressive symptoms to become more severe.\\n\\nKey issues - international level:\\n\\nAs proposed by the World Health Organization (WHO) and National Institute of Mental Health (NIMH), prevention of mental disorders has become a major health need (9), and a primary care internet-based depression prevention intervention strategy should be developed. Such care has already been provided for depression in the U.S. by Dr. Van Voorhees, suggesting the intervention must:\\n\\nhave broad reach into at-risk populations;\\nwork outside of traditional mental health systems;\\nuse new technologies;\\nbuild on previous clinical trials;\\nreduce identified disorders/enhance functional outcomes;\\ninclude families; and\\nbe personalized\\n\\nKey issues - local level Developing new interventions that incorporate the diverse needs and circumstances of Hong Kong adolescents with depressive symptoms in community settings is our key strategic objective. While it is ideal to have a series of primary care physician consultations for at-risk adolescents, this is not available and too expensive for the lower socioeconomic class. This lack is apparent in both the East and the West. The U.S. has built up a new cost-effective prevention strategy for depression in primary care system; however, such a strategy may not be able to be incorporated into the public health sector. Hence, the collaboration between physicians and social workers will be used for this study.\\n\\nInclusion criteria:\\n\\n138 adolescent participants (ages 13 to 21) who experience a moderately elevated level of depressive symptoms on the CES-D scale (score 16-34) will be recruited to join the study. Participants may or may not have had a past history of depression, anxiety and/or substance abuse.\\n\\nOutcome measures to compare between 2 groups:\\n\\ni) depressive episodes and symptoms Assessment of adolescent depression by the Centre of Epidemiological Studies Depression Scale (CES-D) and Depression Anxiety Stress Scale (DASS) are a standard diagnostic test for assessment of adolescent's depression. The scores of both groups would be measured and compared in 3 follow-ups to study the effect and its sustainability of the website intervention.\\n\\nii) use of alcohol and drugs Assessment of drinking and drug use behavior of adolescents by CRAFFT Screening Test, which includes questions regarding alcohol and drug use situations in the past 12 months, and additional assessment for those who show a significant problem. There are 6 questions covering road safety, drug-use habits, and influences of using drugs or alcohol.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Adolescent - Emotional Problem']},\n",
       "       'KeywordList': {'Keyword': ['Adolescent depression',\n",
       "         'internet intervention']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Prevention',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '138',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention group',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Study participants in the intervention group will be given access to an anti-depression website and have four telephone follow-up within the 1-year study period.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Intervention group']}},\n",
       "         {'ArmGroupLabel': 'Control group',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': 'Study participants in the control group will not received any depression-related service other than an interactive anti-smoking website provided by the University of Hong Kong.'}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Intervention group',\n",
       "          'InterventionDescription': 'Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention group']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Depression symptoms',\n",
       "          'PrimaryOutcomeDescription': 'Centre for Epidemiological Studies Depression Scale (CES-D) : at baseline, 3 months, 6 months and 12 months',\n",
       "          'PrimaryOutcomeTimeFrame': '12 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Depression measurement',\n",
       "          'SecondaryOutcomeDescription': 'Depression Anxiety Stress Scale (DASS) : at baseline, 3 months, 6 months and 12 months',\n",
       "          'SecondaryOutcomeTimeFrame': '12 months'},\n",
       "         {'SecondaryOutcomeMeasure': 'alcohol abuse',\n",
       "          'SecondaryOutcomeDescription': 'CRAFFT Screening Test : at baseline, 3 months, 6 months, and 12 months',\n",
       "          'SecondaryOutcomeTimeFrame': '12 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nage 13 to 21\\nexperience a moderately elevated level of depressive symptoms on the CES-D scale (score 16-34)\\nmay or may not have had a past history of depression, anxiety and/or substance abuse\\n\\nExclusion Criteria:\\n\\ncurrently diagnosed with depression, schizophrenia, or bipolar affective disorder ;\\ncurrently taking antidepressants or psychotropic medication ;\\nCES-D score equal or higher than 35, or a proved serious medical illness that causes significant disability or dysfunction ;\\nexhibit significant reading impairment, mental retardation, developmental disabilities\\nserious imminent suicidal risk or other conditions that may require immediate psychiatric hospitalization\\nhave extreme, current drug / alcohol abuse (greater than or equal to 2 on the CRAFFT)',\n",
       "       'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '13 Years',\n",
       "       'MaximumAge': '21 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child', 'Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'David Chim, Dr.',\n",
       "          'OverallOfficialAffiliation': 'The University of Hong Kong',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'The University of Hong Kong',\n",
       "          'LocationCity': 'Hong Kong',\n",
       "          'LocationState': 'Hong Kong',\n",
       "          'LocationCountry': 'China'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M17683',\n",
       "          'ConditionBrowseLeafName': 'Behavior, Addictive',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 98,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04278456',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'EBYU 88'},\n",
       "       'Organization': {'OrgFullName': 'Erzincan University',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Postpartum Depression',\n",
       "       'OfficialTitle': 'The Effect of the Anesthesia Modality Used in Women Giving Birth Under Caesarian Section on Postpartum Depression and/or Postoperative Melatonin Levels'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'February 2020',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'March 21, 2020',\n",
       "        'StartDateType': 'Anticipated'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 21, 2020',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'July 21, 2020',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'February 18, 2020',\n",
       "       'StudyFirstSubmitQCDate': 'February 18, 2020',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 20, 2020',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'February 18, 2020',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 20, 2020',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "        'ResponsiblePartyInvestigatorFullName': 'REMZIYE AYSENUR NALBANT',\n",
       "        'ResponsiblePartyInvestigatorTitle': 'MD',\n",
       "        'ResponsiblePartyInvestigatorAffiliation': 'Erzincan University'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Erzincan University',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Our aim was to diagnose and initiate early treatment for postpartum depression by detecting the changes of melatonin levels in c-sections with different antesthesia modalities.'},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Postpartum Depression',\n",
       "         'Melatonin']}},\n",
       "      'DesignModule': {'StudyType': 'Observational',\n",
       "       'PatientRegistry': 'Yes',\n",
       "       'TargetDuration': '1 Week',\n",
       "       'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
       "        'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
       "       'BioSpec': {'BioSpecRetention': 'Samples Without DNA',\n",
       "        'BioSpecDescription': 'blood samples'},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '300',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'general anesthesia',\n",
       "          'ArmGroupDescription': 'c-section with general anesthesia',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: postpartum depression']}},\n",
       "         {'ArmGroupLabel': 'spinal anesthesia',\n",
       "          'ArmGroupDescription': 'c-section with spinal anesthesia',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: postpartum depression']}},\n",
       "         {'ArmGroupLabel': 'epidural anesthesia',\n",
       "          'ArmGroupDescription': 'c-section with epidural anesthesia',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: postpartum depression']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'postpartum depression',\n",
       "          'InterventionDescription': 'melatonin levels in c-sections with different anesthesia modalities.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['epidural anesthesia',\n",
       "            'general anesthesia',\n",
       "            'spinal anesthesia']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'edinburgh depression scale',\n",
       "          'PrimaryOutcomeDescription': 'below 12 is associated with depression',\n",
       "          'PrimaryOutcomeTimeFrame': '5 months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\npregnant women c-section (using general or regional anesthesia) aged between 18-45 years\\n\\nExclusion Criteria:\\n\\nage under 18 or above 45, history of smoking, a diagnosis with mental retardation, psychiatric patients, use of antipsychotics or antidepressants, patients with sleeping disorders, hormone replacement theraphy patients.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Female',\n",
       "       'GenderBased': 'Yes',\n",
       "       'GenderDescription': 'aged between 18-45 years',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '45 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult']},\n",
       "       'StudyPopulation': 'pregnant women that will give birth by c-section (using general or regional anesthesia) aged between 18-45 years will be included to our study',\n",
       "       'SamplingMethod': 'Non-Probability Sample'},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'DİDEM ONK',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '05053856322',\n",
       "          'CentralContactEMail': 'd.hesapdar@gmail.com'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Remziye Ayşenur NALBANT',\n",
       "          'OverallOfficialAffiliation': 'ERZİNCAN',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Erzincan Byu',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Erzincan',\n",
       "          'LocationCountry': 'Turkey',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'DİDEM ONK',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '05053856322',\n",
       "             'LocationContactEMail': 'd.hesapdar@gmail.com'}]}}]}},\n",
       "      'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24835540',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Andersen LP, Werner MU, Rosenberg J, Gögenur I. A systematic review of peri-operative melatonin. Anaesthesia. 2014 Oct;69(10):1163-71. doi: 10.1111/anae.12717. Epub 2014 May 19. Review.'},\n",
       "         {'ReferencePMID': '24015137',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Maitra S, Baidya DK, Khanna P. Melatonin in perioperative medicine: Current perspective. Saudi J Anaesth. 2013 Jul;7(3):315-21. doi: 10.4103/1658-354X.115316. Review.'},\n",
       "         {'ReferencePMID': '26697084',\n",
       "          'ReferenceType': 'result',\n",
       "          'ReferenceCitation': 'Dianatkhah M, Ghaeli P, Hajhossein Talasaz A, Karimi A, Salehiomran A, Bina P, Jalali A, Ghaffary S, Shahmansouri N, Vejdani S. Evaluating the Potential Effect of Melatonin on the post-Cardiac Surgery Sleep Disorder. J Tehran Heart Cent. 2015 Jul 3;10(3):122-8.'}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000019052',\n",
       "          'ConditionMeshTerm': 'Depression, Postpartum'},\n",
       "         {'ConditionMeshId': 'D000003863', 'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'},\n",
       "         {'ConditionAncestorId': 'D000011644',\n",
       "          'ConditionAncestorTerm': 'Puerperal Disorders'},\n",
       "         {'ConditionAncestorId': 'D000011248',\n",
       "          'ConditionAncestorTerm': 'Pregnancy Complications'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M19660',\n",
       "          'ConditionBrowseLeafName': 'Depression, Postpartum',\n",
       "          'ConditionBrowseLeafAsFound': 'Postpartum Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13082',\n",
       "          'ConditionBrowseLeafName': 'Puerperal Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M12710',\n",
       "          'ConditionBrowseLeafName': 'Pregnancy Complications',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'BXS',\n",
       "          'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}}}}},\n",
       "   {'Rank': 99,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04165681',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'Limbix Spark 01'},\n",
       "       'Organization': {'OrgFullName': 'Limbix Health, Inc.',\n",
       "        'OrgClass': 'INDUSTRY'},\n",
       "       'BriefTitle': 'A Mobile and Virtual Reality Intervention for Adolescent Depression',\n",
       "       'OfficialTitle': 'Evaluating the Feasibility of Limbix Spark: a Cognitive Behavioral Therapy Based Mobile and Virtual Reality Intervention for Adolescent Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'November 2019',\n",
       "       'OverallStatus': 'Recruiting',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'October 12, 2019',\n",
       "        'StartDateType': 'Actual'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2020',\n",
       "        'PrimaryCompletionDateType': 'Anticipated'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'March 2020',\n",
       "        'CompletionDateType': 'Anticipated'},\n",
       "       'StudyFirstSubmitDate': 'November 11, 2019',\n",
       "       'StudyFirstSubmitQCDate': 'November 13, 2019',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 18, 2019',\n",
       "        'StudyFirstPostDateType': 'Actual'},\n",
       "       'LastUpdateSubmitDate': 'November 13, 2019',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 18, 2019',\n",
       "        'LastUpdatePostDateType': 'Actual'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Limbix Health, Inc.',\n",
       "        'LeadSponsorClass': 'INDUSTRY'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No',\n",
       "       'IsFDARegulatedDrug': 'No',\n",
       "       'IsFDARegulatedDevice': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': 'Depression, the most common mental health disorder among adolescents, is a critical health problem within the US. In this study, the feasibility, acceptability, and preliminary efficacy of Limbix Spark, a cognitive behavioral therapy (CBT)- based mobile app + virtual reality (VR) program for helping adolescents live well with depression will be investigated. This program is specifically designed around behavioral activation theory, the idea that completing activities that make a patient feel pleasure or provide a sense of mastery are effective in reducing symptoms of depression. The program involves the use of both VR and a mobile app that include CBT components like psychological assessments, psychoeducation, and skills training. 30 participants aged 12-21 years old with mild to severe depressive symptoms and smartphone access will be enrolled in this study. The primary efficacy outcome measures will be depressive symptoms with anxiety symptoms, functional outcomes, and dimensional scales of positive and negative affect and behavioral activation serving as secondary outcome measures. Qualitative and quantitative feedback on the use of the VR + mobile app (ease of use, comfort, willingness to use again) will be assessed using questionnaires. Engagement and adherence to the program will be assessed by assessing VR and app usage.',\n",
       "       'DetailedDescription': \"Depression, the most common mental health disorder among adolescents, is a major public health concern with significant personal, societal, and economic burdens, particularly as incidence rates are increasing. Effective care for adolescent depression is limited due to lack of access to care, increasingly long waitlists, stigma surrounding mental health, and ineffectiveness of pharmaceutical options. There is an urgent need for accessible, cost-effective, and evidence-based treatment options for adolescents with depression.\\n\\nThe development of effective digital health programs for adolescents is a key strategy to reduce the personal, familiar and societal burden of depression. Such programs provide an innovative way to deliver resources in a cost-effective, accessible fashion. Cognitive-behavioral therapy (CBT) is effective in the prevention and treatment of depression in children and adolescents. Digital forms of CBT have also been shown to be efficacious in the treatment of anxiety and depressive symptoms in youth, however. adherence to such programs in clinical trials and particularly in real world evidence evaluations is low. Virtual reality (VR) holds promise as a way to enhance adherence to and the efficacy of digital CBT for depression.\\n\\nTo address the need for effective, accessible, and engaging treatments for adolescent depression, the objective of this project is to evaluate the feasibility, acceptability, and preliminary evidence of efficacy of Limbix Spark: a 5 week CBT-based mobile + VR self-guided program. Limbix Spark is specifically designed to implement behavioral activation, a CBT skill, which involves completing self-monitored activities that provide a sense of pleasure or mastery in order to reduce depressive symptoms and improve functional outcomes. VR allows adolescents to complete such activities in virtual environments as a potential stepping stone to engaging in similar experiences in the real world.\\n\\n30 participants aged 12-21 years old with mild to severe depressive symptoms and with smart phone access will be enrolled. During a baseline visit, participants or participants' legal guardians, will be asked to provide written informed consent and potential participants under 18 will be asked to provide written assent after study procedures are explained and any questions are answered by study staff in accordance with good clinical practice (GCP) and human subjects research guidelines.\\n\\nAfter consent, all eligible participants will be assigned to complete the 5-week Limbix Spark program. Participants and their legal guardian if under 18 will first complete baseline assessments, including the Patient Health Questionnaire (PHQ-8) Generalized Anxiety Disorder scale (GAD-7), the Positive and Negative Affective Schedule (PANAS-C), the Behavioral Activation for Depression Scale-Short Form (BADS-SF), 20-item Short Form Survey (SF-20), Mood and Feelings Questionnaire Short Parent version (MFQ-PS). Participants will then receive VR equipment, and receive an initial orientation to the Limbix Spark program. Program orientation will include training on how to set up and use the VR headset and how to download and use the mobile app.\\n\\nThe 5 modules in the Limbix Spark program are meant to be completed weekly, however, participants will be allowed to progress through the program at their own pace. Each module contains VR and mobile app components and is expected to take no more than 60 minutes to complete, with no more than approximately 25 min per module of VR content. Modules do not need to be completed in a single session and can be completed over the course of several days. During the program, weekly PHQ-8 assessments will be completed within the mobile app.\\n\\nAt the post-intervention site visit, participants and their legal guardian if under 18 will complete post-program assessments, including the PHQ-8, GAD-7, PANAS-C, MFQ-PS, SF-20, and BADS-SF, as well as a questionnaire about their thoughts and experiences with the Spark program. Participants will also complete a qualitative interview to further understand their experience with the program.\\n\\nOne month after the post-intervention site visit, participants will be sent a 1-month follow up questionnaires via email, including the PHQ-8, GAD-7, PANAS-C, MFQ-PS, SF-20, and BADS-SF, as well as a questionnaire about their thoughts and experiences with the Spark program.\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "       'KeywordList': {'Keyword': ['Adolescence',\n",
       "         'Cognitive Behavioral Therapy',\n",
       "         'Virtual Reality',\n",
       "         'Depression',\n",
       "         'Behavioral Activation']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignInterventionModel': 'Single Group Assignment',\n",
       "        'DesignPrimaryPurpose': 'Other',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '30',\n",
       "        'EnrollmentType': 'Anticipated'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Limbix Spark',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'A 5 week mobile + virtual reality CBT-based program',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Limbix Spark']}}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Other',\n",
       "          'InterventionName': 'Limbix Spark',\n",
       "          'InterventionDescription': '5-week, self-guided mobile + VR CBT-based program for adolescent depression',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Limbix Spark']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Adherence to program',\n",
       "          'PrimaryOutcomeDescription': '% of enrolled participants completing all sessions at post treatment',\n",
       "          'PrimaryOutcomeTimeFrame': 'Post treatment (5 weeks)'},\n",
       "         {'PrimaryOutcomeMeasure': 'Change in depression post treatment',\n",
       "          'PrimaryOutcomeDescription': 'Change in depressive symptoms measured by Personal Health Questionnaire (PHQ-8) (min: 0; max: 24, with higher score indicating more severe depression).',\n",
       "          'PrimaryOutcomeTimeFrame': 'Change from Baseline to Post treatment (5 weeks)'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in depression at one month follow up',\n",
       "          'SecondaryOutcomeDescription': 'Change in depressive symptoms measured by Personal Health Questionnaire (PHQ-8) (min: 0; max: 24, with higher score indicating more severe depression).',\n",
       "          'SecondaryOutcomeTimeFrame': 'Change from Baseline to 1 month follow up (9 weeks)'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nScore of 10 or greater on Patient Health Questionnaire (PHQ-8)\\nEnglish fluency and literacy\\nAccess to a smart phone\\nPatient willing to provide informed consent/assent and have parent/guardian willing to provide informed consent if under 18.\\n\\nExclusion Criteria:\\n\\nSeizure disorder or other neurological disorder\\nPrior diagnosis of or receiving treatment for substance use disorder, bipolar disorder, or psychosis\\nSignificant vision or hearing impairment\\nHospitalized or received residential/inpatient treatment for a suicide attempt or self-harming behaviors within the past 3 months\\nCurrent diagnosis of a reading/learning or intellectual disability.\\nReceiving treatment (including but not limited to medication or psychotherapy) for a cognitive disorder, including attention deficit hyperactivity disorder (ADHD).\\nAre currently participating in a treatment study.\\nPregnancy\\nHistory of significant motion sickness',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'All',\n",
       "       'MinimumAge': '12 Years',\n",
       "       'MaximumAge': '21 Years',\n",
       "       'StdAgeList': {'StdAge': ['Child', 'Adult']}},\n",
       "      'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Jessica Lake, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '1-888-546-2495',\n",
       "          'CentralContactPhoneExt': '708',\n",
       "          'CentralContactEMail': 'jessica@limbix.com'},\n",
       "         {'CentralContactName': 'Aarthi Padmanabhan, PhD',\n",
       "          'CentralContactRole': 'Contact',\n",
       "          'CentralContactPhone': '1-888-546-2495',\n",
       "          'CentralContactPhoneExt': '703',\n",
       "          'CentralContactEMail': 'aarthi@limbix.com'}]},\n",
       "       'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jessica Lake, PhD',\n",
       "          'OverallOfficialAffiliation': 'Director of Research',\n",
       "          'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Limbix Health, Inc.',\n",
       "          'LocationStatus': 'Recruiting',\n",
       "          'LocationCity': 'Los Angeles',\n",
       "          'LocationState': 'California',\n",
       "          'LocationZip': '90266-2558',\n",
       "          'LocationCountry': 'United States',\n",
       "          'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jessica Lake, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '888-546-2495',\n",
       "             'LocationContactPhoneExt': '708',\n",
       "             'LocationContactEMail': 'jessica@limbix.com'},\n",
       "            {'LocationContactName': 'Aarthi Padmanabhan, PhD',\n",
       "             'LocationContactRole': 'Contact',\n",
       "             'LocationContactPhone': '1-888-546-2495',\n",
       "             'LocationContactPhoneExt': '703',\n",
       "             'LocationContactEMail': 'aarthi@limbix.com'}]}}]}},\n",
       "      'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}},\n",
       "   {'Rank': 100,\n",
       "    'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02310529',\n",
       "       'OrgStudyIdInfo': {'OrgStudyId': 'PILL-IPT'},\n",
       "       'Organization': {'OrgFullName': 'Pakistan Institute of Living and Learning',\n",
       "        'OrgClass': 'OTHER'},\n",
       "       'BriefTitle': 'Interpersonal Psychotherapy for Maternal Depression',\n",
       "       'OfficialTitle': 'Randomized Control Trial of an Interpersonal Psychotherapy for Maternal Depression'},\n",
       "      'StatusModule': {'StatusVerifiedDate': 'August 2015',\n",
       "       'OverallStatus': 'Completed',\n",
       "       'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "       'StartDateStruct': {'StartDate': 'March 2014'},\n",
       "       'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2015',\n",
       "        'PrimaryCompletionDateType': 'Actual'},\n",
       "       'CompletionDateStruct': {'CompletionDate': 'January 2015',\n",
       "        'CompletionDateType': 'Actual'},\n",
       "       'StudyFirstSubmitDate': 'November 15, 2014',\n",
       "       'StudyFirstSubmitQCDate': 'December 5, 2014',\n",
       "       'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 8, 2014',\n",
       "        'StudyFirstPostDateType': 'Estimate'},\n",
       "       'LastUpdateSubmitDate': 'August 15, 2015',\n",
       "       'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 18, 2015',\n",
       "        'LastUpdatePostDateType': 'Estimate'}},\n",
       "      'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "       'LeadSponsor': {'LeadSponsorName': 'Pakistan Institute of Living and Learning',\n",
       "        'LeadSponsorClass': 'OTHER'}},\n",
       "      'OversightModule': {'OversightHasDMC': 'No'},\n",
       "      'DescriptionModule': {'BriefSummary': \"Depression related to pregnancy frequently presents postpartum depression, which has deteriorating and lasting negative effects, not only on infant and child well being but also on mother's and father's mental health (Nancy K et al 2009). It is therefore important to introduce interventions aiming to improve mental health of mothers that could minimize the risk of diseases, and have positive effect child's on physical and psychological developmental wellbeing.\\n\\nTherefore, this project has been designed to assess the effectiveness of Interpersonal Psychotherapy for Postnatal Depression in Pakistan.\",\n",
       "       'DetailedDescription': \"Prevalence of depression in the postnatal period is 10% to 17 % in western world ( O 'Hara and Swain 1996; Josseffson et al 2001; Yoshida et al 2001) and 23% to 36% in the developing world (Rahman et al 2003; Patel et al 2002; Husain et al 2006).\\n\\nIn developed countries, studies indicate that maternal depression is associated with long-term emotional, cognitive and behavioral problem in children. There is evidence of link between maternal psychopathology to physical health of child. Research evidence also indicates that long-term negative impact of postnatal depression is on the mother's mental health, on infant's development and on the marital relationship (Reay, Fisher, Robertson, Adams and Owen 2005).\\n\\nbecause of high prevalence of maternal depression in low income countries like Pakistan, the present study is designed to test the effectiveness of Interpersonal Psychotherapy for women with maternal depression. The participants will be recruited from Civil hospital Karachi and also from three different communities. total 50 participants will be recruited and randomized to 2 groups: either intervention or TAU group. Assessment will be done on baseline, after completion of intervention and 3 months after completion of intervention. Assessment will include Edinburg Postnatal depression scale, Patient Health Questionnaire-9, Generalized Anxiety Disorder-7 and Rosenberg Self Esteem scale. Participants in intervention group will receive 12 sessions of Interpersonal Psychotherapy (IPT)\"},\n",
       "      'ConditionsModule': {'ConditionList': {'Condition': ['Maternal Depression']},\n",
       "       'KeywordList': {'Keyword': ['Maternal depression',\n",
       "         'Interpersonal Psycotherapy']}},\n",
       "      'DesignModule': {'StudyType': 'Interventional',\n",
       "       'PhaseList': {'Phase': ['Not Applicable']},\n",
       "       'DesignInfo': {'DesignAllocation': 'Randomized',\n",
       "        'DesignInterventionModel': 'Parallel Assignment',\n",
       "        'DesignPrimaryPurpose': 'Treatment',\n",
       "        'DesignMaskingInfo': {'DesignMasking': 'Single',\n",
       "         'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}},\n",
       "       'EnrollmentInfo': {'EnrollmentCount': '50',\n",
       "        'EnrollmentType': 'Actual'}},\n",
       "      'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Interpersonal Psychotherapy',\n",
       "          'ArmGroupType': 'Experimental',\n",
       "          'ArmGroupDescription': 'Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group). IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected. Intervention will be delivered by trained clinical psychologists.',\n",
       "          'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Interpersonal Psychotherapy']}},\n",
       "         {'ArmGroupLabel': 'Treatment as usual',\n",
       "          'ArmGroupType': 'No Intervention',\n",
       "          'ArmGroupDescription': \"Patients including in this group will be taking only treatment as usual (in Pakistan it means that participants attending in outpatients' clinic at regular intervals and may or may not be taking prescribed medication).\"}]},\n",
       "       'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "          'InterventionName': 'Interpersonal Psychotherapy',\n",
       "          'InterventionDescription': 'Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group).IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected.\\n\\nIntervention will be delivered by trained clinical psychologists.',\n",
       "          'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Interpersonal Psychotherapy']},\n",
       "          'InterventionOtherNameList': {'InterventionOtherName': ['IPT']}}]}},\n",
       "      'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Edinberg Postnatal Depression Scale (EPDS) To test the feasibility and acceptability of interpersonal psychotherapy in women suffering from postnatal depression.',\n",
       "          'PrimaryOutcomeDescription': 'EPDS will be used to assess depression',\n",
       "          'PrimaryOutcomeTimeFrame': '3 months'}]},\n",
       "       'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Patient Health Questionnaire-9 (PHQ-9)',\n",
       "          'SecondaryOutcomeDescription': 'PHQ-9 will be used to assess severity of depression',\n",
       "          'SecondaryOutcomeTimeFrame': '3 and 6 Months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Generalized Anxiety Disorder-7 (GAD-7)',\n",
       "          'SecondaryOutcomeDescription': 'GAD-7 will be used to assess severity of anxiety',\n",
       "          'SecondaryOutcomeTimeFrame': '3 and 6 Months'},\n",
       "         {'SecondaryOutcomeMeasure': 'Rosenberg Self Esteem Scale (RSES)',\n",
       "          'SecondaryOutcomeDescription': 'This scale will ne used to assess self esteem',\n",
       "          'SecondaryOutcomeTimeFrame': '3 and 6 Months'}]}},\n",
       "      'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMothers age 18 years and above older with child below 3 years of age\\nMeet the criteria for mild to moderate depressive symptoms on (EPDS (cut off score above 10) and\\nWere resident of trial catchment area were included in the study.\\n\\nExclusion Criteria:\\n\\nMothers who were suffering from severe depression, with diagnosed learning or physical disability or\\nAny major psychiatric illness other than maternal depression, with Alcohol and substance dependent or\\nActively suicidal were excluded from the study.',\n",
       "       'HealthyVolunteers': 'No',\n",
       "       'Gender': 'Female',\n",
       "       'MinimumAge': '18 Years',\n",
       "       'MaximumAge': '45 Years',\n",
       "       'StdAgeList': {'StdAge': ['Adult']}},\n",
       "      'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Dr. Nusrat Husain',\n",
       "          'OverallOfficialAffiliation': 'PILL',\n",
       "          'OverallOfficialRole': 'Study Director'}]},\n",
       "       'LocationList': {'Location': [{'LocationFacility': 'Civil hospital Karachi',\n",
       "          'LocationCity': 'Karachi',\n",
       "          'LocationState': 'Sindh',\n",
       "          'LocationZip': '72000',\n",
       "          'LocationCountry': 'Pakistan'},\n",
       "         {'LocationFacility': 'Bilal Colony',\n",
       "          'LocationCity': 'Karachi',\n",
       "          'LocationState': 'Sindh',\n",
       "          'LocationCountry': 'Pakistan'},\n",
       "         {'LocationFacility': 'Yousuf Goth',\n",
       "          'LocationCity': 'Karachi',\n",
       "          'LocationState': 'Sindh',\n",
       "          'LocationCountry': 'Pakistan'},\n",
       "         {'LocationFacility': 'Bhitaiabad',\n",
       "          'LocationCity': 'Karachi',\n",
       "          'LocationState': 'Sind',\n",
       "          'LocationCountry': 'Pakistan'}]}},\n",
       "      'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Organizational Website',\n",
       "          'SeeAlsoLinkURL': 'http://pill.org.pk'}]}}},\n",
       "     'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "      'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "          'ConditionMeshTerm': 'Depression'},\n",
       "         {'ConditionMeshId': 'D000003866',\n",
       "          'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "       'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "          'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "         {'ConditionAncestorId': 'D000019964',\n",
       "          'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "         {'ConditionAncestorId': 'D000001523',\n",
       "          'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "       'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "          'ConditionBrowseLeafName': 'Depression',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M5644',\n",
       "          'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "          'ConditionBrowseLeafAsFound': 'Depression',\n",
       "          'ConditionBrowseLeafRelevance': 'high'},\n",
       "         {'ConditionBrowseLeafId': 'M3399',\n",
       "          'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M20419',\n",
       "          'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M3396',\n",
       "          'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'},\n",
       "         {'ConditionBrowseLeafId': 'M13056',\n",
       "          'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "          'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "       'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "          'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "         {'ConditionBrowseBranchAbbrev': 'All',\n",
       "          'ConditionBrowseBranchName': 'All Conditions'}]}}}}}]}}"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "json_response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "number_studies = json_response['FullStudiesResponse']['NStudiesFound']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Rank': 1,\n",
       " 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01083628',\n",
       "    'OrgStudyIdInfo': {'OrgStudyId': '68556-35551-01'},\n",
       "    'Organization': {'OrgFullName': 'University of California, San Francisco',\n",
       "     'OrgClass': 'OTHER'},\n",
       "    'BriefTitle': 'Text Messaging and Cognitive Behavioral Therapy for Depression',\n",
       "    'OfficialTitle': 'Automated Text Messaging to Increase Engagement in Cognitive Behavioral Therapy (CBT) for Depression',\n",
       "    'Acronym': 'HealthySMS'},\n",
       "   'StatusModule': {'StatusVerifiedDate': 'July 2019',\n",
       "    'OverallStatus': 'Completed',\n",
       "    'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "    'StartDateStruct': {'StartDate': 'January 2014'},\n",
       "    'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2016',\n",
       "     'PrimaryCompletionDateType': 'Actual'},\n",
       "    'CompletionDateStruct': {'CompletionDate': 'April 2017',\n",
       "     'CompletionDateType': 'Actual'},\n",
       "    'StudyFirstSubmitDate': 'February 19, 2010',\n",
       "    'StudyFirstSubmitQCDate': 'March 8, 2010',\n",
       "    'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 10, 2010',\n",
       "     'StudyFirstPostDateType': 'Estimate'},\n",
       "    'ResultsFirstSubmitDate': 'December 21, 2018',\n",
       "    'ResultsFirstSubmitQCDate': 'July 2, 2019',\n",
       "    'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 12, 2019',\n",
       "     'ResultsFirstPostDateType': 'Actual'},\n",
       "    'LastUpdateSubmitDate': 'July 2, 2019',\n",
       "    'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 12, 2019',\n",
       "     'LastUpdatePostDateType': 'Actual'}},\n",
       "   'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'},\n",
       "    'LeadSponsor': {'LeadSponsorName': 'University of California, San Francisco',\n",
       "     'LeadSponsorClass': 'OTHER'}},\n",
       "   'OversightModule': {'OversightHasDMC': 'Yes',\n",
       "    'IsFDARegulatedDrug': 'No',\n",
       "    'IsFDARegulatedDevice': 'No'},\n",
       "   'DescriptionModule': {'BriefSummary': 'This study aims to asses whether adding automated text messaging to group cognitive behavioral therapy for depression increases engagement which may lead to improved outcomes.',\n",
       "    'DetailedDescription': \"Background: Cognitive Behavioral Therapy (CBT) for depression is efficacious, but effectiveness is limited when implemented in low-income settings due to engagement difficulties including nonadherence with skill-building homework and early discontinuation of treatment. Automated messaging can be used in clinical settings to increase dosage of depression treatment and encourage sustained engagement with psychotherapy.\\n\\nObjectives: The aim of this study was to test whether a text messaging adjunct (mood monitoring text messages, treatment-related text messages, and a clinician dashboard to display patient data) increases engagement and improves clinical outcomes in a group CBT treatment for depression. Specifically, the investigators aim to assess whether the text messaging adjunct led to an increase in group therapy sessions attended, an increase in duration of therapy attended, and reductions in Patient Health Questionnaire-9 item (PHQ-9) symptoms compared with the control condition of standard group CBT in a sample of low-income Spanish speaking Latino patients.\\n\\nMethods: Patients in an outpatient behavioral health clinic were assigned to standard group CBT for depression (control condition; n=40) or the same treatment with the addition of a text messaging adjunct (n=45). The adjunct consisted of a daily mood monitoring message, a daily message reiterating the theme of that week's content, and medication and appointment reminders. Mood data and qualitative responses were sent to a Web-based platform (HealthySMS) for review by the therapist and displayed in session as a tool for teaching CBT skills.\"},\n",
       "   'ConditionsModule': {'ConditionList': {'Condition': ['Depression']},\n",
       "    'KeywordList': {'Keyword': ['mhealth',\n",
       "      'depression',\n",
       "      'latinos',\n",
       "      'text messaging',\n",
       "      'CBT',\n",
       "      'SMS']}},\n",
       "   'DesignModule': {'StudyType': 'Interventional',\n",
       "    'PhaseList': {'Phase': ['Not Applicable']},\n",
       "    'DesignInfo': {'DesignAllocation': 'Non-Randomized',\n",
       "     'DesignInterventionModel': 'Parallel Assignment',\n",
       "     'DesignPrimaryPurpose': 'Health Services Research',\n",
       "     'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}},\n",
       "    'EnrollmentInfo': {'EnrollmentCount': '85', 'EnrollmentType': 'Actual'}},\n",
       "   'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': \"Group CBT for Depression with MoodText'\",\n",
       "       'ArmGroupType': 'Experimental',\n",
       "       'ArmGroupDescription': 'Group cognitive behavioral therapy utilizing the BRIGHT manual for depression along with automated text messaging for mood monitoring and reminder of session content',\n",
       "       'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Group CBT for Depression with MoodText']}},\n",
       "      {'ArmGroupLabel': 'Group CBT for Depression',\n",
       "       'ArmGroupType': 'Active Comparator',\n",
       "       'ArmGroupDescription': 'Standard group cognitive behavioral therapy utilizing the BRIGHT manual for depression',\n",
       "       'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Group CBT for Depression']}}]},\n",
       "    'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral',\n",
       "       'InterventionName': 'Group CBT for Depression with MoodText',\n",
       "       'InterventionDescription': 'Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.',\n",
       "       'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [\"Group CBT for Depression with MoodText'\"]},\n",
       "       'InterventionOtherNameList': {'InterventionOtherName': ['Group CBT for Depression with HealthySMS']}},\n",
       "      {'InterventionType': 'Behavioral',\n",
       "       'InterventionName': 'Group CBT for Depression',\n",
       "       'InterventionDescription': 'Standard group CBT for depression using BRIGHT manual',\n",
       "       'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group CBT for Depression']}}]}},\n",
       "   'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'PHQ-9 Depression Symptoms',\n",
       "       'PrimaryOutcomeDescription': 'The PHQ-9 (Patient Health Questionnaire - 9) is commonly used to screen for depression and to monitor progression of depressive symptoms over time. The scores represent the following depression severity: 0-4: minimal depression, 5-9: mild depression, 10-14: moderate depression, 15-19: moderately severe, 20-27: severe. A score of 10 is often recommended as the cut-off score for diagnosing an episode of depression that may require treatment.',\n",
       "       'PrimaryOutcomeTimeFrame': '16 weeks'}]},\n",
       "    'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Attendance',\n",
       "       'SecondaryOutcomeDescription': 'Number of sessions attended',\n",
       "       'SecondaryOutcomeTimeFrame': '16 weeks'},\n",
       "      {'SecondaryOutcomeMeasure': 'Duration of Therapy Attended',\n",
       "       'SecondaryOutcomeDescription': 'Number of weeks until patients dropped out of therapy',\n",
       "       'SecondaryOutcomeTimeFrame': '16 weeks'}]}},\n",
       "   'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nParticipation in CBT group at San Francisco General Hospital\\n\\nExclusion Criteria:\\n\\nActive suicidality\\nActive and severe psychosis',\n",
       "    'HealthyVolunteers': 'No',\n",
       "    'Gender': 'All',\n",
       "    'MinimumAge': '18 Years',\n",
       "    'MaximumAge': '100 Years',\n",
       "    'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}},\n",
       "   'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Adrian Aguilera, Ph.D.',\n",
       "       'OverallOfficialAffiliation': 'University of California, San Francisco',\n",
       "       'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "    'LocationList': {'Location': [{'LocationFacility': 'San Francisco General Hospital',\n",
       "       'LocationCity': 'San Francisco',\n",
       "       'LocationState': 'California',\n",
       "       'LocationZip': '94110',\n",
       "       'LocationCountry': 'United States'}]}},\n",
       "   'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Latino Mental Health Research Program',\n",
       "       'SeeAlsoLinkURL': 'http://medschool.ucsf.edu/latino/'}]}},\n",
       "   'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "  'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000',\n",
       "       'FlowGroupTitle': 'Group CBT With Text Messaging Adjunct',\n",
       "       'FlowGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'},\n",
       "      {'FlowGroupId': 'FG001',\n",
       "       'FlowGroupTitle': 'Group CBT for Depression',\n",
       "       'FlowGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}]},\n",
       "    'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study',\n",
       "       'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED',\n",
       "          'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "             'FlowAchievementNumSubjects': '45'},\n",
       "            {'FlowAchievementGroupId': 'FG001',\n",
       "             'FlowAchievementNumSubjects': '40'}]}},\n",
       "         {'FlowMilestoneType': 'COMPLETED',\n",
       "          'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "             'FlowAchievementNumSubjects': '45'},\n",
       "            {'FlowAchievementGroupId': 'FG001',\n",
       "             'FlowAchievementNumSubjects': '40'}]}},\n",
       "         {'FlowMilestoneType': 'NOT COMPLETED',\n",
       "          'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000',\n",
       "             'FlowAchievementNumSubjects': '0'},\n",
       "            {'FlowAchievementGroupId': 'FG001',\n",
       "             'FlowAchievementNumSubjects': '0'}]}}]}}]}},\n",
       "   'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000',\n",
       "       'BaselineGroupTitle': 'Group CBT With Text Messaging Adjunct',\n",
       "       'BaselineGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'},\n",
       "      {'BaselineGroupId': 'BG001',\n",
       "       'BaselineGroupTitle': 'Group CBT for Depression',\n",
       "       'BaselineGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'},\n",
       "      {'BaselineGroupId': 'BG002',\n",
       "       'BaselineGroupTitle': 'Total',\n",
       "       'BaselineGroupDescription': 'Total of all reporting groups'}]},\n",
       "    'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants',\n",
       "       'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000',\n",
       "          'BaselineDenomCountValue': '45'},\n",
       "         {'BaselineDenomCountGroupId': 'BG001',\n",
       "          'BaselineDenomCountValue': '40'},\n",
       "         {'BaselineDenomCountGroupId': 'BG002',\n",
       "          'BaselineDenomCountValue': '85'}]}}]},\n",
       "    'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical',\n",
       "       'BaselineMeasureParamType': 'Count of Participants',\n",
       "       'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "       'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years',\n",
       "             'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                'BaselineMeasurementValue': '0'},\n",
       "               {'BaselineMeasurementGroupId': 'BG001',\n",
       "                'BaselineMeasurementValue': '0'},\n",
       "               {'BaselineMeasurementGroupId': 'BG002',\n",
       "                'BaselineMeasurementValue': '0'}]}},\n",
       "            {'BaselineCategoryTitle': 'Between 18 and 65 years',\n",
       "             'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                'BaselineMeasurementValue': '45'},\n",
       "               {'BaselineMeasurementGroupId': 'BG001',\n",
       "                'BaselineMeasurementValue': '40'},\n",
       "               {'BaselineMeasurementGroupId': 'BG002',\n",
       "                'BaselineMeasurementValue': '85'}]}},\n",
       "            {'BaselineCategoryTitle': '>=65 years',\n",
       "             'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                'BaselineMeasurementValue': '0'},\n",
       "               {'BaselineMeasurementGroupId': 'BG001',\n",
       "                'BaselineMeasurementValue': '0'},\n",
       "               {'BaselineMeasurementGroupId': 'BG002',\n",
       "                'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
       "      {'BaselineMeasureTitle': 'Age, Continuous',\n",
       "       'BaselineMeasureParamType': 'Mean',\n",
       "       'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "       'BaselineMeasureUnitOfMeasure': 'years',\n",
       "       'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                'BaselineMeasurementValue': '51.71',\n",
       "                'BaselineMeasurementSpread': '11.55'},\n",
       "               {'BaselineMeasurementGroupId': 'BG001',\n",
       "                'BaselineMeasurementValue': '51.83',\n",
       "                'BaselineMeasurementSpread': '11.73'},\n",
       "               {'BaselineMeasurementGroupId': 'BG002',\n",
       "                'BaselineMeasurementValue': '51.75',\n",
       "                'BaselineMeasurementSpread': '11.62'}]}}]}}]}},\n",
       "      {'BaselineMeasureTitle': 'Sex: Female, Male',\n",
       "       'BaselineMeasureParamType': 'Count of Participants',\n",
       "       'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "       'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female',\n",
       "             'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                'BaselineMeasurementValue': '38'},\n",
       "               {'BaselineMeasurementGroupId': 'BG001',\n",
       "                'BaselineMeasurementValue': '29'},\n",
       "               {'BaselineMeasurementGroupId': 'BG002',\n",
       "                'BaselineMeasurementValue': '67'}]}},\n",
       "            {'BaselineCategoryTitle': 'Male',\n",
       "             'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                'BaselineMeasurementValue': '7'},\n",
       "               {'BaselineMeasurementGroupId': 'BG001',\n",
       "                'BaselineMeasurementValue': '11'},\n",
       "               {'BaselineMeasurementGroupId': 'BG002',\n",
       "                'BaselineMeasurementValue': '18'}]}}]}}]}},\n",
       "      {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)',\n",
       "       'BaselineMeasureParamType': 'Count of Participants',\n",
       "       'BaselineMeasureUnitOfMeasure': 'Participants',\n",
       "       'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino',\n",
       "             'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                'BaselineMeasurementValue': '45'},\n",
       "               {'BaselineMeasurementGroupId': 'BG001',\n",
       "                'BaselineMeasurementValue': '40'},\n",
       "               {'BaselineMeasurementGroupId': 'BG002',\n",
       "                'BaselineMeasurementValue': '85'}]}},\n",
       "            {'BaselineCategoryTitle': 'Not Hispanic or Latino',\n",
       "             'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                'BaselineMeasurementValue': '0'},\n",
       "               {'BaselineMeasurementGroupId': 'BG001',\n",
       "                'BaselineMeasurementValue': '0'},\n",
       "               {'BaselineMeasurementGroupId': 'BG002',\n",
       "                'BaselineMeasurementValue': '0'}]}},\n",
       "            {'BaselineCategoryTitle': 'Unknown or Not Reported',\n",
       "             'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                'BaselineMeasurementValue': '0'},\n",
       "               {'BaselineMeasurementGroupId': 'BG001',\n",
       "                'BaselineMeasurementValue': '0'},\n",
       "               {'BaselineMeasurementGroupId': 'BG002',\n",
       "                'BaselineMeasurementValue': '0'}]}}]}}]}},\n",
       "      {'BaselineMeasureTitle': 'Region of Enrollment',\n",
       "       'BaselineMeasureParamType': 'Number',\n",
       "       'BaselineMeasureUnitOfMeasure': 'participants',\n",
       "       'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States',\n",
       "          'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                'BaselineMeasurementValue': '45'},\n",
       "               {'BaselineMeasurementGroupId': 'BG001',\n",
       "                'BaselineMeasurementValue': '40'},\n",
       "               {'BaselineMeasurementGroupId': 'BG002',\n",
       "                'BaselineMeasurementValue': '85'}]}}]}}]}},\n",
       "      {'BaselineMeasureTitle': 'PHQ-9',\n",
       "       'BaselineMeasureDescription': 'The PHQ-9 (Patient Health Questionnaire - 9) is commonly used to screen for depression and to monitor progression of depressive symptoms over time. The scores represent the following depression severity: 0-4: minimal depression, 5-9: mild depression, 10-14: moderate depression, 15-19: moderately severe, 20-27: severe. A score of 10 is often recommended as the cut-off score for diagnosing an episode of depression that may require treatment.',\n",
       "       'BaselineMeasureParamType': 'Mean',\n",
       "       'BaselineMeasureDispersionType': 'Standard Deviation',\n",
       "       'BaselineMeasureUnitOfMeasure': 'units on a scale',\n",
       "       'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000',\n",
       "                'BaselineMeasurementValue': '13.36',\n",
       "                'BaselineMeasurementSpread': '5.96'},\n",
       "               {'BaselineMeasurementGroupId': 'BG001',\n",
       "                'BaselineMeasurementValue': '13.13',\n",
       "                'BaselineMeasurementSpread': '4.99'},\n",
       "               {'BaselineMeasurementGroupId': 'BG002',\n",
       "                'BaselineMeasurementValue': '13.25',\n",
       "                'BaselineMeasurementSpread': '5.68'}]}}]}}]}}]}},\n",
       "   'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary',\n",
       "       'OutcomeMeasureTitle': 'PHQ-9 Depression Symptoms',\n",
       "       'OutcomeMeasureDescription': 'The PHQ-9 (Patient Health Questionnaire - 9) is commonly used to screen for depression and to monitor progression of depressive symptoms over time. The scores represent the following depression severity: 0-4: minimal depression, 5-9: mild depression, 10-14: moderate depression, 15-19: moderately severe, 20-27: severe. A score of 10 is often recommended as the cut-off score for diagnosing an episode of depression that may require treatment.',\n",
       "       'OutcomeMeasurePopulationDescription': 'The number of participants analyzed in this intention-to-treat analyses represents the number of participants that provided PHQ-9 scores at the end of the study period, at 16 weeks. Because the PHQ-9 was filled in during psychotherapy sessions, this number is smaller than the original sample (n=44, n=38) due to patient drop-out of psychotherapy.',\n",
       "       'OutcomeMeasureReportingStatus': 'Posted',\n",
       "       'OutcomeMeasureParamType': 'Mean',\n",
       "       'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "       'OutcomeMeasureUnitOfMeasure': 'units on a scale',\n",
       "       'OutcomeMeasureTimeFrame': '16 weeks',\n",
       "       'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "          'OutcomeGroupTitle': 'Group CBT With Text Messaging Adjunct',\n",
       "          'OutcomeGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'},\n",
       "         {'OutcomeGroupId': 'OG001',\n",
       "          'OutcomeGroupTitle': 'Group CBT for Depression',\n",
       "          'OutcomeGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}]},\n",
       "       'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "          'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "             'OutcomeDenomCountValue': '18'},\n",
       "            {'OutcomeDenomCountGroupId': 'OG001',\n",
       "             'OutcomeDenomCountValue': '9'}]}}]},\n",
       "       'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                'OutcomeMeasurementValue': '6',\n",
       "                'OutcomeMeasurementSpread': '4.2'},\n",
       "               {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                'OutcomeMeasurementValue': '12.67',\n",
       "                'OutcomeMeasurementSpread': '6.4'}]}}]}}]}},\n",
       "      {'OutcomeMeasureType': 'Secondary',\n",
       "       'OutcomeMeasureTitle': 'Attendance',\n",
       "       'OutcomeMeasureDescription': 'Number of sessions attended',\n",
       "       'OutcomeMeasurePopulationDescription': 'For the attendance analyses, 3 patients (1 in the intervention and 2 in the control) were excluded, because the study ended before these patients had been offered 16 sessions of psychotherapy.',\n",
       "       'OutcomeMeasureReportingStatus': 'Posted',\n",
       "       'OutcomeMeasureParamType': 'Median',\n",
       "       'OutcomeMeasureDispersionType': 'Standard Deviation',\n",
       "       'OutcomeMeasureUnitOfMeasure': 'sessions',\n",
       "       'OutcomeMeasureTimeFrame': '16 weeks',\n",
       "       'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "          'OutcomeGroupTitle': 'Group CBT With Text Messaging Adjunct',\n",
       "          'OutcomeGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'},\n",
       "         {'OutcomeGroupId': 'OG001',\n",
       "          'OutcomeGroupTitle': 'Group CBT for Depression',\n",
       "          'OutcomeGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}]},\n",
       "       'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "          'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "             'OutcomeDenomCountValue': '44'},\n",
       "            {'OutcomeDenomCountGroupId': 'OG001',\n",
       "             'OutcomeDenomCountValue': '38'}]}}]},\n",
       "       'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                'OutcomeMeasurementValue': '6',\n",
       "                'OutcomeMeasurementSpread': '2.3'},\n",
       "               {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                'OutcomeMeasurementValue': '2.5',\n",
       "                'OutcomeMeasurementSpread': '1.4'}]}}]}}]}},\n",
       "      {'OutcomeMeasureType': 'Secondary',\n",
       "       'OutcomeMeasureTitle': 'Duration of Therapy Attended',\n",
       "       'OutcomeMeasureDescription': 'Number of weeks until patients dropped out of therapy',\n",
       "       'OutcomeMeasurePopulationDescription': 'For the duration of therapy analyses, 3 patients (1 in the intervention and 2 in the control) were excluded, because the study ended before these patients had been offered 16 sessions of psychotherapy.',\n",
       "       'OutcomeMeasureReportingStatus': 'Posted',\n",
       "       'OutcomeMeasureParamType': 'Median',\n",
       "       'OutcomeMeasureDispersionType': 'Full Range',\n",
       "       'OutcomeMeasureUnitOfMeasure': 'weeks',\n",
       "       'OutcomeMeasureTimeFrame': '16 weeks',\n",
       "       'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000',\n",
       "          'OutcomeGroupTitle': 'Group CBT With Text Messaging Adjunct',\n",
       "          'OutcomeGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.'},\n",
       "         {'OutcomeGroupId': 'OG001',\n",
       "          'OutcomeGroupTitle': 'Group CBT for Depression',\n",
       "          'OutcomeGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual'}]},\n",
       "       'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants',\n",
       "          'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000',\n",
       "             'OutcomeDenomCountValue': '44'},\n",
       "            {'OutcomeDenomCountGroupId': 'OG001',\n",
       "             'OutcomeDenomCountValue': '38'}]}}]},\n",
       "       'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000',\n",
       "                'OutcomeMeasurementValue': '13.5',\n",
       "                'OutcomeMeasurementLowerLimit': '1',\n",
       "                'OutcomeMeasurementUpperLimit': '16'},\n",
       "               {'OutcomeMeasurementGroupId': 'OG001',\n",
       "                'OutcomeMeasurementValue': '3',\n",
       "                'OutcomeMeasurementLowerLimit': '1',\n",
       "                'OutcomeMeasurementUpperLimit': '16'}]}}]}}]}}]}},\n",
       "   'AdverseEventsModule': {'EventsFrequencyThreshold': '0',\n",
       "    'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000',\n",
       "       'EventGroupTitle': 'Group CBT With Text Messaging Adjunct',\n",
       "       'EventGroupDescription': 'Group CBT for Depression with MoodText: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.',\n",
       "       'EventGroupSeriousNumAffected': '0',\n",
       "       'EventGroupSeriousNumAtRisk': '45',\n",
       "       'EventGroupOtherNumAffected': '0',\n",
       "       'EventGroupOtherNumAtRisk': '45'},\n",
       "      {'EventGroupId': 'EG001',\n",
       "       'EventGroupTitle': 'Group CBT for Depression',\n",
       "       'EventGroupDescription': 'Group CBT for Depression: Standard group CBT for depression using BRIGHT manual',\n",
       "       'EventGroupSeriousNumAffected': '0',\n",
       "       'EventGroupSeriousNumAtRisk': '40',\n",
       "       'EventGroupOtherNumAffected': '0',\n",
       "       'EventGroupOtherNumAtRisk': '40'}]}},\n",
       "   'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No',\n",
       "     'AgreementRestrictiveAgreement': 'No'},\n",
       "    'PointOfContact': {'PointOfContactTitle': 'Dr. Adrian Aguilera',\n",
       "     'PointOfContactOrganization': 'University of California, Berkeley',\n",
       "     'PointOfContactEMail': 'aguila@berkeley.edu',\n",
       "     'PointOfContactPhone': '510-642-8564'}}},\n",
       "  'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 22, 2020'},\n",
       "   'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003863',\n",
       "       'ConditionMeshTerm': 'Depression'},\n",
       "      {'ConditionMeshId': 'D000003866',\n",
       "       'ConditionMeshTerm': 'Depressive Disorder'}]},\n",
       "    'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001526',\n",
       "       'ConditionAncestorTerm': 'Behavioral Symptoms'},\n",
       "      {'ConditionAncestorId': 'D000019964',\n",
       "       'ConditionAncestorTerm': 'Mood Disorders'},\n",
       "      {'ConditionAncestorId': 'D000001523',\n",
       "       'ConditionAncestorTerm': 'Mental Disorders'}]},\n",
       "    'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5641',\n",
       "       'ConditionBrowseLeafName': 'Depression',\n",
       "       'ConditionBrowseLeafAsFound': 'Depression',\n",
       "       'ConditionBrowseLeafRelevance': 'high'},\n",
       "      {'ConditionBrowseLeafId': 'M5644',\n",
       "       'ConditionBrowseLeafName': 'Depressive Disorder',\n",
       "       'ConditionBrowseLeafAsFound': 'Depression',\n",
       "       'ConditionBrowseLeafRelevance': 'high'},\n",
       "      {'ConditionBrowseLeafId': 'M3399',\n",
       "       'ConditionBrowseLeafName': 'Behavioral Symptoms',\n",
       "       'ConditionBrowseLeafRelevance': 'low'},\n",
       "      {'ConditionBrowseLeafId': 'M20419',\n",
       "       'ConditionBrowseLeafName': 'Mood Disorders',\n",
       "       'ConditionBrowseLeafRelevance': 'low'},\n",
       "      {'ConditionBrowseLeafId': 'M3396',\n",
       "       'ConditionBrowseLeafName': 'Mental Disorders',\n",
       "       'ConditionBrowseLeafRelevance': 'low'},\n",
       "      {'ConditionBrowseLeafId': 'M13056',\n",
       "       'ConditionBrowseLeafName': 'Psychotic Disorders',\n",
       "       'ConditionBrowseLeafRelevance': 'low'}]},\n",
       "    'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM',\n",
       "       'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'},\n",
       "      {'ConditionBrowseBranchAbbrev': 'All',\n",
       "       'ConditionBrowseBranchName': 'All Conditions'}]}}}}}"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "json_response['FullStudiesResponse']['FullStudies'][0]\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "sample_case = json_response['FullStudiesResponse']['FullStudies'][0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['ProtocolSection', 'ResultsSection', 'DerivedSection'])"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sample_case['Study'].keys()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['IdentificationModule', 'StatusModule', 'SponsorCollaboratorsModule', 'OversightModule', 'DescriptionModule', 'ConditionsModule', 'DesignModule', 'ArmsInterventionsModule', 'OutcomesModule', 'EligibilityModule', 'ContactsLocationsModule', 'ReferencesModule', 'IPDSharingStatementModule'])"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "sample_case['Study']['ProtocolSection'].keys()\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'NCTId': 'NCT01083628',\n",
       " 'OrgStudyIdInfo': {'OrgStudyId': '68556-35551-01'},\n",
       " 'Organization': {'OrgFullName': 'University of California, San Francisco',\n",
       "  'OrgClass': 'OTHER'},\n",
       " 'BriefTitle': 'Text Messaging and Cognitive Behavioral Therapy for Depression',\n",
       " 'OfficialTitle': 'Automated Text Messaging to Increase Engagement in Cognitive Behavioral Therapy (CBT) for Depression',\n",
       " 'Acronym': 'HealthySMS'}"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sample_case['Study']['ProtocolSection']['IdentificationModule']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'NCTId': 'NCT01083628',\n",
       " 'OrgStudyIdInfo': {'OrgStudyId': '68556-35551-01', 'NCTId': 'NCT01083628'},\n",
       " 'Organization': {'OrgFullName': 'University of California, San Francisco',\n",
       "  'OrgClass': 'OTHER',\n",
       "  'NCTId': 'NCT01083628'},\n",
       " 'BriefTitle': 'Text Messaging and Cognitive Behavioral Therapy for Depression',\n",
       " 'OfficialTitle': 'Automated Text Messaging to Increase Engagement in Cognitive Behavioral Therapy (CBT) for Depression',\n",
       " 'Acronym': 'HealthySMS'}"
      ]
     },
     "execution_count": 79,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "identification = sample_case['Study']['ProtocolSection']['IdentificationModule']\n",
    "identification"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "<ipython-input-86-0607e1d872ed>:3: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n",
      "  normed = json_normalize(identification)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCTId</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>OfficialTitle</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>OrgStudyIdInfo.OrgStudyId</th>\n",
       "      <th>OrgStudyIdInfo.NCTId</th>\n",
       "      <th>Organization.OrgFullName</th>\n",
       "      <th>Organization.OrgClass</th>\n",
       "      <th>Organization.NCTId</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT01083628</td>\n",
       "      <td>Text Messaging and Cognitive Behavioral Therap...</td>\n",
       "      <td>Automated Text Messaging to Increase Engagemen...</td>\n",
       "      <td>HealthySMS</td>\n",
       "      <td>68556-35551-01</td>\n",
       "      <td>NCT01083628</td>\n",
       "      <td>University of California, San Francisco</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>NCT01083628</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         NCTId                                         BriefTitle  \\\n",
       "0  NCT01083628  Text Messaging and Cognitive Behavioral Therap...   \n",
       "\n",
       "                                       OfficialTitle     Acronym  \\\n",
       "0  Automated Text Messaging to Increase Engagemen...  HealthySMS   \n",
       "\n",
       "  OrgStudyIdInfo.OrgStudyId OrgStudyIdInfo.NCTId  \\\n",
       "0            68556-35551-01          NCT01083628   \n",
       "\n",
       "                  Organization.OrgFullName Organization.OrgClass  \\\n",
       "0  University of California, San Francisco                 OTHER   \n",
       "\n",
       "  Organization.NCTId  \n",
       "0        NCT01083628  "
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from pandas.io.json import json_normalize\n",
    "\n",
    "normed = json_normalize(identification)\n",
    "normed\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    68556-35551-01\n",
       "Name: OrgStudyIdInfo.OrgStudyId, dtype: object"
      ]
     },
     "execution_count": 91,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "NCTid = identification['NCTId']\n",
    "\n",
    "OrgInfo = identification['Organization']\n",
    "OrgInfo['NCTId'] = NCTid\n",
    "\n",
    "OrgStudyIdInfo = identification['OrgStudyIdInfo']\n",
    "OrgStudyIdInfo['NCTId'] = NCTid\n",
    "\n",
    "Org = pd.DataFrame(identification['Organization'], index=[0])\n",
    "OrgStudy = pd.DataFrame(identification['OrgStudyIdInfo'], index=[0])\n",
    "\n",
    "meta = identifcation[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCTId</th>\n",
       "      <th>OrgStudyIdInfo</th>\n",
       "      <th>Organization</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>OfficialTitle</th>\n",
       "      <th>Acronym</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>OrgStudyId</th>\n",
       "      <td>NCT01083628</td>\n",
       "      <td>68556-35551-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Text Messaging and Cognitive Behavioral Therap...</td>\n",
       "      <td>Automated Text Messaging to Increase Engagemen...</td>\n",
       "      <td>HealthySMS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>OrgFullName</th>\n",
       "      <td>NCT01083628</td>\n",
       "      <td>NaN</td>\n",
       "      <td>University of California, San Francisco</td>\n",
       "      <td>Text Messaging and Cognitive Behavioral Therap...</td>\n",
       "      <td>Automated Text Messaging to Increase Engagemen...</td>\n",
       "      <td>HealthySMS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>OrgClass</th>\n",
       "      <td>NCT01083628</td>\n",
       "      <td>NaN</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Text Messaging and Cognitive Behavioral Therap...</td>\n",
       "      <td>Automated Text Messaging to Increase Engagemen...</td>\n",
       "      <td>HealthySMS</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                   NCTId  OrgStudyIdInfo  \\\n",
       "OrgStudyId   NCT01083628  68556-35551-01   \n",
       "OrgFullName  NCT01083628             NaN   \n",
       "OrgClass     NCT01083628             NaN   \n",
       "\n",
       "                                        Organization  \\\n",
       "OrgStudyId                                       NaN   \n",
       "OrgFullName  University of California, San Francisco   \n",
       "OrgClass                                       OTHER   \n",
       "\n",
       "                                                    BriefTitle  \\\n",
       "OrgStudyId   Text Messaging and Cognitive Behavioral Therap...   \n",
       "OrgFullName  Text Messaging and Cognitive Behavioral Therap...   \n",
       "OrgClass     Text Messaging and Cognitive Behavioral Therap...   \n",
       "\n",
       "                                                 OfficialTitle     Acronym  \n",
       "OrgStudyId   Automated Text Messaging to Increase Engagemen...  HealthySMS  \n",
       "OrgFullName  Automated Text Messaging to Increase Engagemen...  HealthySMS  \n",
       "OrgClass     Automated Text Messaging to Increase Engagemen...  HealthySMS  "
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame.from_dict(sample_case['Study']['ProtocolSection']['IdentificationModule'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>variable</th>\n",
       "      <th>value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCTId</td>\n",
       "      <td>NCT01083628</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>OrgStudyIdInfo</td>\n",
       "      <td>68556-35551-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>OrgStudyIdInfo</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Organization</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Organization</td>\n",
       "      <td>University of California, San Francisco</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Organization</td>\n",
       "      <td>OTHER</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>BriefTitle</td>\n",
       "      <td>Text Messaging and Cognitive Behavioral Therap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>OfficialTitle</td>\n",
       "      <td>Automated Text Messaging to Increase Engagemen...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Acronym</td>\n",
       "      <td>HealthySMS</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          variable                                              value\n",
       "0            NCTId                                        NCT01083628\n",
       "3   OrgStudyIdInfo                                     68556-35551-01\n",
       "4   OrgStudyIdInfo                                                NaN\n",
       "6     Organization                                                NaN\n",
       "7     Organization            University of California, San Francisco\n",
       "8     Organization                                              OTHER\n",
       "9       BriefTitle  Text Messaging and Cognitive Behavioral Therap...\n",
       "12   OfficialTitle  Automated Text Messaging to Increase Engagemen...\n",
       "15         Acronym                                         HealthySMS"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame.from_dict(sample_case['Study']['ProtocolSection']['IdentificationModule']).melt().drop_duplicates()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "ename": "AttributeError",
     "evalue": "'str' object has no attribute 'keys'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-49-b782a73e6c90>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m pd.DataFrame.from_dict({(i,j): sample_case['Study']['ProtocolSection']['IdentificationModule'][i][j] \n\u001b[0m\u001b[1;32m      2\u001b[0m                            \u001b[0;32mfor\u001b[0m \u001b[0mi\u001b[0m \u001b[0;32min\u001b[0m \u001b[0msample_case\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Study'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'ProtocolSection'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'IdentificationModule'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mkeys\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      3\u001b[0m                            for j in sample_case['Study']['ProtocolSection']['IdentificationModule'][i].keys()},\n\u001b[1;32m      4\u001b[0m                        orient='index')\n",
      "\u001b[0;32m<ipython-input-49-b782a73e6c90>\u001b[0m in \u001b[0;36m<dictcomp>\u001b[0;34m(.0)\u001b[0m\n\u001b[1;32m      1\u001b[0m pd.DataFrame.from_dict({(i,j): sample_case['Study']['ProtocolSection']['IdentificationModule'][i][j] \n\u001b[1;32m      2\u001b[0m                            \u001b[0;32mfor\u001b[0m \u001b[0mi\u001b[0m \u001b[0;32min\u001b[0m \u001b[0msample_case\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Study'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'ProtocolSection'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'IdentificationModule'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mkeys\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 3\u001b[0;31m                            for j in sample_case['Study']['ProtocolSection']['IdentificationModule'][i].keys()},\n\u001b[0m\u001b[1;32m      4\u001b[0m                        orient='index')\n",
      "\u001b[0;31mAttributeError\u001b[0m: 'str' object has no attribute 'keys'"
     ]
    }
   ],
   "source": [
    "pd.DataFrame.from_dict({(i,j): sample_case['Study']['ProtocolSection']['IdentificationModule'][i][j] \n",
    "                           for i in sample_case['Study']['ProtocolSection']['IdentificationModule'].keys() \n",
    "                           for j in sample_case['Study']['ProtocolSection']['IdentificationModule'][i].keys()},\n",
    "                       orient='index')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
